87￨patients with mild to moderate hypercatabolic arf who were assigned to￨cepd and tpd therapy peritoneal dialysis pd tidal peritoneal dialysis tpd cepd tpd tpd and cepd continuous equilibrating peritoneal dialysis cepd therapy￨solute clearances tpd and cepd normalized creatinine clearances solute clearances ktv normalized creatinine clearances protein loss cepd creatinine and urea clearances potassium and phosphate clearances dextrose absorption protein losses and costs potassium and phosphate clearances￨tpd resulted in higher clearances of solutes than cepd creatinine and urea clearances in mlmin of 994￨sig increase￨highunclear￨highunclear￨highunclear
55￨55 adult patients patients with occluded central venous access devices cvads￨alteplase 20 mg in reestablishing patency to occluded cvads￨patency restoration rates major hemorrhagic or embolic events safety and efficacy highest patency rate￨alfimeprase 30 mg produced the highest patency rate at 120 minutes after the first 60 and second 80 doses￨sig increase￨highunclear￨highunclear￨highunclear
108￨adult and pediatric patients from 1 year of age onehundred eight patients with cvad withdrawal or total occlusion were enrolled and randomized to treatment 104 patients received at least one instillation of study drug and 101 patients completed treatment occluded central venous catheters in oncology patients￨recombinant urokinase urokinase alfa recombinant urokinase ruk placebo￨restoring total cvad function safety and efficacy￨all three concentrations of ruk were significantly superior to placebo in restoring total cvad function patency of all occluded lumens after one or two instillations of study medication 25000 iuml ruk 68 vs placebo 28 p 007 15000 iuml ruk 69 vs placebo 24 p 004 5000 iuml ruk 70 vs placebo 28 p 003￨sig increase￨low￨low￨low
149￨one hundred fortynine patients were randomized 74 received patients were eligible for inclusion if blood could not be withdrawn from their catheter after a period of normal function of at least 48 hours￨central venous access devices cvads alteplase placebo recombinant tissue plasminogen activator alteplase tissue plasminogen activator alteplase￨serious studydrugrelated adverse events no intracranial hemorrhage no major hemorrhage and no embolic events function restoration of the ability to withdraw and infuse through the catheter￨there were no serious studydrugrelated adverse events no intracranial hemorrhage no major hemorrhage and no embolic events￨no diff￨low￨low￨low
not found￨thrombosed central venous catheters fifty dysfunctional central venous catheters proven radiographically to be occluded by thrombus￨recombinant tissue plasminogen activator tpa or 10000 units of urokinase uk repeat radiograph contrast injection urokinase versus recombinant tissue plasminogen activator￨full function￨four catheters randomized to uk had complete resolution of the thrombus after a single dose compared to 13 randomized to tpa p  0036￨sig increase￨highunclear￨highunclear￨highunclear
180￨180 patients were enrolled at 43 sites in the united states and canada adult and pediatric patients with occluded nonhemodialysis cvads of any duration or type most patients were adults although 20 were 18 years of age￨placebo recombinant urokinase ruk tunneled percutaneous catheters recombinant urokinase ruk 5000 iuml or placebo￨incidence of nonhemorrhagic events total catheter patency catheter function restoring catheter function restoration of catheter function to all treated lumens ie total catheter patency occurrence of hemorrhagic and nonhemorrhagic events major hemorrhagic events￨there were no major hemorrhagic events within 72 hr after up to four ruk instillations and the incidence of nonhemorrhagic events was similar among the ruk and placebo groups￨no diff￨low￨low￨low
42￨cancer patients fortytwo patients with vad occlusions refractory to￨urokinase infusions urokinase and heparin urokinase 40000 uh or urokinase with heparin heparin routine urokinase instillations urokinase alone￨fibrin sleeves function of the vads￨fortytwo patients with vad occlusions refractory to routine urokinase instillations were documented by xray cathetergram to have fibrin sleeves at the catheter tips￨sig increase￨highunclear￨highunclear￨highunclear
24930￨geriatric mental health services older adults who underuse these services older primary care patients 2022 patients mental healthsubstance abuse services by older primary care patients primary care patients 65 years old or older n24930 10 sites consisting of primary care and specialty mental healthsubstance abuse clinics mean age735 years 26 female 48 ethnic minority with depression n1390 anxiety n70 atrisk alcohol use n414 or dual diagnosis n148 who were randomly assigned to￨integrated mental health services or enhanced referral to specialty mental health clinics integrated care mental health and substance abuse providers colocated in primary care n999 or enhanced referral to specialty mental healthsubstance abuse clinics￨mental health and substance abuse services mental health and substance abuse visits￨integrated care was associated with more mental health and substance abuse visits per patient mean304 relative to enhanced referral mean191￨sig increase￨highunclear￨highunclear￨highunclear
472￨or 18 years with major depression 49 dysthymia 5 or both 46 patients with cancer adaptc collaborative care management for major depression or dysthymia lowincome patients with cancer intervention patients had access for up to 12 months to a depression clinical specialist supervised by a psychiatrist who offered education structured psychotherapy and maintenancerelapse prevention support patients preferring or assessed to require medication study patients included 472 lowincome predominantly female hispanic patients with cancer age patients with depressive disorders in a lowincome predominantly hispanic population in public sector oncology clinics￨euc collaborative care management enhanced usual care euc￨emotional quality of life and lower pain levels qualityoflife outcomes depressive symptoms phq9 score rates of depression treatment patient health questionnaire9 phq9 depression scale￨improvement was also found for 5point decrease in phq9 score among 722 of intervention patients compared with 597 of euc patients or  199 95 ci 114 to 350 p  02￨sig increase￨low￨low￨low
not found￨managed primary care fortysix primary care clinics in 6 us managed care organizations 27332 consecutively screened patients 1356 with current depressive symptoms and either 12month lifetime or no depressive disorder were enrolled june 1996 to march 1997 patients with depression in managed primary care settings￨qi programs disseminating quality improvement programs usual care mailing of practice guidelines or to 1 of 2 qi programs that involved institutional commitment to qi training local experts and nurse specialists to provide clinician and patient education identification of a pool of potentially depressed patients and either nurses for medication followup or access to trained psychotherapists￨quality of care health outcomes and employment counseling or used antidepressant medication medical visit for mental health problems probability of having any medical visit mental health specialist quality of care mental health outcomes and retention of employment health outcomes probable depression and healthrelated quality of life hrqol and employment￨there were no differences in probability of having any medical visit at any point each p  or  21￨no diff￨highunclear￨highunclear￨highunclear
153￨one hundred fiftythree primary care patients with current depression patients with major and minor depression intervention patients with minor depression￨multifaceted intervention program structured depression treatment program in the primary care setting that included both behavioral treatment to increase use of adaptive coping strategies and counseling to improve medication adherence usual care￨depression severity adherence to antidepressant regimens and satisfaction with care time in depression severity favorable depression outcomes adherence to antidepressant medication satisfaction with care of depression and with antidepressant treatment and reduction of depressive symptoms over time￨intervention patients with minor depression were found to have a significant decrease over time in depression severity on only 1 of 4 study outcome analyses compared with usual care patients￨sig decrease￨highunclear￨highunclear￨highunclear
105￨people aged over 65 years older people older people with depression participants were 105 people aged 60 years or older who scored 5 or more on the geriatric depression scale 53 older people in a primary care setting￨intervention group and 52 to a usual care group usual gp care collaborative care model care managed by a community psychiatric nurse who delivered an intervention comprising a facilitated selfhelp programme with close liaison with primary care professionals and oldage psychiatry according to a defined protocol￨major depressive disorder recovery from depression￨patients in the intervention group were less likely to suffer from major depressive disorder at follow up compared with usual care 032 95 confidence  interval  011 to 093 p  0036￨sig decrease￨low￨low￨low
1500￨patients found to have major depression elderly medical inpatients older medical inpatients 1500 eligible patients who were screened 157 were found to have major depression and consented to participate 78 in the intervention group and 79 in the usual care group consecutive patients aged 65 years or more admitted to general medical services in a primary care hospital between october 1999 and november 2002 were screened for depression with the diagnostic interview schedule dis within 48 hours after admission￨intervention or usual care￨hamilton depression rating scale hamd the medical outcomes 36item short form sf36 the dis the minimental state examination mmse the older americans resources and services oars questionnaire to assess basic and instrumental activities of daily living oarsadl and oarsiadl and the rating scale for side effects severity of illness length of hospital stay health services and medication use mortality and process of care hamd or sf36 scores￨at 6 months there were no clinically or statistically significant differences the 2 groups in hamd or sf36 scores or any of the secondary outcome measures￨no diff￨low￨low￨low
288￨consecutive primary care patients with major depression in the evaluation referred enrolled patients in intervention practices to the implemented ccm and resurveyed at seven months interviewers enrolled 288 ccm site and 258 nonccm site patients primary care￨￨symptom improvement￨enrolled intervention site patients were more likely to receive appropriate antidepressant care 66 versus 43 p  001 but showed no significant difference in symptom improvement compared to usual care￨sig increase￨highunclear￨highunclear￨highunclear
61￨thirtyfive primary care practices in the university of pennsylvania health system sixtyone patients were enrolled in this pilot project￨tdm telephone disease management program telephone disease management tdm or usual care uc￨depression cesd scale depressive symptoms cesd scores clinician adherence depression outcome patient adherence￨the interaction between intervention condition and time was also significant p 05 indicating that tdm patients improved significantly more over time than did uc patients￨sig increase￨highunclear￨highunclear￨highunclear
208￨two hundred and eight patients starting antidepressant treatment for depression￨depression followup care by online messaging depression care management program usual primary care treatment to primary care supported by online care management
                nine primary care clinics of an integrated health system in washington state￨rates of antidepressant adherence lower symptom checklist depression scores additional secondary outcomes antidepressant adherence and use of health services satisfaction with depression treatment feasibility acceptability and effectiveness primary outcome depression severity according to the symptom checklist scale and satisfaction with care a secondary outcome structured assessment severity of depression medication adherence side effects algorithmbased feedback to the patient and treating physician and asneeded facilitation of followup care￨patients offered the program had higher rates of antidepressant adherence 81 continued treatment more than 3 months vs 61 p  0001 lower symptom checklist depression scores after 5 months 095 vs 117 p  0043 and greater satisfaction with depression treatment 53 very satisfied vs 33 p  0004￨sig increase￨low￨low￨low
179￨depressed patients with chronic general medical conditions in primary care practices in puerto rico depressed patients with coexisting chronic general medical conditions receiving treatment for depression in primary care practices in puerto rico depressed patients with chronic medical conditions 179 primary care patients with major depression and chronic general medical conditions￨collaborative care intervention collaborative care model collaborative care or usual care￨clinical symptoms and functional status hopkins symptom checklist social functioning depressive symptoms and improved social functioning depression severity￨collaborative care significantly improved clinical symptoms and functional status of depressed patients with coexisting chronic general medical conditions receiving treatment for depression in primary care practices in puerto rico￨sig decrease￨highunclear￨highunclear￨highunclear
228￨228 patients recognized as depressed by their primary care physicians and given antidepressant medication who had either 4 or more persistent major depressive symptoms or a score of 15 or more on the hopkins symptom checklist depression items at 6 to 8 weeks primary care patients with persistent symptoms of depression￨collaborative care intervention usual care enhanced education and increased frequency of visits by a psychiatrist working with the primary care physician to improve pharmacologic treatment￨adherence to adequate dosage of medication adherence to antidepressants satisfaction with care and depressive outcomes severity of depressive symptoms￨patients in the intervention group received enhanced education and increased frequency of visits by a psychiatrist working with the primary care physician to improve pharmacologic treatment￨sig increase￨highunclear￨highunclear￨highunclear
311￨311 older adults home health care￨enhanced usual care euc that included routine depression screening and staff training in depression care management for older adults or to the intervention group int that included antidepressants andor psychotherapy treatment plus euc￨￨implementing a routine screening protocol using the phq9 and depression care management quality improvements is feasible in diverse home health care organizations and results in consistently better but not statistically significant depression outcomes in the int group￨sig increase￨highunclear￨highunclear￨highunclear
230￨230 mothers with major depression attending postnatal clinics lowincome mothers with depression and who have newly born children lowincome mothers in primarycare clinics in santiago chile￨usual care included all services normally available in the clinics including antidepressant drugs brief psychotherapeutic interventions medical consultations or external referral for specialty treatment multicomponent intervention with usual care multicomponent intervention n114 or usual care￨mean epds number of women taking antidepressants edinburgh postnatal depression scale epds score crude mean epds score epds score￨the decrease in the number of women taking antidepressants after 3 months was greater in the intervention group than in the usual care group multicomponent intervention from 60101 59 95 ci 4969 to 38106 36 2746 usual care from 18108 17 1025 to 11102 11 619￨sig decrease￨low￨low￨low
200￨people with cancer smart oncology 1 their mean age was 566 sd 119 years and 141 71 were women patients with cancer and other medical disorders who are attending specialist medical services regional cancer centre in scotland uk patients with medical disorders such as cancer 200 outpatients who had cancer with a prognosis of greater than 6 months and major depressive disorder identified by screening were eligible and agreed to take part patients who have cancer￨nursedelivered complex intervention￨quality of life anxiety and fatigue but not pain or physical functioning mean symptom checklist20 depression score mean score on the selfreported symptom checklist20 depression scale￨the intervention also improved anxiety and fatigue but not pain or physical functioning￨no diff￨low￨low￨low
45￨stepped care women n  19 versus control depressed women n  20 and selfdiagnosed depressed women n  122 versus nondepressed women n  344 five hundred six mothers of infants from 7 clinics completed surveys at 0 to 1 2 4 6 and 9 months postpartum and a structured clinical interview for dsmiv scid scidpositive depressed women selfdiagnosed depressed women vs nondepressed women women with postpartum depression and evaluate health differences between selfdiagnosed depressed and nondepressed women fortyfive women had scidpositive depression whereas 122 had selfdiagnosed depression￨stepped collaborative care intervention stepped collaborative care or usual care stepped care intervention￨womens knowledge of their postpartum depression diagnosis mothers awareness of their depression diagnosis depressive symptoms and acute care visits worse general and mental health￨selfdiagnosed depressed women vs nondepressed women had more depressive symptoms and acute care visits worse general and mental health and greater impact of health problems on regular activities￨sig decrease￨highunclear￨highunclear￨highunclear
97￨veterans n 97 with depression andor atrisk drinking patients with a behavioral health problem older population of veterans￨telephone disease management tdm program or usual care based on random assignment of their clinician telephonebased disease management program tdm￨overall response rates response rates symptomatic outcomes￨overall response rates favored those assigned to tdm compared with those assigned to usual care 391 responded vs 176 p 0022￨sig increase￨highunclear￨highunclear￨highunclear
not found￨rural primary care patients with asthma and diabetes for rural patients￨usual care with a dmm using telephone and selfreport questionnaires or 2 a dmm using telephone questionnaires and monthly televideo psychiatric consultation emphasizing primary care physician pcp skill development telemedicine telephone and televideo￨health functioning subjects depressive symptoms health status and satisfaction with care satisfaction and retention depression￨there was significant clinical improvement for depression in both groups with a trend toward significance in the more intensive module￨sig increase￨highunclear￨highunclear￨highunclear
not found￨people with these disorders 24 study clusters with an equal proportion of public and private facilities primary care facilities in goa india were assigned 11 by all adults who screened positive for common mental disorders were eligible patients attending public primary care facilities depressive and anxiety disorders in primary care in goa india manas 1160 of 1360 85￨computergenerated randomised sequence to intervention or control enhanced usual care intervention led by lay health counsellors trained lay counsellorled collaborative care intervention collaborative steppedcare intervention offered case management and psychosocial interventions provided by a trained lay health counsellor supplemented by antidepressant drugs by the primary care physician and supervision by a mental health specialist￨recovery from common mental disorders as defined by the international statistical classification of diseases and related health problems10th revision icd10 depression and anxiety disorders￨there were three deaths and four suicide attempts in the collaborative steppedcare group and six deaths and six suicide attempts in the enhanced usual care group￨no diff￨low￨low￨low
not found￨one hundred sixtyeight collaborative care and 186 cl patients who met criteria for major depression andor dysthymia primary care with consultliaison cl care veterans affairs primary care￨collaborative care depression treatment￨sf36 mental component score depression symptomatology proportion of patients receiving prescriptions and cognitive behavioral therapy depressive symptomatology mental health status hopkins symptom checklist scl20 short form sf36 sheehan disability scale￨collaborative care produced greater improvement than cl in depressive symptomatology from baseline to 3 months scl20 change scores but at 9 months there was no significant difference￨sig increase￨highunclear￨highunclear￨highunclear
58￨integrating type 2 diabetes mellitus and depression treatment among african americans older african americans 58 participants aged 50 to 80 years participated older african americans prescribed pharmacotherapy for type 2 diabetes mellitus and depression from physicians at a large primary care practice in west philadelphia￨integrated care intervention or usual care￨adherence to an oral hypoglycemic standard laboratory tests to measure glycemic control and the center for epidemiologic studies depression scale cesd to assess depression medication adherence glycemic control and depression outcomes levels of glycosylated hemoglobin adherence depressive symptoms￨participants in the integrated care intervention had lower levels of glycosylated hemoglobin intervention 67 vs usual care 79 and fewer depressive symptoms cesd mean scores intervention 96 vs usual care 166 compared with participants in the usual care group at 12 weeks￨sig decrease￨highunclear￨highunclear￨highunclear
45￨fortyfive patients were enrolled the majority with preexisting depression depressed medicaid patients in north carolina adult medicaid patients in 2 primary care practices in western north carolina to a gcm intervention or to uc￨gcms generalist care manager gcm gcm￨gcms clinical and functional outcomes 6month patient health questionnaire phq9 scores baseline and 6month short form sf 12 scores medicaid claims data questionnaire on patients perceptions of treatment gcm case notes physician and office staff time study and physician and office staff focus group discussions￨gcms most often addressed comorbid conditions 36 then social issues 27 and appointment reminders 14￨no diff￨highunclear￨highunclear￨highunclear
not found￨cardiac inpatients patients hospitalized with acute cardiovascular disease depressed cardiac patients who were admitted to cardiac units in an urban academic medical center 2011 hospitalized cardiac patients￨multicomponent depression intervention collaborative care program collaborative care depression management program copyright collaborative care and usual care interventions￨mean patient health questionnaire9￨collaborative care subjects were far more likely to receive adequate depression treatment by discharge 719 collaborative care vs 95 usual care p  0001￨sig increase￨highunclear￨highunclear￨highunclear
291￨patients with diabetes and depression often have selfmanagement needs that require betweenvisit support two hundred ninetyone patients with type 2 diabetes and significant depressive symptoms beck depression inventory scores  14 were recruited from a communitybased universitybased and veterans affairs health care systems depressed diabetes patients￨manualized telephone cbt program telephonic counseling plus walking telephonedelivered cognitive behavioral therapy cbt telephonedelivered cbt combined with a pedometerbased walking program￨systolic blood pressure blood pressure patients blood pressure increased physical activity and decreased depressive symptoms patients functioning and quality of life depressive symptoms baseline a1c levels coping and healthrelated quality of life depressive symptoms physical activity levels and diabetesrelated outcomes physical activity step counts pedometer readings depression coping and healthrelated quality of life hemoglobin a1c levels￨this program of telephonedelivered cbt combined with a pedometerbased walking program did not improve a1c values but significantly decreased patients blood pressure increased physical activity and decreased depressive symptoms￨no diff￨highunclear￨highunclear￨highunclear
395￨in 20032004 395 primary care patients with phq9 depression severity scores  or  12 were enrolled and followed for 12 months large urban clinics patients with serious mental illness and current substance dependence were excluded for small clinics without onsite psychiatrists sample comprised mostly elderly white males with substantial physical and behavioral health comorbidity small va communitybased outpatient clinics with no onsite psychiatrists primary care clinics without onsite psychiatrists using telemedicine technologies￨telemedicinebased collaborative care intervention or usual care telemedicinebased collaborative care model adapted telemedicine￨medication adherence treatment response remission health status healthrelated quality of life and treatment satisfaction moderate depression severity larger gains in mental health status and healthrelated quality of life￨intervention patients were more likely to respond by 6 months or  20 p  02 and remit by 12 months or  24 p  02￨sig increase￨highunclear￨highunclear￨highunclear
1801￨one thousand eight hundred one patients aged 60 and older with major depressive disorder older adults eighteen primary care clinics from eight healthcare organizations the mean patient age was 712 65 were women and 77 were white intervention patients had access for 12 months to a depression clinical specialist who coordinated depression care with their primary care physician￨physical component summary pcs collaborative care management mood promoting access to collaborative treatment impact intervention n906 or to a control group receiving usual care￨instrumental activities of daily living iadls mean number of iadl dependencies physical functioning mean pcs rate their health as fair or poor￨intervention patients experienced significantly better physical functioning at 1 year than usualcare patients as measured using betweengroup differences on the pcs of 171 95 confidence interval ci096246 and iadls of 015￨sig increase￨highunclear￨highunclear￨highunclear
249￨persons with the human immunodeficiency virus hiv participants who completed the baseline telephone interview were 249 hivinfected patients with depression of whom 123 were randomized to the intervention and 126 to usual care 3 veterans affairs hiv clinics hiv translating initiatives for depression into effective solutions hitides human immunodeficiency virus clinics￨collaborative care site hiv depression care team a registered nurse depression care manager pharmacist and psychiatrist that delivered up to 12 months of collaborative care backed by a webbased decision support system collaborative care interventions in hiv and other specialty physical health care settings where patients find their medical home￨scl20 item score remission mean scl20 item score 05 and depressionfree days depression and hiv symptom outcomes remission depressionfree days healthrelated quality of life health status hiv symptom severity and antidepressant or hiv medication regimen adherence depression severity measured using the 20item hopkins symptom checklist scl20 and reported as treatment response report treatment response lowering hiv symptom severity￨intervention participants were more likely to report treatment response 333 vs 175 odds ratio 250 95 confidence interval ci 137456 and remission 220 vs 119 225 111454 at 6 months but not 12 months￨sig increase￨low￨low￨low
74￨patients with depression in a primary care setting was evaluated primary care patients diagnosed with a new episode of depression and started on antidepressant medications￨pharmacist interventions ec or uc enhanced care ec or usual care uc￨depression symptoms quality of life medication adherence provider visits or patient satisfaction hopkins symptom checklist diagnostic and statistical manual of mental disorders fourth edition criteria for major depression healthrelated quality of life medication adherence patient satisfaction and use of depressionrelated health care services patients diagnosed with major depression symptoms of depression and quality of life￨there were no statistically significant differences between treatment groups in depression symptoms quality of life medication adherence provider visits or patient satisfaction￨no diff￨highunclear￨highunclear￨highunclear
263￨treated outpatients with major depressive disorder 263 patients in the outpatients with major depressive disorder mdd starting primary care patients with mdd received usual care group and 257 in the￨alone or in combination with the dialogues program venlafaxine er  d venlafaxine extended release er therapy venlafaxine erd venlafaxine er dialogues program￨patient treatment satisfaction on day 112 measured by the 10 point satisfaction with depression care scale sdcs 17item hamilton rating scale for depression hamd17 total score response 50 decrease from baseline hamd17 score and remission hamd17  7￨the percentage of patients with an sdcs very satisfied score 8 at day 112 was not significantly different in the venlafaxine er and venlafaxine erd groups 63 and 58 respectively p  022￨no diff￨highunclear￨highunclear￨highunclear
101￨101 latino patients at a rural family medical center who met criteria for probable major depression latino patients living in rural areas latino primary care patients living in rural settings￨enhanced usual care or eight sessions of cbt delivered by phone by trained bilingual therapists from the community cbt culturally tailored telephonebased cognitivebehavioral therapy cbt telephonebased cognitivebehavioral therapy￨scl depression score depression scores depression outcomes depression symptom severity using the hopkins symptom checklist scl depression items and the patient health questionnaire9 and patient satisfaction￨although limited by small sample size pilot results suggest culturally tailored telephonebased cbt has the potential to enhance access to psychotherapy in an underserved latino population with little access to mental health services￨sig increase￨highunclear￨highunclear￨highunclear
339￨lowincome latinos lowincome latino patients in publicsector primary care clinics 339 latino patients with probable depressive disorders were recruited participants completed a baseline conjoint analysis preference survey￨collaborative care collaborative care intervention intervention or enhanced usual care￨￨compared with patients assigned to usual care those in the intervention group were 21 times as likely to receive preferred treatment￨sig increase￨highunclear￨highunclear￨highunclear
600￨600 patients beginning antidepressant treatment for depression were systematically sampled from 7 groupmodel primary care clinics patients already receiving psychotherapy were excluded primary care patients starting antidepressant treatment￨usual primary care usual care plus a telephone care management program including at least 3 outreach calls telephone care management plus psychotherapy telephone psychotherapy intervention telephone program integrating care management and structured cognitivebehavioral psychotherapy telephone psychotherapy and telephone care management usual primary care for depression with 2 intervention programs telephone care management and telephone care management plus telephone psychotherapy care plus care management integrated with a structured 8session cognitivebehavioral psychotherapy program delivered by telephone￨depression severity hopkins symptom checklist depression scale and the patient health questionnaire patientrated improvement and satisfaction with treatment mean hopkins symptom checklist depression scale depression scores satisfaction and clinical outcomes mean depression scores patientrated improvement satisfaction￨the telephone care management program had smaller effects on patientrated improvement 66 vs 55 p 04 and satisfaction 47 vs 29 p 001 effects on mean depression scores were not statistically significant￨sig increase￨low￨low￨low
not found￨patients with depression￨collaborative care model collaborative care model 75 patients intervention group with subjects receiving usual care￨patient satisfaction drug adherence rate resource utilization clinical improvement￨changes in resource utilization were favorable for the intervention group but differences from the control group did not achieve statistical significance￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with depressive disorders prescribed antidepressant medication depressive illness in general practice￨practice nurse interventions practice nurse support￨￨with respect to the measures used and pilot study objectives identified there were no statistically significant differences between the study groups in treatment adherence to the prescription of antidepressant medication or in the incidence and severity of adverse events to medication￨no diff￨highunclear￨highunclear￨highunclear
405￨cancer patients receiving care in geographically dispersed urban and rural oncology practices 309 patients with depression the 154 patients patients with cancer 202 patients randomly assigned to receive the intervention and 203 to receive usual care were stratified by symptom type 274 patients with pain 137 patients in the intervention group 405 participants enrolled in the study 131 had depression only 96 had pain only and 178 had both depression and pain participating patients had depression patient health questionnaire9 score  or  10 cancerrelated pain brief pain inventory bpi worst pain score  or  6 or both 16 communitybased urban and rural oncology practices involved in the indiana cancer pain and depression incpad trial￨telecare management centralized telecare management coupled with automated symptom monitoring centralized telecare management by a nursephysician specialist team coupled with automated homebased symptom monitoring by interactive voice recording or internet centralized telephonebased care management coupled with automated symptom monitoring￨categorical pain responder depression 20item hopkins symptom checklist hscl20 and pain bpi severity bpi pain severity pain and depression bpi pain and depression hscl depression and pain hscl20 depression severity pain and depression outcomes categorical depression responder￨centralized telecare management coupled with automated symptom monitoring resulted in improved pain and depression outcomes in cancer patients receiving care in geographically dispersed urban and rural oncology practices￨sig increase￨low￨low￨low
38￨latino medicaid health plan members thirtyeight depressed primary care patients contact 929 potentially eligible members and enrolled 38￨telephone depression care management telephone depression care management telephone depression care management  treatment as usual tau versus tau only￨feasibility acceptability and efficacy￨when compared with the group receiving tau there was a trend for the intervention group to experience less depression in time￨sig decrease￨highunclear￨highunclear￨highunclear
1801￨few depressed older adults 1801 patients aged 60 years or older with major depression 17 dysthymic disorder 30 or both 53 eighteen primary care clinics from 8 health care organizations in 5 states recruitment from july 1999 to august 2001 intervention patients had access for up to 12 months to a depression care manager who was supervised by a psychiatrist and a￨usual care collaborative treatment impact collaborative care management program primary care expert and who offered education care management and support of antidepressant management by the patients primary care physician or a brief psychotherapy for depression problem solving treatment in primary care impact intervention￨lower depression severity depression depression treatments satisfaction with care functional impairment and quality of life satisfaction with depression care depressive symptoms quality of life rates of depression treatment functional impairment￨intervention patients also experienced greater rates of depression treatment or 298 95 ci 234379 p001 more satisfaction with depression care or 338 95 ci 266430 p001 lower depression severity range 04 betweengroup difference 04 95 ci 046 to 033 p001 less functional impairment range 010 betweengroup difference 091 95 ci 119 to 064 p001 and greater quality of life range 010 betweengroup difference 056 95 ci 032079 p001 than participants assigned to the usual care group￨sig increase￨low￨low￨low
120￨acutely injured trauma survivors 120 male and female injured surgical inpatients 18 or older at a level i trauma center￨multifaceted collaborative care cc intervention stepped collaborative care usual care uc control condition stepped care that consisted of 1 continuous postinjury case management 2 motivational interviews targeting alcohol abusedependence and 3 evidencebased pharmacotherapy andor cognitive behavioral therapy cc intervention￨rate of alcohol abusedependence quality of mental health care￨the cc group demonstrated no difference 007 95 confidence interval ci 42 to 43 in the adjusted rates of change in ptsd from baseline to 12 months whereas the uc group had a 6 increase 95 ci 3193 during the year￨no diff￨highunclear￨highunclear￨highunclear
16￨injured motor vehicle crash and assault victims physically injured hospitalized trauma survivors physically injured trauma survivors control subjects n18 received surgical inpatients intervention subjects n16￨trauma support specialist who provided counseling consulted with surgical and primary care providers and attempted postdischarge care coordination collaborative interventions collaborative care intervention stepped collaborative care interventions usual posttraumatic care￨ptsd and depressive symptoms episodic alcohol intoxication or functional limitations depressive symptoms intervention activity ptsd symptoms posttraumatic behavioral and emotional disturbances posttraumatic stress disorder ptsd and depressive symptoms episodic alcohol intoxication and functional limitations￨onemonth posttrauma intervention subjects when compared to controls demonstrated statistically significant decreases in ptsd symptoms as well as a reduction in depressive symptoms￨sig decrease￨highunclear￨highunclear￨highunclear
613￨613 patients starting antidepressant treatment patients in primary care starting antidepressant treatment primary care clinics in seattle￨continued usual care or one of two interventions feedback only and feedback plus care management￨depression scores visits antidepressant prescriptions and overall use of health care probability of major depression mean depression scores probability of both receiving at least moderate doses of antidepressants incremental cost of feedback plus care management￨blinded interviews by telephone 3 and 6 months after the initial prescription included a 20 item depression scale from the hopkins symptom checklist and the structured clinical interview for the current dsmiv depression module￨no diff￨highunclear￨highunclear￨highunclear
5￨primary care pc practices￨￨￨the cts and lts were equally successful when these conditions could be met but cts were more successful than lts in less supportive environments￨no diff￨highunclear￨highunclear￨highunclear
405￨405 patients aged  or  18 years starting or changing treatment for depression patients with depression￨reengineering systems￨remission severity of depression depression care￨90 of intervention patients rated their depression care as good or excellent at six months compared with 75 of usual care patients p  00003￨sig increase￨highunclear￨highunclear￨highunclear
55￨patients in public sector oncology clinics 55 lowincome latina patients with breast or cervical cancer and comorbid depression￨collaborative care as part of the multifaceted oncology depression program or usual care￨emotional wellbeing depressive symptoms personal health questionnaire functional assessment of cancer therapy scale￨or50 improvement in depressive symptoms as measured by the personal health questionnaire or451 95 ci1071893￨no diff￨highunclear￨highunclear￨highunclear
577￨a total of 577 patients patients with depression subjects included general practice attenders identified as depressed by their gp practice nurses working with general practitioners to treat people with depression twenty general practices participating in the medical research council general practice research framework took part in the study￨standardized psychiatric assessment by a practice nurse and feedback of information to the general practitioner gp feedback combined with nurseassisted followup care￨change in beck depression inventory bdi scores and in the proportion of patients fulfilling dsmiii criteria for major depression rate of improvement prescription rates of antidepressant medication rate of antidepressant prescription proportion of patients fulfilling criteria for dsmiii major depression bdi mean scores￨a total of 577 patients were recruited 516 89 95 ci  8692 were rated as depressed on the bdi and 474 82 95 ci  7985 met criteria for dsmiii major depression￨no diff￨highunclear￨highunclear￨highunclear
345￨depression in primary care in santiago chile three hundred and forty five women aged 22 to 59 years were studied￨pharmacotherapy with telephone monitoring telephone reinforcement pharmacological intervention usual therapy or a pharmacological intervention with periodical telephone contacts with medical collaboration personnel tm￨favour of tm physical function pain general health energy emotional role mental health and standardized physical and psychic scales of sf36 energy mental health and the standardized psychic scale hamilton depression rating score hdrs and the sf36 to assess depressive symptoms and quality of life respectively￨at 3 months improvement was higher in the tm group in the subscales of physical function pain general health energy emotional role mental health and standardized physical and psychic scales of sf36￨sig increase￨highunclear￨highunclear￨highunclear
191￨patients a total of 191 adults aged 18 to 64 years with panic andor generalized anxiety disorder who were recruited from july 2000 to april 2002 panic and generalized anxiety disorders in primary care￨intervention involved nonmental health professionals who provided patients with psychoeducation assessed preferences for guidelinebased care monitored treatment responses and informed physicians of their patients care preferences and progress via an electronic medical record system under the direction of study investigators telephonebased care management intervention n  116 or to notification alone of the anxiety disorder to patients and their physicians usual care n  75 telephonebased collaborative care telephonebased collaborative care￨anxiety and depressive symptoms mental healthrelated quality of life and employment status mental healthrelated quality of life depressive symptoms reduced anxiety￨telephonebased collaborative care for panic disorder and generalized anxiety disorder is more effective than usual care at improving anxiety symptoms healthrelated quality of life and workrelated outcomes￨sig increase￨low￨low￨low
not found￨20 primary care practices in new york city philadelphia and pittsburgh regions may 1999 through august 2001 older patients patients with minor depression unless suicidal ideation patients with a depression diagnosis n  598 depressed older primary care patients twostage agestratified 6074  or 75 years depression screening of randomly sampled patients enrollment included patients who screened positive and a random sample of screened negative patients￨primary care intervention￨suicidal ideation and depression suicidal ideation and depression severity suicidal ideation resolution of ideation rates of suicidal ideation favorable course of depression in both degree and speed of symptom reduction suicidal ideation suicide rates raw rates of suicidal ideation suicidal ideation and depressive symptoms￨rates of suicidal ideation declined faster p 01 in intervention patients compared with usual care patients at 4 months in the intervention group raw rates of suicidal ideation declined 129 points 294 to 165 compared with 30 points 201 to 171 in usual care p 01￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨7 universitybased and community hospitals in or near pittsburgh pennsylvania participants were 302 postcabg patients with depression 150 intervention 152 usual care and a comparison group of 151 randomly sampled postcabg patients without depression recruited between march 2004 and september 2007 and observed as outpatients until june 2008￨telephonedelivered collaborative care usual care telephonedelivered collaborative care coronary artery bypass graft cabg surgery telephonedelivered collaborative care provided by nurses working with patients primary care physicians and supervised by a psychiatrist and primary care physician telephonedelivered collaborative care￨mental hrql assessment of mood symptoms hamilton rating scale for depression hrsd physical hrql sf36 pcs and functional status duke activity status index dasi and hospital readmissions hrsd score physical functioning dasi depressive symptoms mood symptoms hrql physical functioning and mood symptoms mental healthrelated quality of life hrql mean hrql and physical functioning￨the intervention patients reported greater improvements in mental hrql all p  or  02 sf36 mcs delta 32 points 95 confidence interval ci 0560 physical functioning dasi￨sig increase￨low￨low￨low
not found￨￨￨symptoms of depression as assessed by the phq9￨comprising of both organisational and patient level components collaborative care is a potentially powerful intervention for improving depression treatment in uk primary care￨sig increase￨highunclear￨highunclear￨highunclear
310￨patients with major depression more than usual care 74 small primary care practices in germany from april 2005 to september 2007 310 patients 626 patients age 18 to 80 years with major depression 249 intervention recipients and 278 control patients were assessed 555 patients were included in a modified intentiontotreatanalysis 267 intervention recipients vs 288 control patients patients with major depression￨structured telephone interview￨qualityoflife scores mean phq9 values in depression symptoms chronic illness care adherence to medication and quality of life treatment adherence depression symptoms￨compared with control patients intervention recipients had lower mean phq9 values in depression symptoms 141￨sig decrease￨low￨low￨low
1004￨17 primary care clinics in 4 us cities between june 2006 and april 2008 1004 patients with anxiety disorders with or without major depression aged 18 to 75 years english or spanishspeaking patients with anxiety disorders multiple primary care anxiety disorders panic generalized anxiety social anxiety and posttraumatic stress disorders multiple anxiety disorders in primary care￨cognitive behavioral therapy cbt uc coordinated anxiety learning and management calm flexible treatmentdelivery model￨twelveitem brief symptom inventory bsi12 anxiety and somatic symptoms score anxiety symptoms depression symptoms functional disability and quality of care response and remission rates calm vs uc global anxiety symptoms proportion of responders  or  50 reduction from pretreatment bsi12 score and remitters total bsi12 score  6￨a significantly greater improvement for calm vs uc in global anxiety symptoms was found bsi12 group mean differences of 249￨sig increase￨low￨low￨low
152￨adolescents with a diagnosis of major depressive disorder n  152 were enrolled depressed adolescents receiving antidepressant medication hmo pediatric primary care￨treatmentasusual tau control condition consisting primarily of ssri medication delivered outside the experimental protocol n  75 versus tau ssri plus brief cbt cognitivebehavioral therapy collaborativecare cognitivebehavioral therapy cbt program adjunctive to selective serotonin reuptake inhibitor ssri￨reductions in tau outpatient visits short form12 mental component scale epidemiology depression scale cbt effect major depressive disorder episodes￨no effects were detected for major depressive disorder episodes a nonsignificant trend favoring cbt was detected on the center for epidemiology depression scale p  07￨no diff￨highunclear￨highunclear￨highunclear
211￨participants 211 adults beginning a new treatment episode for major depression 94 of patients assigned to ongoing intervention participated￨ongoing intervention encouraged participating patients to engage in active treatment using practice nurses to provide care management￨report of remission and functioning emotional functioning remission rates and improved indicators of emotional and physical functioning￨ongoing intervention significantly improved both symptoms and functioning at 24 months increasing remission by 33 percentage points 95 confidence interval 7 to 46 improving emotional functioning by 24 points 11 to 38 and physical functioning by 17 points 6 to 28￨sig increase￨low￨low￨low
268￨268 randomized patients 246 92 and 222 83 completed 3 and 12month followup interviews veterans with depression patients screening positive for depression at two veterans affairs medical center general medicine clinic firms primary care patients with depression￨integrating generalist and specialist care￨referral rate to mental health services rate of new prescriptions rates of watchful waiting depressive symptoms or satisfaction greater chart documentation of depression primary outcomes depressive symptoms patient satisfaction with health care￨there was no difference in the rate of new prescriptions for or adequate dosing of antidepressant medications￨no diff￨highunclear￨highunclear￨highunclear
464￨mental health practitioners in primary care 464 randomly recruited patients 120 patients with depression promotorasbriefly trained community health workersin depression care at community health centers community health workers￨structured training program primary care practitioners pcps and promotoras collaboratively followed a clinical algorithm in which pcps prescribed medications andor arranged consultations by mental health professionals and promotoras addressed the contextual sources of depression enhanced care plus the promotora contextual intervention or to enhanced care alone￨depression￨in the quantitative assessment the intervention did not lead to statistically significant improvements in depression odds ratio 433 confidence interval overlapping 1￨no diff￨highunclear￨highunclear￨highunclear
115￨patients with panic disorder in primary care primary care pd patients usual care patients n  58 one hundred fifteen patients with pd from 3 primary care clinics￨collaborative care uc cc interventions pd pharmacotherapy cc or usual care uc educational videotapes and pamphlets pharmacotherapy with the selective serotonin reuptake inhibitor paroxetine￨anxiety depression and disability measures quality of care and clinical and functional outcomes telephone assessments of panic anxiety sensitivity depression and disability variables￨random regression analyses showed that cc patients improved significantly more over time compared with uc patients on anxiety depression and disability measures with the greatest effects at 3 and 6 months￨sig increase￨highunclear￨highunclear￨highunclear
188￨patients with poststroke depression 188 ischemic stroke survivors identified at the time of admission to one of 4 indianapolis hospitals poststroke depression￨activateinitiatemonitor care management program￨depression scores depression response depression response defined as a hamilton depression inventory score 8 remission remission serious adverse events￨serious adverse events did not differ between the 2 groups￨no diff￨low￨highunclear￨low
240￨lowincome women in santiago chile three primarycare clinics in chile 240 adult female primarycare patients with major depression socially disadvantaged patients patients with severe depression primarycare management of depression in lowincome women in santiago chile women with major depression￨multicomponent intervention led by a nonmedical health worker which included a psychoeducational group intervention structured and systematic followup and drug treatment steppedcare programme with usual care stepped care or usual care￨mean hdrs score hamilton depression rating scale hdrs￨despite few resources and marked deprivation women with major depression responded well to a structured steppedcare treatment programme which is being introduced across chile￨sig decrease￨low￨low￨low
not found￨graduate mental health workers case managing depressed primary care nhs patients patients with depression aged 1865 years who had failed to adequately respond to antidepressant treatment three primary care practices in the north east of england 62 patients required screening of 1073 potential patients graduate mental health worker case management of depression in uk primary care￨usual gp care with or without case management￨client satisfaction￨there was little difference in outcome between the two treatment arms but a gradual improvement in symptoms over time was seen￨no diff￨highunclear￨highunclear￨highunclear
not found￨primary care patients beginning antidepressant treatment versus usual care￨telephone psychotherapy and pharmacotherapy structured cbt program telephonebased cognitivebehavioral therapy cbt plus care management copyright 2007 apa￨clinical outcomes average hscl depression scores mean hopkins symptom checklist hscl depression scale scores l derogatis k rickels e uhlenhuth  l covi 1974￨in a repeated measures linear model with adjustment for baseline scores the phone therapy group showed significantly lower mean hopkins symptom checklist hscl depression scale scores l derogatis k rickels e uhlenhuth  l covi 1974 from 6 months to 18 months versus usual care f1 336￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨a group of 1465 health maintenance organization members were identified as depressed high utilizers using a 2stage telephone screening process 410 patients and 407 agreed to enroll 218 in the depression management program dmp practices and 189 in the usual care uc group one hundred sixtythree primary care practices in 3 health maintenance organizations located in different geographic regions of the united states high utilizers of medical care￨depression management program systematic primary carebased depression treatment program dmp intervention￨hamilton depression rating scale hamd and functional status using the medical outcomes study 20item short form sf20 subscales outpatient visit and hospitalization rates general health status depression severity mental health social functioning and general health perceptions scales of the sf20 hamd scores￨improvements in hamd scores were significantly greater in the intervention group at 6 weeks p  04 3 months p  02 6 months p  001 and 12 months p  001￨sig increase￨highunclear￨highunclear￨highunclear
329￨patients with diabetes patients with diabetes and depression patients with diabetes mellitus nine primary care clinics from a large health maintenance organization patients with comorbid major depression andor dysthymia and diabetes mellitus recruitment from march 1 2001 to may 31 2002 329 patients with diabetes mellitus and comorbid major depression andor dysthymia patients with depression and diabetes￨pathways case management intervention usual care antidepressant medication treatment prescribed by the primary care physician or problemsolving therapy delivered in primary care￨depression severity hemoglobin a1c hba1c levels hba1c outcomes glycemic control depression hopkins symptom checklist 90 global improvement and satisfaction with care higher rating of patientrated global improvement adequacy of dosage of antidepressant medication treatment￨when compared with usual care patients intervention patients showed greater improvement in adequacy of dosage of antidepressant medication treatment in the first 6month period odds ratio or 415 95 confidence interval ci 228755 and the second 6month period or 290 95 ci 169498 less depression severity over time z  284 p  004 a higher rating of patientrated global improvement at 6 months intervention 694 vs usual care 393 or 350 95 ci 216568 and 12 months intervention 719 vs usual care 423 or 350 95 ci 214572 and higher satisfaction with care at 6 months or 201 95 ci 118343 and 12 months or 288 95 ci 167497￨sig increase￨low￨low￨low
533￨depressed patients in primary care pc depressed primary care patients 533 patients with major depression andor dysthymia as determined by a screening test done at the time of a routine pc office visit￨pharmacist intervention￨modified beck depression inventory mbdi outcomes recurrent depressive episodes improving ad use rates rates of ad use￨the pharmacist intervention proved equally effective in subgroups traditionally considered difficult to treat those with chronic depression and dysthymia￨sig decrease￨highunclear￨highunclear￨highunclear
232￨primary care panic disorder six primary care clinics associated with 3 university medical schools serving an ethnically and socioeconomically diverse patient population two hundred thirtytwo primary care patients meeting dsmiv criteria for panic disorder￨cognitivebehavioral therapy cbt modified for the primary care setting with up to 6 followup telephone contacts during the next 9 months and algorithmbased pharmacotherapy provided by the primary care physician with guidance from a psychiatrist cognitivebehavioral therapy and medication combined pharmacotherapy and cognitivebehavioral intervention￨minimal anticipatory anxiety and agoraphobia subscale score 10 on fear questionnaire and responding anxiety sensitivity index score 20 and change over time in world health organization disability scale world health organization disability scale￨the combined cognitivebehavioral and pharmacotherapeutic intervention resulted in sustained and gradually increasing improvement relative to treatment as usual with significantly higher rates at all points of both the proportion of subjects remitted 3 months 20 vs 12 12 months 29 vs 16 and responding 3 months 46 vs 27 12 months 63 vs 38 and significantly greater improvements in world health organization disability scale all points and short form 12 mental health functioning 3 and 6 months scores￨sig increase￨highunclear￨highunclear￨highunclear
386￨three hundred eightysix patients with recurrent major depression or dysthymia who had largely recovered after 8 weeks of antidepressant treatment by their primary care physicians primary care patients with a high risk of relapserecurrence who had largely recovered after depression in primary care￨usual primary care 2 primary care visits with a depression specialist and 3 telephone visits antidepressant treatment relapse prevention program￨refill medication prescriptions antidepressant adherence and depressive symptom outcomes depressive symptoms depression outcomes episodes of relapserecurrence adherence to adequate dosage of antidepressant medication￨intervention patients had significantly fewer depressive symptoms but not fewer episodes of relapserecurrence over the 12month followup period￨sig decrease￨highunclear￨highunclear￨highunclear
479￨patients treated in rural and urban primary care practices urban but not rural patients urban patients over 18 months but not rural patients rural versus urban patient populations rural and urban primary care patients 479 depressed primary care patients recruited from 12 practices in 10 states across the country participating in the quality enhancement for strategic teaming study urban or rural patients￨depression disease management program antidepressant medication or specialty care counseling depression disease management￨mental health status￨effects were not mediated by antidepressant medication or specialty care counseling in urban or rural patients￨no diff￨highunclear￨highunclear￨highunclear
302￨two managed care adult primary care clinics 302 patients starting antidepressant drug therapy depression in primary care ten 6minute calls during 4 months by primary care nurses￨nurse telehealth care and peer support peer support telephone￨mental functioning hamilton depression rating scale and the beck depression inventory beck depression inventory treatment satisfaction hamilton depression rating scale￨telehealth care improved mental functioning at 6 weeks 4707 vs 4264 p 004 and treatment satisfaction at 6 weeks 441 vs 417 p 004 and 6 months 420 vs 394 p 001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨individuals with epilepsy adults with epilepsy and comorbid depression adult individuals with epilepsy and clinically significant acute and chronic depression￨pearls intervention pearls a homebased program￨functioning and quality of life depressive symptoms lower depression severity suicidal ideation￨the pearls program a communityintegrated homebased treatment for depression effectively reduces depressive symptoms in adults with epilepsy and comorbid depression￨sig decrease￨highunclear￨highunclear￨highunclear
104￨patients with persistent or recurring depression 104 patients with chronic or recurrent depression groups for chronic depression￨telephone care management and structured disease selfmanagement continued usual behavioral health care usual care plus telephone monitoring and care management by a care manager usual care plus care management plus a peerled chronicdisease selfmanagement group program or usual care plus care management plus a professionally led depression psychotherapy group￨treatment participation rates hopkins symptom checklist depression scale scores major depression structured clinical interview for dsmiv patientrated global improvement ratings treatment satisfaction and adequacy of medication￨participation in care management was high in the three intervention groups￨sig increase￨highunclear￨highunclear￨highunclear
not found￨1998 to 2003￨psychoeducational prevention pep program n112 3 psychiatristenhanced pep n37 and 4 brief cognitive behavioral therapy followed by pep cbtenhanced pep psychoeducational prevention program alone and enriched with psychiatric consultation or cognitive behavioral therapy enhancing the gps usual care uc￨relapse or recurrence the median time to recurrence mean beck depression inventory bdi score depressive disorderfree and symptomfree times bdi severity￨however psychiatristenhanced pep and cbtenhanced pep patients reported lower bdi severity during followup than uc patients mean difference 207 95 confidence interval ci 113300 and 162 95 ci 070255 respectively and pep patients 237 95 ci 135339 and 193 95 ci 092294 respectively￨sig increase￨low￨low￨low
267￨267 adult patients meeting criteria for a dsmiv diagnosis of major depressive disorder assessed by a structured psychiatric interview depression in primary care￨depression recurrence prevention drp program n112 a combination of the drp program with psychiatric consultation pcdrp n39 a combination with brief cognitive behavior therapy cbtdrp n44 and care as usual cau cau psychoeducational selfmanagement intervention￨mean duration of the index episode recovery rate￨we found no evidence that the drp program was more effective than cau and no indications for added beneficial effects of either the psychiatric evaluation or the cbt treatment to the basic format of the drp program￨no diff￨highunclear￨highunclear￨highunclear
4228￨depressed chinese americans in primary care depressed chinese americans in primary care of the study participants 296 7 screened positive for depression 122 41 of whom presented for a psychiatric assessment 104 85 were confirmed with major depressive disorder and 100 96 of these patients depressed chinese americans chinese american patients in a primary care setting n  4228 were screened for depression￨culturally sensitive collaborative treatment culturally sensitive collaborative treatment csct care management or usual care csct￨treatment engagement rate and the secondary outcome was treatment response treatment rate￨patients in the care management and usual care groups did not differ in terms of their outcomes￨no diff￨highunclear￨highunclear￨highunclear
64￨64 participants aged 50 to 80 years participated older adults prescribed pharmacotherapy for depression and hypertension from physicians at a large primary care practice in west philadelphia older primary care patients￨integrated care intervention or usual care￨adherence to an antidepressant medication systolic blood pressure depressive symptoms cesd mean scores diastolic blood pressure antihypertensive medication epidemiologic studies depression scale cesd to assess depression an electronic monitor to measure blood pressure and the medication event monitoring system to assess adherence￨participants in the integrated care intervention had fewer depressive symptoms cesd mean scores intervention 99 vs usual care 193 p 01 lower systolic blood pressure intervention 1273 mm hg￨sig decrease￨highunclear￨highunclear￨highunclear
214￨14 primary care clinics in an integrated health care system in washington state involving 214 participants with poorly controlled diabetes coronary heart disease or both and coexisting depression patients with depression and chronic illnesses patients with depression and poorly controlled diabetes coronary heart disease￨usualcare group or to the intervention group in which a medically supervised nurse working with each patients primary care physician provided guidelinebased collaborative care management￨systolic blood pressure scl20 depression scores satisfaction with care for diabetes coronary heart disease or both p0001 and with care for depression ldl cholesterol levels glycated hemoglobin levels control of medical disease and depression quality of life simultaneous modeling of glycated hemoglobin lowdensity lipoprotein ldl cholesterol and systolic bloodpressure levels and symptom checklist20 scl20 depression outcomes antihypertensive medications￨patients in the intervention group also were more likely to have one or more adjustments of insulin p0006 antihypertensive medications p0001 and antidepressant medications p0001 and they had better quality of life p0001 and greater satisfaction with care for diabetes coronary heart disease or both p0001 and with care for depression p0001￨sig increase￨low￨low￨low
138￨one hundred thirtyeight patients aged 60 years or older with minor depression 514 or dysthymia 486 older adults community senior service agencies in metropolitan seattle wash from january 2000 to may 2003 older adults with social isolation medical comorbidity and physical impairment chronically medically ill older adults with minor depression and dysthymia patients had a mean of 46 sd 21 chronic medical conditions 42 of the sample belonged to a racialethnic minority 72 lived alone 58 had an annual income of less than 10 000 dollars and 69 received a form of home assistance￨problemsolving treatment social and physical activation and potential recommendations to patients physicians regarding antidepressant medications program to encourage active rewarding lives for seniors pearls intervention n  72 or usual care communityintegrated homebased depression treatment￨depressive symptoms and improved health status depressive symptoms complete remission from depression depression and quality of life￨the pearls program a communityintegrated homebased treatment for depression significantly reduced depressive symptoms and improved health status in chronically medically ill older adults with minor depression and dysthymia￨sig decrease￨low￨low￨low
387￨major depression among lowincome predominantly hispanic subjects with diabetes predominantly hispanic patients in safetynet clinics 387 diabetic patients 965 hispanic with clinically significant depression recruited from two public safetynet clinics from august 2005 to july 2007 and followed over 18 months lowincome hispanic subjects￨evidencebased socioculturally adapted collaborative depression care intervention int group included problemsolving therapy andor antidepressant medication based on a steppedcare algorithm firstline treatment choice telephone treatment response adherence and relapse prevention followup over 12 months plus systems navigation assistance enhanced usual care euc group included standard clinic care plus patient receipt of depression educational pamphlets and a community resource list collaborative care management￨depression care and depression and diabetes outcomes a1c diabetes complications selfcare management or bmi form health survey sf12 emotional physical and painrelated functioning sheehan disability financial situation and number of social stressors symptom checklist20 depression score depression functional outcomes and receipt of depression treatment depression improvement￨int patients had significantly greater depression improvement  or 50 reduction in symptom checklist20 depression score from baseline 57 62 and 62 vs the euc groups 36 42 and 44 at 6 12 and 18 months respectively odds ratio 246257 p  0001￨sig increase￨highunclear￨highunclear￨highunclear
418￨adolescent depression in primary care clinics 1999 and 2003 enrolling 418 primary care patients with current depressive symptoms aged 13 through 21 years from 5 health care organizations purposively selected to include managed care public sector and academic medical center clinics in the united states adolescents adolescents in primary care practices￨usual care n  207 or 6month quality improvement intervention expert leader teams at each site care managers who supported primary care clinicians in evaluating and managing patients depression training for care managers in manualized cognitivebehavior therapy for depression and patient and clinician choice regarding treatment modality quality improvement intervention￨satisfaction with mental health care rates of mental health care higher mental healthrelated quality of life depressive symptoms depressive symptoms assessed by center for epidemiological studiesdepression scale cesd score mental healthrelated quality of life assessed by mental health summary score mcs12 and satisfaction with mental health care assessed using a 5point scale￨intervention patients also reported significantly higher rates of mental health care 321 vs 172 p001 and psychotherapy or counseling 320 vs 212 p  007￨sig increase￨highunclear￨highunclear￨highunclear
114￨uk primary care 114 participants 41 to the intervention group 38 to the patient randomized control group and 35 to the clusterrandomized control group￨collaborative care collaborative care  case managercoordinated medication support and brief psychological treatment enhanced specialist and gp communication  or a usual care control￨substantial contamination symptoms of depression phq9 phq9 effect size￨for the intervention compared to the cluster control the phq9 effect size was 063 95 ci 018107￨no diff￨low￨low￨low
217￨217 primary care patients who were recognized as depressed by their primary care physicians and were willing to take antidepressant medication were randomized with 91 patients meeting criteria for major depression and 126 for minor depression patients with depression in primary care with the effectiveness of usual care by the primary care physician primary care patients with major depression or minor depression patients with major and with minor depression￨multifaceted intervention￨symptom checklist90 depressive symptom scale depression severity adherence favorable depressive outcomes intensity and frequency of visits depressive symptoms adequate dosage of antidepressant medication greater adherence shortterm 30day and longterm 90day use of antidepressant medication at guideline dosage levels satisfaction with overall care for depression and antidepressant medication and reduction in depressive symptoms￨in patients with major depression the intervention group had greater adherence than the usual care controls to adequate dosage of antidepressant medication for 90 days or more 755 vs 500 p  01 were more likely to rate the quality of the care they received for depression as good to excellent 930 vs 750 p  03 and were more likely to rate antidepressant medications as helping somewhat to helping a great deal 881 vs 633 p  01￨sig increase￨highunclear￨highunclear￨highunclear
223￨manage pc patients with minor depression or distress patients with minor depression or patients presenting solely with distress 223 pc subjects with minor depression or distress consented to participation in this trial￨telephonebased close monitoring program cm￨overall physical health sf12 pcs scores mh problems psychiatric diagnoses￨those randomized to cm exhibited less mh problems at the conclusion of the trial indicating that the close monitoring program is effective feasible and valuable￨sig increase￨highunclear￨highunclear￨highunclear
not found￨percutaneous endoscopic gastrostomy peg procedures percutaneous endoscopic gastrostomy peg￨antibiotic prophylaxis￨disturbance of healing minor or major wound infection rate of infection including major wound infection￨the rate of infection including major wound infection was lower in the prophylaxis group of patients at both seven and 28 days￨sig decrease￨highunclear￨highunclear￨highunclear
141￨forty patients who for various reasons were already receiving antibiotics one hundred and fortyone patients undergoing peg placement￨percutaneous endoscopic gastrostomy peg placement placebo cefuroxime antibiotic prophylaxis intravenous cefuroxime￨peristomal wound infection erythema and exudate occurrence of a peristomal wound infection at any time within one week of peg insertion￨peristomal wound infection was significantly reduced in patients who received antibiotics either as a single dose of cefuroxime one of 33 3 or in those on antibiotics for prior indications one of 36 3 compared with placebo six of 33 18 p004 and 003 respectively￨sig decrease￨low￨low￨low
96￨ninetysix patients percutaneous endoscopic gastrostomy￨povidoneiodine betadine antiseptic spray c combination of a and b betadine local antiseptic spray cefuroxime cefuroxime and betadine spray percutaneous endoscopic gastrostomy￨cumulative infections stomal infection stomal infection￨no significant difference was observed between the three groups in terms of the number of patients who were given antibiotics for other indications p  0363￨no diff￨highunclear￨highunclear￨highunclear
216￨216 patients percutaneous endoscopic gastrostomy pegresults￨antibiotic prophylaxis percutaneous endoscopic gastrostomy peg ceftriaxone 15 french gastrostomy tube antibiotic prophylaxis￨overall infection rates wound infection rates antibiotic and application costs patients systemic infection rates pneumonia￨antibiotic and application costs were similar in both groups p  0400￨no diff￨highunclear￨highunclear￨highunclear
99￨ninetynine patients completed the study 51 antibiotics 48 placebo patients undergoing percutaneous endoscopic gastrostomy insertion without malignant disease patients without malignant disease patients with benign disease indications for percutaneous endoscopic gastrostomy insertion nonmalignant conditions adult patients without malignant disease who were referred for￨placebo placebo or 22 g coamoxiclav or 2 g cefotaxime if penicillinallergic percutaneous endoscopic gastrostomy insertion antibiotic prophylaxis percutaneous endoscopic gastrostomy￨death percutaneous endoscopic gastrostomy site infection percutaneous endoscopic gastrostomy site and systemic infections systemic infection percutaneous endoscopic gastrostomy site or systemic infection and death￨antibiotic prophylaxis prior to percutaneous endoscopic gastrostomy insertion reduces both percutaneous endoscopic gastrostomy site and systemic infections in patients without malignant disease￨no diff￨low￨low￨low
100￨100 consecutive patients￨antibiotic prophylaxis amoxycillinclavulanic acid 3 x 12 g iv percutaneous endoscopic gastrostomy peg catheter percutaneous endoscopic gastrostomy peg￨peristomal infections major complications risk of peristomal pain complication rate total procedurerelated complication rate neurological disease dysphagia due to oropharyngeal tumors￨the total procedurerelated complication rate was significantly lower in group a than in groups b and c 28 58 and 70 respectively p  001￨sig decrease￨highunclear￨highunclear￨highunclear
633￨633 patients undergoing peg patients potentially at high risk of peristomal infectious complications those with advanced oropharyngeal malignancy multicenter a university tertiarycare hospital and a private practice endoscopy clinic ninetyseven patients who had malignant stenotic oropharyngeal stricture￨prophylactic ceftriaxone placebo new introducer peg gastropexy introducer peg introducer gastropexy kit￨prophylactic antibiotics wound infection scores values of infection scores wound reaction￨wound infection scores were marginally higher in the placebo group but the differences in the values of infection scores between both the groups were not statistically significant during the 7day postpeg followup￨no diff￨low￨low￨low
115￨patients receiving prior 131 hospitalized or nursing home patients referred for fiftyfour patients group 2 were on antibiotics for prior medical indications pregastrostomy peristomal infection after percutaneous endoscopic gastrostomy percutaneous endoscopic gastrostomy￨placebo cefazolin prophylaxis antibiotic prophylaxis extended antibiotic therapy antibiotic prophylaxis cefazolin cefazolin or saline pregastrostomy percutaneous endoscopic gastrostomy￨wound infection peristomal wound infections erythema and exudate overall peristomal wound infection wound infection￨a single dose of cefazolin prophylaxis does not reduce the overall peristomal wound infection in percutaneous endoscopic gastrostomy￨no diff￨low￨low￨low
not found￨percutaneous endoscopic gastrostomyassociated wound infections percutaneous endoscopic gastrostomy￨antibiotic prophylaxis or placebo placebo cefoxitin antibiotic prophylaxis antibiotic prophylaxis￨￨thirtythree patients completed a prospective doubleblind randomized study to compare the effect of antibiotic prophylaxis or placebo on percutaneous endoscopic gastrostomyassociated wound infections￨sig increase￨highunclear￨highunclear￨highunclear
347￨347 patients 251 men 96 women mean age 6025 were included in our study 336 patients 29 were excluded because of incomplete follow up dropout rate 9 percutaneous endoscopic gastrostomy peg￨antibiotic prophylaxis with 4g piperacillin plus 05g tazobactam antibiotic prophylaxis percutaneous endoscopic gastrostomy peg antibiotic prophylaxis with 2 g cefotaxime endoscopic intervention antibiotic prophylaxis￨risk of peristomal wound infection peristomal wound infections of degree iii mean daily combined wound scores severe complications peritonitis￨the control group no antibiotic prophylaxis exhibited significantly more peristomal wound infections of degree iii n  8 than antibiotic prophylaxis group 1 n  0 p  0001 or antibiotic prophylaxis group 2 n  1 p  0012￨sig decrease￨highunclear￨highunclear￨highunclear
106￨106 randomised adult patients with dysphagia 97 received study medication and 84 completed the study departments of internal medicine at six german hospitals￨placebo coamoxiclav before percutaneous endoscopic gastrostomy antibacterial prophylaxis coamoxiclav or identical appearing saline percutaneous endoscopic gastrostomy￨clinically important wound infections infectious complications risk of infectious complications nonwound infections serious comorbidity incidence of peristomal and other infections￨antibiotic prophylaxis with a single dose of coamoxiclav significantly reduces the risk of infectious complications after percutaneous endoscopic gastrostomy and should be recommended￨sig decrease￨low￨low￨low
127￨127 patients men than in women￨placebo folic acid fluoxetine daily fluoxetine folic acid supplement folic acid 500 microg folic acid or an identical looking placebo fluoxetine by folic acid fluoxetine plus folic acid fluoxetine plus placebo￨plasma homocysteine plasma homocysteine plasma folate and homocysteine mean hamilton rating scale score plasma folate baseline hamilton rating scale￨eight 129 patients in the fluoxetine plus folic acid group reported symptoms possibly or probably related to medication whereas in the fluoxetine plus placebo group 19 297 patients reported such symptoms p005￨no diff￨highunclear￨highunclear￨highunclear
123￨123 patients with acute psychiatric disorders dsm iii diagnosis of major depression or schizophrenia had borderline or definite folate deficiency redcell folate below 200 microgramsl and took part in a doubleblind￨placebo￨clinical and social recovery￨among both depressed and schizophrenic patients methylfolate significantly improved clinical and social recovery￨sig increase￨highunclear￨highunclear￨highunclear
96￨senile organic mental disorders with depression ninetysix patients with dementia scoring 1223 at the mini mental state examination mmse and  or  18 at the hamilton depression rating scale hdrs after a 2week placebo runin normofolatemic elderly patients with mild to moderate dementia and depression￨oral 5methyltetrahydrofolic acid trz trazodone trz 5mthf 5methyltetrahydrofolic acid 5mthf￨reys verbal memory rvm test for immediate and delayed recall depressive symptoms and cognitive status depressive symptoms hdrs score clinical recovery hdrs￨5 respectively was obtained at the end of the treatment period p  005 vs week 4 with 5mthf and trzabstract truncated at 250 words￨sig increase￨highunclear￨highunclear￨highunclear
not found￨acutely agitated patients￨haloperidol placebo droperidol droperidol droperidol or placebo￨￨three minutes after the injection haloperidol was needed by only six out of 19 patients of the droperidol group but by 19 patients of the control group￨no diff￨highunclear￨highunclear￨highunclear
27￨27 acutely agitated patients acutely agitated patients￨haloperidol intramuscular injection of 5 mg of droperidol or 5 mg of haloperidol droperidol vs haloperidol droperidol￨￨at 30 minutes following treatment 81 of the patients treated with haloperidol but only 36 treated with droperidol required a second injection p less than 05￨sig increase￨highunclear￨highunclear￨highunclear
not found￨mild to moderate hypertension 28 patients who had a sustained diastolic blood pressure of 95 to 104 mm hg and who had no treatment for it for at least 13 months before the trial but who were otherwise unselected￨low sodium diet restricted sodium diet￨blood pressure systolic and diastolic blood pressure fell￨within each group both systolic and diastolic blood pressure fell to a highly significant extent after a year but there was no significant difference between the groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨young patients with borderline hypertension young subjects with borderline hypertension￨acute salt loading lowsalt diet and of acute salt loading￨intralymphocytic sodium intralymphocytic sodium concentration and blood pressure blood pressure blood pressure and intralymphocytic sodium concentration natriuresis whereas intralymphocytic sodium￨after 12 months the group on free diet showed a significant increase of intralymphocytic sodium but no change in blood pressure was noted￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨index subjects index subjects were selected from the population of milton studied in the may 1981 survey index subjects aged 64 or less with a systolic blood pressure 138179 mmhg 1835238 kpa including those on antihypertensive treatment were invited to participate with their families￨￨age weight height and 24hour urinary excretion of sodium potassium and creatinine 24hour sodium excretion￨potassium output changed very little￨no diff￨highunclear￨highunclear￨highunclear
841￨841 healthy men and women aged 25 to 49 years with diastolic blood pressures of 78 to 89 mm hg￨control treatment group no dietary counseling or to one of four dietary counseling treatment groups reduced calories reduced sodium reduced sodium and calories or reduced sodium and increased potassium￨hypertensive events sodium and weight reductions potassium change blood pressure mean blood pressures mean body weight diastolic pressure￨all four dietary counseling treatment groups had lower mean blood pressures than the control group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨hypertensive patients￨sodium restriction￨blood pressure return of hypertension￨sodium restriction can reduce blood pressure in hypertensive patients￨sig decrease￨highunclear￨highunclear￨highunclear
77￨56 patients 727 completed the study 26 on a lowsodium diet ld and 30 on their usual diet ud 77 previously undiagnosed mildly hypertensive patients mild hypertensives mild hypertension patients with mild hypertension in general practice￨longterm moderate dietary sodium restriction longterm lowsodium diet￨mean urinary sodium excretion blood pressure heart the rate and body weight mean systolic and diastolic blood pressures￨nevertheless the mean systolic and diastolic blood pressures for all diet phase visits were significantly lower in the ld than in ud group 1442￨sig decrease￨highunclear￨highunclear￨highunclear
208￨one hundred and eighty one healthy adult volunteers with a sedentary lifestyle and on pharmacological therapy for hypertension briskly walked for 40 minutes three times per week with or without salt restriction treated hypertensives of the original 208 participants 181 87 completed the study￨brisk walking with or without salt restriction￨systolic blood pressure systolic and diastolic blood pressure blood pressure diastolic blood pressure salt restriction and physical activity￨significant reductions of up to 7 mm hg were found in systolic blood pressure at 3 months for brisk walking alone p  004 and salt restriction alone p  003 but not for the combined intervention p  017￨sig increase￨highunclear￨highunclear￨highunclear
4￨persons with high normal diastolic blood pressure normotensive persons persons with high normal levels of 16821 screenees 2182 men and women aged 30 through 54 years with diastolic blood pressure from 80 through 89 mm hg were selected volunteers recruited from the community treated and followed up at special clinics￨nonpharmacologic interventions four nutritional supplement groups calcium magnesium potassium and fish oil seven nonpharmacologic interventions placebo￨systolic blood pressure systolic blood pressure and intervention compliance measures diastolic blood pressure or systolic blood pressure weight loss diastolic blood pressure change blood pressure diastolic blood pressure lifestyle change groups weight reduction sodium reduction and stress management systolic blood pressure change urinary sodium excretion￨sodium reduction interventions lowered urinary sodium excretion by 44 mmol24 h p less than 01 diastolic blood pressure by 09 mm hg p less than 05 and systolic blood pressure by 17 mm hg p less than 01￨sig decrease￨highunclear￨highunclear￨highunclear
975￨older persons with hypertension four academic health centers older persons a total of 975 corrected men and women aged 60 to 80 years with systolic blood pressure lower than 145 mm hg and diastolic blood pressure lower than 85 mm hg while receiving treatment with a single antihypertensive medication 390 nonobese participants hypertension in older persons 585 obese participants￨nonpharmacologic interventions reduced sodium intake or usual care nonpharmacologic interventions weight loss or reduced sodium intake sodium￨weight loss frequency of cardiovascular events reduced sodium intake￨relative to usual care hazard ratios among the obese participants were 060 95 ci 045080 p001 for reduced sodium intake alone 064 95 ci 049085 p002 for weight loss alone and 047 95 ci 035064 p001 for reduced sodium intake and weight loss combined￨no diff￨low￨low￨low
2382￨nine academic medical centers recruited 2382 men and women age range 3054 years not taking antihypertensive drugs with a diastolic bp of 83 to 89 mm hg a systolic bp lower than 140 mm hg and a body mass index the weight in kilograms divided by the square of the height in meters representing 110 to 165 of desirable body weight overweight people with highnormal blood pressure￨weight loss and sodium reduction intervention￨lowering systolic and diastolic bp hypertension incidence bp decreases weight loss bp levels lowering diastolic bp systolic bp and the incidence of hypertension bp systolic and diastolic bp systolic bp weight weight changes high blood pressure bp average bp incidence of hypertension blood pressure and hypertension incidence sodium excretion￨differences were statistically significant for systolic and diastolic bp in the weight loss group and for systolic bp in the sodium reduction group￨sig increase￨highunclear￨highunclear￨highunclear
30￨prospective study from may 2000 to april 2001 thalassemic children urban tertiary care center thirty thalassemic children having received more than 20 blood transfusions and a serum ferritin greater than 1500￨desferrioxamine dfx deferiprone l1 alone oral deferiprone l1 desferrioxamine deferiprone and in combination on iron chelation iron chelation dfx￨ferritin levels serum ferritin levels mean urinary iron excretion initial serum ferritin levels 24hr urinary iron excretion uie and measurement of serum ferritin levels￨there was no statistically significant difference in mean urinary iron excretion by keeping the initial serum ferritin levels equal though it was found to be more in group iii as compared to other groups￨no diff￨highunclear￨highunclear￨highunclear
144￨patients with thalassemia major onehundred fortyfour consecutive patients with thalassemia major and serum ferritin between 1500 and 3000 ngml thirtysix patients accepted to undergo repeat liver biopsy 21 in the deferiprone and 15 in the deferoxamine group￨deferiprone deferoxamine deferiprone with deferoxamine deferiprone versus deferoxamine deferiprone￨liver iron content liver iron content and fibrosis stage variations serum ferritin reduction of liver and heart iron content reversible side effects variation of the ishak fibrosis stage liver and heart iron contents mean serum ferritin reduction￨no difference in the reduction of liver and heart iron content was found by magnetic resonance between the two groups￨no diff￨highunclear￨highunclear￨highunclear
26￨26 patients with transfusional iron overload ironloaded patients￨oral iron chelator 12dimethyl3hydroxypyrid4one l1 subcutaneous desferrioxamine oral iron chelator l1 and desferrioxamine desferrioxamine￨faecal iron excretion urinary iron excretion mean sd daily urinary iron excretion￨the efficacy of the oral iron chelator 12dimethyl3hydroxypyrid4one l1 was compared with that of subcutaneous desferrioxamine in 26 patients with transfusional iron overload￨sig increase￨highunclear￨highunclear￨highunclear
20￨20 patients with thalassemia￨iron chelating agent deferoxamine deferoxamine￨local reactions urinary iron excretion￨urinary iron excretion was comparable with the two methods but decreased significantly when the total daily dose was administered as a single injection￨no diff￨highunclear￨highunclear￨highunclear
not found￨iron overloaded thalassaemia patients￨desferrioxamine desferrioxamine and deferiprone deferiprone plus dfx desferrioxamine dfx alone dfx combined dfx twice weekly and deferiprone￨mean urine iron excretion skin reactions dfx alone nausea and arthralgia combined therapy serum ferritin￨deferiprone plus dfx produced a greater mean urine iron excretion 101 mgkg24 h than iron intake from blood transfusion in each patient￨sig increase￨highunclear￨highunclear￨highunclear
54￨women with repeated unsuccessful in vitro fertilization ivf cycles due to inadequate ovarian response fifty four women with repeated unsuccessful in vitro fertilization ivf cycles due to inadequate ovarian response to stimulation with human menopausal gonadotropins hmg participated in this study patients with repetitive unsuccessful ivf cycles￨short and long buserelin gonadotropin releasing hormone agonist gnrha buserelin prior to and during induction of ovulation by hmg￨cancellation rate mean follicular phase serum luteinizing hormone lh and progesterone p levels cancellation rates more oocytes per pickup opu more embryos transferred per patient and a higher pregnancy rate￨mean follicular phase serum luteinizing hormone lh and progesterone p levels were significantly lower in group i than in group ii p less than 001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients treated with gnrha starting in different phases of the menstrual cycle patients treated with￨human chorionic gonadotrophin gonadotrophinreleasing hormone analogues gnrha gonadotrophinreleasing hormone analogues￨ovarian response and outcome of invitro fertilization fertilization and cleavage rates ovarian arrest ovarian quiescence pregnancy rate number and size of follicles luteolysis￨patients in group 1 showed a significant decrease p less than 005 in the number and size of follicles developed in comparison to groups 2 and 3￨sig decrease￨highunclear￨highunclear￨highunclear
87￨patients undergoing ivf eightyseven patients undergoing ivf￨gonadotropinreleasing hormone agonist administration gonadotropinreleasing hormone agonist￨fertilization rates number of embryos transferred and pregnancy rates stimulation response and occurrence of luteinizing hormone lh surges stimulation requirements response to stimulation number of follicles aspirated or the number of oocytes obtained￨the fertilization rates number of embryos transferred and pregnancy rates were also similar in both groups￨no diff￨highunclear￨highunclear￨highunclear
186￨one hundred eightysix patients￨gonadotropin stimulation human chorionic gonadotropin hcg luteinizing hormonereleasing hormone lhrh luteinizing hormonereleasing hormone agonists￨cleavage rate of mature oocytes progesterone values ovarian response ongoing pregnancy rate per treatment cycle￨the cleavage rate of mature oocytes was higher in the short protocol 70 versus 56 p less than 001￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨￨triptorelin￨lh serum concentrations hormone serum levels ovarian response￨however this did not translate into higher serum concentrations of androstenedione and e2 and had no significant effect on ovarian response and the outcome of ivfintracytoplasmic sperm injection￨no diff￨highunclear￨highunclear￨highunclear
124￨women attending seven infertility clinics one hundred twentyfour women with tubal or unexplained infertility with normal menstruation and fertile partners￨midluteal buserelin intranasal buserelin acetate buserelin acetate￨live birth rates duration of downregulation clinical pregnancy and live birth rates pregnancy rates per first treatment cycle treatment cycle oocyte retrieval and et clinical pregnancy and live birth rates time to downregulation and pregnancy and live birth rates￨the pregnancy rates per first treatment cycle treatment cycle oocyte retrieval and et were significantly higher when buserelin acetate was started in the midluteal phase￨no diff￨highunclear￨highunclear￨highunclear
132￨132 patients women undergoing controlled ovarian hyperstimulation for assisted reproduction￨gonadotrophinreleasing hormone gnrh agonists 100 microg triptorelin triptorelin￨oestradiol concentrations and in follicle number in the quantity of oocytes collected and fertilized or in the number of embryos obtained or transferred pregnancy rate per transfer implantation rate ivf abortion rate ivf cycle outcome number of fsh ampoules￨a reduced dose of triptorelin is enough for pituitary suppression during ovarian stimulation but provides no significant improvement in ivf cycle outcome when compared with depot formulation￨no diff￨highunclear￨highunclear￨highunclear
30￨30 women divided into 3 groups￨slowrelease preparation of triptorelin dtrp6lhrh an lhrh analogue and human menopausal gonadotropin triptorelin with human menopausal gonadotropin conventional clomiphene citratehuman menopausal gonadotropin combination without lhrh analogue lhrh analogue luteinizing hormone with a gonadoliberin analog triptorelin￨quality of ovarian stimulation vitro fertilization￨inhibition of the endogenous luteinizing hormone using triptorelin improved the results of in vitro fertilization in group ii and group iii women but the short regimen was distinctly less compelling and less expensive than the long regimen￨sig increase￨highunclear￨highunclear￨highunclear
55￨patients undergoing in vitro fertilizationembryo transfer ivfet fiftyfive patients twentysix patients in group￨gnrh coh gonadotropinreleasing hormone agonist gnrha initiation either preceding or concurrent with controlled ovarian hyperstimulation coh gonadotropinreleasing hormone agonist￨spontaneous abortion rate serum luteinizing hormone progesterone and testosterone levels serum gonadotropin and ovarian steroid hormone levels as well as fertilization spontaneous abortion and live birth rates live birth rateretrieval fertilization biochemical and clinical pregnancy rates￨patients in group ii had significantly higher serum luteinizing hormone progesterone and testosterone levels during stimulation with human menopausal gonadotropins hmg before oocyte retrieval p  005￨sig increase￨highunclear￨highunclear￨highunclear
70￨low responder patients undergoing ivf low responder ivf patients seventy low responder patients less than three mature follicles in a previous cycle with normal basal follicle stimulating hormone concentrations and a previous cancelled ivf cycle￨gonadotrophins combined with stop versus nonstop protocol of gnrh analogue administration gonadotrophin releasing hormone analogue gnrha nonstop protocol long gnrha suppression with high doses of gonadotrophins and ii stop protocol in which gnrha administration￨ovulation pregnancy rate number of oocytes number of ampoules of gonadotrophins required implantation rate cancellation rate number of mature oocytes￨a significantly higher number of mature oocytes were obtained in the study group stop protocol compared to the control group nonstop protocol 87  09 versus 62￨sig increase￨highunclear￨highunclear￨highunclear
not found￨ninetyone patients having their first attempt at ivf￨sc buserelin acetate subcutaneous sc buserelin acetate human menopausal gonadotropin hmg gonadotropinreleasing hormone agonist gnrha buserelin acetate gonadotropinreleasing hormone agonist￨median total amount of hmg higher fertilization rate pregnancy rates per initiated cycle and per embryo transfer follicular recruitment oocyte recovery and fertilization rates fertilized oocytes cleaved embryos￨there were significantly more follicles p  00001 oocytes p  00008 fertilized oocytes p  00001 and cleaved embryos p  00001 and a higher fertilization rate p  00047 in patients in group 1￨sig increase￨highunclear￨highunclear￨highunclear
not found￨three hundred eight patients having their first ever ivf attempt patients undergoing in vitro fertilization ivf patients undergoing in vitro fertilization￨gonadotropinreleasing hormone agonists gnrha pituitary desensitization with gnrha followed by hmg clomiphene citrate and hmg gonadotropinreleasing hormone agonists human menopausal gonadotropin hmg alone for ovarian simulation 3day ultrashort course of gnrha and hmg￨pregnancy and live birth rates per cycle commenced or per embryo transfer number of embryos cleaved and transferred cancellation rate mean number of oocytes collected or fertilized and number of cases of failed fertilization￨there was a significant difference in the number of embryos cleaved and transferred among the groups but there were no significant differences in the cancellation rate mean number of oocytes collected or fertilized and number of cases of failed fertilization￨no diff￨highunclear￨highunclear￨highunclear
13￨poor responders undergoing in vitro fertilization sixtythree patients with previous poor response to coh￨gonadotropinreleasing hormone analogue gnrha￨ovarian stimulation patterns and ivf outcome stimulation characteristics and clinical pregnancy rates number of retrieved oocytes cancellation rate basal fsh level￨a significantly higher cancellation rate was noted in the study group than in the controls 225 versus 5 respectively￨sig increase￨highunclear￨highunclear￨highunclear
18￨eighteen highly selected patients 9 patients who were exposed to a longterm protocol day 21 and 13 control patients￨gonadotropinreleasing hormone agonists shortterm administration of buserelin hoechst ag franfurtmain frg gonadotropinreleasing hormone agonist￨oocytes fertilization rate and embryo quality agonistinduced luteinizing hormone lh and folliclestimulating hormone fsh follicular recruitment and subsequent ivf￨the shortterm regimen did not improve the follicular recruitment and appeared to reduce the oocytes fertilization rate and embryo quality when compared with prolonged administration of peptide￨no diff￨highunclear￨highunclear￨highunclear
not found￨all male partners had a normal spermiogram all patients suffered from tubal infertility and were not older than 40 years￨conventional treatment with hmg alone gnrh agonist and patients in group iii commenced the hmg treatment gnrh agonist buserelin buserelin ovarian stimulation regimens gonadotropinreleasing hormone gnrh agonist￨pregnancy rate per cycle number of retrieved oocytes and the fertilization rate￨the pregnancy rate per cycle or per patient in the group with a shortterm gnrhagonist regimen is significantly higher compared to that of the group using the conventional hmg treatment￨sig increase￨highunclear￨highunclear￨highunclear
not found￨outpatient fertility clinic of a university tertiary care center the hôpital a béclère clamart france one hundred eightytwo in vitro fertilization ivf candidates undergoing new or repeat ivf cycles at hôpital a béclère over a 4month period controlled ovarian hyperstimulation￨hmg gonadotropinreleasing hormone agonist gnrha and human menopausal gonadotropin hmg gonadotropinreleasing hormone agonist desensitization￨number of oocytes plasma luteinizing hormone response to coh pregnancy rate pr tolerance peak estradiol level and the hmg requirement amount of hmg required plasma lh￨no elevation of plasma lh occurred in either group￨no diff￨highunclear￨highunclear￨highunclear
42￨42 ovulatory patients with mechanical infertility￨lhrha gonadotrophin hcg human menopausal gonadotrophin hmg progesterone 50 mg injections and human chorionic dtrp6luteinizing hormonereleasing hormone standard luteinizing hormonereleasing hormone agonist lhrha￨premature luteinization or luteolysis fertilization rate cleavage rate pregnancyembryo transfer implantation rate￨there was no evidence of premature luteinization or luteolysis in either group￨no diff￨highunclear￨highunclear￨highunclear
90￨90 patients on their first attempt at in vitro fertilization and embryo transfer ivfet￨gonadotropin releasing hormone agonist gnrha gonadotropin releasing hormone agonist￨number of oocytes retrieved and fertilized the number of embryos transferred and the pregnancy rate per initiated cycle peak serum estradiol level number of oocytes retrieved and fertilized fertilization rate per oocyte number of embryos transferred and pregnancy rate per initiated cycle fertilization rates per oocyte number of follicles greater peak estradiol level￨the number of follicles greater than 17 mm and the peak estradiol level were significantly p  05 higher in the long protocol than those in the short protocol￨sig increase￨highunclear￨highunclear￨highunclear
86￨university teaching hospital eightysix infertile couples undergoing ivfet attempt under rules for ireland￨protocol gonadotropinreleasing hormone human menopausal gonadotropin protocol gonadotropinreleasing hormone agonist gnrha downregulation regimen gonadotropinreleasing hormone agonist￨ovarian response cancellation fertilization and pregnancy rates￨no significant differences found between day 1 and day 21 initiation￨no diff￨highunclear￨highunclear￨highunclear
230￨a total of 230 normoovulatory women￨gonadotrophinreleasing hormone agonist gonadotrophinreleasing hormone gnrha agonists exogenous gonadotrophins decapeptylgnrh￨pregnancy rate gonadotrophin secretion gonadotrophin secretion and ovarian parameters of ivf cycles plasma free alpha subunit and dimeric lh concentrations while plasma oestradiol response￨detections of free alpha subunit and dimeric lh were performed by highly specific two site monoclonal immunoradiometric assays￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨sixty low responders who were recruited on the basis of results in previous cycles university hospital ivf unit low responders who were undergoing in vitro fertilizationembryo transfer￨gnrh agonist￨number and quality of embryos available for transfer￨a modified long minidose protocol appears to be superior to a modified megadose flare protocol in terms of oocyte yield and cycle outcome￨sig increase￨highunclear￨highunclear￨highunclear
not found￨two hundred sixteen cycles￨longacting gonadotropinreleasing hormone agonist￨cancellation rate mature oocytes and more embryos with good morphology ovarian suppression number of oocytes￨ovarian suppression was significantly more prompt in group b follicle cysts were diagnosed in 19 and 16 of groups a and b respectively their appearance and regression were significantly more rapid in group b cycles￨sig increase￨highunclear￨highunclear￨highunclear
not found￨borderline personality disorder january 1998 and february 2000 20 subjects that completed treatment patients with borderline personality disorder identified using the structured clinical interview for dsmiv axis ii disorders￨dialectical behavior therapy dbt placebo combined dialectical behavior therapy and fluoxetine fluoxetine￨depression anxiety anger expression dissociation and global functioning￨timebygroup interaction effects revealed no significant group differences in scores from pretreatment to posttreatment on any measure￨no diff￨highunclear￨highunclear￨highunclear
49￨patients with recurrent selfharm patients n49 presenting after an act of repeated selfharm￨n3 efas eicosapentaenoic acid plus 09 g decosahexaenoic acid n22 or placebo omega3 fatty acid supplementation n3 efa longchain omega3 essential fatty acid n3 efa supplementation￨suicidal behaviour scores for impulsivity aggression and hostility scores for depression suicidality and daily stresses￨at 12 weeks the n3 efa group had significantly greater improvements in scores for depression suicidality and daily stresses￨sig increase￨low￨low￨low
not found￨women meeting the diagnostic and statistical manual of mental disorders fourth edition structured clinical interview ii criteria for borderline personality disorder women with borderline personality disorder￨topiramate placebo topiramate￨body weight and additional side effects somatization interpersonal sensitivity anxiety hostility phobic anxiety and global severity index scales of the symptom checklist obsessivecompulsive depression paranoid ideation and psychoticism scales weight loss borderline psychopathology healthrelated quality of life and interpersonal problems changes on the symptomchecklist on the sf36 health survey and on the inventory of interpersonal problems additional weight loss￨in the sf36 health survey significant differences were observed on all 8 scales all p  001 or p  0001￨sig increase￨low￨low￨low
15￨borderline personality disorder 28 patients who met revised diagnostic interview for borderlines and diagnostic and statistical manual of mental disorders fourth edition criteria for bpd borderline personality disorder bpd and 13 patients to receive￨placebo lamotrigine flexibledose lamotrigine or placebo￨total affective lability scale scores zanbpd impulsivity item affective lability scale total score and ii the affective instability item of the zanarini rating scale for borderline personality disorder zanbpd￨a secondary finding was that patients in the lamotrigine group had significantly greater reductions in scores on the zanbpd impulsivity item p  0001￨sig decrease￨low￨highunclear￨highunclear
not found￨90 symptomatic borderline inpatients￨haloperidol placebo placebo haloperidol amitriptyline and haloperidol amitriptyline amitriptyline￨global functioning depression hostility schizotypal symptoms and impulsive behavior global depression hostile depression and schizotypal symptom pattern acute state symptoms severity of schizotypal symptoms hostility and suspiciousness￨haloperidol 416 mgday produced significant improvement over placebo in global functioning depression hostility schizotypal symptoms and impulsive behavior￨sig increase￨highunclear￨highunclear￨highunclear
20￨women with borderline personality disorder and bipolar ii disorder twenty subjects 30 female subjects aged 18 to 40 years who met revised diagnostic interview for borderlines and dsmiv criteria for borderline personality disorder and dsmiv criteria for bipolar ii disorder women with borderline personality disorder and comorbid bipolar ii disorder women with criteriadefined borderline personality disorder and comorbid bipolar ii disorder￨placebo divalproex sodium divalproex sodium and placebo divalproex sodium or placebo divalproex sodium￨interpersonal sensitivity angerhostility and depression scales of the symptom checklist 90 scl90 as well as the total score of the modified overt aggression scale moas efficacy and safety adverse effects interpersonal sensitivity and angerhostility￨primary outcome measures were changes on the interpersonal sensitivity angerhostility and depression scales of the symptom checklist 90 scl90 as well as the total score of the modified overt aggression scale moas￨no diff￨highunclear￨highunclear￨low
60￨borderline personality disorder patients with borderline personality disorder sixty patients with borderline personality disorder￨olanzapine or placebo placebo dialectical behavior therapy dialectical behavior therapy plus placebo olanzapine olanzapine dialectical behavior therapy plus olanzapine￨efficacy and safety depression anxiety and impulsivityaggressive behavior￨olanzapine was associated with a statistically significant improvement over placebo in depression anxiety and impulsivityaggressive behavior￨sig increase￨highunclear￨highunclear￨highunclear
42￨42 male subjects 42 of 44 meeting dsmiv criteria for bpd borderline personality disorder bpd men with borderline personality disorder men with bpd male borderline patients￨topiramate placebo topiramate￨weight loss four staxi scales state anger mild weight loss￨significant changes on four staxi scales state anger p  01 trait anger p  05 anger out p  01 anger control p  01 were observed in the subjects treated with topiramate￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨borderline personality disorder patients cgibpd adult patients with borderline personality disorder sixty dsmiv borderline personality disorder patients borderline personality disorder patients with borderline personality disorder￨placebo ziprasidone ziprasidone ziprasidone or placebo￨efficacy and tolerability depressive anxiety psychotic or impulsive symptoms scales and selfreports related to affect behavior psychosis general psychopathology domains and clinical safety￨analysis of variance indicated no statistically significant differences between ziprasidone and placebo in the cgibpd￨no diff￨low￨low￨low
40￨borderline personality disorder forty bpd patients 25 female 15 male patients with schizophrenia bipolar disorder or current major depression were excluded women and men￨placebo olanzapine olanzapine and placebo olanzapine￨weight gain total score for the 9 bpd criteria on a 1to7 likert scale the clinical global impressions scale modified for borderline personality disorder cgibpd singleitem clinical global impressions scale cgi￨olanzapine was found to be significantly p 05 superior to placebo on the cgi￨sig increase￨highunclear￨highunclear￨highunclear
108￨borderline personality disorder one hundred eight consecutively admitted borderline inpatients defined by gundersons diagnostic interview for borderline patients and dsmiiir criteria randomly assigned to 38 phenelzine 36 haloperidol and 34 placebo trials inpatient unit of a tertiary care university psychiatric hospital serving a large public catchment area borderline personality disorder patients￨neuroleptic haloperidol haloperidol placebo phenelzine sulfate phenelzine and haloperidol phenelzine monoamine oxidase inhibitor antidepressant phenelzine sulfate placebo and haloperidol pharmacologic dissection￨depression hamilton rating scale beck depression inventory global severity global assessment scale symptom checklist90 items scl90 anxiety angerhostility scl90 inpatient multidimensional psychiatric scale imps bussdurkee hostility inventory psychoticism schizotypal symptom inventory scl90 imps impulsivity ward scale barratt impulsiveness scale selfreport test of impulse control and borderline psychotherapy borderline syndrome index efficacy depression borderline psychopathologic symptoms and anxiety￨threeway comparisons between groups indicated superior efficacy for phenelzine followed by placebo and haloperidol on measures of depression borderline psychopathologic symptoms and anxiety￨sig increase￨low￨low￨low
20￨female subjects with borderline personality disorder twenty subjects 30 female subjects meeting revised diagnostic interview for borderlines and dsmiv criteria for borderline personality disorder women with moderately severe borderline personality disorder women with borderline personality disorder￨omega3 fatty acid treatment placebo ethyleicosapentaenoic acid eepa and placebo eepa￨￨analyses that used randomeffects regression modeling and controlled for baseline severity showed eepa to be superior to placebo in diminishing aggression as well as the severity of depressive symptoms￨sig increase￨highunclear￨highunclear￨highunclear
28￨28 female subjects meeting revised diagnostic interview for borderlines and dsmiv criteria for bpd female borderline personality disorder patients nineteen subjects women meeting criteria for borderline personality disorder bpd￨olanzapine or placebo placebo olanzapine olanzapine￨weight gain selfreported changes on anxiety depression paranoia angerhostility and interpersonal sensitivity scales of the symptom checklist90 efficacy and safety￨weight gain was modest in the olanzapinetreated group but was significantly higher than in those treated with placebo p  02￨sig increase￨highunclear￨highunclear￨highunclear
14￨female subjects meeting revised diagnostic interview for borderlines dibr and dsmiv criteria for borderline personality disorder fourteen subjects women meeting criteria for borderline personality disorder without concurrent major depressive disorder women with borderline personality disorder￨olanzapine olanzapinefluoxetine combination ofc fluoxetine olanzapinefluoxetine combination fluoxetine olanzapine olanzapine monotherapy fluoxetine monotherapy￨clinicianrated scales measuring depression the montgomeryasberg depression rating scale and impulsive aggression the modified overt aggression scale weight gain chronic dysphoria and impulsive aggression impulsive aggression and severity of depression efficacy and safety￨however olanzapine monotherapy and ofc seem to be superior to fluoxetine monotherapy in treating both of these dimensions of borderline psychopathology￨no diff￨highunclear￨highunclear￨highunclear
13￨severely ill borderline patients patients with borderline personality disorder volunteer subjects with mild to moderately severe borderline personality disorder symptomatic volunteers with borderline personality disorder￨placebo fluoxetine￨global mood and functioning anger and depression￨this decrease was independent of changes in depression￨no diff￨highunclear￨highunclear￨highunclear
50￨patients with borderline and schizotypal disorder without the foregoing symptoms fifty outpatients with borderline andor schizotypal personality disorder￨thiothixene navane or placebo thiothixene vs placebo thiothixene thiothixene hydrochloride￨regardless of diagnosis on illusions ideas of reference psychoticism obsessivecompulsive symptoms and phobic anxiety but not on depression￨significant drugplacebo differences were found regardless of diagnosis on illusions ideas of reference psychoticism obsessivecompulsive symptoms and phobic anxiety but not on depression￨sig increase￨highunclear￨highunclear￨highunclear
16￨borderline personality disorder patients with borderline personality disorder sixteen outpatients meeting structured clinical interview for dsmiv axis ii personality disorders criteria for borderline personality disorder￨placebo divalproex sodium with placebo divalproex sodium￨global measures cgii and gas global symptom severity clinical global impressionsimprovement scale cgii and functioning global assessment scale gas as well as in specific core symptoms depression aggression irritability and suicidality global symptomatology level of functioning aggression and depression￨there was significant improvement from baseline in both global measures cgii and gas following divalproex sodium treatment￨sig increase￨highunclear￨highunclear￨highunclear
43￨patients with borderline personality disorder subjects meeting criteria for the structured clinical interview for dsmiiir personality disorders for borderline personality disorder 43 women and 9 men￨aripiprazole placebo aripiprazole￨selfinjury statetrait anger expression inventory changes in scores on the symptom checklist scl90r the hamilton depression rating scale hamd the hamilton anxiety rating scale hama and the statetrait anger expression inventory headache insomnia nausea numbness constipation and anxiety￨primary outcome measures were changes in scores on the symptom checklist scl90r the hamilton depression rating scale hamd the hamilton anxiety rating scale hama and the statetrait anger expression inventory and were assessed weekly￨no diff￨highunclear￨highunclear￨highunclear
24￨24 female subjects meeting structured clinical interview for dsmiv scid criteria for bpd women meeting the criteria for borderline personality disorder bpd female borderlinepatients￨placebo lamotrigine lamotrigine￨body weight four staxi scales stateanger traitanger angerout angercontrol anger and aggression selfreported changes on the anger scales of the trait anger expression inventory staxi￨the only exception p  005 was found on the angerin scale where a difference of only 85 p  02 was found￨no diff￨low￨low￨low
29￨female borderline personality disorder patients women with borderline personality disorder 29 female subjects response rate 935 meeting scid structured clinical interview for dsmiv criteria for borderline personality disorder women who meet the criteria for borderline personality disorder￨topiramate placebo topiramate￨weight loss selfreported changes on the anger subscales of the statetrait anger expression inventory staxi 4 subscales of the staxi stateanger traitanger angerout angercontrol efficacy and safety stateanger traitanger and anger￨topiramate appears to be a safe and effective agent in the treatment of anger in women with borderline personality disorder as defined by scid criteria￨sig increase￨low￨low￨low
not found￨female patients with borderline personality disorder patients with borderline personality disorder and one study of impulsive aggressive patients with different personality disorders 38 nonschizophrenic nonbipolar female patients with borderline personality disorder borderline personality disorder patients with borderline personality disorder borderline personality disorder patients female borderline patients￨fluvoxamine ssri fluvoxamine placebo fluvoxamine ssri ssris selective serotonin reuptake inhibitors ssris￨rapid mood shift impulsivity and aggression subscales from the borderline personality disorder severity index impulsivity and aggression scores rapid mood shifts￨fluvoxamine but not placebo produced a robust and longlasting reduction in the scores on the subscale for rapid mood shifts￨sig increase￨highunclear￨highunclear￨highunclear
20￨borderline personality disorder 20 borderline inpatients in a doubleblind parallel￨carbamazepine placebo￨￨no significant positive effects of the drug were found￨no diff￨low￨low￨low
10￨032 liters ten male patients with stable copd age 672 patients with chronic obstructive pulmonary disease patients with stable chronic obstructive pulmonary disease copd￨nebulizer salbutamol via an mdi with an inspireasetm spacer a rotahalertm or a devilbiss 646tm placebo salbutamol delivered via three different devices a drypowder inhaler dpi a metereddose inhaler mdi with a largevolume spacer and a jet nebulizer neb salbutamol￨maximum fev1 and in area under the timeresponse curve aucfev1 maximum fev1 and aucfev1 forced expiratory volume￨with the 1000 microg dose dpi and mdi produced equally greater improvements in both maximum fev1 and aucfev1 than neb￨sig increase￨highunclear￨highunclear￨highunclear
36￨patients with copd 36 patients with chronic obstructive pulmonary disease copd￨ipratropium bromide inhaled from rmt ipratropium bromide ipratropium bromide using respimat mdi or rmt respimat rmt ipratropium cumulative ipratropium bromide rmt￨bronchodilatory effect safety and efficacy￨greater bronchodilatory effect was obtained from half the cumulative dose of ipratropium rmt 10 microg per puff when compared with the mdi 20 microg per puff￨sig increase￨highunclear￨highunclear￨highunclear
15￨fifteen hospitalised patients 11 male with copd patients with regard to fev10 forced expiratory capacity fvc residual volume rv and specific conductance sgaw patients with chronic obstructive pulmonary disease copd￨placebo terbutaline via turbuhaler 10 and 25 mg and terbutaline via a cfc inhaler terbutaline turbuhaler and chlorofluorocarbon cfc terbutaline administered via a dry powder inhaler turbuhaler and via a chlorofluorocarbon cfc terbutaline￨peak expiratory flow pef fvc and sgaw rv fev10￨inhalation of terbutaline in different doses and from different devices induced a decrease in rv an increase in fvc and sgaw and a less pronounced increase in fev10￨sig increase￨highunclear￨highunclear￨highunclear
1030￨1030 patients patients undergoing lumbar spine radiography 1030 consecutive referrals for lumbar spine radiography from general practice￨frontal lumbar spine radiograph￨radiation burden￨specific important conditions such as infection malignancy and benign tumours were not missed on the lateral view alone in our study population￨no diff￨highunclear￨highunclear￨highunclear
471￨patients with acute lowback pain who are at risk for vertebral cancer osteomyelitis acute fracture or herniated disk 471 patients with acute lowback pain in three teaching hospital walkin clinics￨￨actual roentgenogram use older age longer duration of symptoms reflex asymmetry and point vertebral tenderness￨roentgenograms were obtained at the initial visit in 99 patients 211 the number would have increased to 217 461 if the criteria had been used￨no diff￨highunclear￨highunclear￨highunclear
1378￨patients presenting with low back pain lbp patients presenting with lbp totally 1190 patients answered the index test question and were available for interview at 1 year 1378 patients presenting with lbp to one of 126 participating gps were included￨￨￨in hindsight we would question whether an rctsetting emphasizing nonspecific lbp is suitable for this kind of research￨no diff￨highunclear￨highunclear￨highunclear
482￨37 patients 482 patients who were examined in a level ii emergency department patients with lower back pain who have a history of neoplasm￨lumbosacral spine radiographs￨neurologic deficit back pain neoplastic involvement neurologic deficit￨no fracture required decompression￨no diff￨highunclear￨highunclear￨highunclear
491￨metastatic disease  3 lesions without trauma or other benign explanation 310 patients aged 50 years or older 226 73 had scans in category a 64 21 in category b and 21 7 in category c thirty patients 6 had malignancy involving bone 29 among those aged 50 years or older patients aged 50 years or older 10 16 of 64 with equivocal scan findings category b and 19 90 of 21 with widespread abnormalities category c had malignancy involving bone patients aged 50 years or older 491 patients with new or recurrent complaints of musculoskeletal pain and no previously known malignancy 181 patients younger than 50 years 161 89 had category a and 20 11 had category b scans￨bone scintigraphy￨yield of bone scintigraphy musculoskeletal pain￨initial radiographs of symptomatic sites showed lytic or blastic bone abnormalities suggestive of malignancy in 16 59 of the 29 older patients in whom this diagnosis was confirmed￨no diff￨highunclear￨highunclear￨highunclear
1172￨patients presenting to primary care settings with acute low back pain 1172 consecutive patients receiving primary care for acute low back pain was recruited from primary care clinics in sydney australia patients presenting to a primary care provider with back pain previously undiagnosed serious pathology is rare￨￨￨despite the low prevalence of serious pathology most patients 804 had at least 1 red flag median 2 interquartile range 13￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with a chief complaint of back pain back pain patients￨￨erythrocyte sedimentation rate esr and anemia back pain￨findings significantly associated with underlying cancer p less than 005 were age greater than or equal to 50 years previous history of cancer duration of pain greater than 1 month failure to improve with conservative therapy elevated erythrocyte sedimentation rate esr and anemia￨no diff￨highunclear￨highunclear￨highunclear
621￨621 walkin patients with lbp primary care￨￨yield of explanatory xray findings low back pain lbp￨the yield of explanatory xray findings was over three times greater among patients with indications for radiography than among those without￨sig increase￨highunclear￨highunclear￨highunclear
117￨premature infants 117 preterm infants delivered before 34 weeks of gestation with birth weights less than 1500 g and perforated necrotizing enterocolitis at 15 pediatric centers to undergo preterm infants with perforated necrotizing enterocolitis preterm infants￨primary peritoneal drainage or laparotomy with bowel resection laparotomy versus peritoneal drainage primary peritoneal drainage with laparotomy and bowel resection￨dependence on parenteral nutrition 90 days postoperatively and length of hospital stay mean sd length of hospitalization total parenteral nutrition survival￨the type of operation performed for perforated necrotizing enterocolitis does not influence survival or other clinically important early outcomes in preterm infants￨no diff￨low￨low￨low
69￨extremely low birth weight elbw infants with intestinal perforation elbw infants with intestinal perforation inclusion criteria were birthweight or1000 g and pneumoperitoneum on xray necrotizing enterocolitis or isolated perforation sixtynine patients￨peritoneal drainage or laparotomy peritoneal drain or laparotomy httpisrctnorg primary peritoneal drainage primary peritoneal drainage required delayed laparotomy￨survival delayed laparotomy sixmonth survival 6month survival delayed laparotomy or died￨sixmonth survival was 1835 514 with a drain and 2133 636 with laparotomy p  03 difference 12 95 ci 11 34￨no diff￨low￨low￨low
not found￨patients with critical limb ischaemia undergoing polytetrafluoroethylene ptfe bypass to belowknee arteries 2010 european society for vascular surgery￨ptfe bypass vein collar or not in two groups  bypass to the popliteal artery belowknee femoropopliteal belowknee fempopbk and more distal bypass femorodistal bypass femdist elsevier ltd copyright c￨patency and limb salvage￨logranktest for the whole kaplanmeier life table curve showed no statistically significant differences with or without vein collar primary patency p  00853 p  0228 secondary patency p  0317 p  0280 limb salvage p  0757 p  0187 for fempopbk and femdist respectively￨no diff￨highunclear￨highunclear￨highunclear
89￨from january 281999 to november 1 2000 104 patients were enrolled in 10 north american centers patients with critical limb ischemia without saphenous vein infragenicular arterial bypass ninetyone bypasses were performed in 89 patients with a mean age of 73 years range 4790￨ptfe grafts with distal vein modification ptfe graft with vein cuff precuffed polytetrafluoroethylene graft to a vein cuffed polytetrafluoroethylene graft ptfe graft with distal vein modification￨secondary patency and limb salvage rates acute ischemia limb salvage rate primary patency operative mortality￨at 1 year and 2 years the limb salvage rate was 72 and 65 for the precuffed group and 75 and 62 in the vein cuffed group p  088￨no diff￨highunclear￨highunclear￨highunclear
not found￨eightyseven patients mf 231 undergoing 89 femorointrapopliteal bypass operations with eptfe grafts for critical limb ischaemia patients referred to two teaching hospital vascular surgery units in the uk for the treatment of critical limb ischaemia patients having femoroinfrapopliteal bypass with eptfe grants for critical limb ischaemia￨avf distal arteriovenous fistula control group without avf femoroinfrapopliteal bypass femoroinfrapopliteal ptfe bypass￨cumulative rates of primary patency and limb salvage graft patency and limb salvage rate graft patency or limb salvage￨the differences between the avf and control groups did not reach statistical significance in terms of either graft patency or limb salvage at any stage after operation logrank test￨no diff￨highunclear￨highunclear￨highunclear
36￨between 1996 and 2000 39 bypass grafting procedures in 36 patients were performed for limbthreatening ischemia patients with limbthreatening ischemia patients who need bypass grafting for limb salvage for limbthreatening ischemia￨spliced vein versus polytetrafluoroethylene graft with a distal vein cuff singlepiece vein option for bypass grafting adequate vein for splice no composite sequential option and limbthreatening ischemia spliced vein bypass grafting versus polytetrafluoroethylene grafting with a distal vein cuff anticoagulation therapy with warfarin sodium spliced vein bypass grafting spliced group 19 bypass grafts or polytetrafluoroethylene grafting with a distal vein cuff cuff group 20 bypass grafts spliced vein bypass grafting and polytetrafluoroethylene bypass grafting with a distal vein cuff￨limb salvage rates overall survival rate secondary patency rate primary patency rate need revision or reoperation for wound complications reoperation for wound complications￨the secondary patency rate was 87 and 59 p 05 with limb salvage rates of 94 and 85 for spliced and cuff groups respectively￨no diff￨highunclear￨highunclear￨highunclear
150￨one hundred fifty grafts were to the aboveknee popliteal artery 96 to the belowknee popliteal artery and 15 to tibial vessels two hundred sixtyone bypass operations were randomized 133 to vein cuff and 128 to no vein cuff￨cuffed and uncuffed aboveknee popliteal artery ptfe bypass grafts infrainguinal polytetrafluoroethylene bypass grafting with and without vein interposition cuff at the distal anastomosis interposition vein cuff improved the shortterm and mediumterm patency and limb salvage rates of femoralaboveknee and femoralbelowknee popliteal artery polytetrafluoroethylene ptfe bypass￨limb salvage rates 2year patency rates patency rates 12month patency rates patency rate distal anastomosis interposition vein cuff￨there was no improvement in the patency rate with the use of a distal anastomosis interposition vein cuff in femoralaboveknee popliteal ptfe bypass grafts but there was a statistically significant advantage when ptfe bypass grafts were anastomosed to the popliteal artery below the knee￨no diff￨highunclear￨highunclear￨highunclear
59￨59 patients with critical leg ischaemia and no suitable veins for grafting￨adjuvant avfistula avfistula group avfg femocrural ptfe bypass and distal vein cuff with or without an adjuvant avfistula￨mean postoperative anklebrachial index abi leg salvage patency rate￨the primary and secondary patency rate at 2 years was 29 and 40 for the avfg and 36 and 40 for the cg ns￨no diff￨highunclear￨highunclear￨highunclear
not found￨osteomyelitis thirty adults mean age 52 years￨ciprofloxacin antimicrobial therapies antimicrobial therapy oral ciprofloxacin therapy oral ciprofloxacin￨diarrhea treatment failure or relapse￨seven of 14 50 percent ciprofloxacintreated infections are cured at up to 13 months followup and three infections appear improved￨no diff￨highunclear￨highunclear￨highunclear
not found￨biopsyproven osteomyelitis caused by susceptible organisms￨ciprofloxacin oral ciprofloxacin broadspectrum cephalosporin or a nafcillinaminoglycoside combination parenteral antibiotics ciprofloxacin monotherapy￨adverse reactions clinical success rates persistent klebsiella pneumoniae infection￨our data indicate that oral ciprofloxacin monotherapy is as safe and effective as conventional parenteral therapy in cases of osteomyelitis caused by susceptible organisms￨no diff￨highunclear￨highunclear￨highunclear
19￨chronic osteomyelitis￨oral ofloxacin ceftazidime oral ofloxacin parenteral agents cefazolin ofloxacin parenteral antibiotics ofloxacin￨tolerated￨oral ofloxacin appears comparable to parenteral antibiotics in chronic osteomyelitis due to susceptible organisms and oral ofloxacin offers advantages in economics and convenience￨sig increase￨highunclear￨highunclear￨highunclear
not found￨fourteen patients who had chronic osteomyelitis twelve patients of similar age who had chronic osteomyelitis and received chronic osteomyelitis in adults￨ciprofloxacin standard parenteral antibiotic therapy oral ciprofloxacin oral ciprofloxacin standard parenteral antibiotic therapy consisting of nafcillin clindamycin and gentamicin singly or in combination￨average duration of antibiotic therapy￨oral administration of ciprofloxacin was as effective and safe as parenteral therapy for the treatment of osteomyelitis in these adults￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with chronic staphylococcal osteomyelitis￨nafcillin alone with nafcillin plus rifampin nafcillin therapy and nafcillinrifampin therapy￨mild neutropenia favorable clinical response toxicity chronic osteomyelitis￨eight of ten patients in the combined treatment group had a favorable clinical response with followup of two to four years as compared to four of eight in the nafcillin group p  2￨sig increase￨highunclear￨highunclear￨highunclear
not found￨chronic osteomyelitis twentyseven patients had documented infections with quinolonesensitive organisms and received either￨fluoroquinolones lomefloxacin levofloxacin and ciprofloxacin levofloxacin ciprofloxacin lomefloxacin lomefloxacin levofloxacin or ciprofloxacin ciprofloxacin lomefloxacin or levofloxacin oral fluoroquinolones￨grampositive bacteria efficacy and safety￨lomefloxacin was effective therapy for five of seven 71 patients and ciprofloxacin was effective therapy for two of five patients 40￨sig increase￨highunclear￨highunclear￨highunclear
18￨osteomyelitis caused by gramnegative bacilli 18 patients 17 males 1 female with gramnegative osteomyelitis￨tobramycin ceftazidime ceftazidime tobramycin and ticarcillin ceftazidime or ticarcillin and tobramycin￨serum glutamic oxalacetic transaminase and serum glutamic pyruvic transaminase efficacy and safety￨all nine patients receiving tobramycin and ticarcillin had the osteomyelitis arrested after the initial treatment￨no diff￨highunclear￨highunclear￨highunclear
not found￨hospitalized patients with diagnosis of chronic osteomyelitis and isolation of susceptible organisms to thirtytwo patients were enrolled 16 in each group￨oral ofloxacin imipenemcilastatin ofloxacin imipenemcilastatin ofloxacin and imipenemcilastatin ofloxacin￨efficacy and tolerance￨our trial suggests that oral ofloxacin is as effective as parenteral therapy with betalactam antibiotics in the treatment of osteomyelitis which could allow a reduction of the period of hospitalization and economic costs￨sig increase￨highunclear￨highunclear￨highunclear
282￨282 subjects 55 completed the 12 months study opiumdependent subjects in iran over a treatment period of 12 months￨opiumdependent individuals who met the dsmiv criteria for opioid dependence and were seeking treatment buprenorphine￨completion rates￨completion rates by dosage group were 46 269 for the 1 mg dose group 102 596 for the 3 mg dose group and 134 784 for the 8 mg dose group p 000￨no diff￨highunclear￨highunclear￨highunclear
40￨a total of 40 opioiddependent patients were detoxified opioid dependence￨baclofen placebo baclofen￨opioids and alcohol use according to urinalysis and selfreport ratings intensity of opioid craving assessed with a visual analogue scale opioid withdrawal symptoms as measured by the short opiate withdrawal scale and depression scores on the hamilton inventory opiate withdrawal syndrome and depressive symptoms intensity of opioid craving and selfreported opioid and alcohol use rates of opioidpositive urine tests treatment retention retention in treatment￨nonsignificant but generally favorable responses were seen in the baclofen group with other outcome measures including intensity of opioid craving and selfreported opioid and alcohol use￨no diff￨low￨low￨low
141￨141 patients in a careoftheelderly unit who were assessed to have a high risk of developing pressure ulcers using the waterlow score were recruited 70 were nursed using￨extra pressurerelieving equipment huntleigh nimbus 3 in conjunction with the aura cushion group a and 71 using the pegasus cairwave therapy system in conjunction with the proactive 2 seating cushion pressurerelieving systems￨average length of stay heel ulcers incidence of hospitalacquired pressure ulcers￨there were three main findings for nonheel ulcers and overall improvement there was no statistically significant difference between the two products tested for heel ulcers there was a significant difference p  0019 with more patients healing in group a than in group b￨no diff￨highunclear￨highunclear￨highunclear
20￨twenty patients aged 916 years with skeletal anterior open bite￨acrylic posterior biteblocks posterior repelling magnet splints￨dental and skeletal vertical relationships￨the patients who wore acrylic posterior biteblocks also showed improvement in the dental and skeletal vertical relationships especially during the first months￨sig increase￨highunclear￨highunclear￨highunclear
40￨angle class i skeletal anterior open bite malocclusion forty turkish children 26 girls and 14 boys with angle class i skeletal anterior open bite￨fränkels function regulator fr4 appliance frankels function regulator fr4 therapy lipseal training and the fr4 appliance￨spontaneous downward and backward growth direction￨the results indicate that a spontaneous downward and backward growth direction of the mandible observed in the control group could be changed to a upward and forward direction by fr4 therapy￨sig increase￨highunclear￨highunclear￨highunclear
30￨30 patients aged 4674 with the onset of symptoms within 36 h were enrolled into the study after appropriate screening acute stroke patients￨acupuncture acupuncture conventional supportive treatment￨dizziness neurologic status neurologic outcome￨a significantly better neurologic outcome was observed in the acupuncture group on day 28 and day 90￨sig increase￨highunclear￨highunclear￨highunclear
78￨78 patients with severe hemiparesis of the left or right side within 10 days of stroke onset 40 to a stroke patients￨acupuncture control group receiving daily physiotherapy and occupational therapy sensory stimulation acupuncture￨balance mobility adl ql and days spent at hospitalsnursing homes motor function balance and adl barthels index quality of life ql￨patients given sensory stimulation recovered faster and to a larger extent than the controls with a significant difference for balance mobility adl ql and days spent at hospitalsnursing homes￨sig increase￨highunclear￨highunclear￨highunclear
104￨one hundred four consecutive patients acute stroke patients 40 years of age admitted to hospital because of an acute stroke stroke patients￨acupuncture treatment conventional stroke rehabilitation acupuncture electroacupuncture￨daily life activities and quality of life mobility problems stroke patients ability to perform daily life activities their healthrelated quality of life and their use of health care and social services neurological score and the barthel and sunnaas activities of daily living index scores health care and social services￨there were no differences between the groups with reference to changes in the neurological score and the barthel and sunnaas activities of daily living index scores after 3 and 12 months￨no diff￨highunclear￨highunclear￨highunclear
106￨one hundred six chinese patients with moderate or severe functional impairment stroke rehabilitation unit in hong kong￨acupuncture traditional chinese manual acupuncture acupuncture control arm receiving standard modalities of treatment which included physiotherapy occupational and speech therapy and skilled medical and nursing care and the intervention arm receiving in addition traditional chinese manual acupuncture￨fuglmeyer assessment barthel index and functional independence measure respectively at weeks 0 5 and 10 performed by blinded assessors￨no statistically significant differences were observed between the 2 arms for any of the outcome measures at week 10 or outcome changes over time￨no diff￨highunclear￨highunclear￨highunclear
150￨stroke rehabilitation 7 university and district hospitals in sweden 150 patients with moderate or severe functional impairment were included￨acupuncture and transcutaneous electrical nerve stimulation subliminal electrostimulation acupuncture acupuncture or transcutaneous electrical nerve stimulation with muscle contractions acupuncture and transcutaneous nerve stimulation acupuncture including electroacupuncture b sensory stimulation with highintensity lowfrequency transcutaneous electrical nerve stimulation that induces muscle contractions and c lowintensity subliminal highfrequency electrostimulation control group￨functional outcome or life satisfaction functional outcome and quality of life motor function activities of daily living function walking ability social activities and life satisfaction at 3month and 1year followup￨at 3month and 1year followups no clinically important or statistically significant differences were observed between groups for any of the outcome variables￨no diff￨highunclear￨highunclear￨highunclear
15￨patients with osteosarcoma primary osteosarcoma two patients who failed mtxcf and requested alternative treatment with i fifteen patients￨mtxcf intraarterial cisdiamminedichloroplatinum ii iacdp and highdose methotrexate with citrovorum factor rescue mtxcf intraarterial cisdiamminedichloroplatinum ii with highdose methotrexate and citrovorum factor rescue￨clinical radiographic angiographic and pathologic parameters￨in the mtxcf arm there were four responses three complete responses one partial response whereas in the ia cdp arm there were nine responses seven complete responses two partial responses￨no diff￨highunclear￨highunclear￨highunclear
not found￨n  38 in postpartum patients who had moderate to severe pain after episiotomy￨placebo acetaminophen ibuprofen and acetaminophen ibuprofen ibuprofen￨relative analgesic efficacy adverse effects pain intensity difference total pain relief and reduction of pain relief of postpartum episiotomy pain pain severity and relief on categorical scales￨ibuprofen 400 mg was more effective than acetaminophen 1000 mg for the sum of pain intensity difference total pain relief and reduction of pain by more than 50 p less than 05 suggesting a more rapid onset of action and a more prolonged effect by ibuprofen 400 mg￨sig increase￨highunclear￨highunclear￨highunclear
500￨patients with moderate to severe postpartum pain 500 postpartum patients experiencing moderate to severe pain a single oral dose of an￨aspirincaffeine combination 800 mg aspirin 65 mg caffeine placebo acetaminophen acetaminophen alone 1000 mg acetaminophen acetaminophenaspirin combination aspirincaffeine acetaminophen 648 mg aspirin acetaminophenaspirin aspirincaffeine combination versus acetaminophenaspirin combination versus acetaminophen versus placebo caffeine￨pain relief adverse reactions￨at 3 and 4 hours the acetaminophenaspirin combination as well as the aspirincaffeine combination were significantly superior to acetaminophen alone￨sig increase￨highunclear￨highunclear￨highunclear
not found￨two hundred female inpatients who had severe pain associated with a recent episiotomy procedure￨acetaminophen analgesia acetaminophen plus 60 mg phenyltoloxamine citrate placebo antihistamine phenyltoloxamine acetaminophen alone acetaminophen phenyltoloxamine￨analgesic activity analgesia spid total and global ratings￨the combination was significantly superior to acetaminophen alone for all analgesic measures including spid total and global ratings￨sig increase￨highunclear￨highunclear￨highunclear
not found￨pain after episiotomy￨placebo paracetamol and placebo ibuprofen ibuprofen paracetamol￨visual analogic scale a verbal scale and pain relief scores lower pain score abdominal pain pain relief relief of postepisiotomy pain pain intensity quality of pain relief pain score￨ibuprofen was more effective after one hour than either of the other two drugs whatever the scale or parameter used￨sig increase￨highunclear￨highunclear￨highunclear
53￨fiftythree depressed patients chronic pain forty subjects 20 with fluoxetine and 20 with￨fluvoxamine fluoxetine fluoxetine and 100 mgdie of fluvoxamine action ssri selective serotonine reuptake inhibitors fluoxetine vs fluvoxamine fluoxetine￨level of analgesia neuropathic component of pain intensity and quality of pain quid and depressionanxiety symptoms with the hamilton rating scale hamd intensity and overall quality of pain deteriorated pain depressive symptoms analgesic profile and the quality global or neuropathic of pain analgesic efficacy￨the intensity and overall quality of pain deteriorated at day 14 in the fluvoxamine group and improved in those treated with fluoxetine￨sig decrease￨highunclear￨highunclear￨highunclear
3￨painful diabetic neuropathy patients who did not improve on gabapentin monotherapy and then received painful diabetic neuropathy in patients whose pain did not improve with gabapentin monotherapy￨gabapentin placebo gabapentin monotherapy gabapentin and venlafaxine gabapentin plus venlafaxine with gabapentin plus placebo gabapentin plus venlafaxine gabapentin venlafaxine gabapentin and venlafaxine gabapentin plus placebo￨quality of life and mood disturbance pain reduction mood disturbance and quality of life pain reduction safety and efficacy￨1 gabapentintreated patients showed statistically significant improvement in pain reduction as well as improvement in quality of life and mood disturbance when compared with placebotreated patients￨sig increase￨low￨low￨low
not found￨diabetic neuropathy patients with painful diabetic polyneuropathy￨nortriptyline and fluphenazine nortriptylinefluphenazine combination￨significant relief of both pain and paresthesia relief of pain or paresthesia￨significant relief of both pain and paresthesia was obtained with this combination￨sig decrease￨highunclear￨highunclear￨highunclear
24￨treating postherpetic neuralgia 24 patients postherpetic neuralgia￨placebo nortriptyline amitriptyline amitriptyline￨median blood level excellent pain relief￨we found good to excellent pain relief in 16 of 24 patients p less than or equal to 0001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨diabetic neuropathy symptoms nineteen patients completed the study￨clomipramine vs desipramine vs placebo desipramine clomipramine plus desmethylclomipramine placebo imipramine clomipramine day1 and 200 mg desipramine clomipramine plus desmethylclomipramine clomipramine clomipramine and desipramine clomipramine￨diabetic neuropathy symptoms side effect ratings symptoms of neuropathy plasma concentrations desipramine levels plasma concentration￨both clomipramine and desipramine significantly reduced the symptoms of neuropathy as measured by observer and self rating in comparison with placebo￨no diff￨highunclear￨highunclear￨highunclear
12￨painful diabetic neuropathy twelve patients with severe painful diabetic neuropathy in the lower extremities￨imipramine imipramine and placebo placebo imipramine￨pain paresthesia dysesthesia numbness and nocturnal aggravation plasma levels of imipramine and its metabolite desipramine￨the plasma levels of imipramine and its metabolite desipramine were significantly higher in patients who benefited from imipramine treatment￨sig increase￨highunclear￨highunclear￨highunclear
not found￨severe pain groups of patients of either sex with pain indication of trigeminal neuralgia tension headache or postherpatic neuralgia received doses of￨clomipramine clomipramine or amitriptyline clomipramine and amitriptyline clomipramine amitriptyline￨depression and anxiety level tolerated￨the results after three months of treatment showed that clomipramine 1 was better than amitriptyline in treating trigeminal neuralgia 2 tended to be better in the treatment of tension headache and 3 amitriptyline is better in treating postherpatic neuralgia￨sig increase￨highunclear￨highunclear￨highunclear
37￨painful polyneuropathy in diabetics and nondiabetics thirtyseven patients with diabetic and nondiabetic painful polyneuropathy diabetic and nondiabetic patients￨placebo amitriptyline and maprotiline maprotiline amitriptyline maprotiline and placebo amitriptyline amitriptyline￨adverse side effects pain daily ratings of pain intensity on a 10step verbal scale 0  no pain and 10  worst thinkable pain pain and depression polyneuropathy pain particular pain quality severe side effects global rating of the analgesic effect on a 5step verbal scale pain relief scale pain relief reduced pain pain mean values of pain reduction 10step verbal scale pain reduction plasma concentration comprehensive psychopathological rating scale cprs global rating of pain relief mean values of the daily ratings of pain intensity depression￨amitriptyline was slightly better than maprotiline p  05 tested by repeated measures analysis of variance anova￨sig increase￨highunclear￨highunclear￨highunclear
not found￨15 patients could be included in the statistical analysis￨imipramine placebo citalopram selective serotonin reuptake inhibitor citalopram citalopram￨steadystate plasma concentration side effects nausea and vomiting or gastric upset and diarrhea tolerated sideeffect ratings symptoms of neuropathy plasma concentration of citalopram diabetic neuropathy symptoms￨citalopram significantly relieved the symptoms of neuropathy as measured by both observer and selfrating in comparison with placebo￨sig increase￨highunclear￨highunclear￨highunclear
not found￨18 patients in a doubleblind crossover study with￨imipramine placebo placebo mianserin and imipramine mianserin tricyclic antidepressant mianserin imipramine plus desipramine mianserin￨symptoms of neuropathy￨the mianserin plus desmethylmianserin plasma concentration ranged from 85 to 850 nmoll1 with the highest concentration in a patient who was a poor metabolizer of both sparteine and mephenytoin￨no diff￨highunclear￨highunclear￨highunclear
30￨atypical facial pain thirty patients suffering from chronic pain who had been diagnosed with afp after a thorough clinical examination were recruited twenty patients completed the trial atypical facial pain afp￨placebo venlafaxine antidepressant venlafaxine a serotonin and a weak noradrenaline reuptake inhibitor venlafaxine￨anxiety depression and adverse effects pain intensity reduction pain relief serum concentration pain intensity and pain relief escape medication venous blood samples anxiety and depression scores adverse effects￨there was no significant difference in pain intensity reduction between the maximum tolerated dose of venlafaxine 75 mg in most cases and the placebo￨no diff￨highunclear￨highunclear￨highunclear
40￨forty patients were assigned to one of the treatment sequences and 29 completed all three study periods painful polyneuropathy￨imipramine placebo tricyclic antidepressants tca venlafaxine tca imipramine venlafaxine 225 mg and imipramine venlafaxine￨rated pain paroxysms constant pain and touch and pressureevoked pain by use of 0 to 10point numeric rating scales touchevoked pain individual pain scores for pain paroxysms constant pain and pressureevoked pain pain relief individual pain scores￨the sum of the individual pain scores during treatment week 4 was lower on venlafaxine 80 of baseline score p  0006 and imipramine 77 p  0001 than on placebo 100 and did not show any statistical difference between venlafaxine and imipramine p  044￨sig decrease￨low￨low￨low
25￨painful diabetic neuropathy twentyfive typeii diabetic patients with pain attributed to diabetic neuropathy and a minimum score of 2 on a pain intensity scale ranging from 0 no pain to 4 excruciating pain all 25 patients completed the trial￨gabapentin amitriptyline monotherapy gabapentin titrated from 1200 mgday to a maximum of 2400 mgday or amitriptyline gabapentin gabapentin vs amitriptyline amitriptyline￨pain reductions adverse events paresthesia scores pain and paresthesia associated with diabetic neuropathy efficacy and tolerability weekly pain intensity and paresthesia intensity measured on two categorical scales￨gabapentin produced greater pain reductions than amitriptyline mean final scores were 19 vs 13 points below baseline scores p  0026￨sig increase￨highunclear￨highunclear￨highunclear
54￨fortyseven patients  18 diabetics and 29 nondiabetics  completed the study￨tricyclic antidepressants placebo￨individual pain ratings rated constant pain lancinating pain paroxysms touchevoked pain and pain on pressure by use of 010 point numeric rating scales pain in polyneuropathy complete good or moderate pain relief lower total pain score painful polyneuropathy￨none of the individual pain ratings were significantly changed by st johns wort as compared to placebo p009033￨no diff￨highunclear￨highunclear￨highunclear
28￨28 patients with chronic oralfacial pain two patients had mixed elements of neurogenic and musculoskeletal pain￨placebo amitriptyline amitriptyline￨depression scores pain patients ratings of the intensity of experimental heat stimuli hamilton depression scores amitriptyline reduced pain musculoskeletal pain pain reduction chronic facial pain￨amitriptyline reduced the depression scores in the depressed group but had no effect on the depression scores in the nondepressed group￨sig decrease￨highunclear￨highunclear￨highunclear
250￨persons infected with the human immunodeficiency virus hiv patients with hivassociated symptomatic lowerextremity peripheral neuropathy pain due to hivrelated peripheral neuropathy pain due to hivrelated peripheral neuropathy in hivinfected patients 250 patients enrolled 239 were in the acupuncture comparison 125 in the factorial option and 114 in the sar option vs control points option and 136 patients were in the amitriptyline comparison 125 in the factorial option and 11 in 10 us cities￨standardized acupuncture regimen vs control points amitriptyline placebo sar amitriptyline or the combination compared with placebo acupuncture and amitriptyline amitriptyline option vs placebo standardized acupuncture regimen sar and amitriptyline hydrochloride amitriptyline vs placebo amitriptyline￨pain scale pain reduction relieving pain mean pain scores pain score￨for both the acupuncture and amitriptyline comparisons changes in pain score were not significantly different between the 2 groups￨no diff￨low￨low￨low
16￨cancer patients with neuropathic pain patients with neuropathic cancer pain patients on morphine therapy sixteen advanced cancer patients with neuropathic pain on systemic morphine therapy no longer receiving oncologic treatment presenting moderate pain about 4 or more but less than 7￨amitriptyline or equivalent drops of placebo placebo amitriptyline amitriptyline￨drowsiness confusion and dry mouth spitzers quality of life score worst pain neuropathic cancer pain analgesia global pain intensity adverse effects least pain intensity or the pain opioid consumption pain intensity symptoms and adverse effects mood sleep patients preference quality of life analgesic effects￨there were no substantial differences between the two treatments in spitzers quality of life score and for each item￨no diff￨highunclear￨highunclear￨highunclear
13￨thirteen patients were analysed breast cancer￨placebo venlafaxine and inactive placebo venlafaxine amitriptyline venlafaxine￨anxiety and depression average daily pain intensity pain intensity and pain relief number of tablets pain relief anxiety and depression average pain relief diary and the maximum pain intensity venlafaxine concentrations and excellent pain relief venous blood samples low venlafaxine concentrations neuropathic pain pain anticholinergic effects adverse effects￨the average daily pain intensity as reported in the diary primary outcome was not significantly reduced by venlafaxine compared with placebo￨no diff￨highunclear￨highunclear￨highunclear
not found￨dysesthetic pain in traumatic myelopathy￨placebo trazodone hydrochloride trazodone trazodone hydrochlorideday or placebo trazodone hydrochloride￨neurologic examination and assessment of side effects mcgill pain questionnaire sternbach pain intensity scale and zung pain and distress index side effects pain measures dysesthetic pain pain quality and intensity￨no significant changes were noted in reported pain measures between patients allocated to the active drug group and those given placebo during the course of the protocol￨no diff￨highunclear￨highunclear￨highunclear
49￨10 to 20 percent of people with from herpes zoster shingles 49 patients with phn postherpetic neuralgia￨placebo amitriptyline and fluphenazine amitriptyline and fluphenazine fluphenazine postherpetic neuralgia phn amitriptyline￨pain visual analog scales vas the mcgill pain questionnaire mpq and a sideeffects scale￨a statistically significant decrease was seen in pain in groups 1 and 2 and no significant changes were seen in groups 3 and 4￨no diff￨highunclear￨highunclear￨highunclear
59￨fiftynine patients referred for painful diabetic neuropathy of the lower extremities￨imipramine hydrochloride or amitriptyline hydrochloride imipramine or amitriptyline￨complete remission of lower extremity pains depression and return of depression test scores substantial degrees of depression during psychiatric interview and by kupferdetre test scores￨treatment with imipramine hydrochloride or amitriptyline hydrochloride resulted in complete remission of lower extremity pains in all patients in 10￨sig increase￨highunclear￨highunclear￨highunclear
37￨burning mouth pain chronic burning mouth pain thirtyseven carefully selected women aged 39 to 71 mean 586 years￨trazodone placebo antidepressant trazodone trazodone￨dizziness and drowsiness relieve burning mouth pain pain or painrelated symptoms pain and painrelated symptoms￨there were no significant differences between the groups in treatment effects for pain or painrelated symptoms￨no diff￨low￨low￨low
not found￨central poststroke pain 39 patients in a placebocontrolled longterm study patients with acute thalamic stroke in preventing central poststroke pain thirtynine patients 23 women and 16 men age range 36 to 68 years with central poststroke pain participated￨placebo amitriptyline amitriptyline￨average se time to pain pain rate central poststroke pain￨the placebo group showed a pain rate of 21 within 1 year after the diagnosis of thalamic stroke compared with 17 in the group under prophylactic treatment with amitriptyline￨sig decrease￨highunclear￨highunclear￨highunclear
58￨58 patients with postherpetic neuralgia￨mean amitriptyline placebo lorazepam 05 to 6 mgd or lactose placebo lorazepam lorazepam amitriptyline amitriptyline￨postherpetic neuralgia serum tricyclic levels severe depressive reactions pain greater relief￨greater relief was associated with higher amitriptyline doses up to the maximum dose of 150 mgd and with higher serum tricyclic levels￨sig increase￨highunclear￨highunclear￨highunclear
not found￨seventytwo patients older than 60 years of age who received a diagnosis of herpes zoster hz elderly patients with acute herpes zoster postherpetic neuralgia with￨amitriptyline or placebo placebo amitriptyline￨pain prevalence pain prevalence￨results showed that early treatment with lowdose amitriptyline reduced pain prevalence by more than onehalf p  005 odds ratio 291￨sig decrease￨low￨low￨low
84￨persons with sci persons with spinal cord injury sci spinal cord injury persons with sci eightyfour participants with sci and chronic pain￨amitriptyline or an active placebo benztropine mesylate amitriptyline￨pain intensity or painrelated disability chronic pain chronic pain and improving painrelated physical and psychosocial dysfunction￨no significant differences were found between the groups in pain intensity or painrelated disability posttreatment in either intenttotreat analyses or analyses of study completers￨no diff￨low￨low￨low
57￨patients with painful diabetic neuropathy comparing pain in diabetic neuropathy in 46 patients fiftyseven patients￨desipramine placebo fluoxetine desipramine serotonin reuptake fluoxetine with placebo norepinephrine reuptake desipramine amitriptyline and fluoxetine fluoxetine and placebo norepinephrine reuptake desipramine amitriptyline and desipramine fluoxetine amitriptyline amitriptyline￨pain relief of pain pain relief globally￨the differences in responses between amitriptyline and desipramine and between fluoxetine and placebo were not statistically significant but both amitriptyline and desipramine were superior to placebo￨no diff￨highunclear￨highunclear￨highunclear
145￨painful neuropathy in hiv infection patients with hivassociated painful sensory neuropathy 145 patients assigned equally to￨placebo amitriptyline amitriptyline mexiletine or matching placebo amitriptyline and mexiletine amitriptyline or mexiletine mexiletine￨pain relief pain symptoms tolerated change in pain intensity between baseline and the final visit￨neither amitriptyline nor mexiletine provide significant pain relief in patients with hivassociated painful sensory neuropathy￨no diff￨low￨low￨low
76￨seventysix patients with bms diagnosed according to the criteria in the literature and integrating the diagnostic interview schedulerevised for a complete psychiatric assessment with no possible local or systemic causes and without concurrent major depression patients with bms burning mouth syndrome￨placebo paroxetine amisulpride sertraline serotonin reuptake inhibitors ssris paroxetine and sertraline amisulpride ssris and amisulpride￨vas hamd and hama scores and qualitative visual analogue scale vas for pain intensity the hamilton rating scale for depression hamd the hamilton rating scale for anxiety incidence of side effects serious adverse events burning mouth symptoms shorter response latency efficacy and tolerability clinical global impressions scale cgi￨all 3 treatment regimens resulted in a significant improvement from baseline in burning mouth symptoms at week 8 as demonstrated by the quantitative mean reduction in vas hamd and hama scores and qualitative percentage of responders analyses￨sig increase￨highunclear￨highunclear￨highunclear
33￨33 patients postherpetic neuralgia postherpetic neuralgia phn￨nortriptyline nt nortriptyline amitriptyline at amitriptyline￨pain relief intolerable side effects relief of steady brief or skin pain by visual analog scales for pain and pain relief mood disability satisfaction￨we found no difference with regard to relief of steady brief or skin pain by visual analog scales for pain and pain relief mood disability satisfaction or preference between the two drugs￨no diff￨highunclear￨highunclear￨highunclear
16￨diabetic neuropathy sixteen patients with severe dpn participated in the study patients with severe distal symmetrical predominantly sensitive diabetic polyneuropathy dpn￨placebo nortriptylinefluphenazine nf vs carbamazepine cmz nortriptylinefluphenazine vs carbamazepine cmz nf￨efficacy and tolerance pain or paresthesia pain and paresthesia hba1 fasting serum glucose and safety tests side effects￨no statistically significant differences were observed between both therapies for either pain or paresthesia￨no diff￨highunclear￨highunclear￨highunclear
35￨thirtyfive patients patients with postherpetic neuralgia phn postherpetic neuralgia￨maprotiline mt noradrenergic maprotiline amitriptyline at amitriptyline￨relief of steady pain brief pain and pain on tactile stimulation depression ratings￨side effects were troublesome with both agents￨no diff￨highunclear￨highunclear￨highunclear
48￨sixtyfive patients attending a pain relief clinic chronic pain￨amitriptyline alone distigmine alone amitriptyline and distigmine started together or addition of distigmine to preexisting treatment with amitriptyline amitriptyline and distigmine distigmine and amitriptyline distigmine distigmine amitriptyline￨pain and increased saliva flow pain pain and no subjectively noticeable mouth dryness saliva flow pain intensity pain and produced unpleasant mouth dryness￨distigmine alone also decreased pain and increased saliva flow sometimes to the point of discomfort whereas amitriptyline alone in this particular series did not significantly reduce pain and produced unpleasant mouth dryness￨sig increase￨highunclear￨highunclear￨highunclear
15￨15 patients with central poststroke pain cpsp but without signs of depression￨placebo carbamazepine carbamazepine amitriptyline and carbamazepine amitriptyline amitriptyline￨pain pain relief median total ami and nortriptyline concentrations effect and plasma concentration side effects global rating of the analgesic effect on a 5step verbal scale comprehensive psychopathological rating scale cprs daily ratings of pain intensity on a 10step verbal scale￨five of the 14 patients treated with carbamazepine reported some pain relief but the effect did not reach statistical significance when compared to placebo￨no diff￨highunclear￨highunclear￨highunclear
15￨breast cancer 15 patients￨placebo placebo and amitriptyline amitriptyline amitriptyline￨drug concentrations number of daily activities disturbed by the pain the finnish mcgill pain questionnaire adverse effects anxiety depression pressure threshold and grip strength adverse effects pain intensity visual analogue and verbal rating scales pain intensity and pain relief neuropathic pain￨the poor responders reported significantly more adverse effects with amitriptyline and placebo than the good responders￨sig increase￨highunclear￨highunclear￨highunclear
60￨neuropathic pain patients 60 patients with neuropathic pain for 8 weeks 55 patients completed the study￨venlafaxine xr placebo venlafaxine￨detection thresholds electrical and heat ongoing pain intensity vas patient satisfaction side effects global efficacy and tolerance allodynia and pinprick hyperalgesia pain intensity and escape medication pain threshold and the summation threshold to electrical stimuli and the summation threshold to heat stimuli degree of the temporal summation to electrical and heat stimuli vas scores pinprick hyperalgesia allodynia detection and pain thresholds to electrical and heat stimuli temporal summation of repetitive electrical and heat stimuli￨the areas of allodynia and pinprick hyperalgesia decreased significantly in venlafaxine groups compared to the placebo￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients with obvious cardiovascular disease not an uncommon problem in the  or  65 year age group patients with postherpetic neuralgia postherpetic neuralgia￨tricyclic antidepressants tramadol 600mg and clomipramine 100mg or clomipramine 100mg with or without levomepromazine tramadol clomipramine with or without levomepromazine clomipramine and levomepromazine neuroleptic levomepromazine clomipramine tramadol and clomipramine opioid therapy antidepressant clomipramine tramadol￨analgesic efficacy and tolerability incidence of adverse events average pain level of moderate to very severe sensitivity and depression parameters￨the incidence of adverse events for all patients was similar in both groups tramadol 765 clomipramine with or without levomepromazine 833￨no diff￨highunclear￨highunclear￨highunclear
21￨25 enrolled patients who completed the study patients with stable glycemic control and neuropathic pain twentyeight veterans were referred by their primary care providers diabetic peripheral neuropathy pain￨gabapentin gabapentin and amitriptyline amitriptyline hydrochloride gabapentin gabapentin with amitriptyline amitriptyline￨moderate or greater pain relief pain relief mean pain score and global pain score pain relief pain relief measured by pain scale with verbal descriptors and global pain score assessment neuropathic pain￨although both drugs provide pain relief mean pain score and global pain score data indicate no significant difference between gabapentin and amitriptyline￨no diff￨highunclear￨highunclear￨highunclear
45￨fortyfive patients were admitted to the study 27 with oncological peripheral nerve lesions 6 with post herpetic neuralgias 10 with not oncological nerve lesions 2 with central nervous lesions 23 patients were treated with chronic cancer pain with deafferentation component￨trazodone antidepressants antidepressant agents trazodone and amitriptyline amitriptyline and trazodone amitriptyline￨pain intensity hours of sleep hours standing and lying side effects mood anxiety weakness therapeutic analgesic efficacy￨the therapeutic analgesic efficacy of the two drugs proved to be similar￨no diff￨highunclear￨highunclear￨highunclear
100￨postmastectomy pain syndrome pmps 100 patients scheduled for either partial or postmastectomy pain syndrome￨venlafaxine xr acetaminophenoxycodone tablets pca morphine venlafaxine venlafaxine or placebo radical mastectomy with axillary dissection venlafaxine￨incidence of pmps axilla pain pain scores edema phantom pain or sensory changes postoperative opioid use incidence of chest wall pain phantom breast pain arm pain neuropathic pain￨there was a significant decrease in the incidence of chest wall pain 55 vs 19 p  00002 arm pain 45 vs 17 p  0003 and axilla pain 51 vs 19 p  00009 between the control group and the venlafaxine group respectively￨sig decrease￨highunclear￨highunclear￨highunclear
84￨￨placebo dothiepin dothiepin prothiaden￨pain relief psychogenic facial pain psychogenic facial pain pain free￨the results showed the superiority of dothiepin over placebo in achieving pain relief 71 of patients were pain free in the dothiepin group at nine weeks compared with 47 in the placebo group￨sig increase￨highunclear￨highunclear￨highunclear
244￨painful diabetic neuropathy patients with painful diabetic neuropathy 244 adult outpatients with metabolically stable type 1 or 2 diabetes with painful diabetic neuropathy￨venlafaxine er placebo venlafaxine er venlafaxine venlafaxine extendedrelease er venlafaxine￨clinically important ecg changes scores on the daily 100 mm visual analog pain intensity vaspi and pain relief vaspr scales baseline pain intensity clinical global impressionsseverity of illness and the clinical global impressionsimprovement patient global rating of pain relief and percentage of patients achieving 50 reduction in pain intensity mean vaspr scores nausea and somnolence efficacy and safety￨mean vaspr scores in the 150225 mg group were significantly greater than placebo at week 6 44 vs 60 mm p  0001￨sig increase￨low￨low￨low
235￨painful diabetic neuropathy two hundred thirtyfive patients patients with painful diabetic neuropathy involving the feet￨topical capsaicin topical capsaicin and oral amitriptyline capsaicintreated patients received inactive capsules and amitriptylinetreated patients applied vehicle cream topical capsaicin and oral amitriptyline capsaicin cream or amitriptyline capsules capsaicin amitriptyline￨interference with daily activities by pain systemic side effects pain status sleeping and walking pain systemic side effect visual analogue scale of pain intensity and measurements of interference by pain with functional activities safety and efficacy￨by the end of the study the interference with daily activities by pain had diminished significantly p  001 in both groups including improvements in sleeping and walking￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨diabetic neuropathy 9 patients￨imipramine placebo imipramine plus desipramine imipramine￨symptomatic peripheral diabetic neuropathy￨despite some adverse effects especially of an anticholinergic nature the patients generally preferred imipramine to placebo￨sig increase￨highunclear￨highunclear￨highunclear
41￨neuropathic pain￨bupropion sr bupropion sustainedrelease sr placebo bupropion sr or placebo￨interference of pain on quality of life dry mouth insomnia headache gastrointestinal upset tremor constipation and dizziness pain relief effective and well tolerated mean average pain score neuropathic pain relief￨side effects experienced with bupropion sr were not doselimiting and consisted primarily of dry mouth insomnia headache gastrointestinal upset tremor constipation and dizziness￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨imipramine paroxetine selective serotonin reuptake inhibitor paroxetine imipramine and placebo paroxetine imipramine plus desipramine￨symptoms in peripheral diabetic neuropathy side effects and no withdrawal symptoms peripheral nerve function depressive symptoms intolerable side effects plasma concentrations diabetic neuropathy symptoms symptoms of neuropathy withdrawal symptoms￨neither paroxetine nor imipramine caused changes in objective measures of peripheral nerve function￨no diff￨highunclear￨highunclear￨highunclear
52￨a group of patients referred to a multidisciplinary pain clinic for the management of chronic intractable pain for which no substantial organic cause could be demonstrated 52 patients entering the 12week trial 20 withdrew before completion chronic pain￨amitriptyline vs placebo amitriptyline￨pain global improvement￨subjective reports indicated a greater reduction in pain at 2 and 4 weeks on amitriptyline but no difference at 6 weeks￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients suffering from central pain central pain￨tricyclic antidepressants chlorimipramine and nortriptyline placebo tricyclic antidepressants￨efficacy and tolerability analgesic effect of tricyclic antidepressants￨the results clearly indicate the better analgesic effect of tricyclic antidepressants over placebo p less than 00001￨sig increase￨highunclear￨highunclear￨highunclear
76￨seventysix patients with phn fifty patients completed two periods and 44 patients completed all three postherpetic neuralgia￨placebo morphine 91 mg or methadone opioids versus antidepressants tricyclic antidepressants tca opioids and tca treatment periods opioid tca and placebo nortriptyline 89 mg or desipramine tca and placebo￨opioids and tca reduced pain pain intensity 0 to 10 scale pain relief 0 to 100 and cognitive function cognitive measure pain ratings pain relief pain with opioids￨more patients completing all three treatments preferred opioids 54 than tca 30 p  002￨sig increase￨low￨low￨low
not found￨pain in amputees thirtynine persons with amputationrelated pain lasting more than 6 months￨placebo active placebo benztropine mesylate amitriptyline￨initial pain scores primary outcomes average pain intensity and secondary outcome measures disability satisfaction with life handicap￨no significant differences were found between the treatment groups in outcome variables when controlling for initial pain scores￨no diff￨highunclear￨highunclear￨highunclear
26￨26 postherpetic neuralgia patients 6 weeks of treatment with￨desipramine placebo desipramine norepinephrine reuptake desipramine amitriptyline￨psychiatric interview pain relief pain relief postherpetic neuralgia￨nineteen patients completed both treatments 12 reported at least moderate relief with desipramine and two reported relief with placebo￨no diff￨highunclear￨highunclear￨highunclear
200￨chronic human neuropathic pain human chronic neuropathic pain 200 consenting adult patients￨doxepincapsaicin placebo doxepin capsaicin and doxepincapsaicin capsaicin doxepin 0025 capsaicin placebo doxepin capsaicin or doxepincapsaicin cream doxepin doxepin hydrochloride 0025 capsaicin and a combination of 3 3 doxepin and 0025 capsaicin placebo cream capsaicin doxepin hydrochloride capsaicin and a combination of both produces analgesia doxepin cream 13 capsaicin doxepin and capsaicin￨sensitivity and shooting pain daily basis overall pain shooting burning paraesthesia and numbness using a 010 visual analogue scale burning pain analgesic efficacy overall pain￨overall pain was significantly reduced by doxepin capsaicin and doxepincapsaicin to a similar extent￨sig increase￨highunclear￨highunclear￨highunclear
82￨48 patients with painful mono and polyneuropathies patients with painful mono and polyneuropathies 82 patients with chronic pain resulting from mononeuropathy were treated with￨clomipramine anafranil psychotropic drugs acetylsalicylic acid clomipramine￨￨it seems possible that clomipramine activates serotonincontaining neurons of the endorphinmediated analgesia system that control pain transmission in the cns￨sig increase￨highunclear￨highunclear￨highunclear
20￨painful diabetic neuropathy 20 patients with painful diabetic neuropathy￨desipramine placebo desipramine norepinephrine reuptake desipramine amitriptyline active placebo amitriptyline￨pain pain relief￨pain relief tended to be greater in depressed patients but relief was also observed in patients who did not show an antidepressant effect￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with op poisoning patients with organophosphorous pesticide op poisoning 97 years and 27 acute organophosphorous pesticide poisoning￨nahco3 sodium bicarbonate bicarbonate sodium bicarbonate nahco3￨arterial blood ph hospitalization days￨hospitalization days were statistically higher p  0037 in the controls 559￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨16 patients was treated with 10 mg￨individual neuroleptic treatment haloperidol individual haloperidol￨extrapyramidal side effects￨a superiority of the individually adapted treatment over standardized treatment could be demonstrated neither for the therapeutic target parameters nor for the side effect variables￨no diff￨highunclear￨highunclear￨highunclear
63￨63 acutely ill schizophrenic patients newly admitted to the hospital acute schizophrenic patients￨haloperidol haloperidol￨serious adverse reactions therapeutic efficacy￨haloperidol was well tolerated by the patients there were no serious adverse reactions￨no diff￨highunclear￨highunclear￨highunclear
40￨all patients were classified as being thought disordered or nonthought disordered schizophrenic using psychometric methods 40 patients two groups 40 acutely ill schizophrenic patients￨liquid haloperidol daily the other group 16 mg of liquid haloperidol daily haloperidol￨￨on 5 days during the 21day treatment the psychopathological state of the patient was evaluated by means of the amdp system￨sig decrease￨highunclear￨highunclear￨highunclear
106￨106 patients with schizophrenia or schizoaffective disorder research diagnostic criteria acute schizophrenia 58 patients exposed only to nt dosages of￨neuroleptic threshold nt doses of haloperidol haloperidol neuroleptic￨distressing extrapyramidal side effects hostility￨higher dosages given to 47 patients did not lead to greater improvement in measures of psychosis but did produce slightly greater declines in measures of hostility￨no diff￨highunclear￨highunclear￨highunclear
87￨eightyseven newly admitted inpatients with schizophrenia￨oral haloperidol haloperidol￨side effects side effects￨side effects were minimal in all three treatment groups and there were no differences in side effects among the groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨acute schizophrenic patients￨haloperidol hl￨hl plasma level hl steadystate plasma levels and clinical improvement hl steadystate levels and clinical improvement extrapyramidal effects haloperidol plasma level clinical improvement￨no difference in clinical improvement was observed between the two groups as a whole although the highdose group had a faster initial improvement￨no diff￨highunclear￨highunclear￨highunclear
24￨24 psychotic patients￨haloperidol￨￨doses of 4 mgday of haloperidol appear to be as effective as higher doses in the treatment of psychosis￨sig increase￨highunclear￨highunclear￨highunclear
95￨95 acutely psychotic patients acute psychosis with reassignment of initial nonresponders￨haloperidol hpdl haloperidol plasma levels￨plasma levels￨there were no significant differences in clinical outcome between the three plasma level ranges in phase a￨no diff￨highunclear￨highunclear￨highunclear
22￨22 patients with firstepisode schizophrenia￨haloperidol￨likelihood of clinical response hyperprolactinemia and extrapyramidal side effects d2 occupancy wide range of d2 occupancy d2 receptor occupancy was determined with 11craclopride and positron emission tomography and clinical response extrapyramidal side effects and prolactin levels hyperprolactinemia and extrapyramidal side effects￨the degree of receptor occupancy predicted clinical improvement hyperprolactinemia and extrapyramidal side effects￨sig increase￨highunclear￨highunclear￨highunclear
not found￨schizophrenic patients with acute exacerbation and drug levels twentytwo schizophrenic inpatients schizophrenia￨haloperidol haloperidol￨brief psychiatric rating scale extrapyramidal symptoms￨patients with high levels improve to a lesser extent or even worsen in negative symptoms showing a nonstatistically significant trend to present more extrapyramidal symptoms￨no diff￨highunclear￨highunclear￨highunclear
not found￨acutely psychotic inpatients with relatively good prognoses twenty acutely psychotic male psychiatric inpatients￨haloperidol high and lowdose haloperidol￨acute psychotic symptoms degree or rapidity of symptom alleviation￨both groups improved at one hour one day and seven days after starting treatment and neither group differed as to degree or rapidity of symptom alleviation￨no diff￨highunclear￨highunclear￨highunclear
65￨schizophrenia and schizoaffective disorder 65 patients with acutely exacerbated schizophrenia or schizoaffective disorder￨haloperidol haloperidol￨antipsychotic efficacy plasma levels plasma haloperidol levels￨for most patients plasma levels not exceeding 12 ngml yield the best results in the first 3 weeks of treatment￨no diff￨highunclear￨highunclear￨highunclear
24￨twentyfour patients mean age 1217￨glucocorticosteroids h1antihistamines  intranasal glucocorticosteroids h1antihistamine loratadine  intranasal glucocorticosteroid mometasone furoate intranasal glucocorticosteroids h1antihistamine  intranasal glucocorticosteroid intranasal glucocorticosteroid mometasone furoate￨number of eosinophils in both nasal smear and biopsy total symptom score furthermore npif and nasal biopsy findings daytime eye symptoms score npif values subjective parameters daytime nasal symptoms score daytime eye symptoms score and nighttime symptoms score and objective parameters nasal smear nasal peak inspiratory flow npif and nasal biopsy daytime nasal symptoms score nighttime symptoms score￨however there was a significant improvement in nighttime symptoms score between groups i and ii p  001 versus p  005￨sig decrease￨highunclear￨highunclear￨highunclear
487￨487 households 242 placebo and 245 zanamivir were enrolled with 1291 contacts randomly assigned to receive once a person with a suspected case of influenza was identified index patient treatment of all other household members contacts  or 5 years old was initiated￨zanamivir placebo prophylaxis inhaled zanamivir zanamivir prophylaxis zanamivir zanamivir or placebo￨protective efficacy protective efficacy tolerated￨zanamivir was well tolerated and was effective in preventing influenza types a and b within households where the index patient was not treated￨no diff￨highunclear￨low￨low
184￨eligible patients were children 9 years of age and under who had febrile influenza symptoms of no more than 36h duration children with oseltamivirresistant influenza a h1n1 virus infection 184 patients 61 61 and 62 in the 40mg group 20mg group and oseltamivir group respectively children with influenza virus infection￨laninamivir octanoate oseltamivir group longacting neuraminidase inhibitor laninamivir octanoate with oseltamivir longacting neuraminidase inhibitor laninamivir octanoate cs8958 versus oseltamivir oseltamivir laninamivir 40mg group a group given 20 mg laninamivir￨tolerated time to alleviation of influenza illness median time to illness alleviation￨laninamivir octanoate markedly reduced the median time to illness alleviation in comparison with oseltamivir in patients infected with oseltamivirresistant influenza a h1n1 virus and the reductions were 609 h for the 40mg group and 662 h for the 20mg group￨sig decrease￨low￨low￨low
408￨children with influenza a infection children 13 years of age 408 randomized children who received the study drug oseltamivir 203 and placebo 205 98 had laboratoryconfirmed influenza influenza a 79 and influenza b 19 children 13 years of age with laboratoryconfirmed influenza during the seasons of 20072008 and 20082009 eligible children￨oseltamivir suspension or a matching placebo oseltamivir placebo oseltamivir￨incidence of acute otitis media median time to resolution of illness parental work absenteeism￨among children with influenza a oseltamivir treatment started within 24 hours shortened the median time to resolution of illness by 35 days 30 vs 65 days p  006 in all children and by 40 days 34 vs 73 p  006 in unvaccinated children and reduced parental work absenteeism by 30 days￨sig decrease￨low￨low￨low
471￨children five to twelve years of age children 5 to 12 years of age parallel group multicenter study conducted in the northern hemisphere during the 1998 and 1999 influenza season enrolled 471 patients with influenzalike symptoms for  or  36 h patients￨zanamivir placebo zanamivir￨relief medications symptomatic influenza a and b viral infections normal activities efficacy safety and tolerability median time to symptom alleviation influenzapositive by culture serology or polymerase chain reaction influenza infection rates￨zanamivirtreated patients returned to normal activities significantly faster and took significantly fewer relief medications than placebotreated patients￨sig decrease￨low￨low￨low
277￨277 households with 298 index cases 62 with laboratoryconfirmed influenza and 812 contacts aged  or 1 year ill index cases with influenza in households￨oseltamivir oseltamivir treatment with or without postexposure prophylaxis postexposure prophylaxis pep pep￨protective efficacy￨pep of household contacts of those with influenza reduces the secondary spread of influenza in families when the initial household case is treated￨sig decrease￨highunclear￨highunclear￨highunclear
179￨asthmatic children 612 years of age asthmatic children adults and children influenzainfected children with asthma￨placebo oral oseltamivir oseltamivir oseltamivir tamiflu oseltamivir￨time to freedom from illness forced expiratory volume asthma exacerbations area under the symptom scorehour curve the proportion of patients with asthma exacerbations and changes in forced expiratory volume pulmonary function safe and welltolerated exacerbation frequency￨oseltamivirtreated patients also experienced fewer asthma exacerbations up to day 7 68 versus 51 p  0031￨sig increase￨highunclear￨highunclear￨highunclear
51￨fiftyone patients with clinical and urodynamic diagnoses of stress urinary incontinence￨suprapubic versus transurethral bladder drainage suprapubic n  24 or transurethral n  27 bladder drainage after vaginal surgery suprapubic bladder drainage￨length of hospitalization postoperative normal bladder functions febrile morbidity￨postoperative use of suprapubic bladder drainage significantly reduced febrile morbidity calculated as fever index p less than 01 and length of hospitalization p less than 05￨sig decrease￨highunclear￨highunclear￨highunclear
100￨100 patients who were blindly randomized to have either an￨continuous bladder drainage with catheterization at abdominal hysterectomy indwelling foley catheter or an inout catheterization￨urinary retention after operation requiring bladder emptying urinary tract bacteriuria infection rate and postoperative morbidity retention of urine urinary symptoms and infection￨in addition 29 of the catheterized group had urinary tract bacteriuria compared with 13 of the uncatheterized group p  0025￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨visual internal urethrotomy urethral stricture by direct visual internal urethrotomy￨cure rate￨in a randomized trial treatment of urethral stricture by direct visual internal urethrotomy with 3 days of postoperative catheterisation was found to be sufficient given minimal complications and had a cure rate of 85 after 6 months and 80 after 1 year followup￨no diff￨highunclear￨highunclear￨highunclear
118￨118 consecutive patients who had undergone transurethral resection of the prostate turp or bladder neck incision bni underwent tom by one of the three methods￨tom micturition tom￨￨the infusion tom took a mean 13 h less than the other two methods which were statistically indistinguishable￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨￨￨￨removing the catheter at midnight allows patients to return to a normal voiding pattern more rapidly and to leave hospital earlier￨sig increase￨highunclear￨highunclear￨highunclear
50￨fifty women undergoing vaginal plastic repair to either 1 or 3 days catheterization￨transurethral foley catheterization￨postoperative urinary retention mean postoperative stay rate postoperative urinary retention urinary tract infection and stay postoperative￨of 25 patients catheterized for both group postoperative urinary retention occurred in 2 8 and required a new catheter￨no diff￨highunclear￨highunclear￨highunclear
180￨18 patients with the 180 patients were evaluated 101 with latex and 79 with bardex ic catheters￨radical prostatectomy bardex ic foley catheter silvercoated bardex ic catheter bardex ic catheter￨median catheterization time bacteriuria onset of bacteriuria￨there was no significant difference in bacteriuria after 14 days 500 vs 533￨no diff￨highunclear￨highunclear￨highunclear
86￨86 patients with genuine stress incontinence who underwent a modified burch coplosuspension 42 patients who had the 43 patients who had the￨transurethral foley catheter removed postoperatively the next morning transurethral indwelling catheter left￨postoperative urinary tract infection rates immediate voiding difficulties success rates￨the postoperative urinary tract infection rates of groups a and b were 166 and 233 respectively  p005￨no diff￨highunclear￨highunclear￨highunclear
90￨urinary tract infections and asymptomatic bacteriuria after vaginal plastic surgery 90 women undergoing￨vaginal plastic surgery suprapubic and transurethral catheter drainage of the bladder suprapubic and transurethral catheters￨urinary tract infection and asymptomatic bacteriuria asymptomatic bacteriuria at catheter removal mean duration of catheterization rate of mechanical complications postoperative urinary tract infection mechanical complications￨asymptomatic bacteriuria at catheter removal was found in 210 of suprapubic and in 125 of transurethral catheter patients￨no diff￨highunclear￨highunclear￨highunclear
54￨54 patients￨postoperative catheter treatment after optical internal urethrotomy optical internal urethrotomy with and without catheter￨recurrence rate voiding interview uroflowmetry and retrograde urethrography￨no significant difference in recurrence rate was found between the two groups studied by means of voiding interview uroflowmetry and retrograde urethrography￨no diff￨highunclear￨highunclear￨highunclear
213￨213 patients who underwent transurethral surgery for benign prostatic hyperplasia 213 patients￨transurethral resection and 24 hours following transurethral incision of prostate￨costeffective safe and comfortable￨we conclude that systematic removal of the catheter at the aforementioned periods is costeffective safe and comfortable for the patient￨no diff￨highunclear￨highunclear￨highunclear
50￨fifty patients with diagnoses of pelvic floor relaxation or stress urinary incontinence￨transurethral open bladder drainage postoperative transurethral catheterization with two technics for bladder drainage transurethral closed or transurethral open bladder drainage after vaginal surgery for pelvic floor relaxation transurethral closed bladder drainage￨urinary tract infection postoperative normal bladder function￨postoperative normal bladder function resumed more rapidly when transurethral closed drainage was used p  005￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨prostatectomy￨￨￨resumption of normal voiding is necessary before prostatectomy patients can be discharged from hospital￨sig increase￨highunclear￨highunclear￨highunclear
89￨prostatic resection patients n  89 patients with preoperatively sterile urine patients with preoperatively sterile urine undergoing￨cefotaxime 1 transurethral prostatectomy turp turp continuous bladder irrigation cefotaxime 1 g intramuscular im cefotaxime 1 g cefotaxime￨bacteriuria 105 organismsml and positive blood cultures and duration of hospital stay days severe infectious complications￨in study 1 infection was significantly reduced with respect to all parameters in the group receiving two doses of cefotaxime and total drug treatment costs were halved￨sig increase￨highunclear￨highunclear￨highunclear
not found￨fortyeight patients who had undergone transurethral resection of the prostate urinary catheters after transurethral resection of the prostate￨catheter removal midnight versus early morning urethral catheter removal after transurethral resection of the prostate￨length of hospital stay time to first void volume of first void time between catheter removal and discharge from hospital weight of prostatic resection and tissue pathology pathology weight of prostatic resection mean volume of first void or time to first void after catheter removal time between catheter removal and discharge from hospital time to first void or the volume of the first void￨there was no significant difference between the 2 groups with respect to pathology weight of prostatic resection mean volume of first void or time to first void after catheter removal￨no diff￨highunclear￨highunclear￨highunclear
106￨syndrome 106 patients submitted to vaginal surgery￨foley catheter transurethral vesical drainage vaginal surgery drainage and vesical reeducation￨time under vesical drainage presented a minor frequency of urinary retention￨the results show that those patients who were less time under vesical drainage presented a minor frequency of urinary retention after surgery 243 vs 307 and 437￨sig decrease￨highunclear￨highunclear￨highunclear
250￨250 women who underwent hysterectomy and who did not require bladder suspension or strict fluid treatment￨￨rate of febrile events urinary tract infections or need for recatheterization perception of pain length of catheterization subjective pain assessment pain recatheterization fever rate of recatheterization febrile morbidity symptomatic urinary tract infections or subjective pain assessments symptomatic urinary tract infections￨the early removal of indwelling catheters after operation was not associated with an increased rate of febrile events urinary tract infections or need for recatheterization￨no diff￨highunclear￨highunclear￨highunclear
75￨after transurethral resection of the prostate patients readiness for discharge and the day of discharge after transurethral resection of the prostate turp 75 consecutive patients undergoing turp who were randomized to either have their catheter removed in the standard manner 38 patients or to undergo bladder infusion before a trial of voiding tov on the second day after turp 37 patients￨bladder infusion before catheter removal bladder infusion with standard catheter removal￨rate of readiness for discharge￨bladder infusion before a tov after turp significantly increases the rate of readiness for discharge allowing an early decision to discharge on the second day in a large proportion of patients￨sig increase￨highunclear￨highunclear￨highunclear
91￨stress urinary incontinence burch or marshallmarchettikrantz after retropubic incontinence surgery ninetyone women undergoing￨retropubic surgery transurethral foley catheterization￨infection voiding problems delayed voiding￨delayed voiding occurred in 13 289 and 10 217 patients respectively and 5 111 and 3 65 respectively received a new catheter￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨urethral catheterization before vaginal cleansing and 2 urethral catheterization after vaginal cleansing￨urinary symptoms and fever postoperative bacteriuria at catheter removal postoperative urinary tract infection uti sequence of vaginal cleansing and urethral catheterization bacteriuria incidence of uti incidences of preoperative asymptomatic bacteriuria voiding discomfort￨no significant difference was noted in the incidence of uti 5 vs 10 p  025 with a trend towards less uti in group 1￨no diff￨highunclear￨highunclear￨highunclear
92￨ninetytwo patients with preoperative sterile urine undergoing stress urinary incontinence andor genital descensus￨suprapubic or transurethral postoperative catheter drainage suprapubic versus transurethral bladder drainage after colposuspensionvaginal repair transurethral catheter drainage colposuspension or vaginal repair operation￨postoperative bacteriuria prevalence of significant bacteriuria rates of both clinical cystitis and asymptomatic significant bacteriuria rate of postoperatively impaired bladder emptying￨at followup after one year postoperative bacteriuria was closely correlated to increased rates of both clinical cystitis and asymptomatic significant bacteriuria￨sig decrease￨highunclear￨highunclear￨highunclear
628￨twentyfour patients who underwent radical hysterectomy and pelvic node dissection for cervical carcinoma 628 patients￨urinary drainage following radical hysterectomy continuous postoperative drainage by urethral and suprapubic catheters￨catheter efficacy and morbidity urinary tract infection duration of continuous catheter drainage￨there were no statistically significant differences in either the duration of continuous catheter drainage before the return of spontaneous voiding or the incidence of urinary tract infection in the two groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients undergoing radical perineal prostatectomy￨radical perineal prostatectomy radical perineal prostatectomy￨￨this trial determined that early catheter removal may be feasible and desirable in patients undergoing radical perineal prostatectomy￨sig increase￨highunclear￨highunclear￨highunclear
160￨urinary catheters one hundred and sixty patients were entered into the study patients resuming normal voiding patterns￨￨volume of urine￨patients who had their catheters removed at midnight passed a greater volume of urine with both their first 268 ml compared with 177 ml p00001 and second voids 322 ml compared with 195 ml p00001 than their counterparts in the 0600 group￨sig increase￨highunclear￨highunclear￨highunclear
59￨59 patients￨transurethral prostatectomy turp turp transurethral prostatectomy￨length of hospital stay incidence of complications and the duration of postoperative hospital stay shorter postoperative hospital stay￨catheter removal on day 1 led to a significantly shorter postoperative hospital stay 23 days versus 33 days and did not incur a higher incidence of complications￨sig decrease￨highunclear￨highunclear￨highunclear
62￨sixtytwo patients were admitted into the study and followedup for two years￨postoperative catheter drainage and the value of hydraulic selfdilatation of the urethra after internal urethrotomy internal urethrotomy￨￨a randomized prospective study was set up to assess the role of postoperative catheter drainage and the value of hydraulic selfdilatation of the urethra after internal urethrotomy￨sig increase￨highunclear￨highunclear￨highunclear
52￨patients undergoing the pereyra surgical procedure patients with urethral catheter between january 1994 and july 1995 fifty two patients with urinary stress incontinence underwent pereyra procedure 31 female patient with￨suprapubic drainage cistofix ch 15 and 17 urethral catherization with a latex foley catheter recatheterizacion suprapubic vesical drainage bladder drainage suprapubic and urethral catheterization￨postoperative acute urinary retention urinary retention recatheterization sponatneous micturition and urinary retention duration of suprapubic vesical drainage with suprapubic catheter￨urinary retention after 7 days was present in 2399 with suprapubic vesical drainage and 285 with urethral catheter￨sig decrease￨highunclear￨highunclear￨highunclear
100￨one hundred patients were included six patients were excluded four in the standard prolonged catheterisation group and two in the not prolonged catheterisation group after vaginal prolapse surgery patients undergoing anterior colporrhaphy￨short term versus long term catheterisation transurethral catheter￨mean duration of hospitalisation mean duration of catheterisation residual volumes exceeding 200 ml and need for recatheterisation recatheterisation urinary tract infection mean duration of catheterisation and hospital stay positive urine cultures￨residual volumes exceeding 200 ml and need for recatheterisation occurred in 9 in the standard prolonged catheterisation group versus 40 of patients in the not prolonged catheterisation group or 015 95 ci 0045047￨sig increase￨low￨low￨low
39￨39 patients with ischemic cerebral infarction human stroke￨hyperbaric oxygen hyperbaric oxygen or air￨neurological deficits￨we interrupted the study when we noticed what appeared to be a trend favoring the airtreated patients whose neurological deficits were less severe mean￨no diff￨highunclear￨highunclear￨highunclear
33￨patients with acute ischemic stroke 33 patients presenting with acute ischemic stroke who did not receive thrombolytics over a 24month period acute ischemic stroke￨hbo hyperbaric oxygen therapy hbo hyperbaric oxygen therapy monoplace hyperbaric chamber pressurized with 100 o2 to 25atm absolute ata hyperbaric oxygen￨stroke scores efficacy safety and feasibility complications of treatment and mortality at 90 days percentage of patients with improvement at 24 hours national institutes of health stroke scale nihss and 90 days nihss barthel index modified rankin scale glasgow outcome scale modified rankin scale￨there were no differences between the groups at 24 hours p044￨no diff￨low￨low￨low
34￨patients who experienced middle cerebral artery occlusion and were seen within 24 hours of onset 34 patients were randomized 17 to 27 patients 13 in the sham group and 14 in the hbo group completed a full course of therapy acute ischemic stroke￨hyperbaric oxygen hbo therapy hbo hyperbaric treatment with air and 17 to hyperbaric treatment with 100 oxygen hyperbaric oxygen active hbo or sham air treatment￨ischemic damage therapeutic efficacy of hbo orgogozo scale score orgogozo scale time from stroke onset to randomization and orgogozo scale scores neurological deterioration myocardial infarction pretherapeutic and posttherapeutic scores rankin score￨moreover no statistically significant improvement was observed in the hbo group at 6 months and 1 year according to rankin score p  78 and our own 10point scale p  50￨no diff￨low￨low￨low
29￨children 29 children￨saline solution dexamethasone dexamethasone￨mechanical ventilation postbypass inflammatory response inflammatory response tumor necrosis factoralpha levels temperature supplemental fluids alveolararterial oxygen gradient and days of mechanical ventilation interleukin6 levels alveolararterial oxygen gradients complement component c3a and absolute neutrophil count supplemental fluid mean rectal temperature inflammatory mediator release serial blood analyses for interleukin6 tumor necrosis factoralpha complement component c3a and absolute neutrophil count￨dexamethasone caused an eightfold decrease in interleukin6 levels and a greater than threefold decrease in tumor necrosis factoralpha levels after cpb p  005￨sig decrease￨highunclear￨highunclear￨highunclear
30￨thirty children with congenital heart disease undergoing cpb children undergoing cardiac surgery for congenital heart disease pediatric patients undergoing openheart surgery￨lowdose mp highdose methyl prednisolone mp cardiopulmonary bypass cpb methyl prednisolone￨elevated liver enzymes blood urea nitrogen and creatinine postoperative il and crp levels postoperative il6 and 8 levels neutrophil count crp and il6 and 8 levels serum interleukin il6 and 8 levels acute phase reactants and blood biochemistry peak levels systemic inflammatory response plasma il6 and 8 levels creactive protein crp levels and polymorphonuclear leukocyte counts postoperative core temperature duration of mechanical ventilation period of stay in intensive care unit oxygenation indices and biochemical parameters safety and efficacy￨in both groups plasma il6 and 8 levels were elevated above the preoperative levels at 2 and 24 hours after declamping￨sig decrease￨highunclear￨highunclear￨highunclear
20￨after paediatric cardiac surgery twenty children weighing 10 kg received children after open cardiac surgery￨glucocorticoids dexamethasone dexamethasone ag or s100b saline￨inflammatory response clinical course creactive protein von willebrand factor antigen vwf oxygenation body temperature fluid balance leucocyte and platelet counts days in the icu or days on mechanical ventilation creactive protein concentration release of vwf clinical course creactive protein s100b protein and von willebrand factor antigen oxygenation body temperature fluid balance leucocyte and platelet counts days in the intensive care unit icu and days on mechanical ventilation￨dexamethasone decreased creactive protein concentration on the first postoperative day p005 but did not affect the release of vwf￨no diff￨highunclear￨highunclear￨highunclear
29￨twentynine pediatric patients undergoing bypass procedures￨intraoperative mp intraoperative methylprednisolone mp to intraoperative mp alone steroid administration combined steroids intraoperative mp alone combined preoperative and intraoperative mp preoperative and intraoperative mp￨myocardial mrna expression for il6 mcp1 and icam1 indexes of o2 delivery reduced fluid requirements lower body temperature and lower deltaavo2 lower serum il6 and increased il10 myocardial inflammatory mediator mrna expression oxygen delivery and reduces postbypass inflammatory mediator expression serum il6 and il10 cardiopulmonary function intubation time cicu length of stay fluid balance arteriovenous o2 difference deltaavo2 and inotrope requirements￨compared with intraoperative mp alone combined preoperative and intraoperative mp was associated with reduced myocardial mrna expression for il6 mcp1 and icam1 both before and after bypass p005￨sig increase￨highunclear￨highunclear￨highunclear
38￨pancreatic head carcinoma patients who are candidates for surgical treatment of carcinoma of the pancreatic head 38 patients resectional surgery was performed for carcinoma of the caput pancreatis ampullary distal common bile duct and pancreatic duct￨preoperative biliary drainage was accomplished via an endoprosthesis introduced during endoscopic retrograde cholangiopancreatography preoperative biliary drainage￨incidence of early complications preoperative biliary drainage intrabiliary pressure biliary infection bacteremia and intraoperative bleeding￨in group b however the intrabiliary pressure was higher than in group a and was associated with heightened incidence of biliary infection bacteremia and intraoperative bleeding￨sig increase￨highunclear￨highunclear￨highunclear
87￨87 patients patients with hilar lesions malignant obstructive jaundice patients with distal obstruction patients with malignant obstructive jaundice￨early elective surgery endoscopic biliary drainage followed by exploration 43 preoperative endoscopic drainage preoperative endoscopic drainage successful stent insertion endoscopic drainage￨level of biliary obstruction hyperbilirubinaemia indocyanine green retention and serum albumin concentration overall morbidity rate mortality rate incidence of cholangitis and failed endoscopic drainage liver function effective biliary drainage￨the overall morbidity rate 18 patients versus 16 and mortality rate six patients in each group were similar in the two treatment arms irrespective of the level of biliary obstruction￨no diff￨highunclear￨highunclear￨highunclear
35￨surgical unit iv liaquat university of medical and health sciences jamshoro from january 2007 to december 2007 mean age of patients who had primary closure done n  16 was 460 168 patients who underwent primary closure was usd1945 415 thirtyfive patients were included in the study of which 16 patients underwent primary closure thirtyfive patients were included in the study￨primary closure versus ttube drainage after open choledochotomy￨cbd bile leakage recurrence of cbd stones bile leakage postoperative hospital stay biliary peritonitis total cost of treatment postoperative jaundice￨primary cbd closure is a safe and cost effective alternative to routine ttube drainage after open choledochotomy￨no diff￨highunclear￨highunclear￨highunclear
117￨patients with biliary lithiasis after choledochotomy supplemented by either 117 patients who underwent surgery￨ttube drainage or primary common bile duct closure￨mortality rate postoperative bacteremia and ttube bile infection postoperative bacteremia early morbidity rate￨to compare the incidence of postoperative bacteremia in patients with biliary lithiasis after choledochotomy supplemented by either ttube drainage or primary common bile duct closure 117 patients who underwent surgery are presented in this clinical trial￨no diff￨highunclear￨highunclear￨highunclear
not found￨48 patients by a questionnaire sent at a median of 28 years following operation thirtyseven patients underwent primary closure and 26 underwent closure over ttube￨primary closure versus ttube drainage of the cbd operationabstract primary duct closure versus ttube drainage￨abdominal pains jaundice or pancreatitis nor needed further biliary surgery postoperative stay duration of operation incidence of wound infection surgical or other complications￨there was no significant difference in the duration of operation incidence of wound infection surgical or other complications following operation between the two groups￨no diff￨highunclear￨highunclear￨highunclear
19￨patients were grouped by disease process rheumatoid arthritis ra avascular necrosis avn trauma and hemophilic arthropathy ha and type of prosthesis total vs hemiarthroplasty shoulder arthroplasty in the young patient patients with ra who had a total shoulder arthroplasty scored higher than patients with hemiarthroplasty 22 shoulder implant arthroplasties in 19 patients age 50 or younger at surgery￨￨telephone interview written questionnaire and radiographic examination accelerated deterioration of function of shoulder arthroplasties shoulder function￨patients with ra who had a total shoulder arthroplasty scored higher than patients with hemiarthroplasty￨sig increase￨highunclear￨highunclear￨highunclear
not found￨fortyseven shoulder surgeries for rheumatoid arthritis 18 arthroscopic synovectomies 10 total shoulder replacements 19 humeral head replacements￨￨pain relief and range of motion rom improvement pain relief rheumatoid shoulder nonprogressive arthrosislike erosive collapse and mutilating patterns pain relief and rom improvement￨for the collapsetype shoulders we could not obtain pain relief or rom improvement with arthroscopic synovectomy but did obtain pain relief with prosthetic replacement￨no diff￨highunclear￨highunclear￨highunclear
not found￨preoperative diagnoses in the remainder were osteoarthritis 20 rheumatoid arthritis 26 rotator cuff tear arthropathy 1 and posttraumatic arthrosis 1￨copeland surface replacement shoulder arthroplasty humeral head surface replacement hemiarthroplasty arthroscopic subacromial decompression￨nonprogressive osteolysis constant scores￨constant scores for the whole group improved from a mean preoperative score of 164 range 836 to 540 range 2083 at last followup p  05￨sig increase￨highunclear￨highunclear￨highunclear
267￨80 patients with 103 tsas at a mean of 154 320 consecutive tsas performed in 267 patients between 1974 and 1988￨total shoulder arthroplasty tsa￨survivorship rates shoulder and hand dash questionnaire revision or complication range of motion and strength rheumatoid arthritis total shoulder arthroplasty longterm survivorship functional outcome and quality of life relief of pain shoulder range of motion and strength juvenile rheumatoid arthritis mean dash score￨dislocation occurred earlier than other causes of revision or complication p  05 analysis of variance￨no diff￨highunclear￨highunclear￨highunclear
26￨33 rheumatoid patients treated with hemispherical cup resurfacing hemiarthroplasty of the shoulder without medullary fixation 6 bilaterally were reviewed after mean 44 26 years 39 patients followed for 26 years￨cup hemiarthroplasty￨shoulder function and radiographic deterioration radiographic signs of loosening mean proximal migration shoulder function or pain proximal migration and glenoid erosion median constant score￨proximal migration and glenoid erosion did not correlate with shoulder function or pain￨no diff￨highunclear￨highunclear￨highunclear
not found￨58 consecutive neer ii total shoulder replacements in 49 rheumatoid patients rheumatoid disease￨total shoulder replacement cemented glenoid and pressfit humeral components￨external rotation moderate or severe pain mean range of active elevation satisfactory performance of the activities of daily living pain on unusual activity￨there were satisfactory improvements in the mean range of active elevation 53 degrees to 75 degrees and external rotation 5 degrees to 38 degrees satisfactory performance of the activities of daily living had been maintained throughout followup￨no diff￨highunclear￨highunclear￨highunclear
35￨patients with osteoarthritis and rheumatoid arthritis who have had humeral head replacement alone 35 shoulders with osteoarthritis and 32 shoulders with rheumatoid arthritis and followedup for an average of 93 years￨humeral head replacement￨pain relief active elevation satisfactory pain relief revision to total shoulder arthroplasty￨satisfactory pain relief was achieved in 44 66 and 52 of the shoulders 78 were described by patients as being much better or better￨no diff￨highunclear￨highunclear￨highunclear
not found￨20 shoulders with patients with rheumatoid arthritis patients with rheumatoid arthritis undergoing total shoulder arthroplasty rheumatoid arthritis patients undergoing total shoulder arthroplasty￨cuff repair by augmented subscapularis transposition subscapularis muscle transposition rotator cuff repair by augmented subscapularis transposition rotator cuff repair by augmented subscapularis transposition via the leedskeio artificial ligament￨postoperative complications incidence of radiolucency and upward migration of shoulder components￨final clinical scores hospital for special surgery scoring system and the incidence of radiolucency and upward migration of shoulder components in 20 shoulders with rotator cuff repair by augmented subscapularis transposition were superior to those of 19 shoulders with cuff repair by subscapularis transposition alone and similar to those of 22 shoulders with intact rotator cuffs￨sig increase￨highunclear￨highunclear￨highunclear
26￨24 patients with rheumatoid arthritis 20 women 4 men to have either a cemented or pressfit stem rheumatoid patients￨cement and pressfit humeral stem fixation￨average rotation level of evidence￨the average rotation for all axes was less than 025 degrees for both groups and the average translation was less than 032 mm for all three axes including subsidence which was less than 01 mm for the uncemented stems￨no diff￨highunclear￨highunclear￨highunclear
51￨62 neer mark ii total shoulder arthroplasties performed during the period from 1981 to 1990 on 51 patients with rheumatoid arthritis rheumatoid arthritis total shoulders with rheumatoid arthritis￨total shoulder replacement hemiarthroplasty with a cemented humeral prosthesis￨average pain relief range of movement abduction force or function proximal humeral migration range of movement and function pain relief range of movement abduction force nor function progressive radiographic loosening proximal migration good pain relief￨also component loosening did not significantly influence the average pain relief range of movement abduction force or function￨no diff￨highunclear￨highunclear￨highunclear
not found￨303 consecutive cases 152 total shoulder arthroplasties and 63 hemiarthroplasties with a minimum 2year followup between january 1 1976 and december 31 1991 195 total shoulder arthroplasties and 108 hemiarthroplasties were performed in 247 patients in patients with rheumatoid arthritis patients with an intact rotator cuff twenty patients had died and 1 was lost to followup patients with a thin or torn rotator cuff all 303 shoulders were included in the survival analysis one hundred and eightyseven total shoulder arthroplasties and 95 hemiarthroplasties with complete preoperative evaluation operative records and minimum 2year followup mean 116 years or followup until revision were included in the clinical analysis￨tsa hemiarthroplasty and tsa total shoulder arthroplasty versus hemiarthroplasty￨pain relief improvement in abduction and lower risk of revision surgery external rotation total shoulder arthroplasty tsa pain and motion pain relief risk for revision pain and abduction glenoid periprosthetic lucency active abduction glenoid erosion￨there was not a significant difference in improvement in pain and motion comparing hemiarthroplasty and tsa for patients with a thin or torn rotator cuff￨no diff￨highunclear￨highunclear￨highunclear
79￨seventynine patients with 89 replacements were available for followup a minimum of 5 years after the operation mean 122 years range 5 to 17 years total shoulder arthroplasty with the neer prosthesis 113 total shoulder replacement arthroplasties performed with a neer prosthesis between 1975 and 1981￨￨probability of implant survival humeral component loosening relief from moderate or severe pain radiographic evidence of definite loosening humeral component bonecement radiolucencies complications requiring reoperation glenoid loosening active abduction￨active abduction improved by an average of 40 degrees to an average of 117 degrees￨sig increase￨highunclear￨highunclear￨highunclear
40￨40 shoulder arthroplasties in patients with rheumatoid arthritis all patients were clinically evaluated using the hospital for special surgery 100point scoring system rheumatoid arthritis￨rotator cuff repair￨rotator cuff postoperative clinical score quality of the repair of the ruptured cuff￨the clinical score of the shoulders with good repair of the rotator cuff improved considerably and continued to improve even after the firstyear followup examination￨sig increase￨highunclear￨highunclear￨highunclear
7￨patients with severe rheumatoid arthritis and irreparable rotator cuff rupture patients with rheumatoid arthritis and nonreconstructible rotator cuff lesions seven patients with rheumatoid arthritis 8 shoulders with nonreconstructible rotator cuff lesions and larsen stagev radiographic changes of the glenoid and the humeral head underwent a grammont reverse shoulder arthroplasty￨￨septic implant loosening 1 shoulder aseptic glenoid loosening 2 and failed acromion osteosynthesis following the transacromial approach 3 constant score shoulder instability mean strength￨the constant score improved from a mean of 17 points range 4 to 25 preoperatively to a mean of 63 points range 41 to 79 at a mean of 54 months range 48 to 73 after shoulder arthroplasty￨sig increase￨highunclear￨highunclear￨highunclear
not found￨between 1986 and 1998 seventyfive shoulders underwent surface replacement arthroplasty thirtythree hemiarthroplasties and fortytwo total shoulder arthroplasties for the treatment of rheumatoid arthritis rheumatoid arthritis￨shoulder arthroplasty with a stemmed prosthesis￨degree of superior subluxation level of evidence mean range of active flexion average constant score localized lucencies￨the mean range of active flexion improved from 50 degrees in the hemiarthroplasty group and 47 degrees in the total shoulder replacement group to 101 degrees and 104 degrees respectively￨sig increase￨highunclear￨highunclear￨highunclear
not found￨thirtyfive shoulders in twentynine patients twentyone women and eight men with an average age of 614 years patients with rheumatoid arthritis patients with rheumatoid arthritis affecting the glenohumeral joint patients with advanced rheumatoid arthritis from 1997 to 2000 fortytwo durom cup hemiprostheses￨durom cup surface replacement cemented durom cup surface replacement￨glenoid depth loosening of the prosthesis or changes in cup position mean constant score endoprosthetic loosening glenohumeral subluxation and glenoid bone loss￨over the fiveyear followup period proximal migration of the cup increased in 63 of the shoulders and the glenoid depth increased in 31￨sig increase￨highunclear￨highunclear￨highunclear
105￨105 shoulder arthroplasties in patients with rheumatoid arthritis patients with rheumatoid arthritis￨￨medial migration survival constantmurley and association of shoulder and elbow surgeons score superior migration of the humeral component￨in spite of the use of an uncemented humeral stem no implant was radiologically loose or at risk￨no diff￨highunclear￨highunclear￨highunclear
not found￨17 total shoulder replacements using the reversed delta iii prosthesis in patients with rheumatoid arthritis of the glenohumeral joint complicated by rotator cuff dysfunction rheumatoid arthritis with rotator cuff dysfunction￨￨median constantmurley score￨radiographical analysis revealed evidence of lucencies about the humeral component in all cases and about the glenoid component in five cases￨no diff￨highunclear￨highunclear￨highunclear
not found￨twelve shoulders with rheumatoid arthritis ra and irreparable rotator cuff tears rheumatoid arthritis with irreparable rotator cuff tear osteoarthritis with massive rotator cuff tears￨conventional hemiarthroplasty bipolar shoulder prosthesis bipolar shoulder prosthesis￨satisfactory deltoid arm level mean preoperative constant score preoperative and postoperative scores preoperative condition of the rotator cuff complication rate average constant score￨preoperative and postoperative scores of the rheumatoid group were not significantly different from the arthritis group p0001￨no diff￨highunclear￨highunclear￨highunclear
103￨patients90 patients with biomodular system 103 with the initial nottingham tsr and 34 patients with the current nottingham tsr system￨nottingham tsr prosthesis uncemented nottingham total shoulder replacement prosthesis system nottingham tsr uncemented total shoulder arthroplasty prostheses biomodular initial nottingham tsr and current nottingham tsr systems￨4year survivorship disabling pain annual cumulative survivorship values 8year survivorship survival 8year and 11year survivorship rates￨glenoid component loosening was the main factor of prosthesis failure in both prostheses and mainly occurred in the first 4 postoperative years￨sig increase￨highunclear￨highunclear￨highunclear
10￨patients with ra who require patients with rheumatoid arthritis ra 16 shoulders with underlying ra that underwent patients with rheumatoid arthritis 10 patients with fullthickness rotator cuff tears￨arthroscopic rotator cuff debridement arthroscopic rotator cuff tear debridement operative intervention￨pain pain pain relief functional gains￨motion did not improve in either group￨no diff￨highunclear￨highunclear￨highunclear
21￨twentythree shoulders in twentyone patients were identified patients with fullthickness rotator cuff tears patients with rheumatoid arthritis who had undergone repair of a rotator cuff tear at our institution from 1988 to 2002 patients with rheumatoid arthritis nine shoulders had a partialthickness tear and fourteen had a fullthickness tear￨rotator cuff repair￨median duration of follow durable pain relief and patient satisfaction pain functional outcome and overall patient satisfaction active elevation overall pain satisfaction￨patients with both partial and fullthickness rotator cuff tears had significant improvements in terms of overall pain p  005 and satisfaction p  005￨sig increase￨highunclear￨highunclear￨highunclear
63￨children of parents with intellectual disability parents with intellectual disability to promote child health and home safety in the preschool years 63 parents were recruited for the study with 45 parents 40 mothers and 5 fathers from 40 families completing the project￨￨parental health intelligence and literacy effective regardless of parental health literacy skills and iq parental health and safety behaviours number of safety precautions parents￨the intervention improved parents ability to recognize home dangers to identify precautions to deal with these dangers and resulted in a significant increase in the number of safety precautions parents implemented in their homes with all gains being maintained at 3 months postintervention￨sig decrease￨highunclear￨highunclear￨highunclear
42￨respiratory distress syndrome 42 infants with clinical and radiographic evidence of severe respiratory distress syndrome to receive either￨highfrequency jet ventilation highfrequency jet ventilation or conventional ventilation￨mortality rates air leaks bronchopulmonary dysplasia intraventricular hemorrhage incidence of air leaks mortality or morbidity rates bronchopulmonary dysplasia mortality rates neonatal mortality or pulmonary morbidity rates intraventricular hemorrhage￨we conclude that early use of highfrequency jet ventilation does not prevent or substantially reduce mortality or morbidity rates associated with assisted ventilation￨no diff￨highunclear￨highunclear￨highunclear
130￨a total of 130 patients were included in the final analysis 65 were randomized to preterm infants with uncomplicated respiratory distress syndrome preterm infants with birth weights between 700 and 1500 g and gestational age 36 weeks who required mechanical ventilation with fio2 030 at 2 to 12 hours after surfactant administration received surfactant by 8 hours of age were 20 hours old and had been ventilated for 12 hours eight tertiary neonatal intensive care units premature infants with uncomplicated rds￨hfjv cv to hfjv highfrequency jet ventilation hfjv and conventional ventilation cv highfrequency jet ventilation hfjv￨survival incidence of bpd at 28 days retinopathy of prematurity airleak pulmonary hemorrhage grade iii ivh and other complications bpd risk of grade iiiiv ivh andor pvl positive endexpiratory pressure peep h2o severe neuroimaging abnormalities pvl andor grade iiiiv ivh incidence of bpd oxygenation survival gas exchange airway pressures airleak intraventricular hemorrhage ivh periventricular leukomalacia pvl and other nonpulmonary complications severe ivhpvl peak inspiratory pressure and deltap paco2 peak inspiratory pressurepeep paco2 between cv and hfjv adverse outcomes￨the incidence of bpd at 36 weeks of postconceptional age was significantly lower in babies randomized to hfjv compared with cv 200 vs 404￨no diff￨low￨low￨low
73￨73 premature infants who met the inclusion criteria gestational age of less than 33 weeks birth weight of more than 500 g age of less than 24 hours need for assisted ventilation with peak inspiratory pressure of more than 16 and fio2 more than 030 and roentgenographic evidence of respiratory distress syndrome premature infants with respiratory distress syndrome￨conventional mechanical ventilation conventional n  36 or to highfrequency jet n  37 ventilation highfrequency jet ventilation hfjv highfrequency jet ventilation￨pulmonary morbidity arterial blood gases mean number of days oxygen was required number of days ventilated or length of hospital stay pulmonary outcomes occurrence of air leaks need for oxygen or ventilation develop cystic periventricular leukomalacia poor outcome grade iv hemorrhage cystic periventricular leukomalacia or death mean birth weight and gestational age adverse outcomes￨there were no differences in pulmonary outcomes occurrence of air leaks need for oxygen or ventilation at 36 weeks postconception and there were no differences in the mean number of days oxygen was required number of days ventilated or length of hospital stay￨no diff￨highunclear￨highunclear￨highunclear
600￨contraceptive practices of couples 170 women 569 had started using contraceptives whereas 129 431 had decided to start contraceptive use in the next 6 months 600 women was done in two groups matched for age parity and socioeconomic status at the department of obstetrics and gynaecology shifa foundation community health centre shifa international hospital islamabad pakistan￨contraceptive counseling and educational leaflets counseling and educational leaflets nonintervention group was not given any formal contraceptive advice￨contraceptive uptake started contraceptive use￨there is a definite increase in contraceptive uptake in women provided with educational leaflets and counseling session with a shift toward use of more reliable contraceptive methods￨sig increase￨highunclear￨highunclear￨highunclear
4277￨rural women 4277 women living in households served by the lhwp and those living in control areas rural pakistan￨lhwp￨￨women served by lady health workers are significantly more likely to use a modern reversible method than women in communities not served by the programme or150 95 ci104216 p0031 even after controlling for various household and individual characteristics￨sig increase￨highunclear￨highunclear￨highunclear
not found￨traditional medical practitioners to delivery family planning services in uttar pradesh traditional medical practitioners in the delivery of family planning services after a brief training period￨￨￨the impact of their involvement was reflected in increased knowledge of permanent as well as reversible contraceptive methods and in higher contraceptive use rates especially of reversible methods adopted by women younger than 25 years from 8 percent to 37 percent in the intervention villages as compared with increased knowledge and use from 13 percent to 25 percent of permanent methods alone in the control villages￨sig increase￨highunclear￨highunclear￨highunclear
866￨500 women attending antenatal clinics in each of three centers edinburgh scotland shanghai peoples republic of china cape town south africa￨contraceptive counseling standard advice routinely given in that setting expert contraceptive advice￨undergo sterilization prevalence of contraceptive use pregnancy rate contraceptive uptake patterns of contraceptive usage and pregnancy rates￨in edinburgh participants were more likely to undergo sterilization p  001 than controls otherwise there were no differences among edinburgh shanghai or cape town in either the methods of contraception chosen or in the methods used over time￨sig increase￨highunclear￨highunclear￨highunclear
246￨brazilian women who have undergone abortion use contraceptive methods july 2008 to september 2009 enrolling 246 women randomly distributed in intervention n123 and control n123 groups women in the postabortion period postabortion women in the northeast of brazil￨contraceptive counseling individualized contraceptive counseling personalized counseling￨probability of adherence contraceptive acceptability￨the strategy on individualized contraceptive counseling increased the acceptance and the use of contraceptive methods and increased the adequate use of the methods￨sig increase￨highunclear￨highunclear￨highunclear
297￨iran 297 individuals 100 subjects in the cbd group and 197 subjects in the control group from four major remote areas of hamedan iran￨cbd communitybased distribution cbd￨level of contraceptive knowledge contraceptive continuation rates contraceptive usage￨this controlled field trial study involved 297 individuals 100 subjects in the cbd group and 197 subjects in the control group from four major remote areas of hamedan iran￨sig increase￨highunclear￨highunclear￨highunclear
876￨three groups of new mothers a total of 876 women were allocated and followed up syria￨postnatal home visits 4 postnatal home visits a one visit b or no visit c￨￨a significantly higher proportion of mothers in groups a and b reported exclusively breastfeeding their infants 285 and 30 respectively as compared with group c 20 who received no visits￨sig increase￨highunclear￨highunclear￨highunclear
200￨200 pregnant women and 100 spouses couples knowledge and practice of contraception in mansoura egypt￨antenatal counselling￨￨counselling sessions improved the couples knowledge and practice in the study group￨sig increase￨highunclear￨highunclear￨highunclear
72￨seventytwo patients with 94 hcc nodules thirtysix patients with 48 nodules small hepatocellular carcinoma hepatocellular carcinoma hcc￨radiofrequency ablation and percutaneous microwave coagulation therapy rf ablation rf ablation and pmc radiofrequency rf ablation and percutaneous microwave coagulation pmc pmc￨number of treatment sessions per nodule rates of residual foci of untreated disease residual foci of untreated disease major complications therapeutic effect residual foci of untreated disease and complications of rf ablation and pmc complete therapeutic effect￨major complications occurred in one patient treated with rf ablation and in four patients treated with pmc p 36￨no diff￨highunclear￨highunclear￨highunclear
142￨small hepatocellular carcinoma in cirrhosis 102 patients with hepatic cirrhosis and either single hcc 5 cm in diameter or smaller or as many as three hccs each 3 cm or smaller overall number of lesions 142 randomly received either small hepatocellular carcinoma hcc in patients with cirrhosis￨radiofrequency thermal ablation versus percutaneous ethanol injection percutaneous ethanol injection pei rf ablation radiofrequency rf thermal ablation pei￨one and 2year eventfree survival rates one and 2year survival rates local recurrencefree survival rates one and 2year local recurrencefree survival rates￨one and 2year local recurrencefree survival rates were 98 and 96 in the rf group and 83 and 62 in the pei group respectively univariate rr  017￨no diff￨highunclear￨highunclear￨highunclear
63￨patients were new to capd n  39 or had a new capd catheter or had had no episodes of peritonitis or exitsite infection in the previous 12 months n  24 continuous ambulatory peritoneal dialysis 63 adult patients￨twin versus singlebag disconnect systems￨purchase cost of fs total cost of capd cumulative incidence of peritonitis total cost of infection peritonitis length of hospitalization for peritonitis or exitsite infection efficiency and total cost of freeline solo fs twinbag and basic y by singlebag systems￨length of hospitalization for peritonitis or exitsite infection was 98 days in six patients with by versus 17 days in two patients with fs￨no diff￨highunclear￨highunclear￨highunclear
147￨capd 147 patients commencing capd￨￨total costs number of peritonitis episodes average peritonitisfree interval peritonitisrelated hospitalization cost per bag cost of the twin bag peritonitis incidence and associated hospitalizations￨y system and twin bag use was associated with a reduction of 50 and 75 peritonitis incidence respectively in patients on capd￨sig increase￨highunclear￨highunclear￨highunclear
100￨one hundred patients with endstage renal failure between 10 and 70 years of age with good handeye coordination and not anticipated to receive a living related transplant within 6 months continuous ambulatory peritoneal dialysis￨conventional spike oset and uvxd techniques continuous ambulatory peritoneal dialysis capd conventional spike technique c the oset o and uvxd u ultraviolet irradiation connection box￨technique survival corresponding esi rates costeffective training time details of peritonitis and exitsite infection esi including the costs of antibiotic treatment outpatient visits hospital stays technique and patient survival peritonitis rates￨there was no significant difference in technique survival in the three treatment groups￨no diff￨highunclear￨highunclear￨highunclear
82￨82 patients￨ultra twin bag system or the ultra yset system which uses only the drainage bag already attached to the y connecting tubing continuous ambulatory peritoneal dialysisrelated infections with different ytubing exchange systems continuous ambulatory peritoneal dialysis capd technique￨peritonitis rate peritonitis rates exitsite infections 1yr infectionfree survival rates￨exitsite infections were lower with the ultra twin bag system one episode per 125 patient months compared with the ultra yset system one episode per 283 patient months although this difference was not statistically significant p  0084￨sig increase￨highunclear￨highunclear￨highunclear
not found￨175 years or to the ysystem group b 32 patients age 551 62 new capd patients group a 30 patients age 555 continuous ambulatory peritoneal dialysis￨standard method standard continuous ambulatory peritoneal dialysis capd system with that of a new method consisting of a yshaped set filled with sodium hypochlorite yconnector and disinfectant￨incidence of peritonitis￨lifetable analysis showed a significant difference between the incidence of peritonitis in the two groups￨no diff￨highunclear￨highunclear￨highunclear
60￨sixty consenting patients with no significant physical disabilities who commenced capd after may 1987 were entered and followed for a minimum of 12 months continuous ambulatory peritoneal dialysis￨peritonitis with conventional versus oset techniques flushdisconnect osystem baxter deerfield il os and a conventional system ii baxter￨episodes of peritonitis incidence of peritonitis exitsite infections median survival time to first peritonitis episode episode of peritonitis￨os patients experienced 28 episodes of peritonitis 134 monthspatientepisode compared with 88 49 monthspatientepisode in cs p less than 0005￨no diff￨highunclear￨highunclear￨highunclear
40￨capd patients patients receiving continuous ambulatory peritoneal dialysis forty patients in each arm of the trial were matched for age range 2067 years mean 49 years and remained in the study for similar periods range 336 months mean 141 months￨yset dialysis delivery system continuous ambulatory peritoneal dialysis capd￨episodes of peritonitis rate of episodes caused by staphylococcus aureus streptococci enterococci corynebacteria enterobacteria or pseudomonads peritonitis rates peritonitis rates incidence of catheter exit wound infections￨in the yset group there were significantly fewer episodes caused by coagulasenegative staphylococci and acinetobacter spp￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨new patients who had never used other systems of continuous ambulatory peritoneal dialysis a total of 120 new endstage renal failure patients of three regional hospitals continuous ambulatory peritoneal dialysis 60 patients on the b system and 51 on the y system were analyzable￨doublebag and yset disconnect systems doublebag disconnect system b versus a yset disconnect system y doublebag and yset disconnect system￨grampositive infections peritonitis rate exit site infection clinical outcome and patients acceptance to the procedure peritonitis rates gramnegative infections exit site infection rates￨patients on the b system had a better acceptance of the procedure than patients on the y system as assessed by a sixitem 10point questionnaire total score 431￨sig increase￨highunclear￨highunclear￨highunclear
107￨children and adolescents with obsessivecompulsive disorder 53 children 39 adolescents or children and adolescents than for adults 54 children 41 adolescents patients with obsessivecompulsive disorder one hundred eightyseven patients 107 children aged 6 to 12 years and 80 adolescents aged 13 to 17 years￨placebo selective serotonin reuptake inhibitor sertraline hydrochloride sertraline sertraline sertraline hydrochloride sertraline and placebo￨nimh gocs childrens yalebrown obsessive compulsive scale cybocs the national institute of mental health global obsessive compulsive scale nimh gocs efficacy vital sign determinations laboratory findings or electrocardiographic measurements cgi incidence of insomnia nausea agitation and tremor adverse medical events safety and efficacy￨in intenttotreat analyses patients treated with sertraline showed significantly greater improvement than did placebotreated patients on the cybocs adjusted mean 68vs￨sig increase￨low￨low￨low
not found￨23 years with severe primary obsessivecompulsive disorder nineteen children mean children with obsessivecompulsive disorder childhood obsessivecompulsive disorder￨clomipramine hydrochloride placebo clomipramine￨observed and selfreported obsessions and compulsions depressive symptoms obsessivecompulsive symptoms￨there was a significant improvement in observed and selfreported obsessions and compulsions that was independent of the presence of depressive symptoms at baseline￨sig increase￨highunclear￨highunclear￨highunclear
128￨children and adolescents adults with mood and anxiety disorders 128 children who were 6 to 17 years of age who met the criteria for social phobia separation anxiety disorder or generalized anxiety disorder and who had received psychological treatment for three weeks without improvement children with anxiety disorders children and adolescents with social phobia separation anxiety disorder or generalized anxiety disorder￨fluvoxamine fluvoxamine placebo￨anxiety adverse events pediatric anxiety rating scale anxiety disorders￨on the clinical global impressionsimprovement scale 48 of 63 children in the fluvoxamine group 76 percent responded to the treatment as indicated by a score of less than 4 as compared with 19 of 65 children in the placebo group 29 percent p0001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨children and adolescents with generalized anxiety disorder separation anxiety disorder andor social phobia anxious youths youths with social phobia and generalized anxiety disorder anxious youths 717 years old who had significant functional impairment childhood anxiety disorders￨placebo fluoxetine fluoxetine￨tolerated except for mild and transient headaches and gastrointestinal side effects efficacy and tolerability anxiety symptoms and improving functioning￨youths with social phobia and generalized anxiety disorder responded better to fluoxetine than placebo but only social phobia moderated the clinical and functional response￨no diff￨highunclear￨highunclear￨highunclear
14￨14 children and adolescents with ocd ages 8 to 15 years old children with ocd children and adolescents with obsessivecompulsive disorder adults with major depressive disorder and obsessivecompulsive disorder ocd but not in patients below 18 years old￨fluoxetine placebo fluoxetine and placebo￨cybocs total score obsessivecompulsive symptom severity cgiocd tolerated efficacy and safety childrens yalebrown obsessive compulsive scale cybocs and the clinicians global impressionobsessive compulsive disorder scale cgiocd￨the cybocs total score decreased 44 n  7 p  003 after the initial 8 weeks of fluoxetine treatment compared with a 27 decrease n  6 p  13 after placebo￨sig decrease￨highunclear￨highunclear￨highunclear
120￨children and adolescents with obsessivecompulsive disorder children and adolescents with obsessivecompulsive disorder ocd 120 randomized subjects discontinued early subjects aged 8 to 17 years meeting dsmiiir criteria for ocd were recruited from july 1991 to august 1994 subjects who had not responded after 6 weeks could discontinue the doubleblind phase of the study and enter a longterm openlabel trial of￨fluvoxamine placebo fluvoxamine 50 to 200 mgday or placebo fluvoxamine fluvoxamine 27 placebo￨adverse events cybocs scores mean childrens yalebrown obsessive compulsive scale cybocs scores insomnia and asthenia tolerated and efficacious safety and efficacy￨significant p  05 differences between fluvoxamine and placebo were observed for all secondary outcome measures at all visits￨no diff￨low￨low￨low
488￨2008 massachusetts medical society at a dose of up to 200 mg per day a combination of 488 children between the ages of 7 and 17 years who had a primary diagnosis of separation anxiety disorder generalized anxiety disorder or social phobia to receive 14 sessions of childhood anxiety children with anxiety disorders￨placebo sertraline and cognitive behavioral therapy or a placebo cognitive behavioral therapy and sertraline sertraline cognitive behavioral therapy sertraline cognitive behavioral therapy sertraline￨anxiety disorders severity of anxiety insomnia fatigue sedation and restlessness clinician global impressionimprovement scale pediatric anxiety rating scale adverse events including suicidal and homicidal ideation￨combination therapy was superior to both monotherapies p0001￨sig increase￨low￨low￨low
293￨48 academic and community centers in the united states children and adolescents pediatric social anxiety disorder a volunteer sample of 293 outpatients age 8 to 17 who met diagnostic criteria for social anxiety disorder and were enrolled between february 2000 and march 2003 participated children and adolescents with generalized social anxiety disorder￨venlafaxine er venlafaxine er placebo venlafaxine er or placebo￨treatmentemergent suicidality social anxiety scale child or adolescent version sasca and for responder analysis a dichotomized social anxiety disorder clinical global impressionsimprovement cgii score￨compared with placebo intenttotreat random regression analyses indicated a statistically significant advantage for venlafaxine er p  001 on the sasca￨sig increase￨low￨low￨low
30￨childhood and adolescent anxiety disorders thirty patients mean 126 years diagnosed with overanxious or avoidant disorders participated in the study children and adolescents with overanxious and avoidant disorders￨alprazolam alprazolam placebo￨tolerated and adverse effects clinical laboratory cognitive and qualitative eeg measurements efficacy and safety￨relative to baseline eeg acute alprazolam administration increased beta power in the right occipital lead and chronic administration increased beta power in both leads￨sig increase￨highunclear￨highunclear￨highunclear
not found￨controlled trials were conducted at 59 sites in 2000 and 2001 generalized anxiety disorder in children and adolescents participants 6 to 17 years of age who met dsmiv criteria for generalized anxiety disorder received a pediatric generalized anxiety disorder￨extendedrelease venlafaxine placebo venlafaxine flexible dosage of extendedrelease venlafaxine n157 or placebo￨response rate cgi improvement score 3 asthenia anorexia pain and somnolence efficacy and safety efficacy safety and tolerability overall score on the nine delineated items pediatric anxiety rating scale hamilton anxiety rating scale screen for child anxiety related emotional disorders and the severity of illness and improvement scores from the clinical global impression scale cgi height weight blood pressure pulse and cholesterol levels composite score for nine delineated items from the generalized anxiety disorder section of a modified version of the schedule for affective disorders and schizophrenia for schoolage children￨the extendedrelease venlafaxine group showed statistically significant improvements in the primary and secondary outcome measures in study 1 and significant improvements in some secondary outcome measures but not the primary outcome measure in study 2￨sig increase￨low￨low￨low
17￨children setc for children and adolescents with social phobia youths ages 7 to 17 childhood social phobia￨fluoxetine pill placebo and social effectiveness therapy placebo fluoxetine and setc fluoxetine￨social skills decreasing anxiety in specific social interactions and enhancing ratings of social competence social distress and behavioral avoidance and increasing general functioning selfreports parent ratings independent evaluator ratings and behavioral assessment￨both fluoxetine and setc were more efficacious than placebo in reducing social distress and behavioral avoidance and increasing general functioning￨sig decrease￨highunclear￨highunclear￨highunclear
16￨fifteen placebo nonresponders children with elective mutism sixteen subjects with elective mutism￨placebo fluoxetine fluoxetine￨ratings of elective mutism anxiety and social anxiety rated by clinician parents and teachers clinician and teacher ratings￨subjects treated with fluoxetine were significantly more improved than placebotreated subjects on parents ratings of mutism change and global change￨sig increase￨highunclear￨highunclear￨highunclear
22￨generalized anxiety disorder in children and adolescents 22 children and adolescents age 517 years who met the dsmiv criteria for generalized anxiety disorder according to the anxiety disorders interview schedule for childrenrevised and who had a hamilton anxiety rating scale score  or  16 children and adolescents children with generalized anxiety disorder￨sertraline placebo sertraline or pill placebo placebo￨hamilton anxiety scale total score psychic factor and somatic factor and the clinical global impression severity and improvement scales hamilton anxiety scale and the clinical global impression scale generalized anxiety disorder safety and efficacy￨the hamilton anxiety scale total score psychic factor and somatic factor and the clinical global impression severity and improvement scales showed significant differences with treatment in favor of sertraline over placebo beginning at week 4￨sig increase￨highunclear￨highunclear￨highunclear
207￨children and adolescents children and adolescents with obsessivecompulsive disorder 207 patients pediatric obsessivecompulsive disorder children 711 years of age and adolescents 1217 years of age meeting dsmiv criteria for obsessivecompulsive disorder￨placebo paroxetine paroxetine￨childrens yalebrown obsessivecompulsive scale cybocs total score safety efficacy and safety adverse events￨the adjusted mean difference 345 in favor of paroxetine was statistically significant 95 confidence interval560 to 129 p002￨no diff￨low￨low￨low
425￨patients children and adolescents pediatric social anxiety disorder 319 were included in the intentiontotreat population paroxetine n  163 placebo n  156 322 children 811 years of age and adolescents 1217 years of age with social anxiety disorder as their predominant psychiatric illness children and adolescents with social anxiety disorder four hundred twentyfive patients were screened and 322￨placebo paroxetine paroxetine￨decreased appetite insomnia adverse events adverse events vomiting efficacy and tolerability￨withdrawals due to adverse events were infrequent 55 9163 for paroxetine and 13 2156 for placebo￨no diff￨low￨low￨low
15￨15 children aged 7 to 13 years adult anxiety disorders twelve children completed the trial children with anxiety disorders childhood anxiety disorders￨clonazepam clonazepam czp placebo czp￨drowsiness irritability andor oppositional behavior￨nine children appeared to have moderate to significant clinical improvement but statistical comparisons on several ratings failed to confirm a trend in favor of czp￨no diff￨highunclear￨highunclear￨highunclear
43￨children and adolescents with ocd between 1991 and 1998 43 patients child and adolescent obsessivecompulsive disorder ocd￨placebo fluoxetine or placebo fluoxetine fluoxetine￨lower cybocs scores adverse medication effects tolerated and effective cgii scale safety and efficacy childrens yalebrown obsessive compulsive scale cybocs and the clinical global impressionimprovement cgii scale￨fluoxetine patients n  21 had significantly lower cybocs scores than placebo patients n  22 after 16 but not 8 weeks￨sig decrease￨highunclear￨highunclear￨highunclear
112￨children and adolescents children and adolescents with obsessivecompulsive disorder children and adolescents with ocd children and adolescents with ocd 3 academic centers in the united states and enrolling a volunteer outpatient sample of 112 patients aged 7 through 17 years with a primary diagnostic and statistical manual of mental disorders fourth edition diagnosis of ocd and a childrens yalebrown obsessivecompulsive scale cybocs score of 16 or higher patients were recruited between september 1997 and december 2002￨cbt and sertraline combined cbt placebo sertraline shortterm ocdspecific cognitivebehavior therapy cbt or medical management with selective serotonin reuptake inhibitors cbt alone sertraline alone combined cbt and sertraline or pill placebo cognitivebehavior therapy sertraline and their combination￨remission rate change in cybocs score rate of clinical remission acceptable and well tolerated￨the 3 active treatments proved acceptable and well tolerated with no evidence of treatmentemergent harm to self or to others￨no diff￨low￨low￨low
not found￨childhood and adolescent obsessivecompulsive disorder children and adolescents with obsessive compulsive disorder￨clomipramine hydrochloride placebo clomipramine hydrochloride cmi versus placebo￨yalebrown obsessive compulsive scale score child version of the yalebrown obsessive compulsive scale and the national institute of mental health global rating scale effective and well tolerated￨at the end of 8 weeks cmitreated patients showed a mean reduction in yalebrown obsessive compulsive scale score of 37 compared to 8 in the placebo group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨pediatric obsessivecompulsive disorder for obsessivecompulsive disorder ocd children and adolescents treated with￨paroxetine or to placebo placebo paroxetine￨relapse rates psychiatric comorbidity ocd response phase i and relapse risk of relapse response rates clinical global impressionimprovement scale and the childrens yalebrown obsessive compulsive scale rate of relapse oppositional defiant disorder￨ocd response phase i and relapse phase ii criteria were based on the clinical global impressionimprovement scale and the childrens yalebrown obsessive compulsive scale￨no diff￨highunclear￨highunclear￨highunclear
103￨eligible patients aged 7 to 17 n  103 children and adolescents child and adolescent obsessivecompulsive disorder ocd￨placebo fluoxetine or placebo fluoxetine fluoxetine￨ocd obsessivecompulsive disorder childrens yalebrown obsessive compulsive scale cybocs tolerated effective and well tolerated ocd symptoms rate of discontinuation for adverse events efficacy and tolerability￨fluoxetine was associated with significantly greater improvement in ocd as assessed by the cybocs p  026 and other measures than was placebo￨sig increase￨highunclear￨highunclear￨highunclear
638￨asthma 638 adult and adolescent patients with moderate asthma who entered the prebaseline theophylline titration period 154 were withdrawn prior to randomization 71 due to theophyllinerelated adverse effects 484 patients comprised the intenttotreat population￨theophylline and placebo theophylline placebo salmeterol salmeterol aerosol 42 micrograms extendedrelease theophylline capsules or placebo inhaled longacting bronchodilator salmeterol with the oral bronchodilator theophylline salmeterol theophylline or placebo￨asthma symptoms reducing nighttime awakenings and reducing the daily use of albuterol mean morning pef mean serum theophylline concentration tolerated mean predose fev1 overall satisfaction with their asthma medication gastrointestinal adverse events￨salmeterol was also significantly more effective than theophylline or placebo p  02 in improving asthma symptoms reducing nighttime awakenings and reducing the daily use of albuterol￨sig increase￨low￨low￨low
26￨26 subjects with mild to moderate asthma and a history of frequent nocturnal symptoms who previously demonstrated decrements in am lung function￨theophylline theo theophylline placebo theo inhaled bitolterol bitolterol bitol a longacting beta 2agonist￨nocturnal asthma symptoms sleep latency total sleep time percentage of total sleep time spent in stages 1 2 and 34 and in rem sleep daytime and nocturnal pulmonary symptoms and lung dysfunction￨theo was not found to disrupt sleep as sleep latency total sleep time percentage of total sleep time spent in stages 1 2 and 34 and in rem sleep were similar during each regimenabstract truncated at 250 words￨no diff￨highunclear￨highunclear￨highunclear
189￨patients with reversible airway obstruction moderatetosevere asthma one hundred and eighty nine asthmatic patients patients with moderatetosevere asthma￨salmeterol theophylline inhaled salmeterol and individually dosetitrated slowrelease theophylline salmeterol dry powder 50 microg bid via a diskhaler n92 or dosetitrated slowrelease theophylline capsules theodur bid￨serum theophylline level mean morning pef pef symptoms or additional salbutamol medication forced expiratory volume in one second fev1 or peak expiratory flow pef median percentage of nights with no asthma symptoms clinical efficacy incidence of gastrointestinal symptoms gastric irritation nausea and vomiting￨the incidence of gastrointestinal symptoms gastric irritation nausea and vomiting was greater among patients receiving theophylline 11 than with salmeterol 3￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with nocturnal asthma outpatients at a single center male and female patients who were at least 18 years old with nocturnal asthma baseline fev1 50 to 90 of predicted and who required regular bronchodilator therapy￨theophylline and placebo theophylline placebo salmeterol salmeterol and placebo inhaled salmeterol salmeterol and extendedrelease theophylline inhaled corticosteroids cromolyn and nedocromil salmeterol￨improving morning and evening peak expiratory flow pef percentage of days and nights with no albuterol use and decreased daytime albuterol sleep quality nocturnal fev1 levels polysomnographic measures of sleep quality nocturnal spirometry nocturnal polysomnography sleep questionnaires and daily measurements of lung function and symptoms efficacy safety patient perceptions of sleep sleep quality global scores sleep architecture￨salmeterol was superior to theophylline p  or  005 in maintaining nocturnal fev1 levels and was superior to placebo p  or  005 in improving morning and evening peak expiratory flow pef and in decreasing nighttime albuterol use￨sig increase￨low￨highunclear￨low
64￨patients with moderate asthma 64 patients with asthma in the moderate persistent asthma category patients who still have symptoms on treatment with moderate persistent asthma￨oral zafirlukast 20 mg twice daily second group or sustainedrelease theophylline inhaled formoterol second controller medications longacting beta2agonist leukotriene receptor antagonist and sustainedrelease theophylline inhaled corticosteroid budesonide inhaled corticosteroids formoterol￨maximum side effect asthma symptom score nighttime peak expiratory flow pef variability forced expiratory volume in 1 sec fev1 asthma symptom scores daytime and nighttime supplemental terbutalin use asthma exacerbations and adverse events overall asthma control lung function asthma symptom scores and supplemental terbutalin use criteria asthma symptom score daytime efficacy and safety￨formoterol treatment resulted in significantly greater and earlier improvements compared with the other two groups in several criteria pef variability 179￨sig increase￨highunclear￨highunclear￨highunclear
96￨patients with nocturnal asthma nocturnal asthma ninety six patients with nocturnal asthma forced expiratory volume in one second fev1 6090 of predicted value reversibility  or  15 at least two nocturnal awakenings per week￨tk salmeterol inhaled salmeterol sml theophylline and ketotifen po theophylline combined with ketotifen￨successfailure success being defined as the complete disappearance of nocturnal symptomsawakening efficacy sml efficacy and tolerance of sml sml and tk sideeffects￨there was a statistically significant difference between sml and tk for this criterion 46 and 39 success with sml during periods i first 28day period and ii following the crossover compared to only 15 and 26 with tk respectively p  001￨sig increase￨highunclear￨highunclear￨highunclear
15￨patients with nocturnal asthma 15 patients with stable nocturnal asthma overnight peak expiratory flow rate pefr fall  or  15  or  1 asthmatic awakeningweek using a doubleblind doubledummy crossover design with 14d therapy limbs￨inhaled salmeterol or oral theophylline theophylline cognitive testing and polysomnography￨otherwise daytime cognition trough plasma theophylline concentration overnight pefr falls nocturnal cough and wheeze sleep quality and cognitive performance quality of life visual vigilance sleep architecture nocturnal arousals sleep quality quality of life and daytime cognitive function￨visual vigilance improved on salmetrol p  005 but otherwise daytime cognition was unaffected￨sig increase￨highunclear￨highunclear￨highunclear
112￨asthmatic patients with asthmatic patients 112 patients￨salmeterol vs slowrelease theophylline theophylline salmeterol inhaled salmeterol salmeterol and theophylline salmeterol￨subjective assessment of efficacy day and nighttime symptoms additional salbutamol requirement quality of life total number of adverse events fev1 and fvc efficacy and safety￨salmeterol showed a greater and more significant efficacy than theophylline in reducing both day and nighttime symptoms p  0001 and in reducing additional salbutamol requirement p  0001￨sig decrease￨highunclear￨highunclear￨highunclear
141￨patients with reversible airways disease patients with moderate asthma 141 patients with moderate reversible airways disease￨theophylline salmeterol inhaled salmeterol 50 micrograms salmeterol via a metered dose inhaler or individually dosetitrated oral theophylline theophylline therapy salmeterol theophylline￨adverse events effective and better tolerated mean morning peak expiratory flow pef lung function data and symptom scores number of nights efficacy and tolerability daytime symptoms nighttime awakenings pef￨there was also a significant increase in the number of nights p  0013 and days p  0001 on salmeterol when no additional salbutamol was required compared with theophylline￨sig increase￨low￨low￨low
16￨3 patients had gastrointestinal disturbances during theophylline treatment nocturnal asthma patients with nocturnal asthma 16 patients￨theophylline theophylline uniphyllin salmeterol versus nocturnal administration of retard theophyllinecomparison salmeterol and theophylline salmeterol salmeterol over theophylline￨number of nights with an overnight fall in pefr nights with none or rare symptoms peak expiratory peak flow rate pefr rare nocturnal symptoms and c none or rare early morning symptoms￨12 patients preferred salmeterol over theophylline p  005￨sig increase￨highunclear￨highunclear￨highunclear
100￨patients with colorectal liver metastases colorectal liver metastases 100 patients￨hepaticartery floxuridine infusion conventional symptom palliation hepaticartery infusion of floxuridine continuous hepaticartery floxuridine infusion￨overall survival normalquality ie normal symptom scores survival for physical symptoms anxiety quality of life and survival serum aspartate aminotransferase and bilirubin measurements serum carcinoembryonic antigen concentration quality of life and survival￨there was a significant prolongation p  003 in overall survival in floxuridinetreated patients compared with controls median 405 vs 226 days￨sig increase￨highunclear￨highunclear￨highunclear
183￨183 patients randomized between january 1985 and february 1990 asymptomatic patients with advanced colorectal cancer asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy between january 1985 and march 1987 43 patients were randomized at one of the hospitals 36 of which were interviewed with a questionnaire at randomization￨mfl initial chemotherapy initial chemotherapy with sequential methotrexate5fu with leucovorin rescue mfl￨since symptomfree survival progressionfree survival and survival adverse effects symptomfree survival progressionfree survival and survival toxicity symptomfree survival and survival without reduced quality of life￨since symptomfree survival progressionfree survival and survival were statistically significantly longer in the group of patients randomized to mfl also in this associated study it is concluded that initial chemotherapy can prolong symptomfree survival and survival without reduced quality of life during the treatment period￨sig increase￨highunclear￨highunclear￨highunclear
61￨patients with advanced gastric and colorectal cancer between january 1991 and may 1992 61 patients with inoperable cancer 18 gastric 22 pancreatic or biliary and 21 colorectal pancreaticbiliary cancer patients patients suffering from gastric and pancreaticbiliary cancer advanced gastrointestinal cancer￨chemotherapy primary chemotherapy in addition to best supportive care or to best supportive care palliative chemotherapy￨prolonged high quality of life incremental costs per gained year of life overall survival and qualityadjusted survival costeffectiveness survival quality of life and prolong survival average cost for all medical care￨more patients in the primary chemotherapy group 1933 58 had improvedprolonged high quality of life qolpatient minimum duration 4 months than in the best supportive care group 828 29 p  005￨sig increase￨highunclear￨highunclear￨highunclear
84￨liver metastases from colorectal cancer with hepatic artery occlusion intraportal patients with nonresectable liver metastases and no extrahepatic cancer eightyfour patients were considered for randomization of whom 24 were excluded at laparotomy because of extrahepatic cancer n  17 or resectable lesions n  5 patients with nonresectable liver metastases and no extrahepatic metastases from colorectal cancer thirtytwo patients six patients were excluded after randomization because of major protocol violations￨5fluorouracil infusion and oral allopurinol temporary hepatic artery occlusion no regional or systemic treatment 5fluorouracil 5fu and oral allopurinol regional therapy 5fu￨toxicity mean and median survival survival benefit median survival time￨this study identified a treatment modality that prolongs survival in patients with nonresectable liver metastases and no extrahepatic metastases from colorectal cancer suggesting that control subjects receiving no therapy may not be necessary in future randomized trials￨sig increase￨highunclear￨highunclear￨highunclear
not found￨situ hybridization fish for the chromosomes x y 13 16 18 21 and 22 in ama couples aged  or 37 years with a control group without pgdas from the 400 200 for pgdas and 200 controls couples couples with advanced maternal age patients with ama￨blastocyst transfer with or without preimplantation genetic diagnosis blastocyst transfer combined with pgdas￨aneuploidy rate positive serum hcg rates per transfer and per cycle implantation rate with fetal heart beat￨significantly fewer embryos were transferred in the pgdas group than in the control group p0001￨sig decrease￨highunclear￨highunclear￨highunclear
200￨two hundred patients with recurrent failed implantation 139 patients underwent ovarian stimulation and preimplantation genetic screening was performed in 72 patients ivficsi patients with poor implantation women with repeated implantation failure patients with recurrent failed implantation benefit from preimplantation genetic diagnosis for aneuploidy￨pgs ivfintracytoplasmic sperm injection￨clinical pregnancy rate embryonic morphology and chromosomal status number of transferred embryos and clinical pregnancy rate implantation rates implantation rate number of embryos transferred￨it can be concluded that preimplantation genetic screening does not increase the implantation rates after ivfintracytoplasmic sperm injection in women with repeated implantation failure￨no diff￨highunclear￨highunclear￨highunclear
320￨320 patients calculated to be included in the study 56 and 53 patients advanced maternal age ama ama patients women of advanced maternal age ama patients or38 years of age after pgs using fish analysis for chromosomes x y 13 16 18 21 and 22￨pgs employing preimplantation genetic screening pgs preimplantation genetic screening￨clinical pregnancy rate pregnancy rate￨the clinical pregnancy rate in the pgs group was 89 95 ci 29196 compared with 245 95 ci 138383 in the control group giving a difference of 156 95 ci 18294 p  0039￨no diff￨low￨low￨low
not found￨infertile ama patients infertile patients of advanced maternal age women of advanced maternal age ama sixtytwo infertile ama couples undergoing fertility treatment￨vitro fertilization ivf￨spontaneous abortion rate delivery rates fertilization and blastocyst developmental rates implantation rates average number of embryos transferred￨preimplantation aneuploidy testing does not appear to statistically significantly improve outcome parameters in infertile ama patients however a trend toward a decrease in the spontaneous abortion rate with a subsequent higher delivery rate was observed￨no diff￨highunclear￨highunclear￨highunclear
447￨women under the age 36 women under the age of 36 following singleembryo transfer couples with a female partner younger than 36￨single blastocyst in a cycle with or without pgs using fish￨delivery rate live birth delivery rates live birth delivery rate normal diploid status￨the absence of a beneficial treatment effect in this randomized clinical trial provides no arguments in favour of pgs to improve live birth delivery rate following singleembryo transfer in women under the age 36￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨blastocyst biopsy followed by preimplantation genetic screening pgs￨￨we report a randomized clinical trial of blastocyst biopsy followed by preimplantation genetic screening pgs for aneuploidy using 5colour fish￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients with ama  or 35 years women aged at least 35 years copyright 2010 american society for reproductive medicine patients with advanced maternal age ama patients with ama￨preimplantation genetic screening pgs preimplantation genetic screening￨clinical ir ongoing ir live born rate per embryo transferred reproductive outcome￨fewer embryos were transferred in the pgs group 16  06 than in the control group 20  06￨sig decrease￨low￨low￨low
23￨infertile women predicted to have a good prognosis as defined by age 39 years normal ovarian reserve body mass index 30 kgm2 presence of ejaculated sperm normal uterus or2 previous failed ivf cycles￨pgs preimplantation genetic screening pgs blastomere biopsy on day 3 after fertilization pgs group and 24 women underwent routine ivf control group￨pregnancy implantation multiple gestation and live birth rates clinical pregnancy rate pregnancy implantation or live birth rates embryo implantation rate multiple birth rate vitro fertilization ivf cycle outcome live birth rate￨in a good prognosis population of women pgs does not appear to improve pregnancy implantation or live birth rates￨no diff￨highunclear￨highunclear￨highunclear
35￨35 patients with an acute relapse of multiple sclerosis ms multiple sclerosis￨placebo or intravenous treatment and oral placebo receiving 500 mg of methylprednisolone methylprednisolone placebo methylprednisolone￨acute relapse of ms disability or functional scores adverse effects￨there was no significant difference in response when disability or functional scores were compared in the two groups￨no diff￨highunclear￨highunclear￨highunclear
16￨multiple sclerosis 16 patients with multiple sclerosis ms￨methylprednisolone ivmp prednisone methylprednisolone and oral prednisone oral prednisone￨mean area under the concentrationtime curve auc the main component of bioavailability￨at 24 hours the mean area under the concentrationtime curve auc the main component of bioavailability did not differ between groups p  0122￨sig decrease￨highunclear￨highunclear￨highunclear
42￨42 patients with clinically definite relapse in ms received oral and 38 intravenous acute relapses of multiple sclerosis￨methylprednisolone placebo oral and intravenous methylprednisolone oral steroid regimens￨kurtzkes expanded disability status scale edss hausers ambulatory index and an armfunction index edss￨there were no significant differences between the two groups at any stage of the study in any measurement taken the mean difference in edss at 4 weeks adjusted for baseline level was 007 grades more in those taking oral steroids 95 ci 046 to 060￨no diff￨low￨low￨low
40￨patients with multiple sclerosis ms experiencing a recent relapse patients with a clinical relapse within the previous 2 weeks and at least 1 gadolinium gdenhancing lesion on a screening brain mri scan were included forty patients with ms￨methylprednisolone oral methylprednisolone omp methylprednisolone iv mp vs oral methylprednisolone omp omp￨safety tolerability and clinical efficacy profiles of the 2 routes of administration edss over time number of gadoliniumenhancing lesions gadoliniumenhancing lesions number of gdenhancing lesions efficacy tolerability and safety expanded disability status scale edss and brain mri dualecho and postcontrast t1weighted scans tolerated and adverse events reduction of gdenhancing lesions￨both groups showed an improvement of edss over time p  0001 without betweengroup difference at week 4￨sig decrease￨highunclear￨highunclear￨highunclear
158￨patients with preoperative biliary drainage between 2006 and 2009 158 patients who underwent pd￨external pancreatic duct stent external stent inserted across the anastomosis to drain the pancreatic duct n  77 or no stent ct scan pancreaticoduodenectomy external drainage stent versus no stent￨hospital stay overall pf mortality morbidity and pf rates pf rate defined as amylaserich fluid amylase concentration 3 times the upper limit of normal serum amylase level morbidity mortality rate pancreatic fistula rate delayed gastric emptying pf and overall morbidity rates￨stented group had a significantly lower overall pf 26 vs 42 p  0034 morbidity 415 vs 617 p  001 and delayed gastric emptying 78 vs 272 p  0001 rates compared with nonstented group￨sig decrease￨highunclear￨highunclear￨highunclear
120￨120 patients undergoing pancreaticoduodenectomy with endtoside pancreaticojejunal anastomosis￨radiologic or surgical intervention pancreaticoduodenectomy with external drainage stent versus no stent for pancreaticojejunal anastomosis pancreaticoduodenectomy external stent inserted across the anastomosis to drain the pancreatic duct n  60 or no stent external drainage of pancreatic duct with a stent￨hospital stay pancreatic fistula demographic data underlying pathologies pancreatic consistency and duct diameter overall morbidity pancreatic fistula rate hospital mortality leakage rate of pancreaticojejunostomy￨hospital stay was significantly shorter in the stented group mean 17 vs 23 days p  0039￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨43 patients who had pj with an external stent group e or pj with an internal stent group i after a pancreaticoduodenectomy pd￨pancreaticojejunostomy with an internal stent after a pancreatoduodenectomy pj with an external stent versus an internal stent￨pancreatic fistula mortality and postoperative hospital stay pancreatitis pancreatic fistula￨pancreatic fistula occurred in 8 patients 364 in group e while it only was seen in 7 patients 333 in group i pancreatitis was recognized in 3 patients in group e while there was no patient in whom an obstruction due to an internal stent was suspected￨no diff￨highunclear￨highunclear￨highunclear
238￨two hundred thirtyeight patients￨internal pancreatic duct stenting internal pancreatic duct stenting plastic pediatric feeding tube used to stent the pancreaticojejunostomy anastomosis pancreatic duct stenting pancreatic stent s or no stent ns￨fistula rates pancreatic fistulas rate of pancreatic fistula pancreatic fistula rate￨a nonstatistically significant increase in the pancreatic fistula rate in the s group persisted after adjusting for the operating surgeon and technical details of the operation eg anastomotic technique anastomotic orientation pancreatic duct size and number of intraabdominal drains placed￨sig increase￨highunclear￨highunclear￨highunclear
not found￨100 patients who underwent￨pancreaticoduodenectomy external drainage with pancreaticojejunostomy for pancreaticoduodenectomy￨median postoperative hospital stay pancreatic fistula criteria median stay incidence of pancreatic fistula￨the median postoperative hospital stay was 21 days range 8163 d in the internal drainage group which was shorter than the median stay of 24 days range 2188 d in the external drainage group p  016￨no diff￨highunclear￨highunclear￨highunclear
959￨patients with type 2 diabetes patients previously treated with combination oral therapy 959 patients￨rosiglitazone placebo rosiglitazone placebo or rosiglitazone￨hba1c concentration hepatotoxicity glycemic control adverse event tolerated weight and serum lipids hyperglycemia￨clinically significant decreases from baseline in hba1c were observed in drugnaive patients at all rosiglitazone doses and in patients previously treated with oral monotherapy at rosiglitazone 8 mg od and 4 mg bid￨sig increase￨highunclear￨highunclear￨highunclear
402￨patients with type 2 diabetes enrolled subjects with a diagnosis of type 2 diabetes treated with patients with type 2 diabetes and dyslipidemia￨rosiglitazone placebo diet alone or oral monotherapy and dyslipidemia not treated with any lipidlowering agents pioglitazone and rosiglitazone pioglitazone pioglitazone pioglitazone and rosiglitazone￨ldl cholesterol ldl particle size plasma lipids triglycerides hdl cholesterol ldl particle concentration and ldl particle size hdl cholesterol ldl particle concentration triglyceride levels￨ldl particle concentration was reduced with pioglitazone and increased with rosiglitazone p  0001￨sig decrease￨highunclear￨highunclear￨highunclear
598￨individuals with type 2 diabetes over a 12month period a total of 598 patients type 2 diabetes total patients with type 2 diabetes￨rosiglitazone glibenclamide rosiglitazone rosiglitazone and glibenclamide￨hba1c levels fasting plasma glucose fpg haemoglobin a1c hba1c fasting insulin and its precursor peptides and lipids highdensity lipoprotein cholesterol ratios tolerated insulin resistance plasma insulin proinsulin split proinsulin and free fatty acid levels fasting insulin and proinsulin glycaemic control insulin resistance and proinsulin levels efficacy and safety mean fpg levels￨rosiglitazone therapy reduced plasma insulin proinsulin split proinsulin and free fatty acid levels compared with glibenclamide￨sig decrease￨highunclear￨highunclear￨highunclear
203￨203 patients randomly assigned to patients with type 2 diabetes￨glyburide glb rosiglitazone rsg rsg rosiglitazone and glyburide￨ambulatory blood pressure lv mass index ejection fraction left ventricular lv mass index ejection fraction and left ventricular enddiastolic volume hyperglycemia lv enddiastolic volume cardiac structure or function cardiovascular function and glycemic control glycemic control hba1c and fpg ambulatory diastolic blood pressure fasting plasma glucose fpg and hba1c￨ejection fraction did not change in either group￨no diff￨highunclear￨highunclear￨highunclear
4360￨patients with type 2 diabetes 4360 patients￨rosiglitazone rosiglitazone metformin or glyburide monotherapy thiazolidinediones rosiglitazone and metformin glyburide glyburide rosiglitazone rosiglitazone metformin and glyburide metformin metformin or glyburide￨fasting plasma glucose time to monotherapy failure weight gain and edema levels of fasting plasma glucose and glycated hemoglobin insulin sensitivity and betacell function lower risk of cardiovascular events glycemic durability gastrointestinal events hypoglycemia cumulative incidence of monotherapy failure durability of the treatment effect￨glyburide was associated with a lower risk of cardiovascular events including congestive heart failure than was rosiglitazone p005 and the risk associated with metformin was similar to that with rosiglitazone￨sig increase￨low￨low￨low
17￨nine subjects 17 subjects with type 2 diabetes inadequately controlled on a maximized oral antihyperglycemic double regimen of subjects with type 2 diabetes￨rosiglitazone glimepiride and metformin rosiglitazone versus insulin sulfonylureas and metformin rosiglitazone or insulin insulin premixed 7030 before their evening meal rosiglitazone￨disposition index betacell function recovery of pancreatic betacell function fasting plasma glucose fasting proinsulin and insulin levels frequently sampled intravenous glucose tolerance test and glucagon stimulation test for cpeptide acute insulin response to glucose proinsulintoinsulin ratio￨rosiglitazone but not insulin induced a recovery of pancreatic betacell function as evidenced by the restoration of the firstphase insulin response to glucose improvement in the disposition index and a decrease in the proinsulintoinsulin ratio in subjects with type 2 diabetes in whom oral antihyperglycemic therapy failed￨sig increase￨highunclear￨highunclear￨highunclear
45￨patients with type 2 diabetes 45 patients with newly diagnosed or diettreated type 2 diabetes patients with newly diagnosed type 2 diabetes￨rosiglitazone placebo thiazolidinedione rosiglitazone and metformin fluorine18labeled fluorodeoxyglucose and positron emission tomography pet during euglycemichyperinsulinemic clamp and onelegged exercise rosiglitazone metformin￨skeletal muscle glucose uptake synergic action of insulin and exercise peripheral insulin sensitivity skeletal muscle glucose uptake muscle insulin responsiveness insulin responsiveness wholebody glucose uptake skeletal muscle or wholebody insulin sensitivity exerciseinduced increment during insulin stimulation mean glycosylated hemoglobin￨the skeletal muscle glucose uptake was increased by 38 p  001 and wholebody glucose uptake by 44 in the rosiglitazone group￨sig increase￨highunclear￨highunclear￨highunclear
95￨95 patients completed the study patients affected by type 2 diabetes and metabolic syndrome 99 type 2 diabetic patients with metabolic syndrome 48 males and 47 females 23 males and 24 females aged 52 25 males and 23 females aged 54  4 with cglitazone type 2 diabetic patients treated with￨rosiglitazone glimepiride plus metformin and rosiglitazone plus metformin glimepiridemetformin glimepiride glimepiride and rosiglitazone rosiglitazonemetformin metformin￨sideeffects significant tc ldlc and apo b improvement glycated haemoglobin decrease mean fasting plasma glucose and postprandial plasma glucose levels significant bmi decrease transient sideeffects fasting plasma insulin and postprandial plasma insulin body mass index bmi glycaemic control lipid profile total cholesterol tc lowdensity lipoproteincholesterol ldlc highdensity lipoproteincholesterol and triglycerides and lipoprotein parameters apolipoprotein ai and apolipoprotein b apo b homeostasis model assessment index improvement glucose and lipid parameters transaminases cholesterolaemia￨significant tc ldlc and apo b improvement p  005 respectively was present in glimepiride group after 12 months compared with the baseline values and these variations were significant p  005 between groups￨sig increase￨highunclear￨highunclear￨highunclear
91￨group 20 women 22 men mean sd age 54 5 years 3 study sites in italy patients with diabetes and metabolic syndrome treated with patients with type 2 dm and metabolic syndrome who did not respond adequately to or experienced aes with diet and either a 91 patients were enrolled in the study 87 patients completed it all patients were required to have poor glycemic control with or to have experienced  or 1 adverse effect ae with diet and oral hypoglycemic agents such as sulfonylureas or metformin both given up to the maximum tolerated dose patients with type 2 diabetes mellitus dm and metabolic syndrome g  p group 24 women 21 men mean sd age 53 6 years patients with type 2 dm duration  or 6 months and with metabolic syndrome￨glimepiride with pioglitazone or rosiglitazone glimepiride plus pioglitazone or rosiglitazone glimepiride glimepiride plus pioglitazone sulfonylurea or metformin glimepiride glimepiride plus rosiglitazone g  r oral pioglitazone metformin oral rosiglitazone pioglitazone and rosiglitazone￨plasma aminotransferase activities lipid and lipoprotein variables treatment tolerability glucose and lipid variables and tolerability mean values for plasma hba1c concentration metabolic effects glycemic control body mass index bmi glycemic control glycosylated hemoglobin hba1c fasting and postprandial plasma glucose and insulin levels fpg ppg fpi and ppi respectively and homeostasis model assessment index lipid profile total cholesterol tc lowdensity lipoprotein cholesterol ldlc highdensity lipoprotein cholesterol hdlc and triglycerides tg and lipoprotein variables apolipoprotein apo lipid risk factors for cardiovascular disease lipid metabolism mean bmi￨patients in the g  p and g  r groups experienced significant increases in mean bmi at 12 months compared with baseline 492 and 617 respectively both p  005￨sig increase￨highunclear￨highunclear￨highunclear
6￨type 2 diabetic subjects diabetic patients human subjects with metabolic syndrome and coronary artery disease type 2 diabetic patients type 2 diabetic patients 30 in the treatment group and 34 in the placebo group￨rosiglitazone placebo rosiglitazone ppargamma agonist rosiglitazone￨plasma adiponectin fasting plasma glucose hba1c insulin resistance index and bmi plasma adiponectin level mean plasma adiponectin level plasma adiponectin levels metabolic variables and adiponectin levels plasma levels of adiponectin￨in the rosiglitazone group mean plasma adiponectin level was increased by more than twofold p  00005 whereas no change was observed in the placebo group￨sig increase￨highunclear￨highunclear￨highunclear
252￨enrolled patients n  252 were adults having type 2 diabetes for at least 1 year with hba1c values type 2 diabetes after unsatisfactory response to sulphonylurea or metformin monotherapy type 2 diabetes￨rosiglitazone repagliniderosiglitazone repaglinide plus rosiglitazone repaglinide or rosiglitazone monotherapy sulphonylurea or metformin rosiglitazone monotherapy repaglinide monotherapy rosiglitazone monotherapy and combination therapy repaglinide plus rosiglitazone repaglinide rosiglitazone or repagliniderosiglitazone repaglinide monotherapy repaglinide￨minor hypoglycaemic events baseline hba1c values changes in hba1c values primary or fasting plasma glucose values secondary hba1c response individual weight gains tolerated mean changes in hba1c values glycaemic reductions fasting plasma glucose values￨mean changes in hba1c values at the end of treatment were greater for repagliniderosiglitazone therapy 143 than for repaglinide 017 or rosiglitazone 056 monotherapy￨sig decrease￨highunclear￨highunclear￨highunclear
92￨patients with type 2 diabetes type 2 diabetes mellitus ninetytwo subjects with suboptimally controlled diabetes mellitus hemoglobin a1c hba1c 70￨rosiglitazone metformin and rosiglitazone rosiglitazone and metformin rosiglitazone metformin rosiglitazone 4 mg once daily or metformin￨hscrp levels change in hscrp maximal cimt progressed regression of maximal cimt change in hscrp and maximal cimt mean cimt glycemic control inflammation and subclinical atherosclerosis hscrp highsensitivity creactive protein levels￨rosiglitazone compared to metformin induced a prompt and profound reduction in hscrp levels independent of its effect on glycemia￨no diff￨highunclear￨highunclear￨highunclear
112￨112 chinese patients with type 2 diabetes and conventional oad failure were recruited 112 patients mean age sd was 582110 y median 58 y range 37 to 84 y patients with conventional oral antidiabetic drug failure chinese patients with type 2 diabetes and secondary conventional oad failure 1 y of treatment with patients with secondary oral antidiabetic drug oad failure￨rosiglitazone or bedtime isophane insulin rosiglitazone rosiglitazone￨adverse effects 5 early morning hypoglycemia and 1 anxiety hemoglobin a1c concentrations highdensity lipoprotein cholesterol levels glycemic control adverse effects 2 ankle edema and 2 gastrointestinal disturbance highdensity lipoprotein cholesterol concentrations body mass index fasting glucose efficacy and tolerability glycemic index other clinical profiles and tolerability￨both rosiglitazone n56 and insulin n56 significantly improved fasting glucose 24 and 37 mmoll respectively and hemoglobin a1c concentrations 11 and 13 respectively￨sig increase￨highunclear￨highunclear￨highunclear
not found￨diabetic patients with metabolic syndrome all patients began patients with diabetes and metabolic syndrome treated with￨rosiglitazone metformin plus thiazolidinediones pioglitazone or rosiglitazone metformin plus pioglitazone or metformin plus rosiglitazone metformin metformin pioglitazone pioglitazone pioglitazone and rosiglitazone￨lipid and lipoprotein variables metabolic effects significant total cholesterol lowdensity lipoprotein cholesterol highdensity lipoprotein cholesterol triglycerides apolipoprotein ai and apolipoprotein b improvement body mass index glycated haemoglobin fasting plasma glucose postprandial plasma glucose fasting plasma insulin postprandial plasma insulin homeostasis model assessment index total cholesterol lowdensity lipoprotein cholesterol highdensity lipoprotein cholesterol triglycerides apolipoprotein ai and apolipoprotein b
                significant decreases in glycated haemoglobin fasting plasma glucose postprandial plasma glucose fasting plasma insulin and postprandial plasma insulin homeostasis model assessment index glycaemic control￨homeostasis model assessment index improved at 12 months in both groups￨sig increase￨highunclear￨highunclear￨highunclear
318￨patients with type 2 diabetes inadequately controlled on metformin monotherapy 318 patients￨metforminglibenclamide 50025 mg tablets initial daily dose 10005 mg or metformin 500 mg plus rosiglitazone metformin plus rosiglitazone metforminglibenclamide tablets metforminglibenclamide metforminglibenclamide tablets vs metformin plus rosiglitazone therapy metforminglibenclamide￨fasting plasma glucose symptomatic hypoglycaemia hba1c and fasting plasma glucose fasting plasma glucose levels tolerated hypoglycaemic events hba1c change in hba1c efficacy and safety frequency of adverse gastrointestinal events￨metforminglibenclamide tablets resulted in significantly greater reductions in hba1c and fasting plasma glucose compared with metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨4 mgd individuals with type 2 diabetes mellitus patients with type 2 diabetes mellitus patients with type 2 diabetes mellitus showing poor glycemic control with sulfonylurea therapy patients with type 2 diabetes mellitus who showed poor glycemic control with￨glimepiride rosiglitazone metformin rosiglitazone and metformin￨plasma resistin levels plasma concentrations of resistin lipid profiles plasma glucose levels plasma adiponectin concentrations anthropometric parameters fasting plasma glucose hba1c total cholesterol triglyceride highdensity lipoprotein cholesterol free fatty acids and adiponectin concentrations￨after 6 months of treatment the reduction in plasma glucose levels was similar between the 2 groups￨no diff￨highunclear￨highunclear￨highunclear
60￨young children young children sixty children from the primary 1 reception classes of three glasgow schools took part volunteers were ordinary parents from the same areas￨roadside training￨pedestrian competence￨significant improvements relative to controls were found in all children following training￨sig increase￨highunclear￨highunclear￨highunclear
181￨kindergarten and elementary school children kindergarten students at 10 urban elementary schools one hundred eightyone children￨safety education program￨safety knowledge￨there was no statistical difference in the change between pretest and posttest scores of children who participated in the safety city program and those in the control group crossing the street p  29 calling 911 p  41 stranger avoidance p  57￨no diff￨highunclear￨highunclear￨highunclear
100￨100 pregnant patients admitted to the labour room of lok nayak hospital new delhi￨4 intracutaneous injections of sterile water or normal saline 05ml￨progress of labour and fetal outcome pain scores pain scores progress of labour and fetal outcome￨there was significant reduction of pain scores in the sterile water group but not in the normal saline group at 10 45 and 90 minutes after injection￨sig decrease￨highunclear￨highunclear￨highunclear
99￨ninetynine pregnant women at term requiring pain relief for severe lower back pain during the first stage of labour labour ward with approximately 3000 deliveries annually in a suburban area near gothenburg sweden￨placebo labour pain treated with cutaneous injections of sterile water 01 ml sterile water without salt intracutaneously￨reduction of labour pain visual analogue scores relief of pain median reductions in visual analogue scores analgesic effect or pain median visual analogue scale pain score for labour pain￨the median visual analogue scale pain score for labour pain was significantly lower compared with initial values in the two study groups and compared with placebo at 10 and 45 minutes after treatment￨sig decrease￨low￨low￨low
100￨pain relief in labor 100 women in the active phase of labor and who complained of low back pain￨isotonic saline subcutaneous injection of sterile water￨pain perception numerical rating scale initial pain score relief scores pain relief analgesic efficacy￨the initial pain score was the same in both groups and pain relief was expressed by both groups irrespective of the solution injected but the sterile water group had significantly higher relief scores compared to those receiving saline￨no diff￨highunclear￨highunclear￨highunclear
45￨fortyfive pregnant women in the first stage of labour presenting with lower back pain￨placebo pethidine meperidine intracutaneous injections of sterile water placebo treatment isotonic saline￨mean vas score￨in the group that received intracutaneous sterile water injections the mean vas score was significantly more reduced compared to the placebo group at 10 min p less than 0001 45 min p less than 002 and at 90 min p less than 005 after the treatment￨sig decrease￨highunclear￨highunclear￨highunclear
272￨272 women in labor complaining of severe low back pain￨sterile water blocks intradermal sterile water blocks sterile water or saline solution blocks￨analgesic effect patient acceptability degree of analgesia adverse effects pain intensity low back labor pain￨pain scoring 1 and 2 hours after the blocks were given showed a significantly higher degree of analgesia in the sterile water group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨labour pain one hundred 100 consecutive patients￨placebo subcutaneous sterile water injection normal saline as a placebo subcutaneous sterile water injection￨pain severity median pain score pain score maternal age and weight gestational age parity and gravidity and degree of effacement labour pain￨the two groups were not significantly different regarding maternal age and weight gestational age parity and gravidity and degree of effacement￨no diff￨low￨low￨low
50￨fifty pregnant women at term requiring pain relief for severe low back pain during the first stage of labor thai women￨intracutaneous injections of sterile water placebo 4 intracutaneous injections of 01 ml sterile water n  25 or isotonic saline as placebo￨back pain time to delivery and rate of instrumental and cesarean delivery mean pain reduction mean pain scores relief of low back labor pain pain scores￨mean pain reduction were significantly greater in the treatment group compared to the placebo group at 30 minutes￨sig increase￨highunclear￨highunclear￨highunclear
not found￨all infants had a postconceptual age of less than 46 weeks at the time of surgery predisposed infants expremature infants 28 expremature infants undergoing inguinal herniotomy￨sevoflurane and spinal anaesthesia spinal anaesthesia sevoflurane supplemental caudal analgesia before skin incision￨bradycardia and apnoea apnoea hypoxaemia or bradycardia cardiorespiratory function unacceptable number of postoperative cardiorespiratory complications￨none of the remaining patients in group 2 demonstrated an unacceptable number of postoperative cardiorespiratory complications￨no diff￨highunclear￨highunclear￨highunclear
not found￨formerly premature infants eighteen formerly premature infants scheduled for inguinal herniorrhaphy and who were less than 51 wk postconceptional age formerly premature infants undergoing inguinal herniorrhaphy￨general anesthesia group ga atropine halothane and nitrous oxide or the spinal anesthesia group sa hyperbaric tetracaine spinal anesthesia￨postoperative minimum spo2 and minimum heart rate respiratory rate chest wall impedance electrocardiogram ecg and hemoglobin o2 saturation spo2 postoperative apnea bradycardia and oxygen desaturation minimum heart rate incidence of postoperative central apnea postoperative hemoglobin oxygen desaturation and bradycardia postoperative minimum spo2 apnea spells periodic breathing and episodes of hemoglobin oxygen desaturation and bradycardia￨30 respectively p  005 and had lower postoperative minimum spo2 and minimum heart rate than they had preoperatively 790￨sig decrease￨highunclear￨highunclear￨highunclear
40￨highrisk infants undergoing highrisk infants undergoing inguinal herniorrhaphy highrisk infants preterm or formerly preterm undergoing inguinal hernia repair forty patients all highrisk infants who underwent unilateral or bilateral herniorrhaphies￨spinal anaesthesia general anaesthesia herniorrhaphy general and spinal anaesthesia￨respiratory morbidity length of hospital stay postoperative respiratory morbidity inguinal hernia inpatient hospital stay postoperative respiratory complications￨there was a significant difference in respiratory morbidity between the two groups as well as a significant difference in the inpatient hospital stay￨no diff￨highunclear￨highunclear￨highunclear
not found￨former preterm infants thirtysix former preterm infants undergoing inguinal hernia repair were studied￨spinal anesthesia without ketamine sedation general anesthesia spinal and general anesthesia general or spinal anesthesia general inhalational anesthesia with neuromuscular blockade spinal anesthesia also received sedation with im ketamine 12 mgkg prior to placement of the spinal anesthetic spinal anesthesia using 1 tetracaine 0406 mgkg in conjunction with an equal volume of 10 dextrose and 002 ml epinephrine 11000 spinal anesthesia and adjunct intraoperative sedation with ketamine￨postoperative bradycardia prolonged apnea or periodic breathing incidence of apnea no prior history of apnea postoperative apnea respiratory pattern and heart rate prolonged apnea with bradycardia￨when infants with no prior history of apnea were analyzed separately there was no statistically significant increased incidence of apnea in children receiving general versus spinal anesthesia with or without ketamine sedation￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with severe cognitive impairment severe dementia seventytwo people residing in national health service uk care facilities who had clinically significant agitation in the context of severe dementia people with severe dementia￨placebo aromatherapy with melissa essential oil n  36 or placebo sunflower oil placebo oil aromatherapy aromatherapy with essential oil of melissa officinalis lemon balm aromatherapy￨cmai score clinically significant agitation cohenmansfield agitation inventory cmai and quality of life indices percentage of time spent socially withdrawn and percentage of time engaged in constructive activities measured with dementia care mapping agitation side effects behavioral and psychological symptoms quality of life indices￨quality of life indices also improved significantly more in people receiving essential balm oil mannwhitney u test percentage of time spent socially withdrawn z  26 p  005 percentage of time engaged in constructive activities z  35 p  001￨sig increase￨low￨low￨low
21￨dementia twentyone patients￨aromatherapy massage aromatherapy and massage am conversation and aromatherapy ca and massage only m aromatherapy￨frequency of excessive motor behaviour motor behaviour￨a random controlled trial of the relaxing effects of an aromatherapy massage on disordered behaviour in dementia was conducted￨sig increase￨highunclear￨highunclear￨highunclear
70￨persons with dementia are distressing to both patients and their caregivers chinese patients with dementia demented people in hong kong seventy chinese older adults with dementia were recruited half chinese older persons with dementia￨lavandula angustifolia lavender lavender aromatherapy lavandula angustifolia copyright c active group lavender inhalation￨cnpi scores agitated behaviours chinese versions of cohenmansfield agitation inventory ccmai and neuropsychiatric inventory cnpi mean ccmai total scores￨in summary lavender is effective as an adjunctive therapy in alleviating agitated behaviours in chinese patients with dementia￨sig increase￨highunclear￨highunclear￨highunclear
3086￨3086 adult smokers 151 practices general medical practices￨computerbased interventions alone or in addition to conventional practitionerdelivered advice computerbased practitioner delivered and combined smoking interventions intervention programs consisting in the delivery of 1 brief advice by the practitioner 2 individually tailored computergenerated letters or 3 a combination of both interventions￨odds of point abstinence from smoking smoking abstinence￨negative binomial regression analysis revealed that the number of interventions provided was higher in practices allocated to the tailored letter and combination intervention groups by 215 p01 and 127 p02 respectively compared to the brief advice intervention group￨sig increase￨highunclear￨highunclear￨highunclear
426￨four hundred and twentysix male and 42 female clients general smokers at an annual physical examination 413 males and 76 females￨smoking cessation instruction encouragement card one month after instruction and abstainers of the i group were awarded a telephone card at the 6month followup￨12month abstinence rates abstinence rates￨a multivariate analysis of smoking cessation showed that lower nicotine dependency strong determination for smoking cessation and being female were significant factors for abstinence at the 6month followup￨sig increase￨highunclear￨highunclear￨highunclear
311￨general practices in newcastle australia 311 patients identified as smokers by a screening question were enrolled in the study general practice￨brief statement of advice from the general practitioner as well as three pamphlets those in the structured intervention group were given strategies which included attitude and behavioural change programmes smoking cessation programmes￨cessation rates￨significant differences between controls and the structured behavioural change group were found at the one month follow up but only for self reported abstinence￨sig increase￨highunclear￨highunclear￨highunclear
not found￨asbestosexposed smoking men undergoing screening in a mandated program for naval shipyard workers patients who have medical problems or perceive themselves to be at risk smoking behavior of asbestosexposed workers smokers with abnormal pulmonary function who receive￨behavioral counseling physician counseling simple warning or 3 to 5 min of behavioral cessation counseling￨prolonged abstinence rates subjects smoking status￨prolonged abstinence rates among abnormal pft subjects 37 did not differ from those of normals 59￨no diff￨highunclear￨highunclear￨highunclear
60￨60 diabetic patients aged less than 40 years young diabetic smokers patients abstained from smoking for only a few hours before attending the stop smoking clinic￨health counselling antismoking advice￨urinary cotinine concentrations cigarette consumption breath co measurement of breath carbon monoxide co and urinary cotinine a metabolite of nicotine myocardial infarction￨there was a small but significant reduction of breath co in the patients seen at home by the health visitor but the urinary cotinine concentrations were unchanged￨sig increase￨highunclear￨highunclear￨highunclear
not found￨two hundred smokers who were judged by their general practitioner to be motivated to stop smoking￨nicotine gum nicotine chewing gum￨￨at one year follow up 155 overall had stopped smoking 14 in the low and 17 in the high contact group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨30 work site physicians included in the study 100 to 150 employees 504 subjects classified as smokers at baseline receiving simple advice group a and 591 the more￨worksite intervention active programme￨prevalence of smoking mean symptoms score for depression percentage of smokers who stopped smoking smoking cessation￨the prevalence of smokers did not differ significantly at baseline 329 and 324 p075￨no diff￨highunclear￨highunclear￨highunclear
1445￨middleaged men middleaged men of advice to stop smoking 714 men in the intervention group were recalled for a series of personal interviews with a doctor 1445 male smokers aged 4059 at high risk of cardiorespiratory disease￨smoking cessation￨mortality range prevalence of sputum production and dyspnoea ventilatory function rate of decline blood pressure levels mortality￨there were no evident effects on blood pressure levels nor on electrocardiographic findings over three years nor on sickness absence over one year￨no diff￨highunclear￨highunclear￨highunclear
not found￨1238 south australian smokers￨nonintervention control group or a group which received firm general practitioner advice to quit smoking plus literature minimal smoking cessation intervention￨￨at oneyear followup 75 of smokers in the minimal advice group who had quit for six or more months remained nonsmokers compared with 32 in the control group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨289 patients in a family practice setting smoking cessation in family practice￨ncg advice and nicotine chewing gum prescription nicotine chewing gum ncg prescription physician antismoking intervention￨rates of abstinence￨the ncg group had higher rates of abstinence at all followup points but the difference approached statistical significance at 3 months only p less than 10￨no diff￨highunclear￨highunclear￨highunclear
250￨ambulatory clinic patients smokers at two outpatient sites￨minimalcontact smoking cessation intervention provider intervention only pi provider intervention plus selfhelp manual pim and usual care control group c providerinitiated minimalcontact intervention￨quit smoking￨both pi and pim proved to be superior to usual care in motivating attempts to quit at both onemonth and sixmonth followups and logistic regression analyses indicated that participants receiving the selfhelp manual in addition to the health provider message were between two and three times more likely to quit smoking during the study period than were participants in either of the other study groups￨sig increase￨highunclear￨highunclear￨highunclear
1499￨a total of 34 randomly selected general practices from a german region participation rate 87 smoking cessation in general practice 1499 consecutive patients aged 1870 years with daily cigarette smoking participation rate 80 general medical practice￨i computergenerated tailored letters and ii practitionerdelivered brief advice for smoking cessation against an assessmentonly condition proactive interventions lowcost interventions tailored letters intervention group received up to three individualized personal letters computertailored letters and physiciandelivered brief advice￨7day point prevalence abstinence 6month prolonged abstinence￨using complete case analysis the tailored letters intervention was significantly more effective than brief advice for 24hour odds ratio or￨sig increase￨highunclear￨highunclear￨highunclear
1462￨patients 1462 patients two multicentre trials with new patients attending hospital or a chest clinic because of a smoking related disease 1392 patients￨compared 1 advice only 2 advice supplemented by a signed agreement 3 advice supplemented by a series of letters of encouragement and 4 advice supplemented by a signed agreement and a series of letters of encouragement￨success rates success rates stop smoking cessation rate stopping smoking￨such small improvements in success rates are worth while especially if they can be achieved cheaply and on a wide scale￨sig increase￨highunclear￨highunclear￨highunclear
432￨cancer patients cancer patients n  432￨usual care or a national institutes of health nih physicianbased smoking intervention brief physicianinitiated quitsmoking strategies￨7day point prevalence abstinence quit smoking baseline desire to quit risk of relapse quit rates￨at the 6month followup there was no significant difference in quit rates between the usual care 119 and intervention 144 groups and there was no significant difference between the usual care 136 and intervention 133 groups at the 12month followup￨no diff￨highunclear￨highunclear￨highunclear
200￨37 patients who completed the treatment programme and attended all the follow up visits 57 were abstinent at three years two hundred cigarette smokers who attended a general practice patients to stop smoking sixty four patients attended the educational consultation and first follow up visit of these 45 were not smoking at the first follow up visit 30 maintained abstinence up to six months and 22 were still not smoking after three years￨nonintervention control intensive programme￨smoking state￨thirty five patients in the treatment group were abstinent at three years compared with eight in the control group p less than 0001￨sig increase￨highunclear￨highunclear￨highunclear
923￨general practice in italy fortyfour nonsmoking general practitioners volunteered for the study patients of primary care physicians to quit smoking and sustain cessation 923 smoking clients unselected for motivation toward quitting to four different intervention groups i￨minimal intervention consisting of one single counselling session and a brief handout on quitting techniques ii repeated counselling including reinforcing sessions at months 1 3 6 and 9 iii repeated counselling and use of nicotine gum and iv repeated counselling and spirometry smoking cessation interventions￨lack of power contamination and low attendance￨in no treatment group was the outcome significantly different from that for onetime counselling at the p less than 005 level￨no diff￨highunclear￨highunclear￨highunclear
659￨midlife and older smokers for midlife and older smokers ages 5074 reaching midlife and older smokers thirtynine practices accruing five or more patients per practice were included in the analyses older adults￨immediate intervention experimental condition were trained to deliver brief quitsmoking advice and counseling usual care with physiciandelivered brief quitsmoking advice and counseling delayed intervention control practices followed usual care procedures officebased smoking cessation program￨quitting selfreported quit rates smoking abstinence 6month abstinence included number of previous quit attempts quitting for 24 hr in the past year desire to quit confidence in quitting perceived health benefits and lower nicotine dependence￨outpatient medical practices assigned to the immediate intervention experimental condition were trained to deliver brief quitsmoking advice and counseling￨sig increase￨highunclear￨highunclear￨highunclear
350￨subjects were 350 daily smoking pregnant women and 274 daily smoking nonpregnant women 1834 years of age large number of general practitioners gps among pregnant and nonpregnant women 187 gps in western norway￨simple smoking intervention programme￨prevalence abstinence rate continuous abstinence rate cigarette consumption￨the prevalence of both pregnant and nonpregnant women who stopped smoking was higher in the intervention than in the control groups￨sig decrease￨highunclear￨highunclear￨highunclear
151￨physicianbased smoking cessation 151 patients were advised to stop smoking and were asked to participate in the program if judged sufficiently motivated by the physicians 13 physicians working in the open health care system￨nicotine chewing gum nicotine gum vs no gum￨abstinence outcomes￨the results at 12 months were that long followup showed a trend p less than 012 toward being better than short followup while nicotine gum was significantly better than no gum p less than 005 in maintaining abstinence￨sig increase￨highunclear￨highunclear￨highunclear
6052￨6052 adult patients who consulted their doctors in six oxfordshire general practices between october 1980 and february 1981 2110 35 were smokers general practice￨control nonintervention group a group that received verbal and written antismoking advice from the general practitioner a group that received this advice and also a demonstration of exhaled carbon monoxide￨stopped smoking urinary concentrations of cotinine rate of misreporting￨after one year 72 of smokers replied to a postal follow up questionnaire 11 of the control group claimed to have stopped smoking compared with 15 in the group that received advice alone 17 in the exhaled carbon monoxide group and 13 in the health visitor group￨sig increase￨highunclear￨highunclear￨highunclear
238￨family practice patients two hundred thirtyeight patients from the intervention group 178 from the control group and 47 from the comparison group were followed up with a telephone interview at 6 months cigarettesmoking patients of two busy family practices in southeast michigan￨physicians brief smoking cessation counseling control group receiving routine care or an intervention group receiving in addition to routine care smoking cessation counseling from their physician￨quit attempts quit rates￨intervention group patients made significantly more quit attempts than did those in the control group p less than 001 which was similar to the comparison group￨sig decrease￨highunclear￨highunclear￨highunclear
2901￨mothers of newborns fortynine oregon pediatric offices enrolled 2901 women who were currently smoking or had quit for pregnancy using a brief survey at the newborns first office visit￨environmental tobacco smoke ets￨readiness to quit and attitude toward and knowledge of ets maternal smoking and relapse maternal quitting or relapse relapse￨the intervention reduced smoking 59 vs 27 and relapse 55 vs 45 at 6month followup but logistic regression analysis at 12 months revealed no significant treatment effect￨sig decrease￨highunclear￨highunclear￨highunclear
647￨six hundred fortyseven patients fortyone southern ontario family physicians volunteered for the study and subsequently participated in a fourhour training program on smoking cessation techniques￨￨sustained cessation rates￨the 95 confidence interval on the difference between the groups was 28 in favor of the brief intervention group to 73 in favor of the group offered followup￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨autonomysupportive or a controlling interpersonal style￨quit rates￨the intervention did not have a direct effect on quit rates however structural equation modeling supported the selfdetermination process model of smoking cessation￨no diff￨highunclear￨highunclear￨highunclear
not found￨primary care physicians sample of 70 physicians and 518 of their patients￨computerbased tailored intervention to increase smoking cessation counseling computertailored intervention intervention or control conditions￨smoking cessation counseling advise assistprovide referral assistdiscuss medication number of quit attempts quit rates and smoking behaviors number of days quit￨intervention patients were 177 ci 094 334p  0078 times more likely than controls to be abstinent 12 versus 8 a difference that approached but did not reach statistical significance and surpassed controls on number of days quit 184 versus 122 p  05 but not on number of quit attempts￨no diff￨highunclear￨highunclear￨highunclear
not found￨smoking cessation from family physicians family physicians advice to cigarette smokers during a routine office visit￨routine advice￨outcomedesire to stop smoking￨no significant differences were found in the three measures used to determine outcomedesire to stop smoking an attempt to stop and success in stoppingbetween the control and intervention groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨people aged 60 and over people aged 60 and older respond to assistance in stopping smoking￨￨standardized measure of breathlessness￨the intervention group also showed some improvements in a standardized measure of breathlessness￨sig increase￨highunclear￨highunclear￨highunclear
not found￨208 smokers￨physicianbased intervention￨attempts to quit￨among the 208 smokers in the intervention group there were more attempts to quit and they were more successful than in the 216 smokers in the control group￨sig increase￨highunclear￨highunclear￨highunclear
1938￨general practitioners advice to stop smoking general practitioners advice against smoking cigarette smokers who attended the surgeries including those who did not wish to stop and those in the gum group who did not try the gum 47 1938 cigarette smokers who attended the surgeries of 34 general practitioners in six group practices￨nonintervention controls b advice plus booklet and c advice plus booklet plus the offer of nicotine gum nicotine chewing gum￨relapse rate success rate￨this study was designed to see whether the offer and prescription of nicotine chewing gum would enhance the efficacy of general practitioners advice to stop smoking￨sig increase￨highunclear￨highunclear￨highunclear
43￨patients with copd in daily general practice smocc in total 43 general practices with 392 patients participated in nijmegen the netherlands in 20012002 chronic obstructive pulmonary disease copd patients with copd in general practice smocc patients with copd compared smoking cessation counseling according to an intensified minimal intervention strategy with usual care￨smoking cessation counseling protocol￨actually quit smoking quit attempt quit rates￨significantly more smokers in the experimental group made a quit attempt 449 versus 365 and actually quit smoking than in the control group 160 versus 88￨sig increase￨highunclear￨highunclear￨highunclear
530￨adult smokers 530 smoking patients dutch general practitioners twentytwo general practitioners and their practice assistants￨minimal contact smoking cessation program￨sustained abstinence abstinence rates￨at 12month followup selfreported abstinence rates including nonrespondents as smokers differed significantly between intervention subjects and controls 134 vs 73 point prevalence odds ratio 151 p  005￨sig increase￨highunclear￨highunclear￨highunclear
369￨thirtyseven family practice physicians at three of group healths outpatient facilities participated 369 individuals designated by study design for referral only 14 even investigated the classes￨physician counseling 2 mailed letters and educational materials designed by the national cancer institute nci and 3 referral to smoking cessation classes smoking cessation interventions￨point prevalence of quitting patient participation rates antismoking behavior quit quit and relapse or cut down￨none of the interventions had any effect on point prevalence of quitting as determined 89 months later by selfreport￨no diff￨highunclear￨highunclear￨highunclear
not found￨1450 women experienced 1 or more cvd outcomes participants were 40 years or older with a history of cvd or 3 or more cvd risk factors and were followed up for a mean duration of 94 years from 19951996 to 2005 8171 female health professionals at increased risk in a 2 x 2 x 2 factorial design women at high risk for cvd women￨ascorbic acid vitamin e vitamins c and e and beta carotene active ascorbic acid and vitamin e ascorbic acid vitamin c beta carotene antioxidant vitamins￨ascorbic acid active vitamin e vitamin e cardiovascular events ascorbic acid vitamin e or beta carotene on cardiovascular events risk of cardiovascular disease cvd myocardial infarction stroke coronary revascularization or cvd death￨there were no significant interactions between agents for the primary end point but those randomized to both active ascorbic acid and vitamin e experienced fewer strokes p value for interaction 03￨no diff￨low￨low￨low
289￨two hundred and eightynine patients with als of less than 5 years duration treated with amyotrophic lateral sclerosis￨placebo antioxidant vitamin e alphatocopherol alphatocopherol riluzole alphatocopherol vitamin e alphatocopherol or placebo als riluzole￨severe state b biochemical markers of oxidative stress rate of deterioration of function assessed by the modified norris limb scale survival and motor function als health state scale plasma levels of thiobarbituric acid reactive species biochemical markers of oxidative stress survival glutathione peroxidase activity in plasma patients given alphatocopherol￨after 3 months treatment analysis of oxidative stress markers showed an increase in glutathione peroxidase activity in plasma p  00389 and a decrease in plasma levels of thiobarbituric acid reactive species p  00055 in the group of patients given alphatocopherol in combination with riluzole￨sig increase￨low￨low￨low
3365￨precancerous gastric lesions in 1995 3365 eligible subjects adults aged 3564 years in 13 randomly selected villages in linqu county shandong province china were identified and given baseline endoscopies in 1994 advanced precancerous gastric lesions 3365 eligible randomized subjects represented 935 of those with baseline endoscopy and included all baseline histologic categories except gastric cancer￨placebo vitamin or garlic supplementation placebos amoxicillin and omeprazole vitamins or garlic supplements onetime h pylori treatment and longterm vitamin or garlic supplements vitamin c vitamin e and selenium for 73 years vitamin supplement and aged garlic extract and steamdistilled garlic oil for 73 years garlic supplement￨precancerous gastric lesions severe chronic atrophic gastritis intestinal metaplasia dysplasia or gastric cancer prevalence of precancerous gastric lesions combined prevalence of dysplasia or gastric cancer normal gastric mucosa gastric cancer incidence gastric cancer￨longterm vitamin or garlic supplementation had no beneficial effects on the prevalence of precancerous gastric lesions or on gastric cancer incidence￨no diff￨low￨low￨low
11324￨patients who had myocardial infarction after myocardial infarction from october 1993 to september 1995 11324 patients surviving recent  or  3 months myocardial infarction￨vitamin e dietary supplementation with n3 polyunsaturated fatty acids and vitamin e vitamin e n3 pufa￨death nonfatal myocardial infarction and stroke cardiovascular death fatal events risk of death￨treatment with n3 pufa but not vitamin e significantly lowered the risk of the primary endpoint relativerisk decrease 10 95 ci 118 by twoway analysis 15 226 by fourway analysis￨sig decrease￨low￨low￨low
136￨patients with knee osteoarthritis oa one hundred seventeen subjects 59 vitamin e 58 136 patients with knee oa american college of rheumatology clinical and radiographic criteria knee osteoarthritis￨supplementary vitamin e placebo vitamin e and placebo vitamin e vitamin e antioxidants vitamin c beta carotene retinol equivalents￨tibial cartilage volume cartilage volume loss loss of medial and lateral tibial cartilage cartilage volume￨dietary levels of antioxidants vitamin c beta carotene retinol equivalents had no effect on cartilage volume loss￨no diff￨low￨low￨low
81￨institutionalized elderly subjects 81 elderly subjects in a geriatric center during a 2year period￨micronutrient supplementation vitamin supplementation trace elements zinc and selenium alone or associated with vitamins daily placebo trace elementszinc 20 mg selenium 100 micrograms vitamins vitamin c 120 mg betacarotene 6 mg alphatocopherol 15 mg or a combination of trace elements and vitamins at equal doses￨low serum values in vitamin c folate zinc and selenium infectious morbidity infectious events vitamin and trace element serum levels￨after 6 months of supplementation a significant increase in vitamin and trace element serum levels was obtained in the corresponding treatment groups a plateau was then observed for the whole study￨sig increase￨highunclear￨highunclear￨highunclear
22071￨healthy men 12 years of supplementation with beta 1273 men had any malignant neoplasm except nonmelanoma skin cancer 22071 male physicians 40 to 84 years of age in the united states 11 percent were current smokers and 39 percent were former smokers at the beginning of the study in 1982￨beta carotene placebo carotene￨number of cases of lung cancer incidence of malignant neoplasms cardiovascular disease or death number of men with myocardial infarction incidence of malignant neoplasms and cardiovascular disease overall incidence of malignant neoplasms or cardiovascular disease or in overall mortality number of deaths from cancer￨there were also no significant differences in the number of cases of lung cancer 82 in the beta carotene group vs 88 in the placebo group the number of deaths from cancer 386 vs 380 deaths from any cause 979 vs 968 or deaths from cardiovascular disease 338 vs 313 the number of men with myocardial infarction 468 vs 489 the number with stroke 367 vs 382 or the number with any one of the previous three end points 967 vs 972￨no diff￨low￨low￨low
not found￨patients with stable angina pectoris angina pectoris angina pectoris patients 48 patients with both stable angina and positive chest pain plus ishemic st depression maximal exercise treadmill tests all 48 patients had positive selective coronary arteriograms 75 per cent obstruction of at least a major coronary artery andor q wave ecg evidence of previous myocardial infarction minnesota criteria￨vitamin e placebo￨frequency of chest pain performance of serial maximal exercise treadmill tests serial systolic time interval measurements and daily angina diaries exercise capacity improve left ventricular function￨no statistically significant differences between the two treatment studied￨no diff￨highunclear￨highunclear￨highunclear
100￨elderly patient elderly medical patients on an intentiontotreat basis 100 patients with 90 power p  005 elderly medical inpatients one hundred and six elderly medical inpatients￨placebo albumin nutritional supplementation vitamin andor glucose energy supplementation glucose energy and vitamin supplementation glucose alone andor vitamin supplementation￨mental test score barthel score or length of stay weight and  3 gl increase in serum albumin changes in barthel activities of daily living length of stay and mental test score mts￨there were no significant differences in mental test score barthel score or length of stay between the two groups￨no diff￨low￨low￨low
47￨healthy noninstitutionalized elderly subjects thirtyfive individuals completed the oneyear study healthy elderly fortyseven subjects aged 6179 years￨vitamin and trace element supplementation placebo or micronutrient supplementation placebo vitamin and trace element supplement￨cd57 natural killer cells immune function t cells cd4 cells and cd4 cd8 ratio￨cellmediated immune function assessed by the number of t cells and subsets remained constant in the supplemented group and there was a significant increase in cd57 natural killer cells￨sig increase￨highunclear￨highunclear￨highunclear
267￨residents of linxian peoples republic of china two hundred sixtyseven subjects fulfilled all eligibility criteria and 238 89 completed the trial subjects had histologically confirmed mild or moderate esophageal squamous dysplasia at baseline esophageal squamous cell carcinoma subjects with mild esophageal squamous dysplasia￨selenomethionine and celecoxib placebo selenomethionine 200 microg daily andor celecoxib esophagogastroduodenoscopy selenomethionine nor celecoxib selenomethionine vs placebo celecoxib vs placebo celecoxib￨mild esophageal squamous dysplasia dysplasia grade overall dysplasia progression moderate esophageal squamous dysplasia dysplasia regression esophageal squamous carcinogenesis￨celecoxib status did not influence changes in dysplasia grade overall p  78 or by baseline histology subgroup￨no diff￨low￨low￨low
1383￨1383 participants underwent full skin examination by a dermatologist in the followup period basalcell and squamouscell carcinomas of the skin 250 of them developed 758 new skin cancers during the followup period cutaneous squamouscell carcinoma participants were 1621 residents of nambour in southeast queensland australia￨placebo sunscreen betacarotene supplementation daily sunscreen application and betacarotene supplementation sunscreen plus placebo tablets betacarotene only or placebo sun protection factor 15plus sunscreen to the head neck arms and hands and betacarotene supplementation￨skincancer rates rates of either type of skin cancer incidence of basalcell carcinoma incidence of basalcell and squamouscell carcinomas incidence of first new skin cancers incidence of squamouscell carcinoma￨in terms of the number of tumours there was no effect on incidence of basalcell carcinoma by sunscreen use or by betacarotene but the incidence of squamouscell carcinoma was significantly lower in the sunscreen group than in the no daily sunscreen group 1115 vs 1832 per 100000 061 046081￨no diff￨low￨low￨low
not found￨￨broad spectrum antioxidant capsule placebo￨distance logmar visual acuity dry armd cortical opacification of the right lens self perceived stabilization of vision decreased intake of cardioprotective nutrients vitamin e zinc magnesium b6 and folate adverse gastrointestinal symptoms￨however group two antioxidant also had increased cortical opacification of the right lens p  004 compared to group one placebo￨sig increase￨highunclear￨highunclear￨highunclear
652￨elderly individuals elderly persons 652 noninstitutionalized individuals aged 60 years or older enrolled from 2 communitybased sampling strategies in the wageningen area of the netherlands conducted from 1998 to 2000￨placebo vitamin e vs no vitamin e vitamin e multivitaminmineral supplementation at physiological dose nor 200 mg of vitamin e daily multivitaminmineral and vitamin e supplementation daily vitamin e and multivitaminmineral supplementation multivitaminminerals 200 mg of vitamin e both or placebo￨1024 respiratory tract infection episodes incidence and severity of acute respiratory tract infections illness severity nurse telephone contact home visits and microbiological and serological testing in subsets of patients suboptimal ascorbic acid severity of infections incidence and severity of selfreported acute respiratory tract infections incidence rate ratio of acute respiratory tract infection for multivitaminmineral supplementation immune response suboptimal alphatocopherol plasma concentration restriction of activity acute respiratory tract infections￨number of symptoms 6 38 vs 4 38 p 03 presence of fever 367 vs 252 p 009 and restriction of activity 523 vs 411 p 02￨no diff￨low￨low￨low
not found￨twentyone longterm care facilities institutionalized seniors seven hundred sixtythree subjects from 21 longterm care facilities nursing home residents elderly institutionalized population 748 subjects mean age 85 were included in the intentiontotreat analysis￨placebo multivitamin and mineral supplementation multivitamin and mineral supplementation daily or placebo vitamin and mineral supplementation multivitamin￨number of hospital visits episodes of infection antibiotic usage antibiotic use and hospitalization rates total number of infections number of infections per subject infectious episodes rate of infections￨subjects without dementia had a greater rate of infections than those with dementia or144 95 ci119176￨sig increase￨low￨low￨low
not found￨160 patients in 6 german centres with either probable or definite als according to the el escorial criteria and a disease duration of less than 5 years treated with amyotrophic lateral sclerosis￨placebo antioxidant vitamin e alphatocopherol vitamin e therapy vitamin e riluzole alphatocopherol￨rate of deterioration of function assessed by the modified norris limb and bulbar scales manual muscle testing bmrc spasticity scale ventilatory function and the sickness impact profile sip als19 vital signs heart rate and blood pressure an ecg and veps survival calculating time to death tracheostomy or permanent assisted ventilation according to the wfncriteria of clinical trials adverse experiences and serious adverse events height and weight￨neither the primary nor the secondary outcome measures could determine whether a megadose of vitamin e is efficacious in slowing disease progression in als as an addon therapy to riluzol￨no diff￨low￨low￨low
not found￨patients undergoing surveillance for barretts oesophagus n 100 on longterm proton pump inhibitors seventytwo patients completed the study patients on longterm acidsuppression therapy￨placebo vitamin e dietary antioxidants vitamin c vitamins c and e￨gastric juice ascorbic acid and total vitamin c plasma ascorbic acid total vitamin c and vitamin e mucosal malondialdehyde chemiluminescence and dna damage levels gastric juice ascorbic acid and total vitamin c levels gastric juice plasma and mucosal measurements of vitamin levels and markers of dna damage￨gastric juice ascorbic acid and total vitamin c levels were raised significantly in the supplemented group p001 but supplementation had no effect on the mucosal level of this vitamin￨sig increase￨highunclear￨highunclear￨highunclear
189￨lifelong male smokers 189 male smokers￨glutathione stransferase m1 genotype placebo vitamin e￨baseline ccaimt values ccaimt progression atherosclerosis progression progression of atherosclerosis progression of atherosclerosis mean 2year progression￨smokers with gstm10 genotype had a tendency to higher baseline ccaimt values than those with gstm11 097 versus 092 mm p009￨sig increase￨low￨low￨low
501￨healthy volunteers 501 uk participants aged 6074 elderly volunteers￨seleniumd as highselenium yeast or placebo yeast selenium selenium supplementation placebocontrolled intervention￨mean sd total mood scores pomsbi questionnaires mood profile of moods states  bipolar form pomsbi questionnaire quality of life short form 36 sf36 questionnaire and plasma selenium mood or quality of life mood and quality of life quality of life plasma selenium total mood or moodsubscale scores￨four hundred fortyeight participants completed the pomsbi questionnaires at both time points with no significant differences in total mood or moodsubscale scores seen between doses￨no diff￨low￨low￨low
14641￨men male physicians middleaged and older men 14641 us male physicians enrolled who were initially aged 50 years or older including 754 men 51 with prevalent cardiovascular disease at randomization￨placebo vitamin e nor vitamin c supplementation vitamin c alone placebo vitamin e vitamin e vitamin e or vitamin c supplementation vitamin e or vitamin c vitamin e and vitamin c vitamin c vitamin c daily vitamins e and c￨major cardiovascular events nonfatal myocardial infarction nonfatal stroke and cardiovascular disease death incidence of major cardiovascular events total stroke major cardiovascular events risk of hemorrhagic stroke risk of major cardiovascular events total mortality but vitamin e vitamin c cardiovascular mortality total myocardial infarction￨compared with placebo vitamin e had no effect on the incidence of major cardiovascular events both active and placebo vitamin e groups 109 events per 1000 personyears hazard ratio hr 101 95 confidence interval ci 090113 p  86 as well as total myocardial infarction hr 090 95 ci 075107 p  22 total stroke hr 107 95 ci 089129 p  45 and cardiovascular mortality hr 107 95 ci 090128 p  43￨no diff￨low￨low￨low
88￨pressure ulcers patients from 11 nursing homes and 1 hospital participated eightyeight patients were randomized￨ascorbic acid supplementation ascorbic acid￨mean absolute healing rates healing of pressure ulcers closure rate relative healing rates and healing velocities wound survival healing rates of wound surfaces and clinimetric changes over 12 weeks wound closure probability per unit time￨mean absolute healing rates were 021 and 027 cm2week in the intervention and control group respectively pi of the adjusted difference 017 to 013￨no diff￨highunclear￨highunclear￨highunclear
39￨patients with systemic lupus erythematosus sle 39 patients with sle patients with systemic lupus erythematosus￨longterm antioxidant vitamins vitamins c and e placebo placebo or vitamins 500 mg vitamin c and 800 iu vitamin e daily￨fmd and vwf and pai1 levels changes in allantoin and antioxidant levels and change in endothelial function oxidative stress markers and antioxidant levels malondialdehyde mda and allantoin erythrocyte superoxide dismutase and glutathione peroxidase plasma total antioxidant power as frap value and ascorbic acid and vitamin e concentrations change in lipid peroxidation lipid peroxidation oxidative stress and antioxidant defense and endothelial function endothelial function oxidative stress markers and endothelial function plasma ascorbic acid and alphatocopherol concentrations endothelial function flowmediated dilatation fmd of the brachial artery and plasma concentration of von willebrand factor vwf and plasminogen activator inhibitor type 1 pai1 plasma mda￨after treatment plasma ascorbic acid and alphatocopherol concentrations were significantly p  005 increased only in the vitamintreated group associated with a significant decrease p  005 in plasma mda￨sig increase￨low￨low￨low
160￨patients with coronary disease patients with coronary disease and low hdl levels patients with coronary disease and low plasma levels of hdl 160 patients with coronary disease low hdl cholesterol levels and normal ldl cholesterol levels￨simvastatin plus niacin vitamins simvastatinniacin plus antioxidants or placebos placebo simvastatin and niacin antioxidant vitamins simvastatinniacin plus antioxidants simvastatinniacin and antioxidantvitamin therapy simvastatinniacin simvastatin plus niacin simvastatin plus niacin simvastatinniacinplusantioxidants lipidmodifying therapy and antioxidant vitamins antioxidant vitamins￨arteriographic evidence of a change in coronary stenosis and the occurrence of a first cardiovascular event death myocardial infarction stroke or revascularization average stenosis progressed mean levels of ldl and hdl cholesterol￨the mean levels of ldl and hdl cholesterol were unaltered in the antioxidant group and the placebo group these levels changed substantially by 42 percent and 26 percent respectively in the simvastatinniacin group￨no diff￨low￨low￨low
725￨elderly patients elderly people 725 institutionalized elderly patients 65 years from 25 geriatric centers in france institutionalized elderly patients institutionalized elderly people￨antioxidant supplementation placebo oral daily supplement of nutritional doses of trace elements zinc and selenium sulfide or vitamins beta carotene ascorbic acid and vitamin e or a placebo vit vitamin supplementation zinc and selenium trace elements zinc sulfate and selenium sulfide or vitamins beta carotene ascorbic acid and vitamin e￨delayedtype hypersensitivity skin response humoral response antibody titers incidence of urogenital infections survival analysis delayedtype hypersensitivity skin response antibody titers number of patients without respiratory tract infections immunity and infections humoral response￨antibody titers after influenza vaccine were higher in groups that received trace elements alone or associated with vitamins whereas the vitamin group had significantly lower antibody titers p05￨sig increase￨low￨low￨low
90￨urban midwestern veterans administration hospital from august 1999 to may 2001 agerelated macular degeneration armd ninety patients with atrophic armd were referred by ophthalmologists at two chicagoarea veterans medical facilities atrophic agerelated macular degeneration￨lutein antioxidant supplementation trial last placebo lutein and antioxidant supplementation lutein alone or lutein lutein or lutein together with antioxidants vitamins and minerals lutein 10 mg l in group 2 a lutein 10 mgantioxidantsvitamins and minerals broad spectrum supplementation formula la and in group 3 a maltodextrin placebo￨vfo14 questionnaires conceming subjective glare recovery snellen equivalent visual acuity mean eye macular pigment optical density net subjective improvement￨in groups 1 l and 2 la mean eye macular pigment optical density increased approximately 009 log units from baseline snellen equivalent visual acuity improved 54 letters for group 1 l and 35 letters for group 2 la and contrast sensitivity improved￨sig increase￨low￨low￨low
not found￨people with one or more major cardiovascular risk factors 4495 people 2583 female mean age 644 years people with one or more of the following hypertension hypercholesterolaemia diabetes obesity family history of premature myocardial infarction or individuals who were elderly people at cardiovascular risk￨vitamin e antiplatelets and antioxidants aspirin lowdose aspirin and vitamin e aspirin vitamin e￨total cardiovascular events cardiovascular death severe bleedings￨aspirin lowered the frequency of all the endpoints being significant for cardiovascular death from 14 to 08 relative risk 056 95 ci 031099 and total cardiovascular events from 82 to 63 077 062095￨sig decrease￨low￨low￨low
109￨elderly nursinghome residents one hundred and nine patients were enrolled into a doublemasked placebocontrolled trial at an academically affiliated nursing home fiftysix patients frail elderly nursinghome patients￨single capsule containing 1000 iu of vitamin a placebo vitamin a and placebo vitamin a supplements vitamin a supplementation single capsule containing 200000 iu of vitamin a antibiotictreated infections￨infection rates incidence of infection￨the infection rates in the vitamin a and placebo groups were 47 and 43 per 1000 days of followup respectively relative risk 11 95 ci 06 20￨no diff￨low￨low￨low
635￨subjects aged 40 to 69 years living in one village in akita prefecture a highrisk area for gastric cancer in japan were recruited through annual health checkup programs 120 subjects in the lowdose group vitamin c 50 mg and 124 subjects in the 635 subjects diagnosed as having chronic gastritis on the basis of serum pg levels after excluding ineligible cases 439 subjects￨vitamin c supplementation highdose group vitamin c￨serum pepsinogen level and helicobacter pylori infection change of pgiii ratio gastric mucosal atrophy serum pepsinogen pg level helicobacter pylori h pylori  infection and cytotoxinassociated gene a cag a status￨the difference in the change of pgiii ratio between baseline and after 5year follow up was statistically significant between the intervention groups among those who completed the supplementation  025 for the lowdose group and  013 for the highdose group p  0046￨sig increase￨highunclear￨highunclear￨highunclear
31￨older institutionalized people one hundred sixtyfour residents aged 60 and older from 31 homes were initially randomized of these 119 726 completed the study older people living in longterm care nursing and residential homes in liverpool united kingdom￨placebo micronutrient supplementation influenza vaccine micronutrient supplement providing the reference nutrient intake for all vitamins and trace elements or identical placebo micronutrient supplement￨seroconversion serum concentrations of vitamins a c d3 e folate and selenium antibody response￨a micronutrient supplement providing the reference nutrient intake administered over 8 weeks had no beneficial effect on antibody response to influenza vaccine in older people living in longterm care￨no diff￨low￨low￨low
1312￨seven dermatology clinics in the eastern united states patients with carcinoma of the skin patients were treated for a mean sd of 45 28 years and had a total followup of 64 20 years 1312 patients mean age 63 years range 1880 years with a history of basal cell or squamous cell carcinomas of the skin were randomized from 1983 through 1991￨selenium per day or placebo selenium supplementation placebo selenium treatment￨total cancer mortality and total cancer incidence 218 new squamous cell skin cancers selenium toxicity cause mortality and total cancer mortality total cancer incidence and the incidences of lung prostate and colorectal cancers total cancer incidence basal cell skin cancer incidences of lung colorectal and prostate cancers incidence of cancer incidences of basal and squamous cell carcinomas of the skin incidence of basal cell or squamous cell skin cancer cause mortality total cancer mortality￨there were 377 new cases of basal cell skin cancer among patients in the selenium group and 350 cases among the control group relative risk rr 110 95 confidence interval ci 095128 and 218 new squamous cell skin cancers in the selenium group and 190 cases among the controls rr 114 95 ci 093139￨no diff￨low￨low￨low
1035￨patients with angiographically proven symptomatic coronary atherosclerosis patients with established ischaemic heart disease patients with coronary disease cambridge heart antioxidant study chaos 2002 patients with angiographically proven coronary atherosclerosis were enrolled and followed up for a median of 510 days range 3981 1035 patients were assigned￨vitamin e alphatocopherol placebo vitamin e alphatocopherol treatment alphatocopherol alphatocopherol capsules containing 800 iu daily for first 546 patients 400 iu daily for remainder 967 received identical placebo capsules￨subsequent risk of myocardial infarction mi and cardiovascular death cardiovascular deaths rate of nonfatal mi combination of cardiovascular death and nonfatal mi as well as nonfatal mi alone risk of nonfatal mi plasma alphatocopherol concentrations cardiovascular death and nonfatal mi￨alphatocopherol treatment significantly reduced the risk of the primary trial endpoint of cardiovascular death and nonfatal mi 41 vs 64 events relative risk 053￨sig decrease￨low￨low￨low
29584￨29584 adults who received individuals of ages 4069 were recruited in 1985 from four linxian communes￨nutrients a retinol and zinc b riboflavin and niacin c vitamin c and molybdenum and d beta carotene vitamin e and selenium daily vitamin and mineral supplementation retinol and zinc riboflavin and niacin vitamin and mineral supplementation dietary supplementation with specific vitamins and minerals￨total mortality cancer mortality cancer rates mortality and cancer incidence mortality rates stomach cancer￨significantly p  03 lower total mortality relative risk rr  091￨sig decrease￨low￨low￨low
800￨800 subjects enrolled in a clinical trial of deprenyl selegiline and tocopherol 13 years earlier parkinson disease pd 747 subjects maintaining a most likely diagnosis of pd throughout 6 years of active followup two hundred ninetysix deaths were recorded￨levodopa￨severity and rate of worsening of parkinsonism and response to levodopa symmetry of parkinsonism gait dysfunction as an initial symptom severity of parkinsonism and rate of worsening of parkinsonism standardized mortality ratios severity of parkinsonism and rate of worsening of parkinsonism survival￨there was no difference in the standardized mortality ratios across gender or age group￨no diff￨highunclear￨highunclear￨highunclear
39876￨initially healthy persons healthy women womens health study conducted between 1992 and 2004 39 876 apparently healthy us women aged at least 45 years apparently healthy persons￨naturalsource vitamin e placebo vitamin e supplementation vitamin e or placebo and aspirin or placebo vitamin e vitamin e￨total mortality ischemic or hemorrhagic stroke incidences of total cancer 482 major cardiovascular events cardiovascular disease and cancer cancer deaths cardiovascular death composite end point of first major cardiovascular event nonfatal myocardial infarction nonfatal stroke or cardiovascular death and total invasive cancer cardiovascular mortality colon cancers incidences of myocardial infarction￨for cardiovascular death there was a significant 24 reduction rr 076 95 ci 059098 p  03￨no diff￨low￨low￨low
not found￨endstage renal disease space haemodialysis patients with prevalent cardiovascular disease haemodialysis patients with preexisting cardiovascular disease n196 aged 4075 years at baseline from six dialysis centres haemodialysis patients with preexisting cardiovascular disease chronic haemodialysis patients haemodialysis patients with prevalent cardiovascular disease supplementation with 800 iuday￨antioxidants placebo vitamin e supplementation vitamin e 800 iuday vitamin e or matching placebo￨oxidative stress cardiovascular disease outcomes composite variable consisting of myocardial infarction fatal and nonfatal ischaemic stroke peripheral vascular disease excluding the arteriovenous fistula and unstable angina composite cardiovascular disease endpoints and myocardial infarction total mortality and cardiovasculardisease mortality myocardial infarction cardiovascular disease or total mortality￨oxidative stress is greater in haemodialysis patients with prevalent cardiovascular disease than in those without suggesting a role for oxidative stress in excess cardiovascular disease in haemodialysis￨sig increase￨low￨low￨low
not found￨subjects with confirmed histologic diagnoses of multifocal nonmetaplastic atrophy andor intestinal metaplasia two precancerous lesions gastric dysplasia￨antioxidant supplements and antihelicobacter pylori therapy ascorbic acid antihelicobacter pylori triple therapy andor dietary supplementation with ascorbic acid betacarotene or their corresponding placebos￨regression rates rates of regression relative risks curing the h pylori infection rate of regression of the precursor lesions￨all three basic interventions resulted in statistically significant increases in the rates of regression relative risks were 48 95 confidence interval ci  16142 for antih pylori treatment 5￨no diff￨highunclear￨highunclear￨highunclear
not found￨1980 subjects in tachira state venezuela whose population is at high risk for gastric cancer￨placebo dietary supplementation with vitamin c vitamin e and betacarotene vitamin e antioxidant micronutrients antioxidant vitamin supplementation betacarotene combination of vitamin c nutritional supplementation￨precancerous gastric lesions overall rate ratios median plasma vitamin levels overall regression rates regression rate progression rates progression rate￨there was no statistically significant difference in progression rate rate ratio  092 95 confidence interval ci  074 to 115 or regression rate rate ratio  109 95 ci  090 to 133 between vitamin and placebo groups￨no diff￨low￨low￨low
not found￨men and women  or 40 years old with an ldl cholesterol level  or 337 mmoll 130 mgdl and no clinical signs or symptoms of cvd healthy individuals healthy men and women at low risk for cvd eligible participants￨dlalphatocopherol 400 iu per day or placebo placebo alphatocopherol supplementation vitamin e supplementation alphatocopherol supplementation￨circulating oxidized ldl atherosclerosis progression and cvd events lowdensity lipoprotein oxidation reduced ldl oxidative susceptibility progression of imt imt change rates rate of change in the common carotid artery farwall intimamedia thickness imt assessed by computer imageprocessed bmode ultrasonograms raised plasma vitamin e levels vitamin e intake and cardiovascular disease cvd risk￨compared with placebo alphatocopherol supplementation significantly raised plasma vitamin e levels p00001 reduced circulating oxidized ldl p003 and reduced ldl oxidative susceptibility p001￨sig increase￨low￨low￨low
409￨chronic smokers populations with high oxidant stress 409 male and female smokers aged 55 years smokers￨vitamin e supplementation placebo vitamin e supplementation natural vitamin e or placebo vitamin e￨intimamedia thickness ldl oxidative susceptibility progression of carotid atherosclerosis determined by intimamedia thickness of the right common carotid artery change in systemic arterial compliance and lowdensity lipoprotein ldl oxidative susceptibility over time rate of change in systemic arterial compliance progression of carotid atherosclerosis carotid intimamedia thickness imt and systemic arterial compliance sac￨vitamin e supplementation is ineffective in reducing the progression of carotid atherosclerosis as measured by intimamedia thickness in chronic smokers￨sig decrease￨low￨low￨low
341￨patients with alzheimers disease of moderate severity 341 patients received the alzheimers disease patients with moderately severe impairment from alzheimers disease treatment with selegiline or alphatocopherol slows the progression of disease￨selegiline alphatocopherol alphatocopherol vitamin e 2000 iu a day both selegiline and alphatocopherol or placebo selective monoamine oxidase inhibitor selegiline placebo￨minimental state examination time to the occurrence of any of the following death institutionalization loss of the ability to perform basic activities of daily living or severe dementia defined as a clinical dementia rating of 3 alphatocopherol￨despite random assignment the baseline score on the minimental state examination was higher in the placebo group than in the other three groups and this variable was highly predictive of the primary outcome p0001￨sig increase￨low￨low￨low
445￨agerelated cataract fourhundredandfortyfive patients were eligible 297 were randomized 231 78 were followed for two years 158 53 were followed for three years 36 12 were followed for four years consecutive adult american and english outpatients with early arc were recruited￨react oral antioxidant micronutrient mixture placebo vitamin or placebo oral antioxidant micronutrients mgday betacarotene 18 vitamin c 750 and vitamin e 600￨cataract severity area increase  pixels opaque ipo￨funding surgery worldwide for agerelated cataract arc a leading cause of blindness is a huge economic burden￨sig decrease￨low￨low￨low
83￨eightythree patients with liver cirrhosis and with positive history of hcv infection patients with liver cirrhosis and positive for hcv patients with chronic hepatitis c virus hcv infection often develop liver cirrhosis and hepatocellular carcinoma hcc patients with liver cirrhosis patients with liver cirrhosis and a history of hcv infection￨vit e alphatocopherol vit e alphatocopherol￨cumulative tumorfree survival and cumulative survival rate cumulative survival serum levels of alphatocopherol albumin alanine aminotransferase alt and total cholesterol and platelet count platelet count serum albumin alt and total cholesterol liver function suppress hepatocarcinogenesis serum level of alphatocopherol mean serum concentration of alphatocopherol￨patients treated with alphatocopherol tended to live longer without development of hcc but the difference was not statistically significant￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with mild to moderate alcoholic hepatitis patients with mild to moderate alcoholic hepatitis in a double blind alcoholic hepatitis￨vitamin e vitamin e placebo￨serum aminotransferases and serum bilirubin serum creatinine monocyte nuclear nuclear factorkappa b binding activity serum hyaluronic acid prothrombin time￨as regards markers of hepatic fibrogenesis vitamin e treatment decreased serum hyaluronic acid p005 while serum aminoterminal peptide of type iii procollagen did not change in either group￨sig increase￨low￨highunclear￨low
1906￨1906 screened volunteers 1193 eligible subjects with early or no cataract aged 55 to 80 years were enrolled and followed up for 4 years￨vitamin e supplementation placebo vitamin e natural vitamin e in soybean oil encapsulated in gelatin or a placebo vitamin e￨rate of cataract extraction incidence of or progression of nuclear cortical or posterior subcapsular cataracts progression of cortical cataract incidence or rate of progression of agerelated cataracts nuclear cataract 4year cumulative incidence rate￨for nuclear cataract the corresponding rates were 129 and 121 p  077￨no diff￨low￨low￨low
29133￨25 563 men 29 133 male smokers aged 50 to 69 years received￨alphatocopherol and betacarotene supplementation alphatocopherol and betacarotene alphatocopherol alphatocopherol 50 mg betacarotene 20 mg both agents or placebo supplemental alphatocopherol and betacarotene￨total mortality sitespecific cancer incidence and total and causespecific mortality and calendar timespecific risk for lung cancer incidence and total mortality incidence of cancer and mortality overall posttrial relative risk rr for lung cancer incidence risk of lung cancer and total mortality cancer incidence and causespecific mortality cancer incidence and total and causespecific mortality￨for prostate cancer incidence n  672 the rr was 088 95 ci 076103 for participants receiving alphatocopherol compared with nonrecipients￨no diff￨highunclear￨highunclear￨highunclear
67￨alcoholic cirrhotics patients with more severe liver disease 67 subjects decompensated ambulatory alcoholic cirrhotics￨vitamin e supplementation longterm vitamin e supplementation placebo tablets vitamin e longterm oral 500 mg vitamin e daily supplementation￨serum vitamin e levels vitamin e levels alcohol ingestion and hospitalization rates hepatic laboratory parameters mortality or hospitalization rates alphatocopherol levels mortality￨oral supplementation significantly increased serum vitamin e levels in the experimental group￨sig increase￨highunclear￨highunclear￨highunclear
30￨thirty chf patients age 754 07 mean sem lv ejection fraction lvef  or 35 elderly patients with chf elderly patients with heart failure due to lv systolic dysfunction chronic heart failure chf elderly patients with chronic heart failure￨placebo longterm multiple micronutrient supplementation micronutrient supplementation cardiac magnetic resonance scanning capsules containing a combination of highdose micronutrients calcium magnesium zinc copper selenium vitamin a thiamine riboflavin vitamin b6 folate vitamin b12 vitamin c vitamin e vitamin d and coenzyme q10 or placebo￨qol score slight deterioration lv volumes and lvef and qol scores lvef left ventricular lv function levels of proinflammatory cytokines and qualityoflife qol qualityoflife and left ventricular function tumour necrosis factoralpha and its soluble receptors tnfr1 and tnfr2 sixminute walk test and inflammatory cytokine levels lv volumes￨sixminute walk test and inflammatory cytokine levels remained unchanged in both groups￨no diff￨low￨low￨low
not found￨1434 dm individuals  or  55 years of age with the hp 22 genotype patients with type 2 diabetes mellitus dm a subgroup of middleaged individuals with both type 2 diabetes mellitus and the haptoglobin 22 genotype dm individuals with the hp 22 genotype a subgroup that comprises 2 to 3 of the general population￨vitamin e supplementation vitamin e placebo haptoglobin hp￨myocardial infarction stroke and cardiovascular death oxidative stress individuals receiving vitamin e cardiovascular events￨at the first evaluation of events 18 months after initiating the study the primary outcome was significantly reduced in individuals receiving vitamin e 22 compared with placebo 47 p001 and led to early termination of the study￨sig increase￨low￨low￨low
72￨poststroke patients stroke survivors 72 stroke patients 47 males age 653 patients admitted to a rehabilitative hospital for stroke rehabilitation 129 years admitted to a rehabilitation hospital for sequelae of firstever ischemic stroke and divided them into 4 subgroups￨placebo n3 fatty acids antioxidant and n3 supplementation supplementary antioxidants and n3 fatty acids alone or in combination daily oral antioxidants n3 polyunsaturated fatty acids group 3 both supplements and group 4 placebo￨low plasma vitamin status functional status lower mortality neurological severity or in disability￨at the 1year followup we observed a trend for lower mortality p  0060 in subgroups treated with n3 fatty acids but without significant differences in rehabilitation result status among groups￨no diff￨low￨low￨low
12741￨men 12741 french adults 7713 women aged 3560 years and 5028 men aged 4560 years￨antioxidant vitamins and minerals supplements antioxidant supplementation placebo ascorbic acid vitamin e 30 mg betacarotene 6 mg selenium 100 microg and zinc 20 mg or placebo supplementation in vitamins and mineral antioxidants antioxidant supplementation￨total mortality relative risk rr for total cancer incidence total cancer incidence ischemic cardiovascular disease incidence and total mortality total cancer incidence and total mortality incidence of cancers ischemic cardiovascular diseases and mortality ischemic cardiovascular disease incidence and mortality reduced risk of total cancer incidence and total mortality￨no late effect of antioxidant supplementation was revealed 5 years after ending the intervention neither on ischemic cardiovascular disease incidence and mortality in both genders nor on cancer incidence in women￨no diff￨low￨low￨low
9541￨7030 patients enrolled at these centers 916 were deceased at the beginning of the extension 1382 refused participation 3994 continued to take the study intervention and 738 agreed to passive followup patients with vascular disease or diabetes mellitus of the initial 267 hope centers that had enrolled 9541 patients 174 centers participated in the hopetoo trial december 21 1993 and april 15 1999 of patients at least 55 years old with vascular disease or diabetes mellitus was extended hope￨longterm vitamin e supplementation placebo vitamin e supplementation vitamin e natural source vitamin e 400 iu or matching placebo￨heart failure and hospitalizations for heart failure heart failure unstable angina and revascularizations hospitalization for heart failure major cardiovascular events cancer incidence cancer deaths and major cardiovascular events cardiovascular events and cancer cancer incidence cancer incidence cancer deaths and major cardiovascular events myocardial infarction stroke and cardiovascular death risk of cancer cancer death and major cardiovascular events cancer and cardiovascular events median duration cancer or major cardiovascular events higher risk of heart failure cancer deaths￨patients in the vitamin e group had a higher risk of heart failure rr 113 95 ci 101126 p  03 and hospitalization for heart failure rr 121 95 ci 100147 p  045￨sig decrease￨low￨low￨low
not found￨elderly longstay patients thirty elderly longstay patients￨placebo placebo or dietary supplementation with vitamins a c and e dietary antioxidants vitamins a c and e dietary supplementation with vitamins a c and e￨nutritional status and cellmediated immune function absolute number of t cells proliferation of lymphocytes in response to phytohaemagglutinin immune function￨following vitamin supplementation cellmediated immune function improved as indicated by a significant increase in the absolute number of t cells p less than 005 t4 subsets p less than 005 t4 to t8 ratio p less than 001 and the proliferation of lymphocytes in response to phytohaemagglutinin p less than 001￨sig increase￨highunclear￨highunclear￨highunclear
52￨patients with pad fiftytwo subjects patients with claudication pain secondary to peripheral arterial disease pad￨placebo vitamin e or placebo vitamin e and placebo vitamin e polestriding with vitamin e n  13 polestriding with placebo polestriding instruction and training vitamin e without exercise n 13 and placebo without exercise polestriding exercise and vitamin e polestriding exercise vitamin e alphatocopherol￨treadmill walking duration perceived distance and walking speed walking impairment questionnaire and perceived physical function rand short form36 subjects ratings of perceived leg pain walking ability and perceived quality of life qol exercise tolerance exercise tolerance and perceived qol constant workrate and incremental treadmill tests ratings of perceived claudication pain￨ratings of perceived claudication pain were significantly less after the polestriding training program p 002￨sig decrease￨highunclear￨highunclear￨highunclear
2297￨squamous cell skin cancer in moderaterisk subjects 526 subjects had a first new skin cancer moderaterisk subjects a total of 2297 freeliving subjects were enrolled subjects resided in arizona median age 63 years and had a history of more than 10 actinic keratoses and at most 2 squamous cell carcinoma scc or basal cell carcinoma bcc skin cancers￨placebo retinol supplementation placebo supplementation retinolsupplemented subjects with placebo oral retinol retinol￨hazard ratio of first new bcc time to first new scc or bcc hazard ratio￨comparing retinolsupplemented subjects with placebosupplemented subjects showed a hazard ratio for first new scc of 074 95 confidence interval 056099 p  004￨no diff￨low￨low￨low
35533￨baseline eligibility included age 50 years or older african american men or 55 years or older all other men a serum prostatespecific antigen level of 4 ngml or less and a digital rectal examination not suspicious for prostate cancer 35533 men from 427 participating sites in the united states canada and puerto rico randomly assigned to 4 groups prostate cancer and other cancers relatively healthy men￨placebocontrolled trial selenium and vitamin e cancer selenium vitamin e oral selenium 200 microgd from lselenomethionine and matched vitamin e placebo vitamin e placebo selenium and vitamin e vitamin e selenium  vitamin e selenium vitamin e selenium  vitamin e and placebo selenium placebo selenium  vitamin e or placebo  placebo selenium or vitamin e alone or in combination￨type 2 diabetes mellitus risks of prostate cancer lung colorectal and overall primary cancer hazard ratios￨there were statistically nonsignificant increased risks of prostate cancer in the vitamin e group p  06 and type 2 diabetes mellitus in the selenium group relative risk 107 99 ci 094122 p  16 but not in the selenium  vitamin e group￨no diff￨low￨low￨low
161￨161 healthy volunteers aged 39 to 56 years volunteers with coronary disorders 147 volunteers who qualified for the analysis seven of the 73 volunteers receiving 3 mg dalphatocopheryl acetate daily and none of the 74 volunteers receiving 100 mg had coronary disorders including myocardial damage p  002￨vitamin e dietary supplementation with 100 mg dalphatocopheryl acetate 100 or 3 mg of dalphatocopheryl acetate￨lowdensity lipoprotein cholesteroltotal toc ratio a parameter of the inhibition of peroxidation of lowdensity lipoprotein cholesterol peroxidation of lowdensity lipoprotein cholesterol mean serum total tocopherol toc concentration￨the mean serum total tocopherol toc concentration in the 100mg group was significantly higher than that in the 3mg group 6 months after the start of the study and this raised value was maintained throughout the study the level in the 3mg group did not change significantly from the baseline value￨sig increase￨highunclear￨highunclear￨highunclear
92￨49 participants consumed a mv and 43 a matched p for 6 months aged care residents 92 aged care residents￨multivitamin mv tablet multivitamin supplementation daily mv or placebo￨nutritional status quantitative heel ultrasound qus mobility muscle strength and falls vitamin b12 1780403 pmol l1 serum vitamin b12 and folate concentrations and increased serum 25ohd adequate 25ohd concentrations qus mean number of falls nutritional status and bone quality serum 25ohd serum micronutrients body weight qus rate of falls hand grip strength and the timed up and go test￨there was a greater increase in the mv vs p group for serum 25ohd￨sig increase￨highunclear￨highunclear￨highunclear
121￨a total of 121 subjects heavy smokers￨vitamin intervention vitamins or placebo placebo antioxidant vitamins vitamins c and e and betacarotene￨dna damage dropout rates polycyclic aromatic hydrocarbondna adducts and oxidative dna damage 8oxo or hydroxydeoxyguanosine in mononuclear and oral cells plasma levels￨all four measures of dna damage decreased in both groups the betweengroup differences were not statistically significant￨no diff￨highunclear￨highunclear￨highunclear
769￨patients with mild cognitive impairment subjects with the amnestic subtype of mild cognitive impairment 769 subjects were enrolled and possible or probable alzheimers disease developed in 212 mild cognitive impairment￨placebo vitamin e daily 10 mg of donepezil daily or placebo vitamin e and donepezil vitamin e donepezil vitamin e￨likelihood of progression to alzheimers disease clinically possible or probable alzheimers disease secondary outcomes were cognition and function mild cognitive impairment rate of progression to alzheimers disease probability of progression to alzheimers disease￨there were no significant differences in the rate of progression to alzheimers disease between the vitamin e and placebo groups at any point either among all patients or among apolipoprotein e epsilon4 carriers￨no diff￨low￨low￨low
not found￨older people mavis trial people aged 65 or over older people living at home 910 men and women aged 65 or over who did not take vitamins or minerals￨routine multivitamin daily multivitamin and multimineral supplementation or placebo placebo multivitamin and multimineral supplements￨quality of life quality of life morbidity from infections contacts with primary care for infections self reported days of infection and quality of life antibiotic prescriptions hospital admissions adverse events and compliance￨supplementation did not significantly affect contacts with primary care and days of infection per person incidence rate ratio 096 95 confidence interval 078 to 119 and 107 090 to 127￨no diff￨low￨low￨low
129￨48 patients who had not completed the study 7 had died 33 had not returned to their physician for an examination and 8 had had a followup colonoscopy or sigmoidoscopy fifteen patients had to be excluded because a review of pathology indicated that their polyps were not adenomatous one hundred thirtyseven people 75 of eligible subjects completed the study polyps were observed in the second colonoscopy in 414 of 70 subjects on vitamin supplements and in 507 of 67 subjects on two hundred patients believed to be free of polyps after removal of at least one colorectal polyp 129 subjects with complete information on demographic and dietary factors who had completed the trial￨vitamin supplementation vitamins c and e ascorbic acid and alphatocopherol or a placebo placebos￨recurrence of colorectal polyps relative risk of polyp occurrence￨two hundred patients believed to be free of polyps after removal of at least one colorectal polyp were randomized to receive a supplement of 400 mg each of ascorbic acid and alphatocopherol or a placebo￨no diff￨low￨low￨low
1805￨1805 patients who had had a recent nonmelanoma skin cancer to receive either persons with a previous nonmelanoma skin cancer￨beta carotene beta carotene 50 mg of beta carotene or placebo￨initial plasma beta carotene level mean number of new nonmelanoma skin cancers median plasma beta carotene level rate of occurrence of the first new nonmelanoma skin cancer occurrence of new skin cancers￨there was also no significant difference between treated and control groups in the mean number of new nonmelanoma skin cancers per patientyear￨no diff￨highunclear￨highunclear￨highunclear
423￨423 postmenopausal women with at least one 15 to 75 coronary stenosis at baseline coronary angiography patients with intercurrent death or myocardial infarction mi postmenopausal women with coronary disease postmenopausal women july 1997 to january 2002 in 7 clinical centers in the united states and canada￨hrt or antioxidant vitamin supplements hormone replacement therapy and antioxidant vitamin supplements conjugated equine estrogen plus 25 mgd of medroxyprogesterone acetate for women who had not had a hysterectomy or matching placebo and 400 iu of vitamin e twice daily plus 500 mg of vitamin c twice daily or placebo hormone replacement therapy hrt and antioxidant vitamins vitamin placebo hrt nor antioxidant vitamin supplements angiographic vitamin and estrogen hrt placebo￨annualized mean sd change in minimum lumen diameter mld death nonfatal mi or stroke mean sd interval coronary atherosclerosis coronary progression￨there was no interaction between the 2 treatment interventions￨no diff￨low￨low￨low
864￨patients adhered well to the prescribed regimen and 751 completed the fouryear clinical trial patients one year and four years after they entered the study￨beta carotene plus vitamins c and e beta carotene and vitamins c and e vitamin e placebo beta carotene 25 mg daily vitamin c antioxidant vitamins antioxidant vitamins￨incidence of adenomas the relative risk for beta carotene colorectal adenoma￨neither treatment appeared to be effective in any subgroup of patients or in the prevention of any subtype of polyp defined by size or location￨no diff￨low￨low￨low
617￨elderly nursing home residents april 1998 to august 2001 at 33 longterm care facilities in the boston mass area 617 persons aged at least 65 years and who met the studys eligibility criteria were enrolled 451 73 completed the study elderly individuals elderly persons￨vitamin e supplementation capsule containing half the recommended daily allowance of essential vitamins and minerals placebo vitamin e supplementation vitamin e placebo capsule administered daily vitamin e￨respiratory tract infections antibiotic use incidence or number of days with infection for all upper or lower respiratory tract infections incidence of respiratory tract infections number of persons and number of days with respiratory tract infections upper and lower and number of new antibiotic prescriptions colds upper respiratory tract infections lower respiratory tract infections￨vitamin e had no significant effect on incidence or number of days with infection for all upper or lower respiratory tract infections￨no diff￨low￨low￨low
not found￨t1dm patients with high cholesterol received type 1 diabetic patients treated with￨vitamin e supplementation vitamin e placebo atorvastatin￨lipoprotein peroxidation and composition plasma malondialdehyde lowering of lipids and plasma malondialdehyde serum tocopherol serum cholesterol and triglycerides vitro peroxidation ldl  vldl fraction lipids and peroxidation blood biochemistry lowdensity lipoprotein ldl subfractions and lipid peroxidation thiobarbituric reactive substances￨plasma malondialdehyde decreased by 35 in both groups p  0002 but not when adjusted for lipids￨no diff￨highunclear￨highunclear￨highunclear
not found￨18314 participants who were at high risk for lung cancer because of a history of smoking or asbestos exposure￨stopping betacarotene and retinol supplements placebo daily betacarotene 30 mg and retinyl palmitate caret betacarotene and retinyl palmitate￨cardiovascular disease mortality relative risk of cardiovascular disease mortality incidence of death and a higher rate of cardiovascular disease mortality incidence of lung cancer relative risks of lung cancer mortality incidence of lung cancer other cancers and death excess risks of lung cancer cause mortality lung cancer incidence lung cancer and cardiovascular disease mortality￨smoothed relative risk curves for lung cancer incidence and allcause mortality indicated that relative risks remained above 10 throughout the postintervention followup￨sig decrease￨low￨low￨low
61￨patients with primary biliary cirrhosis given oral antioxidant supplementation fatigue associated with primary biliary cirrhosis sixtyone patients with primary biliary cirrhosisassociated fatigue￨placebo and antioxidant supplementation vitamins a c and e selenium methionine and ubiquinone placebo oral antioxidant supplementation oral antioxidant supplementation￨fatigue fisk scores fatigue scores adverse effects￨small improvements in fisk scores were recorded during placebo therapy median improvement 4 p  003￨no diff￨low￨low￨low
520￨hypercholesterolemic persons subjects were 520 smoking and nonsmoking men and postmenopausal women aged 45 to 69 years with serum cholesterol  or 50 mmoll 193 mgdl 440 846 of whom completed the study men but not women subjects with either low baseline plasma vitamin c levels or cca plaques￨vitamin e and slowrelease vitamin c combined vitamin c and e supplementation vitamin e vitamin e plus 250 mg of slowrelease vitamin c antioxidant supplementation vitamin e￨slope of mean ccaimt mean ccaimt atherosclerotic progression carotid atherosclerosis hdl cholesterol atherosclerotic progression￨in men this treatment effect was 37 95 ci 4 to 69 p0028￨sig increase￨highunclear￨highunclear￨highunclear
3318￨persons with esophageal dysplasia adults with esophageal dysplasia adults with precancerous lesions of the esophagus individuals with esophageal dysplasia 3318 persons with cytologic evidence of esophageal dysplasia￨daily supplementation with 14 vitamins and 12 minerals or placebo supplementation with multiple vitamins and minerals placebo control placebo￨cumulative esophagealgastric cardia death rates risk of total mortality esophagealgastric cardia cancer mortality and cancer incidence cumulative cancer incidence rates cerebrovascular disease￨no substantial shortterm beneficial effect on incidence or mortality for this type of cancer occurred following daily supplementation with multiple vitamins and minerals among adults with precancerous lesions of the esophagus￨no diff￨low￨low￨low
not found￨smokers with  or 10 cigarettes per day and serum cotinine  or 25 ngml were eligible for the study female smokers gstm1null women suggeststhat certain subgroups￨placebo exposuretobap antioxidant vitamin supplementation antioxidant vitamin supplementation 500 mg vitamin c and 400 iu vitamin e dlalphatocopherol daily or placebo antioxidant supplementation￨risk of lung cancer bapdna adducts bapdna adduct levels smoking habits and blood samples mean level of smokingrelated bapdna adducts bapdna adducts highperformance liquid chromatography plasma cotinine vitamin levels and gstm1 genotype￨among treated women bapdna adducts decreased by 31 compared with women on placebo p  003￨sig increase￨low￨low￨low
76￨children and adolescents with adhd and comorbid tic disorders study subjects were 7 to 17 years old met diagnostic and statistical manual of mental disordersiv criteria for adhd and had concurrent tourette syndrome or chronic motor tic disorder children and adolescents with attention deficithyperactivity disorder adhd and comorbid tic disorders￨atomoxetine placebo atomoxetine￨discontinuation rates cgi severity of adhdpsychiatric symptoms scale score yale global tic severity scale total score reduction of tic severity safe and well tolerated exacerbate tic symptoms vital sign adverse event or electrocardiographic or laboratory measures tic symptom selfreport total score body weight and rates of treatmentemergent decreased appetite and nausea adhd rating scale total score heart rate clinical global impressions cgi ticneurologic severity scale score￨no other clinically relevant treatment differences were seen in any other vital sign adverse event or electrocardiographic or laboratory measures￨no diff￨highunclear￨highunclear￨highunclear
20￨boys with attentiondeficithyperactivity disorder adhd comorbid with tourettes syndrome adhd and comorbid tourettes syndrome 20 subjects in three cohorts￨methylphenidate mph and dextroamphetamine dex placebo dex￨tic severity￨relatively high doses of mph and dex in the first cohort produced significant increases in tic severity which were sustained on higher doses of dex but which attenuated on mph￨sig increase￨highunclear￨highunclear￨highunclear
not found￨children with tic disorders and attention deficit hyperactivity disorder subjects from a specialty tic disorders clinic children with tic disorders and adhd thirtyfour medicationfree subjects 31 boys and three girls with a mean age of 104 years with adhd combined type and a tic disorder participated children with tic disorders and attention deficit hyperactivity disorder adhd￨guanfacine or placebo placebo guanfacine guanfacine￨tic severity clinical global improvement scale continuous performance test commission errors total score on the teacherrated adhd rating scale mean score on the parentrated hyperactivity index blood pressure and pulse efficacy and safety￨on the continuous performance test commission errors decreased by 22 and omission errors by 17 in the guanfacine group compared with increases of 29 in commission errors and of 31 in omission errors in the placebo group￨sig increase￨highunclear￨highunclear￨highunclear
136￨children with tics children with comorbid tics children with attention deficit hyperactivity disorder adhd and tourette syndrome ts 136 children with adhd and a chronic tic disorder thirtyseven children￨clon clon alone mph alone combined clon  mph or placebo placebo clon alone 33 were administered clon  mph methylphenidate methylphenidate and clonidine clonplacebo dose titration weeks 58 added mphplacebo￨tic severity adverse effect adhd conners abbreviated symptom questionnaireteacher moderate or severe sedation￨clon appeared to be most helpful for impulsivity and hyperactivity mph appeared to be most helpful for inattention￨no diff￨low￨low￨low
37￨individuals with tourettes syndrome ts tourettes syndrome children with ts children with ts  adhd thirtyseven children with tsadhd between the ages 7 to 13 years and of normal intellect were recruited and 34 31 males 3 females completed the entire protocol￨desipramine placebo clonidine desipramine clonidine clonidine and desipramine￨tic severity hopkins motorvocal tic severity scale the tourette syndrome severity scale or the yale global tic severity scale drug blood levels linear analogue rating parent cbcl hyperactivity subscale and teacher cbcl subscales nervousoveractive anxious and unpopular adhd included parent and teacher child behavior checklists cbcl continuous performance tests and neuropsychologic tests of executive function global linear analogue scale￨desipramine showed a statistically significant improvement on a global linear analogue scale but not on the hopkins motorvocal tic severity scale the tourette syndrome severity scale or the yale global tic severity scale￨sig increase￨highunclear￨highunclear￨highunclear
not found￨children with comorbid chronic multiple tic disorder attentiondeficithyperactivity disorder adhd in children ages 612 years with tourettes syndrome 96 or chronic motor tic disorder 4 children with chronic tic disorder two cohorts of prepubertal children n  71 received￨placebo and three doses of mph mphir therapy immediaterelease methylphenidate mphir immediaterelease methylphenidate￨mphir effectively suppressed adhd oppositional defiant disorder and peer aggression behaviors tic frequency and severity overall severity of tic disorder or obsessivecompulsive disorder behaviors extensive battery of parent teacher child and physiciancompleted rating scales and laboratory tasks safety and efficacy￨there was no evidence that mphir altered the overall severity of tic disorder or obsessivecompulsive disorder behaviors￨no diff￨highunclear￨highunclear￨highunclear
41￨children and adolescents with chronic tic disorder and comorbid attentiondeficithyperactivity disorder fortyone children and adolescents with chronic tic disorders including tourette disorder and comorbid adhd children and adolescents with chronic tic disorders and adhd diagnoses children and adolescents with chronic tic disorders and comorbid adhd￨desipramine placebo desipramine desipramine and placebo noradrenergic tricyclic antidepressant desipramine hydrochloride￨heart rate and blood pressure core symptoms of adhd adhd rating scale tic symptoms yale global tic severity scale tic response rate equal response in motor and phonic tic symptoms tic and adhd symptoms tolerated without meaningful adverse effects inattentive symptoms and hyperactiveimpulsive symptoms adhd response rate rated adhd and tic symptoms weekly and monitored adverse effects laboratory findings and cardiovascular parameters tolerability and efficacy￨treatment with desipramine was well tolerated and was associated with robust clinically significant reductions in tic and adhd symptoms in children and adolescents with chronic tic disorders and adhd diagnoses￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨twentyfour subjects 21 boys 3 girls mean age 12 years were enrolled at two sites university of rochester and baylor college of medicine children with ts fifteen subjects completed the study children with tourettes syndrome and attention deficit hyperactivity disorder children and adolescents with comorbid tourettes syndrome ts￨placebo dadhs￨ygtss total score adhd and tic severity were total scores on the dupaul attention deficit hyperactivity scale dadhs and the yale global tic severity scale ygtss￨the primary analysis revealed no statistically significant beneficial effect of deprenyl on the dadhs￨no diff￨low￨low￨low
20￨psoriatic arthritis￨etretinate tigason and ibuprofen ibuprofen vitamin etretinate etretinate etretinate tigason and ibuprofen￨esr haemoglobin creactive protein and histidine skin lesions￨in addition significant improvement in esr haemoglobin creactive protein and histidine occurred in the etretinate group￨sig increase￨highunclear￨highunclear￨highunclear
25￨twenty five patients with psoriatic arthritis patients with psoriatic arthritis￨placebo colchicine￨adverse clinical effects increased creatine kinase values￨no significant difference was noted between colchicine or placebo treatment for the primary outcome measure lansbury joint count or any of the seven secondary outcome measures￨no diff￨low￨low￨low
24￨psoriatic arthritis psa
                twentyfour patients with active psa￨placebo sulfasalazine sulfasalazine placebo patients sulfasalazine therapy￨cutaneous involvement disease activity joint scores 50 ft walking time and global patient assessment duration of morning stiffness￨six patients in the placebo group crossed over to an 8 week open label phase and demonstrated significant improvements in joint scores 50 ft walking time and global patient assessment￨sig increase￨low￨highunclear￨low
82￨82 patients with psoriatic arthritis requiring remittive drug therapy patients with psoriatic arthritis￨oral gold compound auranofin and intramuscular gold thiomalate auranofin auranofin intramuscular gold thiomalate and placebo￨ritchie articular index visual analogue pain score and esr efficacy and safety￨there were statistically significant falls in ritchie articular index visual analogue pain score and esr at 12 and 24 weeks following im￨sig decrease￨highunclear￨highunclear￨highunclear
37￨thirtyseven patients with psoriatic arthritis psoriatic arthritis￨placebo and oral pulse methotrexate therapy placebo methotrexate lowdose pulse methotrexate methotrexate￨serum total bilirubin￨methotrexate was superior to placebo only in physician assessment of arthritis activity and in improvement of the amount of skin surface area with psoriasis￨sig increase￨highunclear￨highunclear￨highunclear
238￨two hundred thirtyeight patients with psoriatic arthritis patients with rheumatoid arthritis patients with psoriatic arthritis￨auranofin placebo auranofin auranofin and placebo￨physicians global assessment and functional scores polyarthritis￨auranofin treatment was statistically superior to placebo treatment according to physicians global assessment and functional scores￨sig increase￨highunclear￨highunclear￨highunclear
221￨patients with psa two hundred twentyone patients with psa were recruited from 15 clinics psoriatic arthritis￨ssz or placebo placebo sulfasalazine and placebo ssz sulfasalazine ssz￨westergren erythrocyte sedimentation rate adverse reactions response rates joint pain tenderness and swelling scores and physician and patient global assessments nonspecific gastrointestinal complaints including dyspepsia nausea vomiting and diarrhea￨the westergren erythrocyte sedimentation rate declined more in the psa patients taking ssz than in those taking placebo p  00001￨sig increase￨highunclear￨highunclear￨highunclear
30￨30 patients psoriatic arthritis￨sulphasalazine sulphasalazine sasp placebo sasp￨sasp tolerated and potentially beneficial exacerbation or remission of psoriasis￨greater improvement occurred in those patients on active treatment than on placebo with more benefit being detected in those patients with the symmetrical polyarticular but seronegative pattern of arthritis associated with a high acutephase response￨sig increase￨highunclear￨highunclear￨highunclear
120￨117 patients who qualified three patients did not qualify due to missing data after baseline psoriatic arthritis patients with psoriatic arthritis 81 patients who completed the 6 months study period ssz  38 placebo  43 120 patients were included in nine centres￨sulphasalazine ssz placebo sulphasalazine ssz￨efficacy and tolerability adverse events pain pain patients overall assessment of joint and skin improvement morning stiffness ritchie articular index esr and crp￨pain was the only statistically significantly different primary outcome variable at end point in favour of ssz in the itt analysis￨no diff￨low￨low￨low
39￨thirtynine patients with active psa recruited from two rheumatology units psoriatic arthritis￨sulphasalazine sasp placebo entericcoated sulphasalazine sasp or placebo￨articular index visual analogue scale duration of morning stiffness and esr￨in addition to articular index the sasp group improved significantly in terms of visual analogue scale duration of morning stiffness and esr￨sig increase￨highunclear￨highunclear￨highunclear
not found￨haemodialysis patients￨recombinant human erythropoietin lowdose rhuepo rhuepo recombinant human erythropoietin rhuepo￨renal anaemia mean haemoglobin levels renal anemia￨at the end of 12 weeks of treatment with rhuepo the mean haemoglobin levels had risen from 69￨sig increase￨highunclear￨highunclear￨highunclear
not found￨two groups of 10 capd patients renal anemia patients on continuous ambulatory peritoneal dialysis capd patients￨recombinant human erythropoietin rhuepo recombinant human erythropoietin rhuepo￨renal anemia hemoglobin levels￨after 16 weeks of treatment with rhuepo the hemoglobin levels rose from 66￨sig increase￨highunclear￨highunclear￨highunclear
not found￨capd patients￨epo recombinant erythropoietin￨reticulocyte count plasma hemoglobin levels hemoglobin level higher hb level frequency of exogenous peritonitis hematocrit and hb levels mean epo dose￨the rest of clinical and biochemical parameters did not suffer any significant modifications￨no diff￨highunclear￨highunclear￨highunclear
173￨haemodialysis patients 173 chronic renal failure patients￨epoetin beta epoetin epoetin￨renal anaemia timeadjusted area under the haematocrit hct curve auc￨in all three analyses the 90 cis were within the prespecified equivalence ranges for both the difference between treatment groups for hct auc and the ratio of mean weekly epoetin beta dose￨no diff￨highunclear￨highunclear￨highunclear
158￨one hundred and fiftyeight patients delivered ktv 10 where kdialyserrenal urea clearance tdialysis time and vfiltration volume obtained by urea kinetic modelling stable haemodialysis patients haemodialysis patients￨sc epoetin beta intravenous iron supplementation subcutaneous sc epoetin epoetin beta subcutaneous epoetin beta erythropoietin￨mean haemoglobin levels haemoglobin levels stable haemoglobin levels￨once weekly sc administration of epoetin beta is as safe and effective in maintaining haemoglobin levels in stable haemodialysis patients as two or three times weekly administration of the same total dose￨no diff￨highunclear￨highunclear￨highunclear
33￨anemic capd patients thirtythree anemic patients on continuous ambulatory peritoneal dialysis capd treatment for endstage renal failure completed the study patients were recruited from two university hospitals and five county hospitals￨recombinant human erythropoietin rhuepo rhuepo sc recombinant human erythropoletin rhuepo administered subcutaneously sc￨￨the 22 increase p  003 took place during the last two weeks￨sig increase￨highunclear￨highunclear￨highunclear
not found￨15 patients were grouped arbitrarily into 7 patients with a skinfold of more than 20 mm at the injection site and 8 patients with a skinfold of less than 20 mm at the injection site patients undergoing continuous ambulatory peritoneal dialysis capd￨recombinant human erythropoietin epoetin erythropoietin epoetin￨injection frequency and skinfold thickness￨the dose reduction correlated with skinfold thickness the reduction was seen only in the patients with skinfolds of less than 20 mm￨sig decrease￨highunclear￨highunclear￨highunclear
63￨migraine 63 patients suffering from migraine with or without aura patients with migraine meeting the ihs criteria 30 patients treated with gabapentin￨gabapentin gabapentin placebo￨frequency and intensity of migraine brain gaba levels headache frequency tolerated adverse events somnolence dizziness tremor fatigue and ataxia￨no patients withdrew gabapentin was well tolerated adverse events somnolence dizziness tremor fatigue and ataxia generally were transient and mild to moderate in severity and in 13 patients 27 only occurred￨no diff￨highunclear￨highunclear￨highunclear
not found￨migraine 62 patients 378￨gabapentin migraine gabapentin￨effectiveness and safety asthenia mild adverse effects pain lasts abdominal pain number of attacks drowsiness dizziness￨no serious adverse events occurred￨no diff￨highunclear￨highunclear￨highunclear
not found￨523 patients n  128 patients with international headache societydefined migraine who met criteria suggesting the need for prophylactic therapy￨gabapentin enacarbil placebo gen 1200 mg gen 1800 mg gen 2400 mg or gen 3000 mg placebo gabapentin enacarbil gen￨number of migraine headache days￨gen did not significantly differ from placebo for migraine headache prophylaxis￨no diff￨low￨low￨low
20￨elderly people than a flexibility exercise program seniors￨communitybased resistance exercise and flexibility exercise progressive resistance training flexibility training community based progressive resistance training program flexibility program progressive resistance training￨strength gait and balance improvements strength gait balance and quality of life left sided biceps strength sf36 quality of life measures right sided quadriceps strength left sided quadriceps strength functional reach￨progressive resistance training had a greater effect than flexibility training on right sided quadriceps strength mean difference between groups  77 95 ci 36118 p  0003 manova left sided quadriceps strength mean difference  99 95 ci 56142 p  0003 manova left sided biceps strength mean difference  152 95 ci 117192 p  0003 manova functional reach mean difference  117 95 ci 71163 p  0003 manova and step test mean difference  86 95 ci 38134 p  0003 manova￨sig increase￨highunclear￨highunclear￨highunclear
45￨elderly women who were active but nonexercising prior to the study healthy elderly women elderly women in only 10 weeks older women 45 healthy active women aged 7087 years elderly women remain unclear elderly women￨exercise training aerobic training at 76 endurance and resistance exercise resistance training rt 73 rt and endurance training endurance training and resistance training￨plasma lipoprotein profiles plasma lipoprotein response control lipoproteins total cholesterol to hdl ratio 1mile walk times and heart rate ldl cholesterol and total cholesterol hdl cholesterol and decreased triglycerides highdensity lipoprotein hdl cholesterol and low levels of lowdensity lipoprotein ldl cholesterol blood samples total cholesterol hdl cholesterol and ldl cholesterol plasma lipoprotein levels eight repetition maximum of all rt exercises weight and diet￨both triglycerides and the total cholesterol to hdl ratio increased significantly while total cholesterol hdl cholesterol and ldl cholesterol remained unchanged￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨65 to 74yrold women healthy older women healthy women 31 healthy￨low and highresistance training￨force power and functional abilities maximal treadmill walking speed vertical jumping and box stepping￨all training groups significantly increased force power and functional abilities maximal treadmill walking speed vertical jumping and box stepping at week 8 in the range from 65 to 208 with no further improvement at week 16 except maximal treadmill walking speed but no significant differences were observed between the three groups￨sig increase￨highunclear￨highunclear￨highunclear
not found￨old age older adults￨resistance training￨maximal isometric knee extension torque electromyographic emg activity legextension and legpress exercises vastus lateralis muscle fascicle force￨training altered the angletorque relation a displacing it by 931 towards higher torque values p  005 and b shifting the optimal angle from 70 deg corresponding torque 1214￨sig increase￨highunclear￨highunclear￨highunclear
54￨elderly care rehabilitation ward in a community hospital fiftyfour consecutive patients referred for rehabilitation￨physiotherapyconventional therapy and additional leg strengthening exercises￨handgrip strength incidence of falls and the change in strength￨in these handgrip strength improved more in those given additional exercise than conventional physiotherapy 21 kg versus 03 kg p  005￨sig increase￨highunclear￨highunclear￨highunclear
47￨chronic obstructive pulmonary disease copd men with copd 47 men with copd mean fev1  40 predicted and low testosterone levels mean  320 ngdl men with chronic obstructive pulmonary disease￨testosterone and resistance training testosterone supplementation testosterone testosterone  resistance training testosterone injections placebo injections  no training testosterone injections  no training placebo injections  resistance training or testosterone injections  resistance training testosterone supplementation and resistance training testosterone enanthate injected weekly with or without resistance training￨lean body mass nadir serum testosterone concentration repetition maximum leg press strength body composition and muscle function￨increase in onerepetition maximum leg press strength averaged 172 with testosterone alone 174 with resistance training alone and 268 with testosterone  resistance training p  0001￨sig increase￨highunclear￨highunclear￨highunclear
33￨elderly patients who have had a hip fracture perform moderate to highintensity exercise at home people with hip fracture thirtythree elderly people 24 women 9 men mean  786 years of age sd  68 range  6489 who had completed a regimen of physical therapy following hip fracture participated in the study￨home exercise program of moderate or highintensity exercise aerobic training portable progressive resistance exercise machine resistance training group an aerobic training group or a control group highintensity exercise￨isometric lowerextremity force 6minutewalk distance free gait speed mental status and physical function distance walked force produced gait speed and physical function depressive symptoms isometric force 6minutewalk distance and gait speed heart rate￨isometric force improved to a greater extent in the intervention groups than in the control group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨elderly women healthy 6579yearold women￨control co highintensity hi or lowintensity lo training group exercise program high and lowintensity resistance training￨hi maintained bmd muscle strength thigh tissue composition thigh muscle strength fiber crosssectional area csa and tissue composition 1rm thigh lean tissue mass ltm fat mass and bone mineral density bmd gcm2 bmd thigh muscle strength dynamic muscle strength thigh muscle strength fiber area and tissue composition￨there was no significant effect of either exercise program on thigh tissue composition except for bmd at the 13 site middle third of the femur where lo and co groups experienced a decline p  005 of 22  05 and 18￨no diff￨highunclear￨highunclear￨highunclear
not found￨twelve women 73 older adults 7 years and 18 men 73￨concentric training isometriconly isokinetic concentriconly or isokinetic eccentriconly 12week training program maximal isometric and isokinetic resistance training maximal isokinetic eccentriconly resistance training to those elicited by maximal isometriconly or maximal isokinetic concentriconly resistance training resistance training￨strength and functional mobility peak isometric and isokinetic concentric and eccentric knee extensor strength concentric work concentric power stair ascent and descent and gait speed voluntary strength isometric concentric and eccentric and functional mobility step time gait speed peak concentric work and concentric power stair ascent and descent performance peak isometric and isokinetic concentric and eccentric strength￨all three training groups demonstrated an increase in peak isometric and isokinetic concentric and eccentric strength following 12 weeks of training p 01￨sig increase￨highunclear￨highunclear￨highunclear
39￨patients with chronic heart failure patients with chronic heart failure chf thirtynine chf patients new york heart association functional class2305 left ventricular ejection fraction 287 age 6511 years 336 malefemale chf patients￨resistance exercise training moderateintensity resistance exercise training strength and endurance of the knee and elbow extensors and flexors vo2peak hrv fbf at rest and fbf activated by forearm exercise or limb ischemia resistance training ex n19 consisting of mainly isokinetic hydraulic ergometry interspersed with rest intervals or continuance with usual care con￨strength endurance heart rate variability and forearm blood flow skeletal muscle strength and endurance vo2peak fbf and hrv skeletal muscle strength and endurance aerobic power vo2peak heart rate variability hrv and forearm blood flow fbf strength increased for ex limb ischemia fbf￨moderateintensity resistance exercise training in chf patients produced favorable changes to skeletal muscle strength and endurance vo2peak fbf and hrv￨sig increase￨highunclear￨highunclear￨highunclear
31￨healthy older men older men older adults thirtyone healthy men 6574 yr￨combined resistance and cardiovascular training 16wk training period 2 dwk1 of resistance training alone s endurance training alone e or combined resistance once weekly and endurance once weekly training se on muscle mass maximal strength and power of the leg and arm extensor muscles and maximal workload wmax by using a incremental cycling test prolonged combined resistance and endurance training￨arm strength in s s and seinduced muscle hypertrophy maximal strength￨there were no significant differences between s and seinduced muscle hypertrophy 11 and 11 and maximal strength 41 and 38 gains of the legs as well as between e and seinduced wmax 28 and 23 gains￨no diff￨highunclear￨highunclear￨highunclear
42￨exercise laboratory in a university faculty of sport and health sciences women aged 42 medicallyscreened women aged 7678 years drawn from the population register to strength n16 endurance n15 or control n11 groups medicallyscreened elderly women older women women aged 7678 years￨supervised individually tailored 18week strength or endurance training programme strength training endurance training strength or endurance training 18week strength or endurance training￨cardiovascular fitness peak oxygen uptake cycle ergometer peak power peak power per kg body weight￨peak oxygen uptake increased from 181 to 197 ml x kg1￨sig increase￨highunclear￨highunclear￨highunclear
not found￨older adults twentyeight communitydwelling men and women aged 65 to 78￨singleset 1set or threeset 3set exercise group 1set￨6m walk 6m backwards walk 400m walk floor rise to standing and stair climbing ability body composition isokinetic and isometric knee extensor strength muscle function and physical performance physical performance included timed chair rise usual and fast muscle endurance gains stair climbing test muscle strength and endurance gains isotonic muscle strength 1rm of the seven exercises isokinetic and isometric knee extensor strength and muscle endurance for the chest press and leg press exercises physical performance and body composition isotonic muscle strength￨similarly muscle endurance gains were greater for the 3set than the 1set group p01 with no significant difference between groups for isokinetic and isometric knee extensor strength￨sig increase￨highunclear￨highunclear￨highunclear
10￨nursing homes in copenhagen denmark frail elders twentyone frail nursing home residents aged 86 to 95 completed the study￨physical exercise resistance training of knee extensors and flexors three times a week for 12 weeks the remaining 11 participants served as a control group who joined social activities supervised by an occupation therapist￨muscle strength plasma levels of stnfri muscle strength muscle strength plasma levels of tnfalpha soluble tnf receptor stnfr1 and interleukin il6 plasma levels of tnfalpha and stnfri or il6￨the training program improved muscle strength but did not affect plasma levels of tnfalpha and stnfri or il6￨no diff￨highunclear￨highunclear￨highunclear
not found￨sixty communitydwelling adults 60 years with major or minor depression depressed elderly persons older depressed patients older adults￨high intensity progressive resistance training prt supervised high intensity prt 80 maximum load or low intensity prt low intensity weight training versus general practitioner care￨hamilton rating scale of depression score personality type selfefficacy and locus of control vitality qualityoflife scale quality of life sleep quality and selfefficacy sleep quality depressive symptoms strength gain￨high intensity prt is more effective than is low intensity prt or gp care for the treatment of older depressed patients￨sig increase￨highunclear￨highunclear￨highunclear
not found￨older adults previously untrained older adults previously untrained male and female participants 71653 y￨periodised and fixed repetition training protocol￨strength gains fr per total body strength￨fr p 001 and per p 001 groups experienced significant strength gains compared to c but were not different from each other￨sig increase￨highunclear￨highunclear￨highunclear
70￨elderly men with relative testosterone insufficiency seventy sedentary community dwelling men for 12 weeks in men between ages of 65 and 85 years with relative testosterone insufficiency elderly men￨modest testosterone supplementation and exercise placebo testosterone supplementation testosterone and exercise testoderm transdermal system applied daily vs placebo system and additionally randomized to a homebased resistance exercise program testosterone testosterone and a homebased strengthening program group 1 testosterone plus exercise group 2 testosterone plus no exercise group 3 placebo plus exercise and group 4 placebo plus no exercise resistance exercise program or no additional exercise￨social functioning role physical quality of life and body composition serum testosterone general health quality of life quality of life alone nor in body composition parameters quality of life assessed by the short form36 questionnaire and body composition measured by dual xray absorptiometry scan body composition and quality of life￨there was a significant interaction of testosterone and exercise on quality of life in the domains of physical functioning p  003 role physical p  001 general health p  0049 and social functioning p  004￨sig increase￨highunclear￨highunclear￨highunclear
112￨older adults one hundred twelve healthy older adults 69￨con explosive resistance training pneumatic resistance machines￨average strength average strength average peak power average muscle endurance￨peak muscle power may be improved similarly using light moderate or heavy resistances whereas there is a doseresponse relationship between training intensity and muscle strength and endurance changes￨sig increase￨highunclear￨highunclear￨highunclear
16￨chronic heart failure chf older women with chf sixteen older women with chf were compared with 80 agematched peers without chf patients￨exercise training progressive resistance training or control stretching exercises chf highintensity progressive resistance training progressive resistance training￨skeletal muscle skeletal muscle characteristics and overall exercise performance resting cardiac indexes muscle strength muscle endurance citrate synthase activity 6min walk distance strength￨21 in skeletal muscle were independently predictive of improved 6min walk distance r2  078 p  00024￨sig increase￨highunclear￨highunclear￨highunclear
52￨20 exercisers median age 795 range 76 to 93 years and 20 controls median age 795 range 75 to 90 years healthy very old women fiftytwo healthy women were recruited through local and national newspapers healthy women aged 75 and over women aged 75 and older subjects were matched for age and habitual physical activity￨progressive resistance exercise control or an exercise group ikes pre and posttraining progressive resistance strength training resistance training￨functional ability tests were chair rise kneel rise rise from lying on the floor 118m selfpaced corridor walk stair climbing functional reach stepping up stepping down and lifting weights onto a shelf hgs isometric knee extensor strength ikes isometric elbow flexor strength iefs handgrip strength hgs leg extensor power lep and anthropometric indices body impedance analysis arm muscle circumference and body weight normal pace kneel rise time iefs strength power and selected functional abilities lep￨progressive resistance exercise can produce substantial increases in muscle strength and in power standardized for body weight in healthy very old women￨sig increase￨highunclear￨highunclear￨highunclear
36￨active women over sixty older women thirtysix women over the age of 60 671 active women over 60 years of age￨isotonic training 3 daysweek on polaris machines heavyresistance training heavyresistance weight training weighttraining wt n  18 or control con n  18 group resistance training￨body composition body fatness and lean tissue mass excluding skeletal mass overall program adherence percent body fat of weight trainers muscle strength of the weight trainers muscular strength body composition percent fat and lean tissue mass and program adherence lean tissue mass￨increases in muscle strength of the weight trainers were significant for all seven exercises 565 with the greatest gains in the shoulder and trunk muscles￨sig increase￨highunclear￨highunclear￨highunclear
84￨thirtysix participants ages 6084 older adults healthy older adults￨cvt and rt rt and both enhanced arm and chest strength more than cvt pre and posttraining cvt exercise training and physical activity concurrent cardiovascular and resistance training submaximal exercise test gxt five repetitionmaximum strength tests 5rm and the aahperd functional fitness test cvt or rt alone￨aahperd strength and agility scores cardiovascular fitness and 5rm performance resting heart rate and ratepressure product lower exercise diastolic blood pressure and rating of perceived exertion increased gxt duration increased leg back and shoulder 5rm scores and improved aahperd flexibility coordination and cardiovascular endurance scores￨all exercise treatment groups revealed lower resting heart rate and ratepressure product lower exercise diastolic blood pressure and rating of perceived exertion increased gxt duration increased leg back and shoulder 5rm scores and improved aahperd flexibility coordination and cardiovascular endurance scores￨sig decrease￨highunclear￨highunclear￨highunclear
40￨forty male and female subjects 692￨exercise training control group or 6 mo of endurance et or resistance training rt￨muscle size glycolytic atp supply oxidative capacity energetic pathways oxidative capacity contractile atp demand mitochondrial volume density muscle oxidative properties glycolytic atp synthesis and contractile atp demand￨only the rt group exhibited change in structural properties a rise in mitochondrial volume density 31 and muscle size 10￨sig increase￨highunclear￨highunclear￨highunclear
24￨healthy communitydwelling elderly persons older persons at risk for disability 24 healthy men and women who were 65 years of age or older mean age sd 704 4 years range 65 to 79 years a healthy communitydwelling elderly population healthy elderly persons￨resistance training resistance training weight training resistancetraining program nonexercising control group￨walking endurance submaximal walking endurance leg strength and walking endurance exhaustive submaximal walking time measured at an intensity of 80 of baseline peak aerobic capacity leg strength and change in walking endurance peak aerobic capacity fatfree mass of the leg￨neither group showed a change in peak aerobic capacity or in wholebody composition although fatfree mass of the leg increased in the exercise group￨no diff￨highunclear￨highunclear￨highunclear
not found￨outpatient clinical research center at an urban universityaffiliated teaching hospital frail older individuals 45 years recruited as a subset of a larger project evaluating rhgh and exercise in older people who underwent 62 quadricepmuscle biopsies frail older subjects thirtyone consenting older subjects mean age 713 moderately frail older people￨igf placebo growth hormone administration and exercise recombinant human growth hormone rhgh with or without a structured resistance exercise program rhgh administered subcutaneously daily at bedtime rhgh and a structured resistance exercise program structured resistance exercise with placebo injections or placebo injections only rhgh￨body composition muscle strength rhgh and muscle strength serum insulinlike growth factori circulating igfi levels isokinetic dynamometry strength tests proportion of type 2 fibers￨muscle strength increased significantly in both the rhghexercise 556 p 0004 as well as the exercise alone 478 p 0005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨communityliving older adults fortyfive communitydwelling participants aged 62 years or older￨control￨dynamic strength strength gains peak vertical and anteriorposterior ground reaction forces stride length vertical obstacle heel clearance limb flexion at obstacle crossing horizontal foot placement and vertical landing velocity stride duration obstructed gait function obstaclecrossing stride velocity￨significant strength improvements p005 ranging between 197 and 285 were recorded in the experimental group￨sig increase￨highunclear￨highunclear￨highunclear
20￨patients with osteoarthritis of the knee joint twenty volunteers with osteoarthritis of the knee joint￨8week isokinetic musclestrengthtraining program musclestrength training￨arthritis activity all strength measures pain and stiffness functional health status mobility right leg flexion and left leg extension extension and flexion strength of the right and left legs the 50foot walk time range of motion at the knee joint the osteoarthritis screening index oasi and the arthritis impact measurement scale aims￨the experimental group significantly increased in all strength measures while the control group increased in only right leg flexion and left leg extension across the training period￨sig increase￨highunclear￨highunclear￨highunclear
64￨sixtyfour volunteers average age 835 years from an independentliving facility advanced old age￨resistance training and walking resistance training and walking exercise walking resistance training or control groups￨body strength shoulder flexibility and agility and balance exercise functional fitness functional fitness included upper and lower body strength hip and shoulder flexibility agility and balance coordination blood pressure and resting heart rate￨both exercise groups showed significant improvements relative to control group in upper and lower body strength shoulder flexibility and agility and balance exercise￨sig increase￨highunclear￨highunclear￨highunclear
not found￨disabled older women with coronary heart disease who participate in disabled older women with coronary heart disease can perform resistance training at an intensity sufficient to improve measured and selfreported physical function n  30 706 older disabled women with coronary heart disease￨strength training resistance training resistance training￨physical function measures overall measured physical function score physical function measures for domains of upper body strength continuousscale physical functional performance test lower body strength body composition aerobic capacity or selfreported physical function balance and coordination￨resistance training led to improved measures for domains of upper body strength 18 vs 6 lower body strength 23 vs 6 endurance 26 vs 1 balance and coordination 29 vs 2 and 6min walk 15 vs 7￨sig increase￨highunclear￨highunclear￨highunclear
102￨enrolled 102 nondisabled communitydwelling older people aged 66 to 87 identified from the medicare beneficiary list younger older adults older persons older male exercisers nondisabled older adults￨homebased exercise program￨perceived anger tension and overall social functioning isokinetic upper and lower extremity muscle strength psychologic wellbeing and health status knee extensor strength perceived vigor muscle strength psychological wellbeing and health status￨older male exercisers achieved significant differences relative to controls in perceived anger tension and overall social functioning￨sig increase￨highunclear￨highunclear￨highunclear
17￨older adults healthy older adults fortysix communitydwelling healthy men n  29 and women n  17 aged 65 to 79 years￨resistance exercise highintensity resistance training 1 ex1 2 ex2 or 3 ex3 resistive training￨lean mass muscle strength gains quadriceps strength muscle strength and neuromuscular performance risk of falls and fracture dynamic muscle strength 1rm muscle strength neuromuscular performance￨for each of the eight exercises muscle strength increased in the exercise groups relative to co p  01 with no difference among ex1 ex2 and ex3 groups at any measurement interval￨sig increase￨highunclear￨highunclear￨highunclear
7￨older adults 18 subjects 7 women and 11 men aged 6579 years￨strength training￨strength changes repetition maximum scores￨no significant interaction was observed between time and group and therefore no difference in strength changes between training once a week versus twice a week after 9 weeks￨no diff￨highunclear￨highunclear￨highunclear
215￨215 older persons to either a older adults with disabilities older persons with disabilities￨exercise videotaped exercise routines performed with elastic bands of varying thickness homebased resistance exercise training group or a waiting list control group￨extremity strength improvements physical and overall disability high rates of exercise adherence tandem gait adverse health effects health benefits￨relative to controls subjects who participated in the program achieved statistically significant lower extremity strength improvements of 6 to 12 a 20 improvement in tandem gait and a 15 to 18 reduction in physical and overall disability at the 6month followup￨sig increase￨highunclear￨highunclear￨highunclear
105￨patients with osteoarthritis osteoarthritis oa 105 community living participants aged 50 years and over with clinical oa of the hip or knee￨resistance exercise programme hydrotherapy hydrotherapy resistance exercise programme hydrotherapy based strengthening programme￨strength and physical function strength walk speed and self efficacy satisfaction compliance rates functional gains outcome assessments muscle strength dynamometry six minute walk test womac oa index total drugs sf12 quality of life adelaide activities profile and the arthritis selfefficacy scale left quadriceps strength strength and function right quadriceps strength￨the hydrotherapy group increased left quadriceps strength only at follow up and this was significantly different from the control group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨sixtyfour participants men and women healthy inactive men and women elderly men and women￨resistance exercise machines leg extension leg curls and leg press resistance training high intensity hi versus a moderate mi or lowintensity li training program hi strength training￨strength gains knee extension power output isokinetic knee extension muscular performance￨manova repeated measures revealed that the hi group demonstrated the most strength gains following a speed specificity pattern most considerable improvement occurred at or near slow speeds from 73 to 112 for male and from 23 to 152 for female￨sig increase￨highunclear￨highunclear￨highunclear
not found￨five hospitals in auckland new zealand and sydney australia two hundred fortythree frail older people frail older people elderly subjects fitness frail older people after hospitalization frail older people after hospital discharge￨intensity quadriceps resistance exercise vitamin d supplementation vitamin d vitamin d supplementation vitamin d calciferol 300000 iu or placebo tablets and 10 weeks of highintensity homebased quadriceps resistance exercise or frequencymatched visits vitamin d and homebased quadriceps resistance exercise quadriceps resistance exercise and vitamin d￨physical health according to the shortform health survey physical performance risk of musculoskeletal injury physical performance and selfrated function physical health or falls￨there was no effect of either intervention on physical health or falls but patients in the exercise group were at increased risk of musculoskeletal injury risk ratio  36 95 confidence interval  1580￨no diff￨low￨low￨low
44￨forty four healthy sedentary women mean age 688 years volunteered for this study elderly women￨exercise training progressive resistance exercise pre exercise group or a control group resistance training￨strength gains bone mineral density bmd dynamic leg strength and the bmd of the femoral neck wards triangle and the lumbar spine unilateral biceps curl bmd bilateral leg press body weight grip strength flexibility waist to hip ratio or the sum of eight skinfolds muscular strength and bone density￨statistical analyses analysis of covariance showed significant strength gains p  001 in bilateral bench press  29 bilateral leg press  19 and unilateral biceps curl  20￨sig increase￨highunclear￨highunclear￨highunclear
not found￨twentyfour functionally limited older adults 74676 years functionally limited older adults 22 women 2 men unsteady older adults￨frt resistance and functional training resistance rt functional ft practicing everyday tasks ie chair rises or functional  resistance frt training which featured both shortening and lengthening movements￨dynamic steadiness isometric steadiness knee extensor steadiness adaptations knee extensor position fluctuations lengthening fluctuations shortening fluctuations steadiness isometric shortening or lengthening contractions changes￨rt induced a 37 reduction in shortening fluctuations at 5 of mvc and 35 reduction in lengthening fluctuations at both 30 and 65 of mvc￨sig decrease￨highunclear￨highunclear￨highunclear
221￨221 older adults mean age 69 years￨rom st strength training strength training st or rangeofmotion rom exercises lowerextremity strength training￨rate of loss mean rate of joint space narrowing jsn frequency of knee oa progression in jsn consensus ratings incidence and progression of knee osteoarthritis incidence and progression of knee oa extremity strength isokinetic lowerextremity strength and highly standardized knee radiographs strength and exhibited less frequent progressive jsn￨compared with rom st decreased the mean rate of joint space narrowing jsn in osteoarthritic knees by 26 p  not significant￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨twenty frail residents 5 from nh 15 from al aged 75 to 99 years at one ltc facility frail elderly in a ltc facility a longterm care facility frail longterm care facility ltc residents￨strength and flexibility program group exercise ex or recreational therapy c group exercise program seated range of motion rom exercises and strength training￨physical and cognitive function ppt scores mmse functional outcomes timed getupandgo test tug berg balance scale physical performance test ppt and minimental status exam mmse￨there was a significant overall impact across the four measures of the exercise intervention p  0013￨sig increase￨highunclear￨highunclear￨highunclear
45￨healthy elderly subjects older adult female subjects 45 healthy elderly females average age 699 15 subjects￨endurance and strength training endurance trained et 15 subjects to strength training st and 15 subjects to no training nt exercise training st￨vo2max most time domain and all frequency domain measures of hrv hr hrv measures￨training resulted in a significant increase in vo2max in the et 74 p  0005 group only￨sig increase￨highunclear￨highunclear￨highunclear
30￨older women thirty women with selfreported disability aged 73  1 body mass index 301  11 kgmn￨highvelocity resistancetraining program hi highvelocity resistance training leg press lp and knee extension ke exercises at 70 of the onerepetition maximum irm hi or lo￨lp and ke relative training force and total work 1rm strength skeletal muscle peak power ke lp peak power lp and ke 1rm muscle strength lp power onerepetition maximum 1 rm and peak power for ke and lp￨although lp and ke 1rm muscle strength increased similarly in both groups asa result of the training p  001 lp peak power increased significantly more in hi than in lo 267 w vs 139 w p  001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨selected lowrisk patients after coronary artery bypass surgery cardiac patients twentysix postcoronary bypass male subjects mean 19 months after bypass aged 60 men after coronary artery bypass surgery￨cwt maximum voluntary contraction circuit weight training circuit weight training cwt without an aerobic exercise component resistance training￨muscular strength peak oxygen consumption peak vo2 and myocardial oxygen demand mvo2 aerobic capacity and myocardial oxygen demand peak vo2 nor reduce mvo2 during isometric isodynamic and dynamic exercise rate pressure product during isometric and isodynamic exercise ischemic symptoms nor electrocardiographic changes peak vo2 rate pressure product muscular strength peak vo2 strength￨strength increased by 18 p  0005 in five out of seven exercises in the training group but was unchanged in the control group￨sig increase￨highunclear￨highunclear￨highunclear
46￨patients with knee oa fortysix community dwelling patients aged 55 years or older with knee pain and radiographic evidence of knee oa older adults with knee osteoarthritis￨strength training progressive strength training program or a nutrition education program attention control home based progressive strength training high intensity homebased progressive strength training program￨western ontario and mcmaster universities osteoarthritis womac index pain and physical function subscales physical function clinical signs and symptoms of osteoarthritis oa physical performance quality of life and selfefficacy strength pain physical function and quality of life pain knee extension strength selfreported physical function clinical knee examination muscle strength physical performance measures and questionnaires to measure quality of life variables￨high intensity home based strength training can produce substantial improvements in strength pain physical function and quality of life in patients with knee oa￨sig increase￨low￨low￨low
32￨32 subjects 8 women and 8 men mean age 701 sem 10 years elderly humans 32 elderly sedentary subjects elderly sedentary adults 8 women and 8 men mean age 705 sem 09 years served as controls￨strength training 8week strength training programme shortterm strength training programme strength training programme￨cd3 cell count cd4 cell count resting lymphocyte subsets and stress hormone concentrations cd20 cell count absolute counts of lymphocyte subsets cd20 cd3 cd3cd4 cd3cd8 cd3cd56cd16 resting adrenaline noradrenaline and cortisol concentrations or distributions of lymphocyte subsets strength took place baseline cortisol concentration bilateral leg extension￨baseline cortisol concentration p  001 cd20 cell count p  005 cd3 cell count p  005 and cd4 cell count p  001 decreased in both groups secondary to circannual variations between winter and summer￨sig increase￨highunclear￨highunclear￨highunclear
not found￨62 communitydwelling women with a mean age of 68 years older adult women￨accessible exercise intervention strength training resistance training intervention utilizing elastic bands￨mental or physical health functioning strength and healthrelated quality of life strength and healthrelated quality of life hrqol strength tests and hrqol￨results revealed significant increases in three major muscles compared to the control group￨sig increase￨highunclear￨highunclear￨highunclear
439￨older disabled persons with osteoarthritis of the knee 18 months conducted at 2 academic medical centers a total of 365 83 participants completed the trial 439 communitydwelling adults aged 60 years or older with radiographically evident knee osteoarthritis pain and selfreported physical disability older adults with knee osteoarthritis￨aerobic exercise aerobic exercise program a resistance exercise program and a health education program structured exercise programs aerobic training aerobic exercise and resistance exercise with a health education program￨selfreported disability score range 15 disability physical performance and pain car task knee pain questionnaire knee pain score range 16 performance measures of physical function xray score aerobic capacity and knee muscle strength time to lift physical disability questionnaire mean se time to get in and out of a car pain score xray scores faster times on the lifting and carrying task overall compliance mean se time to climb and descend stairs￨older disabled persons with osteoarthritis of the knee had modest improvements in measures of disability physical performance and pain from participating in either an aerobic or a resistance exercise program￨sig increase￨highunclear￨highunclear￨highunclear
24￨elderly group 6 females and 4 males age 766 elderly people twentyfour subjects were randomly assigned into a training group 10 females and 4 males age 762 seventyfiveyearold females￨12week training program maximal resistance training systematic resistance training training program and a control￨maximum strength maximum oxygen uptake body fat content fatfree body mass muscle strength body fat mass ergometrical fitness maximum strength￨resistance training that consisted of two training sessions per week was found to be at least as efficient as resistance training that included three training sessions per week provided that the number of sets performed were equal￨no diff￨highunclear￨highunclear￨highunclear
26￨26 adults age 65 individuals with moderate chronic kidney disease consuming a lowprotein diet 10 sd years with chronic kidney disease not on dialysis therapy￨control group n  12 for 12 weeks while counseled to consume a lowprotein diet protein resistance training resistance training￨nutritional status serum crp levels muscle strength il6 levels inflammatory mediators serum creactive protein crp and interleukin6 il6￨serum crp levels were reduced in subjects undergoing resistance training 17 mgl compared with controls 15 mgl p  005￨sig decrease￨highunclear￨highunclear￨highunclear
26￨patients who performed resistance training by a mean sd of 4 patients with chronic renal insufficiency patients with renal failure tufts university boston massachusetts patients with chronic renal insufficiency treated with a lowprotein diet 26 older patients with moderate renal insufficiency 17 men 9 women who had achieved stabilization on a lowprotein diet￨resistance training lowprotein diet plus resistance training n  14 or a lowprotein diet alone resistance training￨mean protein intake protein utilization and muscle mass muscle strength leucine oxidation and serum prealbumin levels total body potassium and type total body potassium midthigh muscle area type i and ii musclefiber crosssectional area and protein turnover￨improvement in muscle strength was significantly greater with resistance training 32￨sig increase￨highunclear￨highunclear￨highunclear
39￨thirtynine men and women mean age older adults 63 years with belowaverage leg extensor power communitydwelling older adults￨strength and power training power training strengthtraining st n  13 or powertraining strength training power training￨maximal strength physical function peak anaerobic power continuous scale physical functional performance test total score continuous scale physical functional performance test maximal strength and anaerobic power￨maximal strength was significantly greater for the st group than for the c group p 015 after the intervention￨sig increase￨highunclear￨highunclear￨highunclear
not found￨older men older men subjected to a 24 week st protocol followed by prolonged detraining fifty two healthy but inactive older men mean sd age 712 41 years￨low intensity training list n  18 55 1rm or high intensity training hist strength training st￨high intensity training elicited greater p005 gains low intensity training improved p005 strength strength and mobility gains strength anaerobic power and whole body physical function anaerobic power strength anaerobic power and mobility upper and lower body strength anaerobic power wingate testing and mobility timed up and go walking climbing stairs mobility muscular strength anaerobic power and mobility￨although low intensity training improved p005 strength 4266 anaerobic power 10 and mobility 57 high intensity training elicited greater p005 gains 6391 in strength 1725 in anaerobic power 914 in mobility￨sig increase￨highunclear￨highunclear￨highunclear
10￨inactive older individuals thirtytwo inactive older men 65  78 yr inactive older adults￨control c strength training st cardiovascular training ct and combination of strength and aerobic training sa aerobic training strength training and their combination strength training cardiovascular training and their combination resistance training￨vo2max body weight and height hip flexion extension abduction and adduction shoulder extension flexion and adduction knee flexion elbow flexion and sitandreach score concentric strength 1rm in bench and leg press body weight and height physical activity level and maximal oxygen uptake st and sa isokinetic and concentric strength sitandreach performance elbow flexion knee flexion shoulder flexion and extension and hip flexion and extension ct￨st and sa increased significantly p  005 sitandreach performance elbow flexion knee flexion shoulder flexion and extension and hip flexion and extension both at mid and posttraining￨sig increase￨highunclear￨highunclear￨highunclear
32￨elderly people 32 subjects aged 6084 mean age 713 depressed elders volunteers aged 60 and above with major or minor depression or dysthymia￨progressive resistance training prt supervised prt program three times a week or an attentioncontrol group prt progressive resistance training￨social functioning role emotional depression scores hamilton rating scale of depression adverse events strength morale and quality of life vitality strength physiologic capacity quality of life morale function and selfefficacy without adverse events median compliance depression measures beck depression inventory quality of life subscales of bodily pain￨quality of life subscales of bodily pain p  001 vitality p  002 social functioning p  008 and role emotional p  02 were all significantly improved by exercise compared to controls￨sig decrease￨highunclear￨highunclear￨highunclear
8￨young or elderly healthy individuals or subjects with ra eight subjects with rheumatoid arthritis ra eight healthy young 2230 yr and eight healthy elderly 6580 yr individuals six healthy elderly 6580 yr nontraining control subjects aging and chronic inflammation￨progressive resistance strength training highintensity progressive resistance strength training progressive resistance training￨pbmc subsets interleukin il1 beta tumor necrosis factoralpha tnf il6 il2 or pge2 production lymphocyte proliferation or dth response peripheral blood mononuclear cell pbmc subpopulations cytokine and prostaglandin pg e2 production proliferative response and delayed type hypersensitivity dth skin response immune function￨training did not induce changes in pbmc subsets interleukin il1 beta tumor necrosis factoralpha tnf il6 il2 or pge2 production lymphocyte proliferation or dth response in any of the training groups compared with control subjects￨no diff￨highunclear￨highunclear￨highunclear
98￨communitydwelling older women ninetyeight women older adults communityliving older women￨functional tasks exercise and resistance exercise functional tasks exercise programme function group a resistance exercise programme resistance group or normal activity group control group resistance exercise programme functional tasks exercise programme exercise programmes￨mean change in hrqol and physical activity scores sf36 health survey questionnaire and selfreported physical activity sf36 physical functioning score healthrelated quality of life and physical activity older adults healthrelated quality of life hrqol and habitual physical activity selfreported physical functioning score physical activity￨at 3 months no difference in mean change in hrqol and physical activity scores was seen between the groups except for an increased sf36 physical functioning score for the resistance group compared with the control group p  0019 and the function group p  0046￨no diff￨highunclear￨highunclear￨highunclear
100￨many frail elders one hundred functionally impaired communitydwelling men and women 776 frail communitydwelling elders￨strength training exercise participants received strengthening exercises￨endurance balance or disability strength gain on chair rise performance chair rise performance gait speed and in mobility tasks such as gait transfers stooping and stair climbing physical health status gain in gait speed strength gain lower extremity strength physical performance and disability falls efficacy balance endurance or disability measures physical performance and disability strength gain on mobility skills￨the impact of strength gain on chair rise performance was significant in participants who were more impaired p  04￨sig increase￨highunclear￨highunclear￨highunclear
not found￨31 communitydwelling older adults with diabetes mean age  661 years older adults older adults with diabetes older diabetics￨strength training strength training longterm resistive training exercise ex or control co￨strength gains time effect for mobility as performance mobility and strength timed up and go 50foot walk and walking up and down 8 stairs strength and mobility baseline strength or mobility values￨there was a group and time effect as the ex group increased 314 p 001 in strength for all muscle groups after the first 6 months of training and the strength gains were retained for the duration of the training intervention￨sig increase￨highunclear￨highunclear￨highunclear
not found￨healthy inactive older adults ages 6074 years volunteer subjects older adults￨resistance training heavy 80 of 1 repetition maximum 1rm and moderate 60 of 1rm resistance training heavy resistance training group hrt n  11 or moderate resistance training group mrt n  12 and participated in 12 weeks of strength training heavy and a moderate resistance training￨1rm strength strength and functional performance functional performance functional performance 1rm lowerbody strength chairrising time walking velocity stairclimbing time and flexibility￨performance measurements included 1rm lowerbody strength chairrising time walking velocity stairclimbing time and flexibility￨sig increase￨highunclear￨highunclear￨highunclear
98￨older adults with low bone mass 98 communitydwelling women with low bone mass between the ages of 75 to 85 years old older women with low bone mass older aged 7585 years communitydwelling women with low bone mass ie osteopenia or osteoporosis￨exercise intervention exercise programs resistance training agility training and general stretching resistance and agility training resistance and agility training￨healthrelated quality of life change in back pain baseline physical activity level and class attendance back pain and healthrelated quality of life quality of life back pain and its related disability and healthrelated quality of life healthrelated quality of life and changes in the domains of pain and physical function back pain and its related disabilities￨all three types of groupbased exercise programs significantly reduced back pain and its related disabilities but only resistance and agility training significantly improved healthrelated quality of life in communitydwelling older women with low bone mass￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨older scandinavian men and women 35 scandinavian men and women aged 7077 years 12 of whom formed a control group￨heavyresistance training heavyresistance training 85 of onerepetition maximum rm￨knee extension dynamic muscle strength area of both type 1 and type 2 fibers in the biceps brachii muscle elbow flexion and knee extension dynamic and isokinetic strength elbow flexion and knee extension dynamic strength isokinetic strength measurements￨muscle biopsies n  20 taken at the start and after the first 11 weeks of training showed a significant increase in the area of both type 1 and type 2 fibers in the biceps brachii muscle and a positive significant correlation between the percentage increase in the proportional area of type 2 fibers in the vastus lateralis muscle and the percentage increase in knee extension dynamic muscle strength￨sig increase￨highunclear￨highunclear￨highunclear
not found￨nutritionally at risk older adults following lower limb fracture frail undernourished older adults with a fallrelated lower limb fracture experience one hundred nutritionally at risk older adults hospitalized following a fallrelated lower limb fracture￨daily multinutrient energydense oral supplement oral nutrition supplementation and resistance training nutritional supplementation and resistance training triweekly resistance training combined treatment n  24 or attention control plus usual care and general nutrition and exercise advice resistance training without concurrent nutrition support￨weight loss significant weight loss weight risk of weight loss health outcomes weight change quadriceps strength gait speed quality of life and health care utilization￨those receiving resistance training alone lost more weight than those receiving the combined treatment p 0029￨sig decrease￨highunclear￨highunclear￨highunclear
27￨older women elderly women mean age 69 elderly women twentyseven healthy women￨control or exercise group resistance exercise 12wk resistance training program resistance training￨strength changes type ii fiber area muscle hypertrophy response muscle strength type i fiber area crosssectional area of type ii muscle fibers￨increases in muscle strength of the exercising subjects were significant compared with baseline values 28115 in all muscle groups￨sig increase￨highunclear￨highunclear￨highunclear
20￨twenty healthy men age 6574 yr older men older population￨resistance and aerobic training aerobic training at and resistance training rt cycle ergometer rtat group or 18 wk of at on a cycle ergometer atat group￨vo2peak capillary density capillary supply and vo2peak number of capillaries per fiber perimeter length￨vo2peak was increased after both rt and at p  005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨older adults communityliving older adults adults n  105 age 6885 with at least mild deficits in strength and balance were selected from a random sample of enrollees in a health maintenance organization￨strength training using weight machines n  25 endurance training using bicycles n  25 and strength and endurance training strength and endurance training￨gait balance or physical health status outpatient clinic visits sustain hospital costs risk of falling gait balance fall risk and health services gait tests balance tests physical health status measures selfreported falls up to 25 months of followup and inpatient and outpatient use and costs gait balance physical health status fall risk and health services￨between 7 and 18 months after randomization control subjects had more outpatient clinic visits p  06 and were more likely to sustain hospital costs over 5000 p  05￨sig decrease￨low￨low￨low
42￨fortytwo volunteers aged 50 years and above 6 months to 6 years after a single mild to moderate stroke older longterm stroke survivors￨control group of upper extremity stretching or a prt group that received a 12week supervised highintensity resistance training program consisting of bilateral leg press lp unilateral paretic and nonparetic knee extension ke ankle dorsiflexion df and plantarflexion pf exercises highintensity resistance training supervised highintensity progressive resistance training prt￨paretic ankle df paretic ankle pf functional performance function and disability singlerepetition maximum strength 6minute walk stairclimb time repeated chairrise time and habitual and maximal gait velocities muscle strength selfreported function and disability nonparetic ke lower extremity strength function and disability selfreported function and disability nonparetic ankle pf paretic ke performancebased measure of function late life function and disability instrument llfdi￨singlerepetition maximum strength significantly improved in the prt group for lp 162 paretic ke 314 and nonparetic ke 382 with no change in the control group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with chronic heart failure chf following twentyfour men and women age 639 years meansd with stable moderate chronic heart failure left ventricular ejection fraction 3010 patients with chf patients with chronic heart failure patients with chf under supervision of a physical therapist￨leg exercise training comprehensive local muscle training￨aerobic working capacity and quality of life and decreases neurohormonal activation peak oxygen uptake exercise capacity and quality of life and reduces catecholamine levels quality of life aerobic and functional working capacity distance walked in a 6min walking test healthrelated quality of life p0001 and plasma norepinephrine levels peak oxygen uptake p002 and quality of life scores￨no changes were found in the control group except for decreased peak oxygen uptake p002 and quality of life scores p003￨no diff￨highunclear￨highunclear￨highunclear
11￨old adults healthy old adults 6580 yr completed 16 wk of heavyload 80 of maximum n  11￨strength training strength and steadiness training strength training heavyload steadiness training n  6 or no training steadiness training￨muscle volume onerepetition 1rm load maximal electromyogram signal of quadriceps femoris coefficient of variation cv maximal voluntary contraction force￨the coefficient of variation cv for force during submaximal isometric contractions did not change with training for any group￨no diff￨highunclear￨highunclear￨highunclear
1￨1 years range 56 to 70 subjects who had recently lost a mean of 9 18 older mean  se 61￨resistance and aerobic training aerobic training exercise training aerobic or weight training exercise￨body weight body composition and energy metabolism weight loss resting metabolism or fat oxidation rates body weight body composition and metabolism resting metabolism or fat oxidation resting or postprandial￨neither type of training reversed the depressions in resting metabolism or fat oxidation rates ie resting or postprandial that had occurred as a consequence of the prior weight loss￨no diff￨highunclear￨highunclear￨highunclear
34￨patients with chronic airflow limitation thirty four patients with chronic airflow limitation forced expiratory volume in one second fev1 38 of predicted values were stratified for fev1 to vital capacity vc ratio less than 40 and arterial oxygen desaturation during exercise and randomised to a￨control or weightlifting training group weightlifting training weightlifting exercise￨muscle strength and endurance time adherence dyspnoea and mastery of daily living activities maximum cycle ergometer exercise capacity or distance walked￨responses to a chronic respiratory questionnaire showed significant improvements in dyspnoea and mastery of daily living activities in the trained group￨sig increase￨highunclear￨highunclear￨highunclear
39￨postmenopausal women forty postmenopausal white women 50 to 70 years of age participated in the study 39 women completed the study exercise laboratory at tufts university boston mass osteoporotic fractures￨highintensity strength training exercises highintensity strength training￨femoral neck bone mineral density and lumbar spine bone mineral density muscle mass muscle strength and dynamic balance muscle strength 24hour urinary creatinine for muscle mass and backward tandem walk for dynamic balance total body bone mineral content￨muscle mass muscle strength and dynamic balance increased in the strengthtrained women and decreased in the controls p  03 to  001￨sig increase￨highunclear￨highunclear￨highunclear
20￨twenty subjects were randomly included in one experimental group age 73 6 years old and one control group age 75 elderly population from the rural north of portugal￨progressive strength training intensity progressive strength training program￨functional reach test frt and the timed getupandgo test tug functional task performance mean frt results￨mean tug results from the pretest were significantly lower than mean results from posttest￨sig decrease￨highunclear￨highunclear￨highunclear
31￨healthy older women 31 healthy women 68￨exercise training st or comt at st combined aerobic and strength training comt or no training nt aerobic at andor strength training st￨relative vo2peak peak aerobic power vo2peak muscle strength left ventricular lv morphology and diastolic filling vo2peak muscle strength lv morphology and diastolic filling overall muscle strength peak aerobic power left ventricular morphology and muscle strength lv morphology and diastolic filling upper and lower extremity strength￨upper and lower extremity strength were significantly higher after 12 weeks of st or comt with no change after at or nt￨sig increase￨highunclear￨highunclear￨highunclear
not found￨elderly males with chronic obstructive pulmonary disease copd elderly male copd patients 18 homedwelling male patients age range 6580 years with a mean forced expiratory volume in the first second fev1 of 46 elderly male copdpatientsa pilot study￨heavy resistance training heavy resistance training re performed heavy progressive resistance training resistance training group re n  9 or a control group conducting breathing exercises￨muscle size strength and physical function crosssectional area csa of quadriceps assessed by mri isometric and isokinetic knee extension strength isometric trunk strength leg extension power normal and maximal gaitspeed on a 30 m track stair climbing time number of chair stands in 30 s lung function fev1 and selfreported health isokinetic knee extension strength maximal gait speed 14 stair climbing time 17 isometric trunk flexion 5 and selfreported health muscle size knee extension strength leg extension power functional performance and selfreported health￨in re the following improved p  005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨older persons healthy men 60 years of age older adults healthy older men group n  10 age 68￨rt resistance training rt nonexercise control resistance training￨leg press and bench press maximal strength size or systolic function of the senescent left ventricle leg press maximal strength left ventricular morphology and systolic function lv cavity size wall thickness mass or systolic function left ventricular lv morphology and systolic function lv morphology and systolic function￨rt was not associated with changes in lv cavity size wall thickness mass or systolic function after 4 8 12 and 16 weeks of exercise￨no diff￨highunclear￨highunclear￨highunclear
not found￨people aged  or  65 years with depressive symptoms were recruited via general practices thirty two people entered the trial older people older people with depressive symptoms and its impact on depressive symptoms three hundred and forty six people responded to the study invitation of whom 22 had depressive symptoms geriatric depression scale gds30 score  or  11 older depressed patients older people with depression can be successfully recruited to a community based prt program older depressed people attending a communitybased progressive resistance training prt program￨communitybased strength training program prt physical activity programs local prt program three times per week for 10 weeks or a brief advice control group prt intervention￨depressive symptoms depressive status gds scores depressive status physical and psychological health functional and quality of life status￨at six months there was a trend for the prt intervention group to have lower gds scores than the comparison group but this finding did not reach significance p  008￨sig decrease￨highunclear￨highunclear￨highunclear
39￨muscle biopsy samples of 7 young 2027 yr 12 middleaged 4760 yr and 14 older 65 yr people 39 people aged 4679 yr￨resistance exercise training exercise vs nonintervention control exercise training￨mhciix transcript levels of isoforms of mhc mhci mhciia and mhciix fsr of mhc fractional synthesis rate fsr of mhc transcript levels of mhciia and mhciix mhci mrna levels transcript levels of mhci mixed muscle protein transcript levels and synthesis rate of muscle mhc and response to resistance exercise￨exercise increased fsr of mhc by 47 p  001 and mixed muscle protein by 56 p  005￨sig increase￨highunclear￨highunclear￨highunclear
110￨persons over 75 years older persons relatively healthy older persons eleven subjects 20 had musculoskeletal complaints related to resistive training but all were able to complete the program with modifications subjects n  110 mean age 80￨resistive and balance exercises resistive training balance training control group attended 5 healthrelated discussion sessions resistive or balance training resistive training using simple equipment resistive training￨summed peak moment maximal gait velocity and chair rise time overall leg strength gait velocity and chair rise time maximal gait velocity or chair rise time isokinetic strength knee extension and flexion hip abduction and extension and plantar and dorsiflexion postural control summed isokinetic moments n m of 8 leg movements hip knee and ankle flexionextension and hip abductionadduction safety and efficacy￨the effect of resistance training was significant manova f  211 p  0001 but balance training did not improve strength and there was no interaction positive or negative between balance and resistive training￨sig increase￨highunclear￨highunclear￨highunclear
155￨men with prostate cancer receiving androgen deprivation therapy 155 men with prostate cancer who were scheduled to receive men with prostate cancer men receiving androgen deprivation therapy for prostate cancer￨resistance exercise program three times per week for 12 weeks 82 men or to a waiting list control androgen deprivation therapy resistance exercise androgen deprivation therapy resistance exercise intervention resistance exercise￨fatigue and diseasespecific quality of life as assessed by selfreported questionnaires interference from fatigue on activities of daily living body composition higher levels of upper body body weight body mass index waist circumference or subcutaneous skinfolds quality of life and muscular fitness higher quality of life healthrelated quality of life muscular fitness muscular fitness and body composition￨the 12week resistance exercise intervention did not improve body composition as measured by changes in body weight body mass index waist circumference or subcutaneous skinfolds￨no diff￨highunclear￨highunclear￨highunclear
43￨highly functioning older adults fortythree volunteers over the age of 70 years healthy older persons healthy highfunctioning older volunteers copyright 2001 by the american congress of rehabilitation medicine and the american academy of physical medicine and rehabilitation￨resistance training walking group moderate intensity exercise 30 minutes daily 6 days weekly highvelocity resistance training with a selfpaced walking program highvelocity training velocity training￨leg extensor power at resistance body weight peak power leg press peak power and leg extensor strength functional performance 6minute walk distance short physical performance battery physical performance test and medical outcomes study shortform health survey functional task performance￨strength improved 22 in the powertrained individuals and 12 in the walkers p 0001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨communitydwelling older women twentyone communitydwelling women aged 70 and older with a short physical performance battery sppb score between 4 and 10 out of 12￨progressive resistancetraining program using weighted vests for resistance with exercises designed to be specific to mobility tasks and have a component performed at the fastest possible velocity increased velocity exercise specific to task invest n11 or a control exercise group control n10 which performed slowvelocity lowresistance exercise weighted vest exercise invest training￨gait speed and chair stand muscle power balance and physical performance chair stand and sppb score muscle power balance and mobility leg power chair stand time leg power balance and mobility￨in comparison to control group invest group manifested significant improvements p05 in leg power across measurements obtained at 75 to 90 of the onerepetition maximum￨sig increase￨highunclear￨highunclear￨highunclear
14￨14 elderly women aged 6879 years and seven young controls older women older subjects elderly women￨strength training strength training￨muscle size size and contractility specific force strength whole muscle size and specific force muscle size and strength and type i singlefiber size and contractility￨in single fibers no changes in size and contractility were noted after 2 weeks but specific force was higher in the training group after 12 weeks￨sig increase￨highunclear￨highunclear￨highunclear
not found￨healthy elderly subjects subjects participated in 6 months of progressive rex training elderly men and women adults aged 6083 yr sixtytwo men and women 684￨high or lowintensity resistance exercise rex hex￨serum levels of bonespecific alkaline phosphatase bap osteocalcin oc and pyridinoline crosslinks pyd total body femoral neck and lumbar spine bone mineral density bmd and biochemical markers of bone turnover resistance exercise and bone turnover bap bone mineral density bmd of the femoral neck bmd total strength oc bone turnover 1rm￨bone mineral density bmd of the femoral neck significantly p  005 increased by 196 for the hex group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨76 to 78 yearold women elderly women￨physical training strength and endurance training intensive strength and endurance training￨ke torque ke torquebody mass and walking speed individual changes in ke torquebody mass isometric knee extension ke and flexion kf strength and walking speed ke torque and ke torquebody mass maximal walking speed isometric muscle strength and walking speed￨individual changes in ke torquebody mass before and after 18 weeks of training averaged 191 in the strength group 309 in the endurance group and 20 in the controls￨sig increase￨highunclear￨highunclear￨highunclear
71￨hypogonadal elderly male recuperative care patients very frail elderly patients frail elderly males between 1999 and 2004 71 subjects mean age 782 64 yr 86 white were enrolled￨placebo testosterone lowresistance exercise muscle strength training and testosterone testosterone enanthate or placebo progressive resistance muscle strength training prmst and testosterone￨strength gains functional performance aggregate functional performance score midthigh crosssectional muscle area strength muscle mass and function￨change in aggregate functional performance score the sum of 4 functional performance test scores did not differ between the four intervention groups nor with highintensity prmst compared with lowresistance exercise 7￨no diff￨highunclear￨highunclear￨highunclear
86￨eightysix elderly people with limited mobility and dependence in at least one activity of daily living were recruited to a home exercise study sixtynine of the original 86 completed the 6month study with five dropouts from the strength group ten dropouts from the mobility group and two dropouts from the health education group subjects mean age 82 years elderly people with poor mobility￨physiotherapist who gave both verbal and written instruction home exercise programme strength exercise group a mobility exercise group or a health education group￨￨the results showed a trend towards improvement in both the exercise groups in both sit to stand and timed get up and go tests but this failed to attain statistical significance￨sig increase￨highunclear￨highunclear￨highunclear
not found￨women aged 6784 yr elderly women women aged 6784 yr￨resistance exercise re n  15 or control resistance training￨exercise time or training effects mononuclear cell cd3 cd3cd4 cd3cd8 cd19 and cd3cd16cd56 number lymphocyte proliferative lp response to mitogen natural cellmediated cytotoxicity ncmc and serum cortisol levels ncmc lp response blood samples strength cd3 cd3cd4 or cd3cd8 cells￨no significant group exercise time or training effects were found for cd3 cd3cd4 or cd3cd8 cells but there was a significant exercise time effect for cd3cd16cd56 cells￨no diff￨highunclear￨highunclear￨highunclear
not found￨older adults fiftyfive communitydwelling adults mean age  711 adults age 65 and older￨dynamic resistance strength training program￨ability to walk backward gait velocity and balance slower gait velocity enhanced balance gait velocity￨at posttest the exercisers demonstrated slower gait velocity enhanced balance and an improved ability to walk backward although none of these posttest measures was significantly different from the control group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨older women 681 years with low bone mineral density older women with low bone mineral density￨resistance training￨igfbp1 and igfbp3 levels resting igf1 levels igf1 bioavailability strength gain insulinlike growth factor1 igf1 bioavailabilty repetition maximums igfbp1igf1 and igfbp3igf1 ratios igf1 levels￨resistance training resulted in significant p005 increases in repetition maximums across all exercises range 4178￨sig increase￨highunclear￨highunclear￨highunclear
42￨older adults fortytwo older adults mean age  72 21 in the resistance and control groups completed the 14week project￨14week resistance training program resistance training￨ankle strength training intensity postural control and gait velocity strength postural control and gait velocity plantar flexion or postural control ankle dorsiflexion training resistances and gait velocity isokinetic ankle strength training intensity postural stability and gait velocity dorsiflexion￨following the training the resistance group exhibited improved ankle dorsiflexion training resistances and gait velocity but showed no change in plantar flexion or postural control￨sig increase￨highunclear￨highunclear￨highunclear
22￨twentytwo institutionalized elders mean age 815 years frail elders￨supervised hi free weightbased training placebo free weightbased resistance training program highintensity strength training hi n  8 lowmoderate intensity strength training li n  6 or weightfree placebocontrol training lowmoderate versus highintensity progressive resistance training￨ke strength and endurance and the 6minute walking test ke strength and endurance stairclimbing power and chairrising time sixminute walking distance changes in strength ke maximal strength ke endurance and functional performance as assessed by 6minute walking chairrising and stairclimbing tests and by selfreported disability muscle function functional limitations and selfreported disability￨ke strength and endurance stairclimbing power and chairrising time improved significantly in the hi and li groups compared with the pc group￨sig increase￨highunclear￨highunclear￨highunclear
102￨patients with knee oa adults with osteoarthritis of the knee patients with knee osteoarthritis oa 102 volunteer subjects with oa of the knee randomized to isometric n32 and dynamic n35 resistance training groups or a control n35￨strength exercises isometric versus dynamic resistance training dynamic versus isometric resistance training dynamic or isometric resistance training￨knee pain knee joint pain knee pain time to descend and ascend stairs time to perform all 4 functional tasks pain and functioning￨in the isometric group time to perform all 4 functional tasks decreased p05 by 16 to 23￨sig decrease￨highunclear￨highunclear￨highunclear
131￨adults age 65 years and older with limited functional ability adults who are functionally limited older adults one hundred thirtyone older adult individuals￨resistance training aerobic walking or combined resistance training and aerobic walking resistance training aerobic walking combined resistance and aerobic walking groups or a nonexercise control group respective exercise intervention￨functional ability￨analysis of covariance indicated that all three exercise intervention groups significantly improved measures of functional ability with the resistance group demonstrating the most consistent gains over the six measures￨sig increase￨highunclear￨highunclear￨highunclear
not found￨twentyfive residents of a longterm care facility 7594 yrs older adults frail older adults￨knee extensor strength and power were measured on an isokinetic dynamometer exercise group ex n  18 underwent simple progressive lower body resistance exercises specifically aimed at improving muscle power 3 timeswk the control subjects con n  7 maintained their usual daily activities simple progressive exercise training simple progressive lower body exercise training￨performance of functional activities functional test the 8foot upandgo chair stand and walk time￨significant increases were found in the ex group for eccentric 44 and concentric 60 average power p  005 and improvements were seen on each functional test the 8foot upandgo chair stand and walk time improved by 31 66 and 33 respectively p  005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨old age older subjects relative to young adults￨strength training strength training strength training program￨pf and dorsiflexion df isometric mvc torques ankle joint stability deficit in plantarflexion pf maximal voluntary contraction mvc torque surface electromyographic activity of the triceps surae and tibialis anterior muscles strength in pf￨the strength training program was very effective in improving strength in pf 245 and it thus reduced the dftopf mvc torque ratio in addition it also induced gains in df 76￨sig increase￨highunclear￨highunclear￨highunclear
113￨older persons with knee osteoarthritis one hundred thirteen men and women between 50 and 80 years old with diagnosed osteoarthritis of the knee outpatient veterans affairs medical center clinic and an affiliated university hospital osteoarthritis of the knee￨patient education isokinetic exercise isokinetic quadriceps exercise versus an educational intervention isokinetic exercise isokinetic exercise of the quadriceps muscle three times weekly over 8 weeks or a series of 4 discussions and lectures led by health care professionals￨strength gains overall status positive functional outcomes pain scores isokinetic and isometric quadriceps strength pain and function determined by categorical and visual analog scales and overall status using physician and patient global evaluations by the arthritis impact scale version 2 western ontario mcmasters arthritis index and medical outcome study short form 36 pain and function￨both treatment groups showed significant strength gains p  05 which occurred over a wider velocity spectrum for the exercise group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with symptomatic peripheral arterial disease patients with peripheral arterial disease 6 years 5 men 4 women 6 years 4 men 7 women or a control group n  9 66 subjects with peripheral arterial disease￨progressive resistance training program resistance training￨percentage of myosin heavy chain type iib myosin adenosine triphosphatase histochemistry 10 repetition maximum leg press and calf press strengths type i and type ii fiber areas and capillary density proportion of type iibab fibers muscle strength and alters skeletal muscle composition￨there were significant increases in type i and type ii fiber areas and capillary density also increased significantly in the training group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨untrained men and women participants older adults older adult￨resistancetraining intensity￨strength gain strength gains total of 1rm strengthgain response￨by weeks 12 and 18 all training groups were significantly stronger than controls p  001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨disabled communitydwelling elders disabled elderly outpatients large tertiary care outpatient rehabilitation department fifteen elders 6285 yrs old referred for physical therapy with one or more impairments including lowerlimb arthritis￨highintensity functional training ft or strength training st intensive ft intervention home practice in rapid and correct execution of locomotor activities of daily living including gait stepping and sit to stand or progressive resistive st using elastic bands with intensity therapist contact and home practice similar to those of ft functional vs strength training￨dynamic balance control and coordination while performing daily life tasks gait speed maximum knee torque extremity strength hip abduction ankle dorsiflexion knee flexion ankle plantarflexion and knee extension￨both groups significantly improved their combined lowerextremity strength hip abduction ankle dorsiflexion knee flexion ankle plantarflexion and knee extension p  0003 but no statistical difference between the st and ft group gains p  0203 was found￨sig increase￨highunclear￨highunclear￨highunclear
29￨patients with peripheral arterial disease patients with peripheral arterial disease patients with intermittent claudication twentynine patients with disabling claudication patients with intermittent claudication with continued improvement over 24 weeks of training￨treadmill training program walking exercise program combined program of strengthening and treadmill walking exercise strength training program supervised walking exercise on a treadmill 3 hwk at a work intensity sufficient to produce claudication strength training 3 hwk of resistive training of five muscle groups of each leg or a nonexercising control group treadmill walking exercise versus strength training initial walking exercise strength training combined strength and treadmill training program and treadmill training treadmill training alone supervised treadmill walking exercise program supervised treadmill walking exercise supervised walking exercise program supervised treadmill training￨peak walking time peak exercise performance and communitybased functional status exercise performance peak oxygen consumption vo2 and the onset of claudication pain peak vo2 or claudication onset time peak exercise performance￨the combined strength and treadmill training program and treadmill training after 12 weeks of strength training resulted in increases in peak exercise performance similar to those observed with 12 weeks of treadmill training alone￨sig increase￨highunclear￨highunclear￨highunclear
not found￨healthy males and females aged 6080 years currently enrolled in a 2year resistance training program older people elderly groups 6070 years 38 males and 36 females 7080 years 25 males and 43 females￨con progressive weightlifting training exercise ex or control con longterm resistance training progressive treadmill walking and stair climbing knee extensor crosssectional areas￨bone mineral density peak cycling power output dynamic muscle strength muscle size and functional capacity symptom limited treadmill walking endurance knee extensors 1 rm strength dynamic strength exercise capacity muscle and bone￨the crosssectional areas of the knee extensors increased significantly by 55 in ex but were unchanged in con￨sig increase￨highunclear￨highunclear￨highunclear
100￨63 women and 37 men enrolled in the study was 871 06 years range 72 to 98 94 percent of the subjects completed the study very elderly people 100 frail nursing home residents over a 10week period elderly people￨exercise training placebo progressive resistance exercise training multinutrient supplementation both interventions exercise training and nutritional supplementation highintensity resistance exercise training￨stairclimbing power muscle strength gait velocity crosssectional thighmuscle area level of spontaneous physical activity total energy intake muscle weakness or physical frailty￨stairclimbing power also improved in the exercisers as compared with the nonexercisers by 284￨sig increase￨highunclear￨highunclear￨highunclear
not found￨thirty subjects completed the trial thirtysix subjects 6086 yr elderly subjects after longterm unilateral disuse elderly men and women recovering from longterm muscle disuse and subsequent hip surgery elderly individuals￨12wk rehabilitation program consisting of either 1 strength training 3 timeswk for 12 wk 2 electrical muscle stimulation￨maximal muscle strength rapid muscle force rate of force development rfd muscle activation and muscle size maximal isometric muscle strength contractile impulse muscle csa muscle strength emg and rate of force development mean electromyogram signal amplitude of vastus lateralis contractile rfd muscle mass maximal isometric strength rfd and muscle activation￨mean electromyogram signal amplitude of vastus lateralis was larger in the strengthtraining than in the standardrehabilitation group at 5 and 12 wk p  005￨sig increase￨highunclear￨highunclear￨highunclear
57￨70 to 79yrold men and women 57 healthy volunteers 25 males 32 females eight of 14 subjects 57 who began jogging intervals at week 14 incurred an injury two of eight 25 of the men and all of the women 6 of 6￨aerobic and resistance training￨walk training vo2max one repetition maximum 1rm strength testing chest press and leg extension strength incidence of injury and program adherence￨stren improved significantly in chest press and leg extension strength p less than or equal to 005 while wj and cont showed no change￨sig increase￨highunclear￨highunclear￨highunclear
8￨eight schizophrenic inpatients with pip syndrome schizophrenic patients displaying selfinduced water intoxication schizophrenic patient with pip syndrome psychosis intermittent hyponatremia and polydipsia￨naloxone naloxone or placebo naloxone naloxone or naltrexone placebo saline injection endogenous opioid system￨weight gain duration and intensity of excessive drinking maximum weight gain suppression of polydipsia body weights pip syndrome￨naloxone decreased the maximum weight gain per day significantly in five cases￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨a group of 98 third trimester pregnant women all patients were admitted to the hospital upon diagnosis for baseline evaluation￨ritodrine￨acidotic ph hospital until delivery suspicion of intrauterine fetal growth retardation acute fetal distress rate of abnormal values￨the prevalence of lowbirthweight infants for their gestational age was 4773 in the treatment group and 4074 in the control group￨no diff￨highunclear￨highunclear￨highunclear
140￨dependent participants n140 laammaintained cocainedependent patients￨cm hc laam contingency management cm procedures lc laam opioid and cocaine laam cocaine￨opioid withdrawal symptoms overall opioid use￨overall opioid use was least in the hc and hy groups opioid use decreased most rapidly over time in the hc group relative to the hy lc and ly groups￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨opioidaddicted persons fourteen methadone maintenance individuals￨methadone maintenance cognitivebehavioral versus nondirective group treatment program cognitivebehavioral cb versus discussiontype disc group in developing adaptive behavioral skills and selfevaluations￨anxiety depression and situational nonassertiveness￨posttreatment and followup results indicated that the cb group was significantly more successful than the disc group in lowering reported levels of anxiety depression and situational nonassertiveness￨sig increase￨highunclear￨highunclear￨highunclear
110￨opiate addicts beginning a new treatment episode on a methadone maintenance program opiate addicts one hundred ten subjects completed the study intake procedure and kept three or more appointments within the first six weeks of the project￨supportiveexpressive psychotherapy or cognitivebehavioral psychotherapy psychotherapy￨standardized psychological tests independent observer ratings and continuous records of licit and illicit drug use￨all three treatment groups showed significant improvement but patients receiving the additional psychotherapies showed improvement in more areas and to a greater degree than those who received counseling alone and with less use of medication￨sig increase￨highunclear￨highunclear￨highunclear
not found￨the sample was 58 male 75 minority group average age 45 years and in methadone treatment for an average of five years unemployed methadone patients 168 patients who completed followup interviews treatment programs in new york city and was funded by the national institute on drug abuse￨standard vocational counseling methadonemaintained patients  the customized employment supports ces model methadone￨competitive employment or total earnings￨however there were no significant differences for competitive employment or total earnings￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients enrolled in a methadonemaintainence program who continued to use heroin abstinence reinforcement and a￨4 interventions 1 contingent vouchers for opiatenegative urine specimens daily methadone hydrochloride maintenance methadone hydrochloride methadone combined contingent vouchers and methadone methadone maintenance methadone￨percentage of opiatenegative urine specimens duration of sustained abstinence opiatenegative urine specimens thrice weekly urinalysis abstinence reinforcement reduced selfreported frequency of use and selfreported craving￨contingent vouchers and a methadone dose increase each significantly increased the percentage of opiatenegative urine specimens during intervention￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨drug abusers fortyseven heroin addicts being treated at the new york va methadone clinic￨￨￨in keeping with the main hypothesis the experimental subjects when compared with controls showed a greater decrease in their use of heroin and other illicit drugs during the postintervention period￨sig increase￨highunclear￨highunclear￨highunclear
81￨heroin dependent individuals n37 enrolling in two mmt clinics in wuhan china received standard mmt services consisting of daily medication at the clinics and infrequent additional services on demand mmt programs in wuhan china participants were 81 male￨mmt with weekly individual bdrc behavioral drug and hiv risk reduction counseling bdrc methadone maintenance treatment mmt mmt manualguided behavioral drug and hiv risk reduction counseling￨reductions of hiv risk behaviors and illicit opiate use and treatment retention hiv risk behaviors￨participants in mmtbdrc achieved both greater reductions of hiv risk behaviors p001 as indicated by the scores on a short version of the aids risk inventory and of illicit opiate use as indicated by the proportions of opiate negative test results during the active phase of the study and the followup p0001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨73 opiate addicts￨cognitivebehavioural group psychotherapy local routine mmt or to routine mmt plus group psychotherapy psychotherapy methadone maintenance treatment mmt psychotherapy￨￨a controlled trial was conducted evaluating cognitivebehavioural group psychotherapy as a measure to reduce concomitant drug use in methadone maintenance treatment mmt￨sig decrease￨highunclear￨highunclear￨highunclear
127￨study participants were opioiddependent patients n  127 newly admitted to an ambulatory treatment program that provides￨behavioral contingencies motivated stepped care condition msc n  65 with behavioral contingencies to specifically motivate counseling attendance vs a standard stepped care condition ssc n  62 without these contingencies behavioral contingencies methadone￨rate of counseling attendance counseling attendance lower rate of poor treatment response￨the msc vs ssc condition was associated with a higher rate of counseling attendance 83 vs 44 p  001 and a lower rate of poor treatment response 46 vs 79 p  001￨sig increase￨highunclear￨highunclear￨highunclear
252￨participants were 252 heroin and cocaineabusing outpatients on methadone maintenance￨contingency management and methadone voucher condition noncontingent contingent on cocainenegative urines or split cocaine and heroin with a methadone methadone￨frequency of dsmiv opiate and cocaine dependence diagnoses percentages of urine specimens negative for heroin cocaine and both simultaneously￨the split 100mg group was the only group to achieve a longer duration of simultaneous negatives than its samedose noncontingent control group￨sig increase￨low￨low￨low
not found￨￨tp intervention￨￨urinalysis results indicate that the tp intervention was significantly more effective in reducing illicit drug use than either the ua or std interventions￨sig increase￨highunclear￨highunclear￨highunclear
not found￨psychiatric disorders in opiate addicts who were also participating in a fullservice methadone hydrochloride maintenance program methadonemaintained opiate addicts seventytwo opiate addicts￨shortterm interpersonal psychotherapy shortterm interpersonal psychotherapy ipt￨￨a clinical trial was used to evaluate shortterm interpersonal psychotherapy ipt as treatment for psychiatric disorders in opiate addicts who were also participating in a fullservice methadone hydrochloride maintenance program￨sig decrease￨highunclear￨highunclear￨highunclear
220￨two hundred and twenty patients entering an mmp￨methadone maintenance programs mmp standard care 12session harm reduction group intervention methadone￨selfefficacy sexual risk quiz unsafe sexual practices￨posttreatment hrg patients scored higher on a sexual risk quiz and reported increased selfefficacy in high risk sexual situations￨sig increase￨highunclear￨highunclear￨highunclear
not found￨77 cocainedependent methadone patients￨copyright c standard treatment or standard treatment with cm￨cocaine abstinence￨patients in the cm condition submitted more cocainenegative samples and attended more groups than patients in standard treatment￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients seventyfour cocainedependent methadone outpatients￨contingent prizes versus vouchers in cocaineusing methadone contingency management cm interventions standard treatment st st plus a maximum of 585 in contingent vouchers or st plus￨longer durations of abstinence lda￨cm participants achieved longer durations of abstinence lda than st participants and cm conditions did not differ significantly in outcomes or amount of reinforcement earned￨no diff￨highunclear￨highunclear￨highunclear
166￨166 patients assigned to one of three treatments opioid dependence￨buprenorphinenaloxone buprenorphinenaloxone maintenance therapy standard medical management and either onceweekly or thriceweekly medication dispensing or enhanced medical management and thriceweekly medication dispensing￨adherence frequency of illicit opioid use selfreported frequency of illicit opioid use the percentage of opioidnegative urine specimens and the maximum number of consecutive weeks of abstinence from illicit opioids￨the three treatments had similar efficacies with respect to the mean percentage of opioidnegative urine specimens standard medical management and onceweekly medication dispensing 44 percent standard medical management and thriceweekly medication dispensing 40 percent and enhanced medical management and thriceweekly medication dispensing 40 percent p082 and the maximum number of consecutive weeks during which patients were abstinent from illicit opioids￨no diff￨highunclear￨highunclear￨highunclear
135￨universitybased research clinic opioiddependent outpatients 135 volunteer adult outpatients who met dsmiv criteria for opioid dependence￨therapistdelivered cra treatment with vouchers b computerassisted cra treatment with vouchers or c standard treatment interactive computer program interactive computerbased behavioral therapy intervention grounded in the community reinforcement approach cra plus voucherbased contingency management model of behavior therapy computerized behavior therapy buprenorphine￨￨the therapistdelivered and computerassisted cra plus vouchers interventions produced comparable weeks of continuous opioid and cocaine abstinence m  798 and 778 respectively and significantly greater weeks of abstinence than the standard intervention m  469 p  05 yet participants in the computerassisted cra condition had over 80 of their intervention delivered by an interactive computer program￨sig increase￨highunclear￨highunclear￨highunclear
84￨psychiatrically impaired patients in community methadone programs psychiatrically symptomatic opiatedependent patients during methadone maintenance treatment in community programs volunteers in three community programs a total of 84 subjects were evaluated at both followup points￨individual psychotherapy psychotherapy methadone supportiveexpressive psychotherapy counseling plus supplemental drug counseling or to counseling plus supportiveexpressive psychotherapy￨￨one month after the extra therapy ended both groups had made significant gains but there were no significant differences between groups￨no diff￨highunclear￨highunclear￨highunclear
180￨opiatedependent patients on methadone maintenance 151 subjects patients who are opiate dependent and on methadone maintenance opiate addicts one hundred eighty subjects￨cra and cra with relapse prevention crarp community reinforcement approach cra￨weekly urinalysis drug screens and addiction severity index asi scores￨the combined cra groups did significantly better than the standard group in the following areas consecutive opiatenegative urinalysis 3 weeks and the 6month asi drug composite score￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨fiftythree new intakes methadone maintenance patients￨drugfree urines or to a noncontingent procedure￨￨lower baseline rate of drugfree urines was strongly associated with successful outcome whereas the type of drug abused cocaine vs benzodiazepines did not influence outcomes￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨opioid dependent participants n  120 maintained on thriceaweek m w f buprenorphine plus therapist and computerbased counseling were randomized to receive a medication contingencies mc  thrice weekly dosing schedule vs daily attendance and singleday 50 dose reduction imposed upon submission of an opioid andor cocaine positive urine sample b voucher contingency vc  escalating schedule for opioid andor cocaine negative samples with reset for drugpositive samples or c standard care sc buprenorphine medication versus voucher contingencies￨total weeks of abstinence￨vc resulted in better 12week retention 85 compared to mc 58 p  0009 but neither differed from sc 76 retained￨sig increase￨highunclear￨highunclear￨highunclear
not found￨heroin dependent individuals n24 in muar malaysia￨standard services bmt physician administered advice and support and weekly noncontingent medication pickup or enhanced services nursedelivered manualguided behavioral drug and hiv risk reduction counseling bdrc and abstinencecontingent takehome buprenorphine acb 7 day supply maximum behavioral drug and hiv risk reduction counseling bdrc with abstinencecontingent takehome buprenorphine manualguided behavioral drug and hiv risk reduction counseling and abstinencecontingent takehome buprenorphine buprenorphine officebased buprenorphine maintenance treatment bmt￨hiv risk behaviors retention proportion of opioidnegative urine tests selfreported drug use and selfreported hiv risk behaviors overall proportions of opiate negative urine toxicology tests proportion of opioidnegative urine tests￨the proportion of opioidnegative urine tests increased significantly over time for both groups p0001 and the reductions were significantly greater in the enhanced services group p005 enhanced services group achieved higher overall proportions of opiate negative urine toxicology tests 87 vs 69 p004 and longer periods of consecutive abstinence from opiates 103 weeks vs 78 weeks p0154￨sig increase￨highunclear￨highunclear￨highunclear
not found￨six communitybased methadone maintenance drug abuse treatment clinics in locations across the united states substance abusers three hundred eightyeight stimulantabusing patients enrolled in methadone maintenance programs for at least 1 month and no more than 3 years￨methadone maintenance treatment￨average cost of prizes stimulant abstinence total number of stimulant and alcoholnegative samples provided percentage of stimulant and alcoholnegative samples provided longest duration of abstinence retention and counseling attendance￨groups did not differ on study retention or counseling attendance￨no diff￨highunclear￨highunclear￨highunclear
82￨eightytwo participants who had received one year of methadone maintenance treatment and had urinalysis and selfreport data for illicit drug use six months after treatment were examined￨visual representation counseling techniques standard treatment as usual or standard treatment supplemented with free mapping or free plus guide mapping￨￨compared to participants receiving standard treatment participants randomly assigned to the free plus guide mapping condition had significantly lower opiate use based on urinalysis and selfreport data￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨160 cocaine abusers maintained on maintained patients￨desipramine contingency management cm placebo plus cm dmi buprenorphine desipramine dmi￨lower dmi plasma levels￨self reported opiate and cocaine use and depressive and opioid withdrawal symptoms showed no differences among the groups and symptom levels did not correlate with urine toxicology results￨no diff￨highunclear￨highunclear￨highunclear
78￨patients who injected drugs and used cocaine during methadone treatment n  78 methadonemaintained patients who inject drugs participants in the 2 abstinencereinforcement groups could earn takehome methadone doses for providing opiate and cocainefree urine samples participants in 1 of those groups also could earn 5800 us dollars in vouchers for providing cocainefree urine samples over 52 weeks￨cocaine abstinence abstinencereinforcement groups or to a usual care control group￨cocaine abstinence￨both abstinencereinforcement interventions increased cocaine abstinence but the addition of the voucher intervention resulted in the largest and most sustained abstinence￨sig increase￨highunclear￨highunclear￨highunclear
116￨participants n116 heroin and cocaine using outpatients￨methadone and individual counseling contingency management cm prizebased cm or to receipt of prize draws noncontingently on a schedule yoked to the cm group methadonemaintained opiate and cocaineusing outpatients￨hivrisk taking behaviour scale rates of simultaneous cocaineopiatepositive urine specimens hiv risk behaviors hrbs scores injectionrelated drugtaking behaviors hiv risktaking behaviour￨cm targeted toward cocaine and heroin use produces significant reductions in injectionrelated drugtaking behaviors associated with heightened risk for getting or transmitting hiv￨sig decrease￨highunclear￨highunclear￨highunclear
67￨sixty mothers receiving substance abusing women substance abusing mothers 67 women receiving￨recovery training rt relational psychotherapy rpmg relational psychotherapy mothers group rpmg supportive parenting group intervention￨child maltreatment selfreported and cocaine abuse based on urinalyses emotional adjustment and depression￨at the end of the 6month treatment period rpmg mothers showed marginally significant improvement on child maltreatment selfreported and cocaine abuse based on urinalyses when compared with rt mothers notably children of rpmg mothers reported significantly greater improvement in emotional adjustment and depression than children of rt mothers￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients with apd antisocial personality disorder apd opioiddependent patients with antisocial personality subjects n  100 met diagnostic and statistical manual of mental disorders criteria for opioid dependence and apd using a structured clinical interview subjects with low and high levels of psychopathy and with and without other psychiatric comorbidity￨behavioral approach highly structured contingency management intervention or a control condition methadone treatment￨counseling attendance and some indication of lower psychosocial impairment￨the experimental intervention increased attendance in subjects with low and high levels of psychopathy and with and without other psychiatric comorbidity￨sig decrease￨highunclear￨highunclear￨highunclear
20￨sd age was 135 patients aged between 8 and 18 years with a sore throat from clinically suspected infectious mononucleosis were eligible children with suspected infectious mononucleosis acute exudative pharyngitis associated with infectious mononucleosis twenty patients were recruited in each group mean￨placebo dexamethasone dexamethasone vs placebo dexamethasone dexamethasone or a placebo￨visual analog scale diary of symptoms and rated their pain on a visual analog scale pain relief￨in comparison with the placebo group a significantly greater proportion of patients given dexamethasone achieved pain relief within the first 12 hours 1220 vs 519 p 03￨sig increase￨low￨low￨low
not found￨ninetyfour patients with infectious mononucleosis and symptoms  or  7 days acute infectious mononucleosis￨acyclovir placebo oral acyclovir acyclovir and prednisolone prednisolone￨oropharyngeal epsteinbarr virus ebv shedding duration of general illness sore throat weight loss or absence from school or work￨oropharyngeal epsteinbarr virus ebv shedding was significantly inhibited during the treatment period p  02 mannwhitney rank test￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨nondiabetic renal disease patients who do not respond adequately to the dual blockade patients with nondiabetic nephropathy 32 nondiabetic nephropathy patients with proteinuria exceeding 05 gday were enrolled after more than 12 weeks of￨reninangiotensinaldosterone system raas reninangiotensinaldosterone system triple blockade triple blockade group in which 25 mg of spironolactone daily was added to the acei and arb combination treatment and a control group in which 1 mg of trichlormethiazide or 20 mg of furosemide spironolactone angiotensinconverting enzyme inhibitor and angiotensin ii receptor blocker raas acei 5 mg enalapril and arb 50 mg losartan combination treatment aldosterone blocker spironolactone aldosterone blocker angiotensinconverting enzyme inhibitor acei and angiotensin ii receptor blocker arb aldosterone￨urinary protein and urinary type iv collagen urinary type iv collagen level blood pressure mean serum creatinine potassium and blood pressure urinary protein level￨after 1 year of treatment the urinary protein level decreased by 58 p005 with the triple blockade but was unchanged in the controls￨sig decrease￨highunclear￨highunclear￨highunclear
20￨patients with diabetic nephropathy patients with diabetic nephropathy and nephrotic range albuminuria diabetic nephropathy twenty caucasian patients with diabetic nephropathy and nephrotic range albuminuria 2500 mg24 h despite recommended￨spironolactone 25 mg once daily and matched placebo placebo aldosterone antagonism with spironolactone angiotensinconverting enzyme inhibitor or an angiotensin ii receptor blocker spironolactone aldosterone spironolactone antihypertensive treatment￨night blood pressure albuminuria albuminuria 24h ambulatory blood pressure and glomerular filtration rate gfr nephrotic range albuminuria and blood pressure nephrotic range albuminuria adverse events 24h blood pressure renal and cardiovascular outcome median range number of antihypertensive drugs￨no patients were excluded due to adverse events￨no diff￨low￨low￨low
not found￨twentyone type 2 diabetic patients with nephropathy diabetic nephropathy 1566 type 2 diabetic patients with nephropathy￨spironolactone 25 mg once daily and matched placebo spironolactone antihypertensive treatment including diuretics and maximally recommended doses of an ace inhibitor andor an arb ace inhibitor or an angiotensin ii receptor blocker arb ace inhibitor and arb spironolactone￨diastolic 24h abp tolerated 24h abp albuminuria geometric mean range albuminuria and blood pressure gfr change in albuminuria systolic 24h abp fractional clearance of albumin albuminuria 24h ambulatory blood pressure abp and glomerular filtration rate gfr￨spironolactone treatment induced an insignificant reversible reduction in gfr of 3 mlmin per 173 m2 03 to 6 p  008￨no diff￨highunclear￨highunclear￨highunclear
not found￨diabetic nephropathy twenty caucasian type 1 diabetic patients with persistent macroalbuminuria despite antihypertensive treatment including ras blockade completed this doublemasked randomized crossover trial type 1 diabetic patients with diabetic nephropathy 831￨spironolactone 25 mg once daily and matched placebo placebo aldosterone antagonism with spironolactone spironolactone angiotensinconverting enzyme ace inhibitors or angiotensin ii receptor blockers reninangiotensin system ras blockade aldosterone spironolactone￨albuminuria 24hour blood pressure and glomerular filtration rate gfr fractional albumin clearance orthostatic dizziness tolerated blood pressure albuminuria and blood pressure gfr albuminuria from geometric mean￨624 to 1106 mg24hour on placebo treatment p  0001 and a reduction in fractional albumin clearance of 35 20 to 46 p  0001￨sig increase￨highunclear￨highunclear￨highunclear
82￨patients with chronic kidney disease chronic kidney disease patients 83 patients with chronic kidney disease already treated with angiotensinconverting enzyme inhibitors andor angiotensin type 1 receptor antagonists￨aldosterone receptor antagonists angiotensinconverting enzyme inhibitors andor angiotensin type 1 receptor antagonists alone and served as controls spironolactone spironolactone aldosterone￨glomerular filtration rate estimated glomerular filtration rate baseline aldosterone levels proteinuria serum potassium levels proteinuria and retard renal progression proteinuria and kidney function￨after 1 month of therapy with spironolactone estimated glomerular filtration rate decreased more in patients treated with spironolactone than in controls￨sig increase￨highunclear￨highunclear￨highunclear
not found￨type 2 diabetic nephropathy patients from two outpatient clinics with a followup of 1 year type 2 diabetic patients with macroalbuminuria despite longterm use of an ace inhibitor or angii receptor blocker￨spironolactone spironolactone to angiotensinconverting enzyme ace inhibition or angiotensin ii angii receptor antagonism placebo spironolactone￨estimated glomerular filtration rate egfr proteinuria blood pressure and renal function albuminuria bp hyperkalemia proteinuria blood pressure bp and renal function albuminuria and gfr urinary albumin to creatinine ratio bp and biochemical parameters potassium concentrations￨albuminuria decreased by 406 95 confidence interval ci 234578 and bp by 7 mmhg 212 mmhg3 mmhg 16 mmhg with spironolactone but did not change with placebo￨sig decrease￨low￨low￨low
38￨38 schizophrenic patients￨epm traditional clinicalpharmacological approach epm model combined with psychotropic drugs paradoxical model plus psychodrugs and a group treated by the conventional clinical approach schizophrenia￨brief psychiatric rating scale social activity according to the strausscarpenter outcome scale and an interactive test￨with regard to all measures number of dropouts symptoms according to the brief psychiatric rating scale social activity according to the strausscarpenter outcome scale and an interactive test￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with comorbid schizophrenia and alcohol or drug abuse or dependence patients with comorbid schizophrenia and substance use disorders patients with schizophrenia and substance use disorders patients with these disorders￨motivational interviewing cognitive behavior therapy and family intervention over routine psychiatric care alone motivational interviewing cognitive behavior therapy and family intervention integrated psychological and psychosocial treatment program routine care with a program of routine care integrated with motivational interviewing cognitive behavior therapy and family or caregiver intervention￨positive symptoms and in symptom exacerbations patients general functioning￨the integrated treatment program resulted in significantly greater improvement in patients general functioning than routine care alone at the end of treatment and 12 months after the beginning of the study￨sig increase￨highunclear￨highunclear￨highunclear
151￨151 relatives of 99 chronic dsmiii schizophrenics schizophrenic patients￨￨relapse rates￨no difference existed between the groups with respect to rehospitalization data￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨￨￨an education program which was part of a controlled trial of intervention with families of schizophrenic patients is described and evaluated￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨counseling caregivers of relatives with schizophrenia family caregivers of patients with schizophrenia￨counseling program￨￨as part of a controlled study of the effectiveness of a counseling program for family caregivers of patients with schizophrenia we conducted a comprehensive examination of the process￨sig increase￨highunclear￨highunclear￨highunclear
55￨family members of 55 patients with schizophrenia￨psychoeducational support group or to a control group￨psychological distress coping behavior and family satisfaction knowledge of schizophrenia and greater satisfaction with health care services rehospitalization rates￨psychological distress coping behavior and family satisfaction did not appear affected by support group participation nor were support groups associated with lower rehospitalization rates for patients￨no diff￨highunclear￨highunclear￨highunclear
36￨thirtysix schizophrenic patients living in high expressed emotion ee parental households schizophrenic patients￨￨relapse rates schizophrenic relapse relapses￨relapses in the intervention group although fewer were not significantly different from the control group￨no diff￨highunclear￨highunclear￨highunclear
151￨patients with schizophrenia schizophrenic patients living with or independent of family i patients who were living with family n  97 the other studied patients who were living independent of family n  54 151 patients with schizophrenia or schizoaffective disorder diagnosed according to research diagnostic criteria patients who lived with family￨personal therapy personal therapy￨relapse rates psychotic decompensations rate of psychotic relapse recurrent psychotic episodes extensive psychiatric histories psychotic and affective relapse adverse outcomes￨among patients living with family personal therapy was more effective than family and supportive therapies in preventing psychotic and affective relapse as well as noncompliance￨sig increase￨highunclear￨highunclear￨highunclear
42￨fortytwo families thirtyfour mental health professionals from 17 public mental health centers in italy selected 71 families of consumers with schizophrenia￨psychoeducational family intervention￨relatives social contacts and perception of professional support functional outcomes of schizophrenia social relationships interests in obtaining a job maintenance of social interests and management of social conflicts number of patients with poor or very poor global personal and social functioning patients clinical status personal and social functioning and social network as well as relatives burden social resources and perception of professional support￨a significant improvement was found for the intervention group in patients social relationships interests in obtaining a job maintenance of social interests and management of social conflicts￨sig increase￨highunclear￨highunclear￨highunclear
11￨schizophrenic patients living in high contact with relatives having high expressed emotion ee relatives group for schizophrenia￨education plus family therapy or education plus a relatives group￨minuscule relapse rate relapse rate reduction in ee￨the relapse rate over nine months in the family therapy stream was 8 while that in compliant families in the relatives group stream was 17￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨families with at least one high expressed emotion ee relative schizophrenic patients patients from lowee families￨prophylactic behavioural intervention with families education only or routine treatment behavioural intervention￨relapse rates changes in criticism and marked emotional overinvolvement eoi reduction of hostility extensive changes relapse rates￨relapse rates over nine months after discharge were significantly lower for patients in the two behavioural intervention compared with education only and routine treatment groups￨sig increase￨highunclear￨highunclear￨highunclear
not found￨schizophrenia￨￨￨the nimh treatment strategies in schizophrenia tss collaborative study group investigated the efficacy of antisychotic drug maintenance strategies involving reduced medication exposure in interaction with applied and supportive family management for the longterm treatment of schizophrenia￨sig increase￨highunclear￨highunclear￨highunclear
50￨people with schizophrenia￨additional support programme control group receiving treatment as usual tau￨levels of expressed emotion ee number of medium and longterm poor clinical outcomes￨a reduction in levels of expressed emotion ee significantly more frequent in those receiving the additional support programme than just the informative occurred after treatment completion￨sig increase￨highunclear￨highunclear￨highunclear
not found￨thirtyfour pairs of englishspeaking consumers and family members and 25 vietnamesespeaking pairs and vietnamesespeaking families living with schizophrenia newly arrived nonenglish speaking migrant group firstgeneration vietnamese families and for englishspeaking families￨cognitivebehavioral intervention multiplefamily group treatment for english multiplefamily group or a control group￨relapse rates number of relapse episodes the presence and severity of symptoms as measured by the brief psychiatric rating scale bprs and the scale for the assessment of negative symptoms and social functioning as measured by the family burden scale the health of the nation outcome scale and the quality of life scale bprs ratings relapse and symptoms relapse rates￨relapse rates immediately after treatment were significantly lower for the multiplefamily group than for the control group 12 and 36 percent and relapse rates were also lower during the followup period 25 and 63 percent￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨schizophrenic patients in china urban families of schizophrenic patients in china and feasible given the constraints of the chinese mental health system families of schizophrenic patients appropriate for chinas complex family relationships and unique social environment sixtythree dsmiiir schizophrenic patients living with family members￨standard care or a familybased intervention that included monthly 45minute counselling sessions focused on the management of social and occupational problems medication management family education family group meetings and crisis intervention￨levels of family burden duration of employment duration of rehospitalisation￨family intervention was associated with significantly lower levels of family burden￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨family caregivers of patients with schizophrenia chinese family caregivers of a relative with schizophrenia compared with routine family support services in hong kong fortyeight family caregivers from two psychiatric outpatient clinics￨experimental mutual support and usual outpatient care￨family service utilization levels of family burden and increased family functioning duration of patient rehospitalization the total number of days of psychiatric hospitalization￨families allocated to the mutual support group experienced decreased levels of family burden and increased family functioning and these changes were significantly greater than those of the controls at both postintervention time points￨sig decrease￨highunclear￨highunclear￨highunclear
106￨106 outpatients with schizophrenia or schizoaffective disorder who were receiving services from a large community mental health center outpatients with schizophrenia or schizoaffective disorder who received patients with schizophrenia in psychoeducational multiplefamily group treatment￨psychoeducational multiplefamily group treatment standard care or standard care plus multiplefamily group treatment educate patients and their family members about the biological basis of mental illness and treatment to improve illness management and coping skills and to provide social support standard care￨rate of psychiatric hospitalization hospitalization outcomes￨it was only marginally associated with lower use of crisis services and it was not associated with the amount of outpatient service time￨no diff￨highunclear￨highunclear￨highunclear
not found￨all carers of patients with a psychotic disorder from a defined population were approached carers of patients with a psychosis￨support programme￨stressappraisalcoping model of caregiving outcome measures psychological morbidity negative appraisal coping or social support severity of caregiving difficulties￨the carers programme did not offer any significant advantage on any of the outcome measures psychological morbidity negative appraisal coping or social support￨no diff￨highunclear￨highunclear￨highunclear
106￨patients with chronic psychosis carers of all patients identified with a first episode of psychosis in a defined psychiatric catchment area of north london one hundred and six carers were recruited to the study families of patients with a first episode of psychosis carers of patients with a first episode of psychotic illness￨brief intervention comprising education and advice about the disorder from a support team or to usual care from community psychiatric services brief educational and advice support service￨number of days spent relatives satisfaction￨the authors found no differences over time between the randomized arms for relatives satisfaction f  23 p  0￨no diff￨highunclear￨highunclear￨highunclear
82￨eightytwo outpatients with dsmiiir schizophrenia or schizoaffective disorder outpatients with schizophrenia schizophrenia￨maintenance antipsychotic medication crisis intervention tau prp￨outcome rates relapse and rehospitalization rates baseline global assessment scale score positive and negative syndrome scale scores antipsychotic medication￨the prp teams were much more likely than the tau psychiatrists to identify prodromal episodes before patients met objective relapse criteria or needed hospitalization￨no diff￨highunclear￨highunclear￨highunclear
2￨patient and relative education in community psychiatry patients with schizophrenia and for their relatives was conducted in two community mental health centres in arhus and viborg denmark￨eightsession psychoeducational programme￨timetorelapse knowledge relapse compliance insight and satisfaction and relative outcome measures were knowledge and satisfaction knowledge of schizophrenia compliance insight into psychosis psychosocial function general assessment of function or in relatives expressed emotion scores postintervention schizophrenia subscore of the brief psychiatric rating scale verona service satisfaction scale scores￨no differences were found between the groups regarding compliance insight into psychosis psychosocial function general assessment of function or in relatives expressed emotion scores postintervention or at 1year followup￨no diff￨highunclear￨highunclear￨highunclear
not found￨parents of schizophrenics in clinicbased individual treatment groups and homebased family treatment groups￨￨illness and social functioning patient social functioning￨pretherapy and posttherapy measures of negative as were significantly predictive of relapse within the ninemonth treatment period for patients in individual treatment￨sig increase￨highunclear￨highunclear￨highunclear
172￨172 acutely psychotic patients aged 18 to 45 years with dsmiiir schizophrenic disorders￨single or multiplefamily psychoeducational treatment psychoeducational multiplefamily group treatment vs psychoeducational singlefamily treatment￨relapse rate rehospitalization rates and psychotic symptoms 2year cumulative relapse rates index hospital discharge psychotic relapse symptom status medication compliance rehospitalization and employment relapse hazard ratio￨rehospitalization rates and psychotic symptoms decreased significantly and medication compliance was high to an equal degree in both modalities￨sig increase￨highunclear￨highunclear￨highunclear
not found￨41 schizophrenic patients in a veterans administration va mental health clinic clinic psychiatrists who were blind to the patients assignment revealed that 3 14 patients who received behavioural family management as well as customary care as compared with 11 55 patients who received customary care alone had symptomatic exacerbations during the first year of treatment schizophrenia￨customary care alone home behavioural family management bfm￨monthly brief psychiatric rating scale bprs ratings￨to test further the highly successful outcomes of a controlled study of inhome behavioural family management bfm for schizophrenic patients a clinicbased version of this intervention was compared with customary care alone for 41 schizophrenic patients in a veterans administration va mental health clinic￨sig increase￨highunclear￨highunclear￨highunclear
218￨two hundred and eighteen patients displaced subcapital femoral fracture in patients of 70 years or more is presented￨surgical treatment internal fixation versus hemiarthroplasty manipulative reduction and internal fixation using garden screws thompson hemiarthroplasty through a posterior moore approach and thompson hemiarthroplasty through an anterolateral mckee approach￨mobilisation mortality￨there is no significant difference in the mortality of the internal fixation and posterior arthroplasty groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients under 34 weeks gestation with a lecithinsphingomyelin ls ratio less than 20￨antenatal corticosteroids plus thyrotropinreleasing hormone intravenous thyrotropinreleasing hormone along with intramuscular corticosteroids control group receiving only corticosteroids corticosteroids and thyrotropinreleasing hormone￨fetal lung maturation fetal lung maturation bronchopulmonary dysplasia￨compared with the control group the group receiving antenatal corticosteroids plus thyrotropinreleasing hormone showed a greater posttherapy increase in ls ratio fewer respirator days and a lower incidence of bronchopulmonary dysplasia￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨combined hormonal therapy￨￨it is unclear whether the benefit of antenatal trh and steroid therapy on end points such as death or bpd would persist if surfactant was also used￨no diff￨highunclear￨highunclear￨highunclear
not found￨four hundred five liveborn infants 378 mothers likely to be delivered between 24 and 326 weeks gestation preterm infants￨placebo thyrotropinreleasing hormone to antepartum glucocorticoid treatment antepartum thyrotropinreleasing hormone thyrotropinreleasing hormone to antepartum betamethasone antepartum thyrotropinreleasing hormone and betamethasone betamethasone￨number of deaths fell incidence of chronic lung disease severe respiratory distress syndrome incidence of respiratory distress syndrome adverse outcome chronic lung disease or death￨the number of deaths fell from 14 to one relative risk 008 95 confidence interval 001 to 063￨sig decrease￨low￨low￨low
not found￨one hundred ninety women received respiratory distress syndrome women with singleton pregnancies  33 weeks of gestation who received neonates weighing  10 kg received￨prenatal thyrotropinreleasing hormone and corticosteroids placebo antenatal thyrotropinreleasing hormone to prenatal corticosteroids thyrotropinreleasing hormone antenatal thyrotropinreleasing hormone and corticosteroids antenatal betamethasone prophylactic surfactant￨air leaks frequency of respiratory distress syndrome neonatal mortality￨there were no differences in the frequency of respiratory distress syndrome relative risk 117 95 confidence interval 093 to 148 use of oxygen at age 28 days 114 080 to 162 or neonatal mortality 105 079 to 138￨no diff￨low￨low￨low
225￨225 women were recruited who delivered 275 babies pregnant women at risk of preterm delivery who had been prescribed a course of corticosteroids to enhance fetal maturation￨antenatal thyrotrophinreleasing hormone placebo trh antenatal thyrotrophinreleasing hormone trh￨death or chronic lung disease intraventricular haemorrhage and necrotising enterocolitis risk of death and severe morbidity respiratory morbidity in particular respiratory distress syndrome maternal side effects death of the baby or chronic lung disease￨stratified analysis did not reveal any differences between the two groups depending on how long before the time of delivery the mother had received the trh or placebo￨no diff￨low￨low￨low
404￨404 women with threatened preterm delivery at less than 32 weeks gestation received verylowbirthweight infants after prenatal 103 infants who were fully treated and of less than 1500 g birthweight were evaluated during the neonatal period treated infants￨thyrotropinreleasing hormone and glucocorticoid betamethasone plus placebo trh prenatal glucocorticoid thyrotropinreleasing hormone trh betamethasone betamethasone plus trh￨adverse outcomes death or continuing oxygen requirement chronic lung disease cld severe respiratory distress syndrome incidence of other complications of prematurity total incidence of respiratory distress syndrome respiratory disease neonatal respiratory morbidity respiratory distress syndrome and chronic lung disease cld develop￨there were significantly fewer adverse outcomes defined as death or continuing oxygen requirement in the trh group than in the steroidalone group both at 28 days and when infants reached 36 weeks postconceptional age￨sig decrease￨low￨low￨low
996￨preterm infants 981 women and their 1134 liveborn infants 996 women at 13 north american centers who were in preterm labor at 30 weeks gestation in a doubleblind g gestational age 27921 vs 27921 weeks sex or race 769 infants born at  or  32 weeks gestation were defined as the group at risk￨antenatal thyrotropinreleasing hormone antenatal thyrotropinreleasing hormone therapy placebo antenatal thyrotropinreleasing hormone￨death pulmonary morbidity neonatal complications chronic lung disease or death mean sd birth weight frequencies of respiratory distress syndrome chronic lung disease or death of the infant on or before the 28th day after delivery and secondary outcomes were respiratory distress syndrome and chronic lung disease or death severity of lung disease￨similarly there were no differences in outcome between the treatment and placebo groups for the infants born at 32 weeks gestation￨no diff￨low￨low￨low
20￨20 patients relapsed and resistant hodgkins disease patients with active hodgkins disease for whom conventional therapy had failed patients with relapsed and resistant hodgkins disease￨highdose chemotherapy and radiotherapy with autologous bonemarrow transplantation abmt autologous bonemarrow transplantation beam plus abmt and 20 minibeam chemotherapy beam  carmustine etoposide cytarabine and melphalan plus abmt abmt￨survival and progressionfree survival￨however both eventfree survival and progressionfree survival showed significant differences in favour of beam plus abmt p  0025 and p  0005 respectively￨no diff￨highunclear￨highunclear￨highunclear
284￨patients with relapsed hodgkins lymphoma from a total of 284 patients included 241 responding patients patients with histologically confirmed relapsed hl patients with relapsed hodgkins lymphoma hl￨chemotherapy sequential cyclophosphamide methotrexate and etoposide sequential highdose chemotherapy shdct dexamethasone cytarabine and cisplatinum dexamethasone cytarabine and cisplatin fftf highdose chemotherapy hdct followed by autologous stemcell transplantation pbsct myeloablative therapy with carmustine beam carmustine etoposide cytarabine and melphalan followed by pbsct￨risk of recurrence os adverse effects toxicity and protocol violations early relapse multiple relapse anemia or b symptoms remission rates overall survival os and toxicity fftf mortality￨patients treated in arm b had longer treatment duration and experienced more toxicity and protocol violations p  05￨sig increase￨highunclear￨highunclear￨highunclear
161￨relapsed chemosensitive hodgkins disease 161 patients between 16 and 60 years of age with relapsed hodgkins disease patients with relapsed hodgkins disease patients with chemosensitive first relapse of hodgkins disease irrespective of length of initial remission 17 patients were excluded from the study after randomisation ten given￨dexabeam and seven given beamhsct dexabeam or highdose beam and transplantation of haemopoietic stem cells conventional aggressive chemotherapy without stemcell transplantation dexabeam highdose chemotherapy followed by transplantation of autologous haemopoietic stem cells beamhsct dexabeam autologous haemopoietic stemcell transplantation haemopoietic stem cells aggressive conventional chemotherapy dexabeam dexamethasone and carmustine etoposide cytarabine and melphalan￨overall survival freedom from treatment failure￨freedom from treatment failure at 3 years was significantly better for patients given beamhsct 55 than for those on dexabeam 34 difference 21￨sig increase￨highunclear￨low￨highunclear
30￨thirty primigravidae with a low bishop score￨pge2￨uterine activity uterine activity cervical dilatation￨cervical dilatation was achieved with less uterine activity in the pge2 group especially during the shorter latent phase￨sig decrease￨highunclear￨highunclear￨highunclear
60￨60 primigravidae￨prostaglandin e2 intravaginal prostaglandin e2 and intravenous oxytocin￨incidence of caesarean section mean inductiondelivery interval cervical status￨this was significantly greater in those patients who received extraamniotic prostaglandin gel and they also showed significant decreases in the mean inductiondelivery interval and in the incidence of caesarean section￨sig increase￨highunclear￨highunclear￨highunclear
152￨152 women were admitted for induction of labor with a term singleton pregnancy and cephalic presentation were recruited￨vaginal misoprostol and extraamniotic prostaglandin f2alpha gel misoprostol with extraamniotic prostaglandin f2alpha pgf2alpha gel misoprostol misoprostol misoprostol 50 microg intravaginally or extraamniotic pgf2alpha gel oxytocin￨risk for duration of induction to vaginal delivery augmentation of labor with oxytocin mean duration of induction risk for duration 24 h duration of induction fetal outcome￨the mean duration of induction was shorter in the misoprostol group 152 vs 236 h p002￨sig decrease￨low￨low￨low
not found￨two hundred and sixtyone patients of varying parity and cervical ripeness were given￨prostaglandin e2 pce2 in tylose gel either vaginally 20 mgm or extraamniotically 03 mgm prior to planned surgical induction extraamniotic and vaginal prostaglandin e2￨￨surgical inductions was avoided in 52 per cent of the vaginal group and 40 per cent of the extraamniotic group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨159 oral surgery outpatients￨placebo diflunisal dolobid acetaminophen diflunisal diflunisal acetaminophencodeine acetaminophen codeine phosphate 60 mg and placebo￨analgesic efficacy side effects peak analgesia￨both doses of diflunisal were significantly more effective than acetaminophen alone and produced peak analgesia comparable to that of the acetaminophencodeine combination￨sig increase￨highunclear￨highunclear￨highunclear
161￨161 primiparous women suffering from moderate to severe postepisiotomy pain postoperative pain after episiotomy￨diflunisal diflunisal and aspirin placebo aspirin￨pain relief analgesic efficacy pain rating assessments effective relief of pain￨the analgesic efficacy of aspirin tailed off after 4 hours but pain relief with 500 mg diflunisal was still evident after 8 hours￨sig increase￨highunclear￨highunclear￨highunclear
201￨postoperative dental pain twohundred and one outpatients with postoperative pain following oral surgery￨placebo diflunisal aspirin and placebo diflunisal aspirin and placebo diflunisal aspirin￨total and peak analgesia peak and total analgesia adverse effects￨all doses of diflunisal were significantly superior to aspirin and placebo at each hour from hour 3 through hour 12￨sig increase￨highunclear￨highunclear￨highunclear
132￨postoperative pain 132 inpatients with postoperative pain￨placebo acetaminophen 600 mg with codeine 60 mg and placebo acetaminophen diflunisal diflunisal acetaminophencodeine acetaminophen diflunisal acetaminophen and acetaminophencodeine combination and placebo￨analgesic effect analgesic efficacy total or peak analgesia total and peak analgesia￨acetaminophen alone and the acetaminophencodeine combination were significantly superior to placebo for most measures of analgesia and their effects were significant for 4 and 5 hours respectively￨sig increase￨highunclear￨highunclear￨highunclear
199￨postoperative oral surgery pain one hundred ninetynine outpatients with pain following oral surgery￨placebo diflunisal aspirin and placebo diflunisal diflunisal zomepirac and aspirin zomepirac sodium 100 mg aspirin 650 mg or placebo aspirin diflunisal zomepirac sodium aspirin and placebo￨duration of analgesia total and peak analgesia total analgesia￨the onset of analgesia was comparable for 1000 mg diflunisal zomepirac and aspirin but more rapid for these treatments than for 500 mg diflunisal￨no diff￨highunclear￨highunclear￨highunclear
120￨patients after meniscectomy 120 patients receiving doses of patients suffering from moderate to severe pain after meniscectomy￨diflunisal oxyphenbutazone placebo aspirin￨analgesic effect hourly pain scores pain severity￨in a comparative study against oxyphenbutazone 200 mg tid hourly pain scores made on the first postoperative day showed that a single dose of 500 mg diflunisal produced comparable relief over a 12hour period to that with 2 doses of 200 mg oxyphenbutazone￨sig increase￨highunclear￨highunclear￨highunclear
130￨130 hospitalized patients with pain following meniscectomy pain after meniscectomy￨diflunisal suprofen diflunisal and placebo suprofen 200 mg and suprofen￨pain indices interval scale and a visual analogue scale pain intensity￨suprofen 200 mg and suprofen 400 mg were found to be as efficacious as diflunisal 750 mg in a singledose doubleblind randomized study of 130 hospitalized patients with pain following meniscectomy￨sig increase￨highunclear￨highunclear￨highunclear
125￨a referral burn center population 125 burn patients admitted within 24 hours of injury who were matched by age burn size and presence or absence of inhalation injury￨hyperbaric oxygen hyperbaric oxygen hbo hbo￨mortality number of operations and length of stay for the survivors￨there were no statistically significant differences between the two groups for the outcome measures of mortality number of operations and length of stay for the survivors￨no diff￨highunclear￨highunclear￨highunclear
24￨patients with refractory epilepsy twentyfour patients with frequent drugresistant seizures took part￨placebo gammavinyl gaba gabatransaminase inhibitor gammavinyl gaba￨adverse effects particularly drowsiness and mood changes mean weekly seizure frequency complex partial and tonicclonic total number of seizures serum concentrations of phenytoin￨serum concentrations of phenytoin were lower during gammavinyl gaba treatment than during placebo p less than 005 but the concentrations of other anticonvulsants given concomitantly did not change￨sig decrease￨highunclear￨highunclear￨highunclear
24￨24 patients with refractory epilepsy refractory epilepsy￨vigabatrin gammavinylgaba vgb placebo vgb adjuvant vigabatrin￨partial seizures seizure control seizure frequency loss of efficacy serum vgb concentrations￨an overall reduction in median seizure numbers failed to reach statistical significance n  19 placebo 52 vgb 32 ns 95 ci 18 to 24￨no diff￨low￨low￨low
97￨ninetyseven patients entered this sevencentre patients with uncontrolled partial seizures uncontrolled partial seizures patients with partial seizures￨vigabatrin vigabatrin placebo￨seizure frequency efficacy and tolerability overall incidence of adverse events drowsiness and visual disturbances diplopia ataxia visual abnormalities￨no significant differences were observed between dose groups for the overall incidence of adverse events although drowsiness and visual disturbances diplopia ataxia visual abnormalities showed a doserelated increase with vigabatrin treatment￨no diff￨highunclear￨highunclear￨highunclear
not found￨epilepsy patients with focal epilepsy whose complex partial seizures￨placebo antiepilepsy drug vigabatrin vigabatrin and placebo vigabatrin vigabatrin with placebo vigabatrin￨psychological effects vigabatrin serum levels cognitive abilities and quality of life￨at the end of the study there were no differences between the vigabatrin and placebo groups on any cognitive variable or on any measure of mood and adjustment￨no diff￨highunclear￨highunclear￨highunclear
23￨epilepsy 23 adult outpatients with severe drugresistant epilepsy 17 with partial seizures￨placebo vigabatrin and placebo vigabatrin vigabatrin gammavinyl gaba gvg vigabatrin￨electrocardiogram ecg electroencephalogram eeg and visual auditory and somatosensoryevoked potentials total number of seizures seizure frequency total number of seizures and the number of partial seizures severe adverse effects mild drowsiness efficacy and tolerability appearance of vertigo headache dysarthria and ataxia￨both the total number of seizures and the number of partial seizures were significantly reduced by vigabatrin p less than 001￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨19 patients who completed the study 17 had partial seizures eight of whom had secondary generalization and two who had primary generalized seizures n  1 intolerance to gvg therapy n  2 or poor seizure record n  1 therapyresistant epileptic patients￨placebo oral gvg placebo gvg vigabatrin gammavinyl gaba vigabatrin gvg￨antiepileptic efficacy seizures seizure frequency global efficacy ratings plasma concentrations weekly seizure occurrence adverse effects drowsiness confusion nausea irritability and constipation￨compared with placebo gvg was associated with a significant reduction in seizure frequency p less than 001 with 11 of 19 patients experiencing greater than 50 reduction in weekly seizure occurrence two showing a 2550 reduction four unchanged and two showing an increase in seizures￨sig decrease￨highunclear￨highunclear￨highunclear
30￨thirtyone patients with severe drugresistant epilepsy entered the study patients with severe complex partial epilepsy thirty patients completed both periods drugresistant epilepsy 15 patients presenting with￨vigabatrin vigabatrin placebo vigabatrin therapy￨multifocal electroencephalographic abnormalities plasma concentrations efficacy and good tolerability complex partial seizures temporal electroencephalographic abnormalities seizure frequency tolerability￨no significant treatment effect was found for the remaining 15 patients who presented with mixed seizure types multifocal electroencephalographic abnormalities and high seizure frequencies￨no diff￨highunclear￨highunclear￨highunclear
not found￨forty five patients with refractory partial seizures ten of 20 patients on￨vigabatrin vigabatrin placebo antiepileptic drug vigabatrin￨seizure frequency cognitive function including measures of memory and concentration mood and behaviour motor speed and overall score partial seizures and cognitive function complex partial seizure frequency median complex partial seizure frequency response to vigabatrin￨vigabatrin was associated with a significant reduction in a measure of motor speed and overall score on a design learning test in the first 20 weeks of treatment￨sig increase￨highunclear￨highunclear￨highunclear
174￨174 patients with previously uncontrolled complex partial seizures with or without secondary generalization patients with uncontrolled complex partial seizures￨vigabatrin vigabatrin vgb placebo vgb￨fatigue drowsiness and dizziness vgb adverse events median monthly frequency of seizures laboratory parameters brain magnetic resonance imaging evoked potentials cognitive function or psychosocial tests therapeutic successes seizure frequency efficacy and safety￨vigabatrin was well tolerated causing no clinically significant changes in laboratory parameters brain magnetic resonance imaging evoked potentials cognitive function or psychosocial tests￨no diff￨highunclear￨highunclear￨highunclear
21￨partial epilepsy twentyone patients suffering from difficult to control complex partial seizures participated 18 patients completed the trial￨placebo gammavinyl gammaaminobutyric acid gaba gammavinyl gaba gammavinyl gaba￨seizures seizure frequency serum levels￨three patients 17 experienced a 75 reduction in seizure frequency and in 8 44 the seizures were reduced by at least 50￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with partial seizures adult patients with difficult to control complex partial seizures andor partial seizures secondarily generalized patients with refractory epilepsy patients with difficult to control complex partial seizures and for partial seizures secondarily generalized adult complex partial seizures adult patients with a definite diagnosis of complex partial seizures andor partial seizures secondarily generalized were recruited from 10 canadian centres patients with difficult to control partial seizures￨placebo vgb active medication or placebo vigabatrin vigabatrin vgb￨efficacy and tolerability frequency of complex partial seizures and partial seizures secondarily generalized serious systemic toxicity minor neurological side effects￨vigabatrin was found to be an effective and welltolerated antiepileptic drug when used as adjunctive therapy in patients with difficult to control complex partial seizures and for partial seizures secondarily generalized￨sig increase￨highunclear￨highunclear￨highunclear
496￨496 symptomatic asthmatic patients with a history of exacerbations on 500800 micrograms microg inhaled corticosteroids ics twice daily bd in a broadly representative group of 100 hospitals and general practices in six countries moderatetosevere asthma￨fluticasone propionate fp fp250 fp250 microg bd salmeterol fluticasone propionate￨number of severe exacerbations tolerance and a low incidence of exacerbations mean morning peak expiratory flow rates ampef￨smfp250 also resulted in more symptomfree days and nights p  0002 and days and nights with no relief medication p  0001￨sig decrease￨highunclear￨low￨low
132￨adult asthma 132 adult asthmatics who were symptomatic on 500 microg x day1 inhaled￨formoterol and beclomethasone formoterol fumarate solution aerosol beclomethasone dipropionate bdp beclomethasone￨safety and tolerability evaluations overall mean morning premedication pef mean morning premedication peak expiratory flow rate pef overall number of puffs of rescue medication and asthma symptom scores￨the overall mean morning premedication pef for the entire treatment period was higher in the formoterobdp group p0002￨sig increase￨highunclear￨highunclear￨highunclear
514￨514 adults symptomatic patients with asthma￨beclomethasone 168 micrograms plus salmeterol beclomethasone 168 micrograms plus salmeterol 42 micrograms twice daily or beclomethasone beclomethasone plus salmeterol inhaled corticosteroids salmeterol with inhaled corticosteroids beclomethasone salmeterol corticosteroid therapy￨asthma exacerbation and adverse event frequency rates symptom control and increased pulmonary function evening peak expiratory flow asthma symptom scores symptomfree days supplemental albuterol use and days and nights not requiring albuterol￨there were no significant differences between treatment groups in the number of patients with abnormal response to corticotropin stimulation at treatment week 24￨no diff￨low￨low￨low
not found￨patients with asthma not controlled by bdp 500 microgram twice daily or the equivalent 738 patients at 72 centers￨salmeterol bdp 1000 microgram twice daily bdp 1000 beclomethasone dipropionate bdp inhaled steroids￨lung function and symptom control without altering bhr or increasing exacerbation rates bronchial hyperresponsiveness bhr to histamine exacerbation rates peak expiratory flow rates pefrs and symptom scores percentage of symptomfree and rescuefree days and nights efficacy and safety￨both the salm 50 and salm 100 groups had a significantly increased percentage of symptomfree and rescuefree days and nights compared with the bdp 1000 group and there was no difference between the two salmeterol groups￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with moderate to severe asthma who are symptomatic on their existing dose of corticosteroid three hundred and fiftythree asthmatic patients who remained symptomatic despite treatment with budesonide 8001200 microg day1 or equivalent￨salmeterol 50 microg and fluticasone propionate 250 microg seretide advair viani 50250 microg twice daily or budesonide salmeterolfluticasone propionate combination sfc sfc salmeterolfluticasone propionate combination therapy budesonide￨evening pef control of daytime symptoms evening peak expiratory flow pef daytime and nighttime symptom scores and daytime and nighttime use of rescue salbutamol pef mean morning pef￨sfc also provided significantly better control of daytime symptoms and a significantly greater reduction in the requirement for rescue salbutamol compared with budesonide￨sig decrease￨highunclear￨highunclear￨highunclear
56￨asthma fiftysix asthmatic subjects previously not wellcontrolled on inhaled corticosteroids￨corticosteroid fluticasone propionate fp salmeterol salm fluticasone propionate inhaled fluticasone with and without salmeterol fp400  salm inhaled fp 500 microg twice a day fp 1000 or fp 200 microg twice a day plus salm￨submucosal mast cells fev1 peak expiratory flow submucosal mast cell and eosinophil counts bronchial mucosal biopsy specimens bronchial washings bw and bronchoalveolar lavage number of submucosal mast cells or eosinophils airway inflammation￨this was accompanied by a significant improvement in peak expiratory flow in the fp400  salm group in both the morning and evening compared to the fp1000 group￨sig increase￨highunclear￨highunclear￨highunclear
274￨asthmatic patients not controlled by a low or intermediate dose of inhaled corticosteroids patients with mild to moderate asthma 274 patients￨salmeterol fluticasone propionate salmeterol 50 micrograms twice daily plus the run in dose of fluticasone propionate or twice the run in dose of fluticasone propionate corticosteroids or 250 micrograms twice daily if pretrial dose was 8001200 micrograms inhaled corticosteroids￨adverse effects forced expiratory volume morning and evening pef lung function and symptom control efficacy and safety daily records of peak expiratory flow pef symptom scores and clinic lung function mean increase in morning pef￨the improvements in both the morning and evening pef were better in the salmeterol than in the fluticasone propionate group the mean increase in morning pef being 19 lmin higher 95 ci 110 to 261 and in evening pef being 16 lmin 95 ci 184 to 240 higher in the salmeterol group￨sig increase￨low￨low￨low
136￨136 male and female patients at least 12 years of age with asthma forced expiratory volume in 1 second fev between 50 and 80 of predicted asthma patients with asthma treated with shortacting beta2agonists alone patients with asthma who had not previously been treated with inhaled corticosteroids￨fluticasone propionate salmeterol combined with fluticasone propionate salmeterol and fluticasone propionate inhaled salmeterol and fluticasone monotherapy and combination therapy salmeterol salmeterol 42 microg fluticasone propionate 88 microg fluticasone propionate 220 microg salmeterol 42 microg plus fluticasone propionate 88 microg salmeterol 42 microg plus fluticasone propionate 220 microg or placebo￨fev safety measurement patientrated data peak expiratory flow asthma symptom scores percent of days with no asthma symptoms pulmonary function and symptom control￨patients treated with salmeterol combined with fluticasone propionate had improvements over baseline in fev at endpoint that were at least twice as great 06 to 07 l as improvements in patients treated with salmeterol 03 l or fluticasone propionate alone 03 l p  05￨sig increase￨highunclear￨highunclear￨highunclear
not found￨1272 corticosteroidtreated patients group b mild persistent asthma subjects with mild asthma receiving no or only a small dose of inhaled corticosteroid 698 corticosteroid free patients group a￨budesonide and formoterol longacting inhaled betaagonist formoterol budesonide plus 45 microg formoterol 200 microg budesonide or 200 microg budesonide plus 45 microg formoterol budesonide plus 45 microg formoterol or placebo inhaled corticosteroid budesonide budesonide￨lung function time to the first severe asthma exacerbation and poorly controlled asthma days risk for severe exacerbations severe exacerbations￨in group a budesonide alone reduced the risk for severe exacerbations by 60 and poorly controlled days by 48 adding formoterol increased lung function with no change in other end points￨sig increase￨low￨low￨low
not found￨patients currently stable on mediumdose ics while maintaining asthma control￨fluticasone propionate fp combined with salmeterol fp fluticasone propionate 250 microg administered twice daily inhaled corticosteroid ics fluticasone propionate 100 microg and salmeterol fp 100 microg bid administered via diskus￨fev1 morning peak expiratory flow percent of symptomfree days and daily albuterol use worsening asthma￨secondary efficacy measures included fev1 morning peak expiratory flow percent of symptomfree days and daily albuterol use￨sig increase￨low￨low￨low
641￨246 patients received￨fluticasone propionatesalmeterol fp fluticasone propionatesalmeterol fsc fsc 10050 microg twice daily or fluticasone propionate fp fsc￨morning peak expiratory flow symptom scores rescue albuterol use and asthma control mean morning peak expiratory flow￨secondary efficacy endpoints also showed fsc 10050 microg twice daily to be more effective than fp 250 microg twice daily alone￨no diff￨low￨low￨low
373￨373 patients with asthma mean age 42 years fev1 78 of predicted reversibility 21 patients with moderate persistent asthma￨fluticasone propionate symbicort turbuhaler budesonideformoterol 16045 microg one inhalation twice daily or floventflixotide diskus fluticasone propionate budesonide symbicort budesonide and formoterol corticosteroid fluticasone propionate symbicort budesonideformoterol fluticasone propionate alone budesonideformoterol￨tolerated lung function reducing use of reliever medication and improving control of moderate persistent asthma morning pef nighttime awakenings efficacy and safety risk of an exacerbation￨significantly greater increases in morning pef the primary efficacy variable were observed in patients treated with budesonideformoterol compared with fluticasone propionate 274 lmin vs 77 lmin p  0001￨sig increase￨low￨low￨low
49￨49 patients with uncontrolled asthma despite budesonide 100 mug bid patients with asthma and persistent symptoms despite the use of lowdose inhaled corticosteroids￨placebo budesonide 400 mug bid additional formoterol additional montelukast and placebo budesonide montelukast inhaled corticosteroids formoterol and highdose budesonide￨symptom scores morning peak expiratory flow and forced expiratory volume methacholine airway responsiveness airway inflammation and responsiveness eosinophilic airway inflammation sputum eosinophil count￨highdose budesonide had the broadest range of beneficial effects on other outcomes including symptom scores morning peak expiratory flow and forced expiratory volume in one second￨sig increase￨low￨low￨low
39￨thirtynine patients with uncontrolled moderatetosevere asthma￨hydrofluoroalkane 143abeclomethasone dipropionate hfabdp fluticasonesalmeterol combination or mediumdose hydrofluoroalkane 134abeclomethasone fluticasone propionatesalmeterol fpsm combination methacholine dpiadministered bdp twice daily dpibdp fp and 50 microg of sm hfabdp￨fev1 peak expiratory flow and quality of life symptoms and emotions hfabdp suppression of plasma and urinary cortisol and serum osteocalcin levels lung function surrogate inflammatory markers diary card responses quality of life and safety￨after highdose inhaled corticosteroid stepping down with the combination inhaler conferred further improvements in bronchoprotection bronchodilatation and clinical control but not inflammatory markers compared with that seen with a medium dose of inhaled corticosteroid￨sig increase￨low￨low￨low
233￨patients n  233 mild persistent asthma patients adult mild persistent asthma patients adult patients with mild persistent asthma who are already on lowdose inhaled steroids 14 years 45 males patients with moderate to severe asthma￨salmeterol salmeterol with beclomethasone beclomethasone dipropionate bdp beclomethasone￨frequency of adverse events quality of life evening pef￨quality of life improved with both treatments but without significant statistical differences between the groups￨no diff￨low￨low￨low
177￨children with asthma 177 children already treated with children with moderate asthma￨salmeterol beclomethasone with salmeterol inhaled corticosteroids beclomethasone salmeterol salmeterol 50 microg twice daily bdp400salm beclomethasone 200 microg twice daily bdp800 or placebo bdp400￨changes in airway responsiveness fev1 pd20 methacholine symptom scores and exacerbation rates growth lung function and symptoms fev1 fev1 and pd20 methacholine￨no significant differences between groups were found in fev1 pd20 methacholine symptom scores and exacerbation rates after 1 yr￨no diff￨low￨low￨low
680￨asthma six hundred eighty patients with asthma previously uncontrolled with lowdose inhaled corticosteroids patients who are symptomatic while taking lowdose inhaled￨sl fp corticosteroids mediumdose fp mediumdose taa fluticasone taa salmeterol vs triamcinolone mediumdose fluticasone propionate fp mediumdose triamcinolone acetonide taa and combined lowdose fp plus salmeterol sl fp 220 microg bid taa￨pulmonary function and asthma symptom control fev1 morning and evening pef and percent symptomfree days fev1 rescue albuterol use number of nighttime awakenings and overall asthma symptom scores fev1 peak expiratory flow pef supplemental albuterol use nighttime awakenings asthma symptoms and physician global assessment￨compared with taa 600 microg bid treatment with fp 220 microg bid significantly increased fev1 morning and evening pef and percent symptomfree days and significantly reduced rescue albuterol use number of nighttime awakenings and overall asthma symptom scores p  or  0035￨sig increase￨low￨low￨low
500￨500 patients with asthma that was well controlled by patients with asthma patients with asthma mild persistent asthma patients with asthma who have persistent symptoms￨salmeterol fluticasone plus salmeterol fluticasone montelukast inhaled corticosteroids inhaled fluticasone fluticasone propionate plus salmeterol￨free of asthma symptoms rate of treatment failure and decreased asthma control hazard ratio time to treatment failure rates of treatment failure￨the hazard ratio for both comparisons was 16 95 confidence interval 11 to 26 p003￨no diff￨low￨low￨low
467￨adult patients with mildtomoderate asthma not fully controlled on low doses of inhaled corticosteroid alone adult patients whose mildtomoderate asthma adults with mildtomoderate asthma 467 patients with a mean fev1 of 82 predicted received 12 weeks of treatment with￨corticosteroid budesonide and formoterol budesonideformoterol budesonide and formoterol budesonide budesonideformoterol￨evening peak expiratory flow pef nighttime and daytime symptom scores and use of reliever medication adverse events percentage of symptomfree days and asthmacontrol days relative risk of an asthma exacerbation evening pef mean morning pefthe primary efficacy measure efficacy and safety￨the increase in mean morning pefthe primary efficacy measurewas significantly higher for budesonideformoterol compared with budesonide alone 165 lmin vs 73 lmin p  0002￨sig increase￨highunclear￨highunclear￨highunclear
203￨203 patients with moderatetosevere asthma who remained symptomatic despite treatment with 500 microg patients with asthma who were poorly controlled with patients with suboptimally controlled asthma￨formoterolbeclomethasone formoterol foradil formoterol inhaled corticosteroids ics ics foradil formoterol fumarate beclomethasone inhaled corticosteroids formoterol twice daily foradil aerolizer novartis in addition to beclomethasone 500 microg twice daily or beclomethasone 1000 microg twice daily and placebo corticosteroids￨mean morning premedication peak expiratory flow pef pef urinary cortisolcreatinine ratio hypothalamicpituitaryadrenal axis￨significant differences in the urinary cortisolcreatinine ratio between treatment groups at 12 weeks p0001 indicated suppression of the hypothalamicpituitaryadrenal axis in the patients on beclomethasone 1000 microg twice daily￨sig increase￨low￨low￨low
not found￨patients with asthma remain symptomatic in spite of chronic treatment with symptomatic moderate asthma symptomatic asthmatics 365 symptomatic patients with moderate asthma aged 18 years and receiving ics in a dose equivalent to 1000 microg 76 study centres￨fluticasone fluticasone propionate fp inhaled corticosteroids ics combined salmeterol fluticasone therapy salmeterol xinafoate combined salmeterol fluticasone therapy sfc salmeterol 50 microg and fluticasone salmeterolfluticasone propionate fluticasone propionate beclomethasone propionate￨morning pefr morning peak expiratory flow rate pefr pefr and symptom control quality of life forced expiratory volume in 1 second fev1 asthma symptom scores and use of rescue medication efficacy and safety percentage of symptomfree days￨combined salmeterol fluticasone therapy resulted in significantly greater improvements in pefr and symptom control than doubling the dose of fp￨sig increase￨low￨low￨low
50￨50 symptomatic patients with asthma who were receiving airway biopsies and bronchoalveolar lavage in asthma symptomatic patients with asthma￨placebo fluticasone ics corticosteroid ics therapy salmeterol￨mast cells lymphocytes or macrophages in bal or biopsies bal lymphocyte activation allergic airway inflammation eg1positive eosinophils bronchial biopsies and bal deterioration of airway inflammation clinical status￨after treatment with salmeterol there was no deterioration of airway inflammation as assessed by mast cells lymphocytes or macrophages in bal or biopsies but rather a significant fall in eg1positive eosinophils in the lamina propria from a median 183 to 76 cellsmm p  001 which was not seen after treatment with fluticasone￨no diff￨low￨low￨low
437￨patients who remain symptomatic while receiving fp as compared with increasing the dose of fp patients with persistent asthma 437 patients aged 12 years and older and receiving fp 88 microg twice daily for 2 to 4 weeks￨fluticasone propionate fp salmeterol salmeterol to fluticasone propionate fp 220 microg twice daily salmeterol fluticasone propionate salmeterol therapy￨adverse events and asthma exacerbations fev1 symptom scores nighttime awakenings and supplemental albuterol use safety lung function and symptom control adverse event profiles morning peak expiratory flow efficacy and safety￨over weeks 1 to 24 morning peak expiratory flow was increased by 47 lmin from baseline with salmeterol treatment as compared with 24 lmin with fp 220 microg twice daily p  001 while the percent of symptomfree days increased from baseline by 26 of days as compared with 10 of days p  001￨sig increase￨low￨low￨low
60￨asthma 60 patients with moderate asthma￨formoterol inhaled corticosteroids ics budesonide plus placebo twice daily bud800 or 100 microg of budesonide plus 12 microg of formoterol twice daily bud200f budesonide plus formoterol budesonide budesonide lowdose budesonide plus formoterol￨proportion of eosinophils eg2 cells other inflammatory cells or ecp levels in sputum clinical asthma control median sputum eosinophils sputum markers of airway inflammation￨no significant changes in the proportion of eosinophils eg2 cells other inflammatory cells or ecp levels in sputum were observed over the ensuing 1yr treatment with bud200f or bud800￨no diff￨low￨low￨highunclear
429￨429 adult asthmatic patients who still had symptoms despite maintenance treatment with 200 micrograms twice daily inhaled asthma patients with symptoms on existing inhaled corticosteroid￨salmeterolbdp salmeterol xinafoate bdp salmeterol beclomethasone dipropionate bdp￨mean evening pef mean morning peak expiratory flow adverse effects or exacerbations of asthma salmeterolbdp in diurnal variation of pef all time points and in use of rescue bronchodilator salbutamol and daytime and nighttime symptoms￨there were significant differences in favour of salmeterolbdp in diurnal variation of pef all time points and in use of rescue bronchodilator salbutamol and daytime and nighttime symptoms some time points￨no diff￨low￨low￨low
not found￨patients experiencing symptoms on lowdose beclomethasone￨salmeterol salmeterol salmeterol xinafoate beclomethasone dipropionate beclomethasone dipropionate therapy beclomethasone inhaled corticosteroids corticosteroid therapy￨efficacy and safety peak expiratory flow pef and forced expiratory volume in 1 sec fev1 and in reducing symptoms of asthma sleep loss nighttime awakenings and use of albuterol￨salmeterol added to lowdose beclomethasone was superior p  or  005 to doubling the dose of beclomethasone in improving peak expiratory flow pef and forced expiratory volume in 1 sec fev1 and in reducing symptoms of asthma sleep loss nighttime awakenings and use of albuterol￨sig increase￨low￨low￨low
46￨46 subjects with pdc 62 maxillary canines￨￨successful eruption time required for canine eruption success rate prevalence rates of successful canine eruption and the amount of time for canine eruption cervical vertebral maturation successful or unsuccessful canine eruption￨there was no significant difference between the two interceptive approaches in the time required for canine eruption￨no diff￨highunclear￨highunclear￨highunclear
75￨75 subjects with pdc 92 maxillary canines palatally displaced canines￨extraction of the primary canine only eg extraction of the primary canine and cervicalpull headgear ehg and an untreated control group cg￨successful eruption success rate￨the cephalometric superimposition study showed a significant mesial movement of the upper first molars in the cg and eg when compared with the ehg￨sig increase￨highunclear￨highunclear￨highunclear
not found￨eighty were appropriate for gestational age and of these 25 fed successfully by nasogastric tube and 16 tolerated nasoduodenal feeding until 1600 g one hundred successive infants weighing less than 1500 low birthweight infants￨nasoduodenal feeding￨calorie intake or growth rates￨one hundred successive infants weighing less than 1500￨no diff￨highunclear￨highunclear￨highunclear
not found￨infants of birth weight under 1400 g forty three infants under 1400 g were fed by a infants of low birth weight￨bolus nasogastric continuous nasogastric or transpyloric route continuous nasogastric bolus nasogastric and transpyloric feeding￨growth rate oral energy input￨there were more complications with transpyloric feeding and no identifiable benefits in the growth rate oral energy input or chosen biochemical indices of nutrition￨no diff￨highunclear￨highunclear￨highunclear
not found￨gestational age infants with a birth weight of less than 1700 gm admitted to the childrens hospital in denver small preterm infant￨gavage or transpyloric nasojejunal feedings transpyloric and intermittent gavage feeding￨caloric intake growth parameters weight length and head circumference serum total protein levels feedingrelated complications duration of intravenous fluid supplementation and length of hospitalization gestational age birth weight and morbidity￨no significant differences were observed for caloric intake after 4 days of age growth parameters weight length and head circumference serum total protein levels feedingrelated complications duration of intravenous fluid supplementation and length of hospitalization￨no diff￨highunclear￨highunclear￨highunclear
21￨21 lowbirthweight infants lowbirthweight infants￨continuous nasojejunal and intermittent nasogastric feedings nasojejunal feedings￨weight loss cumulative weight gain caloric and fluid intake percent weight lost blood chemistry values and complications abnormalities of blood chemistry or significant complications weight gain caloric intake and fluid intake￨weight loss was less in the nj group p less than 001￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨￨nasoduodenal versus nasogastric feeding￨practicality effectiveness and safety average weight gain faster weight gain￨the nasoduodenal group appeared to have a clear advantage over the nasogastric group for the overall period in terms of caloric intake 131 calkgday vs 106 calkgday average weight gain 16 gmday vs 10 gmday and safety￨sig increase￨highunclear￨highunclear￨highunclear
not found￨fortyfour appropriately grown preterm infants of birthweight 115 kg￨nasojejunal nj or nasogastric ng feeding at birth￨bodyweight or occipitofrontal circumference delivery mean body weight and mean occipitofrontal circumference mean weight velocity and mean occipitofrontal circumference velocity poor weight gain mean incremental weight velocity during nj feeding mean caloric intake￨at expected date of delivery mean body weight and mean occipitofrontal circumference were significantly smaller in the nj group￨sig increase￨highunclear￨highunclear￨highunclear
601￨four urban native american clinics over controls within four urban indian health clinics 601 native american smokers doctors helping smokers dhs￨smoking cessation strategies￨number of quit attempts and future quit intentions smoking cessation￨number of quit attempts and future quit intentions were greater in the intervention group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨participants included 355 maori and 1350 nonmaori￨regular personalised text messages providing smoking cessation advice support and distraction￨report quitting￨a mobile phonebased cessation programme was successful in recruiting young maori and was shown to be as effective for maori as nonmaori at increasing shortterm selfreported quit rates￨sig increase￨highunclear￨highunclear￨highunclear
134￨indigenous maori population in new zealand 134 maori smokers aged 1670 years who smoked more than 10 cigarettes per day￨bupropion placebo bupropion￨continued abstinence from smoking at 3 and 12 months rates of continued abstinence￨at each time point continued abstinence was better for the subjects allocated to bupropion with a risk ratio for abstinence over all time points of 244 95 ci 122 to 488￨sig increase￨low￨low￨low
not found￨indigenous people three indigenous communities in the northern territory forty indigenous smokers selfselected to receive￨nicotine patches free nicotine patches￨consumption of tobacco cessation rates smoking behaviour￨seventysix per cent of the nicotine patches group and 51 of the brief intervention only group had reduced their consumption of tobacco￨sig decrease￨highunclear￨highunclear￨highunclear
253￨outpatients taking lowmolecularweight heparin to go home immediately and hospitalized patients taking lowmolecularweight heparin to be discharged early patients with acute proximal deepvein thrombosis patients with proximal deepvein thrombosis at home￨unfractionated heparin intravenous standard unfractionated heparin lowmolecularweight heparin 1 mg of enoxaparin standard heparin intravenous standard heparin lowmolecularweight heparin warfarin￨longer plasma halflife better bioavailability recurrent thromboembolism major bleeding￨lowmolecularweight heparin can be used safely and effectively to treat patients with proximal deepvein thrombosis at home￨no diff￨highunclear￨highunclear￨highunclear
108￨deep venous thrombosis with a low molecular weight consecutive patients n108 with acute leg dvt confirmed by duplex proximal deep venous thrombosis dvt￨heparin tinzaparin acenocoumarol tinzaparin alone or ufh and acenocoumarol low molecular weight heparin lmwh tinzaparin versus unfractionated heparin ufh tinzaparin￨extended overall recanalization thrombus regression reflux distribution and the incidence of complications overall incidence of major events mortality dvt recurrence pulmonary embolism major bleeding heparininduced thrombocytopenia thrombus regression ultrasonographic clot volume score an index of recanalization￨the overall incidence of major events mortality dvt recurrence pulmonary embolism major bleeding heparininduced thrombocytopenia was significantly different p0035 in favor of tinzaparin 7 versus 17 events￨no diff￨highunclear￨highunclear￨highunclear
201￨patients with proximal deep vein thrombosis and no symptoms of pulmonary embolism two hundred one patients presenting with proximal deep vein thrombosis without known risk factors for pulmonary embolism or hemorrhagic complications￨lowmolecularweight heparin proximal deep vein thrombosis with a lowmolecularweight heparin￨clinical outcome total costs rates of primary efficacy outcome cost consequences incidence of venous thromboembolism recurrence pulmonary embolism or major bleeding￨there was no increase in the rates of primary efficacy outcome in the patients treated at home vs in the hospital 30 vs 39 while a cost reduction of 56 was demonstrated for outpatient management￨no diff￨highunclear￨highunclear￨highunclear
201￨patients with proximal lower limb dvt proximal lower limb deepvein thrombosis 201 patients with proximal lower limb dvt from 13 centers in brazil￨unfractionated heparin enoxaparin enoxaparin 15 mgkg subcutaneous sc od or intravenous iv unfractionated heparin ufh warfarin deepvein thrombosis dvt ufh￨rate of recurrent dvt recurrent dvt confirmed by venography or ultrasonography and safety endpoints included bleeding and serious adverse events duration of hospital stay rate of pulmonary embolism pe hospitalization efficacy and safety￨the duration of hospital stay was significantly shorter with enoxaparin than with ufh 3 versus 7 days￨sig decrease￨highunclear￨highunclear￨highunclear
202￨patients with proximalvein thrombosis patients with deepvein thrombosis symptomatic outpatients with proximalvein thrombosis but no signs of pulmonary embolism seventeen of the 198 patients who received￨standard heparin standard unfractionated heparin intravenous unfractionated heparin intravenous standard heparin administered in the hospital 198 patients or fixeddose subcutaneous lowmolecularweight heparin￨recurrent thromboembolism quality of life major bleeding recurrent venous thromboembolism major bleeding quality of life and costs physical activity and social functioning￨quality of life improved in both groups￨no diff￨highunclear￨highunclear￨highunclear
298￨symptomatic deepvein thrombosis 18 centers in 4 countries 298 patients with symptomatic deepvein thrombosis who were eligible for home treatment outpatient setting with intravenous unfractionated heparin in hospital￨unfractionated heparin unfractionatedheparin deepvein thrombosis treatment using oncedaily subcutaneous enoxaparin enoxaparin heparin enoxaparin and unfractionatedheparin once and twicedaily lowmolecularweight heparin unfractionated heparin in hospital￨pulmonary emboli deepvein thrombosis and pulmonary embolism recurrent deepvein thromboses efficacy and safety bleeding events and adverse events￨the incidences of bleeding events and adverse events in the enoxaparin and unfractionatedheparin groups were similar￨no diff￨highunclear￨highunclear￨highunclear
455￨displaced intracapsular hip fractures in the elderly 455 patients aged over 70 years with a displaced intracapsular fracture of the proximal femur 455 patients￨hemiarthroplasty or internal fixation hemiarthroplasty versus internal fixation￨lower transfusion requirements survival limb shortening shorter length of anaesthesia lower operative blood loss pain and mobility mortality￨for the survivors assessed at one two and three years from injury there were no differences with regard to the outcome for pain and mobility￨no diff￨highunclear￨highunclear￨highunclear
207￨two hundred and seven patients were randomized to be treated with one of the three operations and ninetyone healthy older patients healthy older patients with a displaced intracapsular fracture of the hip￨total hip replacement reduction and fixation bipolar hemiarthroplasty and total hip arthroplasty bipolar hemiarthroplasty with cement and total hip replacement with cement displaced intracapsular hip fractures fixation or bipolar hemiarthroplasty bipolar hemiarthroplasty￨hiprating questionnaire and the euroqol health status measure functional outcome scores mortality and complications rate of secondary surgery direct health service costs mortality rates worst hipratingquestionnaire and euroqol scores￨arthroplasty is more clinically effective and costeffective than reduction and fixation in healthy older patients with a displaced intracapsular fracture of the hip￨sig increase￨highunclear￨highunclear￨highunclear
409￨displaced fractures of the neck of the femur 409 patients aged 70 years and over with subcapital fractures graded as garden 3 or 4 in a twoyear prospective multicentre study from 12 swedish hospitals patients who were mentally confused bedridden or in a nursinghome were excluded from the survey primary arthroplasty for displaced fractures of the neck of the femur in patients over 70 years of age 450 patients at two years￨internal fixation versus arthroplasty internal fixation or arthroplasty￨mortality rate of failure severe pain￨after two years the rate of failure was 43 in the internal fixation if and 6 in the arthroplasty group p  0001￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨23 patients median age 80 years healthy older people with displaced cervical hip fractures 47 patients after cervical hip fracture 47 patients with a cervical hip fracture garden 3 or 4 and fully ambulatory before the fracture￨fixation with hansson hookpins charnley hip replacement hip replacement used outdoor walking aids hip replacement hookpins and total hip replacement￨social function postoperative deaths hospital stay healing complications and 2 dislocations￨there were no postoperative deaths and no significant differences in hospital stay￨no diff￨highunclear￨highunclear￨highunclear
104￨acute femoral neck fractures 104 patients with an acute femoral neck fracture comparing internal fixation von bahr screws with primary prosthetic replacement christiansen endoprosthesis￨internal fixation versus primary prosthetic replacement￨blood transfusion earlier postoperative mobilization hospitalization time postoperative mortality rate morbidity rate￨internal fixation proved to be a less timeconsuming operation gave a shorter hospitalization time and was associated with a significantly reduced morbidity rate compared with prosthetic replacement￨sig decrease￨highunclear￨highunclear￨highunclear
222￨elderly patients intracapsular displaced femoral neck fractures inclusion criteria were age above 60 ability to walk before the fracture and no major hip pathology regardless of cognitive function 222 patients 165 74 women mean age 83 years 112 patients and bipolar cemented hemiarthroplasty 110 patients￨hemiarthroplasty hemiarthroplasty or internal fixation internal fixation or hemiarthroplasty closed reduction and two parallel screws internal fixation￨mean eq5d index score eq5d visual analogue scale mean harris hip score complications barthel index hip function harris hip score health related quality of life eq5d activities of daily living barthel index￨hemiarthroplasty is associated with better functional outcome than internal fixation in treatment of displaced fractures of the femoral neck in elderly patients￨sig increase￨low￨low￨low
129￨one hundred and twentynine participants displaced subcapital hip fractures in patients over 70 years old inclusion criteria were displaced hip fracture and age over 70 years￨surgical operation they underwent hemiarthroplasty total hip arthroplasty￨barthel index and harris hip score barthel index scores harris hip scores range of passive hip motion merete berlin germany total arthroplasty￨the range of passive hip motion in the three groups of patients did not differ significantly p005￨no diff￨highunclear￨highunclear￨highunclear
19￨displaced subcapital fractures of femur13 year two hundred and ninety patients over the age of 65 years active patients with a displaced subcapital fracture of the femur patients following each of the three principal methods of treatment for displaced subcapital fractures of the femur nineteen patients were subsequently excluded￨closed reduction and internal fixation with a sliding compression screw plate or uncemented austin moore hemiarthroplasty or cemented howse ii total hip arthroplasty tha internal fixation and hemiarthroplasty tha internal fixation versus hemiarthroplasty versus total hip arthroplasty￨dislocation rate least pain average harris hip scores revision rate pain and mobility mortality￨despite high early complications tha resulted in least pain and most mobility both in the short and longterm and was encouraging with a revision rate of only 625￨no diff￨highunclear￨highunclear￨highunclear
60￨patients with severe cognitive dysfunction elderly patients with severe cognitive impairment 60 patients with an acute displaced fracture of the femoral neck and with a mean age of 84 years￨internal fixation versus hemiarthroplasty internal fixation with cannulated screws or hemiarthroplasty using an uncemented austin moore prosthesis￨severe cognitive impairment general complications and the rate of mortality eq5dindex score total number of surgical procedures complications revision surgery the status of activities of daily living adl hip function according to the charnley score and the healthrelated quality of life hrqol according to the euroqol eq5d proxy report mobility rate of hip complications￨there was a trend towards decreased mobility in the hemiarthroplasty group p  0066￨no diff￨highunclear￨highunclear￨highunclear
280￨patients aged 65 to 79 years displaced intracapsular fracture of the proximal femur displaced intracapsular fractures of the hip in 280 patients aged 65 to 79 years displaced intracapsular fracture in a mobile and mentally competent patient under the age of 80 years￨cemented thompson hemiarthroplasty or a cemented monk bipolar hemiarthroplasty internal fixation or cemented hemiarthroplasty￨mean survival time local complications mean patient survival￨the mean patient survival was significantly higher in the group undergoing reduction and internal fixation 79 months compared with that with a cemented thompson hemiarthroplasty or a cemented monk bipolar hemiarthroplasty 61 months and 68 months respectively￨sig increase￨highunclear￨highunclear￨highunclear
32￨32 displaced femoral neck fractures in patients over 75 years old to receive displaced femoral neck fractures in patients over 75 years old displaced femoral neck fractures in patients over 75 years￨internal fixation or hemiarthroplasty thompson hemiarthroplasty internal fixation￨￨we decided to study whether internal fixation would prove superior to hemiarthroplasty even in displaced femoral neck fractures in patients over 75 years old￨no diff￨highunclear￨highunclear￨highunclear
43￨unstable intracapsular hip fractures in the elderly fortythree elderly patients with an intracapsular hip fracture displaced intracapsular hip fractures in elderly patients￨endoprosthetic replacement osteosynthesis osteosynthesis versus endoprosthesis osteosynthesis dhs versus primary hemiarthroplasty ha￨clinical morbidity mortality rates fracture or operationrelated complications duration of the operation and the perioperative blood loss￨no difference could be demonstrated in the mortality rates fracture or operationrelated complications or the need for secondary intervention￨no diff￨highunclear￨highunclear￨highunclear
20￨a reference group of 9 patients who had undergone tha because of arthrosis was chosen after femoral neck fracture twenty patients patients with a femoral neck fracture￨osteosynthesis or total hip arthroplasty tha osteosynthesis versus primary total hip arthroplasty￨marked osteopenia bone and muscle mass bone mass and muscle volume of the middle femur cortical bone mineral density bmd bone volume bone mass and muscle volume of the thigh and the bmd of the distal femur and proximal tibia￨after the operation the fracture patients had a lower harris score than the arthrosis patients and this was most pronounced among those who had undergone osteosynthesis￨sig increase￨highunclear￨highunclear￨highunclear
60￨displaced intracapsular femoral neck fractures in demented patients 60 demented patients with displaced intracapsular femoral neck fractures comparing internal fixation n  31 with hemiarthroplasty n  29￨internal fixation and hemiarthroplasty cannulated screws versus hemiarthroplasty hemiarthroplasty￨postoperative mortality mortality rate failure of internal fixation loss of blood and more wound complications￨there are no randomised trials comparing internal fixation and hemiarthroplasty for a displaced intracapsular femoral neck fracture in relation to mental state￨no diff￨highunclear￨highunclear￨highunclear
102￨elderly relatively healthy lucid patients with a displaced fracture of the femoral neck 102 patients of mean age 80 years with an acute displaced fracture of the femoral neck displaced femoral neck fractures in the elderly￨total hip replacement internal fixation internal fixation if with two cannulated screws or total hip replacement thr thr￨hip complications revision surgery hip function according to charnley and the healthrelated quality of life hrqol according to euroqol eq5d reduction in hrqol eq5d index score failure rate hip complications number of revision procedures hip function severe cognitive dysfunction￨hip function was significantly better in the thr group at all followup reviews regarding pain p  0005 movement p  005 except at 4 months and walking p  005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨232 patients of either gender aged 2869 years and weighing 54110 kg patients with mild to moderate essential hypertensiona population analysis￨candesartan placebo angiotensin at ii receptor at1subtype antagonist candesartan￨trough concentrations diastolic blood pressure systolic blood pressure systolic and diastolic blood pressure￨systolic and diastolic blood pressure were lowered by the treatment in a dosedependent fashion￨sig decrease￨highunclear￨highunclear￨highunclear
200￨patients with systemic hypertension two hundred patients randomized in the study with 177 patients completing the trial￨eprosartan placebo eprosartan￨bp 24h change in bp changes in 24h and trough blood pressure bp ambulatory bp￨eprosartan is a new nonphenyl angiotensin ii receptor blocker which has been approved for the treatment of hypertension￨sig increase￨highunclear￨highunclear￨highunclear
60￨3 mmhg 173 13 60 patients 53 10 years with essential hypertension mean blood pressure bp￨hctz valsartan 80 mg hydrochlorothiazide hctz 25 mg or placebo valsartan hctz 3 at1receptor blockade placebo 0 hydrochlorothiazide at receptor blockade hctz and placebo￨augmentation index reduction systolic and diastolic blood pressure sbp dbp augmentation index in essential hypertension blood pressure reduction augmentation index augmentation index valsartan radial artery pressure central aortic pressure wave and augmentation index vascular function￨augmentation index reduction was greater with valsartan 22  11 than with hctz 3￨sig increase￨highunclear￨highunclear￨highunclear
366￨366 patients with a group mean sitting diastolic blood pressure of 101 hypertensive patients with mildtomoderate hypertension patients with essential hypertension￨losartan placebo losartan 50 mg and losartan placebo losartan 50 mg or losartan placebo and losartan losartan potassium losartan cozaar an angiotensin ii receptor antagonist￨potential blood pressure response systolic and diastolic sitting blood pressures baseline plasma renin activity and reduction in peak and trough blood pressure efficacious and well tolerated sitting diastolic blood pressure blood pressure lowering sitting diastolic blood pressure trough blood pressures rebound hypertension￨based on trough blood pressures at week 12 active drug both arms was more effective than placebo in lowering sitting diastolic blood pressure with a very small additional benefit associated with increasing the dose of losartan to 100 mg in patients who did not reach the target blood pressure after the first 6 weeks on losartan 50 mg￨sig increase￨highunclear￨highunclear￨highunclear
567￨567 patients patients with mildtomoderate hypertension mildtomoderate hypertension￨losartan placebo irbesartan and losartan two angiotensin ii at1 subtype receptor antagonists angiotensin ii receptor antagonists irbesartan and losartan placebo 100 mg losartan￨trough seated diastolic blood pressure sedbp and trough seated systolic blood pressure sesbp adverse events ae and discontinuations because of ae blood pressure reductions tolerated antihypertensive effect antihypertensive efficacy and tolerability￨the 300 mg dose of irbesartan was associated with the lowest incidence of adverse events ae and discontinuations because of ae￨no diff￨highunclear￨highunclear￨highunclear
502￨eligible patients n  502 with a baseline mean seated diastolic blood pressure sedbp of 100 to 115 mm hg￨placebo hctz monotherapy olmesartan medoxomilhctz combination therapy placebo olmesartan medoxomilhctz 20125 mg and olmesartan medoxomilhctz hydrochlorothiazide hctz olmesartan medoxomil plus hctz olmesartan medoxomilhctz olmesartan medoxomil and hydrochlorothiazide olmesartan medoxomilhctz combination therapy angiotensin ii receptor blocker olmesartan medoxomil placebo olmesartan medoxomil monotherapy￨sedbp and sesbp sedbp control blood pressure bp tolerated bp reductions change in mean trough sedbp efficacy and safety sedbp and seated systolic blood pressure sesbp￨all olmesartan medoxomilhctz combinations significantly reduced sedbp and sesbp compared with placebo in a dosedependent manner￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with stage i and stage ii hypertension￨placebo angiotensin ii receptor blocker tasosartan and placebo 50 mg tasosartan singleblind placebo￨sitting systolic blood pressure sbp efficacy and tolerability mean sitting diastolic blood pressure sidbp troughtopeak ratio rate of response sidbp mean 24hour blood pressure reduction 24hour efficacy sidbp￨compared with placebo tasosartan produced significantly p 05 greater reductions in both sidbp 94￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨adults with uncomplicated essential hypertension baseline seated diastolic blood pressure 115 mm hg and  or  95 mm hg essential hypertension￨angiotensin ii receptor antagonists losartan placebo angiotensin ii receptor antagonist valsartan to losartan valsartan valsartan 50 mg losartan or placebo angiotensin ii antagonists valsartan and losartan￨headache and dizziness incidence of adverse events incidence of adverse experiences ae effective and well tolerated mean blood pressures seated systolic and diastolic blood pressures number of responders tolerability￨valsartan produced a significantly higher number of responders 62 than losartan 55 p  02 at the 8 week treatment endpoint￨sig increase￨highunclear￨highunclear￨highunclear
203￨both black and white patients with hypertension in black patients hypertensive black and white patients black than white adults in the us
                black n  348 and white n  203 patients with mildtomoderate hypertension patients with differing baseline levels of aldosterone￨losartan eplerenone placebo monotherapy aldosterone blocker eplerenone eplerenone 50 mg the angiotensin ii receptor antagonist losartan 50 mg or placebo placebo eplerenonetreated and losartan placebo and losartan eplerenone and losartan eplerenone￨systolic blood pressure sbp mean diastolic blood pressure dbp efficacy and tolerability tolerated blood pressure dbp sbp and dbp efficacy and tolerability￨for reduction of systolic blood pressure sbp eplerenone was superior to placebo and losartan in all patients combined and in black patients and was superior to placebo in white patients￨sig increase￨highunclear￨highunclear￨highunclear
440￨african american adults with mild to moderate hypertension adult african americans with mild to moderate hypertension 440 patients were african americans with hypertension african american patients patients usually require treatment with drugs from  or  2 antihypertensive classes to achieve adequate blood pressure control￨placebo losartan monotherapy placebo losartan monotherapy randomized188 to placebo losartan monotherapy losartan plus hctz losartan alone and in combination with hydrochlorothiazide hctz losartanhctz losartan alone and in combination with hydrochlorothiazide losartan monotherapy and 59 to losartanhctz￨antihypertensive efficacy and safety response rate antihypertensive efficacy and safety incidence of clinical and laboratory adverse events and evaluating mean changes in pulse body weight electrocardiographic parameters and laboratory test results mean sidbp sisbp and sidbp lowering sisbp and sidbp response rate with losartan hctz sitting systolic blood pressure sisbp incidence of clinical adverse events severe blood pressure elevations￨sitting systolic blood pressure sisbp was significantly lowered with losartan monotherapy by 64 mm hg compared with placebo reduction of 23 mm hg￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨357 men and women enrolled in the trial with an untreated sitting diastolic bp of 95 to 114 mm hg and ambulatory daytime diastolic bp  or 85 mm hg￨losartan placebo enalapril coerverapamil coerverapamil hydrochloride each evening enalapril and losartan enalapril each morning enalapril losartan and placebo placebo and losartan losartan each morning verapamil￨circadian rhythm of bp and heart rate bp heart rate and the heart rate systolic bp product earlymorning blood pressure heart rate and the ratepressure product mean 24hour bp reductions in early morning bp by coerverapamil blood pressure bp heart rate and the heart rate systolic bp product morning heart rate the ratepressure product and the rateofrise of bp￨results were similar at weeks 4 and 8 for all treatment groups except that the magnitude of change was greater at week 8￨no diff￨highunclear￨highunclear￨highunclear
440￨440 subjects aged 18 years mildtomoderate hypertension subjects with mildtomoderate hypertension￨olmesartan medoxomil placebo olmesartan medoxomil olmesartan medoxomil and amlodipine calcium channel blocker amlodipine besylate amlodipine amlodipine angiotensin ii receptor blocker olmesartan medoxomil￨antihypertensive efficacy and safety antihypertensive efficacy ambulatory and seated dbp and sbp mean 24h ambulatory systolic blood pressure sbp mean reductions in ambulatory and seated bp sbp goal tolerated 24h ambulatory blood pressure monitoring abpm and by seated cuff blood pressure bp measurements mean 24h diastolic blood pressure dbp mean seated trough cuff dbp and sbp measurements and response and control rates￨olmesartan medoxomil and amlodipine produced significantly greater reductions in ambulatory and seated dbp and sbp compared with placebo￨sig increase￨highunclear￨highunclear￨highunclear
308￨three hundred eight patients  or 35 years of age with isolated systolic hypertension defined as trough sitting blood pressure between 140 and 200 mm hg systolic and between 70 and 89 mm hg diastolic patients with isolated systolic hypertension￨losartan losartanbased treatment regimen placebo losartanbased treatment regimen and placebo losartan 50 mg n157 or placebo￨mean trough sitting sbp antihypertensive efficacy reduction in sitting sbp isolated systolic hypertension sbp antihypertensive efficacy and tolerability￨the reduction in sitting sbp was significantly greater for losartan than placebo￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients with mildtomoderate hypertension￨hctz placebo hydrochlorothiazide hctz￨trough seated blood pressure efficacy safety pharmacokinetics and pharmacodynamics rebound hypertension or adverse events trough seated diastolic blood pressure angiotensin ii and aldosterone levels plasma irbesartan concentrations blood pressure tolerated￨at week 8 statistically significant reductions over placebo were observed in trough seated blood pressure with all irbesartan doses  or  50 mg￨sig decrease￨highunclear￨highunclear￨highunclear
348￨348 adult outpatients with mildtomoderate uncomplicated essential hypertension￨placebo enalapril angiotensin converting enzyme ace inhibitor enalapril valsartan one or placebo valsartan and enalapril valsartan and enalapril valsartan valsartan placebo and enalapril angiotensin ii antagonist￨antihypertensive efficacy and systemic tolerability mean sitting diastolic blood pressure sdbp incidence of coughing response rates sdbp or ssbp sdbp change in sitting systolic blood pressure ssbp and response rates diastolic and systolic blood pressures￨similar falls were found in both of the active treatment groups with mean changes in sdbp at 8 weeks of 95 mmhg for valsartan and 94 mmhg for enalapril 45 mmhg for placebo￨no diff￨highunclear￨highunclear￨highunclear
215￨sixteen centers in italy caucasian patients n  215 aged  or  18 years with seated diastolic blood pressure 95110 mmhg and ambulatory diastolic blood pressure adbp  or  85 mmhg￨placebo irbesartan therapy￨trough office seated diastolic blood pressure and seated systolic blood pressure peak ratios adverse events blood pressures mean 24 h adbp and ambulatory systolic blood pressure and were well tolerated blood pressure ambulatory blood pressure monitoring 24hour blood pressure control safety and tolerability seated systolic blood pressure ambulatory blood pressure and trough office blood pressure lowerings ambulatory systolic blood pressure￨all irbesartan regimens reduced trough office seated diastolic blood pressure and seated systolic blood pressure after 2 and 8 weeks of treatment all p  001 versus placebo except for seated systolic blood pressure in patients in the 75 mg irbesartan once a day group￨sig decrease￨low￨low￨low
not found￨mild to moderate hypertension 1293 patients screened 818 633 were enrolled at 47 centers patients with mild to moderate hypertension men and women between 18 and 80 years of age with mild to moderate hypertension defined as mean supine diastolic blood pressure dbp between 95 and 114 mm hg during the last 2 weeks of the placebo runin period and systolic blood pressure sbp between 114 and 200 mm hg immediately before randomization￨telmisartan 80 mghctz telmisartan 40 mghctz 125 mg and telmisartan 80 mghctz placebo hctz monotherapy hctz telmisartan and hctz hydrochlorothiazide hctz telmisartanhctz doses and placebo telmisartan hydrochlorothiazide monotherapy telmisartan plus hydrochlorothiazide versus telmisartan telmisartan telmisartan monotherapy telmisartan 40 mghctz thiazide monotherapy telmisartan 80 mghctz￨mean supine dbp and sbp antihypertensive efficacy plasma renin activity and safety parameters including treatmentemergent adverse events physical findings electrocardiograms and serum electrolyte levels mean supine trough sbpdbp mean supine dbp tolerated supine trough dbp sbp and dbp mean supine sbp￨telmisartan 40 mghctz 125 mg significantly reduced mean supine sbp by 188 mm hg a benefit of 66 mm hg compared with telmisartan 40 mg and 119 mm hg compared with hctz 125 mg both p  001￨sig decrease￨low￨highunclear￨highunclear
736￨736 adults with uncomplicated essential hypertension stages 1 to 3 adults with essential hypertension patients with essential hypertension￨placebo valsartan placebo or valsartan￨msdbp to baseline levels laboratory values incidence of dizziness symptomatic orthostatic hypotension blood pressure mean sitting systolic blood pressure mssbp and responder rates adverse experiences safety and tolerability variables included data on adverse experiences rebound hypertension and clinical laboratory evaluations msdbp and mssbp tolerability efficacy and safety mean sitting diastolic blood pressure msdbp responder rates￨statistically significant differences in responder rates at end point were seen for doses of valsartan of 80 mg and above compared with placebo whereas the responder rates for valsartan 20 mg was not significantly different from that for placebo￨sig increase￨highunclear￨highunclear￨highunclear
not found￨subjects with essential hypertension hypertensive subjects hypertensive humans￨convertingenzyme inhibition angiotensin ii type 1 at1 receptors placebo angiotensin ii type 1 receptors￨diameter or distensibility sem mean blood pressure radial but not carotid artery wall thickness baseline levels of active renin and angiotensin i and ii blood pressure reduction blood pressure cardiovascular hypertrophy blood pressure changes radial artery wall thickness carotid wall thickness and diameter￨with irbesartan mean blood pressure decreased significantly and proportionally to the baseline levels of active renin and angiotensin i and ii￨sig decrease￨highunclear￨highunclear￨highunclear
734￨patients with mildtomoderate essential hypertension 734 men and women￨placebo lisinopril valsartan angiotensinconverting enzyme inhibitor lisinopril valsartan 8080 mg twice daily 563 mm hg valsartan valsartan 80 mg titrated to valsartan 160 mg once daily or valsartan 80 mg twice daily lisinopril 10 mg titrated to lisonopril angiotensinconverting enzyme ace inhibitor lisinopril and placebo valsartan and lisinopril angiotensin ii antagonist￨frequency of drug related cough sitting systolic blood pressure ssbp and percentage of successful responders mean sitting diastolic blood pressure sdbp efficacy safety and tolerability sdbp tolerability and safety￨all active treatment groups were shown to demonstrate significant reductions in sdbp compared to placebo at endpoint of therapy least mean square reduction from baseline￨sig increase￨highunclear￨highunclear￨highunclear
123￨patients with mildtomoderate hypertension patients with hypertension a total of 123 patients were randomized of whom 112 patients completed the study￨antihypertensive agents placebo angiotensin ii receptor antagonist valsartan valsartan 80 mg orally once daily or placebo dl placebo 42 dl placebo 60 valsartan valsartan valsartan therapy dietary runin period under placebo angiotensin ii receptor antagonist valsartan￨systolic blood pressure fasting plasma glucose and glycosylated haemoglobin levels safe and well tolerated lipid profile and glucose metabolism total and ldl cholesterol levels blood pressure diastolic blood pressure total cholesterol levels of triglycerides highdensity lipoprotein cholesterol very lowdensity lipoprotein vldl triglycerides vldl cholesterol and apolipoprotein b levels of both lowdensity lipoprotein ldl cholesterol￨no significant changes were observed in the levels of triglycerides highdensity lipoprotein cholesterol very lowdensity lipoprotein vldl triglycerides vldl cholesterol and apolipoprotein b after valsartan treatment￨no diff￨highunclear￨highunclear￨highunclear
683￨683 patients with seated diastolic blood pressure sedbp between 95 and 110 mm hg patients with mildtomoderate hypertension mildtomoderate hypertension￨hctz placebo hydrochlorothiazide irbesartan plus hctz irbesartan and hydrochlorothiazide hctz￨bp reduction bp sedbp and seated systolic bp trough sedbp tolerated serious adverse events￨all treatments were well tolerated there were no treatmentrelated serious adverse events￨no diff￨highunclear￨highunclear￨highunclear
243￨patients with systemic hypertension patients aged 65 years with those aged  or 65 years 243 patients with mildtomoderate systemic hypertension sitting diastolic blood pressure sitdbp 95114 mm hg￨placebo eprosartan daily eprosartan a nonbiphenyl nontetrazole angiotensin iireceptor antagonist eprosartan once daily or placebo eprosartan angiotensin ii antagonist￨tolerated and effective all clinic blood pressure measurements total number of adverse events sitdbp7508 mm hg and sitting systolic blood pressure sitsbp blood pressure reduction proportion of patients responding sitdbp￨the 95 confidence intervals for the difference from placebo were 81 to 41 for sitdbp and 110 to 40 for sitsbp both p00001￨no diff￨low￨low￨low
652￨patients with mildtomoderate hypertension mean sitting diastolic blood pressure dbp  or 95 and 110 mm hg hypertensive patients patients with mildtomoderate hypertension 652 patients￨placebo irbesartan 150 mg or placebo novel oral renin inhibitor aliskiren with placebo aliskiren aliskiren￨antihypertensive efficacy and safety trough sbp adverse events and number of patients discontinuing therapy mean sitting dbp trough mean sitting dbp and systolic blood pressure sbp safety and tolerability safety and tolerability profile antihypertensive effect￨aliskiren 300 and 600 mg lowered mean sitting dbp significantly more than irbesartan 150 mg p005￨sig decrease￨highunclear￨highunclear￨low
not found￨mild to moderate hypertension hypertensive patients patients with mild to moderate uncomplicated essential hypertension￨placebo kt3671 40 mg 80 mg 160 mg or placebo kt3671 a new angiotensin ii at 1 receptor blocker kt3671 with that of placebo kt3671 with placebo￨trough mean sitting office dbp ambulatory blood pressure monitoring abpm mean daytime dbp daytime and night time mean abpm office systolic bp antihypertensive effect and tolerability and safety adverse events office sbp tolerated systolic and diastolic abpm mean ambulatory systolic and diastolic pressure office dbp￨office dbp was significantly lower with kt3671 40 mg but not the other 2 dosage groups 32 95 cl 61  03 p  003￨sig decrease￨highunclear￨highunclear￨highunclear
334￨334 patients with moderate to severe essential hypertension￨olmesartan medoxomil olmesartan medoxomil placebo olmesartan medoxomil qd or 25 10 or 40 mg olmesartan medoxomil bid￨mean ambulatory systolic blood pressure ambulatory blood pressure measurements ambulatory and cuff blood pressure mean 24hour ambulatory diastolic blood pressure diastolic and systolic blood pressure diastolic troughtopeak ratios antihypertensive efficacy efficacy and safety￨treatment with olmesartan medoxomil resulted in a significant placeboadjusted reduction of mean 24hour ambulatory diastolic blood pressure of 96 mm hg 122 mm hg and 106 mm hg in the 5￨sig decrease￨highunclear￨highunclear￨highunclear
1039￨sd age 630 1039 patients age 3684 years with ish seated sbp 150179 mmhg and patients with isolated systolic hypertension ish patients with ish￨angiotensin ii receptor antagonist telmisartan placebo hctz hctz 125 mg or placebo hydrochlorothiazide hctz telmisartan hydrochlorothiazide 125 mg or placebo￨response rate percentage achieving the target fall in sbp and the change from baseline in seated trough dbp incidence and severity of adverse events and physical examination and laboratory parameters systolic blood pressure sbp allcausality adverse events tolerability sbp seated trough sbp seated diastolic blood pressure dbp￨allcausality adverse events occurred in 199 176 and 203 receiving telmisartan 20 40 and 80 mg respectively 209 receiving placebo and 220 receiving hctz 125 mg￨no diff￨highunclear￨highunclear￨highunclear
871￨patients with essential hypertension 871 adult out￨combination therapy of valsartan placebo hctz hctz to valsartan monotherapy valsartan valsartan and hydrochlorothiazide valsartan thiazide diuretics hydrochlorothiazide hctz vs placebo or vs valsartan or hctz alone hctz 125 mg or 25 mg to lower msdbp and mssbp￨msdpb and mssbp hypokalaemia msdbp tolerated dizziness and headache antihypertensive efficacy and tolerability mean sitting systolic blood pressure mssbp mean sitting diastolic blood pressure msdbp￨all combination regimens produced a statistically significantly greater reduction in msdpb and mssbp than the corresponding monotherapies￨sig decrease￨low￨low￨low
576￨patients with mild to moderate essential hypertension patients with essential hypertension￨placebo baseline period to 8 weeks of oncedaily doubleblind treatment with losartan potassium placebo placebo and enalapril maleate losartan potassium a specific and selective angiotensin ii receptor antagonist enalapril maleate 20 mg or placebo enalapril maleate losartan potassium calculatedabstract￨blood pressure supine systolicdiastolic pressure blood pressure changes supine diastolic pressure￨at 24 hours after dosing the blood pressure changes obtained with losartan potassium 50 mg were essentially identical to those obtained with enalapril maleate 20 mg￨no diff￨highunclear￨highunclear￨highunclear
122￨patients with mildtomoderate hypertension 122 adult outpatients￨valsartan 10 mg 40 mg 80 mg 160 mg or placebo placebo valsartan placebo valsartan￨msudbp and msusbp symptomatic orthostatic hypotension blood pressure lowering responder rates trough mean supine diastolic blood pressure msudbp headache trough mean supine systolic blood pressure msusbp responder rates and troughpeak ratio blood pressure orthostatic changes in diastolic or systolic blood pressure efficacy and tolerability￨all treatments significantly reduced msudbp and msusbp at 4week endpoint compared to baseline p  0001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨men and women aged 2080 years with primary hypertension and sitting diastolic blood pressure dbp 95114 mm hg after a 4week placebo runin period￨losartan losartan and placebo placebo novel angiotensin ii antagonist candesartan cilexetil candesartan cilexetil 8 mg n82 candesartan cilexetil 16 mg n84 losartan 50 mg n83 or placebo candesartan cilexetil candesartan cilexetil￨trough sitting dbp placebo corrected troughpeak ratio blood pressure trough dbp￨compared with placebo treatment trough dbp was significantly reduced by a mean 95 ci of 89 60 118 mm hg with 8 mg and 103 74￨sig decrease￨highunclear￨highunclear￨low
703￨mild to moderate hypertension in a clinical trial 703 males and females aged 1875 years with a sitting diastolic blood pressure of 95115 mmhg entered the trial and 604 completed the 12week protocol 40 clinical centers throughout the united states hypertension￨losartan losartan  625 mg hydrochlorothiazide losartan placebo losartan  125 mg hydrochlorothiazide losartan and hydrochlorothiazide losartan and 125 mg hydrochlorothiazide hydrochlorothiazide alone or 5 placebo hydrochlorothiazide losartan alone hydrochlorothiazide alone or placebo￨mean trough sitting diastolic blood pressure mean trough sitting systolic blood pressure sitting diastolic and systolic blood pressures adverse events sitting diastolic blood pressure tolerated blood pressure￨sitting diastolic blood pressure fell 40 mmhg with placebo 72 mmhg with 125 mg hydrochlorothiazide 72 mmhg with 50 mg losartan 93 mmhg with 50 mg losartan  625 mg hydrochlorothiazide and 132 mmhg with 50 mg losartan  125 mg hydrochlorothiazide￨sig decrease￨low￨highunclear￨highunclear
365￨patients with systemic hypertension 365 adult patients with systemic hypertension and mean sitting diastolic blood pressure bp of 95 to 114 mm hg￨placebo or candesartan cilexetil placebo candesartan cilexetil a potent at1 selective longacting angiotensin ii receptor blocker candesartan cilexetil￨trough sitting and standing measurements of diastolic and systolic bp bp responder rates trough sitting diastolic bp efficacy tolerability and safety safety and tolerability mean changes in bp tolerability and safety profiles sitting diastolic and systolic bp￨the 16 and 32mg doses were consistently significantly superior to placebo in antihypertensive effect with regard to all bp measurements including peak 6 hours after treatment trough sitting and standing measurements of diastolic and systolic bp￨sig increase￨highunclear￨highunclear￨highunclear
not found￨nonblack hypertensive patients whose baseline untreated clinical diastolic blood pressures were 95 mm hg or higher and whose average 24hour ambulatory diastolic blood pressures were 85 mm hg or higher￨losartan potassium losartan placebo losartan hydrochlorothiazide angiotensin ii receptor blocker losartan￨systolic and diastolic blood pressures incidence of adverse events 24hour ambulatory systolicdiastolic blood pressure measurements clinical and 24hour ambulatory blood pressures tolerated blood pressure decrements antihypertensive effects blood pressure effects clinical diastolic blood pressure￨the effects of losartan 50 mg twice daily were not significantly different from those of losartan 100 mg once daily but as expected the effects were greater than those of losartan 50 mg once daily p  05￨no diff￨highunclear￨highunclear￨highunclear
207￨patients with mild to moderate hypertension 207 patients with mild to moderate hypertension diastolic blood pressure dbp 100 to 114 mmhg￨telmisartan and enalapril enalapril placebo enalapril 20 mg or placebo telmisartan enalapril placebo￨bp reductions supine systolic blood pressure sbp troughpeak dbp ratios pharmacokinetic and pharmacodynamic parameters bp bp reduction sd values for cmax supine heart rate supine dbp telmisartan plasma concentrations sbp and dbp mean blood pressure bp supine sbp￨the bp reductions after 4 weeks of treatment with telmisartan were no different from those achieved with enalapril￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients  or 60 years of age with isolated systolic hypertension elderly patients with isolated systolic hypertension￨hctz placebo hydrochlorothiazidehctz eprosartan eprosartan mesylate￨pulse pressure sitsbp mean sitting systolic blood pressure sitsbp￨reductions were also noted in standing sbp monotherapy p0001 combination therapy p003￨sig decrease￨highunclear￨highunclear￨highunclear
223￨patients with mildtomoderate hypertension 223 patients with mildtomoderate hypertension defined as clinic diastolic blood pressure dbp 95 and 114 mm hg clinic systolic blood pressure sbp 140 and 200 mm hg and 24h ambulatory dbp￨losartan placebo losartan telmisartan telmisartan angiotensin ii receptor antagonists telmisartan and losartan telmisartan telmisartan 40 mg telmisartan 80 mg losartan 50 mg or placebo selective at1 receptor antagonists telmisartan and losartan￨antihypertensive efficacy and tolerability profiles tolerated effective and well tolerated dbp ambulatory blood pressure monitoring abpm sbp and dbp 24h mean blood pressure￨compared with losartan telmisartan 80 mg produced significantly p  005 greater reductions in both sbp and dbp during all monitored periods of the 24h period while telmisartan 40 mg produced significantly greater reductions in sbp and dbp in the nighttime period 1001 pm to 559 am p  005 and in dbp in the morning period 600 am to 1159 am￨sig increase￨highunclear￨highunclear￨highunclear
not found￨278 patients 187 men91 women with a mean age of 53495 years range 30 to 70 years and a baseline sitting diastolic blood pressure dbp of 95 to 114 mm multicenter trial at 21 sites in the united states and canada patients with essential hypertension￨tasosartan therapy placebo tasosartan placebo￨incidence of adverse events ambulatory blood pressure bp monitoring tolerated baseline sitting systolic blood pressure sbpdbp ambulatory sbpdbp headache incidence￨moreover significant p  05 placeboadjusted differences in ambulatory sbpdbp and a significant doseresponse relationship p  001 were observed with all tasosartan dosages during the 24h daytime and nighttime periods￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨￨placebo 200 mg sibuprofen 400 mg sibuprofen 400 mg racemic ibuprofen or placebo ibuprofen sibuprofen racemic ibuprofen and placebo racemic ibuprofen￨plasma levels of immunoreactive betaendorphin peak analgesia similar duration of action and a low incidence of adverse effects acute pain and plasma betaendorphin levels analgesia￨both doses of sibuprofen resulted in significantly greater analgesia over the first 60 minutes in comparison to racemic ibuprofen and placebo the 400 mg dose of sibuprofen also produced greater analgesia at 2 and 3 hours￨sig increase￨highunclear￨highunclear￨highunclear
not found￨seventyeight motor vehicle accident survivors with chronic greater than 6 months ptsd or severe subsyndromal ptsd motor vehicle accident survivors￨cognitive behavioral therapy cbt supportive psychotherapy support cognitive behavioural therapy￨￨scores on the caps showed significantly greater improvement for those in cbt in comparison to the wait list and to the support conditions￨sig increase￨highunclear￨highunclear￨highunclear
21￨twentyone subjects were entered and 18 completed posttraumatic stress disordered sexual assault victims adult female sexual assault victims￨eye movement desensitization and reprocessing emdr eye movement desensitization and reprocessing emdr￨standard clinician and selfadministered ptsd and related psychopathology scales ptsd and depression￨results indicated that subjects treated with emdr improved significantly more on ptsd and depression from pre to posttreatment than control subjects leading to the conclusion that emdr was effective in alleviating ptsd in this study￨sig increase￨highunclear￨highunclear￨highunclear
not found￨battered women cttbw with ptsd battered women with ptsd thirtyseven ethnically diverse women￨immediate or delayed cttbw cttbw cognitive trauma therapy cognitive trauma therapy￨￨cttbw was efficacious across ethnic backgrounds￨no diff￨highunclear￨highunclear￨highunclear
125￨one hundred twentyfive ethnically diverse women battered women with ptsd cttbw battered women with posttraumatic stress disorder ptsd cttbw￨immediate or delayed cttbw cognitive trauma therapy cognitive trauma therapy￨depression and guilt and substantial increases in selfesteem￨ptsd remitted in 87 of women who completed cttbw with large reductions in depression and guilt and substantial increases in selfesteem￨sig decrease￨highunclear￨highunclear￨highunclear
36￨thirtysix patients with ptsd posttraumatic stress disorder￨image habituation training and applied muscle relaxation individual treatment with imaginal exposure image habituation training  iht or applied muscle relaxation amr or eye movement desensitization emd￨￨despite a failure to demonstrate differences among groups there was some suggestion that immediately after treatment emd was superior for intrusive memories￨no diff￨highunclear￨highunclear￨highunclear
45￨posttraumatic stress disorder in rape victims rape victims with posttraumatic stress disorder ptsd n  45￨stress inoculation training sit prolonged exposure pe supportive counseling sc or waitlist control wl cognitivebehavioral procedures and counseling￨ptsd symptoms raperelated distress general anxiety and depression ptsd symptoms￨all conditions produced improvement on all measures immediately posttreatment and at followup￨no diff￨highunclear￨highunclear￨highunclear
58￨participants with posttraumatic stress disorder ptsd posttraumatic stress disorder fiftyeight civilian survivors of trauma with ptsd￨imaginal exposure alone and imaginal exposure with cognitive restructuring cognitive restructuring cr with prolonged imaginal exposure ie iecr ie or supportive counseling sc￨reduced ptsd and depression ptsd and maladaptive cognitive styles￨further iecr participants had greater reductions in ptsd and maladaptive cognitive styles than ie participants at followup￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨325 individuals participated in 1 or both assessments posttraumatic stress disorder male vietnam veterans vietnam veterans 360 men￨psychotherapy traumafocused group psychotherapy or a presentcentered comparison treatment that avoided trauma focus￨psychiatric symptoms functional status quality of life physical health and service utilization avoidance and numbing and possibly ptsd symptoms ptsd severity￨although posttreatment assessments of ptsd severity and other measures were significantly improved from baseline intentiontotreat analyses found no overall differences between therapy groups on any outcome￨no diff￨highunclear￨highunclear￨highunclear
20￨20 patients victims of rape in adulthood or adult victims of childhood sexual abuse selected according to dsmiiir criteria chronic posttraumatic stress disorder in victims of sexual aggression￨psychological treatment cognitive restructuring and b progressive relaxation training￨success rate￨most treated patients improved but the success rate was higher in all measures in the exposure and cognitive restructuring group immediately on posttreatment and at followup￨sig increase￨highunclear￨highunclear￨highunclear
not found￨posttraumatic stress disorder￨cbt variant trauma treatment protocol ttp emdr and a cognitivebehavior trauma treatment protocol ttp￨￨it was found that ttp was both statistically and clinically more effective in reducing pathology related to ptsd and that this superiority was maintained and in fact became more evident by 3month followup￨sig increase￨highunclear￨highunclear￨highunclear
60￨posttraumatic stress disorder ptsd￨emdr and relaxation training relaxation training or eye movement desensitization and reprocessing emdr ptsd treatments exposure therapy emdr and relaxation training￨emdr and relaxation comparative efficacy speed and adverse effects efficacy speed and incidence of symptom worsening numbing and hyperarousal symptoms￨treaments did not differ in attrition in the incidence of symptom worsening or in their effects on numbing and hyperarousal symptoms￨no diff￨highunclear￨highunclear￨highunclear
48￨women with posttraumatic stress disorder and histories of childhood sexual abuse survivors of childhood sexual abuse with posttraumatic stress disorder ptsd survivors of childhood sexual abuse with ptsd female survivors of childhood sexual abuse with ptsd fortyeight female survivors of childhood sexual abuse with ptsd￨individual psychotherapy and pharmacotherapy 15week affectmanagement treatment group or to a wait list control condition management treatment am￨posttreatment symptoms of ptsd and dissociation￨our findings suggest that an affectmanagement group treatment is beneficial as an adjunct to individual psychotherapy and pharmacotherapy for survivors of childhood sexual abuse with ptsd￨sig increase￨highunclear￨highunclear￨highunclear
58￨fiftyeight women with posttraumatic stress disorder ptsd related to childhood abuse￨skills training 2phase cognitivebehavioral treatment or a minimal attention wait list skills training￨affect regulation problems interpersonal skills deficits and ptsd symptoms￨compared with those on wait list participants in active treatment showed significant improvement in affect regulation problems interpersonal skills deficits and ptsd symptoms￨sig increase￨highunclear￨highunclear￨highunclear
not found￨postraumatic stress disorder ptsd traumatic stress 22 patients from a universitybased clinic serving the outside community predominantly rape and crime victims who completed at least one active session of treatment after three preparatory sessions￨pe emdr reprocessing emdr and prolonged exposure pe￨postsession suds subjective units of distress suds ratings ptsd scores dropout rate ptsd symptoms ptsd and depression symptoms￨successful treatment was faster with emdr as a larger number of people 7 of 10 had a 70 reduction in ptsd symptoms after three active sessions compared to 2 of 12 with pe￨sig increase￨highunclear￨highunclear￨highunclear
114￨chronic nightmares in sexual assault survivors with posttraumatic stress disorder 114 participants completed followup at 3 andor 6 months 1995 to 1999 among 168 women in new mexico 95 had moderatetosevere ptsd 97 had experienced rape or other sexual assault 77 reported lifethreatening sexual assault and 58 reported repeated exposure to sexual abuse in childhood or adolescence patients with posttraumatic stress disorder ptsd￨imagery rehearsal therapy irt irt in 3 sessions controls received no additional intervention but continued any ongoing treatment imagery rehearsal therapy￨nfq and improved sleep nightmare frequency questionnaire nfq pittsburgh sleep quality index psqi ptsd symptom scale pss and clinicianadministered ptsd scale caps chronic nightmares improve sleep quality number of nightmares clinical severity frequency of disturbing dreams improves sleep quality ptsd symptoms posttraumatic stress symptoms ptsd symptom severity nightmares sleep and ptsd￨posttraumatic stress symptoms decreased by at least 1 level of clinical severity in 65 of the treatment group compared with symptoms worsening or not changing in 69 of controls chi21  1280 p001￨sig increase￨low￨low￨low
60￨traumatized young women 60 women between the ages of 16 and 25 traumatized young women￨brief psychological intervention emdr or an active listening al control eye movement desensitization and reprocessing emdr￨outcome measure beck depression inventory statetrait anxiety inventory penn inventory for posttraumatic stress disorder impact of event scale tennessee selfconcept scale￨prepost effect sizes for the emdr group averaged 156 compared to 065 for the al group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨posttraumatic stress disorder ptsd and depression one hundred seventyone female rape victims chronic posttraumatic stress disorder in female rape victims￨cognitiveprocessing therapy cpt with prolonged exposure and a minimal attention condition ma cpt cognitiveprocessing therapy with prolonged exposure and a waiting condition￨clinicianadministered ptsd scale the ptsd symptom scale the structured clinical interview for dsmiv the beck depression inventory and the traumarelated guilt inventory￨the 2 therapies had similar results except that cpt produced better scores on 2 of 4 guilt subscales￨no diff￨highunclear￨highunclear￨highunclear
22￨police officers with posttraumatic stress disorder posttraumatic stress disorder ptsd fortytwo police officers with the diagnosis of ptsd participated in the study 22￨manualized psychotherapy to waitlist control eclectic psychotherapy eclectic psychotherapy bep￨ptsd￨at posttest and at followup bep had produced significant improvement in ptsd in work resumption and in some comorbid conditions￨sig increase￨highunclear￨highunclear￨highunclear
not found￨sudanese refugees living in a ugandan refugee settlement n  43 who were diagnosed as suffering from posttraumatic stress disorder ptsd￨net 4 sessions of supportive counseling sc or psychoeducation pe net narrative exposure therapy net narrative exposure therapy supportive counseling and psychoeducation narrative exposure therapy￨￨these results indicate that net is a promising approach for the treatment of ptsd for refugees living in unsafe conditions￨sig increase￨highunclear￨highunclear￨highunclear
not found￨ninetysix female assault victims with chronic posttraumatic stress disorder ptsd posttraumatic stress disorder in female assault victims￨exposure therapy stress inoculation training and their combination 4 treatment conditions prolonged exposure pe stress inoculation training sit combined treatment pesit or waitlist control wl￨ptsd severity depression and anxiety sit and pesit severity of ptsd and depression￨all 3 active treatments reduced severity of ptsd and depression compared with wl but did not differ significantly from each other and these gains were maintained throughout the followup period￨no diff￨highunclear￨highunclear￨highunclear
125￨patients with metastatic breast cancer 125 women with metastatic breast cancer 102 participants during this 12month period and these participants compose the study population￨supportiveexpressive group therapy and distress supportiveexpressive group therapy and educational materials supportiveexpressive group psychotherapy supportiveexpressive therapy￨profile of mood states total mood disturbance total mood disturbance traumatic stress symptoms￨primary analyses based on all available data indicated that participants in the treatment condition showed a significantly greater decline in traumatic stress symptoms on the impact of event scale effect size 025 compared with the control condition but there was no difference in profile of mood states total mood disturbance￨sig decrease￨highunclear￨highunclear￨highunclear
112￨posttraumatic stress disorders 112 persons suffering from serious disorders resulting from traumatic events bereavement acts of violence and traffic accidents that had taken place not more than 5 years before￨brief psychotherapy hypnotherapy and psychodynamic therapy psychotherapeutic methods￨traumarelated symptoms￨the results indicated that treated cases were significantly lower in traumarelated symptoms than the control group￨sig decrease￨highunclear￨highunclear￨highunclear
87￨87 patients with posttraumatic stress disorder of at least 6 months duration seventyseven patients completed treatment￨prolonged exposure imaginal and live alone cognitive restructuring alone combined prolonged exposure and cognitive restructuring or relaxation without prolonged exposure or cognitive restructuring exposure andor cognitive restructuring￨posttraumatic stress disorder￨the pattern of results was similar regardless of rater statistical method measure occasion and therapist￨no diff￨highunclear￨highunclear￨highunclear
not found￨thirty five combat veterans diagnosed with combatrelated ptsd combatrelated posttraumatic stress disorder posttraumatic stress disorder ptsd￨biofeedbackassisted relaxation n  13 or c routine clinical care serving as a control eye movement desensitization and reprocessing edmr psychotherapeutic interventions￨apparent habituation effect emdr condition number of selfreport psychometric and standardized interview measures￨psychophysiological measures reflected an apparent habituation effect from pretreatment to posttreatment but were not differentially affected by treatment condition￨no diff￨highunclear￨highunclear￨highunclear
24￨twentyfour participants who had a diagnosis of post traumatic stress disorder ptsd￨stress inoculation training with prolonged exposure sitpe￨selfreport and observerrated measures of ptsd and selfreport measures of depression degree of intrusion symptoms emdr￨on global ptsd measures there were no significant differences between the treatments at the end of therapy￨no diff￨highunclear￨highunclear￨highunclear
290￨290 patients with recurrent urinary tract infection￨placebo nitrofurantoin placebo methenamine hippurate nitrofurantoin or trimethoprim placebo methenamine hippurate nitrofurantoin and trimethoprim alone trimethoprim￨chronic pyelonephritis recurrent urinary tract infections￨during the followup period of 1 year 632 recurred in the placebo group 342 in the methenamine hippurate group 250 in the nitrofurantoin group and 104 in the trimethoprim group￨no diff￨highunclear￨highunclear￨highunclear
145￨gynecologic surgery patients with positive cultures 145 patients undergoing routine gynecologic laparotomy or vaginal plastic surgery using a foley catheter for 24 h antibiotics were not used￨hiprex or placebo methenamine placebo methenamine hippurate￨urinary tract infection incidence of postoperative bacteriuria and urinary tract infection postoperative asymptomatic bacteriuria asymptomatic bacteriuria postoperative bacteriuria and urinary tract infection￨urinary tract infection was diagnosed in 10 cases 139 in the placebo group and two cases 27 in the methenamine group p  003￨no diff￨low￨low￨low
161￨spinal cord injury patients spinal cord injury patients who had had at least 1 bout of bacteriuria 161 male hospital patients to determine if prophylactic administration of￨ascorbic acid or antibacterials trimethoprimsulfamethoxazole nalidixic acid methenamine hippurate or nitrofurantoin macrocrystals prophylactic antibacterial therapy ascorbic acid￨bacteriuria infections bacteriuria urinary tract infections￨none of the drugs tested appeared to be statistically effective in the doses used in preventing bacteriuria in these patients￨no diff￨highunclear￨highunclear￨highunclear
543￨people with neuropathic bladder following spinal cord injury sci patients with neuropathic bladder following sci 543 eligible predominantly community dwelling patients were invited to participate in the study of whom 305 56 agreed eligible participants were people with sci with neurogenic bladder and stable bladder management￨methenamine hippurate mh or cranberry tablets placebo￨urinary tract infections uti time to occurrence of a symptomatic uti￨multivariate analysis revealed that patients randomized to mh did not have a significantly longer utifree period compared to placebo hr 096 95 ci 068135 p075￨no diff￨low￨low￨low
not found￨patients with ureteric catheters patients with clinical signs of urinary tract infection evidence of infectious stones or a positive urine culture were excluded all patients had a bladder catheter during eswl patients admitted for eswl treatment in order to establish the requirement for prophylactic treatment with antibiotics during this procedure￨trimethoprim  sulphamethoxazole or mecillinam group a methenamine hippurate￨infectious rate occurrence of bacteriuria infectious complications￨with respect to infectious complications there were no differences between groups a and c between groups b and c or between group a and bc whereas an unexplained slightly higher infectious rate was recorded for group b compared with group a￨no diff￨highunclear￨highunclear￨highunclear
not found￨asymptomatic bacteriuria of pregnancy patients attending an antenatal clinic￨￨number of patients developing clinical pyelonephritis fetal maturity at delivery and birth weight￨the number of patients developing clinical pyelonephritis fetal maturity at delivery and birth weight were recorded for treatment and control groups and compared with the equivalent results obtained from the total population of patients seen at the clinic￨no diff￨highunclear￨highunclear￨highunclear
109￨after vaginal surgery one hundred and nine consecutive patients undergoing surgery for uterovaginal prolapse followed by￨prophylactic treatment with methenamine hippurate mh or no mh prophylaxis methenamine hippurate indwelling urinary catheter￨urinary tract infection bacteriuria￨significantly less bacteriuria occurred in the mhtreated patient group￨sig decrease￨highunclear￨highunclear￨highunclear
391￨391 women of whom 300 completed 6 cycles￨lowdose oral contraceptives￨intermenstrual bleeding imb rate of occurrence report leg cramps imb report amenorrhea￨spotting was perceived as a side effect more often with ortho 1011 and ortho 777 use than with triphasil p less than 001￨sig increase￨highunclear￨highunclear￨highunclear
458￨four hundred and fiftyeight women were followed for 3586 cycles￨biphasic and one triphasic norgestrelethinyl estradiol ee regimens ethinyl estradiol preparation biphasic and one triphasic norgestrelethinyl estradiol regimens￨intermenstrual bleeding total hormonal ingestion￨cycle control was good with all three regimens but the incidence of intermenstrual bleeding was higher with the triphasic￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨106 alcoholdependent patients 20 to 60 years of age without severe liver disease hospitalized for a 21day rehabilitation program alcoholdependent patients during a program of alcohol rehabilitation heavy smokers￨placebo combination of micronutrients betacarotene 6 mg vitamin c antioxidant nutrients selenium vitamin e 30 mg zinc vitamin c supplementation￨hospital stay serum indicators lycopene changes serum concentrations of vitamin c serum retinol alphatocopherol vitamin c carotenoids xinc and selenium biochemical indicators of vitamin carotenoid and trace element levels outcome vitamin c retinol alphatocopherol zeaxanthinlutein betacryptoxanthin lycopene alpha and betacarotene zinc and selenium micronutrient status indicators retinol and alphatocopherol concentrations decreased zinc and selenium levels￨at the end of the hospital stay serum indicators were significantly improved in the supplement group as compared to the placebo group for vitamin c alphatocopherol betacarotene zinc and selenium conversely lycopene changes were higher in the placebo group than in supplement group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients with mild to moderate alcoholic hepatitis patients with mild to moderate alcoholic hepatitis in a double blind alcoholic hepatitis￨vitamin e vitamin e placebo￨serum aminotransferases and serum bilirubin serum creatinine monocyte nuclear nuclear factorkappa b binding activity serum hyaluronic acid prothrombin time￨as regards markers of hepatic fibrogenesis vitamin e treatment decreased serum hyaluronic acid p005 while serum aminoterminal peptide of type iii procollagen did not change in either group￨sig increase￨low￨highunclear￨low
32￨chronic hepatitis c patients 32 patients with chronic hepatitis c￨ribavirin combination therapy alphatocopherol and ascorbic acid vitamins ribavirin corrected interferon with ribavirin alphatocopherol corrected and ascorbic acid vitamins or not controls alphatocopherol and ascorbic acid eicosapentaenoic acid fatty acid compositions vitamins and ribavirin￨epa in erythrocytes hemoglobin levels epa level eicosapentaenoic acid epa concentrations in erythrocytes or plasma ribavirin concentration hemoglobin level￨supplementation of alphatocopherol and ascorbic acid attenuates the ribavirininduced decrease of epa in erythrocyte membrane phospholipids in chronic hepatitis c patients￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨alcoholics admitted for detoxification alcoholic patients admitted for detoxification￨oral supplementation with an antioxidant cocktail vitamin e beta carotene vitamin c and selenium placebo antioxidant supplementation 0006abstract￨molar proportion of linoleic acid 57a mean rise rate of fall between serum aspartate transaminase ast concentration low serum concentrations of vitamin e rate of resolution of a serum marker of free radical activity and abnormal serum biochemistry￨alcoholics had low serum concentrations of vitamin e compared with controls 156 mgl￨sig decrease￨highunclear￨highunclear￨highunclear
61￨patients with primary biliary cirrhosis given oral antioxidant supplementation fatigue associated with primary biliary cirrhosis sixtyone patients with primary biliary cirrhosisassociated fatigue￨placebo and antioxidant supplementation vitamins a c and e selenium methionine and ubiquinone placebo oral antioxidant supplementation oral antioxidant supplementation￨fatigue fisk scores fatigue scores adverse effects￨small improvements in fisk scores were recorded during placebo therapy median improvement 4 p  003￨no diff￨low￨low￨low
not found￨chronic hepatitis b 32 patients￨vitamin e supplementation vitamin e supplementation vitamin e lamivudine vitamin e interferonalpha treatment￨alanine aminotransferase alt normalization hbvdna negativization complete response normal alt and negative hbvdna recurrence of viremia￨a complete response normal alt and negative hbvdna was obtained in 7 47 patients taking vitamin e and in none of the controls p00019￨no diff￨highunclear￨highunclear￨highunclear
120￨120 patients with chronic hepatitis c not responsive to alpha twelve hospitals in lombardy italy 120 consecutive patients affected by biopsyproven chronic hepatitis c who had been nonresponders to a previous course of alphainterferon administered at the dosage of 36 million units mu three times a week tiw for 6 months￨alphainterferon alone antioxidant drugs combined with alphainterferon nacetyl cysteine and vitamin e natural interferonalphan3 6 or 9 mu tiw interferon oral supplementation with nacetyl cysteine and vitamin e alphainterferon natural interferonalphan3 in association with oral administration of nacetyl cysteine 1200 mgday and vitamin e 600 mgday￨sustained biochemical response rates response rate￨neither endtherapy biochemical response nor sustained biochemical response rates were improved by the combination treatment and in no case was clearance of the virus from serum observed￨no diff￨highunclear￨highunclear￨highunclear
83￨eightythree patients with liver cirrhosis and with positive history of hcv infection patients with liver cirrhosis and positive for hcv patients with chronic hepatitis c virus hcv infection often develop liver cirrhosis and hepatocellular carcinoma hcc patients with liver cirrhosis patients with liver cirrhosis and a history of hcv infection￨vit e alphatocopherol vit e alphatocopherol￨cumulative tumorfree survival and cumulative survival rate cumulative survival serum levels of alphatocopherol albumin alanine aminotransferase alt and total cholesterol and platelet count platelet count serum albumin alt and total cholesterol liver function suppress hepatocarcinogenesis serum level of alphatocopherol mean serum concentration of alphatocopherol￨patients treated with alphatocopherol tended to live longer without development of hcc but the difference was not statistically significant￨no diff￨highunclear￨highunclear￨highunclear
51￨fiftyone naive chronic hepatitis c patients￨vitamin e supplementation ribavirin therapy antioxidants vitamin e supplementation vitamin e alphainterferonribavirin therapy control or therapy plus vitamin e 800 iu bd standard alphainterferon and ribavirin ribavirin ribavirin￨haemoglobin and reticulocyte percentage symptoms and healthrelated quality of life sustained viral response healthrelated quality of life haemolytic anaemia alanine aminotransferase alt haemoglobin and reticulocyte percentage haemoglobin and alt reduction￨sustained viral response was not significantly different between vitamin e 1118 and control 616 groups￨no diff￨highunclear￨highunclear￨highunclear
130471￨against hepatitis b virus and primary liver cancer in qidong hepatitis b virus hbv infection and primary liver cancer plc general population of 130471 226 hepatitis b surface antigen hbsagpositive persons￨selenium selenized yeast tablet or an identical placebo￨hbv infection plc incidence selenium se level and regional cancer incidence￨fouryear animal studies showed that dietary supplement of se reduced the hbv infection by 772 and liver precancerous lesion by 758 of ducks caused by exposure to natural environmental etiologic factors￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients suffering from viral hepatitis c patients refractory to alphainterferon therapy suffering from hepatitis c with patients suffering from viral hepatitis we treated 23 hepatitis c patients refractory to alphainterferon therapy with high doses of￨vitamin e vitamin e placebo￨plasma levels of the alphatocopherol liver damage rapid relapse of alt and ast elevation vitamin e levels alanine aminotransferase alt and aspartate aminotransferase ast parallel vitamin e plasma levels and plasma lipids alt levels aminotransferase status￨alt levels in responders were lowered by 46 and ast levels were lowered by 35 after 12 weeks of vitamin e treatment￨sig decrease￨highunclear￨highunclear￨highunclear
62￨62 patients with chronic hepatitis c who had been admitted to our hospital patients with chronic hepatitis c￨ascorbic acid or a group not receiving ascorbic acid control group interferon therapy ascorbic acid ascorbic acid￨retinopathy cumulative incidence of cottonwool spots lowest platelet counts cumulative incidence of hemorrhage median platelet counts￨ascorbic acid was not considered to be useful for the prevention of the retinopathy associated with ifn therapy in patients with chronic hepatitis c￨no diff￨highunclear￨highunclear￨highunclear
67￨alcoholic cirrhotics patients with more severe liver disease 67 subjects decompensated ambulatory alcoholic cirrhotics￨vitamin e supplementation longterm vitamin e supplementation placebo tablets vitamin e longterm oral 500 mg vitamin e daily supplementation￨serum vitamin e levels vitamin e levels alcohol ingestion and hospitalization rates hepatic laboratory parameters mortality or hospitalization rates alphatocopherol levels mortality￨oral supplementation significantly increased serum vitamin e levels in the experimental group￨sig increase￨highunclear￨highunclear￨highunclear
23￨twentythree patients were included patients with hepatitis c virus infection chronic hepatitis c virusinfected patients￨ascorbic acid 500 mg dalphatocopherol 945 iu and selenium 200 microg or placebo tablets placebo antioxidant supplementation vitamin c e and selenium￨serum alanine aminotransferase and log10transformed plasma hepatitis c virusrna serum alanine aminotransferase plasma hepatitis c viral load as well as oxidative and antioxidant markers erythrocyte activities of antioxidative enzymes glutathione reductase superoxide dismutase and catalase or plasma levels of oxidative markers malondialdehyde and 2aminoadipic semialdehyde hepatitis c viral load transaminases and oxidative status plasma ascorbic acid and alphatocopherol activity of erythrocyte glutathione peroxidase alanine aminotransferase viral load or oxidative markers￨no differences were observed in serum alanine aminotransferase and log10transformed plasma hepatitis c virusrna between the groups or changes from the baseline at any time￨no diff￨low￨low￨low
19￨19 hospitalized patients with severe alcoholic cirrhosis 16 patients who received either￨daily 100 micrograms selenium selenium supplementation placebo￨mean 14c aminopyrine breath test an indicator of liver function impaired selenium status lipid peroxidation and liver function 14c aminopyrine breath test plasma selenium plasma selenium thiobarbituric acid reactants which reflects lipid peroxidation￨14c aminopyrine breath test improved in three out of four seleniumsupplemented patients and in three out of six placebo patients but the small number of patients did not allow statistical evaluation￨sig increase￨highunclear￨highunclear￨highunclear
37￨patients with cirrhosis and portal hypertension cirrhosis thirtyseven portal hypertensive patients with cirrhosis patients with cirrhosis patients with cirrhosis show intrahepatic endothelial dysfunction characterized by an impaired flowdependent vasorelaxation￨ascorbic acid placebo acute ascorbic acid ascorbic acid￨hepatic and systemic hemodynamics ascorbic acid and malondialdehyde mda hepatic venous pressure gradient mda levels intrahepatic endothelial dysfunction postprandial increase in portal pressure hepatic or systemic hemodynamics endothelial dysfunction ascorbic acid levels levels of ascorbic acid and increased levels of mda￨ascorbic acid reverts endothelial dysfunction in other vascular disorders via the increase of no bioavailability through the neutralization of superoxide anions thus preventing the scavenging of no by superoxide￨sig increase￨highunclear￨highunclear￨highunclear
not found￨chronic hepatitis c 24 interferonalpha ifnnaive patients with chronic hepatitis c￨interferonantioxidant combination therapy ifn monotherapy vitamin e supplementation vitamin e antioxidative cotherapy teac and elevated tbars ifn and nacetylcysteine nacetylcysteine nac 1800 mgday plus sodium selenite vitamin e￨oxidative stress viral load liver histology reappearance of detectable hepatitis c virus hcv rna andor reelevation of altactivity changes in histology normalization of alt reduction of viral rna serum levels of glutathione selenium vitamin e erythrocyte glutathione peroxidase trolox equivalent antioxidative capacity teac thiobarbituric acid reactive substances tbars￨vitamin e treated patients had a 24 greater chance 95 ci 10555 of obtaining a complete response and had significantly greater reduction in viral load p  0028 than patients without vitamin e relapses ie reappearance of detectable hepatitis c virus hcv rna andor reelevation of altactivity occurred in 7 out of the 11 responders within 6 months after termination of therapy group a 23 group b 12 and group c 46￨sig increase￨highunclear￨highunclear￨highunclear
not found￨thirtysix 20 male 16 female mean discriminant function df patients with acute alcoholic hepatitis severe alcoholic hepatitis patients with a severe alcoholic hepatitis acute alcoholic hepatitis￨nacetylcysteine for one week and vitamins ae biotin selenium zinc manganese copper magnesium folic acid and coenzyme q daily for 6 months antioxidant therapy alone or with corticosteroids placebo antioxidant therapy alone or in combination with corticosteroids￨oxidative stress white cell count 6month survival 180day survival survival mortality within 6 months￨180day survival was not significantly different between patients receiving drug and placebo 528 vs 558 p0699￨no diff￨low￨low￨low
not found￨sexual dysfunction in male alcoholics male alcoholics 15 subjects given six subjects 1 placebo 5 vitamin a who developed liver abnormalities during treatment underwent liver biopsies five had fibrosis or cirrhosis thirty abstinent male alcoholics with sexual dysfunction￨placebo vitamin re 10000 iu vitamin a or placebo￨partial or full recovery of sexual functioning sexual functioning luteinizing hormone￨a significant decrease in luteinizing hormone was noted in the group given vitamin a compared with the placebotreated group￨sig increase￨highunclear￨highunclear￨highunclear
100￨chronic hcv infection patients who are nonresponders to interferon patients with chronic hepatitis c virus hcv infection one hundred chronic hcv infection patients failed in interferon treatment chronic hepatitis c after failure of interferon￨antioxidants placebo antioxidant therapy combined intravenous and oral antioxidants or placebo or oral treatment alone antioxidant therapy combined oral and intravenous antioxidant therapy combined antiviral and antioxidant therapy￨liver enzymes hcvrna levels and histology hcvrna levels histology activity index hai score alt levels safety and efficacy￨in part ii of the trial oral administration of antioxidants was not associated with significant alterations in any of the end points￨no diff￨low￨low￨low
100￨couples undergoing iui by a single healthcare provider with random assignment to either 100 patients 95 underwent ovarian stimulation before iui 35 with one hundred infertile women enrolled from a single infertility practice who met the inclusion and exclusion criteria for iui were enrolled￨rigid tomcat kendall sovereign mansfield ma or flexible timed iui was performed with either rigid tomcat or flexible cook insemination catheters clomiphene citrate combined with a single dose of gonadotropins flexible versus rigid intrauterine insemination catheters clomiphene citrate alone￨pregnancy rate per cycle length of infertility day3 fsh level number of prior iui cycles total motile sperm count days of abstinence infertility diagnoses insemination ratings and stimulation protocols pregnancy rates￨no differences were noted between groups for the following age length of infertility day3 fsh level number of prior iui cycles total motile sperm count days of abstinence infertility diagnoses insemination ratings and stimulation protocols￨no diff￨highunclear￨highunclear￨highunclear
784￨two hundred fiftyone infertile couples undergoing 784 consecutive iui treatments￨gynetics catheter gynetics medical products hamontachel belgium or the makler cannula sefimedical instruments haifa israel makler cannula gynetics catheter￨cumulative pregnancy rates similar pregnancy frequency of bleeding sample regurgitation ease of introduction of the catheter the presence of bleeding and semen regurgitation after removal of the catheter pregnancy rates pregnancy and cumulative pregnancy rates￨however there was no significant difference in pregnancy rates with use of either the gynetics catheter or the makler cannula￨no diff￨highunclear￨highunclear￨highunclear
75￨patients were classified into following two groups patients who had ulc in 24 h were in group i n  28 and patients who had elc mean interval 422 between 2001 and 2003 75 patients with biliary colic 75 cases patients with biliary colic 9 patients made a total of 13 return visits to the emergency department with recurrent attacks of biliary colic or complications of gallstone disease￨elective laparoscopic cholecystectomy elc urgent laparoscopic cholecystectomy ulc laparoscopic cholecystectomy urgent laparoscopic cholecystectomy ulc￨conversion to open cholecystectomy operative time postoperative hospital stay costs and complications mean operative time conversion to open cholecystectomy hospital stay time￨conversion to open cholecystectomy increased from 0 in group i to 172 in group ii p  005￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨c 2009 british journal of surgery society ltd adults admitted to hospital with a first episode of biliary colic or acute cholecystitis acute gallbladder disease newly diagnosed acute gallbladder disease￨delayed laparoscopic cholecystectomy early laparoscopic cholecystectomy￨visual analogue scale scores of health total costs of care qualityadjusted life year qaly gains￨visual analogue scale scores of health were 7294 versus 8463 p  0012 and the meansd￨sig increase￨highunclear￨highunclear￨highunclear
54￨admitting acute ischemic stroke patients acute stroke patients fiftyfour patients meeting the inclusion criteria were randomized￨scmu stroke care monitoring unit versus a conventional stroke unit￨mortality need for institutional care and 2 mortality modified rankin scale mrs and barthel index bi￨poor outcome was seen in 7 259 patients in the scmu group and in 13 481 in the su group p016￨no diff￨highunclear￨highunclear￨highunclear
2￨very early rehabilitation or intensive telemetry after stroke stroke patients 32 patients mean age  65 years mean baseline modified nih score  6 stroke patients within 36 h of symptom onset￨4 nurseled treatment protocols a standard stroke unit care b em c am or d combined em and am active mobilisation em and automated monitoring am￨feasibility and safety rankin score￨on unadjusted comparisons the em patients were significantly p  005 more likely to mobilise very early within 1 h of randomisation and to achieve walking by day 5 and were less likely to develop complications of immobility￨sig increase￨low￨low￨low
268￨two hundred sixtyeight patients were enrolled acute stroke patients stroke patients 268 firstever ischemic stroke patients admitted to our cerebrovascular department and allocated according to the availability of beds to the su or cerebrovascular unit cu acute ischemic stroke patients￨￨mean duration of these complications mortality and outcome at discharge medical and neurological complications and length of hospitalization￨cu 24 days p002 and the outcome in patients experiencing complications covered by the monitoring protocol was significantly better in the su 66 than in the cu 35 group p00001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨fallfractures in the elderly evaluated by means of a hospital based injury recording system in norway the norwegian municipalities of harstad intervention and trondheim reference from 1 july 1985 to 30 june 1993 22970 person years in harstad and 158911 in trondheim￨￨hospital admission rates fallfracture rates rates of fracture from falls￨rates of fracture from falls did not decline in nursing homes but decreased 263 in private homes p  001￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨against injuries among the elderly in a who safe community against injuries among the elderly￨interorganizational prevention program participatory communitybased prevention program￨total morbidity rate risk of severe or fatal morbidity falls total morbidity rates￨falls decreased or showed a tendency to decrease in the age groups 65 to 79yold in the study area while they increased in the older age group￨no diff￨highunclear￨highunclear￨highunclear
1200￨eightyeight subjects 83 from the tai chi villages and 5 from the control villages participated and practiced in the tai chi program the group labeled tai chi practitioners older people people aged 65 years and older in taiwan 6 rural villages in taichung county 1200 subjects participated in the initial assessment n472 participants or tai chi villagers and 4 villages served as control villages n728 participants or control villagers￨educational intervention tai chi exercise communitybased tai chi program￨fear of falling tinetti balance scale injurious falls functional balance and gait balance gait and fear of falling tinetti gait scale injurious falls balance gait and fear of falling injurious falls￨no significant changes in the fear of falling were detected among the tai chi practitioners tai chi villagers and control villagers￨no diff￨highunclear￨highunclear￨highunclear
60￨patients presenting with a first episode of primary spontaneous pneumothorax 60 patients with a first episode of primary spontaneous pneumothorax primary spontaneous pneumothorax￨manual aspiration chest tube drainage manual aspiration versus chest tube drainage￨immediate success recurrence rates success rates￨oneweek success rates were 25 out of 27 93 in the intentiontotreat manual aspiration group and 28 out of 33 85 in the chest tube drainage group p  04￨no diff￨highunclear￨highunclear￨highunclear
470￨patients with an unfavorable cervix 470 patients with unfavorable bishop scores 34 patients with an unfavorable bishop score of 34￨prostaglandin vaginal gel 2 mg or intracervical gel prostaglandin e2 intravaginal gel prostaglandin e2 gel￨cumulative rate of deliveries￨in patients with unfavorable bishop scores the intravaginal application route resulted in a better cervical ripening a shorter induction to delivery interval and a higher cumulative rate of deliveries during 24 h p001￨sig increase￨highunclear￨highunclear￨highunclear
59￨fiftynine pregnant women￨prostaglandin e2 prepidil gel prostaglandin e2 gel oxytocin￨route of delivery or fetal outcome cervical bishop scores shorter inductiontodelivery intervals lower maximum doses of oxytocin and fewer days of induction systemic side effects￨compared to control subjects patients in the group given prepidil had significant increases in cervical bishop scores shorter inductiontodelivery intervals lower maximum doses of oxytocin and fewer days of induction￨sig increase￨highunclear￨highunclear￨highunclear
30￨patients at risk for placental insufficiency patients with unfavorable bishop scores￨intracervical prostaglandin e2 gel placebo prostaglandin e2 intracervical gel￨uterine hyperactivity severe fetal heart rate decelerations mean change in bishop score success of softening time to labor and time to delivery uterine contractions lasting￨twentythree of 30 treated patients had uterine contractions lasting greater than four hours and eight patients delivered during the observation period￨no diff￨highunclear￨highunclear￨highunclear
111￨women with an unfavorable cervix onehundred eleven women with an unfavorable cervix who underwent labor induction￨prostaglandin analogs dinoprostone and misoprostol dinoprostone misoprostol prostaglandin analogs misoprostol cytotec dinoprostone gel prepidil and dinoprostone insert cervidil misoprostol dinoprostone misoprostol dinoprostone prostaglandin preparations dinoprostone gel￨proportion of women who reached complete dilation overall mean cost per patient that was incurred by labor induction efficacy and cost mean bishop score change sd mode of delivery or to the adverse maternalneonatal outcome￨misoprostol is more costeffective than the comparable commercial dinoprostone prostaglandin preparations as an adjuvant to labor induction in women with an unfavorable cervix￨no diff￨highunclear￨highunclear￨highunclear
not found￨41 patients received the￨pge2gel gel containing pge2 and 10 gel without prostaglandin pge2 placebo gel prostaglandin e2 prostaglandin e2 pge2￨cervical state cervical state bishop score￨cervical state did not change significantly bishop score 36 and 40 after 24 hours in patients receiving placebo gel￨no diff￨highunclear￨highunclear￨highunclear
68￨three participants who delivered by cesarean section soon after gel administration were excluded from further analysis sixtyeight women scheduled for elective induction of labor at term￨labor utilizing vaginal vs intracervical prostaglandin e2 intracervical vs vaginal prostaglandin e2 pge2 gel 05 mg intracervical pge2 vaginal pge2 gel￨uterine hyperstimulation and perinatal outcome inductionactive labor intervals￨uterine hyperstimulation and perinatal outcome were similar in both groups￨no diff￨highunclear￨highunclear￨highunclear
208￨208 patients at term 104 pge2 and 104 placebo with an unripe cervix bishop score less than 5 and with a medical indication for induction of labour￨placebo pge2 prostaglandin e2 gel intracervical pge2 gel application oxytocin prostaglandin e2￨myometrial hypercontractility cervical ripening success rate length of labour￨since signs of myometrial hypercontractility were observed in the pge2 treated group as compared to the control group p  001 the authors advocate careful cardiotocographic monitoring for at least three hours after the gel application￨sig increase￨highunclear￨highunclear￨highunclear
100￨100 pregnant women 53 women who received the￨placebo gel intravaginal prostaglandin e2 gel prostaglandin e2 intracervical prostaglandin e2 gel prostaglandin e2 gel￨mean change in cervical score mean applicationtodelivery interval incidence of uncomplicated spontaneous labor incidence of cesarean delivery incidence of cesarean delivery overall cesarean delivery rate overall cesarean section rate￨the 53 women who received the placebo gel had an outcome similar to that of the 47 women who received the prostaglandin e2 gel￨sig increase￨highunclear￨highunclear￨highunclear
not found￨preinduction cervical softening normal nulliparous women at term with low bishop scores￨endocervical prostaglandin e2 gel prostaglandin e2 pge2 gel 05 mg of pge2 placebo pge2 vaginal tablet and placebo￨safety and efficacy success rate overall success￨overall success defined as a progression in bishop score of at least 3 points within 12 hours was achieved in 2240 55 of the gel group 1541 37 in the tablet treated women and 840 20 in those receiving placebo￨no diff￨highunclear￨highunclear￨highunclear
70￨pregnant women with an unripe uterine cervix￨preinduction intracervical application of a highly viscous prostaglandin e2 gel placebo prostaglandin e2 pge2 gel￨serious adverse reactions successful cervical ripening spontaneous delivery￨no serious adverse reactions were observed￨no diff￨low￨low￨low
226￨226 healthy pregnant women at term all women had a modified cervical score of less than or equal to 4￨intracervical gel conventional waxbased pge2 vagitories pessaries vagitories containing 25 mg pge2 prostaglandin e2 pge2 prostaglandin e2 given by intracervical gel or vagitory￨frequency of fetal distress outcome of labor assisted delivery rates or maternal side effects success rate cervical scores parity gestational length maternal characteristics indications for induction or preinduction cervical scores rate of spontaneous birth￨there was no significant difference in parity gestational length maternal characteristics indications for induction or preinduction cervical scores between the treatment groups￨no diff￨highunclear￨highunclear￨highunclear
83￨83 patients evaluated 44 were given vaginal gel and 39 were given eightythree patients undergoing labor induction￨intracervical gel prostaglandin e2 prostaglandin e2 gel oxytocin intravaginal and intracervical prostaglandin e2 gel￨effectiveness and safety incidence of spontaneous versus induced labor need for oxytocin augmentation geltoinduction interval bishop score change maximum oxytocin dose maximum dilatation rate length of labor cesarean section rate fetal apgar scores fetal umbilical vein ph or fetal umbilical artery efficacy and safety￨no statistically significant differences were observed between the two treatment groups with respect to the incidence of spontaneous versus induced labor need for oxytocin augmentation geltoinduction interval bishop score change maximum oxytocin dose maximum dilatation rate length of labor cesarean section rate fetal apgar scores fetal umbilical vein ph or fetal umbilical artery￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients undergoing induction for a variety of maternal and fetal indications￨prostaglandin e2 gel preinduction intracervical prostaglandin e2 prepidil gel prostaglandin gel oxytocin￨reduced oxytocin infusion duration cesarean delivery rate cervical inducibility reduced induction to delivery intervals fetal distress uterine hyperstimulation untoward reaction efficacy and safety￨p less than 00001 resulting in a lower cesarean delivery rate 26 vs 47 per cent p greater than 005￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨30 postterm pregnant women with low cervical scores￨pericervical pge2 instillation pericervical application of either 3 ml of 09 saline or 3 ml of 09 saline containing 15 mg pge2 pge2 placebo￨pgfm serum levels serum pgfm and progesterone levels levels of maternal serum 1314dihydro15ketopgf2 alpha and progesterone￨twelve patients in the pge2 group and two in the placebo group were delivered within 24 h p less than 0001￨sig increase￨highunclear￨highunclear￨highunclear
110￨one hundred and ten women with highrisk pregnancy and unripe cervix highrisk pregnancies￨intravaginal prostaglandin e2 gel prostaglandin e2 gel prostaglandin e2￨efficacy safety efficacy failure rate labor uterine hypertonus associated with fetal bradycardia labor characteristics such as ripening time and cesarean section rate cervical ripening and labor induction￨the 2 mg intravaginal gel and the 05 mg intracervical gel were equally effective and more effective than the 1 mg intravaginal gel in labor characteristics such as ripening time and cesarean section rate but not in labor time￨no diff￨highunclear￨highunclear￨highunclear
42￨￨pge2 prostaglandin e2 preinduction ripening oxytocin preinduction cervical ripening with 025 mg prostaglandin e2 pge2￨myometrial hyperstimulation induction of labor with oxytocin acute fetal distress failures of induction of labor￨there were four failures of induction of labor in group 2 and none in group 1 p  005￨no diff￨highunclear￨highunclear￨highunclear
61￨fifteen women in the thirty women 61 pregnant women at 38 weeks or greater gestation with bishop scores less than 9￨placebo pge2 prostaglandin e2 cervical ripening intracervical placement of 05 mg pge2 gel with placebo intracervical pge2 gel intracervical prostaglandin pg e2 gel￨median interval to delivery of 2 days transvaginal cervical length fetal fibronectin and bishop score intervals to delivery and shortened labor interval to delivery and duration of labor active phases of labor cervical length fetal fibronectin status or bishop scores median interval to delivery￨the median interval to delivery was significantly shorter in the pge2 group at 25 days compared with placebo at 7 days p  02￨sig decrease￨low￨low￨low
63￨sixtythree patients were randomized to intracervical n  33 or fortysix patients who required only a single dose of￨posterior fornix dinoprostone intracervical versus posterior fornix dinoprostone dinoprostone￨cesarean delivery rate antepartum fever hyperstimulation apgar scores birth weight or umbilical artery ph request for initial pain medications maternal age race parity maternal height or weight or indication for induction student t test fisher exact test wilcoxon test mannwhitney u test cesarean delivery rate infectious morbidity or other complications of labor reduced time to delivery with intracervical length of time to delivery reduced time to active labor ruptured membranes number of patients managed with artificial rupture of membranes￨there was also no difference in cesarean delivery rate antepartum fever hyperstimulation apgar scores birth weight or umbilical artery ph￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with low bishop score at term admission criteria single pregnancy with bishop score of 04 gestational age of 3741 weeks intact membranes no previous cesarean section no bleeding or abnormal cardiotocography at admission lowbishopscore pregnancy￨dinoprostone removable pge2 vaginal insert versus pge2 cervical gel￨umbilical artery ph cesareans for fetal distress shorter inductiontodelivery time incidence of cesarean sections cervical priming and labor induction incidence of abnormal cardiotocography during labor hyperkinetic labor vaginal prostaglandins￨dinoprostone vaginal insert is more efficient than cervical gel in promoting cervical priming and labor induction in lowbishopscore patients at term￨sig increase￨highunclear￨highunclear￨highunclear
60￨sixty term pregnant women with unripe cervix patients with an unfavorable cervical state patients with a more favorable cervical state cervical score 4 or 5￨prostaglandin e2 pge2 in 2 ml of gel intracervically or 4 mg of pge2 prostaglandin e2￨gastrointestinal side effects myometrial activity￨gastrointestinal side effects were registered after intravaginal but not after intracervical application￨no diff￨highunclear￨highunclear￨highunclear
69￨sixtynine women admitted for labor induction 69 women randomized 35 received the gel and 34 the polymer￨dinoprostone gel containing 05 mg of dinoprostone oxytocin￨rate of hyperstimulation average costs complications safety efficacy and cost fetal or maternal morbidity efficacy safety and cost￨both groups were similar with respect to change in bishop score starttodelivery interval amount of oxytocin required mode of delivery and success of induction￨no diff￨highunclear￨highunclear￨highunclear
52￨6 patients were excluded because of violation of protocol 106 term pregnant patients with unfavorable local condition bs less than or equal to 5 and indication to induction of labour because of mother or fetus problems￨amniotomy and oxytocin pge2 prostaglandin e2￨collateral effects￨our results show that intracervical pge2 gel seems to have a better effect on the ripening of the cervix than the intravaginal one if we only consider the proposition of softening success group a 1452 group b 648￨sig increase￨highunclear￨highunclear￨highunclear
514￨five hundred fourteen pregnant women at or near term with medically indicated inductions and unfavorable cervical induction features bishop score 04￨dinoprostone cervical gel dinoprostone gel￨fetal heart rate abnormalities median inductiontovaginal delivery time spontaneous labor oxytocininduced labor side effects￨during the observation period spontaneous labor occurred in a significantly greater percentage of patients in the treatment group 27 than in the control group 2￨sig increase￨highunclear￨highunclear￨highunclear
not found￨women with an unfavorable cervix all uncomplicated pregnancies at term gestation who were candidates for a vaginal delivery with a bishop score of  or  6 women with an unfavorable cervix at 37 weeks gestation￨placebo prostaglandin e2 and estradiol prostaglandin e2 gel prostaglandin gel or estrogen prostaglandin gel or estrogen cream initiated labor inert lubricant jelly estrogen cream￨￨in the three groups no differences were observed among 128 subjects in the weekly bishop scores cervical dilatation or gestational age upon admission to the labor and delivery suite the percentage of patients presenting with spontaneous labor or ruptured membranes the number of postdate inductions or neonatal outcome￨no diff￨highunclear￨highunclear￨highunclear
not found￨subjects in whom induction of labor cervical ripening inclusion criteria included 1 a bishop score of  or  7 2 a cervix  4 cm dilated and 3  or  2 cm of cervical dilatation if effacement was  70￨cervidil versus prepidil prepidil intracervical prostaglandin e2 gel or cervidil n  37 a controlledrelease hydrogel pessary as a cervical ripening agent oxytocin prostaglandin e2 agents prostaglandin e2 prepidil and cervidil prostaglandin e2￨hospital stay time to achieve cervical ripening bishop scores time to achieve active labor efficacy and safety￨the following mean times were shorter for the pessary group than for the gel group 1 insertion of the ripening agent to vaginal delivery 206 vs 264 hours p  0017 2 time to achieve cervical ripening 111 vs 152 hours p  0001 3 time to achieve active labor 183 vs 255 hours p  0019 and 4 hospital stay 37 vs 44 days p  003￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨women with bishop score 4 or less cervical ripening and labor induction￨pge2 vaginal and cervical prostaglandin gel vaginal pge2 gel intravaginal and intracervical prostaglandin e2 pge2 gel oxytocin intravaginal pge2￨vaginal delivery oxytocin for labor induction relation to cesarean delivery rate apgar scores at 5 minutes and arterial umbilical cord ph￨there were no significant differences in relation to cesarean delivery rate apgar scores at 5 minutes and arterial umbilical cord ph although the power of our study was limited to detect differences in proportions of adverse outcomes￨no diff￨highunclear￨highunclear￨highunclear
113￨patients with unfavorable inducibility prospects 113 women with an unripe cervix 57 women were given￨prostaglandin e2 vaginal suppositories intracervical prostaglandin gel prostaglandin e2 prostaglandin suppositories each containing 25 mg pge2 intracervical gel containing 1 mg pge2 in 5 g hydroxypropylmethyl cellulose￨sideeffects cesarean sections inductiondelivery interval instrumental vaginal deliveries and cesarean sections fetal distress￨there was no significant difference between the two groups in the use of instrumental vaginal deliveries and cesarean sections nor was there any difference with regard to fetal distress￨no diff￨highunclear￨highunclear￨highunclear
25￨patients with an unfavorable cervix￨intracervical versus intravaginal pge2 placebo pge2 pge2 suppositories￨myometrial activity mean cervical score hyperactivity gastrointestinal discomfort￨significantly better results for both cervical priming and labor induction were obtained after intracervical pge2gel application than after treatment with placebo or vaginal suppositories￨sig increase￨highunclear￨highunclear￨highunclear
88￨premature rupture of the membranes at term 88 women with term prelabor rupture of membranes￨dinoprostone intracervical pge2 intracervical dinoprostone￨rates of clinical amniotits mean duration of labour maternal or neonatal morbidity uterine tachysystole mode of delivery and apgar score￨intracervical administration of dinoprostone with prelabor rupture of membrane at term and unripened cervix shortens the interval to delivery without a significant increase of maternal or neonatal morbidity￨no diff￨highunclear￨highunclear￨highunclear
90￨enrolled women with postdate pregnancies with bishop score  or  6 who were undergoing antepartum fetal heart rate testing patients with postdate pregnancies with unfavorable cervices postdate pregnancies patients with postdate pregnancies￨prostaglandin e2 gel prostaglandin e2 intracervical gel prepidil or a placebo gel￨induction rate number of antepartum tests labor inductions or cesarean sections the maximum oxytocin dosage or the interval from admission to delivery￨there were no significant differences in the number of antepartum tests labor inductions or cesarean sections the maximum oxytocin dosage or the interval from admission to delivery in the prostaglandin e2 gel and placebo gel groups n  90￨no diff￨highunclear￨highunclear￨highunclear
208￨cases presenting with an unfavorable cervical state 208 pregnant women consecutively admitted for induction of delivery with bishop scores 05 were included￨pge2 minprostin gel minprostin tablets prostaglandin e2 prostaglandin e2 gel minprostin vaginal tablets oxytocin minprostin intracervical gel prostaglandin e2￨delivery rates analgesia labor induction mean number of applications shorter inductiondelivery interval rates of cesarean section side effects￨minprostin gel group i and minprostin tablets group ii were equally effective in ripening the cervix￨no diff￨highunclear￨highunclear￨highunclear
124￨124 patients were included in the study￨prostaglandin gel intracervically applied prostaglandin prostaglandin gel￨surgical deliveries age duration of pregnancy and percentage share of primiparae￨coarser side effects did not occur in our group and there is also no higher incidence of surgical deliveries￨no diff￨highunclear￨highunclear￨highunclear
440￨postterm pregnancy four hundred forty patients with uncomplicated pregnancies at 41 weeks gestation￨expectant management placebo placebo gel labor versus expectant management intracervical prostaglandin e2 gel prostaglandin e2 gel immediate induction of labor prostaglandin e2 gel or placebo gel nonstress testing and amniotic fluid volume assessment twice per week￨mean birth weight or the frequency of macrosomia cesarean delivery rate fetal deaths adverse perinatal outcome neonatal seizures intracranial hemorrhage the need for mechanical ventilation or nerve injury￨adverse perinatal outcome in otherwise uncomplicated pregnancies of  or  41 weeks is very low with either of the management schemes described￨no diff￨highunclear￨highunclear￨highunclear
118￨one hundred eighteen women with confirmed indication for induction of labor before 41 completed weeks patients who had medical or obstetric indications for delivery before 41 completed weeks patients with a medical or obstetric indication for delivery before 41 completed weeks of gestation by preinduction cervical ripening with patients with an indication for delivery￨prostaglandin pg e2 gel pge2 pge2 gel prostaglandin e2 gel intracervical pge2 gel or placebo￨cesarean rate maximum oxytocin dose required to establish progressive labor apgar score or umbilical artery ph change in bishop score interval to complete dilation maximal oxytocin dose required to establish labor and route of delivery apgar scores and umbilical artery ph￨the cesarean rate was also significantly lower in the pge2 group 131 versus 316 p  016￨sig decrease￨highunclear￨highunclear￨highunclear
90￨ninety patients admitted for labor induction with a bishop score 8 preinduction cervical ripening￨prostaglandin e2 slow release vaginal pessary cervidil oxytocin prostaglandin e2 delivery methods prostaglandin e2 intracervical gel prostaglandin e2 intracervical gel prepidil￨mean change in bishop score mean time to delivery￨no difference was demonstrated in mean time to delivery 283 versus 240 hours p  19 or percent requiring cesarean section￨no diff￨highunclear￨highunclear￨highunclear
45￨patients with low bishop scores￨prostaglandin e2 gel prostaglandin e2 gel pge2 placebo pge2￨efficacy and safety spontaneous labor rate￨bishop scores were altered in all patients not proceeding to labor spontaneously but the changes were most significant in the low and highdose groups￨no diff￨highunclear￨highunclear￨highunclear
23￨all patients with verified dates at least 41 67 weeks pregnant and enrolled in an antepartum testing schedule￨placebo pge2 intracervical pge intracervical prostaglandin prostaglandin e2 pge2 suspended in methylcellulose or a placebo of the gel alone prostaglandin￨incidence of patients going into labor obstetric outcome bishop score lag time from dosage to delivery spontaneous versus induced labor cesarean section rate length of labor and neonatal outcome￨there were no significant differences between the groups except in the incidence of patients going into labor within 72 hours￨no diff￨highunclear￨highunclear￨highunclear
125￨125 pregnant women with unfavorable cervices bishop scores less than or equal to 6￨viscous intracervical gel once daily or pge2 pessaries pge2 prostaglandin medication￨cervical ripening effective inducing regular contractions methods of delivery neonatal parameters apgar scores umbilical artery blood ph and standard base excess vaginal delivery effective inducing vaginal delivery￨as estimated by life table analysis the pessaries were significantly more effective inducing vaginal delivery compared to intracervical gel 24 h p less than 0025 48 h p less than 001 logrank test and vaginal delivery was obtained within 24 h48 h in 5072 of the women in the pessary group and in 2955 of the women in the intracervical group￨sig increase￨highunclear￨highunclear￨highunclear
285￨parous and nulliparous women with favorable and unfavorable cervical features women with various degrees of cervical ripeness 285 participants three exclusions was performed with sealed envelopes stratified for parity and bishop score￨endocervical and vaginal prostaglandin e2 gel￨cesarean section cervical ripeness frequencies of delivery instrumental vaginal delivery￨endocervical prostaglandin e2 had a more marked effect on cervical ripeness than did vaginal prostaglandin e2 but this did not result in any differences in more substantive outcomes￨sig increase￨highunclear￨highunclear￨highunclear
416￨￨oxytocin induction and compared with 404 nongel controls endocervical pge2 gel pge2 gel pge2￨successful initial induction inductiondelivery interval cesarean sections￨in addition the inductiondelivery interval was shortened median times 90 h vs 113 h and fewer cesarean sections were performed 16 vs 21 in the pge2 gel series￨no diff￨highunclear￨highunclear￨highunclear
100￨between august 1988 and april 1989 100 women underwent induction of labour for medical reasons women with bishops score between 4 and 6 4 groups were similar in mothers age gestational age and parity￨pge2 intracervical dinoprostone pge2 225 mg on a spongel introduced into the posterior vaginal fornix prostaglandin e2￨cervical ripening andor induction of labour￨the results obtained showed a significant increase in bishops score 12 hours after cervical ripening irrespective of the way pge2 was administered from 23￨sig increase￨highunclear￨highunclear￨highunclear
79￨79 pregnant women￨dinoprostone dinoprostone prostaglandin e2 gel dinoprostone gel or placebo gel dinoprostone gel oxytocin￨cesarean section rate inductiontodelivery interval or in cesarean section rate￨contrary to current opinion intracervical dinoprostone gel does not appreciably lower the cesarean section rate when used at this dose and route before labor is induced￨no diff￨highunclear￨highunclear￨highunclear
119￨women with fetuses at high risk of fetal hypoxia one hundred and nineteen women with singleton pregnancy and cephalic presentation requiring induction of labour in the presence of an unfavourable cervix bishop score  or  4 were studied five patients were excluded because of failure to comply with the protocol patients with an unfavourable cervix￨atad ripener device prostaglandin e2 vaginal pessary and prostaglandin e2 intracervical gel cervical ripening before induction of labour pge2 intracervical gel and 39 received at least one 3 mg pge2 intravaginal pessary￨vaginal delivery rate duration of labour emergency caesarean section￨the pge2 pessary appears to be more effective with 68 of patients either going into labour during cervical ripening or succeeding in the cervical ripening compared to around 50 in the atad and pge2 gel groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨100 evaluable cases received hospitalized patients with an unfavorable cervix bishop score  or  4 at  or  35 weeks and requiring induction of labor￨intracervical and intravaginal prostaglandin e2 intracervical therapy prostaglandin e2 prostaglandin e2 prostaglandin e2 gel intravaginal 25 mg gel placebocontrolled manner￨cervical ripening and induction of labor stimulate regular contractions safety and effectiveness bishop score uterine hyperstimulation￨compared with intracervical therapy prostaglandin e2 given intravaginally was more likely to significantly change the bishop score 604 vs 404 p  004 and stimulate regular contractions 729 vs 481 p  001￨sig increase￨highunclear￨highunclear￨highunclear
31￨17 men in the two groups african as in caucasian and chinese men with azoospermia achieved in a total of 8398 85 men african men four men in sagamu withdrew 31 healthy men 21 black were recruited in cape town and 21 men in sagamu nigeria￨oral desogestrel with depot testosterone sagamu desogestrel hormonal male contraception oral progestogen with depot testosterone testosterone later increased to 400 mg readministered 12weekly￨azoospermia lipoprotein or haemoglobin concentrations￨there were no significant changes in lipoprotein or haemoglobin concentrations in any group￨no diff￨highunclear￨highunclear￨highunclear
not found￨normal men twentyeight men￨400 mg testosterone pellets sc implant containing the progestogen etonogestrel implanon with depot testosterone depot testosterone progestogen with testosterone￨marked suppression of spermatogenesis complete suppression of gonadotropins spermatogenic suppression body weight hemoglobin hematocrit or highdensity lipoprotein cholesterol concentrations testosterone concentrations sperm concentrations azoospermia￨there were no significant changes in body weight hemoglobin hematocrit or highdensity lipoprotein cholesterol concentrations during treatment￨no diff￨highunclear￨highunclear￨highunclear
36￨36 normal men aged 2042 yr n  18 in each group normal men￨placebo levonorgestrel and testosterone testosterone t t enanthate in conjunction with the progestogen levonorgestrel lng t enanthate administration￨induction of azoospermia or severe oligospermia serum high density lipoprotein cholesterol severe oligospermia or azoospermia time to azoospermia sperm production hemoglobin azoospermia rates azoospermia average weight gain￨36 in men given t plus lng p  005 compared to only a 18￨sig increase￨highunclear￨highunclear￨highunclear
not found￨healthy eugonadal men twentysix healthy men￨oestradiol single subdermal implantation of either 600 mg testosterone alone t n  11 or together with 10 mg te10 n  7 or 20 mg te20 n  8 oestradiol oestradiol￨peak plasma oestradiol body composition lipids prostatespecific antigen haematological or biochemical variables proportions achieving azoospermia total and free testosterone￨there were no significant treatmentrelated changes in body composition lipids prostatespecific antigen haematological or biochemical variables￨no diff￨highunclear￨highunclear￨highunclear
51￨normal men 51 normal men￨placebo chronic testosterone sesame oil 1 ml or t enanthate testosterone t enanthate￨monthly lh and fsh levels by ria and twice monthly sperm counts luteinizing hormone folliclestimulating hormone and sperm production serum t levels mild truncal acne weight gain suppressing lh fsh and sperm production hematocrit lh fsh and sperm production t levels lh and fsh levels and sperm counts￨t enanthate 300 mgweek was no more effective than 100 mgweek in suppressing lh fsh and sperm production￨no diff￨highunclear￨highunclear￨highunclear
24￨twentyfour healthy young men aged 2049 young men 100 group enrolled in similar studies￨oral dsg plus im testosterone enanthate 150 microg of dsg plus 50 mg of testosterone dsg 150t 50 150 microg of dsg plus 100 mg of testosterone dsg 150t 100 or 300 microg of dsg plus 100 mg of testosterone m testosterone lng 125t oral desogestrel dsg plus testosterone dsg dsg plus testosterone oligoazoospermia im testosterone alone or 150 microg of oral lng plus 100 mg of i desogestrel plus testosterone￨weight gain and highdensity lipoprotein suppression gain weight weight gain azoospermia weight gain and serum highdensity cholesterol hdl suppression azoospermia serum hdl levels density lipoprotein hdl suppression and weight gain￨dsg 150 or 300 plus t 100 suppressed spermatogenesis as effectively as lng 125t 100 and more effectively than dsg 50t 100 or testosterone alone￨sig increase￨highunclear￨highunclear￨highunclear
16￨male contraception men participating in contraceptive trials 16 volunteers receiving the young healthy men n  8group￨initial loading dose of 400 mg 19nortestosterone hexyloxyphenylpropionate 19nthpp placebo implant buserelin implant lh and fsh 19nthpp 19nthppbuserelin gnrh agonist buserelin depot gonadotropinreleasing hormone agonist￨maximal suppression of spermatogenesis suppression of pituitary and testicular function serum lh and fsh￨in the group receiving only 19nthpp serum lh and fsh were markedly suppressed and remained low during the treatment phase￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨normal young men￨intramuscular t undecanoate plus depot lng oral lng daily tlng 31 n  20 or 625 microg of oral lng intramuscular t enanthate 100 mg weekly plus oral levonorgestrel lng intramuscular t enanthate intramuscular testosterone enanthate tlng 31 highdosage parenteral testosterone t esters alone or in combination with a progestogen eg depot medroxyprogesterone tlng levonorgestrel￨hematology or chemistry profiles weight gain and suppression of serum highdensity lipoprotein cholesterol hdl levels serum hdl cholesterol levels weight gain gain weight weight gain and hdl suppression weight gain or hdl suppression serum lowdensity lipoprotein cholesterol levels azoospermia￨serum hdl cholesterol levels declined significantly in both groups percentage decline month 6 of treatment vs baseline 120￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨normal men normal men￨oral desogestrel with depot testosterone oral desogestrel desogestrel with a longacting testosterone preparation testosterone testosterone pellets￨lh and fsh gonadotrophin secretion without adverse metabolic or behavioural effects lipoproteins fibrinogen or sexual behaviour during treatment and minor falls in haematocrit and haemoglobin concentration sperm concentration fell testosterone concentrations￨there were no significant changes in lipoproteins fibrinogen or sexual behaviour during treatment and minor falls in haematocrit and haemoglobin concentration￨no diff￨highunclear￨highunclear￨highunclear
15￨caucasian and chinese men caucasian populations all caucasian men thirty men in edinburgh and 36 men in shanghai received 150 or 300 microg caucasian men spermatogenesis to azoospermia in both caucasian and chinese men￨desogestrel po oral desogestrel with testosterone pellets oral desogestrel with depot testosterone￨highdensity lipoprotein cholesterol fell weight gain sperm concentrations azoospermia spermatogenesis testosterone concentrations￨highdensity lipoprotein cholesterol fell by 15 in caucasian men but was unchanged in the chinese men both groups showed some weight gain￨sig decrease￨highunclear￨highunclear￨highunclear
16￨sixteen normal men men receiving male contraceptive regimens￨desogestrel testosterone to dihydrotestosterone dht finasteride a 5alphareductase inhibitor testosterone testosterone pellets standard androgenprogestogen treatment alone control group or with finasteride￨gonadotropin and testosterone concentrations luteinizing hormone and folliclestimulating hormone dht concentrations fell suppression of spermatogenesis with azoospermia testosterone concentrations￨significant suppression of luteinizing hormone and folliclestimulating hormone was achieved within 2 weeks of treatment in both groups while testosterone concentrations were maintained in the normal physiological range￨no diff￨highunclear￨highunclear￨highunclear
354￨354 healthy men male contraception male hormonal contraception male hormonal contraception￨etonogestrel eng implant combined with testosterone undecanoate tu injections placebo low or highrelease eng implant sc combined with im tu injections placebo implant and injections eng implant with tu injections￨median recovery time spermatogenesis suppression and safety tolerated adverse events such as weight gain mood changes acne sweating or libido change suppression￨as compared with the placebo group more men in the active treatment groups reported adverse events such as weight gain mood changes acne sweating or libido change￨sig increase￨low￨low￨low
not found￨healthy male volunteers male hormonal contraception￨novel combination of oral etonogestrel eng and im testosterone decanoate td oral progestogen etonogestrel intramuscular androgen testosterone decanoate￨gonadotropins efficacy hormone profiles and safety sperm concentration trough testosterone levels weight and cholesterol faster suppression recovery of sperm counts and gonadotropins to normal levels￨after treatment cessation recovery of sperm counts and gonadotropins to normal levels occurred in both groups￨no diff￨highunclear￨highunclear￨highunclear
39￨normal volunteers thirtynine healthy male volunteers age 2045 yr another 29 subjects hormonal male contraception normal men￨combined norplant ii levonorgestrel implants norplant ii transdermal and injectable testosterone jadelle four capsules delivering approximately 160 microgd levonorgestrel lng plus t patch norplant ii plus t enanthate te injection transdermal t patches daily testoderm tts oral lng te injections￨serum shbgs serum lng levels severe oligozoospermia trough serum lng levels suppression of serum highdensity lipoprotein cholesterol serum free t levels weight hematocrit clinical chemistry or prostatespecific antigen levels effective suppression of sperm output persistent sperm concentrations serum fsh and lh levels steadystate serum lng levels azoospermia serum total t spermatogenesis suppression serum shbg total serum t￨in the t patchonly group serum shbg was not suppressed and total serum t was higher than baseline levels￨sig increase￨highunclear￨highunclear￨highunclear
not found￨male contraception fifty normal men￨norethisterone enanthate plus testosterone undecanoate norethisterone enanthate nete plus testosterone undecanoate tu tu plus placebo tu 1000 mg plus placebo placebo plus placebo nete 200 mg plus tu￨spermatogenesis reproductive hormones testis and prostate prostate volumes semen analyses blood drawings physical examinations and prostate ultrasounds gonadotropin sperm suppression and prostatic effects azoospermia￨prostate volumes did not change significantly in either group￨no diff￨highunclear￨highunclear￨highunclear
10￨healthy volunteers￨200mg t pellets plus a single im injection of 300 mg depot medroxyprogesterone acetate dmpa progestinandrogen combination depot testosterone enanthate depot progestin￨plasma lh and fsh azoospermic or severely oligozoospermic plasma epitestosterone serious adverse effects sperm output stable physiological t levels sex hormonebinding globulin levels plasma total and free testosterone levels prostatespecific antigen and lipids total low or high density lipoprotein cholesterol and triglycerides￨plasma lh and fsh measured by a twosite immunoassay were suppressed in a dosedependent fashion by t and further suppressed by the addition of dmpa￨sig increase￨highunclear￨highunclear￨highunclear
35￨men thirtyfive normal volunteers were recruited in 3 clinics and were randomly assigned to 1 of 3 doses 1 12 men 2 11 men or 4 12 men ment ac implants￨7 alphamethyl19nortestosterone ment ethylene vinyl acetate implants containing ment acetate ac alphamethyl19nortestosterone implants￨sperm counts serum ment levels testosterone lh and fsh levels erythrocyte count hematocrit and hemoglobin and a decrease in shbg azoospermia￨none of the subjects in the 1implant group exhibited oligozoospermia sperm count 3 millionml￨no diff￨highunclear￨highunclear￨highunclear
not found￨male contraception hypogonadal men normal healthy male volunteers￨testosterone buciclate￨serum t levels lh and fsh serum levels of lh serum lh and fsh serum sex hormonebinding globulin suppression of spermatogenesis to oligozoospermia serum levels of dihydrotestosterone dht serum lh and t azoospermia mean serum levels￨serum levels of lh as well as total and free t at baseline and after tb injection were lower in the responders than in the nonresponders￨sig increase￨highunclear￨highunclear￨highunclear
not found￨normal men￨physiologic t plus highdosage levonorgestrel lng placebo physiologic testosterone levonorgestrel and testosterone t enanthate and lng lng physiologic exogenous t enanthate and lng t enanthate combined with placebo lng lng 0 n  18 or with 500 mg of lng levonorgestrel exogenous highdosage testosterone t t enanthate￨hdl levels serum levels of hdl cholesterol severe oligoazoospermia uniform severe oligoazoospermia spermatogenesis and circulating gonadotropin levels adverse metabolic side effects weight gain and hdl cholesterol suppression dosage of lng weight gain and suppression of serum highdensity lipoprotein hdl cholesterol levels￨serum levels of hdl cholesterol decreased in all of the groups but the effect was larger as the dosage of lng increased 44 vs 134 203 and 224 decrease in hdl levels from baseline in the lng 0 lng 125 lng 250 and lng 500 groups respectively p  006 for lng 125 compared with lng 0 and p  005 for lng 250 and lng 500 compared with lng 0￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨twentytwo men n  56group￨testosterone enanthate te levonorgestrel lng 5alphareductase inhibitor dutasteride or longacting gnrh antagonist acyline to combination testosterone plus levonorgestrel lng 125 microg orally daily plus acyline novel combination contraceptive regimens te  lng  dutasteride lng 125 microg plus dutasteride 05 mg orally daily 3 acyline 300 microgkg testosterone and levonorgestrel combined with a 5alphareductase inhibitor or gonadotropinreleasing hormone antagonist dutasteride￨serum gonadotropins and androgens and sperm concentration serum gonadotropin levels sperm concentrations serum dihydrotestosterone levels severe oligospermia additional suppression of gonadotropins or sperm concentration azoospermia￨serum dihydrotestosterone levels were significantly p  005 decreased in the dutasteride group throughout the treatment period to a nadir of 31 baseline wk 7￨sig increase￨highunclear￨highunclear￨highunclear
29￨fourteen men completed 48 weeks of healthy men healthy men n  29￨progestogen and testosterone testosterone with a progestogen etonogestrel implants testosteroneetonogestrel regimen synthetic androgen 7alphamethyl19nortestosterone ment testosterone 7alphamethyl19nortestosterone ment 2 etonogestrel implants with either 600mg testosterone pellets repeated every 12 weeks or 2 ment implants￨peak ment levels hemoglobin concentrations rose and high density lipoproteincholesterol hdlc loss of libido spermatogenic suppression testosterone concentrations￨hemoglobin concentrations rose and high density lipoproteincholesterol hdlc fell in both groups￨sig decrease￨highunclear￨highunclear￨highunclear
130￨one hundred and thirty subjects one hundred and ten men completed 48 weeks of treatment fourteen subjects discontinued treatment due to adverse events￨etonogestrel rods 204 mg etonogestrel and 400 mg testosterone decanoate subcutaneous etonogestrel implants with injectable testosterone decanoate injectable testosterone decanoate testosterone decanoate￨efficacy of suppression mean trough testosterone concentrations weight and decline in highdensity lipoprotein cholesterol frequent escape from gonadotrophin suppression peak testosterone concentrations mean haemoglobin levels suppression sperm concentrations￨suppression was slower in group ii which also demonstrated more frequent escape from gonadotrophin suppression than groups i and iii￨sig increase￨highunclear￨highunclear￨highunclear
not found￨chinese men white men sixtytwo healthy chinese men male hormonal contraception chinese men male contraceptive by reversibly suppressing spermatogenesis to azoospermia or severe oligoazoospermia in 95 of chinese men￨4 lng rods injectable testosterone undecanoate alone progestin levonorgestrel lng testosterone undecanoate tu tu 1000 mg by im injection levonorgestrel implants 4 lng implants￨spermatogenic suppression sperm counts serum testosterone t luteinizing hormone folliclestimulating hormone and lng serum chemistry attainment of azoospermia￨during treatment group ii demonstrated a trend toward a greater attainment of azoospermia than groups i and iii 90 vs 62 group i vs 67 group iii p 09￨sig increase￨highunclear￨highunclear￨highunclear
24￨twentyfour healthy male volunteers 332 adult men￨desogestrel and testosterone enanthate dsg oral dsg synthetic oral progestogen desogestrel dsg administered with low dose testosterone t oral progestogen combined with testosterone dsg and 100 mg t enanthate t enanthate￨suppression of sperm density high density lipoprotein cholesterol sperm density total cholesterol high density lipoprotein cholesterol and low density lipoprotein cholesterol pituitarytesticular functions mean lh and fsh levels suppression of spermatogenesis pituitarytesticular axis and lipid metabolism lipid metabolism azoospermia￨there was no consistent difference in mean lh and fsh levels among the three groups during treatment or recovery except that fsh remained detectable in a higher proportion of samples from the group receiving 300 microg dsg with 50 mg t enanthate￨no diff￨highunclear￨highunclear￨highunclear
not found￨chinese and nonchinese men two different ethnic groups academic medical center in the united states and the research institute in china forty nonchinese and 40 chinese healthy male volunteers chinese men two centers with two treatment groups￨lng plus t implants lng levonorgestrel lng with testosterone t implants levonorgestrel implants￨suppression of spermatogenesis severe oligozoospermia suppression of spermatogenesis to severe oligozoospermia suppression to severe oligozoospermia spermatogenesis suppression t implant extrusion acne and increased hemoglobin efficiency of suppression to severe oligozoospermia￨suppression to severe oligozoospermia was less in the nonchinese men 59 after t alone p  0020 this difference disappeared with combined treatment 89￨sig decrease￨highunclear￨highunclear￨highunclear
27￨fortythree 2145yearold healthy men 27 men completed the suppression phase 27 men completing the suppression phase all have recovered to sperm levels azoospermia or severe oligozoospermia 3 x 106ml in normal men requiring contraception 16 men discontinued for various reasons male hormonal contraception￨transdermal 5 alphadihydrotestosterone dht transdermal dht andractimr besins iscovesco paris france and one subdermal lng implant jadelle leiras turku finland 2 transdermal dht and two subdermal lng implants 3 transdermal dht and four subdermal lng implants 4 transdermal dht and oral lng microluton schering germany or 5 transdermal dht only subcutaneous levonorgestrel implants and transdermal dihydrotestosterone gel subcutaneous levonorgestrel lng oral lng and transdermal dht￨serum luteinizing hormone lh serum fsh blood count lipid profile liver function tests prostatespecific antigen psa sex hormone binding globulin shbg prolactin or cortisol serum testosterone concentrations st serum oestradiol concentrations se2 mixed antiglobulin reaction marigg mariga or tray agglutination test tat￨there were no changes in blood count lipid profile liver function tests prostatespecific antigen psa sex hormone binding globulin shbg prolactin or cortisol￨no diff￨highunclear￨highunclear￨highunclear
30￨chinese men healthy chinese men 30 healthy volunteers male hormonal contraception chinese men￨depot medroxyprogesterone acetate dmpa and testosterone undecanoate tu tu plus dmpa tu plus 150 mg dmpa tu testosterone undecanoate and depot medroxyprogesterone acetate tu plus 300 mg dmpa￨consistent azoospermia or severe oligozoospermia serious adverse effects sperm concentrations￨consistent azoospermia or severe oligozoospermia was achieved and maintained in all volunteers during the treatment period except for two men in the tualone group who experienced a rebound in sperm concentrations￨no diff￨highunclear￨highunclear￨highunclear
20￨twenty healthy male volunteers in each center male hormonal contraception healthy men￨tu alone or in combination with 200 mg of nete im norethisterone enanthate tu alone or in combination with norethisterone enanthate nete testosterone undecanoate longacting injectable testosterone undecanoate tu￨maximum concentration and area under the curve auc for serum total and free testosterone t serum gonadotropins levels and sperm concentration accumulation ratios of serum total and free t levels average concentration and auc of serum total and free t￨tu 1000 mg im alone or with nete at 8weekly intervals resulted in linear increases in average concentration and auc of serum total and free t with each injection￨sig increase￨highunclear￨highunclear￨highunclear
30￨thirty healthy men participated￨gonadotropin suppression by gnrh antagonist cetrorelix with testosterone ct group or with additional administration of the gestogen desogestrel ctd group for 4 wk before testicular biopsy progestogen￨reduced expression of 5alphareductase type suppression of gonadotropins and sperm production expression of steroidogenic enzymes gene expression inhibinalpha and the spermatocyte marker acrosinbinding protein￨inhibinalpha and the spermatocyte marker acrosinbinding protein were significantly lower in the ctd but￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨healthy men healthy men for 1620 weeks men who became azoospermic￨gnrh antagonist nalglu 100 microgramskgday sc plus t enanthate 200 mg im weekly or placebo gonadotropin releasinghormone antagonist plus testosterone t versus t alone sc injections daily plus t enanthate￨weight gain development of acne hematocrit and hemoglobin azoospermia t levels pretreatment gonadotropin levels azoospermic gonadotropin levels￨there was a trend toward higher pretreatment gonadotropin levels and lower sperm counts in men who became azoospermic￨sig increase￨highunclear￨highunclear￨highunclear
not found￨normal volunteers received￨tu  200 mg nete tu and nete longacting t ester testosterone undecanoate tu with norethisterone net enanthate e tu nete testosterone undecanoate with oral or injectable norethisterone preparations￨spermatogenesis and azoospermia contraceptive efficacy body weight erythrocytes hemoglobin and hematocrit and decrease in highdensity lipoprotein cholesterol and alkaline phosphatase liver enzymes suppression of gonadotropins￨in all groups marked suppression of gonadotropins resulted in a significant decrease of spermatogenesis and azoospermia in 1314 1112 and 1214 men in groups i to iii respectively￨sig decrease￨highunclear￨highunclear￨highunclear
480￨225 patients with confirmed influenza eligible patients 480 adults aged 18 to 65 years within 36 h of onset of influenzalike symptoms adults￨chinese herbs placebo￨adverse event profiles cough median symptom score temperature and symptoms on diary cards severity of fever severity of illness￨the influenzaconfirmed patients reported reductions in the severity of fever p  0002 cough p  0023 and expectoration p  0004 after oneday of treatment with antiwei compared to placebo￨sig decrease￨low￨low￨low
20￨20 men with chronic nonfluent aphasia nonfluent aphasia￨placebo bromocriptine or placebo bromocriptine bromocriptine￨patients speech fluency language content overall degree of aphasia severity or nonverbal cognitive abilities patients language and nonverbal cognitive skills￨when compared with placebo treatment bromocriptine did not significantly improve the patients speech fluency language content overall degree of aphasia severity or nonverbal cognitive abilities￨no diff￨highunclear￨highunclear￨highunclear
56￨geriatric patients with acute cerebral ischemia a total of 56 patients were enrolled of whom 27 were given patients displaying acute cerebral ischemia￨hydroxyethyl starch venous infusion and low dose heparin placebo piracetam￨flow rate efficacy and tolerance￨analysis of the recorded computer tomography map gave an improvement coefficient 2 flow rate marginally or better improved for 23 piracetam patients as compared with 5 placebo patients p  0001 uleman test￨sig increase￨highunclear￨highunclear￨highunclear
45￨primary tooth extraction fortyfive children ages 612 who needed primary mandibular molar tooth extraction were treated in paediatric dental clinics with treatment preceded by local anaesthesia and analgesic drugs during the preoperative period paediatric patients who receive adequate analgesia during mandibular primary tooth extraction children￨placebo ibuprofen paracetamol and placebo ibuprofen preemptive ibuprofen paracetamol and placebo ibuprofen and paracetamol￨kruskalwallis and mannwhitney u tests pain scores selfreport scores pain reaction 2011 bspd iapd and blackwell publishing ltd￨additionally ibuprofen exhibited lower pain scores p  005 compared to paracetamol at the 15min p  0001 and 4h p  0009 periods￨sig decrease￨low￨low￨low
41￨orthodontic pain fortyone orthodontic patients aged 9 years 3 months to 16 years 11 months who were to undergo separator placement￨placebo preemptive andor postoperative ibuprofen therapy preemptive ibuprofen therapy postoperative ibuprofen therapy ibuprofen taken orally 1 hour before separator placement and 400 mg ibuprofen ibuprofen￨pain pain scores￨the results revealed that preemptive ibuprofen therapy significantly decreased pain that was experienced 2 hours after separator placement and at bedtime￨sig decrease￨highunclear￨highunclear￨highunclear
63￨sixtythree adolescent patients mean age 13 years pain associated with orthodontic separator placement patients requiring analgesics for orthodontic discomfort patients undergoing pain after orthodontic separator placement￨lactose placebo taken orally 1 hour before separator placement and 400 mg of ibuprofen placebo preoperative ibuprofen lactose placebo ibuprofen orthodontic treatment ibuprofen taken orally 1 hour before separator placement and a lactose placebo￨pain pain with chewing￨patients were randomly assigned to 1 of 3 experimental conditions 1 400 mg of ibuprofen taken orally 1 hour before separator placement and a lactose placebo taken orally immediately after the appointment 2 a lactose placebo taken orally 1 hour before separator placement and 400 mg of ibuprofen taken orally immediately after the appointment or 3 a lactose placebo taken orally 1 hour before separator placement and again immediately after the appointment￨sig increase￨highunclear￨highunclear￨highunclear
60￨sixty children aged 210 years requiring primary teeth extractions were selected to participate in the study children adults￨acetaminophen ibuprofen acetaminophen and placebo ibuprofen preoperative ibuprofen acetaminophen and placebo￨pain relief experience postextraction pain postextraction pain￨although there was a trend toward reduced postextraction pain reported by the parents the preoperative administration of neither analgesic was found to be statistically superior by chisquare analysis to placebo administration￨no diff￨highunclear￨highunclear￨highunclear
not found￨children receiving dental care children adults pediatric dental patients 4 to 10yearold children following various dental procedures￨preoperative analgesic administration acetaminophen￨postoperative pain￨there is a trend toward reduced postoperative pain in the acetaminophen pretreatment groups￨sig decrease￨highunclear￨highunclear￨highunclear
35￨osteoarthritis of the knee patients age mean  675 years sd  130 who had osteoarthritis oa and a chronic knee contracture￨ultrasound exercise preceded by either ultrasound n  34 or sham ultrasound￨knee active range of motion rom goniometry or pain visual analogue scale active rom pain and gait velocity￨ultrasound increases soft tissue extensibility and may be an effective adjunct in the treatment of knee contractures secondary to connective tissue shortening￨sig increase￨highunclear￨highunclear￨highunclear
100￨one hundred patients with bilateral knee osteoarthritis women with knee osteoarthritis women with osteoarthritic knees￨ultrasound  hot packs and isokinetic exercise group 4 received hot packs and isokinetic exercise and group 5 served as controls and received only isokinetic exercise hot pack shortwave diathermy ultrasound and tens shortwave diathermy  hot packs and isokinetic exercise transcutaneous electrical nerve stimulation  hot packs and isokinetic exercise hot pack with a transcutaneous electrical nerve stimulator or shortwave diathermy physical agents administered before isokinetic exercise￨isokinetic strength pain and functional status visual analog scale scores and scores on the lequesne index pain and disability index scores muscular strength exercise performance reduced pain and improved function￨patients in the study groups had significantly greater reductions in their visual analog scale scores and scores on the lequesne index than did patients in the control group group 5￨sig increase￨highunclear￨highunclear￨highunclear
140￨patients with knee osteoarthritis patients with knee osteoarthritis oa 140 subjects with bilateral knee oa altman grade ii￨integrated therapy isokinetic exercises isokinetic exercise and pulse ultrasound for periarticular soft tissue pain group iii received isokinetic exercise pulse ultrasound and intraarticular hyaluronan therapy￨walking speed disability pain and disability muscle peak torques lequesnes index knee range of motion peak muscle torques of knee flexion and extension and ambulation speed range of motion and ambulation speed muscular strength visual analog scale pain and rates of attrition￨both group ii and group iii had significant gains in muscular strength after treatment and at followup group iii showed the greatest gains￨sig increase￨highunclear￨highunclear￨highunclear
120￨taiwan medical university hospital patients with knee osteoarthritis oa one hundred twenty subjects with bilateral knee oa altman grade ii knee osteoarthritis￨isokinetic muscle strengthening exercises isokinetic exercise and continuous us group iii received isokinetic exercise and pulsed us treatment and group iv was the control group isokinetic exercise outpatient exercise program ultrasound us isokinetic muscular strengthening exercises￨walking speed disability knee pain periarticular soft tissue disorders pain and disability muscle peak torques knee range of motion rom visual analog scale for pain and muscle peak torques ambulation speed and the lequesne index angular velocity peak torques rom and ambulation speed muscular strength greatest muscular strength gains￨patients in group iii also showed the greatest increase in walking speed and decrease in disability after treatment and at followup￨sig increase￨highunclear￨highunclear￨highunclear
67￨patients with knee oa knee osteoarthritis oa sixtyseven patients mean age 548 7 knee osteoarthritis￨1 mhz frequency or 1 wattcm2 power continuous ultrasound for 5 min n  34 or sham us ultrasound us therapy therapeutic ultrasound placebo￨pain on movement assessed by visual analog scale vas pain reduction knee pain total womac scores western ontario and mcmaster universities osteoarthritis index womac scores and 50 meters walking time vas score￨in the treatment group the improvement in vas score was statistically and significantly higher p  0001 and more pronounced than in the placebo group￨sig increase￨low￨low￨low
172￨14 psychiatric hospitals in finland sweden norway and denmark 172 chronic schizophrenic patients and the planned 6 months test period was completed by 57 patients receiving schizophrenic patients￨perphenazine enanthate clopenthixol decanoate clopenthixol decanoate￨hostilesuspiciousness bprs and social interest nosie30 cgi bprs and nosie30￨the influence of side effects on the patients functioning was found to be slightly but not significantly more troublesome in the perphenazine enanthate patients￨sig decrease￨highunclear￨highunclear￨highunclear
45￨45 female chronic schizophrenic patients hostile and restless schizophrenic patients￨perphenazinenanthate and fluspirilene longacting neuroleptics perphenazinenanthate and fluspirilene authors transl perphenazinenanthate￨psychopathological and somatic symptoms ampsyndromes of hostility hypochondria and autonomic symptoms￨a significant difference with regard to perphenazinenanthate was found in the ampsyndromes of hostility hypochondria and autonomic symptoms￨sig decrease￨highunclear￨highunclear￨highunclear
51￨fiftyone participants hospitalized patients with cystic fibrosis twentytwo participated during one subsequent admission and were assigned to the opposite form of chest percussion￨manual or mechanical chest percussion manual and mechanical chest percussion￨mechanical percussion severity of illness mean national institutes of health score forced expiratory volume at 1 second forced vital capacity and forced expiratory flow￨mean improvement in forced expiratory volume at 1 second forced vital capacity and forced expiratory flow between 25 and 75 of forced vital capacity￨sig increase￨highunclear￨highunclear￨highunclear
22￨hospitalized patients with cystic fibrosis twentytwo cf patients ages 8 to 44 years undergoing a total of 33 hospitalizations for acute pulmonary exacerbation community and childrens hospital acutecare wards hospitalized cystic fibrosis cf patients undergoing an acute pulmonary exacerbation￨flutter device to standard chest physiotherapy supervised flutter therapy or standard manual cpt flutter device flutter to standard manual chest physiotherapy cpt￨complete pulmonary function tests pfts clinical score cs complications including hemoptysis hypoxemia and pneumothorax efficacy and safety hospital admission to discharge￨mean percent change in cs and pft results between cpt and flutter groups showed no significant difference from hospital admission to discharge￨no diff￨highunclear￨highunclear￨highunclear
not found￨cystic fibrosis patients with cystic fibrosis￨conventional physiotherapy conventional chest physiotherapy￨vital capacity shwachman clinical score forced expiratory flow forced expiratory volume mean annual rates of decline mean annual rate of decline for forced expiratory flow￨patients who performed the forced expiratory technique alone had mean annual rates of decline that were significantly different from zero for forced expiratory volume in 1 second p less than 0001 forced expiratory flow between 25 and 75 of vital capacity p less than 0001 and shwachman clinical score p less than 0004￨sig increase￨highunclear￨highunclear￨highunclear
16￨patients with cystic fibrosis cf cystic fibrosis cf patients 16 cf children and adults￨ipv versus standard manual chest physiotherapy intrapulmonary percussive ventilator to standard aerosol and chest physiotherapy ipv￨lung function and anthropometric measures spirometric measures numbers of hospitalizations use of oral or iv antibiotics or anthropometric measurements￨no significant differences in spirometric measures numbers of hospitalizations use of oral or iv antibiotics or anthropometric measurements were detected between the standard aerosolchest physiotherapy group and the ipv group over the duration of the trial￨no diff￨highunclear￨highunclear￨highunclear
50￨hospitalized patients with cystic fibrosis 50 cf patients admitted for acute pulmonary exacerbation cystic fibrosis cf patients admitted for acute pulmonary exacerbation cf patients￨hfcc and cpt conventional physiotherapy cpt hfcc high frequency chest compression hfcc high frequency chest compression and conventional chest physiotherapy hfcc or cpt￨clinical status and pft admission clinical status and pulmonary function tests pft￨on admission clinical status and pulmonary function tests pft in the hfcc group were not significantly different from those measured in the cpt group￨no diff￨highunclear￨highunclear￨highunclear
not found￨cystic fibrosis forty patients ages 6 to 17 years with shwachman scores between 52 and 93 attending the cystic fibrosis clinic￨physiotherapy with the pep technique physiotherapy by the positive expiratory pressure pep technique with a pep mask astra meditec versus conventional postural drainage and percussion pdp conventional postural drainage and percussion versus positive expiratory pressure physiotherapy￨fev1 pulmonary function fvc clinical status and pulmonary function forced vital capacity fvc fev1 and fef2575￨the differences between treatment groups were statistically significant for the changes in fvc p  002 and fev1 p  004￨sig increase￨highunclear￨highunclear￨highunclear
10￨10 patients with cystic fibrosis patients with cystic fibrosis￨positive expiratory pressure pep mask with postural drainage positive expiratory pressure pep mask pep mask therapy￨sputum production symptom score or peak expiratory flow rate sputum production or change in lung function￨there was no significant difference in sputum production or change in lung function between each technique as assessed by the physiotherapist￨no diff￨highunclear￨highunclear￨highunclear
17￨seventeen patients with cf hospitalized means length of stay  130 patients with cystic fibrosis cf patients with cystic fibrosis hospitalized patients with cf￨bronchial hygiene therapy consisted of postural drainage cycle ergometer exercise sessions and one bronchial hygiene treatment session per day ex group n  9 or a group that participated in three bronchial hygiene treatment sessions substituting regular exercise bronchial hygiene therapy bronchial drainage and exercise￨coughing pulmonary function and exercise response heart rate and arterial oxygen saturation response pulmonary function and exercise response￨pulmonary function and exercise response were significantly improved over the period of hospitalization in both groups the improvements were the same in the two groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨cystic fibrosis older patients￨pep mask with forced expiratory coughing was compared with conventional physiotherapy￨symptom scores sputum production or simple lung function tests￨no difference was shown in symptom scores sputum production or simple lung function tests￨no diff￨highunclear￨highunclear￨highunclear
142￨142 patients with chronic sacrococcygeal pilonidal sinus chronic sacrococcygeal pilonidal sinus￨primary closure group modified layopen incision curettage partial lateral wall excision and marsupialization versus total excision with primary closure cefazoline metronidazole￨morbidity and recurrence rates median time before return to work healing failure and early bridging healing time wound breakdown median healing time healing failure and hematoma wound infection operating time healing time time before return to work morbidity rate and recurrence rate￨the median healing time in group a was significantly longer than in group b 7 range 316 weeks vs 2 range 29 weeks p0001￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨77 patients with chronic sacrococcygeal pilonidal sinus chronic sacrococcygeal pilonidal sinus rizgary teaching hospital erbil kurdistan iraq from january 1997 to august 2003￨excision and primary closure open method excision and healing by secondary intention and group b 40 patients for whom primary midline suturing was performed after excision of the pilonidal sinus primary midline suturing￨operating time hospitalstay time off from work and wound healing time￨the statistical analysis of the total number of postoperative complications of both techniques showed a significant difference p  00401 while the differences were insignificant for each complication when analyzed separately￨sig decrease￨highunclear￨highunclear￨highunclear
55￨fiftyfive patients with chronic pilonidal disease chronic pilonidal disease￨simple bascoms technique versus bascoms cleft closure cleft closure bascoms simple surgery n  29 or cleft closure n  26 under local anesthetic￨disease recurrence time to healing heal and proceeded to cleft closure removal of sutures disease recurrence￨fifty of 55 91 patients were contacted for followup evaluation disease recurrence occurred in 2 of 24 after bascoms simple surgery and in 0 of 26 after cleft closure￨no diff￨highunclear￨highunclear￨highunclear
46￨46 patients with chronic pilonidal sinus disease 24 treated by rhomboid flap transposition and 22 by deep suturing technique university department of surgery united arab emirates￨transposed rhomboid flap deep suturing pilonidal sinus by primary closure with a transposed rhomboid flap rhomboid flap transposition￨mean hospital stay early mobility and recurrence healed their wounds primarily￨all patients in the rhomboid flap transposition group healed their wounds primarily compared with 17 in the primary deep suturing group 77￨sig increase￨highunclear￨highunclear￨highunclear
110￨one hundred ten patients who had chronicstage pilonidal sinus chronic pilonidal sinus patients￨surgical excision and primary closure closed technique excisional surgical procedures obeids surgical excision￨longer hospital stays infection rates length of hospital stay length of time to return to work wound infection rate and recurrence rate recurrence rates￨although patients with primary closure had significantly longer hospital stays p  005 than patients in the open group they returned to work significantly earlier p  005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨chronic pilonidal disease￨excision e excision with suture e  s and excision with suture under cover with clindamycin e  s  c e  s  c￨times of healing recurrence rates excision of recurrences total time of healing￨healing without formation of new sinuses occurred equally frequent after excision e excision with suture e  s and excision with suture under cover with clindamycin e  s  c￨no diff￨highunclear￨highunclear￨highunclear
34￨y advancement flap closure thirtyfour patients with stage 4 or recurrent pilonidal sinus disease who underwent v￨vertical suture line unrelated to midline vlum n18 and vertical suture line related to midline vlrm n16 suction drains vlum vy advancement flap closures￨median length of the postoperative hospital stay flap necrosis local haematomas or seromas￨none of the patients with or without a suction drain developed flap necrosis local haematomas or seromas￨no diff￨highunclear￨highunclear￨highunclear
not found￨29 patients 24 males and five females and underwent between april 2000 and february 2003 83 patients 68 male and 15 female aged between 19 and 31 years mean 266 scheduled for elective operations for pilonidal sinus disease 26 patients 22 males and four females and underwent 28 patients 22 males and six females and underwent￨wide resection of the skin and subcutaneous tissue and their wounds left opened for secondary intention healing wide resection of the skin and subcutaneous tissue of the natal cleft followed by primary closure of the wound in two layers after insertion of suction drain excisional surgical procedures limited excision of the fistulous tract and their wounds were left opened for secondary intention healing￨operative time demographic data operative time hospital stay operative blood loss postoperative pain wound healing time and patients satisfaction shortest wound healing time shortest hospital stay operative blood loss and postoperative pain rate of recurrence longest healing time￨they also had the shortest hospital stay operative blood loss and postoperative pain￨sig decrease￨highunclear￨highunclear￨highunclear
200￨patients with primary sacrococcygeal pilonidal disease spd primary sacrococcygeal pilonidal disease two hundred consecutive patients with spd￨rhomboid excision and the limberg flap procedure limberg flap excision and primary closure￨no recurrence mobilization earlier time to resumption of work shorter duration of hospital stay shorter duration of operation postoperative pain postoperative complications duration of operation postoperative pain time to first mobilization length of hospital stay postoperative complications time to resumption of work recurrence and time to recurrence￨however postoperative pain was less p  0001 mobilization earlier p  0001 duration of hospital stay shorter p  0001 time to resumption of work shorter p  0001 and postoperative complications fewer p  0001 in group 2￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients who presented with chronic natal cleft pns disease chronic pilonidal sinus pns disease 380 patients of chronic pns between july 2002 and november 2006 a randomized trial was conducted in the department of general surgery riyadh medical complex riyadh kingdom of saudi arabia patients who came with an acute pilonidal abscess complicated were excluded from the study￨excision with or without primary closure emc excision with midline closure emc group or excision without closure ewc group excision with or without primary closure ewc￨hospital stay recurrence rate wound infection wound infection healing time time off work and the recurrence rate mean healing time and time off work￨median follow up of emc group was 363 months range 1052 months while it was 352 months range 1351 months for ewc group￨no diff￨highunclear￨highunclear￨highunclear
70￨68 of 70 patients were followed for a mean of 2922 range 644 months after wide excision plus classic limberg flap group 1 n35 and after group 2 n33 pilonidal disease￨asymmetric modified limberg flap closure asymmetric modified limberg flap wide excision plus classic limberg flap or wide excision plus asymmetric modified limberg flap￨time off from work infection rate complications time to suture removal vacuum effect￨there were two recurrences in the inferior part of the suture line in group 1 and none in group 2 which showed no statistical difference p0493￨no diff￨highunclear￨highunclear￨highunclear
50￨fifty patients with the disease recurrence group a and fifty patients presenting for operative treatment for the first time group b were observed￨￨recurrence rates recurrence method of excision and open wound healing recurrence￨recurrence was found in three 6 group a patients and two 8 group b patients operated on by the method of excision and open wound healing￨no diff￨highunclear￨highunclear￨highunclear
72￨young males 72 patients in each arm by secondary intention of the wound after excision of the sacral pilonidal sinus￨secondary intention conventional surgery zplasty and delayed healing￨bleeding hematoma infection and recurrence healing of the wound and disease recurrence return to normal activity duration of hospitalization healing postoperative complications regarding bleeding hematoma infection or recurrence￨there was no difference in postoperative complications regarding bleeding hematoma infection or recurrence during the followup period in two arms￨no diff￨highunclear￨highunclear￨highunclear
100￨one hundred patients 100 patients￨limberg and karydakis procedures standard limberg or karydakis procedures￨time off work and off driving and also the visual analogue scale scores wound infection rate infection rate complications need for analgesia and wound dressing periods of time off work and off driving￨both procedures can be safely performed in pilonidal disease with a standard length of stay in hospital and a similar loss of productive power￨no diff￨highunclear￨highunclear￨highunclear
not found￨sacrococcygeal pilonidal disease in total 49 patients who either underwent open excision and secondary healing group a 25 patients or liaquat university hospital jamshoro  fatima hospitalbaqai medical university karachi from june 2004 to july 2007 sacrococcygeal pilonidal sinus disease spd patients with primary or recurrent spd group b 24 patients were enrolled in the study￨open excision with secondary healing versus rhomboid excision with limberg transposition flap rhomboid excision and limberg flap open excision and secondary healing with rhomboid excision and limberg flap￨complete healing of the wound total hospitalization period duration of operation duration of operation postoperative pain duration of hospital stay postoperative complications and time to recurrence pain perception recurrence rate￨the recurrence rate was also significantly lower in patients who underwent limberg rotation flap p  0005￨sig decrease￨highunclear￨highunclear￨highunclear
60￨120 of 164 patients with chronic pilonidal sinus treated between april 1987 and april 1989 chronic pilonidal sinus 60 patients were treated by￨excision and primary suture and 60 by excision and open packing￨numbers of late complications morbidity morbidity incidence of early complications bleeding that needed treatment wound breakdown infection haematoma or wound pain number of postoperative visits required and length of sick leave taken early complications￨excision and primary closure of chronic pilonidal sinus causes less morbidity and is more cost effective than excision and open packing￨sig decrease￨highunclear￨highunclear￨highunclear
100￨four patients were excluded from the excision and closure group leaving 96 patients for analysis 100 patients with a mean followup of 29 months￨￨cure rate initial primary healing recurrence rate mean healing time healing time and duration of sickleave￨initial primary healing was significantly more frequent after excision and primary closure 4546 98 compared with excision and healing by secondary granulation 3650 72￨sig increase￨highunclear￨highunclear￨highunclear
100￨from 1993 to 1996 100 patients were submitted to excision of chronic pilonidal sinus with local anaesthesia￨local anaesthesia￨mean wound healing wound healing and the return to normal activity return to normal activity wound healing postoperative complications￨shortterm results showed 6 120 postoperative complications in group a vs 10 200 in group b longterm results showed 9 180 complications in group a vs 7 140 in group b mean wound healing was 58 days range 2993 in group a￨no diff￨highunclear￨highunclear￨highunclear
not found￨young adults from january 2000 to november 2003 100 consecutive age and sexmatched patients with chronic pilonidal sinus disease￨excision and primary closure or rhomboid excision and limberg flap￨social functioning length of hospital stay time to return to work and to complete healing shorter hospital stay earlier healing shorter time off work lower ratio of complications lower pain perception and improved general health perception general health perception pain mean postoperative visual analogue scale scores quality of life quality of life and patient comfort time to complete healing p001 time off work p001 and wound infection rate times to sitting on toilet and walking without pain￨times to sitting on toilet and walking without pain showed significant differences between the groups p006 and p001 respectively￨sig decrease￨highunclear￨highunclear￨highunclear
140￨pilonidal disease patients undergoing surgery for pilonidal disease with unroofing and marsupialization um or rhomboid excision and limberg flap relp procedures one hundred forty consecutive patients with pilonidal sinus￨relp unroofing and marsupialization vs rhomboid excision and limberg flap um or relp procedures￨quality of life scores duration of operation and hospital stay shorter time periods to walk return to daily activities or sit without pain and to return to work or school and fewer complications visual analog scale and the mcgill pain questionnaire postoperative pain healing time quality of life clinical outcomes and quality of life time to final healing￨time to final healing was significantly shorter and quality of life scores on the cwis were higher in patients receiving relp than in those receiving um￨sig increase￨highunclear￨highunclear￨highunclear
not found￨children under five children 155 caregivers given prepacked tablets 91 n141 adhered to the recommended dosage while only 42 n61 of 144 who were provided syrup did children aged 0 children under five in subsaharan africa￨prepacked tablets or syrup by random assignment chloroquine tablets vs chloroquine syrup prepacked chloroquine tablets chloroquine syrup￨￨the cost of treatment with tablets was about onequarter that of syrup and 62 n96 of caregivers preferred tablets￨no diff￨highunclear￨highunclear￨highunclear
436￨malaria at the adult outpatient department of port moresby general hospital adult patients who were prescribed standard antimalarial drugs following clinical and microscopic diagnosis of malaria 436 patients 322 patients 179 males and 143 females completed the study compliance with malaria treatment at port moresby general hospital adult outpatient department￨prepackaging antimalarial drugs and counselling prepackaging and counselling instructions were applied control group a with counselling but no prepackaging and control group b with neither counselling nor prepackaging￨￨as an additional beneficial observation prepackaging is likely to eliminate errors and possible contamination of the products during dispensing￨sig increase￨highunclear￨highunclear￨highunclear
not found￨vivax malaria patients compliance with treatment for plasmodium vivax malaria in china￨drug packaging chloroquine and 8day primaquine blister packs containing antimalarial drugs￨level of real compliance patients compliance treatment compliance rate￨the results show that blister packaging significantly improved patients compliance p  0001 over traditional means of dispensing antimalarial drugs there was no difference in treatment compliance between 3day and 8day courses when the drugs were in blister packs￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨prepackaging antimalarial drugs￨waiting time compliance￨the intervention which tended to improve both case and drug management at facilities was well accepted by health staff and did not involve them in additional working time￨sig increase￨highunclear￨highunclear￨highunclear
not found￨nonmalefactor infertility couples with nonmalefactor infertility 415 eligible and consenting couples at four uk centres￨intracytoplasmic sperm injection icsi conventional invitro fertilisation versus intracytoplasmic sperm injection icsi icsi or traditional ivf ivf or icsi￨pregnancy rate per cycle mean associated laboratory time implantation rate number of gestation sacs per embryo replaced expressed as a percentage pregnancy and fertilisation rates implantation rate￨the implantation rate was higher in the ivf group than in the icsi group 95318 30 vs 72325 22 relative risk 135 95 ci 104176￨sig increase￨low￨low￨low
80￨eighty patients undergoing either unilateral hip or knee joint replacement surgery￨ultrasound guided fascia iliaca block ultrasoundguided fascia iliaca block fascia iliaca compartment block by either loss of resistance or ultrasound guidance￨sensation and motor function femoral motor block knee extension complete loss of sensation in the anterior medial and lateral aspects of the thigh incidence of femoral incidence of sensory loss obturator motor block hip adduction frequency of femoral and obturator motor block frequency of sensory loss￨using ultrasound guidance there was a statistically significant increase in the incidence of sensory loss in the medial aspect of the thigh from 60 to 95 p  001￨sig increase￨highunclear￨highunclear￨highunclear
90￨ninety patients scheduled for surgery of the forearm or hand￨ultrasoundguided method with the nerve stimulatorguided method lidocaine ultrasoundguided axillary brachial plexus block axillary brachial plexus block nerve stimulatorguided and doubleinjection nd group ultrasoundguided and doubleinjection ud group and ultrasoundguided and singleinjection us group nerve stimulatorguided method lidocaine with 5 mg kg1 epinephrine ultrasoundguided singleinjection with those of doubleinjection￨success rate of performing the block incidence of adverse events satisfactory sensory and motor blockades￨the incidence of adverse events was significantly higher in the nd group 20 compared with that in the us group and the ud group 0 p  003￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨lateral sagittal infraclavicular blocks eighty patients asa 12￨electrical nerve stimulation and ultrasound guidance nerve stimulation group ns or ultrasoundguided blocks epinephrine electrical nerve stimulation or ultrasound guidance mepivacaine￨time until readiness for surgery quantified discomfort during the block and pain related to tourniquet ischemia on a numeric rating scale 010 median tourniquet pain success rates block performance time onset time for sensory block median discomfort time until readiness for surgery￨median discomfort related to the block procedure was 1 in both groups p  092 and median tourniquet pain was 05 in group ns and 1 in group us p  32￨no diff￨highunclear￨highunclear￨highunclear
40￨upper limb surgery forty patients￨conventional landmarkbased plexus anaesthesia or to an ultrasoundguided approach using a 13 mhz linear array transducer both interscalene and axillary techniques ultrasound guidance ultrasoundguided brachial plexus anaesthesia￨quality of brachial plexus anaesthesia ultrasound guidance quality of sensory and motor blockade onset and completeness of sensory incidence of paraesthesia￨ultrasound guidance also significantly reduced p0012 the incidence of paraesthesia during the performance of the blocks￨sig decrease￨highunclear￨highunclear￨highunclear
60￨60 patients undergoing hip surgery following trauma￨bupivacaine 20 ml 05 bupivacaine 30 ml 05 bupivacaine￨onset time quality and the onset time overall success quality of sensory block￨overall success for the 3in1 block in group a was 95 and in groups b and c 80￨sig increase￨highunclear￨highunclear￨highunclear
160￨160 patients american society of anesthesiologists physical status classification iiii scheduled for traumarelated upper arm surgery￨ropivacaine interscalene brachial plexus blockade direct ultrasound visualization or with the aid of nerve stimulation to guide needle placement ultrasonography ultrasonographic guidance￨sensory and motor blockade parameters success rate of interscalene brachial plexus blockade sensory motor and extent of blockade surgical anesthesia￨surgical anesthesia was achieved in 99 of patients in the ultrasound vs 91 of patients in the nerve stimulation group p  01￨no diff￨highunclear￨highunclear￨highunclear
not found￨sixty american society of anesthesiology physical status iiii patients receiving multiple injection axillary brachial plexus block￨ultrasound and nerve stimulation guidance nerve stimulation ultrasound guidance axillary brachial plexus block with 20 ml ropivacaine￨onset of sensory block median range number of needle passes procedurerelated pain patient acceptance onset of motor block￨procedurerelated pain was reported in 6 patients 20 of group us and 14 patients 48 of group ns p  0028 patient acceptance was similarly good in the two groups￨no diff￨highunclear￨highunclear￨highunclear
30￨lateral midfemoral sciatic nerve block sixtyone patients scheduled for foot and ankle surgery thirty patients underwent a￨ropivacaine lateral block of the sciatic nerve at the midfemoral level guided by ultrasound ultrasound guidance ultrasound combined with nerve stimulation block without ultrasound group es￨quality of the sensory block and the tolerance to the pneumatic tourniquet number of attempts to obtain an adequate motor response success rate of nerve location at the first attempt quality and duration of both sensory and motor blocks and anesthetic distribution success of sciatic nerve location￨the success of sciatic nerve location at the first attempt was significantly more frequent in the us group than in the es group 766 versus 419 p  0001￨sig increase￨highunclear￨highunclear￨highunclear
60￨60 patients undergoing knee arthroscopy￨sciatic nerve block femoral nerve block with ropivacaine 05 using either nerve stimulation group ns n  30 or ultrasound ropivacaine ultrasound guidance￨￨ultrasound guidance provided a 42 reduction in the meav of ropivacaine 05 required to block the femoral nerve as compared with the nerve stimulation guidance￨sig decrease￨highunclear￨highunclear￨highunclear
188￨patients undergoing elective hand surgery one hundred and eightyeight patients completed the study￨ultrasound guidance standardized solution containing 2 lidocaine with 1200000 epinephrine and 05 bupivacaine￨block success rate axillary bruising and pain success rate of axillary brachial plexus block￨block success rate was higher in groups us and usns 828 and 807 than group ns 629 p  001 and 003 respectively￨sig increase￨highunclear￨highunclear￨highunclear
60￨carpal tunnel release sixty patients undergoing ambulatory endoscopic carpal tunnel release￨mepivacaine median and ulnar nerve blocks using either sensorymotor nerve stimulation n  30 or ultrasound guidance ultrasoundguided wrist nerve blocks ultrasound or nerve stimulationguided wrist blocks￨median time success rate onset time of complete sensory block nerve blocks performance time and onset time of complete sensory block￨median time to perform both median ultrasound 55 4860 vs nerve stimulation 100 65150 seconds p  002 and ulnar ultrasound 57 5070 vs nerve stimulation 80 60105 seconds p  02 nerve blocks were significantly shorter in the ultrasound group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients undergoing elective hand surgery￨ultrasound guidance with nerve stimulation assistance continuous infraclavicular brachial plexus block using nonstimulating catheter group traditional nerve stimulation tr stimulating catheter group stimulating catheter st or ultrasoundguided catheter placement with nerve stimulation assistance group ultrasound guidance with nerve stimulation assistance us stimulating catheters continuous infraclavicular brachial plexus blocks using nonstimulating catheter stimulating catheter and ultrasoundguided catheter placement with nerve stimulation assistance ultrasoundguided continuous infraclavicular brachial plexus block with stimulating catheter and traditional technique￨motor and sensory blocks secondary catheter failure pain relief primary block success axillary nerve secondary catheter failure threshold stimulating current and resulting response spread of drug on reinjection￨the primary block success was significantly higher in the us group 96 us 58 st 59 tr p00005￨sig increase￨highunclear￨highunclear￨highunclear
44￨posterior popliteal sciatic nerve block fortyfour asa iiii patients undergoing posterior popliteal sciatic nerve block with 20 ml of 075￨nerve stimulation or ultrasound guided nerve block ultrasound vs nerve stimulation multiple injection technique ropivacaine ultrasound guidance￨time needed for block performance and procedural pain needle redirections success rate procedural pain￨ultrasound guidance reduced needle redirections p  001 were associated with less procedural pain p  0002 and required less time to perform p  0002￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨forty patients asa physical status ii or iii undergoing hip surgery after trauma￨bupivacaine ultrasonographic guidance￨analgesic effect incidental arterial puncture onset of sensory blockade heart rate noninvasive blood pressure and oxygen saturation sensory block and onset time quality and the onset of the sensory block quality of the sensory block￨the quality of the sensory block after injection of the local anesthetic was also significantly better in group us compared with group ns us 15￨sig increase￨highunclear￨highunclear￨highunclear
74￨74 patients undergoing elective major foot or ankle surgery￨ultrasound guidance sciatic nerve block at the popliteal fossa guided by either ultrasonography group us transverse view needle in plane approach above the sciatic nerve bifurcation or nerve stimulation lidocaine with 1200000 epinephrine and 15 ml of 05 bupivacaine￨block success sensory and motor function success rate of sciatic nerve block block procedure time or complications quality of popliteal sciatic nerve block block success rate success of sciatic nerve block higher success faster onset and progression of sensorimotor block￨ultrasound guidance resulted in higher success faster onset and progression of sensorimotor block without an increase in block procedure time or complications￨sig increase￨highunclear￨highunclear￨highunclear
80￨eighty patients￨bupivacaine ultrasonic guidance and neurostimulation compared with a supraclavicular technique that used anatomical landmarks and neurostimulation lidocaine ultrasoundguided neurostimulatorconfirmed supraclavicular block epinephrine ultrasoundguided neurostimulatorconfirmed supraclavicular block group us supraclavicular block guided in real time by a twodimensional ultrasonic image with neurostimulator confirmation of correct needle position and group ns supraclavicular block using the subclavian perivascular approach also with neurostimulator confirmation￨quality of supraclavicular block major complication surgical anesthesia without supplementation general anesthesia complete block of all nerve territories onset of motor and sensory block for the musculocutaneous median radial and ulnar nerves quality safety and execution time of supraclavicular block quality of ulnar block partial or complete sensory block of all nerve territories proportion of successful blocks decrease block execution time￨no patient in group us and 8 of patients in group ns required general anesthesia p  012￨no diff￨highunclear￨highunclear￨highunclear
56￨fiftysix asa physical status iiii patients presenting for elective hand surgery￨lidocaine ultrasound guidance epinephrine ultrasound guidance axillary block performed by either a transarterial technique group ta or an ultrasoundguided perivascular approach ultrasonographic guidance￨success rate of a perivascular axillary plexus block complete motor or sensory loss￨by 30 min postinjection there were no significant differences between groups ta and us in terms of the proportion of patients demonstrating a complete motor or sensory loss￨no diff￨highunclear￨highunclear￨highunclear
not found￨popliteal sciatic nerve block￨levobupivacaine popliteal sciatic nerve block with doubleinjection performed using anatomical landmarks and neurostimulation ns group n  30 versus combined ultrasound and neurostimulation guidance combined ultrasound and neurostimulation guidance￨block time block time success rate number of needle passes success rate of popliteal sciatic nerve block￨combined ultrasound and neurostimulation guidance does not decrease block time but increases the success rate of popliteal sciatic nerve block observed at 30 min￨no diff￨highunclear￨highunclear￨highunclear
100￨100 consecutive patients patients with a severe motor deficit and hemianopia or hemiinattention stroke patients hemiplegic upper limb in the acute phase after stroke chronic stroke patients￨sensorimotor stimulation or to a control group therapeutic intervention specific therapeutic intervention specific intervention￨adverse effects level of impairment brunnströmfuglmeyer test and disability action research arm test barthel index￨patients in the experimental group performed better on the brunnströmfuglmeyer test than those in the control group throughout the study period but differences were significant only at followup￨sig increase￨highunclear￨highunclear￨highunclear
90￨subjects were 90 patients admitted to holy family hospital in vancouver canada within 12 weeks after a first stroke consenting subjects￨occupational therapy approaches similar medical and nursing care and physical therapy￨￨results showed no statistically significant differences between the two treatment groups on the three outcome measures￨no diff￨highunclear￨highunclear￨highunclear
not found￨twentynine patients completed the experiment hemiplegic stroke patients acute stroke patients hemiplegic patients fortysix stroke survivors￨standard rehabilitation treatment and standard treatment plus ts thermal intervention thermal stimulation ts ts intervention￨recovery rates performance of brunnstrom stage and wrist extension and sensation brunnstrom stage modified motor assessment scale grasping strength angles of wrist extension and flexion sensation by monofilament and muscle tone by modified ashworth scale sensory and motor functional outcomes￨ts on the paretic hand significantly enhances the recovery of several aspects of sensory and motor functions in hemiplegic stroke patients￨sig increase￨highunclear￨highunclear￨highunclear
not found￨twentythree stroke patients stroke patients￨intermittent pneumatic compression ipc supplementary to their conventional physiotherapy a placebo treatment namely sham shortwave therapy intermittent pneumatic compression with a passive treatment strategy standard physiotherapy combined with intermittent pneumatic compression treatment intermittent pneumatic compression￨￨both groups improved in somatosensation over time but the experimental group improved more than the control group p 0036 or 811 improvement versus 309￨sig increase￨highunclear￨highunclear￨highunclear
not found￨twentyone subjects right or left hemiparesis able to walk 100 feet with or without a cane partially opened and closed the hand partially elevated the shoulder and elbow against gravity patients 6 months to 7 years poststroke following an neuroplasticity patients stable poststroke￨group a sensory training 4 weeks motor training 4 weeks or group b motor training 4 weeks sensory training 4 weeks outpatient rehabilitation program sensory and motor rehabilitation supervised learning based sensory motor training￨upper extremity ue function and independence functional independence and ue function fine motor sensory discrimination and musculoskeletal performance￨greater than 20 p  001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨thirtysix acute stroke patients 18 tens group 18 control group who experienced their first stroke were studied acute inpatient medical care setting of a university hospital acute hemiplegia acute stroke patients￨tens shortterm electrical stimulation neurodevelopmental exercises￨hand movement scores hand function kinaesthesia sense and position sense￨both groups showed improvement in hand movement scores p 005 whereas hand function improved only in the tens group p 005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨men who have sex with men in south florida in 2004 men who have sex with men men who have sex with men in south florida￨social marketing campaign￨social marketing campaign materials knowledge clinic visits or testing or treatment for syphilis syphilis infections￨exposure to social marketing campaign materials increased from 180 at baseline to 365 at followup p 001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨men who reported sex with men msm testing at the campaign clinic were monitored and compared with those testing at two other central london clinics at gay and bisexual men in london particularly targeting those of black and south european origin and those under the age of 25 years old using peer images￨multimedia hiv testing campaign aimed￨number of msm testing￨there was a 45fold rise p  0001 in msm testing at the campaign clinic￨sig increase￨highunclear￨highunclear￨highunclear
not found￨stable subjects with abpa n  29 stable allergic bronchopulmonary aspergillosis subjects with stable abpa allergic bronchopulmonary aspergillosis abpa subjects with abpa￨itraconazole antifungal agent itraconazole placebo itraconazole￨exacerbations requiring oral corticosteroids eosinophilic airway inflammation systemic immune activation and exacerbations sputum eosinophils igg levels to a fumigatu s serum ige levels systemic immune activation eosinophilic airway inflammation airway inflammation serum total ige and igg levels to a fumigatu s and blood eosinophil counts sputum eosinophil cationic protein levels￨there were fewer exacerbations requiring oral corticosteroids in those treated with itraconazole compared with in the placebo group p 03￨sig increase￨low￨low￨low
10￨noninvasive pulmonary aspergillosis ten patients seven with allergic bronchopulmonary aspergillosis and three with mycetoma were studied asthmatic patients treated with￨antifungal agent ketoconazole placebo ketoconazole ketoconazole￨concentrations of serum igg specific for aspergillus fumigatus fell symptom scores adverse effects serum igg concentration￨in the treated group n  6 concentrations of serum igg specific for aspergillus fumigatus fell significantly during treatment mean reduction 42 sem 22 compared with determinations preceding the study￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients who met immunologic and pulmonaryfunction criteria for corticosteroiddependent allergic bronchopulmonary aspergillosis allergic bronchopulmonary aspergillosis patients with corticosteroiddependent allergic bronchopulmonary aspergillosis￨itraconazole itraconazole twice daily or placebo placebo￨rate of adverse events relapse exercise tolerance or pulmonaryfunction tests or resolution or absence of pulmonary infiltrates serum ige concentration￨the rate of adverse events was similar in the two groups￨no diff￨low￨low￨low
982￨active rheumatoid arthritis 982 patients patients with active rheumatoid arthritis ra with an inadequate response to mtx therapy alone￨placebo subcutaneous certolizumab pegol methotrexate mtx certolizumab pegol plus methotrexate placebo plus methotrexate certolizumab pegol 200 or 400 mg plus mtx lyophilized certolizumab pegol mtx or placebo plus mtx placebo plus mtx￨response rate progression of structural joint damage and improved physical function physical function mean radiographic progression acr20 response rates ra signs and symptoms efficacy and safety￨differences in acr20 response rates versus placebo were significant at week 1 and were sustained to week 52 p  0001￨sig increase￨low￨low￨low
36￨patients with rheumatoid arthritis thirtysix patients 32 patients received a patients were predominantly female 3036 had a mean age of 56 yr and a mean duration of ra of 13 years￨placebo prednisolone cdp870 single openlabel infusion of either 5 or 20 mgkg cdp870 novel pegylated humanized antitnf fragment cdp870￨proportion of patients with acr20 improvement proportion of patients with acr50 improvement￨cdp870 is effective was very well tolerated in this small study and has an extended duration of action following one or more intravenous doses￨sig increase￨highunclear￨highunclear￨highunclear
209￨two hundred nine female adolescents aged 15 through 19 years who were treated for c trachomatis genitourinary infection one hundred twelve subjects returned for followup 5 to 7 months after enrollment and comprise the study subjects highrisk female adolescents urban family planning and sexually transmitted disease clinics￨standard control or experimental behavioral intervention behavioral intervention behavioral intervention￨rates of reinfection with c trachomatis vaginal intercourse higher cognitive complexity multiinstrument questionnaire measuring sexual behavior condom practices attitudes and beliefs cognitive complexity sociodemographics and motivation￨multivariable logistic regression analysis controlling for condom use at enrollment demonstrated that the experimental intervention odds ratio  28 p  003 and the higher cognitive complexity odds ratio  46 p  002 independently contributed to greater condom use at followup￨sig increase￨highunclear￨highunclear￨highunclear
409￨women 409 women recruited from family planning clinics in northern california hiv risk reduction among women￨condom use instructions skills training experimental 4session female condom skills training intervention or the comparison 4session womens general health promotion intervention female condom skills training￨female condom use and protected sexual acts male condom use percentage of sexual acts￨the increase in the percentage of sexual acts protected by female condoms from baseline to the 6month followup was greater for the experimental group￨sig decrease￨highunclear￨highunclear￨highunclear
62￨62 sexuallyactive single girls adolescent girls 33 sexuallyactive single girls￨hiv risk reduction intervention hiv intervention communitybased small group hiv risk reduction intervention￨several risk behaviors￨data obtained at a 3month followup assessment showed that girls who received the hivrelated intervention improved their hivrelated knowledge and enhanced their motivation for risk reduction compared to girls who received a control health promotion intervention￨sig increase￨highunclear￨highunclear￨highunclear
715￨clinicbased sample in atlanta georgia african american adolescent females seeking sexual health services african american adolescent females african american adolescent females n  715 aged 15 to 21 years seeking sexual health services￨hiv prevention program audio computerassisted selfinterview and provided selfcollected vaginal specimens for std testing sexually transmitted diseasehuman immunodeficiency virus sexual riskreduction intervention￨proportion of condomprotected sex acts chlamydial infection psychosocial mediators of stdhivpreventive behaviors incident chlamydial infections recurrent chlamydial infection￨adolescents in the intervention also reported a higher proportion of condomprotected sex acts in the 60 days preceding followup assessments mean difference 1084 95 ci 527 to 1642 p  001 and less frequent douching mean difference 076 95 ci 115 to 037 p  001￨sig decrease￨low￨low￨low
553￨553 lowincome african american adolescent girls with a baseline age of 11 to 14 years participated in the study african american adolescent females african american adolescent females￨hiv riskreduction intervention delivered by mothers with an hiv riskreduction intervention delivered by health professionals and with a health promotion intervention delivered by mothers￨hiv transmission knowledge condom attitudes and selfefficacy to use condoms￨the results revealed that over a 6month period compared to girls in the health promotion intervention the girls in the hiv riskreduction interventions had significant higher scores on hiv transmission knowledge condom attitudes and selfefficacy to use condoms￨sig increase￨highunclear￨highunclear￨highunclear
1210￨young women young women at risk for hivsexually transmitted disease std diverse populations of young atrisk women a proactively recruited sample of 1210 heterosexually active nonmonogamous nonpregnant women aged 1824 years recruited june 1999april 2000 85 completed the 6month followup two managed care plans in washington state and north carolina with followup at 3 and 6 months￨minimal selfhelp intervention usual care theorybased tailored minimal selfhelp intervention mailed computergenerated selfhelp magazine individually tailored on survey items including stage of readiness to use condoms barriers to condom use partner type condom samples and a condomcarrying case￨intercourse episodes percentage of women using condoms during the previous 3 months overall and by partner type and proportion of total episodes of intercourse￨significantly more intervention women carried condoms discussed condoms with partners and had higher selfefficacy to use condoms with primary partners￨sig increase￨low￨low￨low
424￨africanamerican and hispanic women mexicanamerican and africanamerican women at high risk for sexually transmitted disease enrolled women with nonviral sexually transmitted diseases sexually transmitted disease among minority women 424 mexicanamericans and 193 africanamerican women were enrolled 313 were assigned to the intervention group and 304 to the control group￨sex and culturespecific behavioral intervention standard counseling about sexually transmitted diseases behavioral intervention￨infection rates rate of participation rates of subsequent infection rates of chlamydial and gonorrheal infection subsequent chlamydial or gonorrheal infection rates of retention￨a riskreduction intervention consisting of three smallgroup sessions significantly decreased the rates of chlamydial and gonorrheal infection among mexicanamerican and africanamerican women at high risk for sexually transmitted disease￨sig decrease￨highunclear￨highunclear￨highunclear
2￨2 prenatal clinics pregnant women aged 14 to 25 years n  1047 to mean age of participants was 204 years 80 were african american￨hiv intervention individual care attentionmatched group care and group care with an integrated hiv component￨reduced biological behavioral and psychosocial risks for hiv condom use and decreased unprotected sexual intercourse sexually transmitted infection sti incidence repeat pregnancy sexual risk behavior and psychosocial risks sti incidence￨according to intenttotreat analyses women assigned to the hivprevention group intervention were significantly less likely to have repeat pregnancy at 6 months postpartum than individualcare and attentionmatched controls they demonstrated increased condom use and decreased unprotected sexual intercourse compared with individualcare and attentionmatched controls￨sig increase￨highunclear￨highunclear￨highunclear
522￨522 sexually experienced african american girls aged 14 to 18 years screened from december 1996 through april 1999 at 4 community health agencies african american adolescent girls￨hiv prevention intervention￨chlamydia infections and selfreported pregnancy sexual risk behaviors sexually transmitted diseases stds and pregnancy and enhance mediators of hivpreventive behaviors consistent condom use defined as condom use during every episode of vaginal intercourse other outcome measures were sexual behaviors observed condom application skills incident std infection selfreported pregnancy and mediators of hivpreventive behaviors￨to evaluate the efficacy of an intervention to reduce sexual risk behaviors sexually transmitted diseases stds and pregnancy and enhance mediators of hivpreventive behaviors￨no diff￨low￨low￨low
198￨participants were 198 unmarried female college students mean age  186 years who received a sexually active young women young women￨multicomponent intervention 1session condom promotion intervention or a control stress management intervention condom promotion intervention theorybased intervention￨benefits acceptance of sexuality control over the sexual encounter attitudes toward condoms and selfefficacy￨the condom promotion intervention led to increased selfreported condom use up to 6 months following intervention as well as positive changes in perceived benefits of condom use affective attitudes toward condom use and condom users perceived acceptance of sexuality control over the sexual encounter perceived selfefficacy for condom use and intentions to use condoms￨sig increase￨highunclear￨highunclear￨highunclear
not found￨adolescent mothers adolescent mothers offered in pregnant minor and parenting programs in los angeles county sample included young women n  497 of predominantly poor latina backgrounds who had complete data from baseline to the oneyear followup￨human immunodeficiency virus hiv prevention program￨aids knowledge and intentions to use condoms and fewer sex partners￨the treatment group demonstrated statistically significant improvements in aids knowledge and intentions to use condoms and fewer sex partners at the sixmonth followup as compared to the control group￨sig increase￨highunclear￨highunclear￨highunclear
3407￨3003 women in all 12 study neighborhoods on condom knowledge attitudes use and awareness of power materials promoting female and male condoms male condoms for 1525 yearoldwomen six of the 12 study neighborhoods 3407 women at precampaign in 12 western us neighborhoods on female and male condom awareness attitudes and use￨social marketing campaign power social marketing campaign￨awareness of attitudes toward and use of female￨we found no differences between neighborhoods with and without the power campaign with regard to our primary outcomes￨no diff￨highunclear￨highunclear￨highunclear
not found￨female college students participants were 78 undergraduate females m  20 years 76 europeanamerican who reported inconsistent condom use or multiple sexual partners collegeaged women￨onesession intervention based on the informationmotivationbehavioral skills imb model b a onesession informationonly intervention info or c a waitlist control wlc guided sexually transmitted disease std riskreduction intervention theorybased stdprevention program￨stdrelated knowledge number of sexual partners sexual risk behavior￨these results provide partial support for the hypothesis that an imb modelbased intervention leads to reductions in sexual risk behavior and suggest directions for future research￨sig increase￨highunclear￨highunclear￨highunclear
not found￨all female marine recruits n2288 in training were approached participants who had no history of stis or pregnancy young sexually active women who are not seeking health care young women￨cognitivebehavioral interventions to prevent stis or ups or to prevent physical training injuries and cancer cognitivebehavioral interventions￨pregnancy chlamydia trachomatis neisseria gonorrhoeae and trichomonas vaginalis postintervention sti or up odds ratio behavioral risk and preventing stis and ups risky sexual behaviors￨this randomized controlled trial indicates that cognitivebehavioral interventions are effective for reducing behavioral risk and preventing stis and ups in young sexually active women who are not seeking health care￨sig decrease￨low￨low￨low
123￨urban childrens hospital adolescent clinic and inpatient service female adolescents diagnosed as having an std intervention participants met with an educator at 1 3 and 6 months to discuss interim sexual history and review the intervention highrisk adolescent girls adolescent girls who have had an std one hundred twentythree adolescents with cervicitis or pelvic inflammatory disease￨individualized safer sex intervention safer sex intervention standard std education or to watch a videotape and have an individualized intervention session￨condom use and recurrent sexually transmitted disease std sexual risk knowledge and more positive attitudes toward condoms rate of recurrent std behaviors sexual risk knowledge attitudes toward condoms and condom use negotiation skills￨at 1 month compared with control participants intervention participants had increased sexual risk knowledge and more positive attitudes toward condoms and tended to use condoms more with a nonmain partner￨sig increase￨highunclear￨highunclear￨highunclear
542￨542 women at high risk for sexually transmitted infections stis and unintended pregnancy￨nontailored educational intervention general contraceptive information and nontailored advice computerbased tailored feedback using a multimedia program transtheoretical modeltailored expert system intervention￨rates of incident sti or unintended pregnancy likely to report use of dual contraceptive methods￨the computerbased transtheoretical modeltailored intervention resulted in a 70 increase in reported dualmethod contraceptive use in a group of women at high risk for stis and unintended pregnancy￨sig increase￨highunclear￨highunclear￨highunclear
400￨four hundred black and latina teenage women completed a questionnaire about their sexual behaviors young women who use and latina female adolescents￨inexpensive hivprevention interventions hormonal contraception lowcost theorybased intervention to promote dual method use by black video and get counseling or d receive usual care￨￨at 3month followup those who saw the video and received counseling were 25 times more likely to have used a condom at last intercourse with their main partner than teens in the usual care group￨sig increase￨highunclear￨highunclear￨highunclear
300￨adolescent females std risk 300 urban adolescent girls a￨interactive video behavioral intervention standalone interactive video intervention￨condom failures knowledge about sexually transmitted diseases stds b selfreported sexual risk behavior and c std acquisition￨selfreports revealed that those assigned to the interactive video were significantly more likely to be abstinent in the first 3 months following initial exposure to the intervention and experienced fewer condom failures in the following 3 months compared to controls￨sig decrease￨highunclear￨highunclear￨highunclear
12￨twelve pregnant women patients with the syndrome of hemolysis elevated liver enzymes and low platelets hellp pregnancies at 24 to 37 weeks gestation 25 antepartum patients with atypical severe preeclampsia expressed as hellp syndrome￨dexamethasone corticosteroids￨hellp syndrome maternal platelet count urinary output lactic dehydrogenase alanine aminotransferase and postponement of delivery lactic dehydrogenase and alanine aminotransferase maternal platelet count maternal urinary output syndrome of hemolysis elevated liver enzymes and low platelets hellp￨in the corticosteroidtreated group the maternal platelet count significantly increased p  0006 whereas lactic dehydrogenase and alanine aminotransferase significantly decreased over time p  003 and p  0005 in comparison to the 13 women who did not receive corticosteroids￨sig increase￨highunclear￨highunclear￨highunclear
60￨women with hellp syndrome 60 pregnant women with hellp syndrome who were treated at the perinatology department of the study center between january 2005 and february 2008 pregnant women with hellp syndrome 30 subjects while remaining 30 subjects received pregnant women diagnosed with hellp hemolysis elevated liver enzymes and low platelet count syndrome￨betamethasone placebo betamethasone￨diastolic blood pressure values hematological and metabolic complications maternal mortality percentage of women who received platelet transfusion platelet counts alanine aminotransferase aspartate aminotransferase and lactate dehydrogenase levels systolic blood pressure values￨the alterations in platelet counts alanine aminotransferase aspartate aminotransferase and lactate dehydrogenase levels of women treated with betamethasone were statistically similar to those of the placebo group￨no diff￨highunclear￨highunclear￨highunclear
not found￨postpartum hellp syndrome patients with postpartum hellp syndrome￨dexamethasone dexamethasone or betamethasone dexamethasone betamethasone dexamethasone and betamethasone￨mean arterial blood pressure need for readmission to the obstetrical recovery room course of postpartum hemolysis elevated liver enzymes low platelets hellp syndrome antihypertensive treatment￨patients in the dexamethasone group required less antihypertensive treatment than the betamethasone group 6 vs 50 p001 and also had a decreased need for readmission to the obstetrical recovery room 0 vs 22 p003￨sig decrease￨highunclear￨highunclear￨highunclear
40￨mothers with hellp syndrome forty patients were enrolled in the study 19 in the dexamethasone arm and 21 in the betamethasone arm gravid women with hellp syndrome￨betamethasone dexamethasone or betamethasone dexamethasone and betamethasone dexamethasone￨mean arterial pressure urinary output aspartate aminotransferase activity laboratory values platelet count lactate dehydrogenase activity aspartate aminotransferase activity and clinical parameters mean arterial pressure urinary output antepartum hellp hemolysis elevated liver enzymes and low platelet count syndrome￨intravenously administered dexamethasone appears to be more effective than intramuscularly administered betamethasone for the antepartum treatment of mothers with hellp syndrome￨sig increase￨highunclear￨highunclear￨highunclear
132￨pregnant women women with hellp syndrome 132 women with hellp syndrome pregnant and puerperal women￨placebo dexamethasone dexamethasone￨time to recovery of platelet counts aspartate aminotransferase mean duration of hospitalization lactate dehydrogenase duration of hospitalization￨no significant differences were found in the time to recovery of platelet counts hazard ratio 12 95 ci 0818 lactate dehydrogenase hazard ratio 09 95 ci 0515 aspartate aminotransferase hazard ratio 06 95 ci 0411 and to the development of complications￨no diff￨low￨low￨low
30￨patients with hellp syndrome thirty cases with hellp syndrome parturients with hellp syndrome￨corticosteroid control group did not receive any steroid medication dexamethasone postpartum corticosteroids￨length of hospitalization mean arterial blood pressure mean serum aspartate aminotransferase level mean urine volume per hour and mean platelet count arterial blood pressure urine output hematocrit ratio platelet count serum alanine and aspartate aminotransferases and uric acid levels￨the study group showed statistically significant improvement in mean arterial blood pressure mean serum aspartate aminotransferase level mean urine volume per hour and mean platelet count p  005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨hellp syndrome parturients with hellp syndrome who received a patients with postpartum hellp syndrome 17 mothers who initially received￨short course of postpartum dexamethasone therapy dexamethasone dexamethasone hellp syndrome who received no corticosteroids￨liver enzymes and blood pressure blood pressure urinary output lactic dehydrogenase aspartato aminotransferase and alanine aminotransferase values time in platelet count platelet count￨relative to the control group the platelet count increased significantly by 30 h postpartum p  001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with this form of severe preeclampsia patients with advanced cases 40 parturients with the syndrome were recruited￨control group received no corticosteroids intravenous dexamethasone￨mean arterial pressure mean arterial pressure urinary output platelet count lactic dehydrogenase and aspartate aminotransferase urinary output mean arterial pressure platelet count lactic dehydrogenase and aspartate aminotransferase urinary output lactic dehydrogenase and aspartate aminotransferase platelet count mean arterial pressure and urinary output every 2 hours hematocrit and platelet count every 6 hours and lactic dehydrogenase aspartate aminotransferase and alanine aminotransferase overall maternal morbidity and mortality￨relative to the control group the mean arterial pressure became significantly decreased at 22 hours in the steroidtreated group p  003 urinary output increased significantly by 16 hours p  002 the platelet count increased significantly by 24 hours p  005 and both lactic dehydrogenase and aspartate aminotransferase decreased significantly by 36 hours p  004 and p  005 respectively￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨twenty patients in whom pregnancy was complicated by antepartum or postpartum hellp syndrome patients with hellp hemolysis elevated liver enzymes low platelets count syndrome￨placebo corticotherapy dexamethasone postpartum corticosteroid therapy corticosteroids￨maternal morbidity￨it permitted a rapid correction of the thrombopenia from the 24th hour but its effect on hemolysis marker was later from the 36th hour￨sig decrease￨highunclear￨highunclear￨highunclear
31￨selected patients with a hellp syndrome remote from term prolonged administration of 31 pregnant women with hellp syndrome with an onset before 30 weeks gestation patients with hellp syndrome remote from term￨prednisolone or placebo placebo prednisolone highdose prednisolone￨early onset hellp hemolysis elevated liver enzymes and low platelets syndrome serious maternal morbidity consequence of liver rupture platelet count entrytodelivery interval and the number of recurrent hellp exacerbations in the antepartum period mean entrydelivery interval risk of a recurrent hellp exacerbation￨platelet count recovered faster in the prednisolone group as compared to the placebo group mean 17 days versus 62 days p001￨sig increase￨low￨low￨low
not found￨subjects with oral leukoplakia in kerala india 43 complaint subjects on placebo 42 on vitamin a and 46 on beta carotene subjects with highrisk leukoplakias with oral cancer 160 fishermen and women with oral precancerous lesions￨oral leukoplakia with vitamin a and beta carotene vitamin a alone or beta carotene alone placebo oral vitamin a retinyl acetate 300000 iuweek x 12 months n  50 or beta carotene￨blood saliva and urine samples serum alpha tocopherol remission of oral leukoplakia major toxicities complete regression rates serum beta carotene concentration serum retinol levels￨vitamin a administration resulted in a significant remission of oral leukoplakia without any side effects of prolonged vitamin a supplementation￨no diff￨low￨low￨low
44￨44 patients with this disease to receive￨13cisretinoic acid 13cisretinoic acid placebo 13cisretinoic acid 24 patients or placebo￨histologic response cheilitis facial erythema and dryness and peeling of the skin were common conjunctivitis and hypertriglyceridemia dysplasia toxic effects relapse size of the lesions￨there were major decreases in the size of the lesions in 67 percent 16 patients of those given the drug and in 10 percent 2 patients of those given placebo p  00002 dysplasia was reversed in 54 percent 13 patients of the drug group and in 10 percent 2 patients of the placebo group p  001￨sig decrease￨highunclear￨highunclear￨highunclear
57￨oropharyngeal leukoplakia 57 patients￨placebo nonselective cyclooxygenase cox inhibitors ketorolac ketorolac tromethamine oral rinse cyclooxygenase inhibitor ketorolac ketorolac 10 ml of a 01 ketorolac rinse solution￨area of oral leukoplakia visually obtaining bidimensional measurement of the size of leukoplakia lesions adverse events change in histology histological assessment of the leukoplakia major response rate complete response and partial response￨major response rate complete response and partial response was 30 for ketorolac and 32 for the placebo arm￨no diff￨low￨low￨low
not found￨￨placebo vitamin a therapy placebo capsules tobaccobetel nut chewers kerala india with welldeveloped oral leukoplakias vitamin vitamin a￨loss of polarity of basal cells complete remission number of layers of spinous cells subepidermal lymphocytic infiltration￨over the 6month period of vitamin a administration the number of layers of spinous cells decreased in 85 of the participants the loss of polarity of basal cells was reduced from 722 to 222 of chewers subepidermal lymphocytic infiltration was greatly diminished from 667 to 55 of chewers and nuclei with condensed chromatin disappeared from the epidermal layer 722 before to 0 at the end of the trial￨sig decrease￨highunclear￨highunclear￨highunclear
22￨oral leukoplakia￨topical bleomycin placebo bleomycin topical bleomycin bleomycin dimethylsulphoxide dmso￨clinical size of the lesion histological reduction in dysplasia￨of the patients who received bleomycin decrease in clinical size of the lesion was achieved p  0001 and histological reduction in dysplasia was seen p  0094￨sig increase￨highunclear￨highunclear￨highunclear
21￨twentyone volunteers 16 men five women with oral leucoplakia histologically diagnosed￨acitretin placebo tablets without acitretin￨concentrations of acitretin in plasma saliva and tissue serum aspartate aminotransferase alanine aminotransferase cholesterol and triglycerides acitretin concentration in plasma and tissue laboratory values clinical remission￨the acitretin concentration in plasma and tissue ranged from 0 to 50 mg with no difference between groups a and b and it was very high in saliva ranging from 49 to 43 mg with higher concentrations in group a than in group b due to a longer adhesion time in group a￨no diff￨highunclear￨highunclear￨highunclear
58￨oral leukoplakia fiftyeight clinically and histologically diagnosed patients of oral leukoplakia￨placebo lycopene oral lycopene￨mean response￨patients receiving lycopene in both regimes show highly significant difference in response as compared to placebo group c￨sig decrease￨highunclear￨highunclear￨highunclear
20￨human oral precancerous mucosa lesions fiftynine oral mucosa leukoplakia patients diagnosed by established clinical and pathological criteria patients with oral mucosa leukoplakia using a mixed tea product developed by the authors 20 healthy subjects￨control group placebo and glycerin treatment￨incidence of micronucleated exfoliated oral mucosa cells oral lesion micronuclei and chromosome aberration rate size of oral lesion number and total volume of the silverstained nucleolar organizer regions agnor and the proliferating index of proliferation cell nuclear antigen pcna in oral mucosa cell nuclei cell proliferation￨in pathological examination there were significant differences p  0 05 in the number and total volume of the silverstained nucleolar organizer regions agnor and the proliferating index of proliferation cell nuclear antigen pcna in oral mucosa cell nuclei between the treated group and the control group which indicates that cell proliferation was decreased in the treated patients￨sig decrease￨highunclear￨highunclear￨highunclear
10￨10 patients with oral leukoplakia￨13cisretinoic acid placebo isotretinoin gel or a placebo 13cisretinoic acid isotretinointopically treated oral leukoplakia￨oral lesions size and clinical appearance of the lesions count of the apoptotic bodies apoptotic bodies percentage of bcl2positive cells bcl2 positivity￨immunohistochemical analysis for bcl2 protein showed that before treatment a weak positivity of the basal layers with a focal positivity of some parabasal cells was present five out of nine specimens were positive￨sig increase￨highunclear￨highunclear￨highunclear
57￨hip fracture surgery fiftyseven patients patients requiring surgery for an isolated hip fracture of less than 48 h received￨tranexamic acid placebo saline or tranexamic acid 15 mg kg1 given at skin incision and 3 h later tranexamic acid￨rate of erythrocyte transfusion erythrocyte transfusion efficacy and safety probability of vascular events￨the rate of erythrocyte transfusion was 42 with tranexamic acid and 60 with placebo p006￨no diff￨low￨low￨low
397￨397 patients with macular edema after brvo macular edema after brvo 2011 american academy of ophthalmology patients with study eye bestcorrected visual acuity bcva 2040 or central subfield thickness 250 μm were to receive macular edema following branch retinal vein occlusion eligible patients patients with macular edema after branch retinal vein occlusion brvo￨intraocular injections of 03 mg or 05 mg ranibizumab ranibizumab injections ranibizumab or sham injections ranibizumab￨new ocular or nonocular safety events rapid reduction in cft central foveal thickness cft mean change from baseline bcva letter score baseline bcva letter score bcva￨no new ocular or nonocular safety events were identified￨no diff￨low￨low￨low
30￨patients with cystoid macular edema secondary to perfused branch retinal vein occlusion cystoid macular edema in branch retinal vein occlusion patients with perfused branch retinal vein occlusion thirty eyes of 30 consecutive patients with cystoid macular edema secondary to nonischemic branch retinal vein occlusion￨bevacizumab and macular grid laser photocoagulation glp bevacizumab macular laser grid photocoagulation bevacizumab glp group or to intravitreal bevacizumab ib intravitreal bevacizumab intravitreal bevacizumab injection￨bcva and lower cmt values bcva and reduces cmt logarithm of minimum angle of resolution logmar bestcorrected visual acuity bcva central macular thickness cmt baseline bcva bcva￨the group receiving bevacizumab had better bcva and lower cmt values at all time points p  005￨sig decrease￨highunclear￨highunclear￨highunclear
53￨epileptic patients fiftythree hospital outpatients with epilepsy￨anticonvulsant therapy combination of complianceimproving strategies patient counselling a special medication container selfrecording of medication intake and seizures and mailed reminders to collect prescription refills and attend clinic appointments￨plasma anticonvulsant levels and prescription refill frequencies and seizure frequency compliance and seizure frequency seizure frequency patient compliance and clinical control￨compliance and seizure frequency were unaltered in the control group￨no diff￨highunclear￨highunclear￨highunclear
283￨people with epilepsy aged over 15 years who were registered with 37 general practitioners patients knowledge of epilepsy and their emotional state younger people those who had left school after 16 years of age those with gcses and people who belonged to selfhelp groups had higher two hundred and fiftyone out of 283 89 of the patients with epilepsy completed questionnaires and entered the study at stage 1 one hundred and ninetysix out of 232 84 of those who entered the study who remained in the practices and were eligible returned questionnaires at stage 2￨special nurse nurse intervention epilepsy nurse or usual care￨depression scores risk of depression patients levels of knowledge of epilepsy knowledge scores average duration of epilepsy knowledge anxiety and depression knowledge levels￨a nurserun clinic reduced the risk of depression for people with no recent epilepsy attack but knowledge levels were not affected￨no diff￨highunclear￨highunclear￨highunclear
1275￨people with active epilepsy n  1275 from 82 practices people with epilepsy￨￨doctorheld card practices proportion of seizure seizure frequency medicationrelated sideeffects￨a doctorheld prompt and reminder card is effective in improving the recording of key clinical information for people with epilepsy is felt to be useful by gps and is completed more often than a patientheld card￨sig increase￨highunclear￨highunclear￨highunclear
90￨patients who have less general education have less knowledge of epilepsy newly diagnosed epilepsy ninety people with new epilepsy completed the trial neurologists in the united kingdom uk recruited adults with newly diagnosed epilepsy people with newly diagnosed epilepsy￨epilepsy nurse specialist or usual medical care nurse intervention epilepsy nurse specialist￨questionnaire assessing patients knowledge of epilepsy the hospital anxiety and depression scale and patients reported satisfaction with the advice and explanations provided on key epilepsyrelated topics knowledge of epilepsy scores knowledge scores￨the introduction of a nurse specialist in epilepsy is associated with a significant increase in patient reports that enough advice has been provided￨sig increase￨highunclear￨highunclear￨highunclear
not found￨primary health care workers from 24 clinics in the zvimba district in zimbabwe attended a workshop to improving their knowledge in the diagnosis and management of generalized tonicclonic seizures patients with epilepsy in zimbabwe patients with epilepsy￨patientinformation pamphlets￨frequency of clinic attendance mean seizure frequencies and mean serum levels of phenobarbitone￨community health worker education led to a 74 increase in patient recruitment as well as a marked improvement in patient drug compliance over the 6month study period￨sig increase￨highunclear￨highunclear￨highunclear
242￨patients with epilepsy moses 242 patients were aged from 16 to 80 years patients from 22 epilepsy centers in germany austria and switzerland even patients with a long history of epilepsy and with additional handicaps or diseases benefitted from the moses program￨moses moses group treatment group or waitinglist group control group educational treatment program￨seizure frequency and satisfaction knowledge seizure outcome tolerability of antiepileptic drug aed therapy fewer side effects generic instruments sf36 rosenberg selfesteem scale von zerssen depression scale and epilepsyspecific scales restrictions in daily life epilepsyrelated fears coping with epilepsy and adaptation generic questionnaires sf36 selfesteem￨participants of the moses program also improved in seizure outcome p  0041 and became more satisfied with the therapy better tolerability of antiepileptic drug aed therapy fewer side effects p  0014￨sig increase￨highunclear￨highunclear￨highunclear
not found￨participants were general practitioners from 68 practices in tayside scotland and 1133 of their patients with selfreported epilepsy treated with antiepileptic medications aeds scottish national epilepsy guideline in primary care￨intensive intervention intermediate intervention control intermediate intervention plus a nurse specialist who supported and educated practices￨sf36 healthrelated qualityoflife instrument processofcare measures patient quality of life or quality of epilepsy care battery of prevalidated epilepsyspecific qualityoflife instruments￨none of the intervention strategies led to improvements in patient quality of life or quality of epilepsy care￨no diff￨low￨low￨low
114￨one hundred fourteen adult patients with uncontrolled epilepsy patients with epilepsy￨interactive 1day group education program followed by extended nurse followup and counseling structured nurseled intervention program nurseled intervention program￨quality of life qol physical role limitations qol quality of life medication effects￨qol was significantly improved from inclusion to completion of study in the intervention group p0019 mainly in the subitems for health discouragement p001 medication effects p0035 and physical role limitations p005￨sig increase￨highunclear￨highunclear￨highunclear
38￨thirtyeight outpatients matched according to seizure type and frequency￨waitinglist control psychoeducational treatment program sepulveda epilepsy education program see￨overall understanding of epilepsy medication compliance 50item truefalse test specifically designed to evaluate the see program the washington psychosocial seizure inventory the beck depression inventory lubins depression adjective checklist the statetrait anxiety inventory the acceptance of disability scale and sherers selfefficacy scale hazardous medical selfmanagement practices blood levels of antiepileptic drugs aeds fear of seizures￨significant differences between the two groups were found on the three major subscales of the 50item truefalse test￨no diff￨highunclear￨highunclear￨highunclear
28￨twentyeight patients twentythree patients completed the study exercise n  14 control n  9 patients with epilepsy patients with epilepsy￨12week outpatient exercise program exercise program supervised exercise program exercise or to continue their current level of activity with no planned intervention control￨clinical and behavioral outcomes overall quality of life and two domain scores seizure activity physical selfconcept and vigor that improved and total mood disturbance active seizures behavioral outcomes seizure frequency behavioral qolie89 poms psdq selfesteem and clinical seizure activity antiepileptic drug aed concentrations outcomes￨the overall quality of life and two domain scores improved from baseline to week 12 in the exercise group p  0031 while the control group score did not change p  0943￨sig increase￨highunclear￨highunclear￨highunclear
251￨patients with epilepsy in general practice 251 patients aged over 15 years who were taking antiepileptic drugs or had a diagnosis of epilepsy and an attack in the past two years who met specified inclusion criteria and had responded to a questionnaire 127 patients were randomised to a nurse run clinic of whom 106 83 attended six general practices in the south thames region patients with epilepsy￨nurse run epilepsy clinics nurse run clinics versus usual care nurse run clinics￨level of advice recorded as having been given on drug compliance adverse drug effects driving alcohol intake and self help groups questionnaire responses￨for this intervention group compared with the usual care group there was a highly significant improvement in the level of advice recorded as having been given on drug compliance adverse drug effects driving alcohol intake and self help groups￨sig increase￨highunclear￨highunclear￨highunclear
62￨sixtytwo patients with an aep score of or45 were enrolled from a consecutive group of 200 consenting adults with epilepsy￨aep aep with usual care without the aep￨aep scores seizure rates qolie89 score mean change in quality of life in epilepsy inventory qolie89 total scores￨mean change in quality of life in epilepsy inventory qolie89 total scores was not different between groups but for the entire sample qolie89 change was greater for patients having a 15point improvement in aep scores than for those with a 0 to 15point improvement or a worsened score 24 vs 12 vs 3 analysis of variance p  0008￨no diff￨highunclear￨highunclear￨highunclear
595￨patients who reported having seen the nurse at least once in the two years users were compared with those who had not nonusers epilepsy specialist nurses 595 adult patients known to have epilepsy in 14 general practices and who answered questionnaires at baseline and two years later￨primary care based epilepsy specialist nurse service￨quality of care communication and satisfaction￨users of the new service were significantly more likely than nonusers to have discussed 8 of 11 topics asked about epilepsy odds ratios ors ranging from 242 to 791 with their general practitioner gp and 2 of the 11 topics with the hospital doctor ors 559 5 74￨sig increase￨highunclear￨highunclear￨highunclear
178￨178 asymptomatic female family practice patients aged 50 to 69 years￨￨￨a randomized controlled study that evaluated a recall system and patient education material by mail in 178 asymptomatic female family practice patients aged 50 to 69 years showed no effect on the proportion of patients who had cancer screening tests p  20 and a significant adverse effect on the mean number of tests performed p  05 after 4 months￨sig increase￨highunclear￨highunclear￨highunclear
not found￨women 40 to 79 years of age who were past due for cancer screening pap tests and mammograms in a lowincome managed care program women who reported having to take time off from work to see a doctor had lower odds of getting screened￨physician letters and phone calls physician reminder letter and a telephone contact￨￨the odds of receiving all needed cancer screening tests during followup were four times higher in the intervention group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨women with prior abnormal mammograms women with abnormal mammogram results women with abnormal mammograms￨mailing psychoeducational materials mailed psychoeducational materials￨adherence￨we conclude that mailed psychoeducational materials may be an effective mechanism to improve adherence among women with abnormal mammogram results￨sig increase￨highunclear￨highunclear￨highunclear
not found￨female members of a large health maintenance organization seven thousand seventyseven female health maintenance organization members aged 5074 years with no prior mammogram in the previous 30 months or aged 2064 years with no prior pap smear in the previous 36 months women who do not use health care services￨screening mammograms and papanicolaou pap smears letter inviting them to make an appointment for a mammogram or a pap smear in addition to the letter a reminder manually placed in the patients medical chart alerting providers of that members need for screening or their usual care patient reminder letters as a first step in a mammography or pap smear screening outreach program￨receive pap smears pap smears￨we recommend the use of patient reminder letters as a first step in a mammography or pap smear screening outreach program￨sig increase￨highunclear￨highunclear￨highunclear
6￨women aged 65 to 70 years old were at least as likely to respond to the invitation as women aged 45 to 64 women aged 45 to 70 five out of six randomly selected general practices in drummoyne participated￨general practitionerwritten invitations letter from their general practitioner gp￨￨an attendance of 38 per cent was obtained for women whose gp chose to send a letter with an appointment compared to 24 per cent for women whose gp chose to send a general invitation without an appointment￨sig increase￨highunclear￨highunclear￨highunclear
not found￨screening by asian women women with asian names from a batch of general practices where high proportions of patients were asian who were invited for screening￨linkworker intervention giving encouragement and explanations about breast screening linkworker intervention￨attendance￨no difference in attendance was found between the intervention and control groups 49 per cent and 47 per cent￨no diff￨highunclear￨highunclear￨highunclear
not found￨all women had had a mammogram 1 year previously and were due for another mammogram women ages 50 and older from the deighton family practice center in southfield mich women who received these interventions to mammogram screening rates in a control group￨reminder letter from the radiology department mammography reminder letter followed by a phone call from the physicians office staff if no mammogram￨mammogram screening rates mammogram screening rate￨a mammogram was obtained by 33 of women in group 1 37 of women in group 2 and 57 of women in group 3￨sig increase￨highunclear￨highunclear￨highunclear
3291￨3291 women aged 5064 years who were due to be called for breast screening for the first time breast screening in inner london three neighbouring health districts in inner south east london 2 health behaviours￨￨exercise smoking diet change and breast selfexamination sociodemographic factors health behaviours and attitudes beliefs and intentions average attendance rate attitudes beliefs and intentions attendance perceived importance of regular screening for cervical and breast cancer and intentions to go for breast screening￨age and other risk factors for breast cancer were unrelated to attendance as was the distance between home and the screening centre￨no diff￨highunclear￨highunclear￨highunclear
321￨321 women who were recruited were demographically diverse participants ages 35 and older had a mammogram within an appropriate interval subjects were recruited from a variety of sources including patients seen in a community health center women referred by the national black womens health project nbwhp residents of public and senior citizen housing projects and persons identified in various community settings￨lay health workers lhws cancer screening intervention￨￨there was little variation by source of recruitment in compliance with screening recommendations except that referrals from nbwhp were more likely p less than 001 to have had a pap test and breast selfexamination while residents of public housing projects were somewhat less likely to have done so￨no diff￨highunclear￨highunclear￨highunclear
2064￨patients who had failed to attend for breast screening and whether women from different ethnic groups benefited equally multiethnic populations women who had not taken up their original invitation 2064 women aged 5064 years who had failed to attend for breast screening￨￨attendance￨the response was best in indian womenit was 19 in the intervention group and 5 in the control group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨women aged 45 to 69 who had not attended for screening at the mobile breast xray programme of the central sydney area health service were randomly selected from the 1989 electoral listing older women responded at least as well as younger women￨intervention group who received letters from the program inviting them to attend at a specified time control group who did not receive invitations￨￨overall 33 per cent of women 53 of 163 who were sent invitations attended for screening compared to 9 per cent of those not invited 7 of 80 p less than 0001￨sig increase￨highunclear￨highunclear￨highunclear
460￨women aged 65 and older older women four hundred and sixty women identified from physician practices￨grocery coupon control or a twostep intervention physician letter and peer counseling call￨screening mammography￨the most dramatic difference was in the higher odds that women in the intervention group would obtain a mammogram within 2 months odds ratio  105￨sig decrease￨highunclear￨highunclear￨highunclear
34￨fecally incontinent patients after implantation 27 of 34 patients fecal incontinence 34 consecutive patients 31 women median age 57 years range 3373 years￨stimulation on or off sacral nerve stimulation￨anal sphincter function ability to postpone defecation quality of life score for symptom severity frequency of fecal incontinence episodes frequency of fecal incontinence and urgency episodes delay in postponing defecation score severity feeling of improvement preference for on or off quality of life and manometric measurements fi￨in the final period of the study the frequency of fecal incontinence episodes decreased significantly p  0005 in patients with the stimulator on￨sig decrease￨highunclear￨highunclear￨highunclear
2￨selected patients with fecal incontinence two patients with passive fecal incontinence who had been implanted for nine months with a permanent sacral nerve stimulator and electrode patients with fecal incontinence￨sacral nerve stimulation sacral nerve stimulation￨squeeze pressure resting pressure and rectal threshold and urge volumes fecal incontinence diaries anorectal physiological tests and qualityoflife assessments sf36 health survey number and severity of episodes of incontinence fecal incontinence quality of life qualityoflife measurements￨there was an increase in squeeze pressure patient 1 70 vs 100 cm h2o patient 2 60 vs 90 cm h2o off vs on with moderate increases in resting pressure and rectal threshold and urge volumes￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨nulliparous women 32 to 34 weeks pregnant were recruited from june 8 to july 31 1992 at the offices of family physicians and obstetricians who practice at the hôpital du saintsacrement in quebec city 174 women who delivered during the study period 104 598 were approached by a midwife and 46 264 were randomized perineal trauma by perineal massage during pregnancy￨intervention group practiced daily 10minute perineal massage and completed a diary and those in the control group had standard care perineal massage￨perineal massage diaries￨no woman in the control group practiced massage￨no diff￨highunclear￨highunclear￨highunclear
not found￨perineal trauma at birth pregnant women with n  493 and without n  1034 a previous vaginal birth from 5 hospitals in the province of québec canada￨perineal massage perineal trauma by perineal massage perineal massage￨frequency of sutured vulvar and vaginal tears womens sense of control and satisfaction with the delivery experience incidence of delivery with an intact perineum￨there were no differences between the groups in the frequency of sutured vulvar and vaginal tears womens sense of control and satisfaction with the delivery experience￨no diff￨low￨low￨low
861￨eight hundred and sixtyone nulliparous women with singleton pregnancy and fulfilling criteria for entry to the trial between june 1994 and october 1995￨antenatal perineal massage antenatal perineal massage￨tear rates instrumental deliveries￨comparison of the group assigned to massage with the group assigned to no massage showed a reduction of 61 in second or third degree tears or episiotomies￨sig decrease￨highunclear￨highunclear￨highunclear
309￨309 patients with crc from saarland germany one and three years after diagnosis using the qlqc30 questionnaire and the tumour specific module qlqcr38 patients with colorectal cancer colorectal cancer patients￨￨quality of life overall quality of life￨improvements in quality of life from the first to the third year after diagnosis in patients who remained free of disease were very modest and limited to less financial difficulties a better future perspective and fewer stomarelated problems￨sig increase￨highunclear￨highunclear￨highunclear
62￨fiveyear survivors treated for low or very low rectal cancer with an advancedcomplex coloanal procedure with the qol of patients submitted to a standard ape with a definitive abdominal stoma thirtytwo patients group 2 had undergone a radical advanced and complex procedure to avoid the abdominal stoma very low rectal cancer with or without a permanent abdominal stoma thirty patients group 1 had an ape with permanent abdominal stoma sixtytwo patients operated on radically for low or very low rectal cancer who came for their fifth year followup visit and were free from cancer were studied￨￨quality of life quality of life qol￨patients without a terminal abdominal stoma had a better score in six categories of the qol 30 and in two categories of the cr38￨sig increase￨highunclear￨highunclear￨highunclear
516￨373 patients 12 to 18 months after surgery 261 patients patients with rectal cancer 516 patients who had undergone surgery for rectal cancer in our department from 1992 to 2002 were included￨￨sexual life sexuality and quality of life symptom and function scales sexuality quality of life and sexuality￨both genders had impaired sexual life however males had significantly higher values and felt more distressed by this impairment￨sig increase￨highunclear￨highunclear￨highunclear
142￨142 consecutive patients who underwent surgery for ultralow rectal carcinoma from january 1991 to december 2004 were reviewed retrospectively elder patients with planned coloanal pullthrough anastomosis patients with rectal cancer￨ultralow anterior resection ular modern sphincterpreserving surgery ape￨readmitted stenosis and anastomotic leakage generic and cancerspecific quality of life questionnaires quality of life qol quality of life failure rate rate of rehospitalisation and rate of nonreversed temporary stomas failure stoma￨the failure rate was higher for older patients p  0005 and for coloanal pullthrough anastomosis p  0001￨sig increase￨highunclear￨highunclear￨highunclear
121￨one hundred twentyone patients in complete remission more than 2 years after diagnosis diseasefree survivors of rectal cancer￨￨social functioning higher selfesteem eortc qlqc30 physical scores anxiety quality of life qol pain quality of life￨eortc qlqc30 physical scores were also higher among rectal cancer survivors than in the general norwegian or german population p 0005￨sig increase￨highunclear￨highunclear￨highunclear
14￨patients after fourteen patients undergoing abdominoperineal extirpation and 26 undergoing anterior resection rectal cancer￨abdominoperineal extirpation anterior resection versus abdominoperineal extirpation￨quality of life generic quality of life instrument sf36 together with a new symptomspecific fecal incontinence quality of life scale quality of life total score of the symptomspecific scale￨the only significant difference between the two groups was found in the total score of the symptomspecific scale in favour of anterior resection p  002￨sig increase￨highunclear￨highunclear￨highunclear
98￨colorectal cancer patients qol colorectal cancer patients with colectomy and the validation of the functional assessment of cancer therapycolorectal ninetyeight colorectal cancer patients￨cancer therapycolorectal the factc￨performance status rating neuroticism scale in the eysenck personality questionnaire and functional living indexcancer quality of life overall qol￨we found convergent and divergent validity and good reliability of the factc patients overall qol was lower at one month after colectomy and recovered to the presurgery level at six months after colectomy￨sig increase￨highunclear￨highunclear￨highunclear
154￨chinese patients with eortc qlqcr29 all cancer patients qlqc30 and for colorectal cancer patients qlqcr29 curatively treated patients with rectal cancer patients with stage iiii rectal cancer who were treated curatively in a single institution were accrued prospectively patients with either pre or postoperative chemoradiotherapy curatively treated patients with rectal cancer in a prospectively collected cohort chinese rectal cancer patients with currently widely used qol questionnaires a total of 154 patients were assessed￨￨median time of completion scales qlqc30 module quality of life quality of life faecal incontinence and diarrhea bowel dysfunction diarrhea and faecal incontinence male or female sexual function symptoms of defaecation and embarrassment with bowel movement￨for patients with different treatment modalities faecal incontinence and diarrhea were significantly higher in radiation group p  0002 and p  0001 respectively and no difference in male or female sexual function was found between radiation group and nonradiation group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients 519 patients who had undergone surgery for rectal cancer from january 1997 to january 2003 were included in the study patients aged 69 and younger while patients aged 70 and older suffered from fatigue younger patients patients with rectal cancer￨rectal surgery surgical procedures abdominoperineal resection apr versus anterior resection ar￨severe impairment of sexuality postoperative quality of life qol and sexual function sexuality quality of life physical function and overall quality of life and higher values for fatigue severe emotional symptoms physical function and overall quality of life sexual life scales of function and symptoms￨physical function and overall quality of life were better in patients aged 69 and younger while patients aged 70 and older suffered from fatigue￨sig increase￨highunclear￨highunclear￨highunclear
132￨patients operated on for low rectal cancer all patients had undergone one of four operations low anterior resection with colorectal or coloanal anastomosis nonstoma group or a total of 132 patients were included for analysis and there were no missing data￨abdominoperineal resection with pseudocontinent perineal colostomy nonstoma group or left lower quadrant colostomy stoma group permanent colostomy and sociodemographic characteristics￨cancer qlqc30 and cr38 questionnaires quality of life scores financial worries body image finance and gastrointestinal symptoms gastrointestinal concerns quality of life quality of life￨stoma patients experienced greater financial worries p  00029 whereas nonstoma patients had greater gastrointestinal concerns p  00098￨sig decrease￨highunclear￨highunclear￨highunclear
53￨fiftythree patients who had anterior resection for low rectal cancer were individually matched with 53 other patients who had an abdominoperineal resection during the same period of time for gender age and socioeconomic status low rectal cancer￨abdominoperineal resection anterior resection￨perception of body image quality of life questionnaires morbidity and quality of life qlqcr38 questionnaire quality of life shortterm and the longterm complication rates global quality of life score tumour recurrence￨there was no significant difference in both the shortterm and the longterm complication rates between the two groups of patients￨no diff￨highunclear￨highunclear￨highunclear
116￨116 patients with locally advanced rectal cancer surgically treated in our hospital from 1994 to 1999 patients surgically treated for locally advanced rectal cancer included sex tumor site and surgical technique patients surgically treated for rectal cancer patients with locally advanced rectal cancer￨￨quality of life scores quality of life￨quality of life scores for the various factors studied showed that quality of life was worse in women in patients with tumors in the middle third of the rectum and in patients undergoing low anterior resection￨sig increase￨highunclear￨highunclear￨highunclear
372￨372 patients with rectal cancer￨sphincter saving operation￨colorectal cancer specific questionnaire on quality of life crc_qol cumulative gastrointestinal problem score total cumulative scores quality of their life global qol smaller mean 0 better quality of life cumulative gender specific indicators quality of life physical function cumulative score￨ostomates and ostomates did not differ regarding the cumulative score of stoolrelated questions 8375￨no diff￨highunclear￨highunclear￨highunclear
not found￨female ostomy survivors younger than age 75 for younger females  age 75 years ostomy had a greater impact on physical wellbeing compared with older females groups surveyed were permanent ostomates cases and those who did not require an ostomy controls￨￨healthrelated quality of life response rate modified city of hope quality of lifeostomy mcohqolostomy and medical outcomes study 36item shortform health survey version 2 sf36v2￨based on the sf36v2 statistically significant and meaningful differences between female cases and controls were observed for seven of the eight scales and on the physical and mental component summary scores￨sig increase￨highunclear￨highunclear￨highunclear
not found￨41 patients each who had undergone￨rectal resection or extirpation rectal resection or excision￨quality of life quality of life inferiority feelings depression and disorders of sexual activity￨the quality of life was significantly better after resection than after excision most clearly so according to the grogono index and this was also reflected in the patients personal assessment￨sig increase￨highunclear￨highunclear￨highunclear
94￨eightytwo 87 percent patients answered the questionnaires 94 patients with no sign of recurrence a minimum of one year after curative surgery after rectal cancer surgery￨￨social functioning general health perception quality of life rand36 questionnaire and questionnaires assessing urinary sexual and bowel dysfunction sexual dysfunction quality of life urinary complaints major bowel dysfunction￨the rand36 questionnaire and questionnaires assessing urinary sexual and bowel dysfunction were administered to 94 patients with no sign of recurrence a minimum of one year after curative surgery￨no diff￨highunclear￨highunclear￨highunclear
329￨abdominoperineal extirpation patients 329 patients returned questionnaires rectal cancer patients who suffer reduced bowel and sexual function rectal cancer patients￨￨quality of life scores quality of life quality of life￨highanterior resection patients had significantly better scores than both lowanterior resection and abdominoperineal extirpation patients￨sig increase￨highunclear￨highunclear￨highunclear
319￨patients who were without recurrent or metastatic disease were identified from the norwegian rectal cancer registry 319 patients studied 229 had undergone ar and 90 apr patients following rectal cancer￨anterior or abdominoperineal resection anterior resection ar or abdominoperineal resection apr￨median time since surgery quality of life qol and functional outcome mean qol scores for body image and male sexual problems incontinence for gas and solid stools eortc questionnaires qlqc30 and qlqcr38 and rectal function worse rectal function mean scores for constipation rectal function quality of life and functional outcome￨mean qol scores for body image and male sexual problems were better following ar than apr p001 also in patients with a low  or  3 cm anastomosis￨sig increase￨highunclear￨highunclear￨highunclear
53￨53 patients with lowlying rectal cancers within 6 cm of the anal verge treated surgically following low rectal cancers￨preoperative radiotherapy rt median dose 45gy with or without concomitant 5fluorouracil sphinctersparing surgery after preoperative radiotherapy transrectal excision rt abdominoperineal resection apr￨median scores qol sexual dysfunction quality of life qol outcomes 3year actuarial overall survival and locoregional control rates eortc qlqc30 and eortc qlqcr38￨although patients having had apr tended to report a lower body image score p  012 and more sexual dysfunction in male patients all apr patients tended to report better physical function future perspective and global qol￨sig decrease￨highunclear￨highunclear￨highunclear
53￨53 patients treated with patients with rectal cancer treated by for locally advanced rectal cancer￨bifractionated rt abdominoperineal resection preoperative radiotherapy rt and surgery preoperative radiotherapy￨sexual dysfunction score symptom scores for fatigue pain gi problems and sleep disturbance quality of life qol gi symptoms sexual function and body image lower body image score emotional state quality of life global qol qol outcome￨at 1 year patients with colostomies reported similar or significantly improved symptom scores for fatigue pain gi problems and sleep disturbance but no such improvements were observed in patients without stomas￨no diff￨highunclear￨highunclear￨highunclear
150￨seventyfour answered two preoperative questionnaires 150 patients with rectal cancer underwent rectal cancer with special reference to pelvic floor dysfunction colorectal disease 2011￨abdominoperineal resection apr or anterior resection ar￨postoperative ejaculation problems mental functioning male sexual function rand 36item health survey qol questionnaire and b selfadministered diseaserelated questionnaire with special reference to anorectal and urogenital function postoperative general qol anal dysfunction after ar anorectal dysfunction survival tumour recurrence and complication rates pelvic dysfunction urinary dysfunction quality of life problems with social functioning urinary incontinence incidence of dysuria anal incontinence￨preoperative radiation was associated with postoperative ejaculation problems p  0028 and anal incontinence p  0012￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨rectal cancer survivors up to 10 years post diagnosis older 75 years old at diagnosis prt survivors 340 survivors response 85 prt survivors 71 were analyzed older prt survivors rectal cancer survivors survivors identified from the eindhoven cancer registry treated with surgery only su or with prt between 1998 and 2007 were included￨preoperative radiotherapy prt preoperative radiotherapy￨general health status sf36 and eortc qlqcr38 sexuality subscale scores poorer body image and more problems with gastrointestinal function male sexual dysfunction and defecation short form36 sf36 health survey questionnaire and the european organization for research and treatment of cancer quality of life questionnairecolorectal 38 eortc qlqcr38 questionnaire￨the sf36 and eortc qlqcr38 sexuality subscale scores of the survivors were compared to an age and sexmatched dutch normal population￨no diff￨highunclear￨highunclear￨highunclear
348￨348 rectal cancer patients who underwent surgery at the st marianna university hospital between 1978 and 1997 164 surviving patients were sent a postal survey consisting of the japanese euroqol instrument with an additional questionnaire on present symptoms and lifestyle one hundred and ten responses were received including 38 from stoma patients postoperative rectal cancer patients￨￨￨the presence of a stoma did not affect the qol of the male patients while it did affect that of the female patients￨no diff￨highunclear￨highunclear￨highunclear
117￨consecutive patients n  117 who underwent curative surgery for rectal cancer with a minimum of 2 years followup and whose disease had not recurred were asked to complete the european organization for research and treatment of cancer qlqc30 and its colorectal cancer module qlqcr38 diseasefree survivors of rectal cancer diseasefree survivors of midlow rectal cancer after curative surgery￨￨presence of stoma physical functioning hrqol levels occurrence of late major complications global health statushrqol and the pain scales constipation healthrelated quality of life hrqol hrqol functional aspects￨overall patients with rectal cancer recover well in the long run with hrqol levels comparable to that of the general population￨sig increase￨highunclear￨highunclear￨highunclear
249￨249 colorectal cancer patients colorectal cancer patients who were given a stoma at the time of their initial operation for cancer or later and those whose initial stoma was removed male patients with a stoma danish colorectal cancer patients with and without a stoma￨￨poorer quality of life problems with constipation sexual problems levels of depression side effects quality of life quality of life poorer social functioning￨male patients with a stoma had more sexual problems than males without a stoma p  0015￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨one hundred seventy patients received a questionnaire and 121 71 responded consecutive patients with an adenocarcinoma of the rectum who underwent surgery at maastricht university medical center or viecuri medical center between 2003 and 2005 were included in this study patients with rectal cancer￨￨cancer core and colorectal cancerspecific qualityoflife questionnaires severe postoperative complications fatigue physical functioning pain quality of life global health status gastrointestinal problems severe postoperative complications￨stoma construction n  51 was associated with a higher global health status 83 vs 75 p  0019 and these patients reported fewer gastrointestinal problems p  0001￨sig increase￨highunclear￨highunclear￨highunclear
301￨301 consecutive patients who had undergone surgery for cancer in the middle or lower third of the rectum were analysed two hundred four patients were eligible for inclusion rectal cancer￨total mesorectal excision abdominoperineal resection apr by performing a transanally double stapled low colorectal anastomosis lra abdominoperineal resection apr and low colorectal anastomosis lra￨quality of life scores response rate disturbed micturition and sexual problems generic eq5d and two diseasespecific questionnaires eortc qlqc30 and eortc qlqcr38 quality of life quality of life overall quality of life￨overall quality of life was good but cpa patients had better quality of life scores than apr and lra patients￨sig increase￨highunclear￨highunclear￨highunclear
not found￨distal rectal cancers eightyfive patients underwent caa 72 with intestinal continuity and 13 with a stoma because of complications and 83 patients underwent apr for a distal rectal cancer between 1995 and 2001 at a single institution and responded to our survey 2011 colorectal disease￨coloanal anastomosis and abdominoperineal resection coloanal anastomosis caa or abdominoperineal resection apr caa￨quality of life qol sexual functioning scores fatigue pain financial difficulties weight loss and chemotherapy side effects qol quality of life constipation and gastrointestinal symptoms￨patients undergoing caa had higher scores better qol for physical functioning lower scores fewer symptoms for fatigue pain financial difficulties weight loss and chemotherapy side effects and higher scores more symptoms for constipation and gastrointestinal symptoms compared with apr patients￨sig increase￨highunclear￨highunclear￨highunclear
50￨all patients were treated in curative attempt and were diseasefree throughout the study patients undergoing abdominoperineal extirpation or anterior resection for rectal cancer patients undergoing patients undergoing low ar fifty patients treated with ar and 23 patients treated with patients undergoing￨ape anterior resection ar or abdominoperineal extirpation ape abdominoperineal resection￨qol favorable qol scores time role function emotional function body image future perspective and micturitionrelated problems and group in favor of ape sleeping problems constipation diarrhea quality of life qol quality of life total qol role function social function body image and future perspective and more gastrointestinal and defecationrelated symptoms￨no significant results were obtained for the remaining scores but patients undergoing ape consistently had more favorable qol scores than those undergoing ar￨no diff￨highunclear￨highunclear￨highunclear
not found￨93 muslim patients after surgery for colorectal carcinoma colorectal disease islamic rectal carcinoma patients receiving counselling patients who underwent surgery for rectal cancer 2011￨abdominoperineal excision ape n  50 sphinctersaving resection lar n  22 or anterior resection including sigmoid colectomy￨healthrelated quality of life hrqol and religious practices sf36 health survey hrqol domain embarrassment scale hrqol sf36 questionnaire and religious practices quality of life measures ascrs fecal incontinence questionnaire scales of lifestyle copingbehaviour and depressionselfperception modified version of the american society of colorectal surgeons ascrs fecal incontinence questionnaire ankara university life standard questionnaire￨no difference was detected in any sf36 health survey hrqol domain among the groups although there were differences within groups before and after surgery￨no diff￨highunclear￨highunclear￨highunclear
not found￨rectal cancer patients in a populationbased sample over time patients undergoing sphincterablating procedures for rectal cancer patients with rectal cancer 160 patients in northern california identified by the california cancer registry￨￨adverse colorectal concerns quality of life hrql lower physical wellbeing and greater adverse colorectal concerns lower physical and emotional wellbeing scores and colorectal concerns scores quality of life hrql￨in general men had lower social wellbeing scores and younger patients had lower physical and emotional wellbeing scores and colorectal concerns scores￨sig increase￨highunclear￨highunclear￨highunclear
32￨32 patients m  21 f  11 treated by patients after restorative surgery for cancer of the rectum￨apr lar￨psychological well being social concerns and marital adjustment better global quality of life p001 physical well being p001 and less surgical sequela quality of life on the following dimensions physical wellbeing psychological wellbeing dietary habits surgical response social concerns body image stress and marital adjustment quality of life dietary habits p003 and tolerance to stress￨patients with lar had a better body image p001 dietary habits p003 and tolerance to stress p004￨sig increase￨highunclear￨highunclear￨highunclear
186￨fortyseven patients had abdominoperineal resection with formation of a permanent colostomy between 1993 and 2003 186 rectal cancer patients were enrolled rectal cancer patients treated with adjuvant chemotherapy rectal cancer patients with or without stomas following primary resection patients with resected dukes b and c colorectal cancer one hundred thirtynine patients had anterior resection of whom 46 had a temporary defunctioning colostomy patients with rectal cancer￨5fluorouracilleucovorin continuous 5fluorouracil￨global healthrelated quality of life subsequent healthrelated quality of life impairment in social functioning quality of life healthrelated quality of life data￨there was no significant difference in global healthrelated quality of life between patients with and patients without a stoma at any time point￨no diff￨highunclear￨highunclear￨highunclear
178￨muslim patients after surgery for rectal carcinoma muslim patients 178 patients who had undergone curative surgery for colorectal carcinoma￨sphinctersaving resection sphinctersacrificing surgery abdominoperineal resection anterior resection including sigmoid colectomy￨patients quality of life sphinctersaving resection religious worship praying and fasting social life and work responsibilities quality of life quality of life work responsibilities sexual life and religious worship￨a significantly  p 0001 greater number of patients in the abdominoperineal resection group stopped praying daily either alone or in a mosque and fasting during ramadan￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with clinical evidence of coexisting acute cholangitis 238 patients admitted within 48 hours after the onset of acute gallstone pancreatitis 103 with a distal bile duct measuring  or 8 mm combined with a total serum bilirubin  or 120 mgdl patients with acute gallstone pancreatitis and biliopancreatic obstruction patients with acute gallstone pancreatitis and biliopancreatic obstruction reduces systemic and local inflammation patients with clinical evidence of biliopancreatic obstruction￨endoscopic retrograde cholangiopancreatography followed by endoscopic papillotomy for bile duct stones eei n  51 or early conservative management ecm ecm endoscopic intervention versus early conservative management early endoscopic intervention endoscopic intervention￨mean ct severity index mortality overall morbidity incidence of local complications persisting bile duct stones changes in organ failure score and computed tomography ct severity index during the first week after admission incidence of local complications and overall morbidity and mortality incidence of bile duct stones mean organ failure score systemic and local inflammation￨no significant differences were found between the eei and ecm groups regarding changes in mean organ failure score p  087 mean ct severity index p  088 incidence of local complications 6 vs 6 p  099 overall morbidity 21 vs 18 p  080 and mortality 6 vs 2 p  1￨no diff￨highunclear￨highunclear￨highunclear
126￨patients with acute biliary pancreatis but without obstructive jaundice early ercp and sphincterotomy acute biliary pancreatitis patients who have acute biliary pancreatitis without obstructive jaundice 58 patients stones were successfully extracted in 57 126 patients￨ercp endoscopic papillotomy endoscopic papillotomy early endoscopic retrograde cholangiopancreatography ercp and papillotomy￨jaundice acute biliary pancreatitis respiratory failure stone removal severe complications overall rate of complications overall mortality mortality due to pancreatitis and complications acute biliary pancreatis￨in patients with acute biliary pancreatis but without obstructive jaundice early ercp and sphincterotomy were not beneficial￨no diff￨highunclear￨highunclear￨highunclear
121￨acute pancreatitis due to gallstones patients with severe attacks who underwent ercp 59 patients who underwent ercp 121 patients with acute pancreatitis thought to be due to gallstones￨ercp urgent endoscopic retrograde cholangiopancreatography ercp and endoscopic sphincterotomy es or with conventional treatment endoscopic retrograde cholangiopancreatography and endoscopic sphincterotomy versus conservative treatment￨hospital stay es 1 death￨hospital stay was also shorter for patients with severe attacks who underwent ercp￨sig decrease￨highunclear￨highunclear￨highunclear
21￨fiftythree patients with sabp  ampullary obstruction in the icu 17 cases and nasobiliary drainage 4 cases were successfully performed in all 21 enrolled patients without the aid of fluoroscopy in the icu patients with severe acute biliary pancreatitis in the intensive care unit patients with sabp in the icu or community hospital￨cti cti  ei early ei without fluoroscopy conservative treatment in the icu cti arm and cti  ei without the aid of fluoroscopy cti  ei arm endoscopic treatments including sphincterotomy  stone removal urgent endoscopic intervention without fluoroscopy early endoscopic intervention ei￨deaths acute physiology and chronic health evaluation ii score decreased acute physiology and chronic health evaluation ii score severe acute biliary pancreatitis sabp￨no deaths were observed in the cti  ei whereas the cti arm had 2 mortalities￨no diff￨highunclear￨highunclear￨highunclear
not found￨acute gallstone pancreatitis gp fourtyfive patients with acute gp acute gallstone pancreatitis￨endoscopic retrograde cholangiopancreatography ercp group n20 and nonercp ercp duodenoscopy supportive treatment combined with traditional chinese medicine duodenoscopy￨incidence of complication length of hospitalization and cost￨the incidence of complication length of hospitalization and cost were markedly lower in patients with severe acute gp in the ercp group than those in the nonercp group p005 in contrast to the 2 mild subgroups of the ercp and nonercp groups p005￨sig decrease￨highunclear￨highunclear￨highunclear
9￨ra patients patients with rheumatoid arthritis fortysix patients with rheumatoid arthritis ra and documented anemia of chronic disease￨recombinant human erythropoietin placebo oral iron in combination with rhuepo human recombinant erythropoietin￨serious adverse effects esr energy level efficacy and secure safety￨in the responders a lower initial crp a significant reduction in esr but not in crp was seen compared to the remaining rhuepo group￨sig increase￨highunclear￨highunclear￨highunclear
17￨seventeen patients with rheumatoid arthritis from five rheumatology care settings patients with rheumatoid arthritis patients with rheumatoid arthritis who had significant anemia rheumatoid arthritis 13 patients who received injections of￨recombinant human erythropoietin corticosteroids placebo recombinant erythropoietin￨hematologic response adverse effects decrease or omission of the erythropoietin dosage hematocrit normal hematocrit level meaningful hematologic response activities of daily living or pain levels excellent hematologic responses to recombinant erythropoietin without toxicity￨meaningful changes were not seen in patients capacity to perform activities of daily living or pain levels during either the 8week randomized study or the 24week openlabel study￨no diff￨highunclear￨highunclear￨highunclear
70￨patients with rheumatoid arthritis and anaemia of chronic disease acd thirty four patients were treated with 240 u kg1 rhu rheumatoid arthritis with rhu patients with rheumatoid arthritis and anaemia of chronic disease 70 patients with active rheumatoid arthritis and acd￨recombinant human erythropoietin rhuepo placebo epo rhu acd recombinant human erythropoietin￨anaemia and disease activity haemoglobin normal haemoglobin levels secondary disease activity measures ritchie index number of swollen joints pain score esr and patients global assessment of disease activity c reactive protein concentrations￨significant differences in favour of the epo group were also observed in the secondary disease activity measures ritchie index number of swollen joints pain score esr and patients global assessment of disease activity￨sig increase￨low￨low￨low
2040￨obstetric unit of corniche hospital abu dhabi in the united arab emirates between 1 january 1991 and 30 june 1991 2040 women twelve patients had to be excluded from the trial oxytocin 5 syntometrine 7 after randomisation because they no longer fulfilled the inclusion criteria￨oxytocin syntometrine oxytocin 10 units or syntometrine 1 ml oxytocin 5 unitsergometrine ergonovine 05 mg by intramuscular injection with delivery of the anterior shoulder of the baby oxytocin oxytocin and syntometrine￨postpartum haemorrhage hypertension nauseavomiting and retained placenta median blood loss rate of post partum haemorrhage nausea vomiting and headache maternal nausea vomiting headache and rise in blood pressure diastolic and systolic blood pressures￨oxytocin 10 units alone was as effective as syntometrine 1 ml in preventing postpartum haemorrhage without an increase in the incidence of retained placenta￨no diff￨low￨low￨low
3497￨active management of third stage of labour two metropolitan teaching hospitals in perth western australia all women who expected a vaginal birth during the period of the trial 3497 women￨oxytocinergometrine oxytoxinergometrine oxytocin and ergometrine oxytocin oxytocin alone and intramuscular oxytocin with ergometrine syntometrine￨postpartum haemorrhage nausea vomiting and increased blood pressure risk of postpartum haemorrhage rates of postpartum haemorrhage nausea vomiting and increased blood pressure￨rates of postpartum haemorrhage  or  500 ml or  or  1000 ml were similar in both arms odds ratio 090 082 95 confidence interval 075 to 107 059 to 114 at 500 ml 1000 ml threshold￨no diff￨low￨low￨low
461￨a university teaching hospital all women delivering in the hospital over the period of the trial except those for whom a cesarean section was planned or who had significant hypertension or cardiac disease four hundred sixtyone women were recruited 230 allocated to￨oxytocin with 05 mg of ergometrine ergometrine plus oxytocin oxytocin plus ergometrine oxytocin plus ergometrine against oxytocin syntometrine ergometrine oxytocin alone oxytocin plus ergometrine oxytocin syntocinon oxytocin￨duration of the 3rd stage of labor postpartum hemorrhage and manual removal of the placenta postpartum blood loss the length of the 3rd stage of labor and the need for manual removal of the placenta nausea vomiting and raised blood pressure need for manual removal of the placenta postpartum blood loss primary postpartum hemorrhage￨judged on the basis of this trial alone oxytocin plus ergometrine is more effective than oxytocin alone in the prevention of postpartum hemorrhage￨sig increase￨low￨low￨low
1000￨one thousand consecutive patients with singleton pregnancy and vaginal delivery in february and march 1993 department of obstetrics and gynaecology prince of wales hospital hong kong￨intramuscular syntometrine and syntocinon syntometrine and syntocinon syntometrine intramuscular syntometrine￨incidence of manual removal of the placenta risk of postpartum haemorrhage nausea vomiting headache and hypertension blood loss￨the two drugs did not differ in their effect on the duration of the third stage￨no diff￨highunclear￨highunclear￨highunclear
42￨42 pregnant women who reported alcohol consumption participated in this pilot study of motivational interviewing pregnant drinkers pregnant women who are at greatest risk women with lower initial consumption levels counseling pregnant drinkers￨motivational interviewing written information about the risks related to drinking during pregnancy or a onehour motivational interview motivational interviewing￨alcohol consumption and peak intoxication levels highest blood alcohol concentration bac levels￨motivational interviewing shows promise as a specific intervention for initiating a reduction in drinking among pregnant women who are at greatest risk￨sig increase￨highunclear￨highunclear￨highunclear
not found￨pregnant women women attending public health maternity clinics completed a screening questionnaire a pretest questionnaire economically disadvantaged pregnant women￨cognitivebehavioral intervention 10minute educational session and a ninestep selfhelp manual selfhelp program selfhelp intervention or usual clinic care and completed a posttest questionnaire￨alcohol consumption alcohol quit rate￨a higher alcohol quit rate was observed among the intervention participants 88 than controls 69￨sig increase￨highunclear￨highunclear￨highunclear
255￨pregnant women achieve abstinence from alcohol pregnant women two hundred fiftyfive pregnant women who were participants in the public health foundation enterprises management solutions special supplemental nutrition program for women infants and children and who reported drinking alcohol were assigned to an assessmentonly or a brief intervention condition and followed to their third trimester of pregnancy￨￨newborn outcomes of gestation birthweight birth length and viability report abstinence birthweights and birth lengths and fetal mortality rates￨newborns whose mothers received brief intervention had higher birthweights and birth lengths and fetal mortality rates were 3 times lower 09 compared with newborns in the assessmentonly 29 condition￨sig decrease￨highunclear￨highunclear￨highunclear
250￨two hundred and fifty eligible women initiating prenatal care pregnancy￨brief intervention￨antepartum alcohol consumption rates of abstinence risk of antepartum drinking prenatal alcohol consumption demographic background and obstetric history of subjects current and lifetime use of alcohol and substances composite addiction severity index scores and antepartum alcohol use￨both the ao and bi groups had reductions in antepartum alcohol consumption but differences in reductions by group were not statistically significant p  005￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with simple traumatic corneal abrasions￨antibiotic ointment and mydriatic alone￨healing rate and level of discomfort level of discomfort healing rate corneal abrasion￨patients treated with antibiotic ointment and mydriatic alone have a significantly improved healing rate compared with those treated with antibiotic ointment mydriatic and a double eye pad with bandage 005  p  002￨sig increase￨highunclear￨highunclear￨highunclear
not found￨corneal healing after corneal foreign body removal 30 patients with corneal epithelial defect due to removal of corneal foreign bodies￨chloramphenicol with continuous application of an eyepad or chloramphenicol without the eyepad￨discomfort￨almost all corneal defects were healed at 24 h and all were healed by 48 h with no statistically significant difference between the two groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨traumatic corneal epithelial defects￨patching vs nonpatching of ceds￨abrasion size healing rate of traumatic ceds rates of healing for patched and nonpatched traumatic corneal epithelial defects ceds percentage of healing and healing rates rate of healing￨this study demonstrates a significant improvement in the healing rate of traumatic ceds in the nonpatched group as compared to the patched group therefore the use of eye patching is not mandatory for corneal epithelial healing to occur￨sig increase￨highunclear￨highunclear￨highunclear
163￨traumatic corneal abrasions one hundred sixtythree patients presenting at the emergency department of a large universityaffiliated hospital with traumatic corneal abrasions eligible patients￨eye patching topical antibiotic ointment and occlusive patch over the affected eye n82 or topical antibiotic ointment 4 times a day without an occlusive patch￨size of the corneal lesions delay from trauma to first ed visit presence of foreign body or siderosis initial degree of discomfort and presence of specific symptoms irritation foreign body sensation photophobia redness and pain degree of discomfort cumulative incidences of healing symptoms of initial discomfort￨eye patching does not appear to be beneficial in the treatment of traumatic corneal abrasions compared with topical antibiotic ointment￨no diff￨highunclear￨highunclear￨highunclear
37￨mean patient age was 10 years and two thirds of the patients were male patients aged 3 to 17 years who were diagnosed with isolated corneal abrasion children children with corneal abrasions treated with an eye patch versus no eye patch 37 patients were enrolled 17 with an eye patch and 18 with no eye patch children with corneal abrasions￨eye patch or no patch group corneal abrasion￨difficulty walking score interference with activities of daily living adl visual analog scale and the number of pain medication doses taken since presentation healing healing comfort and complications abrasion size percent healing initial abrasion size discomfort and interference with adl rate of healing￨there was no difference in discomfort and interference with adl other than greater difficulty walking in the patch group and there were no complications in either group￨no diff￨low￨low￨low
33￨33 patients treated in the emergency department for eye pain and corneal abrasion￨patching and topical antibiotics￨pain of simple corneal abrasions pain of corneal abrasion pain scores visual analog pain score￨there was no significant difference in the mean changes in pain scores between the patched and nonpatched groups￨no diff￨highunclear￨highunclear￨highunclear
46￨fortyeight eyes of 46 patients with corneal erosion sparing bowman membrane￨￨linear speed of reepithelialization mean size of the initial erosion pain analgesia insomnia aspect of the epithelial border intensity and duration of stromal edema descemet folds anterior uveitis and filaments surface speed of reepithelialization incidence and severity of inflammation nor relieve pain￨there were no significant differences between the 2 groups for pain analgesia insomnia aspect of the epithelial border intensity and duration of stromal edema descemet folds anterior uveitis and filaments￨no diff￨highunclear￨highunclear￨highunclear
73￨73 patients who had experienced blood transfusion febrile reactions￨rct hydrocortisone versus antihistamines hydrocortisone￨effective rate of preventing transfusion febrile reactions blood transfusion febrile reactions￨the effective rate of preventing transfusion febrile reactions with benadryl 726 was not significantly different from that with hydrocortisone 863￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients receiving prestorage leukocytereduced singledonor apheresis platelets sdp platelet transfusions thirteen patients had 15 nhtr 154 852 in the treatment arm and 152 746 in the￨placebo acetaminophen 650 mg po and diphenhydramine 25 mg iv or placebo acetaminophen and diphenhydramine acetaminophen and diphenhydramine￨￨premedication prior to transfusion of prestorage leukocyte reduced sdp does not significantly lower the incidence of nhtr as compared to placebo￨no diff￨low￨low￨low
315￨before transfusion or had a documented history of a febrile or allergic transfusion reaction patients were excluded if they had a known allergy to either 315 eligible patients was performed hematologyoncology patients who receive a total of 154 active drug patients were compared to 161 placebo patients inclusion criteria were patients aged 18 to 65 years admitted to the leukemia or bone marrow transplant bmt services￨placebo acetaminophen with diphenhydramine or placebo acetaminophen or diphenhydramine acetaminophen and diphenhydramine pretransfusion medication versus placebo acetaminophen and diphenhydramine￨transfusion reactions overall risk of transfusion reactions reaction symptoms risk of transfusion reactions risk of febrile nonhemolytic transfusion reactions risk of febrile reactions￨there was no significant difference in the overall risk of transfusion reactions between the two groups￨no diff￨low￨low￨low
296￨all students also participated in a 16week normative education facts of life course highrisk female adolescents 296 female adolescents ages 14 to 19 years who were pregnant or parenting andor at risk for drug use￨social skills training social skills trainingsocial network restructuring pals skills training or b a control intervention involving no skills training￨social skills prevalence of alcohol and any drug use￨the prevalence of alcohol and any drug use increased significantly over the three assessment periods in the pals skills group but not in the no skills group￨sig increase￨highunclear￨highunclear￨highunclear
178￨families of substance abusers one hundred and fortyfour methadonetreated parents and their children n  178 ranging in age from 3 to 14 years old two methadone clinics in seattle washington￨family training combined with 9 months of homebased case management methadone￨relapse and problemsolving skills selfreport measures of family management practices deviant peer networks domestic conflict and drug use selfreport measures of rules family attachment parental involvement school attachment and misbehavior negative peers substance use and delinquency childrens behavior or attitudes areas of parent skills parent drug use deviant peers and family management￨one year after the family skills training results indicate significant positive changes among parents especially in the areas of parent skills parent drug use deviant peers and family management￨sig increase￨highunclear￨highunclear￨highunclear
200￨200 young people in the natural groups in which they were recruited to either young people heavier cigarette smokers n95 two hundred young people age range 1620 years currently using illegal drugs with whom contact was established through peers trained for the project￨motivational interviewing n105 or nonintervention educationasusual control condition motivational interviewing discussing alcohol tobacco and illicit drug use singlesession motivational interviewing￨drug consumption and perceptions of drugrelated risk and harm￨in comparison to the control group those randomized to motivational interviewing reduced their of use of cigarettes alcohol and cannabis mainly through moderation of ongoing drug use rather than cessation￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨youths in yunnan china young men rural areas of china males aged 15 to 19 single men illiterate men and the jingpo minority village leaders teachers and women and youth leaders￨￨incidence of new drug users hivaids knowledge and attitudes and recognition of drug problems￨hivaids knowledge and attitudes and recognition of drug problems were all significantly better in the intervention area￨sig increase￨highunclear￨highunclear￨highunclear
817￨817 black youths aged 12 to 16 years at baseline were studied 35 lowincome communitybased intown settings 3 adolescent risk reduction approaches￨parental monitoring intervention parental monitoring intervention informed parents and children together impact alone or with boosters small group facetoface adolescent risk reduction intervention focus on kids fok facetoface intervention alone fok only a facetoface intervention and a parental monitoring intervention fok plus impact or both of the above plus boosters fok plus impact plus boosters￨rates of the other risk behaviors and intentions risk and protective behaviors rates of alcohol and marijuana use rates of sexual intercourse sex without a condom alcohol use and cigarette use and marginally lower rates of risky sexual behavior cigarette use and overall risk intention￨at 12 months after intervention rates of alcohol and marijuana use were significantly lower and cigarette use and overall risk intention were marginally lower among fok plus impact youths compared with fok only youths￨sig decrease￨highunclear￨highunclear￨highunclear
36￨thirtysix rural schools￨intervention combining family and schoolbased competencytraining intervention components classroombased life skills training lst and the strengthening families program￨substance initiation index sii measuring lifetime use of alcohol cigarettes and marijuana and by rates of each individual substance￨relative reduction rates for alcohol initiation were 300 for the combined intervention and 41 for lst only￨sig decrease￨highunclear￨highunclear￨highunclear
13500￨eight pairs of small oregon communities population 1700 to 13 500￨school based prevention programme or the school based programme plus a community programme community intervention comprehensive community wide programme media advocacy b youth antitobacco activities c family communications about tobacco use and d reduction of youth access to tobacco￨prevalence of smokeless tobacco prevalence of weekly cigarette use￨the community programme had significant effects on the prevalence of weekly cigarette use at times 2 and 5 and the effect approached significance at time 4￨sig increase￨highunclear￨highunclear￨highunclear
not found￨young lowincome mexicanamerican women 50 predominantly mexicanamerican lowincome young women￨selective prevention interventions risk and resilience workshop or a health information correspondence course￨knowledge attitudes intentions and behaviors to prevent andor reduce substance use and risky sexual behaviors attitude sexual selfefficacy and resilience scores substance use and risky sexual behavior alcohol or cigarettes￨contraceptive use increased among women in partnered relationships and both condom use and contraceptive use increased among sexually active single young women￨sig increase￨highunclear￨highunclear￨highunclear
329￨329 rural young adolescents￨iowa strengthening families program isfp and the preparing for the drugfree years program pdfy￨￨effects on delayed substance use initiation were shown for both the isfp and the pdfy at a 2year followup￨sig increase￨highunclear￨highunclear￨highunclear
24￨all seventhgrade students in 24 schools in the academic year 19992000 n  6237 at baseline 673 were white and there was 840 retention at final followup 24 schools with 3 conditions dare only dare plus and delayed program control￨additional components included a peerled parental involvement classroom program called on the verge youthled extracurricular activities community adult action teams and postcard mailings to parents￨tobacco use and violence￨plus significantly enhanced the effectiveness of the dare curriculum among boys and was more effective than the delayed program controls underscoring the potential for multiyear multicomponent prevention programs and demonstrating sex differences in response to intervention programs￨sig increase￨highunclear￨highunclear￨highunclear
218￨218 families 91 of the original sample with adolescents aged between 15 and 19 years were reinterviewed children with divorced parents children of divorce￨2 intervention programs mother program 11 group and 2 individual sessions mother plus child program mother program and 11 group sessions for children and a control condition books on postdivorce adjustment￨externalizing problems sexual partners levels of externalizing problems mental health problems 1year prevalence of diagnosed mental disorder externalizing and internalizing problems diagnosed mental disorders drug and alcohol use and number of sexual partners fewer symptoms of mental disorder symptoms of mental disorder rates of diagnoses of mental disorder levels of externalizing problems marijuana alcohol and other drug use and number of sexual partners symptoms of mental disorder￨fewer symptoms of mental disorder p 005 and less alcohol p 005 marijuana p 02 and other drug use p 01￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨innercity african american youth students in grades 5 through 8 and their parents and teachers african american youth twelve metropolitan chicago ill schools and the communities they serve 1994 through 1998￨2 prevention programs sdc and schoolwide climate and parent and community components attentionplacebo health enhancement curriculum hec of equal intensity to the sdc focusing on nutrition physical activity and general health care￨rate of increase in condom use multiple risk behaviors school delinquency violent behavior provoking behavior highrisk behaviors student selfreports of violence provocative behavior school delinquency substance use and sexual behaviors intercourse and condom use recent sexual intercourse￨the sci was significantly more effective than the sdc for a combined behavioral measure 79 improvement vs 51￨sig increase￨highunclear￨highunclear￨highunclear
not found￨parents of substanceabusing adolescents parents of substanceabusing adolescents￨skill training coping skill training program skill training program skill training or delayed treatment condition￨parental coping skills￨skill training resulted in significant improvement in parental coping skills relative to delayed treatment￨sig increase￨highunclear￨highunclear￨highunclear
5￨native american youth substance abuse among native american youth 1396 third through fifthgrade native american students from 27 elementary schools in five states￨intervention arms learned cognitive and behavioral skills skills intervention￨rates of tobacco alcohol and marijuana use outcome assessment batteries measured youths reported use of smoked and smokeless tobacco alcohol and marijuana smokeless tobacco alcohol and marijuana￨community intervention components appeared to exert no added beneficial influence on youths substance use beyond the impact of skills intervention components alone￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨indicated preventive intervention and a universal preventive intervention coping power intervention the universal intervention the combined coping power plus universal intervention or a control condition￨rates of substance use social competence and selfregulation and parents parenting skills￨the interventions also produced effects on 3 of the 4 predictor variable domains childrens social competence and selfregulation and parents parenting skills￨sig increase￨highunclear￨highunclear￨highunclear
not found￨for nonhealing ulcers stage iv patients with nonreconstructible paod all patients had arteriosclerosis 13 also diabetes mellitus vascular patients treated with spinal cord stimulation endstage vascular patients treated with spinal cord stimulation entry criteria included nonreconstructible paod as proven by intraarterial angiography or patient condition ankle systolic pressure  50 mmhg severe rest pain despite analgetic medication and presence of nonhealing foot ulcers or dry gangrene patients with an initial tcpo2 86 fontaine stage iv patients with endstage peripheral arterial occlusive disease paod undergoing 21 day intravenous￨prostaglandin e1 pge1 therapy scs transcutaneous oxygen pressure spinal cord stimulation scs plus pge1￨tcpo2 heal ulcers or toe amputation wounds pain relief and ulcer healing quality of life prior vascular leg surgeries total healing of foot ulcers limb salvage fontaine stage ii claudication pain no rest pain or lesions mean abi frequency of minor and major amputations temporary tcpo2 elevations regional perfusion index sex distribution ischemic skin lesions risk factors and several key group mean physiological values including ankle systolic pressure anklebrachial ratio abi and foot tcpo2 foot tcpo2￨spinal cord stimulation appears to provide a major benefit for lesion improvement in stage iv patients with nonreconstructible paod￨sig increase￨highunclear￨highunclear￨highunclear
25￨twentyfive patients patients with inoperable severe leg ischaemia atherosclerotic n  41 and diabetic n  10 patients having chronic leg ischaemia with rest pain andor ischaemic ulcerations due to technically inoperable arterial occlusions patients with inoperable severe lower limb ischaemia patients with severe inoperable leg ischaemia vascular surgical units in two university hospitals￨scs spinal cord stimulation scs￨limb salvage tissue loss limb salvage rates pain relief limb salvage and amount of tissue loss longterm pain relief amputation rate amputation levels scs provided longterm pain relief but limb salvage￨scs provided longterm pain relief but limb salvage at 18 months was not significantly improved by scs in this rather small study￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with critical limb ischaemia nonsuitable for either primary intervention or reintervention after failing reconstructions from november 1991 until may 1994 120 patients had been enrolled critical limb ischaemia 17 hospitals in the netherlands patients with nonreconstructible critical limb ischaemia￨epidural spinal cord electrical stimulation eses￨limb survival patient survival quality of life and costeffectiveness quality of life￨using lifetable analysis at one year 76 of these randomised patients were alive 41 without amputation and 35 with amputation￨sig increase￨highunclear￨highunclear￨highunclear
not found￨nonreconstructable patients with stable critical leg ischaemia nonreconstructable stable critical leg ischaemia patients with nonreconstructable critical leg ischaemia￨spinal cord stimulation scs scs scsnomatch or without scs noscs spinal cord stimulation￨tcpo2 limb survival rate pain relief pain relief and sufficient paraesthesia coverage probability of limb survival limb survival cumulative limb survival￨in the scsmatch group a significant improvement in pain relief p  0005 and tcpo2 p  0001 was seen￨sig increase￨highunclear￨highunclear￨highunclear
569￨569 patients in a patients with colonic involvement￨placebo prednisone prednisone sulfasalazine or azathioprine azathioprine prednisone or sulfasalazine sulfasalazine￨response of active symptomatic disease￨for patients with quiescent disease none of the drugs was superior to placebo in prophylaxis against flareup or recurrence￨no diff￨highunclear￨highunclear￨highunclear
452￨452 patients with crohns disease one hundred sixty patients were previously untreated 292 patients were previously treated one hundred ninetytwo patients completed the 2yr study period patients with quiescent disease patients who responded initially to treatment of active disease￨6methylprednisolone and sulfasalazine sulfasalazine sulfasalazine 6methylprednisolone 6methylprednisolone combined with 3 g of sulfasalazine 3 g of sulfasalazine alone or placebo 6methylprednisolone sulfasalazine and 6methylprednisolone alone and in combination￨crohns disease activity index cdai small bowel and colon disease small bowel disease￨sulfasalazine alone was least effective in overall comparison of all patients p less than 005 and in all strata￨sig increase￨highunclear￨highunclear￨highunclear
64￨crohns disease fourteen patients were withdrawn because of severe symptoms eight on￨prednisone prednisone￨relapse rate clinical relapse recurrence and extension of the disease withdrawal rate radiological recurrence or extension of disease￨prednisone did not improve the relapse rate nor did it affect recurrence or extension of disease￨no diff￨highunclear￨highunclear￨highunclear
not found￨children under 10 years of age from 1975 to 19978 in 13 english health districts￨￨overall rate of decline rate of decline￨during this unprecedented period of rapid change in usage staff delivering the service remained unaware of the alterations in their own practice￨no diff￨highunclear￨highunclear￨highunclear
not found￨twentytwo hospitals in mexico city and 18 in the northeast region of thailand 1000 consecutively delivered women or for a 6month period whichever was reached sooner￨active multifaceted educational intervention magnesium sulphate￨rhl awareness routine episiotomy policy antibiotics at caesarean section in mexico￨there were no differences in the use of labour companionship magnesium sulphate use for eclampsia corticosteroids for women delivering before 34 weeks and vacuum extraction￨no diff￨low￨low￨low
47￨participants with the sof table n47￨rct cochrane collaboration entities meeting rct ii to receive a cochrane review with or without an sof table￨correct comprehension and time spent finding key results￨participants with the sof table n47 were more likely to agree or strongly agree that it was easy to find results for important outcomes than n25 participants without the sof table68 vs 40 p0021￨sig increase￨highunclear￨highunclear￨highunclear
not found￨nursing￨four interactive sessions covered 1 detailed feedback of baseline data and discussion utilizing audit and feedback 2 why systematic reviews analgesic league tables and choice of drugs to develop an analgesic algorithm see figure 1 3 principles of evidence based health care ebhc including critical appraisal and 4 facilitation and change workshop implementing evidencebased pain management￨movement since surgery and worst pain on movement pain pain level pain ratings postoperative pain outcomes pain￨pain ratings at rest since surgery on movement since surgery and worst pain on movement were significantly reduced compared with baseline in the control wards￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨one hundred and eight of 141 77 health departments participated in this study national sample of public health departments in canada from 2004 to 2006￨￨change in the sum of evidenceinformed healthy body weight promotion policies or programs being delivered at health departments￨the results of this study suggest that under certain conditions tailored targeted messages are more effective than knowledge brokering and access to an online registry of research evidence￨sig increase￨highunclear￨highunclear￨highunclear
not found￨25 obstetric units 4508 pregnancies 25 of the 26 district general obstetric units in two former nhs regions￨educational visits perineal suturing with polyglycolic acid ventouse delivery prophylactic antibiotics educational visit or control group￨antibiotics in caesarean section and use of polyglycolic acid sutures rates of ventouse delivery￨rates of ventouse delivery increased significantly in intervention units but not in control units there was no difference between the two types of units in uptake of other practices￨no diff￨highunclear￨highunclear￨highunclear
11￨11 patients with severe cal fev10  39 chronic airflow limitation cal￨supplemental oxygen o2￨slopes of p01 and lactate over time mild exercise hypoxemia relief of exertional breathlessness slopes of borgve borglactate and velactate blood lactate levels breathlessness ratings borg scale endurance time respiratory drive change in mouth occlusion pressure over the first 01 s of inspiration p01 ventilation ve breathing pattern operational lung volumes gas exchange and metabolic parameters mean sem and mild hypoxemia mean of individual borgtime slopes fell delta paco2time endurance time exertional breathlessness￨with 60 o2 the mean of individual borgtime slopes fell significantly p  005 by 23￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨pink and puffing patients with fixed airways obstruction￨oxygen￨breathing oxygen oxygen relieves breathlessness breathlessness on submaximum exercise exercise tolerance breathlessness and exercise tolerance￨breathing oxygen for five or fifteen minutes before exercise but not during exercise predose resulted in a similar improvement in exercise tolerance￨sig increase￨highunclear￨highunclear￨highunclear
28￨patients with copd all patients had developed a moderate reversible hypercapnia during an acute exacerbation or during exercise testing peak pco2 480 copd patients with reversible hypercapnia 28 patients 26 males 4974 years with copd advanced airflow limitation forced expiratory volume in 1 s percentage of predicted value 408 copd patients with reversible hypercapnia and mild hypoxaemia benefit from￨ltot￨endurance time and mortality endurance time exertional dyspnoea lung function endurance time cycle ergometer dyspnoea score blood gases and ltot compliance exercise dyspnoea score mild hypoxaemia￨after 1 year the endexercise dyspnoea score was significantly lower in the ltot group 45￨sig decrease￨highunclear￨highunclear￨highunclear
5￨￨￨breathlessness exercise duration breathing air arterial saturation at rest resting saturation arterial oxygen desaturation￨breathing oxygen ventilation for a given work load was reduced and exercise duration was increased when compared with air breathing￨sig increase￨highunclear￨highunclear￨highunclear
10￨patients with copd patients with chronic obstructive pulmonary disease copd 47 chronic obstructive pulmonary disease ten males with copd fev1￨randomized constantload cycling at 60 of maximal work rate breathing air hyperoxia 40 o2 60 n2 normoxic helium hyperoxia and normoxic helium heliumhyperoxia￨tidal volume exercise tolerance and respiratory mechanics resistive work of breathing dynamic hyperinflation exercise tolerance exercise time normoxic helium ic and tidal volume heliumhyperoxia intrinsic positive endexpiratory pressure exercise time inspiratory capacity ic work of breathing and exertional symptoms￨hyperoxia and normoxic helium independently reduce dynamic hyperinflation and improve the exercise tolerance of patients with chronic obstructive pulmonary disease copd￨sig increase￨highunclear￨highunclear￨highunclear
not found￨chronically hypoxic copd patients with exertional desaturation  or  88 n41 and 2 to determine whether either baseline characteristics or acute response to o2 predicts shortterm 12 weeks response copd patients chronic obstructive pulmonary disease copd patients￨ambulatory oxygen o2 versus cylinder compressed air of dyspnoeic ambulatory oxygen o2￨crq chronic respiratory questionnaire crq hospital anxiety and depression scale and the short form sf36 quality of life anxiety and depression and in certain domains of the sf36 healthrelated quality of life hrql healthrelated quality of life acceptability or tolerability￨significant improvements were also noted in anxiety and depression and in certain domains of the sf36￨sig increase￨low￨low￨low
29￨normoxemic and hypoxemic chronic obstructive pulmonary disease copd patients 29 nonhypoxemic patients 67 years exercise sao2  88 with copd fev1  36 predicted nonhypoxemic copd patients undergoing nonhypoxemic chronic obstructive pulmonary disease patients￨supplemental oxygen supplemental oxygen in exercise training exercise training while breathing supplemental oxygen 19 w oxygentrained group and 52￨exercise capacity sd work rate exercise tolerance breathing rate training work rate endurance in constant work rate tests￨after training endurance in constant work rate tests increased more in the oxygentrained group 145 minutes than in the airtrained group 105 minutes p  005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with chronic obstructive pulmonary disease copd consecutive patients were screened 78 of 331 were eligible for randomisation to cylinder oxygen cylinder air or usual care following discharge chronic obstructive pulmonary disease patients discharged from hospital following an acute exacerbation patients discharged following an acute exacerbation of copd patients were elderly with high acute healthcare utilisation forced expiratory volume in one second of 1 l and had dyspnoea limiting daily activity but were not hypoxaemic at rest copd patients￨shortburst oxygen therapy placebo shortburst oxygen therapy sbot shortburst oxygen therapy sbot￨healthrelated quality of life hrql acute healthcare utilisation hrql chronic respiratory questionnaire crq 36item shortform health survey hospital anxiety and depression scale except for crq emotion domain time to readmission￨over the 6month study period there were no significant differences between patient groups in hrql chronic respiratory questionnaire crq 36item shortform health survey hospital anxiety and depression scale except for crq emotion domain￨no diff￨low￨low￨low
20￨patients with chronic obstructive pulmonary disease and exerciseinduced hypoxaemia 20 patients with chronic obstructive pulmonary disease and exerciseinduced hypoxaemia￨oxygen supplementation training with air and the other training with oxygen interval walking on a treadmill intensity set according to borg ratings with either air or oxygen administered through a nasal cannula physical training with and without oxygen￨dyspnoea and perceived exertion 6minute walking distance￨training significantly improved the 6minute walking distance by 20 and 14 in the air and oxygen group respectively when the patients were tested on air￨sig increase￨highunclear￨highunclear￨highunclear
14￨patients with copd 14 patients with copd fev1 35 copd￨oxygen acute oxygen supplementation￨dyspnea at isoexercise intensity fivebreath averages of respiratory rate tidal volume and ventilation ve dyspnea and leg fatigue scores arterial and venous blood gases and qleg dyspnea at submaximal exercise and the increases in qo2leg and vo2leg lower limb blood flow and o2 uptake peak vo2leg peak exercise work rate peak exercise capacity peak exercise capacity lower limb blood flow qleg o2 delivery qo2leg and o2 uptake vo2leg peak qo2leg qleg qo2leg and vo2leg dyspnea score and ve qleg vo2leg and leg fatigue￨during submaximal exercise dyspnea score and ve were significantly reduced with o2 p  005 whereas qleg vo2leg and leg fatigue were similar under both experimental conditions￨sig increase￨highunclear￨highunclear￨highunclear
51￨patients with severely hypoxaemic copd patients with copd of varying disease severity and characterized those patients who responded 51 patients with copd￨hyperoxia hyperoxia￨resting ventilation hyperinflation and dyspnoea hyperoxia improved dyspnoea severe airflow obstruction measurements of dyspnoea borg score oxyhaemoglobin saturation spo2 inspiratory capacity ic minute ventilation tidal volume breathing and cardiac frequency dyspnoea and change in ic resting pulmonary hyperinflation ic cardiac frequency and dyspnoea and a significant increase in spo2 degree of airflow obstruction and change in ic resting pattern of ventilation and dyspnoea in copd￨hyperoxia improved dyspnoea but did not significantly alter resting pulmonary hyperinflation in a group of patients with copd of varying severity￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with copd derived no physiological or symptomatic benefit from oxygen breathed for short periods before or after submaximal exercise patients with chronic obstructive pulmonary disease copd patients with chronic obstructive pulmonary disease patients with moderate to severe copd mean forced expiratory volume in 1 second fev1￨oxygen supplementation before or after submaximal exercise￨recovery times visual analogue scales vas perception of breathlessness and walk distance mean breathlessness scores mean walk distance exercise tolerance￨no increase in mean walk distance after oxygen 288 v 283 m and no improvement in mean breathlessness scores 58 v 54 mm or recovery times occurred with oxygen taken either before 177 v 184 seconds or after exercise 182 v 151 seconds￨no diff￨highunclear￨highunclear￨highunclear
24￨patients with chronic obstructive pulmonary disease copd patients with copd and hypoxaemia at peak exercise all patients participated in an inpatient pulmonary rehabilitation programme of 10 weeks duration 24 patients with severe copd who developed hypoxaemia during incremental cycle exercise arterial oxygen saturation sao2 90 at peak exercise patients with severe copd￨supplemental oxygen general exercise training while breathing room air getra group forced expiratory volume in one second fev1 38 of predicted arterial oxygen tension pao2 105 kpa at rest pao2 73 kpa at peak exercise or to get while breathing supplemental oxygen geto2 group fev1 29 pred pao2 102 kpa at rest pao2 72 kpa at peak exercise oxygensupplemented training￨exercise performance while breathing air and oxygen and on quality of life exercise performance six minute walking distance 6mwd stairclimbing weightlifting exercise exercise performance and quality of life breathing room air and quality of life wmax peak carbon dioxide production vco2 and 6mwd while breathing oxygen maximum workload wmax￨training significantly increased wmax peak carbon dioxide production vco2 and 6mwd while breathing oxygen in both groups￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with chronic obstructive pulmonary disease and mild hypoxemia patients with severe copd 26 patients 24 males had a mean age of 73￨supplemental air and oxygen oxygen supplementation￨exercise performance step tests and 6 min walking distance 6mwd 6mwd or steps achieved while breathing supplemental oxygen 6mwd and steps degree of desaturation quality of life indices laboratory exercise performance quality of life 6mwd or steps￨supplemental oxygen increased 6mwd and steps by small statistically significant increments acutely at baseline and after 6 and 12 wk without corresponding falls in borg score￨no diff￨highunclear￨highunclear￨highunclear
not found￨nonhypoxaemic copd patients ten severe copd patients without clinically significant oxygen o2 desaturation during exercise and seven healthy subjects chronic obstructive pulmonary disease copd patients nonhypoxaemic chronic obstructive pulmonary disease patients￨oxygen oxygen supplementation oxygen supplementation dynamic hyperinflation￨dyspnoea score eelv eilv ve and respiratory frequency fr ventilation ve endurance and symptom perception improved endurance time hyperinflation and exercise endurance hyperinflation associated with functional and symptomatic improvement room air endurance time increased with fi dyspnoea rating endinspiratory eilv and endexpiratory eelv lung volume changes inspired oxygen fraction fio2 endurance smaller ve and fr decreases￨at isotime compared to room air there were significant reductions in dyspnoea score eelv eilv ve and respiratory frequency fr with fio203￨sig increase￨highunclear￨highunclear￨highunclear
7￨severe respiratory disability patients with obstructive and with interstitial lung disease patients with chronic respiratory insufficiency 30 patients with severe respiratory disability￨standard six minute walking test and an endurance walking test endurance walking tests or four six minute walking tests with patients breathing either air at a flow rate of 4 1min from a portable cylinder or supplemental oxygen at a flow rate of 2 4 or 6 1min from a portable liquid oxygen supply￨breathlessness endurance walking distances walking distance endurance walking distance exercise ability and breathlessness mean endurance walking distances￨walking distance was increased by more than 50 by comparison with an unburdened walk in seven patients with the endurance walking test but in only three patients with the six minute walking test￨sig increase￨highunclear￨highunclear￨highunclear
14￨fourteen patients with chronic obstructive pulmonary disease copd and arterial oxygen desaturation on exercise mean sd forced expiratory volume in one second fev1 083 028 1 arterial oxygen pressure pao2 838 124 kpa arterial carbon dioxide pressure paco2 595 086 kpa patients with severe chronic obstructive pulmonary disease￨pulsed dose oxygen delivery pdod system with continuous flow oxygen or air during a maximal walking test walking test using air administered via a cylinder or continuous flow oxygen at 2 lmin or by a pdod system￨distance walked using oxygen pdod exercise tolerance mean sd distance walked on continuous flow oxygen mean arterial oxygen saturation sao2 greatest desaturation whilst walking with the air cylinder￨there was no significant difference in the mean arterial oxygen saturation sao2 using the pdod system or with continuous flow oxygen p  033￨no diff￨highunclear￨highunclear￨highunclear
22￨nonhypoxic copd patients twentytwo clinically stable copd patients chronic obstructive pulmonary disease copd￨shortburst oxygen therapy sbot cylinder air or oxygen￨dyspnoea for oxygen respiratory gymnasium and undertook four 6min walk 6mw tests dyspnoea nor improved performance mean timetoresting borg score for air and oxygen dyspnoea mean 6mw distance￨only two subjects demonstrated a clinically significant and consistent reduction in dyspnoea for oxygen compared with air either before or after exercise￨no diff￨highunclear￨highunclear￨highunclear
17￨chronic obstructive airways disease 17 patients with severe airflow obstruction￨supplemental oxygen￨flow rate of supplemental oxygen and cycling endurance time endurance time for cycling at a constant work load exercise performance mean speed exercise capacity mean endurance walking time￨it also increased the mean speed achieved during a six minute walk but this was variable and did not occur in all the subjects￨no diff￨highunclear￨highunclear￨highunclear
20￨patients with severe copd who do not qualify for longterm o2 therapy outpatients from the pulmonary diseases division of a tertiarycare university hospital twenty patients with stable copd with fev1fvc ratios of  50 fev1 levels  55 of the predicted normal value and pao2 levels of  60 mm hg when resting patients with advanced copd without severe resting hypoxemia patients with severe copd￨supplemental oxygen random sequence basal wt bwt wt while breathing compressed air cawt and wt while breathing o2 o2wt placebo supplemental o2￨dyspnea o2 arterial oxygen saturation measured by pulse oximetry spo2 distance walked bwt and cawt dyspnea distance walked and reduce dyspnea o2 administration reduced dyspnea￨in nds patients o2 administration reduced dyspnea by 47 p  0001 but the distance walked did not improve￨sig decrease￨low￨low￨low
31￨nonhypoxemic patients with emphysema 31 subjects with a deficiency of aat mean  sd age  47  7 moderate emphysema and a resting pao2  70 mm hg middleaged adults alpha1 antitrypsin deficiency￨nasal cannula administration of o2 intervention and compressed air control shortterm oxygen o2 administration during activities alpha1 antitrypsin aat￨oxygen saturation spo2 6minute walk distance and end of walk dyspnea exercise performance 6minute walk distance mean values dyspnea dyspnea management lower dyspnea with o2 interaction effect of gender with o2 for dyspnea￨however women experienced less dyspnea when receiving o2 as compared with compressed air p  00025 and although not statistically significant the lower dyspnea with o2 corresponded with an increased walk distance of 79 feet￨sig decrease￨highunclear￨highunclear￨highunclear
20￨patients with chronic obstructive lung disease 20 patients with chronic obstructive lung disease mean fev1 079 l forced vital capacity 230 l￨breathing supplemental oxygen before progressive exercise compressed air or supplemental oxygen from nasal prongs for 10 minutes before exercise progressive treadmill exercise tests￨heart rate and breathlessness score on a visual analogue scale maximum exercise performance and relieve exertional dyspnoea maximum distance walked or maximum heart rate or in the breathlessness score or heart rate mean arterial oxygen saturation sao2￨the mean arterial oxygen saturation sao2 after oxygen 93 was significantly higher than after compressed air 91￨sig increase￨highunclear￨highunclear￨highunclear
18￨patients with chronic obstructive pulmonary disease copd eighteen patients with smoking related copd￨￨visual analogue scale reduced desaturation oxygen maximal dyspnoea time of ascent desaturation and dyspnoea associated with the ascent dyspnoea￨oxygen given before or after the ascent reduced maximal dyspnoea from 491 mm 95 ci 355 to 627 to 417 mm 95 ci 343 to 491 of a 100 mm visual analogue scale reduced desaturation oxygen before 49 95 ci 36 to 62 oxygen after 6 4 53 to 75 air before and after 82 67 to 97 but did not affect time of ascent air before 51 s 95 ci 34 to 69 reduction from training ascent oxygen before 61 s 95 ci 29 to 92 reduction￨sig decrease￨highunclear￨highunclear￨highunclear
82￨patients with chronic obstructive pulmonary disease copd patients with stable copd chronic obstructive pulmonary disease 82 patients mean age 697 yr mean fev1 426 predicted patients with more severe airflow obstruction￨breathing supplemental oxygen changing oxygen or helium concentration breathed heliox28 helium and oxygen￨exercise performance breathlessness lung emptying reduced dyspnea walking distance expiratory flow resistance walking distance while breathing heliox28 endurance shuttle walking distance resting and exercise oxygen saturation and endexercise dyspnea borg scale walking distance meansd 147150 m and reduced borg score￨heliox21 significantly increased walking distance 99101 m and reduced dyspnea borg score 076077 compared with medical air￨sig increase￨highunclear￨highunclear￨highunclear
12￨patients with chronic obstructive pulmonary disease copd despite only mild resting hypoxemia pao2 greater than 60 mm hg 12 patients with severe copd fev1 089 patients with chronic obstructive pulmonary disease and only mild hypoxemia￨doppler echocardiography during a separate supine incremental exercise test fev1fvc oxygen o2￨dyspnea scores by numeric rating scale rise in dyspnea scores heart rate minute ventilation or rvspabstract truncated at 250 words compressed air pao2 severity of dyspnea with right ventricular systolic pressure rvsp exercise tolerance duration of exercise dyspnea duration of exercise dyspnea and endurance￨with endurance testing on compressed air pao2 did not change significantly in the group as whole postexercise pao2 63￨no diff￨highunclear￨highunclear￨highunclear
not found￨33 patients who enrolled and completed followup died one of the 15 who received artemether and three of the 18 who received quinine adult melanesian patients with severe or complicated plasmodium falciparum malaria in papua new guinea￨intramuscular artemether and intravenous quinine intravenous quinine a loading dose of 20 mg quinine dihydrochloride￨temperature defervescence time taken to clear 50 of parasites serious adverse effects overall cerebral malaria pretreatment spontaneous hypoglycaemia plasmodium vivax parasitaemias safety and efficacy hypoglycaemia￨the time taken to clear 50 of parasites was less in those treated with artemether median  8 h range  224 h than in the patients given quinine median  14 h range  225 h p  005￨sig decrease￨highunclear￨highunclear￨highunclear
102￨severe falciparum malaria in southeast thailand one hundred and two thai patients with severe falciparum malaria 92 males and 10 females￨quinine infusion artemether and quinine mefloquine￨died with pulmonary complications fever clearance times patient died with complications neurological sequelae mild transient pain survival rate time to recovery of consciousness left facial palsy severe hearing impairment parasite clearance time qtc wave prolongation complications myasthenia gravislike syndrome￨artemether gave a better survival rate 872 vs 633 and parasite clearance time 54 vs 78 h than quinine￨sig increase￨highunclear￨highunclear￨highunclear
not found￨cerebral malaria patients severe falciparum malaria twentysix patients with severe falciparum malaria￨￨survival rates body weight admission parasitemia hemoglobin and white blood cell count adverse effects parasite and fever clearance times and the time taken to gain consciousness dizziness and vertigo survival rate and side effects adverse effects￨the parasite and fever clearance times and the time taken to gain consciousness in cerebral malaria patients were not significantly different between the two groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨children with lifethreatening malaria african children malawian children with cerebral malaria 83 artemether recipients and 81 quinine recipients￨intramuscular artemether vs intravenous quinine￨overall mortality rates and coma resolution times parasite and fever clearance times survival advantage mortality rates￨these results do not suggest that treatment with artemether would confer a survival advantage in children with lifethreatening malaria￨no diff￨highunclear￨highunclear￨highunclear
43￨moderately severe malaria 30 gambian children 43 children with severe malaria patients studied previously were adults children with moderate or severe falciparum malaria severe malaria in gambian children￨oilsoluble methyl ether of artemesinin qinghaosu chloroquine intramuscular artemether 4 mgkg loading dose followed by 2 mgkg daily or intramuscular chloroquine nivaquine￨clinical haematological biochemical or parasitological measures of therapeutic response tolerated and rapidly effective times to parasite clearance local or systemic toxicity￨there were no significant differences between the two groups in the clinical haematological biochemical or parasitological measures of therapeutic response in survivors and there was no evidence of local or systemic toxicity￨no diff￨highunclear￨highunclear￨highunclear
109￨children with severe malaria severe childhood malaria 109 vietnamese children aged between 3 months and 14 years with severe pfalciparum malaria children living in many tropical regions￨intramuscular artesunate followed by mefloquine chloroquine artemisinin suppositories followed by mefloquine artemisinin suppositories intravenous quinine followed by pyrimethaminesulfadoxine artemisinin suppositories intramuscular artesunate and intravenous quinine￨adverse effect or toxicity parasite clearance times fever clearance time coma recovery or length of hospital stay peripheral reticulocyte counts￨artemisinin suppositories are easy to administer cheap and very effective for treating children with severe malaria￨no diff￨highunclear￨highunclear￨highunclear
not found￨4 patients in each group who presented with cerebral malaria twentyeight male thai patients with severe falciparum malaria￨￨biochemical or ecg changes neurological sequelae cure rate body weight admission parasitemia hematocrit and white cell count median values of parasite and fever clearance times pct and fct transient pain cure rates￨the patients in both groups were comparable in age body weight admission parasitemia hematocrit and white cell count￨no diff￨highunclear￨highunclear￨highunclear
22￨severe malaria with sixtythree patients with severe falciparum malaria all patients were admitted for 28 days to the bangkok hospital for tropical diseases in thailand￨mefloquine artesunate suppository artesunate suppositories artesunate suppository mefloquine tablet oral mefloquine￨admission median glasgow coma score  9 regained consciousness cure rates tolerated and effective efficacy tolerability and delayed neuropsychiatric effects mean sd fever clearance times major adverse drug effects mean sd parasite clearance time rate of parasite reduction￨the cure rates at 28 days of followup in group￨sig increase￨highunclear￨highunclear￨highunclear
167￨uncomplicated and severe falciparum malaria 167 patients were included in the study 61 with acute uncomplicated falciparum malaria and 106 with severe malaria￨￨parasite or fever clearance time pct or fct cure rates curative efficacy￨the pct and fct from either regimen of uncomplicated malaria were significantly faster than those of severe malaria p  0005 and  005 respectively￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨seventynine comatose cerebral malaria patients given standard supportive treatment cerebral malaria￨intravenous artesunate and intravenous quinine specific antimalarial chemotherapy of intravenous quinine intravenous artesunate or artemisinin suppositories artemisinin suppositories￨duration of coma or mortality peripheral asexual parasitaemia￨artesunate and artemisinin reduced peripheral asexual parasitaemia significantly more rapidly than quinine 90 clearance time 16 h 189 h and 345 h respectively but did not significantly reduce the duration of coma or mortality￨sig decrease￨highunclear￨highunclear￨highunclear
103￨nigerian children with cerebral malaria 103 children aged 1260 months with cerebral malaria between 1994 and 1996￨sulphadoxinepyrimethamine intramuscular artemether and intravenous quinine￨immediate efficacy motor disabilities cortical blindness and afebrile seizures adverse reactions￨times to recovery from coma were 24 h iq 1845 and 33 h iq 1957 respectively￨no diff￨highunclear￨highunclear￨highunclear
576￨cerebral malaria in children 576 gambian children with cerebral malaria fiftynine of the 288 children treated with artemether died in the hospital 205 percent as compared with 62 of the 288 treated with quinine 215 percent children with cerebral malaria￨intramuscular artemether and intramuscular quinine artemether or quinine￨odds ratio for death residual neurologic sequelae mortality and residual neurologic sequelae mortality rate local reactions neurologic disease residual neurologic sequelae￨there were fewer local reactions at the injection site with artemether than with quinine 07 percent vs 59 percent p  0001￨no diff￨highunclear￨highunclear￨highunclear
not found￨one hundred and seventy five vietnamese adults with severe and complicated malaria admitted to a rural district hospital￨artemisinin artesunate artemisinin suppositories￨efficacy median time of defervescence median times for recovery of consciousness mortality rates respective median parasite clearance times￨the median time of defervescence was 48 h 95 confident interval ci 3858 h in those given intramuscular im artemether 42 h￨no diff￨highunclear￨highunclear￨highunclear
65￨a government regional referral hospital in ethiopia severe malaria in ethiopia sixty five adult patients of both sexes 32 for artemisinin and 33 for quinine with complicated severe falciparum malaria￨artemisinin suppository with quinine injection rectal artemisinin with intravenous quinine￨vomiting dizziness hypoglycaemia and tinnitus initial parasite density and pct or fst clinical efficacy and safety parasite clearance time pct fever subsidence time fst and coma resolution time crt mortality rates parasitological cure rates tenesmus￨there was no significant different in the parasitological cure rates in both arms of treatment￨no diff￨highunclear￨highunclear￨highunclear
560￨two hundred seventysix received 560 adults with severe falciparum malaria severe malaria in adults vietnamese adults with severe falciparum malaria￨intramuscular quinine dihydrochloride artemether or quinine￨serious side effects time to recovery from coma higher risk of hypoglycemia hospitalization risk of death￨quinine treatment was associated with a higher risk of hypoglycemia relative risk 27 95 percent confidence interval 17 to 44 p  0001 but there were no other serious side effects in either group￨sig decrease￨low￨low￨low
28￨28 adult patients with severe falciparum malaria severe falciparum malaria￨artesunate intramuscular and intravenous artesunate intravenous and intramuscular artesunate￨toxicity mean parasite clearance times￨clinical and parasitological measures of recovery in survivors were similar in the 2 groups with mean fever clearance times of 373 h standard deviation sd  261 h and 315 h sd  242 h and mean parasite clearance times of 334 h sd  139 h and 294 h sd  127 h in the intravenous and intramuscular groups respectively￨no diff￨highunclear￨highunclear￨highunclear
64￨patients with copd chronic obstructive pulmonary disease copd 64 patients randomized to 1 of 3 groups 49 patients who completed training duration of constant workrate exercise was 400 patients with chronic obstructive pulmonary disease￨vf plus exercise training vf plus exercise exercise training plus vf training ventilationfeedback training exercise alone respiratory retraining ventilationfeedback vf training exerciseinduced dynamic hyperinflation exercise alone and 161 vf alone￨exercise tolerance exercise duration expiratory time exercise duration￨the combination of vf plus exercise training decreases exerciseinduced dynamic hyperinflation and increases exercise duration more than vf alone￨sig increase￨highunclear￨highunclear￨highunclear
324￨chronic obstructive pulmonary disease copd 324 patients with stable copd￨breathing exercises breathing exercises be or placebo medicine￨mip mep pdi and pdimax maximum respiratory pressure 320 cases and transdiaphragmatic pressure￨in be group mip increased by 3042 mep 3210 pdi 3094 and pdimax 6559 p  0001￨sig increase￨highunclear￨highunclear￨highunclear
20￨twenty patients with stable copd mean age 678 yr mean fev1 108 1 all limited by ventilation at maximum exercise copd patients￨resistive inspiratory muscle training inspiratory resistive training irt with a p flex device or conventional breathing retraining br conventional breathing retraining irt 12min walking test an incremental progressive exercise on a cycle ergometer and a cycle endurance test￨inspiratory muscle endurance exercise performance lung function or exercise performance exercise performance highest tolerated resistance￨irt produced a significant p less than 005 increase in the highest tolerated resistance but irt and br failed to improve lung function or exercise performance￨no diff￨highunclear￨highunclear￨highunclear
29￨patients with copd patients with chronic obstructive pulmonary disease copd elderly patients with copd people with chronic obstructive pulmonary disease older adults with copd clinically stable patients with copd n  29 age 699 156 predicted female  21￨yoga training yoga training yoga therapy yoga program included asanas yoga postures and visama vritti pranayama timed breathing yoga program yoga program specifically designed for people with copd or usualcare control uc￨6mw distance physical performance psychologic wellbeing and healthrelated quality of life hrqol dyspnearelated distress dyspnea intensity di and dyspnearelated distress dd incremental cycle ergometry and a 6minute walk 6mw test expiratory volume functional performance heart rate oxygen saturation dyspnea and pain￨while yoga training had only small effects on di after the 6mw test effect size es 020 p  060 there were greater reductions in dd in the yoga group compared to uc es 067 p  008￨no diff￨highunclear￨highunclear￨highunclear
40￨patients with copd patients with chronic obstructive pulmonary disease copd patients with copd remains unclear forty copd patients meansd age 66164 fev1 459174 predicted were randomized to rehabilitation n20 or patients with copd undergoing a￨controlled breathing conventional 4week pulmonary rehabilitation program rehabilitation plus controlled breathing pulmonary rehabilitation program controlled breathing using respiratory biofeedback controlled breathing using respiratory biofeedback conventional pulmonary rehabilitation programs￨crq pulmonary function fev1 exercise capacity 6min walking distance 6 mwd healthrelated quality of life chronic respiratory questionnaire crq and cardiac autonomic function rmssd fev1 exercise tolerance 6 mwd pulmonary function exercise capacity pulmonary function quality of life or cardiac autonomic function rmssd￨in patients with copd undergoing a pulmonary rehabilitation program controlled breathing using respiratory biofeedback has no effect on exercise capacity pulmonary function quality of life or cardiac autonomic function￨no diff￨highunclear￨highunclear￨highunclear
206￨chronic obstructive pulmonary disease clients two hundred and six copd clients clients with chronic obstructive pulmonary disease copd in hong kong￨tcq usual care tcq group exercise group and control group tcq program tai chi qigong program tai chi qigong tai chi qigong tcq program practice breathing techniques combined with walking as an exercise￨healthrelated quality of life using st george respiratory questionnairehong kong chinese version and perceived social support using the multidimensional scale of perceived social supportchinese version perceived social support activity domains healthrelated quality of life and perceived social support￨the tcq group showed greater improvements in the symptom f4 4043351 p0010 and activity domains f4 4042611 p0035￨sig increase￨highunclear￨highunclear￨highunclear
40￨forty subjects with chronic obstructive pulmonary disease age  65 dyspnea reduction subjects recruited from the outpatient pulmonary clinic of a universityaffiliated veteran affairs healthcare center adults with moderate to severe chronic obstructive pulmonary disease 102  29 cm h2o were enrolled￨pursedlips breathing 2 expiratory muscle training or 3 control pursedlips breathing expiratory time pursedlips breathing and expiratory muscle training breathing pattern retraining￨standard deviation years forced expiratory volume 1 secondforced vital capacity   46 22 cm h2o and expiratory muscle strength pemax physical function changes over time in dyspnea modified borg after 6minute walk distance 6mwd and shortness of breath questionnaire and functional performance human activity profile and physical function scale of short form 36item health survey dyspnea and functional performance exertional dyspnea and physical function exertional dyspnea relief￨significant reductions for the modified borg scale after 6mwd p  05 and physical function p  02 from baseline to 12 weeks were only present for pursedlips breathing￨sig increase￨highunclear￨highunclear￨highunclear
not found￨2012 american congress of rehabilitation medicine subjects n30 forced expiratory volume in 1s 4213 predicted patients with chronic obstructive pulmonary disease￨dbtp training group tg or a control group cg supervised dbtp copyright diaphragmatic breathing training program diaphragmatic breathing training program dbtp￨diaphragmatic mobility amplitude of the rib cage to abdominal motion ratio rcabd ratio primary outcome and diaphragmatic mobility secondary outcome 6minute walk test and in healthrelated quality of life abdominal motion diaphragm participation thoracoabdominal motion and functional capacity diaphragmatic mobility rcabd ratio 6minute walk test and healthrelated quality of life abdominal motion during voluntary diaphragmatic breathing￨an improvement in the 6minute walk test and in healthrelated quality of life was also observed in the tg￨sig increase￨highunclear￨highunclear￨highunclear
not found￨elderlyonset rheumatoid arthritis elderlyonset rheumatoid arthritis ra patients with active ra diagnosed at age  or  60￨prednisone chloroquine prednisone versus chloroquine prednisone￨bone mass radiographic scores bone loss disease activity and bone mass disease activity and bone mass functional capacity and disease activity￨functional capacity and disease activity improved significantly in both groups and did not differ significantly between the groups except for a greater improvement in the prednisone group at 1 month￨no diff￨highunclear￨highunclear￨highunclear
not found￨fortyeight primary molars with carious lesions carious and noncarious primary dentin in vivo carious dentin in primary teeth￨￨retention rate marginal integrity and pulpal symptoms￨retention rate marginal integrity and pulpal symptoms were identical in both groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨sealed composite restoration placed over a carious lesion and either a traditional outlineform unsealed amalgam or an ultraconservative sealed amalgam restoration￨￨no important clinical differences developed among the three groups of restorations￨no diff￨highunclear￨highunclear￨highunclear
132￨primary care of a novel method of using preformed metal crowns to manage decay in primary molar teeth 132 children aged 310 carious primary molars using preformed metal crowns pmcs cemented with no local anaesthesia caries removal or tooth preparation 128 conventional restorations were placed on 132 control teeth and 128 pmcs on 132 intervention teeth 124 children 94 of the initial sample with a minimum followup of 23 months managing carious primary molars in general dental practice general dental practitioners gdps n  17 in tayside scotland￨￨pulpal health and restoration longevity hall pmcs unacceptable discomfort￨the hall pmcs outperformed the control restorationsa major failures signs and symptoms of irreversible pulpal disease 19 control restorations 15 three hall pmcs 2 p  0000b￨sig decrease￨highunclear￨highunclear￨highunclear
58￨58 patients with exposed pulps deep caries lesions in adults 314 adults from six centres who had received treatment of a tooth with deep caries￨direct complete excavation and direct pulp capping vs partial pulpotomy direct capping or partial pulpotomy￨risk of pulp exposure pulp vitality without apical radiolucency￨we found no significant difference in pulp vitality without apical radiolucency between the two capping procedures after more than 1 yr 318 and 345 difference 27 95 ci 227 266￨no diff￨highunclear￨highunclear￨highunclear
154￨primary and permanent molars a total of 154 teeth 94 primary second molars and 60 young permanent first molars were included in the study from a total of 123 4 to 15yearold patients￨1visit ipt 2visit ipt or direct complete excavation dce 2visit indirect pulp therapy ipt indirect pulp therapy 1 or 2visit indirect pulp therapy￨normal clinical and radiographic conditions preoperative signs and symptoms of irreversible pulpitis deep carious lesions￨a statistically significant difference was found between ipt and dce groups in terms of pulp exposure p05￨sig increase￨highunclear￨highunclear￨highunclear
not found￨primary teeth deciduous molars with acute carious lesions in the inner half of dentin and vital pulp￨calcium hydroxide cement￨level of colonization￨before sealing a larger number of microorganisms was detected in teeth submitted to partial caries removal compared to the complete removal group￨sig increase￨highunclear￨highunclear￨highunclear
127￨permanent posterior teeth with deep carious lesions 116 patients aged 616 yrs mean  102 yrs consisted of 127 teeth with radiographs revealing carious lesions to such a depth that pulp exposure could be expected if direct complete excavation was performed young posterior permanent teeth￨calcium hydroxide calcium hydroxide zincoxideeugenol zoe and a restorative material￨normal clinical and radiographic conditions￨the teeth with no pulp exposure after direct or stepwise excavation showed normal clinical and radiographic conditions at the last checkup mean  43 months￨no diff￨highunclear￨highunclear￨highunclear
not found￨men complaining of lower urinary tract symptoms due to benign prostatic hypertrophy lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom￨naftopidil naf and tamsulosin hydrochloride tam tamsulosin hydrochloride naftopidil￨storage symptoms score of daytime frequency score of the daytime frequency daytime frequency and nocturia lower urinary tract symptoms nocturia storage symptom score of the frequency to the combined score of daytime frequencies and the score of nocturia baseline symptom scores score of nocturia￨in the tam group at 2 weeks however no significant improvement was noted in the increased score of daytime frequency p  01 or nocturia p  02￨no diff￨highunclear￨highunclear￨highunclear
96￨patients with urinary disturbances caused by benign prostatic hyperplasia 96 patients with bph for 8 weeks in a crossover study patients with benign prostatic hyperplasia bph displaying various voiding symptoms￨alpha1adrenoceptor antagonists tamsulosin hydrochloride tam and naftopidil naf tamsulosin hydrochloride and naftopidil￨maximum urinary flow international prostate symptom score￨whereas naf monotherapy decreased the ipss for storage symptoms tam monotherapy decreased the ipss for voiding symptoms￨sig increase￨highunclear￨highunclear￨highunclear
not found￨lower urinary tract symptoms associated with benign prostatic hyperplasia men aged 5484 years with a main complaint of bph￨tamsulosin naftopidil then tamsulosin hydrochloride tamsulosin and naftopidil naftopidil tamsulosin hydrochloride tamsulosin hydrochloride and naftopidil tamsulosin then naftopidil￨intermittency nocturia and quality of life scores therapeutic effects￨tamsulosin was more effective than naftopidil on intermittency nocturia and quality of life scores￨sig increase￨highunclear￨highunclear￨highunclear
153￨patients with lower urinary tract symptoms luts associated with benign prostatic hyperplasia bph lower urinary tract symptoms associated with benign prostatic hyperplasia subjects comprised 153 patients with luts associated with bph￨naftopidil alpha1dselective antagonist naftopidil￨lower urinary tract disease symptom score lutdss the international prostate symptom score ipss the quality of life assessment index the maximum flow rate qmax voiding symptoms qmax overall efficacy voiding symptoms and lutdss residual urine volume lutdss and the ipss frequency of adverse reactions￨in both groups the lutdss and the ipss were significantly improved at the endpoint and no significant intergroup differences were identified￨no diff￨highunclear￨highunclear￨highunclear
49￨fortynine patients with bph mean age 679 benign prostatic hyperplasia benign prostatic hyperplasia bph￨naftopidil alphablocker naftopidil naftopidil alphablocker naftopidil and phytotherapy eviprostat￨quality of life score international prostate symptom score ipss and urodynamic parameters detrusor overactivity symptomatic and urodynamic parameters average and maximum flow rate and bladder capacity cystometric capacity international continence society nomogram grade mean total ipss the total storage and voiding symptom scores￨the mean total ipss the total storage and voiding symptom scores and the quality of life score decreased significantly p  00001 for each variable in the naftopidil group but not in the eviprostat group￨sig increase￨highunclear￨highunclear￨highunclear
17￨seventeen patients thirtyfour patients mean age 724 years sd 43 range 6679 with luts international prostate symptom score ipss 8 secondary to bph lower urinary tract symptoms luts with benign prostatic hyperplasia bph lower urinary tract symptoms with benign prostatic hyperplasia￨alpha1adrenoceptor antagonists alpha1aadrenoceptorselective tamsulosin hydrochloride and alpha1dadrenoceptorselective naftopidil tamsulosin 02 mg followed by naftopidil alpha1dadrenoceptor antagonist naftopidil naftopidil tamsulosin alpha1adrenoceptor antagonists naftopidil and tamsulosin hydrochloride￨luts ipss quality of life qol uroflowmetry and pressureflow study pfs values volume at first desire and maximum desire to void ipss and qol ipss qol uroflowmetry values or pfs values disappearance of involuntary contraction relieving nocturia uroflowmetry values and changes in other pfs values involuntary contractions bladder outlet obstruction￨at baseline there were no significant differences between the groups in ipss qol uroflowmetry values or pfs values except for the volume at maximum desire to void￨no diff￨highunclear￨highunclear￨highunclear
185￨patients with bph benign prostatic hyperplasia benign prostatic hyperplasia bph 185 patients enrolled data for 144 who were eligible for inclusion in the efficacy analysis￨alpha1aalpha1d adrenoceptor ar antagonists naftopidil tamsulosin and naftopidil tamsulosin or naftopidil￨adverse effects storage and voiding symptoms index score blood pressure systolic and diastolic blood pressure clinical efficacy or adverse effects total international prostate symptom score ipss maximum flow rate on free uroflowmetry and residual urine volume efficacy and safety average flow rate changes in the ipss storage score ipss voiding score and qualityoflife qol￨there were statistically significant improvements for all primary and secondary variables in both groups except for residual urine in the tamsulosin group￨sig increase￨highunclear￨highunclear￨highunclear
101￨101 bph patients with storage symptoms storage symptoms associated with benign prostatic hyperplasia benign prostatic hyperplasia bph bph patients with storage symptoms￨alpha1adrenoceptor alpha1ar antagonist monotherapy cotherapy naftopidil and an anticholinergic agent propiverine hydrochloride or 26 mgday of oxybutynin hydrochloride cotherapy naftopidil alpha1ar antagonist and anticholinergic agent naftopidil monotherapy vs naftopidil naftopidil monotherapy monotherapy group or combination therapy anticholinergic agent combined therapy￨median posttherapeutic ruv maximum flow rate qmax and residual urine volume ruv ruv international prostate symptom score ipss and quality of life qol index efficacy and safety￨maximum flow rate qmax and residual urine volume ruv tended to improve in both groups again with no marked differences between groups￨sig increase￨highunclear￨highunclear￨highunclear
60￨60 patients ambulatory surgery patients￨preoperative oral passiflora incarnata placebo oral passiflora incarnata 500 mg passipy irandarouk￨asa physical status duration of surgery basal nrs score sedation at the preset time intervals and discharge time anxiety nrs anxiety scores time interval between arrival in the postanesthesia care unit and discharge to home discharge time postanesthesia care unit and recovery of psychomotor function numerical rating scale nrs psychological variables psychomotor function￨there were no significant differences in psychological variables in the postanesthesia care unit and recovery of psychomotor function was comparable in both groups￨no diff￨highunclear￨highunclear￨highunclear
75￨seventyfive women undergoing elective day case gynaecological surgery￨placebo midazolam iv solution temazepam midazolam iv solution 10 mg temazepam 20 mg or placebo temazepam 20 mg and superior to placebo midazolam solution with temazepam￨anxiety score sedation score patient acceptance anxiolysis sedation or recovery letter deletion and memory tests￨the two treatment groups showed a significant reduction in anxiety score compared with placebo p less than 0002 and p less than 004 for placebo compared with temazepam and midazolam respectively￨sig decrease￨highunclear￨highunclear￨highunclear
60￨sixty patients scheduled for day case surgery￨temazepam placebo of identical appearance temazepam￨postoperative sequelae time to awaken the level of postoperative sedation and the ability to walk unaided￨the time to awaken the level of postoperative sedation and the ability to walk unaided were similar in both groups￨no diff￨highunclear￨highunclear￨highunclear
50￨for day case breast surgery 50 asa i and ii female patients scheduled to undergo day case breast surgery￨placebo midazolam midazolam premedication oral midazolam premedication midazolam propofol￨excellent grade i conditions for insertion of a laryngeal mask airway arterial desaturation during induction of anaesthesia and insertion of a laryngeal mask airway 100mm visual analogue scales vas and the statetrait anxiety inventory stai psychometric questionnaire anxiety heart rate and systolic arterial pressure immediately before induction of anaesthesia vas or stai score anxiolytic effects￨induction of anaesthesia was achieved with a lower dose of propofol p  00009 and excellent grade i conditions for insertion of a laryngeal mask airway were achieved more often after midazolam premedication p  0038￨sig increase￨highunclear￨highunclear￨highunclear
45￨ambulatory surgery patients￨oral alprazolam 05 mg with midazolam placebo midazolam alprazolam alprazolam and midazolam preoperative alprazolam oral alprazolam gynecological laparoscopic surgery￨psychomotor function digit symbol substitution test score anxiety tdt score anxiety scores sedation scores extubation time and discharge times effectiveness and side effects￨at discharge from the postanesthesia care unit the tdt score was greater in both active drug groups compared with placebo p  005￨sig increase￨highunclear￨highunclear￨highunclear
30￨patients who receive significant postoperative opioid analgesics 30 healthy women￨laparoscopic tubal sterilization falope rings placebo midazolam or salineplacebo midazolam midazolam premedication midazolam fentanyl propofol and mivacurium and was maintained with n2o and isoflurane￨postoperative sedation discharge times postoperative sedation and recovery times sedation pacu time and time to dischargereadiness￨midazolam was associated with impairment of performance on the tdt and dsst after premedication administration and 15 tdt and dsst and 30 dsst min after postanesthesia care unit pacu arrival￨sig increase￨highunclear￨highunclear￨highunclear
120￨120 patients presenting for minor urological surgery outpatient anaesthesia￨triazolam placebo midazolam midazolam triazolam and diazepam benzodiazepines midazolam 15 mg and triazolam diazepam 10 mg and placebo midazolam midazolam and triazolam￨￨midazolam was found to produce the greatest degree of amnesia and sedation at the time of anaesthetic induction and triazolam was found to have the greatest degree of residual sedation at the time of discharge four hours postoperatively￨no diff￨highunclear￨highunclear￨highunclear
92￨92 healthy asa physical status i females aged 1542 yr undergoing outpatient dilatation and curettage dc for therapeutic abortion￨propranolol and diazepam diazepam placebo propranolol￨postoperative cognitive recovery anxiety levels anxiolytic properties stai anxiety levels cognitive function statetrait anxiety inventory stai￨there was no difference among the anxiolytic properties of the three medications and all three patient groups showed a significant decrease in anxiety levels after administration of the medication￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients undergoing daycase surgery￨temazepam oxazepam temazepam oxazepam 30 mg and placebo oxazepam and temazepam￨awakening time patient acceptability anxiety and produced sedation￨two hours after surgery no significant sedation was recorded with either drug and simple psychomotor testing showed unimpaired performance￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨midazolam placebo midazolam￨psychomotor performance assessed by digitalsymbol substitution tests patient selfassessment linear analogue scales and observer scores anxiolysis or sedation￨midazolam 15 mg caused significant anxiolysis and sedation preoperatively but also at 2 hours following awakening￨sig increase￨highunclear￨highunclear￨highunclear
150￨one hundred fifty adult outpatients￨midazolam fentanyl midazolam and fentanyl or oxymorphone midazolam and opioid analgesics midazolam vs placebo oxymorphone placebo oxymorphone placebo saline or midazolam￨recall abilities postoperative nausea vomiting incidence of pain worsening of psychomotor skill higher sedation level anxiety level discharge time incidence of intraoperative airway difficulties such as coughing￨although use of opioids increased the incidence of postoperative nausea 42 vs 18 p less than 001 and vomiting 23 vs 2 p less than 001 opioid vs no opioid average recovery times were not affected by opioid administration￨sig decrease￨highunclear￨highunclear￨highunclear
100￨anxious patients who are scheduled for outpatient surgery one hundred adult female patients scheduled for outpatient laparoscopic procedures were studied outpatient anaesthesia￨intravenous narcotics placebo fentanyl meperidine placebo morphine standard anaesthetic regimen sufentanil￨discharge times complete recovery preoperative anxiety postoperative nausea vomiting and other side effects￨the incidence of postoperative nausea vomiting and other side effects was not higher and discharge times were not longer after sufentanil compared to the placebo group￨no diff￨highunclear￨highunclear￨highunclear
50￨fifty asa i and ii patients aged between 2060 years adult pakistani patients￨midazolam oral midazolam placebo midazolam 75 mg or a placebo￨mean heart rate and blood pressure anxiolysis sedation amnesia and psychomotor performance anxiolysis and sedation blood pressure and heart rate psychomotor performance assessed by n deletion test￨psychomotor performance assessed by n deletion test was impaired by midazolam p  0001 and recall of pictures revealed differences p  005 in the groups at one hour after premedication￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients undergoing daycase surgery under general anaesthesia￨diazepam and placebo diazepam placebo diazepam￨preoperative discomfort and apprehension￨diazepam decreased significantly preoperative discomfort and apprehension￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨￨temazepam temazepam premedication temazepam￨delayed recovery times effective anxiolysis￨effective anxiolysis was recorded in the groups that received temazepam 10 or 20 mg and there was no prolongation of delayed recovery times as measured by memory test cards￨sig increase￨highunclear￨highunclear￨highunclear
60￨patients were invited to take part by letter sent the week before gynaecological n  40 or oral n  60 surgery was scheduled daycase patients￨timolol placebo anxiolytic premedication timolol￨indices of anxiety and alertness anxiety return of psychomotor function situational anxiety haemodynamic differences￨haemodynamic differences between the groups were not clinically significant and return of psychomotor function was not delayed by timolol￨no diff￨highunclear￨highunclear￨highunclear
160￨early postmenopausal women  n  160 early postmenopausal nonosteoporotic women￨strontium ranelate placebo or strontium ranelate sr placebo calcium￨bone loss femoral neck and total hip bmd bone resorption hip bmd and biochemical markers of bone turnover lumbar bone mineral density bmd lumbar bmd adjusted lumbar bmd bone alkaline phosphatase￨sr 1 gday significantly increased bone alkaline phosphatase at all time points  p005 compared with baseline and betweengroup analysis showed a significant increase compared with placebo at month 18  p  0048￨sig increase￨low￨low￨low
1649￨1649 postmenopausal women with osteoporosis low bone mineral density and at least one vertebral fracture to receive 2 g of women with postmenopausal osteoporosis massachusetts medical society￨strontium ranelate strontium ranelate calcium and vitamin d supplements placebo oral strontium ranelate per day or placebo￨bone mineral density new vertebral fractures incidence of serious adverse events bone resorption risk of vertebral fracture risk reduction osteoporotic structural damage and bone fragility￨treatment of postmenopausal osteoporosis with strontium ranelate leads to early and sustained reductions in the risk of vertebral fractures￨sig decrease￨low￨low￨low
5091￨5091 postmenopausal women with osteoporosis in a doubleblind women at high risk of hip fracture age  or  74 yr and postmenopausal women with osteoporosis 3640 patients with spinal xrays and by 45 in the subgroup without prevalent vertebral fracture￨strontium ranelate strontium ranelate placebo￨bone mineral density rr of vertebral fractures femoral neck bone mineral density t score incidence of adverse events aes vertebral fractures vertebral fracture risk rr reduction for hip fracture risk of nonvertebral fractures relative risk rr￨rr of vertebral fractures was reduced by 39 p  0001 in the 3640 patients with spinal xrays and by 45 in the subgroup without prevalent vertebral fracture￨sig decrease￨highunclear￨highunclear￨highunclear
353￨postmenopausal osteoporosis 353 osteoporotic women with at least one previous vertebral fracture and a lumbar tscore 24 established postmenopausal vertebral osteoporosisa 2year randomized￨strontium ranelate strontium ranelate sr placebo sr sr therapy￨femoral bmd incidence of new vertebral deformities and biochemical markers of bone metabolism vertebral bmd lumbar bmd adjusted for bone strontium content tolerated lumbar bone mineral density bmd assessed by dualenergy xray absorptiometry number of patients experiencing new vertebral deformities serum levels of bone alkaline phosphatase urinary excretion of crosslinked ntelopeptide a marker of bone resorption incidence of vertebral fractures efficacy and safety￨lumbar bmd adjusted for bone strontium content increased in a dosedependent manner in the intentiontotreat population mean annual slope increased from 14 with 05 gd sr to 30 with 2 gd sr which was significantly higher than placebo p  001￨sig increase￨low￨low￨low
63￨the study groups at entry were comparable for birth weight gestational age postnatal age gender birth depression hematocrit  040 heart rate oxygenation index delivery route maternal chorioamnionitis and maternal magnesium or ritodrine therapy hypotension mean arterial blood pressure  or  30 mm hg in preterm  or  34 weeks of gestation infants with respiratory distress syndrome in the first 24 hours of life we enrolled 63 hypotensive preterm infants preterm infants with respiratory distress syndrome￨dobutamine dopamine and dobutamine dopamine versus dobutamine dopamine￨treatment failure mean arterial blood pressure success￨we conclude that dopamine is more effective than dobutamine for the early treatment of hypotension in preterm infants with respiratory distress syndrome￨sig increase￨highunclear￨highunclear￨highunclear
40￨infants who all had a systolic bp  40 mmhg despite receiving a colloid infusion preterm neonates forty infants with median gestational age 27 weeks range 2333 preterm infants￨dopamine dopamine or dobutamine infusion dobutamine infusion inotropic infusions dobutamine dopamine and dobutamine￨systolic bp gestational or postnatal age or baseline bp rate of inotrope infusion￨there was no significant difference in the gestational or postnatal age or baseline bp of the 20 infants who received dopamine and those 20 who received dobutamine￨no diff￨highunclear￨highunclear￨highunclear
20￨hypotensive preterm infants 20 preterm infants who had protracted arterial hypotension refractory to volume therapy￨doppler ultrasonography of the superior mesenteric artery sma dobutamine or dopamine dopamine dobutamine￨blood pressure and intestinal perfusion mean arterial pressure map intestinal perfusion and blood pressure mean blood flow velocity vascular resistance of sma intestinal perfusion￨vascular resistance of sma indicated by resistance index ri decreased from 081￨sig decrease￨highunclear￨highunclear￨highunclear
4￨critically ill preterm infants 66 pni whose weights were between 1000 to 1500 g and persistent hypotension defined as a mean arterial pressure map of  30 mmhg preterm newborn infants pni￨albumin and dobutamine dopamine and the other dobutamine dopamine 5 albumin infusion albumin and dopamine dobutamine dopamine￨map values pressure response￨there were no differences between groups in initial features￨no diff￨highunclear￨highunclear￨highunclear
not found￨20 hypotensive preterm infants of less than 32 weeks gestation hypotensive very preterm infant￨dobutamine dopamine or dobutamine dopamine dobutamine and dopamine￨mean arterial pressure map percentage lvo increase lvo haemodynamic response infusion rate left ventricular output lvo mean se map￨dobutamine failed to increase map above 30 mm hg in six infants out of 10 whereas dopamine succeeded in all 10 infants￨no diff￨highunclear￨highunclear￨highunclear
50￨50 patients 25 patients with acute severe gastrointestinal haemorrhage had their whole blood coagulation measured using the biobridge impedance clotting time ict￨blood or no blood transfusion unless the haemoglobin fell below 8 gdl or they were shocked early blood transfusion citrated stored blood￨gastrointestinal haemorrhage kaolin cephalin clotting times kcct￨in the transfused group nine patients rebled compared with only one in the nontransfused group p less than 001 chi 2 with yates correction￨sig increase￨highunclear￨highunclear￨highunclear
16￨sixteen cirrhotic patients recovering from a variceal bleeding episode human portal hypertension acutely anemic cirrhotic patients￨blood hemoglobin levels packed red cells or 500 ml of a protein solution erythrocytes or a protein solution￨total blood volume and suppression of vasopressor systems systemic vascular hindrance resistanceblood viscosity degree of liver failure severity of the bleeding episode activation of the endogenous vasopressor systems and hemodynamic parameters blood hemoglobin cardiac output systemic and portal hemodynamics and rheological and hormonal parameters cardiopulmonary pressures wedged hepatic venous pressure hepatic venous pressure gradient￨both groups were similar with respect to the degree of liver failure severity of the bleeding episode activation of the endogenous vasopressor systems and hemodynamic parameters￨no diff￨highunclear￨highunclear￨highunclear
60￨acute hemorrhagenormovolemic haemodilutiondigestive hemorrhage transfusion oldest patients patient with acute hemorrhage acute anemia in high digestive hemorrhage all patients have endoscopic diagnosis and they went evaluated across the study with clinic and laboratory controls 60 patients with acute digestive hemorrhage without haemodynamic failure￨normovolemic haemodilution with crystalloid solutions red cells transfusion￨hospital stay neither the rate of organs failure apache score hematocrit value￨we did not see differences between the groups in the hospital stay neither the rate of organs failure￨no diff￨highunclear￨highunclear￨highunclear
20￨twenty healthy women intending to take oral contraceptives were studied 1 before drug ingestion control and subsequently during the intake of oral contraceptives with 2 139 and 1438￨low and high dose oral contraceptives low estrogen content 20 micrograms ethinyl estradiol and 150 micrograms desogestrel per day and 3 high estrogen content 50 micrograms ethinyl estradiol oral contraceptives with low and high estrogen concentration￨blood coagulation and thrombogenesis fibrinsubendothelial interactions fibrinogen blood flow and wall shear rate fibrin deposition on vascular subendothelium subendothelial deposition of platelets and platelet thrombi deposition of fibrin platelets and platelet thrombi on vascular subendothelium plasma levels of ethinyl estradiol antithrombin iii activity bloodsubendothelium interactions￨4  coverage of the subendothelial surface with fibrin high dose vs control p less than 005￨sig decrease￨highunclear￨highunclear￨highunclear
416￨416 women investigated follicle development over a period of 12 oral contraceptive treatment cycles￨20 micrograms ethinylestradiol ethinylestradiolgestodene preparation containing 30 micrograms ethinylestradiol and 75 micrograms gestodene gestodene ethinylestradiol ethinylestradioldesogestrel￨follicle size ruptured follicles follicular ovarian activity escape ovulation￨the difference between the treatment groups with respect to follicle diameters of 1030 mm and 30 mm was statistically significant p  005 and p  0001 respectively￨no diff￨highunclear￨highunclear￨highunclear
not found￨fiftyfive women using￨loestrin20 20 microgram ethinyl oestradiol and 1 mg norethisterone acetate microgynon30 30 microgram ethinyl oestradiol and 150 microgram levonorgestrel low dose combined oral contraceptives￨accidental pregnancy rates￨despite the small sample size the main finding in the trial is clearcut loestrin20 provides poor cycle control and is thus less acceptable as an oral contraceptive than microgynon30￨no diff￨highunclear￨highunclear￨highunclear
58￨￨gestodene gestodene and 30 micrograms ethinylestradiol75 micrograms gestodene tablets containing 20 micrograms ethinylestradiol ee  75 micrograms gestodene and the other 30 micrograms ee  75 micrograms gestodene￨hdlcholesterol total triglycerides plasma levels of hdlcholesterol and its subfractions ldlcholesterol and apolipoproteins￨analysis of results revealed that there were no statistically significant differences between the two groups with regard to the plasma levels of hdlcholesterol and its subfractions ldlcholesterol and apolipoproteins￨no diff￨highunclear￨highunclear￨highunclear
155￨167 women for 1 to 4 cycles of treatment 155 healthy women￨levonorgestrel with ethinyl estradiol levonorgestrel with 20 microg ethinyl estradiol alesse or loette triphasic norethindrone with ethinyl estradiol levonorgestrel ethinyl estradiol oral contraceptive regimens norethindrone with 35 microg ethinyl estradiol orthonovum 777 or trinovum levonorgestrel with 20 microg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol￨cholesterol concentration adverse events percentages of normal menstrual cycles and the percentages of cycles with intermenstrual and withdrawal bleeding triglyceride and glucose concentrations withdrawal bleeding episode￨most mean changes from baseline laboratory values were comparable between groups although the mean increase in cholesterol concentration was statistically significantly lower in the levonorgestrel with ethinyl estradiol group￨no diff￨highunclear￨highunclear￨highunclear
not found￨healthy sexually active women￨24day oral contraceptive pill 217day triphasic norgestimateethinyl estradiol e2 25microgram oral contraceptive pill ocp 217day norgestimateethinyl e2 or 244day drospirenoneethinyl e2 norgestimateethinyl e2 25microgram regimen drospirenoneethinyl e2 20microgram ocp￨episodes of unscheduled bleeding bleeding bleeding data tolerated unscheduled bleeding days unscheduled bleeding and more scheduled bleeding bleeding patterns scheduled bleeding￨women using the 217day ocp had significantly fewer episodes of unscheduled bleeding than did those using the 244day ocp mean 147 compared with 201 p001￨sig decrease￨highunclear￨highunclear￨highunclear
2430￨10 who collaborating centres for clinical research in human reproduction 2430 women entered the trial and were observed for 28077 womancycles￨oral contraceptives with 50 micrograms or less of ethinyl estradiol ethinyl estradiol norethisterone acetate norethisterone six combined oral contraceptives￨bleeding disturbances nausea and vomiting discontinuation rates for medical reasons discontinuation rates￨however discontinuation rates for medical reasons differed significantly between the treatment groups with the preparation containing 20 micrograms ethinyl estradiol and that containing 400 micrograms norethisterone acetate being associated with higher discontinuation rates due to bleeding disturbances￨sig increase￨highunclear￨highunclear￨highunclear
1000￨one thousand women aged 18 to 40 years requesting oral contraceptive pills university clinics central hospitals and private gynaecological practices in norway sweden and denmark￨oral contraceptive pills both containing 150 micrograms desogestrel but with either 20 micrograms mercilon or 30 micrograms marvelondesolett ethinyl oestradiol ee desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol￨irregular bleeding breakthrough bleeding or spotting reliability cycle control side effects blood pressure body weight and haemoglobin dizziness and mood changes mean blood pressure mean body weight haemoglobin￨irregular bleeding breakthrough bleeding or spotting was significantly more frequent with the 15020 combination in about twothirds of the cycles randomly distributed over the one year of the study￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨oral contraceptives containing 20 micrograms ethinylestradiol75 micrograms gestodene and 30 micrograms ethinylestradiol75 micrograms gestodene gestodene but in combination with 30 micrograms ethinylestradiol oral contraceptive containing 20 micrograms ethinylestradiol ee2 and 75 micrograms gestodene gsd￨intermenstrual bleeding rates contraceptive reliability cycle control and tolerance adverse events blood pressure and body weight intermenstrual bleeding frequency of adverse events cumulative breakthrough bleeding rates spotting rate breakthrough bleeding rate￨the discontinuation rate due to adverse events including intermenstrual bleeding was low 98 for 20 micrograms ee2  75 micrograms gsd and 72 for 30 micrograms ee2  75 micrograms gsd and was in the lower range known for other oral contraceptives￨no diff￨highunclear￨highunclear￨highunclear
1723￨healthy women￨norethindrone acetate 1 mgethinyl estradiol novel norgestimateethinyl estradiol oral contraceptive ortho tricyclen lo new triphasic norgestimate 180215250 microgethinyl estradiol 25 microg regimen ortho tricyclen lo￨compliance and safety data breakthrough bleeding and spotting overall and method failure probabilities of pregnancy breakthrough bleeding and spotting rates contraceptive efficacy￨breakthrough bleeding and spotting was reported by a significantly lower percentage of participants in the ortho tricyclen lo group compared with the loestrin fe 120 group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨healthy thai women between two lowdose￨ethinylestradiol combined with 75 microg gestodene oral contraceptive containing 20 microg ethinylestradiol and 75 microg gestodene oral contraceptives containing 20 microg ethinylestradio175 microg gestodene meliane and 30 microg ethinylestradio175 microg gestodene gynera￨nausea vomiting dizziness and chloasma body weight and blood pressure cycle control efficacy and side effects occurrence of spotting and breakthrough bleeding￨from the study it was demonstrated that the two regimens had no difference in cycle control efficacy and side effects￨no diff￨highunclear￨highunclear￨highunclear
48￨48 volunteers were obtained￨combined onethird ethinyl estradiol eelevonorgestrel lng ethinyl estradiol combined with 100 microg levonorgestrel lng oral contraceptive containing 20 microg ee and 100 microg lng￨hdl2 cholesterol lipid and carbohydrate variables lowdensity lipoprotein cholesterol very lowdensity lipoprotein cholesterol and total triglycerides safe and well tolerated lipid and carbohydrate profiles median values for the fasting levels of insulin cpeptide and free fatty acids fasting glucose levels glucose area under the curve auc￨the median values for the fasting levels of insulin cpeptide and free fatty acids slightly increased or remained unchanged while the fasting glucose levels slightly decreased after 13 treatment cycles￨no diff￨highunclear￨highunclear￨highunclear
1850￨fourhundredtwentysix women aged 18 to 36￨new graduated estrogen formulation with three constantdosed oral contraceptives￨levels of hdlc efficacy side effects metabolic changes and cycle control highdensity lipoprotein cholesterol hdlc lowest rate of breakthrough bleeding btb￨a total of 1850 cycles were completed and analyzed for efficacy side effects metabolic changes and cycle control￨no diff￨highunclear￨highunclear￨highunclear
not found￨463 oc starters or switchers￨20 micrograms and 35 micrograms estrogen preparations low and lowerdose oral contraceptives alesse 20 micrograms ethinyl estradiol ee mircette 20 micrograms ee and ortho tricyclen 35 micrograms ee￨efficacy cycle control and side effects bloating breast tenderness and nausea discontinuation and pregnancy rates￨bloating breast tenderness and nausea were approximately 50 more common in women using 35 micrograms ee as compared to 20 micrograms ee preparations￨sig increase￨highunclear￨highunclear￨highunclear
75￨75 healthy female volunteers aged 1835 years were enrolled 25 volunteers￨drospirenone drsp drsp30ee vs dsg30ee preparation containing 150 microg desogestrel dsg and 30 microg ethinyl estradiol dsg30ee drsp ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol drsp20ee drospirenone ethinyl estradiol ee drsp30ee drsp20ee￨safe and well tolerated antifibrinolytic variables the global clotting tests and ddimer hemostasis variables for fibrinogen and protein s activity￨the changes in the hemostatic variables for drsp20ee were less pronounced compared to dsg30ee and drsp30ee￨sig decrease￨highunclear￨highunclear￨highunclear
505￨women over 30 years of age 505 women received healthy nonsmoking women requiring contraception up to the age of menopause￨desee oral contraceptives gestodene ges 75 mcgethinyl oestradiol ee 30 mcg and desogestrel des 150 mcgee lowdose oral contraceptives minulet and mercilon gesee￨incidence of missed pills headache nausea and metrorrhagia irregular bleeding between withdrawal bleeds cycle length or withdrawal bleeding episode length withdrawal bleeding mean intensity absence of all bleeding adverse reactions weight blood pressure papanicolaou smears or laboratory data normal cycles mean intensity menstrual flow length￨no clinically significant differences were noted in weight blood pressure papanicolaou smears or laboratory data￨no diff￨highunclear￨highunclear￨highunclear
49￨fortynine women participated￨oral contraceptives containing desogestrel oral contraceptives containing 150 mcg desogestrel and 20 mcg ethinylestradiol ee ethinylestradiol￨triglycerides hdlcholesterol and apoprotein a1 fasting blood glucose levels sbp and cbg renin substrate and hemostatic parameters renin substrate metabolic and hemostatic effects antithrombin iii total and free protein s and fibrinogen hemostatic and metabolic effects￨in both groups there was a significant increase in triglycerides hdlcholesterol and apoprotein a1 the same increase was observed for sbp and cbg￨sig increase￨highunclear￨highunclear￨highunclear
not found￨33 volunteers in each group were obtained￨ethinyl estradiol and 75 microg gestodene ethinyl estradiol￨glucose aucs overall change of all hemostatic variables safe and well tolerated hemostatic variables and lipids hemostatic system aucs for insulin and cpeptide metabolic effects hemostatic variables lipids and carbohydrate metabolism carbohydrate metabolism adequate contraceptive reliability individual hemostatic parameters￨both study treatments were safe and well tolerated by the volunteers as shown by the nature and frequency of adverse events the routine laboratory examinations and the physical and gynecological examinations￨no diff￨highunclear￨highunclear￨highunclear
2419￨triminulet n  808 mean age 246 years or n  805 mean age 246 years 2419 healthy women  or  41 years of age minulet n  806 mean age 245 years 698 women were withdrawn from the study 154 due to adverse events￨gestodene monophasic desogestrel mercilon gestodene monophasic gestodene triphasic gestodene and monophasic desogestrelcontaining oral contraceptives monophasic gestodene oral contraceptives containing monophasic gestodene triphasic gestodene oral contraceptives containing gestodene and one containing desogestrel￨intensity of bleeding breast pain metrorrhagia incidence of adverse events breakthrough bleeding andor spotting duration of bleeding abdominal pain tolerated nausea latent period before withdrawal bleeding￨the incidence of adverse events in all treatment groups was similar with the exception of metrorrhagia which occurred in more patients in the desogestrel group than in the gestodene treatment groups p  005￨no diff￨highunclear￨highunclear￨highunclear
not found￨healthy women with normal menstrual cycles￨oral contraceptive regimens monophasic levonorgestrel lng 100 microgramsethinylestradiol ee 20 micrograms alesse or loette and triphasic norethindrone net 5007501000 microgramsee 35 micrograms orthonovum 777 monophasic levonorgestrelethinylestradiol 100 micrograms20 micrograms versus triphasic norethindroneethinylestradiol lngee￨incidence of treatmentemergent adverse events withdrawal bleeding characteristics percentage of cycles classified as normal intermenstrual bleeding total bleeding andor spotting￨withdrawal bleeding characteristics were comparable between the two groups except for the length of the latent period which was significantly longer in the lngee group￨no diff￨highunclear￨highunclear￨highunclear
40￨40 healthy women between the ages of 18 and 30 years￨oral contraceptives containing gestodene and either 20 micrograms or 30 micrograms ethinylestradiol monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol￨tissue plasminogen activator tpa and plasminogen activator inhibitor pai1 fibrinolytic activity fibrinolytic capacity threshold of fibrinolytic inhibition ratio pai1 fibrinolytic response protein s concentration and protein s activity￨there was also an increase in the threshold of fibrinolytic inhibition ratio pai1 in both groups which was less pronounced in the 20 micrograms ee group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨women in preterm labor   35 weeks gestation 110 women 60 in the control group and 50 in the pb group preterm infants￨antenatal phenobarbital pb therapy antenatal pb therapy￨neonatal intracranial hemorrhage ich incidence of neonatal ich moderate and severe ich incidence of all grades of ich hemorrhage overall ich moderate and severe hemorrhages intracranial hemorrhage incidence of any grade of hemorrhage￨antenatal pb therapy results in a significant decrease in moderate and severe ich in infants born at less than 35 weeks gestation￨sig decrease￨highunclear￨highunclear￨highunclear
110￨premature infants we randomly assigned 110 women at less than 31 weeks of periventricular and intraventricular hemorrhage￨gestation to receive 10 mgkg phenobarbital or placebo phenobarbital placebo antenatal phenobarbital￨frequency of grade 3 and grade 4 hemorrhages maternal demographics pregnancy complications antenatal management and route of delivery incidence and severity of intracranial hemorrhage severity of periventricularintraventricular hemorrhage total incidence of periventricularintraventricular hemorrhage severe hemorrhage￨there were no differences in the severity of associated conditions in the babies to explain the difference in the incidence of severe hemorrhage between the study groups￨no diff￨low￨low￨low
100￨premature infants 100 pregnant mexican women who need to interrupt their pregnancy within 2832 weeks of gestation premature infants younger than 32 weeks at birth 42 newborns in the phenobarbital group and 46 in the control group the newborns had phenobarbital levels of 115 57 gmicroliter at birth and of 95 patients with mechanical ventilation￨prenatal phenobarbital prenatal phenobarbital intravenous iv phenobarbital 10 microgramskg phenobarbital￨ivh seivh frequency severe hemorrhages mild seivh frequency of seivh phenobarbital serum concentrations￨ivh was found in 12 patients from the phenobarbital group and in 29 from the control group p  0005 the first group were 11 mild seivh 2 grade i and 9 grade ii and 26 in the control group 4 grade i and 22 grade ii p  0005￨sig increase￨highunclear￨highunclear￨highunclear
150￨one hundred fifty pregnant women destined to deliver infants less than 32 weeks￨phenobarbital￨intraventricular hemorrhage severe intraventricular hemorrhage blood levels intraventricular hemorrhage￨maternally administered phenobarbital appears to be effective in reducing the incidence of intraventricular hemorrhage and lessening its severity￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨very low birth weight infant mothers with arrested premature labor between 26 and 33 weeks gestation infants in the two groups were similar in race birth weight and gestational age￨oral phenobarbital￨conjugated bilirubin levels antenatal phenobarbital and bilirubin metabolism￨conjugated bilirubin levels at birth were significantly higher for infants receiving several days of phenobarbital in utero than no therapy 031￨sig increase￨highunclear￨highunclear￨highunclear
not found￨newborn patients at imminent risk for spontaneous or indicated premature delivery between 2434 weeks gestation premature newborns￨placebo placebo or vitamin k and phenobarbital betamethasone and antibiotics antepartum phenobarbital and vitamin k antepartum phenobarbital and vitamin k antepartum vitamin k and phenobarbital￨intraventricular hemorrhage mild and severe intraventricular hemorrhage mild intraventricular hemorrhage severe intraventricular hemorrhage￨there was a nonsignificant reduction in all grades of intraventricular hemorrhage in the treatment group when compared to the placebo group 482 versus 383 p  05￨sig decrease￨low￨low￨low
25￨fortysix pregnant women less than 35 weeks of gestation neonatal intracerebral hemorrhage￨phenobarbital intravenously antenatal phenobarbital antenatal phenobarbital￨mortality rate moderate or severe hemorrhage neonatal intracerebral hemorrhage intracerebral hemorrhage mortality￨the mortality rate was significantly lower in the phenobarbitaltreated group two of 25 infants than in the control group eight of 23 infants p less than 005￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨premature newborns 39 women destined to deliver babies of less than 32 weeks of gestation￨intravenous loading dose of 700 mg of phenobarbital phenobarbital antenatal phenobarbital antenatal phenobarbital￨intraventricular hemorrhage intraventricular hemorrhage neonatal intraventricular hemorrhage severe hemorrhage￨moreover no severe hemorrhage grade 34 occurred in the treated babies 0 of 21 versus 5 of 18 277 p less than 001￨no diff￨highunclear￨highunclear￨highunclear
12￨neurolepticinduced akathisia￨placebo clonazepam or placebo clonazepam clonazepam clonazepam and placebo￨akathisia scores akathisia￨one week after stopping the drug there was a partial but significant relapse in the treated group as compared with controls in whom the symptoms remained stable￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨older adolescents older adolescents and young adults￨neurolepticinduced akathisia clonazepam placebo clonazepam￨akathisia scores￨clonazepam may be a safe and effective treatment for neurolepticinduced akathisia in this age group￨sig increase￨highunclear￨highunclear￨highunclear
1088￨relapsing multiple sclerosis 1088 patients with multiple sclerosis 18 to 55 years of age with a score of 0 to 55 on the expanded disability status scale and at least one relapse in the previous year or at least two relapses in the previous 2 years￨teriflunomide oral teriflunomide placebo 7 mg of teriflunomide or 14 mg of teriflunomide placebo￨serious infections mri evidence of disease activity elevated alanine aminotransferase levels annualized relapse rate progression of disability proportion of patients with confirmed disability progression diarrhea nausea and hair thinning relapse rates disability progression￨teriflunomide significantly reduced relapse rates disability progression at the higher dose and mri evidence of disease activity as compared with placebo￨sig increase￨low￨low￨low
118￨relapsing multiple sclerosis patients with relapsing forms of multiple sclerosis rms classification of evidence 118 patients with rms￨interferonβ interferonβ ifnβ oral placebo or teriflunomide teriflunomide￨t1gd lesion volume annualized relapse rate acceptable safety and tolerability and reduced mri disease activity t1gd lesion burden number of gadoliniumenhancing t1 t1gd lesions disease activity assessed by mri and relapse rate￨teriflunomide as addon therapy to ifnβ had acceptable safety and tolerability and reduced mri disease activity compared with ifnβ alone￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with the lennoxgastaut syndrome patients with lennoxgastaut syndrome￨placebo cinromide￨seizure reduction or global evaluations￨no difference between cinromide and placebo was shown in terms of seizure reduction or global evaluations￨no diff￨highunclear￨highunclear￨highunclear
139￨139 eligible patients were randomized 138 patients received either eligible patients between 4 and 30 years of age had multiple types of seizures including tonicatonic and atypical absence seizures with a minimum of 90 seizures in the month before baseline and a recent history of a slow spikeandwave pattern on eeg patients with lennoxgastaut syndrome￨rufinamide antiepileptic drug rufinamide placebo rufinamide￨total seizures seizure severity total seizure frequency vomiting somnolence tonicatonic drop attack seizure frequency with rufinamide tonicatonic seizures￨the rufinamide group had a greater improvement in seizure severity p  00041 and a higher 50 responder rate compared with placebo for total seizures p  00045 and tonicatonic seizures p  0002￨sig increase￨low￨low￨low
98￨lennoxgastaut syndrome ninetyeight patients 1 year to 30 years of age with slow spikeandwave patterns on eeg seizure types including drop attacks and either a history of or active atypical absence seizures￨topiramate placebo topiramate or placebo topiramate topiramate adjunctive therapy￨seizure rate major seizures drop attacks and tonicclonic seizures number of drop attacks and major motor seizures seizure severity efficacy and safety￨the most common adverse events in both groups were cns related there were no discontinuations from topiramate therapy due to adverse events￨no diff￨low￨low￨low
68￨patients with lennoxgastaut syndrome lgs sixtyeight patients with lgs aged 226 years lennoxgastaut syndrome￨clobazam clb clobazam clb￨weekly drop seizure rates seizure frequency adverse events nondrop seizures overall symptoms￨weekly drop seizure rates were significantly reduced from baseline in both the highdose and lowdose groups the reduction was significantly greater in the highdose group￨sig decrease￨highunclear￨highunclear￨highunclear
190￨one hundred ninety patients with epilepsy resistant to conventional drug treatment patients with lennoxgastaut syndrome having no history of west syndrome patients with intractable epilepsy￨dn1417 a trh analog dn1417￨global improvement rating gir based on changes in seizure frequency eeg findings and nonparoxysmal clinical manifestations efficacy and adverse reactions gir was slightly to markedly improved￨the responses assessed by gir was slightly to markedly improved in 48 of the patients with lowdose treatment and 55 with highdose treatment￨no diff￨highunclear￨highunclear￨highunclear
not found￨childhood epileptic encephalopathy lennoxgastaut syndrome patients with the lennoxgastaut syndrome patients with multiple types of seizures 73 patients ranging in age from 4 to 36 years who had the lennoxgastaut syndrome￨placebo felbamate￨number of tonicclonic seizures globalevaluation scores frequency of seizures frequency of atonic seizures total frequency of seizures frequency of side effects frequency of refractory partialonset seizures total number of seizures counted during a fourhour period of video recording parents or guardians global evaluations of the patients quality of life and the total number of atonic seizures as reported by parents or guardians￨the globalevaluation scores were significantly higher in the felbamate group than in the placebo group from day 49 to the end of the study￨sig increase￨highunclear￨highunclear￨highunclear
169￨patients with the lennoxgastaut syndrome eligible patients had more than one type of predominantly generalized seizure including tonicclonic atonic tonic and major myoclonic and had seizures on average at least every other day￨antiepileptic drug lamotrigine placebo lamotrigine lamotrigine￨incidence of adverse events except for colds or viral illnesses median frequency of all major seizures frequency of seizures￨there were no significant differences between groups in the incidence of adverse events except for colds or viral illnesses which was more common in the lamotrigine group p005￨no diff￨low￨low￨low
not found￨participating children used 19 different aed combinations at entry children and adolescents with refractory generalized epilepsy children with intractable generalized epilepsies children and adolescents n  30 twenty patients had lennoxgastaut syndrome￨lamotrigine ltg placebo lamotrigine ltg ltg and placebo￨severe seizures or both or improved behavior or improved motor skills or both adverse events seizure frequency plasma levels abnormal biochemical or hematologic findings￨none of the children studied showed abnormal biochemical or hematologic findings or changes in plasma levels of concomitantly administered aeds￨no diff￨highunclear￨highunclear￨highunclear
not found￨45 patients with unstable multifragmented fractures of the radial head from january 2004 to june 2007 unstable multifragmented radial head fractures￨radial head replacement orif group and the radial head replacement group internal fixation radial head replacement with a metal prostheses radial head replacement and open reduction and internal fixation radial head by metal prostheses with open reduction and internal fixation orif￨postoperative complication rate favourable joint function broberg and morrey scores and postoperative complication rate￨good or excellent results p  001￨sig increase￨highunclear￨highunclear￨highunclear
164￨at 2 years 135 82 of 164 patients were available for evaluation displaced radial head fractures￨biodegradable implants versus standard metal fixation biodegradable polylactide pins with standard metal minifragment implants￨functional status broberg and morrey elbow score incidence of complication￨the incidence of complicationfree patients was 37 less in the polylactide group than in the control group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨mason type iii radial head fracture 14 patients who received radial head fractures of mason type iii 12 fresh cases and two old cases of mason type iii radial head fracture￨cement stem and bipolar radial prosthesis orif internal fixation orif with bipolar radial head prosthesis replacement radial head prosthesis replacement internal fixation and prosthesis replacement orif with cannulated screws and kirschner k wires bipolar radial head prosthesis replacement￨￨mean followup of the eight cases in the orif group was 14 months range 1021 months with good results in one case fair in four and poor in three￨no diff￨highunclear￨highunclear￨highunclear
not found￨children with leukemia and their families children with leukemia children with leukemia and their parents￨cdrom or the book you and leukemia by lynn baker interactive cdrom￨feelings of control over their health￨a space adventure was found to be a useful engaging and empowering tool for children with leukemia and can serve as a model for developing future healthrelated educational materials￨sig increase￨highunclear￨highunclear￨highunclear
93￨adolescents with newly diagnosed cancer 93 eligible adolescents 78 46 females and 32 males agreed to participate adolescents newly diagnosed with cancer newly diagnosed adolescents￨selfcare coping intervention￨psychological hopefulness hopelessness selfesteem selfefficacy and symptom distress and clinical outcomes treatment toxicity￨no statistically significant differences between the intervention and control groups or between male and female participants were detected at any measurement point￨no diff￨highunclear￨highunclear￨highunclear
32￨children hospitalized before september 1997 exhibited resistance and anxiety during and after painful procedures children with leukemia during painful procedures 32 children aged 214 years children with leukemia undergo painful procedures such as lumbar puncture and bone marrow aspiration￨￨￨at was shown to be a useful intervention that can prevent permanent trauma and support children and parents during intrusive interventions￨sig increase￨highunclear￨highunclear￨highunclear
64￨64 children ages 5 to 13 years with newly diagnosed cancer to either a children with newly diagnosed cancer￨social skills training experimental treatment group or a school reintegration standard treatment group social skills training explicit training￨classmate and teacher social support internalizing and externalizing behavior problems school competence￨children who received explicit training in social skills reported higher perceived classmate and teacher social support at the 9month followup in comparison to pretreatment levels while parents reported a decrease in internalizing and externalizing behavior problems and an increase in school competence￨sig increase￨highunclear￨highunclear￨highunclear
not found￨small group of adolescents and young adults with cancer adolescent cancer patients￨￨psychologic distress￨a strong relationship was found between the patients and parents amount of psychologic distress￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨plasmodium vivax malaria in india￨primaquine chloroquine￨prevalence of recurrence of parasitaemia with fever radical curative efficacy recurrence recurrence of infection￨the difference in recurrence was not significant p  053￨no diff￨highunclear￨highunclear￨highunclear
not found￨plasmodium vivax infections￨primaquine 5 and 14day primaquine￨relapse rates￨the relapse rates observed over a 6month period of followup were 0 with the 14day regimen 267 with the 5day and 117 when no primaquine treatment was given￨no diff￨highunclear￨highunclear￨highunclear
85￨85 adult thai men with acute plasmodium vivax malaria plasmodium vivax malaria￨chloroquineprimaquine chloroquine primaquine alone primaquine or chloroquine primaquine￨p vivax malaria plasmodium falciparum malaria blood stage antimalarial activity blood stage antimalarial efficacy blood stage antimalarial efficacy parasite clearance times recurrences￨p vivax malaria recurred in 10 17 of 60 patients followed for  or  2 months and plasmodium falciparum malaria developed in another 5 8 without reexposure to infection￨no diff￨highunclear￨highunclear￨highunclear
595￨a total of 595 cases were enrolled individuals with glucose6phosphate dehydrogenase g6pd deficiency were excluded from the trial clinical cases recruited by passive case detection￨primaquine therapy chloroquine placebo primaquine pq￨protective against further episodes of p vivax￨all age groups on supervised or unsupervised treatment showed a similar degree of protection even though the risk of relapse decreased with age￨no diff￨highunclear￨highunclear￨highunclear
273￨273 patients with confirmed plasmodium vivax malaria in mumbai india between july 1998 and april 2000 patients with plasmodium vivax malaria in mumbai india￨no antirelapse therapy supervised 14d 15 14day primaquine primaquine primaquine therapy￨polymerase chain reactionsingle strand conformational polymorphism true relapse rate￨there were 6131 46 recurrences in patients given primaquine compared with 13142 92 in those not given antirelapse therapy￨no diff￨highunclear￨highunclear￨highunclear
80￨80 patients with p vivax infection fortysix of 55 tafenoquine recipients 10 of 13 recipients of chloroquine only and 12 of 12 recipients of completed at least 8 weeks of followup or had relapse￨chloroquine tafenoquine tafenoquine chloroquine plus tafenoquine chloroquine plus primaquine tafenoquine with primaquine primaquine tafenoquine wr238605 versus lowdose primaquine blood schizonticidal dose of chloroquine a tafenoquine￨relapse of plasmodium vivax malaria plasmodium vivax malaria relapse rate of protective efficacy￨the rate of protective efficacy determined on the basis of reduction in incidence density for all recipients of chloroquine plus tafenoquine compared with recipients of chloroquine plus primaquine was 926 95 confidence interval 73999 p042 by fishers exact test￨sig decrease￨highunclear￨highunclear￨highunclear
31￨afghan refugee camp in northwestern pakistan using a process of passive case detection and treatment at the camps clinic vivax malaria in an afghan refugee settlement in pakistan￨chloroquine chloroquine 5 and 14days primaquine therapy chloroquine alone versus chloroquine plus 5days primaquine primaquine primaquine chloroquine alone versus chloroquine plus 14days primaquine￨￨during the first trial 52 129250 of the nonprimaquine group recorded a 2nd clinicalparasitaemic episode and 23 recorded a 3rd whereas 51 128250 of the 5days primaquine group reported a 2nd episode and 21 recorded a 3rd￨sig increase￨highunclear￨highunclear￨highunclear
79￨seventynine adults with plasmodium vivax malaria from the porto velho area of rond nia western amazon region brazil￨chloroquine and primaquine chloroquine cq and primaquine primaquine￨cq resistance￨pcrbased comparison of parasitic dna collected pre and posttreatment was successful for eight of the 10 cases of apparent relapse and indicated that two such cases both given the short regimen of treatment were in fact probable cases of reinfection rather than of relapse￨no diff￨highunclear￨highunclear￨highunclear
46￨at two university centres 46 patients presenting with symptomatic infective blepharitis or blepharoconjunctivitis participated in a doubleblind study of a new blepharitis and blepharoconjunctivitis￨placebo gentamicinbetamethasone gentamicin alone and placebo placebo ointment gentamicin antibioticsteroid ointment containing gentamicin and betamethasone￨rate of recurrence of their symptoms￨there was no significant difference in response to 2 weeks of therapy between the patients treated with this ointment and those treated with either an ointment containing gentamicin alone or a placebo ointment￨no diff￨highunclear￨highunclear￨highunclear
197￨197 patients who were randomized to be treated over 2 weeks with￨bibrocathol eye ointment bibrocathol treatment bibrocathol noviform bibrocathol￨tolerated and safe lid edema lid erythema debris and pouting of meibomian glands patients rated their subjective complaints￨bibrocathol was superior to the control treatment in improving the sum score of the 5 scales by 70 vs 47 points p0001 especially in patients with primarily severe symptoms by 83 vs 48 p00001￨sig increase￨highunclear￨highunclear￨highunclear
20￨subjects eyes twenty patients with a diagnosis of dry eye associated with mgd and a baseline tfllt of or 90 nm baseline difference between experimental and control eyes or 25 nm patients with meibomian gland dysfunction￨tearfilm lipid layer thickness tfllt tfllt￨tfllt tfllt of the control eye mean tfllt skin of the closed eyelids increases tfllt tear film lipid layer thickness￨in comparison there was no significant increase in tfllt of the control eye after 5 minutes p  079 15 minutes p  077 and 30 minutes p  081 of treatment and after 5 minutes following the 30minute treatment period p  020 when compared to baseline tfllt￨no diff￨highunclear￨highunclear￨highunclear
not found￨subjects with clinically diagnosed blepharokeratoconjunctivitis in at least one eye ocular inflammation associated with blepharokeratoconjunctivitis limitation￨dexamethasone 01tobramycin 03 dmt tobradex loteprednol 05tobramycin dexamethasone 01tobramycin loteprednol etabonate 05tobramycin￨iop signs and symptoms composite score safety and efficacy signs and symptoms composite score using a noninferiority metric to compare let to dmt safety endpoints included visual acuity va biomicroscopy intraocular pressure iop assessments and adverse events￨subjects treated with dmt experienced a significant increase in iop versus those treated with let at day 7 day 15 and overall mean sd of 06 23 vs 01 22 p  003 10 30 vs 01 24 p  001 and 23 23 vs 16 17 p  002 respectively￨sig increase￨highunclear￨highunclear￨highunclear
20￨patients with meibomian gland dysfunction mgd meibomian gland dysfunction twenty patients with mgd patients with mgd￨topical nac nac 5 or preservativefree artificial tear topically 4 times a day for a month preservativefree artificial tears treated group served as control topical nacetylcysteine nac therapy nac topical nacetylcysteine￨mean ocular symptoms fluorescein breakup time fbut values and schirmer scores symptom of itching average schirmer increase rate mean ocular symptoms schirmers test scores and fbut values itching symptom symptoms of ocular burning foreign body sensation and intermittent filmy or blurred vision fbut and schirmer scores￨one month of topical nac therapy provided statistically significant improvements in fbut and schirmer scores as compared with the initial study visit￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with simple obstructive mgd and blepharitis who had discontinued all topical medications and tetracyclines received patients with blepharitis and mgd￨placebo oral omega3 dietary supplementation omega3 dietary supplementation dietary supplementation with omega3 fatty acids￨omega6 to omega3 fatty acid ratios in rbcs and plasma ocular surface disease index osdi objective clinical measures including tear production and stability ocular surface and meibomian gland health and biochemical plasma red blood cell rbc and meibum evaluation blepharitis and meibomian gland dysfunction mgd overall osdi score tbut and meibum score changes in meibum content change in tear breakup time tbut meibum score and overall osdi score blepharitis and meibomian gland dysfunction ocular symptoms ocular findings and serum and meibomian gland contents tbut osdi score and meibum score rbc and plasma ratios of omega6 to omega3￨changes in meibum content were observed in the omega3 group p  21 the level of meibum saturated fatty acids decreased￨sig increase￨highunclear￨highunclear￨highunclear
22￨patients with simple mgd patients with simple meibomian gland dysfunction mgd twenty right eyes of 20 patients with simple mgd and 22 right eyes of 22 healthy controls patients with meibomian gland dysfunction￨orgahexa or conventional eye mask new orgahexa eye warmer mask tear film with orgahexa eyemasks￨tear function and ocular surface status eyelid temperature measurements slit lamp examination tear film breakup time schirmer test vital staining tear film lipid layer interferometry and dry eye symptomatology scoring with visual analog scales￨the orgahexa eye warmer improved both tear function and ocular surface status and decreased symptoms significantly without any complications￨no diff￨highunclear￨highunclear￨highunclear
not found￨blepharitis and blepharoconjunctivitis patients with blepharitis and blepharoconjunctivitis 464 patients 230 of whom were treated with￨ciprofloxacin tobramycin eyes tobramycin ciprofloxacin ophthalmic solution topical ciprofloxacin tobramycin ophthalmic solution quinolone antimicrobial agent ciprofloxacin￨eradication or reduction of potentially pathogenic bacteria serious sideeffects￨bacteriological cultures demonstrated eradication or reduction of potentially pathogenic bacteria in 937 of eyes ciprofloxacin versus 889 of eyes tobramycin seven days after starting treatment￨no diff￨highunclear￨highunclear￨highunclear
not found￨recurrent blepharitis and rosacea patients with chronic blepharitis of other aetiologies symptomatic chronic blepharitis￨topical fusidic acid gel fucithalmic and oral oxytetracycline placebo fusidic acid gel placebo oxytetracycline fusidic acid gel and oxytetracycline￨blepharitis and associated rosacea￨seventy five per cent of patients with blepharitis and associated rosacea were symptomatically improved by fusidic acid gel and 50 by oxytetracycline but fewer 35 appeared to benefit from the combination￨no diff￨highunclear￨highunclear￨highunclear
39￨bacterial blepharitis 39 patients with bacterial counts and clinical signs indicative of eyelid infection￨mercuric oxide placebo 1 mercuric oxide yellow ophthalmic ointment￨clinical signs bacterial count cure rate and improvement rate efficacy and safety safety and clinical and quantitative microbiologic efficacy tolerated￨statistical analysis revealed a significant improvement in the clinical signs bacterial count cure rate and improvement rate for subjects taking the active medication compared with those taking the placebo on days 3 and 7￨sig increase￨highunclear￨highunclear￨highunclear
33￨twentysix patients completed the study patients with meibomian gland dysfunction thirtythree patients with symptomatic meibomian gland dysfunction meibomian gland dysfunction posterior blepharitis meibomian gland dysfunction￨topical csa topical cyclosporine a 005 tcsa restasis allergan pharmaceuticals placebo commercially available topical cyclosporine tcsa or placebo refresh plus preservativefree artificial tears￨lid margin vascular injection tarsal telangiectasis and fluorescein staining number of meibomian gland inclusions subjective symptoms and objective signs including meibomian gland inclusions lid margin vascular injection tarsal telangiectasis fluorescein staining tear breakup time and schirmer scores ocular symptoms lid margin vascularity tarsal telangiectasis meibomian gland inclusions tear breakup time and fluorescein staining ocular symptoms￨topical csa did not induce an improvement in the symptoms but it did decrease the number of meibomian gland inclusions in patients with meibomian gland dysfunction￨no diff￨highunclear￨highunclear￨highunclear
20￨forty eyes of 20 patients with noninflamed mgd noninflamed obstructive meibomian gland dysfunction patients with noninflamed obstructive meibomian gland dysfunction mgd￨castor oil eye drops placebo lowconcentration homogenized castor oil eye drops castor oil 2 castor oil and 5 polyoxyethylene castor oil emulsifier lowconcentration homogenized castor oil eye drops oil eye drops or placebo￨symptom scores tear interference grade tear evaporation test results rose bengal scores tear but and orifice obstruction scores symptoms tear interference grade tear evaporation fluorescein and rose bengal scores tear breakup time but and meibomian gland orifice obstruction effective and safe safety and stability tests￨no complications attributable to the eye drops were observed￨no diff￨highunclear￨highunclear￨highunclear
39￨conjunctivitis and blepharitis thirtynine patients 21 treated with￨ciprofloxacin ciprofloxacin ophthalmic solution fusidic acid fusidic acid gel topical ciprofloxacin ciprofloxacin ophthalmic solution ciprofloxacin solution￨mild discomfort and stinging clinical cure or improvement moderate edema and discomfort clinical cure rate acute conjunctivitis efficacy and safety￨the clinical cure rate appeared to be higher with ciprofloxacin than fusidic acid 62 compared with 28 but this was related to the higher proportion of patients with acute conjunctivitis in the ciprofloxacin group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨10 patients using lid scrub on right eyelids and dilute baby shampoo on left eyelids chronic blepharitis 25 patients 80 of whom 2025 wore contact lenses patients used commercial eyelid scrub on right eyelids and a hypoallergenic bar soap on left eyelids patients wearing contact lenses￨eyelid cleaning regimens￨patient symptoms slit lamp findings and overall preferences￨at the end of 4 months 24 625 of the patients noted no difference between soap and lid scrub but 89 1719 of the others preferred the lid scrub￨no diff￨highunclear￨highunclear￨highunclear
40￨seborrhoeic and mixed seborrhoeicstaphylococcal blepharitis forty patients with symptomatic blepharitis￨ketoconazole cream placebo ketoconazole ketoconazole￨normal or markedly improved lids symptoms of blepharitis overall clinical impression pityrosporum numbers symptoms and signs of inflammation symptoms using visual analogue scales appearance of the eyelids and reduction in numbers of pityrosporum yeasts on the eyelids￨treatment efficacy was assessed by improvement of symptoms using visual analogue scales appearance of the eyelids and reduction in numbers of pityrosporum yeasts on the eyelids￨no diff￨highunclear￨highunclear￨highunclear
150￨chronic meibomian gland dysfunction 150 patients 300 eyes who have chronic meibomian gland dysfunction and who didnt respond to lid hygiene and topical therapy for more than 2 months patients with chronic meibomian gland dysfunction patients with chronic meibomian gland dysfunction that were refractory to conventional therapy￨doxycycline control group placebo tbut low dose group doxycycline doxycycline therapy high dose group doxycycline￨subjective symptoms side effects degree of symptomatic improvement number of symptoms￨the high dose group 18 patients 3913 reported side effects more frequently than did the low dose group 8 patients 1739 p0002￨sig increase￨highunclear￨highunclear￨highunclear
57￨fiftyseven patients with mgd 27 men and 30 women￨gammalinolenic acid oral linoleic and gammalinolenic acid 2 omega6 essential fatty acids omega6 fatty acids oral linoleic and gammalinolenic acid tablets containing linoleic acid linoleic and gammalinolenic acid tablets￨corneal staining eyelid margin inflammation eyelid edema symptoms secretion turbidity meibomian gland dysfunction meibomian gland obstruction meibomian gland dysfunction mgd eyelid edema eyelid margin hyperemia meibomian secretion appearance meibomian gland obstruction foam collection in the tear meniscus conjunctival hyperemia conjunctival papillae and corneal staining￨group c had significant reduction in eyelid edema p  0003 foam collection in the tear meniscus p  002 corneal staining p  002 secretion turbidity p  00001 and meibomian gland obstruction p  00001￨sig decrease￨highunclear￨highunclear￨highunclear
21￨twenty patients completed the study patients with posterior blepharitis twentyone patients diagnosed with posterior blepharitis posterior blepharitis￨azithromycin ophthalmic solution topical azithromycin ophthalmic solution 1 azasite inspire pharmaceuticals inc nc usa combined with warm compresses azithromycin azithromycin plus warm compresses 10 patients or compresses alone azithromycin azithromycin azithromycin solution topical azithromycin ophthalmic solution￨mg secretion mg plugging mg secretions and eyelid redness overall symptomatic relief severity of five clinical signs eyelid debris eyelid redness eyelid swelling meibomian gland mg plugging and the quality of mg secretion￨azithromycin ophthalmic solution in combination with warm compresses provided a significantly greater clinical benefit than warm compresses alone in treating the signs and symptoms of posterior blepharitis￨sig increase￨highunclear￨highunclear￨highunclear
not found￨meibomian gland dysfunction meibomian gland dysfunction mgd 34 eyes of 17 mgd patients with decreased￨disposable eyelidwarming device eye warmer disposable eyelidwarming device￨stability and uniformity of the tear lipid layer incidence of normal tear lipid layer tear breakup time but and dryeye symptoms incidence of meibomian gland obstruction tear film lipid layer interference patterns but meibomian gland secretion and dryeye symptoms but and dryeye symptoms￨the eye warmer was applied for 5 minutes to 44 eyes of 22 patients who exhibited decreased tear breakup time but and dryeye symptoms￨sig decrease￨highunclear￨highunclear￨highunclear
10￨fifteen patients with simple mgd and 20 healthy volunteers patients with simple meibomian gland dysfunction mgd patients with mgd 10 patients with mgd who received the warm moist air treatment patients with simple meibomian gland dysfunction￨dr1 tear film lipid layer interference original warm moist air device new warm moist air device warm moist air device￨lipid expression vas scores of ocular fatigue vas scores for symptoms but values fluorescein and rose bengal staining scores schirmer test tear film breakup time safety and efficacy symptoms of ocular fatigue visual analog scales vass tear film lipid layer thickness but dr1 tear film lipid layer interferometry fluorescein staining and rose bengal staining tear stability￨in the 2week trial tear film lipid layer thickness increased in both warm moist air device and warm compress groups with a greater extent of increase in the warm moist air device group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨20 patients￨￨symptomatology￨we had a 79 improvement in symptomatology and a 78 improvement in objective findings￨sig increase￨highunclear￨highunclear￨highunclear
14￨fourteen adult subjects 10 females 4 males mean age  542  96 yr were recruited in a multicenter feasibility clinical trial in durham and cary north carolina and boston massachusetts meibomian gland dysfunction obstructive meibomian gland dysfunction mgd inclusion criteria included previous diagnosis of moderate to severe dry eye dry eye symptoms for at least three months prior daily topical lubricant use and evidence of meibomian gland mg obstruction in the central five glands of both eyes lower eyelids￨￨mean mg secretion score tear breakup time corneal staining score number of mgs yielding liquid secretion and symptom scores￨the mean mg secretion score tear breakup time corneal staining score number of mgs yielding liquid secretion and symptom scores all improved significantly from baseline to 1 week￨sig increase￨highunclear￨highunclear￨highunclear
40￨chronic posterior blepharitis chronic blepharitis included 79 eyes of 40 patients with chronic posterior blepharitis 36 eyes of 18 patients￨100 mg oral nac nac nacetylcysteine nac￨fbut￨fbut was significantly increased p  00001 and the mucous fern pattern was also significantly improved p  00096 in the therapy group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with posterior blepharitis posterior blepharitis￨tobramycin 03dexamethasone topical cyclosporin 005 ophthalmic emulsion cyclosporin tobramycindexamethasone cyclosporin topical cyclosporin￨eyelid health tear breakup time schirmers scores meibomian gland secretion quality symptoms of blurred vision burning and itching posterior blepharitis resolution of lid telangiectasia￨cyclosporin provided greater improvements in schirmers scores p  0001 and tear breakup time p  0018 than tobramycindexamethasone after 12 weeks of treatment￨sig increase￨highunclear￨highunclear￨highunclear
79￨79 patients patients with chronic staphylococcal blepharoconjunctivitis chronic staphylococcal blepharoconjunctivitis with a new￨placebo gentamicin or placebo betamethasone gentamicin gentamicin sulfate and betamethasone phosphate topical steroid antiinfective ophthalmic solution￨total objective signs adverse reactions￨lid cultures showed that the combination and gentamicin were significantly superior to placebo or betamethasone in freeing the lids of staphylococcus￨sig increase￨highunclear￨highunclear￨highunclear
30￨thirty subjects 11 males 19 females range 11 to 26 years of age patients with thermal heatactivated hant and superelastic se nickeltitanium archwires￨orthodontic archwire placementthermoelastic vs superelastic alloys archwire placement￨score tooth pain pain perception frequency of analgesic consumption dental crowding and pain initial orthodontic pain pain perception pain visual analog scale vas vas scores￨the frequency of analgesic consumption was higher in the se than in hant group at day 3 p  05￨sig decrease￨highunclear￨highunclear￨highunclear
74￨consecutive patients attending an orthodontic clinic for routine placement of a fixed appliance￨multiflex versus superelastic￨good quality alginate impressions degree of tooth alignment￨consecutive patients attending an orthodontic clinic for routine placement of a fixed appliance were randomly assigned one of these two initial arch wires￨no diff￨highunclear￨highunclear￨highunclear
128￨one hundred and twentyeight consecutive patients attending an orthodontic university clinic and 2 private practices for routine placement of a fixed appliance￨superelastic nickeltitanium alloy 0014 inch sentalloy light￨paindiscomfort level of discomfort pain and discomfort￨no significant genderspecific differences were found in either archwire group￨no diff￨highunclear￨highunclear￨highunclear
43￨fortythree subjects participated in the study the pain response being assessed by each of the visual analogue scales the questionnaires and an analgesic consumption record￨￨pain and discomfort prevalence intensity and duration of pain nature prevalence intensity and duration of pain pain response pain experience pain pain score￨the pain response was found to be highly and consistently subjective not related to the dental arch crowding sex or social class however a statistically significant association was found between the age and the pain experienced￨no diff￨highunclear￨highunclear￨highunclear
155￨155 dental arches with irregularity  5 mm￨multistrand steel superelastic niti and ionimplanted niti archwires￨effective tooth movement anterior irregularity rate of alignment￨there were no significant differences among wires but the rate of alignment was significantly faster in the lower arch for subjects with the 22 slot appliance￨sig increase￨highunclear￨highunclear￨highunclear
24￨24 patients requiring lower anterior alignment relieving mandibular anterior crowding￨coaxial superelastic nickeltitanium niti and 0016inch superelastic niti superelastic coaxial nickeltitanium vs superelastic singlestranded nickeltitanium￨￨a statistically significant difference p  05 in the mean values of tooth movement demonstrated the superior aligning efficiency of coaxial superelastic niti over singlestranded superelastic niti in relieving lower anterior crowding￨sig increase￨highunclear￨highunclear￨highunclear
60￨sixty patients￨coppernickeltitanium cuniti vs nickeltitanium niti archwires mandibular anterior crowding with coppernickeltitanium vs nickeltitanium wires 0016in cuniti 35 degrees c ormco glendora calif or a 0016in niti modernarch wyomissing pa wire￨severe crowding demographic and clinical characteristics probability of crowding alleviation duration crowding alleviation￨severe crowding 5 on the irregularity index showed a significantly higher probability of crowding alleviation duration relative to dental arches with a score of 5 1385 vs 1131 days hazard ratio 22 p002￨sig increase￨highunclear￨highunclear￨highunclear
56￨112 assigned arch wires from 56 consecutive patients 56 patients requiring both upper and lower fixed appliance therapy￨￨good quality impressions aligning capability￨heat activated nickel titanium arch wires failed to demonstrate a better performance than the cheaper multistrand stainless steel wires in this randomized clinical trial￨no diff￨highunclear￨highunclear￨highunclear
20￨20 patients with crowded dentitions￨titanol or nitinol a conventional nickeltitanium alloy aligning archwire￨coefficient of reliability￨when tooth movement was analysed the mean movement per contact point for titanol was 17 mm and for nitinol 142 mm￨no diff￨highunclear￨highunclear￨highunclear
not found￨participants were primarily male 93 white 79 and never married 82 persons with aids receiving home care 57 home care patients with aids randomly assigning individuals to either￨usual care or casemanaged care over the duration of home services￨quality of life quality of life quality of life and survival quality of wellbeing index qwb￨casemanaged patients showed advantages over the usual care group in descriptive analyses of quality of life and survival￨sig increase￨highunclear￨highunclear￨highunclear
not found￨eligible hivpositive patients receiving care at connecticut childrens medical centers ccmc pediatric and youth hiv program hivinfected pediatric patients improves with homebased intensive nursing intervention pediatric hivinfected patients￨combination antiretroviral therapy art homebased nursing intervention￨medication refill history knowledge score medication adherence adherence selfreport score cd4 tcell counts or viral load￨the knowledge score p  002 and medication refill history p  0002 improved significantly in the intervention group￨sig increase￨highunclear￨highunclear￨highunclear
57￨mean age was 33 93 were male 61 white 34 working 135 mean years education 57 communitydwelling plwa 31 were in the experimental group persons living with aids plwa people with aids plwa persons living with aids￨computer network home care demonstration￨￨post hoc exploration indicated that use of the system did reduce social isolation once participants levels of depression were controlled and that decision making confidence improved as a function of number of accesses￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨women infected with human immunodeficiency virus hiv healthy female subjects hivinfected women 40 hivinfected women with increased waisthip ratio and selfreported fat redistribution x kg1 women infected with human immunodeficiency virus￨supervised homebased progressive resistance training and aerobic exercise program supervised homebased exercise regimen supervised homebased aerobic and progressive resistance training regimen￨maximum oxygen consumption vo2max and strength by 1repetition maximum strength increased at the knee extensors pectoralis knee flexors shoulder abductors ankle plantar flexors and elbow flexors energy and appearance crosssectional muscle area and muscle attenuation cardiorespiratory fitness vo2max cardiorespiratory fitness endurance and body composition lipid levels blood pressure or abdominal visceral fat physical fitness mean total muscle area sem vo2max cardiorespiratory fitness￨strength increased at the knee extensors pectoralis knee flexors shoulder abductors ankle plantar flexors and elbow flexors all p001￨sig increase￨highunclear￨highunclear￨highunclear
6￨african american mothers women caregivers of young children lowincome african american women in their childbearing years emotional distress and perceptions of health among lowincome african american mothers with hiv public health nurses visiting the home or by advanced practice nurses who see hivinfected women in primary care or specialty clinics african american women involved six home visits by registered nurses￨selfcare symptom management intervention or usual care hiv selfcare symptom management intervention￨feelings of stigma negative affective state depressiondejection and tensionanxiety and stigma as well as infections physical function scores emotional distress physical and role function number of infections and aspects of healthrelated quality of life ie perception of health physical function energy health distress and role function depressive symptoms affective state stigma and worry about hiv￨the hiv symptom management intervention has potential as a case management or clinical intervention model for use by public health nurses visiting the home or by advanced practice nurses who see hivinfected women in primary care or specialty clinics￨sig increase￨highunclear￨highunclear￨highunclear
not found￨aids patients severely immunodepressed aids patients 31 malnourished and severely immunodepressed aids patients￨home tpn total parenteral nutrition dietary counselling n  15 or home total parenteral nutrition tpn n  16 via a central venous access after an educational program tpn￨nutritional subjective global assessment subjective selfreported health feeling and karnofsky index survival rate lean body mass infection line sepsis incidence body cell mass￨nutritional subjective global assessment subjective selfreported health feeling and karnofsky index were also improved by tpn￨no diff￨highunclear￨highunclear￨highunclear
99￨hivinfected adults hivinfected patients patients on highly active antiretroviral therapy 99 hivinfected adults￨homebased exercise intervention exercise 15week 20 minutes three times per week homebased aerobic exercise intervention versus usual care￨physical endurance or healthrelated quality of life hrqol cd4 tlymphocyte counts medical outcomes studyhiv health survey overall health subscale physical endurance levels￨in the exercise group there was no improvement in physical endurance or healthrelated quality of life hrqol except in the medical outcomes studyhiv health survey overall health subscale difference  121 95 confidence interval  20222 p  02￨no diff￨highunclear￨highunclear￨highunclear
549￨home health care for hivaids 549 aids patients admitted for medicalsurgical homecare services to the visiting nurse association of los angeles vnala terminally ill aids patients￨experimental transprofessional or control traditional treatment group￨service levels labor delivery costs￨to determine if a transprofessional caremanagement approach experimental group produces savings in service delivery dollars when compared to a traditional treatment approach control group￨sig increase￨highunclear￨highunclear￨highunclear
509￨persons with hiv living in africa and large scale implementation persons infected with human immunodeficiency virus hiv persons with hiv living in rural uganda between april 2001 and november 2002 households of 509 persons with hiv and 1521 hivnegative household members received a persons with human immunodeficiency virus in uganda￨safe water intervention trimethoprim and 800 mg of sulfamethoxazole cotrimoxazole prophylaxis homebased water chlorination and safe storage closedmouth plastic container a dilute chlorine solution and hygiene education safe water system sws or simply hygiene education alone￨incidence and severity of diarrhea diarrhea diarrhea visible blood or mucus in stools diarrhea frequency and severity days of work or school lost due to diarrhea diarrhea episodes￨the sws was equally effective with or without cotrimoxazole prophylaxis p  073 for interaction and together they reduced diarrhea episodes by 67 irr  033 95 ci  024046 p  00001 days with diarrhea by 54 irr  046 95 ci  032066 p  00001 and days of work or school lost due to diarrhea by 47 irr  053 95 ci  034083 p  00056￨no diff￨highunclear￨low￨highunclear
171￨participants were 171 hivinfected adults prescribed a minimum of 3 antiretroviral agents patients prescribed highly active antiretroviral￨communitybased homevisit intervention home visits for 1 year or usual care￨adherence greater medication adherence hivrna level or cd4 cell count medication adherence￨a larger proportion of subjects in the intervention group demonstrated adherence greater than 90 compared with the control group at each time point after baseline￨sig increase￨highunclear￨highunclear￨highunclear
not found￨moderate hdp bp greater than 90 mmhg this study january 1984 to december 1985 includes 63 women mean age 282 years divided into three comparable subgroups age parity risk factors and initial level of sbpdbp moderate arterial hypertension during pregnancy￨sympathomimetic activity ace and an alphabetablocker lab 645abstract ace methyldopa acebutolol labetalol￨uricemia level platelet counts foetal cardiac rythm and occurrence of preeclampsia￨ace   82  27 mmhg p less than 002￨sig decrease￨highunclear￨highunclear￨highunclear
176￨176 pregnant women with mild to moderate hypertension hypertension in pregnancy￨labetalol methyldopa labetalol and methyldopa labetalol or methyldopa labetalol￨average birthweight and the proportion of preterm or smallforgestationalage babies intrauterine death heart rate blood pressure blood glucose respiratory rate and silverman score of the babies neonatal death diastolic blood pressure￨the average birthweight and the proportion of preterm or smallforgestationalage babies were similar in both groups￨no diff￨highunclear￨highunclear￨highunclear
33￨33 women with mild essential hypertension systolic blood pressure 140170 mm hg or diastolic pressure 90110 mm hg on two occasions at least 24 hours apart consecutively referred to two obstetric medical clinics 29 remaining women on entry to the study was 159 weeks 14 women received women with essential hypertension essential hypertension during pregnancy patients with mild hypertension￨methyldopa atenolol placebo atenolol￨mean gestation intrauterine growth retardation mean blood pressure blood pressure and birth weight blood pressure systolic pressure mean diastolic pressure birth weight￨atenolol given from the end of the first trimester in patients with mild hypertension is associated with intrauterine growth retardation￨sig increase￨low￨low￨low
155￨pregnancyinduced hypertension 155 women with pregnancyinduced hypertension who were also given comprehensive nonpharmacological care￨antihypertensive drugs oxprenolol or oxprenolol plus dihydralazine oxprenolol￨gestational age at birth or birthweight proteinuria diastolic blood pressure dbp respiratory distress syndrome number of caesarean sections perinatal deaths severe hypertension andor fetal distress￨these results indicate that early antihypertensive treatment with oxprenolol is safe for the fetus and newborn in pregnancyinduced hypertension but has no advantage over nonpharmacological care in terms of fetal growth￨no diff￨highunclear￨highunclear￨highunclear
300￨thirtyseven women 12 were excluded for various reasons of the remaining 263 patients 90 received no drug 87 received three hundred women with mild chronic hypertension at 6 to 13 weeks gestation chronic hypertension during pregnancy￨methyldopa or labetalol labetalol methyldopa￨systolic and diastolic blood pressures incidences of either superimposed preeclampsia preterm delivery mean systolic or diastolic blood pressures mean gestational age or initial laboratory findings at time of entry abruptio placentae gestational age at delivery birth weight incidence of fetal growth retardation or neonatal head circumference￨patients treated with medications had significantly lower p less than 00001 systolic and diastolic blood pressures throughout gestation compared with the nomedication group￨sig decrease￨highunclear￨highunclear￨highunclear
100￨one hundred pregnant women with hypertension defined as diastolic blood pressure at or above 95 mm hg hypertension in pregnancy￨methyldopa or oxprenolol oxprenolol methyldopa methyldopa and oxprenolol￨systolic blood pressure birth weight placental weight head circumference and apgar score control blood pressure eventual fetal outcome diastolic blood pressure￨the eventual fetal outcome for all patients treated with methyldopa was the same as that for those treated with oxprenolol birth weight placental weight head circumference and apgar score were not significantly different and there were no stillbirths in either group￨no diff￨highunclear￨highunclear￨highunclear
28￨28 women with pregnancy associated hypertension￨propranolol with methyldopa propranolol propranolol or propranolol glucuronide propranolol￨mean peak plasma level of naphthoxylactic acid symptomatic hypoglycaemia mean peak levels of propranolol propranolol glucuronide 4hydroxypropranolol and 4hydroxypropranolol glucuronide maternal hypertension birthweights of the babies￨there was no significant difference in the birthweights of the babies in each group￨no diff￨highunclear￨highunclear￨highunclear
152￨152 patients with mild to moderate nonproteinuric pregnancyinduced hypertension pregnancyinduced hypertension￨placebo labetalol labetalol￨preterm delivery neonatal respiratory distress syndrome and jaundice intrauterine growth retardation and neonatal hypoglycaemia perinatal deaths maternal mean arterial pressure￨there was some reduction in preterm delivery neonatal respiratory distress syndrome and jaundice in the labetaloltreated group￨sig decrease￨highunclear￨highunclear￨highunclear
100￨hypertension during pregnancy one hundred pregnant patients with mild or moderate hypertension followed at the centre hospitalier intercommunal de créteil france patients with hypertension during pregnancy￨nicardipine or metoprolol nicardipine nicardipine nicardipine and metoprolol metoprolol￨umbilical artery resistance maternal systolic and diastolic bp higher birth weights maternal blood pressure bp laboratory indices umbilical doppler velocimetry and neonatal outcome incidence of cesarean delivery for fetal distress neonatal outcome plasma uric acid and creatinine concentrations maternal bp neonatal outcome￨plasma uric acid and creatinine concentrations were increased less markedly in the nicardipine group p  05 and p  01 respectively￨sig decrease￨highunclear￨highunclear￨highunclear
161￨hypertension during pregnancy mild and moderate hypertension in pregnancy one hundred and sixtyone women participated in the study￨metoprololhydralazine metoprolol and hydralazine￨albuminuria birth weight head circumference and apgar score and in the frequencies of respiratory distress bradycardia and hypoglycemia blood pressure control maternal or fetal complications￨the outcome for the newborns was similar in both groups concerning birth weight head circumference and apgar score and in the frequencies of respiratory distress bradycardia and hypoglycemia￨no diff￨highunclear￨highunclear￨highunclear
120￨120 women with mild to moderate pregnancyassociated hypertension who were also initially managed conventionally by bed rest pregnancyassociated hypertension￨atenolol placebo atenolol placebo￨neonatal bradycardia bloodpressure prevented proteinuria and reduced the number of hospital admissions loss of bloodpressure control leading to withdrawal intrauterine growth retardation neonatal hypoglycaemia and hyperbilirubinaemia respiratory distress syndrome systolic bloodpressure￨atenolol given once daily significantly reduced bloodpressure prevented proteinuria and reduced the number of hospital admissions￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨twentysix women with pregnancyinduced hypertension moderate and severe pregnancyinduced hypertension￨labetalol or aldomet labetalol alpha and beta blocking drug labetalol and methyl dopa￨blood pressure adverse effects proteinuria￨more patients went into spontaneous labour following labetalol than following aldomet the bishop score was also higher in this group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨fortyfour consecutive patients referred for treatment because of hypertension greater than 15090 mmhg occurring during pregnancy￨hydralazine alone hydralazine monotherapy pindolol hydralazine hydralazine and pindolol hydralazine combined with pindolol￨fetal outcome hypertensive complications satisfactory blood pressure control diastolic pressure less blood pressure control perinatal mortality￨satisfactory blood pressure control diastolic pressure less than 90 mmhg was achieved in 86 of patients receiving hydralazine alone and 91 of those on combined therapy￨no diff￨highunclear￨highunclear￨highunclear
not found￨thirtytwo consecutive women with pregnancyinduced hypertension of early onset￨pindolol pindolol or methyldopa methyldopa￨diastolic cct and serum creatinine weight of the newborn renal function average time of delivery blood pressure side effects systolic￨a significant drop in systolic p less than 0005 and diastolic p less than 005 blood pressure was observed in the group of patients treated with pindolol as compared with the methyldopa group￨sig decrease￨highunclear￨highunclear￨highunclear
51￨pregnancyinduced hypertension fiftyone women with pregnancyinduced hypertension pih all women fulfilled the pretreatment criteria and were of similar age numbers of previous pregnancies and had systolic blood pressure sbp of between 140 and 160 mmhg and diastolic blood pressure dbp of between 95 and 110 mmhg￨hydrazaline hydralazine monotherapy propranolol hydralazine 13 b hydralazine and propranolol 17 and c hydralazine and pindolol 19 pindolol betaadrenergic blocking agents￨fetal outcome birth weight maternal sideeffects palpitations mean blood glucose blood pressure hypertension sideeffects heart rate￨birth weight was significantly lower in group b where regimen included propranolol compared to that of group c for whom the regimen included pindolol 30447  4438 and 27096￨sig decrease￨highunclear￨highunclear￨highunclear
30￨pregnancy induced hypertension thirty patients matched for age parity socioeconomic status and severity of pregnancy induced hypertension pih￨metoprolol and methyldopa metoprolol or methyldopa methyldopa metoprolol￨mean birth weight of the babies diastolic blood pressure perinatal deaths￨the results suggest metoprolol to be more efficacious with regard to control of hypertension and fetal outcome in cases of pregnancy induced hypertension￨no diff￨highunclear￨highunclear￨highunclear
not found￨twenty mothers with moderate to severe preeclampsia￨labetalol vs hydralazine hydralazine labetalol labetalol trandate or hydralazine apresolin antihypertensive treatment￨neonatal blood pressure heart rate and axillary temperature respiratory rate median cord ph peripheral blood flow number of infants with a cord ph arterial blood gas analysis blood glucose levels￨blood glucose levels were lower in the labetalol group at 6 hours of age p  005￨sig decrease￨highunclear￨highunclear￨highunclear
200￨two hundred primigravid women with mild preeclampsia at 2635 weeks gestation￨labetalol plus hospitalization versus hospitalization alone hospitalization alone or combined with labetalol labetalol￨average days of pregnancy prolongation gestational age at delivery birth weight number of infants admitted to the special care unit or cord blood gas measurements mean systolic or diastolic pressures mean gestational age or initial laboratory findings at time of entry proteinuria creatinine and uric acid blood pressure maternal blood pressure neonatal death frequency of fetal growth retardation￨there were no differences between the two groups in mean systolic or diastolic pressures mean gestational age or initial laboratory findings at time of entry￨no diff￨highunclear￨highunclear￨highunclear
24￨24 patients with systemic sclerosis systemic sclerosis￨selective and specific s2serotonergic receptor antagonist ketanserin placebo ketanserin ketanserin or placebo￨frequency or severity of sideeffects￨ketanserin failed to produce a greater improvement than placebo in functional and objective clinical signs and symptoms as well as in most subjective assessments￨sig increase￨highunclear￨highunclear￨highunclear
not found￨27 cases twentyseven patients with systemic scleroderma and raynauds phenomenon￨placebo ketanserin ketanserine monotherapy with ketanserine￨raynauds phenomenon haemorrheological parameters total blood viscosity plasma viscosity and thixotropism evolution of the raynauds phenomenon or skin changes dysphagia k infinity coefficient of quemadas law￨dysphagia was improved in the ketanserine group p less than 005 but not in the placebo group￨sig decrease￨highunclear￨highunclear￨highunclear
41￨41 patients with primary raynauds phenomenon prp patients with primary raynauds phenomenon patients with prp￨ketanserin placebo ketanserin serotonin receptor blocker ketanserin￨blood chemistry nor systemic blood pressure digital skin temperature dst digital systolic blood pressure dbp and doppler spectral analysis dosa of the radial and ulnar arteries diastolic blood flow velocity of dosa severity score the occurrence of numbness and paresthesia and cold weather provocation frequency and duration of the attacks both per se and combined to a severity score cold sensation numbness paresthesia pain cold water and cold weather provocation and the appearance of spontaneous attacks hypertension both systolic and diastolic blood pressure normalized￨the severity score the occurrence of numbness and paresthesia and cold weather provocation improved significantly on ketanserin treatment￨sig increase￨highunclear￨highunclear￨highunclear
not found￨affected individuals peripheral arterial disease pad patients￨omega3 polyunsaturated fatty acid n3 pufa supplementation n3 pufas 1 g bid omega3 polyunsaturated fatty acid￨plasma soluble thrombomodulin stm and brachial artery flowmediated dilation fmd and the inflammatory status by measuring highsensitivity creactive protein and myeloperoxidase peripheral arterial disease pad endothelial function and inflammatory status inflammatory status levels of inflammatory markers fmd endothelial function endothelial function stm levels lipid pattern disease severity inflammation profile and endothelial function￨in group ii n3 pufas reduced stm levels from the median value of 330 ngml interquartile range 167 372 to 170 ngml 112 337 p004 and improved fmd from 67 37 87 to 100 62 142 p002￨sig increase￨highunclear￨highunclear￨highunclear
not found￨peripheral vascular disease patients with peripheral arterial disease￨eicosapentaenoic acid eicosapentaenoic acid rich oil fish oil eicosapentaenoic acid poor oil as cornolive oil￨whole blood viscosity plasma triglyceride concentration cholesterol and high density lipoprotein cholesterol plasma viscosity haemoglobin concentration packed cell volume or platelet count blood viscosity￨no changes in plasma viscosity haemoglobin concentration packed cell volume or platelet count were seen￨no diff￨highunclear￨highunclear￨highunclear
32￨patients with stable claudication 32 patients with stable claudication patients with claudication￨six capsules of fish oil 18 g eicosapentaenoic acid and 12 g docosahexaenoic acid versus six capsules of corn oil 3 g linoleic acid fish oil supplementation￨blood pressure red cell deformability fibrinogen and lipid levels blood viscosity mean arterial blood pressure fibrinogen levels walking distances and pressure indices blood lipids blood pressure blood lipids and platelet responsiveness viscosity red cell deformability￨no significant changes in walking distances and pressure indices during rest and after exercise occurred despite a significant increase in red cell deformability in the fish oil group￨no diff￨highunclear￨highunclear￨highunclear
120￨120 men and women with stable intermittent claudication peripheral arterial disease patients with lower limb atherosclerosis￨gammalinolenic and eicosapentaenoic acids placebo combination of gammalinolenic and eicosapentaenoic acids or placebo polyunsaturated fatty acids gammalinolenic acid and eicosapentaenoic acid￨cholesterol and lipoprotein concentrations haemostatic and rheological variables the ankle brachial pressure index walking distance and cardiovascular events and death systolic blood pressure haematocrit coronary events small reduction in nonfatal coronary events lipid concentrations walking distance￨there was no difference in walking distance but there was a small reduction in nonfatal coronary events in the fatty acid group 10 cent compared with 15 cent p  005￨no diff￨low￨low￨low
60￨men with pvdic male pvdic patients n  60 men with peripheral vascular disease patients with peripheral vascular disease and intermittent claudication pvdic￨supplement s group consumed 500 mld of a fortified dairy product containing eicosapentaenoic acid epa docosahexaenoic acid dha oleic acid folic acid and vitamins a b6 d and e control c group consumed 500 mld of semiskimmed milk with added vitamins a and d daily supplementation with n3 pufas oleic acid folic acid and vitamins b6 and e￨plasma total cholesterol and apob concentrations total homocysteine walking distance before the onset of claudication plasma concentrations of epa dha oleic acid folic acid and vitamins b6 and e anklebrachial pressure index values blood extractions and clinical explorations￨plasma total cholesterol and apob concentrations decreased in the s group and total homocysteine decreased in those patients with high initial concentrations￨sig increase￨highunclear￨highunclear￨highunclear
32￨patients with vascular disease following fish oil and olive oil supplementation patients with peripheral vascular disease thirtytwo patients with symptomatic and angiographically demonstrated peripheral vascular disease￨fish oil or olive oil olive oil￨leukotriene b5 levels platelet aggregation total cholesterol levels arachidonic acid content of platelet phospholipids neutrophil leukotriene b4 ltb4 generation hdl3c levels serum triglyceride levels eicosapentaenoic acid epa 205 and docosahexaenoic acid dha 226 levels urinary excretion of txb2 and 6ketopgf1 alpha lowdensity lipoprotein cholesterol ldlc and highdensity lipoprotein2 cholesterol hdl2c serum thromboxane b2 txb2 levels plasma lipid levels and platelet and neutrophil function neutrophil paf production and plasma lysopaf platelet fatty acid composition ldlc levels￨fish oil decreased neutrophil leukotriene b4 ltb4 generation following calcium ionophore stimulation by 33 while leukotriene b5 levels increased significantly￨sig decrease￨highunclear￨highunclear￨highunclear
105￨one hundred and five patients undergoing allogeneic or autologous bone marrow transplant or induction therapy for acute leukemia in 1988 and 1989 were studied 96 evaluable patients were evenly distributed over the 3 treatment groups 63 patients received severely myelosuppressed patients￨ciprofloxacin oral ciprofloxacin 500 mg bid or a combination of oral neomycin 250 mg qid polymyxinb 100 mg qid and oral nalidixic acid 1000 mg bid ciprofloxacin ciprofloxacin and 33 received npn polymyxinnalidixic acid polymyxin b sulfatenalidixic acid npn￨bacteremias streptococcal bacteremias fever absolute granulocyte count gramnegative bacteremias side effects￨side effects were not significantly different but compliance with ciprofloxacin was better￨no diff￨highunclear￨highunclear￨highunclear
63￨43 children receiving 28 patients with solid tumors who were starting sixtythree patients with acute leukemia children granulocytopenic children undergoing induction chemotherapy for acute leukemia children with cancer children with leukemia receiving￨chemotherapy placebo oral trimethoprimsulfamethoxazole intensive chemotherapy trimethoprimsulfamethoxazole trimethoprimsulfamethoxazole tmpsmx￨frequency of febrile episodes overall risk for bacterial infection febrile episodes mean duration of granulocytopenia granulocytopenia invasive fungal infection days without fever and without bacteremia frequency of bacteremia and febrile episodes frequencies of confirmed bacteremia￨although the frequency of oral thrush was greater p  02 in the trimethoprimsulfamethoxazole group 256 than in the placebo group 63 invasive fungal infection did not occur￨sig increase￨highunclear￨highunclear￨highunclear
not found￨nonhospitalized adult patients with acute leukemia and chemotherapyinduced neutropenia including twenty five episodes of neutropenia including twenty five episodes of neutropenia which had occurred in 14 patients who were randomly selected either to receive or patients with neutropenia￨not quinolones norfloxacin 800 mg daily or ciprofloxacin fluoroquinolones￨streptococcus infections fever onset during neutropenia infectious morbidity andor mortality hematologic malignancy duration and severity of neutropenia mortality incidence of severe infections proportion of neutropenic episodes without fever empiric use of amphotericin b or fungal infections proportion of neutropenic febrile days￨the use of quinolones was associated with a delay in the fever onset during neutropenia p  00448 a decrease in the proportion of neutropenic febrile days p  00456 a decrease of infections caused by gramnegative bacilli p  0037 and an increase of streptococcus infections p  00857￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients with chemotherapyinduced neutropenia patients with aplasia infections after chemotherapyinduced bone marrow aplasia 52 patients￨placebo vancomycin with pefloxacin pefloxacin and vancomycin pefloxacin with vancomycin pefloxacin alone 51 patients or placebo combined vancomycin and pefloxacine oral pefloxacin plus vancomycin pefloxacin￨episodes of bacteremia￨no differences were noted between patients treated by pefloxacin and those who received a combination of pefloxacin with vancomycin regarding grampositive gram infections and infections with gramnegative gram organisms usually resistant to pefloxacin￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with leukemia and prolonged granulocytopenia sixtythree patients with acute nonlymphoid leukemia anll under cytostatic treatment￨cotrimoxazole prophylaxis cotrimoxazole tmpstx tmpstx￨number of febrile episodes mean duration of severe granulocytopenia deaths due to infection febrile episode rate of infection￨four significant differences were observed between the group given tmpstx 30 patients and the control group 33 patients 1 the mean duration of severe granulocytopenia less than or equal to 500 pmnmm3 before the first febrile episode was longer in prophylaxis group 1426 days versus four in the control group p less than 0001 2 the number of febrile episodes was 37 in tmpstx group and 69 in control group p less than 001 3 23 patients on prophylaxis presented at least one febrile episode versus 33 in the control group p less than 001 4 deaths due to infection were two in the tmpstx group versus 11 in control group p less than 005￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨cancer patients 59 patients who had earlier developed an infection following antineoplastic chemotherapy 30 patients received 48 courses of￨quinolone gcsfofloxacin or ciprofloxacin granulocyte colonystimulating factor gcsf with or without a quinolone gcsf granulocyte colonystimulating factor gcsf alone or gcsfquinolone￨infection who grade iv leukopenia grade iv leukopenia median duration of leukopenia tolerated overall infection rate￨patients with initial leukopenia of grade who iiii had only a 11 infection rate showing no significant difference between the treatment groups￨no diff￨highunclear￨highunclear￨highunclear
24￨neutropenic patients with acute nonlymphocytic leukemia twentyfour neutropenic patients receiving for acute nonlymphocytic leukemia￨ciprofloxacin oral prophylactic ciprofloxacin polymyxin b intensive chemotherapy polymyxin ciprofloxacin with polymyxin b amphotericin b￨20 febrile episodes mean time to the first infectionrelated febrile episode days of fever duration of administration of parental antibiotics￨patients receiving ciprofloxacin also had fewer days of fever average 65 days versus 98 days for the polymyxin b group p less than 002￨sig decrease￨highunclear￨highunclear￨highunclear
1565￨1565 patients underwent randomization 784 to patients who were receiving cyclic chemotherapy for solid tumors or lymphoma and who were at risk for temporary severe neutropenia fewer than 500 neutrophils per cubic millimeter patients receiving chemotherapy for solid tumors or lymphoma￨levofloxacin placebo levofloxacin once daily or matching placebo￨respective rates of probable infection incidence of clinically documented febrile episodes temperature of more than 38 degrees c attributed to infection lung cancer testicular cancer incidence of all probable infections severe infections and hospitalization but did not include a systematic evaluation of antibacterial resistance incidence of fever probable infection and hospitalization hospitalization respective rate of severe infection febrile episode￨among patients receiving chemotherapy for solid tumors or lymphoma the prophylactic use of levofloxacin reduces the incidence of fever probable infection and hospitalization￨sig increase￨low￨low￨low
59￨59 neutropenic patients 59 patients granulocytopenic patients￨vancomycin intravenous systemic vancomycin empiric antibiotic therapy piperacillin ofloxacine vanco vancomycin￨zero grampositive infections number of days with fever  385 degrees c mean number of days of empiric antibiotic therapy￨the number of days with fever  385 degrees c was significantly higher in the control vanco group than in the vanco group 74 vs 37 p  002￨sig increase￨highunclear￨highunclear￨highunclear
42￨immunocompromised patients patients with granulocytopenia 42 patients with metastasised testicular germcell tumours entered the study￨ofloxacin antimicrobial prophylaxis￨fever fever￨no side effects that related to ofloxacin were noted￨no diff￨highunclear￨highunclear￨highunclear
42￨patients with acute leukemia 42 patients with induction treatment of acute myeloblastic and lymphoblastic leukaemia￨trimetroprimsulfamethoxazol biseptol polfa co ofloxacin tarivid hoechst co tarivid and biseptol ketoconazol￨risk of grampositive sepsis occurrence of febrile days febrile episodes the duration of antibiotic treatment the number of sepsis￨there was no significant difference in the occurrence of febrile days febrile episodes the duration of antibiotic treatment the number of sepsis in two groups￨no diff￨highunclear￨highunclear￨highunclear
157￨patients undergoing autologous stemcell transplantation patients undergoing hdt and asct one hundred and fiftyseven patients undergoing highdose chemotherapy hdt and autologous stemcell transplantation asct for hematopoietic malignancies and solid tumors patients receiving hdt with￨asct ciprofloxacin orally and vancomycin intravenously ciprofloxacin and vancomycin antibiotic prophylaxis fluconazole prophylactic antibiotics￨neutropenic febrile episodes total interval of hospitalization time to engraftment or allcause mortality rate of bacteremias neutropenic fever￨prophylactic administration of ciprofloxacin and vancomycin reduced the incidence of neutropenic fever in patients receiving hdt with asct however without affecting the total interval of hospitalization time to engraftment or allcause mortality￨sig decrease￨highunclear￨highunclear￨highunclear
19￨granulocytopenic subjects 19 adult patients with acute leukemia undergoing induction chemotherapy￨trimethoprim and 800 mg sulfamethoxazole trimethoprimsulfamethoxazole ofloxacin ofloxacin trimethoprimsulfamethoxazole tmpsmz￨￨both treatment groups acquired yeasts￨no diff￨highunclear￨highunclear￨highunclear
40￨neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants 40 patients with solid tumors treated with highdose chemotherapy and autologous stem cell transplantation support￨ciprofloxacin ciprofloxacin plus rifampin c  r ciprofloxacinrifampin prophylaxis￨incidence of grampositive bacteremia time elapsed to the onset of fever incidence of febrile episodes amphotericin b use and length of hospital stay￨however c  r combination prophylaxis significantly reduced the incidence of grampositive bacteremia five versus zero episodes but was associated with a higher incidence of drugrelated side effects￨sig decrease￨highunclear￨highunclear￨highunclear
102￨neutropenic patients following neutropenic patients following cytotoxic chemotherapy 102 patients with hematological malignancies￨ofloxacin versus cotrimoxazole cytotoxic chemotherapy cotrimoxazole or ofloxacin cotrimoxazole ofloxacin ofloxacin trimoxazole￨grampositive bacterial or pneumocystis carinii infection skin rashes gramnegative bacteremia incidence of bacteremia fever￨significantly more patients had skin rashes following cotrimoxazole than ofloxacin treatment p less than 005￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨neutropenic patients with treatment being allocated randomly before beginning chemotherapy neutropenic patients with haematological malignancies￨ciprofloxacin ciprofloxacin or ofloxacin ciprofloxacin ciprofloxacin ofloxacin and pefloxacin ciprofloxacin ofloxacin or pefloxacin ofloxacin pefloxacin￨episodes involving gramnegative bacilli bacterial infection faecal anaerobes total numbers￨ciprofloxacin was therefore superior to the other two fluoroquinolones in preventing infections due to gramnegative bacteria in this population of neutropenic patients￨sig increase￨highunclear￨highunclear￨highunclear
34￨adult neutropenic patients with hematologic malignancies patients with chemotherapy induced neutropenia is debatable adult neutropenic patients two groups of patients were includedexperimental group consisting of 36 patients with 41 granulocytopenic episodes and a control group of 34 patients with 41 granulocytopenic episodes university clinic of hematology medical university plovdiv neutropenic patients with hematologic malignancies￨fluoroquinolones fluoroquinolone prophylaxis￨survival rates infectionrelated mortality rate prophylactic efficacy number of infectionfree neutropenic episodes survival rate mortality rate long term survival rates occurrence of infection￨prophylaxis with fluoroquinolones reduced the occurrence of infection in adult neutropenic patients without affecting the longterm survival￨sig decrease￨highunclear￨highunclear￨highunclear
136￨neutropenic cancer patients 136 patients cancer patients following cytostatic treatment￨norfloxacin or pefloxacin norfloxacin and pefloxacin norfloxacin pefloxacin￨infections afebrile gramnegative bacilli granulocytopenia￨only one infection caused by gramnegative bacilli was observed in the pefloxacin group compared with seven in the norfloxacin group p  0019￨sig increase￨highunclear￨highunclear￨highunclear
7￨all patients were nursed in laf rooms with a strict isolation procedure and sterile water and food bacterial infections after bone marrow transplantation allogeneic bone marrow transplantation￨oral broadspectrum nonabsorbable antibiotics vancomycintobramycincolistin ofloxacin 400 mgday and amoxicillin 20 gday group ii vtc received the oral nonabsorbable antibiotics vancomycin 450 mgday tobramycin 450 mgday and colistin 45106 units daily from day absorbable antibiotics ofloxacinamoxicillin￨mean duration of fever￨there were no differences between the two groups in age mean 33 years range 1154 sex diagnosis and mean duration of agranulocytosis 218 days range 1049￨no diff￨highunclear￨highunclear￨highunclear
65￨patients with solid tumors undergoing hdc with pbsct sixtyfive patients patients undergoing highdose chemotherapy hdc with peripheralblood stemcell transplantation pbsct neutropenic cancer patients cancer patients undergoing hdc with￨ciprofloxacin prophylactic antibiotics with either ciprofloxacin rifampin ciprofloxacin regimen with rifampin quinolonebased antibacterial prophylactic regimen ciprofloxacin plus rifampin pbsct rifampin ciprofloxacin and rifampin￨grampositive bacteremia overall incidence of bacteremia occurrence of neutropenia and fever incidence and cause of bacterial infection time to onset and duration of fever requirement for intravenous antimicrobials and length of hospital admission neutropenia and fever￨although there was a trend toward a reduction in the overall incidence of bacteremia 12 v 4 patients and grampositive bacteremia 8 v 2 patients with the addition of rifampin none of these comparisons was statistically significant p 05 and p 09 respectively￨no diff￨highunclear￨highunclear￨highunclear
not found￨granulocytopenic patients with hematologic malignancies 47 patients acute leukemia was the underlying malignancy in 46 episodes patients with hematologic malignancy￨placebo oral prophylactic trimethoprimsulfamethoxazole prophylactic trimethoprimsulfamethoxazole trimethoprimsulfamethoxazole prophylaxis trimethoprimsulfamethoxazole￨overall incidence of infectious complications number of febrile days use of parenteral antibiotics or number of days following randomization to first infectious episode episodes of bacteremia throat and rectal surveillance cultures combined frequency of disseminated candidiasis candidemia and esophagitis of presumed fungal etiology￨trimethoprimsulfamethoxazole prophylaxis resulted in fewer microbiologically documented infections seven versus 15 p  0029￨no diff￨highunclear￨highunclear￨highunclear
not found￨neutropenic patients treated in a protected environment only patients who were afebrile when their polymorphonuclear pmn count fell below 500cumm were admitted to the study seventyeight episodes of therapeutic aplasia consecutive to aplastic patients receiving total gut decontamination and treated in a protected environment￨allogeneic or autologous bone marrow transplant conditioning regimens or to high dose chemotherapy ceftriaxone￨no death episodes of afebrile aplasia median duration of aplasia bacteriemias￨patients in group a had significantly more episodes of afebrile aplasia 345 vs 4 and less bacteriemias 10 vs 48 than those in group b also fever developed later in group a mean 125 vs 6 days￨sig increase￨highunclear￨highunclear￨highunclear
not found￨centers participating in the national cancer institute of canada clinical trials group for acute leukemia or bone marrow autografting neutropenic patients with cancer reduces infections 111 eligible and evaluable patients hospitalized for severe neutropenia neutrophil count  05 x 109l lasting at least 14 days who were receiving neutropenic patients￨ofloxacin plus rifampin norfloxacin norfloxacin ofloxacin quinolonebased antibacterial chemoprophylaxis ofloxacin ofloxacin 400 mg plus rifampin quinolonebased antibacterial prophylaxis cytotoxic therapy￨overall infection rates number of unexplained fevers staphylococcal bacteremia aerobic gramnegative rods febrile neutropenic episodes streptococcal bacteremia incidence of grampositive infections corresponding rates￨no statistically significant difference was found among the treatment arms with respect to the overall incidence of febrile neutropenic episodes as defined for this trial 79 for the norfloxacin group 82 for the ofloxacin group and 77 for the ofloxacin plus rifampin group￨no diff￨highunclear￨highunclear￨highunclear
65￨sixtyfive cancer patients pretreated with nonfebrile granulocytopenic cancer patients with granulocytopenia less than 1000mm3 and without fever granulocytopenic cancer patients￨chemo or radiotherapy norfloxacin￨subsequent infection￨20 of the treated subjects versus 686 of the controls presented a subsequent infection p less than 0001 the lung representing the most frequent site of the infectious disease in both groups 36 and 1424 respectively￨sig decrease￨highunclear￨highunclear￨highunclear
131￨patients with profound neutropenia 131 adult patients with acute leukemia and bone marrow transplant recipients receiving oral patients with acute leukemia and bone marrow transplant recipients receiving￨roxithromycin fluoroquinolone prophylaxis oral roxithromycin ofloxacin fluoroquinolone prophylaxis ofloxacin plus roxithromycin￨adverse events risk of infectionassociated complications including prolonged or secondary fever pneumonia septic shock need for mechanical ventilation andor infectionrelated death and antimicrobial usage for therapy incidence of bacteremia bacteremia efficacy and safety￨adverse events possibly related to the study drugs were slightly more common among the patients receiving the combination treatment p  005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨sixtytwo profoundly granulocytopenic patients with acute leukemia undergoing induction chemotherapy granulocytopenia￨trimethoprimsulfamethoxazole plus nystatin or nalidixic acid plus nystatin nalidixic acid plus nystatin nalidixic acid plus nystatin eight days trimethoprimsulfamethoxazole trimethoprimsulfamethoxazole plus nystatin trimethoprimsulfamethoxazole vs nalidixic acid￨profound granulocytopenia acquisition of gramnegative bacilli infectionrelated deaths median duration of onstudy time prior to documentation of first infection￨acquisition of gramnegative bacilli was more frequent among patients treated with nalidixic acid plus nystatin while filamentous fungi were acquired more frequently by patients receiving trimethoprimsulfamethoxazole plus nystatin p  005￨sig decrease￨highunclear￨highunclear￨highunclear
74￨pv n  76 or patients with chemotherapyinduced neutropenia oral granulocytopenic patients n  74￨pefloxacin plus vancomycin pefloxacin and vancomycin vs gentamicin colistin sulphate and vancomycin gcv gentamicin colistin sulphate and vancomycin gcv pefloxacin￨grampositive and gramnegative infections grampositive organisms episodes of bacteraemia and central venous line infections￨grampositive and gramnegative infections were significantly less frequent in patients receiving pv because of fewer infections with staphylococcus species and enterobacteriaceae￨sig decrease￨highunclear￨highunclear￨highunclear
153￨adult patients undergoing allogeneic or autologous stem cell transplantation hematopoietic stem cell transplantation one hundred and fiftythree patients adult stem cell transplant recipients￨empiric or preemptive antibiotic therapy preemptive and empiric antibiotic therapy preemptive intravenous antibiotic therapy￨number of patients with bloodstream infections proportion of patients developing fever median number of days of fever the time to onset of fever￨although there was no difference between the two arms in the proportion of patients developing fever or in the median number of days of fever the time to onset of fever was a mean of 1 day longer in each patient on the preemptive arm log rank p0001￨no diff￨highunclear￨highunclear￨highunclear
not found￨chemotherapyinduced febrile neutropenic patients acute leukemia eighty patients of acute leukemia￨levofloxacin placebo levofoxacin levofloxacin antibiotic prophylaxis levofloxacin prophylaxis￨bacterial infections and delays the onset of fever isolation of the pathogenic bacteria fever number of patients with fever neutropenia and fever￨levofloxacin reduced the bacterial infections and delays the onset of fever in chemotherapyinduced neutropenia especially in short duration  7 days￨sig decrease￨highunclear￨highunclear￨highunclear
32￨65 patients treated by allogeneic bone marrow transplantation patients less than 5 years old or with severe hepatic abnormalities 32 patients￨acyclovir oral non absorbable antibiotics or with oral absorbable broad spectrum antibiotics ketoconazole capsules containing cephalothin 250 mg gentamicin 20 mg and bacitracin 150 ui pefloxacin 400 mgday and penicillin 3 m uiday bone marrow graft by broadspectrum oral antibiotics absorbable pefloxacin penicillin and non absorbable cephalosporin gentamycin bacitracin￨year survival and the complications median time of decontamination mean number of days of fever mean number of days of agranulocytosis￨the compliance was better in group i but the treatment had to be modified in 9 patients of group i because of liver abnormalitiesabstract truncated at 250 words￨no diff￨highunclear￨highunclear￨highunclear
75￨patients treated with highdose chemotherapy and bone marrow transplantation group and 80 patients in the group without between january 1986 and june 1988 155 patients 73 children and 82 adults who were candidates for bone marrow transplantation￨vancomycin￨incidence of grampositive infections occurrence of documented septicemia documented coccus grampositive infections or fever of unknown origins during aplasia morbidity￨there was no statistical difference in the occurrence of documented septicemia documented coccus grampositive infections or fever of unknown origins during aplasia in the 2 groups￨no diff￨highunclear￨highunclear￨highunclear
56￨acute leukemia patients with acute leukemia undergoing remission induction therapy￨amphotericin b nonabsorbable antimicrobial drugs colistin and neomycin or of absorbable and nonabsorbable drugs trimethoprimsulfamethoxazole tmpsmz and colistin￨incidence of febrile days and of days on parenteral antibiotic therapy median of study time to the first acquired infection duration of severe granulocytopenia and thrombocytopenia localized infections and fever episodes￨the incidence of febrile days and of days on parenteral antibiotic therapy was significantly lower in the group given tmpsmz and colistin p less than 005￨sig decrease￨highunclear￨highunclear￨highunclear
43￨twenty patients 43 patients with acute leukemia acute leukemia neutropenic patients with acute leukemia undergoing induction or reinduction chemotherapy￨trimethoprimsulfamethoxazole oral trimethoprimsulfamethoxazole￨fever days of antibiotic administration days of hospitalization or gramnegative rod bacteremia incidences of superficial skin and overall infections￨the incidences of superficial skin and overall infections were significantly lower in those patients with multiple relapses who received trimethoprimsulfamethoxazole p  0008 however there was no difference between the groups in regard to days of fever days of antibiotic administration days of hospitalization or gramnegative rod bacteremia￨sig decrease￨highunclear￨highunclear￨highunclear
242￨patients with haematological malignancies adult patients n  242 scheduled to receive intensive treatment for haematological malignancies patients with highrisk neutropenia and to monitor the emergence of antimicrobial resistance neutropenic patients￨ciprofloxacin levofloxacin vs ciprofloxacin plus phenethicillin levofloxacin and ciprofloxacin plus phenethicillin ciprofloxacin 500 mg twicedaily plus phenethicillin 250 mg fourtimesdaily levofloxacinresistant vg streptococci levofloxacin oral prophylaxis with either levofloxacin￨failure of prophylaxis defined as the first occurrence of either the need to change the prophylactic regimen or the initiation of intravenous broadspectrum antibiotics efficacy and tolerance time to endpoint occurrence of fever type and number of microbiologically documented infections and administration of intravenous antibiotics￨no differences were noted between the two groups with respect to secondary outcome measures including time to endpoint occurrence of fever type and number of microbiologically documented infections and administration of intravenous antibiotics￨no diff￨highunclear￨highunclear￨highunclear
51￨patients with severe granulocytopenia 51 patients with acute leukaemia undergoing aggressive remission induction chemotherapy for infection prevention severely granulocytopenic patients￨ciprofloxacin combination with nonabsorbable antimycotics ciprofloxacin and norfloxacin norfloxacin ciprofloxacin and norfloxacin￨￨both drugs showed an effective elimination of gramnegative potential pathogens and staphylococcus aureus not affecting the anaerobic flora of the gastrointestinal tract￨no diff￨highunclear￨highunclear￨highunclear
63￨63 neutropenic patients receiving cytotoxic therapy for acute leukemia acute leukemia 42 patients who subsequently received empiric systemic antibiotics for suspected infection neutropenic patients with acute leukemia￨cotrimoxazole norfloxacin with cotrimoxazole norfloxacin norfloxacin￨overall incidence of febrile illness grampositive bacteremias gramnegative bacillary infections￨norfloxacin was more effective than cotrimoxazole for preventing acquisition of aerobic gramnegative bacilli in surveillance cultures￨no diff￨highunclear￨highunclear￨highunclear
48￨chemotherapytreated patients at high risk of developing febrile neutropenia patients treated with chemotherapy fortyeight patients were randomised group g patients who after an episode of fn continued to be treated with the same chemotherapy without reduction of dose intensity￨gcsf granulocytecolony stimulating factor gcsf amoxicillinclavulanate plus ciprofloxacin group gacc antibiotic prophylaxis acc gcsf or gcsf plus oral antibiotics￨recurrence of fn febrile neutropenia fn￨with regard to the side effects there was no significant difference in the two groups￨no diff￨highunclear￨highunclear￨highunclear
60￨60 patients were evaluable during 77 episodes of granulocytopenia 36 episodes in the hospitalized granulocytopenic patients granulocytopenic patients 75 patients during 92 episodes of granulocytopenia￨trimethoprimsulfamethoxazole trimethoprim trimethoprimsulfamethoxazole and trimethoprim trimethoprim trimethoprimsulfamethoxazole￨granulocyte count myelosuppression incidence of infection￨the incidence of infection was higher in the trimethoprim group 50 percent than in the trimethoprimsulfamethoxazole group 39 percent but this did not reach statistical significance￨sig increase￨highunclear￨highunclear￨highunclear
60￨60 patients undergoing bmt for hematologic malignancies￨vancomycin prophylactic vancomycin sterile diet total gut decontamination and had central venous catheters placed surgically vancomycin bone marrow transplantation by systemic vancomycin systemic vancomycin￨grampositive infections empiric antibiotic therapy number of days with fever infection morbidity￨vancomycin was found to be highly effective in preventing grampositive infections that occurred in 11 of 30 patients in the control group versus zero of 30 in the vancomycin group p less than 002￨sig increase￨highunclear￨highunclear￨highunclear
545￨139 patients with acute nonlymphocytic leukemia anll neutropenic patients 545 patients￨trimethoprimsulfamethoxazole tmpsmz or placebo trimethoprimsulfamethoxazole￨infection occurrence of infection or bacteremia bacteremia grampositive cocci￨grampositive cocci were isolated less frequently from tmpsmztreated bacteremic patients but more of their isolates were resistant to tmpsmz than were those from placebo recipients￨sig increase￨highunclear￨highunclear￨highunclear
43￨patients were being treated for germ cell cancer n  15 breast cancer n  16 hodgkins disease n  3 nonhodgkins lymphoma n  4 acute myeloid leukemia n  1 acute lymphoblastic leukemia n  1 and ovarian cancer n  3 patients undergoing highdose chemotherapy and autologous bone marrow transplant patients undergoing autologous bone marrow transplantation patients undergoing highdose fortythree patients undergoing highdose chemotherapy with autologous bone marrow transplant￨acyclovir grampositive prophylaxis to standard antimicrobial prophylaxis norfloxacin vancomycin iv fluconazole vancomycin chemotherapy and autologous bone marrow transplantation prophylaxis for grampositive infections with 106 penicillin intravenously iv prophylaxis against grampositive infections penicillin or vancomycin￨overall infections numbers of deaths duration of broadspectrum antibiotics or incidence of neutropenic fever streptococcal infections￨there were significantly fewer overall infections 10 versus 3 p  0016 and streptococcal infections 9 versus 1 p  00078 in the group receiving grampositive prophylaxis￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨acute leukemia fiftythree profoundly granulocytopenic patients with relapsed acute leukemia who were undergoing reinduction chemotherapy relapsed acute leukemia￨gentamicin plus nystatin trimethoprimsulfamethoxazole plus nystatin or gentamicin plus nystatin trimethoprimsulfamethoxazole trimethoprimsulfamethoxazole plus nystatin gentamicin trimethoprimsulfamethoxazole plus nystatin with gentamicin plus nystatin￨￨furthermore side effects were fewer and compliance was better with trimethoprimsulfamethoxazole plus nystatin￨sig increase￨highunclear￨highunclear￨highunclear
122￨bone marrow transplant patients 122 patients with hematologic malignancies underwent allogeneic marrow transplantation from hlamatched sibling donors and received one of two forms of￨laminar air flow isolation and decontamination laf laf  psa infection prophylaxis while granulocytopenic 1 decontamination and laminar air flow isolation laf 68 patients and 2 laf plus prophylactic systemic antibiotics laf  psa prophylactic systemic antibiotics￨incidence and severity of graftversushost disease or incidence and duration of fever septicemia infection acquisition major local infection￨there was no difference in the incidence and severity of graftversushost disease or incidence and duration of fever￨no diff￨highunclear￨highunclear￨highunclear
38￨38 adult patients with acute leukemia who were undergoing remission induction chemotherapy in regular patient rooms leukemic patients￨oral nonabsorbable antibiotic regimens for infection prophylaxis gentamicin vancomycin and nystatin gvn or gentamicin and nystatin gn vancomycin￨overall alimentary tract microbial suppression acquisition of potential pathogens incidence of bacteremia colonization by newly acquired gramnegative bacilli￨group d streptococcus species were poorly suppressed by gn compared with gvn although no patient developed an infection with these organisms￨no diff￨highunclear￨highunclear￨highunclear
44￨44 patients treated by intensive chemotherapy inducing a prolonged neutropenia granulocytes less than 05109l postchemotherapy agranulocytic patients￨ceftriaxone cef placebo pathogenfree diet and nonabsorbable oral antibiotics nonabsorbable antibiotics ceftriaxone￨febrile episodes￨prophylaxis was continued until the neutropenia resolved granulocytes greater than 05109l or until the onset of infectious symptoms￨no diff￨highunclear￨highunclear￨highunclear
7￨patients undergoing bone marrow transplantation twentysix oncology patients 25 of whom received bone marrow transplants neutropenic patients￨ciprofloxacin placebo ciprofloxacin￨risk factors for infection bioavailability fever microbiologically documented infections￨ciprofloxacin recipients required fewer days of therapeutic antimicrobials median 28 antibioticdays vs 49 p002￨no diff￨low￨low￨low
760￨patients with cancer and profound and protracted neutropenia patients with cancer and neutropenia patients were stratified according to their underlying disease acute leukemia vs solid tumor or lymphoma 760 consecutive adult patients with cancer in whom chemotherapyinduced neutropenia 1000 neutrophils per cubic millimeter patients with acute leukemia and those with solid tumors or lymphoma￨levofloxacin placebo fluoroquinolones oral levofloxacin levofloxacin levofloxacin prophylaxis￨duration of neutropenia microbial resistance bacteremias mortality and tolerability singleagent gramnegative bacteremias bacterial infection rate of microbiologically documented infections￨prophylactic treatment with levofloxacin is an effective and welltolerated way of preventing febrile episodes and other relevant infectionrelated outcomes in patients with cancer and profound and protracted neutropenia￨no diff￨low￨low￨low
551￨convenience sample with a total of 551 granulocytopenic patients 95 of whom had leukemia or underwent bone marrow transplantation granulocytopenic patients with cancer￨placebo oral penicillin v or placebo penicillin v fluoroquinolone prophylaxis oral pefloxacin oral penicillin v combined with a fluoroquinolone pefloxacin pefloxacin￨occurrence of fever andor infection febrile episodes bacteremia occurrence of fever and streptococcal and other grampositive coccal bacteremic infections reduction of fever and streptococcal bacteremia fever or infection without fever streptococcal bacteremic episodes gramnegative rod bacteremias￨fever or infection without fever developed in 190 71 of 268 evaluable patients in the penicillin arm compared with 213 80 of 268 evaluable patients in the placebo arm p  03 95 confidence interval ci for the difference 16 to 1￨no diff￨low￨low￨low
not found￨bone marrow transplant recipients patients who received bone marrow transplantation bmt for the treatment of solid and hematopoietic neoplasms adult inpatients about to undergo bmt for lymphoma leukemia or solid tumors￨cip ciprofloxacin trimethoprim and 800 mg sulfamethoxazole ciprofloxacin cip and trimethoprimsulfamethoxazole tms trimethoprimsulfamethoxazole cip and tms tms￨fever signs or symptoms of infection serious adverse effects or recovery of the absolute granulocyte count agc longer durations of granulocytopenia at agc levels clostridium difficile enterocolitis occurrence of fever during neutropenia time to onset of first fever or overall infection rates granulocytopenia mean peak and trough serum levels of cip overall infection rate incidence of rash or organ toxicity efficacy and safety￨tms prophylaxis was associated with a higher incidence of c difficile enterocolitis and infections caused by gramnegative bacilli as well as a trend toward prolongation of granulocytopenia￨sig decrease￨low￨low￨low
53￨granulocytopenic patients with 53 evaluable patients with neutropenic episodes￨ciprofloxacin vs ciprofloxacin plus amoxicillin ciprofloxacin plus amoxicillin ciprofloxacin￨incidence of grampositive infections number of febrile episodes prevention of grampositive bacteremias￨in conclusion no significant difference was observed between the two groups in prevention of grampositive bacteremias￨no diff￨highunclear￨highunclear￨highunclear
not found￨granulocytopenic patients￨oral nonabsorbable antibiotics parenteral antibiotics trimethoprimsulfamethoxazole￨rectal flora and temporarily destroyed the colonization resistance￨trimethoprimsulfamethoxazole was found to be easily taken to suppress the enterobacteriaceae and to maintain the anaerobic rectal flora for biological stability of the rectal ecosystem￨sig decrease￨highunclear￨highunclear￨highunclear
28￨acute leukemia 28 patients receiving fiftysix patients receiving remission induction treatment for acute leukemia patients with granulocytopenia￨ciprofloxacin ciprofloxacin with trimethoprimsulfamethoxazole and colistin ciprofloxacin ciprofloxacin with trimethoprimsulfamethoxazole plus colistin trimethoprimsulfamethoxazole trimethoprimsulfamethoxazole plus colistin amphotericin b￨tolerated￨no infections caused by gramnegative bacilli were seen in the ciprofloxacin group p less than 002￨no diff￨highunclear￨highunclear￨highunclear
not found￨acute leukemia patients with acute leukemia receiving remission induction treatment patients with acute leukemia receiving remission induction therapy￨ketoconazole sulfamethoxazole and trimethoprim ketoconazole sulfamethoxazole and trimethoprim and ketoconazole sulfamethoxazole and trimethoprim ketoconazole or the combination of sulfamethoxazole and trimethoprim and ketoconazole sulfamethoxazole and trimethoprim￨rate of fungal infection infectious morbidity bacterial infection infectious mortality complete remission rate￨both sulfamethoxazole and trimethoprim and the combination of sulfamethoxazole and trimethoprim and ketoconazole substantially reduced the overall incidence of infection consequent to a marked decrease in bacterial infection￨no diff￨highunclear￨highunclear￨highunclear
128￨128 patients with acute leukemia who received aggressive cytotoxic chemotherapy and were granulocytopenic for a median duration of 30 days patients with acute leukemia and granulocytopenia￨oral ofloxacin trimethoprimsulfamethoxazole ofloxacin ofloxacin￨duration of fever incidence of grampositive bacterial pseudomonas aeruginosa gramnegative bacterial infection efficacy and safety￨ofloxacin was significantly better tolerated than trimethoprimsulfamethoxazole and shortened the duration of fever p  002 and of parenteral antimicrobial therapy for presumed or documented acquired infection p  001￨sig increase￨highunclear￨highunclear￨highunclear
65￨patients with highdose chemotherapy 65 patients 41 received the two planned cycles and 24 received only the first cancer patients with profound neutropenia induced by highdose chemotherapy 65 patients who were scheduled to receive two cycles of highdose cancer patients treated with highdose chemotherapy￨prophylactic imipenem imipenem cyclophosphamide etoposide cisplatin cep chemotherapy￨lower fever incidence length of hospitalization septic shock incidence of grampositive infections gramnegative bacteria infection febrile neutropenia episodes of pneumonia deaths from infection frequency of febrile neutropenia and gramnegative infections￨there were no differences in the incidence of grampositive infections nor in the length of hospitalization between the two treatment arms￨no diff￨highunclear￨highunclear￨highunclear
32￨granulocytopenic patients granulocytopenic patients undergoing chemotherapy for hematologic malignancy￨vancomycinpolymyxin nystatin suspension vancomycin capsules ofloxacin polymyxin capsules ofloxacin ofloxacin tablets￨gramnegative septicemia number of acquired gramnegative bacillary organisms tolerated gastrointestinal side effects efficacy and safety￨ofloxacin was also better tolerated 24 of 30 versus 10 of 32 patients highly compliant p  001 and associated with fewer gastrointestinal side effects one of 30 versus nine of 32 patients with gastrointestinal side effects p  001 than vancomycinpolymyxin￨sig increase￨highunclear￨highunclear￨highunclear
64￨neutropenic patients neutropenic patients a 2year followup study between 1 january 1998 and 31 december 1999 showed 66 significant infections during 700 corrected neutropenic episodes￨ciprofloxacin cip oral ciprofloxacin col cip  col ciprofloxacin  colistin cip  col with neomycin  colistin neo  col ciprofloxacin and colistin￨pyrexial episodes gramnegative bacterial infections staphylococcus aureus infections neutropenic days on intravenous antibiotics proportion of neutropenic days with fever￨only two gramnegative bacterial infections occurred in the cip  col arm compared with 16 in the neo  col arm￨no diff￨highunclear￨highunclear￨highunclear
84￨bone marrow transplant recipients￨ciprofloxacin oral antimicrobial prophylaxis ciprofloxacinvancomycin oral ciprofloxacin or ciprofloxacin plus vancomycin vancomycin vancomycinresistant isolates vancomycin￨number of days to first fever total number of febrile days length of stay and number of transfusions frequency of patients with surveillance cultures positive for coagulasenegative staphylococci incidences of bacteremias￨the addition of vancomycin resulted in a significant decrease in the frequency of patients with surveillance cultures positive for coagulasenegative staphylococci stool cultures 44 versus 23 throat swab cultures 37 versus 19 and alphahemolytic streptococci throat swab cultures 90 versus 60￨sig decrease￨highunclear￨highunclear￨highunclear
48￨48 patients undergoing 75 courses of oncohematologic patients￨penicillin g and cotrimoxazole viridansgroup streptococcal septicemia penicillin aggressive antileukemic therapy cotrimoxazole penicillin g￨streptococcal bacteremia bacteremia and septicemia￨both aerobic gramnegative rods and streptococci which caused infection despite cotrimoxazole prophylaxis were resistant to cotrimoxazole￨no diff￨highunclear￨highunclear￨highunclear
90￨ovarian cancer patients receiving ovarian cancer patients n  45 groups ninety patients were enrolled between the control n  45 and￨ciprofloxacin ciprofloxacin prophylaxis group chemoprophylaxis with ciprofloxacin ciprofloxacin prophylaxis paclitaxel at doses of 135 to 175 mgm2 alone or in combination with a platinum agent paclitaxel￨febrile episodes absolute neutrophil count anc disease status and risk factors for neutropenia febrile neutropenia mean anc and mean length of hospital stay for neutropenic fever febrile morbidity￨fifteen patients in the control group developed febrile neutropenia versus 12 of those in the ciprofloxacin group p  069￨no diff￨highunclear￨highunclear￨highunclear
106￨patients with acute leukemia being treated by remissioninduction chemotherapy acute leukemia patients patients with acute leukemia being treated with cytotoxic remissioninduction chemotherapy one hundred and six consecutive evaluable patients￨empirical antibiotic therapy norfloxacin nflx and amphotericin b amphb norfloxacin norfloxacin and amphotericin b amphotericin b four times daily or amphotericin b only￨fungal infection mean number of days percentage of patients with a gramnegative bacterial infection￨this new combination antimicrobial regimen is safe and effective for prevention of gramnegative bacterial as well as fungal infections in patients with acute leukemia being treated with cytotoxic remissioninduction chemotherapy￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients with acute leukemia or autologous bone marrow transplantation seventythree patients mainly receiving consolidation therapy for acute leukemia or autologous bone marrow transplantation￨nystatin nystatin with norfloxacin norfloxacin￨fever during granulocytopenia bacteremia microbiologically documented infections and fever of unknown origin granulocytopenia￨duration of more than a 39 degrees c fever was much longer in the nystatin group than in the norfloxacin group bacteremia microbiologically documented infections and fever of unknown origin were more frequently seen in the nystatin group but there was no significant difference between the two groups￨sig increase￨highunclear￨highunclear￨highunclear
14￨patients with acute leukemia receiving consolidation chemotherapy acute leukemia 14 treatment patients during 33 episodes and 15 control patients during 34 episodes of granulocytopenia less than 1000 granulocytesmm3 granulocytopenic patients during consolidation chemotherapy￨prophylactic trimethoprimsulfamethoxazole trimethoprimsulfamethoxazole￨incidence of fever hospitalization or infection mean duration of hospital stay to treat fever or infection number of septicemias incidence of febrile episodes hospitalizations to treat fever or infection￨prophylactic trimethoprimsulfamethoxazole did not significantly reduce the incidence of fever hospitalization or infection in granulocytopenic patients during consolidation chemotherapy￨no diff￨highunclear￨highunclear￨highunclear
30￨thirty patients were evaluated in each group children with acute lymphoblastic leukemia children receiving intensive chemotherapy for acute lymphoblastic leukemia￨tmpsmx tmpsmx prophylaxis trimethoprimsulfamethoxazole prophylactic antibiotics trimethoprimsulfamethoxazole tmpsmx or placebo￨toxicity geometric mean of the neutrophil nadir episodes of bacteremia bacterial infections certain bacterial infections delay or dose reduction of chemotherapy￨children receiving tmpsmx had fewer episodes of bacteremia 0 vs 5 and otitis media 3 vs 18￨sig decrease￨highunclear￨highunclear￨highunclear
95￨acute myelogenous leukemia ninetyfive aml patients receiving chemotherapy at catholic hemopoietic stem cell transplantation center from march 1999 to july 1999 acute myelogenous leukemia aml patients receiving chemotherapy￨ciprofloxacin antimicrobial prophylaxis ap with orally absorbable antibiotics roxithromycin selective bowel decontamination fluconazole erythromycin￨occurrence of infection or infection associated death time interval between initiation of chemotherapy and onset of fever white blood cell wbc count at the onset of fever duration of leukopenia wbc  1000mm3 duration of systemic antibiotic therapy mortality due to infection and hospitalization period incidence of fever gram positive bacteria catheter associated infection gram negative bacteria￨infections due to gram negative bacteria decreased to 333 in the ap group vs 92 in the control group but infections due to gram positive bacteria increased to 667 vs 8 in the control group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨fiftytwo patients with nonlymphocytic leukaemia patients with acute nonlymphocytic leukaemia￨trimethoprimsulfamethoxazole plus amphotericin b prophylactic oral trimethoprimsulfamethoxazole trimethoprimsulfamethoxazole￨total number of acquired infections number of patients without any infection infection and fever rate parenteral antibiotics￨a decrease in the total number of acquired infections was found 16 infections in the group given trimethoprimsulfamethoxazole versus 31 in the control group p less than 001￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨smallcell lung cancer patients patients with chemonaïve sclc smallcell lung cancer sclc￨cde cyclophosphamide doxorubicin etoposide placebo standarddose cde intensified cde chemotherapy prophylactic antibiotics ciprofloxacin 750 mg plus roxithromycin prophylactic antibiotics prophylactic ciprofloxacin plus roxithromycin ciprofloxacin and roxithromycin￨febrile leucopenia therapeutic antibiotics gramnegative incidence of febrile leucopenia fl overall number of days of hospitalization grampositive number of infectious deaths incidence of fl the number of infections incidence of fl￨the use of therapeutic antibiotics was reduced p  0013 1sided with less hospitalizations due to fl 31 vs 17 patients p  0013 1sided￨sig decrease￨highunclear￨highunclear￨highunclear
19￨59 granulocytopenic patients with acute leukemia for prevention of bacterial infections neutropenic patients granulocytopenic patients with acute leukemia￨cotrimoxazole norfloxacin nor or cotrimoxazole tmpsmx tmpsmx norfloxacin￨days of fever mean incidence of febrile complications febrile episodes gram negative bacilli gnb time spent febrile intestinal gnb colonization febrile or infectious episodes￨eleven of 16 microbiologically documented infections in the tmpsmx group and 7 of 11 in the nor group were caused by gram negative bacilli gnb￨sig increase￨highunclear￨highunclear￨highunclear
not found￨granulocytopenic patients￨vancomycinpolymyxin norfloxacin norfloxacin￨number of acquired gramnegative bacillary organisms gastrointestinal side effects gramnegative septicemia tolerated￨norfloxacin was better tolerated 30 of 36 versus 16 of 30 patients highly compliant p  002 and associated with fewer gastrointestinal side effects eight of 36 versus 14 of 36 patients p  007￨sig increase￨highunclear￨highunclear￨highunclear
43￨patients with acute leukaemia 43 patients undergoing treatment for acute leukaemia￨cotrimoxazole cotrimoxazole alone cotrimoxazole alone or cotrimoxazole with framycetin and colistin as antibacterial prophylaxis￨time before the onset of the first fever the number of episodes of fever￨there were no significant differences between the two treatment groups in the time before the onset of the first fever the number of episodes of fever or of septicaemia per patient the number of neutropenic days during which patients remained afebrile or did not require systemic antibiotics or the number of resistant organisms acquired￨no diff￨highunclear￨highunclear￨highunclear
not found￨neutropenic patients 42 adult granulocytopenic patients  100 absolute neutrophilsmm3 mean duration 133 days undergoing chemotherapy for acute leukemia at 11 participating veterans administration medical centers all patients acquired trimethoprimresistant organisms granulocytopenic patients with acute leukemia￨placebo trimethoprim tmpsmz trimethoprimsulfamethoxazole prophylaxis trimethoprimsulfamethoxazole tmpsmz￨survival frequency of bacteremia overall infections use of systemic antimicrobial therapy or adverse effects including myelosuppression￨no significant differences in survival frequency of bacteremia overall infections use of systemic antimicrobial therapy or adverse effects including myelosuppression were observed between patients receiving tmpsmz vs those receiving placebo￨no diff￨highunclear￨highunclear￨highunclear
33￨16 patients receiving the thirtythree patients with acute nonlymphocytic leukemia patients with acute nonlymphocytic leukemia￨placebo sam selective antimicrobial modulation sam￨number of major acquired infections reduction of infection￨a decrease in the number of major acquired infections was observed three infections occurred in 16 patients receiving the sam regimen compared with eight infections in 17 patients given the placebo￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨acute leukemia patients authors transl neutropenic patients with acute leukemia receiving￨chemotherapy oral antibiotics neomycin colistin and nystatin in conventional ward isolation 2 no antimicrobial suppression but conventional ward isolation 3 strict isolation filtered air sterilized food and oral antibiotics nonabsorbable antibiotics￨death rate from infection leukemic remission rate tolerated￨the death rate from infection was significantly reduced in patients who received antibiotics for gut flora suppression in conventional ward isolation compared with the corresponding control group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨neutropenic patients receiving therapy for acute leukaemia acute leukaemia 30 patients with acute leukaemia being treated with cytotoxic drugs￨cotrimoxazole cotrimoxazole prophylaxis with cotrimoxazole￨duration of severe neutropenia died of infection rate of infection￨three significant differences were observed between the cotrmoxazole and the control groups i 15 of the 16 94 control patients but only 8 of the 14 57 patients on cotrimoxazole developed infections and required additional antibiotics intravenously ii although the duration of severe neutropenia neutrophils less than 01 times 1091 was similar in the two groups control patients required intravenous antibiotics on average after 2 days of neutropenia whereas patients receiving cotrimoxazole required these only after 12 days and iii the only 2 patients who died of infection were in the control group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨neutropenic children with cancer￨oral amoxicillinclavulanate placebo amoxicillinclavulanate￨fever and infection incidence of febrile or infectious episodes probability of failurefree survival￨this benefit was also associated with a 30 increase in the probability of failurefree survival at day 15 p  0138￨sig increase￨low￨low￨low
not found￨hospitalized granulocytopenic patients hospitalized granulocytopenic patients￨smz prophylactic trimethoprimsulfamethoxazole oral trimethoprimsulfamethoxazole tmpsmz therapy tmp oral prophylactic tmpsmz therapy￨disseminated candidiasis percentage of febrile granulocytopenic days granulocytopenia￨the percentage of febrile granulocytopenic days was significantly reduced in group 1 19 per cent compared to 39 per cent in group 2 p less than 001￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients with acute leukaemia 59 patients median age 47 years range 2172 included 88 episodes of neutropenia each associated with a course of cytotoxic therapy neutropenic patients with acute leukaemia￨ciprofloxacin ofloxacin quinolones ofloxacin ciprofloxacin and cotrimoxazolecolistin￨gramnegative infections compliance problems skin reactions or gastrointestinal intolerance pneumocystis carinii infections adverse reactions microbiologically proven major infections median time￨adverse reactions associated with cotrimoxazolecolistin required discontinuation of medication in 1127 treatment courses because of compliance problems skin reactions or gastrointestinal intolerance￨no diff￨highunclear￨highunclear￨highunclear
53￨moderately granulocytopenic patients fiftythree granulocytopenic patients granulocytopenic patients granulocytopenic patients with new quinolone￨st st  cpfx st alone trimethoprimsulfamethoxazole st alone with st plus ciprofloxacin st and cpfx trimethoprimsulfamethoxaxole st alone with st  ciprofloxacin cpfx￨adverse reactions seventeen febrile episodes febrile episodes￨st  cpfx was significantly effective than st alone p  0005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with small cell carcinoma of the lung receiving intensive chemotherapy patients with small cell carcinoma of the lung patients with newly diagnosed small cell carcinoma of the lung during the initial courses of chemotherapy with 61 patients evaluated 32 were given tmp￨smz placebo trimethoprimsulfamethoxazole placebo tmpsmz trimethoprimsulfamethoxazole tmpsmz tmpsmz cyclophosphamide doxorubicin and etoposide￨infections marrow suppression granulocytopenia incidence of infection number of bacteremias and the mean proportion of study time on broadspectrum antibiotics￨incidence of infection at less than 100 granulocytesmicroliters was significantly reduced in the tmpsmz group 2 infections100 days compared to placebo 11 infections100 days p  0005￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨adult cancer patients receiving adult cancer patients febrile neutropenic cancer patients￨placebo cytotoxic chemotherapy trimethoprimsulfamethoxazole plus erythromycin tmze prophylaxis tmz tmze oral trimethoprimsulfamethoxazole bactrim plus erythromycin tmze￨median interval between the onset of neutropenia and the onset of fever number of deaths from infection neutropenia infectious source incidence of fever adverse reactions￨the incidence of fever was not significantly different between episodes treated with tmze 1827 and those treated with p 1729 nor was there a significant difference in the median interval between the onset of neutropenia and the onset of fever￨no diff￨low￨low￨low
44￨44 granulocytopenic children with malignancies in order to prevent bacterial infections neutropenic children￨norfloxacin norfloxacin prophylactic cotrimoxazole versus norfloxacin trimoxazole cotrimoxazole or norfloxacin￨mean of febrile days and the mean of days with systemic antibiotics number of gramnegative bacilli resistant to cotrimoxazole isolated from stools febrile episodes signs or symptoms of arthropathy￨the number of gramnegative bacilli resistant to cotrimoxazole isolated from stools significantly increased during prophylaxis with cotrimoxazole p less than 0001￨sig decrease￨highunclear￨highunclear￨highunclear
22￨51 granulocytopenic episodes in 22 patients with hematological malignancies during postremission chemotherapy granulocytopenic patients taking aggressive chemotherapy granulocytopenic patients with hematological malignancies during postremission chemotherapy￨oflx ofloxacin ofloxacin oflx therapy oflx plus amphotericinb amph and polymyxinb pl￨episodes of fever and infection prophylactic efficacy incidence of infection￨clinically the prophylactic efficacy was 92 for the oflx regimen and 40 for the control regimen p less than 001￨sig increase￨highunclear￨highunclear￨highunclear
64￨64 consecutive noninfected adults with acute nonlymphocytic leukemia admitted for remission induction acute nonlymphocytic leukemia￨laminar air flow room reverse isolation with oral nonabsorbable antibiotic prophylaxis reverse isolation and prophylactic oral nonabsorbable antibiotics laf laminar air flow room reverse isolation with oral nonabsorbable antibiotics laf plus a routine hospital ward care with antibiotics w plus a or ward care alone w￨incidence of total infection bacteremias pneumonias rectal abscesses urinary tract infection and pharyngitis median survival infectious deaths incidence of infection complete remission rates￨the laf plus a patients had a significantly decreased incidence of total infection bacteremias pneumonias rectal abscesses urinary tract infection and pharyngitis￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨230 leukaemic patients￨ciprofloxacin trimoxazolecolistin colistin cotrimoxazole￨fever infective events infective complications￨bacteraemia due to resistant gramnegative rods occurred only in the cotrimoxazolecolistin group though both regimens were effective for selective gastrointestinal tract decontamination￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨acute alcohol withdrawalcaroverine versus meprobamate￨calciumchannelblocking agent levopromazine caroverine￨clinical efficacy rate tremor speech and coping sedative side effects syndromkurztest skt nurses observation scale for inpatient evaluation nosie ngi the webster scale￨patients of both groups were similar in age weight duration of drinking ingested quantities of alcohol and intensity of withdrawal symptoms in both groups￨no diff￨highunclear￨highunclear￨highunclear
36￨thirtysix hospitalized patients experiencing moderate alcohol withdrawal as measured by a score of at least 10 on the revised clinical institute withdrawal assessment for alcohol scale ciwaar alcohol withdrawal acute alcohol withdrawal￨placebo divalproex sodium an anticonvulsant and antikindling agent and gammaaminobutyric acid enhancer divalproex sodium oxazepam benzodiazepines benzodiazepine divalproex sodium￨progression in severity of withdrawal symptoms mean total milligrams of oxazepam received progression of withdrawal symptoms psychological distress symptom checklist90 side effects and adverse outcomes acute alcohol withdrawal￨mean total milligrams of oxazepam received progression of withdrawal symptoms psychological distress as measured by the symptom checklist90 side effects and adverse outcomes were compared between groups￨no diff￨low￨low￨low
90￨patients with a history of seizures unrelated to alcohol withdrawal were excluded highrisk patients patients with and without subsequent seizures seventyone patients had a history of seizures during prior alcohol withdrawal episodes alcohol withdrawal seizures ninety alcoholic patients enrolled within six hours of the initial alcoholrelated seizure in a withdrawal episode￨diphenylhydantoin intravenous diphenylhydantoin placebo placebo diphenylhydantoin therapy￨response probabilities equivalent diphenylhydantoin serum levels response rates alcohol withdrawal seizures recurrent seizure￨there was no statistically significant difference between the response rates for the two treatments p greater than 005￨no diff￨low￨low￨low
72￨hospitalized patients seventytwo hospitalized patients with alcohol withdrawal symptoms sixty patients completed the treatment successfully￨carbamazepine carbamazepine tegretol and barbital diemal carbamazepine tegretol or barbital  diemal￨efficacy tolerated￨no statistically significant differences were found in efficacy between the two treatments and both drugs were well tolerated￨no diff￨highunclear￨highunclear￨highunclear
45￨patients were kept in hospital and treated with amobarbital 15 patients alcoholics during acute withdrawal under treatment with different pharmacological agents 45 male alcoholics￨oxazepam￨comprehensive psychopathological rating scale lumbar cerebrospinal fluid blood pressure body temperature and pulse rate levels of hva and auditory and visual hallucinations levels of hva in the cerebrospinal fluid￨levels of hva in the cerebrospinal fluid did not differ between the treatment groups and the controls and did not change during treatment￨no diff￨highunclear￨highunclear￨highunclear
20￨twenty inpatients with alcohol dependence according to dsmiv criteria received 11 patients chronic alcohol dependent patients perpetuates sleep disturbances￨clomethiazole placebo clomethiazole clomethiazole or placebo￨disturbed sleep polysomnographic variables of sleep continuitiy and sleep architecture sleep continuity and sleep architecture variables rapid eye movement rem sleep variables￨differences in the polysomnographic variables of sleep continuitiy and sleep architecture at t0 and t1 found between the clomethiazole and the placebo patients correspond to rebound insomnia following discontinuation of clomethiazole￨sig increase￨highunclear￨highunclear￨highunclear
40￨acute alcohol withdrawal syndrome in 40 patients acute alcohol withdrawal￨chlormethiazole chlordiazepoxide chlormethiazole heminevrin and chlordiazepoxide librium chlormethiazole and chlordiazepoxide￨￨analysis indicated both drugs to be of equivalent potency and were equally well tolerated by patients￨no diff￨highunclear￨highunclear￨highunclear
180￨traumatized chronic alcoholic patients with respect to the duration of mechanical ventilation and the frequency of pneumonia and cardiac disorders during their intensive care unit icu stay multipleinjured alcoholdependent patients n180 transferred to the icu after admission to the emergency room and operative management patients who developed actual alcohol withdrawal syndrome patients with cardiac or pulmonary risk a total of 180 patients were included in the study however 21 patients were excluded from the study after assignment n54 intensive care unit patients following trauma￨chlormethiazolehaloperidol flunitrazepamclonidine flunitrazepamhaloperidol alcohol withdrawal therapy regimens￨mechanical ventilation cardiac complications cardiac complications frequency of pneumonia revised clinical institute withdrawal assessment for alcohol scale icu stay duration of mechanical ventilation and major intercurrent complications such as pneumonia sepsis cardiac disorders bleeding disorders and death revised trauma and injury severity score and acute physiology and chronic health evaluation ii score on admission￨cardiac complications were significantly p0047 increased in the flunitrazepamclonidine group￨sig decrease￨highunclear￨highunclear￨highunclear
26￨twentysix alcoholic patients with severe aws and concomitant medical diseases were randomally enrolled in the study medical icu patients alcoholic patients￨clo clomethiazole clo gammahydroxybutyric acid ghb ghb gammahydroxybutyric acid versus clomethiazole￨serious side effects duration of patient withdrawal aws score four major aws symptoms tremor sweating nausea restlessness duration of icu stay￨no serious side effects were detected￨no diff￨highunclear￨highunclear￨highunclear
56￨56 alcoholdependent patients participated￨cbz oxcarbazepine oxc clomethiazole clo therapy carbamazepine cbz oxctia oxcarbazepine oxctiaprid tia combination therapy￨efficacy and tolerability total number of recorded adverse events aes overall tolerability severity of alcohol withdrawal syndrome￨we found no significant differences between groups regarding total number of recorded adverse events aes￨no diff￨highunclear￨highunclear￨highunclear
not found￨group and 27 in the control group alcoholic inpatients alcohol withdrawal syndrome patients during withdrawal from alcohol dependence￨sodium valproate multivitamins and fluid and electrolyte replacement and some received chlormethiazole or other tranquillisers sodium valproate￨seizures withdrawal symptoms occurrence of seizures and other withdrawal symptoms tremulousness nausea sweating disorientation￨other withdrawal symptoms disappeared more quickly in the sodium valproate group even though fewer patients were receiving chlormethiazole￨sig decrease￨highunclear￨highunclear￨highunclear
91￨all patients were excluded who had taken psychoactive drugs before admission 91 patients participated in the study 44 in the diazepam group 47 in the barbital group patients with delirium tremens￨diazepam chlordiazepoxide￨￨no difference between the two drugs tested was found in the milder conditions but barbital was found superior to diazepam in the treatment of fully developed delirium tremens￨no diff￨highunclear￨highunclear￨highunclear
27￨27 inpatients￨gabapentin gabapentin and phenobarbital gabapentin phenobarbital￨withdrawal symptoms or psychological distress breakthrough signs and symptoms of alcohol withdrawal serious adverse events￨there were no significant differences in the proportion of treatment completers between treatment groups or the proportion of patients in each group requiring rescue medication for breakthrough signs and symptoms of alcohol withdrawal￨no diff￨highunclear￨highunclear￨highunclear
98￨newly admitted alcoholdependent patients n  98￨gammahydroxybutyrate ghb gammahydroxybutyrate and clomethiazole placebo clomethiazole￨ratings of alcohol withdrawal symptoms nor requests for additional medication efficacy and safety withdrawal symptoms￨there was no difference between the three treatments in ratings of alcohol withdrawal symptoms nor requests for additional medication￨no diff￨highunclear￨highunclear￨highunclear
127￨male alcoholdependent inpatients n127 with clinically significant alcohol withdrawal symptoms￨placebo and diazepam placebo benzodiazepine diazepam diazepam benzodiazepines lamotrigine placebo diazepam 10 mg tid lamotrigine 25 mg qid memantine 10 mg tid or topiramate 25 mg qid￨observerrated and selfrated withdrawal severity dysphoric mood￨all active medications significantly reduced observerrated and selfrated withdrawal severity dysphoric mood and supplementary diazepam administration compared with placebo￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨fiftyfive patients who had seized from alcohol withdrawal patients with known seizure disorders and those receiving any anticonvulsant were excluded￨phenytoin iv phenytoin or placebo placebo phenytoin￨response probabilities response rates recurrent seizures recurrence of alcohol withdrawal seizures￨there was no statistically significant difference between the response rates for the two treatments p greater than 05￨no diff￨low￨low￨low
100￨one hundred male outpatients were treated for alcohol withdrawal symptoms with either five finnish aclinics alcoholism treatment centres in different parts of the country￨carbamazepine carbamazepine or placebo placebo￨total symptom score￨the change in the total symptom score from the first day of treatment to the second was significantly greater in the carbamazepine group than in the placebo group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨acute alcohol withdrawal sixty inpatient alcoholics presenting with an alcohol withdrawal syndrome after at least one weeks drinking bout patients not requiring sedation￨piracetam or chlormethiazole piracetam and chlormethiazole piracetam￨sleep disturbances decreased libido￨on the whole a small tendency to more symptom items being reduced on piracetam in comparison with chlormethiazole was found￨sig decrease￨highunclear￨highunclear￨highunclear
127￨alcohol withdrawal treatment in intoxicated vs nonintoxicated patients alcoholintoxicated patients intoxicated patients d breath alcohol concentration  or  1 gl￨carbamazepine tiapridecarbamazepine clomethiazole and diazepam tiapridecarbamazepine a vs clomethiazole b tiapridecarbamazepine diazepam c￨efficacy and safety￨efficacy and safety were not different between groups total group delirium 39 seizure 08 except for a lack of efficacy in 18 of intoxicated tiapridecarbamazepine patients￨no diff￨highunclear￨highunclear￨highunclear
not found￨sixtyone patients p  29gp  32 suffering from alcohol dependence icd10 and without any other psychiatric condition or psychotropic medication were included alcohol withdrawal syndrome aws￨gabapentin combined clogp gabapentin gp gp and clo placebo p or gp gp￨mainz alcohol withdrawal scores baseline characteristics eg demographic data severity of aws adverse clinical events primary effectiveness measure amount of clo tolerability￨both itt and completer analyses revealed no significant differences between the groups considering the primary effectiveness measure amount of clo required in the first 24 hours p  61￨no diff￨highunclear￨highunclear￨highunclear
not found￨50 inpatients during a 6day treatment of alcohol withdrawal in a 4site alcohol withdrawal syndrome aws￨placebo oxcarbazepine oxc benzodiazepines carbamazepine cbz clomethiazole clo oxc￨side effects normalization of vegetative parameters craving or improvement of psychopathological parameters efficacy and tolerability oxcarbazepineefficacy and tolerability withdrawal symptoms or craving for alcohol￨no differences were found in the need for rescue medication clo decrease of withdrawal symptoms or craving for alcohol between the oxc and the placebo group￨no diff￨highunclear￨highunclear￨highunclear
71￨seventyone patients undergoing withdrawal from alcohol￨bromocriptine chlordiazepoxide and chlormethiazole placebo oral bromocriptine chlormethiazole or chlordiazepoxide bromocriptine￨alcoholic hepatitis andor cirrhosis￨bromocriptine was ineffective in treating withdrawal symptoms whilst chlormethiazole and chlordiazepoxide were equally effective￨no diff￨highunclear￨highunclear￨highunclear
60￨acute alcohol withdrawal syndrome the acute or primary alcohol withdrawal syndrome paws sixty male alcoholic inpatients￨tetrabamate and chlordiazepoxide￨efficacy and safety drug efficacy diurnal vigilance efficacy and safety side effects￨tetrabamate was found to be as efficient as chlordiazepoxide in reducing the intensity of the paws improving sleep and vital signs rapidly and alleviating anxiety progressively￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨60 inpatients suffering from alcohol withdrawal syndrome￨carbamazepine oxazepam benzodiazepines carbamazepine carbamazepine and oxazepam￨clinical institute withdrawal scalealcohol ciwaa white blood counts￨there was no decrease in white blood counts under carbamazepine￨no diff￨highunclear￨highunclear￨highunclear
68￨alcohol withdrawal syndrome 68 hospitalized patients￨carbamazepine carbamazepine and clomethiazole￨efficacy and tolerability alcohol withdrawal symptoms￨no significant differences between the two treatments could be demonstrated in the parameters studied￨no diff￨highunclear￨highunclear￨highunclear
16￨sixteen patients in moderate alcohol withdrawal￨divalproex sodium depakote benzodiazepines benzodiazepine standard benzodiazepine detoxification depakote detoxification or depakote detox plus maintenance divalproex sodium depakote anticonvulsant divalproex sodium depakote￨symptom reduction sociodemographic or drinking data safety and efficacy￨symptom reduction occurred more rapidly and consistently in the depakote treated patients than in the benzodiazepine control group and at sixweek follow up a greater percentage of patients in the depakote maintenance group were completely abstinent than either detoxonly group￨sig increase￨highunclear￨highunclear￨highunclear
37￨inpatients with alcohol withdrawal syndrome 37 inpatients with alcohol withdrawal￨cbz therapy carbamazepine cbz medical strategies chlormethiazole cmz vs carbamazepine cbz￨verbal memory performance initial impairments in some neuropsychological tests d2 zahlenverbundings test beck depression inventory anxiety sensitivity index￨patients in both groups showed initial impairments in some neuropsychological tests d2 zahlenverbundings test beck depression inventory anxiety sensitivity index with significant improvement during detoxification￨sig increase￨highunclear￨highunclear￨highunclear
not found￨a university medical center substance abuse clinic in charleston sc relatively healthy middleaged outpatients one hundred thirtysix patients in moderate alcohol withdrawal were randomized across 2 levels of detoxification histories 01 or or2 previous medicated detoxifications￨carbamazepine and lorazepam carbamazepine benzodiazepines carbamazepine benzodiazepine lorazepam and the anticonvulsant carbamazepine carbamazepine and lorazepam lorazepam lorazepam￨rebound withdrawal symptoms daily drinking drinking behaviors dizziness motor incoordination or ataxia pruritus but no rash hepatic or hematologic abnormalities symptoms of alcohol withdrawal risk of having a first drink alcohol withdrawal symptoms side effects￨lorazepamtreated patients had a significant rebound of alcohol withdrawal symptoms posttreatment p 007 and the risk of having a first drink was 3 times greater p 04 than for carbamazepinetreated patients￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨consecutive patients admitted to a hospital detoxification unit￨clonidine or chlormethiazole clonidine and chlormethiazole clonidine￨uneventful withdrawals symptomatic orthostatic hypotension standard alcohol withdrawal ratingscale￨all the patients receiving chlormethiazole had uneventful withdrawals￨no diff￨highunclear￨highunclear￨highunclear
34￨thirtyfour patients with severe delirium tremens severe delirium tremens combative patients with severe delirium tremens￨diazepam diazepam paraldehyde 10 ml rectally very 30 minutes or diazepam￨adverse reactions fever tachypnea and tachycardia￨diazepam given under this regimen is a safe and effective sedative for management of combative patients with severe delirium tremens￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients who had previous withdrawals patients with multiple previous alcohol withdrawals receiving￨gabapentin 4day fixeddose taper of gabapentin or lorazepam gabapentin and lorazepam lorazepam vs gabapentin lorazepam lorazepam￨selfreports of depression beck depression inventory sleep disturbances and sleepiness sleep disturbances and daytime sleepiness daytime sleepiness using the epworth sleepiness scale rebound symptoms￨patients with limited previous withdrawals reported similar treatment effects on selfreports of sleep and sleepiness for gabapentin and lorazepam￨no diff￨low￨low￨low
147￨emergency department of an innercity universityaffiliated teaching hospital one hundred fortyseven consecutive adults more than 25 years of age who presented with a witnessed generalized seizure in the setting of chronic alcohol abuse one hundred patients completed the study recurrent alcoholrelated seizures during a sixhour observation period january 1990 through december 1991￨phenytoin placebo phenytoin with normal saline placebo phenytoin or normal saline￨relative risk of recurrence recurrent alcoholrelated seizures recurrent alcoholrelated seizures￨the relative risk of recurrence between groups was 0868 with a 95 confidence interval of 0412 to 1826￨no diff￨low￨low￨low
11￨11 inpatients with uncomplicated alcohol withdrawal syndrome￨divalproex benzodiazepine lorazepam lorazepam divalproex￨demographics or substance use parameters￨there were no significant differences in demographics or substance use parameters between the divalproex group n  6 or the lorazepam group n  5￨no diff￨highunclear￨highunclear￨highunclear
37￨acute withdrawal from alcohol acute alcohol withdrawal￨gabaergic anticonvulsant sodium valproate divalproex sodium depakote and phenobarbital valproate valproate and phenobarbital sodium valproate￨hostilityaggression subjective and objective ratings of abstinence symptoms and subjective mood disturbance hostility scores￨subjective and objective ratings of abstinence symptoms and subjective mood disturbance decreased significantly in intensity in both groups over 5 days but there were no significant treatment differences nor treatment by time interactions￨sig increase￨highunclear￨highunclear￨highunclear
29￨29 patients during therapy of alcohol withdrawal￨oxcarbazepine versus carbamazepine benzodiazepines or clomethiazole carbamazepine oxcarbazepine oxcarbazepine versus carbamazepine￨craving for alcohol efficacy and tolerability cognitive processing speed withdrawal symptoms￨subjectively experienced side effects normalization of vegetative parameters and improvement in the cognitive processing speed did not reveal differences for both groups￨no diff￨highunclear￨highunclear￨highunclear
86￨86 alcoholic men with severe alcohol withdrawal who began a doubleblind controlled study comparing alcohol withdrawal￨carbamazepine benzodiazepine oxazepam 66 carbamazepine n  32 oxazepam￨global psychological distress￨in general the drugs were found to be equally efficacious in treating the withdrawal syndrome and not significantly different with respect to side effects￨no diff￨highunclear￨highunclear￨highunclear
60￨hospitalized patients with predelirium tremens sixty patients admitted to the study five dropped out for various reasons leaving fiftyfive patients who completed the study￨carbamazepine carbamazepine tiapride carbamazepine tegretol and of tiapride sereprile￨total symptoms score and visual analogue scale assessment delirium tremens￨both drugs were effective in the treatment of alcohol withdrawal symptoms no significant difference was found between the two treatments with respect to total symptoms score and visual analogue scale assessment￨no diff￨highunclear￨highunclear￨highunclear
not found￨twenty male alcoholics with alcohol withdrawal syndrome nine subjects given￨oral clonidine clonidine oral carbamazepine clonidine oral chlormethiazole￨sympathetic activity the reninaldosterone system and clinical symptoms plasma catecholamines blood pressure and pulse rate fell￨however plasma catecholamines blood pressure and pulse rate fell more rapidly and to a greater extent during clonidine than following chlormethiazole findings which could have therapeutic implications￨sig increase￨highunclear￨highunclear￨highunclear
20￨20 patients surgery of the carotid artery￨anaesthetized with 02 mgkg1 flunitrazepam bupivacaine vecuronium nitrous oxide and oxygen nifedipine carotid endarterectomy performed under either general anaesthesia ga or cervical epidural anaesthesia cea flunitrazepamfentanylnitrous oxide vs cervical epidural anesthesia flunitrazepam with or without nifedipine ephedrine￨systolic arterial blood pressure pasys blood pressure frequent episodes of peroperative hypertension arterial blood pressure per or postoperative hypotension blood pressure profiles postoperative hypotension per or postoperative hypertension mean arterial blood pressure￨patients in group cea experienced more frequent episodes of peroperative hypertension 82 p less than 002 and postoperative hypotension 51 than group gaabstract truncated at 250 words￨sig decrease￨highunclear￨highunclear￨highunclear
56￨carotid surgery fiftysix patients￨local versus general anaesthesia local la and general anaesthesia ga la￨systolic pressure perioperative neurological deficits blood pressures￨la for carotid endarterectomy is comparable with general anaesthesia regarding peroperative complications but produces significantly higher blood pressures than general anaesthesia￨sig increase￨highunclear￨highunclear￨highunclear
23￨13 patients undergoing regional anesthesia and 3 of the 10 patients undergoing general anesthesia required phenylephrine postoperatively 23 patients undergoing carotid endarterectomy under regional n  13 or general n  10 anesthesia￨phenylephrine￨mean arterial pressure mean arterial pressure pulmonary artery occlusion pressure systemic vascular resistance hemodynamic status systolic pressure intraoperative fluid requirements￨in the general anesthesia group systemic vascular resistance declined significantly below baseline p  005 following the operation accompanied by a decline in mean arterial pressure p  005 and a higher cardiac output￨sig decrease￨highunclear￨highunclear￨highunclear
3526￨participants were randomly assigned to surgery under general n1753 or local n1773 anaesthesia between june 1999 and october 2007 3526 patients with symptomatic or asymptomatic carotid stenosis from 95 centres in 24 countries￨general anaesthesia versus local anaesthesia for carotid surgery gala carotid endarterectomy￨proportion of patients with stroke including retinal infarction myocardial infarction or death quality of life length of hospital stay or the primary outcome in the prespecified subgroups of age contralateral carotid occlusion and baseline surgical risk￨the two groups did not significantly differ for quality of life length of hospital stay or the primary outcome in the prespecified subgroups of age contralateral carotid occlusion and baseline surgical risk￨no diff￨low￨low￨low
not found￨carotid endarterectomy under local anaesthesia￨la cea carotid clamping the mcavmean anaesthesia local anaesthesia la￨percentage reduction in mcavmean blood pressure cerebral blood flow clamp map complication rate combined deathstroke rates transcranial doppler tcd and mean arterial pressure map assessed by continuous intraarterial blood pressure transducer mean middle cerebral artery velocity mcavmean￨the postclamp mcavmean was significantly less in the ga group p  005 and the percentage reduction in mcavmean significantly more for ga procedures p  005￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨twenty postcea patients were interviewed￨carotid endarterectomy performed under local anaesthesia carotid endarterectomy cea under either general ga or local anaesthesia la la cea ga cea local anaesthetic intraoperative experience questionnaire laeq ceaeq￨overall experience and satisfaction with cea anxiety satisfaction or overall experience anxiety specific carotid endarterectomy experience questionnaire ceaeq￨there was no statistically significant difference in anxiety satisfaction or overall experience between anaesthetic techniques￨no diff￨highunclear￨highunclear￨highunclear
50￨￨carotid endarterectomy cea general and regional anesthesia cea￨fallow blood pressure systolic bps mean bpm diastolic bpd heart rate hr and rpp index blood pressure bps and bpm and rpp index￨the results of study shows significant changes of blood pressure bps and bpm and rpp index in t2 time in patinets undergoing ga￨sig increase￨highunclear￨highunclear￨highunclear
107￨fiftyfive patients were classified as ihd and 52 were classified as nihd carotid surgery highrisk patients undergoing carotid endarterectomy from november 1995 to february 1998 107 patients were classified by the cardiologist as cardiac patients ihd history of myocardial infarction previous myocardial revascularization procedures or myocardial ischemia documented by means of positive electrocardiogram ecg stress test results or noncardiac patients nihd no history of chest pain or negative results for an ecg stress test twentyseven of the 55 ihd patients 49 and 24 of 52 nihd patients 46 were operated on under ga￨locoregional versus general anesthesia local anesthesia la and general anesthesia ga la￨suffered myocardial ischemia rate of myocardial ischemia episodes of myocardial ischemia cardiac morbidity and mortality ischemic episodes prevalence of myocardial ischemia myocardial ischemia￨the small number of cardiac complications do not permit us to make any definitive conclusion on the impact of the two anesthetic techniques on early cardiac morbidity but the relationship between perioperative ischemic burden and major cardiac events suggests that la can be used safely even in highrisk patients undergoing carotid endarterectomy￨no diff￨highunclear￨highunclear￨highunclear
186￨patients undergoing carotid endarterectomy carotid surgery 186 patients with symptomatic internal carotid artery ica stenosis  70 or asymptomatic ica stenosis￨locoregional anesthesia locoregional la or general anesthesia ga anesthetic technique￨hypertensive events neurological complication rates cardiopulmonary complication rates number of postoperatively hypotensive episodes systolic blood pressure values perioperative neurological and cardiopulmonary complication rates strokerelated deaths systolic blood pressure values combined strokecardiopulmonary related death￨there were no differences in the number of postoperatively hypotensive episodes systolic blood pressure values  100 mmhg between the two groups￨no diff￨highunclear￨highunclear￨highunclear
84￨eightyfour patients were included methotrexate 26 patients 6mercaptopurine 32 patients placebo 26 patients patients with active cd who have received steroids andor immunosuppressives for at least 4 months during the preceding 12 months and with a current harveybradshaw index of  or  7 were studied patients with chronic active cd chronic steroiddependent cd chronic active crohns disease cd chronic active crohns disease￨placebo 6mercaptopurine and placebo methotrexate 5aminosalicylic acid parenteral methotrexate methotrexate 6mercaptopurine oral methotrexate￨abdominal pain proportion of patients entering first remission mean harveybradshaw index￨methotrexate at a weekly oral dose of 125 mg was found to be moderately better than 6mercaptopurine and placebo in patients with chronic active cd￨sig increase￨highunclear￨highunclear￨highunclear
not found￨all patients who achieved remission were included in a maintaining remission study for 76 weeks patients with inflammatory bowel disease ibd seventytwo steroiddependent ibd patients 34 with ulcerative colitis uc and 38 with crohns disease cd receiving treatment with￨prednisone 6mp mtx 6mercaptopurine or methotrexate 6mp or mtx 5aminosalicylic acid 5asa 6mercaptopurine 6mp and methotrexate mtx￨cd activity index side effects remission￨with regard to achieved remission a significantly higher p 005 rate existed for uc patients in group a 786 than in group c 25 with no statistical differences in group b 583 versus c for cd patients the rates were significantly higher p 0001 and 001 respectively in groups a 937 and b 80 versus c 14￨sig increase￨highunclear￨highunclear￨highunclear
not found￨crohns disease given intramuscularly once weekly patients with crohns disease who enter remission after treatment with patients with chronically active crohns disease who had entered remission after 16 to 24 weeks of treatment with 25 mg of patients with crohns disease often have relapses￨placebo methotrexate methotrexate with placebo￨severe adverse event prednisone for relapse remission nausea￨fewer patients in the methotrexate group than in the placebo group required prednisone for relapse 11 of 40 28 percent vs 21 of 36 58 percent p001￨sig decrease￨low￨low￨low
not found￨in 1995 a cohort of 3373 12yearolds was examined with regard to caries￨￨mean dmft￨analysis of baseline results showed that the social distribution of the study group is comparable to that of the background population as well as to the distribution in rural and urban areas￨sig increase￨highunclear￨highunclear￨highunclear
115￨children with cleft lip andor palate cleft children children with cleft lip andor palate onehundred and fifteen cleft children 59 boys and 56 girls between 22 and 26 months old￨dietary fluoride supplements tablet and liquid fluorides fluoride control tablet and liquid fluoride groups liquid fluoride￨dmf index dmft or dmfs numerical anticaries effect caries increment early childhood caries dmft increment￨the results showed that children in the tablet and liquid groups had a significantly lower dmft increment than in the control group p  005￨sig decrease￨highunclear￨highunclear￨highunclear
263￨manchester primary schoolchildren 263 children in the test schools and 266 in the control schools completed the trial primary schoolchildren in the district prior to water fluoridation being introduced twentytwo primary schools took part half being allocated at random to the public health programme while the other half remained untreated￨fluoride tablet programme￨size of a substantive scheme costs￨economies resulting from an increase in size of a substantive scheme were estimated producing a cost of 198 poundschild over a 3yr period for a tangible benefit of 323 pounds￨sig decrease￨highunclear￨highunclear￨highunclear
160￨one hundred and sixty healthy highcariesrisk children 10 to 12yearold children with high caries risk young adolescents with high caries risk￨xylitol and xylitolfluoridecontaining lozenges xylitol and xylitolfluoride lozenges xylitol or xylitolfluoridecontaining lozenges xylitol xylitolfluoride xylitol and a xylitolfluoride group￨approximal caries development caries incidence mean deltadmfsa value approximal caries incidence dropout rate￨no statistically significant differences in caries incidence could be found between the study groups p  005￨no diff￨highunclear￨highunclear￨highunclear
not found￨376 threeyear old children preschool children￨fluoride dentifrice fluoride dentifrice containing 0025 f acta plus fluoride varnish duraphat fluoride tablets fludent for daily sucking twice a day plus a placebo dentifrice free of fluoride low fluoride dentifrice placebo dentifrice plus fluoride varnish fluoride varnish￨caries increment￨no statistically significant difference in caries increment during the two experimental years was found between the groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨selfcare hemodialysis patients ex n  6 performed endstage renal disease esrd patients patients undergoing an exercise program￨con exercise program cycle ergometry exercise￨resting blood pressure qol scores pulse pressure dialysis efficacy blood pressure and quality of life dialysis efficacy overall increase in ktv duc work performance and perception of quality of life andor alterations in cardiovascular status sf36 questionnaire and wlmax duc serum urea clearance resting blood pressure serum urea clearance ktv and dialysate urea clearance duc￨the exercise program had no effect on qol scores and this was most likely due to the short duration of the exercise program and highfunctioning level of the population studied as compared to normative data for this patient population￨no diff￨highunclear￨highunclear￨highunclear
7￨diabetic patients with ckd m2 with persistent proteinuria obese diabetic patients with ckd patients with obesity diabetes and chronic kidney disease ckd patients with type 2 diabetes obesity body mass index bmi  30 kgm2 and stage 24 ckd estimated glomerular filtration rate egfr 1590 ml obese diabetic patients with chronic kidney disease￨exercise training exercise exercise underwent thrice weekly aerobic training aerobic exercise aerobic exercise plus optimal medical management to medical management alone￨renal functions cardiovascular fitness inflammation and oxidative stress exercise duration caloric intake and body weight and composition change in proteinuria resting systolic blood pressure and 24hour proteinuria gfr hemoglobin glycated hemoglobin serum lipids or creactive protein crp￨exercise did not alter gfr hemoglobin glycated hemoglobin serum lipids or creactive protein crp￨no diff￨highunclear￨highunclear￨highunclear
not found￨hd patients chronic hemodialysis hd patients twelve patients control group lived without chronic hemodialysis patients￨oues physical training oxygen uptake efficiency slope oues combination training of bicycle ergometry walking and jogging for 30 min duration￨oxygen uptake efficiency slope minute ventilation ve carbon dioxide output vco2 and oxygen uptake vo2 exercising heart rate￨in the trained group changes in oues correlated with those in the maximum oxygen uptake r  078 p  0001 and the anaerobic threshold r  061 p  001￨sig increase￨highunclear￨highunclear￨highunclear
58￨fiftyeight volunteer patients were screened for lowrisk status and selected from the dialysis population fifteen sex and agematched sedentary individuals group e  mean age 46964 years comprised a healthy control group for baseline data group a  mean age 464139 years completed a 6month patients with endstage renal disease on hemodialysis 48 patients who completed the study protocol￨exercise training exercise training intense exercise training treadmill exercise test supervised outpatient exercise renal rehabilitation program consisting of three weekly sessions of aerobic and strengthening training on the nondialysis days unsupervised moderate exercise program 6month exercise program during hd exercise training programs￨functional capacity level of anemia the medications and the hd prescription dropout rate peak oxygen consumption vo2 peak exercise time aerobic capacity anaerobic threshold vo2at￨peak oxygen consumption vo2 peak increased by 43 p  005 anaerobic threshold vo2at by 37 p  005 and exercise time by 33 p  005 after training in group a by 24 p  005 18 p  005 and 22 p  005 respectively in b and by 17 p  005 8 p  005 and 14 p  005 respectively in c while both remained almost unchanged in group d￨sig increase￨highunclear￨highunclear￨highunclear
not found￨sixteen of them group amean age 464139 years without clinical features of heart failure participated in a 6month supervised exercise renal rehabilitation program consisting of three weekly sessions of aerobic training 10 group b mean age 514125 years followed a moderate exercise program at home and the other 12 group cmean age 50279 years fifteen sex and agematched sedentary individuals group dmean age 46964 years were the healthy controls 38 endstage renal disease patients on maintenance hd renal patients on hemodialysis hd hemodialysis patients￨exercise training exercise rehabilitation exercise training intense exercise training physical examination laboratory tests treadmill exercise testing mmode and 2d echocardiograms performed at rest and at peak of supine bicycle exercise exercise rehabilitation program￨lv systolic function lvm level of anemia and the hd prescription maximal oxygen consumption ef left ventricular volumes edv esv and mass lvm cardiovascular complications and suffer from impaired exercise capacity exercise time lvidd resting ef svi c supine bicycle exercise ejection fraction ef stroke volume index svi and cardiac output index coi￨the maximal oxygen consumption increased by 43 p0001 and the exercise time by 33 p0001 after training in group a by 17 p0001 and 14 p001 respectively in b and both remained unchanged in group c training in group a was also associated with an increase in lvidd from 52164 to 54061 mm p0001 and lvm 22667 to 24084 g p005 at rest with no change noted in groups b and c following a 6month exercise training in group￨sig increase￨highunclear￨highunclear￨highunclear
70￨hemodialysis patients hemodialysis patients 70 hemodialysis patients from 3 renal units￨intradialyticexercise patients trained 3 timeswk for 6 months on a cycle ergometer and homebasedexercise patients followed a walking program usualcare patients received no specific intervention supervised intradialytic exercise training versus homebased exercise training or usual care intradialytic versus homebased aerobic exercise training exercise interventions￨physical function and greater risk of increased arterial stiffness because of hypertension metabolic disturbances and vascular calcification vascular risk profile 6minute walk test distance intradialytic exercise 14 homebased exercise 11 usual care 5 pulse wave velocity intradialytic exercise 4 homebased exercise physical function and vascular parameters distance traveled during a 6minute walk test and aortic pulse wave velocity augmentation index augmentation pressure as a percentage of central pulse pressure peripheral brachial and central blood pressures measured noninvasively using radial tonometry physical activity and selfreported physical functioning physical function and arterial stiffness￨there were no differences between intradialytic or homebased exercise training and usual care for either physical function or vascular parameters￨no diff￨highunclear￨highunclear￨highunclear
not found￨individuals with endstage renal disease on patients with a greater degree of physical dysfunction needs to be rigorously studied hemodialysis patients administered patients receiving hemodialysis and epo￨placebo hemodialysis therapy nonprogressive program of rangeofmotion exercises progressive resisted isotonic quadriceps and hamstrings exercise and training on a cycle ergometer three times weekly for 12 weeks erythropoietin exercise intervention aerobic and muscle strength training￨symptoms or healthrelated quality of life 6minute walk symptoms questionnaire or sf36 muscle strength physical function subscale physical impairment measures submaximal exercise test aerobic exercise capacity and reduced muscle strength submaximal exercise test muscle strength and 6minute walk test at baseline￨in this highfunctioning sample the exercise program improved physical impairment measures but had no effect on symptoms or healthrelated quality of life￨no diff￨low￨low￨low
20￨twenty patients were selected at random for a 6month hemodialysis hd patients thirtyone uremic patients aged 506116 years on maintenance hd were studied￨exercise renal rehabilitation program exercise renal rehabilitation program errp consisting of 3 weekly sessions of exercise training errp exercise training￨included affective beck depression inventory bdi quality of life quality of life index qli and personality eysenck personality questionnaire epq parameters bdi score value qli selfreport of depression level of depression quality of life physical capacity vo2max bdi depression and changes in vo2max￨after training significant improvement occurred in physical capacity vo2max increased from 16862 to 23276 mlkgmin p  005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨hemodialysis patients some hemodialysis patients￨exercise training program aerobic exercise training program exercise training structured exercise training program￨dysphoric mood maximal aerobic capacity vo2max pleasant activities performance of pleasant activities￨support group participants reported a significant decrease in pleasant activities while there was no change in the exercisers￨sig decrease￨highunclear￨highunclear￨highunclear
60￨30 patients group a dialysis patients hemodialysis patients patients on hemodialysis 30 patients group b and 30 nonuremic sedentary persons group c remained untrained and were used as controls sixty chronic uremic patients mean age 48￨physical training 6month exercise training program exercise training￨vulnerability to arrhythmias fitness level hrv index 24hour vagal cardiac activity maximal oxygen consumption heart rate variability hrv heart rate variability incidence of arrhythmias hrv index and maximal oxygen consumption depressed hrv index arrhythmias cardiac vagal activity at baseline hrv index mean rr sdnn and aerobic capacity hrv index mean nn interval and standard deviation nn sdnn exercise testing duration parasympathetic activity￨at baseline hrv index mean rr sdnn and aerobic capacity were significantly reduced in both hemodialysis groups compared with values in group c also 40 of all patients on hemodialysis and 16 of group c had arrhythmias lown class ii￨sig increase￨highunclear￨highunclear￨highunclear
27￨176 years were recruited from two hemodialysis clinics in valencia spain 27 patients 556￨resistance exercise lowintensity aerobic training resistance training￨exercise capacity muscle strength physical functioning and healthrelated quality of life changeovertime physical function and quality of life changeovertime in right knee extensor muscles dynamometry patients physical functioning physical performance tests evaluated by the sittostandtosit tests and the 6 minutes walking test and knee extensor muscles strength evaluated by isometric dynamometry cardiorespiratory fitness measured by time and mets measure of energy expenditure as ml of oxygen per kg of weight and per minute 1 met is equal to 35 ml o2kgmin achieved on a graded exercise test and quality of life measured by the sf36 questionnaire￨no differences were noted in changeovertime between the two groups in any of the physical performance tests￨no diff￨highunclear￨highunclear￨highunclear
35￨haemodialysis patients thirtyfive patients on haemodialysis with a mean sd age of 488 139 years volunteered to participate in the study￨erythropoietin intradialytic exercise training programme or to control group intradialytic exercise training￨quality of life index mental component scale eysenck personality questionnaire selfreported depression beck depression index included affective beck depression inventory healthrelated quality of life quality of life index living questionnaire of minnesota life satisfaction index and short form36 questionnaire and personality eysenck personality questionnaire parameters physical functioning and psychological status physical component scale of the sf36 exercise time patients quality of life quality of life life satisfaction index healthrelated quality of life indices￨multiple regression analysis indicated that the improvement in quality of life depended on the participation in exercise programmes the effects of training and the reduction in the level of depression￨sig increase￨highunclear￨highunclear￨highunclear
96￨ninetysix haemodialysis patients of the groningen dialysis center sedentary haemodialysis patients in the netherlands￨exercise group lowtomoderate intensity preconditioning exercise programme linked with exercise counselling exercise counselling￨behavioural change physical fitness physiological conditions and healthrelated quality of life weight blood pressure haemoglobin and haematocrit values cholesterol and ktv behavioural change physical fitness physiological condition and healthrelated quality of life behavioural change and physical fitness components such as reaction time manual dexterity lower extremity muscle strength and vo2 peak behavioural change reaction time lower extremity muscle strength ktv and three components of quality of life rand36 scores symptoms and depression￨participating in a lowtomoderate intensity preconditioning exercise programme showed beneficial effects on behavioural change physical fitness physiological conditions and healthrelated quality of life￨sig increase￨highunclear￨highunclear￨highunclear
not found￨endstage renal disease patients patients with esrd patients with endstage renal disease esrd dialysis patients were randomly allocated to an exercise et n  18 age  573 years or control c n  15 age  505  5 years group￨exercise training exercise rehabilitation vo2vt et 107 exercise training programme incremental exercise test￨functional capacity sts60 measurements aerobic and functional capacity vo2 kinetics vo2 peak and vo2 at ventilatory threshold vt vslope peak exercise capacity aerobic and fuctional capacity vo2 peak et￨vo2 kinetics remained unchanged in both groups at 90 vt but a trend p  0059 towards faster kinetics at the 33 w was observed et 496￨no diff￨highunclear￨highunclear￨highunclear
96￨transplant recipients persons at high risk for developing coronary heart disease chd renal transplant recipients ninetysix transplant recipients￨exercise training exercise training alone exercise training ex group n  51 and usual care groups uc multiple risk interventions￨total cholesterol tc level highdensity lipoprotein fraction of cholesterol hdlc and body mass index over time coronary heart disease risk factors hdl cholesterol levels maximal exercise testing and evaluation of chd risk factors and riskfactor categories cardiovascular risk profile chd risk and maximal exercise capacity overall 10year chd risk score chd risk￨no differences were observed between groups except for a trend toward greater improvement in hdl cholesterol levels in the ex group p  007￨sig increase￨highunclear￨highunclear￨highunclear
19￨hemodialysis patients patients with cv disease and eskd 19 hemodialysis hd patients￨no intradialytic exercise initially and exercised regular exercise regular exercise intradialytic exercise￨arterial compliance mean bnp levels cv risk surrogate markers of cv riskarterial compliance and bnp levels arterial compliance and btype natriuretic peptide levels cardiovascular cv disease favor of exercise pwv mean pwv quality of life and physical strength￨there was an overall improvement in pwv and to a lesser extent bnp levels with 3 months of intradialytic exercise compared with no exercise suggesting that regular exercise in eskd may be associated with improvements in arterial compliance and a reduction in cv risk￨sig increase￨highunclear￨highunclear￨highunclear
33￨hemodialysis patients hd patients 20 patients completed the intervention 33 hd patients were included in the study￨hemodialysis hd physical exercise physical exercise exercise￨medical complications aerobic capacity physical function and selfrated health aerobic capacity squat test and physical function and physical component scale sf36 aerobic capacity 2min stair climbing squat test selfrated health sf36 blood pressure and lipids blood pressure and lipids attendance physical function and aerobic capacity￨the eg had a significant increase in aerobic capacity squat test and physical function and physical component scale sf36￨sig increase￨highunclear￨highunclear￨highunclear
30￨thirty patients with a median glomerular filtration rate gfr of 25 mlmin173 m2 range 1043￨exercise training exercise training regular exercise training physical exercise physical training 30 min of bicycling daily or an equal amount of other physical activities or to maintenance of the usual lifestyle￨chronic renal failure progression of renal disease median maximal work capacity￨the median maximal work capacity increased significantly in the exercise group and remained unchanged in the control group during a median observation time of 20 months whereas the rate of progression judged by the slope of gfr versus time plot was equal in the two groups￨sig increase￨highunclear￨highunclear￨highunclear
55￨stable hemodialysis patients sawada study hemodialysis hd patients fiftyfive hd patients￨exercise training predialytic endurance training￨quality of life qol nutritional status and quality of life serum albumin levels and cgr serum albumin levels creatinine generation rate cgr qol scores￨the serum albumin levels and cgr increased in the training group compared with baseline￨sig increase￨highunclear￨highunclear￨highunclear
not found￨13 years receiving longterm haemodialysis 37 sd age 69 dialysis patients maintenance dialysis patients adult haemodialysis patients people with chronic kidney disease and in dialysis patients fifty participants mean￨moderate to highintensity strength training intradialytic lowintensity strength training intradialytic lowintensity progressive strength training strength training lowintensity strength training intradialytic lowintensity strength training or stretching attentioncontrol exercises twice weekly for a total of 48 exercise sessions￨baseline median iqr sppb score exercise adherence adverse events physical performance assessed by the short physical performance battery score sppb functional capacity lower body strength body composition and quality of life sppb physical performance nutritional status and quality of life knee extensor strength leisuretime physical activity and selfreported physical function and activities of daily living adl disability￨moderate to highintensity strength training improves physical performance nutritional status and quality of life in people with chronic kidney disease and in dialysis patients￨sig increase￨highunclear￨highunclear￨highunclear
26￨patients who performed resistance training by a mean sd of 4 patients with chronic renal insufficiency patients with renal failure tufts university boston massachusetts patients with chronic renal insufficiency treated with a lowprotein diet 26 older patients with moderate renal insufficiency 17 men 9 women who had achieved stabilization on a lowprotein diet￨resistance training lowprotein diet plus resistance training n  14 or a lowprotein diet alone resistance training￨mean protein intake protein utilization and muscle mass muscle strength leucine oxidation and serum prealbumin levels total body potassium and type total body potassium midthigh muscle area type i and ii musclefiber crosssectional area and protein turnover￨improvement in muscle strength was significantly greater with resistance training 32￨sig increase￨highunclear￨highunclear￨highunclear
20￨people with chronic renal failure 20 people with chronic renal failure￨exercise coaching￨heart rate change and perceived exertion exertion changes￨distance walked was highly correlated on the three tests heart rate change and perceived exertion were only slightly less consistent￨no diff￨highunclear￨highunclear￨highunclear
11￨patients with endstage renal disease esrd exercising during dialysis versus not exercising eleven patients who met the criteria patients with esrd undergoing hemodialysis hd 11 patients with esrd over a study period of 12 weeks exercising versus nonexercising individuals with endstage renal disease three times weekly who met the following criteria were selected aged 25 to 65 years nondiabetic no current physical activity blood pressure of 16095 mm hg or less at the second hour of hd no unstable angina pectoris ne patients remained sedentary throughout the study￨exercise e and six patients without exercise ne￨adequacy of dialysis ktv and initial levels of each serum protein maximal heart rate hr kilocalorie and protein intakes visceral protein status and caloric intake prealbumin levels exercise serum levels of prealbumin transferrin and predialysis and postdialysis albumin mean intakes prealbumin and postalbumin concentrations mean protein intake visceral proteins feelings of improved health better exercise tolerance and improved appetite and viewed exercise as enjoyable transferrin levels￨transferrin levels were within normal ranges but differed p 05 by group e or ne and time periods￨no diff￨highunclear￨highunclear￨highunclear
65￨hemodialysis patients sixtyfive patients 48 patients who met the criteria for hematocrit and exercise adherence and completed both baseline and post intervention 56￨exercise training treadmill exercise testing rhurecombinant erythropoietin and exercise training usual hematocrit 3033 with no exercise training uh usual hematocrit 3033 plus exercise training uhx normalized hematocrit 4042 with no exercise training nh and normalized hematocrit 4042 plus exercise training nhx￨general health scale exercise capacity and selfreported physical functioning peak oxygen uptake measurements peak oxygen uptake exercise capacity and healthrelated quality of life￨significant effects of exercise were found in peak oxygen uptake measurements p  003 and in selfreported physical functioning as measured by the short form36 questionnaire p  001￨sig increase￨highunclear￨highunclear￨highunclear
167￨transplant recipients one hundred sixtyseven patients￨exercise training exercise training exercise after renal transplantation rtx exercise intervention consisted of individually prescribed programs to be conducted at home with regular phone followup to enhance adherence exercise intervention ex and usual care uc￨body composition sf36 health status questionnaire assessed selfreported functioning peak vo2 physical functioning muscle strength percent fat muscle strength hematocrit and selfreported physical functioning peak oxygen uptake peak vo2 isokinetic muscle testing for muscle strength and dualenergy xray absorptiometry scans for body composition￨compared with the uc group the ex group had significantly greater gains in peak vo2 p0016 percent agepredicted vo2 p003 and muscle strength p005 and a trend toward higher selfreported physical functioning p006￨sig increase￨highunclear￨highunclear￨highunclear
not found￨hemodialysis patients patients with endstage renal disease outpatient hemodialysis unit of the nephrology department uludag university faculty of medicine clinically stable hemodialysis patients n37￨modified yogabased exercise group simplified yogabased rehabilitation program modified yogabased exercise program yogabased exercise program active range of motion exercises￨sleep disturbance 25 grip strength variables pain 37 pain intensity measured by the visual analogue scale vas fatigue vas sleep disturbance vas and grip strength mmhg biochemical variables urea creatinine calcium alkaline phosphatase phosphorus cholesterol hdlcholesterol triglyceride erythrocyte hematocritwere evaluated pain fatigue sleep disturbance and biochemical markers calcium phosphorus hdlcholesterol and triglyceride levels fatigue 55￨improvement of the variables in the yogabased exercise program was found to be superior to that in the control group for all the variables except calcium phosphorus hdlcholesterol and triglyceride levels￨sig increase￨highunclear￨highunclear￨highunclear
20￨20 hemodialysis patients skeletal muscle of dialysis patients hemodialysis patients treated with rhuepotreated hemodialysis patients hemodialysis patients￨exercise training program exercise training rhuepo recombinant human erythropoietin and exercise training recombinant human erythropoietin rhuepo and exercise training￨exercise capacity aerobic exercise capacity maximum lactate values capacity vo2at hemoglobin hb values maximum o2 uptake vo2max vo2 at anaerobic threshold maximum workloads vo2max and vo2at￨exercise training in rhuepotreated hemodialysis patients resulted in an improved aerobic exercise capacity whereas those without exercise training did not have increased capacity￨sig increase￨highunclear￨highunclear￨highunclear
not found￨predialysis and dialysis patients￨exercise coaching and rehabilitation counseling￨sickness impact profile scores hematocrit selfrated karnofsky index of disability physicianrated affect or physicianrated karnofsky index of disability quality of life c symptom scores￨sickness impact profile scores were better in pr than pc at 6 months p  005 and 12 months ns￨sig increase￨highunclear￨highunclear￨highunclear
not found￨hemodialysis patients￨exercise training aerobic physical training endurance exercise training exercise training￨degree of anemia diet or body weight mood level of depression and psychosocial functioning participation in pleasant socially oriented activities lipid and glucose metabolism hematologic function blood pressure and work capacity lipid profile normalized insulin sensitivity and glucose metabolism physical work capacity work capacity greater strength and energy￨exercise training was associated with an improvement in the mood level of depression and psychosocial functioning of these patients the sedentary controls either became more depressed or reduced their participation in pleasant socially oriented activities￨sig increase￨highunclear￨highunclear￨highunclear
not found￨121 15yearold children￨fluoridecontaining varnish duraphat fluoride varnish￨mean caries increment￨the caries prophylactic effect on different tooth surfaces was statistically significant both on proximal and on occlusal surfaces at the 01 level￨sig increase￨highunclear￨highunclear￨highunclear
400￨400 schoolchildren aged 1214 years 400 children￨bifluorid 12 voco gmbh containing 6 sodium fluoride and 6 calcium fluoride and laweflourschüttellack law containing 5 sodium fluoride placebo fluoride varnishes placebo varnish￨cariostatic effect cariesprotective efficacy inhibition of caries increment percentage caries reduction￨after two years there was a significant inhibition of caries increment in all test groups compared to placebo group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨2 years in 225 3yearold children 113 children served as a control group preschool children￨fluoride varnish duraphat￨caries reduction cariesfree still cariesfree average caries increment of 21 surfaces￨thirtyeight percent of the children in the test group and 27 in the control group were still cariesfree￨no diff￨highunclear￨highunclear￨highunclear
381￨children aged 5 years and 9 months newly erupted first permanent molars￨fluoride varnish duraphat￨cariespreventive effect caries reduction￨caries reduction amounted to 56 and the cariespreventive effect was found in molars with shallow and deep fissures￨sig increase￨highunclear￨highunclear￨highunclear
116￨dental caries in fissured and nonfissured surfaces of permanent first molars three groups of 6 to 8yearold schoolchildren caries reduction on different permanent first molar surfaces￨sealant and fluoride varnish sealant and fluoride varnish fluoride varnish￨absolute and percent caries reductions￨compared to the controls sealants resulted in a 68 percent and 87 percent reduction on fissured and nonfissured surfaces respectively￨sig decrease￨highunclear￨highunclear￨highunclear
187￨children of those parents who did not want to participate in the sugar groups 187 children 61 were considered to have completed the study one hundred and eightyseven 4yearsolds preschool children￨buy beverages biscuits breakfast cereals marmalade ice cream jam ketchup sweets and table sugar totally 32 different food items sweetened with invert sugar or sucrose invert sugar for sucrose in combination with fluoride varnish duraphat sucrose s 2 sucroseduraphat sd 3 invert sugar i and 4 invert sugarduraphat id partial substitution of invert sugar for sucrose in combination with duraphat treatment￨caries development mean caries increment mean caries increment including initial lesions￨the mean caries increment including initial lesions was 386 dmfs in the combined groups s and sd n  63 and 310 dmfs in the combined groups i and id n  51 during the 2 years p  034￨sig increase￨highunclear￨highunclear￨highunclear
107￨87 teenagers and compared to a control group n  107 proximal caries progression in teenagers￨fluoride varnish fluoride varnish duraphat sodium fluoride varnish duraphat applications￨proximal caries progression progression of proximal caries lesions caries progression￨the study showed that topical application of fluoride varnish every third month significantly p less than 005 reduced the progression of proximal caries lesions in premolars and molars￨sig decrease￨highunclear￨highunclear￨highunclear
2￨setting university hospital dijon and university hospital nancy patients after idiopathic macular hole surgery one hundred and fortyfour patients 150 eyes idiopathic macular hole mh surgery￨keep the seated p0 group and the facedown position p1 group after the idiopathic mh surgery intervention complete vitrectomy with a fluidair exchange and an intraocular gas tamponade facedown and seated position￨overall anatomic success rate mean va corrected visual acuity va fundus examination and macular optical coherence tomography￨the idiopathic mh sealed in 63 of 72 p0 eyes 875 and 76 of 78 p1 eyes 974 p  027￨no diff￨highunclear￨highunclear￨highunclear
not found￨2011 american academy of ophthalmology sixtynine patients from 6 specialized vitreoretinal units￨pars plana vitrectomy peeling of any epiretinal membrane alleviated positioning after small macular hole surgery strict facedown positioning for 22 of 24 hours or simply to avoid the supine position for 10 days￨closure rates etdrs scores mean gain in visual acuity rate of anatomic closure 3 months after surgery progression of cataract and the rate of other complications mean size of macular holes early treatment diabetic retinopathy study etdrs visual acuity progression of cataract and frequency of complications￨the success rate of surgery for idiopathic macular holes of 400 μm or smaller is not significantly reduced if facedown positioning is replaced by simply taking care to avoid the supine position￨no diff￨low￨low￨low
45￨young patients 45 pediatric cancer patients age 616 years pediatric procedurerelated pain￨analgesic cream eutectic mixture of local anesthetics or emla local anesthetic with selfhypnosis local anesthetic local anesthetic local anesthetic plus hypnosis and local anesthetic plus attention emla with hypnosis￨anticipatory anxiety and less procedurerelated pain and anxiety level of hypnotizability behavioral distress￨results confirmed that patients in the local anesthetic plus hypnosis group reported less anticipatory anxiety and less procedurerelated pain and anxiety and that they were rated as demonstrating less behavioral distress during the procedure￨sig decrease￨highunclear￨highunclear￨highunclear
80￨pediatric oncology patients for lumbar puncture 80 pediatric cancer patients 616 years of age undergoing regular lumbar punctures pediatric oncology patients￨direct hypnosis with standard medical treatment indirect hypnosis with standard medical treatment attention control with standard medical treatment and standard medical treatment alone manualbased clinical hypnosis intervention hypnosis￨level of hypnotizability pain and anxiety behavioral distress￨patients in the hypnosis groups reported less pain and anxiety and were rated as demonstrating less behavioral distress than those in the control groups￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨4 to 7yearold children preschool children receiving diphtheria pertussis and tetanus immunization one hundred fortynine￨active distraction technique￨pain pain and distress nurse or parent visual analog scale scores pain behaviors￨children who were taught to blow out air during their shots had significantly fewer pain behaviors p  04 and demonstrated a trend toward lower subjectively reported pain p  06￨sig decrease￨highunclear￨highunclear￨highunclear
30￨adolescents undergoing painful procedures adolescents with cancer undergoing lumbar punctures lps adolescents with cancer 30 adolescents with cancer 17 in the vr and 13 in the control group undergoing frequent lps￨standard intervention virtual reality vr glasses distraction using virtual reality glasses￨pain using a visual analog scale vas pain subjective evaluation of experience vas scores vas pain scores￨although vas pain scores were not statistically different between the two groups p  077 vas scores tended to be lower in the vr group median vas of 70 range 048 than in the control group median vas of 90 range 059￨no diff￨highunclear￨highunclear￨highunclear
44￨fortyfour preschool children with chronic nonlifethreatening conditions were having intravenous catheters ivs placed for medical tests parentchild dyads parents prior to their preschool childrens medical procedures￨distraction education prior to iv insertion the control group received standard care distraction education intervention￨child behavioral distress or selfreport of pain distraction behavioral distress￨experimental group parents used significantly more distraction than did control group parents during both phases p  0001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨43 patients 20 experimental and 23 comparison who were 4 to 11 years old pediatric patients undergoing venipuncture￨venipuncture parental positioning and distraction￨selfreported pain and fear pain and fear parents and child life specialists cls rated the childs fear and cls rated the childs distress pain fear and distress distress childrens pain fear and distress￨selfreported pain and fear were highly correlated p  001 but not significantly different between the two groups￨no diff￨highunclear￨highunclear￨highunclear
50￨childrens distress during repeated aversive medical procedures fifty children diagnosed with leukemia 25 treatment 25 attention control aged 318 childrens distress during aversive medical procedures￨￨procedural distress anticipatory physiological and selfreport ratings relative￨the present study sought to reduce childrens distress during aversive medical procedures using a brief costeffective intervention aimed at reframing memory￨sig decrease￨highunclear￨highunclear￨highunclear
92￨ninetytwo children 46 years of age and their parents￨nurse coach intervention a nurse coach plus train parent and child intervention or a standard medical care condition children viewing a popular cartoon movie and being coached by nurses and parents to attend to the movie nurse coaching and cartoon distraction￨practical and costeffective childrens coping distress pain and need for restraint nurses and parents coaching behavior and parents and nurses distress￨results indicate that in the two intervention conditions children coped more and were less distressed nurses and parents exhibited more coping promoting behavior and less distress promoting behavior and parents and nurses were less distressed than in the control condition￨sig decrease￨highunclear￨highunclear￨highunclear
39￨pediatric pain management during immunizations participants were 39 4th graders receiving a 3injection vaccination series over a 6month period￨emla anesthetic eutectic mixture of local anesthetics emla distraction versus topical anesthesia￨satisfaction ratings low distress despite reporting moderate anxiety and pain nurse coaching and child coping and less child distress child coping or decreased distress heart rate￨distraction resulted in more nurse coaching and child coping and less child distress than did emla or typical care on an observational measure￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨childrens reactions to injections 42 childmother dyads were recruited from a general pediatric primary care clinic￨parental reassurance parental nonprocedural talk distraction or minimaltreatment control group maternal distraction versus reassurance￨distress crying child distress behavioral distress￨children in the maternal distraction condition exhibited significantly less distress during the immunization injection than those in the reassurance and control conditions￨sig decrease￨highunclear￨highunclear￨highunclear
100￨with children during an acute pain experience 100 children ages 3 years 6 months through 12 years 11 months scheduled for routine blood draws acute pain experience￨distraction distraction technique standard preparation which consisted of being comforted by physical touch and soft voices while experimental subjects were encouraged to use a kaleidoscope as a distraction technique￨pain pain and behavioral distress behavioral distress￨univariate post hoc tests confirmed that the experimental group perceived less pain and demonstrated less behavioral distress than the control group￨sig decrease￨highunclear￨highunclear￨highunclear
200￨two hundred children aged 4565 years receiving routine immunization injections children pain in children￨music distraction distraction distraction with suggestion suggestion and control 2 cognitive strategies suggestion and music distraction￨pain pain relief injection pain pain using a 4point pain scale￨distraction was found to significantly decrease pain whereas suggestion did not￨no diff￨highunclear￨highunclear￨highunclear
117￨children and the impact of agerelated factors on pain selfreport a convenience sample of 117 children scheduled for venipuncture children￨placebo cream with no indication as to the creams purpose and c no cream control group placebo placebo cream￨selfreport ratings of pain needle pain severity faces pain scale and rated their anxiety about the procedure using the childrens anxiety and pain scale pain pain severity scores ratings of painrelated behaviour preprocedural anxiety ratings￨while venipuncture was associated with only mild levels of pain younger children irrespective of treatment group did report more pain than older children￨no diff￨highunclear￨highunclear￨highunclear
not found￨untrained parents or nurses 31 3 to 7yearold children trained in coping skills to 30 who did not receive training￨￨procedural coping and distress behavior￨we compared the procedural coping and distress behavior of 31 3 to 7yearold children trained in coping skills to 30 who did not receive training￨sig increase￨highunclear￨highunclear￨highunclear
30￨30 pediatric cancer patients age 5 to 15 years undergoing bone marrow aspirations pediatric oncology patients for bone marrow aspiration pediatric cancer patients undergoing bone marrow aspirations￨clinical hypnosis versus cognitive behavioral cb coping skills training hypnosis and cb coping skills clinical hypnosis versus cognitive behavioral training hypnosis or cb hypnosis a package of cb coping skills and no intervention￨behavioral distress pain and distress anxiety pain and painrelated anxiety relief of pain pain and anxiety￨results also indicated that children reported more anxiety and exhibited more behavioral distress in the cb group than in the hypnosis group￨sig decrease￨highunclear￨highunclear￨highunclear
100￨100 children aged 612 years attending kuwait government hospital laboratories for venous blood sampling was studied￨￨pain and radial pulse rates￨prepared children reported significantly less pain and radial pulse rates confirmed that they were less distressed by the procedure￨sig decrease￨highunclear￨highunclear￨highunclear
54￨fiftyfour inpatients with chronic schizophrenia schizophrenia￨continuous performance test cpt attention training control group participated in individual sessions during which they viewed video documentaries￨total score brief psychiatric rating scale assessments￨brief psychiatric rating scale assessments before and after the study phase indicated that both groups improved on the total score but the experimental group made significantly more improvement￨sig increase￨highunclear￨highunclear￨highunclear
not found￨twentyfour inpatient schizophrenics and 24 intellectually and demographically matched inpatient mooddisordered controls schizophrenia￨cued condition received instructional cues￨￨schizophrenia is often characterized by compromised neuropsychological functioning especially on tasks sensitive to frontal and temporohippocampal functions but the extent to which cognitive dysfunction can be modified in schizophrenics remains unclear￨sig increase￨highunclear￨highunclear￨highunclear
1194￨pregnant and nonpregnant women 1194 nulliparous women who were in the 20th week of gestation at the beginning of the study hypertensive disorders of pregnancy pregnant women who receive￨calcium supplementation placebo calcium supplementation elemental calcium in the form of calcium carbonate 593 women or placebo￨rates of hypertensive disorders of pregnancy risk of both gestational hypertension and preeclampsia blood pressure low ratios of urinary calcium to urinary creatinine diastolic and systolic blood pressure hypertensive disorders of pregnancy urinary excretion of calcium and creatinine hypertensive disorders of pregnancy gestational hypertension and preeclampsia￨the rates of hypertensive disorders of pregnancy were lower in the calcium group than in the placebo group 98 percent vs 148 percent odds ratio 063 95 percent confidence interval 044 to 090￨sig decrease￨low￨low￨highunclear
not found￨all participants were 17 years of age or less and clinically healthy￨calcium supplementation 20 gm of elemental calcium as calcium carbonate calcium supplementation placebo￨urinary tract infection and chlamydial infection low birth weight dietary calcium intake spontaneous labor and preterm delivery incidence of preterm delivery mean duration of calcium supplementation￨the calcium group had a lower incidence of preterm delivery less than 37 weeks 74 vs 211 p  0007 spontaneous labor and preterm delivery 64 vs 179 p  001 and low birth weight 96 vs 211 p  003￨no diff￨low￨low￨low
201￨nulliparous women 201 healthy nulliparous women￨calcium supplementation placebo calcium supplementation oral elemental calcium￨rate of pregnancy induced hypertension incidence of gestational hypertension incidence of preeclampsia incidence of pregnancy induced hypertension￨the rate of pregnancy induced hypertension was lower in the calcium group than in the placebo group 824 vs 2903 rr  028 95 ci 014059￨sig decrease￨low￨low￨low
260￨selection criteria were age less than 175 years nulliparity first prenatal visit before 20 weeks gestation and residency in quito 2800m altitude two hundred sixty teenaged pregnant girls attending the hospital gínecoobstétrico isidro ayora in quito ecuador were included 125 girls to receive 2000 mg of pregnant teenagers ecuadorian pregnant teenagers￨calcium supplementation placebo calcium supplementation elemental calcium￨risk of preeclampsia systolic bp preeclampsia diagnosis of preeclampsia average daily calcium intake blood pressure bp￨calcium supplementation was associated with a significantly decreased risk of preeclampsia risk reduction 1235 p  001 with 32 n  4 developing preeclampsia in the treatment group versus 155 n  21 in the placebo group￨sig decrease￨low￨low￨low
87￨undernourished mothers during pregnancy on the bone density of the bone density of the neonates eighty seven pregnant women belonging to poor socioeconomic groups of population￨calcium supplementation elemental calcium￨bone density of the neonate bone density￨bone density of the neonate was not related to the birth weight crownheel or crownrump lengths￨no diff￨highunclear￨highunclear￨highunclear
281￨pregnancyinduced hypertension gestational hypertension or preeclampsia in angiotensinsensitive nulliparas sixtythree of 67 angiotensinsensitive nulliparas were evaluable 29 received 281 nulliparous women who had positive rollover tests angiotensin iisensitive patients￨calcium angiotensin oral supplemental calcium placebo placebo tablets angiotensinsensitive women were given 2 gday of oral elemental calcium or placebo calcium supplementation￨incidence of pregnancyinduced hypertension preeclampsia repeat angiotensin sensitivity test incidence of any type of hypertension￨four of 29 calciumtreated subjects 138 95 confidence interval ci 432 developed preeclampsia compared to 15 of 34 441 95 ci 2762 in the placebo group relative risk rr 037 95 ci 015092 p  01￨sig decrease￨low￨low￨low
75￨preterm nulliparous women with mild preeclampsia mild preeclampsia remote from term seventyfive women hospitalized at 2436 weeks gestation because of mild preeclampsia preterm patients with mild disease￨calcium supplementation placebo calcium supplementation elemental calcium 36 women or placebo￨demographic characteristics initial blood pressure measurements and amount of proteinuria blood pressure values gestational age at delivery newborn weights incidence of low apgar scores and umbilical arterial blood gases severe preeclampsia￨eighteen of 36 calciumtreated subjects 50 95 confidence interval ci 3367 developed severe preeclampsia compared with 19 of 39 487 95 ci 3265 in the placebo group relative risk 103 95 ci 064103 p  100￨sig increase￨low￨low￨low
30￨the inclusion criteria were positive rollover test having at least one risk factor for preeclampsia between 28 and 32 weeks of pregnancy and blood pressure less than 14090 mm hg iranian women at high risk of preeclampsia
                thirty pregnant women at high risk of developing preeclampsia iranian women at high risk of developing preeclampsia￨supplementary calcium calcium placebo daily calcium and placebo calcium supplementation placebo meansd372 for calcium calcium supplementation￨hypertension pregnancy induced hypertension systolicdiastolic blood pressure preeclampsia duration of pregnancy reduction of preeclampsia occurrence of preeclamsia￨no major effect on pregnancy induced hypertension was seen 66 in placebo and 76 in calcium group developed hypertension but the onset of hypertension was delayed 3 weeks in the calcium group￨no diff￨highunclear￨highunclear￨highunclear
456￨5 maternity hospitals in australia nulliparous women for the prevention of pregnancyinduced hypertension preeclampsia and preterm birth 456 nulliparas with a singleton pregnancy￨calcium supplementation calcium calcium supplementation calcium 18g oral calcium or an oral placebo￨frequency of pregnancyinduced hypertension preeclampsia and preterm birth risk of preeclampsia risk of preeclampsia and preterm birth risk of hypertension and preeclampsia preterm birth risk of preterm birth frequency of pregnancyinduced hypertension￨treatment with calcium reduced the risk of preeclampsia relative risk 044 95 ci 021090 p  002 and the risk of preterm birth relative risk 044 95 ci 021090 p  002￨no diff￨low￨low￨low
4589￨4589 healthy nulliparous women who were 13 to 21 weeks pregnant to healthy nulliparous women￨calcium placebo receive daily treatment with either 2 g of elemental calcium or placebo calcium supplementation calcium calcium supplementation￨preeclampsia risk of preeclampsia blood pressure and urinary protein excretion numbers of preterm deliveries smallforgestationalage births or fetal and neonatal deaths mean systolic and diastolic blood pressures preeclampsia preeclampsia pregnancyassociated hypertension or adverse perinatal outcomes prevalence of pregnancyassociated hypertension without preeclampsia incidence or severity of preeclampsia or delay its onset hypertensive disorders￨calcium did not reduce the numbers of preterm deliveries smallforgestationalage births or fetal and neonatal deaths nor did it increase urolithiasis during pregnancy￨no diff￨low￨low￨low
36￨thirtysix women with normal single pregnancies between 20 and 35 years of age in the second trimester of gestation 15 weeks normal pregnant women￨calcium placebo calcium supplementation￨blood pressure values blood levels of calcium magnesium phosphorus and proteins blood pressure blood pressure patterns diastolic blood pressure baseline blood pressure measures￨no differences or clear patterns were observed in the blood levels of calcium magnesium phosphorus and proteins between and within groups during gestation￨no diff￨highunclear￨highunclear￨highunclear
72￨adolescent mothers and newborns seventytwo pregnant adolescent mothers adolescent pregnant mothers and their newborns￨orange juice plus calcium dietary calcium ca intervention control orange juice fortified with calcium and dairy calcium tablets dietary calcium intervention calcium diet supplemented with dairy products￨cord blood higher intakes of ca total body calcium ca phosphate p magnesium mg and vitamin 25hydroxyvitamin d d maternal and infant weight length and blood pressure bp higher intakes of p d and mg higher serum folate and d and higher cord d levels ca tablets higher maternal vitamin d and folate serum levels and higher newborn weight and bone mineralization￨mothers in the dairy group had higher intakes of p d and mg higher serum folate and d and higher cord d levels￨sig increase￨highunclear￨highunclear￨highunclear
106￨106 young healthy nulliparous women residing in quito ecuador￨placebo calcium supplementation elemental calcium per day or a placebo￨serum ionized calcium levels risk of pregnancyinduced hypertension pregnancyinduced hypertension systolic and diastolic blood pressure￨calcium supplementation was associated with a significantly decreased risk of pregnancyinduced hypertension with 41 developing pregnancyinduced hypertension in the treatment group versus 279 in the placebo group￨sig decrease￨low￨low￨low
not found￨patients were classified as either having remained normotensive or having developed pih with or without proteinuria women at high risk of pregnancyinduced hypertension highrisk patients pregnancy 500 normotensive primigravid chinese women were recruited in the second trimester of pregnancy on the basis of 80 mm hg  or  map  106 mm hg in the antenatal clinic￨calcium and lowdose aspirin prophylaxis aspirin or calcium supplementation aspirin control lowdose aspirin and calcium supplementation calcium supplementation￨risk of preeclampsia incidence of proteinuric pih nonproteinuric pih incidence of both proteinuric and nonproteinuric pih incidence of pih￨the incidence of both proteinuric and nonproteinuric pih was significantly lower in patients screened out as low risk than in those selected as high risk using a critical value of 60 mm hg for left lateral map p  005￨sig decrease￨highunclear￨highunclear￨highunclear
8325￨women who were recruited before gestational week 20 received nulliparous normotensive women from populations with dietary calcium  600 mgd pregnant women with low calcium intake reduces preeclampsia and preterm delivery low calcium intake pregnant women 8325 women who were assigned randomly￨calcium supplementation supplements 15 g calciumd or placebo placebo calcium supplementation￨eclampsia preeclampsia and preterm delivery secondary outcomes focused on severe morbidity and maternal and neonatal mortality rates severity maternal morbidity and neonatal mortality compliance early preterm delivery preeclampsia severe preeclamptic complications index severe maternal morbidity and mortality index severe gestational hypertension neonatal mortality rate￨the neonatal mortality rate was lower risk ratio 070 95 ci 056088 in the calcium group￨no diff￨low￨low￨low
125￨gambian infants 125 gambian women who received 1500 mg gambian women gambian women during pregnancy on breastmilk calcium concentrations and infant birth weight growth and bone mineral accretion pregnant gambian women￨placebocontrolled calcium supplementation calcium supplementation placebo calcium supplementation￨infant birth weight and gestational age infant wholebody bone mineral content and bone area breastmilk calcium concentrations and infant birth weight growth and bone mineral accretion breastmilk calcium concentrations or infant birth weight growth or bone mineral status growth and bone mineral accretion breastmilk calcium concentration infant birth weight or growth or bone mineral status infant bone mineral status￨calcium supplementation of pregnant gambian women had no significant benefit for breastmilk calcium concentrations or infant birth weight growth or bone mineral status in the first year of life￨no diff￨low￨low￨low
670￨2001 through 2003 in mexico city we randomly assigned 670 women in their first trimester of pregnancy to ingest calcium n  334 or pregnancy 557 participants 83 who completed followup n  336￨calcium supplementation placebo calcium supplementation dietary calcium supplementation￨blood lead levels maternal blood lead levels￨this reduction was more evident in the second trimester 14 p  0001 than in the third 8 p  0107 and was strongest in women who were most compliant those who consumed  or  75 calcium pills 24 p  0001 had baseline blood lead  5 microgdl 17 p  001 or reported use of leadglazed ceramics and high bone lead 31 p  001￨sig decrease￨low￨low￨low
1654￨1654 patients undergoing ercp 413 were included in the study patients with pancreatic or ampullary cancer from august 2003 to april 2006 all patients with an intact papilla who were referred for ercp were eligible￨cannulation technique in ercp conventional contrastassisted cannulation sphincterotomy biliary cannulation using either contrast injection or a guide wire￨serum amylase and lipase tests pep incidence of pep risk of pep overall cannulation success rate suspected sphincter of oddi dysfunction complete filling of the pancreatic duct￨the guidewire technique improves the primary success rate for biliary cannulation during ercp but does not reduce the incidence of pep compared to the conventional contrast technique￨no diff￨highunclear￨highunclear￨highunclear
172￨172 cases with an intact papilla￨wgc or the standard cannulation method with contrast injection std wireguided selective cannulation of the bile duct with a sphincterotome wireguided cannulation wgc wgc￨overall rate of pep success rate of cannulation pep success rate of selective cannulation incidence of pep selective cannulation rate￨after a crossover the cannulation was successful in the second attempt in 364 and 421 and finally in 952 and 100 by the std and wgc method respectively￨no diff￨highunclear￨highunclear￨highunclear
400￨400 consecutive patients with pancreatobiliary disease￨￨pancreatitis serum amylase procedurerelated mortality acute pancreatitis￨in 9 patients in group a vs 39 in group b p  0001 the serum amylase rose to more than 5 times the upper normal limit during the 24 hours after the procedure￨sig increase￨highunclear￨highunclear￨highunclear
400￨2012 american society for gastrointestinal endoscopy 400 consecutive patients with naive papillae who were candidates for ercp were enrolled and randomized fifteen referral endoscopy units￨combined catheter s or catheter c and method withwithout guidewire gw selective bile duct cannulation wgc wireguided cannulation wgc with a sphincterotome s for selective bile duct cannulation sbdc￨pep success rate of sbdc shorten cannulation and fluoroscopy times sbdc success rate or incidence of pep sbdc success rate sbdc time fluoroscopy time and incidence of complications￨there was no significant difference in the sbdc success rate between the groups with and without gw between c and s or among the 4 groups cgw c sgw s￨no diff￨highunclear￨highunclear￨highunclear
300￨tertiarycare academic medical center patients with suspected sod and unintentional pd guidewire cannulation 300 consecutive patients with native papilla and pancreaticobiliary disease who were candidates for therapeutic ercp were randomized from june 2006 to may 2007￨wireguided cannulation wgc wgc wgc without contrast injection or conventional cannulation with contrast injection￨postercp pancreatitis￨in multivariate analysis wgc was a protective factor odds ratio 01 95 ci 00240490 p  004 whereas female sex and sod were risk factors for postercp pancreatitis￨no diff￨highunclear￨highunclear￨highunclear
332￨a young woman developed postercp hemolytic crisis due to glucose6phosphate dehydrogenase deficiency 332 patients￨cannulation with a standard catheter standard ercp catheter and hydrophilic guide wire standard ercp catheter and hydrophilic guide wire hgw hgw￨overall cannulation rate number of insertions of the guide wire into the pancreatic duct success rate of selective cbd cannulation frequency of postinterventional pancreatitis and hemorrhage pancreatic opacifications overall selective cannulation time to cholangiography number of pancreatic opacifications and guidewire pancreatic duct insertions and complication rates procedurerelated mortality￨the overall cannulation rate after crossover was comparable between the two groups standard catheter 84  vs hgw 838  p  019￨no diff￨highunclear￨highunclear￨highunclear
300￨300 patients to￨guidewire cannulation conventional cannulation guidewire cannulation group ii technique conventional cannulation technique using sphinctertome and contrast injection versus guidewire cannulation technique￨rates of overall complication incidence of acute pancreatitis likelihood of postercp pancreatitis rates of accidental pancreatic duct cannulation successful cannulation of the common bile duct acute pancreatitis ease of cannulation of common bile duct assessed by attempts required for common bile duct cannulation  rates of precut sphincterotomy and overall complication rates￨rates of accidental pancreatic duct cannulation were 21 in group i and 27 in group ii p 034￨no diff￨low￨low￨low
4￨patients with acute ischemic stroke treated with thrombolysis ten patients with a mean age of 711143 years and an nihss score of 19833 were treated with hypothermia all patients presented with major ischemic stroke national institutes of health stroke scale nihss score 15 within 6 hours of onset patients undergoing hypothermia hypothermia patients included bradycardia n5 ventricular ectopy n3 hypotension n3 melena n2 fever after rewarming n3 and infections n4 four patients with chronic atrial fibrillation acute ischemic brain damage cool aid acute ischemic stroke patients with acute ischemic stroke￨hypothermia hypothermia￨target temperature rapid ventricular rate mean time from symptom onset to thrombolysis mean duration of hypothermia mean modified rankin scale score myocardial infarctions without sequelae modified rankin scale￨noncritical complications in hypothermia patients included bradycardia n5 ventricular ectopy n3 hypotension n3 melena n2 fever after rewarming n3 and infections n4￨no diff￨highunclear￨highunclear￨highunclear
56￨awake patients with acute stroke 17 patients cases with stroke admitted within 12 hours from stoke onset mean 325 hours 56 patients controls from the copenhagen stroke study matched for age gender initial stroke severity body temperature on admission and time from stroke onset to admission awake patients with acute stroke through surface cooling unselected patients with stroke patients with acute stroke￨pethidine pethidine hypothermic therapy hypothermia modest hypothermia￨blood cytology biochemistry ecgs and body temperature hypothermia final neurological impairment scandinavian stroke scale score body temperature mortality feasibility and safety￨mortality at 6 months after stroke was 12 in cases versus 23 in controls p0 50￨no diff￨highunclear￨highunclear￨highunclear
40￨eighteen patients forty patients with ischemic stroke presenting within 12 hours of symptom onset were enrolled in the study thirteen patients reached target temperature in a mean of 77 acute ischemic brain damage cool aid patients with ischemic stroke patients who cooled well n  8 was 729 patients with acute ischemic stroke￨hypothermia standard medical management endovascular cooling device endovascular cooling￨mean diffusionweighted imaging dwi lesion growth mean dwi lesion growth￨clinical outcomes were similar in both groups￨no diff￨highunclear￨highunclear￨highunclear
39￨acute stroke stroke patients patients were included if they had stroke within 24 hours of onset of symptoms national institutes of health stroke scale nihss score  or 5 initial cbt 3 85 degrees c and white blood cell count  12 600 cellsmm3 they were excluded if they had signs of infection severe medical illness or contraindication to 2 university hospitals thirtynine patients were randomized afebrile patients with acute stroke￨acetaminophen acetaminophen placebo acetaminophen 650 mg or placebo￨cbt change in nihss nihss scores elevated core body temperature cbt mean cbt￨the change in nihss scores from baseline to 48 hours did not differ between the groups p093￨no diff￨low￨low￨low
75￨seventyfive patients with acute ischemic stroke confined to the anterior circulation patients with acute stroke acute ischemic stroke patients with acute ischemic stroke￨acetaminophen paracetamol placebo acetaminophen acetaminophen or with placebo paracetamol acetaminophen￨rectal temperature body temperatures body temperature body temperatures lower body temperatures￨treatment with highdose acetaminophen resulted in 04 degrees c lower body temperatures than placebo treatment at 24 hours 95 ci 01 degrees c to 07 degrees c￨sig decrease￨low￨low￨low
42￨fortytwo consecutive normothermic patients with acute ischemic stroke acute ischemic stroke￨acetaminophen placebo￨fever￨fever of greater than 375 degrees c occurred in 364 of patients in the placebo group compared with 50 in the acetaminophen group fishers exact test p  0014￨sig increase￨highunclear￨highunclear￨highunclear
not found￨adult patients with acute appendicitis￨open or laparoscopic appendectomy laparoscopic appendectomy￨wound infection wound infection incidence wound infection incidence￨wound infection incidence was lower in the laparoscopic group￨sig decrease￨highunclear￨highunclear￨highunclear
83￨acute appendicitis patients with right lower abdominal pain and in the quality of life after the operation patients with suspected appendicitis￨traditional open approach or with a laparoscopic approach laparoscopic appendectomy laparoscopic and open approaches laparoscopic approach￨hospital stay need for narcotics and in visual analog score operative time gastrointestinal quality of life index ovulation bleeding ovarian cyst meckels diverticulum ectopic pregnancy and leiomyoma of the uterus demographic data complications and gastrointestinal quality of life index scores quality of life hospital costs severe infection negative appendectomy rate￨when the groups were compared according to the subgroups of gastrointestinal quality of life index except for diseasespecific items in all categories a significant improvement was seen in the laparoscopically treated patients￨no diff￨highunclear￨highunclear￨highunclear
20￨children treated by laparotomy and by laparoscopy pediatric patients treated for acute appendicitis by laparotomy or by laparoscopy twenty children suffering from acute appendicitis pediatric age￨laparoscopic or laparotomic surgery laparoscopy versus laparotomy￨immunologic function blood samples counts of tlymphocytes and monocytes expressing hladr￨in the postoperative period the counts of tlymphocytes and monocytes expressing hladr were similar in both groups￨no diff￨highunclear￨highunclear￨highunclear
170￨83 patients and 87 were treated laparoscopically 170 patients￨laparoscopic versus conventional appendectomy open appendectomy￨hospital stay shorter time until return to normal physical activity and a shorter duration of complaints surgical and general complications operating time consumption of analgesics and antibiotics and return to work￨no statistically significant differences could be found with respect to surgical and general complications operating time consumption of analgesics and antibiotics and return to work￨no diff￨highunclear￨highunclear￨highunclear
11￨women with clinical signs of acute appendicitis eleven patients undergoing 30 women with clinical signs of appendicitis￨immediate appendicectomy or diagnostic laparoscopy laparoscopy before appendicectomy diagnostic laparoscopy immediate operation￨unnecessary appendicectomy postoperative morbidity rate￨there was no significant difference in postoperative morbidity rate in the two groups￨no diff￨highunclear￨highunclear￨highunclear
50￨fifty female patients between the ages of 16 and 40 years presenting with acute right lower abdominal pain fertileage women young female patients with suspected acute appendicitis young women￨laparoscopic and open appendectomy laparoscopic appendectomy laparoscopy and 25 to an open appendectomy￨unnecessary appendectomies negative for appendicitis diagnostic accuracy rate of negative appendectomies safety and final outcome￨in young women with right lower abdominal pain laparoscopy can give precise diagnosis and reduce the rate of negative appendectomies￨no diff￨highunclear￨highunclear￨highunclear
52￨137 patients with a diagnosis of acute appendicitis patients found to have perforated or normal appendices at histological examination were excluded￨pethidine oral analgesic naproxen sodium laparoscopic appendicectomy laparoscopic appendicectomy laparoscopic and open appendicectomy laparoscopic or open appendicectomy￨time to resumption of fluid and diet intake and length of hospital stay wound infections￨there were five 9 per cent wound infections after open appendicectomy compared with none after the laparoscopic operation p  001￨no diff￨highunclear￨highunclear￨highunclear
129￨twentyone children 24 were perforated children fortythree boys and 45 girls age 1 to 16 years were enrolled 129 children with appendicitis were included￨laparoscopic appendectomy la la and open appendectomy oa laparoscopic appendectomy la gentamycin clindamycin and ampicillin￨postoperative analgesia resumption of oral intake length of hospitalization return to normal activities or morbidity pain relief length of stay return to normal activities or morbidity longer operating times and increased cost￨la is a more expensive alternative and offers no advantages related to pain relief length of stay return to normal activities or morbidity￨no diff￨highunclear￨highunclear￨highunclear
247￨two hundred fortyseven patients￨laparoscopic or open appendectomy laparoscopic versus open appendectomy laparoscopic versus open appendectomy laparoscopic appendectomy￨quality of life scores overall complication rate evaluation of pain and activity scores at base line preoperatively and on every postoperative day as well as resumption of diet and length of stay activity or pain scores but physical health and general scores on the shortform 36 sf36 quality of life assessment activity scores and quality of life complication rates pain scores and medications resumption of diet length of stay or activity scores postoperative complications mortality operating time￨unlike other minimally invasive procedures laparoscopic appendectomy did not offer a significant advantage over open appendectomy in all studied parameters except quality of life scores at 2 weeks￨no diff￨low￨low￨low
523￨patients with suspected acute appendicitis 523 patients was randomized but because of 23 withdrawals the outcome in 500 patients is reported 244 in the laparoscopic group and 256 in the open group￨laparoscopic versus open appendicectomy laparoscopic and open appendicectomy laparoscopic appendicectomy￨postoperative pain hospital stay and complications operating time duration of sick leave￨there was no significant difference in duration of sick leave after operation laparoscopic group 11 days versus open group 14 days￨no diff￨highunclear￨highunclear￨highunclear
169￨adult patients older than 14 years of age with the diagnosis of acute appendicitis routine patient with appendicitis 169 patients randomized 88 to the open and 81 to the laparoscopic group 81 laparoscopic patients 13 16 were converted to open￨laparoscopic appendectomy laparoscopic to open appendectomy preoperative antibiotics open or laparoscopic appendectomy laparoscopic appendectomy￨hospital stay operative time length of operation complications hospital stay and recovery time pelvic inflammatory disease complications perforative appendicitis complications hospital stay cost return to activity and return to work acute appendicitis hospital cost￨laparoscopic appendectomy is comparable to open appendectomy with regard to complications hospital stay cost return to activity and return to work￨no diff￨highunclear￨highunclear￨highunclear
828￨three hundred and one patients were allocated to open appendicectomy and 282 patients to patients with a clinical suspicion of acute appendicitis 583 of 828 consecutive patients consented to participate￨laparoscopy 65 of whom required conversion to open appendicectomy laparoscopic versus open appendicectomy laparoscopy￨short hospital stay hospital stay median time to return to normal activity length of stay in hospital operating time intraperitoneal abscesses operating time postoperative morbidity duration of convalescence and cosmesis wound infections cosmesis wound infections faster recovery earlier return to work and improved cosmesis￨laparoscopy was associated with fewer wound infections p  003 and improved cosmesis p  0001 but the operating time was longer 60 versus 40 min￨sig decrease￨low￨low￨low
201￨201 patients with similar characteristics of appendicitis 104 patients were allocated to the oa group and 97 to the la group￨laparoscopic vs open appendectomy oa or la open appendectomy oa and laparoscopic appendectomy la la￨postoperative pain postoperative complications postoperative pain and fewer wound infections mean hospital stay operative time and technique reintroduction of diet postoperative pain use of analgesia hospital stay and complications mean operative time wound infections￨postoperative pain was significantly less in the la group on the 1st p  0001 and 2nd p  0001 postoperative day resulting in less use of analgesics on both days p  0001￨sig decrease￨highunclear￨highunclear￨highunclear
30￨acute appendicitis 30 patients undergoing surgery due to suspected acute appendicitis either by an open classic technique or by a laparoscopic technique was by collecting samples for blood culturing pre peri and postoperatively to evaluate whether￨laparoscopic appendectomy laparoscopy during carbon dioxide pneumoperitoneum laparoscopy￨positive blood cultures￨no positive blood cultures were demonstrated in the open operated group￨no diff￨highunclear￨highunclear￨highunclear
132￨patients with suspected acute appendicitis from september 2002 to september 2005 132 patients54 women and 78 menwith suspected acute appendicitis male and female patients with suspected acute appendicitis patients with suspected acute appendicitis were prospectively used in male and female patients women of reproductive age were treated laparoscopically while men￨laparoscopic appendectomy laparoscopic appendectomy laparoscopy￨morbidity duration of hospital stay and the time to return to normal activities incidence of wrong diagnosis￨laparoscopic appendectomy took longer to perform without affecting significantly the needs for postoperative analgesia the duration of hospital stay and the time to return to normal activities when compared with open appendectomy in men￨sig decrease￨highunclear￨highunclear￨highunclear
37￨from january 15 1992 through january 15 1993 75 patients older than 9 years patients with acute appendicitis thirtyseven patients were assigned to the open appendectomy group and 38 patients￨laparoscopic appendectomy versus open appendectomy laparoscopic appendectomy group laparoscopic technique laparoscopic appendectomy laparoscopic appendectomies￨acute appendicitis shorter duration of analgesic use and return to full activities sooner postoperatively mean duration of surgery length of hospitalization interval until resumption of a regular diet or morbidity￨this occurred at an average of 25 days for the open appendectomy group versus 14 days for the laparoscopic appendectomy group p  0001￨sig decrease￨highunclear￨highunclear￨highunclear
50￨women of childbearing age 50 patients fertile women 100 patients who fulfilled the inclusion criteria between july 1988 and march 1990 university hospital kuwait￨diagnostic laparoscopy laparoscopy diagnostic laparoscopy laparoscopy￨histological abnormality avoidance of unnecessary appendicectomy length of operating time and length of stay in hospital complications of laparoscopy￨there were no complications of laparoscopy￨no diff￨highunclear￨highunclear￨highunclear
57￨tertiary care urban teaching hospital patients with acute appendicitis twentyseven patients underwent la 2 requiring conversion to an oa a populationbased sample of patients aged  or  12 years weight  497 kg admitted to a surgical teaching service with a clinical diagnosis of acute appendicitis fiftyseven patients were initially enrolled in the study 7 did not complete the study because of a protocol violation fifty patients 19 women and 31 men routine patient with acute appendicitis￨oa laparoscopic appendectomy la oa or la laparoscopic vs open appendectomy open appendectomy oa with laparoscopic appendectomy la￨pain control length of the operation complications postoperative pain control length of hospitalization postdischarge recovery time and hospital charges conversion to oa because of technical difficulties length of hospitalization recovery time time necessary before returning to work or school length of the operation intraoperative and postoperative complications postoperative pain control length of hospitalization postdischarge recovery time and hospital charges complications postoperative pain control length of hospitalization and recovery time total hospital charges operating room charges shorter operative time and lower operating room and hospital charges￨laparoscopic appendectomy does not offer any proved benefits compared with the open approach for the routine patient with acute appendicitis￨no diff￨highunclear￨highunclear￨highunclear
100￨men with atypical pain of uncertain diagnosis and in obese patients women with right iliac fossa pain male patients with suspected appendicitis routine appendectomy in men one hundred men between the ages of 16 and 65 years who had suspected appendicitis￨laparoscopy laparoscopic appendectomy laparoscopic appendectomy over open appendectomy laparoscopy open or laparoscopic appendectomy laparoscopic appendectomy￨visual analog scale length of hospital stay anesthetic time postoperative pain histologic confirmation of appendicitis recovery of bowel function actual operating time duration of anesthetic and operation times postoperative pain duration of ileus and length of hospital stay￨laparoscopic appendectomy required significantly longer anesthetic time 725 minutes versus 55 minutes and actual operating time 45 minutes versus 25 minutes compared with open appendectomy￨sig decrease￨highunclear￨highunclear￨highunclear
87￨november 1 1997 and april 30 2000 children patients eightyseven children aged 4 to 15 years who underwent appendectomy for suspected appendicitis￨laparoscopic appendectomy with those of open appendectomy laparoscopic appendectomy laparoscopic or open appendectomy laparoscopic appendectomy￨operative expenses￨excess operating and complication costs per procedure were 96 euros eur in laparoscopic appendectomy￨no diff￨highunclear￨highunclear￨highunclear
54￨54 patients with a mean age of 295￨laparoscopic appendectomy conventional appendectomy laparoscopic appendectomy laparoscopic and conventional appendectomy￨recovery and duration of work disability time until return to work minor endpoints were postoperative pain fatigue operative time and postoperative morbidity postoperative fatigue pain postoperative morbidity operative time age sex body mass index bmi american society of anesthesiology asa rating job status as well as histologic degree of inflammation of the appendix￨laparoscopic appendectomy has no advantages in terms of convalescence and time to return to work when compared to open appendectomy and should therefore be limited to selected cases￨no diff￨highunclear￨highunclear￨highunclear
35￨35 patients with a presumptive diagnosis of acute appendicitis two patients had a normal appendix 12 had acute appendicitis 14 gangrenous appendicitis and 4 ruptured or abscessed appendicitis 32 patients were randomized 17 to open group i and 15 to patients who were converted from laparoscopic to open appendectomy 3 cases hiv allergic to augmentin or who had contraindications to laparoscopic surgery were excluded from the study 17 patients￨conventional or laparoscopic appendectomy laparoscopic surgery preoperative antibiotic prophylaxis augmentin conventional and laparoscopic surgical procedures conventional open or laparoscopic surgical procedures laparoscopic appendectomy￨positive bacterial culture operative mortality rate bacteriological risk of appendectomy incidence of postoperative morbidity positive blood cultures age asa score symptoms or macroscopic aspect of the appendix risk of bacteraemia￨there was no significant difference between the two groups with regard to the appearance of the appendix￨no diff￨highunclear￨highunclear￨highunclear
40￨forty consecutive patients￨oa laparoscopic appendectomy laparoscopic la and open appendectomy oa la open or laparoscopic￨medians of operative times total costs costeffective appendectomy hospital costs total operation room times median hospital costs postoperative pain or fatigue but return to normal life￨there was no significant difference in postoperative pain or fatigue but return to normal life was faster in the la group 14 versus 26 5 days￨no diff￨highunclear￨highunclear￨highunclear
not found￨contact all patients at 10 years to determine whether they had had a subsequent appendicectomy or had been diagnosed with another abdominal condition that might be relevant to the initial presentation in 19911992 acute appendicitis in women of reproductive age female patients between 16 and 45 years were eligible for inclusion once a clinical decision had been made to perform an appendicectomy for suspected acute appendicitis￨laparoscopy laparoscopy￨hospital stay diagnostic accuracy￨laparoscopy was associated with no added complications no increase in hospital stay in patients who went on to appendicectomy and a reduction in hospital stay for those who underwent laparoscopy alone￨no diff￨highunclear￨highunclear￨highunclear
not found￨premenopausal women with suspected acute appendicitis eighteen patients underwent premonopausal women requiring surgery for suspected acute appendicitis 16 patients female patients aged 1545 years in whom an independent decision to undertake surgical exploration had been made￨laparoscopic or open procedures laparoscopy laparoscopic exploration laparoscopic versus open surgical exploration laparoscopic appendicectomy laparoscopic versus conventional surgical exploration laparoscopic exploration with 1 procedure requiring conversion to lower midline laparotomy￨postoperative recovery analgesic requirement postoperative hospitalisation return to normal activity return to work diagnostic errors mean postoperative hospitalisation postoperative complications acute appendicitis￨the outcome following laparoscopic appendicectomy for confirmed acute appendicitis is at least equivalent to that achieved with conventional appendicectomy￨no diff￨highunclear￨highunclear￨highunclear
70￨n  35 17 male or n  35 15 male and operated on an emergency basis seventy nonselective patients with suspected appendicitis￨la laparoscopic versus open appendectomy open appendectomy laparoscopic appendectomy la laparoscopic￨shorter hospital stay fewer postoperative complications operative findings operating time postoperative complications and length of hospital stay￨we found that la is associated with a shorter hospital stay fewer postoperative complications and better diagnostic accuracy and it is recommended as the procedure of choice for the diagnosis and management of acute appendicitis￨sig increase￨highunclear￨highunclear￨highunclear
60￨female patients with clinical diagnosis of appendicitis 60 female patients to king fahad hospital hofuf alhassa kingdom of saudi arabia from january 1999 to april 2000 females with a clinical diagnosis of appendicitis￨laparoscopic versus open appendectomy laparoscopic appendectomy laparoscopic technique lt or an open technique ot appendectomy by lt or ot￨postoperative narcotic requirement p005 quicker reintroduction of diet and quicker return to normal activity shorter anesthesia and operative time items operative anesthesia length of stay postoperative pain medicine wound healing days to return to normal activity￨the laparoscopic group had a significant reduced postoperative narcotic requirement p005 quicker reintroduction of diet and quicker return to normal activity￨sig decrease￨highunclear￨highunclear￨highunclear
253￨two hundred fiftythree patients with a preoperative diagnosis of acute appendicitis 78 patients la with catgut ligatures lal on 89 and open appendectomy oa on 86￨laparoscopic appendectomy with open appendectomy laparoscopic appendectomy la laparoscopic cholecystectomy laparoscopic appendectomy la la with an endoscopic linear stapler las lal￨wound infections operative time regular activities sooner pain medications overall relative brevity of oa pain mean operative times vomiting postoperatively emesis mean length of postoperative hospital stay rates of readmission rapid return to full activities and las required shorter hospital stays postoperative pain on a visual analogue scale￨wound infections were more common following oa n  11 than lal n  4 or las n  0 p  005  0001￨no diff￨highunclear￨highunclear￨highunclear
64￨64 men 56 875 had appendicitis 27 open 29 laparoscopic procedures men sixtyfour patients with a median age of 25 years range 1884 years men with a clinical diagnosis of acute appendicitis￨open appendectomy with laparoscopic appendectomy open appendectomy laparoscopic n  33 appendectomy laparoscopic appendectomy￨mean time to return to normal activities postoperative death complication rate mean postoperative hospital stay mean operating times￨the complication rate after open appendectomy 258 was not significantly different from that after laparoscopic appendectomy 121￨no diff￨highunclear￨highunclear￨highunclear
57￨all patients were either asa class from july 1992 to august 1993 57 patients were approached preoperatively for randomization to either la n  19 or oa n  18 2 years percent female 26 vs 22 body mass index 24￨laparoscopic appendectomy la laparoscopic versus open appendectomy laparoscopic appendectomy la la and oa￨postoperative intramuscular narcotic analgesic usage postoperative hospital stay return to normal activity mean total hospital bill￨there were no statistically significant differences between the la and oa groups in operative risk mean age 28￨no diff￨highunclear￨highunclear￨highunclear
43￨paediatric patients 43 children between the ages of 7 and 15 years with clinical symptoms of acute appendicitis children￨open appendectomy oa or a laparoscopic appendectomy la laparoscopic versus open appendectomy la￨hospital stay operative time hospital stay operative time￨there were no differences in hospital stay or the postoperative course of the patients￨no diff￨highunclear￨highunclear￨highunclear
148￨148 patients admitted from october 1993 to december 1998 with diagnosis of of pain in right iliac fossa and operated on with a laparoscopic la group 75 cases or open approach oa group 73 cases young women suffering from pain in right lower abfdominal quadrant suspected acute appendicitis in female patients￨laparoscopic appendectomy versus open appendectomy laparoscopic appendectomy laparoscopic appendectomy￨operative time hospital stay pain medication postoperative complications intraoperative complications pain postoperative pain less hospital stay￨the operative time in la group was significantly p  0001 longer 872 minutes than for oa group 652 minutes￨sig increase￨highunclear￨highunclear￨highunclear
not found￨pigs patients with normal renal function undergoing 11 patients allocated randomly to undergo either￨laparoscopic or open appendectomy carbon dioxide pneumoperitoneum or abdominal wall lifting for laparoscopic colectomy carbon dioxide pneumoperitoneum￨plasma potassium concentration plasma potassium concentrations￨despite an increasing metabolic acidosis prolonged carbon dioxide pneumoperitoneum resulted in only a slight increase in plasma potassium concentrations which was both statistically and clinically insignificant￨no diff￨highunclear￨highunclear￨highunclear
7￨151 patients randomized to either a patients with a clinical diagnosis of acute appendicitis 158 patients randomized 7 patients were excluded because of protocol violations conversion to laparotomy in 4 appendix not removed in 3 patients with a diagnosis of acute appendicitis was conducted between october 1992 and april 1994 seven patients 9 who had advanced forms of appendiceal inflammation￨laparoscopic appendectomy with open appendectomy laparoscopic appendectomy laparoscopic versus open appendectomy open appendectomy laparoscopic conversion from laparoscopic to open appendectomy￨histologic classification of normal catarrhal inflamed suppurative and gangrenous appendicitis median operating time narcotic analgesia and an earlier return to normal activity morbidity median time to discharge of 3 days wound infections￨when compared to open appendectomy the laparoscopic group had a longer median operating time 63 minutes versus 40 minutes fewer wound infections 2 versus 11 less requirement for narcotic analgesia and an earlier return to normal activity median 7 days versus 14 days￨sig increase￨highunclear￨highunclear￨highunclear
75￨75 patients admitted at the emergency station of the authors hospital with a final diagnosis of acute appendicitis without tumor formation 26 patients in the oa group 23 in the la group and 26 in the nla group￨needlescopic laparoscopic and open appendectomy laparoscopic and needlescopic appendectomy open oa laparoscopic la and needlescopic nla appendectomy open laparoscopic and needlescopic appendectomy laparoscopic appendectomy￨postoperative pain and shorter hospital stay woundcomplication rate and ileus mean number of the analgesic doses mean durations of hospitalization mean oral intake durations mean operation durations postoperative complication rate or surgical time￨the oa group rendered a greater woundcomplication rate and ileus than did the other two groups but the differences were not detected between the three categories  p  0065 06935￨sig increase￨highunclear￨highunclear￨highunclear
272￨study patients were representative of the eligible population regarding age and stage of appendicitis 272 patients with suspected appendicitis was performed of whom 84 had acute appendicitis one hundred and eight patients￨laparoscopy or conventional appendicectomy conventional appendicectomy initial laparoscopy laparoscopic versus conventional appendicectomy￨postoperative hospital stay pain assessment or complications duration of postoperative convalescence risk of unnecessary appendicectomy rate of misdiagnosis duration of postoperative convalescence￨the risk of unnecessary appendicectomy was significantly p  003 lower after laparoscopy￨sig decrease￨highunclear￨highunclear￨highunclear
52￨fiftytwo consecutive men presenting with signs and symptoms suggestive of acute appendicitis￨laparoscopic versus open appendectomy laparoscopic to open appendectomy laparoscopic appendectomy or open appendectomy laparoscopic appendectomy￨mean time to return to work length of operative times hospital stay lost work days visual analog pain scores and operative costs perceived postoperative pain length of stay hospital stays less postoperative pain operating room costs operative costs￨length of stay averaged 215 h for the laparoscopic group and was not statistically different when compared to the open group￨no diff￨highunclear￨highunclear￨highunclear
63￨adults undergoing cholecystectomy sixtythree children aged 815 yr scheduled for appendectomy children￨laparoscopy open and laparoscopic laparoscopic and open appendectomy laparoscopic versus open appendectomy laparoscopy￨analgesia and postoperative recovery demographic data particularly macroscopic aspect of appendix analgesia sedation delay before eating and walking incidence of urinary retention nausea vomiting postoperative analgesia pain delay of postoperative recovery walking and feeding pain assessment by visual analog scale during the 3 subsequent days amount of nalbuphine administered via a patientcontrolled analgesia system during the first 48 h and responses by children parents and nurses on the overall quality of analgesia operative time￨there was no difference between groups for demographic data particularly macroscopic aspect of appendix analgesia sedation delay before eating and walking incidence of urinary retention nausea vomiting￨no diff￨highunclear￨highunclear￨highunclear
not found￨overweight patients those with a body mass index  or 25 overweight patients patients with a body mass index of 25 or greater activeduty males￨laparoscopic appendectomy with open appendectomy laparoscopic appendectomy open appendectomy laparoscopic appendectomy￨lost workdays postoperative pain or operative time with laparoscopic appendectomy operative time hospital stay less postoperative pain and earlier return to usual activities work postoperative pain aggregate incision length lost workdays postoperative pain or operative time from￨the data from this prospective randomized doubleblind study failed to demonstrate any significant reduction in lost workdays postoperative pain or operative time with laparoscopic appendectomy￨no diff￨highunclear￨highunclear￨highunclear
47￨children randomized to either laparoscopic or open appendectomy for nonperforated appendicitis materials and methods children with the diagnosis of appendicitis 47 patients with appendicitis￨laparoscopic or open appendectomy laparoscopicor open appendectomy laparoscopic appendectomy￨inflammatory response demographic variables including age body weightand duration of symptoms inflammatory parameters body temperature hematocrit leukocytecount or any of the inflammatory markers length of inhospital stay body temperatureleukocyte count hematocrit and serum levels of the inflammatory markers creactive protein interleukin il6 tumor necrosis factor tnf stnfr il1ra sil2r and il8 average postoperative length of stay without any complications￨average postoperative length of stay without any complications was 62 25 days in the open group and 43￨no diff￨highunclear￨highunclear￨highunclear
110￨fertile women scheduled for acute appendectomy fertile women 110 women with acute abdominal pain ages 15 to 47 years in whom the surgeon had decided to perform an appendectomy￨diagnostic laparoscopy laparoscopy open appendectomy or diagnostic laparoscopy then open appendectomy if necessary￨relative risk of removing a healthy appendix appendicitis gynecologic diagnosis￨the relative risk of removing a healthy appendix in open surgery was 66 relative risk range 221 ci as compared with laparoscopy￨no diff￨highunclear￨highunclear￨highunclear
220￨adult patients older than 14 years presenting with signs and symptoms suggestive of acute appendicitis acute appendicitis 220 patients 108 to undergo oa and 112 to undergo la routine patient with appendicitis￨laparoscopic appendectomy la with open appendectomy oa laparoscopic appendectomy la laparoscopic versus open appendectomy la or oa laparoscopy￨hospital stay normal activity wound infections billed charges shorter time until return intraabdominal abscesses operating time time until return to a general diet time until return to normal activity and work length of hospital stay billed charges and postoperative complications postoperative ileus rate for overall complications￨the operating time seemed to be shorter for the oa patients than for the la patients but the difference was not significant la 30￨no diff￨highunclear￨highunclear￨highunclear
198￨patients with active lifestyles one hundred ninetyeight patients with a preoperative diagnosis of acute appendicitis￨laparoscopic appendectomy with open appendectomy laparoscopic appendectomy laparoscopic or open appendectomy laparoscopic and open appendectomy laparoscopic approach laparoscopic appendectomy￨shorter postoperative hospital stay total costs including indirect costs of laparoscopic appendectomy shorter duration of parenteral analgesia total costs of treatment direct and indirect costs earlier return to full activity billed charges and direct costs shorter length of stay and abbreviated recuperative period billed charges total costs direct costs and indirect costs associated with treatment operative morbidity and time to return to work morphineequivalent milligrams of parenteral narcotic￨laparoscopic appendectomy took longer to perform than open appendectomy median 107 vs 91 minutes p 01 and was associated with fewer days to return to a general diet mean 16 versus 23 days p 01 a shorter duration of parenteral analgesia mean 16 versus 22 days p 01 fewer morphineequivalent milligrams of parenteral narcotic median 14 mg versus 34 mg p 001 a shorter postoperative hospital stay mean 26 versus 34 days p 01 and earlier return to full activity median 14 versus 21 days p 02￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨men male patients with suspected appendicitis one hundred men between the age of 15 and 65 admitted to ain shams specialized hospital and el demerdash hospital cairo and to the saudi german hospital saudi arabia between november 1998 and december 2000￨laparoscopic versus open appendicectomy open or laparoscopic appendicectomy laparoscopic appendectomy over open appendectomy laparoscopic appendectomy￨length of hospital stay histologic confirmation of appendicitis clinical parameters duration of anaesthesia operative time duration of ileus and length of hospital stay recovery of bowel function operating time anaesthetic time￨laparoscopic appendectomy required significantly longer anaesthetic time 78 minutes versus 51 and operating time 49 minutes versus 23 compared with open appendectomy￨sig increase￨highunclear￨highunclear￨highunclear
102￨university hospital sweden 102 patients were randomised and 99 were included in the final analysis￨laparoscopic appendicectomy laparoscopic and open appendicectomy￨mean duration of hospital stay period off work indirect costs and time to complete recovery total costs￨laparoscopic appendicectomy has higher direct costs than open operation and is not as costeffective when the longterm outcome is the same in both groups￨no diff￨highunclear￨highunclear￨highunclear
81￨eightyone patients with a diagnosis of acute appendicitis acute appendicitis 81 patients￨laparoscopic versus open appendectomy la or oa laparoscopic appendectomy la and open appendectomy oa la￨number of days in hospital and time to full recovery wound infection rates hospital stay for la intraabdominal abscesses mean time to complete recovery pain scores mean number of narcotic injections mean operative time for la mean hospital stay for la￨the mean hospital stay for la was 323 days compared with 303 days for oa p  0001￨no diff￨highunclear￨highunclear￨highunclear
163￨patients with suspected acute appendicitis patients with laparoscopically confirmed appendicitis one hundred and sixtythree patients with laparoscopically confirmed appendicitis suitable for la￨laparoscopy laparoscopic la and open appendicectomy oa la la or oa laparoscopic versus open appendicectomy￨time to full recovery after la and oa physical activity time to full recovery functional status la and oa in time to full recovery complication rate median hospital stay operating time complications hospital stay and functional status operating time￨functional status was significantly better in the la group 710 days after operation p  0045￨sig increase￨highunclear￨highunclear￨highunclear
57￨57 patients with acute appendicitis we performed open appendectomy in 23 and laparoscopy in 34 patients according to randomization 1000 endoscopic interventions mainly performed at the gallbladder and the stomach and 165 prospectively documented and partly treated patients with acute appendicitis￨laparoscopic or classical appendectomy laparoscopic vs conventional appendectomy laparoscopic appendectomy started endoscopic surgery laparoscopy￨visual analogue scale vas in lying standing and moving position and the postoperative consumption of analgesics￨though laparoscopic appendectomy started endoscopic surgery in general surgery it has yet not reached the acceptance as is the case with cholecystectomy￨no diff￨highunclear￨highunclear￨highunclear
210￨patients with suspected acute appendicitis who presented between january 1992 and december 1994 n  210￨laparoscopic appendectomy la laparoscopic and open appendectomy laparoscopic versus open appendectomy laparoscopic la n  106 and open appendectomy￨operative but less global cost postoperative analgesia global cost patient demographics pathological findings operative time postoperative course and cost postoperative morbidity and hospital readmissions postoperative stay higher operative cost appendix rate mean operative time comfortable postoperative course oral resumption postoperative stay and analgesia￨mean operative time was longer in the la group p  005￨sig increase￨highunclear￨highunclear￨highunclear
121￨patients with trochanteric fracture trochanteric fractures 121 patients￨pfna proximal femoral nail antirotation and dynamic hip screw devices proximal femoral nail antirotation pfna device with those of a traditional extramedullary device the dynamic hip screw dhs pfna device dhs￨overall complication rate longer operative time blood loss functional outcome reoperation rate￨there were no significant differences in functional outcome between the pfna and the dhs groups￨no diff￨highunclear￨highunclear￨highunclear
69￨intertrochanteric fractures of the femur thirteen patients died from preexisting medical conditions 69 patients over the age of 50 years with intertrochanteric femoral fractures￨ambi hip screw and the gamma nail gamma nail and the ambi hip screw￨length of hospital stay urine retention blood loss limb shortening level of mobility image intensifier screening time operative complications￨limb shortening was similar in both groups and was not affected by leaving the gamma nail unlocked distally in unstable fractures￨no diff￨highunclear￨highunclear￨highunclear
400￨197 patients 400 patients entered into the study and 399 followedup to one year or death intertrochanteric fractures of the femur all patients admitted from the local population with intertrochanteric fractured femurs were included￨shorttype gamma nail 203 patients or a richardstype sliding hip screw and plate gamma nail intramedullary fixation device versus the richards sliding hip screw and plate device intramedullary nail versus dynamic screw and plate gamma nail￨femoral shaft fractures lagscrew cutout pain mobility status and range of movement fixation failure and reoperation early or longterm functional status postoperative complications subcapital femoral fracture￨femoral shaft fractures occurred with four in the gamma nail group 2 and none in the richards group p  013￨no diff￨highunclear￨highunclear￨highunclear
100￨100 intertrochanteric fractures of the proximal femur in elderly patients with random use of either a￨gamma nail and the dynamic hip screw dynamic hip screw dhs or a new intramedullary device the gamma nail￨operating time blood loss wound complications stay in hospital place of eventual discharge or the patients mobility failure of proximal fixation cutout￨we found no difference in operating time blood loss wound complications stay in hospital place of eventual discharge or the patients mobility at final review￨no diff￨highunclear￨highunclear￨highunclear
95￨48 patients the gamma nail in 47 95 consecutive patients with peritrochanteric fractures of the femur￨dynamic hip screw dhs gamma nail dynamic hip screw and gamma nail￨￨clinical and radiological outcomes were similar but the gamma nail was associated with a higher incidence of complications in particular fracture of the femur below the implant in eight cases￨sig increase￨highunclear￨highunclear￨highunclear
92￨intertrochanteric fractures of the hip each patient who presented with an extracapsular hip fracture 92 patients with a holland nail and 98 with a dhs preoperative variables included the mini mental test score patient mobility fracture pattern and american society of anesthesiologists grading￨operative stabilisation with either a long intramedullary holland nail or a dhs holland nail with the dynamic hip screw intertrochanteric fracture of the femoral neck with a locked long intramedullary nail with those treated with a dynamic hip screw dhs dhs￨anaesthetic time operating time radiation time and blood loss time to mobilising with a frame wound infection time to discharge time to fracture union and mortality mean time to mobilisation with a frame mean anaesthetic and operation times postoperative blood transfusion mean radiation time mean blood loss￨the mean time to mobilisation with a frame was shorter in the holland nail group dhs 43 days￨sig decrease￨highunclear￨highunclear￨highunclear
10￨trochanteric femur fractures hundred and ten geriatric patients mean age 82 years were runningly included in the study 56 classic nail 54 dhs￨classic nail versus dhs intramedullary hip screw system classicnail and the dynamic hip screw dhs dhs￨functional outcome￨at an average followup of 37 months all fractures were healed with no difference in functional outcome between the two groups￨no diff￨highunclear￨highunclear￨highunclear
146￨146 intertrochanteric fractures￨tgn dynamic hip screw dhs trochanteric gamma nail versus the dynamic hip screw trochanteric gamma nail tgn dhs￨major fracture complications intraoperative blood loss medical complications mortality or length of hospital stay operation time￨any potential for the tgn leading to a less invasive procedure and a more rapid postoperative mobilisation could not be demonstrated￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with unstable intertrochanteric fractures one hundred thirtyone patients 135 fractures who sustained an intertrochanteric fracture intertrochanteric hip fractures￨intramedullary hip screw sliding hip screw or an intramedullary hip screw intramedullary versus extramedullary fixation￨blood loss fluoroscopic time surgical time intraoperative complications rates of functional recovery￨there were no differences in the rates of functional recovery between the two fixation groups￨no diff￨highunclear￨highunclear￨highunclear
60￨oriental patients geriatric patients 60 intertrochanteric fractures of the hip in elderly patients￨compression hip screw chs gamma ap locking nail chs gamma ap asiapacific locking nail gapn￨operation time time to union and the length of sliding of the lag screw intraoperative blood loss mechanical complications such as fracture of the femoral shaft or failure of fixation neck shaft angle￨there were no significant mechanical complications such as fracture of the femoral shaft or failure of fixation in the gamma nail group￨no diff￨highunclear￨highunclear￨highunclear
100￨one hundred elderly patients who had an intertrochanteric femoral fracture one hundred patients fourteen patients who had an intramedullary hipscrew had cortical hypertrophy at the level of the tip of the nail at twelve months postoperatively￨intramedullary hipscrew hemiarthroplasty compression hipscrew compression hipscrew with a plate fifty patients or a new intramedullary device the intramedullary hipscrew￨prevalence of perioperative complications such as bronchopneumonia cardiac failure and urinary tract infection pain mortality rate operative time needed to insert the intramedullary hipscrew intraoperative blood loss intraoperative fracture of the femoral shaft pain without cortical hypertrophy trochanteric wound hematoma sliding of the lagscrew and subsequent shortening of the limb unstable fractures cortical hypertrophy￨the intramedullary hipscrew device was associated with significantly less sliding of the lagscrew and subsequent shortening of the limb in the region of the thigh p  0012 and 0019 respectively these differences were more pronounced when the unstable fractures in the two treatment groups were compared p  0001￨sig decrease￨highunclear￨highunclear￨highunclear
58￨subtrochanteric femoral fractures 58 patients￨closed intramedullary nailing to open reduction and internal fixation using a fixed angle blade plate intramedullary nailing versus fixed angle blade plating intramedullary nailing in or fixed angle blade plating bp internal fixation using a fixed angle blade plate￨revision rate time to surgery operating time receipt of blood transfusions duration of hospital stay or fracture classification￨internal fixation using a fixed angle blade plate for subtrochanteric femoral fractures has higher implant failure and revision rates compared to closed intramedullary nailing￨sig increase￨highunclear￨highunclear￨highunclear
80￨stable trochanteric fractures stable trochanteric hip fractures eighty patients aged 60 and over with stable trochanteric fracture￨gotfried percutaneous compression plate and gamma 3 intramedullary nail minimally invasive osteosynthesis pccp device pccp percutaneous compression plate device and gamma 3 nail￨length of time of operative procedure hemoglobin levels at 6 and 48 h after surgery packed cells units administered and hospital stay hospital stay surgical time blood loss functional outcome at 1year followup neckshaft angle fracture collapse and mortality postoperative complications￨no differences were found in hospital stay surgical time blood loss functional outcome at 1year followup neckshaft angle fracture collapse and mortality￨no diff￨highunclear￨highunclear￨highunclear
210￨aoota 31a2 fractures of the proximal part of the femur two hundred and ten patients presenting with an aoota 31a2 fracture of the proximal part of the femur￨sliding hip screw or a long gamma nail gamma nail with the sliding hip screw long gamma nail or a sliding hip screw￨tipapex distance euroqol 5d outcome scores the mortality rates reoperation rates reoperation within the first postoperative year mortality length of hospital stay transfusion rate change in mobility and residence and quality of life as measured with the euroqol 5d outcome score￨there was no significant difference between the two groups in terms of the euroqol 5d outcome scores the mortality rates after correction for the minimental score or any of the secondary outcome measures￨no diff￨highunclear￨highunclear￨highunclear
200￨200 petrochanteric femoral fractures in elderly patients￨dynamic hip screw and the gamma locking nail gamma nail dynamic hip screw and the gamma locking nail￨femoral shaft fracture intraoperative blood loss rate of wound complications￨there was less intraoperative blood loss and a lower rate of wound complications in the patients treated by the gamma nail￨sig decrease￨highunclear￨highunclear￨highunclear
39￨elderly patients nineteen patients who had been treated with the 95 screwplate nineteen patients in group thirtynine elderly patients with aoota 31a3 intertrochanteric fractures of the femur￨intramedullary nail rather than a 95 screwplate intramedullary nail 95 fixedangle screwplate dynamic condylar screw intramedullary nail proximal femoral nail intramedullary fixation with those of plate fixation reverse oblique and transverse intertrochanteric fractures with use of an intramedullary nail or a 95 degrees screwplate￨operative times fewer blood transfusions and shorter hospital stays implant failure andor nonunion￨patients treated with an intramedullary nail had shorter operative times fewer blood transfusions and shorter hospital stays compared with those treated with a 95 screwplate￨sig decrease￨highunclear￨highunclear￨highunclear
186￨elderly patients 186 fractures treated by either the peritrochanteric fractures￨gamma nails and dynamic hip screws gamma nail or a dynamic hip screw￨intraoperative complications intraoperative bleeding mortality within six months postoperative mobility or hip function shorter convalescence and earlier full weightbearing￨more intraoperative complications were recorded in the gamma nail group mainly due to the mismatching of the femoral component of the nail to the small femurs of chinese people￨sig increase￨highunclear￨highunclear￨highunclear
not found￨120 patients all above 60 years old diagnosed with extracapsular hip fractures classified as ao type 31a2 or type 31a3 unstable trochanteric fractures of patients above 60 years old unstable trochanteric fractures￨tgn ambi tgn and pfn operations pfn ambi tgn and pfn￨￨according to our results the three methods are comparable in the treatment of unstable trochanteric fractures of patients above 60 years old￨no diff￨highunclear￨highunclear￨highunclear
60￨31a2 all surgeons in our unit participated in the study group mean age was 81 years sd  128 range 2396 it was 82 years sd 98 range 4797 in the screwplate group 60 patients hospitalized in an emergency setting for pertrochanteric fractures between december 2003 and june 2004 thirtyone fractures were stable 29 unstable 60 patients 14 men 23 and 46 women 77￨dynamic hip screw synthes and intramedullary fixation targon pf aesculap intramedullary fixation targon pf nail dynamic screw plate and intramedullary fixation targon proximal femoral nail aesculap and the screwplate dynamic hip screw synthes dhs screwplate intramedullary fixation 31a1 intramedullary nailing￨mean blood loss screw migration blood loss patient status asa classification operative data type of implant duration postoperative data blood loss radiographic findings early complications and outcome harris score time to walking mortality mean hospital stay stability complications and cost effectiveness mean harris hip score mean operative time￨mean operative time was 35 minutes for intramedullary nailing and 42 mintues for screwplate fixation￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨fractures of the trochanteric area two groups with thirty fractures of the trochanteric area￨sliding screw plate dynamic hip screw and a miniinvasive static nail sliding screw plates ths locked intramedullary nail with two nonparallel sevenmillimeter cervicocephalic screws￨blood loss postoperative pain surgical procedure time duration of xray irradiation and total blood loss the initial postoperative period complications duration of hospital stay and the time before returning home the time before full weight bearing became effective the functional and social recovery mortality and the quality of immediate and final anatomic restitution and healing time necessary to support full weight bearing walking ability and autonomy recovery but hip function operating time￨postoperative pain p  001 time necessary to support full weight bearing p  002 and time before returning home p  005 were reduced in the nail group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨september 1989 and june 1990 one hundred patients with per and subtrochanteric fractures unstable proximal femoral fractures in the elderly unstable pertrochanteric fractures of geriatric patients three patients in the dhs group with unstable fractures got cranial perforation of the cephalic screw mobilisation￨gammanail or dhs￨operation time for gammanailing intraoperative blood loss of perioperative lethality and in duration of hospital care postoperative blood loss￨the operation time for gammanailing was longer than for dhs implantation and also the postoperative blood loss was higher in the gammanail group￨sig decrease￨highunclear￨highunclear￨highunclear
102￨unstable intertrochanteric fractures in the elderly unstable intertrochanteric femoral fractures in the elderly one hundred and two patients￨intramedullary fixation with an intramedullary hip screw imhs chs compression hip screw chs standard sliding hip screw and the intramedullary hip screw intramedullary hip screw versus sliding hip screw￨radiological or functional outcome mean duration of operation and fluoroscopy screening time technical complications￨the mean duration of operation and fluoroscopy screening time was significantly greater for insertion of the intramedullary hip screw￨sig decrease￨highunclear￨highunclear￨highunclear
203￨unstable trochanteric and subtrochanteric fractures with the proximal femoral nail and the medoff sliding plate 203 patients admitted to two university hospitals with an unstable trochanteric or a subtrochanteric fracture type were included patients with unstable trochanteric or subtrochanteric fractures￨msp pfn proximal femoral nail pfn and the medoff sliding plate msp short intramedullary nail or a dualsliding plate device￨reoperation rate walking ability functional outcome or major complications major complication rate walking ability rising from a chair curb test and additional assessments of abductor strength pain living conditions and complications￨the ability to walk 15 m at 6 weeks was significantly better in the pfn group compared to the msp group with an odds ratio 22 p  004 95 confidence limits 103467￨sig increase￨highunclear￨highunclear￨highunclear
120￨elderly patients hip fractures 120 consecutive patients with an intertrochanteric fracture treated with either extramedullary fixation dynamic hip screw and plate dhs synthesstratec oberdorf switzerland or intramedullary nail gamma nail stryker howmedica freiburg germany and endovis ba citieffe bologna italy￨elsevier ltd screwplating vs intramedullary nailing mmse￨decreased bleeding and postoperative pain reduced postoperative morbidity and faster recovery of function blood loss and the length of operative time mental state mmse their nutritional and immune state and their pulmonary function￨decreased bleeding and postoperative pain reduced postoperative morbidity and faster recovery of function were better but not significant in the group of intramedullary fixation all p005￨no diff￨highunclear￨highunclear￨highunclear
108￨108 patients with a pertrochanteric femoral fracture using either the￨dynamic hip screw dynamic hip screw or a proximal femoral nail dynamic hip screw or the proximal femoral nail proximal femoral nail￨operation time preoperative walking ability￨perioperative or immediate postoperative measures of outcome did not differ between the groups with the exception of operation time￨no diff￨highunclear￨highunclear￨highunclear
206￨206 patients comparing the dynamic hip screw and proximal femoral nail all patients over the age of fiftyfive years presenting with fractures of the trochanteric region caused by a lowenergy injury classified as aoota type 31a1 and a2 206 patients into two study groups those treated by pertrochanteric fractures￨intramedullary nail versus a sliding compression hip screw sliding compression hip screw and an intramedullary nail sliding compression hip screw sliding compression hip screw dynamic hip screw synthesstratec oberdorf switzerland intramedullary nailing￨difficulty of the operation intraoperative complications and blood loss clinical pain social functioning score and mobility score radiologic fracture healing and failure of fixation university level￨there is no advantage to an intramedullary nail versus a sliding compression hip screw for lowenergy pertrochanteric fractures aoota 31a1 and a2 specifically with its increased cost and lack of evidence to show decreased complications or improved patient outcome￨no diff￨highunclear￨highunclear￨highunclear
75￨72 patients 75 consecutive patients with peritrochanteric femur fractures patients with subtrochanteric fractures￨compression hip screw and the gamma nail￨operative morbidity major complications included missed distal locking screws one patient cutting out of the lag screw superiorly￨we found no significant differences in preoperative or intraoperative parameters￨no diff￨highunclear￨highunclear￨highunclear
210￨104 patients and the compression hip screw in 106 210 elderly patients with a new design of the gamma nail trochanteric femoral fractures in elderly patients two hundred ten consecutive patients older than 65 years with trochanteric femoral fractures trochanteric fractures￨trochanteric gamma nail and compression hip screw compression hip screw trochanteric gamma nail or compression hip screw trochanteric gamma nail new intramedullary gamma nail and a compression hip screw￨operative and fluoroscopy times blood loss functional outcome complication rate and failure of fixation fluoroscopy time intraoperative and postoperative complications or rate of fixation failure number of patients transfused and the mean of units of blood transfused operating time functional outcome mortality postoperative walking ability￨there was no difference in intraoperative and postoperative complications or rate of fixation failure between the 2 groups and no case of secondary shaft fracture of the femur was encountered in this study￨no diff￨highunclear￨highunclear￨highunclear
217￨patients with subtrochanteric fractures their mean age was 84 years 65 to 99 and they were reviewed at four and 12 months after surgery unstable trochanteric and subtrochanteric fractures patients with unstable trochanteric fractures 217 patients with an unstable trochanteric or subtrochanteric fracture who had been randomly allocated to treatment by either￨standard gamma nail or the medoff sliding plate internal fixation with a standard gamma nail sgn or a medoff sliding plate msp biaxial dynamisation mode msp sgn￨intraoperative femoral fractures general complications technical failures revision surgery activities of daily living adl hip function charnley score and the healthrelated quality of life hrqol eq5d adl hip function or the hrqol hrqol eq5dindex score rate of technical failure quality of life revision surgery severe general complications wound infections serious general complications and wound infections￨the reduction in the hrqol eq5dindex score was significant in both groups compared with that before the fracture p  0005￨sig increase￨highunclear￨highunclear￨highunclear
3￨between 1993 and 1995 26 patients addressed to our center for a kyle iv 1 fracture￨blade plate versus gamma nail gamma nail 90 degrees blade plate or gamma nail fixation blade plate and the other with gamma nail￨fracture healing￨the two nonunions and the plates breakage didnt need reoperation because of low functional demand￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨intertrochanteric fractures of the femur intertrochanteric fractures of the femur￨sliding screw küntschery nail and a sliding hip screw￨rates of cutting 1year mortality rate￨there was no difference in the rates of cuttingout of the two implants but use of the küntschery nail was associated with a greater incidence of shortening￨no diff￨highunclear￨highunclear￨highunclear
670￨patients with bulky stage iiic or iv ovarian carcinoma in this study or primary surgery in stage iiic or iv ovarian cancer patients with advanced ovarian cancer 670 patients randomly assigned to a study treatment 632 943 were eligible and started the treatment￨neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulking surgery followed by chemotherapy neoadjuvant chemotherapy primary debulking surgery before initiation of chemotherapy iv epithelial ovarian carcinoma fallopiantube carcinoma or primary peritoneal carcinoma to primary debulking surgery followed by platinumbased chemotherapy or to neoadjuvant platinumbased chemotherapy followed by debulking surgery socalled interval debulking surgery￨extensive stage iiic or iv disease complete resection of all macroscopic disease hazard ratio for death intentiontotreat analysis postoperative rates of adverse effects and mortality hazard ratio for progressive disease￨the hazard ratio for death intentiontotreat analysis in the group assigned to neoadjuvant chemotherapy followed by interval debulking as compared with the group assigned to primary debulking surgery followed by chemotherapy was 098 90 confidence interval ci 084 to 113 p001 for noninferiority and the hazard ratio for progressive disease was 101 90 ci 089 to 115￨sig increase￨highunclear￨highunclear￨highunclear
100￨99 cases with normal placentas 49 cases were assigned to the study group 50 cases one hundred women in the third stage of labour after vaginal delivery￨placental cord drainage￨placental cord drainage shortens the duration of third stage labour postpartum hemorrhage uterine atony hypovolemic shock or the need for blood transfusion incidence of postpartum hemorrhage retained placenta manual removal of placenta and the need for blood transfusion placental cord drainage duration of third stage￨there was no postpartum hemorrhage uterine atony hypovolemic shock or the need for blood transfusion in neither groups￨no diff￨highunclear￨highunclear￨highunclear
958￨958 women having a vaginal delivery vaginal deliveries￨drainage method 478 women or controlled cord traction method 480 women for placental delivery placental drainage￨duration of third stage of labour in vaginal deliveries mean duration of third stage of labor mean age parity gestation and birth weight￨the mean duration of third stage of labor was 324 min and 32 min in the placental drainage group in contrast to 857 min and 620 min in controlled cord traction method in primigravida and multigravida respectively￨no diff￨highunclear￨highunclear￨highunclear
104￨2012 national university of health sciences infants with unexplained crying behavior one hundred four patients were randomized infants younger than 8 weeks infants with colic infants with unexplained persistent crying infant colic were recruited between october 2007 and november 2009 at a chiropractic teaching clinic in the united kingdom infant colic￨chiropractic manual therapy parent aware ii infant treated parent unaware and iii infant not treated parent unaware copyright￨crying time crying behavior daily crying diary￨the findings showed that knowledge of treatment by the parent did not appear to contribute to the observed treatment effects in this study￨no diff￨low￨low￨low
28￨infantile colic 28 infants with colic￨cranial osteopathic treatment cranial osteopathic manipulation or no treatment￨time spent crying sleeping and being heldrocked on a 24hour diary overall decline in crying time spent sleeping sleeping parental attention￨overall decline in crying was 63 and 23 respectively for treated and controls improvement in sleeping was 11 and 2￨sig increase￨highunclear￨highunclear￨highunclear
not found￨a private chiropractic practice and the national health services health visitor nurses in the suburb ballerup copenhagen denmark infantile colic￨spinal manipulation spinal manipulation dimethicone￨crying hours of crying￨by trial days 4 to 7 hours of crying were reduced by 1 hour in the dimethicone group compared with 24 hours in the manipulation group p  04￨sig decrease￨highunclear￨highunclear￨highunclear
100￨nine infants were excluded because inclusion criteria were not met and five dropped out leaving 86 who completed the study infantile colic one hundred infants with typical colicky pain￨chiropractic spinal manipulation placebo chiropractic spinal manipulation￨chiropractic spinal manipulation￨thirty two of 46 infants in the treatment group 699 and 24 of 40 in the control group 600 showed some degree of improvement￨no diff￨highunclear￨highunclear￨highunclear
not found￨hivinfected adults 45plus years old hivpositive late middleage and older adults eligible participants reported engaging in at least one occasion of unprotected anal andor vaginal intercourse in the 3 months prior to study enrollment￨telephonedelivered mi one session of telephonedelivered mi or no mi telephonedelivered motivational interviewing mi interventions telephoneadministered motivational interviewing￨risky sexual behavior￨no differences in condom use were observed between 1session mi and control participants￨no diff￨highunclear￨highunclear￨highunclear
not found￨young people living with hiv yplh in los angeles san francisco and new york over 15 months in response to receiving a preventive intervention yplh aged 16 to 29 years n  175 26 black and 42 latino 69 gay men substanceusing hivpositive young people￨yplh 3module intervention totaling 18 sessions delivered by telephone in person or a delayedintervention condition￨hiv risky behaviors and health practices emotional distress￨hiv risky behaviors and health practices were examined among young people living with hiv yplh in los angeles san francisco and new york over 15 months in response to receiving a preventive intervention￨no diff￨highunclear￨highunclear￨highunclear
384￨109 artnaive subjects coenrolled in aids clinical trials group actg 384￨standard clinicbased patient education sc or sc plus structured proactive telephone calls telephone support proactive telephone support￨actg adherence questionnaire overall treatment effect time to regimen failure the kaplanmeier survival curve antiretroviral medication adherence￨for the primary endpoint selfreported adherence a significantly better overall treatment effect was observed in the telephone group p  0023￨sig increase￨low￨low￨low
not found￨n  40 men and women receiving and less than 95 adherent to art to test a single office session followed by four biweekly￨usual care and matched office and cell phonepill count contacts cell phone counseling sessions that were grounded in behavioral selfmanagement model of medication adherence using data from phonebased unannounced pill counts to provide feedbackguided adherence strategies brief behavioral selfregulation counseling￨adherence selfefficacy art adherence￨gains in adherence were paralleled with increased selfefficacy p  005 and use of behavioral strategies for art adherence p  005￨sig increase￨highunclear￨highunclear￨highunclear
79￨seventynine participants hivinfected rural persons with depression hivinfected persons in rural areas persons living with hivaids in rural areas in the united states￨telephonedelivered interpersonal psychotherapy telephonedelivered interpersonal therapy intervention teletherapy usual care control condition or to a sixsession telephonedelivered interpersonal psychotherapy intervention hereafter referred to as the teletherapy group participants in the teletherapy group continued to receive standard services available to them in the community interpersonal psychotherapy delivered via telephone￨depressive symptoms overall levels of psychiatric distress depressive and psychiatric symptoms psychiatric distress depressive and psychiatric symptoms perceptions of loneliness and social support￨the telephonedelivered interpersonal therapy intervention showed potential to reduce depressive and psychiatric symptoms among hivinfected persons in rural areas￨sig decrease￨highunclear￨highunclear￨highunclear
177￨hiv positive outpatients we enrolled 177 persons with beck depression inventory bdi scores scores of 10 among the 160 904 participants who were reinterviewed at 6 months 56 were male and 41 were caucasian with a mean baseline bdi score of 227 coenrolled informal caregivers of hiv patients hiv patients￨psychoeducational telephone support intervention telephonebased intervention telephone support behavioral intervention telephone intervention 12 scheduled psychoeducational calls over 6 months or to an assessmentonly control condition￨depressive symptoms mean bdi scores bdi scores and depression remission￨overall participants mean bdi scores improved 53 points from baseline but intervention group differences on depression outcomes including 50 or greater reduction in bdi scores and depression remission were not statistically significant￨sig decrease￨highunclear￨highunclear￨highunclear
282￨282 subjects enrolled 140 in the usual support measures group and 142 in the calls group persons initiating antiretroviral therapy￨nelfinavir supportive telephone calls sites usual adherence support measures or usual support measures and scripted serial telephone calls serial telephone call￨time to virologic failure virologic failure virologic outcome call completion rates virologic failure likelihood of virologic failure￨virologic failure occurred in 97 34 subjects 52 37 of those in the usual support measures group and 45 32 of those in the calls group time to virologic failure was not different p32￨sig increase￨highunclear￨highunclear￨highunclear
299￨55300 persons were living in small towns and rural areas of the united states at the time of their aids diagnosis participants n299 were recruited through aids service organizations in 13 states and assigned to a hivinfected persons in rural areas of the united states persons living with hivaids in rural areas of the united states￨usual care condition telephonedelivered mental health interventions 8session information support group intervention n84 or an 8session coping improvement group intervention￨depressive and psychological symptoms depression suicidal ideation and anxiety barriers to health care and social services￨ancova revealed that no treatment condition produced reductions in the main outcome measures of depressive and psychological symptoms however information support participants received significantly more support from friends at 4 and 8month followups and reported fewer barriers to health care and social services at 4month followup compared to participants in the other two conditions￨no diff￨highunclear￨highunclear￨highunclear
199￨patients after successful discontinuation of the diet in infants children and adolescents with refractory epilepsy 199 patients enrolled intractable childhood epilepsy epilepsy patients treated with the kd during 1995 through 2003 at the korean multicenters￨ketogenic diet ketogenic diet kd￨efficacy and safety seizure frequency electroencephalography eeg adverse reactions and antiepileptic drug aed number reduction of seizure frequency generalized and focal discharges partial epilepsies efficacy and safety￨eegs showed an improvement in background in 40 727 of 55 patients and a reduction in generalized and focal discharges in 41 577 of 71 and 15 333 of 45 patients￨sig increase￨highunclear￨highunclear￨highunclear
51￨fiftyone children aged 1 to 8 years with more than 10 seizures per week whose electroencephalogram showed generalized epileptiform abnormalities or multifocal spikes and who had failed results when taking at least 2 appropriate antiepileptic drugs 51 children with intractable seizures who were treated with the ketogenic diet patients were enrolled from the clinical practices of 7 sites￨ketogenic diet￨seizures frequency of seizures frequency of seizures free of seizures￨age sex principal seizure type and electroencephalogram were not statistically related to outcome￨no diff￨highunclear￨highunclear￨highunclear
12￨mean age was 3 years range 7 months to 65 years pediatric epilepsy patients with gastrostomy feeding twelve children with static encephalopathy and intractable symptomatic epilepsy children with intractable seizures￨ketogenic diet ketogenic diet via gastrostomy feeding tube ketogenic diet via gastrostomy tube oral ketogenic diet￨seizure frequency diarrhea and weight loss weight loss mean antiepileptic drugs number of antiepileptic drugs seizure reduction mean seizure frequency median seizure reduction￨median seizure reduction at 1 year and 18 months was 61 and 66 respectively p  002￨no diff￨highunclear￨highunclear￨highunclear
9￨adults with refractory epilepsy eligible subjects were 1845 years old with at least two monthly focal seizures with or without secondary generalization documented by 8 weeks followup nine patients were enrolled average age 286 years seven women￨ketogenic diet treatment ketogenic diet kd￨frequency of the seizures cholesterol levels constant ketonuria and increased fat utilization ldl levels average length of kd treatment resting energy expenditure ree substrate utilization body composition and quality of life qol￨the kd increased the cholesterol levels mainly ldl p00001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨epilepsy patients referred and treated for more than 6 months with the ketogenic diet during 19941999 at connecticut childrens medical center the final cohort included 24 of 48 referred patients mean age 65 years range  115 years of age￨￨paroxysmal features hyperuricemia number of antiepileptic drugs seizure frequency epilepsy etiology antiepileptic drug number seizure frequency electroencephalogram backgroundparoxysmal activity and adverse effects at 6 months and 1 year on the ketogenic diet￨intention to treat analysis revealed that 35 17 of 48 achieved more than 50 reduction in seizure frequency and 85 four of 48 were seizurefree by 6 months￨no diff￨highunclear￨highunclear￨highunclear
not found￨fortyeight subjects 24 in each arm were randomized children with intractable epilepsy children ages 1 to 14 years with intractable epilepsy￨fasting versus gradual initiation of the ketogenic diet fasting initiation fastkd or gradual initiation gradkd ketogenic diet kd￨effectiveness acidosis citric acid and sodium citrates severe episodes of hypoglycemia weights electrolytes hydration status vomiting acid balance need for interventions citric acid and sodium citrates bicitra and iv fluids dehydration iv fluids blood glucose vomiting weight fastkd median percentage seizure reduction rate baseline seizure activity￨children in the grad protocol lost significantly less weight p  0006 and had fewer and lesssevere episodes of hypoglycemia p  0001 fewer treatments for acidosis citric acid and sodium citrates p  004 and dehydration iv fluids p  004 but no difference in vomiting was noted￨sig decrease￨highunclear￨highunclear￨highunclear
150￨150 children enrolled prospectively 83 children with difficulttocontrol seizures who were enrolled prospectively in a study of the efficacy of the ketogenic diet and who had remained on the diet for 1 year 150 consecutive children twentynine were free of medications and 28 were on only 1 medication 15 remained on the diet￨￨efficacy and tolerability seizurefree￨there were no known cardiac complications￨no diff￨highunclear￨highunclear￨highunclear
145￨103 children were available for analysis 54 on the ketogenic diet and 49 controls childhood epilepsy 73 children children with treatmentintractable epilepsy 145 children aged between 2 and 16 years who had at least daily seizures or more than seven seizures per week had failed to respond to at least two antiepileptic drugs and had not been treated previously with the ketogenic diet participated children with drugresistant epilepsy since the 1920s￨ketogenic diet￨constipation vomiting lack of energy and hunger seizure reduction mean percentage of baseline seizures tolerability reduction in seizures￨there was no significant difference in the efficacy of the treatment between symptomatic generalised or symptomatic focal syndromes￨no diff￨low￨low￨low
145￨one hundred fortyfive children with intractable epilepsy childhood epilepsy 61 children who started a classical diet and the 64 who started an mct diet data from 94 were available for analysis 45 classical and 49 mct￨classical and mediumchain triglyceride ketogenic diets classical or an mct diet classical and mediumchain triglyceride mct￨serum acetoacetate and betahydroxybutyrate levels seizure frequency tolerability questionnaire and blood ketone levels vomiting mean percentage of baseline seizures efficacy and tolerability tolerability￨there were no significant differences in tolerability except increased reports in the classical group of lack of energy after 3 months and vomiting after 12 months￨no diff￨highunclear￨highunclear￨highunclear
15￨aed treatment resistant epilepsy 15 children with medically intractable epilepsy children and adolescents with medical intractable epilepsy children and adolescents with antiepileptic drug aed treatment resistant epilepsy￨modified atkins diet modified atkins diet￨quality of life and cognition seizure reduction tolerated tolerability and efficacy￨after 3 months six out of the fifteen children 40 had a seizure reduction of more than 50 which was seen in different epileptic syndromes and different age groups￨no diff￨highunclear￨highunclear￨highunclear
26￨twentysix consecutive children were treated with the classical kd from 1996 to 2001 epilepsy syndromes included symptomatic generalized epilepsy 15 idiopathic generalized epilepsy 4 symptomatic partial epilepsy 1 and unclassified epilepsy 6 twelve children 48 were treated for 12 months one still remains on the kd￨ketogenic diet ketogenic diet kd￨seizurefree bone density asymptomatic hypoglycaemia vomiting hyperlipidaemia constipation median duration efficacy and tolerability pancreatitis hypercalcuria￨there were no deaths￨no diff￨highunclear￨highunclear￨highunclear
33￨patients with medically resistant epilepsy medically intractable epilepsy in children 33 consecutive children with medically resistant epilepsy with a group of 50 patients previously treated with kd children with medically resistant epilepsy￨modified atkins diet mad modified atkins diet elsevier ltd mad￨overall tolerance and compliance seizure reduction and tolerability seizure frequency￨although there was a trend for higher incidence of responders in the kd group this failed to reach the level of significance after 6 months 39 on mad and 60 on kd were responders￨no diff￨highunclear￨highunclear￨highunclear
63￨children with epilepsy and migraine 63 children with epilepsy 45 children had epilepsy with migraine hyperkinetic behavior or both and 18 had epilepsy alone 45 children who had epilepsy with recurrent headaches abdominal symptoms or hyperkinetic behavior 25 ceased to have seizures and 11 had fewer seizures during diet therapy 24 children with generalized epilepsy 18 recovered or improved including 4 of 7 with myoclonic seizures and all with petit mal as did 18 of 21 children with partial epilepsy￨oligoantigenic diets placebo oligoantigenic diet treatment￨headaches abdominal pains and hyperkinetic behavior￨in doubleblind placebocontrolled provocation studies symptoms recurred in 15 of 16 children including seizures in eight none recurred when placebo was given￨sig increase￨highunclear￨highunclear￨highunclear
56￨children adolescents and young adults with refractory epilepsy 56 refractory epilepsy young patients age 123 years mean 104 years all with both symptomatic and cryptogenic generalized or partial epilepsies children adolescents and young adults three italian groups of child neuropsychiatrists￨ketogenic diet￨diet efficacy and seizure or epilepsy type age at diet onset sex and etiology of epilepsy seizure frequency seizure frequency side effects urine and blood ketone levels efficacy and safety adverse effects￨this initial experience with the ketogenic diet was effective in difficulttotreat patients with partial and generalized epilepsies though its efficacy dropped significantly by 912 months￨sig increase￨highunclear￨highunclear￨highunclear
not found￨adults with epilepsy adults with intractable epilepsy adults over 18 years of age having at least weekly seizures and prior use of at least two anticonvulsants thirty patients with age ranging from 18 to 53 years were enrolled intractable epilepsy in adults￨modified atkins diet￨blood urea nitrogen bodymass index bmi cholesterol mean weight loss median time to improvement urine calcium to creatinine ratio￨the mean weight loss was 68 kg p  0001￨sig decrease￨highunclear￨highunclear￨highunclear
76￨seventysix patients with refractory childhood epilepsy￨ketogenic diet kd diets with nonlipid ketogenic diet kd￨seizure free outcome antiepileptic efficacy and diet tolerability antiepileptic efficacy seizure reduction antiepileptic efficacy and diet tolerability gastrointestinal symptoms efficacy and tolerability seizure reduction antiepileptic efficacy lipid ratios dietary tolerability 2 dietary tolerability￨antiepileptic efficacy was higher for the 41 than the 31 diet p  005￨sig increase￨highunclear￨highunclear￨highunclear
132￨fortynine apctreated patients and 55 heparintreated patients were evaluated for efficacy and 52 apctreated patients and 55 63 patients received one hundred thirtytwo patients with dic were enrolled in this study disseminated intravascular coagulation￨apc heparin activated protein c and unfractionated heparin human activated protein c apc and unfractionated heparin￨death rate alleviation of bleeding aggravation of bleeding severe adverse events fibrinogen protein c and antithrombin dicrelated organ dysfunction fibrinogenfibrin degradation products ddimer thrombinantithrombin complex tat and plasminplasmin inhibitor complex pic improvement of coagulationfibrinolysis rate of death safety and efficacy platelet count￨fibrinogen protein c and antithrombin were significantly increased in the apc group whereas only protein c was significantly increased in the heparin group￨sig increase￨highunclear￨highunclear￨highunclear
10￨acute leukemia 10 patients with acute leukaemia￨heparin dermatan sulphate ds and heparin h dermatan sulphate￨activated partial thromboplastin time and thrombin time time courses of the coagulation and fibrinolysis markers for dic efficacy and safety￨the time courses of the coagulation and fibrinolysis markers for dic were similar in the two treatment groups except for activated partial thromboplastin time and thrombin time which were prolonged in the h but not in the ds group￨no diff￨highunclear￨highunclear￨highunclear
234￨dic patients n  234 dic patients disseminated intravascular coagulation￨art123 recombinant human soluble thrombomodulin art123 heparin therapy art123 therapy heparin heparin sodium 8 u kg1￨clinical course of bleeding symptoms and mortality rate at 28 days clinical course of bleeding symptoms dic and alleviates bleeding symptoms incidence of bleedingrelated adverse events dic dic resolution rate￨the incidence of bleedingrelated adverse events up to 7 days after the start of infusion was lower in the art123 group than in the heparin group 431 vs 565 p  00487￨sig decrease￨low￨low￨low
not found￨cystic fibrosis cf cystic fibrosis￨alternateday prednisone placebo alternateday prednisone therapy￨morbidity and progression of lung disease height weight vital capacity forced expiratory volume in 1 s peak flow rate erythrocyte sedimentation rate and serum igg pulmonary function mild to moderate lung disease￨the prednisonetreated group required 9 admissions to hospital for cfrelated pulmonary disease compared with 35 for the placebo group￨sig increase￨highunclear￨highunclear￨highunclear
24￨cystic fibrosis patients 24 children with cystic fibrosis￨oral prednisolone placebo prednisolone prednisolone corticosteroids￨interleukin1 alpha soluble interleukin2 receptor and igg concentrations spirometry and serum concentrations of interleukin1 alpha il1 alpha soluble interleukin2 receptor sil2r and igg serum igg and cytokine concentrations change in pulmonary function forced expiratory volume￨the treated group n  12 experienced an increase in forced expiratory volume in one second and forced vital capacity at 14 days however these changes were smaller at 12 weeks￨sig increase￨highunclear￨highunclear￨highunclear
285￨15 north american cystic fibrosis centers we screened 320 patients and enrolled 285 patients from april 1986 to december 1987 patients with mildtomoderate cystic fibrosis during a 4year period patients with cystic fibrosis patients with mild to moderate cystic fibrosis￨prednisone placebo alternateday prednisone therapy￨serum igg concentrations lung function clinical status hospitalizations growth and steroid side effects forced expiratory volume forced vital capacity height z scores abnormalities in glucose metabolism height z scores fell efficacy and safety￨the prednisonetreated groups had a reduction in serum igg concentrations 1 mgkg vs placebo p  0007 2 mgkg vs placebo p  0003￨sig increase￨highunclear￨highunclear￨highunclear
not found￨twenty patients 938 had an abnormal dobutamine stress echocardiogram eleven patients had 15 cardiac events over a mean patients with juvenile onset insulindependent diabetes mellitus who are being considered for kidney andor pancreas transplantation into highor lowrisk groups for future cardiac events patients with insulindependent diabetes mellitus before kidney andor pancreas transplantation before kidney andor pancreas transplantation accurately stratifies patients with juvenile onset insulindependent diabetes being considered for kidney andor pancreas transplantation for risk of future cardiac events￨dobutamine stress echocardiography￨event rates cardiac events including cardiac death nonfatal myocardial infarction unstable angina pulmonary edema and need for coronary revascularization occurring between the time of the dobutamine stress echocardiogram and the last patient followup contact￨the result of the dobutamine stress test independently predicted prognosis in a multivariate analysis p  0003 odds ratio  127￨sig increase￨highunclear￨highunclear￨highunclear
not found￨type i diabetes patients with end stage renal disease eighty patients with type i diabetes and end stage renal disease￨dipyridamolethallium201 scintigraphy and quantitative coronary angiography dipyridamole￨prevalence of coronary artery disease￨there were no significant differences in the accuracy of the two dipyridamole tests sensitivity  85 specificity  85 accuracy  85 for the oral group sensitivity  86 specificity  72 accuracy  79 for the intravenous group￨no diff￨highunclear￨highunclear￨highunclear
30￨endstage renal disease patients with esrd n  97 underwent patients with esrd 30 patients and 25 underwent renal transplantation in the followup period patients with endstage renal disease esrd￨dobutamine stress echocardiography dse dse dobutamine stress echocardiography coronary angiography￨inducible ischemia in 4 and catheterization before death revealed multivessel cad￨dse had a sensitivity of 95 92 for 1vessel 100 for  or  2vessel disease specificity of 86 and accuracy of 90 for the detection of cad￨sig increase￨highunclear￨highunclear￨highunclear
not found￨renal transplant candidates fifty renal transplant candidates with diabetic nephropathy 39 patients or endstage renal disease esrd from other causes 11 patients underwent prospectively performed diabetic renal transplant candidates￨dse prophylactic coronary revascularization coronary angiography dobutamine stress echocardiography dse dse followed by quantitative coronary angiography qca dobutamine stress echocardiography￨cardiac death or mi cardiac death myocardial infarction mi or coronary revascularization sensitivity and specificity of dse for cad diagnosis positive for inducible ischemia￨the sensitivity and specificity of dse for cad diagnosis were respectively 52 and 74 compared with qca stenosis of 50 or greater 75 and 71 compared with qca stenosis greater than 70 and 75 and 76 for stenosis greater than 75 by visual estimate￨sig increase￨highunclear￨highunclear￨highunclear
185￨29 mgd 27 were smokers 86 had hypertension 54 had diabetes 57 were dyslipidemic with endstage renal disease 38 patients who underwent 2010 american society of echocardiography 11 years 64 were men creatinine level of 73 after renal transplantation 185 patients age 56 patients undergoing rt￨atropine preoperative dobutamine stress echocardiography dse coronary angiography￨regional left ventricular wall motion abnormality wma cardiovascular outcome 48month mace angiographic coronary artery disease rate of mace left atrial enlargement 48month mace cardiac death nonfatal acute myocardial infarction and coronary revascularization after rt renal transplantation rt aortic valve sclerosis￨patients with all 3 predictors had a 48month mace of 60 compared with 5 in those with none p  007￨sig increase￨highunclear￨highunclear￨highunclear
not found￨prospective renal transplant recipients highrisk patients with chronic renal failure￨tachycardicstress scintigraphy tachycardicstress exercisepacing scintigraphy with coronary angiography tachycardicstress perfusion imaging￨￨with a negative predictive value of 92 tachycardicstress scintigraphy may reduce the need for unnecessary coronary angiography in these patients￨sig increase￨highunclear￨highunclear￨highunclear
not found￨47 patients mean age 379 years without clinical evidence of coronary artery disease were reviewed diabetic patients undergoing evaluation for transplantation diabetic patients for renal and pancreas transplantation diabetic patients awaiting kidney andor pancreas transplantation diabetic patients with nephropathy before kidney andor pancreas transplantation￨pharmacologic stress thallium scintigraphy and also exercise radionuclide ventriculography with coronary angiography pharmacologic stress thallium scintigraphy pharmacologic stress thallium scintigraphy and exercise radionuclide ventriculography￨pharmacologic stress thallium scintigraphy adverse cardiac outcomes sensitivity￨sensitivity was 62 and specificity was 76 for detecting  or  75 coronary artery stenosis sensitivity was 53 and specificity was 73 for  or  50 stenosis￨sig increase￨highunclear￨highunclear￨highunclear
18￨18 patients with endstage renal disease undergoing maintenance dialysis dialysis patients uremic patients￨electronbeam computerized tomography ebct electronbeam computerized tomography ebct with contemporaneous coronary angiography ebct￨degree of vessel stenosis and calcification score specificity coronary artery calcification calcification score angiographic evidence of stenotic disease￨there was no significant correlation between degree of vessel stenosis and calcification score for individual vessels in patients with a positive calcium scan￨sig increase￨highunclear￨highunclear￨highunclear
126￨one hundred twentysix renal transplant candidates who were classified as at moderate or50 years or high diabetes extracardiac atherosclerosis or clinical coronary artery disease coronary risk underwent myocardial scintigraphy spect dobutamine stress echocardiography and ca and were followed for 6 to 48 months￨coronary angiography coronary angiography ca￨probability of eventfree survival crude probability of surviving free of cardiac events prevalence of cad cardiac events risk stratification￨the probability of eventfree survival at 6 12 24 36 and 48 months were 98 98 94 94 and 94 in patients with 70 stenosis on ca and 97 87 61 56 and 54 in patients with or70 stenosis￨no diff￨highunclear￨highunclear￨highunclear
7￨diabetic patients with endstage renal disease juvenile diabetic patients treated for endstage renal disease eleven consecutive diabetic patients without clinical evidence of coronary artery disease underwent complete cardiac evaluations including coronary arteriography as part of transplant recipient workups seven were women and four were men their mean age was 32 21 to 50 years￨￨progressive disease of the coronary circulation normal renal allograft function and serum lipid levels multifocal atherosclerotic coronary disease positivestress electrocardiograms￨the mode of endstage renal disease treatment serum lipids or blood pressure control could not be linked to mortality￨no diff￨highunclear￨highunclear￨highunclear
140￨patients with endstage renal disease one hundred and forty renal transplant candidates had dse and coronary angiography￨dobutamine stress echocardiography dobutamine stress echocardiography dse￨sensitivity specificity positive and negative predictive values mortality peak systolic velocity psv circumflex artery disease luminal stenosis sensitivity for singlevessel cad ischemic response￨sensitivity for singlevessel cad p005 and circumflex artery disease p005 diagnosis was higher with psv compared with conventional dse analysis￨sig increase￨highunclear￨highunclear￨highunclear
45￨coronary artery disease cad patients with endstage renal failure 45 patients with endstage renal failure undergoing evaluation for renal transplantation nineteen patients 42 had an obstruction of 50 or more in at least one coronary artery￨coronary arteriography dipyridamole spect thallium imaging dipyridamole spect thallium imaging dipyridamole spect thallium imaging dipyridamole single photon emission computed tomography spect thallium￨positive thallium scan sensitivity normal thallium imaging coronary artery disease at cardiac catheterization died of cardiac causes￨the sensitivity was considerably lower than that quoted for nonesrf patients in the literature and significantly lower than a control group of 19 patients without esrf having comparable severity and distribution of cad￨sig increase￨highunclear￨highunclear￨highunclear
30￨patients with chronic renal failure crf patients with normal renal function 30 patients 13 males mean age 57 12 control patients with normal renal function mean creatinine 05 mgdl and 18 patient with crf mean creatinine 25 mgdl all 30 patients had a normal dse based on systolic regional function and a normal coronary angiogram patients with crf patients with chronic renal failure￨dobutamine stress echocardiography dse dse and coronary angiography dobutamine￨filling pressures early diastolic annular velocity e and prolongation of the time to e e a ea dt or ivrt lower s and e velocities left ventricular lv diastolic function time to e at peak stress abnormal tissue doppler tdderived indices conventional peak early e and late a transmitral ea ratio ewave deceleration time dt and isovolumic relaxation time ivrt and tdderived indices lateral annular systolic s early diastolic e and late atrial velocities a time to e and ee annular systolic velocity s￨despite normal coronaries patients with crf demonstrated lower s and e velocities at peak stress compared to the control patients 80￨sig increase￨highunclear￨highunclear￨highunclear
86￨patients with endstage renal disease coronary artery disease eightysix patients under evaluation for renal transplantation and considered at increased patients with chronic renal failure￨digital subtraction fluorography￨significant coronary disease risk of coronary artery disease￨the detection of coronary calcification by digital subtraction fluorography had a sensitivity of 78 and a specificity of 66￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with endstage renal disease esrd following renal transplant pretransplant end stage renal disease patients with esrd patients with esrd using coronary angiography cag as the gold standard enrolled consecutive patients with esrd who underwent cag as a part of pretransplant evaluation to rule out the presence of atherosclerotic cad￨carotid imt carotid intimal medial thickness cimt carotid intimal medial thickness￨sensitivity and specificity mean cimt￨patients with cimt 075 mm were older and had more incidence of diabetes78 vs 47 p0001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨chronic renal failure crf patients crf patients ninetyseven 97 crf patients aged  or 35 were evaluated pretransplant renal chronic failure￨ct scan evaluation of coronary calcium score ccs ccs￨agatston mean score obstructive cad cardiovascular events highest probability of coronary stenosis zero calcium score￨agatston calcium score showed high accuracy for the diagnosis of  or 50 and  or 70 stenosis with area under roc curve auc of 075 and 070 respectively￨no diff￨highunclear￨highunclear￨highunclear
133￨thirtythree patients at high risk for coronary artery disease were selected from a cohort of 133 renal transplant candidates and underwent both dse and ca patients with endstage renal disease risk assessment prior to renal transplantation￨dse coronary angiography ca preoperative dobutamine stress echocardiography versus cardiac arteriography dobutamine stress echocardiography dse￨￨a negative dse coupled with a negative clinical cardiac evaluation was found to practicably exclude the necessity for ca￨no diff￨highunclear￨highunclear￨highunclear
4￨forty 36 male four female type 2 diabetic patients with endstage renal disease esrd mean age of the patients was 492 type 2 diabetes mellitus dm patients undergoing renal transplantation 5 years range 3960 years patients with diffuse diabetic coronary artery disease had negative dse type 2 diabetic patients who are renal transplant candidates type 2 diabetic patients undergoing evaluation for renal transplantation￨dse dobutamine stress echocardiography dse ca dse followed by ca ischaemia imaging dse with coronary angiography ca￨triple vessel disease dse sensitivity and specificity in identifying cad coronary artery disease￨the sensitivity and specificity in identifying cad was 473 and 952 respectively while positive predictive value and negative predictive value was 90 and 66￨sig increase￨highunclear￨highunclear￨highunclear
794￨tuberculosis among adolescents a total of 794 adolescents were recruited into the study for a 79 participation rate adolescents infected adolescents at two health centers serving ethnically diverse populations￨peer counseling and a participantparent contingency contract intervention innovative educational strategies behavioral interventions￨overall rate of treatment completion selfefficacy selfefficacy and mastery￨participants randomized to the peer counseling groups demonstrated significantly greater improvements in selfefficacy and mastery than the usual care control group￨sig increase￨highunclear￨highunclear￨highunclear
558￨san francisco city and county jail san francisco calif 558 inmates enrolled 325 were released before completion of therapy subjects undergoing therapy for latent tuberculosis infection who spoke either english or spanish persons with latent tuberculosis infection after release from jail￨education every 2 weeks while in jail an incentive if they went to the san francisco county tuberculosis clinic within 1 month of release or usual care￨completion of a visit to the tuberculosis clinic within 1 month of release and completion of therapy likely to complete a first visit￨those in the education group were twice as likely to complete therapy compared with controls adjusted odds ratio 22 95 confidence interval 104472 p 04￨sig increase￨low￨low￨low
not found￨two hundred consecutively seen patients who had an injury to either the anterior cruciate ligament or the medial collateral ligament or both￨conservative or a surgical regimen￨￨injuries to the medial collateral ligament could not be demonstrated to benefit from surgical treatment in any respectwith or without surgery the results were excellent￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with cervical pain patients with mechanical neck pain patients presenting with neck pain patients with neck pain￨thoracic manipulation thoracic spine manipulation￨pain levels immediate analgesic effects￨often physical therapists will incorporate manual therapies directed at the cervical spine including joint mobilization and manipulation into the management of patients with cervical pain￨sig decrease￨highunclear￨highunclear￨highunclear
20￨patients with subacute peripheral neurogenic cervicobrachial pain twenty patients with subacute peripheral neurogenic cervicobrachial pain patients with neurogenic cervicobrachial pain￨cervical lateral glide treatment technique contralateral lateral glide technique cervical mobilization and therapeutic ultrasound mobilization or ultrasound group￨range of elbow extension symptom distribution and pain intensity pain intensity area of symptom distribution elbow extension￨significant differences in treatment effects between the 2 groups could be observed for all outcome measures p  or  0306￨sig increase￨highunclear￨highunclear￨highunclear
12￨twelve participants were screened and 6 patients patients with subacute or chronic neck pain patients were recruited in the quad cities in iowa and illinois￨cervical spine hvla sm or to the combined therapeutic approach cervical spine hvla sm combined therapeutic approach thoracic spine and sacroiliac joint highvelocity lowamplitude spinal manipulation hvla sm  cervical spine postisometric relaxation￨neck disability index neck disability index visual analog scale and posttreatment response questionnaire visual analog scale discomfort or an unpleasant reaction￨five patients completed the posttreatment response questionnaire 2 of the 5 indicated they experienced discomfort or an unpleasant reaction from the study treatments￨no diff￨highunclear￨highunclear￨highunclear
70￨subjects presenting with mechanical neck pain seventy patients with mechanical neck pain 25 males and 45 females aged 2055 years subjects suffering from mechanical neck pain mechanical neck pain subjects￨single cervical hvla manipulation single cervical highvelocity lowamplitude hvla manipulation or a control mobilization procedure single cervical highvelocity lowamplitude manipulation hvla thrust or a control group which received a manual mobilization procedure￨flexion neck pain decreased neck pain and increased range of motion neck pain and active range of motion lateral flexions active cervical range of motion and neck pain neck pain and neck mobility neck mobility￨decreased neck pain and increased range of motion were negatively associated for all cervical motions the greater the increase in neck mobility the less the pain at rest￨sig increase￨highunclear￨highunclear￨highunclear
52￨52 patients in general practice￨cervial spine￨painparaesthesia measured rotation pain or stiffness in the neck and painparaesthesia lateral flexion￨manipulation also produced a significant increase in measured rotation that was maintained for three weeks and an immediate improvement in lateral flexion that was not maintained￨sig increase￨highunclear￨highunclear￨highunclear
70￨seventy patients with cervicogenic headache patients with cervicogenic headache￨manipulation treatment and transcutaneous electrical nerve stimulation manipulation treatment and transcutaneous electrical nerve stimulation tens manipulation treatment and tens treatment￨response rate of manipulation treatment headache nrs score frequency lasting time headache nrs scores  frequency lasting time and the rom scores headache nrs score headache degree numeric rating scale nrs frequency lasting time and the range of motion rom of the cervical spine rom scores￨before treatment there were no significant differences in the headache nrs scores  frequency lasting time and the rom scores between the two groups p005￨no diff￨highunclear￨highunclear￨highunclear
75￨seventyfive subjects aged 3055 years from a random sample of 241 employees of the finnish broadcasting company neck pain in occupational health care￨instructions for physiotherapeutic exercises active or passive treatment physiotherapeutic exercises personal exercise program￨neckshoulder pain muscle tenderness and tender thoracic levels￨a statistically significant difference was found in selfreported worst pain by vas at the 12 month followup in favour of the thoracic manipulation group￨sig increase￨highunclear￨highunclear￨highunclear
77￨specialized spinal pain syndrome outpatient unit at townsville general hospital queensland australia managing chronic 13 weeks duration spinal pain syndromes patients with chronic spinal pain syndromes spinal manipulation seventyseven patients without contraindication to manipulation or medication were recruited chronic spinal pain syndromes￨acupuncture nonsteroidal antiinflammatory medication or chiropractic spinal manipulation acupuncture needle acupuncture medication tenoxicam with ranitidine and spinal manipulation￨neck pain spinal manipulation scores of the 1 oswestry back pain disability index 2 neck disability index and 3 three visual analogue scales of local pain intensity neck disability index and 3 reductions on the visual analogue scale￨neither of the other interventions showed any significant improvement on any of the outcome measures￨no diff￨highunclear￨highunclear￨highunclear
not found￨mechanical neck pain patients presenting with unilateral symptoms patients presenting with unilateral neck pain patients n60 2 physical therapists and 1 assessor involved in this study￨random mobilization group by using an opaque concealed envelope unilateral posteroanterior pa mobilization technique mobilization technique￨neck pain at rest and pain on most painful movement pain and active range of motion rom pain and range of motion pain and active cervical rom pain intensity active cervical rom and global perceived effect active cervical rom￨after mobilization there were no apparent differences in pain and active cervical rom between groups￨no diff￨highunclear￨highunclear￨highunclear
100￨outpatient teaching clinic on primary and referred patients one hundred consecutive outpatients suffering from unilateral neck pain with referral into the trapezius muscle were studied seventyeight subjects had a past history of neck pain fiftytwo subjects were manipulated and 48 subjects were mobilized cervical spine thirtyone subjects had been involved in an injurious motor vehicle accident and 28 subjects had other types of minor trauma to the neck patients with mechanical neck pain the mean sd age was 345 130 yr for the manipulated group and 377 125 yr for the mobilized group neck pain patients￨single rotational manipulation highvelocity lowamplitude thrust or mobilization in the form of muscle energy technique manipulation versus mobilization￨neck pain cervical spine range of motion pain intensity pain and range of motion pain range of motion pain disability index pain improvement 101point numerical rating scale nrs101 history of neck pain or level of disability￨there were no significant differences between the two treatment groups with respect to history of neck pain or level of disability as measured by the pain disability index￨no diff￨highunclear￨highunclear￨highunclear
not found￨mechanical neck pain 15 subjects diagnosed with mechanical neck pain￨placebo supine lateral break manipulations cervical rotary manipulations supine cervical rotatory manipulation and the supine lateral break manipulation lateral flexion fixation supine cervical rotary manipulation and the supine lateral break manipulation￨subjective numerical pain rating scale 101 mcgill shortform pain questionnaire and the canadian memorial chiropractic college neck disability index and objective cervical range of motion goniometer and algometer measurement parameters pain andor discomfort￨intergroup analysis did not reveal any significant difference between the 2 groups when comparing the data of the initial consultation and the final consultation indicating that both treatments had a similar or equal effect￨no diff￨highunclear￨highunclear￨highunclear
53￨subjects were recruited from 450 headache sufferers who responded to newspaper advertisements fiftythree subjects suffering from frequent headaches who fulfilled the international headache society criteria for cervicogenic headache excluding radiological criteria cervicogenic headache￨spinal manipulation isolated intervention of highspeed lowamplitude spinal manipulation lowlevel laser in the upper cervical region and deep friction massage highvelocity lowamplitude cervical manipulation￨number of headache hours per day headache intensity per episode￨the use of analgesics decreased by 36 in the manipulation group but was unchanged in the softtissue group this difference was statistically significant p  04 chi 2 for trend￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨twentyone with symptomatic cervical spondylosis or nonspecific neck pain chronic neck pain eighteen patients served as controls and also received￨diazepam￨mean visual analog scales for pain and activity￨statements of outcome by patients and mean visual analog scales for pain and activity showed no significant differences between manipulation and control groups though both tests favored manipulation￨no diff￨highunclear￨highunclear￨highunclear
30￨thirty patients diagnosed with neck pain and restricted cervical spine range of motion without complicating pathosis for at least 1 month were included in the study cervical spine dysfunction outpatient chiropractic clinic technikon natal south africa￨specific therapeutic intervention no other treatment modalities or interventions including medication hvla instrumental mfma manipulation and manual hvla manipulation instrumentdelivered thrust cervical manipulations mfma mechanical force manually assisted mfma manipulation to the cervical spine delivered by means of a handheld instrument activator ii adjusting instrument traditional manualdelivered thrust cervical manipulations instrumental mfma versus manual hvla manipulation specific contact highvelocity lowamplitude hvla manipulation consisting of standard diversified rotarylateral break techniques￨change in left rotation subjective numerical pain rating scale 101 mcgill shortform pain questionnaire and neck disability index and objective goniometer cervical range of motion measurement parameters at specific intervals pain and disability￨the results indicate that both treatment methods had a positive effect on the subjective and objective clinical outcome measures no significant difference being observed between the 2 groups p  025￨no diff￨highunclear￨highunclear￨highunclear
32￨patients experiencing pain during bilateral cervical rotation twentytwo patients study participants included a sample of convenience that included 32 patients referred to physical therapy with complaints of pain in the midcervical region and restricted active cervical rotation￨no intervention upper thoracic translatoric spinal manipulation translatoric spinal manipulation tsm tsm￨cervical pain and cervical active motion restriction cervical rotation and pain cervical pain motion and pain scale measurements cervical pain and range of motion active cervical rotation range of motion pain levels cervical rotation rom cervical inclinometer crom and cervical pain status mdc95￨pain levels perceived during postintervention cervical rotation showed significant improvement during right rotation for patients experiencing pain during bilateral rotation only p05￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with neck pain fortyfive patients 21 females patients with acute neck pain population with mechanical neck pain patients with mechanical neck pain receiving￨electrothermal therapy electrothermal therapy program in addition to a thoracic spine thrust manipulation thoracic spine thrust manipulation thoracic spine manipulation￨disability pain 100mm visual analogue scale disability 100point disability scale and cervical range of motion pain improvement scores pain pain mobility and disability￨the experimental group also experienced significantly greater improvements in disability with a betweengroup difference of 88 points 95 confidence interval ci 75 101 p 001 at the fifth visit and 80 points 95 ci 58 102 p 001 at the 2week followup￨sig increase￨low￨low￨low
24￨chronic cervicogenic headache and associated neck pain private practice in a college outpatient clinic and in the community twentyfour adults with chronic cervicogenic headache￨highvelocity lowamplitude spinal manipulation￨pain relief 100point modified von korff pain and disability scales and headaches in last 4 weeks￨at the 12week followup the advantage was 194 p  035 for 3 visits per week and 181 p  048 for 4 visits per week￨sig increase￨highunclear￨highunclear￨highunclear
not found￨chronic neck pain nine subjects with chronic mechanical neck pain syndromes￨spinal manipulation oscillatory mobilization of the cervical spine￨pressure pain threshold ppt local paraspinal pain threshold levels pressure pain pressure pain thresholds￨in the control group no change in any of the pressure pain thresholds was found￨no diff￨highunclear￨highunclear￨highunclear
960￨neckpain patients 960 eligible patients 336 enrolled in the study patients with neck pain￨chiropractic manipulation and mobilization manipulation with or without heat manipulation with or without electrical muscle stimulation mobilization with or without heat and mobilization with or without electrical muscle stimulation cervical spine manipulation and mobilization￨pain and disability￨mean reductions in pain and disability were similar in the manipulation and mobilization groups through 6 months￨no diff￨highunclear￨highunclear￨highunclear
not found￨symptomatic nasal polyposis sinonasal polyposis subjects with symptomatic endoscopically diagnosed sinonasal polyposis￨oral prednisolone systemic corticosteroids placebo topical and systemic corticosteroids prednisolone mri scanning and quantitative nasendoscopic photography￨polyp size mri nasal symptoms modified 31item rhinosinusitis outcome measure questionnaire physicians assessment nasendoscopy with photography and mri￨the outcome measures correlated with each other the highest level of correlation was between the objective measures of nasendoscopy and mri r2  076 p  001￨sig increase￨low￨low￨low
47￨patients with chronic rhinosinusitis and nasal polyps 47 participants with bilateral nasal polyps￨doxycycline methylprednisolone placebo oral glucocorticoids and doxycycline methylprednisolone and doxycycline methylprednisolone methylprednisolone and doxycycline￨levels of ecp il5 and ige in nasal secretions markers of inflammation such as eosinophilic cationic protein ecp il5 myeloperoxidase matrix metalloproteinase 9 and ige size of nasal polyps nasal symptoms and mucosal and systemic markers of inflammation levels of myeloperoxidase ecp and matrix metalloproteinase 9 in nasal secretions symptoms and objective clinical and biological parameters nasal peak inspiratory flow and symptoms and by nasal endoscopy nasal polyp size concentrations of eosinophils ecp and soluble il5 receptor alpha￨markers of inflammation such as eosinophilic cationic protein ecp il5 myeloperoxidase matrix metalloproteinase 9 and ige were measured in nasal secretions￨sig increase￨low￨low￨low
not found￨patients with severe nasal polyps patients with severe nasal polyps patients with nasal polyps￨oral prednisone intranasal steroids intranasal budesonide treatment no steroid treatment control oral steroids￨improvement of all sf36 domains physical component summary severe nasal polyposis quality of life nasal obstruction sense of smell and polyp size￨patients with nasal polyps showed worse scores on all sf36 domains except for physical functioning compared to the spanish general population￨sig increase￨highunclear￨highunclear￨highunclear
78￨between december 6 2006 and september 21 2007 communitydwelling patients over age 55 years alzheimers disease 78 patients￨50 mg pbt2 250 mg pbt2 or placebo placebo pbt2 acetylcholinesterase inhibitor donepezil galantamine or rivastigmine￨csf abeta42 concentration plasma biomarkers of ad or serum zn2 and cu2 concentrations plasma and csf biomarkers and cognition early ad minimental state examination mmse score between 20 and 26 points or alzheimers disease assessment scalecognitive subscale adascog score adverse event safety efficacy and biomarkers of ad serious adverse events safety and tolerability cognitive efficacy safety efficacy category fluency test adascog mmse and a neuropsychological test battery ntb￨of these tests two executive function component tests of the ntb showed significant improvement over placebo in the pbt2 250 mg group category fluency test 28 words 01 to 54 p0041 and trail making part b 480 s 830 to 130 p0009￨sig increase￨low￨low￨low
36￨alzheimer disease thirtysix subjects patients with moderately severe alzheimer disease￨iodochlorhydroxyquin clioquinol placebo clioquinol a metalproteinattenuating compound mpac￨plasma abeta42 levels plasma zinc levels tolerated￨the effect of treatment was significant in the more severely affected group baseline cognitive subscale score of the alzheimers disease assessment scale 25 due to a substantial worsening of scores in those taking placebo compared with minimal deterioration for the clioquinol group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients who were receiving hemodialysis and who had inadequately controlled secondary hyperparathyroidism despite standard treatment patients receiving hemodialysis massachusetts medical society patients receiving dialysis patients receiving hemodialysis who have uncontrolled secondary hyperparathyroidism￨vitamin d and calcium placebo calcimimetic agent cinacalcet hydrochloride cinacalcet￨intact parathyroid hormone levels serum calciumphosphorus product percentage of patients with values in this range during a 14week efficacyassessment phase safety and effectiveness mean parathyroid hormone values parathyroid hormone levels￨the serum calciumphosphorus product declined by 15 percent in the cinacalcet group and remained unchanged in the placebo group p0001￨sig decrease￨low￨low￨low
21￨twentyone patients undergoing hemodialysis three times per week with plasma pth levels between 300 and 1200 pgml patients with secondary hyperparathyroidism 105 hemodialysis patients with mild secondary hyperparathyroidism patients with secondary hyperparathyroidism caused by endstage renal disease￨placebo￨pth levels fell ionized calcium concentrations predose pth levels plasma parathyroid hormone levels plasma pth and blood ionized calcium levels blood ionized calcium levels plasma pth levels plasma parathyroid hormone pth levels pretreatment pth levels serum total and blood ionized calcium concentrations predose pth levels￨blood ionized calcium levels also decreased after the first dose of r568 but did not change in patients given placebo￨no diff￨highunclear￨highunclear￨highunclear
71￨secondary hyperparathyroidism in endstage renal disease esrd seventyone hemodialysis patients with uncontrolled secondary hyperparathyroidism despite standard therapy with calcium phosphate binders and active vitamin d sterols esrd patients secondary hyperparathyroidism of endstage renal disease￨amg 073placebo calcium and active vitamin d placebo amg￨incidence of vomiting calcium x phosphorus levels pth and calcium x phosphorus levels adverse event rates mean pth plasma pth serum calcium serum phosphorus and calcium x phosphorus levels efficacy and safety￨mean pth decreased by 33 in the amg 073 patients compared with an increase of 3 in placebo patients p  0001￨sig increase￨highunclear￨highunclear￨highunclear
52￨many patients with secondary hyperparathyroidism due to endstage renal disease fiftytwo hemodialysis patients with secondary hyperparathyroidism patients with endstage renal disease hemodialysis patients with secondary hyperparathyroidism￨calcimimetic agent amg 073 ranging from 5 to 100 mg or placebo vitamin d sterols placebo amg￨plasma parathyroid hormone levels serum phosphorus levels plasma pth levels serum calcium concentrations plasma pth levels plasma parathyroid hormone pth￨serum calcium concentrations also decreased by 5 to 10 from pretreatment levels in patients given 50 mg of amg 073 for 8 d but values were unchanged in those who received lower doses￨sig decrease￨highunclear￨highunclear￨highunclear
78￨patients with secondary hyperparathyroidism seventyeight hemodialysis patients with secondary hyperparathyroidism hemodialysis patients with secondary hyperparathyroidism￨vitamin d sterols placebo amg￨calcium pth and calcium x phosphorus levels mean baseline pth safe and well tolerated parathyroid hormone and calcium pth pth serum calcium phosphorus and calcium x phosphorus pth￨pth decreased by 260 in the amg 073treated group compared with an increase of 220 in the placebo group p  0001￨sig increase￨highunclear￨highunclear￨highunclear
395￨patients with chronic kidney disease on dialysis 395 patients received hemodialysis hd and peritoneal dialysis pd patients with pth  or 300 pgml despite traditional therapy secondary hyperparathyroidism in hemodialysis and peritoneal dialysis￨oncedaily oral cinacalcet placebo￨serum calcium phosphorus and ca x p levels effective in rapidly and safely reducing pth ca x p calcium and phosphorus levels nausea and vomiting efficacy and safety parathyroid hormone pth secretion￨oncedaily oral cinacalcet was effective in rapidly and safely reducing pth ca x p calcium and phosphorus levels in patients who received hd or pd￨sig increase￨highunclear￨highunclear￨highunclear
23￨patients with chronic kidney disease 10 patients 8 patients cinacalcet hcl 2 patients hemodialysis patients at doses up to 200 mg once daily patients receiving dialysis 23 patients enrolled 17 patients cinacalcet hcl 6 patients hemodialysis patients￨placebo cinacalcet hydrochloride hcl cinacalcet hcl or placebo cinacalcet hydrochloride cinacalcet hcl￨incidence of adverse events plasma pth concentrations pharmacokinetics pharmacodynamics and safety adverse events pharmacokinetics pharmacodynamics safety and tolerability gastrointestinal events maximal plasma concentration cmax  of cinacalcet plasma parathyroid hormone pth and serum calcium levels median oral clearance plasma concentration median area under the plasma concentrationtime curve￨cinacalcet hcl was reasonably tolerated and the incidence of adverse events was similar between groups 76 cinacalcet 80 placebo￨no diff￨highunclear￨highunclear￨highunclear
48￨women successfully treated for suspected preterm labor consenting women with a singleton gestation and intact membranes who had uterine contractions and 1 cm cervical dilation 80 effacement or progressive cervical change and whose contractions were successfully arrested with intravenous magnesium 48 women women after treatment with intravenous￨placebo terbutaline pump maintenance therapy magnesium sulfate tocolysis terbutaline or normal saline solution placebo pump therapy terbutaline placebo 28￨rates of preterm delivery mean time to delivery￨at random assignment the groups were similar with respect to age race parity previous preterm delivery gestational age and cervical examination￨no diff￨low￨low￨low
not found￨preterm delivery patients in preterm labor defined by progressive cervical change underwent intravenous as necessary and once labor was arrested patients who continued to labor were readmitted for aggressive intravenous therapy￨placebo terbutaline pump magnesium sulfate tocolysis with or without oral indomethacin oral terbutaline terbutaline pump terbutaline pump was switched to oral terbutaline saline pump terbutaline by pump saline by pump blinded or oral terbutaline terbutaline by pump saline by pump and oral terbutaline￨mean gestational age at delivery￨terbutaline by pump saline by pump and oral terbutaline appear equivalent for the prevention of preterm delivery￨no diff￨highunclear￨highunclear￨highunclear
1001￨1001 patients with a preoperative world federation of neurological surgeons score of i ii or iii goodgrade patients who had had a subarachnoid hemorrhage no more than 14 days before planned surgical aneurysm clipping goodgrade patients with aneurysmal subarachnoid hemorrhage patients with acute aneurysmal subarachnoid hemorrhage￨intraoperative cooling during open craniotomy intraoperative hypothermia intraoperative hypothermia￨postoperative neurologic deficits mild intraoperative hypothermia postoperative bacteremia neurologic outcome total length of hospitalization the rates of death glasgow outcome score￨intraoperative hypothermia did not improve the neurologic outcome after craniotomy among goodgrade patients with aneurysmal subarachnoid hemorrhage￨no diff￨low￨low￨low
114￨intracranial aneurysm surgery 900 patients with acute aneurysmal one hundred fourteen patients undergoing cerebral aneurysm clipping with n  52 world federation of neurological surgeons score  or iii and without n  62 acute aneurysmal subarachnoid hemorrhage sah nonobese patients￨mild intraoperative hypothermia hypothermic mild hypothermia￨mild hypothermia frequency of discharge to home frequency of neurological deterioration postoperative critical care requirements respiratory and cardiovascular complications duration of hospitalization and discharge disposition incidence of good longterm outcomes neurological status intubation and rewarming excess morbidity or mortality￨although not achieving statistical significance patients with sah randomized to the hypothermic group when compared with patients in the normothermic group had the following 1 a lower frequency of neurological deterioration at 24 and 72 hours after surgery 21 versus 3741 2 a greater frequency of discharge to home 75 versus 57 and 3 a greater incidence of good longterm outcomes 71 versus 57￨sig increase￨highunclear￨highunclear￨highunclear
281￨a total of 258 motherinfant pairs 918 completed followup january 1998 to august 1999 281 healthy breastfeeding women and their healthy term singleton infants postpartum unit of a university teaching hospital in montreal quebec￨regular pacifier 2 counseling interventions provided by a research nurse trained in location counseling avoidance of pacifier use and suggesting alternative ways to comfort a crying or fussing infant￨cryfuss behavior mean number of pacifier insertions 24hour infant behavior logs detailing frequency and duration of crying fussing and pacifier use total avoidance of pacifier use￨the experimental intervention increased total avoidance of pacifier use 386 vs 160 in the control group reduced daily use 408 vs 557 and decreased the mean number of pacifier insertions per day 08 vs 24 at 4 weeks p001 08 vs 30 at 6 weeks p001 and 13 vs 30 at 9 weeks p 004￨sig increase￨low￨low￨low
602￨unicefwho babyfriendly hospital initiative from ten centres 602 healthy newborns￨unicef group with restrictive fluid supplements and avoidance of bottles and pacifiers during the first 5 days of life or to a standard group with conventional feeding practice￨breastfeeding frequency and duration prevalences of breastfeeding￨no significant differences in breastfeeding frequency and duration could be found unicef vs standard day 5 100 vs 99 2 months 88 vs 88 4 months 75 vs 71 6 months 57 vs 55￨no diff￨highunclear￨highunclear￨highunclear
1021￨1021 mothers highly motivated to breastfeed whose newborns regained birth weight by 15 days￨￨prevalence and duration of breastfeeding prevalence of exclusive breastfeeding at 3 months prevalence or duration of breastfeeding frequency of exclusive and any breastfeeding prevalence of exclusive and any breastfeeding at different ages and duration of any breastfeeding￨furthermore the recommendation to offer a pacifier did not produce a significant decrease in the frequency of exclusive and any breastfeeding at different ages or in the duration of lactation￨no diff￨low￨low￨low
40￨40 pcos patients patients with polycystic ovary syndrome pcos women with pcos pcos patients polycystic ovary syndrome patients undergoing in vitro fertilizationembryo transfer￨rfsh 150 uiday and gnrh antagonist gonadotropinreleasing hormone gnrh antagonist and gonadotropin metformin with gnrh antagonist gonadotropinreleasing hormone antagonist and metformin metformin 15 gday glucophager merck pharm and then stimulated with recombinant folliclestimulating hormone rfsh gnrh agonist gnrh antagonist cetrorelix acetate 025 mgday cetrotider metformin standard short gnrh antagonist protocol￨mean number of mature oocytes number of cleaved embryos vitro fertilization ivfembryo transfer et outcomes cancelled cycles incidence of ovarian hyperstimulation syndrome estradiol levels total number of follicles on the day of human chorionic gonadotropin treatment number of ampoules of rfsh￨a we found a statistically significant p  005 decrease in the number of ampoules of rfsh a vs b 186 vs 248 and estradiol levels a vs b 2400600 vs 3370900 pgml all values meanstandard deviation￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with polycystic ovary syndrome pcos patients with pcos patients with polycystic ovary syndrome undergoing in vitro fertilization￨metformin therapy metformin￨vitro fertilizationintracytoplasmic sperm injection ivficsi outcomes ivficsi outcomes￨metformin does not lead to any improvement in ivficsi outcomes among patients with pcos￨no diff￨highunclear￨highunclear￨highunclear
not found￨normal weight and overweight patients women with pcos seventythree oligoamenorrhoeic women with polycystic ovaries and at least one of the following criteria hyperandrogenaemia elevated lhfsh ratio hyperinsulinism decreased shbg levels or hirsutism were studied women with polycystic ovary syndrome pcos scheduled for ivf stimulation women with polycystic ovary syndrome￨metformin placebo ivficsi metformin￨secondary endpoints number of oocytes fertilization rates embryo quality pregnancy rates and clinical pregnancy rates pregnancy rates following ivf overall clinical pregnancy rates primary endpoints duration of fsh stimulation clinical pregnancy rates pregnancy rates￨pretreatment with metformin prior to conventional ivficsi in women with pcos does not improve stimulation or clinical outcome￨no diff￨low￨low￨low
not found￨patients with pcos undergoing ivficsi cycles women with pcos undergoing ivf treatment patients with pcos undergoing ivficsi treatment using a long gnrh agonist protocol women with polycystic ovary syndrome pcos onehundred and one ivficsi cycles women with pcos undergoing ivf￨placebo placebo pla tablets metformin 52 or to receive placebo metformin metformin metformin met￨reproductive function risk of ohss incidence of severe ovarian hyperstimulation syndrome ohss overall fertilization rate clinical pregnancy rates overall fertilization rates total dose of rfsh required per cycle per embryo transfer median number of oocytes retrieved per cycle￨shortterm cotreatment with metformin for patients with pcos undergoing ivficsi cycles does not improve the response to stimulation but significantly improves the pregnancy outcome and reduces the risk of ohss￨no diff￨low￨low￨low
not found￨women with pcos 172 patients involved in the assisted reproduction program from may 2000 to december 2001 ovarian hyperstimulation syndrome patients undergoing the ovarian stimulation with increased risk of development of ovarian hyperstimulation syndrome due to the polycystic ovarian syndrome￨metformin insulin receptors classic stimulation protocol alone metformin￨risk of ovarian hyperstimulation syndrome risk of ovarian hyperstimulation syndrome development intraovarian androgen levels complex hormonal status estradiol blood levels number of obtained oocytes￨metformin had also significantly reduced estradiol blood levels at the day of hcg application without significant influence on the number of obtained oocytes￨no diff￨highunclear￨highunclear￨highunclear
8￨seventeen insulinresistant women with pcos insulinresistant women with polycystic ovary syndrome pcos insulinresistant women with polycystic ovary syndrome￨metformin buserelin acetate and was continued throughout ovarian stimulation with human recombinant fsh ovarian stimulation with or without metformin cotreatment metformin￨mean number of collected oocytes mean total fsh dose vitro fertilization ivf altered follicle stimulating hormone fsh requirement insulin sensitivity ovarian stimulation and in vitro fertilization fsh requirement￨administration of metformin is therefore likely to increase the number of oocytes collected after ovarian stimulation in insulinresistant women with pcos but is unlikely to reduce the requirement for fsh￨sig increase￨highunclear￨highunclear￨highunclear
23￨23 women without an iud and 10 women with an iud women with and without an intrauterine contraceptive device￨acetylsalicylic acid and paracetamol asa or paracetamol asa and paracetamol placebo￨menstrual blood loss bleeding time bleeding time and basal menstrual blood loss menstrual blood losses menstural blood loss￨neither in women with normal nor in women with small defects in the hemostatic mechanism were statistically significant increases in menstrual blood losses observed during treatment with asa or paracetamol when compared to placebo￨no diff￨highunclear￨highunclear￨highunclear
9￨9 women wearing a lippes loop iud￨indomethacin prostaglandin synthetase inhibitor indomethacin￨menstrual blood loss￨no significant placebo effect was observed￨no diff￨highunclear￨highunclear￨highunclear
21￨women who participated in the study had primary dysmenorrhea of varying intensities twentyone women with intrauterine contraceptive devices iucd and severe dysmenorrhea were studied women with intrauterine contraceptive device￨placebo prostaglandin synthetase inhibitor naproxen naproxen and placebo naproxen naprosyn naproxen￨duration and amount of the menstrual blood flow pain alleviation severe side effects intensity of dysmenorrheic pain dysmenorrhea￨the effect of naproxen was significantly better than that of placebo p less than 001￨sig decrease￨highunclear￨highunclear￨highunclear
55￨55 women three nulliparous￨placebo ibuprofen 600 mg or placebo iud tcu380a and nova t r ibuprofen prostaglandin synthesis inhibitors￨pain pain scores￨no difference in pain scores was evaluated between these￨no diff￨highunclear￨highunclear￨highunclear
not found￨women using intrauterine devices￨intrauterine contraceptive devices placebo prostaglandin synthetase inhibitor naproxen low and highdose naproxen naproxen￨menstrual blood loss menstrual loss menstrual bleeding mean menstrual loss excessive menstrual bleeding mean menstrual blood loss￨low and highdose naproxen reduced menstrual blood loss by 22 and 32 respectively￨sig decrease￨highunclear￨highunclear￨highunclear
28￨￨prostaglandin synthetase inhibitor￨menstrual blood loss and pelvic pain iud associated uterine bleeding menstrual blood loss and pains￨the drug produced an important reduction of the menstrual blood loss and pains￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨a total of 2019 firsttime iud users a total of 1011 and 1008 women￨prophylactic ibuprofen placebo ibuprofen and placebo ibuprofen and other nonsteroidal antiinflammatory drugs nsaids ibuprofen￨iud removal within 12 months of insertion dysmenorrhoea andor increased menstrual bleeding menstrual bleeding and pain hazard ratio for removal for these iudinduced side effects￨during 12 months of observation 190 had the device removed because of dysmenorrhoea andor increased menstrual bleeding 85 in the placebo group and 105 in the ibuprofen group￨sig increase￨low￨low￨low
not found￨20 women wearing iuds￨prostaglandin synthetase inhibitor ibuprofen ibuprofen ibuprofen￨lighter blood loss menstrual blood loss heavier blood loss￨ibuprofen produced a significant reduction in menstrual blood loss the percentage reduction was greater in women using a lippes loop and who had heavier blood loss 39 than in women using a copper device and who had lighter blood loss 25￨sig decrease￨highunclear￨highunclear￨highunclear
24￨many women with iudrelated menorrhagia copper intrauterine devicerelated menorrhagia twentyfour women with iudinduced menorrhagia￨desmopressin or mefenamic acid desmopressin desmopressin vasopressin mefenamic acid￨menstrual blood loss menstrual blood loss measured by pictorial blood loss assessment chart and uterine artery resistance menstrual blood loss uterine artery pulsatility index￨both mechanisms of action may have therapeutic value for the treatment of intrauterine device iudrelated menorrhagia which is believed to be caused not only by altered local haemostasis but alsoaccording to a new hypothesisby decreased vascular uterine resistance￨sig increase￨highunclear￨highunclear￨highunclear
19￨women with intrauterine contraceptive devices 19 women with an intrauterine contraceptive device iucd￨fibrinolysis inhibitor tranexamic acid ta and prostaglandin synthesis inhibitor diclofenac sodium ds ds placebo antifibrinolytic and antiprostaglandin￨menstrual blood loss blood loss excessive menstrual blood loss menstrual bleeding pelvic discomfort change menstrual blood loss￨the placebo treatment did not change menstrual blood loss 1283  156 ml￨no diff￨highunclear￨highunclear￨highunclear
not found￨women fitted with copper iuds￨nonsteroidal antiinflammatory drugs nsaids placebo oral nsaids namely indomethacin alclofenac and flufenamic acid￨iudinduced pain mbl menstrual blood loss mbl and pain excessive iudinduced bleeding￨the 3 drugs tested in this study induced a significant reduction in mbl maximum reduction by flufenamic acid medication less with alclofenac and least with indomethacin medication￨sig increase￨highunclear￨highunclear￨highunclear
17￨uterine pain following intrauterine contraceptive device insertion seventeen subjects￨naproxen sodium intrauterine contraceptive device iud placebo naproxen sodium￨overall relief pain intensity dysmenorrhea and premenstrual uterine pain efficacy of pain relief￨by both these criteria naproxen sodium was statistically significantly superior to placebo p  002 consequently naproxen sodium appears to offer a new treatment modality for pain associated with iud usage￨sig increase￨highunclear￨highunclear￨highunclear
160￨160 women￨antiprostaglandin tolfenamic acid ta antiprostglandin therapy placebo￨pain and reduced bleeding￨ta relieved pain and reduced bleeding after insertion and during three subsequent menstruations without serious sideeffects￨sig decrease￨highunclear￨highunclear￨highunclear
74￨patients with chronic hiv type 1 infection human immunodeficiency type 1 hiv1infected patients 74 patients who had been pretreated with antiretrovirals consisting of 2 nucleoside reversetranscriptase inhibitors nrtis for 1 year followed by 3 years of highly active antiretroviral therapy containing a protease inhibitor patients with a cd4 cell count of  or 350 cellsmicrol and a plasma viral load of 50 copiesml￨cd4 cell countguided therapy￨virological failure adverse events efficacy and safety￨the adverse events were not significantly different among arms p27￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with prolonged undetectable hiv1 viral loads￨￨￨although some disturbances appear at the resumption of therapy no definitive problems are found that preclude such therapeutic approaches from a psychological perspective￨no diff￨highunclear￨highunclear￨highunclear
not found￨chronic infection with human immunodeficiency virus￨longcycle structured intermittent versus continuous highly active antiretroviral therapy longcycle structured intermittent therapy sit 4 weeks without highly active antiretroviral therapy haart haart versus continuous haart￨cd4 or cd8 t cell counts or the percentage of cells that were cd4cd25 cd8cd25 or cd4dr certain toxicity immunologic or virologic parameters cd8cd38 and cd8dr cells lipid hepatic transaminase and creactive protein levels￨after 48 weeks there was no significant difference between groups in lipid hepatic transaminase and creactive protein levels in 41 patients￨no diff￨highunclear￨highunclear￨highunclear
not found￨hivinfected individuals 10 hivinfected individuals receiving effective therapy that resulted in levels of hiv rna 50 copies per ml of plasma and cd4￨highly active antiretroviral therapy continuous highly active antiretroviral therapy haart￨cost and toxicity cd4 or cd8 t cells expressing activation markers or producing ifngamma in response to hiv no increase in cd4 virologic immunologic and toxicity parameters t cells or hiv rna in peripheral blood or lymph node mononuclear cells serum cholesterol and triglyceride levels toxicity and cost cd4 plasma viremia t cell counts hiv proviral dna or replicationcompetent hiv in peripheral cd4￨t cell counts no significant increase in cd4 or cd8 t cells expressing activation markers or producing ifngamma in response to hiv no increase in cd4￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with established infection patients treated in the early stage of infection￨hydroxyurea highly active antiretroviral therapies haart hydroxyurea hu￨￨long term treatment will increase the frequency of i drugrelated side effects ii onset of drugresistant viral strains iii nonadherence of the patients to the treatment￨sig increase￨highunclear￨highunclear￨highunclear
8￨patients with chronic hiv1 infection chronically hiv1infected patients￨structured treatment interruption sti highly active antiretroviral therapy haart￨overall cd4 tcell percentage changes in cd4 tcell differentiation phenotype cd4 tcell percentage peripheral cd4 t cells plasma hiv1 rna rebound￨subjects with variable cd4 tcell percentages tended to have higher prehaart plasma hiv1 rna setpoints and experienced higher levels of plasma hiv1 rna rebound during sti￨sig increase￨highunclear￨highunclear￨highunclear
14￨fourteen chronically hivinfected patients enrolled in the swissspanish intermittent treatment trial ssitt underwent frequent blood sampling patients undergoing repeated structured treatment interruptions sti patients who have never failed treatment before￨identical antiretroviral treatment haart used before sti￨vl plasma hiv rna frequency of detectable hiv rna￨during the first cycle plasma hiv rna increased to  50 copiesml range 6788 in five patients at day 4 in eight patients  100 copiesml at day 8 and in 12 patients  100 copiesml at day 14￨sig increase￨highunclear￨highunclear￨highunclear
20￨patients treated with highly active antiretroviral therapy after dualnucleoside analogue treatment 20 hivinfected thai patients treated with highly active antiretroviral therapy haart and cd4 cell countguided sti after dual nucleoside reversetranscriptase inhibitor nrti treatment patients with major mutations patients with human immunodeficiency virus hiv infection￨structured treatment interruption sti haart￨frequency of reversetranscriptase gene mutations hiv genotypic drug resistance virological failure￨major hiv drugresistance mutations were not induced through cd4 cell countguided treatment interruptions in hivinfected patients successfully treated with haart after dualnrti therapy￨no diff￨highunclear￨highunclear￨highunclear
not found￨chronically hiv1infected chi patients fortyfive earlystage chi patients who were on highly active antiretroviral therapy haart for at least 1 year and underwent sti were included patients with cd4 tcell nadir above 400mm3￨hiv1specific cd4 helper tcell responses￨magnitude and breadth of hiv1specific cd8 tcell responses plasma vl hiv1specific cd4 and cd8 tcell responses final sti hiv1specific cd8 tcell responses plasma viral load vl peripheral blood mononuclear cell pbmc lymphoproliferative lpr response to hiv p24 protein and hiv1 epitopespecific interferongammarelease from cd8 t cells cd4 lprs￨cd4 lprs to p24 increased significantly p  0001 between day 0 of the first sti cycle and 4th sti but decreased thereafter￨sig increase￨highunclear￨highunclear￨highunclear
42￨patients with chronically suppressed hiv1 infection as compared to equal followup of patients on continuous therapy and including a final therapy interruption in both arms fortytwo chronically hivinfected patients on suppressive art with cd4 counts higher than 400 chronic hiv1 infection￨structured therapy interruptions tis￨time to viral rebound safety retention of immune reconstitution and clinical therapy failure studydefined safety criteria viral resistance therapy failure and retention of immune reconstitution viral resistance or therapy failure retention of cd4 t cell numbers on art or retention of lymphoproliferative recall antigen responses￨also secondary analysis showed no difference between the two strategies in terms of safety retention of immune reconstitution and clinical therapy failure￨no diff￨highunclear￨highunclear￨highunclear
60￨60 human immunodeficiency virus hivpositive patients who followed structured treatment interruption sti protocols and who because of good virological response did not resume receipt of highly active antiretroviral therapy haart patients with chronic hiv1 infection with good virological response to structured treatment interruption￨￨low cd8cd38 t lymphocyte count plasma viral load pvl good virological response cd4 t cell count￨the plasma viral load pvl noted after  or 2 years without antiretroviral therapy remained significantly lower than the pvl noted before initiation of haart for 11 of the 26 patients ie for 18 of the 60 patients who had sti performed￨sig decrease￨highunclear￨highunclear￨highunclear
12￨12 patients with viruses expressing the v82a or l90m resistance mutation who had undergone a 3month interruption of therapy and for whom conventional genotyping hiv1infected patients harboring drugresistant virus patients failing antiretroviral therapy￨￨￨kinetic studies demonstrated that viruses expressing resistance mutations could be detected for 5 months after the discontinuation of treatment in some patients￨sig increase￨highunclear￨highunclear￨highunclear
not found￨chronically hiv1infected subjects control subjects n  4 hiv1infected subjects chronic hiv1infected subjects with hiv1 plasma rna levels vl￨structured treatment interruption sti sti with continuous highly active antiretroviral therapy haart maintained vl 400 copies per ml and stable cd4 cd4￨cd4 t cell count from presti level and vl rebound to prehaart baseline augmented cd8 t cell responses t cells vl hiv1specific neutralizing antibodies and ifngammaproducing hiv1specific cd8 and cd4 antiviral immunity t cell counts t cell responses t cells antiviral cd8￨t cell counts and showed no enhancement of antiviral cd8￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients on highly active antiretroviral therapy with cd4 cell counts hivinfected patients followed up prospectively chronic hivinfected patients with good response to highly active antiretroviral therapy￨cd4 cellcountguided treatment interruptions￨median duration of the first interruption median cd4 cell count nadir cd4 cell count median nadir cd4 cell count overall reduction of time on therapy cd4 cells and achieved viral suppression￨the duration of the first interruption and the reduction of time on therapy were related to nadir cd4 cell count￨sig decrease￨highunclear￨highunclear￨highunclear
69￨patients with cd4 cell counts sixtynine patients￨successful antiretroviral therapy cd4 cell countdriven structured treatment interruption sti strategy pulse therapy￨proportion of subjects maintaining cd4 cell count cd4 t cells undetectable plasma hiv rna and their mean cd4 cell count dynamic and predictive variables of cd4 cell loss￨l was not statistically different from the control group￨no diff￨highunclear￨highunclear￨highunclear
not found￨chronic hivpositive patients chronically infected patients undergoing structured treatment interruption￨cd45racd27￨antigendriven interferongamma production vgamma9vdelta2 t cell effectors gammadelta t cells haart resumption and consequent inhibition of hiv replication vgamma9vdelta2 t cell reactivity￨after haart resumption and consequent inhibition of hiv replication vgamma9vdelta2 t cell reactivity was restored both quantitatively and functionally￨sig increase￨highunclear￨highunclear￨highunclear
not found￨chronically hiv1infected patients twelve hiv1 chronically infected adults who had maintained viral suppression  20 copiesml for more than 2 years as well as a cd4cd8 ratio  1 for a median time of 22 months were included in the study chronically hiv1 infected patients after longterm viral suppression hiv1 chronically infected patients with a further longlasting effective virus suppression￨structured treatment interruption sti￨genotypic resistance viral load kinetics of plasma viral rebound adverse events level of expression of tcell activation antigen cd38 on cd8 t cells flow cytometry and cell proliferation assays cd4 t lymphocytes percentage of cd4 and cd8 lymphocytes viral rebound￨sti in chronically hiv1infected patients is not associated with reductions in cd4 t lymphocytes or to clinical complications in this group of patients after 2 years of effective plasma viral suppression￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with chronic hiv1 infection chronic hiv1 infection subjects with at least 2 years virus suppression during antiretroviral therapy and a cd4￨￨plasma virus doubling time viral basic reproductive rate mean time before plasma viral load rebound of hiv1 rna hivspecific cd8 t cell frequencies p24specific t helper response average frequency of hivspecific cd8 t cells hiv dynamics and tcell immunity￨in 1012 interrupter patients a rebound of hiv1 rna was detected in all three structured treatment interruptions sti￨no diff￨highunclear￨highunclear￨highunclear
5￨a cohort of eight consecutive hiv1infected patients in very early stages all the patients were taking highly active antiretroviral therapy haart and were recruited in the coordinating center from a larger study who decided to￨haart discontinue haart￨plasma cerebrospinal fluid csf and lymphatic tissue viral loads resistance to reverse transcriptase or protease inhibitors viral load effective virologic response peak plasma viral load cd8cd38 lymphocytes cd4 lymphocytes plasma viral load mean stimulation indices of lymphocytes treated with phytohemagglutinin pha and cd3 cd8cd28 lymphocytes￨a rebound in plasma viral load was detected in all patients from day 3 to day 31 with a mean doubling time of 201 se 029 days￨sig increase￨highunclear￨highunclear￨highunclear
not found￨28 subjects with chronic hiv infection human immunodeficiency virus hivinfected subjects subjects undergoing structured treatment interruptions￨structured treatment interruption sti￨￨in 14 of 25 and in 3 of 25 subjects the m184v and the l90m mutations respectively were detected as minor populations at different times during sti￨sig increase￨highunclear￨highunclear￨highunclear
105￨105 human immunodeficiency virusinfected patients whose patients who met current united states department of health and human services criteria for starting therapy at the time of therapy initiation were 3 times more likely to resume therapy than were those who did not￨antiretroviral therapy￨mean cd4 cell count cd4 cell counts￨patients with lower cd4 cell counts at therapy initiation were more likely to resume therapy than were those with counts of 500 cellsmm3 200 cellsmm3 relative hazard 44 and 200350 cellsmm3 relative hazard 29￨sig increase￨highunclear￨highunclear￨highunclear
12￨12 patients who had three consecutive stis were studied chronically hiv1 infected individuals during consecutive stis￨lamivudine￨plasma and peripheral blood lymphocyte pbl samples drug susceptibility and their corresponding replication capacities￨consistent with a loss of phenotypic susceptibility to lamivudine the m184v mutation was detected by genotypic analysis direct and clonal sequencing in plasma samples collected from two patients at the end of the second or third sti￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with plasma viral load vl 50 copiesml and cd4 cell count 500 cellsmm3 who interrupted haart chronically hivinfected subjects￨previous structured treatment interruptions stis haart cd4￨likewise cd4 count prior to treatment interruption cd4 nadir median iqr time off therapy length of time without antiretroviral treatment virological control￨cd4 nadir was a significant predictor for treatment reinitiation in a multivariate analysis￨sig increase￨highunclear￨highunclear￨highunclear
26￨26 caucasian men median age 435 years with hiv1 viral loads  500 copiesml for 12 months while on highly active antiretroviral therapy haart who interrupted treatment for a median of 70 weeks range 49103 weeks￨haart interruption means haart￨24hour urinary free cortisol glucose or insulin levels serum lipids glucose and insulin levels during an oral glucose tolerance test 24h urinary free cortisol and 17hydroxycorticosteroids and anthropometric parameters triglycerides glucose metabolism and fat redistribution insulin resistance profiles or anthropometric measurements total cholesterol ldl cholesterol and triglyceride levels low density lipoprotein ldl cholesterol total cholesterol 24hour urinary 17hydroxycorticosteroids￨there were no significant changes in glucose or insulin levels or in anthropometric measurements￨no diff￨highunclear￨highunclear￨highunclear
not found￨chronic hiv infection patients with established infection￨structured therapeutic interruptions stis potent antiretroviral therapy art￨t lymphocyte responses breadth of the hivspecific cd8 t lymphocyte response morbidity and mortality viral recrudescence hivspecific cd8 t lymphocyte frequencies quantity and quality of the poststi response t cell responses￨iv the increase in hivspecific cd8 t lymphocyte frequencies induced by sti was not correlated with decreased viral set point after sti and v hivspecific cd4￨no diff￨highunclear￨highunclear￨highunclear
600￨11 patients 600 patients on successful haart￨efavirenz nevirapine didanosine stavudine saquinavir and ritonavir￨mutations suggestive of drug resistance and plasma saquinavir levels successive hiv rna concentrations drug resistance mutations￨in these patients there was no evidence of mutations suggestive of drug resistance and plasma saquinavir levels were within the expected range￨no diff￨highunclear￨highunclear￨highunclear
10￨10 antiretroviral treatmentnaive hiv1 chronically infected subjects with baseline cd4 tcell counts  500 x 106 cellsl and plasma viral load  5000 copiesml who received highly active antiretroviral therapy haart for 1 year with good response plasma viral load  20 copiesml for at least 32 weeks chronic hiv1 infection￨￨stronger hiv1 specific cellular immune responses mean absolute cd4 tcell counts￨those subjects who controlled viral replication developed significantly stronger hiv1 specific cellular immune responses than subjects lacking spontaneous decline p  005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨20 patients taking haart for chronic hiv infection with vl  20 copiesml￨highly active antiretroviral therapy haart with and without hydroxyurea hu continue haart or haart plus hu haart or haart plus hu haart￨plasma viral load vl setpoint and on hiv1specific responses neutralizing activity na na titers total cytotoxic t lymphocyte ctl response and in lymphoproliferative response lpr higher ctl and lpr levels control of hiv1 replication￨no significant differences were observed between haart and hu groups in na ctl and lpr at any timepoint￨no diff￨highunclear￨highunclear￨highunclear
not found￨chronic hivpositive patients presenting a rapid viral rebound during structured treatment interruption chronic hivinfected patients showing a rapid or delayed viral rebound group a n  14 patients with a rapid viral rebound within one month and group b n  6 patients with a delayed or no viral rebound after a minimum of 4 months￨branched dna￨sustained viral rebound frequencies of cd8 t cells releasing ifngamma after mitogeninduced or gagspecific stimulation cd8 t lymphocytes immunological parameters effectormemory cd8 t cell dynamics plasma viral hivrna value￨in contrast group b patients showed no significant changes in immunological parameters during a prolonged drugfree period￨no diff￨highunclear￨highunclear￨highunclear
25￨20 healthy sex and agematched controls twentyfive patients with chronic hiv infection chronic human immunodeficiency virus infection patients with chronic human immunodeficiency virus hiv infection￨highly active antiretroviral therapy haart haart￨cd4 or cd8 tcell countsmicrol hiv loads and serum concentrations of each cytokine serum levels of the cd8 tcellderived inhibitory molecules interleukin16 il16 monocyte inhibitory protein1beta mip1beta and rantes regulated upon activation normal tcell expressed and presumably secreted and the enhancer of hiv replication monocyte chemotactic protein1 mcp1 serum concentrations of il16 levels of mip1beta serum levels of il16￨at enrolment hivinfected patients showed significantly higher serum concentrations of il16 and rantes and significantly lower concentrations of mcp1 than did healthy controls￨sig increase￨highunclear￨highunclear￨highunclear
133￨133 patients receiving haart with a median cd4 cell count of 740 microl and whose viral load had been undetectable for a median of 21 months human immunodeficiency virus infection outpatient clinics of university hospitals in switzerland and spain￨haart￨median cd4 cell count hivrelated diseases and cd4 cell counts drug resistance necessitating salvage treatment hivspecific cytotoxic tcell responses hivspecific cd8 t cells number of spotforming cells￨hivspecific cd8 t cells increased between week 0 median 343 spotforming cells per million peripheral blood lymphocytes sfc106 pbl and week 52 median 1930 sfc106 pbl but there was an inverse correlation between response and the number of spotforming cells￨sig increase￨highunclear￨highunclear￨highunclear
13￨13 chronically hivinfected patients enrolled in a trial of such socalled structured treatment interruptions stis￨￨clearance rates ctl count and either viral rebound rates or clearance rates viral growth and clearance rates plateau vls viral load vl and hivspecific cd8 tcell cytotoxic tlymphocyte ctl responses￨although numbers of ctls did increase over the same time that viral rebounds decreased there was no correlation between ctl count and either viral rebound rates or clearance rates￨no diff￨highunclear￨highunclear￨highunclear
not found￨chronically infected patients chronically infected individuals with vigorous t cell responses patients with established infection￨highly active antiretroviral therapy haart hydroxyurea and didanosine pandas haart￨baseline viral load cd4 count and length of treatment vigorous hivspecific t cell immune response￨four out of 7 patients in the haart group failed to control hiv by week 6 and had to restart therapy due to either viremia rebound or cd4 decrease￨no diff￨highunclear￨highunclear￨highunclear
26￨46 patients on pd peritoneal dialysis patients with renal anemia 26 patients received pd patients￨oral ferrous succinate intravenous iron sucrose iv iron sucrose intravenous iv iron sucrose￨response rate hb hct sf and tsat levels sex age duration of pd mean dialysate dosage per day erythropoietin dosage per week or hematological parameters mean hb and hct levels of sf and tsat hemoglobin hematocrit serum ferritin sf level and transferrin saturation tsat adverse gastrointestinal effects mean erythropoietin dose safety and efficacy￨levels of sf and tsat were also significantly increased in the iv group and significantly higher than in the oral group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨39 irondeficient uremics starting hemodialysis hemodialyzed patients nine patients control group had no iron supplementation 10 had oral ferrous iron and 20 were treated with￨erythropoietin oral or intravenous iron intravenous iron gluconate￨blood hemoglobin values anemia and iron status hemoglobin levels bone marrow iron stores reduced hemoglobin iron and transferrin saturation￨the hemoglobin levels observed in patients of the control and the oral iron groups at the end of the followup periods were not significantly different from those detected at zero time￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients treated with renal dialysis by a crossover trial renal dialysis patients￨iron dextran ferrous sulphate￨therapeutic or unwanted effects￨there was no significant difference in therapeutic or unwanted effects between the treatments￨no diff￨highunclear￨highunclear￨highunclear
96￨96 ckd anemic patients on patients with chronic kidney disease ckd not on dialysis anemic patients with chronic kidney disease not on dialysis￨iron sucrose intravenous iv iron sucrose intravenous iv iron erythropoietin oral feso4 intravenous iron sucrose￨serious side effects hemoglobintsat mean serum ferritin changes in hemoglobin and ferritin and clinical success ferritintsat criteria hemoglobin values hemoglobinferritintsat hemoglobinferritin hemoglobinferritintsat and hemoglobintsat hemoglobin hemoglobin and ferritin￨iv iron patients had greater increases in mean serum ferritin 288 ngml p  00001 compared to oral iron patients 51 ngml p  ns￨sig increase￨highunclear￨highunclear￨highunclear
75￨adult anemic irondeficient nondialysis ckd ndckd patients orstage 3 not receiving erythropoiesisstimulating agents esas seventyfive patients were analyzed intravenous iron n  36 oral iron n  39 chronic kidney disease￨copyright c intravenous iron or oral iron repletion alone ferrous sulfate oral iron 325 mg tid tsat sodium ferric gluconate complex intravenous iron 250 mg iv￨kdqol scores ferritin cfb quality of life hemoglobin hgb ferritin and transferrin saturation tsat kidney disease quality of life kdqol questionnaire change from baseline cfb to endpoint in hgb values￨intravenous iron caused greater improvements in kdqol scores than oral iron p  005￨sig increase￨low￨low￨low
35￨35 ironreplete patients aged 1 to 20 years pediatric patients receiving hemodialysis patients with endstage renal failure pediatric hemodialysis population eligible patients had received hemodialysis for 2 months had a baseline transferrin saturation tsat￨iron dextran recombinant human erythropoietin rhuepo￨iron stores dose of rhuepo tsat chr baseline hemoglobin hb hematocrit hct reticulocyte hb content chr serum ferritin sf tsat or rhuepo dose￨iron dextran and not oral iron was associated with a significant increase 1385 to 2591 ngml p0003 in sf￨sig increase￨highunclear￨highunclear￨highunclear
40￨predialysis patients of chronic renal failure receiving recombinant human erythropoietin predialysis patients of chronic renal failure crf receiving recombinant human erythropoietin rhuepo crf patients treated with rhuepo 40 adult patients of chronic renal failure￨intravenous iron recombinant human erythropoietin 2000 iu twice weekly subcutaneously oral versus intravenous iron therapy￨serum iron serum ferritin and transferrin saturation haemoglobin reticulocyte count and packed cell volume￨the ferrokinetic studies revealed that serum iron serum ferritin and transferrin saturation decreased significantly in oral iron group whereas significant increase was seen in group b intravenous iron group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨hemodialysis patients chronic kidney disease ckd anemic patients with ckd stage 5d on hemodialysis and on a stable erythropoiesisstimulating agent regimen￨oral iron ferumoxytol ferumoxytol￨transferrin saturation tsat change in hemoglobin larger hemoglobin increase safety overall adverse event rates hemoglobin safety and efficacy￨there was a greater mean increase in transferrin saturation tsat with ferumoxytol compared with oral iron at day 35 p  00001￨sig increase￨highunclear￨highunclear￨highunclear
70￨66 patients received oral po seventy patients received iv chinese hemodialysis patients with renal anemia one hundred and thirtysix patients on maintenance hemodialysis chinese patients chinese patients on maintenance hemodialysis￨intravenous iron sucrose recombinant human erythropoietin epo therapy iron sucrose ferrous succinate iron sucrose venoferr delivering 100 mg iron epo￨hb hct sf and tsat levels response rate total cost of iv serum iron parameters and hb levels duration of hemodialysis dialysis frequency per week epo dosage per week the level of intact parathyroid hormone serum creatinine blood urea nitrogen or hematological parameters levels of sf and tsat mean hb concentration and hct adverse gastrointestinal effects levels of serum ferritin sf transferrin saturation tsat hemoglobin hb and hematocrit hct renal anemia safety and efficacy mean epo dose￨there were no adverse events related to iv￨no diff￨highunclear￨highunclear￨highunclear
not found￨or 110 gl iron replete erythropoietinstimulating agent esanaive 47 diabetic median age 695 years nonanaemic patients with chronic kidney disease one hundred patients ckd stages 35 hb dialysis patients standard deviation ferritin 122 71176 median interquartile range vs 90 microgl 58150 transferrin saturation tsat 22 1826 vs 21 1524 and creatinine 240 195313 vs 230 micromoll 184352￨oral iron sulphate intravenous iron sucrose￨change in hb concentration ferritin and tsat creatinine regression slope ferritin￨tsat 30 2334 vs 21 1824 p  0001 and creatinine 229 188326 vs 272 micromoll 195413 p  ns￨sig decrease￨highunclear￨low￨low
not found￨218 to 116 all ironreplete renal failure patients commencing epo who had a hemoglobin concentration  85 gdl and an initial serum ferritin level of 100 to 800 microgramsliter 206 to 131 patients receiving recombinant human erythropoietin epo thirtyseven patients entered the study 12 iv 13 oral 12 no iron 273 to 359 patients treated with￨iron dextran iron supplementation oral ferrous sulphate 200 mg tds group 3 no iron erythropoietin epo￨hemoglobin concentration reticulocyte count serum ferritin transferrin saturation and epo dose serum ferritin levels hemoglobin response ferritin levels￨there was no difference between the groups supplemented with oral iron and no iron￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with chronic renal failure treated by haemodialysis patients on hemodialysis patients mean age 61 years the malefemale ratio and the spectrum of basic diseases a group of haemodialyzed patients n  61 treated with￨actiferrin intravenous iron supplementation erythropoietin therapy erythropoietin iron supplementation recombinant human erythropoietin rhuepo erythropoiesis￨haematocrit and serum iron concentration serum ferritin values serum ferritin concentration￨the serum ferritin values in group a declined while in group f they increased￨sig increase￨highunclear￨highunclear￨highunclear
45￨patients with low body mass fortyfive anaemic patients with progressive renal insufficiency pri patients with chronic renal failure who are not yet on dialysis patients with progressive renal insufficiency treated with erythropoietin￨ferrous sulphate rhuepo oral ferrous sulphate 200 mg tds or intravenous 300 mg iron sucrose monthly iron treatment erythropoietin rhuepo oral vs intravenous iron supplementation iron sucrose ns￨haemoglobin response and changes in red cell hypochromasia rhuepo serum ferritin dietary protein and energy intake visual analogue scales￨haemoglobin response and changes in red cell hypochromasia were similar in the two groups but serum ferritin was significantly higher in the intravenous group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with nondialysisdependent ckd ndckd ndckd patients with anemia and low iron indices anemic patients with nondialysisdependent ckd￨iv iron sucrose iv iron administration using 1000 mg iron sucrose iron sucrose epoetindarbepoetin therapy ferrous sulfate￨serious adverse drug events ade gfr￨no serious adverse drug events ade were seen in patients administered iv iron sucrose as 200 mg iv over two to five minutes but drugrelated hypotension including one event considered serious occurred in two females weighing less than 65 kg after 500 mg doses were given over four hours￨no diff￨highunclear￨highunclear￨highunclear
304￨304 patients with ckd in a 31 ratio to two 510mg doses of patients who are not on dialysis patients who were not receiving erythropoiesisstimulating agents hemoglobin increased 062 patients with chronic kidney disease ckd patients with ckd patients who were receiving erythropoiesisstimulating agents hemoglobin increased 116￨ferumoxytol intravenous ferumoxytol ferumoxytol￨hemoglobin adverse events tolerated￨treatmentrelated adverse events occurred in 106 of patients who were treated with ferumoxytol and 240 of those who were treated with oral iron none was serious￨no diff￨highunclear￨highunclear￨highunclear
52￨hemodialysis patients fiftytwo hemodialysis patients with initial serum ferritin greater than 100￨intravenous iron dextran oral iron therapy￨mean serum ferritin final mean recombinant human erythropoietin dose erythropoiesis mean hematocrit transferrin saturation￨at study completion 4 months the mean hematocrit was significantly higher in the intravenous group than in the oral iron group 344￨sig increase￨highunclear￨highunclear￨highunclear
not found￨184 111 men people aged 70 with newly diagnosed type 2 diabetes referred to the participating diabetes clinics 96 patients 55 men hospital diabetes clinics patients with newly diagnosed type 2 diabetes esmon study patients with newly diagnosed type 2 diabetes mellitus￨blood glucose concentrations additional education on monitoring self monitoring or no monitoring control self monitoring versus no monitoring control self monitoring of blood glucose￨higher baseline bmi mean sd age depression subscale glycaemic control and psychological indices incidence of hypoglycaemia bmi hba1c psychological indices use of oral hypoglycaemic drugs body mass index bmi and reported hypoglycaemia rates￨monitoring was associated with a 6 higher score on the depression subscale of the wellbeing questionnaire p001￨sig increase￨low￨low￨low
988￨patients with type 2 diabetes mellitus patients not treated with insulin or previously self monitored 40 to 75 years of age with a diagnosis of type 2 diabetes  1 year and standardized hba1c level  75 and 11 two hundred sixty five general practitioners randomized 988 patients itt population but 689 patients were evaluable for the primary criterion patients managed with￨usual recommendations alone conventional assessment group or combined with smbg control group or smbg selfmonitoring of blood glucose smbg self monitoring of blood glucose smbg￨hba1c level stability or worsening change in hba1c level duration of diabetes change in hba1c levels￨at the endpoint hba1c was lower in the smbg group 81￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients with type 2 diabetes mellitus t2dm 2010 ruijin hospital shanghai jiaotong university school of medicine and blackwell publishing asia pty ltd newly diagnosed t2dm patients newonset type 2 diabetes mellitus￨selfmonitoring of blood glucose smbgbased educational and pharmacological intervention selfmonitoring blood glucose smbgbased intervention or an hba1cbased control group￨smbg and hba1c levels median hba1c diabetes regression body mass index percentage of patients achieving a lifestyle score￨the percentage of patients achieving a lifestyle score 12 was significantly greater in the smbg compared with the control group 384 vs 97 respectively p  0001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with type 2 diabetes treated with oral agent monotherapy three diabetic clinics recruited 62 patients of whom five were lost to followup diabetic medicine  2011 diabetes uk patients with type 2 diabetes not receiving insulin￨selfmonitoringbased disease management strategy or usual care ratio 31 and followed up for 6 months selfmonitoringbased disease management strategy￨mean hba1c reduction target level of hba1c body weight reduction mean change in hba1c levels￨at study end 619 of patients in the intervention group and 200 in the control group reached the target level of hba1c  70  53 mmolmol p  0005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨twentythree overweight overweight type 2 diabetic patients body mass index bmi 27544 kgm2 patients aged 4075 participated in a 28week behavioral weight control program￨smbg and dietary carbohydrate cho selfmonitoring of blood glucose sbgm behavioral program or to have smbg and dietary cho counting selfmonitoring of blood glucose￨weight loss baseline hemoglobin hba1c￨the hba1c level showed a progressive decline in experimental subjects p  005 whereas there was no improvement in control subjects￨no diff￨highunclear￨highunclear￨highunclear
453￨48 general practices in oxfordshire and south yorkshire patients with noninsulin treated diabetes 453 patients with noninsulin treated type 2 diabetes mean age 657 years for a median duration of three years and a mean haemoglobin a1c level of 75 noninsulin treated patients with type 2 diabetes￨blood glucose self monitoring with advice for patients to contact their doctor for interpretation of results in addition to usual care n150 and blood glucose self monitoring with additional training of patients in interpretation and application of the results to enhance motivation and maintain adherence to a healthy lifestyle n151 self monitoring of blood glucose￨hba1c level￨at 12 months the differences in hba1c level between the three groups adjusted for baseline hba1c level were not statistically significant p012￨sig increase￨highunclear￨highunclear￨highunclear
610￨610 patients patients with type 2 diabetes treated with a gliclazide modified releasebased regimen 610 patients were randomized 311 to the smbg group and 299 to the nonsmbg group patients with type 2 diabetes￨gliclazide modified release mrbased regimen smbg smbg or nonsmbg selfmonitoring of blood glucose￨hba1c incidence of symptomatic hypoglycaemia￨hba1c decreased from 812 to 695 in the smbg group and from 812 to 720 in the nonsmbg group betweengroup difference was 025 95 ci 006 103 p  00097￨no diff￨highunclear￨highunclear￨highunclear
not found￨majority of noninsulintreated type 2 diabetic patients noninsulintreated type 2 diabetic patients￨blood glucosemonitoring device kept a blood glucoseeating diary and received standardized counseling the control group received nonstandardized counseling on diet and lifestyle mealrelated selfmonitoring of blood glucose mealrelated selfmonitoring of blood glucose within a structured counseling program mealrelated structured selfmonitoring of blood glucose￨glycemic control hba1c levels change in hba1c treatment satisfaction subitems depression body weight total cholesterol and microalbumin changes in body weight lipids and microalbumin and changes in treatment satisfaction and wellbeing￨body weight total cholesterol and microalbumin improved when using a glucometer but there was no statistically significant difference between the two groups￨no diff￨highunclear￨highunclear￨highunclear
208￨208 noninsulintreated poorly controlled diabetic patients￨regular hba1c determinations but no selfmonitoring group bselfurine glucose monitoring￨hba1c number of blood glucose strips decrease of hba1c￨we conclude that regular selfmonitoring has no definite advantage over the usual management for improving metabolic control in noninsulintreated diabetic patients though it may possibly help patients ready to comply with its use￨no diff￨highunclear￨highunclear￨highunclear
54￨noninsulintreated patients with type ii diabetes mellitus fiftyfour patients with type ii diabetes mellitus not treated with insulin who had inadequate glucose control on diet alone or diet and oral hypoglycemic agents were studied diabetic patients not treated with insulin patients with type ii diabetes mellitus patients with type ii noninsulindependent diabetes mellitus not treated with insulin￨glucose selfmonitoring insulin smbg selfmonitoring of blood glucose smbg￨fasting plasma glucose or weight glycosylated hemoglobin values glycemic control mean fasting plasma glucose glycosylated hemoglobin smbg or urine glucose testing￨comparisons between the urinetesting and smbg groups showed no significant differences in mean fasting plasma glucose p greater than 086 glycosylated hemoglobin p greater than 095 or weight p greater than 019￨no diff￨highunclear￨highunclear￨highunclear
52￨fortyone of the anticipated 52 patients patients with type 2 diabetes mellitus t2dm patients were eligible when between 18 and 70 years of age with an hba1c between 7 and 85 using one or two oral blood glucose lowering agents tablettreated type 2 diabetic patients zodiac patients with t2dm who were in persistent moderate glycaemic control whilst not using insulin￨smbg added to usual care or to continue with usual care for one year selfmonitoring of blood glucose smbg sbmg selfmonitoring of blood glucose smbg￨dtsq  dsc type 2 who5 or sf 36 except for the sf 36 dimension health change shortform 36 health survey questionnaire sf36 the type 2 diabetes symptom checklist dscr the diabetes treatment satisfaction questionnaire dtsq and the who wellbeing index who5 furthermore healthrelated quality of life and treatment satisfaction fasting glucose value and three postprandial glucose values￨also there were no significant changes between groups on the dtsq  dsc type 2 who5 or sf 36 except for the sf 36 dimension health change which was lower in the sbmg group mean difference￨no diff￨highunclear￨highunclear￨highunclear
47￨47 children with acute asthma children with acute asthma￨ipratropiumfenoterol fenoterol solution 625 micrograms alone or ipratropium solution fenoterol hydrobromide solution fenoterol ipratropium ipratropium bromide solution ipratropiumfenoterol and fenoterol ipratropium solution fenoterol solution and their combination administered by nebulizer and face mask ipratropiumfenoterol￨fev1 improvement in flow at mid and low lung volumes clinical score oxygen saturation and pulmonary function tests pulmonary function clinical scores heart rate or systolic or diastolic blood pressures occurredabstract truncated at 250 words￨improvement in flow at mid and low lung volumes was significantly greater for the ipratropiumfenoterol combination than for ipratropium alone no significant differences were noted between ipratropiumfenoterol and fenoterol for flow at mid and low lung volumes￨sig increase￨highunclear￨highunclear￨highunclear
not found￨44 episodes of acute asthma occurring in 35 children ranging in age from 13 months to 13 years children with acute asthma￨atropine atropine sulfate inhaled metaproterenol and atropine sulfate inhaled metaproterenol inhaled atropine sulfate inhaled metaproterenol metaproterenol and metaproterenol combined with atropine￨peak expiratory flow rate and pulmonary index therapeutic failures peak flow rate pulmonary index scores￨significant improvement in peak flow rate p less than 04 was noted after the second inhalation of metaproterenol both with and without the combination of atropine sulfate compared with the effects of atropine alone￨sig increase￨highunclear￨highunclear￨highunclear
not found￨40 patients in each group with tal score children with acute asthma attack participating as outpatients pediatric patients￨salbutamol plus 20 microgramsinh ipratropium salbutamolipratropium salbutamol and ipratropium salbutamolipratropium vs salbutamol and ipratropium ipratropium anticholinergic treatment with a beta 2adrenergic medication salbutamol vs ipratropium salbutamolipratropium vs salbutamol pef salbutamol￨acute asthma attack asthma attack pef tal score￨decrease in tal score after 15 min meant p  001 for salbutamolipratropium and salbutamol vs ipratropium￨sig increase￨highunclear￨highunclear￨highunclear
48￨moderately severe acute asthma acute asthma 48 children￨ipratropium inhaled ipratropium bromide fenoterol or a combination of both drugs fenoterol ipratropium and fenoterol￨pulse rate and respiratory rate and assessment of the severity of symptoms￨a doubleblind randomized trial was carried out in 48 children to assess the effects of inhaled ipratropium bromide fenoterol or a combination of both drugs in treating their moderately severe acute asthma￨sig increase￨highunclear￨highunclear￨highunclear
20￨asthmatic children 20 asthmatic children aged 127 years range 49151 years suffering from mild bronchoconstriction mean forced expiratory volume during ls 734 range 5185 asthmatic children suffering from mild bronchoconstriction￨oxitropium bromide and fenoterol 200 micrograms inhaled fenoterol f 200 micrograms inhaled oxitropium bromide ob￨lung function parameters￨both drugs induced a comparable degree of bronchodilatation and no significant differences were found between the ob group and the f group suggesting equipotency for both drugs after a 20 min interval at the 200 micrograms dose level￨no diff￨highunclear￨highunclear￨highunclear
59￨support persons to help smokers quit nonsmoking support persons 59 support persons mean age  36 years 92 female 95 white￨control condition n  30 written materials only or to a social cognitive theorybased intervention n  29 written materials and 5 weekly 20 to 30min telephone counseling sessions telephonebased intervention￨feasibility acceptability and potential efficacy study retention rates outcome expectancies smoking abstinence rates or quit attempts support person selfefficacy lowmoderate levels of motivation to quit￨compared with the control condition the intervention was associated with a significant increase in support person selfefficacy to help their smoker p  034 and outcome expectancies p  025 from baseline to week 6￨sig increase￨highunclear￨highunclear￨highunclear
not found￨smokers registering for a televised cessation program who also expressed interest in joining a support group and who had a nonsmoking buddy￨3 conditions nocontact control discussion and social support social support and relapse prevention training￨abstinence rates level of support and program material use reading the manual and watching tv￨abstinence rates were highest in the social support group followed in order by the discussion group no shows and nocontact controls￨sig increase￨highunclear￨highunclear￨highunclear
563￨five hundred and sixtythree smokers attended groups at a smokers clinic￨social support intervention buddy system social support buddy intervention another person to provide mutual support buddy condition n237 in 14 groups or b to receive the same treatment without the buddy component control￨abstinence rates￨smokers in the buddy condition were no more likely than smokers in the control condition to stay abstinent at 1 4 or 26 weeks￨sig increase￨highunclear￨highunclear￨highunclear
not found￨adolescent nonsmokers to help parents stop smoking forty nonsmoking adolescents 1319 years of age 70 female 93 white adolescents to help a parent stop smoking￨webbased intervention webbased support skills training sst intervention health education he control group n20 or sst￨6month smoking abstinence rate￨this pilot study examined the feasibility and potential efficacy of a webbased support skills training sst intervention for adolescents to help a parent stop smoking￨sig increase￨highunclear￨highunclear￨highunclear
29￨29 employees￨￨smoking behavior level of negative nonsupportive social interactions￨both treatment conditions were equally successful in producing abstinence verified by biochemical analyses and in producing reductions in smoking behavior among nonabstinent subjects at both posttest and 6month followup assessments￨sig increase￨highunclear￨highunclear￨highunclear
2021￨subjects were predominantly moderate to heavy smokers with a history of multiple previous quit attempts and treatments smokers requesting selfhelp materials for smoking cessation n  2021￨telephone counseling selfhelp materials social support instructions and telephone counseling experimental selfquitting guide emphasizing nicotine fading and other nonaversive behavioral strategies b the same selfquitting guide with a support guide for the quitters family and friends c selfquitting and support guides along with four brief counselor calls or d a control guide providing motivational and quit tips and referral to locally available guides and programs selfhelp quit smoking interventions￨adherence to the quitting protocol and quit rates quit rates￨control subjects achieved quit rates similar to those of smokers using the experimental quitting guide with fewer behavioral prequitting strategies and more outside treatments￨sig decrease￨highunclear￨highunclear￨highunclear
24￨twentyfour participants all participants who quit smoking during the program maintained their abstinence at a 6month followup and those who did not quit were smoking less at followup than they had at pretest on all dependent variables￨controlled smoking or a controlled smoking plus partner support condition￨￨however few differences were observed between controlled smoking and controlled smoking plus partner support conditions either during treatment or at the 6month followup￨no diff￨highunclear￨highunclear￨highunclear
99￨smokers n  99￨nicotine gum nicotine gum ng nicotine gum plus psychological treatment ngpt and nicotine gum plus psychological treatment and partner support ngptps￨abstinence rates￨subjects who were closer to their support partners had significantly lower abstinence rates with ngptps than with the other conditions although not significantly at weeks 26 and 52￨sig increase￨highunclear￨highunclear￨highunclear
not found￨1996 to 2001 with 583 women and their partners randomized to womack army medical center wamc at fort bragg in fayetteville north carolina partners who smoked also received cessation aids and related counseling￨wo intervention telephone counseling usual care uc womanonly wo or partnerassisted pa intervention provider advice to quit and a selfhelp guide￨￨intenttotreat analyses showed no significant differences by condition in womens reports of abstinence at any followup￨no diff￨highunclear￨highunclear￨highunclear
96￨96 children with mild to moderate asthma as an adjunct to conventional treatment childhood asthma children children with mild to moderate asthma￨individualised homeopathic remedies placebo individualised homeopathy placebo medication￨active quality of living subscale of the childhood asthma questionnaire subscales of the same questionnaire peak flow rates use of medication symptom scores days off school asthma events global assessment of change and adverse reactions active quality of life score￨there were no clinically relevant or statistically significant changes in the active quality of life score￨no diff￨low￨low￨low
not found￨the material included the presence of at least two proximal angular lesions for the same patient probing pocket depth  or  6 mm bone defect depth  or  3 mm and 2wall defects with crestal involvement relative to the tooth circumference ranging from 90 to 270 degrees 20 intrabony periodontal defects in 10 patients￨guided tissue regeneration guided tissue regeneration gtr with expanded polytetrafluoroethylene barrier membranes and conventional therapy￨bone fill probing depth reduction attachment gain and defect depth￨the results demonstrated that bone regeneration is highly reliable as compared to conventional therapy in cases of severe periodontal bone loss from posterior teeth provided that the principles of gtr are applied￨sig increase￨highunclear￨highunclear￨highunclear
40￨advanced periodontal tissue destruction ii presence of 2 similar contralateral angular bone defects experimental sites located in either the maxilla or the mandible iii the defect site must exhibit a probing pocket depth ppd of  or  6 mm a probing attachment level pal of  or  7 mm and a depth of the intrabony component of  or  3 mm 40 subjects were randomly divided into 4 treatment groups including 10 subjects each 3 membrane groups and one emdogain group all subjects had a good oral hygiene standard were in good general health and did not use any medication 40 subjects aged 3261 years participated￨membrane placement emdogain placement barrier membrane guidor or resolut or periodontal eptfe material amoxicillin￨probing attachment alteration baseline clinical measurements plaque gingivitis ppd pal and soft tissue recession full thickness flaps ppd reduction and pal gain and superior to open flap curettage alone￨it was furthermore demonstrated that clinical improvements were better at sites with deep than at sites with shallow intrabony defects￨sig increase￨highunclear￨highunclear￨highunclear
143￨143 patients recruited in a practicebased research network of 11 offices in 7 countries deep intrabony defects￨gtr guided tissue regeneration bioabsorbable polydllactidecoglycolide membrane￨gains in clinical attachment cal and reductions in probing depth cal gains cal gain predictability of cal gains￨the treatmentassociated difference was statistically significant p  003 after correcting for both center effect and defect anatomy￨sig increase￨highunclear￨highunclear￨highunclear
10￨ten adult patients having moderate periodontitis and one or more radiographically detectable angular defects probing 6 mm to 7 mm in each quadrant were included human infrabony defects￨demineralized bonecollagen gel implants combined graft of autolysed antigenextracted allogeneic aaa bone and microfibrillar collagen zyderm￨probing depths and gaining new attachment preoperative measurements of clinical attachment probing depth and recession￨significant differences were found when comparing the multifaceted bone graft collagenmembrane technique to all others in achieving superior defect fill￨sig increase￨highunclear￨highunclear￨highunclear
30￨30 patients with an infrabony component  or  4 mm were selected￨tissue regeneration gtr with nonresorbable membranes widman modified flap wmf and enamel matrix derivative emd enamel matrix derivative guided tissue regeneration with a nonresorbable membrane and widman modified flap expanded polytetrafluorethylene eptfe gore  tex w l gore and associates flagstaff az usa membranes 10 with wmf and 10 with enamel matrix derivatives emdogain u biora ab malm sweden￨pal gain and pd reduction probing attachment level pal gain probing depth pd reduction and gingival recession rec variation pal gain￨both emdogain enamel matrix derivative and eptfe treatment show significant better results as compared to the wmf procedure in which there were no significant changes in pal gain and pd reduction at baseline and 1 year after surgery￨sig increase￨highunclear￨highunclear￨highunclear
112￨23 vas in controls 112 patients in 8 periodontal practices in 4 countries￨simplified papilla preservation flap with and without a barrier membrane guided tissue regeneration gtr￨25 visual analog scale vas units postoperative complications edema feeling moderate pain clinical attachment level cal and probing depth pd changes baseline tooth mobility cal gains initial pd￨initial pd p 001 and baseline tooth mobility p 0036 were significant covariates￨sig increase￨highunclear￨highunclear￨highunclear
26￨intrabony periodontal defects twentysix patients contributing 26 deep intrabony defects completed the study￨dbmcs calcium sulfate implant and calcium sulfate barrier gingival flap surgery alone gfs control allogeneic freezedried demineralized bone matrixcalcium sulfate dbmcs composite with a cs barrier dbmcs implant￨probing bone level gain gain in probing bone levels probing bone level gain probing depth pd reduction reduced pd and improved attachment levels clinical attachment gain pd reduction and clinical attachment gain￨probing bone level gain was significantly greater in the dbmcs group compared to controls p  005￨sig increase￨highunclear￨highunclear￨highunclear
45￨deep interproximal intrabony defects fortyfive 45 defects in 45 patients￨titanium reinforced membranes positioned just apical to the cementoenamel junction and the modified papilla preservation technique the second group received conventional expanded polytetrafluoroethylene eptfe barrier membranes applied at the alveolar crest the third group was treated with an access flap procedure titanium reinforced membranes eptfe￨clinical attachment level cal and probing depths pd cal gain clinical efficacy￨the groups were well balanced with respect to all prognostic variables￨no diff￨highunclear￨highunclear￨highunclear
36￨deep interproximal intrabony defects thirtysix 36 defects in 36 patients￨bioresorbable membranes bioresorbable membranes positioned coronal to the interproximal bone crest the second group membrane control was treated with conventional nonresorbable eptfe barrier membranes applied coronal to the alveolar crest the third group flap control was treated with an access flap procedure mwf mwf￨baseline oral hygiene and defect characteristics cal gain clinical attachment levels cal and reductions in probing depths clinical efficacy￨no differences were observed in terms of baseline oral hygiene and defect characteristics among the 3 groups indicating that the blocking approach was effective￨no diff￨highunclear￨highunclear￨highunclear
25￨25 patients with two intraosseous periodontal defects each￨mem ab ab group without antibiotics barrier membranes and systemic antibiotics ab group receiving systemic antibiotics membranes mem and antibiotics ab￨probing bone level pbl reduction in probing pocket depth ppd gains in probing attachment level pal￨reduction in probing pocket depth ppd at 12 months postoperatively varied between 254 and 306 mm between the four treatment modalities but overall no main effect of mem or ab was found￨no diff￨highunclear￨highunclear￨highunclear
90￨infrabony defects ninety 90 defects in 90 healthy subjects affected by chronic periodontitis￨guided tissue regeneration gtr with nonresorbable expanded polytetrafluoroethylene eptfe membranes and enamel matrix proteins emp spp technique used as access flap control procedure titaniumreinforced expanded polytetrafluoroethylene membranes emp emp and the simplified papilla preservation spp technique the second group was treated with titaniumreinforced epfte membranes and the spp technique￨residual probing depths clinical attachment levels cal and reduction in probing depth pd cal gain baseline oral hygiene and defect characteristics cal gains gingival recession￨no differences were observed in terms of baseline oral hygiene and defect characteristics among the 3 groups indicating that the blocking approach was effective￨no diff￨highunclear￨highunclear￨highunclear
40￨forty patients each contributing one defect  or 4 mm in depth participated￨conventional flap therapy bioabsorbable membrane guided tissue regeneration bioabsorbable membrane guidor￨clinical attachment level gain clinical attachment level gain nor bone gain baseline probing pocket depths probing pocket depth reduction￨there were no significant differences found between treatment groups for any of the tested variables￨no diff￨highunclear￨highunclear￨highunclear
9￨twenty pairs of sites in nine subjects were treated paired periodontal defects￨guided tissue regeneration conventional surgery￨probing attachment level gains￨at 12 months probing depth reductions were significantly greater at the goretex treated sites p005 but no difference in probing attachment level gains were found when compared with conventional flap surgery￨sig increase￨highunclear￨highunclear￨highunclear
56￨56 patients each of whom displaying one intrabony defect of a depth of at least 6 mm￨emd gtr combination of emd and gtr and flap surgery control enamel matrix proteins and guided tissue regeneration emd guided tissue regeneration principle gtr gtr￨mean ppd reduction mean cal gain cal gain blinded examiner plaque index pli gingival index gi bleeding on probing bop probing pocket depth ppd gingival recession gr and clinical attachment level cal ppd reduction and cal gain￨all three regenerative treatments led to higher cal gain than the control treatment p005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨guided tissue regeneration gtr with bioresorbable barrier membranes versus access flap surgery￨clinical attachment level cal gains frequency distribution of cal changes linear cal gains cal gains probing pocket depth reductions￨at 1year probing pocket depth reductions were 4323 mm in gtr treated sites and 3015 mm in the flap control sites p002 paired ttest￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨infrabony periodontal defects 44 intrabony defects were treated in 16 patients￨conventional flap surgery guided tissue regeneration procedure with bioresorbable membranes versus conventional flap surgery￨attachment levels and probing depths as well as index values for plaque and bleeding on probing￨in all surgical areas treatment resulted in significant improvement of parameters such as attachment levels and probing depths as well as index values for plaque and bleeding on probing￨sig increase￨highunclear￨highunclear￨highunclear
10￨ten human subjects with at least one pair of contralateral periodontal lesions with probing pocket depths of greater than or equal to 5 mm and radiographic evidence of greater than or equal to 40 bone loss were included￨contralateral surgical flap procedures￨probing attachment levels and fill of intrabony defects mean probing attachment loss change of probing attachment levels and amount of bone fill gain of bone in test lesions mean probing attachment gain￨095 mm while no gain was observed in the control lesions p less than 001￨no diff￨highunclear￨highunclear￨highunclear
90￨chronic rhinosinusitis ninety patients with crs￨crs medical or surgical therapy￨subjective and objective parameters of crs total nasal volume in crs visual analogue score vas the sinonasal outcome test20 snot20 the short form 36 health survey sf36 nitric oxide no acoustic rhinometry saccharine clearance time sct and nasal endoscopy￨both the medical and surgical treatment of crs significantly improved almost all the subjective and objective parameters of crs p 01 with no significant difference being found between the medical and surgical groups p 05 except for the total nasal volume in crs p 01 and crs without polyposis p 01 groups in which the surgical treatment demonstrated greater changes￨sig increase￨highunclear￨highunclear￨highunclear
89￨89 patients chronic maxillary sinusitis￨sinus irrigation versus sinus irrigation followed by functional endoscopic sinus surgery functional endoscopic sinus surgery fess sinus irrigation followed by fess sinus irrigation￨￨treatment consisting of sinus irrigation alone prevented surgery in 58 of all patients for 1 year￨no diff￨highunclear￨highunclear￨highunclear
69￨sixtynine children with urinary tract infections urinary infections in children￨gentamicin therapy gentamicin￨radiological abnormality suppression upon rectal￨single dose therapy had significantly less suppression upon rectal p less than 0001 and periurethral p less than 002 flora￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨only patients with at least two consecutive positive cultures of a single pathogen obtained in cleancatch midstream urine samples greater than or equal to 105 colonyforming units per ml urine and susceptible to the respective antibiotic were admitted to the study acute uncomplicated urinary tract infections utis in children nineteen girls and seven boys mean age 55 years received cefadroxil and 18 girls and eight boys mean age 59 years received patients with structural anomalies or with a history of hypersensitivity to cephalosporins or penicillins or abnormal hepatorenal function urinary tract infections in children￨ampicillin cefadroxil cefadroxil and ampicillin￨cure rates positive cultures therapeutic efficacy￨the differences in the cure rates of the two groups were not statistically significant￨no diff￨highunclear￨highunclear￨highunclear
49￨fortynine ambulatory children between 212 and 12 years of age with acute clinically uncomplicated urinary tract infections caused by susceptible organisms uncomplicated pediatric urinary tract infections￨amoxicillin amoxicillin therapy conventional therapy amoxicillin therapy￨cure rate￨the antibodycoated bacteria assay had no predictive value in separating upper and lower tract disease although it may predict underlying radiologic abnormalities￨no diff￨highunclear￨highunclear￨highunclear
not found￨female adolescents thirtyone 12 to 18yearold female adolescents with symptoms of an acute uti and a urine culture with greater than 105￨singledose nu conventional treatment conventional therapy amoxicillin￨bacteriologic cure rate cure rate complete symptom resolution side effects candida vaginitis￨candida vaginitis occurred in 20 of the conventionaldose group nu none of the singledose group￨no diff￨highunclear￨highunclear￨highunclear
19￨children with an acute infection of the lower urinary tract children 19 children￨nitrofurantoin cephalexin￨side effects immediate cure rates tolerated reinfection￨no side effects were noted in either of the treatment groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨fiftyfour girls ages 1 to 12 years with two positive urine cultures greater than 105 women with cystitis girls￨sulfisoxazole amikacin aminoglycoside therapy cfuml e coli￨urinary tract infection positive urine culture urinary tract infections upper and lower urinary tract infections clinical symptoms fever and erythrocyte sedimentation rate￨this difference was not statistically significant p greater than 05￨no diff￨highunclear￨highunclear￨highunclear
135￨childrens lower urinary tract infections one hundred and thirtyfive children with lower uti diagnosed on the basis of fever less than 38 degrees c infants and children￨fosfomycin trometamol ft ft aminoglycoside antibiotic netilmicin nm fosfomycin trometamol versus netilmicin￨erythrocyte sedimentation rate recurrence of infection efficacy and safety persistence of infection￨recurrence of infection was noticed in 7 patients in the ft group and in 9 in the nm group￨no diff￨highunclear￨highunclear￨highunclear
264￨children uncomplicated acute urinary tract infections in girls 264 girls aged 115 years acute urinary tract infection in girls￨sulfamethizole sulfamethizole or alternatively pivmecillinam￨actuarial percentage recurrencefree curves bacterial sensitivity pattern side effects urinary tract infections￨new bacteria after treatment were found less frequently after sulfamethizole for 3 days 4 when compared to sulfamethizole for 10 days 14 and pivmecillinam for 3 days 13 p  0048￨sig increase￨highunclear￨highunclear￨highunclear
100￨100 children 312 years with isolated episodes of symptomatic nonfebrile urinary tract infection cystitis in children￨trimethoprim￨cure rates￨the difference was not statistically significant chi 2  225 p  0134 twotailed￨no diff￨highunclear￨highunclear￨highunclear
not found￨thirtysix girls aged two to 17 years with cultureproven acute uncomplicated lower urinary tract infections and without signs or symptoms of upper urinary tract infection twentysix patients completed the study ten in the singledose group and 16 in the conventional therapy group children￨amoxicillin or conventional therapy singledose antibiotic therapy amoxicillin￨cure rates induction of resistant organisms relapse rates reinfection rates￨a significant difference in the induction of resistant organisms was seen between treatment groups p less than 05￨sig decrease￨highunclear￨highunclear￨highunclear
156￨from a pool of 261 army national guard a total of 156 were randomized to army national guard members who failed the apft 2mile run￨pedometerbased behavioral intervention fitness for life ffl program and a traditional highintensity fitness trad program pedometerbased exercise intervention trad or ffl￨pa improved modestly and coronary risk profile physical activity pa army physical fitness test apft and coronary heart disease risk factors total apft score and 2mile run timescore physical activity fitness and coronary heart disease risk￨for both groups the total apft score and 2mile run timescore improved from baseline to 12 weeks ffl down 74 p  003 trad down 5 p  008 but at 24 weeks they had regressed toward baseline￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨organizational action and personal and team goalsetting was implemented in fall 2005 with a multiracialethnic sample of 1442 employees at 16 worksites of the home depot inc change in physical activity was analyzed in fall 2007 using latent growth modeling and latent transition analysis selfreported moderatetovigorous physical activity and 9000 daily pedometer steps￨moderate and vigorous physical activity and walking moderate or vigorous physical activity physical activity levels￨participants in the intervention had greater increases in moderate and vigorous physical activity and walking compared to participants in a health education control condition￨sig increase￨highunclear￨highunclear￨highunclear
101￨middleaged male whitecollar workers one hundred and one male office workers 30 to 59 years of age with metabolic syndrome risk factors middleaged male japanese whitecollar workers￨life style modification program for physical activity and nutrition program lism10 worksitebased intervention program lism intervention￨metabolic parameters insulin resistancerelated metabolic parameters body weight body mass index fasting plasma glucose insulin and homeostasis model assessment of insulin resistance changes p001￨habitual food group intakes changed significantly in the lism group showing improvements in 14 anthropometric and biochemical parameters contributing to intergroup differences in body weight body mass index fasting plasma glucose insulin and homeostasis model assessment of insulin resistance changes p001￨sig increase￨highunclear￨highunclear￨highunclear
110￨bmi 2540 mean sd age  444 86 years bmi  305 36 male employees at tomago aluminium aged 1865 male shift workers overweight male shift workers 110 overweightobese in october 2009 men￨wp program workplacebased weight loss program workplace powerwp information session program booklets groupbased financial incentives and an online component workplacebased weight loss program￨systolic blood pressure waist circumference resting heart rate weight loss physical activityrelated cognitions weight loss and improved healthrelated outcomes and behaviours waist circumference bmi blood pressure resting heart rate selfreported physical activity and dietary variables and physical activity and dietary cognitions physical activity bmi￨the wp program was feasible and efficacious and resulted in significant weight loss and improved healthrelated outcomes and behaviours in overweight male shift workers￨sig increase￨low￨low￨low
13￨elderly patient elderly by recruiting 13 subjects  75 years of age already fitted with a physiological pacing system￨physiological pacing physiological pacing￨exercise capacity mean distance walked activity of daily living questionnaire in atrioventricular synchronous and ventricular pacing ability to climb stairs exercise tolerance and improves symptoms symptomatic questionnaire score￨no significant difference was found in the ability to climb stairs but there was a marked improvement in the symptomatic questionnaire score 19￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨￨bloodflow variability variability of left atrial antegrade￨variability of left and right atrial and left ventricular bloodflow was studied using transthoracic and transesophageal doppler echocardiography and related to pacemaker mode preference during everyday activity￨sig increase￨highunclear￨highunclear￨highunclear
16￨symptom free patients with ventricular demand vvi pacemakers upgraded to dual chamber devices sixteen patients aged 4184 years who were symptom free during vvi mode pacing for three or more years patients with paroxysmal atrial arrhythmias patients with very intermittent symptomatic bradycardia or atrial fibrillation with a good chronotropic response during exercise￨ventricular demand vvi dual chamber demand ddi and dual chamber universal ddd￨change in subjective general health perception symptoms and objective clinical assessment treadmill exercise and radiological and echocardiographic indices perceived general wellbeing and exercise capacity treadmill times mitral and tricuspid regurgitation￨perceived general wellbeing and exercise capacity p less than 001 and treadmill times p less than 005 were improved in ddd mode but vvi and ddi modes were similar￨sig increase￨highunclear￨highunclear￨highunclear
not found￨twentytwo patients aged 18 to 81 years had an activitysensing dual chamber universal rateresponsive dddr pacemaker implanted for treatment of high grade atrioventricular block and chronotropic incompetence￨rateresponsive pacing modes￨beat to beat variability of cardiac output vvir ventricular demand rateresponsive ddir dual chamber demand rateresponsive ddd dual chamber universal or dddr stroke volume tricuspid regurgitation cardiac output chamber dimensions left ventricular fractional shortening or pulmonary artery pressure mitral regurgitation estimated by doppler color flow imaging perceived general wellbeing exercise capacity functional status and symptoms exercise treadmill time￨perceived general wellbeing exercise capacity functional status and symptoms were significantly worse in the vvir than in dual rateresponsive modes￨sig increase￨highunclear￨highunclear￨highunclear
1474￨a total of 1474 patients at 32 canadian centers patients without chronic atrial fibrillation who were scheduled for a first implantation of a pacemaker to treat symptomatic bradycardia were eligible for enrollment￨physiologic pacing ventricular pacemaker or a physiologic pacemaker physiologic pacing versus ventricular pacing physiologic pacing dualchamber or atrial ventricular pacemaker and 1094 to receive a physiologic pacemaker￨hospitalization for heart failure annual rate of atrial fibrillation rate of atrial fibrillation annual rate of stroke or death due to cardiovascular causes perioperative complications stroke or death due to cardiovascular causes death from any cause atrial fibrillation and hospitalization for heart failure￨the observed annual rates of death from all causes and of hospitalization for heart failure were lower among the patients with a physiologic pacemaker than among those with a ventricular pacemaker but not significantly so annual rates of death 66 percent with ventricular pacing and 63 percent with physiologic pacing annual rates of hospitalization for heart failure 35 percent and 31 percent respectively￨sig decrease￨low￨low￨low
7027￨patients affected by high degree av block without heart failure 14 high degree av block patients using the medtronic synergyst 7027 dual chamber pacemaker who could be programmed alternatively in ddd or vvir mode￨period vvir and ddd pacing 18 wattsminabstract￨atrial natriuretic peptide symptom scores body weight cardiac output symptoms of general wellbeing palpitations dizziness pulsating sensation in the neck or abdomen shortness of breath at rest and during effort chest pain and nyha classification￨a semiquantitative score scale was used to quantify the symptoms of general wellbeing palpitations dizziness pulsating sensation in the neck or abdomen shortness of breath at rest and during effort chest pain and nyha classification￨no diff￨highunclear￨highunclear￨highunclear
210￨29 cases of cerebral ischemia 100 patients paced for total atrioventricular av block or seconddegree av block type ii mobitz and 110 patients paced for sick sinus syndrome sss patients receiving ventricular pacing p  005 paced patients without prior atrial fibrillation patients with ventricular pacing 210 consecutive patients￨brain computed tomography ct scan￨stroke and atrial fibrillation incidence of atrial fibrillation and stroke prevalence of atrial fibrillation and stroke incidence of stroke and atrial fibrillation incidence of stroke incidence of atrial fibrillation cerebral ischemia andor atrial fibrillation￨comparing the different pacing modalities there was an increase in the incidence of stroke in patients receiving ventricular pacing p  005￨sig increase￨highunclear￨highunclear￨highunclear
15￨patients with sick sinus syndrome sss sick sinus syndrome 15 consecutive patients mean age 66￨aairdddr pacing vvir pacing rate adaptive pacing￨physiological responses arrhythmias symptomatology and quality of life incidence of ventricular pacing and arrhythmias holter recording diurnal blood pressure changes ambulatory blood pressure recording and symptom and quality of life level questionnaires and interviews systolic blood pressure paroxysmal atrial fibrillation atrial rate adaptive aair dual chamber rate adaptive dddr and ventricular rate adaptive vvir modes blood pressure arterial pressure intact av conduction antegrade conduction capacity￨despite similar heart rate changes during acute physiological stresses a higher blood pressure was recorded during aair or dddr pacing compared with vvir pacing￨sig increase￨highunclear￨highunclear￨highunclear
407￨patients who require cardiac pacing patients with sinusnode dysfunction patients with sinusnode dysfunction 407 patients 65 years of age or older in 29 centers 53 patients assigned to the average age of the patients was 76 years range 65 to 96 and 60 percent were men elderly patients treated with￨ventricular pacing ventricular pacing and dualchamber pacing dualchamber pacing than with ventricular pacing singlechamber ventricular pacemakers or dualchamber pacemakers dualchamber pacemaker that had been randomly programmed to either ventricular pacing or dualchamber pacing dualchamber pacing￨quality of life or prespecified clinical outcomes including cardiovascular events or death quality of life and clinical outcomes qualityoflife benefits quality of life and cardiovascular functional status quality of life healthrelated quality of life as measured by the 36item medical outcomes study shortform general health survey healthrelated quality of life￨quality of life improved significantly after pacemaker implantation p0001 but there were no differences between the two pacing modes in either the quality of life or prespecified clinical outcomes including cardiovascular events or death￨no diff￨highunclear￨highunclear￨highunclear
19￨many patients with sinus node disease or atrioventricular block have previously received 19 patients previously treated with ventricular pacing for a median time of 6 x 8 years patients with ventricular pacemakers who have not developed permanent atrial fibrillation or flutter￨pacemakers with only ventricular stimulation vvi or vvir dual chamber pacing dddr or ddir vvir or dddrddir pacing￨plasma level of brain natriuretic peptide larger left ventricular enddiastolic dimensions left atrial diameter quality of life quality of life left ventricular systolic function cardiac function and quality of life quality of life and cardiac function￨the plasma level of brain natriuretic peptide was significantly lower in dddr mode p0 x 002￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨all subjects used a patientactivated electrocardiographic ecg recorder throughout the study and additionally underwent patients with paroxysmal atrial tachyarrhythmias fortyeight patients mean age 64 years 58 male with a history of atrial tachyarrhythmias and heart block had a dm pacemaker implanted patients with a history of atrial tachyarrhythmias and 2￨dm pacing modalitiesdddr with mode switching dm dddr with conventional upper rate behavior dr and vvir vrin ambulatory ecg monitoring and a treadmill exercise test￨atrioventricular node ablation dm dm adverse symptoms￨patientperceived wellbeing was significantly better with dm than with dr mode dm 69 dr 60 p  002￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨atrioventricular synchronous pacemakers atrioventricular synchronous ventricular inhibited pacing physiological versus singlerate ventricular pacing￨arterial lactate respiratory rates and perceived exertion ratings during submaximal levels of exercise mean maximal exercise tolerance atrioventricular synchronous pacing maximal and submaximal exercise tolerance￨arterial lactate respiratory rates and perceived exertion ratings during submaximal levels of exercise were higher on ventricular inhibited pacing as well as symptoms scored during the two 3week periods￨sig increase￨highunclear￨highunclear￨highunclear
17￨17 patients with high degree av block￨submaximal exercise tolerance activity sensor modulated ventricular pacing atrioventricular synchronization av synchrony treadmill exercise to moderate exertion and by 24hour holter monitoring￨exercise time borg ratings and respiratory rate during submaximal exercise paced rate paced ventricular rate ventricular rate mean exercise time to submaximal exertion borg 510 exertion ratings and respiratory rate submaximal exercise tolerance atrial synchronous ddd and activity rate modulated ventricular vvir pacing atrial rate during vvir pacing￨paced ventricular rate was however higher and variation in paced rate greater in ddd compared to vvir pacing￨sig increase￨highunclear￨highunclear￨highunclear
16￨sick sinus syndrome with retrograde atrioventricular conduction eight patients presented with sick sinus syndrome and with one exception retrograde atrioventricular conduction and eight age and sex matched patients presented with 21 or complete atrioventricular block 16 patients who had had ddd pacemakers implanted because of frequent syncope eight patients with sick sinus syndrome sick sinus syndrome exercise patients with sick sinus syndrome￨vvi pacing ddd fully automatic and vvi ventricular demand pacing modes dual chamber pacing￨paced rhythm either ddd or vvi vvi and ddd modes maximal atrial rates palpitation and general wellbeing maximal symptom limited exercise maximal effort tolerance shortness of breath￨maximal symptom limited exercise in those with atrioventricular block was significantly higher after one month of ddd pacing than after vvi pacing￨sig increase￨highunclear￨highunclear￨highunclear
not found￨eighteen patients 14 men and 4 women aged 70 complete av block cavb complete heart block￨chronic ddd and dual sensor vvir pacing￨oxygen consumption qualityoflife and cardiopulmonary performance cardiopulmonary parameters a qualityoflife and cardiovascular symptom questionnaire ddd and dual sensor vvir qt and activity pacing modes ddd and dual sensor vvir activity and qt pacing modes overall qualityoflife and cardiovascular symptoms￨overall qualityoflife and cardiovascular symptoms did not significantly differ though three patients felt discomfort during vvir mode￨no diff￨highunclear￨highunclear￨highunclear
2￨dddr pacemaker twentyone patients mean age 68 eighteen patients preferred ddd pacing mode while only one preferred vvir pacing mode￨ddd and dual sensor vvir pacing dualsensor qtactivity ddd pacing dual sensor vvir pacing￨qualityoflife cardiovascular symptoms physical activity psychosocial and emotional functioning and selfperceived health qualityoflife ddd pacing mean total qualityoflife score dyspnea on effort dizzy spells palpitation sweating fatigue lethargy emotional functioning and selfperceived health qualityoflife scores￨significant improvement in the mean total qualityoflife score 205￨sig increase￨highunclear￨highunclear￨highunclear
2010￨2010 patients with sinusnode dysfunction to￨dualchamber pacing 1014 patients or ventricular pacing dualchamber pacing dualchamber atrioventricular and singlechamber ventricular pacing ventricular pacing or dualchamber pacing dualchamber pacing￨risk of atrial fibrillation composite of death stroke or hospitalization for heart failure atrial fibrillation heartfailure score the pacemaker syndrome and the quality of life heartfailure scores rates of hospitalization for heart failure and of death stroke or hospitalization for heart failure risk of atrial fibrillation reduces signs and symptoms of heart failure death from any cause or nonfatal stroke quality of life strokefree survival￨in sinusnode dysfunction dualchamber pacing does not improve strokefree survival as compared with ventricular pacing￨no diff￨low￨low￨low
19￨patients with ddd pacemakers 19 patients with ddd pacemakers that were physiologically paced eight patients 42 insisted on early crossover from vvi to ddd pacing after only 18￨longterm vvi versus ddd pacing vvi versus ddd pacing vvi pacing dual chamber pacing￨exercise capacity exercise performance and health perception exercise performance cardiac chamber size cardiac output functional status and health perception cardiac output exercise peak systolic blood pressure ventriculoatrial va conduction exercise duration ddd pacing and no patient preferred vvi pacing￨22 litersmin p  00001 where significantly greater in the ddd mode￨sig increase￨highunclear￨highunclear￨highunclear
40￨patients with vvi pacing forty unselected patients with dual chamber pacemakers￨vvi pacing to those associated with dual chamber pacing vvi or dual chamber pacing￨pacemaker syndrome blood pressure lv function presence of ventriculoatrial conduction and ability to override the pacemaker shortness of breath dizziness fatigue pulsations in the neck or abdomen cough and apprehension￨the most highly significant p less than 0005 were shortness of breath dizziness fatigue pulsations in the neck or abdomen cough and apprehension￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨fifteen patients with dual chamber pacemakers implanted for atrioventricular block 11 or sinoatrial disease 4 completed a￨intraarterial ambulatory blood pressure during long term dual chamber atrioventricular synchronous ddd and ventricular demand vvi pacing single blind withinpatient comparison of symptoms and 24 hour intraarterial blood pressure during long term atrioventricular synchronous ddd pacing and long term ventricular demand vvi pacing￨ddd pacing mean sd daytime systolic blood pressure sense of general wellbeing during ddd pacing breathlessness fatigue and dizziness systolic blood pressure strong preference for ddd pacing episodes of hypotension￨the patients reported significantly less breathlessness fatigue and dizziness and a significantly greater sense of general wellbeing during ddd pacing than during vvi pacing￨sig increase￨highunclear￨highunclear￨highunclear
20￨eleven patients preferred ddd mode to either vvi or vvir mode elderly patients with complete heart block vvir pacing elderly  or  75 patients patients over 75 with complete heart block patients with preexisting risk factors for the pacemaker syndrome and chronotropic incompetence were excluded active elderly patients with complete heart block both ddd and vvir pacing twenty elderly patients mean age 805 1 years with high grade atrioventricular block and sinus rhythm￨vvi pacing dual chamber and ventricular rate responsive pacing dual chamber universal ddd and ventricular rate response vvir pacing￨corresponding mean se pacemaker syndrome symptom scores exercise performance symptom scores during vvi and vvir pacing patient preference symptom scores daily activity exercises and perceived level of exercise borg score mean se total symptom scores during vvi vvir and ddd pacing exercise performance and borg scores￨exercise performance and borg scores were significantly worse during vvi pacing compared with vvir or ddd pacing but did not significantly differ between vvir and ddd modes￨sig increase￨highunclear￨highunclear￨highunclear
10￨10 patients with programmable dual chamber pacemakers who also had angina pectoris patients with angina pectoris￨ventricular pacing atrial synchronous ventricular pacing exercise test ventricular pacing at 70 beatsmin vvi or atrioventricular synchronous upper rate 150 beatsmin ddd 150 or 100 beatsmin ddd 100￨chest pain episodes of dizziness pacemaker syndrome￨there was significantly less chest pain with this mode than with either of the other modes￨sig decrease￨highunclear￨highunclear￨highunclear
74￨10 consecutive patients aged 2374 presenting with complete anterograde atrioventricular block at rest and on exercise and with an intact atrial rate response received synergyst i medtronic pacemakers patients with complete heart block￨dual chamber pacing ddd and ventricular rate adaptive vvir pacing dual chamber pacing ddd and ventricular rate adaptive pacing activity sensing vvir￨symptom scores for dyspnoea fatigue and mood disturbance exercise time and maximal oxygen consumption retrograde atrioventricular block symptoms and maximal exercise performance resting plasma catecholamine concentrations symptom scores maximal exercise performance on a treadmill and the plasma concentrations of atrial natriuretic peptide adrenaline and noradrenaline pacemaker syndrome resting plasma concentrations of atrial natriuretic peptide￨no significant differences were identified between pacing modes in symptom scores for dyspnoea fatigue and mood disturbance exercise time and maximal oxygen consumption￨no diff￨highunclear￨highunclear￨highunclear
not found￨thirteen patients￨physiological and ventricular pacing chronic ventricular and atrial synchronous pacing￨symptomatic assessment by diary card and monthly symptom scores of shortness of breath palpitation and general wellbeing maximal symptom limited exercise￨symptomatic assessment by diary card and monthly symptom scores of shortness of breath palpitation and general wellbeing was significantly improved during the physiological pacing mode￨sig increase￨low￨low￨low
16￨patients aged over 75 years with complete heart block elderly patients with complete heart block 16 patients aged 7788 years to determine whether elderly patients gain significant benefit from￨ddd vs vvi pacing dualchamber ddd compared with singlechamber ventricular demand vvi pacing￨mean symptom score in ddd mode mean sd total borg scores in ddd mode and vvi mode dizziness breathlessness and fatigue i overall symptoms scores ii exercise tests related to daily activities and iii perceived level of difficulty borg score￨ventricular demand pacing in elderly patients with complete heart block is associated with higher symptom scores reduced exercise ability and greater perceived exercise difficulty compared with dualchamber pacing￨sig increase￨highunclear￨highunclear￨highunclear
78￨advanced parkinsons disease seventy eight patients of either sex with advanced parkinsons disease and treatment complications such as motor fluctuations advanced parkinsonian patients with motor fluctuations patients with advanced parkinsons disease￨placebo pramipexole placebo n44 to a previously stabilised antiparkinsonian medication ergoline dopamine agonist pramipexole pramipexole￨efficacy safety and tolerance fatigue dyskinesia and vivid dreams total score of the unified parkinsons disease rating scale updrs adverse events vital signs laboratory measurements and ecg recordings mean updrs total score updrs total scores subscores part ii iii activities of daily living and motor examination and iv complications of therapy activities of daily living motor function safety and tolerability￨there was a significant improvement of the pramipexole group in updrs total scores subscores part ii iii activities of daily living and motor examination and iv complications of therapy￨sig increase￨low￨low￨low
not found￨advanced parkinsons disease advanced pd patients with motor fluctuations under levodopa treatment￨pramipexole placebo pramipexole￨unified parkinson disease rating scale severity of off periods decreased disability and pd severity motor function efficacy safety gastrointestinal and cardiovascular tolerability time spent in off periods￨adverse effects related to the central nervous system were similar to those reported with other dopamine agonists and the gastrointestinal and cardiovascular tolerability of the compound was satisfactory￨sig increase￨highunclear￨highunclear￨highunclear
247￨advanced parkinsons disease 247 patients with wearing off advanced parkinsons disease pd patients patients with advanced pd with motor fluctuations￨placebo bromocriptine and placebo pramipexole bromocriptine pramipexole pramipexole and bromocriptine international pramipexolebromocriptine￨unified parkinsons disease rating scale updrs parts ii and iii safety data dyskinesia and nausea advanced pd updrs part ii safety tolerance and efficacy￨the updrs part iii showed improvements of 34 for pramipexole p  00006 and 238 for bromocriptine p  001 versus 57 for placebo￨sig increase￨highunclear￨highunclear￨highunclear
not found￨24 vlbw infants with echocardiographic evidence of pda￨indomethacin or placebo prophylactic closure of the patent ductus arteriosus pda prophylactic indomethacin indomethacin indomethacin therapy prophylactic indomethacin￨overall morbidity dilator prostaglandin production respiratory sequelae￨early indomethacin conferred no improvement in respiratory sequelae￨no diff￨highunclear￨highunclear￨highunclear
47￨22 infants who weighed 1000 g or less a major ductus shunt developed in 10 of the 12 given 25 infants weighing more than 1000 g a hemodynamically important ductus shunt developed in only four of the 14 given 47 premature infants less than 1700 g who had subclinical patent ductus arteriosus patent ductus arteriosus in verylowbirthweight infants￨indomethacin or placebo placebo prophylactic indomethacin therapy prophylactic indomethacin therapy prophylactic indomethacin￨later development of large ductus shunts and decreases morbidity duration of oxygen therapy and fewer days necessary to regain birth weight incidence of major shunts fewer surgical ligations duration of oxygen therapy￨in the smaller infants indomethacin therapy was associated with a significantly lower incidence of major shunts fewer surgical ligations a decreased duration of oxygen therapy and fewer days necessary to regain birth weight￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨premature infants with respiratory distress syndrome premature infants with 26 infants less than 48 hours old with severe respiratory distress syndrome who had an asymptomatic patent ductus arteriosus￨indomethacin or placebo indomethacin￨frequency of ductal closure time required for mechanical ventilation time receiving supplemental oxygen or time in the hospital incidence of bronchopulmonary dysplasia intraventricular hemorrhage retinopathy of prematurity or death￨no significant difference was observed in the time required for mechanical ventilation time receiving supplemental oxygen or time in the hospital and there were no significant differences in the incidence of bronchopulmonary dysplasia intraventricular hemorrhage retinopathy of prematurity or death between the two groups￨no diff￨highunclear￨highunclear￨highunclear
88￨indigenous children with asthma primary health care setting on thursday island and horn island and in bamaga torres strait region of northern australia april 2005 to march 2007 childhood asthma conducted by australian indigenous health care workers ihcws childhood asthma by aboriginal and torres strait islander health workers 88 children aged 117 years with asthma diagnosed by a respiratory physician intervention group 35 control group 53 98 indigenous children school children￨asthma education sessions with a trained ihcw or ii no additional asthma education education intervention￨frequency of asthma exacerbations unscheduled visits to hospital or a doctor caused by asthma exacerbation primary outcome number of unscheduled medical visits for asthma quality of life qol and functional severity index asthma knowledge and understanding of asthma action plans aaps and school days missed because of wheezing school days because of wheezing qol score and functional severity index￨significantly more carers in the intervention group could answer questions about asthma medication knew where their aap was kept 84 v 56 and were able to describe the plan 67 v 40￨sig increase￨low￨low￨low
47￨patients with typical trigeminal neuralgia fortyseven patients patients with trigeminal neuralgia￨placebo topical ophthalmic eyedrops proparacaine ipsilateral singleapplication ophthalmic anesthetic eyedrops singleapplication topical ophthalmic anesthesia saline placebo￨frequency of trigeminal neuralgia attacks surgery because of persistent pain frequency of pain pain frequency pain response verbal pain rating scale pain rating scales overall pain status￨no significant difference in outcomes was found between the two groups either when using a verbal pain rating scale p  024 or when comparing overall pain status unchanged improved throughout the study period or temporarily improved p  098￨no diff￨low￨low￨low
12￨trigeminal neuralgia 12 patients with trigeminal neuralgia in a doubleblind crossover study for 2 weeks￨carbamazepine lidocaine tocainide tocainide￨analgesic effect￨the similarity in analgesic effect of the two drugs was striking￨no diff￨highunclear￨highunclear￨highunclear
48￨trigeminal neuralgia 48 patients with trigeminal neuralgia who were refractory to medical therapy￨carbamazepine pimozide pimozide therapy pimozide￨trigeminal neuralgia symptoms adverse effects relieved of their pain￨pimozide was compared with carbamazepine in a doubleblind crossover trial in 48 patients with trigeminal neuralgia who were refractory to medical therapy￨sig increase￨highunclear￨highunclear￨highunclear
6￨trigeminal neuralgia six patients￨tizanidine carbamazepine tizanidine￨efficacy and tolerability visual analog scale vas and the overall efficacy tolerated￨the results indicate that tizanidine was well tolerated but the effects if any were inferior to those of carbamazepine￨no diff￨highunclear￨highunclear￨highunclear
305￨￨twolayer technique of continuous catgut to peritoneum and continuous nylon to sheath and a onelayer technique￨incisional hernias failure rate burst abdomens and 7 wound hernias￨in 162 twolayer closures there were 4 burst abdomens and 7 wound hernias 68 per cent wound failures in 164 onelayer closures there were 5 burst abdomens and 7 hernias 73 per cent failures￨no diff￨highunclear￨highunclear￨highunclear
not found￨consecutive patients undergoing abdominal operationelective and emergency surgerythrough a midline abdominal wound midline abdominal surgical wounds￨suture of the peritoneal layer￨narcotic requirements pain scores or wound complications wound sepsis wound dehiscence and subsequent incisional hernia development postoperative pain￨there was no significant difference in narcotic requirements pain scores or wound complications between the 2 groups￨no diff￨highunclear￨highunclear￨highunclear
79￨cumhuriyet university hospital sivas turkey women undergoing gynecological abdominal surgery 79 eligible women who were enrolled and completed baseline assessments february 2002 and march 2003￨￨pain with visual analogue scale vas scores analgesic requirement and pain scores pain and low vas scores analgesic requirements postoperative pain operative time and length of hospital stay￨the postoperative pain was found higher in the closure group than the nonclosure group p005 when the pain with visual analogue scale vas scores compared￨sig decrease￨low￨low￨low
206￨patients in whom the laparotomy was performed through a previous incision n  51 and those in whom the abdomen had to be opened urgently n  3 were excluded from the trial but studied separately n  54 206 patients undergoing laparotomy in the surgical unit in 1984 both elective and emergency cases were included patients undergoing laparotomy through unscarred tissue a lateral paramedian incision was performed and they were randomized to have either the peritoneum closed n  77 or left open n  75￨peritoneal closure after lateral paramedian incision￨incisional hernias wound integrity incisional hernia￨no incisional hernias have developed in patients in whom a lateral paramedian incision was performed and the peritoneum was closed and one incisional hernia has occurred in the patients in whom the peritoneum was left open￨no diff￨highunclear￨highunclear￨highunclear
69￨69 patients with venous leg ulcers venous leg ulcers￨mechanical debridement placebo lidocaine prilocaine emla cream emla￨pain median number of debridements required for a clean ulcer plasma levels￨emla produces effective pain relief for the debridement of leg ulcers and shortens the time to a clean ulcer￨sig decrease￨highunclear￨highunclear￨highunclear
101￨patients with an amide anaesthetic allergy anaesthetic diabetic ulcers or ulcers  50 cm2 were excluded chronic leg ulcers chronic leg ulcers of arterial venous or arteriovenous aetiology 101 patients 51 emla 50 placebo aged 2999 years who had experienced pain associated with previous debridement were included￨emla or placebo cream topical anaesthetic cream placebo emla lignocaineprilocaine anaesthetic cream￨pain of debridement pain associated with debridement on a 100 mm visual analogue scale vas median patient vas scores pain local reactions efficacy and safety￨local reactions were mainly transient and mild and were observed in roughly the same percentage of placebo and emlatreated patients￨no diff￨highunclear￨highunclear￨highunclear
80￨eighty patients with ulcers of venous or arterial origin participated￨lidocaine lidocaineprilocaine cream emla placebo lidocaine and prilocaine emla and placebo emla cream prilocaine emla￨severe adverse reactions verbal rating scale plasma concentrations maximum individual concentrations median vas pain scores leg ulcers pain pain control￨the median vas pain scores for emla and placebo were 185 and 84 mm p less than 001￨no diff￨highunclear￨highunclear￨highunclear
853￨853 patients enrolled into the trial 688 belonged to a wound aetiology subgroup that included 25 patients and were included in the analysis reported here patients with painful exuding wounds of various aetiologies painful exuding wounds￨ibuprofenreleasing foam dressing lbp ibuprofen foam dressing ibuprofen dressing containing 1125mg of ibuprofen ibuprofen foam or to lbp￨summed pain relief score pain intensity pidd550 and initial pain intensity pain relief and pain intensity daily pain relief pain intensity evaluations total maximum pain relief score analgesic efficacy wound pain wound aetiology￨the ibuprofen foam dressing was associated with significantly greater pain relief than lbp in all different wound aetiology subgroups whether chronic or traumatic acute￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨￨lidocaineprilocaine cream emla emla￨analgesic effect 4point scale and pain from ulcer cleansing on a visual analogue scale local reactions local reactions or adverse effects on granulation tissue ulcer area or bacterial flora pain from cleansing of the leg ulcers and the frequency of postcleansing pain￨no statistically significant differences in local reactions or adverse effects on granulation tissue ulcer area or bacterial flora were observed in the emlatreated patients compared with the control patients￨no diff￨highunclear￨highunclear￨highunclear
30￨thirty subjects with comorbid schizophrenia and alcohol use disorders patients with schizophrenia and alcohol use disorders individuals with schizophrenia and alcoholism￨motivational interviewing motivational interviewing mi or educational treatment et intervention with treatment goals of abstinence andor decreased alcohol use motivational interviewing and an educational intervention mi intervention￨drinking days number of drinking days abstinence rates average blood alcohol concentration and standard ethanol content per drinking day abstinence rates￨subjects randomized to the mi intervention had a significant reduction in drinking days and an increase in abstinence rates when compared to subjects receiving et￨sig increase￨highunclear￨highunclear￨highunclear
149￨149 individuals with dual disorders ie individuals with cooccurring severe mental illness and substance use disorders who were homeless at baseline treating homeless clients with severe mental illness and substance use disorders￨integrated assertive community treatment iact assertive community treatment only acto and standard care control￨psychiatric symptoms and substance use average total costs￨clients in the iact and acto programs were more satisfied with their treatment program and reported more days in stable housing than clients in the control condition￨sig increase￨highunclear￨highunclear￨highunclear
198￨clients with cooccurring severe mental and substance use disorders cooccurring disorders 198 clients in two urban sites who had cooccurring disorders and were homeless or unstably housed￨act communitybased case management assertive community treatment and standard clinical case management￨rate of institutionalization￨however in the site that had lower rates of institutionalization no differences in the rate of institutionalization were found between the two treatment conditions￨no diff￨highunclear￨highunclear￨highunclear
129￨drug abuse in people with severe and persistent mental illness substance abuse in severe and persistent mental illness btsas participants were 129 stabilized outpatients meeting dsm criteria for drug dependence cocaine heroin or cannabis and serious mental illness 395 met dsmiv criteria for schizophrenia or schizoaffective disorder 558 for major affective disorders and the remainder met criteria for severe and persistent mental illness and other axis i disorders drug abuse by people with severe mental disorder communitybased outpatient clinics and a veterans affairs medical center in baltimore md￨btsas or a manualized control condition supportive treatment for addiction recovery star new behavioral treatment￨important communityfunctioning variables including hospitalization money available for living expenses and quality of life urinalysis results from twiceweekly treatment sessions￨the btsas program also had significant effects on important communityfunctioning variables including hospitalization money available for living expenses and quality of life￨sig increase￨highunclear￨highunclear￨highunclear
132￨people with severe mental illness and substance abuse disorders 132 dually diagnosed clients dually disordered clients￨￨psychosocial functioning psychosocial functioning and symptomatology differential effectiveness client psychosocial outcomes and psychiatric and substance abuse symptomatology￨differential effectiveness was evident with clients in the behavioral skills group demonstrating the most positive and significant differences in psychosocial functioning and symptomatology compared with the twelve step recovery approach￨sig increase￨highunclear￨highunclear￨highunclear
54￨patients with comorbid severe mental illness and substance use disorders a universityaffiliated innercity community mental health center and a psychosocial rehabilitation center adults with severe mental illness and substance use disorders fiftyfour patients age 18 to 40 with either schizophrenia or major affective disorder and a substance use disorder￨usual community mental health center and rehabilitation services with or without an innovative group and intensive case management program￨￨oneyear followups detected no significant advantages on patient outcomes for adding the innovative program to usual services￨no diff￨highunclear￨highunclear￨highunclear
103￨jail recidivists with serious mental illness and substance use disorders experimental participants had lower study period psychiatric inpatient and crisis utilization and greater outpatient utilization than did control group participants jail recidivists with cooccurring psychiatric and substance use disorders 103 participants or to service as usual 79 participants￨high fidelity integrated dual disorders treatment program￨arrests and total convictions￨the pre to post reduction for arrests and total convictions was significant in the experimental group but not the control group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨outpatient treatment adherence among psychiatric and dually diagnosed inpatients psychiatric and dually diagnosed patients subjects were 121 psychiatric inpatients 93 77 of whom had concomitant substance abusedependence disorders￨standard treatment st including pharmacotherapy individual and group psychotherapy activities therapy milieu treatment and discharge planning or b st plus motivational interviewing stmi which involved 15 minutes of feedback on the results of a motivational assessment early in the hospitalization and a 1hour motivational interview just before discharge motivational interviewing motivational interviewing￨proportion of patients who attended their first outpatient appointment￨results indicated that the proportion of patients who attended their first outpatient appointment was significantly higher for the stmi group 47 than for the st group 21 chi2  887 df  1 p01 overall and for dually diagnosed patients 42 for stmi vs 16 for st only chi2  768 df  1 p01￨sig increase￨highunclear￨highunclear￨highunclear
23￨patients continuing to use cannabis following initial treatment for firstepisode psychosis fep consecutive admissions to an early psychosis program were screened and consenting individuals using cannabis in the 4 weeks prior to assessment participated young people with firstepisode psychosis n  23 with a clinical control condition psychoeducation pe n  24￨cap cannabisfocused intervention cannabis and psychosis therapy cap cannabisfocused intervention￨cannabis use psychopathology and functional ratings￨there were no significant differences between the cap and pe groups on cannabis use at end of treatment and 6 months postintervention￨no diff￨highunclear￨highunclear￨highunclear
223￨223 patients with dual disorders over three years patients with cooccurring severe mental illness and substance use disorder￨integrated mental health and substance abuse treatment within an assertive community treatment act approach assertive community treatment￨stable community days hospital days psychiatric symptoms and remission of substance use disorder substance abuse and quality of life￨act patients showed greater improvements on some measures of substance abuse and quality of life but the groups were equivalent on most measures including stable community days hospital days psychiatric symptoms and remission of substance use disorder￨no diff￨highunclear￨highunclear￨highunclear
62￨sixtytwo patients with bipolar disorder and current substance dependence treated with mood stabilizers for or2 weeks patients with bipolar disorder and substance dependence￨integrated group therapy versus group drug counseling integrated group therapy n31 or group drug counseling￨number of days of substance use number of weeks ill with a mood episode depressive and manic symptoms￨intentiontotreat analysis revealed significantly fewer days of substance use for integrated group therapy patients during treatment and followup￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨subjects met abuse or dependence criteria on the structured clinical interview for diagnosis scid for alcohol cannabis or amphetamine or they reported hazardous use during the last month of one or more of these drug types on the opiate treatment index oti subjects were volunteers recruited from a major public psychiatric hospital hospitalized psychiatric patients with comorbid substance use disorder in reducing alcohol and other drug aod use￨motivational interviewing individual motivational interview n79 or a selfhelp booklet control condition n81 motivational interview￨aggregate index of alcohol and other drug use polydrug use on the oti￨cannabis use remained high among the sample over the 12month followup period￨sig increase￨highunclear￨highunclear￨highunclear
276￨homeless adults with both a serious mental illness and substance dependence n  276 dually diagnosed homeless adults￨social model residential program providing integrated mental health and substance abuse treatment 2 a communitybased nonresidential program using the same social model approach or 3 a control group receiving no intervention but free to access other community services￨substance use mental health and housing outcomes￨results showed that while substance use mental health and housing outcomes improved from baseline subjects assigned to treatment conditions differed little from control subjects￨sig increase￨highunclear￨highunclear￨highunclear
not found￨all 13 sos participants who proceeded to twentyfive inpatients aged 1835 years with early psychosis and current misuse of nonopioid drugs￨motivational interviewing motivational intervention￨￨engagement remained challenging 39 1641 declined participation and 38 513 in sos only received rapport building￨no diff￨highunclear￨highunclear￨highunclear
65￨people with psychotic disorders people with a psychotic disorder and who reported hazardous alcohol cannabis andor amphetamine use during the preceding month was recruited￨cognitivebehavioural therapy 10session intervention consisting of motivational interviewing and cognitivebehavioural therapy cbt motivational interviewingcbt motivational interviewingcbt intervention￨substance use and improving symptomatology and general functioning depression￨there was a shortterm improvement in depression and a similar trend with regard to cannabis use among participants who received the motivational interviewingcbt intervention together with effects on general functioning at 12 months￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with comorbid schizophrenia and alcohol or drug abuse or dependence patients with comorbid schizophrenia and substance use disorders patients with schizophrenia and substance use disorders patients with these disorders￨motivational interviewing cognitive behavior therapy and family intervention over routine psychiatric care alone motivational interviewing cognitive behavior therapy and family intervention integrated psychological and psychosocial treatment program routine care with a program of routine care integrated with motivational interviewing cognitive behavior therapy and family or caregiver intervention￨positive symptoms and in symptom exacerbations patients general functioning￨the integrated treatment program resulted in significantly greater improvement in patients general functioning than routine care alone at the end of treatment and 12 months after the beginning of the study￨sig increase￨highunclear￨highunclear￨highunclear
not found￨cancer patients normal persons and cancer patients patients with small cell carcinoma of the lung receiving intensive chemotherapy￨placebo￨survival￨the increase in survival was greatest in patients with low pretreatment tcell and alpha2hsglycoprotein levels￨sig increase￨highunclear￨highunclear￨highunclear
211￨metastatic colorectal cancer advanced colorectal cancer￨thymostimulin ts highdose folinic acid fa and fluorouracil fu plus or minus thymostimulin ts folinic acid fa plus fluorouracil fu￨hematological toxicity incidence of febrile episodes and other treatmentrelated toxicities therapeutic efficacy and tolerability mucositis and diarrhoea objective responses￨no difference was observed in terms of hematological toxicity while the ts treated patients experienced a significantly lower incidence of mucositis and diarrhoea p  003￨no diff￨highunclear￨highunclear￨highunclear
150￨patients with aggressive nonhodgkins lymphoma 150 patients with newly diagnosed ig or hgnhl 134 fully evaluable patients 68 treated with ct alone and 66 treated with ct  ts patients with intermediate and highgrade nonhodgkins lymphoma ig hgnhl￨thymostimulin ts macopb ct  ts generation regimens macopb versus promacecytabom doxorubicin epidoxorubicin chemotherapy ct alone or ct  ts ct thymostimulin with combination chemotherapy conventional chemotherapy￨complete remission cr rate survival rates nk activity cr normal hemoglobin levels efficacy and safety￨no difference between the two treatment arms have been observed as regards drugrelated toxicity and the number and severity of infectious episodes￨no diff￨highunclear￨highunclear￨highunclear
26￨small cell lung cancer patients 26 evaluable patients with small cell lung cancer￨thymostimulin hymostimulin cyclophosphamide 4epidoxorubicin and etoposide cisplatin and etoposide with n  15 or without n  11 thymostimulin￨complete response rate and survival myelosuppression fever and documented infectious episodes toxicity and longterm survival￨myelosuppression fever and documented infectious episodes were significantly less severe in thymostimulintreated patients allowing the administration of significantly higher drug doses at shorter intervals between chemotherapy cycles a significant improvement in complete response rate and survival were also observed￨no diff￨highunclear￨highunclear￨highunclear
91￨91 patients with small cell carcinoma of the lung 35 patients with limited disease 18 randomized to thymosin and 17 to no thymosin and 56 with extensive disease 28 thymosin and 28 no thymosin small cell lung cancer￨induction chemotherapy and consolidation radiotherapy induction chemotherapy and radiation therapy thymosin fraction v 60 mgm2 prophylactic cranial irradiation drugs cyclophosphamideadriamycinvincristine and cisplatinetoposide combined modality therapy with and without thymosin fraction v￨response rate response duration or survival overall response rate 3yr survival pattern of toxicity median duration of survival median duration of response￨a comparison of the thymosinversus no thymosintreated patients revealed no difference in response rate response duration or survival whether analyzed as a whole or by extent of disease￨no diff￨highunclear￨highunclear￨highunclear
not found￨36 patients with advanced head and neck carcinomas randomized into two groups￨thymostimulin cgy  700 mg of carboplatin hyperfractionated carboplatin and irradiation 115 cgy  5 mgm2 of carboplatin￨toxicity number of complete remissions distant metastases lymphocyte levels slightly longer diseasefreesurvival interval￨patients included in the b group had a slightly longer diseasefreesurvival interval but 17 of recurrences and 11 of distant metastases were observed in the a group whereas 22 of recurrences and 22 of distant metastases were seen in the b group￨sig increase￨highunclear￨highunclear￨highunclear
57￨hepatocellular carcinoma after hepatectomy by using tace transcatheter hepatic arterial chemoembolization with thymosin alpha1 postoperatively from january 2000 to december 2002 57 patients with hepatocellular carcinoma hepatocellular carcinoma hepatocellular carcinoma patients after hepatectomy￨hepatectomy only combination transcatheter hepatic arterial chemoembolization with thymosin alpha1 hepatectomy plus tace hepatectomy plus tace and thymosin alpha1 postoperatively￨recurrent time median survival recurrent rate recurrent rate recurrent time and median survival period￨the recurrent time were 70 50 and 40 months p0039 respectively and the median survival were 100 70 and 80 months p0002 respectively￨no diff￨highunclear￨highunclear￨highunclear
not found￨lymphoma and myeloma patients patients receiving chemotherapy for malignant diseases two groups of homogeneous and randomized patients diagnosed as having lymphoma and myeloma￨thymostimulin thymostimulin tp1 chemotherapy and thymostimulin￨hematological tolerance to chemotherapy skin reactions and number and severity of infections registered hematological tolerance￨the hematological tolerance to chemotherapy skin reactions and number and severity of infections registered were not significantly different between the 2 groups￨no diff￨highunclear￨highunclear￨highunclear
488￨four hundred eightyeight patients patients with metastatic melanoma￨thymosin alpha 1 interferon alfa or both in combination with dacarbazine dticifnalphatalpha1 16 mg dticifnalphatalpha1 32 mg dticifnalphatalpha1 64 mg dtictalpha1 32 mg dticifnalpha control group dtictalpha1 talpha1 with dacarbazine dtic and interferon alfa ifnalpha talpha1￨duration of response overall survival os and progressionfree survival pfs median os duration of response pfs overall response efficacy and safety￨an increase in pfs was observed in patients given talpha1 versus the control group hazard ratio  080 95 ci 063 to 101 p  06￨sig increase￨highunclear￨highunclear￨highunclear
100￨one hundred patients with advanced carcinoma undergoing highly cancer patients undergoing highly cytotoxic chemotherapy￨thymopentin placebo cytotoxic chemotherapy granulocytecolony stimulating factor with or without thymopentin subcutaneous gcsf thymopentin thymopentin￨febrile episodes fungal infections febrile leukopenia mild nausea and generalized bone pain incidence of chemotherapyrelated fever and leukopenia￨thymopentin was associated with a reduction in febrile episodes as compared to placebo 52 versus 64 but this difference did not reach statistical significance￨sig increase￨highunclear￨highunclear￨highunclear
54￨patients with advanced breast cancer after high dose mitoxantrone therapy 54 patients with advanced breast cancer patients with advanced breast cancer￨mitoxantrone 28 mgm2 intravenous day 1 and granulocytecolony stimulating factor gcsf thymostimulin ts granulocytecolony stimulating factor gcsf with gcsf plus thymostimulin myelosuppressive chemotherapy￨haematological recovery haematological toxicity neutropenic fever median time to reach a neutrophil count incidence duration and severity of clinically or bacteriologically documented infection￨the median time to reach a neutrophil count greater than 05 x 109l was lower in the gcsfts treated group 913 versus 324 days p  00005￨no diff￨highunclear￨highunclear￨highunclear
25￨patients with advanced hepatocellular carcinoma hcc unresectable hepatocellular carcinoma 25 patients received either￨tace tace transarterial chemoembolization tace plus thymalfasin with tace thymalfasin thymosin α1 tace  thymalfasin thymalfasin plus transarterial chemoembolization tace plus thymalfasin tace alone￨survival median overall survival time serious adverse events rates of survival and tumor response including transplant candidacy￨seven patients in each group experienced serious adverse events there were no bacterial infections in the tace  thymalfasin group versus 4 in the taceonly group￨no diff￨highunclear￨highunclear￨highunclear
105￨patients treated with vap and 10 all prs of 46 22 patients with advanced nonsmall cell tumors patients with nonsmall cell lung cancer receiving one hundred five patients with advanced nonsmall cell lung cancer 99 evaluable patients response was seen in 24 2 crs 22 prs of 53 45￨thymosin fraction v immunotherapy during remission induction chemotherapy with vindesine doxorubicin and cisplatin vap vap  thymosin thymosin fraction v immunotherapy vindesine doxorubicin and cisplatin vap chemotherapy vap alone￨median survival duration squamous cell carcinoma graftvshost reaction￨thymosin treatment resulted in decreased graftvshost reaction p  001 and increased suppressor effect on normal mitogen response to cona p  017￨sig decrease￨highunclear￨highunclear￨highunclear
42￨patients with lung cancer lung cancer patients treated with 42 postradiotherapy patients with nonsmall cell lung cancer￨radiotherapy synthetic thymosinalpha 1 placebo synthetic thymosinalpha￨t cell numbers or function normalization of t cell function relapsefree and overall survival￨placebotreated patients did not show any improvement in t cell numbers or function over 15 weeks of serial immune monitoring and exhibited gradual depressions of helper t lymphocyte percentages￨no diff￨highunclear￨highunclear￨highunclear
151￨screening elderly people in primary care elderly people aged 75 years and over in a general practice a total of 151 people￨screening programme￨activities of daily living social functioning sensory functions mental and emotional problems current medical problems blood pressure urinalysis haemoglobin level and compliance with medication￨at follow up the test group scored significantly better than the control group on a morale scale￨sig increase￨highunclear￨highunclear￨highunclear
4340￨general practices in the united kingdom participating in the mrc trial of assessment and management of older people in the community people with visual impairment proportion of people with visual acuity less than 618 in either eye mean 4340 people aged 75 years or over randomly sampled from 20 general practices excluding people resident in hospitals or nursing homes screening older people for impaired vision in primary care people aged 75 or over as part of a multidimensional screening programme￨universal screening assessment and visual acuity testing￨mean composite score of the visual function questionnaire visual acuity testing and referral to eye services relative risk of having visual acuity visual outcomes composite score of 25 item version of the national eye institute visual function questionnaire￨three to five years after screening the relative risk of having visual acuity  618 in either eye comparing universal with targeted screening was 107￨no diff￨low￨low￨low
1559￨from a random sample of health maintenance organization hmo enrollees 65 years and older 1559 ambulatory seniors older adults￨usual care nurse assessment visit and followup interventions targeting risk factors for disability and falls group 1 n  635 a general health promotion nurse visit￨incidence of falls disability and falls incidence of declining functional status￨after 1 year group 1 subjects reported a significantly lower incidence of declining functional status and a significantly lower incidence of falls than group 3 subjects￨sig decrease￨highunclear￨highunclear￨highunclear
863￨elderly people 863 patients aged 70 and over on the practice records 674 were traced and successfully interviewed 350 were assigned to the intervention group 324 as controls general practice in a market town￨￨incidence of fractures fracture rate￨a health visitor visiting a group of people aged 70 and over and using simple preventive measures had no effect on the incidence of fractures￨no diff￨highunclear￨highunclear￨highunclear
not found￨with elderly patients in general practice patients in general practice who were aged over 70￨health visitors working￨quality of life￨independent assessments made at the beginning and end of the study showed that the health visitor in an urban practice had some impact on her caseload of patients she provided more services for them their mortality was reduced and their quality of life improved though the last measure just failed to be statistically significant￨sig decrease￨highunclear￨highunclear￨highunclear
580￨elderly people elderly people living at home 580 subjects aged between 75 and 84 years randomly allocated to intervention 292 or control 288 group general population of elderly people in one of the southern regions of the netherlands￨￨long term institutional care and overall expenditure per person risk of admission self rated health functional state well being loneliness aspects of the mental state depressive complaints memory disturbances and mortality￨no differences were found in long term institutional care and overall expenditure per person in the intervention group exceeded that in the control group by 4￨no diff￨highunclear￨highunclear￨highunclear
92￨adults at risk of diabetes individuals at risk of type 2 diabetes september 2001 to september 2002 in providence ri of 92 overweight adults whose mean sd age was 485 94 years and body mass index 331 38 adults at risk for type 2 diabetes￨internet weight loss program alone vs with the addition of behavioral counseling via email calorie and exercise information and received weekly email behavioral counseling and feedback from a counselor basic internet n  46 or to an internet plus behavioral ecounseling program internet behavioral counseling￨percentage of initial body weight waist circumference weight loss mean sd weight body mass index measured weight and waist circumference￨adding email counseling to a basic internet weight loss intervention program significantly improved weight loss in adults at risk of diabetes￨sig decrease￨highunclear￨highunclear￨highunclear
135￨69 selfdirected women had no contact with study staff overweight middleaged women through the internet 135 women a group of perimenopausal women 48044 years old￨weight maintenance internet intervention or to selfdirected weight maintenance after a 4month weight loss treatment￨weight loss weight regain weight and body composition and diet intake￨while significant weight loss was maintained over followup by both groups of women internet use did not surpass selfdirection in helping to sustain weight loss￨no diff￨highunclear￨highunclear￨highunclear
122￨122 healthy overweight adults age48496 bmi32245 kgm2 18 male
                body weight dietary intake energy expended in physical activity attendance selfmonitoring comfort with technology￨weight maintenance program￨weight loss weight smaller weight loss￨attendance at maintenance meetings was greater for the fips than the is condition over the 1 y maintenance program 54 vs 39 p004￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨prototypical behavioral program and contrasted with the ferguson approach deployed alone￨assessments of weight nutritional knowledge eating behavior and related cognitive variables￨no incremental effects attributable to the software programs appeared￨no diff￨highunclear￨highunclear￨highunclear
481￨two centers in vermont and arkansas from 2003 to 2008 481 healthy overweight adults 28 minority￨behavioral weight loss program with weekly meetings internet n161 inperson internet behavioral weight loss program￨weight loss mean weight loss weight at baseline and 6 months and percent of subjects achieving a 5 and 7 weight loss weight loss for inperson￨weight loss for inperson was significantly greater than the internet and hybrid conditions p005￨sig increase￨highunclear￨highunclear￨highunclear
446￨overweight individuals obese individuals who desire large weight reductions a military medical research center with a population of 17000 activeduty military personnel supplied 446 overweight individuals 222 men 224 women with a mean age of 34 years and a mean bmi of 29￨internetbased weightmanagement interventions behavioral internet treatment bit n227 or usual care internetbased program￨waist circumference weight loss prevent weight gain bmi change in body weight bmi percent body fat and waist circumference￨bit participants also had significant changes in bmi 05 vs 02 kgm2 fdf3662458 percent body fat 04 vs 06 fdf3661045 and waist circumference 21 vs 04 cm fdf3661709 p0001 for all￨sig decrease￨highunclear￨highunclear￨highunclear
101￨patients also participated in four two inperson and two telephonic counseling sessions with a health coach primary care 101 primary care patients with obesity and hypertension￨webbased weight loss intervention￨weight loss website utilization high rates of participant retention moderate weight loss relative to usual care￨intenttotreat analysis showed greater weight loss at 3 months 256 kg 95 ci 360 153 among intervention participants 228￨no diff￨low￨low￨low
104￨overweight adults overweight adults n  104￨nondirective collaborative flexible and directive prescriptive protocol driven ecoach support individualized nondirective or directive weight loss support￨weight loss dietary behavior physical activity and engagement￨for females weight loss η2  010 and changes in waist circumference η2  007 were greater in the directive than in the nondirective and minimal support conditions￨sig decrease￨highunclear￨highunclear￨highunclear
588￨588 individuals bmi  25 kgm2 in a freestanding health maintenance organizalion and achieved an 81 completion rate￨cognitive behavioral approach computerized weight loss intervention optimizes staff time￨weight loss included more computer logons achieving computerselected goals more selfmonitoring increased walking and decreased energy and fat intake weight loss weight loss weight parameters lipid profile plasma glucose blood pressure intervention costs dietary intake and physical activity mean bmis fasting glucose and blood pressure energy and fat intake mean 12month weight losses￨all groups reported a decrease in energy and fat intake and an increase in blocks walked p01￨sig decrease￨highunclear￨highunclear￨highunclear
192￨one hundred ninetytwo adults aged 492￨1 weight loss group session coupons for meal replacements and access to an interactive web site no counseling computerautomated feedback or human email counseling human email counseling computerautomated tailored counseling and no counseling weekly email feedback from a counselor and the computerautomated feedback group received automated tailored messages human email counseling￨weight loss weight losses retention￨providing automated computertailored feedback in an internet weight loss program was as effective as human email counseling at 3 months￨sig increase￨highunclear￨highunclear￨highunclear
not found￨ninetyone healthy overweight adult hospital employees aged 18 to 60 years with a body mass index of 25 to 36 kgm2￨additional behavioral procedures including a sequence of 24 weekly behavioral lessons via email weekly online submission of selfmonitoring diaries with individualized therapist feedback via email and an online bulletin board structured internet behavioral weight loss program 6month weight loss program of either internet education education n  32 with complete data or internet behavior therapy behavior therapy structured behavioral treatment program with weekly contact and individualized feedback￨weight loss body weight and waist circumference weight loss weight weight loss goal initial weight loss and changes in waist circumference changes in waist circumference￨repeatedmeasures analyses showed that the behavior therapy group lost more weight than the education group p 005￨sig decrease￨highunclear￨highunclear￨highunclear
110￨bmi 2540 mean sd age  444 86 years bmi  305 36 male employees at tomago aluminium aged 1865 male shift workers overweight male shift workers 110 overweightobese in october 2009 men￨wp program workplacebased weight loss program workplace powerwp information session program booklets groupbased financial incentives and an online component workplacebased weight loss program￨systolic blood pressure waist circumference resting heart rate weight loss physical activityrelated cognitions weight loss and improved healthrelated outcomes and behaviours waist circumference bmi blood pressure resting heart rate selfreported physical activity and dietary variables and physical activity and dietary cognitions physical activity bmi￨the wp program was feasible and efficacious and resulted in significant weight loss and improved healthrelated outcomes and behaviours in overweight male shift workers￨sig increase￨low￨low￨low
314￨314 participants who had lost a mean of 193 kg of body weight in the previous 2 years to one of three groups a￨control group which received quarterly newsletters 105 participants a group that received facetoface intervention 105 and a group that received internetbased intervention￨weight loss daily selfweighing weight gain over a period of 18 months sd weight gain￨as compared with receiving quarterly newsletters a selfregulation program based on daily weighing improved maintenance of weight loss particularly when delivered face to face￨sig increase￨low￨low￨low
91￨participants 91 community members average age 426 years overweight and obese adults￨cad plus an additional foursession selfmanagement group training cadg n  31 and a waitlist control two computerassisted dieting cad interventions￨moderate weight loss weight regain weight loss and blood chemistry￨however the two intervention groups combined showed a significant though moderate weight loss relative to the control group￨sig decrease￨highunclear￨highunclear￨highunclear
66￨sixtysix women participated￨two motivationally enhanced internet behavioral weight loss programs weekly moderated online chat group sessions led using motivational techniques￨weight loss￨both groups lost weight over time p0001 however the group by time interaction was nonsignificant p019￨no diff￨highunclear￨highunclear￨highunclear
1032￨1032 overweight or obese adults 38 african american 63 women with hypertension dyslipidemia or both who had lost at least 4 kg during a 6month weight loss program phase 1￨monthly personal contact unlimited access to an interactive technologybased intervention or selfdirected control weightloss maintenance intervention behavioral weight loss interventions￨mean weight loss weight from randomization mean entry weight weight weight regain sustaining weight loss below entry weight￨at 30 months weight regain did not differ between the interactive technologybased 52 kg and selfdirected groups 55 kg mean difference 03 kg 95 ci 12 to 06 kg p  51 however weight regain was lower in the interactive technologybased than in the selfdirected group at 18 months mean difference 11 kg 95 ci 19 to 04 kg p  003 and at 24 months mean difference 09 kg 95 ci 17 to 002 kg p  04￨no diff￨low￨low￨low
31￨sixtyfive overweightobese men 43  students 42  nonacademic general staff 15  academic staff mean age 359 sd 111 years mean bmi 306 men participating in an obesity intervention as part of the selfhelp exercise and diet using information technology shedit study men participating in a weightloss intervention￨implement key dietary messages but not those relating to vegetables or alcohol the selfhelp exercise and diet using internet technology￨dietary fibre or alcohol average psf saturated fat mean daily energy intake percentage of energy from fat￨both groups reduced percentage of energy from fat p  005 saturated fat p  0001 and energydensenutrientpoor items p  005 with no change in dietary fibre or alcohol p  005￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients with chemotherapyinduced cytopenia cytopenic patients who receive antimicrobial prophylaxis ap patients with cytopenia after intensive chemotherapy for hematological malignancy￨normal hospital diet nhd lowbacterial diet lbd ap and lbd￨infections and total societal costs colonization of the digestive tract with aerobic gramnegative bacilli and yeasts gut colonization by yeasts or gramnegative bacilli or infections use of antimicrobials days with fever and total societal costs￨no statistically significant differences between treatment groups were observed regarding the primary outcome parameter gut colonization by yeasts or gramnegative bacilli or infections use of antimicrobials days with fever and total societal costs￨no diff￨highunclear￨highunclear￨highunclear
153￨seventyeight patients patients with acute myeloid leukemia aml patients undergoing remission induction therapy for acute myeloid leukemia one hundred fiftythree patients admitted to a highefficiency particulate airfiltered room protected environment pe to receive induction therapy for newly diagnosed aml￨antibacterial and antifungal prophylaxis diet containing no raw fruits or vegetables cooked diet or to a diet containing fresh fruit and fresh vegetables raw diet cooked and noncooked diets￨time to major infection and survival time risk of mortality erm score major infection pneumonia bacteremia or fungemia and death if the true probability of either event major infection fever of unknown origin major infection or death￨time to major infection and survival time were similar in the two groups￨no diff￨highunclear￨highunclear￨highunclear
19￨children with cancer pediatric oncology patients receiving pediatric cancer patients nineteen patients were enrolled￨myelosuppressive chemotherapy neutropenic diet or to food and drug administration fdaapproved food safety guidelines￨infection rates adherence and diet tolerability adherence rate infection rate febrile neutropenia￨infection rates for children with cancer on the neutropenic diet were similar to those for patients following food safety guidelines￨no diff￨highunclear￨highunclear￨highunclear
1180￨all patients 1180 clinically diagnosed bacterial conjunctivitis patients aged 28 days￨moxifloxacin ophthalmic solution moxeza moxiaf moxifloxacin xanthan gumbased 05 moxifloxacin ophthalmic formulation moxiaf￨staphylococcus aureus streptococcus pneumoniae microbiological efficacy microbiological success rate￨moxiaf was also statistically more effective than vehicle in eradicating the three principle conjunctivitis pathogens haemophilus influenzae 985 vs 596 respectively streptococcus pneumoniae 864 vs 500 respectively and staphylococcus aureus 941 vs 800 respectively p0001￨no diff￨highunclear￨highunclear￨highunclear
181￨patients presenting in primary care with the condition receive topical antibiotics adults presenting with a red eye and either mucopurulent discharge or glued eyelids one hundred and eightyone patients were randomised and 163 patients were analysed twentyfive dutch primary care centres￨placebo fusidic acid fusidic acid gel fusidic acid gel 1 or placebo fusidic acid gel and placebo topical antibiotics￨cure rates recovery rates in culturepositive and culturenegative patients median duration of symptoms recovery rates bacterial eradication rates a survival time analysis of the duration of symptoms prevalence of a positive bacterial culture bacterial eradication rate￨the bacterial eradication rate was 76 in the treatment and 41 in the placebo group risk difference  35 95 ci  93 to 604￨no diff￨low￨low￨low
102￨eightyfour patients had proved bacterial conjunctivitis haemophilus influenzae 61 streptococcus pneumoniae 22 both one 66 of these received only topical therapy 102 children aged 1 month to 18 years acute conjunctivitis in children￨topical antibiotic therapy placebo drug polymyxinbacitracin ophthalmic ointment or placebo polymyxinbacitracin￨bacterial pathogen￨the bacterial pathogen was eradicated by day 3 to 5 in 71 and by day 8 to 10 in 79 of patients given antibiotic compared to 19 and 31 of the placebo group p less than 0001￨no diff￨low￨highunclear￨low
not found￨two hundred eightyeight cases of cultureproven bacterial conjunctivities bacterial conjunctivitis￨ciprofloxacin tobramycin placebo tobramycin 03 ciprofloxacin 03 ophthalmic solution￨antibacterial effectiveness various bacterial pathogens antibacterial efficacy￨it eradicated or reduced the various bacterial pathogens in 936 of patients compared to 595 for the placebo￨no diff￨highunclear￨highunclear￨highunclear
326￨326 children aged 6 months to 12 years with a clinical diagnosis of conjunctivitis who were recruited from 12 general medical practices in the uk acute infective conjunctivitis in children in primary care children with infective conjunctivitis in primary care 163 children to receive￨chloramphenicol eye drops with placebo placebo chloramphenicol eye drops and 163 to receive placebo eye drops chloramphenicol treatment￨conjunctivitis episodes adverse events clinical cure survival statistics clinical cure￨clinical cure by day 7 occurred in 128 83 of 155 children with placebo compared with 140 86 of 162 with chloramphenicol risk difference 38 95 ci 41 to 118￨no diff￨low￨low￨low
202￨patients aged 1 year with bacterial conjunctivitis adults and children bacterial conjunctivitis 202 patients randomized to treatment mean sd age 252 243 years 569 female 767 white 109 had cultureconfirmed bacterial conjunctivitis 53 besifloxacin ophthalmic suspension 56 vehicle adults and children with bacterial conjunctivitis￨besifloxacin vehicle formulation without besifloxacin besifloxacin besifloxacin ophthalmic suspension copyright besifloxacin ophthalmic suspension￨clinical resolution and bacterial eradication of the baseline bacterial infection tolerability assessments included ocular adverse events aes changes in visual acuity biomicroscopy and ophthalmoscopy findings and nonocular aes visual acuity and biomicroscopy and ophthalmoscopy findings efficacy and tolerability effective and well tolerated rates of bacterial eradication allergic conjunctivitis times of medication instillation ocular aes conjunctivitis incidence of ocular aes bacterial conjunctivitis rates of clinical resolution efficacy and tolerability clinical resolution and bacterial eradication of the baseline bacterial infection at visit 3 individual clinical outcomes ocular conjunctival discharge and bulbar conjunctival injection at the followup visits and microbial and clinical outcomes for overall bacterial species and individual grampositive and gramnegative bacterial species￨at visit 2 the besifloxacin ophthalmic suspension group had significantly greater rates of clinical resolution compared with the vehicle group 3753 698 vs 2156 375 respectively p  0001 as well as significantly greater rates of bacterial eradication 4653 868 vs 3256 571 p  0001￨sig increase￨low￨low￨low
284￨two hundred and eightyfour patients with acute conjunctivitis acute bacterial conjunctivitis￨placebo norfloxacinplacebo norfloxacin ophthalmic solution with placebo norfloxacin topical norfloxacin￨adverse experiences safety and efficacy￨the proportion of patients who were clinically improved after 5 days treatment was 881 in the norfloxacin group and 716 in the placebo group p less than 001￨no diff￨highunclear￨highunclear￨highunclear
269￨118 patients 60 besifloxacin ophthalmic suspension 58 vehicle patients with bacterial conjunctivitis patients with acute bacterial conjunctivitis 269 patients mean sd age 342 223 years 602 female 825 white with acute bacterial conjunctivitis bacterial conjunctivitis￨fluoroquinolone besifloxacin topical besifloxacin ophthalmic suspension vehicle the formulation without besifloxacin besifloxacin ophthalmic suspension besifloxacin ophthalmic suspension￨clinical resolution of the baseline infection clinical resolution and eradication of the baseline bacterial infection on day 8 in cultureconfirmed patients clinical and microbiologic efficacy efficacious and well tolerated adverse events changes in visual acuity and biomicroscopy and ophthalmoscopy findings blurred vision visual acuity eye irritation rates of bacterial eradication eye pain cumulative frequency of adverse events pinhole visual acuity testing biomicroscopy and culture of the infected eyes￨changes in visual acuity and treatmentemergent events observed on biomicroscopy and direct ophthalmoscopy also were comparable between treatment groups￨no diff￨low￨low￨low
957￨957 patients aged 1 year and older with bacterial conjunctivitis bacterial conjunctivitis three hundred and ninety patients had cultureconfirmed bacterial conjunctivitis￨besifloxacin ophthalmic suspension 06 or vehicle applied topically three times daily for 5 days besifloxacin ophthalmic suspension besifloxacin ophthalmic suspension￨clinical resolution and microbial eradication at visit 3 day 8 or 9 individual clinical outcomes at followup visits and safety adverse events clinical resolution and microbial eradication clinical resolution and microbial eradication of baseline bacterial infection microbial eradication rates￨besifloxacin ophthalmic suspension produces clinical resolution and microbial eradication rates significantly better than vehicle and is safe for the treatment of bacterial conjunctivitis￨sig increase￨highunclear￨highunclear￨highunclear
279￨children and adults with bacterial conjunctivitis eligible male or female participants with a clinical diagnosis of acute bacterial conjunctivitis two hundred and seventynine participants n  130 1 azithromycin in durasite n  149 vehicle age one to 96 years￨azithromycin azithromycin in durasite or vehicle azithromycin ophthalmic solution azithromycin￨clinical resolution of signs and symptoms rating of zero on ocular discharge bulbar and palpebral injection bacterial eradication rates clinical resolution and bacterial eradication rates conjunctival cultures adverse events slitlamp findings and ophthalmoscopy clinical resolution and bacterial eradication adverse event rates￨clinical resolution with azithromycin ophthalmic solution was statistically significant compared with that of vehicle p  030 at visit 3￨sig increase￨low￨low￨low
230￨children from bangladesh 230 male infants and young children 4 to 24 months of age presenting with diarrhea of 2 days duration were admitted to the metabolic research ward of the international centre for diarrheal disease research bangladesh and fed 1010 colonyforming units of 218 vs 381￨lactobacillus paracasei strain st11 placebo new probiotic lactobacillus paracasei strain st11 st11 oral rehydration solution intake lyophilized st11 or placebo st11￨severe rotavirus diarrhea cumulative stool output stool frequency diarrhea resolve stool output and frequency oral rehydration solution intake and excretion of rotavirus nonrotavirus diarrhea diarrhea duration￨no effect of st11 treatment on severe rotavirus diarrhea was observed￨no diff￨low￨low￨low
not found￨children from 2 mo to 12 years of age with acute diarrhoea￨ors nutritional support and s boulardii 250 mg bid and in control group treated with ors and nutritional support only saccharomyces boulardii s boulardii s boulardii boulardii probiotic saccharomyces boulardii￨frequency and duration of acute diarrhoea number of diarrhoeal episode frequency of episodes of diarrhoea side effects diarrhoea duration of diarrhoea frequency and consistency of stools￨baseline characteristics such as mean age and the average frequency of stools were comparable in s boulardii and control group at the time of inclusion in the trial￨no diff￨highunclear￨highunclear￨highunclear
123￨acute diarrhoea 27 rotavirus 21 bacterial aetiology were studied in 123 children aged between 1 and 36 months of age￨placebo isotonic oral rehydration solution ors with osmolarity 311 mosmoll and sodium 90 mmoll whoors or a hypotonic ors with osmolarity 224 mosmoll and sodium 60 mmoll lightors oral rehydration and lactobacillus gg oral rehydration and lactobacillus strain gg lgg lgg 5 x 109 colony forming units of lgg or a matching placebo￨acute diarrhoea shorter duration of diarrhoea shorter duration of watery diarrhoea duration of rotavirus diarrhoea￨patients receiving lgg had a significantly shorter duration of watery diarrhoea mean sd 27 22 days than those receiving the placebo 37 28 days p  003￨sig decrease￨highunclear￨highunclear￨highunclear
73￨acute diarrhea in children children aged 3 to 24 months with acute diarrhea and mild or moderate dehydration were enrolled in the study children with acute diarrhea seventythree children 37 l acidophilus lb 36 placebo were enrolled of whom 40 17 l acidophilus lb 23￨placebo oral rehydration therapy medication lactéol fort sachets laboratoire du lactéol du docteur boucard houdan france containing lyophilized heatkilled lactobacillus acidophilus lb l acidophilus lb to oral rehydration therapy lyophilized heatkilled lactobacillus acidophilus lb to oral rehydration therapy one sachet containing 10 billion of lyophilized heatkilled l acidophilus lb or placebo￨number of rotaviruspositive children with watery stools rotavirus mean duration of diarrhea duration of diarrhea￨mean duration of diarrhea was decreased p  0034 with l acidophilus lb 434 hours versus placebo 570 hours￨sig decrease￨highunclear￨highunclear￨highunclear
40￨acute rotavirus diarrhea in children forty patients between 6 and 36 months of age hospitalized with acute diarrhea 75 rotavirus acute diarrhea acute diarrhea in young children￨1010 to 1011 colonyforming units of l reuteri or a matching placebo lactobacillus reuteri placebo￨watery diarrhea mean sd duration of watery diarrhea diarrhea and colonization of l reuteri colonization of the gastrointestinal tract￨on the second day of treatment only 26 of patients receiving l reuteri had watery diarrhea compared with 81 of those receiving placebo p  00005￨sig decrease￨highunclear￨highunclear￨highunclear
2￨children between 6 and 36 months of age admitted for rotavirusassociated diarrhea rotavirus gastroenteritis two hospitals￨1010 or 107 colonyforming units cfu of l reuteri or a matching placebo bacteriotherapy with lactobacillus reuteri placebo￨mean sd duration of watery diarrhea watery diarrhea duration of watery diarrhea good colonization of the gi tract￨l reuteri effectively colonized the gastrointestinal tract after administration and significantly shortened the duration of watery diarrhea associated with rotavirus￨sig decrease￨highunclear￨highunclear￨highunclear
224￨acute diarrhoea 224 chinese infants 6 to 36 months of age with severe acute diarrhoea and free from moderate or severe malnutrition acute diarrhoea in infants￨probiotics placebo lactosefree milk formula supplemented with bifidobacteria and streptococci lactosefree formula control the same formula but with viable 108cfu b lactis bb12 and 5x107cfu st thermophilus th4 per gram of powder and the same formula with the same microorganisms but with 109cfug and 5x108cfu parenteral rehydration￨duration of the diarrhoea rotavirus infection anthropometric parameters duration of the diarrhoea and rotavirus shedding rotavirus shedding￨the duration of the diarrhoea was not influenced by the intake of probiotics￨no diff￨highunclear￨highunclear￨highunclear
229￨infantile diarrhea 229 infants hospitalized for acute diarrhea in rural india￨lactobacillus gg placebo lactobacillus rhammosus gg minimum dose 10 degrees bacteria or placebo￨duration of diarrhea or numbers of stool￨there was no difference in groups in the duration of diarrhea or numbers of stool on days 3 6 or 10 of treatment￨no diff￨low￨low￨low
571￨children aged 336 months visiting a family paediatrician for acute diarrhoea childrens parents children with acute diarrhoea acute diarrhoea in children 571 children￨probiotics l rhamnosus strain gg five probiotic preparations written instructions to purchase a specific probiotic product oral rehydration solution control group lactobacillus rhamnosus strain gg saccharomyces boulardii bacillus clausii mix of l delbrueckii var bulgaricus streptococcus thermophilus l acidophilus and bifidobacterium bifidum oral rehydration solution alone￨duration of vomiting and fever and rate of admission to hospital safety and tolerance duration of diarrhoea and daily number and consistency of stools daily number of stools median duration of diarrhoea￨median duration of diarrhoea was significantly shorter p0001 in children who received l rhamnosus strain gg 785 hours and the mix of four bacterial strains 700 hours than in children who received oral rehydration solution alone 1150 hours￨sig decrease￨low￨low￨low
40￨acute nonbloody diarrhea in pakistan hospitalized children forty children mean age 13 months were enrolled and after rehydration received either￨placebo oral lactobacillus gg lactobacillus gg￨percentage of children with persistent watery diarrhea acute nonbloody diarrhea vomiting and diarrhea diarrhea￨no significant difference was observed by 48 hours in those presenting with bloody diarrhea￨no diff￨highunclear￨highunclear￨highunclear
not found￨australian aboriginal children in the northern territory admitted to hospital with diarrhoeal disease aboriginal children ages 4 months2 years admitted to hospital with acute diarrhoeal disease 3 loose stools per day aboriginal children with acute diarrhoeal disease acute rotavirus infectious diarrhoea in an indigenous setting with bacterialparasitic diarrhoea￨probiotic therapy placebo oral lactobacillus gg lactobacillus gg￨duration of diarrhoea total diarrhoea stools or diarrhoea score small intestinal functional capacity diarrhoea frequency sucrose breath test￨there was a significant p  005 difference in diarrhoea frequency on day 2 between probiotics 33 loose stools 2543 and placebo 47 3857 groups￨sig decrease￨low￨low￨low
230￨230 rotaviruspositive acute diarrhea children 224 children completed the study 113 in the drug group and 111 in the placebo group acute rotavirus diarrhea in children rotavirus diarrhea in children￨placebo vslsharp3 cd pharma india probiotic mixture vslsharp3 vslsharp3 vslsharp3 probiotic mixture or placebo￨mean loose stool frequency and frequency of ors use and frequency of intravenous fluid use overall ors requirement mean stool frequency and improved stool consistency frequency of vomiting mean loose stool frequency stool consistency and mean frequency of oral rehydration salts ors and intravenous fluids administered overall stools frequency side effects overall recovery rates efficacy and tolerability frequency of loose stools￨even on day 3 mean loose stool frequency and frequency of ors use and frequency of intravenous fluid use was significantly lower in the drug group￨sig increase￨low￨low￨low
not found￨paediatric acute gastroenteritis otherwise healthy children aged between 6 months and 10 years who were admitted for acute diarrhoea 15 males 12 females children with acute gastroenteritis￨placebo s boulardii 250 mg s boulardii saccharomyces boulardii administration saccharomyces boulardii￨serum immunoglobulin a and decreases in creactive protein levels percentage of cd8 lymphocytes daily stool frequency￨the percentage of cd8 lymphocytes on day 7 was significantly higher in group 1 than group 2￨sig increase￨highunclear￨highunclear￨highunclear
75￨seventyfive children aged from 28 days to 24 months with rotavirus diarrhea acute rotavirus diarrhea in children bolivian children children with acute rotavirus diarrhea￨placebo oral nitazoxanide nitazoxanide nitazoxanide vs probiotics nitazoxanide and probiotics nitazoxanide oral rehydration solution alone￨median duration of diarrhea daily stool frequency vomiting and fever median duration of hospitalization duration of diarrhea duration of diarrhea and of hospitalization￨the median duration of hospitalization was significantly shorter p  0017 in patients who received nitazoxanide 81 h and probiotics 72 h compared to patients who received oral rehydration solution alone 108 h￨sig decrease￨low￨low￨low
684￨acute watery diarrhoea of indian children acute watery diarrhoea awd all patients of awd n  684 admitted over 1year period were invited to participate in the study as per predefined inclusion and exclusion criteria 16 patients 646 323 in each arm￨ors with probiotic powder containing 60 million cells of lgg lgg supplementation lactobacillus rhamnosus gg lgg ors alone lactobacillus rhamnosus gg￨daily frequency or duration of diarrhoea or vomiting hospital stay frequency and duration of diarrhoea and vomiting daily frequency and total duration of diarrhoea and vomiting and the length of hospital stay￨lgg supplementation does not decrease the frequency and duration of diarrhoea and vomiting in children with awd and does not reduce hospital stay in these patients￨no diff￨highunclear￨highunclear￨highunclear
113￨113 children aged 247 months with acute diarrhoea  three watery or loose stools in 24 h infants and toddlers suffering from acute diarrhoea infants and toddlers￨placebo probiotic ecn suspension probiotic escherichia coli strain nissle 1917 ecn placebo suspension verum suspension 108 viable ecn cells per millilitre or placebo probiotic escherichia coli nissle 1917 ecn solution than by administering a placebo￨acute diarrhoea median onset of treatment response reduction of daily stool frequency safe and welltolerated￨the number of patients showing a response was clearly higher p  00001 in the ecn group 5255 945 than in the placebo group 3958 672￨sig increase￨low￨low￨low
69￨healthy volunteers young children hospitalized with acute diarrhea sixtynine children acute childhood diarrhea￨oral bacteriotherapy probiotic lactobacillus strains mixture of lactobacillus rhamnosus 190702 and lactobacillus reuteri dsm 12246 1010 colonyforming units of each strain or placebo￨length of hospitalization reduced length of hospital stay period of rotavirus excretion rotavirus antigen acute diarrhea diarrheal phase duration of diarrhea loose stools￨the duration of diarrhea was 82 h in the treatment group vs 101 h in the control group not significant p  007￨no diff￨highunclear￨highunclear￨highunclear
100￨one hundred hospitalized children in myanmar age range  3 months to 10 years were included acute diarrhea acute watery diarrhea in myanmar children￨oral rehydration solution ors boulardii s boulardii saccharomyces boulardii￨duration of diarrhea and normalizes stool consistency and frequency shortening of the duration of diarrhea mean duration of diarrhea￨stools had a normal consistency on day 3 in 38 76 of 50 patients in the s boulardii group compared with only 12 24 of 50 in the control group p  0019￨no diff￨highunclear￨highunclear￨highunclear
not found￨hospitalized children nonhospitalized children with mild diarrhea nonhospitalized children attending daycare centers children in a cohort of children recruited from local daycare centers￨probiotic lactobacillus strains placebo lyophilized lactobacillus rhamnosus 190702 and lactobacillus reuteri dsm 12246 1010 colonyforming units of each strain￨duration of diarrhea and assessment of stool consistency mean duration of diarrhea acute diarrhea duration of diarrhea loose stools time to recovery￨the time to recovery after early treatment was 79 h vs 139 h in the placebo group p  002 1 of 17 patients treated early vs 6 of 13 in the control group still had loose stools 120 h after start of treatment p  003￨no diff￨highunclear￨highunclear￨highunclear
not found￨young children with acute watery diarrhea without malnutrition or associated disease young children with acute watery diarrhea with or without reducing substances in stools children who have reducing sugars in stools children with acute diarrhea and carbohydrate malabsorption one hundred twelve wellnourished children aged 3 to 24 months who were admitted to the hospital with acute watery diarrhea￨infant formula and the same formula subjected to microbial fermentation yogurt same formula fermented with lactobacillus bulgaricus and streptococcus thermophilus feeding yogurt versus milk￨duration of diarrhea and number of stools per day lactose concentration duration of diarrhea and number of stools success rate cessation of diarrhea and appropriate weight gain stool frequency and duration of diarrhea diarrhea clinical failure duration of diarrhea rate of success￨duration of diarrhea and number of stools were significantly less in group y compared with group m fortyeight hours after inclusion diarrhea was still present in 62 of group m versus in 35 of group y p  0002￨sig decrease￨highunclear￨highunclear￨highunclear
100￨100 outpatients between 3 and 24 months old presenting with acute mild to moderate diarrhoea of less than 7 days duration children less than 2 years old with mild or moderate acute diarrhoea acute childhood diarrhoea children less than 2 years old in ambulatory care￨placebo probiotic yeast saccharomyces boulardii s boulardii s boulardii oral rehydration solution ors boulardii saccharomyces boulardii￨number of stools risk of having diarrhoea lasting duration of diarrhoea mean duration of diarrhoea￨a statistically significant difference was observed in the number of stools on the 4th and 7th day favouring the subgroup that received early treatment within the first 48 h of the onset of diarrhoea￨sig decrease￨low￨low￨low
559￨559 patients group acontrols n185 group b n188 and group c n186 indian children acute watery diarrhea awd in indian children all patients of awd admitted over 1 year were included in the study￨oral rehydration solution ors group acontrol orslgg powder containing 1010 colony forming units cfu group b or orslgg powder containing 1012 lactobacillus rhamnosus gg lgg highdose lactobacillus rhamnosus gg cfu lgg 1010 and 1012 cfu￨duration and frequency of diarrhea and vomiting frequency and duration of diarrhea and reduction in hospital stay acute watery diarrhea frequency and duration of diarrhea requirement for intravenous therapy and hospital stay￨the frequency and duration of diarrhea requirement for intravenous therapy and hospital stay were significantly lower in both the intervention groups compared with the controls￨sig decrease￨highunclear￨highunclear￨highunclear
80￨patients with acute viral diarrhea 80 children aged between 3 months and 3 years￨standard therapy  probiotic bifilac randomly placebo standard therapy  placebo￨degree of dehydration duration and volume of oral rehydration salt ors therapy duration and volume of intra venous fluids and duration of rotaviral shedding frequency and duration of diarrhea efficacy and safety of bifilac number of episodes frequency of diarrhea mean duration of diarrhea in days degree of dehydration duration and volume of oral rehydration salt ors therapy duration and volume of intravenous fluid ivf therapy duration of rotaviral shedding p001￨when compared to the placebo bifilac showed clinical as well as statistically significant reduction in number of episodes frequency of diarrhea in a day mean duration of diarrhea in days degree of dehydration duration and volume of oral rehydration salt ors therapy duration and volume of intravenous fluid ivf therapy duration of rotaviral shedding p001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨624monthold hospitalized infants eighty moderately dehydrated breastfeeding children aged between 624 months with acute nonbloody and nonmucoid diarrhea for fewer than four days were included in the study moderately dehydrated hospitalized infants aged 624 months with acute nonbloody and nonmucoid diarrhea acute nonbloody diarrhea￨routine hospital treatment pasteurized cow milk yogurt orally plus routine hospital treatment￨weight gains period of hospitalization and reduction in diarrhea frequency weight gain diarrhea acute diarrhea mean hospitalization days diarrhea frequency mean duration of hospitalization days weight gain and reduction in diarrhea frequency￨significant differences were observed in mean hospitalization days p0035 reduction in diarrhea frequency p0049 and weight gain p0017￨sig increase￨highunclear￨highunclear￨highunclear
not found￨96 malnourished boys aged 4 to 47 months receiving malnourished children with acute diarrhea acute noncholera diarrhea among malnourished children￨fullstrength milk compared with yogurt offered as part of a mixed diet milk formula mf 67 cal100 ml or yogurt formula yf prepared from the same milk formula￨geometric mean stoolreducing substances median range duration of diarrhea total stool weights treatment failure rates median percent weight gain￨stoolreducing substances  1 were detected more frequently in the mf group and the differences were significant for day 3 of the study p  004￨sig increase￨highunclear￨highunclear￨highunclear
140￨children 1 month to 3 years of age with acuteonset diarrhea patients with acuteonset diarrhea of all causes children with rotavirus enteritis children with acute diarrhea one hundred forty children were enrolled in group a and 147 in group￨placebo oral rehydration solution plus placebo or group b receiving the same preparation but with a live preparation of lactobacillus gg oral rehydration solution probiotic lactobacillus gg lactobacillus gg oral rehydration solution containing lactobacillus gg￨diarrhea diarrhea hospital stays duration of diarrhea￨hospital stays were significantly shorter in group b than in group a
                administering oral rehydration solution containing lactobacillus gg to children with acute diarrhea is safe and results in shorter duration of diarrhea less chance of a protracted course and faster discharge from the hospital￨sig decrease￨low￨low￨low
100￨100 children seen by family pediatricians children with mild diarrhea who were observed as outpatients children admitted to the hospital because of diarrhea children with mild diarrhea rotaviruspositive and rotavirusnegative ambulatory children with diarrhea￨live lactobacillus casei strain gg oral rehydration or oral rehydration followed by the administration of lyophilized lactobacillus casei strain gg oral bacterial therapy lactobacillus lactobacillus gg￨duration of rotavirus excretion duration of symptoms and of viral excretion duration of diarrhea duration of diarrhea￨six days after the onset of diarrhea stools in only 4 out of 31 children that received lactobacillus gg were positive for rotavirus compared with positive findings in 25 out of 30 control subjects￨no diff￨highunclear￨highunclear￨highunclear
151￨all children were well nourished or only moderately malnourished mildly dehydrated and received oral rehydration at study commencement infants and toddlers infants and toddlers with diarrhea 4 days young children one hundred fiftyone children aged 147 months with nonspecific diarrhea￨ecn suspension probiotic escherichia coli nissle 1917 versus placebo probiotic escherichia coli nissle 1917 ecn placebo￨kaplanmeier survival analysis diarrhea safe and well tolerated response rate reduction of daily stool frequency to  or 3 watery or loose stools 7day response￨significant differences were observed on days 14 ecn 933 placebo 658 p  00017 and 21 ecn 987 placebo 711 p  0001￨sig increase￨low￨low￨low
304￨acute infectious diarrhea children n  304 aged 3 months to 6 years hospitalized for acute diarrhea children with acute diarrhea￨placebo￨tumor necrosis factoralpha values il10 hospital stay mean duration of diarrhea counts of bifidobacteria and lactobacillus species severity of diarrhea and length of hospital stay interferon gamma and il12￨interferon gamma and il12 were mildly elevated in the probiotics group compared with the placebo group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨male children less than 2 years of age were admitted to a metabolic unit of the department of pediatrics at the federal university of bahia brazil with moderate dehydration acute severe dehydrating diarrhea￨probiotic therapy placebo placebocontrolled fashion oral rehydration solution ors￨diarrhea duration and stool output output of urine stool and vomitus duration of diarrhea￨there was no significant reduction in diarrhea duration and stool output in the group￨no diff￨highunclear￨highunclear￨highunclear
71￨acute watery diarrhea infantile acute watery diarrhea seventyone infants aged 124 months with acute watery diarrhea that presented at department of pediatrics king chulalongkorn memorial hospital bangkok were enrolled after parental signed informed consent all 71 infants completed the present study acute watery diarrhea in infants￨live lactobacillus plus bifidobacterium live lactobacillus plus bifidobacterium 3 x 109 cfu bid and ors and the control group live lactobacillus acidophilus plus bifidobacterium infantis￨stool frequency and duration of hospitalization duration of diarrhea patientscharacteristics and baseline clinical symptoms diarrhea duration￨however the stool frequency and duration of hospitalization were not significantly different p  005 study group vs control group￨no diff￨highunclear￨highunclear￨highunclear
not found￨42 wellnourished children ages 528 months￨oral bacteriotherapy lactobacillus gg human lactobacillus casei strain gg 1010 colonyforming units twice daily for five days or a control group not given lactobacilli lactobacilli￨acute rotavirus diarrhea bacterial enzyme profile urease activity during diarrhea betaglucuronidase betaglucosidase and glycocholic acid hydrolase levels￨no intergroup differences were found in betaglucuronidase betaglucosidase and glycocholic acid hydrolase levels￨no diff￨highunclear￨highunclear￨highunclear
98￨98 children 48 received lactobacillus and 50 the acute diarrhea all children from 6 months to 12 years with acute diarrhea￨lactobacillus acidophilusplacebo placebo tyndalized lactobacillus acidophilus￨ors consumed frequency of stools duration of diarrhea time for rehydration hospital stay weight gain and ivf needed intakeoutput￨in the rotaviral diarrhea and in those who had diarrhea of less then 60 hours the difference did not reach statistical significance￨no diff￨low￨low￨low
123￨68 in the prevention of antibioticassociated diarrhoea and in the treatment of acute diarrhoea 123 patients at 10 centres 78 patients who were given the same treatment but three times daily acute diarrhoea patients with acute enteritis 45 patients being treated with￨placebo lactic acidproducing enterococcus sf68 lactic acidproducing enterococcus sf antibiotics enterococcus sf68 or placebo￨incidence of antibioticassociated diarrhoea acute diarrhoea resolution of bowel abnormalities￨patients with acute enteritis showed a significantly faster resolution of bowel abnormalities during treatment with enterococcus sf68 compared with placebo￨sig decrease￨highunclear￨highunclear￨highunclear
4￨two hundred children children with acute diarrhoea￨placebo s boulardii boulardii placebo placebo saccharomyces boulardii￨duration of hospital stay average stool frequency watery diarrhoea duration of acute diarrhoea and the duration of hospital stay persisting diarrhoea duration of diarrhoea￨s boulardii seems to be a promising agent for the amelioration of the course of acute diarrhoea in children when used therapeutically￨sig increase￨highunclear￨highunclear￨highunclear
87￨87 children 87 children age range 2 months to 6 years with infectious diarrhoea infants and children with a mixture of three lactobacillus rhamnosus strains children￨placebo lactobacillus rhamnosus gg l rhamnosus strains lakcid l at a dose 12 x 1010 cfu or placebo parenteral rehydration￨mean duration of diarrhoea duration of parenteral rehydration adverse events and gastrointestinal tract colonization by administered strains gut colonization adverse events duration of rotaviral diarrhoea duration of diarrhoea time of intravenous rehydration￨administration of l rhamnosus strains shortens the duration of rotaviral diarrhoea in children but not of diarrhoea of any aetiology￨sig decrease￨low￨low￨low
100￨rotavirus positive and negative children with diarrhea hospitalized children acute diarrhea in children altogether 100 children between 6 and 60 months of age￨infloran berna which contains 109 viable lactobacillus acidophilus and 109 bifidobacterium infantis one capsule tid for 4 days and control group lactobacillus acidophilus and bifidobacterium infantis oral bacterial therapy parenteral rehydration only without any medication￨frequency of diarrhea stools duration of diarrhea during hospitalization diarrhea duration of diarrhea at home serum sodium  potassium and dehydration degree duration of diarrhea frequency of diarrhea￨there was no difference between the study group and control group in the frequency of diarrhea stools on the day before admission p  005￨no diff￨highunclear￨highunclear￨highunclear
39￨acute diarrhoea in children young children in the tropics thirtynine children mean age  8 months￨freezedried preparation or placebo placebo oral lactobacillus gg lactobacillus gg￨clinical response mean duration of diarrhoea acute diarrhoea acute watery diarrhoea stool frequency￨stool frequency was less on the second day in the lactobacillus group p  005￨sig decrease￨highunclear￨highunclear￨highunclear
211￨adult patients with acute diarrhea acute diarrhea 211 adults￨sf placebo sf 68 strain bioflorin￨duration and the severity of diarrhea adverse reactions proportion of patients with continuing diarrhea duration of diarrhea mean sd duration of diarrhea￨patients receiving sf 68 had a reduced duration of diarrhea compared with placebo with a highly statistically significant difference between treatments￨sig decrease￨low￨low￨low
50￨transient tachypnea of the newborn fifty infants with transient tachypnea of the newborn￨placebo furosemide oral furosemide￨duration of tachypnea length of hospitalization￨compared with infants in the control group the furosemidetreated group demonstrated no significant difference in the duration of tachypnea nor in the length of hospitalization￨sig decrease￨highunclear￨highunclear￨highunclear
50￨transient tachypnoea of the newborn fifty term infant with ttn￨intravenous frusemide intravenous frusemide intravenous frusemide 2 mgkg or saline placebo frusemide￨weight duration of supplemental oxygen requirement the period of tachypnoea time to discharge from hospital and weight loss in the first 24 h of life and before discharge clinical course of ttn duration of oxygen requirements the period of tachypnoea and the time to hospital discharge￨there were no significant differences between the two groups in the duration of oxygen requirements the period of tachypnoea and the time to hospital discharge￨no diff￨highunclear￨highunclear￨highunclear
77￨subjects with alpha1antitrypsin alpha1at deficiency 77 subjects protease inhibitor type z alpha1antitrypsin deficiency￨augmentation therapy computed tomography ct densitometry infusions of 60 mg x kg1 human alpha1at prolastin or placebo ct densitometry ct￨exacerbation severity exacerbations health status and physiological indices exacerbation frequency changes in ct and forced expiratory volume change in ct lung density￨all methods of densitometric analysis concordantly showed a trend suggestive of treatment benefit pvalues for prolastin versus placebo ranged 00490084￨sig increase￨highunclear￨highunclear￨highunclear
130￨550 patients 130 patients twentysix danish and 30 dutch exsmokers with alpha1antitrypsin deficiency of pizz phenotype and moderate emphysema fev1 between 30 and 80 of predicted participated in a doubleblind trial of patients with alpha1antitrypsin deficiency￨alpha1antitrypsin augmentation therapy alpha1antitrypsin placebo albumin￨loss of lung tissue sem degree of emphysema decline of fev1￨selfadministered spirometry performed every morning and evening at home showed no significant difference in decline of fev1 between treatment and placebo￨no diff￨highunclear￨highunclear￨highunclear
2499￨the study subjects were followed for 3324 personyears median 12 years maximum 28 years men who have sex with men 2499 hivseronegative men or transgender women who have sex with men to receive a combination of two￨oral antiretroviral drugs emtricitabine and tenofovir disoproxil fumarate ftctdf or placebo placebo ftctdf preexposure chemoprophylaxis oral ftctdf￨nausea incidence of hiv rates of serious adverse events detectable blood levels￨nausea was reported more frequently during the first 4 weeks in the ftctdf group than in the placebo group p0001￨sig increase￨low￨low￨low
71￨patients with cervical root compression patients with cervical root compression 71 consecutive patients with mriverified cervical root compression without medullary compression￨physiotherapy cervical collars￨postural performance postural performance or pain intensity cervical pain decreased muscular tension postural performance or pain scores postural performance and reduced neck pain scores￨after treatment the surgery group manifested significant improved postural performance and reduced neck pain scores as compared to the two conservative treatment groups and their postural performance had improved to the same level manifested by healthy controls￨sig increase￨highunclear￨highunclear￨highunclear
61￨sixtyone patients with magnetic resonance images suggesting spondylotic cervical cord compression and clinical signs of cervical myelopathy spondylotic cervical myelopathy 49 patients with mild and moderate spondylotic cervical myelopathy patients with spondylotic cervical myelopathy￨surgical or conservative therapy￨￨there were no significant evoked potential and clinical group changes after 6 months and 2 years in the mild myelopathy group treated either surgically and conservatively whereas patients with severe myelopathy displayed significant improvement in clinical and evoked potential parameters after surgery￨no diff￨highunclear￨highunclear￨highunclear
85￨relapsingremitting multiple sclerosis patients patients with relapsingremitting multiple sclerosis patients with relapsingremitting multiple sclerosis receiving interferon beta 1a 85 patients with relapsingremitting multiple sclerosis 71 female who were already receiving ifnb 1a avonex with expanded disability status scale score of less than 50￨placebo simvastatin simvastatin simvastatin and placebo interferon beta ifnb 1a￨disability status scale score relapse rate safe and well tolerated sd of gadoliniumenhanced and new t2 lesions safety and efficacy total attack number final expanded disability status scale scores total relapse rate expanded disability status scale score and the number of gadoliniumenhanced gd and new t2 lesions in magnetic resonance imaging￨the total attack number in the simvastatin group was significantly lower than placebo group moderate effect size r  029 p  001￨sig decrease￨low￨low￨low
not found￨persons with clinically stable relapsingremitting ms on standard highdose subcutaneous interferon beta1a persons with multiple sclerosis persons with relapsingremitting multiple sclerosis ms￨interferon and atorvastatin atorvastatin placebo placebo or atorvastatin￨relapse with active lesions on mri clinical or mri disease activity blood tests cholesterol levels determination of drug toxicity using blood tests and ecg and determination of msrelated disease activity either clinical relapses or new or contrastenhancing lesions on mri mri and clinical disease activity blinded neurologic examinations and brain mri readings￨main outcome measures were the determination of drug toxicity using blood tests and ecg and determination of msrelated disease activity either clinical relapses or new or contrastenhancing lesions on mri￨no diff￨highunclear￨highunclear￨highunclear
45￨relapsingremitting active multiple sclerosis patients multiple sclerosis patients responding poorly to interferon beta1a alone relapsingremitting multiple sclerosis patients aged 1850 years with contrastenhanced lesions or relapses while on therapy with fortyfive patients￨atorvastatin interferon interferon alone atorvastatin combination therapy interferon  atorvastatin￨safety tolerability and efficacy contrastenhanced lesion number risk for a 1point edss increase number of relapses edss variation and safety laboratory data￨at 24 months group a had significantly fewer contrastenhanced lesions versus baseline p  0007 and significantly fewer relapses versus the two prerandomization years p  0001￨sig increase￨highunclear￨highunclear￨highunclear
307￨0059 naive patients with relapsingremitting multiple sclerosis 307 patients to￨interferon beta placebo interferon beta plus simvastatin n151 or plus placebo simvastatin simvastatin interferon β1a simvastatin 80 mg per day or placebo￨annual rate of documented relapses disease activity adverse events infections or musculoskeletal disorders including myalgia mean number of new or enlarging t2 lesions serum creatine phosphokinase annual rate of documented relapses￨mean number of new or enlarging t2 lesions was 296 in the simvastatin group and 252 in the placebo group ratio of new lesions 117 95 ci 889 to 155 p025￨sig increase￨low￨low￨low
24￨twenty four patients with cf patients with cystic fibrosis patients with cystic fibrosis cf￨placebo oral betacarotene supplementation betacarotene supplementation oral betacarotene supplementation betacarotene￨antibiotic treatment number of pulmonary exacerbations adverse events total antioxidant capacity plasma betacarotene concentration total antioxidant capacity malondialdehyde mda as a marker of lipid peroxidation and clinical parameters shwachmannkulczycki score body mass index bmi height and lung function fev1 shwachmannkulczycki score lung function and bmi plasma concentration of betacarotene pulmonary exacerbations￨initially raised plasma levels of mda fell to normal levels and the total antioxidant capacity showed a nonsignificant trend towards improvement during high dose supplementation￨no diff￨highunclear￨highunclear￨highunclear
26￨children with cf patients with cystic fibrosis cf 26 children with cf ages 718 years children with cystic fibrosis￨placebo zinc supplementation zn supplementation zinc zn￨rate of respiratory tract infections rtis use of antibiotics and plasma cytokines plasma il6 and il8 respiratory tract infections number of days of oral antibiotics plasma zn cu inflammatory cytokines and ex vivo generation of il2￨the number of days of oral antibiotics was lower in zn treated patients compared to placebo p  005￨sig decrease￨highunclear￨highunclear￨highunclear
73￨73 eligible patients into two groups ppms patients in warranted patients with primary progressive multiple sclerosis ppms or transitional ms primary progressive multiple sclerosis￨placebo interferon interferon betaib interferon betaib therapy placebo or interferon beta1b 8 miu￨msfc score t2 lesion volume and ti lesion volume￨significant differences favouring interferon beta1b in the msfc score t2 lesion volume and ti lesion volume at 24 months were observed￨sig increase￨highunclear￨highunclear￨highunclear
50￨primary progressive ms patients with primary progressive ms fifty subjects￨im interferon beta1a 30 microg 60 microg or placebo interferon beta1a￨rate of accumulation of t2 lesion load rate of ventricular enlargement timed 10meter walk ninehole peg test and on mri t2 and t1 brain lesion loads and brain and spinal cord atrophy severe flulike reactions and raised liver enzymes time to sustained progression in disability￨subjects on interferon beta1a 30 microg had a lower rate of accumulation of t2 lesion load than controls p  0025 subjects on 60 microg had a greater rate of ventricular enlargement than controls p  0025￨sig increase￨low￨low￨low
18816￨all participants were followed up until december 1998 hepatocellular carcinoma hcc 18816 people aged 3559 years with hepatitis b virus infection or a history of chronic hepatitis in urban shanghai china people at increased risk hepatocellular carcinoma￨￨hcc mortality 5year survival rate number of hcc hcc mortality rate mortality rate ratio￨thirtytwo people died from hcc in the screened group versus 54 in the control group and the hcc mortality rate was significantly lower in the screened group than in controls being 832100000 and 1315100000 respectively with a mortality rate ratio of 063 95ci 041098￨sig decrease￨low￨low￨low
270￨270 participants 136 active lozenge 134 placebo￨nicotine lozenge placebo smokeless tobacco st￨tobacco abstinence st abstinence nicotine withdrawal symptoms and tobacco craving tobacco abstinence rates tobacco craving and nicotine withdrawal symptoms tobacco craving￨no significant differences were observed between the groups in biochemically confirmed all tobacco abstinence rates at week 12 36 lozenge vs 276 placebo odds ratio or 15 95 ci 0721 p  138￨no diff￨low￨low￨low
16￨sixteen colleges were matched for prevalence of smokeless tobacco use in their combined baseball and football teams and randomly assigned within college pairs to the intervention or the control group college athletes￨smokeless tobacco cessation intervention collegebased smokeless tobacco cessation intervention￨level of smokeless tobacco use smokeless tobacco cessation cessation prevalences￨cessation prevalences were 35 in the intervention colleges and 16 in the control colleges when subjects with unknown quit status were defined as nonquitters￨no diff￨highunclear￨highunclear￨highunclear
not found￨smokeless tobacco users 42 st users using at least 3 cans or pouches per week￨placebo nicotine patch therapy nicotine replacement therapy nrt nicotine therapy nicotine patch￨arousal safe and well tolerated tobacco withdrawal and nicotine toxicity frequency of nicotine toxicity symptoms nausea tobacco withdrawal symptoms restlessness￨no pharmacotherapies have been shown to increase longterm  or  6month abstinence rates among smokeless tobacco st users￨no diff￨highunclear￨highunclear￨highunclear
406￨with smokeless tobacco users 406 adult st users throughout the state of minnesota￨telephone counseling proactive telephonebased counseling telephone counseling with the distribution of a selfhelp manual for st cessation selfhelp manual manual only or b a selfhelp manual plus proactive telephonebased cessation counseling telephone counseling￨cessation rates prolonged abstinence￨prolonged abstinence from all tobacco was 68 and 309 p  001 at 3 months and 98 and 309 p  001 at 6 months in manual only and telephone counseling respectively￨sig decrease￨highunclear￨highunclear￨highunclear
431￨participants were excluded if they used any other form of tobacco except smokeless tobacco or medication to stop smoking within three months of screening or had any preexisting medical or psychiatric condition helping users of smokeless tobacco to quit participants demographics and baseline use of smokeless tobacco were similar 89 189 and 90 196 respectively were men mean age in both groups was 439 participants used smokeless tobacco products about 15 times a day and about 80 first used smokeless tobacco within 30 minutes after awakening 431 participants 213 men and women aged 18 who used smokeless tobacco at least eight times a day with no abstinence period over three months within one year before screening who wanted to quit all tobacco use medical clinics mostly primary care in norway and sweden￨varenicline varenicline placebo varenicline 218 placebo￨fatigue response rate continuous abstinence rate continuous abstinence rate headache nausea serious adverse events sleep disorder safety and tolerability efficacy and safety￨few adverse events led to discontinuation of treatment 9 19 and 4 9 respectively and serious adverse events occurred in two 1 and three 1 participants respectively￨no diff￨low￨low￨low
1585￨setting fiftytwo california colleges 883 subjects in 27 intervention colleges and 702 subjects in 25 control colleges participated as did 48 certified athletic trainers patients or other participants male collegiate baseball athletes certified athletic trainers collegiate baseball athletes 1585 athletes recruited 1248 787 were followed up at 12 months interventions￨oral cancer screening with feedback and brief counseling during the preseason health screenings athletic trainer support for cessation and a peerled educational baseball team meeting athletic trainerdirected spit smokeless tobacco intervention athletic trainerdirected st intervention￨cessation of st use￨the intervention was significantly effective in preventing incident st use but did not significantly increase cessation beyond that seen in the control group￨no diff￨highunclear￨highunclear￨highunclear
221￨with adult moist snuff users 221 adult males using snuff and randomized them into a￨telephone counseling telephonecounseling intervention or a quitmanual comparison group￨￨a significantly higher proportion of subjects randomized to the intervention quit tobacco at each time point compared to the comparison group￨sig increase￨highunclear￨highunclear￨highunclear
41￨rural high school males smokeless tobacco cessation cluster randomized trial with rural high school males adolescent males in rural areas use smokeless tobacco st twentyone rural counties 72 41 randomly selected high schools 56 and 4731 male students 50 participated with 65 retention rural nonsmoking stusing high school males study high schools were randomly selected from a public high school list of california rural counties consenting high schools￨peerled educational sessions and an oral exam by the school nurse who also provided brief tobacco cessation counseling schoolbased nursedirected st cessation program schoolbased nursedirected st intervention￨likely to stop using st￨a higher percentage of baseline nonsmoking st users reported smoking at followup than baseline nonstusing smokers who reported using st￨sig decrease￨highunclear￨highunclear￨highunclear
60￨60 patients to 12 weeks of the 4mg smokeless tobacco users￨nicotine lozenge or placebo smokeless tobacco st placebo nicotine lozenges assisted selfhelp intervention ash with telephone support￨composite withdrawal symptoms and adverse events abstinence rates￨no significant differences were observed in abstinence rates between the two groups at 3 or 6 months￨no diff￨highunclear￨highunclear￨highunclear
518￨male users of moist snuff and chewing tobacco n  518 general population of smokeless tobacco users￨smokeless tobacco intervention usual care or intervention smokelesstobacco cessation intervention￨proportion of patients who quit￨longterm success was defined as no smokeless tobacco use at both 3 and 12month followups with those lost to followup counted as smokeless tobacco users￨no diff￨highunclear￨highunclear￨highunclear
2523￨smokeless tobacco users 2523 adult st users￨smokeless tobacco st webbased cessation program interactive tailored webbased intervention enhanced condition versus a more linear textbased website basic condition￨enhanced condition quit quit rates￨we conclude that a tailored interactive webassisted cessation program can be an efficacious method for assisting adult st users to quit￨sig increase￨highunclear￨highunclear￨highunclear
not found￨adolescent spit tobacco addiction spit tobacco addiction among adolescents￨nicotine patches placebo behavioural therapy placebo patches active nicotine patches quarterly stage based telephone counselling￨cessation rates for active and placebo patch mean cessation rates cessation rate cessation rates spit tobacco cessation rate￨the cessation rates for active and placebo patch were not significantly different exact two sided p  022 while the combined patch groups had a significantly greater cessation rate than usual care exact two sided p  004￨no diff￨highunclear￨highunclear￨highunclear
410￨410 adult nonsmoking chewing tobacco users￨nicotine patches placebo nicotine replacement transdermal nicotine replacement 15mg nicotine patch plus behavioral treatment or placebo patch plus behavioral treatment behavioral treatment of 2 pharmacy visits 2 support calls and selfhelp materials￨chewers chances of abstinence relapse￨the difference in relapse no chewing for 7 consecutive days between the active patch group 33 and placebo group 48 was significant at 6 months p  003￨sig decrease￨highunclear￨highunclear￨highunclear
198￨rural and urban users one hundred ninetyeight st users smokeless tobacco cessation￨lifesign a credit cardsized computer designed for gradual st cessation and half received the enough snuff selfhelp manual and a video telephone support￨selfreported rates of sustained abstinence￨selfreported rates of sustained abstinence no tobacco use at two months and six months were 245 for the manualvideo condition and 184 for the lifesign condition￨no diff￨highunclear￨highunclear￨highunclear
not found￨users in 75 feeforservice dental practices in oregon￨brief officebased intervention with all tobacco￨￨the authors found that the dental hygienistdelivered intervention was effective in getting smokeless tobacco users to quit at three and 12 months and to sustain abstinence at both three and 12 months￨sig increase￨highunclear￨highunclear￨highunclear
not found￨smokeless tobacco users slt users in five northwestern states were recruited to call a tollfree number and 1069 users￨smokeless tobacco slt cessation selfhelp cessation programs manualonly condition or an assisted selfhelp condition which included the manual a targeted video and two support phone calls￨￨significant betweengroup differences were not found for either the 12 or 18month pointprevalence measure of abstinence from either slt only or all tobacco products using outcomes based on either the responder or intentiontotreat outcomes￨no diff￨highunclear￨highunclear￨highunclear
not found￨spit tobacco users n  402 n  100101 in each condition spit tobacco users with￨active nicotine versus placebo patch transdermal nicotine system and mint snuff nicotine patch and mint snuff nicotine patch and mint snuff a nonnicotine product nicotine patch￨craving withdrawal symptoms craving and withdrawal symptoms shortterm abstinence craving and withdrawal signs and symptoms￨the results showed that the nicotine patch was effective in increasing shortterm abstinence over the placebo patch and in reducing craving and withdrawal signs and symptoms from spit tobacco￨sig increase￨highunclear￨highunclear￨highunclear
44￨high school athletes fortyfour randomly selected high schools in rural california male high school baseball athletes ninetythree percent of eligible baseball athletes participated yielding 516 subjects in 22 intervention schools and 568 subjects in 22 control schools￨spit tobacco st intervention spit smokeless tobacco intervention￨prevalence of st initiation prevalence of cessation￨there was no significant difference between groups in the prevalence of st initiation￨no diff￨highunclear￨highunclear￨highunclear
not found￨sixty activeduty male participants were identified as st users during their annual preventive health screening and randomly assigned to young males smokeless tobacco￨populationbased health intervention smokeless tobacco st minimalcontact intervention or usual care motivational interviewing style for a cessation program consisting of a treatment manual video and two supportive phone calls from a cessation counselor￨cessation rates￨three and 6month followup contacts found that the cessation rates reported by intervention participants were double those reported by participants receiving usual care 41 vs 17 at 3 months 37 vs 19 at 6 months￨sig increase￨highunclear￨highunclear￨highunclear
68￨sixtyeight adult aged  or  18 years old regular users of st who were motivated to stop using st spit tobacco users￨bupropion placebo bupropion sustained release sr or placebo bupropion￨6month weight change weight gain nicotine withdrawal symptoms and weight change prevalence tobacco abstinence rate prevalence abstinence rate pointprevalence tobacco abstinence rate mean weight change abstinence rates￨after 7 weeks of medication subjects on bupropion reported significantly less p or  0034 nicotine withdrawal than placebo￨sig decrease￨low￨low￨low
not found￨tobacco abstinence among st users adult st users￨bupropion sr bupropion sr placebo bupropion sr and placebo￨7day pointprevalence tobacco abstinence rates 7day pointprevalence tobacco abstinence rate prolonged and continuous tobacco abstinence rates craving and nicotine withdrawal and weight gain mean sd weight change craving and weight gain tobacco abstinence rates prolonged and continuous tobacco abstinence rates 7day pointprevalence abstinence efficacy and safety￨the 7day pointprevalence tobacco abstinence rates did not differ between bupropion sr and placebo at the end treatment 531 versus 464 odds ratio or 13 p0301￨no diff￨low￨low￨low
210￨smokeless tobacco users participants n  210￨nicotine gum nicotine polacrilex versus placebo gum placebo behavioral and pharmacological treatment￨withdrawal symptoms withdrawal symptoms￨survival curve analysis showed that any of the 3 treatment groups involving group behavioral therapy or placebo gum were equally effective and superior to the minimal contact plus 2 mg of nicotine gum treatment in terms of abstinence￨no diff￨highunclear￨highunclear￨highunclear
27￨patients treated with 27 patients with type 1 diabetes￨continuous subcutaneous insulin infusion versus multiple daily insulin injection intensive insulin therapy with insulin lispro csii continuous subcutaneous insulin infusion csii and multiple daily insulin injection mdi with insulin lispro intensive insulin therapy mdi￨glycemic control hypoglycemic events and quality of life glycemic control reported hypoglycemic events or quality of life hypoglycemic events hba1c dqol subscales glycemic control hba1c level patient reports of hypoglycemic events quality of life assessed at 9 months using the diabetes quality of life dqol questionnaire￨there were no statistically significant differences between treatment groups for any of the dqol subscales￨no diff￨low￨low￨low
not found￨ten insulindependent cpeptidenegative diabetic subjects insulindependent diabetic subjects￨continuous subcutaneous insulin infusion csii against multiple insulin injections portable insulin infusion pumps subcutaneous insulin injection regimen actrapid  ultratard or by continuous subcutaneous insulin infusion csii￨csii mean blood glucose concentration and urinary glucose excretion￨mean blood glucose concentration and urinary glucose excretion were lower at most points during the study on csii than on injection therapy￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨38 type 1 children with diabetes age 416 yr following a 35months runin phase children with type 1 diabetes mellitus children with diabetes￨insulin pump vs injection treatment￨quality of life and impact of disease scores metabolic control frequency of severe hypoglycaemia pedsql and impact scores standardized qualityoflife pediatric quality of life inventory pedsql and impact of disease scores symptomatic hypoglycaemia and lowered haemoglobin a1c quality of life and impact of disease￨treatment group comparisons did not show significant improvement￨no diff￨highunclear￨highunclear￨highunclear
21￨twentyone patients with insulindependent diabetes mellitus iddm csii patients and 88￨ict icf continuous subcutaneous insulin infusion csii with intensified conventional treatment ict using the novopen￨hba1c number of hypoglycaemic episodes overall mean blood glucose￨overall mean blood glucose was slightly but significantly lower during csii than during ict￨sig increase￨highunclear￨highunclear￨highunclear
32￨thirtytwo youth with type 1 diabetes age 821 years children and adolescents with type 1 diabetes youth with type 1 diabetes pediatric patients￨mdi treatment with oncedaily glargine and premealsnack insulin aspart or csii with insulin aspart glargine csii continuous subcutaneous insulin infusion csii therapy continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine￨lower hba1c and premeal glucose levels hba1c total daily insulin dose tdd selfmonitored blood glucose readings and adverse events fasting selfmonitored blood glucose lowering hba1c levels hba1c levels tdd￨fasting selfmonitored blood glucose was similar in both groups but lunch dinner and bedtime readings were significantly lower in the csii group p  001￨no diff￨highunclear￨highunclear￨highunclear
10￨ten pregnant women affected by type i diabetes mellitus observed for the first time during the iiiii month of pregnancy pregnant women with type 1 diabetes mellitus￨intensified traditional insulin therapy and micropump therapy continuous subcutaneous insulin infusion with micropump cpi 9100 lilly group b underwent intensified insulin therapy￨eventual presence of urinary keton bodies and hypoglycemic crisis need of insulin the maternal body weight gain the week and mode of delivery the neonatal weight and the maternal and fetal complications blood glucose levels mean glycemic values￨in both the groups the mean glycemic values during fast and two hours after meals and the eventual presence of urinary keton bodies and hypoglycemic crisis were evaluated during the course of pregnancy these parameters turned out to be identical in the two groups￨no diff￨highunclear￨highunclear￨highunclear
32￨41 cpeptidenegative type 1 diabetic patients age 435103 years 21 men and 20 women bmi 24024 kgm2 diabetes duration 200113 years on intensified insulin therapy mdi with regular insulin or lispro n  9 csii with regular insulin n  32 in diabetes type 1 diabetic patients type 1 diabetic patients on intensified treatment￨pump therapy continuous subcutaneous insulin infusion and multiple daily injection regimens continuous subcutaneous insulin infusion csii and multiple daily injections mdi by using the shortacting insulin analog lispro intensified insulin therapy with lispro￨bg levels blood glucose bg frequency of hypoglycemic events frequency of hypoglycemic episodes mean insulin doses sd of all the bg values hba1c values￨bg levels were lower with csii 16527 vs 17533 mgdl p005￨no diff￨highunclear￨highunclear￨highunclear
20￨young diabetic patients￨multiple insulin injections using a pen injector versus insulin pump treatment multiple insulin injections mii using a pen injector novopen continuous subcutaneous insulin infusion csii￨mean insulin requirement frequency of blood glucose values physical discomfort mean blood glucose mbg fasting plasma ketone bodies fasting plasma free fatty acids ffa fasting plasma human growth hormone hgh fasting plasma glucagon or serum fructosamine￨when comparing csii and mii no significant differences could be demonstrated in mean blood glucose mbg fasting plasma ketone bodies fasting plasma free fatty acids ffa fasting plasma human growth hormone hgh fasting plasma glucagon or serum fructosamine￨no diff￨highunclear￨highunclear￨highunclear
10￨ten otherwise healthy patients participated age 365 yr very longterm uncomplicated insulindependent diabetes mellitus iddm longterm uncomplicated insulindependent diabetes mellitus iddm￨continuous subcutaneous insulin infusion csii and multiple injection technique mit pump versus pen treatment￨creatinine and blood pressure urinary albumin excretion uae glomerular filtration rate gfr and renal plasma flow rpf kidney function glycaemic control and kidney function glycaemic control glycaemic control￨glycaemic control was significantly better on csii as compared to mit p  001 or prestudy conventional treatment ct p  003 whereas there was no difference between mit and ct￨sig increase￨highunclear￨highunclear￨highunclear
5￨adult type i diabetes compliant adult patients with type i diabetes continuous five patients with insulindependent diabetes￨insulin therapy multiple insulin injections intensive conventional and insulin pump therapies insulin infusion￨plasma glucose concentration mean plasma glucose and hemoglobin a1c concentrations and the frequency of hypoglycemic reactions￨mean plasma glucose and hemoglobin a1c concentrations and the frequency of hypoglycemic reactions were significantly less with pump therapy despite apparently equal compliance with both therapies￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨sixteen insulindependent diabetic children and adolescents diabetic children￨shortterm subcutaneous insulin infusion￨symptomatic hypoglycemia mean blood glucose mvalue and 24h glycosuria blood glucose peaks￨mean blood glucose mvalue and 24h glycosuria were similar in both types of treatment￨no diff￨highunclear￨highunclear￨highunclear
72￨childrenadolescents at onset of type 1 diabetes mellitus who were treated with either seventytwo childrenadolescents 717 yr of age￨continuous subcutaneous insulin infusion csii or multiple daily injections mdi mdi natural protamine hagedorn nph insulin twice daily and rapidacting insulin csii treatment￨metabolic control episodes of ketoacidosis severe hypoglycemia treatment satisfaction hemoglobin a1c insulin doses weight and height diabetes treatment satisfaction questionnaire severe episodes of hypoglycemia and ketoacidosis￨treatment satisfaction was higher in the csii group although there was no difference in metabolic control compared with the mdi group￨sig increase￨highunclear￨highunclear￨highunclear
19￨patients with newly diagnosed type 1 diabetes imdiab 8 twentythree patients between 12 and 35 years old mean 19 patients who remained in the study for its duration patients with type 1 diabetes￨supplemental nicotinamide na intensive insulin therapy combined with na continuous subcutaneous insulin infusion csii versus intensive subcutaneous insulin therapy isit continuous subcutaneous insulin infusion versus intensive insulin therapy￨csii metabolic control insulin dose hemoglobin a1c hba1c and cpeptide baseline cpeptide￨the insulin requirement for the entire duration of the study but not at entry and 3 months was significantly higher in csii compared with isit patients 062￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with a history of longterm poor glycemic control 79 patients in 11 dutch centers type 1 diabetic patients with longstanding poor glycemic control type 1 diabetes for patients with longstanding poor glycemic control￨continuous subcutaneous insulin infusion and intensive injection therapy continuous subcutaneous insulin infusion continuous subcutaneous insulin infusion￨glycemic control and healthrelated quality of life weight gain scores on the shortform 36item subscales general health and mental health hba1c selfreported hypoglycemic events and blood glucose memory meter read outs number of mild hypoglycemic episodes quality of life stability of blood glucose selfmeasurement values￨scores on the shortform 36item subscales general health and mental health improved in the continuous subcutaneous insulin infusion group compared with stable values in the injection group p  0048 and 0050 respectively￨sig increase￨highunclear￨highunclear￨highunclear
39￨93 years old mean patients with type 1 diabetes well controlled with csii thirtynine patients 381￨csii with lispro or mdi with lispro and glargine continuous subcutaneous insulin infusion csii csii and mdi with glargine glargine insulin glargine￨glycated haemoglobin hba1c 76 glucose standard deviation mean amplitude of glycaemic excursions mage lability index and average daily risk range adrr blood glucose variability blood glucose profile hba1c number of episodes of hypo and hyperglycaemia lipid profile free fatty acids ffa growth hormone and treatment satisfaction frequency of hypoglycaemic episodes csii blood glucose levels treatment satisfaction glucose variability hyperglycaemic episodes lability index￨the difference was significant only before breakfast considering glucose standard deviation p  0011 significant overall using mage p  0016 and lability index p  0005 and not significant using adrr￨sig increase￨highunclear￨highunclear￨highunclear
45￨fortyfive diabetic patients 18 to 45 years of age with mild or no retinopathy￨continuous subcutaneous insulin infusion csii multiple injections mls and conventional insulin treatment cit nearnormoglycemia csii and mi￨diameter of retinal veins mean blood glucose values glycosylated hemoglobin hba1 retinopathy blood pressure levels or duration of diabetes amplitudes of oscillatory potentials oscillatory potentials and lengthened macular recovery time oscillatory potentials electroretinography erg and macular recovery time nyctometry oscillatory potentials macular recovery time and diabetic retinopathy microaneurysms and hemorrhages csii and cit macular recovery time oscillatory potentials or nyctometry￨no changes in oscillatory potentials or nyctometry were observed and no pretreatment characteristics of these parameters predicted the occurrence of these ischemic lesions￨no diff￨highunclear￨highunclear￨highunclear
7￨twelve diabetic subjects seven patients opted to continue with the millhill infuser and five with the medijector￨csii and 3 mo with mi bedtime ultralente and premeal boluses of regular insulin continuous subcutaneous insulin infusion csii using the millhill infuser muirhead medical products ltd london england with multiple injections mi using the medijector derata corporation minneapolis minnesota continuous subcutaneous insulin infusion millhill infuser versus multiple injections medijector￨nerve conductivity and a decreased protein excretion sural nerve conductivity blood glucose and glycosylated hemoglobin prestudy preprandialpostprandial glucose levels proteinuria￨prestudy preprandialpostprandial glucose levels were 147215 mgdl and improved to 108138 mgdl during csii and to 115139 mgdl during mi with glycosylated hemoglobin of 129 91 and 87 respectively￨sig increase￨highunclear￨highunclear￨highunclear
50￨type 1 diabetic patients previously treated with csii one hundred patients 742 vs 1664 452 vs 777￨mdi therapy multiple daily injection mdi therapy of bolus insulin aspart and basal insulin glargine insulin aspartinsulin glargine csii therapy with insulin aspart csii continuous subcutaneous insulin infusion csii of insulin aspart mdi therapy aspart immediately before each meal and glargine insulin aspart and glargine￨mean serum fructosamine levels major hypoglycemia risk of hypoglycemia hypoglycemic episodes auc glucose￨major hypoglycemia was infrequent￨no diff￨highunclear￨highunclear￨highunclear
23￨patients twentythree children and adolescents with type 1 diabetes mellitus children with type 1 diabetes mellitus using the continuous glucose monitoring system cgms children and adolescents with type 1 diabetes mellitus tertiary care universityaffiliated medical center￨cgms multiple daily injections mdi and continuous subcutaneous insulin infusion csii continuous subcutaneous insulin infusion￨mean sd hemoglobin a1c levels rate and magnitude of hypoglycemia smaller 24hour area under the curve for hypoglycemia nocturnal and 24hour hypoglycemia glucose levels glycemic patterns 24hour duration and area under the curve for hyperglycemia mean duration of postprandial withintarget glucose levels rate of hyperglycemia hemoglobin a1c levels and glucose level profiles shorter duration of nocturnal hypoglycemia rate of diurnal hypoglycemic events postprandial hypoglycemia and hyperglycemia￨areas under the curve were significantly larger during mdi for nocturnal and 24hour hypoglycemia p 01 and04 respectively and for postprandial hypoglycemia and hyperglycemia p 03 and05 respectively￨sig increase￨highunclear￨highunclear￨highunclear
33￨elders with hip fracture thirty three elders age  65 years were tracked from hospital discharge to 12 months postfracture￨gerontologic advanced practice nurse as postacute care coordinator for 6 months who intervened with each elder regardless of the postacute care setting making biweekly visits andor phone calls nursing intervention model￨health function and returnhome outcomes several activities and instrumental activities of daily living and no differences in health depression or living situation hip fracture outcomes￨the treatment group had better function at 12 months on several activities and instrumental activities of daily living and no differences in health depression or living situation￨no diff￨highunclear￨highunclear￨highunclear
293￨two hundred ninetythree older people who had undergone surgery for a fractured hip 121 in the treatment study and 172 in the prevention study older people hip fracture in older people￨psychiatric intervention psychological treatment￨depressive symptoms functional and pain outcomes geriatric depression scale and hospital anxiety and depression scale for mood functional tests for mobility and pain measures incident depression￨there were no differences in the functional and pain outcomes￨no diff￨highunclear￨highunclear￨highunclear
209￨a total of 209 women were recruited with an average age of 810 years sd69 older adults following a hip fracture older women posthip fracture￨exercise plus exercise only plus only ie motivation or routine care exercise plus program￨overall trajectory of time in exercise trajectories of recovery time spent exercising￨a statistically significant difference in the overall trajectory of time in exercise was seen p001 with more time spent exercising in all three treatment groups￨no diff￨highunclear￨highunclear￨highunclear
176￨hip fracture after hip fracture hip fracture patients one hundred seventysix patients who underwent surgery for a primary unilateral hip fracture￨multiplecomponent intervention complex intervention usual care control arm n  86 or a brief motivational videotape supportive peer counseling and highintensity musclestrength training￨functional recovery rolephysical domain mental health physical functioning rolephysical and social functioning domains of the sf36 general health efficacy and safety￨change in general health p  02 and mental health p  01 domain scores was also directionally consistent with the study hypothesis￨no diff￨highunclear￨highunclear￨highunclear
126￨older people hospitalized elders with hip fracture due to falling hospitalized elderly patients with hip fracture due to falling older people with hip fractures hip fracture patients aged 65 years and older n  126 hospitalized due to falling and discharged from a medical centre in northern taiwan hip fracture patients require ongoing medical and longterm care services hip fracture patients￨discharge plan comparison group the routine care or experimental group the discharge planning intervention discharge planning intervention￨physical outcomes and quality of life quality of life length of hospitalized stay rate of readmission repeat falls and survival and activities of daily living mean total sf36 scores length of stay rate of readmission and rate of survival and improved activities of daily living￨the discharge planning intervention decreased length of stay rate of readmission and rate of survival and improved activities of daily living for intervention group compared with those of control group￨sig increase￨highunclear￨highunclear￨highunclear
223￨223 patients 223 hip fracture patients hip fracture patients they were over 64 years of age mean 81 with no history of mental deterioration and acutely admitted to hospital from independent living conditions￨short portable mental status questionnaire spmsq and a feedback program￨postoperative mental impairment mean total continuous hospitalization mental status postoperative cognitive deterioration￨there was a low incidence of postoperative cognitive deterioration in both groups compared with historical controls￨no diff￨highunclear￨highunclear￨highunclear
100￨100 patients improves adl after hip fracture 100 eligible patients aged  or  65 years with independent residence hip fracture patients to perform adl and iadl hip fracture patients￨early individualized postoperative occupational training ot program ot or control group conventional care individualized postoperative occupational therapy training￨kleinbell adl scale and a modified version of the disability rating index adl and iadl abilities selfreported fear of pain and pain when performing adl and iadl￨at discharge the ot group had better ability to dress to take care of personal hygiene and bathing activities independently and to make toilet visits￨sig increase￨highunclear￨highunclear￨highunclear
304￨three hundred four nondemented persons at least 65 years of age who underwent surgical repair of a hip fracture at two hospitals in new haven ct and returned home within 100 days older persons after hip fracture￨homebased multicomponent rehabilitation program daily living adl disabilities functional therapy versus usual care￨gait performance social activity levels two timed mobility tasks balance or lower extremity strength upper extremity strength￨compared with participants who received usual care those in the multicomponent rehabilitation program showed slightly greater upper extremity strength at 6 months p  04 and a marginally better gait performance p  08￨sig increase￨low￨low￨low
64￨64 patients with chronic rhinosinusitis chronic rhinosinusitis￨placebo macrolide antibiotics macrolide roxithromycin￨sinonasal outcome test20 snot20 measurements of peak nasal inspiratory flow saccharine transit time olfactory function nasal endoscopic scoring and nasal lavage assays for interleukin8 fucose and a2macroglobulin snot20 score nasal endoscopy saccharine transit time and il8 levels in lavage fluid p05 olfactory function peak nasal inspiratory flow or lavage levels for fucose and a2macroglobulin￨no significant improvements were noted for olfactory function peak nasal inspiratory flow or lavage levels for fucose and a2macroglobulin￨no diff￨low￨low￨low
200￨two hundred women requesting abortion in early pregnancy gestational age less than 56 days and choosing surgical termination￨vacuum aspiration va or mva manual vacuum aspiration mva mva manual vacuum aspiration￨rate of complications with mva frequency of complete abortion￨there was no significant difference in frequency of complete abortion two patients in each group subsequently needed recurettage because of incomplete evacuation￨no diff￨highunclear￨highunclear￨highunclear
not found￨performing abortions of pregnancies of 710 menstrual weeks gestation by vacuum aspiration￨vacuum aspiration 8 mm diameter metal and flexible plastic cannulae￨incidence of cannula obstruction rates of specific complications blood loss and the need for secondary procedures to complete the abortion￨the rates of specific complications blood loss and the need for secondary procedures to complete the abortion were not significantly different for the two types of cannulae￨no diff￨highunclear￨highunclear￨highunclear
84￨first trimester abortion first trimester elective abortion eightyfour women seeking abortions at less than 10 weeks gestation￨manual versus electric aspiration manual vacuum aspiration manual and electric vacuum aspiration abortion by manual or electric vacuum aspiration￨pain levels or satisfaction pain noise disturbance and overall satisfaction with the abortion procedure amounts of anesthesia required and complication rates￨there were no significant differences in pain levels or satisfaction reported by patients however significantly more women in the electric group were bothered by noise 19 vs 2 p  003￨no diff￨highunclear￨highunclear￨highunclear
not found￨women requesting pregnancy terminations￨electric vacuum aspiration eva manual vacuum aspiration mva mva eva manual vacuum aspiration and electric vacuum aspiration￨pain anxiety or bleeding￨the two groups did not however differ in their reports of pain anxiety or bleeding or in the acceptability of their method￨no diff￨highunclear￨highunclear￨highunclear
420￨first trimester abortion conducted at kandang kerbau hospital in singapore from september 1973 to april 1975 420 physically healthy gravidas￨vacuum aspiration d  c and vacuum aspiration￨numbers of women with one or more complications estimated blood loss blood loss￨estimated blood loss was significantly lower for patients treated by va 323 ml than for patients treated by d  c 390 ml at 6 to 10 weeks gestation but the difference in blood loss was not statistically significant at 11 to 12 weeks gestation￨sig decrease￨highunclear￨highunclear￨highunclear
114￨114 women undergoing firsttrimester abortions patients undergoing￨manual vacuum aspirator and electric vacuum curettage devices electric vacuum curettage electric vacuum curettage and manual vacuum aspirator￨pain pain level with cervical dilatation level of pain with visual analog scales mean procedure times pain perception and procedure time level of pain patient pain perception￨the level of pain after aspiration did not vary significantly in patients who had abortions performed by residents or faculty￨no diff￨highunclear￨highunclear￨highunclear
53￨epileptic patients fiftythree hospital outpatients with epilepsy￨anticonvulsant therapy combination of complianceimproving strategies patient counselling a special medication container selfrecording of medication intake and seizures and mailed reminders to collect prescription refills and attend clinic appointments￨plasma anticonvulsant levels and prescription refill frequencies and seizure frequency compliance and seizure frequency seizure frequency patient compliance and clinical control￨compliance and seizure frequency were unaltered in the control group￨no diff￨highunclear￨highunclear￨highunclear
22￨adults with epilepsy twentytwo adults with epilepsy were recruited from hospitalbased epilepsy clinics people with epilepsy the mean age of participants was 43 years and 68 were men￨social cognitive theory and principles of motivational interviewing mi telephonebased selfmanagement program fivesession intervention with a nurse trained in mi counseling￨￨ninetyfive percent of the 55 planned mi sessions and the 44 planned courtesy calls for those in the control group were completed demonstrating high acceptance of the program￨sig increase￨highunclear￨highunclear￨highunclear
50￨fifty patients with epilepsy epileptic patients￨￨serum levels￨the patients information scores improved significantly in all three groups but the combination of data presented at interview both orally and in written form was markedly superior to the other methods￨sig increase￨highunclear￨highunclear￨highunclear
81￨81 patients with epilepsy￨implementation intention intervention tablet taking electronic registration of pill bottle openings medication event monitoring system mems￨adherence relative￨intervention participants showed improved adherence relative to controls on all three outcomes￨sig increase￨highunclear￨highunclear￨highunclear
38￨thirtyeight outpatients matched according to seizure type and frequency￨waitinglist control psychoeducational treatment program sepulveda epilepsy education program see￨overall understanding of epilepsy medication compliance 50item truefalse test specifically designed to evaluate the see program the washington psychosocial seizure inventory the beck depression inventory lubins depression adjective checklist the statetrait anxiety inventory the acceptance of disability scale and sherers selfefficacy scale hazardous medical selfmanagement practices blood levels of antiepileptic drugs aeds fear of seizures￨significant differences between the two groups were found on the three major subscales of the 50item truefalse test￨no diff￨highunclear￨highunclear￨highunclear
42￨persons with multiple sclerosis persons with multiple sclerosis ms 42 participants with ms and mdd￨paroxetine or placebo paroxetine￨hamd score treatment response fatigue anxiety and selfreported quality of life hamilton rating scale for depression hamd￨treatment effects were greater among the participants who completed the study 786 of completers had a treatment response compared with 421 of controls p073￨sig increase￨low￨low￨low
28￨patients without medical or neurologic disease half of the treated patients 28 patients with multiple sclerosis and major depressive disorder 14 patients￨desipramine placebo desipramine and individual psychotherapy and 14 to placebo plus psychotherapy￨hamilton rating scale for depression￨clinical judgments indicated that patients treated with desipramine improved significantly more than the placebo group￨sig increase￨highunclear￨highunclear￨highunclear
9￨9 patients with essential hypertension hypertensive patients￨spironolactone placebo spironolactone￨systemic blood pressure systolic and diastolic blood pressures orthostatic response blood pressure heart rate response to cold pressure and handgrip tests as well as blood flow in the calf and finger vessels systemic blood pressure to the handgrip and cold pressure tests dilatation of muscle and skin arteries blood flow through muscle and skin vessels vascular resistance systemic blood pressure limb blood flow heart rate sitting systolic and diastolic blood pressure￨spironolactone did not significantly change the response of systemic blood pressure to the handgrip and cold pressure tests￨no diff￨highunclear￨highunclear￨highunclear
373￨373 patients with a cvc 163 in the preintervention period and 210 in the postintervention period were studied neonates with a central venous catheter cvc from a neonatal intensive care unit database￨audiovisual education multimodal approach to central venous catheter hub care using 2 chlorhexidine in 70 isopropyl alcohol and education of medical staff by audiovisual presentations￨crbsi rates incidence of gramnegative septicemia crbsi rate umbilical vein catheter￨the incidence of gramnegative septicemia also decreased￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨￨infection rates rate of cabsis average cabsi rates relative rate rr and confidence intervals cis￨hierarchical regression modeling showed that the only significant predictor of an observed decrease in infection rates was the collective use of the insertion and maintenance bundles as demonstrated by the relative rate rr and confidence intervals cis rr 057 95 ci 045074 p  0001￨no diff￨highunclear￨highunclear￨highunclear
not found￨twentyfour bed surgicaltraumaburn intensive care units in an urban university hospital ventilatorassociated pneumonia rates in a surgical intensive care unit all mechanically ventilated patients that were admitted to the intensive care unit between june 1 2004 and may 31 2005￨simple lowcost oral care protocol chlorhexidine gluconate chemical solution￨staff compliance total cost ventilatorassociated pneumonia rates ventilatorassociated pneumonia risk of acquiring ventilatorassociated pneumonia￨there was an overall reduction in ventilatorassociated pneumonia without a change to the gramnegative or grampositive microorganism profile￨no diff￨highunclear￨highunclear￨highunclear
not found￨four adult intensive care units in a 583bed tertiary care hospital￨￨ventilatorassociated pneumonia rates￨by identifying issues evaluating patient care processes performing literature searches and monitoring compliance the team implemented numerous interventions including policy and procedure changes purchasing of equipment and implementation of various education tools￨no diff￨highunclear￨highunclear￨highunclear
not found￨1400bed universityaffiliated urban teaching hospital between january 2000 and december 2003 all patients admitted to the medical icu were surveyed prospectively for the development of catheterassociated bloodstream infection￨education program￨rate of catheterassociated bloodstream infection bloodstream infection medicalcare costs and patient morbidity￨education programs may lead to a substantial decrease in medicalcare costs and patient morbidity attributed to central venous catheterization when implemented as part of mandatory training￨sig decrease￨highunclear￨highunclear￨highunclear
106￨two geographically proximate medical centers inclusive of five intensive care units located in the southwestern region of the united states had significant variations in their vap rates 106 ventilated patients￨￨vap rates icu length of stay￨vap rates changed at both hospitals although the change was not statistically significant￨no diff￨highunclear￨highunclear￨highunclear
4283￨eighteenbed surgicalburntrauma intensive care unit icu in an urban teaching hospital 4283 patients were admitted to the icu between january 1 1998 and december 31 2000￨education program￨cost morbidity and mortality bloodstream infections catheterrelated bloodstream infections infection rate number of primary bloodstream infections￨after the implementation of the education module the number of primary bloodstream infections fell to 26 in 7044 catheter days 37 per 1000 catheter days a decrease of 66 p  0001￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨￨vap￨incidence of ventilatorassociated pneumonia ranges average cost of a vap vap rates incidence of vap hospital stay and drives up hospital costs￨vap did not decrease with institution of the ventilator bundle alone￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients requiring mechanical ventilation who developed ventilatorassociated pneumonia between october 1 1999 and september 30 2001 five intensive care units in barnesjewish hospital an urban teaching hospital one hundred ninetyone￨education program education intervention￨rate of ventilatorassociated pneumonia occurrence of ventilatorassociated pneumonia episodes of ventilatorassociated pneumonia hospital rate of ventilatorassociated pneumonia incidence of ventilatorassociated pneumonia￨following implementation of the education module the rate of ventilatorassociated pneumonia decreased to 81 episodes in 14171 ventilator days 57 per 1000 ventilator days a decrease of 576 p 001￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨￨￨bloodstream infections incidence of central lineassociated bloodstream infection clabsi￨after an educational intervention in 3 intensive care units 34 central lineassociated bloodstream infections occurred in 11582 central venous catheter cvcdays compared with 45 episodes in 10661 cvcdays before intervention 422 vs 294 episodes per 1000 cvcdays 309 reduction p  03 wilcoxon rank sum test p  11 poisson regression analysis￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨27 public wards￨iclns￨percentage of incorrect practices￨after education the percentage of incorrect practices in the test group 36 was significantly lower than the 48 in the control group p less than 005 chi 2  425￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨￨catheter management protocol￨average incidence incidence of crb fell infection rate￨the incidence of crb fell from an average level of 697 per 1000 catheterdays during the control period to an average of 168 during the study period￨no diff￨highunclear￨highunclear￨highunclear
677￨six hundred and seventyseven adult patients mechanically ventilated for 48 h were included in the study population￨￨vap incidence rates vap infection rates mortality prolonged hospitalization and costs incidence rates of vap￨vap infection rates reduced by 51 from a mean of 13212 in the preintervention period to 65151000 device days in the postintervention period mean difference 67 95 ci 29104 p 002￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨all patients were documented to be without paraaortic lymph node metastasis by pretherapy staging paraaortic lymphadenectomy fortyfive evaluable patients with stage iiib carcinoma of the uterine cervix surgically staged stage iiib cervical cancer￨placebo planned continuous therapy pelvic radiation for 6 weeks plus intrauterine radium hydroxyurea plus pelvic radiation versus placebo plus pelvic radiation continuous therapy or splitcourse radiation hydroxyurea splitcourse therapy 2week rest after 3000 rads plus radium￨leukopenia wbc less median dose of pelvic radiation estimated 5year progressionfree survival rate 5year progression free survival rate anemia thrombocytopenia radiation skin reaction diarrhea or radiationinduced complications requiring surgical correction￨leukopenia wbc less than 2500mm3 was significantly increased in the patients given hydroxyurea as compared to those given placebo p less than 001￨sig increase￨highunclear￨highunclear￨highunclear
40￨40 patients with figo international federation of gynaecology and obstetrics stage iib carcinoma of the uterine cervix all 40 patients were followed up for longer than 5 years 52 to 92 years or until death carcinoma of the uterine cervix￨hydroxyurea placebo hydroxyurea￨leukopenia white blood cell count less lifetable survival anemia thrombocytopenia radiationinduced skin reaction and radiationinduced intestinal reaction￨there was no statistically significant difference relative to anemia thrombocytopenia radiationinduced skin reaction and radiationinduced intestinal reaction between the patients given placebo or those given hydroxyurea￨no diff￨highunclear￨highunclear￨highunclear
130￨patients with stage iib cancer without biopsy proof of aortic node metastasis women with carcinoma of the uterine cervix women with stage iiib cervical cancer 130 evaluable women with stages iib and iiib international federation of gynecology and obstetrics carcinoma of the uterine cervix￨hydroxyurea or placebo continuous or splitcourse radiation therapy placebo continuous radiation therapy hydroxyurea hydroxyurea￨longer survival survival￨of all patients with stage iib cancer without biopsy proof of aortic node metastasis a significant improvement in survival p less than 001 was achieved in the hydroxyura group 740 as compared to the patients receiving placebo 435￨sig increase￨highunclear￨highunclear￨highunclear
not found￨twentyfive patients with figo stage iiib carcinoma of the cervix nonsurgically staged stage iiib cervical cancer patients with figo stage iiib carcinoma of the uterine cervix who were documented to be without paraaortic lymph node metastasis by pretherapy staging paraaortic lymphadenectomy piver et al j surg oncol 35 129134 1987 these patients either refused surgical staging or because of medical conditions could not undergo pretherapy paraaortic lymphadenectomy￨placebo pelvis by megavoltage radiation therapy followed by 2500 cgy to point a by intracavitary and vaginal radiumcesium dna synthesis hydroxyurea h hydroxyurea hydroxyurea plus pelvic irradiation versus placebo plus pelvic irradiation￨leukopenia wbc less median pelvic cgy anemia thrombocytopenia radiation skin reactions diarrhea or radiation induced complications requiring surgical correction￨there was no statistically significant difference relative to anemia thrombocytopenia radiation skin reactions diarrhea or radiation induced complications requiring surgical correction￨no diff￨highunclear￨highunclear￨highunclear
not found￨participants reporting one or more risks intimate partner violence englishspeaking women 18 years or older less than 26weeks pregnant and receiving prenatal care at one of the five participating clinics in the san francisco area￨provider cueing summary cueing sheets alerting them to their patients risks and suggesting counseling statements￨ipv discussions provider cueing intimate partner violence ipv￨provider cueing resulted in 85 of the ipvintervention group reporting discussions with their provider compared to 235 of the control group p0001￨sig increase￨highunclear￨highunclear￨highunclear
54￨fiftyfour women lowincome pregnant women with intimate partner violence lowincome pregnant women with recent intimate partner violence ipv￨￨initial feasibility acceptability and efficacy likelihood of a major depressive episode ptsd or ipv symptoms of ptsd and depression￨the intervention did not significantly reduce the likelihood of a major depressive episode ptsd or ipv during pregnancy or up to 3month postpartum￨no diff￨highunclear￨highunclear￨highunclear
1178￨children born to mothers with low levels of psychologic resources 1178 consecutive lowincome pregnant women with no previous live births to participate and we randomized 735 85 were unmarried 47 mexican american 35 white nonmexican american 15 black and 3 american indianasian prenatal and infancy home visiting by paraprofessionals and by nurses from child age 2 through age 4 years￨nursedelivered program￨sensitivity and responsiveness subsequent miscarriages domestic violence behavioral adaptation number of subsequent pregnancies womens educational achievement use of substances use of welfare or childrens externalizing behavior problems subsequent pregnancies participation in education and work use of welfare marriage cohabitation experience of domestic violence mental health substance use and sense of mastery observations of motherchild interaction and the home environment tests of childrens language and executive functioning and mothers reports of childrens externalizing behavior problems low birth weight newborns superior executive functioning advanced language sense of mastery and better mental health￨there were no statistically significant effects of either nurse or paraprofessional visits on the number of subsequent pregnancies womens educational achievement use of substances use of welfare or childrens externalizing behavior problems￨no diff￨highunclear￨highunclear￨highunclear
not found￨intimate partner violence during pregnancy abused pregnant women￨standard care and an empowerment intervention￨neighbors to call police if violence began severe psychological abuse hide money available bank account numbers healthrelated quality of life adoption of safety behaviors and use of community resources￨however there was no statistically significant difference in healthrelated quality of life adoption of safety behaviors and use of community resources between women in the two groups￨no diff￨highunclear￨highunclear￨highunclear
1044￨intimate partner violence in pregnancy women with severe intimate partner violence africanamerican women 1044 women were recruited women with minor intimate partner violence￨intervention n521 or usual care psychobehavioral intervention￨intimate partner violence and pregnancy outcomes intimate partner violence recurrence birth outcomes recurrent episodes of intimate partner violence victimization mean gestational age preterm neonates episodes postpartum￨women with severe intimate partner violence showed significantly reduced episodes postpartum or 039 95 ci 018082 the number needed to treat was 27￨sig decrease￨low￨low￨low
329￨pregnant women urban public health prenatal clinics participants were 329 pregnant physically abused hispanic women abused pregnant women￨￨severity of abuse intimate partner violence violence scores￨at 6 12 and 18month followup there were no statistically significant differences among the intervention groups￨no diff￨highunclear￨highunclear￨highunclear
1000￨two prenatal clinics in the pacific northwest and rural midwest pregnant women at risk for or in abusive relationships experience very stressful and complex lives pregnant women experiencing or at risk for abuse pregnant women at risk for or in abusive relationships 1000 women who spoke english and were 13 to 23 weeks pregnant at time of recruitment￨individualized nursing case management individualized nursing care management abuse video and had access to a nurse case manager 247￨stress scores￨compared to the control group the differences were in the predicted direction but not statistically different￨no diff￨highunclear￨highunclear￨highunclear
not found￨eleven babies 6 in the control group and 5 in the treatment group were withdrawn from the trial due to early death from extreme prematurity 7 babies early return to the referring hospital 3 babies and elective treatment with intravenous immunoglobulin for severe congenital septicaemia 1 baby sixtysix preterm infants of less than 30 weeks gestation consecutively admitted to either of two neonatal intensive care units preterm infants￨prophylactic intravenous immunoglobulin routine intensive care only or prophylactic intravenous immunoglobulin￨serum igg bloodcultureproven septicaemia￨serum igg was significantly higher with treatment and achieved levels comparable to those of normal fullterm babies at the same postnatal age￨sig increase￨highunclear￨highunclear￨highunclear
2416￨premature infants group n  1204 or a control group n  1212 verylowbirthweight infants 2416 infants were stratified according to birth weight 501 to 1000 g and 1001 to 1500 g￨immune globulin therapy intravenous immune globulin placebo immune globulin￨incidence of necrotizing enterocolitis incidence of hospitalacquired infections respiratory distress syndrome bronchopulmonary dysplasia intracranial hemorrhage the duration of hospitalization or mortality grampositive cocci adverse reactions septicemia nosocomial infections nosocomial infections of the blood meninges or urinary tract rate of hospitalacquired infections rate of nosocomial infections￨immune globulin therapy had no effect on respiratory distress syndrome bronchopulmonary dysplasia intracranial hemorrhage the duration of hospitalization or mortality￨no diff￨low￨low￨low
61￨61 vlbw infants were enrolled and divided into the ivig group n  31 and the control group n  30 very low birthweight infants￨saline infusion prophylactic intravenous immunoglobulin therapy prophylactic ivig therapy intravenous immunoglobulin ivig￨perinatal and neonatal characteristics igg levels low serum immunoglobulin g levels￨the results showed there were no major differences in the perinatal and neonatal characteristics between the two groups consistently higher igg levels were found in the ivig group and the age of first documented sepsis was earlier in the control group￨no diff￨highunclear￨highunclear￨highunclear
not found￨infants matched for gestational age sex and birth weight preterm and low birth weight infants￨intravenous polyvalent immunoglobulin preparation intraglobulin biotest pharma west germany intravenous immunoglobulin no immunoglobulin￨infection rate adverse effect frequency of infection and serum immunoglobulin concentrations neonatal sepsis immunoglobulin concentrations￨infection rate in the control group was 16 8 of 50 while in each of the treated groups it was 4 2 of 50￨sig decrease￨highunclear￨highunclear￨highunclear
588￨premature infants with very low birth weights a total of 588 neonates neonates weighing 500 to 1750 g at birth neonates lowbirthweight neonates premature infants weighing between 500 and 1750 g at birth treatment with￨placebo intravenous infusions of immune globulin immune globulin immune globulin intravenous immune globulin￨mean length of the hospital stay mean days of hospitalization tolerated mild reversible adverse reactions mortality morbidity and nosocomial infection risk of nosocomial infection risk of a first nosocomial infection￨there was a significant reduction in the risk of a first nosocomial infection in the recipients of immune globulin as compared with the placebo recipients relative risk 07 95 percent confidence interval 05 to 09￨sig decrease￨low￨low￨low
240￨126 patients 240 infants of very low birth weight less than 1300 g late sepsis in verylowbirthweight infants￨albumin placebo placebo ivig intravenous immunoglobulin ivig intravenous gammaglobulin￨number who developed sepsis igg levels median peak level of serum igg sepsis￨at 70 days the number who developed sepsis was similar in the two groups 20 for those who received ivig vs 23 for those who received placebo￨no diff￨low￨highunclear￨low
not found￨preterm neonates 20 preterm neonates weighing 710 to 1800 g￨intravenous immune globulin placebo intravenous immune globulin dl x￨serum igg levels serum igg heart rate respiratory rate urine output blood glucose serum osmolality bun sgpt ph blood gasses serum electrolytes total or direct bilirubin blood leukocyte concentration absolute neutrophil count or blood platelet concentration red blood cell concentration nosocomial infection serum igg levels￨no differences in heart rate respiratory rate urine output blood glucose serum osmolality bun sgpt ph blood gasses serum electrolytes total or direct bilirubin blood leukocyte concentration absolute neutrophil count or blood platelet concentration were observed between the intravenous immune globulin ivig and placebo recipients before or following ivig administration￨no diff￨low￨low￨low
133￨infants were stratified into two groups infants with birth weight less than or equal to 1500 g and gestational age less than or equal to 34 weeks and infants with birth weight greater than 1500 g and receiving intensive care and assisted ventilation preterm very low birth weight infants forty infants in group 1 and 25 in group 2 served as controls highrisk neonates 133 highrisk neonates￨intravenous gammaglobulin therapy gammaglobulin therapy gammaglobulin￨death safety and effectiveness incidence of infection or septicemia side effects serum total igg and group b streptococcus escherichia coli and cmvspecific igg levels incidence of infection￨infection was the main cause of death in one treated and six control infants in group 1 p less than 004￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨low birth weight infants 200 patients who were eligible for the study 600 to 2000 gm birth weight 115 patients preterm infants￨placebo intravenously administered immune globulin ivig immune globulin￨episodes of sepsis serum igg levels nosocomial sepsis ivig acquired nosocomial sepsis persistent hepatic or renal abnormalities blood pressure serum igg levels￨all patients in the placebo group in whom sepsis developed had serum igg levels￨sig increase￨low￨low￨low
76￨76 premature newborn infants with gestational age of 34 weeks or less forty infants were given 05 gkg ivig on the first day of life and 36 infants with similar gestational age and birth weight￨intravenous immunoglobulin intravenously administrated immunoglobulin ivig ivig therapy￨frequency of proven sepsis overall mortality rates overall mortality rate or mortality rate mortality rate attributable to infection￨the overall mortality rates in the two groups were not different either 350 vs 444 p  005￨no diff￨highunclear￨highunclear￨highunclear
235￨highrisk preterm infants highrisk premature infants two hundred thirtyfive premature newborns￨immunoglobulin ig therapy placebo intravenous immunoglobulin therapy￨episodes of certain infection episodes of probable infection incidence of certain or probable infection￨no significant differences were observed in the incidence of certain or probable infection in treated and control infants￨no diff￨low￨low￨low
46￨premature infants 46 premature newborn infants who were treated with￨intravenous immunoglobulins intravenous immunoglobulin￨incidence of sepsis mortality due to sepsis total mortality and minor infections￨no significant differences were observed between the two groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨very low birthweight infants very low birth weight infants was studied on 102 neonates at the children hospital bangkok from february 1988 to february 1990￨intravenous immunoglobulin prophylaxis immunoglobulin intravenous immunoglobulin￨mortality rate infection rate￨the mortality rate was also higher in group iii than in group i and group ii￨sig decrease￨highunclear￨highunclear￨highunclear
116￨very low birth weight neonates 116 selected neonates with very low birth weight￨standard doses of intravenously administered immunoglobulins ivig immunoglobulins￨infection rate or severity of infection￨no difference in infection rate or severity of infection could be observed between the treated neonates and the control group￨no diff￨highunclear￨highunclear￨highunclear
80￨premature newborn infants 80 preterm newborn infants who were divided into two groups 40 preterm newborns received preterm infants￨control group group b n  40 did not receive ivig ivig prophylactically intravenous immunoglobulin intravenous immunoglobulin ivig￨mortality bacteremia igg concentrations￨bacteremia was determined in three blood cultures in group a and eight in group b particularly saureus and senteritis￨sig increase￨highunclear￨highunclear￨highunclear
80￨80 infants were enrolled 37 of birthweight less than or equal to 1500 g and 43 of birthweight 15012000 preterm newborn infants preterm infants￨intravenous preparation of gammaglobulin intravenous gammaglobulin preparation intravenous gammaglobulin￨occurrence of sepsis serum igg￨the postdose increment of serum igg did not differ significantly in infants with and without sepsis the postdose serum disappearance rate in concentration appears identical in the two groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨premature neonates premature infants we prospectively entered 753 neonates with birth weight 500 to 2000 gm gestation  or  34 weeks and age  or  12 hours into a multicenter￨intravenous immune globulin prophylaxis ivig 500 mgkg or albumin intravenously administered immune globulin ivig￨change in serum igg or halflife of igg maternal and neonatal risk factors for infection serum igg concentration serum igg values lateonset sepsis sepsis death and death as a result of infection￨the serum igg concentration was increased p  005 in ivigtreated patients for 8 weeks￨sig increase￨highunclear￨highunclear￨highunclear
565￨565 communityresident patients with mild to moderate alzheimers disease entered a 12week runin period in which they were randomly allocated 565 patients with alzheimers disease ad2000 alzheimers disease￨placebo donepezil cholinesterase inhibitors cholinesterase inhibitors donepezil and placebo donepezil￨relative risk of entering institutional care entry to institutional care and progression of disability defined by loss of either two of four basic or six of 11 instrumental activities on the bristol activities of daily living scale badls relative risk of progression of disability or entering institutional care behavioural and psychological symptoms carer psychopathology formal care costs unpaid caregiver time adverse events or deaths progression of disability disability dependency behavioural and psychological symptoms carers psychological wellbeing or delay in institutionalisation￨no significant benefits were seen with donepezil compared with placebo in institutionalisation 42 vs 44 at 3 years p04 or progression of disability 58 vs 59 at 3 years￨no diff￨low￨low￨low
96￨patients with earlystage alzheimer disease enrolled patients with earlystage alzheimer disease earlystage alzheimer disease￨donepezil placebo donepezil￨alzheimer disease assessment scalecognitive subscale minimental state examination minimental state examination the computerized memory battery test the clinical dementia rating scalesum of the boxes the patient global assessment scale and the apathy scale efficacy modified alzheimer disease assessment scalecognitive subscale safe and well tolerated computerized memory battery test subscales facial recognition￨donepeziltreated patients showed greater mean improvement compared with placebotreated patients on the following computerized memory battery test subscales facial recognition p  007 in the intenttotreat population and p  04 in the fully evaluable population first and last name total acquisition p  02 and nameface association delayed recall p  04￨sig increase￨low￨low￨low
763￨patients with alzheimer disease patients with ad mild to moderately severe alzheimer disease ad￨donepezil placebo donepezil hydrochloride donepezil￨alzheimers disease assessment scalecognitive subscale scores alzheimers disease assessment scalecognitive subscale and the clinical dementia ratingsum of the boxes cognition and global function safety and efficacy￨donepezil hydrochloride is a selective acetylcholinesterase inhibitor approved for the symptomatic treatment of mild to moderately severe alzheimer disease ad￨sig increase￨highunclear￨highunclear￨highunclear
818￨patients with mild to moderately severe alzheimers disease ad eight hundred and eighteen patients with mild to moderately severe ad patients with mild to moderately severe ad￨donepezil or placebo donepezil placebo donepezil￨cognition and global function cognitive and global function sum of the boxes of the clinical dementia rating scale cdrsb a modified interview for deterioration in daily living activities in dementia iddd and a patient rated quality of life assessment cognitive performance test the alzheimers disease assessment scalecognitive subscale adascog and a global evaluation the clinicians interviewbased impression of change with caregiver input cibic plus functional skills efficacy and safety￨statistically significant improvements in cognitive and global function were observed as evaluated by adascog and cibic plus respectively in both the 5 and 10 mgday donepezil groups compared with placebo￨sig increase￨low￨low￨low
290￨patients with moderate to severe ad two hundred ninety patients with moderate to severe ad baseline standardized minimental state examination score of 517 patients with moderate to severe alzheimers disease ad patients with moderate to severe alzheimers disease and the effect on caregiver burden patients resided in the community or in assisted living facilities who did not require skilled 24hour nursing care￨donepezil placebo donepezil￨levels of caregiver stress with a modified multipleitem caregiver stress scale css caregiver time spent assisting patients with basic and instrumental adls disability assessment for dementia dad the modified instrumental activities of daily living iadl scale iadl and the modified physical self maintenance scale psms activities of daily living adls and social functioning caregiving competence personal gain and management of distress iadl and psms mean change css total and individual domain scores caregiving time and lower levels of caregiver stress overall distribution of caregiver ratings￨iadl and psms mean change from baseline scores for donepeziltreated patients showed a slower decline during the study than placebotreated patients week 24 locf mean treatment differences iadl  683 p 0001￨sig increase￨low￨low￨low
268￨japan 268 patients were enrolled and 39 of these 15 were withdrawn patients with mild to moderately severe alzheimers disease for 24 weeks in a doubleblind patients with alzheimers disease patients with mild to moderately severe alzheimers disease￨donepezil placebo donepezil hydrochloride donepezil￨cognitive performance test the japanese version of the alzheimers disease assessment scale  cognitive subscale adasj cog p  0003 and a clinical global assessment the japanese version of the clinical global impression of change cognitive and global function effective and well tolerated incidence of drugrelated adverse events sum of the boxes of the clinical dementia rating cdrsb the mental function impairment scale menfis and the caregiverrated modified crichton scale cmcs￨the superiority of donepezil was also shown by secondary measures the sum of the boxes of the clinical dementia rating cdrsb the mental function impairment scale menfis and the caregiverrated modified crichton scale cmcs￨no diff￨low￨low￨low
not found￨sd age 75095 years with probable alzheimer disease and scores of 20 or less on the informationmemoryconcentration subscale of the blessed dementia scale alzheimer disease in patients drawn from clinical practice patients with alzheimer disease who are encountered in clinical practice memory disorders units at massachusetts general and brigham and womens hospitals boston sixty individuals 30 men and 30 women mean clinical practice￨donepezil therapy donepezil therapy placebo placebo donepezil hydrochloride donepezil hydrochloride therapy donepezil donepezil vs placebo￨change in alzheimers disease assessment scale cognitive subscale scores diarrhea nausea subscale scores caregiverrated global impression specific tests of explicit memory or verbal fluency￨there was no associated change in caregiverrated global impression donepezil vs placebo proportion improved 024 vs 022 proportion worsened 027 vs 035 p  34 or on specific tests of explicit memory or verbal fluency￨no diff￨low￨low￨low
28934￨112 men were in the alpha tocopherol alone group 112 men in the beta carotene alone group 96 men in the alpha tocopherol and beta carotene group and 105 men in the placebo group male smokers 28934 male smokers 5069 years of age at the start south western finland finnish male smokers unaffected by alpha tocopherol or beta carotene supplements 425 men had cataract surgery because of senile or presenile cataract during the follow up￨alpha tocopherol 50 mg per day beta carotene 20 mg per day both alpha tocopherol and beta carotene or placebo placebo alpha tocopherol or beta carotene alpha tocopherol and with beta carotene alpha tocopherol and beta carotene supplementation￨incidence of cataract extractions beta carotene smoking duration visual acuity and total cholesterol incidence of cataract operations￨supplementation with alpha tocopherol or beta carotene does not affect the incidence of cataract extractions among male smokers￨no diff￨low￨low￨low
445￨agerelated cataract fourhundredandfortyfive patients were eligible 297 were randomized 231 78 were followed for two years 158 53 were followed for three years 36 12 were followed for four years consecutive adult american and english outpatients with early arc were recruited￨react oral antioxidant micronutrient mixture placebo vitamin or placebo oral antioxidant micronutrients mgday betacarotene 18 vitamin c 750 and vitamin e 600￨cataract severity area increase  pixels opaque ipo￨funding surgery worldwide for agerelated cataract arc a leading cause of blindness is a huge economic burden￨sig decrease￨low￨low￨low
798￨cataracts apc cataract progression in south india rural south india initial enrolment was 798 subjects￨placebo interventional antioxidant supplements antioxidant supplementation with beta carotene vitamins c and e antioxidant supplements beta carotene and vitamins c and e antioxidant supplements￨cortical and posterior subcapsular opacities and nuclear colour changes best corrected visual acuity change myopic shift and failure of treatment change in nuclear opalescence over time￨there was no significant difference between placebo and active treatment groups for either the primary or secondary outcome variables￨no diff￨low￨low￨low
1906￨1906 screened volunteers 1193 eligible subjects with early or no cataract aged 55 to 80 years were enrolled and followed up for 4 years￨vitamin e supplementation placebo vitamin e natural vitamin e in soybean oil encapsulated in gelatin or a placebo vitamin e￨rate of cataract extraction incidence of or progression of nuclear cortical or posterior subcapsular cataracts progression of cortical cataract incidence or rate of progression of agerelated cataracts nuclear cataract 4year cumulative incidence rate￨for nuclear cataract the corresponding rates were 129 and 121 p  077￨no diff￨low￨low￨low
22071￨large population of healthy men men on cataract or cataract extraction male us physicians aged 40 to 84 years n  22 071￨placebo beta carotene and agerelated cataract carotene supplementation beta carotene beta carotene supplementation￨number of cases cataract extraction overall incidence of cataract￨there was no difference between the beta carotene and placebo groups in the overall incidence of cataract 998 cases vs 1017 cases relative risk rr 100 95 confidence interval ci 091109 or cataract extraction 584 vs 593 rr 100 95 ci 089112￨no diff￨low￨low￨low
11545￨men 11545 apparently healthy us male physicians 50 years or older without a diagnosis of cataract at baseline agerelated cataract in a large cohort of men￨placebo vitamin e and c supplements supplementation with alternateday vitamin e or daily vitamin c vitamin e placebo vitamin e and daily use of 500 mg of vitamin c vitamin c or placebo daily vitamins e vitamin e or placebo￨￨longterm use of vitamin e and c supplements has no appreciable effect on cataract￨no diff￨low￨low￨low
not found￨people with one or more major cardiovascular risk factors 4495 people 2583 female mean age 644 years people with one or more of the following hypertension hypercholesterolaemia diabetes obesity family history of premature myocardial infarction or individuals who were elderly people at cardiovascular risk￨vitamin e antiplatelets and antioxidants aspirin lowdose aspirin and vitamin e aspirin vitamin e￨total cardiovascular events cardiovascular death severe bleedings￨aspirin lowered the frequency of all the endpoints being significant for cardiovascular death from 14 to 08 relative risk 056 95 ci 031099 and total cardiovascular events from 82 to 63 077 062095￨sig decrease￨low￨low￨low
39876￨and agerelated cataract in a randomized trial of women thirtynine thousand eight hundred seventysix apparently healthy female health professionals aged 45 years or older apparently healthy female health professionals with 97 years agerelated cataract in women agerelated cataract defined as an incident agerelated lens opacity responsible for a reduction in bestcorrected visual acuity to 2030 or worse based on selfreport and confirmed by medical record review￨placebo vitamin e supplementation vitamin e 600 iu naturalsource vitamin e on alternate days or placebo vitamin e￨posterior subcapsular cataract incidence of cataract￨there was no significant difference between the vitamin e and placebo groups in the incidence of cataract 1159 vs 1217 cases relative risk rr 096 95 confidence interval ci 088104￨no diff￨low￨low￨low
197￨acutely ill voluntary patients with severe mental illness one hundred ninetyseven patients were enrolled in the 2year research program and followed for 10 months for urban poor severely ill voluntary patients who usually require hospitalization to an alternative experimental program consisting of a day hospital linked to a crisis residence voluntary patients who would have been admitted to the hospital 83 were appropriate for the experimental program￨conventional inpatient program￨symptoms functioning social adjustment quality of life and satisfaction with clinical services upon admission to the study at discharge from the index admission measures of symptoms overall functioning and social functioning clinical functional social adjustment quality of life and satisfaction outcome measures￨the clinical functional social adjustment quality of life and satisfaction outcome measures were not statistically different for the patients in the two treatment conditions however there was a slightly more positive effect of the experimental program on measures of symptoms overall functioning and social functioning￨no diff￨highunclear￨highunclear￨highunclear
not found￨schizophrenic patients was tested by means of a longitudinal randomized experiment with 34 experimentals and 16 controls 38 percent could be treated satisfactorily in a day program that included a very active ambulatory service schizophrenic patients￨￨total cost of treatment￨the new approach did not improve prognosis with respect to psychiatric symptomatology social role disabilities or number of readmissions during the first year of followup￨no diff￨highunclear￨highunclear￨highunclear
91￨ninetyone patients admitted as emergencies suffering from neurosis personality disorder or adjustment reaction￨￨patient satisfaction￨clinical outcome was similar in the day care and inpatient groups but patient satisfaction was significantly greater in day patients￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients who would normally have been admitted to an open inpatient unit￨￨psychopathology social functioning interpersonal functioning social network and social support￨no differences in effectiveness were found between the two forms of treatment although more patients accepted and completed day treatment and day patients were more satisfied￨no diff￨highunclear￨highunclear￨highunclear
179￨carers of day hospital patients acute psychiatric illness 77 43 patients had schizophrenia teaching hospital in an inner city area 179 patients with acute psychiatric illness referred for admission who were suitable for random allocation to day hospital or inpatient treatment carers of all patients with acute psychiatric illness￨￨cost effectiveness clinical and social outcomes clinical symptoms social functioning and burden on relatives median direct costs indirect costs￨clinical and social outcomes were similar at 12 months except that inpatients improved significantly faster than day patients and burden on relatives was significantly less in the day hospital group at one year￨sig increase￨low￨low￨low
1117￨acutely ill psychiatric patients december 2000 to september 2003 in 5 european countries with a sample of 1117 voluntarily admitted patients￨￨psychopathologic symptoms treatment satisfaction and quality of life psychopathology treatment satisfaction subjective quality of life and social disabilities social functioning￨day hospital care was as effective as conventional inpatient care with respect to psychopathologic symptoms treatment satisfaction and quality of life￨sig increase￨highunclear￨highunclear￨highunclear
not found￨at preschool children preschool children￨coercive intervention aimed at parents and an educational intervention aimed educational intervention￨safety restraints￨the safety restraint use of children in the control and coercive intervention groups did not change significantly as a result of intervention￨no diff￨highunclear￨highunclear￨highunclear
not found￨3609 boostereligible children those aged 48 years and weighing 1836 kg 4080 lb child passengers in motor vehicles￨multifaceted community booster seat campaign￨￨once children have outgrown car seats booster seats protect from injury better than lap and shoulder belts alone￨sig increase￨highunclear￨highunclear￨highunclear
213￨a total of 213 families 778 of those eligible from intervention sites and 149 families 719 of those eligible from concurrent comparison sites agreed to participate and completed the trial families of low income children attending preschool enrichment programs in washington state children attending preschool head start programs in two regions were eligible￨injury prevention program delivered by school based home visitors￨feasibility acceptability and effectiveness injury prevention knowledge or behavior probability of having a working detector￨among families without a working smoke detector at baseline the intervention was associated with an increased probability of having a working detector at follow up relative risk rr 33 95 confidence interval ci 13 to 86￨sig increase￨highunclear￨highunclear￨highunclear
not found￨cystic fibrosis patients with chronic p aeruginosa lung infection cystic fibrosis patients with chronic pseudomonas aeruginosa lung infection forty patients with cystic fibrosis and chronic bronchopulmonary pseudomonas aeruginosa infection￨placebo inhalations of isotonic saline placebo colistin inhalation therapy colistin inhalation therapy colistin inhalation intravenous antipseudomonas chemotherapy￨clinical symptom score maintenance of pulmonary function and inflammatory parameters￨colistin treatment was superior to placebo treatment in terms of a significantly better clinical symptom score maintenance of pulmonary function and inflammatory parameters￨sig increase￨highunclear￨highunclear￨highunclear
98￨twentyone children under age 6 years ninetyeight subjects young children with cystic fibrosis￨inhaled tobramycin placebo tobramycin solution￨pseudomonas aeruginosa pa density clinical indices markers of inflammation or incidence of adverse events airway pa density serum creatinine or audiometry and no episodes of significant bronchospasm pa density no pa￨no abnormalities in serum creatinine or audiometry and no episodes of significant bronchospasm were observed in association with active treatment￨no diff￨highunclear￨highunclear￨highunclear
22￨22 cf patients patients with cystic fibrosis cf cf patients pseudomonas aeruginosa colonization in cystic fibrosis￨tobramycin placebo placebo aerosolized tobramycin or placebo tobramycin inhalation aerosolized tobramycin￨time to conversion from a p aeruginosapositive to a p aeruginosanegative respiratory culture lung function parameters and markers of inflammation antibiotic efficacy delay p aeruginosa pulmonary infection￨lung function parameters and markers of inflammation did not change in either group during treatment￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with cystic fibrosis infected with pseudomonas aeruginosa older patients with cystic fibrosis infected with pseudomonas aeruginosa￨nebulized 1 ceftazidime gentamicin and carbenicillin ceftazidime gentamicin and carbenicillin and 3 saline inhaled ceftazidime￨mean forced expiratory volume mean forced vital capacity mean peak expiratory flow on ceftazidime 299 litresmin and on gentamicin and carbenicillin 297 litresmin forced expiratory volume￨mean forced vital capacity on gentamicin and carbenicillin 293 litres was also greater than on saline p less than 005￨no diff￨highunclear￨highunclear￨highunclear
247￨cf patients with chronic p aeruginosa infection patients with cystic fibrosis cf patients with cystic fibrosis and pseudomonas aeruginosa infection cf patients with p aeruginosa chronic infection 247 patients￨tobramycin placebo tobramycin highly concentrated solution for inhalation tsi aerosolized tobramycin bramitob nebulized tobramycin or placebo tsi aerosolized tobramycin￨tolerability and safety of tsi microbiologic outcomes need for parenteral antipseudomonal antibiotics adverse events reporting audiometry and renal function serum creatinine and auditory function adverse events fev1 forced expiratory volume in 1 second fev1 percentage of predicted normal forced vital capacity fvc forced expiratory flow efficacy and tolerability mic of isolated p aeruginosa strains bodyweight and body mass index p aeruginosa susceptibility minimum concentration required to inhibit 90 of strains mic90 rates of p aeruginosanegative culture p aeruginosa persistence and superinfection need for hospitalization and parenteral antipseudomonal antibiotics loss of schoolworking days due to the disease and nutritional status bodyweight and body mass index pulmonary function and microbiologic outcome decreased hospitalizations increased nutritional status and was well tolerated￨patients treated with tsi had fewer lost schoolworking days due to the disease p  0001￨sig decrease￨low￨low￨low
29￨children and adolescents with cystic fibrosis 29 children and adolescents with cystic fibrosis over 2 years￨nebulized gentamicin gentamicin aerosol nebulized saline mixture nebulized gentamicin￨clinical symptoms deterioration in pulmonary function antibiotic usage days in hospital and development of pseudomonas aeruginosa antibiotic usage days in hospital or clinical symptoms deterioration in lung function￨there was no difference in progress between the two treatment regimes for those subjects with p aeruginosa in sputum at the beginning of the study nor was there any difference in the number developing p aeruginosa in sputum￨no diff￨highunclear￨highunclear￨highunclear
115￨cystic fibrosis cf patients cystic fibrosis patients with cystic fibrosis chronically infected with pseudomonas aeruginosa onehundred and fifteen patients aged  or  6 yrs cf patients chronically infected with p aeruginosa￨tobramycin nebuliser solution tns or colistin tns nebulised tobramycin tobramycin nebuliser solution tns and nebulised colistin￨sputum p aeruginosa density changes in sputum p aeruginosa density tobramycincolistin minimum inhibitory concentrations and safety assessments bacterial load forced expiratory volume lung function efficacy and safety evaluation of the relative change in lung function￨tobramycin nebuliser solution significantly improved lung function of patients with cystic fibrosis chronically infected with pseudomonas aeruginosa but colistin did not in this study of 1months duration￨sig increase￨highunclear￨highunclear￨highunclear
59￨patients with cystic fibrosis colonized with pseudomonas aeruginosa patients with cystic fibrosis cf fiftynine patients patients with cf and p aeruginosa infection￨tobramycin placebo tobramycin or placebo administered twice daily via the pari lc plus nebulizer and pari turboboy compressor highly concentrated nebulized tobramycin highly concentrated 300mg4ml tobramycin solution for inhalation tsi￨concentration of tobramycin attained in sputum renal or auditory toxicity fev1 proportion of patients with drugrelated adverse events tolerated pulmonary function and microbiology efficacy safety and local pharmacokinetics pulmonary function forced expiratory volume in 1 second fev1 forced vital capacity fvc and forced expiratory flow at the midportion of vital capacity fef2575 p aeruginosa susceptibility microbiologic results and in vitro minimum inhibitory concentration for 90 of strains mic90 adverse events audiometry bone conduction at 2508000hz frequency laboratory tests physical examination and general health condition efficacy and safety mean sputum concentrations of tobramycin pulmonary function and microbiologic outcome￨the 4week administration of a highly concentrated tsi significantly improved pulmonary function and microbiologic outcome compared with placebo and was well tolerated￨sig increase￨highunclear￨highunclear￨highunclear
47￨cystic fibrosis patients with cystic fibrosis 47 mildly to moderately affected patients￨cephaloridine cloxacillin orally prophylactic antibiotics antibiotic prophylaxis inhaled cephaloridine and the other received no inhaled antibiotic cloxacillin￨incidence of respiratory tract infections or hospital admissions clinical scores radiologic scores or rate of change of pulmonary function rates of carriage of staphylococcus aureus general progression of cystic fibrosis carriage of haemophilus influenzae￨carriage of haemophilus influenzae was greater in the group not receiving inhaled antibiotic 55 vs 20￨sig increase￨highunclear￨highunclear￨highunclear
32￨cf patients cystic fibrosis cf patients chronically infected with pseudomonas aeruginosa cystic fibrosis patients 32 patients with a mean  sd age of 18586 years were included in the study patients with cf cf patients subjects￨tobramycin inhaled tobramycin inhaled tobramycin￨lung function colistin forced expiratory volume forced vital capacity personal preference￨similar changes were observed in forced vital capacity 25129 in the 80 mg tobramycin group versus 2596 in the 300 mg tobramycin group￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients n  211  or 6 yr  or 3 tis courses within previous year fev1  or  25 and  or 75 predicted values patients with cystic fibrosis cf on maintenance treatment for pseudomonas aeruginosa pa airway infection chronic airway pseudomonas aeruginosa in cystic fibrosis patients with cf patients with cf using frequent tis therapy￨aztreonam lysine placebo azli and placebo aztreonam azli inhaled aztreonam lysine aztreonam lysine for inhalation azli tobramycin inhalation solution tis azli or placebo￨time to need for additional inhaled or intravenous antipseudomonal antibiotics median time to need for additional antipseudomonal antibiotics for symptoms of pulmonary exacerbation changes in respiratory symptoms cf questionnairerevised cfqr respiratory scale pulmonary function fev1 and sputum pa density adverse events fev1 tolerated mean cfqr respiratory scores sputum pa density safety and efficacy respiratory symptoms and pulmonary function￨azli improved mean cfqr respiratory scores 501 points p  002 fev1 63 p  0001 and sputum pa density 066 log10 cfug p  0006 compared with placebo no azli doseresponse was observed￨sig increase￨low￨low￨low
71￨patients with cystic fibrosis patients with clinically stable cystic fibrosis patients with cystic fibrosis and p aeruginosa infections seventyone patients with stable pulmonary status were recruited from seven us centers for the treatment of cystic fibrosis￨tobramycin placebo tobramycin and placebo aminoglycosides such as tobramycin strength physiologic saline placebo aerosolized tobramycin￨pulmonary function the density of p aeruginosa in sputum ototoxicity nephrotoxicity and the emergence of tobramycinresistant p aeruginosa density of p aeruginosa ototoxicity nor nephrotoxicity forced expiratory volume forced vital capacity forced expiratory flow at the midportion of the vital capacity safety and efficacy￨a decrease in the density of p aeruginosa in sputum by a factor of 100 p  0001 was found during all periods of tobramycin administration￨sig decrease￨highunclear￨highunclear￨highunclear
520￨520 patients mean age 21 years patients with cystic fibrosis and pseudomonas aeruginosa infection patients with cystic fibrosis￨tobramycin placebo inhaled tobramycin inhaled tobramycin inhaled tobramycin or placebo￨pulmonary function the density of p aeruginosa in sputum and hospitalization density of p aeruginosa tolerated and improved pulmonary function forced expiratory volume detectable ototoxic or nephrotoxic effects density of p aeruginosa in sputum risk of hospitalization￨inhaled tobramycin was not associated with detectable ototoxic or nephrotoxic effects or with accumulation of the drug in serum￨no diff￨low￨low￨low
not found￨patients with cystic fibrosis colonized with pseudomonas aeruginosa twentyseven patients with cystic fibrosis and endobronchial colonization with pseudomonas aeruginosa￨tobramycin inhaled tobramycin ml saline tobramycin solution￨deterioration nephro or ototoxicity pulmonary function and clinical status￨there was no evidence of significant nephro or ototoxicity￨no diff￨highunclear￨highunclear￨highunclear
400￨400 young persons with cystic fibrosis cf and mild lung disease young cf subjects with mild lung disease only 184 of 400 planned subjects young persons with cf and mild lung disease￨tobramycin solution tobramycin solution for inhalation tsi tobi chiron corp￨rate of lung function decline as measured by forced expiratory volume in 1 sec fev1 hospitalization and concomitant antibiotic use worsening of respiratory symptoms respiratory hospitalizations concomitant antibiotic use hospitalization antibiotic use school days missed and nutritional status safety lung function decline rate￨an interim safety review showed a 242fold risk of respiratory hospitalization for control group subjects p  0020 and the study was terminated￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨￨efficacy safety costeffectiveness and quality of life￨we provide motivation for the use of two effectiveness outcomes time to allcause discontinuation and composite endpoints that combine outcomes from multiple domains such as efficacy safety costeffectiveness and quality of life￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with dementia patients with dementiarelated psychosis patients with moderatetosevere psychotic symptoms associated with dementia were recruited from outpatient or residential settings￨placebo olanzapine olanzapine risperidone and placebo risperidone placebo and risperidone olanzapine and risperidone￨neuropsychiatric functioning overall discontinuation abnormally high prolactin levels incidence of discontinuation due to adverse events behavioral disturbances neuropsychiatric inventory and clinical global impressionseverity of psychosis scale vital sign electrocardiographic measure or laboratory hematology and chemistry including glucose except for cholesterol incidence of weight gain￨treatmentemergent extrapyramidal symptoms were more numerous for risperidone than placebo or olanzapinetreated patients￨sig increase￨highunclear￨highunclear￨highunclear
345￨a total of 345 patients elderly patients with a dsmiv diagnosis of dementia of the alzheimers type vascular dementia or a combination of the 2 ie mixed dementia and significant aggressive behaviors elderly nursinghome patients with dementia￨placebo or risperidone solution risperidone or placebo placebo risperidone￨extrapyramidal symptoms aggression agitation and psychosis somnolence and urinary tract infection aggression agitation and psychosis of dementia psychotic symptoms subscale cmai total nonaggression subscale cohenmansfield agitation inventory cmai the behavioral pathology in alzheimers disease behavead rating scale and the clinical global impression of severity cgis and of change cgic scales cmai total aggression score aggressive behavior cgis and the cgic scores aggression agitation and psychosis associated with dementia efficacy and safety￨a similar improvement was also seen for the cmai total nonaggression subscale p 002 and for the behavead total p 001 and psychotic symptoms subscale p 004￨no diff￨low￨low￨low
652￨patients with psychotic symptoms associated with ad in longterm or continuingcare settings patients n  652 with ad and delusions or hallucinations patients with alzheimers disease elderly patients with alzheimers dementia ad￨placebo or fixeddose olanzapine placebo olanzapine olanzapine￨cognition or any other vital sign or laboratory measure including glucose triglyceride and cholesterol behavioral disturbances psychosis and overall behavioral disturbances npinh bprs tolerated endpoint cgic scores psychotic symptoms and behavioral disturbances weight anorexia and urinary incontinence npinh psychosis total scores sum of delusions hallucinations itemsprimary efficacy measure extrapyramidal symptoms nor of total adverse events￨there were significant overall treatmentgroup differences in increased weight anorexia and urinary incontinence with olanzapine showing numerically higher incidences￨sig increase￨highunclear￨highunclear￨highunclear
180￨latino gay and bisexual men lgbm latino gay and bisexual men new york city in which 180 lgbm￨hivprevention intervention￨￨at the time of this writing no randomized controlled trial rct of an intervention to reduce unsafe sex among latino gay and bisexual men lgbm had been published￨no diff￨highunclear￨highunclear￨highunclear
162￨urban gay and bisexual men 162 methamphetaminedependent scidverified gbm in los angeles county dependent gay and bisexual men gbm￨methamphetamine standard cognitive behavioral therapy cbt n40 contingency management cm n42 combined cognitive behavioral therapy and contingency management cbtcm n40 and a culturally tailored cognitive behavioral therapy￨sexual risk behaviors methamphetamine dependence and hivrelated sexual risk behaviors methamphetamine use and sexual risk behaviors unprotected receptive anal intercourse urai retention￨statistically significant differences in retention f3158378 p02 in longest period of consecutive urine samples negative for methamphetamine metabolites f31581180 p001 and in the treatment effectiveness score were observed by condition during treatment f3158735 p001 with post hoc analyses showing the cm and cbtcm conditions to perform better than standard cbt￨sig increase￨highunclear￨highunclear￨highunclear
248￨anonymous testing site in san francisco california between may 1997 and january 2000 participants were 248 msm with a history of at least one previous negative hiv test result and selfreported uai receptive or insertive in the previous 12 months with partners of unknown or discordant hiv status men who have sex with men msm and among men with a history of repeat testing for hiv hivnegative men gay male repeat testers for hiv￨standard hiv test counseling plus a cognitivebehavioral intervention and two control groups received only standard hiv test counseling￨￨a novel counseling intervention focusing on selfjustifications significantly decreased the proportion of participants reporting uai with nonprimary partners of unknown or discordant hiv status at 6 and 12 months from 66 to 21 at 6 months and to 26 at 12 months p 002 p 001 as compared with a control group when added to standard clientcentered hiv counseling and testing￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨gay men n92 who had slipped up kept diaries of their sexual behaviour for 16 weeks￨specific encounter detailed reconstruction of a slipup but without any questions about selfjustifications posters examination of posters specially designed for the study that focused on selfjustifications and control no intervention￨sexual risktaking￨after 4 weeks they were allocated to one of 3 conditions specific encounter detailed reconstruction of a slipup but without any questions about selfjustifications posters examination of posters specially designed for the study that focused on selfjustifications and control no intervention￨sig increase￨highunclear￨highunclear￨highunclear
109￨gay men men n  109 who had slipped up broken their safe sex rules by having unprotected anal intercourse kept diaries of their sexual behaviour for 16 weeks￨brief interventionsselfjustifications evaluation of selfjustifications and standard examination of posters used in aids educationand a control diary only￨incidence of sexual activity￨in the postintervention period the 3 groups did not differ in the incidence of sexual activity or in the proportion who slipped up at least once but the selfjustifications group were less likely to have had multiple slipups￨no diff￨highunclear￨highunclear￨highunclear
336￨men who have sex with men hivnegative men who have sex with men msm n  336￨pcc or usual counseling uc brief cognitive counseling with hiv testing paraprofessional counselors pcc singlesession personalized cognitive counseling pcc intervention￨satisfying counseling experience sexual risk number of episodes of unprotected anal intercourse uai with any nonprimary partner of nonconcordant hiv serostatus acceptability efficacy and acceptability highrisk sexual behavior uai levels of hiv nonconcordant uai risk reduction￨risk reduction in the pcc arm was sustained from 6 to 12 months at 19 p  0181 whereas risk significantly decreased in the uc arm to 22 during this interval p  0001 vs 6 months p  0756 vs pcc at 12 months￨no diff￨low￨low￨low
not found￨men who have sex with men msm￨￨selfefficacy communication skills social norms and enjoyment of unprotected anal intercourse sexual risk behavior￨we describe the intervention tested in explore an hiv prevention trial aimed at men who have sex with men msm and test the empirical basis of the individually tailored intervention￨sig increase￨highunclear￨highunclear￨highunclear
585￨fivehundred and eightyfive hivpositive persons sexually active prior to enrollment hivpositive patients during medical visits hiv1 seropositive patients hivpositive patients presenting with risky behavioral profiles participants with casual partners at baseline six hiv clinics in california￨brief safersex counseling safersex counseling￨uav gainframe arm hiv transmission behaviors selfreported unprotected anal or vaginal intercourse uav￨among participants who had two or more sex partners at baseline uav was reduced 38 p  0001 among those who received the lossframe intervention￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨hivpositive people people living with hiv infection hivpositive men and women men n233 and women n99 living with hivaids￨fivesession group intervention focused on strategies for practicing safer sexual behavior or 2 a fivesession contactmatched healthmaintenance support group standardofcare comparison￨hiv transmission rates risk of hiv transmission hiv transmission risks transmissionrisk behaviors￨the intervention to reduce risk of hiv transmission resulted in significantly less unprotected intercourse and greater condom use at followup￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨gay men 1484 men and new clients increased at the gay specific gum service￨barbased peerled communitylevel intervention peer education within bars gay specific genitourinary medicine gum services and a freephone hotline￨sexual health behaviours hepatitis b vaccination hiv testing unprotected anal intercourse uai with casual partners negotiated safety and amongst men reporting uai with a regular partner the proportion who knew their own and their partners hiv status￨significant differences in sexual health behaviours were observed across locations and across time but the only significant intervention effects were amongst men who had direct contact with the intervention with higher uptake of hepatitis b vaccination and hiv testing￨sig increase￨highunclear￨highunclear￨highunclear
318￨participants n  318 were recruited from bars bathhouses and erotic bookstores and through homosexual africanamerican organizations street outreach media advertisements and personal referrals of individuals aware of the study africanamerican homosexual and bisexual men￨hiv risk reduction intervention triple session experimental group or a waitlist control group￨sexual behavior hiv highrisk sexual behavior frequency of unprotected anal intercourse risky sexual behavior levels of risky behavior￨participants in the triple session intervention greatly reduced their frequency of unprotected anal intercourse from 46 to 20 at the 12month followup evaluation and from 45 to 20 at the 18month followup evaluation￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨participants were recruited in los angeles milwaukee new york and san francisco people living with hiv nine hundred thirtysix hivinfected participants considered to be at risk of transmitting hiv of 3818 persons screened people living with hiv plh￨cognitive behavioral intervention programs cognitive behavioral intervention behavioral intervention￨mean transmission risk acts risk of transmission greatest reduction￨cognitive behavioral intervention programs can effectively reduce the potential of hiv transmission to others among plh who report significant transmission risk behavior￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨young people living with hiv yplh in los angeles san francisco and new york over 15 months in response to receiving a preventive intervention yplh aged 16 to 29 years n  175 26 black and 42 latino 69 gay men substanceusing hivpositive young people￨yplh 3module intervention totaling 18 sessions delivered by telephone in person or a delayedintervention condition￨hiv risky behaviors and health practices emotional distress￨hiv risky behaviors and health practices were examined among young people living with hiv yplh in los angeles san francisco and new york over 15 months in response to receiving a preventive intervention￨no diff￨highunclear￨highunclear￨highunclear
not found￨gay men of all eligible men 456 78 were recruited as they entered treatment for a substance use disorder gay men undergoing substance use disorder treatment￨safe sex intervention experimental condition treatment for substance use disorder plus a safe sex intervention regular substance use disorder treatment￨sexual risktaking unprotected anal intercourse uai￨although levels of risk within each wave were never significantly different between the two treatment groups reductions in unprotected anal intercourse uai with a nonmonogamous partner for both groups from the baseline wave1 levels were uniformly significant all ps  05￨no diff￨highunclear￨highunclear￨highunclear
387￨hivindividuals n  387 who reported engaging in unprotected sex with hiv or partners of unknown serostatus hiv individuals￨single counseling session targeting problem areas identified by the participant in 3 possible intervention domains ie condom use negotiation disclosure b a singlesession comprehensive intervention that covered all 3 intervention domains c the same comprehensive intervention plus 2 monthly booster sessions or d a 3session diet and exercise attentioncontrol condition￨sexual risk behaviors of hivindividuals sexual risk behaviors median number of unprotected sex acts unprotected sex acts￨testing behavioral interventions to increase safer sex practices of hiv individuals has the potential to significantly reduce the number of new infections￨sig increase￨highunclear￨highunclear￨highunclear
811￨hivseropositive gay and bisexual men 811 participants met the inclusion criteria for outcome analyses hivseropositive gay and bisexual men were recruited from new york city and san francisco￨enhanced peerled intervention peerled behavioral intervention￨transmission risk or serostatus disclosure transmission risk audio computerassisted self interview acasi assessments receptive anal intercourse transmission risk behavior and serostatus disclosure￨compared with the standard intervention fewer men assigned to the enhanced intervention reported unprotected receptive anal intercourse with a negative or unknownserostatus partner at 3 months 21 versus 26 p  005￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨youths living with hiv hivinfected youths hivinfected youths aged 13 to 24 years n  310 27 african american 37 latino￨preventive intervention 2module stay healthy and act safe intervention totaling 23 sessions or 2 a control condition￨stay healthy module number of positive lifestyle changes and active coping styles social support coping￨subsequent to the stay healthy module number of positive lifestyle changes and active coping styles increased more often among females who attended the intervention condition than among those in the control condition￨sig increase￨highunclear￨highunclear￨highunclear
not found￨homosexual men in us cities participants were men from each city who went to gay bars popular homosexual men in the community and trained them to spread behaviourchange endorsements and recommendations to their peers through conversation￨communitylevel hivprevention intervention￨mean frequency of unprotected anal intercourse mean percentage of occasions of anal intercourse populationlevel of risk behaviour￨populationlevel of risk behaviour decreased significantly in the intervention cities compared with the control cities at 1year followup after exclusion of surveys completed by transients and men with exclusive sexual partners in a citylevel analysis in the intervention cities we found a reduction in the mean frequency of unprotected anal intercourse during the previous 2 months baseline 168 occasions followup 059 p  004 and an increase in the mean percentage of occasions of anal intercourse protected by condoms baseline 447 followup 668 p  002￨sig decrease￨highunclear￨highunclear￨highunclear
15205￨5 cities community members who encouraged behavior change among injection drug users their female sex partners sex workers nongayidentified men who have sex with men highrisk youth and residents in areas with high sexually transmitted disease rates￨theorybased communitylevel intervention communitylevel hiv intervention￨￨at the community level movement toward consistent condom use with main p  05 and nonmain p  05 partners as well as increased condom carrying p  0001 was greater in intervention than in comparison communities￨sig increase￨highunclear￨highunclear￨highunclear
50￨gay men gay men in the uk this communitybased rct recruited 50 men of whom 42 were hivpositive or untested and 32 reported status unknown or serodiscordant uai in the previous 12 months￨￨making sexual choices physical safety hiv and sti transmission knowledge and sexual negotiation skills knowledge skills attitudinal or behavioural differences hiv and sti transmission knowledge and comfort with sexual choices￨at eight weeks those attending the group reported significant gains over their control in making sexual choices physical safety hiv and sti transmission knowledge and sexual negotiation skills￨sig increase￨highunclear￨highunclear￨highunclear
276￨young men who have sex with men ymsm in st petersburg russia and sofia bulgaria fiftytwo msm social networks were recruited through access points in highrisk community venues young men who have sex with men in russia and bulgaria network members n  276￨hiv prevention intervention ninesession program that provided training and guidance in delivering ongoing theorybased hiv prevention advice to other network members￨￨the percentage who engaged in ui with multiple partners reduced from 315 to 129 p  002￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨gay men in a small city to serve as behavior change endorsers to their peers hiv human immunodeficiency virus infection men patronizing gay clubs in the intervention city and in two matched comparison cities￨￨hiv risk behavior reduction proportion of men who engaged in any unprotected anal intercourse￨the opinion leaders acquired social skills for making these endorsements and complied in talking frequently with friends and acquaintances￨sig increase￨highunclear￨highunclear￨highunclear
271￨hivinfected individuals 271 hivinfected persons who donated blood to the new york blood center￨education and support program structured intervention program structured intervention or community referral group￨unsafe sexual activity behavior change sexual behavior psychological distress and psychological help seeking and immune function￨donors randomized to the structured intervention program did not report significantly more behavior change at the 1year followup￨no diff￨highunclear￨highunclear￨highunclear
1741￨male prostitutes and other patrons in new york city hustler bars urban sample of men at high risk for hiv infection 1741 male prostitutes and bar patrons￨hiv prevention program￨paid unprotected sexual intercourse and oral sex￨analyses indicated significant reductions in paid unprotected sexual intercourse and oral sex following the intervention￨sig decrease￨highunclear￨highunclear￨highunclear
68￨depressed persons with hiv infection persons with hiv disease depressed hivinfected persons sixtyeight depressed men with hiv infection￨cognitivebehavioral and support group brief therapies session cognitivebehavioral groups eightsession social support groups or a comparison condition cognitivebehavioral or social support group therapy￨depression hostility and somatization overall psychiatric symptoms symptoms of distress maladaptive interpersonal sensitivity anxiety and frequency of unprotected receptive anal intercourse￨relative to the comparison group both the cognitivebehavioral and social support group therapies produced reductions in depression hostility and somatization￨sig decrease￨highunclear￨highunclear￨highunclear
343￨gay men 23 sexual health clinics in london we determined that few participants had attended other sexual health clinics 343 gay men with an acute sexually transmitted infection or who reported having had unprotected anal intercourse in the past year sexual health clinic in london sexually transmitted infections among gay men￨cognitive behavioural intervention￨unprotected anal intercourse￨this behavioural intervention was acceptable and feasible to deliver but it did not reduce the risk of acquiring a new sexually transmitted infection among these gay men at high risk￨no diff￨low￨low￨low
64￨64 gay men infected with human immunodeficiency virus hiv men with hiv￨stress management training stress reduction training￨sexual behavior and immune functioning sexual partners lymphocyte numbers and function￨compared to those randomized to a wait list control treatment subjects reported significantly fewer sexual partners in the prior month at posttest 110 vs 229 for controls￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨abusing patients with hivaids in a public general hospital received a substance abusers with hivaids￨brief contact condition or received 12 months of case management delivered by paraprofessionals substance￨substance use hiv transmission risk physical health psychological status and quality of living situation￨in both conditions a significant decrease occurred in a range of problems from intake to the 6month interview followed by no significant pattern of change at 12 and 18month interviews￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨homosexual asian and pacific islander men homosexual api 329 selfidentified homosexual api recruited in san francisco between 1992 and 1994￨skills training group or a waitlist control group positive selfidentity and social support 2 safer sex education 3 eroticizing safer sex and 4 negotiating safer sex￨number of sexual partners hiv risk hiv risk reduction number of partners unprotected anal intercourse￨chinese and filipino men further benefited from the intervention treatment subjects from these two ethnic groups reduced unprotected anal intercourse at followup by more than half when compared to their counterparts odds ratio  041 95 ci 019089 p  0024￨sig decrease￨highunclear￨highunclear￨highunclear
44￨at homosexual and bisexual men homosexual and bisexual men￨skills training peerled interventions both involved a lecture on safer sex and one provided a skillstraining component aids riskreduction interventions targeted￨sexual behavior￨in sessions providing skills training condom use increased on average by 44 between pretest and second followup compared with only 11 on average in sessions which did not provide such training￨sig increase￨highunclear￨highunclear￨highunclear
300￨young gay men n  300 young gay men￨communitylevel hiv prevention intervention￨proportion of men engaging in any unprotected anal intercourse hiv risk reduction￨no significant changes occurred in the comparison community over the same period￨no diff￨highunclear￨highunclear￨highunclear
not found￨eighty patients studied prospectively were randomised into patients with ala admitted to king edward viii hospital durban between october 1983 and december 1984 were analysed to test the validity of the criteria derived from the first part of the study patients with complicated diseases￨aspiration or nonaspiration metronidazole￨￨common factors in patients with complicated diseases were determined to formulate and test indications for aspiration￨no diff￨highunclear￨highunclear￨highunclear
not found￨large amoebic liver abscess twenty nine patients of ala with a cavity larger than 5 cm￨percutaneous therapeutic needle aspiration metronidazole 800 mg tid for 10 days combined with needle aspiration metronidazole therapy alone needle aspiration percutaneous needle aspiration￨haematological and biochemical variables clinical parameters viz fever pain and abdominal tenderness mean duration of hospitalization pain intensity and abdominal tenderness￨reduction in pain intensity and abdominal tenderness from grade 2 to 1 also occurred earlier in group a 07￨sig decrease￨highunclear￨highunclear￨highunclear
57￨41 patients uncomplicated amebic liver abscess 57 patients admitted for suspected amebic liver abscess during a 15month period sixteen patients were excluded from the trial uncomplicated amebic liver abscess￨amebicidal therapy alone or amebicidal therapy coupled with imageguided percutaneous therapeutic aspiration percutaneous therapeutic aspiration￨subjective improvement in symptoms after aspiration length of hospitalization and duration of time to becoming afebrile￨no statistically significant benefit was demonstrated in the aspiration group for the two objective parameters evaluated length of hospitalization and duration of time to becoming afebrile￨no diff￨highunclear￨highunclear￨highunclear
39￨thirtynine patients with amoebic liver abscess ala admitted to the central hospital of hué vietnam adult patients with an abscess located in the right liver lobe and an abscess diameter of 6 to 10 cm were included nineteen patients were treated with￨metronidazole metronidazole alone or in combination with ultrasoundguided needle aspiration￨clinical symptoms fever pain in right upper abdomen and liver tenderness and the laboratory parameters erythrocyte sedimentation rate white blood cells haemoglobin and creactive protein and the abscess size improvement of liver tenderness￨improvement of liver tenderness was significantly faster in the aspiration group during the first 3 days p  0001 whereas all the other parameters showed no differences between the two groups￨sig increase￨highunclear￨highunclear￨highunclear
33￨amoebic liver abscesses amoebic liver abscess 33 patients with clinically serologically and ultrasonographically confirmed amoebic liver abscess￨percutaneous drainage in combination with medicamentous therapy metronidazole and chlorochin or a combination of medicamentous therapy and percutaneous drainage￨shorter duration of amoebic liver abscess resolution time￨shorter duration of amoebic liver abscess resolution time in the group of patients treated with the combined therapy was observed particularly in the first four weeks of the treatment￨sig decrease￨highunclear￨highunclear￨highunclear
48￨48 women with chronic pelvic pain women with chronic pelvic pain people with health problems￨written disclosure written emotional disclosure disclosure writing￨health status evaluative pain intensity ratings stressful consequences of their pain disclosure or positive events control outcome variables sensory or affective pain disability affect￨compared with control writing disclosure led to less disability among women with higher baseline ambivalence over emotional expression or higher catastrophizing and to increased positive affect among women with higher baseline negative affect￨sig decrease￨highunclear￨highunclear￨highunclear
106￨twenty percent of the patients had had negative sexual experiences such as childhood sexual abuse or rape women with chronic pelvic pain one hundred six patients with chronic pelvic pain￨laparoscopy￨pelvic pain organic causes of pelvic pain postcoital pain￨both groups were similar with respect to clinical characteristics of the patients and the severity of their pain as assessed by various pain parameters￨no diff￨highunclear￨highunclear￨highunclear
not found￨chronic pelvic pain in women women university hospital gynaecology clinic women with pelvic pain of at least 6 months duration were eligible￨lofexidine hydrochloride lofexidine placebo alpha2adrenoceptor agonist lofexidine hydrochloride￨vas chronic pelvic pain diary vas summary and daily diary visual analog scales for pain vas and a 5 point self rating scale￨919 women randomized to lofexidine completed the study compared to 1420 of those randomized to placebo￨sig increase￨low￨low￨low
116￨patients with adhesions and chronic abdominal pain 116 patients enrolled for diagnostic laparoscopy 100 were randomly allocated either patients with chronic abdominal pain￨laparoscopic adhesiolysis or no treatment laparoscopic adhesiolysis diagnostic laparoscopy laparoscopic adhesiolysis 52 or no treatment￨quality of life substantial pain relief vas score chronic abdominal pain pain visual analogue score vas score scale 0100 pain change score use of analgesics and quality of life score￨both groups reported substantial pain relief and a significantly improved quality of life but there was no difference between the groups mean change from baseline of vas score at 12 months difference 3 points p053 95 ci 7 to 13￨no diff￨low￨low￨low
12￨12 women with evidence of pelvic congestion young women￨intravenous dihydroergotamine placebo dihydroergotamine dhe intravenous saline￨pelvic veins pelvic congestion with pain pelvic congestion pain relief intensity of pain pelvic congestion and pelvic pain pain￨after dhe there was a mean reduction of 35 in the diameter of the pelvic veins measured and the contrast medium cleared rapidly with a visible reduction in pelvic congestion￨sig decrease￨highunclear￨highunclear￨highunclear
84￨pelvic congestion lower abdominal pain due to pelvic congestion women with pain associated with demonstrable pelvic congestion eightyfour women with abnormal pelvic venography￨mpa alone mpa plus psychotherapy placebo alone and placebo plus psychotherapy placebo medroxyprogesterone acetate and psychotherapy medroxyprogesterone acetate mpa psychotherapy mpa￨visual analogue scale pain score pain score￨during treatment mpa showed a significant benefit in terms of a reduction in visual analogue scale pain score with 73 of women reporting at least 50 improvement compared with 33 of those treated with placebo￨sig increase￨highunclear￨highunclear￨highunclear
23￨women with chronic pelvic pain 23 women from a general gynecology clinic to either doubleblind￨sertraline placebo sertraline or placebo￨psychological function pain and functional disability pain or functional disability￨there were no significant improvements in pain or functional disability noted on sertraline compared to placebo￨no diff￨low￨low￨low
47￨pelvic congestion 47 patients with pure pelvic congestion syndrome patients with chronic pelvic pain symptomatic patients complaining of chronic pelvic pain and in a totally asymptomatic group of patients requesting tubal ligation￨goserelin acetate medroxyprogesterone acetate mpa goserelin goserelin acetate versus medroxyprogesterone acetate goserelin and medroxyprogesterone acetate￨severe pelvic signs and symptom scores lowest rates of sexual functioning psychological status and sexual functioning sexual functioning and reduction of anxiety and depressive states pelvic venographic improvement￨at 1 year after treatment goserelin remained superior to mpa in terms of pelvic venographic improvement as an objective measure￨sig increase￨highunclear￨highunclear￨highunclear
48￨women with light or moderate degree pelvic adhesions department of gynecology leiden university medical center the netherlands 24 women patients with intraperitoneal adhesions and chronic pelvic pain women with pelvic adhesions 48 women known by laparoscopy to have stage iiiv pelvic adhesions￨surgical adhesiolysis and 24 to a control group who did not have surgery surgery adhesiolysis with no surgery￨pelvic pain pelvic pain assessed by the mcgill pain score subjective pain assessment and disturbance of daily activities￨after 912 months there were no significant differences between the two groups overall with regard to pelvic pain￨no diff￨highunclear￨highunclear￨highunclear
35￨amyotrophic lateral sclerosis 35 sporadic amyotrophic lateral sclerosis sals patients￨glutathione peroxidase selenium supplementation exogenously administered selenium se antioxidants amino acids a ca2 channel blocker such as nimodipine￨superoxide dismutase cuzn sod catalase cat glutathione reductase gr activity of both gshpx and cuzn sod disturbed oxidativeantioxidative balance activity of glutathione peroxidase gshpx activity of gshpx￨the results revealed significantly decreased activity of both gshpx and cuzn sod in sals patients compared with the control￨sig decrease￨highunclear￨highunclear￨highunclear
133￨one hundred four patients 53 in the selegiline group and 51 in the placebo group completed the 6month trial 133 patients with classical als and symptoms for less than 3 years 133 patients 67 were randomized to receive patients with als￨placebo selegiline hydrochloride eldepryl selegiline￨rate of clinical progression or outcome of als cell death rate of progression appel als total score rate of change of the appel als total score an index of disease severity that incorporates strength and function in limbs respiratory function and bulbar function adverse reaction worsening depression baseline characteristics and mean appel als total score monthly rate of change￨both groups were comparable for baseline characteristics and mean appel als total score 705 points for the selegiline group and 706 for the placebo group￨no diff￨low￨low￨low
110￨one hundred ten consecutive patients who fulfilled the diagnostic criteria for amyotrophic lateral sclerosis followed up at monthly intervals for 12 months amyotrophic lateral sclerosis patients with amyotrophic lateral sclerosis￨acetylcysteine or placebo placebo radical scavenging agent acetylcysteine acetylcysteine￨survival and disease progression 12month survival rates of disease progression still alive survival muscle strength pulmonary function disability and bulbar function￨rates of disease progression as expressed by decline in muscle strength pulmonary function disability and bulbar function were similar in both groups￨sig increase￨low￨low￨low
289￨two hundred and eightynine patients with als of less than 5 years duration treated with amyotrophic lateral sclerosis￨placebo antioxidant vitamin e alphatocopherol alphatocopherol riluzole alphatocopherol vitamin e alphatocopherol or placebo als riluzole￨severe state b biochemical markers of oxidative stress rate of deterioration of function assessed by the modified norris limb scale survival and motor function als health state scale plasma levels of thiobarbituric acid reactive species biochemical markers of oxidative stress survival glutathione peroxidase activity in plasma patients given alphatocopherol￨after 3 months treatment analysis of oxidative stress markers showed an increase in glutathione peroxidase activity in plasma p  00389 and a decrease in plasma levels of thiobarbituric acid reactive species p  00055 in the group of patients given alphatocopherol in combination with riluzole￨sig increase￨low￨low￨low
not found￨amyotrophic lateral sclerosis als￨coenzyme q10 coq10 coq10 placebo￨als functional rating scalerevised alsfrsr score￨the primary outcome in both stages was a decline in the als functional rating scalerevised alsfrsr score over 9 months￨no diff￨low￨low￨low
10￨10 patients suffering from amyotrophic lateral sclerosis amyotrophic lateral sclerosis￨placebo selective and irreversible monoamine oxidaseb maob inhibitor￨maob activity in blood platelets￨in the preliminary analysis performed so far no obvious retardation in the progress of the disease could be observed with deprenyl treatment￨no diff￨highunclear￨highunclear￨highunclear
not found￨lowbirthweight infants who are breastfed special care nursery with followup telephone calls after discharge from the hospital fifty infants with birth weights less than 1500 g and whose mothers planned to breastfeed randomized to 2 groups￨skintoskin contact with standard contact maternalinfant skintoskin contact ssc vs standard contact sc ssc experimental and sc control￨infant physiological data ie oxygen saturation heart rate respiratory rate and axillary temperature maternal milk production and duration of breastfeeding lowbirthweight infants physiological profile maternal milk production and duration of breastfeeding oxygen saturation infant temperature heart rate or respiratory rate stable milk production￨oxygen saturation was higher during ssc than during sc p  001 11 of the oxygen saturation recordings during ssc vs 24 during sc indicated the values less than 90 p  001￨sig increase￨highunclear￨highunclear￨highunclear
28￨of very low birth weight neonates very low birth weight infants kangaroo mother care by nurses and mothers babies whose birth weight was less than 1500 grams were included in the study once they were stable 28 neonates￨kangaroo mother care kmc kangaroo mother care standard care incubator or open care system kmc kangaroo￨weight gain earlier hospital discharge weight gain earlier hospital discharge number of mothers exclusively breastfeeding their babies breast feeding rates weight gain and length of hospitalization￨kmc managed babies had better weight gain earlier hospital discharge and more impressively higher exclusive breastfeeding rates￨sig increase￨highunclear￨highunclear￨highunclear
71￨babies less than 1500 g seventy one infants were randomised very low birthweight infants and their mothers￨￨￨separation between mothers and very low birthweight infants is often prolonged with subsequent psychological distress behaviour problems and lactation failure￨no diff￨highunclear￨highunclear￨highunclear
62￨low birthweight infants in addis ababa ethiopia sixtytwo infants were enrolled as kangaroo mother care kmc and the remaining 61 were conventional method of care cmc cases 259 babies weighing less than 2000 g during the study period and a total of 123 475 per cent low birthweight infants kangaroo mother care￨kmc early kangaroo mother care early kangaroo mother care￨survival majority of deaths mean birthweight cmc babies died￨cmc babies died during the study p005 and ci of 95 per cent￨no diff￨highunclear￨highunclear￨highunclear
not found￨infants with lbw  2000 g who satisfied outofrisk criteria of tolerance of food and weight stabilisation stabilised lowbirthweight infants isidro ayora maternity hospital in quito ecuador￨kmm and control standard incubator care kmm￨cost of care serious illness lowerrespiratorytract disorders apnoea aspiration pneumonia septicaemia general infections deaths unscheduled clinic visits severe morbidity mortality￨during 6 months of followup the kmm group had a significantly lower rate than the control group of serious illness lowerrespiratorytract disorders apnoea aspiration pneumonia septicaemia general infections 7 5 vs 27 18 p  0002 although differences between the groups in less severe morbidity were not significant￨sig decrease￨highunclear￨highunclear￨highunclear
146￨verylowbirthweight vlbw 1501 g infants with or without exposure to short duration of skintoskin contact stsc during their stay in a neonatal intensive care unit one hundred and fortysix infants were randomised but only 126 were enrolled stsc group n  64 controls n  62 vlbw infants stable vlbw infants￨stsc￨mean duration of maternal education head circumference breastfeeding rate at discharge number of years of maternal education weight gain and head growth￨infants in the stsc group had better mean weekly increase in head circumference 10 cm sd  03 vs 07 cm sd  03 p  00001 and higher breastfeeding rate at discharge 297 vs 145 p  004￨sig increase￨highunclear￨highunclear￨highunclear
30￨premature and smallforgestationalage infants thirty motherinfant dyads in two australian neonatal nurseries￨ccc kangaroo mother care kmc and conventional cuddling care ccc kmc kangaroo mother care and conventional cuddling care￨parental stress scale nicu equal weight gain equal length of stay in the hospital and equal duration of breastfeeding infant weight gain temperature maintenance during kmc and ccc and length of hospital stay￨the results showed no difference between groups on the parental stress scale nicu or the parental expectations survey￨no diff￨highunclear￨highunclear￨highunclear
73￨73 infants intervention 37 control 36 were included lbw infants at a referral hospital in madagascar stable lowbirthweight infants￨earlier continuous kangaroo mother care kmc earlier versus later continuous kangaroo mother care kmc￨incidence of morbidities body weight loss adverse events and duration of hospitalization mortality￨body weight loss from birth to 24 h postbirth was significantly less in earlier kmc infants compared with later kmc infants￨sig decrease￨low￨low￨low
not found￨infants who met eligibility criteria or32 wk of gestation or1500 g minimal ventilatory support and hemodynamically stable infants receiving skintoskin care ssc grew more rapidly and had a shorter duration of hospital stay compared with infants held by their parents in a traditional way￨traditional holding th or ssc skintoskin care versus traditional holding￨weight accretion or linear growth head growth￨no significant differences were observed in weight accretion or linear growth￨no diff￨highunclear￨highunclear￨highunclear
110￨low birth weight infants over 16 month period 110 neonates mean gestational age was 3548￨kangaroo mother care group and control group using a random number table standard care incubator or open care system kmc kangaroo mother care kmc￨duration of kmc mean birth weight duration of hospital stay care taking activities like bathing diapering sleeping with their babies and spent more time beyond usual care taking total attachment score￨the total attachment score 2446164 in the kmc group was significantly higher than that obtained in control group 1822179 p 0001￨sig increase￨highunclear￨highunclear￨highunclear
206￨206 neonates with birth weight low birth weight infants lbw babies  2000 g￨cmc conventional care kangaroo mother care kmc and conventional methods of care cmc intervention group kmc103 received kangaroo mother care kmc kangaroo mother care￨growth and reduces morbidities level iii nicu average daily weight gain hypothermia hypoglycemia and sepsis average weight gain per day kmc time to discharge head circumference￨the weekly increments in head circumference kmc 075 cm vs cmc 049 cm p  002 and length kmc 099 cm vs cmc 07 cm p  0008 were higher in the kmc group￨no diff￨highunclear￨highunclear￨highunclear
not found￨newborn infants 2000 grams 1084 newborns 2000 all newborn infants 2000￨kangaroo mother care kmc kmc kangaroo mother versus traditional care￨nosocomial infections mortality infectious episodes hospital stay after eligibility and growth and feeding patterns growth indices hospital stay risk of dying￨hospital stay after eligibility was shorter in kmc primarily for infants￨sig increase￨low￨low￨low
65￨fifty percent of infants were male and 50 were nonwhite healthy preterm infants by their mothers during the early weeks of the infants life facilitated coregulation between mother and infant at 6 months of age sixtyfive motherinfant dyads with mean gestational age at birth of 33 weeks￨brief social visits had no holding constraints and participated in all assessments uninterrupted holding with either blanket baby wrapped in blanket and held in mothers arms or the kangaroo baby in skintoskin contact on mothers chest method supportive nursing intervention￨coregulation behavior coregulation of the dyads responses during the play episodes of the stillface paradigm and vitality in infant efforts to reengage the mother during the neutral face portion of the stillface procedure￨post hoc analysis showed that dyads who were supported in kangaroo holding displayed more coregulation behavior during play than dyads in the blanketholding group￨sig increase￨highunclear￨highunclear￨highunclear
89￨mothers admitted in hospitals kangaroo mother care in mumbai fortyfour babies 89 neonates￨kangaroo care cmc kangaroo mother care kmc and conventional method of care cmc hypothermia kmc￨respiratory rates incidence of hyperthermia sepsis apnea onset of breastfeeding and hospital stay higher oxygen saturations￨there were no statistically significant differences in the incidence of hyperthermia sepsis apnea onset of breastfeeding and hospital stay in two groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨1 y in three tertiary and teaching hospitals in addis ababa ethiopia yogyakarta indonesia and merida mexico hospital kmc for stabilized lbwi 10001999 low birthweight infants 649 low birthweight infants lbwi 10001999 g died before eligibility￨kmc kangaroo mother care￨mean daily weight gain incidence of severe disease hypothermia effectiveness feasibility acceptability and cost of kangaroo mother care kmc￨exclusive breastfeeding at discharge was more common in kmc infants in merida 80 vs 16 and overall 88 vs 70￨sig increase￨highunclear￨highunclear￨highunclear
141￨141 patients were included in the study hirsutism related to polycystic ovary syndrome patients who were referred to our reproductive endocrinology outpatient clinic because of complaints of hirsutism polycystic ovary syndrome￨cyproterone acetate oral contraceptive containing 2 mg cyproterone acetate pelvic ultrasonography spironolactone lowdose combined oral contraceptive ketoconazole cyproterone oral contraceptive and spironolactone￨decrement level in hirsutism scoring sideeffects hirsutism scoring and lipid and hormonal levels free testosterone levels highdensity lipoproteincholesterol levels￨the free testosterone levels decreased after treatment in all groups but the decrement ratios did not differ significantly among groups although the decrease in free testosterone levels with treatment seemed to be higher in the ketoconazole group than in groups 1 2 and 3 570￨no diff￨highunclear￨highunclear￨highunclear
45￨fortyfive hirsute women were enrolled in the study 29 were hyperandrogenic and 16 had idiopathic hirsutism hirsutism department of obstetrics and gynecology university of pisa pisa italy￨cpa 25 mg plus ethinyl e2 ee n  13 or flutamide cpa plus ee finasteride antiandrogen with progestational activity flutamide a nonsteroidal antiandrogen and finasteride finasteride cpa and flutamide cyproterone acetate cpa finasteride flutamide and cpa finasteride￨levels of total and free t androstenedione a dheas sex hormonebinding globulin dihydrotestosterone and 3alphaandrostanediol glucuronide total t levels ferrimangallwey score levels of total and free t a dihydrotestosterone and 3alphaandrostanediol glucuronide hirsutism score hirsutism￨finasteride cpa and flutamide are equally effective in decreasing hirsutism despite different mechanisms of action￨no diff￨highunclear￨highunclear￨highunclear
22￨hirsutism twentytwo women with idiopathic hirsutism￨flutamide and cyproterone acetate cyproterone acetate flutamide flutamide or cyproterone acetate￨hirsutism scores ferrimangallwey scores levels of testosterone sex hormonebinding globulin￨ferrimangallwey scores were decreased significantly in both groups at the end of 9 months￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨hirsutism fortytwo premenopausal patients with hirsutism were selected￨spironolactone and an oral contraceptive oc containing 150 microg desogestrel and 30 microg ethinyl e2 or 50 mg cpa spironolactone and cpa spironolactoneoral contraceptive versus cyproterone acetateestrogen regimens spironolactone cyproterone acetate cpa and spironolactone￨hirsutism scores hirsutism scores￨hirsutism scores were decreaded significantly in both groups at the end of 9 months￨sig increase￨highunclear￨highunclear￨highunclear
48￨hirsutism 48 hirsute women￨sequential cyproterone acetateestrogen versus spironolactoneoral contraceptive spironolactone and cpa spironolactone antiandrogen drugs cyproterone acetate cpa and spironolactone concomitant estrogen therapy￨hair diameter milder side effects hair growth and androgen levels plasma testosterone levels diameter of the hair medulla fell total hair diameter fell￨measured objectively total hair diameter fell by 171 with spironolactone p less than 0001 and by 168 with cpa p less than 0001￨sig decrease￨highunclear￨highunclear￨highunclear
39￨thirtynine hirsute women with idiopathic or functional ovarian hyperandrogenism hirsutism thirtythree patients completed the 9month study period￨triptorelin cpa or flutamide triptorelin cpa and flutamide triptorelin triptorelin cyproterone acetate cpa and flutamide in combination with an oral contraceptive flutamide flutamide triphasic oral contraceptive cpa longacting gonadotropinreleasing hormone agonist triptorelin flutamide and cyproterone acetate￨hirsutism scores serum lipid concentrations ferrimangallwey score hepatic function and gonadal and adrenal steroid profiles ferrimangallwey score hirsutism score￨triptorelin has no advantages over flutamide and cpa and is the most expensive of the three drugs tested￨no diff￨highunclear￨highunclear￨highunclear
10￨polycystic ovarian disease 10 patients with polycystic ovarian disease pco￨lhrh superagonist dtrp6lhrh cyproterone acetate or a longacting gonadotropinreleasing hormone agonist cyproterone acetate cpa￨basal and stimulated gonadotropin levels urinary 3 alphaandrostanediol and plasma dehydroepiandrosterone sulfate levels dehydroepiandrosterone sulfate fell into the castrate range urinary 3 alphaandrostanediol excretion complete gonadotropin inhibition basal plasma gonadotropin levels plasma estrogen and androgen levels plasma estradiol estrone testosterone and androstenedione levels acne and seborrhoea and normalization of ovarian size￨plasma estradiol estrone testosterone and androstenedione levels significantly decreased but urinary 3 alphaandrostanediol and plasma dehydroepiandrosterone sulfate levels did not change significantly￨sig increase￨highunclear￨highunclear￨highunclear
116￨parkinsons disease onehundredandsixteen patients early parkinsonian patients treated with￨placebo selegiline and levodopa selegiline or placebo levodopa selegiline￨median time to reach￨longterm side effects appeared later in the selegiline group although the difference was not significant￨no diff￨low￨low￨low
25￨25 newly diagnosed elderly sufferers from idiopathic parkinsonism stratified for sex and hoehn and yahr functional staging newly diagnosed idiopathic parkinsonism￨placebo selegiline monotherapy￨worsening of rigidity rigidity time course of physical and psychological responses￨no significant treatment effect was seen on the other cardinal signs￨no diff￨highunclear￨highunclear￨highunclear
201￨201 patients with early untreated parkinsons disease pd early parkinsons disease patients n  321￨lazabemide placebo lazabemide￨frequency of adverse experiences progression of disability￨the frequency of adverse experiences did not differ among the treatment groups￨no diff￨highunclear￨highunclear￨highunclear
782￨between 1985 and 1990 782 patients with denovo pd patients with early mild pd was evaluated by the pd research group of the united kingdom pdrguk￨dopamine agonist bromocriptine levodopa plus dopa decarboxylase inhibitor levodopa plus decarboxylase inhibitor and selegiline or bromocriptine levodopa bromocriptine￨mortality disability and adverse events disability scores rates of dystonias and onoff fluctuations severe dyskinesias pretreatment disability levels motor complications incidence of dyskinesias mortality mortality in pd￨patients randomized to bromocriptine had a significantly lower incidence of dyskinesias than those randomized to levodopa rate ratio 073￨sig decrease￨highunclear￨highunclear￨highunclear
41￨patients with mild parkinsons disease pd one hundred one untreated pd patients patients with early pd￨deprenyl and levodopa placebo placebo deprenyl and levodopacarbidopa sinemet placebodeprenyl  bromocriptine placebodeprenyl  sinemet group iii deprenyl  bromocriptine bromocriptine￨updrs score extent of deterioration deterioration in unified parkinsons disease rating score updrs￨no difference in the extent of deterioration was detected in patients randomized to sinemet versus bromocriptine￨no diff￨highunclear￨highunclear￨highunclear
44￨44 patients with pd needing levodopa therapy after the initial doubleblind treatment with parkinsons disease pd￨placebo selegiline therapy selegiline levodopa selegiline combined with levodopa placebo or selegiline￨parkinsonian disability initiation of additional dopaminergic therapy therapeutic efficacy mortality occurrence of motor fluctuations￨selegiline induced a significant p  0001 slowing in the need to increase the daily levodopa dose in order to compensate for the progression of the disease￨sig decrease￨highunclear￨highunclear￨highunclear
157￨140 patients received parkinson disease pd one hundred fiftyseven de novo pd patients￨levodopa placebo levodopa therapy vs placebo selegiline or placebo￨safe and well tolerated updrs total score mean dosage of levodopa progression of disease disability unified parkinson disease rating scale updrs total score activities of daily living￨compared with placebo selegiline slowed the progression of disease disability as measured by the unified parkinson disease rating scale updrs total score p  0003 or by motor p  0002 and activities of daily living p  00002 subscores￨sig decrease￨highunclear￨highunclear￨highunclear
54￨fiftyfour patients patients with early parkinsons disease￨mptp 1methyl4phenyl1236tetrahydropyridine placebo deprenyl selegiline placebo treatment groups and followed until ldopa therapy￨disease progression average time until ldopa kaplanmeier survival curves￨analysis of kaplanmeier survival curves for each group showed that deprenyl delayed the need for ldopa therapy the average time until ldopa was needed was 3121 days for patients in the placebo group and 5489 days for patients in the deprenyl group￨sig increase￨highunclear￨highunclear￨highunclear
163￨one hundred and sixtythree patients with early pd parkinsons disease pd￨placebo levodopa and benserazide combined with selegiline or placebo selegiline or placebo levodopa selegiline copyright lippincott williams  wilkins levodopa and placebo￨severity of parkinsonism levodopa requirements and the development of endofdose motor fluctuations severe parkinsonism￨results indicated that patients treated with the combination of selegiline and levodopa developed markedly less severe parkinsonism and required lower doses of levodopa during the fiveyear study period than patients treated with levodopa and placebo￨sig decrease￨highunclear￨highunclear￨highunclear
624￨624 patients with early parkinsons disease who were not receiving dopaminergic treatment and a subgroup fo 120 patients who died during the trial patients who were recruited from 93 hospitals between 1985 and 1990 and who had died before december 1993 in arms 1 and 2 patients with early mild parkinsons disease 520 subjects in arms 1 and 2 and for 104 subjects patients with newly diagnosed parkinsons disease￨levodopa and selegiline levodopa and selegiline treatment levodopa and a dopa carboxylase inhibitor levodopa and a dopa decarboxylase inhibitor in combination with selegiline arm 2 or bromocriptine alone arm 3￨revised diagnosis disability rating scores autonomic or cardiovascular events other clinical features or drug interactions excess mortality possible dementia and a history of falls before death hazard ratio￨cause specific death rates showed an excess of deaths from parkinsons disease only hazard ratio 25 13 to 47￨sig increase￨low￨low￨low
800￨early parkinsons disease￨tocopherol and deprenyl placebo active tocopherol and deprenyl placebo active deprenyl and tocopherol placebo or both active drugs tocopherol deprenyl a monoamine oxidase inhibitor and tocopherol a component of vitamin e that traps free radicals￨onset of disability prompting the clinical decision to begin administering levodopa ratings for parkinsons disease motor performance￨the ratings for parkinsons disease improved during the first three months of deprenyl treatment the motor performance of deprenyltreated patients worsened after the treatments were withdrawn￨sig increase￨low￨low￨low
224￨twentythree children were excluded from the final analysis because they did not complete the study febrile children two hundred and twentyfour children aged 6 months to 5 years with rectal temperatures greater than or equal to 30 degrees 104 degrees f￨sponging alone or with medication including a single oral dose of aspirin 15 mgkg or paracetamol 15 mgkg or ibuprofen sponging and antipyretic medication aspirin and ibuprofen￨antipyretic efficacy rectal temperatures￨during the first 30 min of intervention sponging was found to be more effective than all of the three medications￨sig decrease￨highunclear￨highunclear￨highunclear
52￨feverish children at home homes of willing families with a feverish child recruited after consulting one of 21 participating general practitioners in southampton feverish illness at home 52 children aged from 3 months to 5 years with axillary temperatures before treatment of  or  378 degrees c and  40 degrees c
                response to advice assessed over four hours temperature assessed by continuous data logging from an axillary thermistor acceptability of treatment to child and parent scored on likert scales immediately after treatment and on return to health￨unwrapping warm sponging plus unwrapping paracetamol plus unwrapping and paracetamol and warm sponging plus unwrapping paracetamol paracetamol paracetamol or warm sponging treatments￨￨paracetamol increased the time below 372 degrees c in four hours by 109 95 confidence interval 74 to 145 minutes compared with unwrapping warm sponging caused the fastest reduction in temperature￨sig decrease￨highunclear￨highunclear￨highunclear
225￨young children 225 children 6 months to 6 years of age who presented with acute less than or equal to 4 days fever greater than or equal to 38 degrees c per rectum without evident bacterial focus of infection young children with fever of presumed viral origin￨placebo paracetamol paracetamol antipyresis paracetamol liquid 1015 mgkg or placebo paracetamol￨alertness activity mean duration of subsequent fever mood comfort appetite or fluid intake￨there were no significant differences between treated and placebo groups in mean duration of subsequent fever 347 vs 361 h or other symptoms 729 vs 717 h￨no diff￨low￨low￨low
127￨febrile children children n  34 in 127 children 2 to 11 years of age with fever 101 degrees to 104 degrees f￨ibuprofen suspension 10 mgkg acetaminophen elixir placebo ibuprofen acetaminophen and placebo ibuprofen suspension acetaminophen placebo liquids ibuprofen ibuprofen￨antipyretic efficacy percentage of fever reduction blood samples oral temperatures pulse blood pressure and respiration efficacy tolerability safety tolerated clinical or laboratory abnormalities￨antipyretic efficacy for temperatures greater than 1025 degrees f was 10 mgkg ibuprofen greater than 5 mgkg greater than 10 mgkg acetaminophen greater than placebo￨sig increase￨highunclear￨highunclear￨highunclear
178￨children less than 6 years of age who had an initial temperature of at least 388 degrees c 1019 degrees f febrile children 178 children aged 3 months to 12 years children￨ibuprofen vs acetaminophen placebo ibuprofen ibuprofen and acetaminophen antipyresis￨antipyretic response efficacy￨ibuprofen 5 mgkg was minimally effective in children less than 6 years of age who had an initial temperature of at least 388 degrees c 1019 degrees f￨sig increase￨highunclear￨highunclear￨highunclear
80￨febrile children was undertaken at the queen elizabeth central hospital blantyre eighty children aged between 6 and 54 months with axillary temperatures of between  or  385 degrees c and  or  40 degrees c and a clinical diagnosis consistent with upper respiratory tract infection andor malaria febrile children children receiving tepid sponging were sponged from head to toe except the scalp by leaving a thin layer of water on the body￨oral paracetamol paracetamol paracetamol tepid sponging versus paracetamol￨rapid reduction of fever body temperature discomfort convulsions crying irritability vomiting and shivering￨paracetamol is clearly more effective than tepid sponging in reducing body temperature in febrile children in a tropical climate￨sig increase￨highunclear￨highunclear￨highunclear
50￨plasmodium falciparum malaria children with infectious diseases children with plasmodium falciparum malaria receive 50 children with p falciparum malaria￨mechanical antipyresis alone or in combination with paracetamol intravenous quinine paracetamol routine antipyretic therapy￨parasite clearance time induced concentrations of tnf and the production of oxygen radicals rectal body temperature and parasitaemia production of oxygen radicals plasma concentrations of tnf and interleukin6 parasite clearance time mean fever clearance time production of tnf and oxygen radicals plasma concentrations and inducible concentrations of tumour necrosis factor tnf and interleukin6￨however the induced concentrations of tnf and the production of oxygen radicals were significantly lower in children treated with paracetamol than those who received mechanical antipyresis alone￨sig decrease￨highunclear￨highunclear￨highunclear
37￨37 otherwise healthy children aged 2 to 12 years with acute intercurrent febrile illness emergency department and inpatient units of a large metropolitan universitybased childrens hospital in michigan￨ibuprofen placebo and acetaminophen placebo acetaminophen ibuprofen vs acetaminophen ibuprofen ibuprofen￨antipyretic efficacy antipyretic efficacy adverse effects oral temperature temperature decrement and longer duration of antipyresis￨ibuprofen provided greater temperature decrement and longer duration of antipyresis than acetaminophen when the two drugs were administered in approximately equal doses￨sig increase￨low￨low￨low
73￨seventythree children with acute febrile illnesses febrile young patients￨acetaminophen and acetaminophen sponging vs acetaminophen acetaminophen￨smallest temperature reduction reduction of fever greatest temperature reduction￨the greatest temperature reduction was seen in the combined acetaminophen plus sponging group￨sig increase￨highunclear￨highunclear￨highunclear
72￨seventytwo children between 1 and 12 years of age entered the study￨acetaminophen acetaminophen placebo placebo￨activity itching appetite activity and overall condition time to last vesicle formation time to total scabbing and time to total healing time to total scabbing duration or severity of childhood varicella￨the following results were better in the placebo group p less than 05 time to total scabbing 56 days sd 25 versus 67 days sd 23 in the acetaminophen group and itching on day 4 in the placebo group symptom score 29 sd 020 vs 22 sd 026￨sig decrease￨low￨low￨low
53￨peptic ulcer with helicobacter pylori fiftythree patients suffering from gastroduodenal peptic ulcer with helicobacter pylori￨metronidazole 500 mg every 8 h plus tetracycline colloidal bismuth subcitrate qulcer amoxicillin metronidazole colloidal bismuth subcitrate cbs￨ulcerous healing helicobacter pylori eradication highest clearing index￨the three schemes of treatment were effective for ulcerous healing with 705 823 and 782 respectively without significant differences￨no diff￨highunclear￨highunclear￨highunclear
not found￨thirty two patients with helicobacter pylori positive duodenal ulcers resistant to treatment helicobacter pylori positive resistant duodenal ulcers treated with patients with unhealed ulcers patients with healed ulcers￨tinidazole colloidal bismuth subcitrate plus antibiotics or sucralfate alone colloidal bismuth subcitrate plus antibiotics sucralphate 4 gday or colloidal bismuth subcitrate 480 mgday plus amoxycillin￨h pylori eradication cumulative relapse rates complete healing rates overall healing rates￨cumulative relapse rates at 12 months were 12 two of 17 in patients in whom h pylori had been eradicated and 100 10 of 10 in those with persistent infection after short term therapy p  005￨no diff￨highunclear￨highunclear￨highunclear
155￨155 patients with h pylori and a duodenal ulcer verified endoscopically which had either bled within the previous 24 hours or was causing dyspepsia patients with duodenal ulcer￨omeprazole bismuth 120 mg tetracycline 500 mg and metronidazole bismuth tetracycline and metronidazole￨duodenal ulcers number of duodenal ulcers presence or absence of h pylori by urease testing microscopy and culture of antral biopsy specimens duodenal ulcer and side effects eradication of h pylori mild dizziness￨duodenal ulcers were found in four 5￨no diff￨low￨low￨low
104￨patients with recurrent duodenal ulcer 104 patients with h pylori infection and recurrent duodenal ulcer with either￨placebo bismuth therapy identicalappearing placebos amoxicillin metronidazole ranitidine and amoxicillin plus metronidazole ranitidine￨helicobacter pylori and the recurrence of duodenal ulcer side effects mainly diarrhea ulcers duodenal ulcers￨among the 52 patients given antibiotics h pylori was eradicated in 46 as compared with 1 of the 52 given placebo 89 percent vs 2 percent p  0001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨helicobacter pyloriinfected gastric ulcer patients eightysix h pyloripositive gastric ulcer patients helicobacter pyloriinfected gastric ulcer patients by combination therapies￨lpz 30 mg plus clarithromycin proton pump inhibitor lansoprazole lpz lpz 30 mg plus plaunotol amoxicillin lpz 30 mg plus ecabet sodium omeprazole lpz 30 mg plus plaunotol 480 mg plus clarithromycin lpz 30 mg plus ecabet sodium 2￨h pylori eradication rates￨h pylori eradication rates as diagnosed by culture histology urease test and 13curea breath test 4 weeks after stopping therapy were 0 0 8 45 6 46 and 62 respectively in groups ivii￨no diff￨highunclear￨highunclear￨highunclear
26￨26 patients with duodenal ulcers refractory to treatment with h2receptor antagonists for 812 weeks patients with refractory duodenal ulcers six patients on bismuth whose ulcers remained unhealed or relapsed early after healing￨helicobacter pylori infection treatment colloidal bismuth subcitrate metronidazole tetracycline hydrochloride￨healing and longterm relapse rates helicobacter pylorinegative ulcer relapse ulcer healing ulcers healed￨on bismuth only one patient became helicobacter pylorinegative 833 p  00001 but ulcers healed in 812 patients 67 p  ns￨no diff￨highunclear￨highunclear￨highunclear
76￨patients with duodenal ulcer one hundred twentytwo patients￨colloidal bismuth subcitrate amoxicillin plus metronidazole ranitidine amoxicillin metronidazole amoxicillin and metronidazole ranitidine￨rates of h pylori eradication ulcers reinfection rates early reinfection and ulcer recurrence￨reinfection rates at 6 months were 421 and 151 in groups b and c respectively p  05￨no diff￨highunclear￨highunclear￨highunclear
62￨sixtytwo patients with active duodenal ulcer which healed within 8 weeks of seven patients whose ulcer recurred after discontinuation of eleven patients whose ulcer did not heal after an 8 week￨triple therapy triple therapy nizatidine￨ulcer relapse cumulative rate of recurrence persistence of h pylori infection helicobacter pylori and reduction of duodenal ulcer relapse ulcer recurrence and h pylori infection efficacy and side effects frequency of ulcer relapse￨the cumulative rate of recurrence was significantly higher in group i than in group ii 90 vs 30 at 12 months p  001￨sig decrease￨highunclear￨highunclear￨highunclear
154￨patients with active duodenal ulcer and h pylori onehundred and fiftyfour patients patients with duodenal ulcer disease￨antimicrobial treatment placebo clarithromycin 500 mg tds or placebo omeprazole plus clarithromycin clarithromycin omeprazole with or without clarithromycin omeprazole plus clarithromycin omeprazole omeprazole plus placebo￨ulcers ulcer healed eradication of h pylori duodenal ulcer healing and ulcer recurrence recurrence of duodenal ulcer 12month recurrence incidence of sideeffects￨omeprazole plus clarithromycin dual therapy eradicated h pylori in 83 of patients with duodenal ulcer and significantly decreased 12month recurrence from 76 to 6￨sig increase￨low￨low￨low
73￨seventythree patients with endoscopically verified h pylori positive active duodenal ulcer disease￨omeprazole alone followed by longterm famotidine omeprazolebased triple eradication regimen helicobacter pylori eradication￨h pylori positive duodenal ulcer ulcer relapse rate reinfection rate h pylori reinfection and ulcer relapse￨h pylori recurred in 13 patients and the reinfection rate was 448 over two years￨no diff￨highunclear￨highunclear￨highunclear
not found￨60 patients with helicobacter pylori hp infection and duodenal ulcer du￨omeprazole omeprazole bismuth subcitrate metronidazole and amoxicillin tg or ii omeprazole￨healing￨healing was similar in both groups at two four weeks￨no diff￨highunclear￨highunclear￨highunclear
396￨patients with active or a recent history of duodenal ulcer 396 patients enrolled in the study 352 met the entry criteria for duodenal ulcer status and h pylori positivity patients with active duodenal ulcer disease or history of duodenal ulcer disease within the past year and h pylori infection￨lansoprazole with amoxicillin triple versus dual therapy lansoprazole tidamoxicillin lansoprazole monotherapy lansoprazole clarithromycin andor amoxicillin lansoprazole 30 mg clarithromycin 500 mg and amoxicillin lansoprazolebased triple therapy without additional acid suppression therapy lansoprazole bidclarithromycin clarithromycin amoxicillin lansoprazole bidamoxicillin tid clarithromycin with lansoprazole lansoprazole lansoprazole clarithromycin and amoxicillin triple therapy proton pump inhibitor and antibiotics￨ulcers eradication rates eradication of h pylori and ulcer recurrence ulcer recurrence free of ulcer efficacy and safety￨among the dual therapies higher eradication rates occurred when lansoprazole with amoxicillin or clarithromycin with lansoprazole was administered tid￨sig increase￨highunclear￨highunclear￨highunclear
160￨patients n  160 with gastric ulcer and a positive h pylori screening test gastric ulcer patients patients with active gastric ulcer patients with gastric ulcer 18 centres in germany hungary and poland￨omeprazole omeprazole 20 mg clarithromycin 500 mg and amoxycillin 1000 mg oac or omeprazole 20 mg clarithromycin 250 mg and metronidazole 400 mg omc or with omeprazole omeprazole triple therapy￨ulcer relapse urea breath test ubt and histology helicobacter pylori infection eradication rates pp gastric ulcer relapses healing and relapse of gastric ulcer safe and effective for eradication of h pylori￨eradication rates pp were oac 83 95 ci 6893 omc 93 95 ci 8098 and o 3 95 ci 013￨no diff￨highunclear￨highunclear￨highunclear
not found￨109 patients infected with h pylori who had a recently healed duodenal 83 patients or gastric ulcer 26 patients as confirmed by endoscopy patients with duodenal or gastric ulcer patients with healed ulcers who had participated in randomized controlled trials￨ranitidine plus triple therapy triple therapy plus ranitidine ranitidine therapy ranitidine tetracycline 2 g metronidazole 750 mg and bismuth subsalicylate￨ulcer recurrence healing of duodenal or gastric ulcer longterm recurrence of gastric or duodenal ulcer probability of recurrence ulcer recurrence recurrence of gastric and duodenal ulcer disease￨fifty percent of patients who received ranitidine alone for healing of duodenal or gastric ulcer had a relapse within 12 weeks of healing￨no diff￨highunclear￨highunclear￨highunclear
208￨patients with active duodenal ulcer two hundred and eight patients with active duodenal ulcer associated with confirmed h pylori infection patients with active duodenal ulcer associated with h pylori infection helicobacter pyloriassociated duodenal ulcer patients with duodenal ulcer associated with h pylori infection￨placebo clarithromycin clarithromycin and omeprazole with omeprazole monotherapy clarithromycin 500 mg or placebo omeprazole monotherapy clarithromycin and omeprazole omeprazole and placebo clarithromycin and omeprazole dual therapy omeprazole￨clarithromycin resistance ulcer recurrence￨clarithromycin and omeprazole dual therapy is simple and welltolerated and leads to consistently high eradication rates for patients with duodenal ulcer associated with h pylori infection￨no diff￨low￨low￨low
85￨85 patients endoscopically diagnosed of duodenal ulcer h pylori positive patients with ulcer healing after treatment￨placebo triple therapy omeprazole amoxicillin and clarithromycin ranitidine therapy omeprazole plus antibiotic placebo ranitidine placebo omeprazole 7days triple therapy ranitidine￨ulcer relapse ulcer healing and h pylori eradication rates eradication helicobacter pylori eradication healing rate eradication rate severity of inflammation and intestinal metaplasia relapse and gastritis outcome￨histopathological results showed statistically significant differences p  005 between eradicated and non eradicated patients in terms of severity of inflammation and intestinal metaplasia but not in terms of atrophy￨sig increase￨highunclear￨highunclear￨highunclear
56￨one hundred and fourteen duodenal ulcer patients￨triple therapy h pylori eradication clarithromycin metronidazole omeprazole￨ulcer relapse ulcer healing rate ulcer recurrence testing of h pylori status recurrence of duodenal ulcers success rate of pain control healing ulcers recurrence of duodenal ulcer endoscopic relapse eradication of h pylori infection￨the ulcer healing rate was 902 95 confidence interval 95 ci 7997 in the omeprazole group at 6 weeks as compared to 833 95 ci 7093 in the triple therapy group p  038￨no diff￨highunclear￨highunclear￨highunclear
152￨helicobacter pylori infectiongerman gastric ulcer study three university hospitals two teaching hospitals and by six practising gastroenterologists 152 patients with gastric ulcers 152 randomized patients five were excluded because of gastric cancer￨bismuth subsalicylate amoxicillin omeprazole omeprazole monotherapy tinidazole￨subsequent relapse rates gastric ulcer relapse helicobacter pylori infection gastric ulcer h pylori negative gastric ulcer disease gastric ulcer relapse rates gastric ulcer relapse￨gastric ulcer relapse was observed in 49 of patients who were h pylori positive and in 2 who were h pylori negative after treatment￨sig increase￨highunclear￨highunclear￨highunclear
270￨270 patients with an h pyloriassociated duodenal ulcer patients with duodenal ulcers￨omeprazole plus 750 mg amoxicillin placebo amoxicillin triple therapy omeprazole plus amoxicillin omeprazole and amoxicillin omeprazole omeprazole plus placebo￨cure of h pylori infection pylori cure rate cure h pylori infection cumulative 12month relapse rates cure rates of h pylori infection cure helicobacter pylori infection￨cure rates of h pylori infection were 91 in the omeprazole plus amoxicillin group 0 in the omeprazole plus placebo group and 89 and 0 respectively performing an intentiontotreat analysis￨no diff￨low￨low￨low
229￨patients with an h pyloriassociated duodenal ulcer curing helicobacter pylori and duodenal ulcers patients who are resistant to or who are unable to tolerate macrolide or imidazolecontaining therapies 132 whose ulcers had healed entered the 24week posttreatment observation phase 229 patients with confirmed h pylori infection at baseline were evaluated￨macrolide or imidazole therapy placebo alternative nonmacrolide nonimidazole treatment regimen rbc 400 mg bid for 4 weeks and placebo rbc plus amoxicillin amoxicillin ranitidine bismuth citrate rbc plus amoxicillin ranitidine bismuth citrate plus amoxicillin rbc￨h pylori status culture histology and clotest and ulcer relapse tolerated healed ulcers higher h pylori cure rates cure of h pylori infection and for healing duodenal ulcers duodenal ulcer healing￨the combination of rbc plus amoxicillin resulted in higher h pylori cure rates 55 and higher duodenal ulcer healing 74 than did either treatment alone￨sig increase￨highunclear￨highunclear￨highunclear
45￨fortyfive patients with endoscopically proven duodenal ulcers refractory to h2receptor antagonists and h pylori infection patients with duodenal ulcers refractory to h2receptor antagonists patients with healed ulcers￨omeprazole colloidal bismuth subcitrate 480 mgday plus metronidazole 750 mgday and tetracycline￨recurrence rates relapse rate rate of ulcer relapse refractory duodenal ulcer healing and relapse ulcer healing￨the relapse rate at the 3rd month was 117 217 in the triple therapy group and 60 610 in the omeprazole group p  00248￨no diff￨highunclear￨highunclear￨highunclear
105￨veterans affairs hospital one hundred and five patients with endoscopically verified duodenal ulcers duodenal ulcer healing￨antimicrobial therapy triple therapy ranitidine plus triple therapy triple therapy antibiotics plus bismuth tetracycline 750 mgd of metronidazole and 5 or 8 bismuth subsalicylate ranitidine￨ulcer healing videoendoscopic assessment of ulcer status cumulative percentages of patients with healed ulcers duodenal ulcer healing￨combined therapy with antih pylori agents and ranitidine was superior to ranitidine alone for duodenal ulcer healing￨sig increase￨highunclear￨highunclear￨highunclear
50￨50 patients with active duodenal ulcer and h pylori infection duodenal ulcer patients japan fortytwo patients completed the study￨teprenone cimetidine amoxicillin granules and 250 mg metronidazole helicobacter pylori￨histological gastritis relapse rate cumulative relapse rates h pylori eradication cumulative relapse rate healing and relapse of duodenal ulcers duodenal ulcer healing and ulcer relapse healing rates grade of gastritis and the quality of the ulcer scar white scarring￨h pylori eradication occurred in 0 of the cimetidine group and in 737 of the doubletherapy group p  0004￨no diff￨highunclear￨highunclear￨highunclear
125￨gastric ulcer patients 125 patients with gastric ulcer patients who were helicobacter pyloripositive at inclusion￨metronidazole 400 mg bid clarithromycin 250 mg bid omeprazole ome plus two antibiotics omc with omeprazole plus placebo op op ome 20 mg and placebo omc helicobacter pylori￨gastric ulcer relapse intestinal metaplasia remission gastric ulcers prevalence of h pylori eradication rate￨the prevalence of h pylori was 82 and the eradication rate 88 in the omc group and 3 in the op group￨no diff￨highunclear￨highunclear￨highunclear
149￨patients with active duodenal ulcer duodenal ulcer patients patients n  149 patients with acute duodenal ulcer using 15 centres across canada￨omeprazole triple therapies omeprazole omeprazole based triple therapy omeprazole 20 mg metronidazole 400 mg and clarithromycin 250 mg omc or omeprazole 20 mg amoxycillin 1000 mg and clarithromycin￨eradication rates helicobacter pylori ulcer healing and ulcer relapse h pylori eradication eradication and relapse rates tolerated and compliance ulcer healing intentiontotreat helicobacter pylori and ulcer healing ulcer healing safe and effective for eradication healing and the prevention of relapse￨the differences in the eradication and relapse rates between o vs omc and o vs oac were statistically significant all p  0001￨no diff￨highunclear￨highunclear￨highunclear
100￨100 consecutive patients with endoscopically established duodenal ulcer 97 with positive rapid urease test on antral biopsy specimens were admitted into the study and 81 completed the trial￨acetaminophen and antacids placebo amoxycillin and 250 mg clarithromycin metronidazole￨duodenal ulcer relapse healing of duodenal ulcer duodenal ulcer healed healing of duodenal ulcer and clearance as well as eradication of h pylori h pylori clearance and eradication identified h pylori clearance healing rates 13curea breath test clearance of h pylori￨treatment with an antibiotic only regimen was effective for the healing of duodenal ulcer and clearance as well as eradication of h pylori contributed significantly to the healing￨sig increase￨low￨low￨low
100￨patients with h pylori infection and gastric ulcers 1 patient with a recurrent ulcer who had received antibacterial treatment and in 10 of the 12 patients with recurrent ulcers a total of 100 patients patients with gastric ulcers seen on endoscopy and with h pylori infection confirmed by smear or culture gastric ulcers associated with helicobacter pylori￨antibacterial therapy without medication omeprazole antibacterial agents 120 mg of bismuth subcitrate 500 mg of tetracycline and 400 mg of metronidazole￨rate of their recurrence recurrent gastric ulcers ulcer healing mean  sd duration of pain gastric ulcers￨at five weeks h pylori had been eradicated in 41 of the 45 patients in the antibacterialtreatment group 911 percent 95 percent confidence interval 829 to 993 and in 5 of the 40 in the omeprazole group 125 percent 95 percent confidence interval 23 to 227 p  0001￨no diff￨highunclear￨highunclear￨highunclear
not found￨peptic ulcer seventyfive active pu patients with h pylori infection h pyloriassociated peptic ulcers pu￨killing helicobacter pylori quadruple therapy chinese and western integrated regimen killing helicobacter pylori quadruple therapy lansoprazole 30 mg qd plus clarithromycin 250 mg bid plus amoxycillin 500 mg tid each for 10 d 2 killing hp quadruple therapygroup b the three above drugs plus killing h pylori capsule 6 capsules bid for 4 wk and 3 placebogroup￨recurrence rate of pu eradication of h pylori and healing quality of ulcer healing quality of ulcer recurrence rate of ulcer healing rate of pu and h pylori eradication rate h pylori eradication and ulcer healing quality￨the healing quality of ulcer in group b was superior to that in groups c and a p005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨ninetysix outpatients with h pyloripositive duodenal ulcer duodenal ulcer patients duodenal ulcer patients pretreated with helicobacter pyloripositive duodenal ulcer patients￨amoxycillin 1 lansoprazoleantibiotic combinations amoxycillin or classical triple therapy amoxycillin lansoprazole alone lansoprazole 30 mg bd lansoprazole with amoxycillin lansoprazole tinidazole antibioticlansoprazole combinations amoxycillin vs standard triple therapy lansoprazole with amoxycillin or lansoprazole classical triple therapy tripotassium dicitratobismuthate 240 mg bd amoxycillin 1￨duodenal ulcer healing rates eradication of h pylori￨eradication of h pylori was significantly better with lansoprazole with triple therapy than with either lansoprazole with amoxycillin or lansoprazole alone 90 vs 55 vs 3 respectively￨sig increase￨highunclear￨highunclear￨highunclear
68￨68 patients with gastric ulcers and 51 with duodenal ulcers all were h pyloripositive japanese peptic ulcer patients￨lansoprazole plus amoxycillin acid secretion inhibitors lansoprazole and amoxycillin lansoprazole lansoprazole plus amoxycillin group lansoprazole alone regimen plus amoxycillin lansoprazole alone group lansoprazole￨curing helicobacter pylori infection and peptic ulcer recurrence curative effects on h pylori infection helicobacter pylori infection recurrence rate cure rate for h pylori infection and the ulcer recurrence rate cure rates cure rate for h pylori infection￨the cure rate for h pylori infection was 42 in patients receiving lansoprazole alone and 385 in patients receiving lansoprazole plus amoxycillin p  001 for gastric ulcers and 0 in patients receiving lansoprazole alone and 619 in patients receiving lansoprazole plus amoxycillin p  0001 for duodenal ulcers￨no diff￨highunclear￨highunclear￨highunclear
107￨107 patients with benign gastric ulcer associated with h pylori malignancy was diagnosed in 19 24 were not infected with h pylori four withdrew because of adverse events and 18 failed to attend for start of treatment leaving 107 patients eligible for analysis 35 omeprazole alone 72 helicobacter pylori infection teaching and district general hospitals between 1991 and 1994 172 patients were enrolled￨omeprazole amoxycillin omeprazoleamoxycillin omeprazole plus amoxycillin￨h pylori eradication and healing of gastric ulcers recurrence rates eradication rates eradication of h pylori relapse with gastric ulcer relapse￨in the omeprazoleamoxycillin group 93 6772 95 confidence interval 84 to 98 of gastric ulcers healed and 83 2935 66 to 94 in the omeprazole group p  0103￨no diff￨low￨low￨low
59￨fiftynine patients with active gastric ulcer￨amoxicillin omeprazole placebo omeprazole 20 mg twice daily for 4 weeks plus placebo￨erosive oesophagitis gastric ulcer relapse helicobacter pylori infection helicobacter pylori eradication percentage of eradication idiopathic gastric ulcer percentage of healing gastric ulcer relapse and helicobacter pylori reinfection gastric ulcer healing helicobacter pylori and healing and prevention of gastric ulcer recurrence healing and recurrence of benign gastric ulcer￨during a 12month followup gastric ulcer relapsed in 2032 63 of the persistently helicobacter pylori positive patients￨no diff￨highunclear￨highunclear￨highunclear
401￨401 h pyloripositive patients with more than or equal to two gus gastric ulcer patients￨placebo placebo antimicrobials esomeprazole eac eac and placebo esomeprazolebased triple therapy esomeprazole triple therapy amoxicillin clarithromycin placebo for 3 weeks eac and placebo eac esomeprazole monotherapy￨helicobacter pylori h pylori healing of ulcer and prevention of relapse eradication of h pylori healing of gu and prevention of relapse eradication rates of helicobacter pylori gastric ulcer healing and prevention of relapse eradication rates tolerated free of gus￨eradication rates at 4 weeks or 8 weeks were 82 for eac and e20 77 for eac and placebo and 95 for e20 bid and e20 intentiontotreat analysis￨no diff￨highunclear￨highunclear￨highunclear
not found￨japanese ulcer patients japanese peptic ulcer patients japanese patients with h pyloripositive active gastric ulcers or duodenal ulcers￨lpz 30 mg plus ampc 750 mg and cam lansoprazole lpzamoxicillin ampcclarithromycin cam lansoprazole amoxicillin and clarithromycin lpz ampc lpz 30 mg ampc 750 mg and cam￨pylori eradication rate eradication rates eradication rate of h pylori and safety successful eradication eradication rates of h pylori￨the eradication rates of h pylori in the full analysis set were 0 in group alpzonly 875 in group blac200 and 892 in group clac400 for gastric ulcer and 44 in group alpzonly 911 in group blac200 and 837 in group clac400 for duodenal ulcer￨no diff￨highunclear￨highunclear￨highunclear
not found￨peptic ulcer patients infected with h pylori 445 88 duodenal ulcer 357 gastric ulcer patients with peptic ulcers￨conventional treatment including acid decreasing therapy with a histamine h2receptor antagonist or proton pump inhibitor ppi ppi plus amoxicillin and clarithromycin dual therapy including one antibiotic plus aciddecreasing therapy￨eradication of h pylori infection eradication rates relapse rate of peptic ulcer no recurrence relapse rate of peptic ulcers intentiontotreat eradication rates￨no recurrence was noted in the duodenal ulcer patients and only 4 of gastric ulcers recurred after successful eradication during followup for 5 years￨no diff￨highunclear￨highunclear￨highunclear
232￨duodenal ulcer two hundred and thirty two h pylori positive patients with active duodenal ulcer patients with duodenal ulcer￨rbc 400 mg twice daily alone rbc400clar and rbc 800clar rbc800clar rbc400clar clarithromycin ranitidine bismuth citrate with clarithromycin ranitidine bismuth citrate rbc and clarithromycin clar dual therapy ranitidine bismuth citrate rbc 400 mg twice daily alone rbc400 rbc 400 or 800 mg twice daily coprescribed with clarithromycin￨ulcer relapse duodenal ulcer healing and absence of ulcer recurrence safe and well tolerated h pylori eradication rates trough plasma bismuth concentrations￨the coprescription regimens gave high h pylori eradication rates determined using two tests clotest and 13curea breath test for the presence of the organism￨no diff￨highunclear￨highunclear￨highunclear
100￨duodenal ulcer du patients colonized with helicobacter pylori one hundred du patients chilean du patients chilean duodenal ulcer patients￨bismuth subsalicylate tablets triple therapy plus omeprazole metronidazole omeprazole 4wk tripleantibiotic therapy with amoxicillin omeprazole alone￨ulcer healing rate relapse rate longterm du recurrence rate reinfection rate eradication rate of h pylori low h pylori reinfection rate￨the difference higher relapse rate for omeprazoletreated patients was significant p  0001 by the second evaluation 4 months after treatment￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with an hpassociated duodenal ulcer du￨combined ome  amx ome  amx ome omeprazole monotherapy ome amoxicillin omeprazole and amoxicillin omeprazole￨hp eradication cumulative du relapse rates cumulative relapse rates du relapse rates￨hp eradication was achieved in 82 of the ome  amx group but in 0 of the ome group￨no diff￨highunclear￨highunclear￨highunclear
120￨patients infected with helicobacter pylori infected patients 120 patients with h pylori and gastric ulcers to￨proton pump inhibitor plus two antibiotics proton pump inhibitor plus amoxicillin and clarithromycin proton pump inhibitor alone proton pump inhibitor therapy￨gastric ulcer healing heal gastric ulcers healing rates gastric ulcers￨triple therapy eradicated h pylori in 51 patients intentiontotreat 84 95 confidence interval ci 7593￨no diff￨highunclear￨highunclear￨highunclear
59￨59 patients with duodenal ulcers who were positive for h pylori infection seventeen patients were treated with￨colloidal bismuth subcitrate cbs triple therapy cbs tetracycline and metronidazole ranitidine￨recurrence rates of duodenal ulcers recurrence of duodenal ulcers healed ulcers h pylori infection helicobacter pylori h pylori eradication and duodenal ulcer recurrence ulcer recurrence helicobacter pylori infection and the recurrence of duodenal ulcers recurrence of ulcers￨the recurrence rates of duodenal ulcers confirmed by endoscopy in these three groups were 64 33 and 0 at the third month and 73 67 and 5 at the sixth month respectively￨no diff￨highunclear￨highunclear￨highunclear
119￨119 patients 97 m 22 f mean age 39 duodenal ulcer patients with gastric h pylori infection￨famotidine h2 receptor antagonist versus a oneweek antibiotic therapy antibiotics 500 mg amoxicillin qid and 500 mg tinidazole tidantibiotic group or their placebo placebo antibiotic versus maintenance therapy￨duodenal ulcer relapse relapse rate overall failure rate absence of healing relapse duodenal ulcer recurrence rate of ulcer relapse side effects ulcer relapse rates gastric acid secretion healing rate￨however the overall failure rate absence of healing relapse was lower p  004 logrank test in the antibiotic group in which all relapses but one were observed in h pylori positive patients￨no diff￨highunclear￨highunclear￨highunclear
95￨larger group of h pyloripositive patients with active duodenal ulcer 95 patients￨clarithromycin ranitidine bismuth citrate with clarithromycin ranitidine bismuth citrate rbc pylorid tritec rbc 400 mg bid alone rbc400 n  31 or rbc 400 mg bid or 800 mg bid in coprescription with clarithromycin￨helicobacter pylori and for ulcer healing pylori eradication assessed by antral and corpus urease tests and histology and by 13c urea breath test h pylori eradication rates rates of ulcer healing helicobacter pylori eradication rate￨the coprescription regimens gave significantly higher observed h pylori eradication rates 82 and 74 for rbc400  clar and rbc800  clar compared with rbc400 0 p  001￨sig increase￨highunclear￨highunclear￨highunclear
115￨gastric and duodenal ulcers patients who did not use nsaids or asa peptic ulcers 115 patients￨placebo nonsteroidal antiinflammatory drug nsaid and acetylsalicylic acid asa quadruple therapy 28 2 dual therapy n30 3 triple therapy lansoprazole and placebo lansoprazole￨ulcer relapses ulcer healing and relapse rate ulcer healing rate helicobacter pylori eradication ulcer relapse rate eradication rate of h pylori healing rates￨the ulcer healing rate was 100 95 confidence interval ci 95100 in h pylorinegative and 83 95 ci 6794 in h pyloripositive patients p001￨no diff￨highunclear￨highunclear￨highunclear
112￨chinese with peptic ulcer disease between november 1993 and june 1994 112 patients with active h pylori positive peptic ulcer￨omeprazoleamoxicillin bismuth subsalicylate omeprazole plus amoxicillin amoxicillin omeprazoleamoxicillin and triple therapy metronidazole omeprazoleamoxicillin omeprazole ranitidine bid or 400 mg cimetidine￨ulcer healing rate ulcer healing rates good eradication rates adverse effects eradication rate of h pylori side effect￨eleven patients in the triple therapy group suffered from adverse effects 458 p  005 as compared with other groups￨sig decrease￨highunclear￨highunclear￨highunclear
262￨h pyloriinfected patients with endoscopically documented duodenal ulcer either currently or within the past year 67 of patients with active or recently healed duodenal ulcer two hundred sixtytwo patients met enrollment criteria and were treated￨lansoprazole and amoxicillin dual therapy lansoprazole 30 mg tid alone or 4 amoxicillin amoxicillin plus lansoprazole amoxicillin lansoprazole twice daily plus amoxicillin amoxicillin plus omeprazole lansoprazole 30 mg tid plus amoxicillin lansoprazole omeprazole￨h pylori status ulcer prevalence amoxicillin resistance helicobacter pylori infection ulcer prevalence cure of h pylori infection pylori infection￨the minimal inhibitory concentration of lansoprazole for h pylori in vitro is lower than that for omeprazole prompting interest in treatment with amoxicillin plus lansoprazole￨no diff￨highunclear￨highunclear￨highunclear
42￨fortytwo duodenal ulcer patients infected with h pylori￨h2blocker and triple therapy triple therapy with bismuth amoxicillin and metronidazole h2blocker therapy with famotidine￨rate of h pylori infection healing rate to h2blocker therapy endoscopic evaluation of ulcer status and bacteriologic identification of h pylori ulcer remission rate ulcer recurrence rate ulcer remission￨triple therapy had a similarly high healing rate to h2blocker therapy 100 vs 905 at two months of followup￨no diff￨highunclear￨highunclear￨highunclear
183￨one hundred and eighty three patients with active du￨omeprazole om 20 mg for 4 wk plus amoxycillin 3 g daily and metronidazole amoxycillin metronidazole and omeprazole omeprazole om om 20 mg for 4 wk plus matching placebo￨bacterial colonization and inflammatory scores healed of their ulcers percentage of eradication helicobacter pylori eradication and prevention of ulcer recurrence gastroduodenitis activity and gastric surface epithelium lesions transient worsening of corpus gastritis hp eradication and prevention of duodenal ulcer recurrence eradication of hp and prevention of duodenal ulcer du recurrence￨rapid complete and persistent suppression of gastroduodenitis activity and gastric surface epithelium lesions was observed in most hperadicated group￨no diff￨highunclear￨highunclear￨highunclear
27￨185 h pyloripositive gastric ulcer patients gastric ulcer patients twentyseven patients were excluded because of lack of compliance or missed followup examinations one patient receiving amoxicillin discontinued treatment owing to side effects￨amoxicillin placebo amoxicillin omeprazoleamoxicillin omeprazole and amoxicillin omeprazole omeprazoleplacebo￨helicobacter pylori infection cure of h pylori infection￨on an intentiontotreat basis omeprazoleamoxicillin led to cure of h pylori infection in 671 47 of 70 of patients not using nonsteroidal antiinflammatory drugs nsaidsaspirin asa and in 467 14 of 30 of those taking nsaidsasa p  005￨no diff￨highunclear￨highunclear￨highunclear
66￨patients with no past history of duodenal ulcer 66 patients with duodenal ulcer scar 53 were h pyloripositive and 13 were h pylorinegative thirteen h pylorinegative patients patients with no clinical history of duodenal ulcer h pyloripositive patients patients with duodenal ulcer scar and no past history of duodenal ulcer￨helicobacter pylori eradication￨duodenal ulcer recurrence active duodenal ulcer recurrence active duodenal ulcer recurrence ulcer scar changes and h pylori status duodenal ulcer scar￨there was no duodenal ulcer recurrence in 43 h pylorinegativecured patients 0 which was significantly different in terms of duodenal ulcer recurrence p0001￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨ligament reconstruction basal joint arthroplasty without tendon interposition ligament reconstruction alone tendon interposition tendon interposition ligament reconstruction was performed to suspend the first metacarpal in addition to placement of a rolled tendon interposition to fill the void created by resection of the trapezium￨two and threepoint pinch strength range of motion of the thumb grip strength lateral pinch strength the ability to perform activities of daily living or subjective satisfaction￨there was no difference between the two groups in range of motion of the thumb grip strength lateral pinch strength the ability to perform activities of daily living or subjective satisfaction with the procedure￨no diff￨highunclear￨highunclear￨highunclear
15￨fifteen patients with disabling pain and isolated tmc oa were included in the study￨tmc trapeziometacarpal joint tmc trapezium resection arthroplasty with abductor pollicis longus apl stabilization￨radiographic examination pinch strength median values for both key pinch and tripod pinch pain strength stability and range of motion signs of foreignbody reaction pain free￨the median values for both key pinch and tripod pinch increased compared with before surgery in the spacer group but not in the apl group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨basal joint arthritis of the thumb women with primary osteoarthritis￨ligament reconstructiontendon group ii interposition technique trapeziectomy with or without tendon interpositionligament reconstruction￨remaining trapezial space and key pinch force trapezial height pain relief patient satisfaction mobility dashscore key pinch force and gripping force￨both techniques gave favourable results and there were no significant differences for pain relief patient satisfaction mobility dashscore key pinch force and gripping force￨no diff￨highunclear￨highunclear￨highunclear
43￨fortythree patients￨simple trapeziectomy trapeziectomy alone control or with a ligament reconstruction and tendon interposition lrti using an abductor pollicis longus tendon slip trapeziectomy with and without ligament reconstruction and tendon interposition￨￨both groups expressed equal satisfaction with the operation and there were no significant differences between the two treatment groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨osteoarthritis of the trapeziometacarpal joint twentysix patients were operated because of osteoarthritis of the trapeziometacarpal joint all 13 patients in the swanson group and 11 of the 13 in the 26 patients￨swanson versus apl arthroplasty apl swanson silicone trapezium implant or a tendon interposition arthroplasty using a strip of the abductor pollicis longus tendon apl￨major radiographic cyst formation thumb pinch strength and range of motion pain relief pain with heavy work no infection or clinical silicone synovitis￨thumb pinch strength and range of motion were not significantly different in the two groups￨no diff￨highunclear￨highunclear￨highunclear
550￨enrolled 550 women 15 patients who were assigned to secondary surgery 7 percent patients who had advanced ovarian cancer and residual tumor exceeding 1 cm in diameter after primary surgery advanced ovarian carcinoma 296 patients had died and 82 had progressive disease 216 eligible patients patients with advanced ovarian carcinoma in whom primary cytoreductive surgery￨postoperative paclitaxel plus cisplatin chemotherapy alone secondary cytoreductive surgery to postoperative chemotherapy secondary surgical cytoreduction followed by chemotherapy and 208 to receive chemotherapy alone paclitaxel plus cisplatin￨relative risk of death progressionfree survival and overall survival progressionfree survival or overall survival likelihood of progressionfree survival￨the likelihood of progressionfree survival in the group assigned to secondary surgery plus chemotherapy as compared with the chemotherapyalone group was 107 95 percent confidence interval 087 to 131 p054 and the relative risk of death was 099 95 percent confidence interval 079 to 124 p092￨sig increase￨highunclear￨highunclear￨highunclear
319￨eligible patients had residual lesions measuring more than 1 cm in diameter after primary surgery 319 patients who underwent randomization 278 could be evaluated 140 patients who underwent surgery and 138 patients who did not advanced epithelial ovarian cancer￨cyclophosphamide and cisplatin debulking surgery after induction chemotherapy debulking surgery or no surgery￨death or severe morbidity progressionfree and overall survival median survival survival rate progressionfree and overall survival lengthened progressionfree and overall survival risk of death￨progressionfree and overall survival were both significantly longer in the group that underwent surgery p  001￨sig increase￨highunclear￨highunclear￨highunclear
37￨patients with advanced ovarian cancer patients with advanced ovarian cancer who have bulky  2 cm residual disease after primary surgery seventynine patients were entered into the study thirtyseven patients eligible patients ovarian cancer patients with bulky residual disease after primary surgery who are considered well enough to receive cisplatinum based chemotherapy and further surgery hospitals in the west midlands advanced epithelial ovarian cancer￨intervention debulking surgery intervention debulking surgery combination chemotherapy alone or combined with intervention debulking surgery￨survival median survival survival￨the median survival for the intervention debulking surgery group was 15 months 95 ci 1020 mo and that of those randomised to chemotherapy alone which was 12 months 95 ci 816 mo were not significantly different hazard ratio  071 95 ci 044113￨no diff￨highunclear￨highunclear￨highunclear
10￨pediatric charcotmarietooth disease type 1a 10 affected children 20 legs aged 314 years pediatric cmt1a￨botulinum toxin type a bonta botulinum toxin￨radiographic alignment serious adverse events foot posture ankle flexibility and strength assessed every 6 months safe and welltolerated progression of pes cavus in cmt1a￨at 24 months the intramuscular bonta injections proved safe and welltolerated but did not affect the progression of pes cavus in cmt1a￨no diff￨highunclear￨highunclear￨highunclear
154￨patients with a cavus or higharched foot frequently experience foot pain painful cavus foot people with a cavus foot type one hundred fiftyfour participants with chronic musculoskeletal foot pain and bilateral cavus feet￨control group receiving simple sham insoles custom foot orthoses￨foot health status questionnaire foot pain scores function scores physical functioning foot pain function quality of life and plantar pressure loading plantar pressure￨foot pain scores improved more with custom foot orthoses than with the control difference 83 points 95 confidence interval ci 12 to 153 points p  022￨sig decrease￨low￨low￨low
22￨22 athletes with cavus feet in 2 athletes with cavus feet￨neutralcushioned running shoes neutralcushioned running shoes asics nimbus 6 and brooks glycerin 3 and a control condition dunlop volley neutralcushioned running shoes￨plantar pressures plantar pressures rearfoot pressure plantar pressure loading and comfort peak pressure and pressuretime integrals contact time and area increased in both neutralcushioned running shoes￨compared with the control both neutralcushioned running shoes significantly reduced peak pressure and pressuretime integrals by 17 to 33 p  001￨sig decrease￨highunclear￨highunclear￨highunclear
30￨subjects with different foot types while wearing various offtheshelf foot orthotics thirty healthy young adults 10 with each foot type￨￨quadriceps and gluteus medius electromyographic activity less vastus lateralis activity surface electromyographic activity greater vastus medialis and gluteus medius activity￨less vastus lateralis activity was found with the vertical jump with all orthotic conditions again regardless of foot type￨no diff￨highunclear￨highunclear￨highunclear
12￨12 patients polycystic ovary syndrome￨pulsatile gonadotrophin releasing hormone stimulation after mediumterm pituitary suppression gnrh agonist gnrha pulsatile gonadotrophin releasing hormone gnrh￨ovulation and pregnancy rates ovulation rates spontaneous abortion￨ovulation rates were similar￨no diff￨highunclear￨highunclear￨highunclear
8￨patients suffering from polycystic ovarian disease patients with polycystic ovarian disease eight women underwent￨pulsatile gonadotropinreleasing hormone gnrh gonadotropin combined exogenous gonadotropins and pulsatile gonadotropinreleasing hormone induction of ovulation with both combined therapy and pure exogenous folliclestimulating hormone alone￨premature luteinization￨no premature luteinization and a single follicular growth were recorded with the modified combined regimen￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with polycystic ovary syndrome women referred to the infertility clinic catharina hospital eindhoven the netherlands twentyeight infertile patients with pcos infertile patients with polycystic ovary syndrome pcos treated with either￨pulsatile intravenous gonadotropinreleasing hormone after gonadotropinreleasing hormone agonist pretreatment versus clomiphene citrate pulsatile iv gnrh pulsatile iv gnrh after gnrhagonist gnrha downregulation or clomiphene citrate cc gnrha downregulation or cc￨serum concentrations of e2 lh and fsh serum concentrations of e2 lh and fsh serum p and sonography confirmed ovulation serum lh concentration lh ovarian sonography and serum concentrations of e2 lh and fsh￨in ovulatory cycles no statistically significant differences were observed during the follicular phase comparing serum concentrations of e2 lh and fsh between the treatments￨no diff￨highunclear￨highunclear￨highunclear
50￨fifty patients with electrophysiologically confirmed idiopathic cts patients with idiopathic carpal tunnel syndrome carpal tunnel syndrome carpal tunnel syndrome cts patients with cts￨decompressive surgery and steroid injection steroid injection open carpal tunnel release surgery vs steroid injection open carpal tunnel release 25 patients or to a single injection of steroid￨median nerve distal motor latencies and sensory nerve conduction velocity mean improvement in gss symptomatic improvement symptomatic and neurophysiologic outcome mean grip strength symptom relief in terms of the global symptom score gss which rates symptoms on a scale of 0 no symptoms to 50 most severe￨compared with steroid injection open carpal tunnel release resulted in better symptomatic and neurophysiologic outcome but not grip strength in patients with idiopathic carpal tunnel syndrome over a 20week period￨sig increase￨low￨low￨low
80￨carpal tunnel syndrome cts eighty wrists were randomly assigned to the surgery group and 83 wrists to the carpal tunnel syndrome 163 wrists with a clinical and neurophysiologic diagnosis of cts￨local steroid injection group local steroid injection surgical decompression versus local steroid injection surgical decompression versus local steroid injection local steroid injection versus surgical decompression￨severity of cts nocturnal paresthesias visual analog scale score for nocturnal paresthesias percentage of wrists￨at 6 and 12 months the percentages of responders were 855 versus 763 p  0163 and 699 versus 750 p  0488 for local steroid injection and surgical decompression respectively￨no diff￨highunclear￨highunclear￨highunclear
64￨sixtyfour women who were planning to have a cesarean delivery women undergoing cesarean delivery￨music therapy routine care and music therapy control group received routine care only￨anxiety womens physiologic measures level of anxiety and satisfaction during cesarean delivery womens physiologic measures anxiety and satisfaction during cesarean delivery￨our results indicated that compared to the control group the experimental group had significantly lower anxiety and a higher level of satisfaction regarding the cesarean experience￨sig increase￨highunclear￨highunclear￨highunclear
87￨patients with corticosteroiddependent crohns disease patients with crohns disease with corticosteroid dependence eightyseven patients patients with crohns disease￨sargramostim 6 microgkg subcutaneously once daily or placebo placebo sargramostim recombinant human granulocytemacrophage colonystimulating factor sargramostim study drug plus corticosteroid therapy 2 a forced corticosteroid tapering phase steroidsparing properties of sargramostim study drug plus prednisone corticosteroids sargramostim￨corticosteroidfree remission corticosteroidfree remission crohns disease activity index cdai corticosteroidfree response cdai decreased by  or 100 and induction of remission experience musculoskeletal pain injection site reactions and dyspnoea healthrelated quality of life￨sargramostim was more effective than placebo for inducing corticosteroidfree remission in patients with crohns disease with corticosteroid dependence￨sig increase￨low￨low￨low
124￨active crohns disease patients with active crohns disease 124 patients with moderatetosevere active crohns disease to￨receive 6 mug of sargramostim per kilogram per day or placebo placebo sargramostim sargramostim therapy sargramostim￨cdai score clinical response defined by a decrease from baseline of at least 70 points in the crohns disease activity index cdai rates of either type of clinical response and of remission quality of life serious adverse events disease severity disease severity and the healthrelated quality of life and adverse events mildtomoderate injectionsite reactions and bone pain￨mildtomoderate injectionsite reactions and bone pain were more common in the sargramostim group and three patients in this group had serious adverse events possibly or probably related to treatment￨sig increase￨low￨low￨low
1784￨1 emergency departments wards and intensive care units of 5 university hospitals and 2 all locations outside hospitals in 2 midsized cities 1784 adults who had cardiac arrest￨standard or acd cpr active compressiondecompression cardiopulmonary resuscitation modified minimental state examination mmse active compressiondecompression acd cardiopulmonary resuscitation cpr and standard cpr￨survival or neurologic outcomes median mmse score of survivors survival until hospital discharge survival survival survival to hospital discharge￨for inhospital patients there were no significant differences between the standard n  368 and acd n  405 cpr groups in survival for 1 hour 351 vs 346 p  89 in survival until hospital discharge 114 vs 104 p  64 or in the median mmse score of survivors 37 in both groups￨no diff￨low￨low￨low
200000￨adult patients with prehospital nontraumatic cardiac arrest treated by the micu 23 patients mean value std cpr 119 patients with prehospital cardiac arrest in a physicianmanned emergency medical system physicianmanned mobile intensive care unit micu of a university hospital serving a population of 200000￨standard chest compression according to american heart association aha recommendations cardiac resuscitation active compressiondecompression cardiopulmonary resuscitation acd cpr active compressiondecompression cardiopulmonary resuscitation￨rate of patients regaining a spontaneous circulation rosc hospital discharge rate and mean carbon dioxide content survival rosc rates￨four patients 133 in group 1 and three patients 115 in group 2 were discharged group 1 v group 2 ns￨no diff￨highunclear￨highunclear￨highunclear
154000￨145 acd patients 54 patients 13 survived to discharge 302 patients with similar baseline characteristics patients with cardiac arrest of presumed cardiac origin￨active compressiondecompression acd cpr applied by emergency medical service ems acd cpr cardiopump or standard cpr active compressiondecompression cardiopulmonary resuscitation￨prevalence of bystander cpr cerebral outcome mean score￨in 4 years cpr was attempted in a total of 431 cardiac arrests 54 patients 13 survived to discharge 302 patients with similar baseline characteristics were randomised￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients who had cardiac arrest outside the hospital all patients who survived to one year had cardiac arrests that were witnessed patients who had cardiac arrest in the paris metropolitan area or in thionville france more than 80 percent of whom had asystole￨active compressiondecompression cardiopulmonary resuscitation cpr active compressiondecompression cpr standard cpr standard cardiopulmonary resuscitation and active compressiondecompression resuscitation￨rate of hospital discharge without neurologic impairment longterm survival rates oneyear survival rate rate of survival to hospital discharge without neurologic impairment and the neurologic outcome active compressiondecompression cpr neurologic status survival asystole or pulseless electrical activity￨active compressiondecompression cpr performed during advanced life support significantly improved longterm survival rates among patients who had cardiac arrest outside the hospital￨sig increase￨highunclear￨highunclear￨highunclear
not found￨outofhospital cardiac arrest in two cities emergency medical services ems of a large san francisco and mediumsized fresno city in california victims of outofhospital cardiopulmonary arrest￨handheld suction device vs standard manual cpr active compressiondecompression cpr vs standard cpr active compressiondecompression acd cardiopulmonary resuscitation cpr standard manual cpr according to american heart association guidelines or acd cpr acd￨hospital discharge hospital admission return of spontaneous circulation return of spontaneous circulation admission to the intensive care unit survival to hospital discharge and neurological function at hospital discharge cerebral performance category score at discharge￨similarly in san francisco there was no difference between the acd group and standard cpr group in return of spontaneous circulation 19 vs 21 p  65 hospital admission 135 vs 145 p  79 hospital discharge 47 vs 55 p  80 or cerebral performance category score at discharge 22 vs 26 p  31￨no diff￨highunclear￨highunclear￨highunclear
53￨fiftythree consecutive patients after cardiac arrest undergoing 64 resuscitation attempts were studied 30 women 23 men mean 13 years range 38 to 96 human subjects after cardiac arrest sd age 71 patients with inhospital cardiac arrest￨standard manual or active compressiondecompression cardiopulmonary resuscitation active compressiondecompression active compressiondecompression resuscitation active compressiondecompression cardiopulmonary resuscitation￨return of spontaneous circulation and 24h survival spontaneous return of circulation 24h survival and survival to hospital discharge resuscitation success cardiopulmonary hemodynamic function 24h survival spontaneous return of circulation survival to hospital discharge￨active compressiondecompression cardiopulmonary resuscitation is a new method that improves cardiopulmonary hemodynamic function in animal models and humans after cardiac arrest￨sig increase￨highunclear￨highunclear￨highunclear
576￨576 patients stdcpr n309 acdcpr n267 were analysed victims of prehospital cardiac arrest￨active compressiondecompression resuscitation active compressiondecompression acd cardiopulmonary resuscitation cpr and standard cpr standard or acdcpr￨interval between collapse and defibrillation return of spontaneous circulation survival to be admitted to the intensive care unit survival to hospital discharge and neurological outcome hospital discharge proportion of patients receiving bystander cpr￨there was no difference between the stdcpr and acdcpr groups in survival to admission to the intensive care unit 136 vs 138 p093 or hospital discharge 48 vs 60 p067￨no diff￨highunclear￨highunclear￨highunclear
220￨patients with outofhospital ca treated by emergency medical services ems personnel 220 patients scpr n  114 acdcpr n  106￨active compressiondecompression cardiopulmonary resuscitation acdcpr standard manual cpr scpr with acdcpr active compressiondecompression resuscitation￨survival rates and neurological prognosis rosc neurological outcome survival rates and neurological outcome return of spontaneous circulation rosc hospital admission and discharge rates hospital admission standard scoring systems cerebral and overall performance categories cpc and opc hospital discharge￨the treatment groups were similar with respect to age sex time interval from collapse to cpr defibrillation and first adrenaline medication￨no diff￨highunclear￨highunclear￨highunclear
270000￨patients with outofhospital cardiac arrest in st paul minn victims of outofhospital cardiac arrest all normothermic victims of nontraumatic cardiac arrest older than 8 years who received cpr￨active compressiondecompression acd cardiopulmonary resuscitation standard cpr new cpr technique acd cpr active compressiondecompression cpr￨mean emergency medical services call response interval return to baseline neurological function at hospital discharge hospital discharge rates hospital discharge rate ventilation and coronary perfusion return to baseline neurological function return of spontaneous circulation icu admission and neurological recovery downtime survival to the icu return of spontaneous circulation admission to the intensive care unit icu return of baseline neurological function alert and oriented to person place and time survival to hospital discharge survival to hospital discharge with return of baseline neurological function and complications return of spontaneous circulation complication rates￨no statistically significant differences were found between hospital discharge rates 12 23 of 53 for acd cpr vs 13 17 of 77 for standard cpr return to baseline neurological function 10 19 of 53 for acd cpr vs 13 17 of 77 for standard cpr or return to baseline neurological function at hospital discharge nine 17 of 53 for acd cpr vs 12 16 of 77 for standard cpr￨no diff￨highunclear￨highunclear￨highunclear
71￨group meansd age was 747125 years and 58 n41 had a national institutes of health stroke scale score 7 patients at 24 hours after stroke were recruited from 2 melbourne metropolitan stroke units seventyone patients were recruited and randomized with 2 dropouts by 12 months￨standard care sc or sc plus very early mobilization vem￨contamination of standard care safe and feasible intervention efficacy and costeffectiveness higher dose of mobilization achieved in vem number of deaths ischemic strokes number of deaths at 3 months adverse events including falls and early neurologic deterioration compliance with physiologic monitoring criteria and patient fatigue after interventions￨the intervention protocol was successfully delivered achieving vem dose targets double sc p0003 and faster time to first mobilization p0001￨sig increase￨low￨low￨low
125￨125 women with world health organization class ii anovulation received 50 mg of￨clomiphene citrate ovulation induction therapy human chorionic gonadotropin clomiphene citrate alone clomiphene citrate plus hcg￨pregnancy outcomes and midluteal p levels but luteal phase length pregnancy outcomes and luteal function￨there were no statistically significant differences between groups regarding pregnancy outcomes and midluteal p levels but luteal phase length was longer in group a￨no diff￨highunclear￨highunclear￨highunclear
not found￨anovulatory women treated with￨spontaneous ovulation versus hcgtriggered ovulation hcg clomiphene citrate￨ovulation and pregnancy rates￨no statistically significant differences were observed between the two groups in terms of ovulation and pregnancy rates￨no diff￨highunclear￨highunclear￨highunclear
154￨patients with a cavus or higharched foot frequently experience foot pain painful cavus foot people with a cavus foot type one hundred fiftyfour participants with chronic musculoskeletal foot pain and bilateral cavus feet￨control group receiving simple sham insoles custom foot orthoses￨foot health status questionnaire foot pain scores function scores physical functioning foot pain function quality of life and plantar pressure loading plantar pressure￨foot pain scores improved more with custom foot orthoses than with the control difference 83 points 95 confidence interval ci 12 to 153 points p  022￨sig decrease￨low￨low￨low
not found￨rheumatoid arthritics￨foot orthoses vs placebo orthoses foot orthoses￨disability and pain measures pain and disability￨on the basis of findings of no effect on disability and pain measures this study indicates no benefit of functional posted foot orthoses over placebos￨no diff￨highunclear￨highunclear￨highunclear
4￨4 general community hospitals in finland in 19971998 with a followup period of 12 months patients with hallux valgus two hundred nine consecutive patients mean age 48 years 93 women with a painful bunion and a hallux valgus angle 35 degrees or less￨surgery vs orthosis vs watchful waiting surgical osteotomy￨number of painful days cosmetic disturbance and footwear problems were least and functional status and satisfaction pain intensity visual analog scale 0100 patient assessment of global improvement number of painful days cosmetic disturbance footwear problems functional status and treatment satisfaction pain intensity￨at 1 year pain intensity decreased more in the surgical than in the control groups adjusted mean difference 19￨sig decrease￨low￨low￨low
255￨plantar fasciitis two hundred fiftyfive subjects￨individual mechanical modalities custommade orthoses overthecounter arch supports or tension night splints￨firststep pain or pain felt￨no statistically significant difference was noted among treatment groups with respect to final outcomes based on firststep pain or pain felt during the day￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with ra rheumatoid arthritis￨foot orthoses only when prescribed under normal medical care custom manufactured rigid foot orthoses under podiatry supervision foot orthoses early foot orthosis intervention￨ffi scores for total score foot pain minor adverse reactions such as tender spots blisters and callus foot disability foot pain and disability using the foot function index ffi along with disease activity tolerance and adverse reactions ffi total score￨area under the curve analysis showed a statistically significant reduction in ffi scores for total score p  0026 foot pain p  0014 and foot disability p  0016 when intervention was compared to control scores￨sig increase￨highunclear￨highunclear￨highunclear
not found￨plantar fasciitis fortythree patients 34 women and nine men with a mean age of 46 years with plantar fasciitis￨foot orthoses and night splints alone or combined foot orthoses foot orthoses and night splints foot orthoses and anterior night splints night splints alone foot orthoses￨side effects pain reduction function footrelated quality of life pain functional limitations and quality of life￨at 12 weeks pain reduction of 30 to 50 compared to baseline were seen p  003￨sig decrease￨highunclear￨highunclear￨highunclear
135￨plantar fasciitis people with plantar fasciitis one hundred and thirtyfive participants with plantar fasciitis from the local community were recruited to a universitybased clinic￨sham orthosis soft thin foam a prefabricated orthosis firm foam or a customized orthosis semirigid plastic foot orthoses￨pain and function mean function score mean pain score￨the customized and prefabricated orthoses used in this trial have similar effectiveness in the treatment of plantar fasciitis￨no diff￨low￨low￨low
40￨children with jia and foot pain n  40 children with juvenile idiopathic arthritis children with juvenile idiopathic arthritis jia￨supportive athletic shoes with a medial longitudinal arch support and shock absorbing soles worn alone custommade semirigid foot orthotics with shock absorbing posts custom foot orthotics￨pain and functional status foot pain and functional limitations pain speed of ambulation and selfrated activity and functional ability levels pain for supportive athletic shoes pediatric pain questionnairevisual analog scale vas timed walking foot function index ffi and the physical functioning subscale of the pediatric quality of life inventory pedsql foot pain speed of ambulation activity limitations level of disability overall pain child healthrelated quality of life pain and improving function￨except for a reduction in pain for supportive athletic shoes paired t test p  0011 neither the offtheshelf shoe inserts nor the supportive athletic shoes worn alone showed significant effect on any of the evaluation measures￨sig increase￨highunclear￨highunclear￨highunclear
28￨patients with rheumatoid arthritis twentyeight subjects referred to twentyfour subjects completed the study￨foot orthoses and supportive shoes occupational therapy semirigid and soft orthoses￨pain relief for metatarsalgia pain metatarsal phalangeal mtp joint pain synovitis or function mean pain scores mtp joint synovitis and lower extremity function￨a reduction in mean pain scores from baseline to final visits showed that semirigid orthoses had a highly significant effect on pain￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨nulliparous women in spontaneous labor at term￨active management of labor or traditional management oxytocin￨cesareansection rate frequency of dystocia arrest of labor maternal or neonatal morbidity rate of cervical dilation rate of delivery by cesarean section average length of labor infectious complications dystocia rate of vaginal delivery without increasing maternal or neonatal morbidity rate of cesarean section￨for the women assigned to active management n  351 the cesareansection rate was 105 percent as compared with 141 percent for those assigned to traditional management n  354 p  018￨no diff￨highunclear￨highunclear￨highunclear
not found￨nulliparous clinic patients in spontaneous labour at term three hundred and six parturients 152 received active management of labour 154 were more selectively managed nulliparous labour women in true labour who received comparable continuous supportive midwifery care￨amniotomy and oxytocin infusion oxytocin and amniotomy oxytocin amniotomy and oxytocin oxytocin active management of labour￨labour duration mode of delivery spontaneous vaginal delivery rate neonatal outcome maternal characteristics caesarean section rate￨amniotomy was more often performed 91 versus 57 p 001 and oxytocin more often used 53 versus 27 p  001 in the active management group￨sig increase￨highunclear￨highunclear￨highunclear
221￨and 227 control women received nigerian district hospital setting two hundred and twentyone nulliparous women fulfilling selected inclusion criteria￨routine labour management active management of labour￨caesarean risk maternal infectious morbidity uterine hyperstimulation syndromes ruptured uterus or neonatal apgar scores labour rate of caesarean section caesarean section￨there were no significant differences in maternal infectious morbidity uterine hyperstimulation syndromes ruptured uterus or neonatal apgar scores between the two groups￨no diff￨highunclear￨highunclear￨highunclear
975￨lowrisk nulliparous pregnancies in a setting with limited resources lowrisk nulliparous pregnant women nine hundred and seventyfive low risk nulliparous pregnant women￨active management labor program conventional management labor program active management of a labor program￨rate of cesarean section and other labor outcomes shortened first stage of labor and total duration of labor rate of cesarean section and labor outcomes cesarean delivery rates￨the subjects in the active management program had significantly shortened first stage of labor and total duration of labor compared with the conventional group 5380￨sig decrease￨highunclear￨highunclear￨highunclear
331￨nulliparous women in spontaneous labour at term with singleton pregnancy and cephalic presentation and without fetal distress￨routine care oxytocin￨rates of newborn nursery admission neonatal acidosis low apgar scores or postpartum haemorrhage maternal satisfaction with labour care relative risk of prolonged labour length of first stage of labour prolonged labour satisfaction with labour care rate of caesarean section rate of caesarean section maternal satisfaction or other maternal or newborn morbidity rate of caesarean section and prolonged labour without influencing maternal satisfaction mode of delivery duration of labour and maternal satisfaction￨there were no differences between groups in the rates of newborn nursery admission neonatal acidosis low apgar scores or postpartum haemorrhage￨no diff￨low￨low￨low
1934￨women with fullterm uncomplicated pregnancies who spontaneously went into labor the protocoleligible subgroup women meeting these criteria who had been randomly assigned to the activemanagement group were admitted to a separate unit where their labor was managed by trained certified nursemidwives 1934 nulliparous women at low risk of complications of pregnancy before 30 weeks gestation to active management of labor or to a usualcare group nulliparous women women delivering their first babies￨early amniotomy and treatment with highdose oxytocin￨percentage of women in whom labor lasted longer rate of cesarean section median duration of labor rate of maternal fever￨there was no difference between groups in the rate of cesarean section either among all women active management 195 percent usual care 194 percent or in the protocoleligible subgroup active management 109 percent usual care 115 percent￨no diff￨highunclear￨highunclear￨highunclear
405￨nulliparous labor patients who were undergoing active management of labor were diagnosed as being in labor on the basis of having painful palpable contractions accompanied by 80 cervical effacement underwent early amniotomy 405 lowrisk term nulliparous patients to either an labor￨epidural analgesics active management of labor n  200 or our usual care control protocol oxytocin epidural analgesia￨rate of cesarean section length of labor persisted despite the use of epidural analgesics epidural analgesics length of labor cesarean section rate￨fiftyfive percent of patients received epidural analgesics a reduction in length of labor persisted despite the use of epidural analgesics active management 112 hours vs control 133 hours p  0001￨sig decrease￨highunclear￨highunclear￨highunclear
60￨60 nulliparous women￨hypnotic induction hypnotic analgesia relaxation and breathing exercises typically used in childbirth education hypnotic analgesia and skill mastery combined with childbirth education childbirth education and skill mastery using an ischemic pain task￨pain depression scores￨highly susceptible hypnotically treated women had lower depression scores after birth than women in the other 3 groups￨sig decrease￨highunclear￨highunclear￨highunclear
26￨women with intraamniotic infection 26 women and immediately after umbilical cord clamping in 19 women￨intrapartum ampicillin and gentamicin intrapartum versus postpartum antibiotic treatment￨microbiologic results the gestational age or the birth weight mean peak postpartum temperature mean postpartum stay neonatal sepsis shorter neonatal hospital stay mean number of febrile days￨intrapartum treatment led to a lower incidence of neonatal sepsis 0 versus 21 p  03 and a shorter neonatal hospital stay 38 versus 57 days p  02 when compared with postpartum treatment￨no diff￨highunclear￨highunclear￨highunclear
not found￨pregnant women with intraamnionic infection to receive either￨dual agent therapy ampicillin and gentamicin or triple agent therapy ampicillin gentamicin and clindamycin clindamycin￨neonatal morbidity or mortality incidence of endometritis frequency of vaginal and cesarean delivery￨there was no significant difference in the incidence of endometritis between the two groups 10 of 69 versus 5 of 64 p  ns￨no diff￨highunclear￨highunclear￨highunclear
285￨infants during immunization injections a consecutive sample of 285 infants infants age range 2 weeks to 18 months ambulatory care clinic of a large tertiary care center￨no intervention or drank 2 ml of sterile water or 2 ml or a 12 sucrose solution sterile water or sucrose solution cried￨pain vocalizations￨twoweekold infants who received either the sterile water or sucrose solution cried significantly less than infants who received no intervention f592p005￨no diff￨highunclear￨highunclear￨highunclear
not found￨pediatric test center in 7 to 12yearold children and during vaccination at school in 9 to 11yearold children children￨chewing gum￨pain ratings pain response pain responses affective state ratings of pain intensity and affective state￨affective state before the painful stimulus was related to pain response in the girls and in the boys in the test center but not in the schools￨sig increase￨highunclear￨highunclear￨highunclear
243￨158 infants under age 6 months 243 children between age 0 and 48 months receiving their routine vaccinations 85 children age 6 to 48 months infancy infants and children attending a wellchild unit￨breastfeeding or no breastfeeding during immunization sucrose or lidocaineprilocaine 12 sucrose solution lidocaineprilocaine cream or no intervention lidocaineprilocaine￨childrens hospital of eastern ontario pain scale cheops crying time and pain score by a pediatrician using the neonatal infant pain scale nips crying time and pain scores pain pain reduction￨no difference in outcome was seen between the sucrose and lidocaineprilocaine treatment groups￨no diff￨highunclear￨highunclear￨highunclear
259￨259 infertile women aged 1839 yr patients undergoing in vitro fertilization and embryo transfer￨rhlh gnrh agonist rhfsh rhlh or uhcg human recombinant luteinizing hormone uhcg recombinant human lh rhlh￨number of total biochemical and clinical pregnancies and the embryo implantation rate moderate or severe ohss ohss numbers of oocytes moderate ovarian hyperstimulation syndrome ohss efficacy and safety number of oocytes retrieved per follicle￨the numbers of oocytes retrieved after uhcg or rhlh administration were not significantly different between the four different doses of rhlh when compared with each corresponding uhcg group nor when compared with the pool of all uhcg groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients n  100 or 35 years with ivf indication￨10000 iu urinary and 250 microg recombinant human chorionic gonadotropin hcg uhcg with rhcg uhcg 10000 iu or rhcg￨adverse events predominantly injectionsite reactions total number of oocytes retrieved percentage of mature oocytes number of injected oocytes fertilization rates and number of embryos transferred efficacy and safety￨no statistical differences were found between groups in relation to total number of oocytes retrieved percentage of mature oocytes number of injected oocytes fertilization rates and number of embryos transferred￨no diff￨highunclear￨highunclear￨highunclear
not found￨ovulatory infertile women undergoing a single cycle of assisted reproduction technology women undergoing assisted reproduction technology twenty tertiary care us infertility centers two hundred ninetyseven￨recombinant human chorionic gonadotropin rhcg recombinant hcg recombinant hcg sc 500 microg of recombinant hcg sc or 10000 u usp urinary hcg rhcg ovidrel to urinary hcg profasi recombinant hcg￨adverse events mean numbers of oocytes numbers of 2pn fertilized oocytes adverse safety events laboratory changes local tolerance and immunogenicity oocyte maturity embryo development and luteal function as well as pregnancy and pregnancy outcome efficacy and safety￨recombinant hcg is effective and well tolerated in the induction of final follicular maturation and luteinization in women undergoing assisted reproduction technology￨sig increase￨highunclear￨highunclear￨highunclear
89￨47 patients receiving an 89 patients randomly assigned to one of the two study groups women treated for icsi 42 women who received a women treated with icsi for male factor infertility￨rhcg recombinant hcg intramuscular im injection of 10000 iu uhcg recombinant hcg rhcg urinary hcg uhcg subcutaneous sc injection of 250 microg rhcg and group b icsi uhcg￨rate of mature oocytes rate of metaphase ii oocytes the number and the rate of mii oocytes rate of metaphase ii oocytes a number of metaphase ii oocytes with mature cytoplasm and a rate of metaphase ii oocytes with mature cytoplasm calculated from total mii oocytes￨patients treated with rhcg showed a rate of metaphase ii oocytes a number of metaphase ii oocytes with mature cytoplasm and a rate of metaphase ii oocytes with mature cytoplasm calculated from total mii oocytes statistically higher than in patients treated with uhcg￨sig increase￨highunclear￨highunclear￨highunclear
30￨university teaching hospital thirty ivf patients patients undergoing in vitro fertilization ivf￨hcg or recombinant human lh recombinant human lh recombinant human luteinizing hormone lh recombinant human lh hcg recombinant luteinizing hormone￨ivf outcome serum progesterone concentrations peripheral vascular resistance mean arterial pressure cardiac output peripheral vascular resistance and serum levels of progesterone plasma concentrations of aldosterone norepinephrine and plasma renin activity ovarian response and ivf outcome pregnancy rate￨recombinant human lh is associated with less intense circulatory changes than hcg when it is given to induce final follicular maturation and luteal phase support in ivf procedures￨no diff￨highunclear￨highunclear￨highunclear
not found￨infertile women undergoing￨recombinant hcg and 7500 iu of urinary hcg urinary or recombinant hcg recombinant and urinary hcg ivfintracytoplasmic sperm injection icsi recombinant and urinary human chorionic gonadotropin￨stimulation parameters serum and follicular e2 p t and hcg levels number of oocytes serum and ff e2 p hcg and t levels serum and ff hormone measurements proportion of mature oocytes fertilization rate and pregnancy rate pr serum and follicular fluid ff hormone levels￨stimulation parameters serum and follicular e2 p t and hcg levels were similar in the recombinant and urinary hcg groups￨no diff￨highunclear￨highunclear￨highunclear
84￨84 women ovarian stimulation￨rhcg recombinant follicle stimulating hormone gonalf recombinant and urinary hcg 5000 iu urinary hcg uhcg profasi 250 microg recombinant human chorionic gonadotrophin rhcg ovidrel￨number of oocytes retrieved per follicles aspirated the number of mature oocytes normally fertilized oocytes and cleaved embryos concentrations of progesterone number of oocytes retrieved per patient receiving either compound￨since the confidence intervals for the difference of the number of oocytes retrieved between the two treatment groups were within the bounds defined by the multitrial protocol equivalence between rhcg and uhcg could be declared￨no diff￨low￨low￨low
190￨women undergoing ovulation induction for assisted reproduction treatment 190 women received a single sc women undergoing ovulation induction for assisted reproduction treatmentrecombinant hcg versus urinary hcg￨rhcg recombinant human fsh rfsh gonalfr recombinant human chorionic gonadotrophin rhcg ovidrelr and urinary hcg uhcg profasir 250 microg rhcg uhcg￨serum progesterone concentrations clinical pregnancy rate mean number of oocytes incidence of adverse events mean number of mature oocytes incidence of injectionsite reactions tolerated serum hcg concentrations live birth rate￨the incidence of injectionsite reactions was significantly lower in the rhcg group p  00001￨sig decrease￨highunclear￨highunclear￨highunclear
990￨extremely preterm infants thirty female infants with a median gestational age of 266 weeks between 241287 and a birth weight of 675 g 370990￨postnatal estradiol and progesterone replacement e2 and p replacement aiming to maintain plasma levels equaling the intrauterine levels or no replacement￨postnatal bone mineral accretion plasma levels of e2 p fsh and lh uterine volume calcium and phosphorus in spot urine specimens and bone mineral accretion uterine volumes increased and fsh and lh as indicators for biological effectiveness bone mineral accretion rates chronic lung disease plasma levels of e2 and p￨the bone mineral accretion rates tended to be higher and the incidence of chronic lung disease tended to be lower 0 vs 29 p  0097￨sig decrease￨highunclear￨highunclear￨highunclear
41￨fortyone women with threatened preterm labor for whom a clinical decision was made to prescribe antenatal corticosteroids and tocolysis women with threatened preterm labor and cervical length more than 15 mm should not receive￨tocolysis tocolysis corticosteroid therapy cervical length measured by transvaginal ultrasound antenatal corticosteroids￨cervix longer￨tocolysis was given to only seven women 333 in the ultrasound group compared with 20 100 in the control group rr 03 95 ci 015054￨no diff￨low￨low￨low
not found￨preterm premature rupture of membranes women with singleton pregnancies complicated by preterm prom at 2434 weeks gestation women with preterm premature rupture of membranes prom fortyseven and 45 subjects￨endovaginal ultrasound or no vaginal sonography endovaginalultrasound group had weekly vaginal probe ultrasound scans endovaginal ultrasound￨incidence of maternal infection mean latency period initial cervical length neonatal deaths incidence of chorioamnionitis endometritis neonatal infection￨there were no significant differences in the incidence of chorioamnionitis 28 and 20 endometritis 6 and 9 or neonatal infection 17 and 20￨no diff￨highunclear￨highunclear￨highunclear
100￨one hundred women were randomized women with threatened ptl women with threatened preterm labor women with preterm labor ptl￨sonographic cervical length cl and fetal fibronectin ffn￨mean time for evaluation length of evaluation in triage length of evaluation incidence of spontaneous preterm birth sptb￨the knowledge of cl and ffn was associated with reduction in length of evaluation in women with cl  or  30 mm and in incidence of sptb in all women with ptl￨sig increase￨highunclear￨highunclear￨highunclear
400￨four hundred children aged 6 to 12 years with refractive error of spherical equivalent 100 to 600 diopters d and astigmatism of 150 d or less three hundred fortysix 865 childhood myopia asian children￨atropine or vehicle eye drops once nightly for 2 years atropine topical atropine placebo topical atropine atropine￨axial length myopia progression and axial elongation mean progression of myopia and of axial elongation tolerated and effective in slowing the progression of low and moderate myopia and ocular axial elongation occurrence of adverse events efficacy and safety myopia progression spherical equivalent refraction as measured by cycloplegic autorefraction and change in ocular axial length￨the differences in myopia progression and axial elongation between the 2 groups were 092￨no diff￨low￨low￨low
48￨myopia in a random population of children who are known to be very susceptible to myopia children 48 myopic children aged six to 15 years￨undercorrection￨progression myopic progression￨undercorrection produced a slight but not statistically significant increase in myopic progression over the 18month period equal to 017 d compared to full correction￨no diff￨highunclear￨highunclear￨highunclear
96￨ninetysix patients were evaluated 32 in each group myopia￨atropine cyclopentolate atropine 1 eye drops every other night group 2 received cyclopentolate 1 eye drops every night and group 3 received normal saline eye drops every night atropine and cyclopentolate￨progression of myopia mean myopic progression￨the mean myopic progression was 0219 d in the atropine group 0578d in the cyclopentolate group and 0914d in the saline group￨no diff￨highunclear￨highunclear￨highunclear
not found￨schoolchildren two hundred and forty mildly myopic schoolchildren aged 911 years￨minus lenses with full correction for continuous use the reference group 2 minus lenses with full correction to be used for distant vision only and 3 bifocal lenses with 175 d addition spectacle use and accommodation￨school achievement accidents or satisfaction with glasses myopic progression myopic progression average reading distance spherical equivalents rate of myopic progression￨the differences in the increases of the spherical equivalents were not statistically significant in the right eye but in the left eye the change in the distant use group was significantly higher 187 d than in the continuous use group 146 d p  002 students t test￨no diff￨highunclear￨highunclear￨highunclear
not found￨myopia in a treatment group of 138 121 retained subjects wearing progressive lenses pal add 150 d and in a control group of 160 133 retained subjects wearing single vision lenses sv hong kong children between the ages of 7 and 105 years￨progressive addition spectacle lenses￨spherical equivalent refractive error and axial length both measured using a cycloplegic agent myopia and axial length progression of myopia refractive error or axial length￨after 2 years there had been statistically significant increases in myopia and axial length in both groups however there was no difference in the increases that occurred between the two groups￨no diff￨highunclear￨highunclear￨highunclear
469￨children were recruited at four colleges of optometry in the united states and were ethnically diverse 469 children mean age at baseline 93 myopia in children comet enrolled 469 children ages 611 years with myopia between 125 and 450 d spherical equivalent￨progressive addition lenses pals svl single vision lenses svls conventional spectacle treatment pals with a 200 addition n  235 or svls progressive addition lenses versus single vision lenses pal￨change in axial length of the eyes as assessed by ascan ultrasonography progression of myopia in comet children mean changes in axial length number of prescription changes progression of myopia as determined by autorefraction after cycloplegia axial length of eyes of children prescription change￨use of pals compared with svls slowed the progression of myopia in comet children by a small statistically significant amount only during the first year￨sig decrease￨low￨low￨low
178￨178 chinese juvenileonset acquired myopes aged 713 years 050 to 300 one hundred and fortynine subjects 75 in sv and 74 in pal completed the 2year study chinese children￨progressive addition lenses pals pal group or single vision sv progressive addition lenses￨depth of vitreous chamber included myopia progression and ocular biometry baseline spherical equivalent refraction myopia progression￨different near phoria p  001 and gender p  002 caused different treatment effects when wearing sv lenses￨sig decrease￨highunclear￨highunclear￨highunclear
383￨school age children 6 through 12 years of age with myopia between 1 and 4 diopters astigmatism or 2 diopters no prior contact lens wear no other ocular pathologies 428 singaporean children childrens myopia￨intervention rigid gas permeable contact lenses rigid gas permeable lenses rigid gas permeable rgp contact lens wear spectacle or rgp lens correction￨spherical equivalent axial length rate of myopia progression cycloplegic subjective refraction keratometry and axial length￨rigid gas permeable lenses did not slow the rate of myopia progression even among children who used them regularly and consistently￨no diff￨highunclear￨highunclear￨highunclear
117￨children with myopia schoolaged children healthy children aged 8 to 12 years with a spherical equivalent of 075 to 400 diopters d and astigmatism of 100 d or less￨placebo relatively selective m1 antagonist pirenzepine hydrochloride pirenzepine pirenzepine ophthalmic gel or a placebo control twice daily for 1 year pirenzepine ophthalmic gel pirenzepine￨safety and efficacy myopia adverse effects safety and efficacy￨pirenzepine is effective and relatively safe in slowing the progression of myopia during a 1year treatment period￨sig increase￨low￨low￨low
39￨46 children in that study who completed 54 months of followup myopic children with esophoria children with nearpoint esophoria￨￨pattern of change in myopia degree of myopia vitreous chamber growth rate of myopia progression myopia progression￨during the first 24 months the pattern of change in myopia differed between the two groups p  0041 with those in bifocals showing slower progression￨no diff￨highunclear￨highunclear￨highunclear
28￨thirtytwo children all with near point esophoria twentyeight children completed the study￨correction with singlevision or with bifocal lenses containing a 125 d and￨slow myopia progression myopia progression axial length and refraction￨progression was much faster during the first 6 months which was during the school year than during the second 6 months which included all of the summer vacation 064 dyr vs 029 dyr￨sig decrease￨highunclear￨highunclear￨highunclear
353￨three hundred fiftythree healthy children 6 to 12 years old with a spherical equivalent se of 075 to 400 diopters d and astigmatism of or100 d subjects underwent a baseline complete eye examination and regular examinations over a 1year period children with myopia schoolaged children 7 academic centers and clinical practices in asia￨placebo placeboplacebo pirenzepine ophthalmic gel relatively selective m1antagonist pirenzepine ophthalmic gel gel 2 gel twice daily gelgel 2 gel daily evening placebogel or vehicle twice daily placeboplacebo￨mean se refraction adverse events safety and efficacy￨of the 15 serious adverse events reported in 12 subjects all in the active groups none was ophthalmic in nature all subjects recovered and only 1 abdominal colic preceded by a flu was judged possibly related to treatment￨no diff￨low￨low￨low
92￨japanese children ninetytwo children fulfilling the inclusion criteria age 612 years spherical equivalent refractive errors 125 to 600 d￨progressive addition lenses pals singlevision lenses svls progressive addition lenses wearing pals near addition 150 d followed by 18 months of svls wearing svls followed by 18 months of wearing pals￨myopia progression myopia progression as determined by cycloplegic autorefraction￨the use of pals slowed myopia progression although the treatment effect was small as previously reported in ethnically diverse children in the united states￨no diff￨low￨low￨low
94￨94 myopes aged 914 years￨undercorrected group or a fully corrected control group￨rapid myopia progression and axial elongation myopia progression￨undercorrection produced more rapid myopia progression and axial elongation anova f13741432 p001￨sig increase￨highunclear￨highunclear￨highunclear
207￨124 subjects who completed the study subjects who entered the study at an early age with a large amount of myopia and tended to be the least rapid for subjects who entered the study at a later age with a small amount of myopia juvenile myopia each of 207 children between the ages of 6 and 15 years wore single vision lenses 100 d add bifocals or 200 d add bifocals for a period of 3 years￨bifocal lenses￨rate of progression￨it was also found that subjects having withtherule astigmatism progressed more slowly than those having no astigmatism or againsttherule astigmatism￨sig decrease￨highunclear￨highunclear￨highunclear
135￨one hundred thirtyfive 73 girls and 62 boys myopic chinese canadian children myopia of  or 100 diopters d with myopic progression of at least 050 d in the preceding year children with high rates of myopic progression 135 children mean age 1029 years se 015 years mean visual acuity 308 children with an annual progression rate of at least 050 d children with high rates of progression after 24 months￨bifocal lenses singlevision lenses n  41 2 150d executive bifocals n  48 or 3 150d executive bifocals with a 3prism diopters basein prism in the near segment of each lens bifocal and prismatic bifocal spectacles￨axial length secondary axial elongation prismatic bifocals myopic progression myopic progression axial length￨axial length increased an average of 062 mm se 004 mm 041 mm se 004 mm and 041 mm se 005 mm respectively￨no diff￨highunclear￨highunclear￨highunclear
116￨116 subjects to myopia progression in children￨rigid gaspermeable contact lenses rgps and soft contact lenses scls rigid contact lenses wear rgps or scls￨axial growth of the eyes myopia progression axial growth steep corneal meridian corneal curvature 3year change in spherical equivalent cycloplegic autorefraction￨the axial growth of the eyes was not significantly different between treatment groups ancova p  57￨no diff￨highunclear￨highunclear￨highunclear
186￨one hundred and eightysix children from 6 to 13 years of age myopic children￨atropine atropine eye drops or a control treatment￨mean myopic progression fast myopic progression myopic progression controlling myopia myopia progression￨all atropine groups showed significantly less myopic progression than the control group 106061 dy p001￨sig decrease￨highunclear￨highunclear￨highunclear
227￨two hundred and twentyseven schoolchildren with myopia aged from 6 to 13 years who were stratified based on gender age and the initial amount of myopia myopia in children 188 patients available for the followup￨atropine with multifocal glasses multifocal glasses and single vision spectacles atropine andor multifocal lenses atropine atropine and multifocal glasses￨axial length corneal power r009 anterior chamber depth mean progression of myopia progression of myopia intraocular pressure￨the progression of myopia was significantly correlated with the increases of axial length r  065 p  00001 but not with the changes of corneal power r009 anterior chamber depth r  0023 lens thickness r  008 or intraocular pressure￨sig increase￨highunclear￨highunclear￨highunclear
210￨younger children with parental myopia chinese children n  210 with myopia 075 d to 350 d sphere cylinder or150 d chinese children aged 6 to 16 years younger children 6 to 12 years with parental history of myopia n  100￨conventional singlevision spectacle lenses￨rates of progression progression changes in central cycloplegic autorefraction and eye axial length respectively peripheral refraction rate of progression of myopia￨there were no statistically significant differences in the rate of progression of myopia between the control and novel lens wearing eyes for the age group 6 to 16 years￨no diff￨highunclear￨highunclear￨highunclear
50￨uncomplicated typhoid fever in laos patients had been ill for a median range of 8 230 days 50 adults with cultureconfirmed uncomplicated typhoid fever in vientiane laos￨chloramphenicol oral chloramphenicol versus ofloxacin ofloxacin oral chloramphenicol￨median range fever clearance times ileal perforation￨three days ofloxacin was more effective than 14 days chloramphenicol for the inpatient treatment of typhoid fever irrespective of antibiotic susceptibility and was of similar cost￨sig increase￨highunclear￨highunclear￨highunclear
123￨123 adults with fever and signs of uncomplicated typhoid fever isolates of 21 of 64 patients with positive cultures egypt that included patients with multidrug resistance￨ciprofloxacin azithromycin azithromycin azithromycin and ciprofloxacin ampicillin chloramphenicol and trimethoprimsulfamethoxazole￨blood cultures defervescence maximum daily temperatures￨these results indicated that azithromycin and ciprofloxacin were similarly effective both clinically and bacteriologically against typhoid fever caused by both sensitive organisms and mdr s typhi￨no diff￨highunclear￨highunclear￨highunclear
235￨eightynine of 116 children children with uncomplicated multidrugresistant typhoid fever vietnamese children 235 vietnamese children￨oral ofloxacin shortcourse ofloxacin ofloxacin￨nalidixic acidresistant nar adverse events fever clearance times duration of hospitalisation￨eightynine of 116 children randomised to 2 days and 107119 randomised to 3 days were blood culturepositive and eligible for analysis￨no diff￨highunclear￨highunclear￨highunclear
108￨107 uncomplicated multidrugresistant typhoid fever in children vietnamese children between 1 and 15 years of age with suspected typhoid fever 108 children enrolled 100 were blood culture positive for salmonella typhi and 86 of the isolates were multidrug resistant￨oral ofloxacin treatment ofloxacin￨adverse effects therapeutic responses fever and symptoms six clinical failures￨short courses of ofloxacin are simple inexpensive safe and effective for the treatment of uncomplicated multidrugresistant typhoid fever￨no diff￨highunclear￨highunclear￨highunclear
107￨107 adults with uncomplicated enteric fever 95 of whom had positive blood cultures for s typhi and 5 for s paratyphi adults with uncomplicated enteric fever caused by nalidixic acid sensitive strains of s typhi enteric fever￨fluoroquinolones oral ofloxacin ofloxacin￨￨there were 7 treatment failures one in the 2 d group and 6 in the 3 d group p  007￨no diff￨highunclear￨highunclear￨highunclear
438￨438 patients enrolled of whom 286 were  or  14 years old 228 had blood cultures positive for salmonella species s typhi 207 s paratyphi a 19 and s choleraesuis 2 multidrugresistant typhoid epidemic of multidrugresistant typhoid in southern vietnam￨ofloxacin regimens ofloxacin￨toxicity￨otherwise both regimens were completely effective there were no proven carriers and there was no evidence of toxicity particularly in children￨no diff￨highunclear￨highunclear￨highunclear
20￨multiresistant typhoid fever twenty patients patients with resistant strains of salmonella typhi and patients with sensitive strains￨ciprofloxacin ceftriaxone ciprofloxacin ciprofloxacin therapy￨clinical failure mean duration of fever￨the mean duration of fever was four days in the ciprofloxacin group and about five days in the ceftriaxone group p  004￨no diff￨highunclear￨highunclear￨highunclear
55￨55 adult patients with enteric fever to compare￨chloramphenicol ciprofloxacin and chloramphenicol ciprofloxacin￨clinical cure and time to defervescence blood and bone marrow cultures and cytokine profiles cytokine production capacity￨although ciprofloxacin was more effective in the elimination of salmonella enterica serovars typhi and paratyphi a from bone marrow than chloramphenicol there was still an impressive persistence of salmonella in the bone marrow culture 67￨no diff￨highunclear￨highunclear￨highunclear
844￨children and adults clinically diagnosed with enteric fever uncomplicated enteric fever in children and adults 352 patients had bloodcultureconfirmed enteric fever 175 were treated with uncomplicated enteric fever 844 patients with a median age of 16 iqr 922 years￨chloramphenicol chloramphenicol gatifloxacin gatifloxacin versus chloramphenicol gatifloxacin￨treatment failure stoolculture positive treatment failure which consisted of at least one of the following persistent fever at day 10 need for rescue treatment microbiological failure relapse until day 31 and entericfeverrelated complications fever clearance time late relapse and faecal carriage culturepositive relapses adverse events late relapses median time to fever clearance positive stool culture positive stool cultures￨the median time to fever clearance was 395 days 95 ci 368468 in the chloramphenicol group and 390 days 358427 in the gatifloxacin group hr 106 086132 p059￨no diff￨low￨low￨low
not found￨￨pefloxacin￨clinical cure and bacterial eradication rates￨causative microorganisms were salmonella typhi 8 in group a 11 in group b and salmonella paratyphi b 14 in group a 13 in group b￨no diff￨highunclear￨highunclear￨highunclear
241￨vietnamese children and adults with uncomplicated typhoid fever multidrugresistant and nalidixic acidresistant typhoid fever 241 enrolled patients 187 were eligible for analysis 186 s enterica serovar isolates of salmonella enterica serovar mdrnar typhoid fever eightyseven percent 163187 of the patients were children of the s enterica serovar typhi isolates 88 165187 were mdr and 93 173187 were nar￨ofloxacin azithromycin fluoroquinolones nar azithromycin ofloxacinazithromycin combination ofloxacinazithromycin ofloxacin ofloxacin chloramphenicol ampicillin and trimethoprimsulfamethoxazole￨positive fecal carriage immediately posttreatment fever clearance time tolerated clinical cure rate￨the clinical cure rate was 64 4063 with ofloxacin 76 4762 with ofloxacinazithromycin and 82 5162 with azithromycin p  0053￨no diff￨highunclear￨highunclear￨highunclear
60￨typhoid fever sixty hospitalized patients 40 men and 20 women aged from 17 to 64 years affected by severe proven typhoid sepsis￨chloramphenicol pefloxacin pefloxacin￨clinical efficacy and safety￨the two groups of patients were statistically homogeneous regarding both age and sex and all patients were followed for 30 days after the end of therapy￨no diff￨highunclear￨highunclear￨highunclear
69￨69 patients with enteric fever 522 of whom had infection with multidrugresistant mdr strains of salmonella typhi or s paratyphi adult men and nonpregnant and nonlactating women enteric fever￨ciprofloxacin￨serious side effects negative stool cultures growth of s typhi in stool culture relapse sd time required for defervescence￨a 100 cure was observed in each treatment group and no serious side effects were observed￨no diff￨highunclear￨highunclear￨highunclear
42￨typhoid fever in adults 42 patients with bacteriologically documented typhoid fever received either 400 mg￨cotrimoxazole pefloxacin pefloxacin bid pefloxacin￨apyrexia and resolution of digestive and neurological symptoms￨apyrexia and resolution of digestive and neurological symptoms were obtained in a significantly shorter time with pefloxacin than with cotrimoxazole￨sig decrease￨highunclear￨highunclear￨highunclear
390￨390 patients before enrollment uncomplicated enteric fever uncomplicated culture positive enteric fever patients with clinically diagnosed uncomplicated enteric fever meeting the inclusion criteria￨gatifloxacin versus cefixime gatifloxacin or cefixime gatifloxacin gatifloxacin group hr95ci gatifloxacin cefixime cefixime￨overall treatment failure acute treatment failure and relapse fever clearance time fever clearance times acute clinical failure￨median 95 confidence interval fever clearance times were 92 hours 84114 hours for gatifloxacin recipients and 138 hours 105164 hours for cefiximetreated patients hazard ratio95ci  2171 15453051 p00001￨no diff￨low￨low￨low
not found￨adults admitted to a hospital with uncomplicated enteric fever multidrugresistant or nalidixic acidresistant enteric fever 88 blood cultureconfirmed patients were enrolled in the study 86 with salmonella enterica serovar typhi and 2 with s enterica serovar paratyphi a￨azithromycin azithromycin and ofloxacin chloramphenicol ampicillin and cotrimoxazole and nalidixic acidresistant enteric fever azithromycin ofloxacin￨nalidixic acid resistant fever clearance time positive fecal cultures overall clinical cure rate tolerated efficacy and safety￨the mic90 range of azithromycin was 8 4 to 16 microgramml for the isolates￨no diff￨highunclear￨highunclear￨highunclear
358￨358 children and adults with suspected typhoid fever uncomplicated typhoid fever in children and adults in vietnam 287 patients had blood culture confirmed typhoid fever 145 patients received￨azithromycin ciprofloxacin and ofloxacin gatifloxacin gatifloxacin and azithromycin￨excellent efficacy and safety profile fever clearance time overall treatment failure median fct efficacy and safety overall treatment failure clinical or microbiological failure development of typhoid feverrelated complications relapse or faecal carriage of s typhi￨the median fct was 106 hours in both treatment arms 95 confidence interval ci 94118 hours for gatifloxacin versus 88112 hours for azithromycin logrank test p  0984 hr 95 ci  10 080126￨no diff￨low￨low￨low
not found￨41 patients 63 of these isolates were resistant to multiple antibiotics enteric fever￨oral ofloxacin ceftriaxone ofloxacin and ceftriaxone ofloxacin ampicillin chloramphenicol sulfamethoxazole trimethoprim and tetracycline￨salmonella typhi acute treatment failures and one relapse mean standard deviation fever clearance times complete cure￨shortcourse treatment with oral ofloxacin 5 days is significantly better than that with ceftriaxone 3 days and will be of particular benefit in areas where multiresistant strains of s typhi are encountered￨sig increase￨highunclear￨highunclear￨highunclear
287￨heterogeneous congestive heart failure population 287 patients admitted to the hospital with the primary or secondary diagnosis of chf left ventricular dysfunction of less than 40 or radiologic evidence of pulmonary edema for which they underwent diuresis￨4 major components early discharge planning patient and family chf education 12 weeks of telephone followup and promotion of optimal chf medications chf cm￨chf readmissions total inpatient and outpatient median costs and readmission median cost taking chf medication 90day readmission rates 90day readmission rate￨total inpatient and outpatient median costs and readmission median cost were reduced 14 and 26 respectively for the intervention group￨sig decrease￨highunclear￨highunclear￨highunclear
44￨patients with heart failure in the 1st month after discharge heart failure patients are regularly admitted to hospital and frequently use multiple medication patients with heart failure a general teaching hospital in tilburg the netherlands fortyfour patients were included in the control group and 41 in the intervention group￨clinical pharmacist discharge service control group receiving regular care by doctors and nurses￨frequency of prescription errors in the discharge medication and medication discrepancies after discharge combined discrepancy or prescription error percentage of medications with a discrepancy or prescription error￨the percentage of medications with a discrepancy or prescription error in the control group was 146 and in the intervention group it was 61 rr 042 95 ci 027066￨sig decrease￨highunclear￨highunclear￨highunclear
276￨hospital of the university of pennsylvania hospitalized elderly patients were 70 years and older and were placed in selected medical and surgical cardiac diagnosticrelated groups 276 patients and 125 caregivers￨comprehensive discharge planning comprehensive discharge planning protocol￨readmissions fewer total days rehospitalized lower readmission charges and lower charges for health care services patient outcomes length of initial hospital stay length of time between initial hospital discharge and readmission and rehospitalization rates and charges for care charges for initial hospitalization rehospitalizations health services after discharge and nurse specialist services delaying or preventing rehospitalization￨from the initial hospital discharge to 6 weeks after discharge patients in the medical intervention group had fewer readmissions fewer total days rehospitalized lower readmission charges and lower charges for health care services after discharge￨sig decrease￨highunclear￨highunclear￨highunclear
665￨six hundred sixtyfive consecutive inpatients aged 70 and older intervention group ig n  317 control group cg n  348 older adults six acute geriatric units agus in paris and its surroundings very old inpatients￨comprehensive chronic medication review education on selfmanagement of disease and detailed transitionofcare communication with outpatient health professionals multimodal geriatric dischargeplanning intervention multimodal comprehensive dischargeplanning intervention￨emergency rehospitalizations or emergency department ed visits rehospitalizations and ed visits readmitted to hospital eventfree survival￨this intervention was effective in reducing rehospitalizations and ed visits for very elderly participants 3 but not 6 months after their discharge from the agu￨no diff￨low￨low￨low
362￨hospitalized elderly patients elderly patients patients aged 75 years and older on four or more medicines who had been discharged from three acute general and one longstay hospital to a pharmacy intervention or usual care 362 patients of whom 181 were randomized to each group we collected hospital and general practice data on at least 91 and 72 of patients respectively at each followup point and interviewed between 43 and 90 of the study subjects elderly hospitalized patients￨pharmacy discharge plan￨proportion of patients readmitted to hospital number of deaths attendance at hospital outpatient clinics and general practice and proportion of days in hospital over the followup period together with patients general wellbeing satisfaction with the service and knowledge of and adherence to prescribed medication readmission to hospital within 6 months￨there were no significant differences between the groups in the proportion of patients readmitted to hospital between baseline and 3 months or 3 and 6 months￨no diff￨low￨highunclear￨low
50￨fifty hip fracture patients were recruited from a medical centre in taipei taiwan and randomly divided into two groups mean age of 50 hip fracture patients was 7875 sd 699 years hip fracture patients fracture patients￨routine discharge nursing care and the experimental group received comprehensive discharge planning dischargeplanning programme comprehensive dischargeplanning service￨functional status length of stay functional status selfcare knowledge and quality of life qol mean length of stay selfcare knowledge￨the selfcare knowledge of the experimental group was higher than that of the control group f  11569 p  0001￨sig increase￨highunclear￨highunclear￨highunclear
60￨falls and autonomy in the elderly 60 patients mean age 835 yr who were hospitalized for falling were recruited from the acute medicine department older patients hospitalized for falling￨home visits occupational therapist￨falls autonomy hospitalization for falling institutionalization and death rate of falls hospitalization for falls institutionalization and death￨during the followup period the rate of falls hospitalization for falls institutionalization and death were not significantly different between the two groups￨no diff￨highunclear￨highunclear￨highunclear
189￨chronically ill populations patients and general practitioners patients n  189 with chronic cardiorespiratory diagnoses were recruited from respiratory cardiovascular and general medical wards at two tertiary hospitals￨multidisciplinary postdischarge continuance of care intervention discharge care plan in accordance with that outlined in the australian enhanced primary care package completed before discharge and sent to the patients general practitioner and other community service providers for review￨hospital length of stay quality of life discharge satisfaction and hospital length of stay perceptions of mental quality of life length of stay discharge planning involvement health service access confidence with discharge procedures and opinion of discharge based on previous experience quality of life involvement and satisfaction with discharge care and hospitalgeneral practitioner integration extent and speed of hospitalgeneral practitioner communication￨length of stay showed no difference between groups￨no diff￨highunclear￨highunclear￨highunclear
749￨749 englishspeaking hospitalized adults mean age 499 years￨reengineered hospital discharge program￨selfreported preparedness for discharge and frequency of primary care providers followup within 30 days of discharge adverse events emergency department visits and hospitalizations within 30 days of discharge rehospitalization hospital utilization rate of hospital utilization￨the intervention was most effective among participants with hospital utilization in the 6 months before index admission p  0014￨sig increase￨low￨low￨low
not found￨hospitalized patients of 65 years and over from the municipality of rødovre elderly people from the hospital municipality of rødovre and four hospital departments in the county of copenhagen 138 participants in the control group underwent the usual procedures in connection with admission to hospital￨￨number of diagnostic procedures during hospitalization the number of deaths the diagnoses on discharge and the functional capacity average stay in hospital total number of beddays￨three patients from the control group were discharged to residential institutions as compared with none in the intervention￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨individuals with heart failure patients with congestive heart failure￨hospitaltohome transition￨mlhfqs physical dimension and emotional dimension subscales overall minnesota living with heart failure questionnaire mlhfq score generic quality life sf36 physical component mental component and general health subscales quality of life healthrelated quality of life hrql healthrelated quality of life diseasespecific and generic measures rates of readmission and emergency room use￨differences in generic quality life as assessed by the sf36 physical component mental component and general health subscales were not significantly different between the transition and usual care groups￨sig increase￨highunclear￨highunclear￨highunclear
243￨having recruited 243 patients a total of 162 patients completed the full protocol 81 randomly assigned to intervention and 81 to control mean age of control patients 75 years mean age of intervention patients 73 years evaluation of a hospitalbased community liaison pharmacy service in northern ireland patients aged more than 55 years and taking more than 3 prescribed drugs who had been admitted to the medical unit of a district general hospital in northern ireland￨hospital based community liaison pharmacy service￨￨the intervention group patients when compared with control patients had a significant reduction p  0005 in drug mismatch between drugs prescribed at discharge and taken at home and had a greater knowledge of their drug regimen 1014 days after discharge p  0001￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨highrisk patients 70 years of age or older who were hospitalized with congestive heart failure older adults elderly patients with congestive heart failure￨multidisciplinary intervention nursedirected multidisciplinary intervention comprehensive education of the patient and family a prescribed diet socialservice consultation and planning for an early discharge a review of medications and intensive followup￨rates of readmission within 90 days of hospital discharge quality of life and costs of care quality of life and reduce hospital use and medical costs number of readmissions for heart failure number of readmissions overall cost of care qualityoflife scores survival￨a nursedirected multidisciplinary intervention can improve quality of life and reduce hospital use and medical costs for elderly patients with congestive heart failure￨sig decrease￨highunclear￨highunclear￨highunclear
1396￨nine veterans affairs medical centers we randomly assigned 1396 veterans hospitalized with diabetes chronic obstructive pulmonary disease or congestive heart failure to receive either half of those with congestive heart failure 504 patients had disease in new york heart association class iii or iv 30 percent of those with diabetes 751 patients had endorgan damage and a quarter of those with chronic obstructive pulmonary disease 583 patients required￨usual care or an intensive primary care intervention home oxygen treatment or oral corticosteroids￨days of rehospitalization satisfied with their care rates of readmission qualityoflife scores rate of rehospitalization￨the patients in the intervention group were more satisfied with their care p  0001 but there was no difference between the study groups in qualityoflife scores which remained very low p  053￨sig increase￨low￨low￨low
98￨98 patients  or  70 years of age mean 79 6 years admitted with documented congestive heart failure elderly patients with congestive heart failure 550bed secondary and tertiary care university teaching hospital￨nonpharmacologic multidisciplinary intervention social services to facilitate discharge planning dietary teaching by a hospital dietician and close followup after discharge by home care and the study team￨mean number of days hospitalized rehospitalization within the 90day interval and the cumulative number of days hospitalized during followup readmissions repetitive hospitalizations hospital readmissions 90day readmission rate￨the 90day readmission rate was 333 217449 for the patients receiving the study intervention n  63 compared with 457 292622 for the control patients n  35￨no diff￨highunclear￨highunclear￨highunclear
267￨267 patients patients admitted to the ctus between july and october 1990 except those who were admitted directly to an intensive care unit or whose death was expected within 48 hours two of four general medical clinical teaching units ctus￨standard medical care or standard medical care plus mtc services mtc medical team coordinator mtc￨length of hospital stay mean length of stay satisfied with their medical care length of hospital stay￨the mtc intervention reduced the mean length of stay by 197 days p less than or equal to 004 95 confidence interval ci 102 to 292 days￨no diff￨low￨low￨low
835￨half of the highrisk patients 13255 patients screened 835 study participants were identified as at risk for frequent health care resource use￨discharge planning￨length of the index hospital stay unscheduled readmission￨those patients receiving early systematic discharge planning experienced an increased likelihood of successful return to home after hospital admission and a decreased chance of unscheduled readmission for the 9month study period￨sig increase￨highunclear￨highunclear￨highunclear
141￨of 141 randomized patients 111 787 met eligibility criteria geriatric patient admitted from the emergency department private nonprofit academic medical center in a densely populated urban area adults 70 years of age and older admitted from the emergency department to the medicine service nonicu admission who did not have an internist on staff at the admitting hospital emergently admitted older adults￨geriatric evaluation and management model￨cost per patient for laboratory including cardiology graphics services total cost pharmacy costs length of stay total cost of acute hospital care cost of laboratory pharmacy and rehabilitation services mortality or discharge disposition shorter length of stay days of hospitalization cost of hospitalization hospital costs￨patients in the intervention group had 21 fewer days of hospitalization but this shorter length of stay was not statistically significant p  0108￨no diff￨highunclear￨highunclear￨highunclear
152￨patients receiving conventional multidisciplinary care 152 stroke patients undergoing rehabilitation￨integrated care pathway icp icp care coordinated by an experienced nurse n76 or conventional multidisciplinary care￨or length of hospital stay mean duration of physiotherapy higher quality of life scores barthel activities of daily living index institutionalization mortality rates￨patients receiving conventional multidisciplinary care improved significantly faster between 4 and 12 weeks median change in barthel activities of daily living index 6 versus 2 p001 and had higher quality of life scores at 12 weeks 65 versus 59 p007 and 6 months 72 versus 63 p0005￨sig increase￨low￨low￨low
758￨2 acute care universityaffiliated hospitals two acute care hospitals￨personnel to nursing social work physiotherapy occupational therapy or dietary services for potential discharge planning early discharge planning￨length of hospital stay prolonged hospital stay feasibility and efficacy shorter length of stay length of stay￨in hospital a the cases n  421 referred for early discharge planning had significantly shorter length of stay mantelcox p  003 than controls n  420 who were identical for all factors predictive of prolonged length of stay￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients admitted to a small community teaching hospital promptly reconnect patients to their medical home after hospital discharge￨userfriendly patient discharge form and upon arrival at home a telephone outreach from a nurse at their primary care site￨undesirable outcomes￨a lowcost dischargetransfer intervention may improve the rates of outpatient followup and of completed workups after hospital discharge￨sig increase￨highunclear￨highunclear￨highunclear
40￨forty volunteers blepharoplasty￨sodium bicarbonate pain from injection of buffered versus unbuffered local anesthetics given for upper lid and lower lid blepharoplasty local anesthesia￨hemostasis or duration of action onset of action hemostasis or duration of action painful and better tolerated￨no difference in hemostasis or duration of action was noted between the buffered or unbuffered solutions but the buffered solution produced faster onset of action￨no diff￨highunclear￨highunclear￨highunclear
200￨urban ed adults with simple linear lacerations without vascular compromise were enrolled laceration repair seven of 200 enrolled patients were excluded due to improper data collection and 13 were removed from final statistical analysis due to need for additional anesthetic treatment failures leaving 180 subjects for final analysis￨lidocaine lidocaine with epinephrine plain 1 lidocaine with epinephrine and 05 diphenhydramine with epinephrine injectable anesthetics buffered 1 lidocaine lidocaine with epinephrine and buffered lidocaine with epinephrine epinephrine and lidocaine with epinephrine injectable anesthetics epinephrine diphenhydramine diphenhydramine plain lidocaine lidocaine with epinephrine diphenhydramine with epinephrine￨vas readings pain of infiltration and effectiveness of anesthesia pain with infiltration demographic data pain of injection and suturing according to a 10cm visual analog scale vas￨the two buffered compounds were slightly less painful to inject than was lidocaine with epinephrine but statistical comparisons did not reach significance￨no diff￨highunclear￨highunclear￨highunclear
10￨patients undergoing liposuction n  8 blepharoplasty n  7 mammaplasty n  6 and in volunteers n  10 pain during subcutaneous injection of local anaesthetic￨lignocaine with adrenaline lignocaineadrenaline￨pain￨in all four groups the buffered solution caused significantly less pain p  0001 except for mammaplastyp  002￨sig decrease￨highunclear￨highunclear￨highunclear
40￨30 patients 10 patients 40 patients undergoing correction of their prominent ears￨lignocaine ph adjusted lignocaine to lignocaine commercial lignocaine in one ear and the same preparation reconstituted with 1 ml of 84 sodium bicarbonate ph adjusted lignocaine￨obliterating pain pain on infiltration linear analogue pain scores￨buffered lignocaine imparts a significant reduction in pain on infiltration compared to the commercial preparation at both room and body temperature￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨traumatic laceration￨lidocaine lidocaine and buffered lidocaine￨preference ratio pain scores pain of infiltration￨it was found that buffered lidocaine had a preference ratio of 30 over unbuffered lidocaine 95 confidence interval 186 to 484￨no diff￨highunclear￨highunclear￨highunclear
280￨280 healthy adult patients assigned randomly to seven different groups￨lidocaine benzyl alcohol 09 in normal saline 2chloroprocaine 3 lidocaine 1 lidocaine 1 with preservative alkalinized lidocaine 1 with preservative normal saline alkalinized lidocaine benzyl alcohol in normal saline benzyl alcohol catheter placement without previous drug injection alkalinized lidocaine catheter placement normal saline￨pain scores highest mean pain scores mean pain score pain 10cm visual analog pain scale vaps lowest mean pain scores pain of intradermal injection￨alkalinized lidocaine 07  018 had the lowest mean pain score for iv￨sig decrease￨highunclear￨highunclear￨highunclear
20￨twenty patients patients undergoing cardiac catheterization￨lidocaine￨mean pain score severity of pain￨the mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine 27￨sig decrease￨highunclear￨highunclear￨highunclear
98￨98 patients were entered in the study patients aged 16 years and over presenting to the accident and emergency department with a condition requiring digital nerve blockade were considered for inclusion in the study￨injection of both alkalinised and nonalkalinised lignocaine lignocaine￨pain scores pain of digital nerve blockade pain of injection for digital nerve blockade￨the mean difference in pain scores between the nonalkalinised and alkalinised injections was 0739 p  0001 95 confidence interval 047 to 101￨no diff￨highunclear￨highunclear￨highunclear
21￨twentyone patients undergoing bilateral open carpal tunnel decompression open carpal tunnel decompression￨lidocaine local anaesthetic buffered with 84 nahco3 adrenaline lidocaine with sodium bicarbonate￨pain visual analogue scale￨pain especially its burning element was evaluated on a visual analogue scale and was significantly reduced with the buffered solution￨sig decrease￨highunclear￨highunclear￨highunclear
80￨80 healthy women receiving epidural analgesia during labor after catheter placement labor epidural catheter insertion￨lidocaine lidocaine 15 group lb lidocaine 15 with 84 sodium bicarbonate group le lidocaine 15 with epinephrine 1200000 and group leb lidocaine epinephrinecontaining rather than plain lidocaine epinephrine epinephrinecontaining lidocaine epinephrinecontaining lidocaine with bicarbonate epinephrine 1200000 and 84 sodium bicarbonate local anesthetic mixtures epinephrine andor sodium bicarbonate￨superficial bleeding and pain superficial bleeding tolerated and caused no cardiovascular disturbances infiltration pain superficial bleeding amount of superficial bleeding at the catheter site pain during local anesthetic infiltration and epidural catheter movement during labor pain while bicarbonate reduced it verbal score epidural catheter movement￨the addition of epinephrine did not increase pain while bicarbonate reduced it verbal score scale 010 3622 vs 2618 p004￨sig increase￨low￨low￨low
not found￨100 patients received skin wheals with commercially prepared￨lidocaine intradermal anesthesia and comparison of intravenous catheter gauge sodium bicarbonate lidocaine or lidocaine￨catheter insertions pain scores visual analogue pain scores pain scores pain pain of intradermal injection￨there was no statistically significant difference in pain scores between the two local anesthetic solutions￨no diff￨highunclear￨highunclear￨highunclear
7￨subjects for this study were seven children ages 618 years observed during 101 dialysis treatments skin infiltration prior to hemodialysis children requiring hemodialysis￨lidocaine sodium bicarbonate lidocaine l and one containing buffered lidocaine bl￨pain of infiltration or pain of cannulation￨comparisons of selfreported pain and behavioral observations for l versus bl revealed no significant differences for pain of infiltration or pain of cannulation￨no diff￨highunclear￨highunclear￨highunclear
64￨patients undergoing carpal tunnel decompression sixtyfour adult patients carpal ligament decompression under local anaesthesia￨plain lidocaine lidocaine c alkalinized lidocaine alkalinized lidocaine and group c n22 warmed and alkalinized lidocaine￨vas scores on skin infiltration visual analogue scale vas infiltration pain pain on needle insertion and on infiltration injection pain pain on needle insertion pain score￨in groups b and c alkalinized lidocaine the vas scores on skin infiltration were significantly lower than in group a while the pain score in group c alkalinized and warmed lidocaine was significantly lower than in group b￨sig decrease￨highunclear￨highunclear￨highunclear
25￨patients who were allocated to receive￨topical anesthesia with either plain plain group n  25 or alkalinized lidocaine lidocaine alkalinized lidocaine alkalinized lidocaine solution sodium bicarbonate to a plain 1 lidocaine solution￨vas scores on skin infiltration pain on intravenous and epidural catheterization vas score on epidural needle insertion pain verbal analog scale vas pain vas score on intravenous needle insertion￨although the vas score on intravenous needle insertion did not differ between the two groups the vas score on epidural needle insertion was significantly lower in the alkalinized group 13￨no diff￨highunclear￨highunclear￨highunclear
46￨46 women who participated￨lidocaine sodium bicarbonate￨pain pain scores pain scale￨buffering lidocaine with sodium bicarbonate significantly reduced pain scores reported by 46 women who participated in this randomized doubleblind study￨sig increase￨highunclear￨highunclear￨highunclear
184￨surgical patients 184 adult surgical patients￨lidocaine with nahco3 lidocaine with and without 01 meqml of sodium bicarbonate nahco3 lidocaine lidocaine plus nahco3￨pain of skin infiltration intensity of pain using a 100 mm visual analog scale vas pain on skin infiltration catheter gauge and pain pain of skin infiltration and intravenous catheterization￨lidocaine plus nahco3 caused significantly less pain on skin infiltration median vas  4 range  0 to 51 than did lidocaine alone vas  8 range  0 to 48 p  0008￨sig decrease￨highunclear￨highunclear￨highunclear
40￨40 patients outpatient operations￨buffered or control local anaesthetic solutions bicarbonate adrenaline lignocaine with adrenaline ph buffered lignocaine with adrenaline lignocaine￨pain mean pain score￨the mean pain score for the buffered solution was significantly lower than the control solution 306 vs 434 p  0002￨sig decrease￨highunclear￨highunclear￨highunclear
31￨adults university hospital emergency department thirtyone patients were enrolled￨lidocaine plain lidocaine digital nerve blocks by injection of buffered lidocaine￨pain of infiltration￨buffered lidocaine was significantly less painful to administer than plain lidocaine p  001 t  421￨sig decrease￨highunclear￨highunclear￨highunclear
30￨30 consecutive patients undergoing bilateral identical eyelid surgery eyelid anesthesia eyelid surgery￨lidocaineepinephrine solution bacteriostatic saline diluted solution on one side and stock solution on the other and group 3 received buffered solution on one side and bacteriostatic saline diluted solution lidocaine solutions lidocaine with 1100000 epinephrine 2 2 lidocaine with 1100000 epinephrine buffered 91 with 84 sodium bicarbonate and 3 2 lidocaine with 1100000 epinephrine diluted 19 with 09 bacteriostatic saline solution with benzyl alcohol￨mean intraoperative pain scores mean injection pain scores bacteriostatic saline modified solution 5point scale to rate the perceived pain on injection and the pain felt￨comparison of mean injection pain scores showed that buffered solution was significantly less painful than unmodified solution 22 versus 31 p  005 bacteriostatic saline modified solution was significantly less painful than unmodified solution 09 versus 33 p  005 bacteriostatic saline modified solution was significantly less painful than buffered solution 12 versus 23 p  005￨sig decrease￨highunclear￨highunclear￨highunclear
136￨136 children children and adults with simple lacerations children or adults children and adults for the repair of simple lacerations￨lidocaine placebo plain lidocaine pl with buffered lidocaine bl￨adult visual analog scores infiltration pain 10point pain score median vas median nurserated pain score visual analog pain score vas￨the parents median vas was 45 for pl and 40 for bl￨no diff￨low￨low￨low
64￨64 consecutive patients undergoing open carpal tunnel decompression under local anaesthetic to assess the pain experienced on injection of open carpal tunnel decompression￨lidocaine buffered with sodium bicarbonate ph 74 plain lidocaine￨pain scores mean pain scores￨the results showed no statistical difference in the pain scores reported by patients￨no diff￨highunclear￨highunclear￨highunclear
70￨neonates seventy infants with a central venous catheter cvc in place￨central venous catheterrelated coagulasenegative staphylococcal sepsis vancomycin total parenteral nutritioneither the standard solution or a solution containing 25 micrograms of vancomycin per milliliter￨regained birth weight earlier catheterrelated sepsis colonization of catheters by coagulasenegative staphylococci incidence of catheterrelated coagulasenegative staphylococcal sepsis cvc reinsertion adverse effects￨the colonization of catheters by coagulasenegative staphylococci was reduced from 40 to 22 p  003 in the vancomycin group catheterrelated sepsis was reduced from 15 to no cases p  0004￨sig decrease￨low￨low￨low
not found￨newborn infants undergoing percutaneous central venous catheterization seventyfive infants median birth weight 1240 gm median age at catheter insertion 3 days received newborn infants with central venous silicone elastomer catheters neonates with central venous catheters without using prophylaxis with an antibiotic 100 mgkg per day 73 infants in the control group median birth weight 1170 gm median age 2 days received￨no routine prophylactic antibiotic treatment amoxicillin amoxicillin prophylaxis prophylactic amoxicillin￨number of thrombotic septicemia bacterial contamination of the catheter tip at removal duration of catheterization￨no infant receiving amoxicillin had septicemia whereas two infants 27 in the control group did suspected septicemia positive clinical and laboratory findings but negative blood culture results was found in 3 infants in the amoxicillin group and in 6 of the control group not significantly￨no diff￨highunclear￨highunclear￨highunclear
37￨vlbw infants receiving parenteral nutrition 72 infants in the study 37 were randomized to very low birthweight infants￨vancomycin infusions vancomycin vancomycin prophylaxis￨cons infection episodes of cons bacteraemia episode of cons bacteraemia coagulasenegative staphylococcal bacteraemia cons infections cons bacteraemia￨two babies in the treatment group had more than one episode of cons bacteraemia compared with nine in the control group p  002￨sig decrease￨highunclear￨highunclear￨highunclear
60￨ventilator dependent trauma patients 60 enrolled patients who had comparable demographics between groups patients were eligible if they were older than 15 years and either a glasgow coma score gcs 4 with a negative brain computed tomography ct critically ill multiple trauma patients patients who required tracheostomy for facialneck injuries￨tracheostomy intention to treat strategy of tracheostomy placement￨length of ventilator dependence length of ventilator support pneumonia rate or death number of days of mechanical ventilation frequency of pneumonia or icu length of stay number of days of mechanical ventilation frequency of pneumonia and length of intensive care unit icu stay￨there was no significant difference between groups in any outcome variable including length of ventilator support pneumonia rate or death￨no diff￨highunclear￨highunclear￨highunclear
74￨74 trauma patients who were expected to require extended intubation￨prolonged tracheal intubation￨complications laryngotracheal pathology and respiratory infections length of intubation and type of patient injury complication incidence major laryngotracheal pathology as identified by endoscopy and respiratory infections￨significantly more complications occurred in rigidposture headinjured patients than in any other trauma grouping but there was no significant difference in the complication incidence between the two tracheostomy groups within that classification￨sig increase￨highunclear￨highunclear￨highunclear
120￨patients requiring mechanical ventilation one hundred and twenty patients projected to need ventilation 14 days critically ill medical patients critically ill medical patients needing prolonged mechanical ventilation￨delayed tracheotomy early percutaneous tracheotomy within 48 hrs or delayed tracheotomy percutaneous dilational tracheotomy to prolonged translaryngeal intubation delayed tracheotomy percutaneous dilational tracheotomy￨cumulative frequency of pneumonia mortality and accidental extubation mechanical ventilation pneumonia mortality damage to mouth and larynx accidental extubations￨early group showed significantly less mortality 317 vs 617 pneumonia 5 vs 25 and accidental extubations compared with the prolonged translaryngeal group 0 vs 6￨sig decrease￨highunclear￨highunclear￨highunclear
600￨12 italian icus from june 2004 to june 2008 of 600 adult patients enrolled without lung infection who had been ventilated for 24 hours had a simplified acute physiology score ii between 35 and 65 and had a sequential organ failure assessment score of 5 or greater mechanically ventilated adult icu patients patients who had worsening of respiratory conditions unchanged or worse sequential organ failure assessment score and no pneumonia 48 hours after inclusion were randomized to early tracheotomy n  209 145 received patients requiring prolonged ventilation￨tracheotomy or late tracheotomy tracheotomy tracheotomy late tracheotomy￨incidence of pneumonia and increasing the number of ventilatorfree and intensive care unit icufree days number of ventilatorfree days number of icufree days and number of patients in each group who were still alive incidence of ventilatorassociated pneumonia ventilatorassociated pneumonia hazard ratio of developing ventilatorassociated pneumonia￨among mechanically ventilated adult icu patients early tracheotomy compared with late tracheotomy did not result in statistically significant improvement in incidence of ventilatorassociated pneumonia￨no diff￨low￨low￨low
194￨one hundred ninetyfour nonmelancholic depressed outpatients with features of atypical depression took part patients with dysthymic disorder￨imipramine placebo phenelzine imipramine and placebo placebo imipramine hydrochloride phenelzine sulfate and placebo￨￨significantly more patients responded to phenelzine 71 than to imipramine 48 which benefited significantly more patients than placebo 26￨sig increase￨highunclear￨highunclear￨highunclear
67￨67 patients dysthymic disorders patients over 40 years suffering from dysthymic disorders as diagnosed according to dsm iii￨imipramine placebo minaprine and imipramine minaprine minaprine￨hamilton depression rating scale￨minaprine was better tolerated than imipramine according to the physicians tolerance rating p  005 and produced significantly fewer symptoms of the autonomic nervous system as compared to imipramine p  001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨amisulpride and viloxazine viloxazine amisulpride￨hamilton depression scale the widlocher psychomotor retardation scale and the andreasen negative symptoms scale￨the hamilton depression scale the widlocher psychomotor retardation scale and the andreasen negative symptoms scale were used for evaluating cases￨no diff￨highunclear￨highunclear￨highunclear
416￨416 outpatients 271 women and 145 men aged 25 to 65 years with dsmiiirdefined earlyonset primary dysthymia without concurrent major depression patients suffering from this chronic affective disorder￨sertraline vs placebo and p imipramine placebo sertraline hydrochloride and imipramine hydrochloride sertraline pharmacotherapy sertraline imipramine or placebo sertraline and imipramine imipramine vs placebo￨selfrated version of the inventory of depressive symptoms montgomeryasberg depression rating scale adverse events 17item hamilton rating scale for depression hopkins symptom checklist response rates safety and efficacy￨both active treatments resulted in significantly reduced scores on the 17item hamilton rating scale for depression p  04 and p  01 for sertraline and imipramine vs placebo respectively the montgomeryasberg depression rating scale p  01 and p  003 vs placebo respectively hopkins symptom checklist p  05 and the selfrated version of the inventory of depressive symptoms p  05￨sig decrease￨highunclear￨highunclear￨low
50￨fifty outpatients with dysthymic disorder dsmiii dysthymic disorder patients with major depressive disorder￨imipramine placebo ritanserin ritanserin imipramine and placebo ritanserin imipramine and placebo￨side effects￨although imipramine had slightly greater efficacy than ritanserin it also had significantly more side effects￨sig increase￨highunclear￨highunclear￨highunclear
315￨patients were male or female outpatients aged between 18 and 65 years meeting dsmiiir criteria for dysthymia primary type with late or early onset chronic depression dysthymia a total of 315 patients dysthymia dsmiiir￨imipramine placebo moclobemide moclobemide moclobemide and imipramine moclobemide and imipramine moclobemide imipramine and placebo￨efficacy variables ie hamilton rating scale for depression final overall efficacy assessment clinical global impression and symptom check list selfrating anticholinergic symptoms and sleepiness hamilton rating scale for depression safety and antidepressant efficacy pure dysthymia and in doubledepression dsmiiir symptom criteria￨anticholinergic symptoms and sleepiness were significantly more frequent side effects on imipramine than on moclobemide or on placebo and the investigators final overall assessment of tolerability significantly favoured moclobemide over imipramine￨sig increase￨highunclear￨highunclear￨highunclear
265￨265 adult outpatients with dysthymic disorder dsmiii associated with clinically manifest anxiety according to fda criteria anxiousdepressed patients￨tianeptine placebo monotherapy amitriptyline￨anxiousdepressive symptomatology clinical ratingscale scores somatic anxiety madrs total scores hars scores global clinical rating and patients selfrating hscl montgomery and asberg depression rating scale madrs the hamilton anxiety rating scale hars and the checklist for the evaluation of somatic symptoms of jd guelfi and cb pull chess 82 initial madrs total score￨analysis of madrs total scores showed an important and rapid improvement in tianeptine and amitriptyline groups reaching statistical significance as soon as d7￨sig increase￨highunclear￨highunclear￨highunclear
32￨32 dysthymic patients 32 patients suffering from major depression major depression with melancholia and dysthymic disorder dsmiii melancholias and dysthymic disorders￨imipramine phenelzine imipramine and high dose phenelzine￨￨in 32 dysthymic patients phenelzine in high doses was found to be superior to imipramine￨sig increase￨highunclear￨highunclear￨highunclear
not found￨school children aged 810 years school children with initially a low to moderate level of iodine deficiency school children￨iodine interventions iodized salt by researchers with an iodine concentration of 25 ppm group b purchased iodized salt from the market iodized oil capsules containing 400 mg iodine￨median urinary iodine iodine deficiency salt iodine content￨the median urinary iodine was 94 microg l1 at baseline and increased in all groups to  200 microg l1 at the 6month followup￨sig increase￨highunclear￨highunclear￨highunclear
334￨children with goitre compared with those without 404 334 children 168 boys 166 girls at the age of 10 years living in an area of iodine deficiency children 286 children still participated in the study￨voluntary intake of iodinated salt iodinated salt group b n  188 noniodinated salt iodinated salt containing 20 mg of iodine￨neck circumference goitre prevalence and iodine excretion iodine excretion iodine excretion￨iodine excretion in the urine was significantly lower in children with goitre compared with those without 404￨sig decrease￨highunclear￨highunclear￨highunclear
35￨35 pregnant women who live in an area with moderate iodine deficiency￨iodide salt iodoprophylaxis￨thyroidstimulating hormone serum levels iodine excretion and thyroid volume iodine excretion thyroid volume thyroid size thyroid gland size￨the iodine excretion at the third trimester in the treated group was significantly p less than 001 higher than that of group b 1000￨sig increase￨highunclear￨highunclear￨highunclear
60￨women 1540 y and young children  or  6 y from two longhouse villages in the iodinedeficient district of lubok antu sarawak were compared young rural sarawakian children young children in rural sarawak￨salt￨goiter prevalences urinary iodine excretions mean iodine concentrations median urinary iodine excretions mean iodine concentration￨there were significant and sustained increases in median urinary iodine excretions of both women and young children in menjiling in mengkak however significant and sustained increases in median urinary iodine excretions were observed only in women while the median urinary iodine excretions of children remained essentially unchanged throughout the study period￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨potassium iodide or potassium iodate plain unfortified salt￨￨during the same period goitre prevalence remained unchanged in the control zone which received plain unfortified salt￨sig decrease￨highunclear￨highunclear￨highunclear
33￨33 patients with pathologically confirmed malignant ovarian germ cell tumors mogct were referred after initial surgical procedure at the department of oncology hospital de la santa creu malignant ovarian germ cell tumors i 12 patients stage ii 6 patients stage iii 11 patients stage iv 3 patients and unstaged 1 patient the median age was 22 years range 10 to 39 patients with mogct￨postoperative chemotherapy with pombacepav or other platinumcontaining regimens￨alive without evidence of disease recurrence￨no patient has developed recurrence￨no diff￨highunclear￨highunclear￨highunclear
not found￨sixteen ovarian germcell malignancy ogcm patients between 1983 and 1999￨bap bep bap therapy bleomycin actinomycind and cisplatin bap group n10 bleomycin actinomycind and cisplatin bleomycin etoposide and cisplatin￨fiveyear survival rate low hemoglobin alopecia adverse drug reactions adrs neutrophil count￨the fiveyear survival rate was 875 in the bap group and 833 in the bep group and the difference was not significant p05954￨no diff￨highunclear￨highunclear￨highunclear
252￨acute ischemic stroke patients commencing within 72 h of onset acute brain infarction two hundred and fiftytwo patients were initially enrolled￨edaravone novel free radical scavenger edaravone mci186 placebo edaravone￨functional outcome modified rankin scale subarachnoid hemorrhage and disseminated intravascular coagulation￨a significant improvement in functional outcome was observed in the edaravone group as evaluated by the modified rankin scale p  00382￨sig increase￨low￨low￨low
33￨33 women with spasmodic dysmenorrhea 29 women with congestive dysmenorrhea￨relaxation alone or assigned to a waitinglist control condition relaxation training alone or with imagery relaxation alone or relaxation plus imagery or assigned to a waitinglist control condition￨symptom severity general discomfort resting time and medication use￨in experiment 2 18 additional congestives were treated with a coping skills package or this package plus relaxation these two groups were compared with the two congestive groups from experiment 1￨sig increase￨highunclear￨highunclear￨highunclear
11￨eleven female volunteers primary dysmenorrhea￨skin temperature training or emg training of the frontalis muscle biofeedback training skin temperature and emg training￨￨there was no significant difference between treatments f  47 and no significant interaction effect f  174￨no diff￨highunclear￨highunclear￨highunclear
not found￨primary dysmenorrhea fifteen dysmenorrhea sufferers￨emg biofeedback and relaxation training relaxation training relaxation training with emg biofeeddback relaxation training with no feedback or no treatment biofeedback training￨symptoms of dysmenorrhea emg activity level of emg activity elevated level of emg activity￨subjective reports indicated that the symptoms of dysmenorrhea improved for the biofeedback group during training but did not improve for the relaxation or control groups￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨pain management training￨pain discomfort interference and time loss￨following treatment these subjects reported significant reductions in pain discomfort interference and time loss due to dysmenorrheic symptoms relative to their own baselines and to an untreated control group￨sig decrease￨highunclear￨highunclear￨highunclear
24￨childhood crohns disease all 24 children 24 children with active crohns disease seventeen of the children were sex and height matched with healthy siblings of other patients￨dietary intake and nutritional treatment￨energy intake subsequent growth velocity energy intake but vegetables disease activity and duration of remission mean energy intake￨subsequent growth velocity was significantly better in the group treated with the elemental diet despite a greater and more sustained increase in energy intake in the group treated with steroids￨sig increase￨highunclear￨highunclear￨highunclear
55￨fiftyfive children age 132 years children with active steroiddependent crohns disease cd children with newly diagnosed crohns disease children with newly diagnosed moderatetosevere cd￨placebo 6mercaptopurine and prednisone 6mp and prednisone prednisone 6mp prednisone 6mp or placebo 6mercaptopurine 6mp￨duration of steroid use maintenance of remission growth adverse events mild leukopenia aminotransferase activity￨in the 6mp group the duration of steroid use was shorter p0001 and the cumulative steroid dose lower at 6 12 and 18 months p001￨sig decrease￨highunclear￨highunclear￨highunclear
17￨seventeen children with active crohns disease of the small intestine seven children￨elemental diet flexical intramuscular adrenocorticotrophic hormone followed by oral prednisolone with sulphasalazine￨height velocity lloydstill disease activity index erythrocyte sedimentation rate c reactive protein and albumin concentrations and body weight￨the elemental diet was equally effective in inducing an improvement in lloydstill disease activity index erythrocyte sedimentation rate c reactive protein and albumin concentrations and body weight as the high dose steroid regimen￨sig increase￨highunclear￨highunclear￨highunclear
not found￨major liver resection noncirrhotic patients undergoing major liver resection noncirrhotic patients undergoing liver resection patients undergoing major liver resection noncirrhotic patients undergoing major liver resection￨ischemic preconditioning ip with continuous clamping or intermittent clamping ic ip with inflow occlusion intermittent portal triad clamping versus ischemic preconditioning with continuous clamping￨median icu transectionrelated blood loss hospital stay blood loss and shorter transection time demographics asa score type of hepatectomy duration of inflow occlusion range 3075 minutes and resection surface postoperative liver injury postoperative liver injury and intraoperative blood loss peak values of ast alanine aminotransferase and alt aspartate aminotransferase as well as the area under the curve auc of the postoperative transaminase course postoperative complications resection time the need of blood transfusion icu and hospital stay as well as postoperative complications and mortality￨the transectionrelated blood loss was 146 versus 250 ml p  0008 and when standardized to the resection surface 12 versus 18 mlcm p  001 for ip and ic respectively￨sig decrease￨highunclear￨highunclear￨highunclear
108￨between october 2002 and september 2004 108 consecutive patients scheduled to undergo hepatectomy without bilioenterostomy were enrolled￨hepatectomy with intermittent pedicle occlusion ipo hepatectomy using ipo hepatectomy￨bilirubin ratio serum total bilirubin level transection area per unit transection time bilirubin ratio￨the transection area per unit transection time was significantly greater in the latter group median range 10 0421 versus 08 0015 cm2min p  0046￨sig increase￨highunclear￨highunclear￨highunclear
not found￨18 patients we performed hepatectomy in cirrhosis cirrhosis￨continuous and intermittent hepatic pedicle clamping continuous portal triad clamping during liver transection continuous versus intermittent portal triad clamping￨postoperative liver function tests and coagulation profile blood loss operative blood loss operative findings operative mortality postoperative complications￨there were no significant differences between the two groups with regard to postoperative liver function tests and coagulation profile￨no diff￨highunclear￨highunclear￨highunclear
80￨patients with normal liver and undergoing minor hepatectomies patients undergoing minor liver resections cirrhotic patients with minor liver resections eighty patients undergoing minor hepatic resection￨complete versus selective portal triad clamping ast complete clamping cc or selective clamping sc selective hemihepatic vascular occlusion technique cc￨amount of hemorrhage high central venous pressure hvpg 10 mm hg and intraoperative blood loss blood loss alt blood loss measurements of liver enzymes alanine aminotransferase alt aspartate aminotransferase ast and postoperative evolution feasibility safety efficacy amount of hemorrhage postoperative complications and ischemic injury of selective clamping portal pressure and the hepatic venous pressure gradient hvpg postoperative morbidity￨there were no differences on postoperative morbidity between groups 38 versus 29 p  038￨no diff￨highunclear￨highunclear￨highunclear
54￨liver resections performed under selective vascular exclusion fiftyfour patients with resectable liver tumors￨ischemic preconditioning ip group n  27 or with intermittent vascular occlusion ischemic preconditioning versus intermittent vascular occlusion intermittent vascular occlusion technique￨surgical parameters aspartate transaminase levels and apoptosis apoptotic activity higher caspase3 levels blood aspartate transaminase levels￨for warm ischemic time less than 40 minutes no significant difference was noticed between the 2 groups apart from caspase3 activity which was higher in the ivo group than in the ip group 172￨no diff￨highunclear￨highunclear￨highunclear
58￨cirrhotic patients with an overall ischemic time of greater than 60 minutes university hospital and tertiary referral center 58 cirrhotic patients who underwent complex central liver resections with a wide transection plane cirrhotic patients who undergo complex central hepatectomy with a wide liver transection plane cirrhotic patients patients with cirrhosis￨hemihepatic and total hepatic occlusion techniques hemihepatic inflow occlusion total hepatic inflow clamping central liver resection selective clamping of ipsilateral blood inflow￨overall liver ischemic and total operative times postoperative morbidity and postoperative changes in liver enzyme levels operative blood loss and incidence of blood transfusion blood loss overall liver ischemic times liver transection areas operative procedures and area of liver transection plane operative blood loss need for blood transfusion and postoperative morbidity occlusion of hepatic blood inflow hospital deaths￨intermittent hemihepatic and total occlusion of hepatic blood inflow are safe in cirrhotic patients with an overall ischemic time of greater than 60 minutes￨sig increase￨highunclear￨highunclear￨highunclear
52￨major liver resection fiftytwo noncirrhotic patients undergoing major liver resections major liver resections patients undergoing major liver resections under portal triad clamping ptc or under hepatic vascular exclusion hve￨intraoperative and postoperative courses under ptc n  24 or under hve portal triad clamping or hepatic vascular exclusion￨intraoperative blood losses blood loss mean operative duration and mean clampage duration hemodynamic intolerance mean length of postoperative hospital stay postoperative abdominal collections and pulmonary complications￨postoperative abdominal collections and pulmonary complications were 25fold higher after hve but without statistical significance whereas the mean length of postoperative hospital stay was longer after hve￨no diff￨highunclear￨highunclear￨highunclear
86￨liver resection patients with abnormal liver parenchyma patients undergoing patients undergoing major or minor hepatectomy and nature of nontumorous liver parenchyma eightysix patients undergoing liver resections￨cpc ipc liver resections under continuous pedicular clamping cpc or intermittent pedicular clamping ipc continuous versus intermittent portal triad clamping￨major postoperative deterioration of liver function intraoperative blood loss during liver transsection postoperative liver enzymes and serum bilirubin levels blood loss￨in the cpc group postoperative liver enzymes and serum bilirubin levels were significantly higher in the subgroup of patients with abnormal liver parenchyma￨sig increase￨highunclear￨highunclear￨highunclear
13￨13 patients undergoing elective partial liver resection￨10min clamp5min release regime group 1 or a 20min clamp10min release regime hepatic vascular inflow occlusion reperfusion ph and plco2￨liver tissue ph carbon dioxide and oxygen partial pressures ph liver tissue ph partial pressure of carbon dioxide plco2 and partial pressure of oxygen plo2￨in group 2 n  7 the plco2 increased and ph decreased significantly after 10 min of clamping with a further significant change after 20 min￨sig increase￨highunclear￨highunclear￨highunclear
118￨hepatocellular carcinoma patients with cirrhosis one hundred and eighteen 118 patients hcc patients with cirrhosis hepatocellular carcinoma hcc patients with cirrhosis￨cio or a modified technique of hepatic vascular exclusion mthve cio with or without occlusion of the icv below the liver in complex mesohepatectomy modified technique of hepatic vascular exclusion￨incidence of blood transfusion blood loss minimized bleeding limited hepatic function damage and low rate of postoperative complications liver enzyme changes bilirubin or morbidity amount of blood loss measurement of liver enzymes and postoperative progress blood loss during liver transection￨thus incidence of blood transfusion was significantly greater in patients of the cio group p0041￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with recurrent uti or following acute pyelonephritis during pregnancy all pregnant women inclusion criteria were acute symptomatic lower uti acute cystitis significant bacteriuria  or 103 patients with asymptomatic bacteriuria or acute pyelonephritis pregnant women￨fosfomycintrometamol fosfomycin trometamol￨therapeutic success clinical cure and bacteriological eradication of uropathogens urinary tract infection uti￨therapeutic success clinical cure and bacteriological eradication of uropathogens was achieved in 952 of the patients treated with fosfomycintrometamol versus 900 of those treated with ceftibuten p nonsignificant￨no diff￨highunclear￨highunclear￨highunclear
101￨hospitalized women with 12 to 34 weeks of pregnancy with clinical and bacteriological diagnosis of acute pyelonephritis acute pyelonephritis during pregnancy one hundred and one patients were randomized 49 to receive acute pyelonephritis in pregnancy￨cefuroxime cefuroxime versus cephradine cefuroxime cephradine second generation cephalosporins cfps cefuroxime curocefr glaxo wellcome 750 mg tid iv or cephradine cefuroxime and cephradine￨rate of failure rate of resistance of isolated uropathogens rate of bacteriological cure efficacy safety and cost febrile days faster clinical recovery￨patients in the cefuroxime group hed fewer febrile days mean 17 vs 22 p  005 faster clinical recovery mean 27 vs 31 days p  005 a higher rate of bacteriological cure at 28 days 788 and 592 p  005 and lower rate of failure 212 vs 408 p  005￨sig decrease￨highunclear￨highunclear￨highunclear
67￨antenatal pyelonephritis 67 pregnant women who were then treated with appropriate intravenous antibiotics until afebrile and asymptomatic for 48 h￨antibiotic therapy intravenous antibiotics followed by oral antibiotics vs intravenous antibiotics alone antibiotic therapy with oral medication oral nitrofurantoin 100 mg qid or no further antibiotic therapy￨antibiotic suppression risk of recurrent pyelonephritis pyelonephritis positive uc urine cultures uc readmission for pyelonephritis￨completion of 10 days of antibiotic therapy with oral medication does not significantly reduce the risk of recurrent pyelonephritis immediately postparenteral treatment￨no diff￨highunclear￨highunclear￨highunclear
103￨acute uncomplicated urinary tract infections 103 symptomatic pregnant women 103863 obstetric patients with cystitis characterized by urinary urgency and frequency dysuria pyuria and suprapubic discomfort in the absence of systemic symptoms such as fever and costovertebral angle tenderness seventeen patient were excluded since they did not return for followup￨ampicillin nitrofurantoin or ampicillin oral nitrofurantoin￨asymptomatic bacteriuria acute pyelonephritis incidence of cystourethritis overall cure escherichia coli￨overall cure varied from 87 to 89 without any great differences between the regimens￨no diff￨highunclear￨highunclear￨highunclear
179￨g eleven 69 of 159 subjects delivered prematurely 523 acute pyelonephritis in pregnancy 159 subjects had urine cultures positive for organisms one hundred seventynine pregnant women earlier than 24 weeks gestation who had acute pyelonephritis pyelonephritis in pregnancy￨ampicillin and gentamicin 2 iv oral cephalexin cefazolin or 3 intramuscular ceftriaxone ceftriaxone ampicillin and gentamicin cefazolin or ceftriaxone￨length of hospitalization hours until becoming afebrile days until resolution of costovertebral angle tenderness or infecting organism birth outcomes hospital length of stay average birth weight blood cultures recurrent pyelonephritis￨there were no statistically significant differences in length of hospitalization hours until becoming afebrile days until resolution of costovertebral angle tenderness or infecting organism￨no diff￨highunclear￨highunclear￨highunclear
not found￨thirteen of 46 28 outpatients hospitalization exceeded 24 hours twentyone percent of women evaluated were excluded acute pyelonephritis in pregnancy after 24 weeks acute pyelonephritis in pregnancy beyond 24 weeks gestation ninetytwo gravidas past 24 weeks gestation￨oral cephalexin intramuscular ceftriaxone￨positive urine cultures acute pyelonephritis clinical responses or birth outcomes￨there were no significant differences in clinical responses or birth outcomes of inpatients or outpatients treated for acute pyelonephritis after 24 weeks gestation if they completed their assigned protocols￨no diff￨low￨low￨low
160￨160 children aged from 4 to 12 years presenting to an emergency department with acute asthma acute asthma acute asthma in children￨salbutamol 5 mg via the jn salbutamol 25 mg via the jn salbutamol via jet nebuliser vs spacer salbutamol delivered by jet nebuliser jn with salbutamol salbutamol￨pef￨the improvement from baseline at 30 min in the clinical score was 187 for jn and 143 for pmdi p009 and at 60 min was 215 for jn and 112 for pmdi p00001￨sig increase￨highunclear￨highunclear￨highunclear
44￨44 asthmatic patients who presented to the emergency department with acute severe fev1 less than 50 percent predicted airflow obstruction asthmatics with severe airflow obstruction emergency department asthmatics with acute severe airflow obstruction￨mdia and jet nebulizer placebo aerosolized metaproterenol metaproterenol delivered by metereddose inhaler mdi with a spacer device aerochamber a and by jet nebulizer metaproterenol￨fvc and fev1 mean percentage of improvement in fvc and fev1 bronchodilator response￨the mean percentage of improvement in fvc and fev1 in the a group was 335 and 490 percent respectively￨sig increase￨highunclear￨highunclear￨highunclear
75￨patients with acute airflow obstruction acute airflow obstruction subjects in each group 22 copd and 53 asthma 75 patients 45 men and 30 women ages 1873 chi 44 years who presented to the emergency room with acute asthma and copd￨mdi with inspirease reservoir spacer metaproterenol 065 mgpuff via the mdi with inspirease plus nebulizer with placebo or placebo mdi with inspirease plus nebulizer with 15 mg metaproterenol continuous flow nebulizer and metereddose inhaler with reservoir bag bronchodilator aerosols delivered by continuous flow nebulizers￨fev1 and dyspnea scores serum theophylline levels￨there was no significant outcome difference between the two treatments in either diagnostic group￨no diff￨highunclear￨highunclear￨highunclear
27￨27 children nine children per group of between three and six years of age with acute asthma young children with acute asthma￨terbutaline administered by nebuhaler and by nebulizer terbutaline sulphate￨mean baseline clinical score mean clinical scores￨no significant difference was found in the mean baseline clinical score among the three groups and a significant decline occurred in the mean clinical scores in all groups by 15 minutes which was maintained to 60 minutes after the dose was administered￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with acute asthma patients with acute asthma acute asthma forty patients forced expiratory volume in 1 s fev1 115￨albuterol placebo albuterol￨maximal bronchodilation fev1￨albuterol by metered dose inhaler provided similar bronchodilation to that achieved by wet nebulization in patients with acute asthma￨no diff￨low￨low￨low
196￨196 patients with acute asthma aged 415 y acute asthma￨homemade nonvalved spacer for bronchodilator therapy salbutamol through an alternative homemade nonvalved spacer nvs 500 ml mineral water plastic bottle or an oxygendriven nebulizer odn salbutamol￨clinical features oxygen saturation sao2 and the best of three peak expiratory flow rate pefr measurements efficacy and safety clinical and functional respiratory parameters pefr and sao2 pefr sao2 frequency of side effects efficacy and safety heart rate￨during the asthma attacks the odn group needed a prolonged observation in the emergency room p  0000000￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨sixtyfour 12 to 60monthold children with acute recurrent wheezing 32 per group pediatric emergency wards at 2 tertiary teaching hospitals preschool children with recurrent wheezing￨albuterol albuterol highdose albuterol by metereddose inhaler plus a spacer device versus nebulization￨pulmonary index values pulmonary index hospitalization ease of use acceptability and pulse oximetry saturation hospitalization￨less than 10 of the children 3 in each group required hospitalization 2 in each group attributable to treatment failure￨no diff￨low￨low￨low
44￨asthmatic patients 44 adults with asthma peakflow rate varying between 120 and 200 lmin adult asthma patients with nonsevere obstruction￨fenoterol fenoterol jet nebulization and spacer device￨peakflow meter bronchodilation￨no significant difference in bronchodilation was seen between groups a and b
                fenoterol through a spacer can replace inhalation in adult asthma patients with nonsevere obstruction￨no diff￨highunclear￨highunclear￨highunclear
18￨eighteen children with acute asthma children with salbutamol dispensed by the volumatic dispenser or by a nebulizer acute asthma in children with￨salbutamol salbutamol either through a nebulizer and face mask or a dosemetered inhaler spacer volumatic and tidal breathing mechanism nebulized salbutamol￨sideeffect pulmonary function bronchodilation￨no difference in bronchodilation was obvious between the methods of treatment￨no diff￨highunclear￨highunclear￨highunclear
27￨patients with lifethreatening asthma 27 adult asthmatics presenting to the emergency department ed with an fev1 30 predicted subjects with acute severe asthma acute severe asthma with￨chlorofluorocarbon cfcmdi inhaled albuterol salbutamol albuterol solution 5 mg via a nebulizer puritanbennett raindrop lawrenceville ga impelled with oxygen o2 at 8 lmin group b baseline fev1 of 06 015 l received albuterol 400 microg via a cfcmdi attached to a 145ml valved aerosol holding chamber aerochamber trudell medical london on and group c baseline fev1 of 06 017 l received albuterol powder albuterol aerosol and dry powder steroids dexamethasone nebulized solution inhaled albuterol delivered via jet nebulizer metered dose inhaler with spacer or dry powder inhaled albuterol￨population demographics baseline fev1 and arterial blood gas values on air cardiovascular adverse events fev1￨the 6h area under the curve fev1 improved similarly with the three delivery methods despite differences in the total dose administered￨sig increase￨highunclear￨highunclear￨highunclear
33￨33 children 6 to 14 years of age with forced expiratory volume in 1 second fev1 between 20 and 70 of predicted values and who were seen in the emergency department with acute asthma were studied children with acute asthma￨aerosolized albuterol or placebo by mdispacer followed immediately by albuterol or placebo spacer device mdispacer inhaled albuterol albuterol administered by nebulizer versus spacer device￨rate of improvement of clinical score respiratory rate arterial oxygen saturation or fev1 heart rate clinical score respiratory rate arterial oxygen saturation and fev1￨with the exception of heart rate which increased in the nebulizer group and decreased in the mdispacer group p  005 no difference in the rate of improvement of clinical score respiratory rate arterial oxygen saturation or fev1 was noted during the 40minute study period between children who received albuterol by nebulizer and those who received it by mdispacer￨sig increase￨highunclear￨highunclear￨highunclear
150￨a cross sectional study was conducted at emergency room er of national institute of child health nich karachi between october 2000 to march 2001 children were categorized into mild moderate and severe asthma according to medical scoring system children with acute asthma exacerbation in the er 150 children 6 months and older with a history of wheeze and presenting with an acute asthma exacerbation￨beta2agonist by metered dose inhaler mdi with accessory device ad beta2agonist salbutamol by mdiad group a or svn￨all variables dyspnoea use of accessory muscles cyanosis respiratory rate heart rate blood pressure oxygen saturation pulsus paradoxus and wheeze and peak expiratory flow rate pefr pefr baseline characteristics and asthma severity￨pefr increased significantly in both the groups after completion of treatment but pefr was not statistically significant when compared in between groups￨no diff￨highunclear￨highunclear￨highunclear
60￨young hospitalised asthmatic children sixty hospitalised children with asthma aged 15 years acute asthma￨￨￨there were no differences between groups in the score over time or secondary outcome measures￨no diff￨highunclear￨highunclear￨highunclear
60￨60 subjects with acute asthma aged between 1 to 12 years clinical and laboratory assessment of severity at recruitment included acute exacerbation of asthma in children acute asthma￨aerosolized salbutamol aerosolized salbutamol either via nebulizer group i or mdispacer jet nebulizer and metered dose inhaler mdi with spacer jet nebulizer and metered dose inhaler with spacer device salbutamol￨severe dyspnea and intercostal muscle retraction subjective assessment recovery parameters heart rate respiratory rate pulsus paradoxus arterial blood gas analysis all cases and peak expiratory flow rate wherever possible￨mdispacer is as effective as a nebulizer for the aerosolized administration of salbutamol in an acute exacerbation of asthma in children￨no diff￨highunclear￨highunclear￨highunclear
not found￨forty children mean age of 1135 years with acute asthma attacks acute asthma attacks￨placebo salbutamol salbutamol and placebo￨heart rate response cost of treatment costs for medication and spacer devices side effects clinical score forced expiratory volume in one second and side effects clinical score and variation of forced expiratory volume efficacy side effects and cost of treatment of acute asthma attacks￨the cost of treatment was higher for the nebulizer and commercially available spacer p  00001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with acute severe asthma acute severe asthma in the ed asthmatic patients presenting to the emergency department ed with acute severe asthma forced expiratory volume in the first second fev1 less than 50 of predicted￨metereddose inhaler plus spacer mdispacer or by wet nebulization neb neb mdispacer or nebulization salbutamol nebulized salbutamol salbutamol￨salbutamol absorption and higher plasma level incidence of tremor pefr and fev1 anxiety larger systemic absorption of salbutamol salbutamol plasma levels side effects mean peak expiratory flow rate pefr and fev1￨additionally the neb group presented a higher incidence of tremor p03 and anxiety p04 reflecting larger systemic absorption of salbutamol￨sig increase￨highunclear￨highunclear￨highunclear
28￨28 hospitalized asthmatic patients into three groups hospitalized asthmatic patients￨mdi therapy nebulized metaproterenol nebulized albuterol nebulizer therapy albuterol by mdi with inspirease￨fvc and fev1 initial spirometry rates of spirometric improvement and duration of hospitalization daily rates of spirometric improvement and duration of hospitalization￨both nebulizer regimens resulted in significant improvements in both fvc and fev1 by 30 min after initial hospital betaagonist treatment￨sig increase￨highunclear￨highunclear￨highunclear
60￨children  or  six years of age patients  or  six years of age with the diagnosis of acute asthma exacerbation urban childrens hospital emergency department in a pediatric emergency department sixty patients were enrolled in the study￨aerosolized albuterol delivered by mdispacer albuterol￨respiratory rate respiratory rate and percent predicted peak expiratory flow rate pefr respiratory rate and percent predicted pefr￨all three treatment groups showed significant improvement following albuterol therapy in both percent predicted respiratory rate and percent predicted pefr￨sig increase￨highunclear￨highunclear￨highunclear
not found￨acute asthma in an emergency department ed emergency department treatment of severe asthma thirtyfive patients 10 to 45 years of age seeking treatment at an ed for acute asthma thirtythree of 35 patients were treated successfully with the study protocol became asymptomatic and were discharged home￨albuterol by inhaler plus placebo albuterol by nebulizer plus placebo placebo albuterol by nebulizer or by a metereddose inhaler having a holding chamber attachment hereafter inhaler￨maximum mean fev1 baseline mean fev1 fvc or pefr mean fev1 mean fev1 fvc or pefr forced expiratory volume in 1 s fev1 forced vital capacity fvc and peak expiratory flow rate pefr￨there was no detectable difference in effectiveness of albuterol administered by nebulizer or the inhaler system for treatment of acute asthma￨no diff￨low￨low￨low
not found￨participants were children 1 to 4 years of age with moderate to severe acute asthma emergency department at a childrens hospital young children with moderate and severe acute asthma￨placebo placebo mdi spacer versus nebulizer albuterol by metered dose inhaler mdi and spacer versus nebulizer albuterol 600 microg by mdi by spacer aerochamber followed by placebo￨clinical score respiratory rate and oxygen saturation wheezing admission rates of tremor or hyperactivity costs and effectiveness costs and effectiveness baseline characteristics and asthma severity clinical score heart rate respiratory rate auscultatory findings and oxygen saturation mean cost of each emergency department presentation heart rate￨the mdi and spacer combination was a costeffective alternative to a nebulizer in the delivery of albuterol to young children with moderate and severe acute asthma￨sig increase￨low￨low￨low
111￨children with severe asthma one hundred and eleven children with acute asthma acute asthma￨terbutaline and the nebuliser group received 2 ml 50 mg terbutaline solution diluted with 2 ml 09 saline terbutaline by either a metered dose inhaler mdi with a valved holding chamber or a nebuliser driven by air￨peak expiratory flow pef clinical severity score forced expiratory volume frequency of oxygen desaturation sao2 mean sd oxygen saturation spirometry pulse oximetry and clinical severity scoring system pef￨the baseline data of the two groups were not significantly different￨no diff￨highunclear￨highunclear￨highunclear
152￨152 children 2 years and older with a history of at least two episodes of wheezing presenting to the ed with an acute asthma exacerbation children with acute asthma exacerbations in the ed acute asthma exacerbations in children urban pediatric emergency department ed in bronx ny￨betaagonists by metereddose inhaler mdi with a spacer device betaagonist albuterol by an mdi with spacer or by a nebulizer￨episodes of vomiting asthma severity score peak expiratory flow rate in children 5 years or older and oxygen saturation heart rate mean changes in respiratory rate asthma severity score and peak expiratory flow rate oxygen saturation number of treatments given administration of steroids in the ed and admission rate￨fewer patients in the spacer group had episodes of vomiting in the ed 9 vs 20 p  04 and patients in the nebulizer group had a significantly greater mean percent increase in heart rate from baseline to final disposition 15 vs 5 p  001￨sig decrease￨highunclear￨highunclear￨highunclear
61￨sixty one children older than 3 years admitted to a large teaching hospital and a district general hospital with acute asthma completed the study children admitted to hospital with acute asthma children admitted with acute asthma acute asthma in hospital￨salbutamol 100 microg by means of a metered dose inhaler and spacer up to one hourly salbutamol￨morbidity and readmission rates clinical effectiveness acceptability and cost benefit median hospital stay drug costs asthma disability scores￨large volume spacers are an acceptable cost effective alternative to nebulisers in treating children admitted with acute asthma provided that the children can use the mouthpiece and symptoms are not severe￨no diff￨highunclear￨highunclear￨highunclear
not found￨12 patients entered a within patient cross over trial of 4￨insulin regimenstwice daily semisynthetic human soluble and insulin zinc suspension actrapidmonotard hm twice daily porcine soluble and insulin zinc suspension actrapidmonotard twice daily porcine soluble and isophane insulin velosulininsulatard and thrice daily porcine soluble insulin actrapid supplementing once daily bovine ultralente insulin ultratard￨mvalues mean hba1c or fasting lipids prelunch blood glucose hba1c values mean hba1c capillary blood glucose series mvalues hba1c and fasting lipids glycaemic control severe hypoglycaemic events￨patients achieved significantly p less than 001 lower prelunch blood glucose on velosulininsulatard than on any other regimen but severe hypoglycaemic events were more common p less than 005 on this regimen￨sig decrease￨highunclear￨highunclear￨highunclear
40￨type 1 diabetic patients forty patients with type 1 diabetes 20 newly diagnosed and 20 with diabetes of 520 years duration￨￨total frequency of hypoglycaemia frequency severity and symptomatology of hypoglycaemia capillary blood glucose concentration symptomatic response to hypoglycaemia episodes of hypoglycaemia total frequency of symptomatic hypoglycaemia symptoms of hypoglycaemia frequency of severe hypoglycaemia occurrence of asymptomatic biochemical hypoglycaemia frequency severity and symptomatology of hypoglycaemia severe hypoglycaemia￨on comparison of the treatment periods with human and porcine insulins no differences were demonstrated in the total frequency of symptomatic hypoglycaemia 310 vs 306 episodes patient1 3months1 p  094 the frequency of severe hypoglycaemia 01 vs 02 episodes patient1 3months1 p  044 the occurrence of asymptomatic biochemical hypoglycaemia 075 vs 068 episodes patient1 3months1 p  081 and the capillary blood glucose concentration at the onset of hypoglycaemic symptoms 26￨no diff￨highunclear￨highunclear￨highunclear
not found￨six cpeptidedeficient diabetic patients diabetic patients with fasting hyperglycaemia￨porcine lente insulin porcine soluble plus human ultralente with porcine soluble plus porcine lente insulins￨blood glucose mean fasting and postbreakfast blood glucose levels fasting concentrations of glycerol and nonesterified fatty acids overall mean blood glucose concentrations￨mean fasting and postbreakfast blood glucose levels were significantly lower with human ultralente as were fasting concentrations of glycerol and nonesterified fatty acids p less than 005￨sig increase￨highunclear￨highunclear￨highunclear
94￨94 diabetic patients established on treatment with porcine n  47 or bovine n  47 established diabetic patients￨biosynthetic human insulin insulin took part biosynthetic human insulin bhi￨bloodglucose responses fasting blood glucose modified m index and total daily insulin requirement hypoglycaemic episodes mean glucose level and the modified m index hypoglycaemia while taking bhi mean glucose level￨in bovineinsulintreated patients blood glucose before the evening insulin injection was higher on bhi than on bovine insulin 116 vs 100 mmoll￨sig increase￨highunclear￨highunclear￨highunclear
96￨96 insulintreated diabetic patients￨￨incidence of hypoglycaemia igg insulin antibody levels glycosylated haemoglobin levels fasting blood glucose level￨igg insulin antibody levels were identical after human insulin treatment 57  04 microgramsl compared to pork insulin treatment 59  05 microgramsl￨no diff￨highunclear￨highunclear￨highunclear
not found￨diabetes in children 14 children￨porcine insulin standard monocomponent porcine insulin insulin b human versus porcine insulin￨clinical symptoms glycosylated haemoglobin and home blood glucose monitoring overall diabetic control duration of diabetes insulin dose and daily carbohydrate intake onset time and faster peak action time of human insulin blood glucose control￨no clinical reactions to human insulin occurred and there was no significant difference in the daily insulin dose between porcine and human insulin￨no diff￨highunclear￨highunclear￨highunclear
15￨15 patients aged 2058 years mean age36 years were treated with human insulin and 16 diabetics aged 1961 years mean age34 years with mc pork insulin thirtyone diabetic patients never previously treated with insulin￨semisynthetic human insulin mc pork insulin semisynthetic human and porcine monocomponent mc insulin novo during5year observation 005abstract￨level of antibodies serum insulinbinding antibodies￨the development of insulinbinding antibodies during the first year of observation was more rapid in patients treated with mc pork insulin but thereafter it was similar in the two studied groups￨sig increase￨highunclear￨highunclear￨highunclear
50￨50 patients referred by their physicians because of complaints of lack of awareness of hypoglycaemia on human insulin they had had diabetes for a mean of 20 sd 12 years and 70 had good or acceptable glycaemic control patients who reported a reduction of awareness of hypoglycaemia after changing treatment patients reporting lack of hypoglycaemia awareness￨porcine insulin porcine and human insulin human and porcine insulins￨mean percentage of hypoglycaemic episodes hypoglycaemia awareness frequency timing severity or awareness of hypoglycaemia￨we could find no statistically significant differences between the insulin species with respect to glycaemic control or the frequency timing severity or awareness of hypoglycaemia￨no diff￨highunclear￨highunclear￨highunclear
not found￨877 gm compared with 3340 fortythree insulinrequiring pregnant  20 weeks gestation women previously treated with animal insulin diabetic pregnant women infants born to mothers receiving infants of diabetic mothers pregnant diabetic women infants born to mothers receiving human insulin weighed 2880￨human insulin human versus animal species insulin￨glucose excursions insulin antibody levels insulin per kilogram of body weight maternal hyperglycemia or hypoglycemia￨women receiving human insulin required significantly less insulin per kilogram of body weight and showed significant dampening of glucose excursions p  005 for each comparison￨sig decrease￨highunclear￨highunclear￨highunclear
138￨one hundred and thirty eight patients participated newly diagnosed insulin dependent diabetic children with respect to development of insulin antibodies metabolic control and bcell function newly diagnosed insulin dependent diabetic children treated with￨porcine insulin monocomponent human insulin and porcine insulin monocomponent human insulin or monocomponent porcine insulin￨metabolic control insulin dosage and bcell function level of igg insulin binding or the percentage of patients with insulin antibodies log insulin binding values￨there was no difference between the two patient groups throughout treatment either in the level of igg insulin binding or the percentage of patients with insulin antibodies igginsulin greater than 0012 ul￨no diff￨highunclear￨highunclear￨highunclear
9￨9 patients maintained bovine insulin 9 changed to monopic porcine insulin proinsulin less than 10 ppm and 10 to human insulin proinsulin less than 1 ppm type i diabetics who changed from bovine insulin to monopic porcine and monocomponent human insulin type 1 diabetes mellitus twenty eight type i diabetic patients treated with￨bovine insulin with forms more purified of swine and human insulin bovine insulin proinsulin less￨metabolic control insulin antibodies ia fasting blood sugar fbs 24 hour glucosuria and glycated protein gp￨in conclusion there was no improvement of metabolic control in spite of a decrease of ia in type i diabetics treated during 6 months with less immunogenic insulin preparations￨no diff￨highunclear￨highunclear￨highunclear
43￨43 eligible patients in group a and 41 in group 94 aged type 1 diabetic patients on animal insulin aged longstanding type 1 diabetic patients to human insulin￨continue their usual insulin group a n  48 or convert to equivalent preparations of human insulin￨sem and glycosylated haemoglobin frequency and severity of hypoglycaemia hypoglycaemia duration of diabetes hba1c values frequency and intensity of hypoglycaemic episodes quality of life anxiety level hba1c values￨however the anxiety level was significantly lower in group b type 1 diabetic patients were efficiently and safely switched from animal to human insulin without aggravating the incidence of hypoglycaemia in spite of two major risk factors ie advanced age and diabetes of long duration￨sig decrease￨highunclear￨highunclear￨highunclear
30￨insulindependent diabetes mellitus thirty type i diabetic patients who were treated for at least 2 years with a combination of regular and lente monocomponent porcine insulins￨porcine insulin continued porcine insulin treatment or a transfer to the corresponding semisynthetic human insulins￨hemoglobin a1 levels￨the glycemic control as assessed by hemoglobin a1 levels tended to deteriorate in the human insulin group during the first 3 months of the trial and then return to the baseline level￨sig decrease￨highunclear￨highunclear￨highunclear
21￨twentyone patients with noninsulindependent diabetes who had not previously received patients with noninsulindependent diabetes who require insulin therapy noninsulindependent diabetes￨insulin therapy human semisynthetic insulin human semisynthetic insulin and porcine insulin human semisynthetic insulin 10 patients or with an equivalent porcine insulin regimen￨sex ratio age body mass index duration of diabetes cpeptide concentrations baseline metabolic control and initial insulin requirements human semisynthetic insulin and porcine insulin adverse reactions injectionsite anomalies or drugrelated biochemical abnormalities fasting and postprandial plasma glucose levels the concentration of glycosylated haemoglobin serum lipid levels insulin dose and body weight￨no adverse reactions injectionsite anomalies or drugrelated biochemical abnormalities were noted in either group￨no diff￨highunclear￨highunclear￨highunclear
not found￨diabetic patients with high titers of insulin antibody twentynine noninsulindependent diabetic chinese subjects previously treated with the human n  16 and pork insulin n  13￨conventional porcine isophane insulin nph highly purified pork insulin nordisk denmark or human insulin of recombinant dna origin eli lilly usa￨insulin antibody levels immunogenicity glycated hemoglobin values glycated hemoglobin and fasting blood sugar values daily insulin dose fasting blood sugar levels daily insulin doses￨daily insulin dose increased significantly from a mean of 51 units to 57 units p less than 001 4 months after beginning the studyabstract truncated at 250 words￨sig increase￨highunclear￨highunclear￨highunclear
not found￨22 patients fulfilled this criterion elderly type 2 diabetic patients sixtysix patients with secondary failure to oral hypoglycaemic therapy￨humulinzn 12 patients or neulente insulin￨fasting blood glucose concentration hypoglycaemia blood glucose control￨the patients not treated with insulin showed a significant p less than 005 improvement in blood glucose control 2 months after inpatient assessment but this improvement was not sustained to 6 months￨sig decrease￨highunclear￨highunclear￨highunclear
66￨66 insulindependent diabetic subjects pretreated with diabetic subjects pretreated with sixtyfive patients previously pretreated with beef insulin￨pork or beef insulin human insulin and purified beef insulin of the same preparations regular and nph insulin pork insulin human insulin recombinant dna or a purified pork insulin preparation regular and nph insulin human insulin recombinant dna￨severe hypoglycemic attacks or skin reactions fasting and 1h postprandial blood glucose hba1c and daily insulin dosage￨no severe hypoglycemic attacks or skin reactions were reported￨no diff￨highunclear￨highunclear￨highunclear
17￨diabetic patients reporting hypoglycaemia unawareness after transferring to human insulin 17 patients with insulin dependent diabetes mellitus of more than five years duration who had reported altered hypoglycaemia awareness within three months of transferring to human insulin diabetic patients with a history of hypoglycaemia unawareness diabetic patients who reported loss of hypoglycaemia awareness after transferring to human insulin teaching hospital recruiting from diabetes clinics of five teaching hospitals and one district general hospital￨hypoglycaemia with human and porcine insulin insulin slow fall hypoglycaemic clamping with porcine and human insulin￨136 hypoglycaemic episodes biochemical hypoglycaemia mean adrenaline response glycaemic control and frequency of hypoglycaemic episodes￨during controlled hypoglycaemia the mean adrenaline response was 138 nmoll240 min for both insulins neurohormonal responses were triggered at 30 se 02 versus 31 02 mmoll of glucose for adrenaline and 25 01 versus 25 01 mmoll for subjective awareness￨no diff￨highunclear￨highunclear￨highunclear
20￨20 diabetic subjects newly treated with newly treated diabetic subjects￨semisynthetic human insulin and purified porcine insulin insulin porcine insulin semisynthetic human insulin novo and highly purified monocomponent￨binding activity insulin binding activity￨human insulin was shown to be indistinguishable from porcine insulin of comparable purity with respect to plasma glucose and glycosylated hemoglobin levels and insulin dose requirements￨no diff￨highunclear￨highunclear￨highunclear
198￨latinamerican diabetic patients 198 patients from 6 latin american countries a total 198 patients completed the study and were considered evaluable 94 were assigned to the animal insulin group and 104 to the human insulin group latinamerican insulinrequiring diabetic patients￨rdna human insulin￨fasting blood glucose level glycohemoglobin levels episodes of mild hipoglycemia severe unwarned hypoglycemia efficacy and safety￨there were no statistically significant initialfinal changes in the rest of the parameters evaluated although a trend of reduction in glycohemoglobin levels was observed in both groups￨no diff￨highunclear￨highunclear￨highunclear
135￨newly diagnosed type 1 insulindependent diabetic children newly diagnosed diabetic children one hundred and thirtyfive patients at diagnosis of diabetes age 118 years mean age 93 years newly diagnosed type 1 insulindependent diabetic children￨monocomponent porcine insulin monocomponent human insulin human monocomponent insulin monotard mc  actrapid mc or monotard hm  actrapid hm monocomponent human and porcine insulin￨mean insulin antibody levels immunogenicity antibody values insulin antibody values￨at all times the mean insulin antibody levels and the percentage of antibodypositive patients were lower in the human group compared with the porcine group￨sig increase￨highunclear￨highunclear￨highunclear
21￨diabetic children 21 diabetic children￨human insulin and porcine insulin semisynthetic human insulin semisynthetic human insulin and highly purified porcine insulin￨incidence of hypoglycaemia concentrations of antibody reactive with porcine and human insulins glycosylated haemoglobin values higher fasting blood glucose concentrations￨concentrations of antibody reactive with porcine and human insulins were similar for the two treatment groups although greater fluctuation was observed in the amount of antibody reactive with human insulin￨sig increase￨highunclear￨highunclear￨highunclear
10￨twenty iddm patients age 1955 duration 336 years used￨velosulin and insulatard twice daily for 12 weeks doubleblinded to species human h or porcine p￨nocturnal blood glucose blood glucose levels total reported symptomatic episodes number of episodes numbers of episodes of nocturnal or reported hypoglycaemia biochemical hypoglycaemia total hba1 daily insulin doses￨biochemical hypoglycaemia 35 mmol l1 was observed on 39 of the 80 patientnights studied 4875￨no diff￨highunclear￨highunclear￨highunclear
88￨￨human insulin recombinant dna origin and iletin ii pork insulin human insulin￨insulin antibody determinations￨patient followup was done throughout the program by glycohemoglobin assays and selfmonitoring of blood glucose levels￨no diff￨highunclear￨highunclear￨highunclear
7￨16 noninsulindependent diabetic subjects not previously exposed to insulin diabetic subjects with human insulin except those who have developed insulin allergy or those at risk or with a history of allergy noninsulindependent diabetics sixteen patients￨monocomponent porcine insulin monocomponent porcine n  7 insulin human and porcine insulins semisynthetic human insulin novo and highly purified monocomponent porcine insulin￨mean insulin antibody titer significant insulin antibody adverse reaction efficacy and immunogenicity delayed rise of insulin antibodies￨no adverse reaction to either type of insulins was noted￨no diff￨highunclear￨highunclear￨highunclear
20￨twenty type i patients participated￨meal human regular insulin was used with ultralente insulins and comprised 39 bovine insulin human and bovine longacting insulins daily injection of human ultralente b two daily injections of human ultralente c one daily injection of bovine ultralente and d two daily injections of bovine ultralente￨metabolic control severe hypoglycemia blood glucose daily profiles insulin doses hemoglobin alc total and ultralente daily insulin doses frequency of mild hypoglycemia occurrence of hypoglycemia￨44 uday p less than 001 yet the metabolic control achieved was virtually identical during both phases hemoglobin alc 86￨sig increase￨highunclear￨highunclear￨highunclear
24￨diabetic patients treated with highly purified porcine insulin to semisynthetic human insulins of identical formulation twenty four insulin dependent diabetics type i diabetes￨porcine insulin n  11 or human insulin highly purified semisynthetic insulin and highly purified porcine insulin￨mean preprandial capillary blood glucose glycosylated haemoglobin or insulin dose local or systemic adverse reactions insulin antibody levels￨there were no significant changes within the groups nor differences between the groups in mean preprandial capillary blood glucose glycosylated haemoglobin or insulin dose during the first 24 weeks of the study￨no diff￨highunclear￨highunclear￨highunclear
108￨108 patients at four centres in a doubleblind controlled study of eight months duration￨semisynthetic human insulin￨antihuman insulin antibodies glycated haemoglobin hypoglycaemic symptoms the total daily insulin dose and the ratio of short to intermediateacting insulin antibovine insulin antibodies glycaemic control insulin dose and antiinsulin antibodies prelunch blood glucose prebreakfast blood glucose blood glucose￨glycated haemoglobin showed no significant change six months after transfer from either bovine or porcine to human insulin￨no diff￨highunclear￨highunclear￨highunclear
not found￨twentytwo insulindependent diabetic patients insulindependent diabetes mellitus￨porcine nph insulin nordisk semisynthetic human nph insulin novo industri semisynthetic human nph insulin and porcine nph insulin human insulin porcine insulin￨mean hba1c hypoglycaemic events fasting blood glucose level blood glucose level glycosylated haemoglobin insulin requirements and frequency of hypoglycaemic events 24hour blood glucose profiles insulin requirements￨no difference was found in 24hour blood glucose profiles￨no diff￨highunclear￨highunclear￨highunclear
not found￨32 subjects with longterm insulindependent diabetes mellitus iddm 18 subjects started with human and 14 with porcine insulin diabetes mellitus￨human and porcine insulin regular insulin and with protamine nph insulin￨warning symptoms of hypoglycaemia hunger and sweating without concomitant neuroglycopenic symptoms neuroglycopenic symptoms awareness of hypoglycaemia hypoglycaemia blood glucose profiles and hba1c values hypoglycaemia￨hunger and sweating without concomitant neuroglycopenic symptoms were significantly more frequent as initial warning symptoms during porcine than during human insulin 41 vs 20 whereas neuroglycopenic symptoms were more frequent during human insulin￨no diff￨highunclear￨highunclear￨highunclear
not found￨all patients met the following criteria receiving treatment with fast acting soluble insulin and long acting protamine insulin performing multiple daily fingerstick blood glucose self measurements and had stable glycaemic control with about one mild hypoglycaemic episode a week during the preceding two months diabetes outpatient department of a university teaching hospital in berne switzerland 12 patients with a history of recurrent hypoglycaemic coma and the 32 patients without such a history 44 patients 25 men 19 women aged 14 to 60 years with insulin dependent diabetes mellitus 493 questionnaires on hypoglycaemia 234 during treatment with human insulin and 259 during treatment with porcine insulin￨human insulin human insulin and porcine insulin human or porcine insulin￨symptoms and awareness of hypoglycaemia report lack of concentration report hunger questionnaire recording autonomic and neuroglycopenic symptoms insulin doses and blood glucose glycated haemoglobin a1c and fructosamine concentrations restlessness￨insulin doses and blood glucose glycated haemoglobin a1c and fructosamine concentrations were similar during the two treatment periods￨no diff￨highunclear￨highunclear￨highunclear
47￨insulindependent diabetes mellitus 47 insulindependent diabetic patients￨purified pork or human insulin actrapid and monotard novo human insulin novo￨incidence of hypoglycemic reactions mean levels of fasting plasma glucose glycohemoglobin and daily insulin dosages￨mean levels of fasting plasma glucose glycohemoglobin and daily insulin dosages showed no statistical differences between the two groups and there was no significant difference in the incidence of hypoglycemic reactions￨no diff￨highunclear￨highunclear￨highunclear
26￨participants were 26 individuals with history of bp insulin dosage greater than or equal to 200 uday and insulin binding capacities greater than 0216 nm 30 muml serum twentyone participants completed the study patients with insulin antibodymediated immunologic resistance patients with insulinantibodymediated insulin resistance patients with history of antibodyinduced beef insulin resistance to treatment with beef pork human and sulfated beef insulin￨￨mean fasting plasma glucose mean insulin dosage uday immunological and metabolic responses anamnestic immunological response and deterioration of metabolic control insulin dosageday fasting plasma glucose percentage hba1 insulin antibody binding capacity iabc bound insulin bi percentage binding of 125ilabeled b p and h insulins and receptor inhibition factor rif mean iabc bound insulin rif and percentage of b p and h bound￨mean fasting plasma glucose 121 mm and hba1 11 were significantly higher on b than on p h and sb￨sig decrease￨highunclear￨highunclear￨highunclear
101￨adults with schizophrenia 101 children 82 boys and 19 girls mean sd age 8827 years massachusetts medical society children with autism and serious behavioral problems children with autistic disorder children with autistic disorder who have serious behavioral disturbances autistic disorder accompanied by severe tantrums aggression or selfinjurious behavior in children 5 to 17 years old￨placebo risperidone risperidone￨score on the irritability subscale of the aberrant behavior checklist and the rating on the clinical global impressions  improvement cgii scale cgii scale average weight gain increased appetite fatigue drowsiness dizziness and drooling irritability score effective and well tolerated rate of a positive response safety and efficacy￨risperidone was effective and well tolerated for the treatment of tantrums aggression or selfinjurious behavior in children with autistic disorder￨no diff￨low￨low￨low
not found￨adults with autistic disorder and other pervasive developmental disorders symptoms of autism in adults thirtyone adults age meansd 28173 years with autistic disorder n17 or pervasive developmental disorder not otherwise specified n14 patients with autism￨placebo openlabel risperidone serotonin2adopamine d2 antagonist risperidone risperidone risperidone￨extrapyramidal effects cardiac events or seizures repetitive behavior p001 aggression p001 anxiety or nervousness p02 depression p03 irritability p01 and the overall behavioral symptoms of autism p02 social behavior and language￨other than mild transient sedation risperidone was well tolerated with no evidence of extrapyramidal effects cardiac events or seizures￨no diff￨highunclear￨highunclear￨highunclear
not found￨12 subjects with nonexudative amd associated with a relative scotoma and central fixation mean age 81 years sd 507 years people with agerelated macular degeneration amd agerelated macular degeneration￨coloured light filter overlays￨reading rates reading rates in amd￨coloured light filter overlays are unlikely to provide a clinically significant improvement in reading rates for people with nonexudative amd associated with a relative scotoma and central fixation￨no diff￨highunclear￨highunclear￨highunclear
not found￨geriatric patients with post disciform stage exudative agerelated macular degeneration armd or ocular histoplasmosis geriatric patients post exudative maculopathy 37 patients in the low vision program at the central blind rehabilitation center￨￨reading speed and duration of comfortable reading speed reading speed and duration with cctv illuminated stand magnifier and spectacle lenses￨reading speed and duration with cctv illuminated stand magnifier and spectacle lenses were compared for 37 patients in the low vision program at the central blind rehabilitation center￨no diff￨highunclear￨highunclear￨highunclear
225￨people with agerelated macular degeneration by relocating the retinal image people with agerelated macular degeneration patients with agerelated macular degeneration 225 participants completed the trial median age 81 years participants with agerelated macular degeneration received a￨optimal refractive correction 1 custom incorporating bilateral prisms to match participants preferred power and base direction 2 standard incorporating standard bilateral prisms 6 prism diopters delta base up for logmar placebo prism spectacles standard lowvision assessment and the prescription of conventional lowvision aids￨25item national eye institute visual functioning questionnaire and the melbourne lowvision adl activities of daily living distance logmar va reading speed critical print size visual functioning questionnaires and observed visual task performance￨we found no significant effect of treatment group on any of the outcome measures including va the primary outcome adjusted for baseline p  63￨no diff￨low￨low￨low
not found￨patient population comprised 70 sequential visually impaired subjects hospital ophthalmology lowvision clinic￨various electronic vision enhancement systems eves eves with monitor or headmounted display hmd viewing and stand eves with monitor viewing electronic vision enhancement systems eves￨task performance￨reading with the optical magnifier was slower than with the mouse or stand eves with monitor viewing at smaller print sizes p 05￨sig decrease￨highunclear￨highunclear￨highunclear
10￨ten patients with early onset macular disease eomd and 10 with agerelated macular disease amd used the four hmds habitual spectacles and previously prescribed optical lvas to complete a range of clinical measurements and everyday visual tasks patients with macular disease￨electronic headmounted devices hmds jordy flipperport maxport and nuvision with conventional optical lowvision aids lvas￨distance intermediate and near acuities and contrast sensitivity distance and intermediate acuity￨flipperport and jordy provided significantly better distance and intermediate acuity than the previously prescribed optical lvas but near acuity and contrast sensitivity were not consistently better with any of the hmds￨sig increase￨highunclear￨highunclear￨highunclear
10￨people with low vision￨lves vs a popular nonheadmounted video magnifier the cctv headmounted video magnifier lowvision enhancement system lves with closedcircuit tv cctv￨￨the critical print size the smallest print size that could be read at maximum reading speed improved significantly for all participants using lves compared with unaided vision￨sig increase￨highunclear￨highunclear￨highunclear
22￨￨closedcircuit televisions cctvs patient reading performance and preference optical devices handheld cctv innoventions magnicam or standmounted cctv optelec clearview or tsi genie￨subject reading speed duration and preference initial reading performance￨subject reading speed and duration were significantly greater with the cctv systems than with optical devices however no significant performance differences were found between the two types of cctvs￨sig increase￨highunclear￨highunclear￨highunclear
39￨39 subjects from five low vision clinics and compared to a commercial stand magnifier￨￨￨the reading speed of subjects with the new magnifiers increased over time and there was a significant change in preference over time￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨alternative computer visual interface the virtual retinal display vrd￨highest visual acuity reading speed and acuity tests￨fortysix percent of subjects had highest visual acuity while viewing the vrd 30 of subjects had highest acuity viewing the crt and 24 of subjects had equal acuity across the two displays￨sig increase￨highunclear￨highunclear￨highunclear
108￨counselling mothers on their childrens exposure to environmental tobacco smoke smoking mothers in reducing young childrens exposure to environmental tobacco smoke 108 ethnically diverse mothers who exposed their children aged 4 years to tobacco smoke in the home children from environmental tobacco smoke in their homes low income homes in san diego county california￨behavioural counselling￨childrens mean urine cotinine concentrations cotinine concentration￨at 12 months the cotinine concentration in the counselled group was 556 482 to 630 that of controls￨sig increase￨low￨low￨low
291￨households with healthy children large sample of racially and ethnically diverse lowincome families targeting lowincome families with young children participantssmoking parentscaregivers n  291 who had children who were younger than 3 years and who were recruited through primary care settings lowincome households with young children children who are younger than 5 years live with a smoker smoking parents of young children￨project kiss motivational intervention 45minute motivational interviewing session at the participants home with a trained health educator and 4 followup telephone counseling calls motivational intervention mi or a selfhelp sh comparison condition passive smoke exposure theorydriven exposure reduction intervention￨6month nicotine levels nicotine levels household nicotine levels￨the 6month nicotine levels were significantly lower in mi households￨sig decrease￨highunclear￨highunclear￨highunclear
204￨asthmatic latino children san diego california two hundred four latino children ages 317 years with asthma participated latino children￨no additional service control condition or to coaching for ets exposure reduction experimental condition asthma management and environmental tobacco smoke exposure reduction coaching to reduce environmental tobacco smoke ets exposure￨ets exposure and childrens urine cotinine cotinine prevalence cotinine levels mean cotinine levels￨cotinine prevalence decreased from 54 to 40 among coached families while it increased from 43 to 49 among controls￨sig increase￨highunclear￨highunclear￨highunclear
41￨22 subjects in the intervention and 8 in the control group fortyone mothers participated in the study 26 in the intervention group and 15 in the control group child exposure to tobacco smoke interviews regarding mothers smoking habits and selfreported maternal smoking￨environmental tobacco smoke ets counseling method smokefree children￨cotinine levels saliva cotinine samples mean cotinine level cotinine￨after the intervention cotinine levels were reduced in the intervention group 165 ngml and increased in the control group 346 ngml￨sig increase￨highunclear￨highunclear￨highunclear
143￨latino childrens exposure to environmental tobacco smoke ets areas of san diego county with a large latino population 143 latino parentchild pairs latino children￨lay delivered intervention environmental tobacco smoke exposure￨￨significant or near significant time main effects were seen for childrens hair cotinine per cent confirmed reducers and in particular parent reports of exposure￨sig increase￨highunclear￨highunclear￨highunclear
518￨offices of 28 physicians pediatricians and family practitioners and two hospitalbased clinics in the greater portland me area 518 enrolled motherinfant pairs 103 mothers reported that they smoked 10 or more cigarettes per day environmental tobacco smoke exposure during infancy￨￨followup urine cotinine measurements mean log ratio of the followup to initial urine cotinine measurements￨the mean log ratio of the followup to initial urine cotinine measurements was 6 lower in the intervention group than in the control group￨sig decrease￨highunclear￨highunclear￨highunclear
181￨a total of 181 families were recruited to the study in the immediate postnatal period on the basis of a self report questionnaire relating to known family vulnerability factors￨subgroup receiving home based shortterm dynamic therapy from a social worker early homebased intervention series of home visits from a child health nurse￨quality of maternalinfant attachment maternal mood and child health parameters quality of maternalinfant attachment maternal mood secure attachment maternal mood and child health parenting stress index and the edinburgh post natal depression scale￨in particular significant and positive differences were found in parenting with the intervention group feeling less restrictions imposed by the parenting role greater sense of competence in parenting greater acceptability of the child and the child being more likely to provide positive reinforcement to the parent￨sig increase￨highunclear￨highunclear￨highunclear
6527￨elementary schools in four states 6527 subjects in 96 schools in california louisiana minnesota and texas answered questions about behaviors and potential correlates of smoking as part of the catch health behavior questionnaire in spring 1994 elementary school students￨￨smoking experimentation￨school intervention condition was not a factor in the prediction of experimentation￨no diff￨highunclear￨highunclear￨highunclear
501￨501 families with an asthmatic child aged 212 years living with a parent who smoked parents of asthmatic children advising parents of asthmatic children on passive smoking advise parents of asthmatic children￨￨salivary cotinine concentrations salivary cotinine concentrations￨a brief intervention to advise parents of asthmatic children about the risks from passive smoking was ineffective in reducing their childrens exposure to environmental tobacco smoke￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨274 lowincome households containing a child aged 412 years who had asthma￨community health worker intervention highintensity group receiving 7 visits and a full set of resources or a lowintensity group receiving a single visit and limited resources￨asthma symptom days caregiver qualityoflife score pediatric asthma caregiver qualityoflife score￨asthma symptom days declined more in the highintensity group although the acrossgroup difference did not reach statistical significance p138￨no diff￨highunclear￨highunclear￨highunclear
479￨large urban childrens hospital 166 subjects mothers receiving a smoking cessation intervention emphasizing health risks of environmental tobacco smoke ets for their children have a higher quit rate than 1 mothers receiving routine smoking cessation advice or 2 a control group four hundred seventynine mothers￨smoking cessation intervention either aimed at their childs health or their own health or to a control group receiving safety information￨quit rate cigarettesday or stage of change cigarettesday location smoking occurred and knowledge of ets effects maternal smoking behavior knowledge of ets effects￨there was no impact of group assignment on the quit rate cigarettesday or stage of change￨no diff￨highunclear￨highunclear￨highunclear
not found￨parents of young children 952 smoker fathers and mothers 952 smoker fathers and mothers of chinese children aged 5 years￨telephone counselling intervention group received printed selfhelp materials and threesession telephonebased smoking cessation counselling delivered by trained counsellors the control group received printed selfhelp materials only proactive telephone counselling smoking cessation intervention￨crude odds ratio of quitting self reported 24 h point prevalence quit rate and selfreported continuous quit rate and biochemically validated quit rate absolute risk reduction prevalence quit rate￨the absolute risk reduction was 79 95 confidence interval 378 to 1201￨no diff￨low￨low￨low
not found￨121 infants of smoking mothers￨homebased intervention program￨prevalence of persistent lower respiratory symptoms infant passive smoking and lower respiratory illness infant urine cotinine excretion￨the prevalence of persistent lower respiratory symptoms was lower among interventiongroup infants of smoking mothers whose head of household had no education beyond high school intervention group 146 and controls 340￨sig decrease￨highunclear￨highunclear￨highunclear
731￨mothers living in disadvantaged inner city areas disadvantaged inner city mothers on maternal and child health outcomes 731 women from culturally diverse backgrounds with infants￨supportive listening home visits by a support health visitor shv or a year of support from community groups providing drop in sessions home visiting andor telephone support cgs standard health visitor services postnatal social support￨maternal smoking maternal depression￨at 12 and 18 months there was little impact for either intervention on the main outcomes child injury shv relative risk 099 95 confidence intervals 068 to 145 cgs 091 061 to136 maternal smoking shv 086 062 to 119 cgs 097 072 to 133 or maternal depression shv 086 062 to119 cgs 093 069 to 127￨no diff￨low￨low￨low
40￨40 mothers who smoked ten or more cigarettes per day according to their own statement￨￨consumption of tobacco products concentrations of the nicotine metabolite cotinine￨confronting mothers with their initial concentrations of cotinine was not found to be an additional factor reducing tobacco consumption￨no diff￨highunclear￨highunclear￨highunclear
not found￨women with young children young mothers women smokers with young children under the age of 6 who called the cis were given￨american lung association guide freedom from smoking for you and your family and one third received clearing the air telephone counseling tailored selfhelp smoking cessation guides￨smoking behavior attempt quitting and quitting behavior￨there were no significant differences between subjects in the three groups in use of the selfhelp guides methods used to attempt quitting and quitting behavior￨no diff￨highunclear￨highunclear￨highunclear
1483￨a total of 1483 women were randomized into the intervention n  752 and control n  731 group general paediatric wards of four major hospitals in hong kong participants were nonsmoking mothers of sick children admitted to the paediatric ward and with smoking husbands living in the same household children mothers of sick children to decrease passive smoking exposure￨health education intervention nursing educational intervention nurses 1 standardized health advice 2 two purposedesigned booklets about preventing exposure to passive smoking and helping fathers quit 3 a no smoking sticker￨￨baseline comparison showed no significant differences between the two groups in the mothers actions to protect the children from passive smoking exposure￨no diff￨highunclear￨highunclear￨highunclear
not found￨mothers and fathers smoking during the postpartum hospitalization parents who were current smokers 1 cigarette even a puff in past 30 days or recent quitters smoked since 1 month before conception were eligible for the study a total of 101 64 of 159 eligible parents enrolled in the study n  53 control subject n  48 intervention including 72 71 current smokers and 29 29 recent quitters enrolling mothers and fathers into tobacco treatment services during the immediate postpartum hospital stay parents of all newborns who were delivered at a hospital child birth center￨intervention or usual care control condition￨7day abstinence cotinineconfirmed 7day abstinence rates feasibility and acceptability 24hour quit attempts smoking outcomes￨enrolling mothers and fathers into tobacco treatment services during the immediate postpartum hospital stay is feasible and seems to stimulate quit attempts￨sig increase￨highunclear￨highunclear￨highunclear
1142￨young children to parental tobacco smoke 1142 eligible couples parents of newborn babies 1015 were recruited the intervention was offered to 402 and not to 613 families￨educational program￨proportion of mothers who stopped smoking social class and smoking behavior￨the effect was stronger in mothers and in higher social groups￨sig increase￨highunclear￨highunclear￨highunclear
not found￨children with asthma who are exposed to environmental tobacco smoke child with asthma parents smoking behavior in their homes￨passive smoking and advice to quit smoking inside the home￨tobacco smoke￨more treatment 35 than control 17 subjects reported smoking outside their homes at posttest and their childrens cotinine levels were lower but this difference was not statistically significant￨sig increase￨highunclear￨highunclear￨highunclear
150￨150 mothers with children aged 4 years or younger were recruited childrens exposure to environmental tobacco smoke ets community clinics￨behavioral counseling program measuresonly control condition or an intervention consisting of seven behavioral counseling sessions behavioral counseling￨mothers smoking rates childrens urinary cotinine concentrations behavioral contracting selfmonitoring problem solving and positive reinforcement acceptable testretest reliability and validity of measures￨childrens urinary cotinine concentrations did not show significant change over time in either group￨no diff￨highunclear￨highunclear￨highunclear
1062￨by 1999 652 8yold children continued participation childrens tobacco smoke exposure in 1990 1062 healthy infants parental smoking and childrens exposure to tobacco smoke￨least twice a year individualized nutrition and lifestyle counselling repeated infancyonset lifestyle counselling alters parental smoking repeated lifestyle counselling￨serum cotinine concentrations parents smoking serum cotinine concentration childrens cotinine values parental smoking detectable serum cotinine concentration￨however counselling led to no differences in parental smoking between the two groups or in exposure of the intervention and control children to tobacco smoke￨no diff￨highunclear￨highunclear￨highunclear
not found￨nurses to help smoking parents of sick children quit smoking eighty parents who brought their sick children to the hospital were entered into the study parents of sick children￨individualized motivational intervention individualized motivational intervention imi imi from a trained nurse counselor and telephone reminders￨quit rate￨the quit rate at 1 month was 75 95 ci 021 in the intervention group and 25 95 ci 07 in the control group￨no diff￨highunclear￨highunclear￨highunclear
2901￨mothers of newborns fortynine oregon pediatric offices enrolled 2901 women who were currently smoking or had quit for pregnancy using a brief survey at the newborns first office visit￨environmental tobacco smoke ets￨readiness to quit and attitude toward and knowledge of ets maternal smoking and relapse maternal quitting or relapse relapse￨the intervention reduced smoking 59 vs 27 and relapse 55 vs 45 at 6month followup but logistic regression analysis at 12 months revealed no significant treatment effect￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨peoples republic of china prc since the 1960s 12 schoolbased tobaccouse preventionpeoples republic of china may 1989january elementary school students and motivate fathers who smoke to quit the zhejiang center for health education developed and implemented a schoolbased smokingintervention program in the jiangan district of hangzhou from may 1989 through january 1990￨￨cigarette smoking tobacco consumption￨in 1984 when the prevalence of cigarette smoking was 61 among men and 7 among women approximately 250 million persons in prc smoked tobacco products 1￨sig increase￨highunclear￨highunclear￨highunclear
184￨infancy one hundred and eightyfour women who had smoked during pregnancy￨minimal contact group or to a followup only comparison group health education intervention program￨maternal smoking passive smoking￨there were no differences between the groups in the exposure of infants to tobacco smoke￨no diff￨highunclear￨highunclear￨highunclear
443￨families with preschool children 443 consecutive families with one or two smoking parents attending mother and child health centres in oslo norway eighty families 18 dropped out during the study period￨￨daily smoking and smoking quantity passive smoking smoking behaviour￨we found no significant differences between the groups with respect to change in smoking behaviour￨no diff￨highunclear￨highunclear￨highunclear
not found￨smoker parents of children with asthma lowincome parents of children with asthma 136 usualcare controls 128 interventiongroup parents recruited from south australian pediatric hospital outpatient waiting rooms were given￨feedback regarding urinary cotinine and brief tailored advice written and verbal feedback about their 1 to 11yearold childs urinary cotininetocreatinine level information booklets and two telephone calls encouraging a ban on smoking at home￨total daily consumption or consumption in front of the child childrens urinary cotinine level or parental smoking cessation having banned smoking￨the intervention did not change parents propensity to create or maintain bans on smoking in their homes or otherwise change smoking habits to reduce their childrens exposure to ets￨no diff￨highunclear￨highunclear￨highunclear
363￨mothers who received routine smoking cessation advice which focused on their own health or a control group of mothers 363 mothers mothers receiving a￨environmental tobacco smoke ets control group receiving no smoking cessation advice smoking cessation intervention brief intervention smoking cessation intervention either aimed at their childrens health n  111 or their own health￨maternal smoking rate of cessation of smoking and smoking location change￨provision to mothers of both groups of health risks of tobacco smoke resulted in significantly higher rate of cessation of smoking and smoking location change than those of the control group with child intervention group having significantly higher rate of cessation of smoking and smoking location change than those of the maternal intervention group p  005￨sig decrease￨highunclear￨highunclear￨highunclear
95￨asthmatic children eightnine subjects 93 completed the study 95 children￨regular care from a family physician or pediatrician comprehensive home and ambulatory program home and ambulatory program￨small airway function asthma severity school absenteeism medical visits theophylline levels or records of asthma symptoms￨after 1 year more study than control families 721 vs 331 p  006 reported that their asthmatic child took responsibility for the asthma management￨sig increase￨highunclear￨highunclear￨highunclear
not found￨asthmatic children families of asthmatic children 6 to 17 years including at least one parent who smoked in the home recruited from four pediatric allergy clinics asthmatic childrens exposure to environmental tobacco smoke ets￨behavioral counseling intervention behavioral counseling to reduce ets exposure selfmonitoring control and usual medical care control￨￨significantly greater change occurred in the counseling group than the control groups and was sustained throughout the 2 years of followup￨sig increase￨highunclear￨highunclear￨highunclear
303￨socioeconomically disadvantaged sample of women smokers pediatric clinics serving an ethnically diverse population of lowincome families in the greater seattle wash area lowincome women women selfidentified women smokers n  303 whose children received care at participating clinics￨pediatric clinic smoking cessation intervention smoking cessation intervention motivational message from the childs clinician a guide to quitting smoking and a 10minute motivational interview with a nurse or study interventionist pediatricbased smoking cessation intervention￨response rates abstinence rates￨at both followups abstinence rates were twice as great in the intervention group as in the control group 77 vs 34 and 135 vs 69 respectively￨no diff￨highunclear￨highunclear￨highunclear
476￨at 2 yrs of age the intervention group n  222 had less asthmalike symptoms including wheezing shortness of breath and nighttime cough than the control group n  221 443 infants were followedup for 2 yrs 476 highrisk children￨multifaceted educational intervention control group receiving usual care or 2 an intervention group in which families received instruction from nurses on how to reduce exposure of newborns to mite pet and food allergens and passive smoking￨incidence of asthmalike symptoms asthmalike symptoms total and specific immunoglobulin e￨no significant differences in total and specific immunoglobulin e were found between the groups￨no diff￨highunclear￨highunclear￨highunclear
16￨16 children with cystic fibrosis cf and mild lung disease fev1 95 healthy children cystic fibrosis￨receive or not noninvasive nutritional supplementation￨skeletal muscle strength and power skeletal muscle strength and energy intake body composition protein biochemistry muscle power respiratory muscle strength and use of dietary supplements￨skeletal muscle strength and power were similar to those of healthy children as were respiratory muscle strength and endurance￨no diff￨highunclear￨highunclear￨highunclear
102￨102 children with cystic fibrosis aged between 2 and 15 years who were moderately malnourished children with cystic fibrosis who are moderately malnourished improve nutritional and other outcomes children with cystic fibrosis who were moderately malnourished seven specialist paediatric cystic fibrosis centres and their associated shared care clinics and seven smaller paediatric cystic fibrosis clinics children with cystic fibrosis￨oral protein energy supplements oral protein energy supplements￨nutritional status body mass index centile￨long term use of oral protein energy supplements did not result in an improvement in nutritional status or other clinical outcomes in children with cystic fibrosis who were moderately malnourished￨no diff￨low￨low￨low
not found￨72 patients who were enrolled 67 completed the study patients with stable asthma of mild to moderate severity who were treated with￨formoterol longacting beta2agonist formoterol inhaled corticosteroids shortacting beta2agonist terbutaline formoterol 6 micrograms twice daily 24 micrograms twice daily 12 micrograms once daily terbutaline 500 micrograms four times daily or placebo terbutaline methacholine￨tachyphylaxis diurnal control of morning and evening peak flow￨each of the four active treatments exhibited significant tachyphylaxis p  005 to protection against methacholine challenge when comparing firstlast dose as geometric mean protection ratio versus baseline￨sig increase￨highunclear￨highunclear￨highunclear
234￨mildtomoderate asthma 234 patients 150 male and 84 female patients 12 to 73 years old patients with asthma who have symptoms not controlled by antiinflammatory drugs￨placebo salmeterol salmeterol with albuterol salmeterol 2adrenoceptor agonist salmeterol￨morning peak expiratory flow rate salmeterol mean overall symptom score number of days with symptoms and of nights with awakenings forced expiratory volume adverse reactions￨the mean overall symptom score was improved most by salmeterol treatment p  005 with the number of days with symptoms and of nights with awakenings decreasing by 22 percent and 52 percent respectively there were no differences in results between albuterol treatment and placebo administration￨sig increase￨highunclear￨highunclear￨highunclear
45￨severe asthmatic children children with asthma forty five children aged 514 years were enrolled asthmatic children who were symptomatic despite treatment with inhaled corticosteroids in a dose of at least 400 microgday over a one month period paediatric asthma￨salmeterol inhaled corticosteroids salmeterol salmeterol salmeterol 50 microg bd salmeterol 100 microg bd and salbutamol salbutamol￨efficacy asthma control morning and evening pef rates and spirometric indices bronchial hyperreactivity morning pef rate tolerated symptom scores morning and evening peak expiratory flow pef rates use of rescue medication spirometric indices and histamine challenge mean morning pef￨all three treatments improved asthma control morning and evening pef rates and spirometric indices with no change in bronchial hyperreactivity￨no diff￨low￨low￨low
388￨asthmatic patients thirty six patients in the salmeterol and 49 in the salbutamol group withdrew during the 12 months of the study three hundred and eighty eight patients with mild to moderate reversible airways obstruction forced expiratory volume in one second fev1￨salmeterol nor salbutamol salmeterol salmeterol and salbutamol salmeterol 50 micrograms twice daily or salbutamol salmeterol salbutamol￨peak expiratory flow rates pef asthma symptoms mean morning pef fev1 worsening of control of asthma mean diurnal variation in pef lung function￨salmeterol produced a significantly higher mean morning pef mean difference compared with salbutamol 21 95 ci 1231 lmin and a significant reduction in mean diurnal variation in pef from 30 lmin at baseline to 11 34 lmin at baseline to 32 lmin during salbutamol treatment￨sig increase￨highunclear￨low￨low
140￨140 adults with mild to moderate asthma enrolled from 14 respiratory clinics across canada￨salmeterol salmeterol and salbutamol placebo salbutamol￨asthmaspecific quality of life quality of life individual domains activity limitation symptoms emotional function and exposure to environmental stimuli asthma quality of life questionnaire and spirometry at the end of each treatment period and 2 daily asthma symptoms morning and evening peak expiratory flow rates pefrs and rescue salbutamol use asthmaspecific quality of life￨asthmaspecific quality of life both overall and for the individual domains activity limitation symptoms emotional function and exposure to environmental stimuli was better with salmeterol than with placebo p  00001 and better with salmeterol than with salbutamol p  0001￨sig increase￨low￨low￨low
120￨120 moderate asthma patients aged between 1870 yrs patients with asthma￨salmeterol inhaled salmeterol 50 micrograms bid or inhaled salbutamol 400 micrograms bid salmeterol￨asthma quality of life aqlq and rs utilities lung function and change in quality of life quality of life asthma quality of life questionnaire aqlq 2 living with asthma questionnaire lwaq 3 sickness impact profile sip 4 rating scale rs and standard gamble sg utilities rating scale utilities￨except for the aqlq the correlation between change in lung function and change in quality of life was generally low￨no diff￨highunclear￨highunclear￨highunclear
301￨301 patients with road￨formoterol salbutamol￨peak expiratory flow pef measurements the overall mean morning pef duration of action efficacy and tolerability acute reversibility and longterm efficacy￨the tolerability of each drug as reflected by adverse reactions and global assessment was equally good in both groups￨no diff￨highunclear￨highunclear￨highunclear
451￨451 adolescent and adult patients with mildtomoderate asthma asthma in adolescent and adult patients￨placebo salmeterol salmeterol powder 50 micrograms twice daily with albuterol 180 micrograms four times daily or placebo salmeterol salmeterol powder albuterol aerosol￨morning and evening peak expiratory flow percentage of nights without awakening and asthma symptoms percentage of predicted fev1 forced expiratory volume electrocardiographic activity￨significant improvements in morning and evening peak expiratory flow percentage of nights without awakening and asthma symptoms were observed with salmeterol￨sig increase￨highunclear￨highunclear￨highunclear
not found￨asthmatic children children with bronchial asthma two groups of 11 children each with stable asthma￨formoterol and salbutamol formoterol formoterol or salbutamol salbutamol or 2 x 24 micrograms formoterol in monotherapy salbutamol andor formoterol formoterol histamine￨bronchodilatory effect betaadrenoceptor density on mnl and no significant side effects bronchial hyperreactivity bronchial hyperreactivity and betaadrenoceptor density lung function values before and after drug inhalation specific airway resistance sraw forced expiration volume fev1 vital capacity vc lung function￨no changes in the betaadrenoceptor density on mnl and no significant side effects were seen throughout the trial period￨no diff￨highunclear￨highunclear￨highunclear
228￨mildtomoderate asthma 228 patients aged 12 to 76 years with mildtomoderate asthma patients with asthma who use frequent asneeded shortacting bronchodilators despite antiinflammatory treatment patients with mildtomoderate asthma￨inhaled salbutamol inhaled salmeterol salmeterol and salbutamol salmeterol salbutamol salmeterol salbutamol￨morning peak expiratory flow adverse events fev1 symptoms and lung function percentage of nights with no awakenings efficacy and safety￨a single morning dose of salmeterol produced improvement in fev1 that was significantly greater p  or  0012 than that produced by two doses of salbutamol taken 6 hours apart when patients were assessed 3 to 6 hours and 10 to 12 hours after the dose￨sig increase￨highunclear￨highunclear￨highunclear
243￨243 adult patients adult asthma patients with mild to moderate asthma￨salmeterol salmeterol 50 micrograms bd via a diskhaler glaxo inhaler n  121 or terbutaline 500 micrograms qds via a reservoir powder inhaler device longacting inhaled bronchodilator salmeterol with the established inhaled bronchodilator terbutaline salmeterol salmeterol and terbutaline terbutaline￨daytime and nighttime asthma scores percentage of symptomfree days and nights use of additional inhaled bronchodilator and percentage of days and nights mean morning peak expiratory flow pef diurnal variation in pef efficacy and safety pef mean evening￨significant improvements with salmeterol by comparison with terbutaline were also observed in daytime and nighttime asthma scores percentage of symptomfree days and nights use of additional inhaled bronchodilator and percentage of days and nights when no additional inhaled bronchodilator was neededabstract truncated at 250 words￨sig increase￨highunclear￨highunclear￨highunclear
25180￨25180 patients with asthma considered to require regular treatment with bronchodilators who were recruited by their general practitioner n  3516 patients with severe asthma on entry asthmatic patients who require regular bronchodilator treatment￨salmeterol or salbutamol salmeterol with salbutamol salmeterol and salbutamol salmeterol serevent salmeterol salmeterol to one taking salbutamol salbutamol￨mortality and admissions to hospital overall control of asthma medical withdrawals due to asthma serious adverse events asthma events including deaths￨treatment over 16 weeks with either salmeterol or salbutamol was not associated with an incidence of deaths related to asthma in excess of that predicted￨no diff￨highunclear￨highunclear￨highunclear
539￨patients with mildtomoderate persistent asthma patients with mild to moderate persistent asthma patients with asthma 539 adult asthma patients over 12 weeks adult patients with mildtomoderate persistent asthma￨salmeterol salmeterol 42 microg via metereddose inhaler twice daily or albuterol 180 microg four times daily inhaled corticosteroid salmeterol versus albuterol salmeterol￨quality of life domain activity limitation asthma symptoms emotional function environmental exposure scores asthmaspecific quality of life controlling asthma symptoms asthmaspecific quality of life efficacy and safety efficacy safety pulmonary function quality of life pulmonary function and asthma symptoms global aqlq score asthma quality of life questionnaire aqlq￨treatment with salmeterol twice daily produced significantly greater improvements from baseline in all quality of life domain activity limitation asthma symptoms emotional function environmental exposure scores and in the global aqlq score at 12 weeks p  or  038 compared with albuterol treatment four times daily￨sig increase￨highunclear￨highunclear￨highunclear
92￨patients with mild to moderate asthma 29 general practitioners offices asthmatic patients treated in general practice ninetytwo patients with stable asthma￨salmeterol salmeterol serevent and salbutamol ventoline salmeterol 50 micrograms bid or salbutamol salbutamol salbutamol￨peak expiratory flow rate pefr morning and evening before medication asthma symptomscore and use of additional doses of prn￨salbutamol were statistically significant￨no diff￨highunclear￨highunclear￨highunclear
304￨304 patients 146 men 158 women aged 1879 years ill during 0164 years patients with reversible obstructive airway disease road patients with reversible obstructive airway disease￨inhaled formoterol dry powder dp 12 micrograms bid formoterol and salbutamol placebo formoterol inhaled formoterol dry powder formoterol salbutamol dp 400 micrograms inhaled formoterol salbutamol￨efficacy tolerability profile tolerability morning and evening asthma symptoms and sleep disturbances efficacy and safety￨the bronchodilating effect of formoterol assessed by morning premedication pefr was significantly superior to placebo p  00001 and salbutamol p  00001￨sig increase￨highunclear￨highunclear￨highunclear
157￨patients with mild to moderate bronchial asthma 165 patients 157 patients were analysed￨placebo salmeterol regular inhaled salbutamol and salmeterol salbutamol and salmeterol salbutamol salbutamol 400 micrograms qid salmeterol 50 micrograms bid or placebo via a diskhaler salmeterol salbutamol￨minor exacerbation rates evening pefr asthma score mean morning and evening peak expiratory flow rate pefr a composite daily asthma score and minor and major exacerbation rates rebound deterioration in asthma control lung function or bronchial hyperresponsiveness corresponding major exacerbation rates mean morning pefr time spent in major exacerbation daytime symptoms efficacy and safety￨relative to placebo the mean morning pefr increased by 30 lmin 95 ci 26 to 35 for salmeterol but did not change for salbutamol￨sig increase￨low￨low￨low
667￨667 moderate asthmatics who had a forced expiratory volume in one second fev1 or asthmatic patients￨salmeterol salmeterol with salbutamol glucocorticosteroids salbutamol￨peak expiratory flow rate pefr diurnal variation in pefr nocturnal and daytime symptoms and use of additional salbutamol morning and evening pefr safety and clinic lung function tolerated efficacy and tolerability￨throughout the first three month treatment period both morning and evening pefr were significantly higher on treatment with salmeterol than salbutamol mean differences between the treatments 30 lmin1 for morning p  0001 and 11 lmin1 for evening p  001￨sig increase￨highunclear￨highunclear￨highunclear
847￨eight hundred and fortyseven asthmatic children aged between 4 and 16 mean 101 years requiring inhaled beta 2agonist treatment children with mild to moderate asthma children with asthma childhood asthma￨salmeterol salmeterol 50 micrograms bd and 278 patients salbutamol 200 micrograms bd salmeterol 25 micrograms salmeterol 50 micrograms and salbutamol salmeterol salbutamol￨efficacy and safety symptomfree nights daily morning and evening peak expiratory flow pef adverse events mean morning pef incidence of asthma exacerbations lung function rate of occurrence of exacerbations￨patients receiving salmeterol 50 micrograms bd had significantly more symptomfree nights p  001 and a higher percentage of rescue bronchodilatorfree days p  001￨sig decrease￨highunclear￨highunclear￨highunclear
20￨20 asthmatic subjects￨salmeterol salmeterol or salbutamol￨fev1 or ar airway responsiveness mean pefr fev1 and ar peak expiratory flow rate pefr￨there were no statistically significant changes in fev1 or ar between the runin period and any of the post treatment measurements for either of the treatments used￨no diff￨highunclear￨highunclear￨highunclear
60￨patients with bronchial asthma patients with mildtomoderate asthma 53 analyzable patients 25 were of the salmeterol group and 28 of the salbutamol group￨salmeterol salmeterol 50 mg twice a day or salbutamol inhaled salmeterol salbutamol￨morning pefr and asthma symptoms scores improvement rate of morning fev1 and pefr number of rescue medication inhaled side effects heart rate blood pressure serum potassium dosage and electrocardiograms symptoms improvement rate nocturnal symptoms side effects values of fev1 efficacy and safety￨our results showed that in the runin period there were not differences among the groups comparing the values of fev1 in  predicted morning pefr and asthma symptoms scores￨no diff￨highunclear￨highunclear￨highunclear
145￨145 stable adult asthmatics in a 12wk multicenter trial stable asthma￨formoterol formoterol 12 micrograms twice a day or albuterol inhaled formoterol a longacting beta 2agonist with inhaled albuterol￨morning fev1 30 min postdrug mean baseline fev diurnal variation in prebronchodilator peak flow rates number of asthma episodes number of sleep disruptions￨morning fev1 30 min postdrug was significantly higher in the formoterol group at weeks 2 and 8 the trend not reaching statistical significance at other times￨sig increase￨highunclear￨highunclear￨highunclear
367￨patients with mildtomoderate asthma with asthma symptoms and related the effectiveness of these therapies between patients who used concurrent inhaled corticosteroids ics and those who did not 367 adult asthmatics patients with asthma￨salbutamol sb salmeterol sm placebo inhaled sb ics salmeterol and salbutamol￨morning and evening peak expiratory flows pef assessment of asthma symptoms and use of rescue medication pef percentage of symptomfree days and rescuefree days and nights with no sleep disturbance￨sb was more effective than p in increasing evening pef and the percentage of symptomfree days p  005 and rescuefree days p  00001￨sig increase￨highunclear￨highunclear￨highunclear
541￨541 patients patients with mild to moderate persistent asthma￨formoterol powder placebo formoterol formoterol formoterol dry powder inhaler with albuterol metereddose inhaler placebo or albuterol formoterol 12 microg twice daily formoterol￨adverse events adverse effects and clinical laboratory parameters nocturnal awakenings efficacy safety and tolerability asthma symptom scores morning and evening peak expiratory flow rates lung function asthma symptoms and frequency of rescue albuterol use rescue medication￨morning and evening peak expiratory flow rates were more improved with formoterol and formoterol provided significantly greater improvements in asthma symptom scores compared with both albuterol and placebo￨sig increase￨low￨low￨low
190￨190 patients with a forced expiratory volume in one second fev1 or peak expiratory flow rate pefr of 3075 predicted and 15 reversibility to inhaled bronchodilator asthmatic patients asthmatic patients who were not controlled on high doses of moderatetosevere asthmatics uncontrolled on highdose inhaled steroids￨inhaled salbutamol inhaled salmeterol inhaled steroids salmeterol beclomethasone dipropionate bdp￨morning pefr diurnal variation symptomfree nights adverse event profile lung function and reduces asthma symptoms rescuefree nights fev1 efficacy and safety￨the sm group had significantly more symptomfree nights than the sb group p  0001 and also more rescuefree nights p  004￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨343 patients received either eightynine percent used inhaled corticosteroids patients with asthma￨placebo formoterol 12 microg bid f terbutaline 500 microg qid t or placebo qid longacting beta2agonist formoterol and the shortacting terbutaline formoterol with terbutaline via turbuhaler formoterol or terbutaline￨nighttime asthma efficacy and safety morning pef￨formoterol turbuhaler 12 microg bid was more effective than terbutaline turbuhaler 05 mg qid and placebo￨sig increase￨highunclear￨highunclear￨highunclear
397￨397 adults with mild to moderate asthma￨placebo formoterol lowdose formoterol formoterol turbuhaler 6 micrograms bid terbutaline￨bronchodilator response mean morning peak expiratory flow pef morning pef￨f was better than t p  0014 and p p  00001 in improving morning pef￨sig increase￨highunclear￨highunclear￨highunclear
20￨asthmatic patients receiving highdose inhaled corticosteroids asthmatic patients requiring highdose inhaled steroids 20 patients with moderate to severe asthma who were all receiving highdose inhaled corticosteroids and inhaled beta 2agonist on demand￨placebocontrolled manner either salmeterol salmeterol inhaled salmeterol albuterol salmeterol inhaled salmeterol and albuterol￨reduced requirement of rescue albuterol soluble interleukin 2r sil2r eosinophil cationic protein ecp and tryptase of salmeterol tlymphocyte activation concentrations of ecp and tryptase serum concentration of sil2r efficacy rating better morning and mean peak expiratory flow daytime and nocturnal symptoms￨compared with albuterol salmeterol treatment was associated with better morning and mean peak expiratory flow p  0013 and 0016 respectively less daytime and nocturnal symptoms p  0008 and 001 respectively reduced requirement of rescue albuterol p  004 and better efficacy rating by patients p  004￨sig increase￨highunclear￨highunclear￨highunclear
90￨patients with abdominoperineal resection 90 patients with resection of colorectal carcinoma￨mezlocillin and 05 g metronidazole￨aerobic bacteria wound infection￨besides those 26 infections of the urinary tract were observed which occurred significantly more often after the oneshot dose 409 than with the shorttime prophylaxis 186￨sig increase￨highunclear￨highunclear￨highunclear
157￨elective colorectal surgery 157 patients undergoing elective colorectal surgery￨doxycycline doxycycline prophylaxis metronidazole or doxycycline metronidazole doxycycline￨anaerobic bacteria infectious complications￨doxycycline thus was significantly more effective in preventing complications in general but metronidazole gave superior protection against anaerobes￨sig increase￨highunclear￨highunclear￨highunclear
62￨mean age of the population was 645 years 56 patients patients having a history of allergy to betalactam antibiotics and those with preoperative infection were excluded 115 cases a 36 patients b 37 patients c 42 patients colonic and rectal surgery two hundred and seventeen patients undergoing abdominal colonic and rectal surgery received after randomization the following regimen group a 74 patients seventyseven patients had rectal cancer and 82 patients cancer of the colon twentyfive patients had inflammatory bowel disease and in 33 others disease such as polyposis was present￨metronidazole ornidazole or metronidazole 05 g intravenous at the induction of anaesthesia and 05 g intravenous with the last injection of cefotaxime cefotaxime cefotaxime 1 g intravenous at the induction of anaesthesia￨severe sepsis sepsis severe sepsis severe sepsis included septicaemia peritonitis intraabdominal abscess and extraabdominal infections with death￨postoperative peritonitis was not seen￨no diff￨highunclear￨highunclear￨highunclear
not found￨elective colorectal surgery undertaken in district general hospitals patients undergoing elective colorectal surgery￨netilmicin and metronidazole piperacillin￨incidence of operationrelated infection chest or urinary tract infection major lifethreatening sepsis overall incidence of operationrelated infection￨there was no significant difference in the incidence of operationrelated infection chest or urinary tract infection￨no diff￨highunclear￨highunclear￨highunclear
628￨628 patients from seven finnish hospitals patients undergoing colorectal surgery colorectal surgery￨aminoglycoside ceftriaxone ceftriaxone with tinidatsole versus aminoglycoside netilmycin 150 mg or tobramycin￨wound infection wound infection rate perioperative blood loss duration of the operation type of operation and drainage￨wound infection was related to the amount of perioperative blood loss duration of the operation type of operation and drainage in the aminoglycoside group￨sig decrease￨highunclear￨highunclear￨highunclear
132￨132 patients who underwent elective surgery of the colon the value of bowel preparation with a conventional oral antibiotic preparation of 125 patients who were available for assessment 61 received ne and 64 em￨neomycinerythromycin ne oral neomycin plus erythromycin erythromycinmetronidazole erythromycinmetronidazole em￨￨two wound infections occurred in patients receiving em neither due to anaerobic bacteria but seven wound infections developed in patients given ne p  0057 five of them caused by anaerobic bacteria￨no diff￨highunclear￨highunclear￨highunclear
700￨700 emergency and elective highrisk abdominal operations abdominal surgery￨prophylactic antibiotics metronidazole plus 1 g cephazolin￨antibiotic plasma concentrations nonfatal deep sepsis appendicitis wound infection rates wound infection rates postoperative infection body mass index bmi￨wound infection rates which included minor and delayed infections were similar in both groups group p 57 of 342 167 per cent group t 55 of 358 154 per cent 95 per cent confidence intervals for the difference being 41 to 67 per cent￨no diff￨highunclear￨highunclear￨highunclear
77￨77 patients undergoing elective colorectal surgery elective colorectal surgery￨cefoxitin systemic antibiotic prophylaxis cefoxitin and cephalothin systemic antibiotics￨postoperative sepsis transient skin rashes infection rate specific drug toxicity￨the reduction in the infection rate in the group treated by cefoxitin was statistically significant p less than 002￨sig decrease￨highunclear￨highunclear￨highunclear
116￨116 consecutive patients undergoing colorectal surgery to compare single dose prophylaxis with wound infection after large bowel surgery￨mezlocillin mezlocillin to cefuroxime plus metronidazole cefuroxime plus metronidazole￨wound infection rates overall wound infection rate￨when trivial wound infections were disregarded the wound infection rates were 11 and 16 respectively which again was not statistically significant￨no diff￨highunclear￨highunclear￨highunclear
1010￨wound infection after abdominal surgery 1010 patients undergoing abdominal surgery involving the viscera￨antibiotics cefotaxime plus metronidazole cefoxitin￨￨this study demonstrated that a singledose antibiotic regimen was as effective as a multipledose regimen in the prophylaxis of wound infections following abdominal surgery￨sig increase￨highunclear￨highunclear￨highunclear
34￨34 patients who underwent elective colorectal surgery￨prophylactic cefotaxime cefotaxime metronidazole￨septic complications￨the results indicate that prophylactic cefotaxime and metronidazole are effective in reducing the incidence of septic complications following colorectal surgery nevertheless a study with a larger number of patients is needed to reach a definitive conclusion￨sig increase￨highunclear￨highunclear￨highunclear
624￨abdominal operations 624 consecutive eligible patients undergoing abdominal operations￨preincisional intraparietal augmentin amoxycillinclavulanic acid 12 g augmentin antibiotic injected intravenously at induction of anaesthesia￨incidence of wound infections incidence of other major or minor infective or noninfective postoperative complications￨no significant differences were found in the incidence of other major or minor infective or noninfective postoperative complications between the groups￨no diff￨highunclear￨highunclear￨highunclear
169￨one hundred sixtynine patients were randomized and 146 patients were evaluable elective colorectal surgery elective colon surgery patients undergoing elective colorectal surgery￨antibiotics cefoxitin prophylactic regimens oral neomycin and erythromycin intravenous cefoxitin and a combination of both oral and intravenous antibiotics oral antibiotics systemic and oralsystemic antibiotics￨septic complications septic complications major anastomotic failures incidence of wound infection￨there was no advantage between any of the groups in the incidence of wound infection 3968￨no diff￨highunclear￨highunclear￨highunclear
103￨patients undergoing elective colorectal surgery colorectal surgery￨metronidazole prophylaxis nalidixic acid metronidazole parenteral singledose antimicrobial prophylaxis metronidazole or 1 g metronidazole  3 g nalidixic acid￨surgical infection infection rate￨because of an unacceptably high rate of surgical infection in all three groups 36 29 and 39 p greater than 01 among the first 103 evaluable patients the study was discontinued￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨cefazolin￨hospital stay incidence of wound infection postoperative wound infection￨the incidence of wound infection was significantly reduced p less than 001 from 32 in the control group to 10 in the treated group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨elective colorectal surgery￨doxycycline tinidazole 2 g and doxycycline placebo tinidazole and doxycycline tinidazole￨nonfatal intraabdominal complication wound sepsis perineal sepsis￨only one serious but nonfatal intraabdominal complication 14 was observed in this group￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨ticarcillinclavulanic acid timentin cefotaxime￨total costs nonwound infectious morbidity adverse reactions timentin associated wound infection rate betalactamase corrected￨among 224 evaluable cases the timentin associated wound infection rate 07 nonwound infectious morbidity 88 adverse reactions 19 and total costs 1415 were not statistically different than that of the control drug￨no diff￨highunclear￨highunclear￨highunclear
929￨929 surgical procedures in a prepaid group practice 929 surgical cases 812 evaluable receiving preoperatively prophylaxis with either￨cephalosporin prophylaxis cefoperazone cephalosporin cefoperazone and cefotaxime 50000 cefazolin and greater than 200000 cefoxitin cefoperazone or cefotaxime fda approved cefotaxime￨abnormally elevated prothrombin times annualized cost savings nonwound infectious morbidity postoperative wound infectious morbidity rates infectious morbidity or adverse reactions side effects￨nonwound infectious morbidity was 58 p greater than 005 for cefoperazone mostly urinary tract infections causes by escherichia coli streptococcus faecalis and staphylococcus spp￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients undergoing postoperative infections in colonic surgery after enteral bacitracinneomycin￨elective colonic surgery mezlocillin 4 g  oxacillin whole gut irrigation 101 balanced salt solution neomycin 1 gl  bacitracin 50000 iul  clindamycin clindamycin or parenteral mezlocillinoxacillin prophylaxis￨intraoperative wound contamination rate of postoperative wound infection rate of wound infection degree of wound contamination and the occurrence of wound infection frequency of surgical wound infection intraoperative wound contamination and other postoperative infections￨other infections were least frequent in group c four of 29 patients but were not significantly different to groups b six of 30 and a nine of 31￨no diff￨highunclear￨highunclear￨highunclear
496￨prophylaxis against infections after cleancontaminated abdominal surgery 496 patients undergoing abdominal surgery￨ceftriaxone or ampicillin  metronidazole antibiotic prophylaxis ampicillinmetronidazole ceftriaxone ceftriaxone vs ampicillin  metronidazole￨deep wound infections incisional wound infections infectious complications￨no significant intergroup difference was found between the respective overall rates of infectious complications 32 and 49￨no diff￨highunclear￨highunclear￨highunclear
403￨403 evaluable patients 206 received colorectal surgery￨cefoxitin cefotetan vs multipledose cefoxitinantimicrobial prophylaxis cefotetan￨mean postoperative hospital stay number of patients with infections at nonsurgical sites respiratory and urinary tract phlebitis and septicemia abdominal wound infection rate￨the abdominal wound infection rate was 112 percent in group a and 91 percent in group b difference not significant￨no diff￨highunclear￨highunclear￨highunclear
136￨elective gastrointestinal tract surgery 136 patients aged 18 to 75 undergoing elective gastrointestinal surgery￨perioperative cefoxitin cefotaxime and multipledose cefoxitin antibiotic prophylaxis cefotaxime 1 g preoperatively or cefoxitin cefotaxime￨infection rates overall infection rates￨there were no significant differences in the infection rates between subgroups￨no diff￨highunclear￨highunclear￨highunclear
not found￨two groups of 25 patients each were randomly selected patients undergoing elective colorectal surgery elective colorectal surgery 50 patients who underwent elective colorectal surgery￨shortterm antibiotic prophylaxis metronidazole plus amikacin ornidazole 1 g by intravenous infusion plus ceftriaxone metronidazole 05 g plus neomycin ornidazole plus ceftriaxone prophylactic antibiotic therapy metronidazole 05 g plus amikacin 500 mg iv￨wound infection￨wound infection occurred in 1 case of group a versus 2 cases of group b p greater than 025￨no diff￨highunclear￨highunclear￨highunclear
352￨three hundred fifty two patients 175 receiving elective colorectal surgery fortyfive patients were withdrawn from the study after randomization￨ampicillin cefoxitin cefoxitin ampicillin and metronidazole metronidazole￨postoperative septic complications septic complications frequency of septic and nonseptic complications￨the frequency of septic and nonseptic complications was not statistically significant different between the two regimens￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients undergoing elective major colorectal surgery elective colorectal surgery￨ampicillin cefoxitin sulbactamampicillin sulbactam a betalactamase inhibitor with ampicillin￨significant wound sepsis serious side effects minor wound sepsis deep sepsis or anastomotic leak rates￨there was no difference between the groups in deep sepsis or anastomotic leak rates sulbactam four patients cefoxitin seven patients￨no diff￨highunclear￨highunclear￨highunclear
17￨emergency and elective colorectal surgery colorectal surgery￨mezlocillin with cefuroxime plus metronidazole mezlocillin cefuroxime plus metronidazole cefuroxime and metronidazole￨severe wound infection total number of surgically related infections￨there were two episodes of septicaemia each in the mezlocillin group￨no diff￨highunclear￨highunclear￨highunclear
509￨509 patients undergoing abdominal surgery 230 patients with a postoperative wound infection after general surgery￨coamoxiclav versus cefuroxime plus metronidazole cefuroxime zinacef glaxo uk plus metronidazole flagyl mb uk cefuroxime and metronidazole cefuroxime plus metronidazole cefuroximemetronidazole￨infection rates wound infection rate demographic details type and duration of surgery risk factors associated with surgical procedures and postoperative management total wound infection rate￨coamoxiclav was given to 230 patients with a total wound infection rate of 56 and cefuroxime plus metronidazole were given to 225 patients with a total wound infection rate of 3￨no diff￨highunclear￨highunclear￨highunclear
267￨267 patients who underwent elective colorectal surgery patients undergoing colorectal surgery￨placebo or tinidazole doxycycline tinidazole tinidazole and doxycycline￨postoperative infections infectious complications reoperations additional use of antibiotics and a shorter hospital stay￨patients who received tinidazole and doxycycline had significantly fewer infectious complications reoperations additional use of antibiotics and a shorter hospital stay￨sig decrease￨highunclear￨highunclear￨highunclear
229￨patients undergoing elective colorectal surgery in two district general hospitals two hundred and twentynine patients patients undergoing elective colorectal surgery in a district general hospital￨prophylactic singledose intravenous antibiotic regimes intravenous iv latamoxef disodium cefuroxime and metronidazole￨serious postoperative bleeding and no serious adverse reactions effectiveness and safety incidence of major wound infection poor performance status operative contamination and wound infections overall mortality death￨there was a low incidence 13 of serious postoperative bleeding and no serious adverse reactions were noted￨no diff￨highunclear￨highunclear￨highunclear
42￨elective colorectal surgery fortytwo patients admitted for elective colorectal surgery￨doxycycline tinidazole tinidazole and doxycycline or doxycycline tinidazole and doxycycline￨abdominal wound infection postoperative infections wound sepsis￨no significant difference in postoperative infections between the two groups could be demonstrated￨no diff￨highunclear￨highunclear￨highunclear
169￨169 patients undergoing colorectal surgery colorectal surgery￨ciprofloxacin oral antibiotic prophylaxis gentamicin plus metronidazole or oral ciprofloxacin plus metronidazole oral ciprofloxacin￨proportion of patients with wound infections and other infective complications postoperative wound infections￨the proportion of patients with wound infections and other infective complications was significantly less p  002 in those receiving oral ciprofloxacin￨sig decrease￨highunclear￨highunclear￨highunclear
221￨19 hospitals 221 randomized patients 208 105 amoxycillinclavulanic acid 103 cefotetan aged 66 200 patients eligible patients patients undergoing elective colorectal surgery 12 years mean elective colorectal surgery￨amoxycillinclavulanic acid and cefotetan amoxycillinclavulanic acid vs cefotetan amoxycillinclavulanic acid 22 g or cefotetan amoxycillinclavulanic acid with cefotetan￨occurrence of infection of intestinal origin either minor wound cellulitis or major abscess peritonitis septicaemia colorectal cancer sd￨most infections occurred before the 10th postoperative day 8 failures at this time estimated by the kaplanmeier method￨no diff￨highunclear￨highunclear￨highunclear
not found￨colorectal surgicalprophylaxis￨single high dose gentamicin metronidazole 500 mg preoperatively or multiple standard dose gentamicin gentamicin plus metronidazole metronidazole gentamicin￨infection rates diabetes mellitus deep surgical site infection ssi rates superficial ssis￨a subset analysis of prolonged operations found significantly fewer superficial ssis in the single high dose group than in the multiple standard dose group with rates of 222 627 vs 55 1120 respectively p 0021￨sig decrease￨highunclear￨highunclear￨highunclear
72￨patients scheduled for elective resection of colorectal cancer colorectal surgery authors transl sepsis after colorectal surgery 72 patients were studied￨metronidazole and kanamycin parenteral antibiotic prophylaxis￨microbial concentrations occurrence of postoperative sepsis postoperative sepsis therapeutic intraoperative serum levels￨there was no significant difference in the occurrence of postoperative sepsis between the two groups a total of 72 patients￨no diff￨highunclear￨highunclear￨highunclear
101￨101 consecutive patients were covered 22 had to be excluded and 7 withdrawn after randomization 72 cases elective colon surgery￨classical prophylaxis clindamycin and gentamicin c  g antibiotic prophylaxis cefoxitin ce preventive preoperative antibiotic therapy￨septic complications possibly caused by opening of the colon wound infection anastomotic failure colocutaneous fistula episodes of sepsis urinary tract infection and pneumonia￨episodes of sepsis urinary tract infection and pneumonia were similar in both groups￨no diff￨highunclear￨highunclear￨highunclear
152￨eight patients receiving 152 consecutive patients requiring emergency or complicated colorectal surgery emergency and complicated colorectal surgery￨gentamicin and metronidazole cefotetan cefotetan or to fiveday cover with gentamicin aminoglycoside metronidazole￨wound infection rates rates of postoperative infection intraabdominal abscesses prolongation of prothrombin time incidence of intraabdominal abscess clinical bleeding￨although wound infection rates were lower in the cefotetan group the incidence of intraabdominal abscess was similar in both groups￨no diff￨highunclear￨highunclear￨highunclear
97￨nosocomial infections during contaminated surgery contaminated surgery 97 patients suffering by colorectal surgery￨pefloxacin  metronidazole pefloxacin  metronidazole pefloxacin pefloxacin pefloxacin plus metronidazole metronidazole netilmicin 200 mg im netilmicin plus metronidazole netilmicin  metronidazole￨urinary infections appearance of postsurgical infections abdominal urinary respiratory and wound infections nosocomial infections intraabdominal infection wound infections respiratory infections￨efficacy of prophylaxis in patients was evaluated in terms of appearance of postsurgical infections abdominal urinary respiratory and wound infections￨sig decrease￨highunclear￨highunclear￨highunclear
859￨abdominal surgery 859 evaluable patients randomized into two groups treated with￨antimicrobial prophylaxis chemoprophylaxis only or chemo and immunoprophylaxis surgical antimicrobial prophylaxis antimicrobial chemoimmunoprophylaxis immuno and chemoprophylactic treatment thymostimulin cefotetan and thymostimulin￨respiratory tract infections total infectious episodes abdominal abscess surgical site infection￨results in the two different groups were significantly different regarding abdominal abscess and the total infectious episodes in the surgical site with lower frequency in patients receiving both thymostimulin and the antibiotic cefotetan￨sig decrease￨highunclear￨highunclear￨highunclear
1002￨1002 patients randomly assigned to study groups 901 451 in the ertapenem group and 450 in the cefotetan group qualified for the modified intentiontotreat analysis and 672 338 in the ertapenem group and 334 in the cefotetan group were included in the perprotocol analysis elective colorectal surgery patients undergoing elective colorectal surgery￨ertapenem versus cefotetan prophylaxis antibiotic prophylaxis with ertapenem cefotetan￨rate of overall prophylactic failure absence of surgicalsite infection anastomotic leakage or antibiotic use 4 weeks postoperatively failure rate overall incidence of clostridium difficile infection efficacy and safety￨ertapenem is more effective than cefotetan in the prevention of surgicalsite infection in patients undergoing elective colorectal surgery but may be associated with an increase in c difficile infection￨sig increase￨low￨low￨low
not found￨elective colorectal surgery￨systemic timentin intravenous timentin ticarcillin and clavulanic acid￨postoperative wound infection rates of postoperative septicemia wound infection rate type of hospital public or private wound infection rate￨the rates of postoperative septicemia 3 vs 4 percent and intraabdominal abscess 5 vs 8 percent were similar￨no diff￨highunclear￨highunclear￨highunclear
226￨226 patients patients with cfu greater than or equal to 5￨metronidazole iv selective cefuroxime prophylaxis metronidazole cefuroxime￨cent infection rate number of colonyforming units cfu postoperative infections rate of sepsis￨addition of cefuroxime reduced the 412 per cent infection rate to 83 per cent p  0003￨no diff￨highunclear￨highunclear￨highunclear
4￨colorectal surgery￨doxycycline  tinidazole doxycycline antibiotic prophylaxis doxycyclinetinidazole vs doxycycline￨septic complications incidence of abdominal and of perineal wound infections￨when the four surgical blocks were separately considered however the difference between the two regimens was found to be mainly due to rectal operations following which the incidence of abdominal and of perineal wound infections was significantly lower with the combined regimen than with doxycycline alone￨no diff￨highunclear￨highunclear￨highunclear
143￨surgical site infection and methicillinresistant staphylococcus aureus infection after elective colorectal surgery surgical site infection and methicillinresistant staphylococcus aureus mrsa infection after elective colorectal surgery 143 patients 71 for group 1 and 72 for group 2 were eligible￨oral antimicrobial prophylaxis cefotiam mechanical bowel cleansing with polyethylene glycol alone group 1 or mechanical cleansing plus oral antimicrobial prophylaxis with kanamycin and erythromycin￨blood loss incidence of mrsa infection including at surgical and remote sites incidence of a surgical site infection risk of surgical site infection mrsa infection￨a multivariate logistic regression analysis showed that the risk of surgical site infection was influenced by the choice of the chemical bowel preparation p  003 and blood loss p  001 while an mrsa infection was predominantly influenced by blood loss p  001 followed by coexisting underlying diseases p  007￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients undergoing colon surgery colon surgery￨systemic antibiotic moxalactam metronidazole moxalactam￨infection rate wound infection rate￨the data obtained demonstrated that the reduced infection rate was not the result of a reduction in the bacterial content of the colon alone but due to the prophylactic agents used for elective colon surgery￨no diff￨highunclear￨highunclear￨highunclear
542￨abdominal surgical wound infection 542 consecutive emergency and elective abdominal operations with one group of patients receiving tetracycline peritoneal and wound lavage and the other a single intravenous injection of 1 g latamoxef at induction of anaesthesia￨latamoxef latamoxef against peroperative tetracycline lavage tetracycline peroperative tetracycline lavage￨￨monitoring of operative and postoperative bleeding revealed no evidence except in one doubtful case of excessive bleeding associated with the use of a single dose of latamoxef￨no diff￨highunclear￨highunclear￨highunclear
57￨patients undergoing elective colorectal procedures or surgery for obstruction of the small bowel elective colorectal surgery or operation for obstruction of the small bowel patients receiving appropriate prophylactic agents fiftyseven assessable patients 27 patients receiving￨elective colorectal surgery cefoxitin prophylactic antibiotics cefoxitin iv or im cefonicid intravenously iv or intramuscularly im 1 hr before surgery only or 2 g of￨intraabdominal abscess adverse effects septic complications wound infections￨two of 27 patients receiving cefoxitin developed wound infections and one developed an intraabdominal abscess 11￨no diff￨highunclear￨highunclear￨highunclear
34￨34 patients receiving iv 32 patients receiving elective colon surgery￨elective colonic surgery cefazolin alone oral metronidazol metronidazole flagylcefazolin kefzol cefazolin￨local wound infection septicemia anastomotic dehiscence or death rate of postoperative infection￨no significant difference was observed concerning local wound infection septicemia anastomotic dehiscence or death￨no diff￨highunclear￨highunclear￨highunclear
195￨one hundred and ninetyfive patients undergoing abdominal surgical procedures patients undergoing colorectal operations abdominal surgery￨cefmetazole and cefoxitin oral neomycin and erythromycin cefmetazole cefoxitin cefoxitin￨colorectal operations operative site infection rate adverse effects￨the operative site infection rate was 65 for cefmetazole and 77 for cefoxitin p greater than 005￨no diff￨highunclear￨highunclear￨highunclear
not found￨45 patients received￨oral neomycin and erythromycin metronidazole and gentamicin neomycinerythromycin mannitol solution metronidazolegentamicin￨uncomplicated postoperative course wound infections￨both groups were comparable in sex age clinical diagnosis and type of operation performed￨no diff￨highunclear￨highunclear￨highunclear
not found￨colorectal surgery￨ceftriaxonemetronidazole neomycin and erythromycin peroral neomycin sulfateerythromycin￨￨in an open prospective and randomized investigation on the prophylactic efficacy of peroral neomycin sulfateerythromycin base vs intravenous ceftriaxonemetronidazole preparation in colorectal surgery no significantly diverging results between regimens were recorded 127 37 and 227 74 wound infections respectively￨sig increase￨highunclear￨highunclear￨highunclear
not found￨five emergency cases were admitted to the study colorectal surgery￨doxycycline doxycycline prophylaxis metronidazole v doxycycline prophylaxis metronidazole antimicrobial prophylaxis￨infection rates total infection rate postoperative infection postoperative anaerobic infection￨the difference in infection rates 241  5 v 733  21 was statistically significant￨no diff￨highunclear￨highunclear￨highunclear
294￨294 patients elective colorectal surgery￨metronidazole and 30 g ampicillin antibiotics prophylactic antibiotic treatment or ampicillin 1 g x 3 and metronidazole metronidazole and ampicillin￨deep wound infection frequencies of anastomotic dehiscences intraabdominal abscesses sepsis and pulmonary infections￨no differences were found in the two groups between frequencies of anastomotic dehiscences intraabdominal abscesses sepsis and pulmonary infections￨no diff￨highunclear￨highunclear￨highunclear
203￨203 consecutive patients undergoing elective colorectal surgery elective colorectal surgery￨topical ampicillin ampicillin 1 g x 3 and metronidazole ampicillin and metronidazole topical ampicillin￨deep wound infection or dehiscence￨deep wound infection or dehiscence was seen in 12 of 105 having both administrations of antibiotics and in nine of 98 having only intravenous antibiotics￨no diff￨highunclear￨highunclear￨highunclear
153￨153 patients undergoing elective colorectal surgery elective colorectal surgery￨cefotetan intravenously with induction of anaesthesia piperacillin cefotetan with piperacillin cefotetan￨wound infection septic deaths haematological or biochemical abnormalities adverse reaction wound infections￨no significant haematological or biochemical abnormalities were detected￨no diff￨highunclear￨highunclear￨highunclear
102￨102 elective operations patients with inflammatory bowel disease treated preoperatively with colorectal surgery￨salicylazosulfapyridine doxycycline cefoxitin cefoxitin and doxycycline cefoxitin cefoxitin or doxycycline￨wound infections anastomotic leakage￨patients with inflammatory bowel disease treated preoperatively with salicylazosulfapyridine run a greater risk of postoperative infection in spite of the prophylaxis￨sig decrease￨highunclear￨highunclear￨highunclear
102￨one hundred and two patients undergoing elective colorectal surgery elective colorectal surgery￨doxycycline doxycycline prophylaxis doxycycline preoperatively and 01 g of doxycycline￨acceptable rate of postoperative infections infection rate￨the infection rate was 10 in the onedose treatment group and 10 in the fourdose treatment group￨no diff￨highunclear￨highunclear￨highunclear
350￨350 patients elective colon and rectal surgery￨standard mechanical bowel preparation perioperative parenteral cefoxitin group a or preoperative oral neomycin and erythromycin in addition to perioperative cefoxitin￨wound infections rates of wound sepsis infection rate wound infection rate anastomotic dehiscence intraabdominal abscesses lower infection rates￨intraabdominal abscesses p less than 001 and anastomotic dehiscence p less than 005 were also significantly reduced in group b patients￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨517 patients infection after elective colorectal surgery subjects559 patients admitted for elective colorectal operations nine swedish hospitals￨doxycycline 400 mg and metronidazole doxycycline and metronidazole fosfomycin and metronidazole fosfomycinmetronidazole fosfomycin 8 g and metronidazole metronidazole doxycyclinemetronidazole doxycycline with metronidazole￨remote infection rates pneumonia urinary tract and central venous line incidence of all types of infection mortality and side effects risk of infection overall abdominal infection rates wound deep and septicaemia￨there were no significant differences between the groups for any of the outcome measures studied the overall abdominal infection rates wound deep and septicaemia being 46 and 74 and the remote infection rates pneumonia urinary tract and central venous line 151 and 128 respectively￨no diff￨highunclear￨highunclear￨highunclear
315￨elective colorectal operations￨cefotetan and metronidazole cefotetan alone with cefotetan and metronidazole antibiotic prophylaxis cefotetan￨incidence of operationrelated infection￨there was no statistical difference in the incidence of operationrelated infection between the two groups￨no diff￨highunclear￨highunclear￨highunclear
61￨61 patients undergoing elective surgery for colorectal cancer elective colorectal surgery￨cefuroxime combined antibiotics cefuroxime 075 g plus metronidazole 05 g iv imipenemcilastatin metronidazole cefuroxime and metronidazole￨severity of sepsis rate of surgical infections￨no significant differences were found in terms of the rate of surgical infections 9 in group a and 16 in group b infections not of surgical origin were found only in group b 104￨no diff￨highunclear￨highunclear￨highunclear
111￨111 patients were selected for the study group a 59 group b 52 patients colorectal surgery patients 160 patients￨amoxicillinclavulamid acid antibiotic combination mezlocillinmetronidazole intraoperative one shot antibiotic application mezlocillinmetronidazole and amoxicillinclavulanic acid￨wound infections abdominal wound healing bacterial infections￨in the postoperative course 53 group a and 67 group b of the patients developed bacterial infections￨no diff￨highunclear￨highunclear￨highunclear
50￨36 evaluable patients had an infection at the operation site colorectal surgery￨cefuroxime metronidazoleplacebo metronidazolenetilmicin and one metronidazoleplacebo peroperative systemic prophylaxis metronidazole netilmicin cefuroxime or placebo metronidazole and netilmicin￨wound abscess infection rates￨five out of 36 evaluable patients had an infection at the operation site￨no diff￨highunclear￨highunclear￨highunclear
3￨fifty patients were excluded from analysis sepsis in colorectal surgery three hundred and thirty patients were considered eligible for the trial￨cefazolin and 1 g metronidazole cefazolin and metronidazole antibiotic prophylaxis ceftriaxone metronidazole￨sensitivity patterns number of postoperative urinary tract and respiratory tract infections incidence of wound infections overall incidence of wound sepsis￨patients in the cefazolin and metronidazole group had a significantly higher number of postoperative urinary tract and respiratory tract infections than the other two groups combined p less than 001￨sig decrease￨highunclear￨highunclear￨highunclear
194￨elective colorectal surgery 194 patients who underwent elective colorectal surgery for carcinoma￨oral neomycin and erythromycin metronidazole and gentamicin oral and systemic antibiotics prophylactic antibiotics oral antibiotics alone systemic metronidazole and gentamicin￨postoperative septic complications related to colorectal surgery risks of postoperative sepsis incidence of sepsis￨patients who received oral antibiotics alone group a had significantly higher risks of postoperative sepsis when compared with patients in either group b or group c￨sig increase￨highunclear￨highunclear￨highunclear
65￨elective oncological colorectal surgery elective colorectal surgery 65 patients undergoing elective surgery for colorectal cancer￨rigorous mechanical cleansing of the bowel enemas laxatives received lowresidue diet 3 days preoperatively and were given oral metronidazole cefotetan cefotetan versus clindamicin plus aztreonam aztreonam anaesthesia plus aztreonam clindamicin￨overall incidence of postoperative septic complications rate of surgical infections urinary tract infections 1 case and respiratory tract infections anastomotic leakages￨no significant differences were found in terms of the rate of surgical infections 31 in group a 132 and 0 in group b urinary tract infections 1 case and respiratory tract infections 2 cases were observed only in group b￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients undergoing upper gastrointestinal appendiceal colonic or biliary operations patients undergoing abdominal surgery abdominal surgical prophylaxis￨amoxycillinclavulanate and mezlocillin mezlocillin amoxycillin amoxycillinclavulanate augmentin amoxycillinclavulanate￨overall wound infection rates deep infections￨when subgroups were examined for total infections no significant difference was seen between antibiotic groups in patients undergoing cleanpotentially contaminated operations or contaminated operations although more deep infections were encountered in the amoxycillinclavulanate group in comparison with the mezlocillin group in contaminated operations￨no diff￨highunclear￨highunclear￨highunclear
244￨244 patients elective colorectal operations ninetyfive patients 39 were either excluded before randomisation or withdrawn leaving 149 for analysis￨ampicillin prophylactic singledose fosfomycin and metronidazole neomycin bacitracin metronidazole and ampicillin bacitracin 250 mg plus neomycin metronidazole￨overall infection rate infective complications￨the overall infection rate was 17 of 149 evaluable patients 11 95 ci 68 to 177￨no diff￨low￨low￨low
55￨cefazolinhundred fiftyfive patients￨metronidazole vs erythromycin neomycin and cefazolin metronidazole and erythromycin erythromycin neomycin and cefazolin metronidazole￨overall septic complication rate￨the resulting difference between the overall septic complication rate in patients receiving erythromycin neomycin and cefazolin 109 percent and the rate in patients receiving metronidazole alone 319 percent was significant￨sig decrease￨highunclear￨highunclear￨highunclear
295￨patients undergoing abdominal and vaginal hysterectomy patients undergoing colorectal gynecologic or urologic surgery 295 patients undergoing colorectal surgery 175 patients undergoing transurethral resection of the prostate colorectal gynecologic and urologic surgery￨cefotaxime both combined with clindamycin placebo aztreonam aztreonam alone or combined with clindamycin gentamicin￨number of urinary tract infections incidence of perineal wound and intraabdominal infections incidence of infection efficacy and safety incidence of abdominal wound infection￨the prophylactic regimen significantly reduced the number of urinary tract infections p less than or equal to 00001￨sig decrease￨highunclear￨highunclear￨highunclear
119￨colorectal operations patients undergoing surgical procedures of 4 hours or less infection rates of 48 and 40 respectively 119 patients undergoing colorectal operations￨cefoxitin versus erythromycin neomycin and cefazolin oral erythromycin neomycin and parenteral cefazolin cefoxitin perioperative parenteral cefoxitin cefoxitin prophylaxis erythromycinneomycincefazolin￨wound infection wound infection rate￨patients receiving cefoxitin had a higher wound infection rate than patients receiving erythromycinneomycincefazolin 125 v 32 respectively p  06￨sig decrease￨highunclear￨highunclear￨highunclear
660￨44 patients in the elective colorectal surgery 660 consecutive patients who were to undergo elective colorectal operations during a 48 month period january 1987january 1991 93 14 were withdrawn after randomisation leaving 567 for assessment￨cefotaxime 2 g plus metronidazole flagyl 15 g intravenously at induction of anaestesia cefotaxime claforan cefotaximemetronidazole cefotaxime alone cefotaxime and metronidazole cefotaxime￨anastomosis developed leaks wound infections wound infection incidence of intraabdominal abscesses￨in the cefotaxime group 22 of the 241 patients who had an anastomosis developed leaks 9 compared with 8 of the 239 in the cefotaximemetronidazole group 3￨no diff￨highunclear￨highunclear￨highunclear
164￨elective colorectal resectional surgery 164 patients who underwent elective colorectal resectional surgery￨amoxycillin plus clavulanic acid amoxycillin cefotaxime plus metronidazole amoxycillin and clavulanic acid versus cefotaxime and metronidazole cefotaxime and metronidazole￨deep surgical infection wound infection deep infection￨wound infection occurred in 15 patients 91 and deep surgical infection in 4 24￨no diff￨highunclear￨highunclear￨highunclear
197￨patients undergoing elective colorectal operations who had been prepared with mechanical bowel cleansing and oral antimicrobial agents 96 patients received patients undergoing elective colorectal operations elective colorectal operations all 197 patients who completed the study received￨mechanical bowel preparation and oral neomycinerythromycin base cefoxitin parenteral cefoxitin mechanical bowel preparation and oral antibiotics perioperative parenteral cefoxitin no parenteral antibiotics￨incidence of wound infections overall incidence of intraabdominal septic complications incidence of abdominal wound infection￨the overall incidence of intraabdominal septic complications was 73 7 of 96 in the control group no cefoxitin and 5 5 of 101 in the treatment group cefoxitin￨no diff￨highunclear￨highunclear￨highunclear
440￨440 patients undergoing elective colorectal surgery elective colorectal surgery￨amoxycillinclavulanic acid amoxycillinclavulanic acid prophylaxis clindamycin and gentamicin clindamycin  gentamicin￨surgical wound healing intraabdominal infections￨intraabdominal infections were more frequent in the clindamycin  gentamicin arm of the study fishers exact test p  0035￨sig increase￨highunclear￨highunclear￨highunclear
30￨two groups of 30 patients with a similar number of the usual risk factors 60 cases colorectal surgery￨cefoxitine 2 g and piperacillin cefoxitin versus piperacillin cefoxitine and piperacillin￨equivalent prophylactic effectiveness￨analysis of the results showed that the two antibiotics had equivalent prophylactic effectiveness congruent to 6 in colorectal surgery￨no diff￨highunclear￨highunclear￨highunclear
100￨colon surgery 100 patients undergoing elective colorectal surgery elective colorectal surgery￨cefazolin kefzol ornidazole tiberal versus cephazolinplacebo cefazolin and ornidazol co versus cefazolin and placebo cp￨reduction of anaerobic bacterias time of hospitalization incidence of wound infection￨the time of hospitalization was reduced from 203 days cp to 167 days co p less than 005 s￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨one hundred and thirtyone patients received university of melbourne colorectal group elective colorectal surgery￨tinidazole prophylaxis tinidazole ticarcillin systemic antibiotic active against both aerobic and anaerobic bacteria with an oral antibiotic agent active￨clinical anastomotic leakage rate mortality wound infection rate￨the wound infection rate was 8 in those patients receiving ticarcillin prophylaxis and 20 in those receiving tinidazole p less than 005￨no diff￨highunclear￨highunclear￨highunclear
102￨university of melbourne colorectal group elective colorectal surgery 102 patients patients undergoing elective colorectal surgery 101 patients￨oral tinidazole tinidazole prophylactic antibiotic regimens￨clinical anastomotic leakage rate mortality of patients receiving timentin prophylaxis wound infection rate￨the wound infection rate was 24 percent in the patients receiving timentin and 14 percent in those receiving tinidazole p  001￨no diff￨highunclear￨highunclear￨highunclear
311￨acute and elective colorectal surgery 311 patients undergoing acute or elective colorectal surgery￨prophylactic antibiotics antibiotic prophylaxis￨abdominal wound infection blood transfusion infectious complications anastomotic leakage postoperative infectious complications￨thirtyfour patients 109 per cent developed abdominal wound infection 17 patients 55 per cent intraabdominal abscess and 16 patients 51 per cent anastomotic leakage￨no diff￨highunclear￨highunclear￨highunclear
60￨elective colonic surgery 60 patients undergoing￨ornidazole and gentamicin elective colonic surgery perioperative infection prophylaxis￨anaerobic pathogens￨no anaerobic pathogens were detected in any of the cases￨no diff￨highunclear￨highunclear￨highunclear
70￨seventy patients patients undergoing elective colectomy for biopsyproven carcinoma or adenomatous polyps elective colorectal surgery for malignancy￨cefamandole mechanical bowel preparation and received oral neomycin and erythromycin base oral antibiotics perioperative prophylactic cefamandole no parenteral antibiotics￨wound infections wound infection￨there were no wound infections in the 34 patients receiving cefamandole and only one wound infection 28 percent in the 36 control patients￨no diff￨highunclear￨highunclear￨highunclear
118￨elective colonic surgery fiftyeight patients were treated and 60 were controls 182 patients was carried out 118 patients colorectal surgery￨doxycycline vibramycin doxycycline active substance or placebo ampicillin￨wound sepsis rate frequency of abdominal septic complications abdominal wound sepsis rate adverse ecological effects wound sepsis abdominal wound sepsis intraabdominal complications and septicaemia￨a significantly lower incidence of abdominal wound sepsis intraabdominal complications and septicaemia was found in the doxycycline group 124 compared to the controls 45￨sig decrease￨highunclear￨highunclear￨highunclear
98￨university of melbourne colorectal group elective colorectal surgery patients undergoing elective colorectal surgery￨prophylactic antibiotic singledose regimens mezlocillin timentin a combination of ticarcillin and clavulanic acid mezlocillin a semisynthetic penicillin￨postoperative wound infection wound infection rate￨the wound infection rate was 106 percent in patients receiving timentin and 97 percent in those receiving mezlocillin p greater than 05￨no diff￨highunclear￨highunclear￨highunclear
not found￨elective colorectal surgery￨cefotetan cefuroxime plus metronidazole cefotetan cefotetan with cefuroxime plus metronidazole￨adverse reactions rates of other infective complications wound infection rates￨there was no significant difference in wound infection rates between the two groups 147 for cefotetan and 139 for cefuroxime plus metronidazole or the rates of other infective complications￨no diff￨highunclear￨highunclear￨highunclear
97￨97 patients scheduled to undergo elective surgery for colorectal carcinoma colon surgery￨metronidazole alone metronidazolee and tobramycin metronidazole and tobramycin metronidazolalone group given a placebo infusion instead of tobramycin aminoglycoside metronidazole￨overall postoperative infection rate￨the overall postoperative infection rate was 196 with no statistically significant difference between the two groups￨no diff￨highunclear￨highunclear￨highunclear
400￨11 patients receiving 400 patients undergoing elective colorectal surgery 41 patients who were excluded or withdrawn wrong dose inappropriate operation established sepsis or concurrent disease thirteen of the 164 abdominal or perineal wounds were infected by 15 strains of bacteroides spp elective colorectal surgery￨metronidazole and gentamicin with a single preparation amoxycillinclavulanate amoxycillinclavulanate amoxycillinclavulanate with metronidazole plus gentamicin metronidazole plus gentamicin￨septicaemia perineal sepsis abdominal wound sepsis postoperative diarrhoea intraabdominal abscess clostridium difficile￨intraabdominal abscess occurred in 8 of those who received amoxycillinclavulanate compared with 6 of those given metronidazole plus gentamicin￨no diff￨highunclear￨highunclear￨highunclear
3￨98 patients undergoing elective colon surgery elective colon surgery￨tobramycin antibiotics prophylactic antibiotics metronidazole erythromycin gluceptate and metronidazole erythromycin￨overall wound infection prolonged hospital stay wound infections tolerated￨the overall wound infection was 144 with no difference between erythromycin and metronidazole￨no diff￨highunclear￨highunclear￨highunclear
not found￨colorectal surgery￨standard antibiotic regimen cefotiam plus 500 mg metronidazole cefotiam against a standard dose of 2 g cefotiam both in combination with 500 mg metronidazole￨wound sepsis adverse side effects antibiotic concentrations in samples of serum subcutaneous fatty tissue and colonic wall￨the concentrations after administration of 2 g cefotiam were higher as expected and without any adverse side effects￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients undergoing abdominal operations patients undergoing elective intraabdominal operations￨cefazolin moxalactam and cefazolin moxalactam 83 patients or cefazolin￨postoperative infections overall infection rate￨infection rates stratified by types of surgery were similar for both regimens￨no diff￨highunclear￨highunclear￨highunclear
188￨188 patients undergoing appendicectomy or colorectal surgery to test the efficacy of prophylactic parenterallyadministered antibiotics in the prevention of infection appendicectomy and colorectal surgery￨gentamicinmetronidazole￨￨the results show the effectiveness of the association gentamicinmetronidazole 94 of infections compared to the control group with no antibiotics 391 of infections x2  141 p less than 0001￨no diff￨highunclear￨highunclear￨highunclear
100￨one hundred patients completed the study 48 were treated with colorectal surgery￨penicillin and streptomycin cefotaxime￨postoperative septic complications insufficiency of the anastomosis rupture of the wound wound infection￨it is concluded that shortterm prophylaxis with cefotaxime is as effective as longterm prophylaxis with penicillin and streptomycin￨sig increase￨highunclear￨highunclear￨highunclear
not found￨221 colorectal surgery patients￨gentamicin collagen sponge gentamicincontaining collagen sponge gentamicincollagen sponge systemic gentamicinmetronidazole gentamicin￨tolerated and no adverse events mean duration of hospital stay postoperative wound infection rate postoperative wound infection rates￨the postoperative wound infection rate was significantly lower in group i patients than group ii 56 6107 and 184 21 114 respectively p  001￨sig decrease￨highunclear￨highunclear￨highunclear
492￨317 clinically evaluable patients 161 received 492 patients undergoing elective colorectal surgery elective colorectal surgery patients undergoing elective colorectal surgery￨alatrofloxacin and cefotetan trovafloxacin trovafloxacin cefotetan alatrofloxacin alatrofloxacin with cefotetan alatrofloxacin￨successful clinical response rates time of hospital discharge adverse events efficacy and safety￨no statistically significant betweentreatment difference was detected in successful clinical response rates at the end of the study 72 for each group￨no diff￨highunclear￨highunclear￨highunclear
100￨one hundred patients were studied 50 men and 50 women with a mean age of 666 years elective colorectal surgery patients undergoing elective colorectal surgery￨doxycycline netilmicin plus metronidazole netilmicin with metronidazole and doxycycline￨wound infections postoperative sepsis overall infection rate￨it is concluded that there is no statistically significant difference on the incidence of postoperative wound sepsis in patients undergoing elective colorectal surgery between the group given doxycycline for five days and the group given netilmicin plus metronidazole for one day￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients undergoing elective colorectal operations elective operations of the colon or rectum￨ampicillin topical ampicillin prophylaxis cefotaxime￨wound infection wound infection rate rates of wound dehiscence intraabdominal abscess or anastomotic leakage￨wound infection occurred in five of 81 patients who had topical application of ampicillin compared with six of 89 patients who did not receive prophylaxis the difference was not significant￨sig increase￨highunclear￨highunclear￨highunclear
not found￨atrisk abdominal surgery elderly patients having emergency surgery 900 patients￨augmentin prophylactic antibiotics intravenous augmentin amoxycillin 250 mg and clavulanic acid￨septic and sepsisrelated deaths nonfatal deep sepsis length of postoperative hospital stay duration of postoperative fever or the use of antibiotics for postoperative infection wound infection rates￨there was no difference in the other outcome measures studied which included nonfatal deep sepsis length of postoperative hospital stay duration of postoperative fever or the use of antibiotics for postoperative infection￨no diff￨highunclear￨highunclear￨highunclear
1238￨abdominal surgery 1238 patients undergoing abdominal surgery￨ceftriaxone sodium ceftriaxone sodium serum halflife 80 hours and cefamandole naftate and sodium carbonate serum halflife 08 hours ceftriaxone sodium 1 gd intravenously or cefamandole naftate and sodium carbonate cefamandole and ceftriaxone cefamandole naftate and sodium carbonate ceftriaxone metronidazole cephalosporin therapy￨incidence of wound infection￨no significant difference was noted in the incidence of wound infection ie 56 for the ceftriaxone group 95 confidence interval 38 to 74 and 69 for the cefamandole group 95 confidence interval 49 to 89￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients undergoing bowel surgery colon and rectum surgery￨metronidazole tinidazole￨rate of postoperative wound infections postoperative complications￨the rate of postoperative wound infections was not significantly different in the groups p  009￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨neomycin plus 025 g metronidazol tid mezlocillin plus 05 g metronidazole￨septic complications￨there was no statistically significant difference between both chemoprophylaxis groups p  010￨no diff￨highunclear￨highunclear￨highunclear
31￨elective colorectal surgical resections elective colorectal resections￨placebo oral neomycin neomycin placebo mannitol mechanical bowel preparation combined with oral neomycin and shortterm perioperative intravenous flagyl 1day mechanical bowel preparation with 10 mannitol combined with oral neomycin and shortterm perioperative intravenous flagyl mannitol combined with oral neomycin and shortterm perioperative intravenous flagyl￨septic complications septic complication rate￨no complications were observed from either the 10 mannitol solution or the intravenous flagyl at either clinical hematologic or biochemical assessment￨no diff￨highunclear￨highunclear￨highunclear
40￨forty patients with ulcerative colitis or familial polyposis coli received a patients undergoing colectomy mucosal proctectomy and ileoanal anastomosis patients undergoing colectomy with ileoanal anastomosis￨intravenous antibiotics cefoxitin placebo cefoxitin antibiotics mechanical and oral antibiotic bowel preparation intravenous cefoxitin￨colectomy mucosal proctectomy and ileal pouchanal anastomosis intraabdominal pelvic or wound infections overall postoperative morbidity￨no differences in overall postoperative morbidity were observed and neither group developed intraabdominal pelvic or wound infections￨no diff￨highunclear￨highunclear￨highunclear
52￨52 patients with colorectal neoplasms who underwent elective surgery colorectal surgery for cancer￨cefuroxime￨wound sepsis type of sepsis operative mortality￨wound sepsis was demonstrated in 115 of cases of group a and 230 of group b p less than 001 another type of sepsis was observed in 34 of group a and 115 of group b p less than 0001￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨elective colorectal surgery sixty assessable patients undergoing elective colonic and rectal surgery￨cefuroxime plus metronidazole cefuroxime plus 500 mg metronidazole metronidazole cefuroximemetronidazole￨primary wound infections sterile cultures￨bacteriologic examination of the anastomoses abdominal walls and wounds showed significantly more sterile cultures in the combination group although more aerobic cefuroximeresistant isolates were seen in this group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨colorectal surgery￨doxycycline tinidazole tinidazole or placebo doxycycline prophylaxis￨￨there were no significant differences between randomized groups on either preoperative tinidazole or placebo added to pre per and postoperative doxycycline￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients undergoing elective colorectal operations colon before elective colorectal surgery 327 evaluable patients￨ciprofloxacin ciprofloxacin 500 mg bid preoperative cathartic group oa n  159 or no oral antibiotic antibiotic prophylaxis piperacillin 4 g iv￨postoperative wound infection median postoperative hospital stay operationrelated infection of any type￨ignoring the treatment group the median postoperative hospital stay was 17 days interquartile range 10 days for infected patients and 11 days interquartile range 4 days for those not infectedabstract truncated at 250 words￨sig decrease￨highunclear￨highunclear￨highunclear
86￨patients undergoing colorectal operations 86 patients undergoing colorectal operations septic complications associated with elective operations of the colon and rectum￨gentamicin and metronidazole latamoxef moxalactam gentamicin and metronidazole and moxalactam gentamicin and metronidazole or moxalactam moxalactam￨perineal wound sepsis wound sepsis develop abnormal bleeding￨perineal wound sepsis 31 per cent was significantly more common than abdominal wound sepsis 7 per cent￨sig increase￨highunclear￨highunclear￨highunclear
215￨two hundred and fifteen patients scheduled to undergo elective surgery of the colon elective colon surgery￨oral versus systemic antibiotic prophylaxis placebo combined and systemic antibiotic prophylaxis identical placebos neomycin and metronidazole amikacin and metronidazole combined oral and systemic antibiotics combined versus systemic antibiotics systemic alone systemic antibiotics￨wound infections surgical site infections wound fat rates of postoperative surgical site infections risk differences risk ratios rrs and 95 confidence intervals cis wound infections and wound fat￨wound infections occurred in 5 patients in the combined group but in 17 in the systemic group p  001 rr  029 95 ci 011075￨sig increase￨low￨low￨low
289￨289 patients enrolled in a multicenter trial of the 239 evaluable patients 164 received colorectal surgery￨cefotetan cefotetan and cefoxitin cefoxitin cefotetan versus multipledose cefoxitin cefotetan and 75 cefoxitin￨postoperative infectious complications success rates incidence of major wound infection mean concentrations of cefotetan in plasma specimens of colon and subcutaneous fat safety and effectiveness satisfactory bacteriologic response rates adverse reactions successful clinical response rates median increase in oral body temperature￨nonobese patients and patients whose surgical procedures lasted less than 4 hours treated with either drug had significantly higher success rates p less than 001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨abdominoperineal excision of the rectum 41 patients who received both systemic and topical prophylaxis and in 18 of the 38 with only systemic antibiotics patients undergoing abdominoperineal amputation of the rectum￨gentamicin 80 mg and metronidazole gentamicin 160 mg  metronidazole topical antibiotics￨perineal wound infection￨impairment of cellmediated immunity was associated with significantly heightened rate of wound infection and these patients did not benefit from topical antibiotics￨no diff￨highunclear￨highunclear￨highunclear
750￨750 patients undergoing elective biliary gastric or colorectal surgery￨shortterm or longterm antibiotic prophylaxiscefotaxime for biliary or gastric and gentamicinmetronidazole￨corresponding mortality positive reaction delayed cutaneous hypersensitivity postopertive infectious complications nor mortality septic complication or mortality rates incidence of postoperative infectious complications￨there was no significant difference in septic complication or mortality rates following shortterm vs longterm prophylaxis￨no diff￨highunclear￨highunclear￨highunclear
119￨119 consecutive patients undergoing elective colorectal operations comparing the results in a group receiving purely parenteral antimicrobial prophylaxis with those in one having a combined oral and parenteral regimen￨￨rates of infective complications wound infection rates isolations of enterococci￨the rates of infective complications were higher in the parenteral than in the combined group the difference in wound infection rates being statistically significant the figures were 276 percent and 139 percent respectively p  04￨sig decrease￨highunclear￨highunclear￨highunclear
97￨elective colorectal and biliary surgery patients who developed sepsis did not have a prolonged hospital stay strict criteria 97 patients undergoing elective biliary 44 or colorectal 53 surgery cases￨mpt perioperative prophylaxis with either cefoxitin mefoxin msd or metronidazole penicillin and tobramycin mpt cefoxitin prophylactic antimicrobials￨sepsis subsequent infection rate￨a positive wound culture at the end of the operation was more common after colorectal surgery 302 than after biliary surgery 46 and was associated with a higher subsequent infection rate p  002￨sig increase￨highunclear￨highunclear￨highunclear
411￨sepsis after elective colorectal procedures 349 evaluable patients 411 patients undergoing elective colorectal surgery elective colorectal surgery￨imipenem cefuroxime plus metronidazole imipenem prophylaxis￨surgical infections efficacy and safety￨surgical infections occurred in 92 264 per cent of 349 evaluable patients￨no diff￨highunclear￨highunclear￨highunclear
not found￨elective colorectal surgery elective colorectal surgery after mechanical bowel preparation with￨gentamicin and metronidazole or metronidazole alone metronidazole and gentamicin metronidazole alone mannitol metronidazole mannitol and whole gut irrigation￨incidence of superficial wound infections serious infections￨although no serious infections were observed in either group the incidence of superficial wound infections was relatively high 19 in the group with metronidazole and gentamicin prophylaxis and 25 in the other group￨no diff￨highunclear￨highunclear￨highunclear
154￨154 patients undergoing elective colorectal surgery elective colorectal surgery￨aztreonammetronidazole and cefotaximemetronidazole aztreonammetronidazole and cefotaximemetronidazole aztreonam￨wound sepsis sepsis￨a significant excess of wound sepsis in the aztreonam group was seen 2371 vs 970 chi 2 660 p less than 001￨sig decrease￨highunclear￨highunclear￨highunclear
143￨after elective colorectal surgery 143 patients were recruited but 15 patients were subsequently excluded due to the use of additional antibiotics for the treatment of pulmonary or urinary infection or early postoperative death without wound infection elective colorectal surgery 128 evaluable patients six of the 63 patients 95 in the￨prophylactic ampicillinsulbactam ampicillinsulbactam gentamicin and metronidazole prophylactic ampicillinsulbactam with gentamicin and metronidazole￨risk of wound infection wound infection￨of the 128 evaluable patients six of the 63 patients 95 in the ampicillinsulbactam group and seven of the 65 patients 107 in the gentamicin and metronidazole group developed wound infection￨no diff￨highunclear￨highunclear￨highunclear
135￨126 patients with d treatment 20 elective colorectal surgery patients admitted for elective colorectal surgery￨doxycycline plus metronidazole and doxycycline doxycycline d alone doxycycline  1500 mg of metronidazole d  m metronidazole￨mean hospital stay postoperative septic complications septic complications surgical procedure￨most postoperative infections were superficial wound infections 14 of 24 patients and the mean hospital stay in the two treatment groups was equal￨no diff￨highunclear￨highunclear￨highunclear
90￨ninety patients colorectal surgery￨systemic antibiotic therapy oral and systemic antibiotics electric colorectal surgery and was prepared for operation with oral preoperative antibiotic therapy systemic peroperative therapy peroperative systemic antibiotic therapy oral antibiotic therapy￨total number of septic complications wall abscesses fistulas subdiaphragmatic abscesses septicemia peritonitis￨the number of each type of septic postoperative complication and their total did not differ between the group treated by oral antibiotics prior to operation and the group treated peroperatively with systemic antibiotic therapy￨no diff￨highunclear￨highunclear￨highunclear
89￨patients undergoing elective abdominal surgery 89 evaluable patients receiving cefmetazole 39 patients receiving￨cefmetazole versus cefoxitin cefmetazole or cefoxitin cefoxitin￨minimal toxicity￨both regimens were acceptable with minimal toxicity￨no diff￨highunclear￨highunclear￨highunclear
300￨three hundred consecutive elective colorectal resections all patients had preoperative mechanical colon cleansing with colorectal surgery￨oral antibiotic neomycin and metronidazole oral sodium phosphate and intravenous antibiotic prophylaxis with cefoxitin antibiotic prophylaxis prophylactic antibiotic administration prophylactic antibiotics mechanical colon cleansing group b one dose of oral antibiotic group c no oral antibiotics￨wound infection suture dehiscence urinary infections pneumonia postoperative ileus or intraabdominal abscess nausea nausea vomiting and abdominal pain abdominal pain vomiting￨abdominal pain was recorded in 13 10 and 4 of patients p 0077￨no diff￨highunclear￨highunclear￨highunclear
not found￨after elective colorectal surgery elective colonic and rectal surgery￨cefoxitin peroperative cefoxitin cefoxitintreated and placebo placebo￨postoperative abdominal wound infections postoperative abdominal wound infections￨septic complications remote from the abdominal wound eg intraabdominal abscesses occurred in both cefoxitintreated and placebotreated patients but numbers were too small for meaningful analysis￨no diff￨highunclear￨highunclear￨highunclear
250￨250 patients were performed 14 district general and teaching hospitals most patients had surgery for carcinoma of the colon or rectum 1018 adults having colorectal operations colorectal surgery￨cefuroxime 15 g intravenously plus metronidazole cefotaxime plus metronidazole cefotaxime 1 g intravenously plus metronidazole cefuroxime 750 mg intravenously plus metronidazole prophylactic antibiotic regimens cefuroxime plus metronidazole￨presence of pus death or discharge from hospital extended hospital stay death rates wound infection rates incidence of postoperative complications the median duration of hospital stay 12 days and antibiotic tolerance wound infections wound infection￨wound infection rates were group 1 32453 71 95 confidence interval 47 to 94 group 2 33454 73 95 confidence interval 49 to 96￨no diff￨highunclear￨highunclear￨highunclear
not found￨elective large intestine surgery￨orthograde bowel lavage alone group i versus combined bowel lavage and parenteral antibiotic prophylaxis with 4 gm cefoxitin￨septic complications duration of hospitalization rate of septic complications rate of anastomotic leakages septic wound complications￨orthograde bowel lavage alone proved to be of no effect in reducing the rate of septic complications when used without antibiotic perioperative shorttermprophylaxis and therefore cannot be recommended to be used solely￨no diff￨highunclear￨highunclear￨highunclear
615￨615 patients undergoing elective colorectal surgical procedures patients ranged in age from 19 to 92 years median 66 years the majority were male 540 and most 777 had neoplastic disease patients undergoing colorectal surgery colorectal surgery￨ceftriaxone  metronidazole cefepime  metronidazole metronidazole intravenous cefepime  metronidazole or ceftriaxone  metronidazole prophylactic antimicrobial regimens preoperative infusions of 2 g cefepime n307 or 2 g ceftriaxone antimicrobial prophylaxis￨primary site infections tolerated￨antimicrobial prophylaxis was successful in preventing primary site infections in 928 of patients in the cefepime  metronidazole arm and 929 of patients in the ceftriaxone  metronidazole arm￨no diff￨highunclear￨highunclear￨highunclear
not found￨84 patients elective colorectal surgery￨doxycycline doxycycline and tinidazole low residue diet and bowel cleansing antimicrobial regimens bacitracinneomycin tablets tinidazole￨serious side effects wound infection rate￨the wound infection rate was 37 10 patients in group￨no diff￨highunclear￨highunclear￨highunclear
4￨53 consecutive patients undergoing elective colorectal surgery largebowel surgery four patients were withdrawn from the study for various reasons leaving 49 patients for analysis￨kanamycin 500 mg plus clindamycin cathartics and saline enemas or with an elementary diet antibiotic combination￨wound infections 24hour systemic antibiotic prophylaxis frequency of all wound infections frequency of the grade ii wound infections alone￨the frequency of all wound infections grade i  grade ii was 8 in the treatment group 25 patients versus 667 in the control group 24 patients￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients undergoing biliary and gastrointestinal surgery wound sepsis after biliary and gastrointestinal surgery patients undergoing colorectal surgery who received￨mezlocillin cefuroxime metronidazole cefuroxime and metronidazole￨wound infection rate wound infection rates￨no difference in wound infection rates was seen in patients following appendicectomy biliary or gastrooesophageal surgery￨no diff￨highunclear￨highunclear￨highunclear
49￨49 patients had entered it colorectal surgery￨metronidazoleplacebo metronidazoleplacebo and metronidazolefosfomycin metronidazolefosfomycin fosfomycin metronidazole￨septic complications surgical infection rate anaerobic sepsis adverse reactions surgical sepsis￨no septic complications occurred in the 26 patients 0 receiving metronidazolefosfomycin p less than 001￨no diff￨highunclear￨highunclear￨highunclear
916￨patients with nonrheumatic atrial fibrillation nraf 916 patients with nraf and a recent  or  15 days cerebral ischemic episode nonrheumatic atrial fibrillation￨indobufen and 454 on warfarin warfarin indobufen sifa studio italiano fibrillazione atriale indobufen oral anticoagulation￨combined incidence of nonfatal stroke including intracerebral bleeding pulmonary or systemic embolism nonfatal myocardial infarction and vascular death gastrointestinal bleeding frequency of noncerebral major bleeding complications￨the frequency of noncerebral major bleeding complications was low only four cases 09 of gastrointestinal bleeding were observed all of them in the warfarin group￨no diff￨highunclear￨highunclear￨highunclear
not found￨bmt patients with moderatesevere acute graftversushost disease gvhd who responded to primary treatment with corticosteroids thirty patients with moderatesevere acute gvhd who responded by 14 days were eligible for random assignment of their steroid tapering schedule￨total pred prednisone therapy￨chronic gvhd and survival resolution of acute gvhd median pred dose required to achieve complete resolution of acute gvhd active gvhd￨the median pred dose required to achieve complete resolution of acute gvhd was not different between the two groups 1300 mgm2 for the long taper patients and 1800 mgm2 for the short taper patients￨no diff￨highunclear￨highunclear￨highunclear
95￨patients were stratified at randomization for age  20 years disease acute leukemia chronic myeloid leukemia cml nonneoplastic disease disease status earlyadvanced and gvhd prophylaxis italian group for bone marrow transplantation all patients aged 1 to 55 years were recipients of unmanipulated bmt from hla identical sibling donors ninetyfive patients undergoing an allogeneic bone marrow transplant bmt and developing acute graftversushost disease agvhd￨cyclosporincyclosporin  methotrexate high or lowdose 6methylprednisolone lowdose intravenous 6methylprednisolone highdose 6mpred￨response rate 3year actuarial trm cmv infections response to treatment and evolution of agvhd to grade iiiiv cytomegalovirus cmv infections transplantrelated mortality trm and relapse actuarial survival actuarial trm median interval cmv infections trm and survival￨the actuarial survival at 3 years was 63 versus 62 p  9 with a median follow up of 580 and 778 days￨no diff￨highunclear￨highunclear￨highunclear
27￨twentyseven babies￨placebo 4mlkg of undiluted 5 dextrose sodium bicarbonate sodium bicarbonate bicarb group and 28 to receive 5 dextrose intravenous sodium bicarbonate solution dextrose sodium bicarbonate or 5 dextrose￨death or abnormal neurological examination at discharge cerebral oedema encephalopathy multiorgan dysfunction intraventricular haemorrhage ivh and arterial ph at 6h neurologically abnormal at discharge incidence of encephalopathy survival and neurological outcome survival or immediate neurological outcome intraventricular haemorrhage ivh and the mean arterial ph death or abnormal neurological examination at discharge need for inotropic support￨the incidence of encephalopathy 74 versus 63 cerebral oedema 52 versus 30 need for inotropic support 44 versus 29 intraventricular haemorrhage ivh and the mean arterial ph at 6hrs were similar between the two groups￨sig increase￨low￨low￨low
542￨from june 1994 women who were hiv seronegative or hiv2 positive during the screening could enroll in the intervention study in which participants reported once a month to a confidential clinic where they received health education condoms and std treatment if indicated female sex workers female sex workers in abidjan côte divoire before and during an intervention study to control sexually transmitted diseases std 542 women enrolled in the study 225 42 had at least one outcome assessment￨￨hiv1 seroincidence rate gynecologic examination hiv serology and laboratory tests for std￨during the study the hiv1 seroincidence rate was slightly lower in the intensive than in the basic strategy 53 versus 76 per 100 personyears p  05￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨sex workers sex workers in use of female and male condoms for safer sex in urban zimbabwe human immunodeficiency virus hiv and sexually transmitted infections stis in our cohort at enrollment 86 tested hiv positive and 34 had at least one sti￨male and female condoms￨￨consistent male condom use with clients increased from 0 to 52 in group a and from 0 to 82 in group b between enrollment and first followup 2 weeks later and remained high throughout the study￨sig increase￨highunclear￨highunclear￨highunclear
not found￨female sex workers risk of hiv women were a median of 35 years old 61 were married and they had an average of two children female sex workers female sex workers in chennai india female sex workers n  100 in chennai￨microenterprise intervention microenterprise interventions￨sexual risk behaviors number of paying clients number of sex partners hiv risk behaviors￨intervention participants reported a significantly lower number of sex partners and significant increases in income at the 6month followup compared to control participants￨sig decrease￨highunclear￨highunclear￨highunclear
93￨eighty women completed the onemonth followup interview sex workers in pretoria 93 women who reported recent substance use and sex trading women receiving the womanfocused intervention￨modified standard hiv intervention or to a womanfocused hiv prevention intervention daily alcohol and cocaine￨rates of sexual risk and violence￨at followup findings showed decreases in the proportion of women reporting unprotected sex and the daily use of alcohol and cocaine￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨sex workers sex workers in india sex workers￨sonagachi model intervention sustainable communitylevel hiv intervention￨overall condom use proportion of consistent condom users￨overall condom use increased significantly in the intervention community 39 compared with the control community 11 and the proportion of consistent condom users increased 25 in the intervention community compared with a 16 decrease in the control community￨sig increase￨highunclear￨highunclear￨highunclear
255￨sex establishments in four cities in thailand male or female condom 34 sex establishments 249 women in the malefemale condom group and 37 sex establishments 255 women in the male condom group￨sex workers were instructed to use male condoms consistently male condom group and one in which sex workers had the option of using the female condom if clients refused or were not able to use male condoms malefemale condom group￨incidence rate of stds gonorrhoea chlamydial infection trichomoniasis and genital ulcer disease male condom use proportion of unprotected sexual acts weighted geometric mean incidence rate of stds￨condom use was very high in both groups 979 and 973  of all sexual acts respectively p  005￨no diff￨highunclear￨highunclear￨highunclear
400￨sexually transmitted diseases stds among a group of female sex workers fsws in guangxi china female sex workers in china four hundred fsws￨vct intervention or a control group receiving standard of care std testing and treatment cultural adaptation of voluntary counseling and testing vct intervention voluntary counseling and testing vct intervention￨hivstd related knowledge and perceptions condom use and history of stds infection rate of stds￨in addition the intervention group had a significantly lower infection rate of stds than the control group at followup￨sig decrease￨highunclear￨highunclear￨highunclear
901￨sex workers in madagascar already exposed to intensive male condom promotion in two public dispensaries in madagascar a total of 901 sex workers alternative male and female condom promotion strategies targeting sex workers in madagascar￨female condom promotion
                peer education only or peer education supplemented with individual clinicbased counselling supplemental intervention individual clinicbased counselling as a supplement to peer education￨levels of reported protection reduced sti prevalence￨no substantial differences in levels of reported protection were noted between study groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨filipina commercial sex workers female commercial sex workers fcsws￨sabt intervention based on 1 peer influence 2 manager training 3 combined peermanager influence or 4 usual care control condition multilevel social actionbased theory sabt intervention￨higher hivaids knowledge lower probability of contracting hiv and increased condom use￨hiv testing increased 86 from baseline n  980 to followup n  903 and was significantly associated with higher hivaids knowledge lower probability of contracting hiv and increased condom use￨no diff￨highunclear￨highunclear￨highunclear
1000￨male condom promotion among madagascar sex workers 1000 female sex workers in madagascar￨supplementing peer promotion peer education supplemented by individual risk reduction counselling by a clinician peer  clinic versus condom promotion by peer educators only peer only￨aggregate prevalence estimated odds ratios ors for chlamydia gonorrhoea trichomoniasis and aggregate sti baseline sti prevalences aggregate sti prevalence￨1000 female sex workers in madagascar were randomised to two study arms peer education supplemented by individual risk reduction counselling by a clinician peer  clinic versus condom promotion by peer educators only peer only￨sig increase￨highunclear￨highunclear￨highunclear
not found￨female sex workers in a 16 month replication trial of the￨frame to motivate change based on reframing sex work as valid work increasing disclosure of profession and instilling a hopeful future orientation reflected in desire for more education or training 3 improved skills in sexual and workplace negotiations sonagachi empowerment intervention control community n106 receiving standard care of std clinic condom promotion and peer education￨knowledge of stds and condom protection refusal condom decisionmaking and ability to change work contract but not ability to take leave 4 built social support by increasing social interactions outside work social function participation and helping other sex workers and 5 addressed environmental barriers of economic vulnerabilities by increasing savings and alternative income￨we previously demonstrated significant condom use increases among female sex workers in a 16 month replication trial of the sonagachi empowerment intervention n110 compared to a control community n106 receiving standard care of std clinic condom promotion and peer education in two randomly assigned rural towns in west bengal india basu et al 2004￨sig increase￨highunclear￨highunclear￨highunclear
120￨streetbased female sex workers in yerevan armenia female sex workers fsws￨intervention or waitlist control hiv prevention intervention hiv intervention￨psychosocial mediators of safer sex￨over the 6month followup fsws in the intervention reported more consistent condom use with clients p  004 and were more likely to apply condoms on clients p  0001￨sig increase￨highunclear￨highunclear￨highunclear
924￨female sex workers in tijuana and ciudad juarez mexico female sex workers 924 female sex workers 18 years or older without known hiv infection living in tijuana and ciudad juarez who had recently had unprotected sex with clients to a 30minute behavioral intervention or a didactic control condition￨behavioral intervention￨cumulative sexually transmitted illness incidence number and percentage of protected sex acts number of unprotected sex acts incidence density￨we observed a 40 decline in cumulative sexually transmitted illness incidence p  049 in the intervention group￨sig decrease￨highunclear￨highunclear￨highunclear
287￨patients with atrial fibrillation who had participated in a major clinical trial may 1997 to april 1998 287 patients from the spaf iii aspirin cohort study in which patients with atrial fibrillation and a relatively low risk of stroke received 325 mgd of atrial fibrillation fourteen centers that participated in the stroke prevention in atrial fibrillation spaf￨audiobooklet ab decision antithrombotic therapy ab ab group vs usual care alone control group aspirin￨realistic expectations about the risk of stroke and hemorrhage decisional conflict and satisfaction￨patients in the ab group were more knowledgeable and had more realistic expectations about the risk of stroke and hemorrhage in the ab group 5380 correctly estimated different risks in the control group 1628 gave correct estimates￨sig increase￨highunclear￨highunclear￨highunclear
42￨￨enhanced followup or treatment warfarin telephone followup￨warfarin knowledge￨enhanced treatment resulted in significant improvement in warfarin knowledge 86 versus 71￨sig increase￨highunclear￨highunclear￨highunclear
2000￨patients with chronic nonvalvular atrial fibrillation patients with nonvalvular atrial fibrillation smaaf study patients with atrial fibrillation smaaf study in comparison with a group of patients given conventional care by a general practitioner or specialist patients with nonvalvular atrial fibrillation￨oral anticoagulation￨maintenance of the inr value in the individual target range inr variance the course of complications over time and the cost efficiency of selfmanagement numbers of thromboembolic and hemorrhagic complications￨two thousand patients suitable for selfmanagement will be assigned at random to either the selfmanagement group or the control group￨sig increase￨highunclear￨highunclear￨highunclear
100￨100 patients receiving longterm oral anticoagulant therapy referred to a danish clinic for selfmanagement￨oral anticoagulant therapy selfmanaged oral anticoagulant therapy selfmanagement of oral anticoagulant therapy including a teaching program of selfmanagement followed by 6 months of selfmanagement or 6 months of conventional management selfmanagement versus conventional management of oral anticoagulant therapy￨selfmanagement intentiontotreat analysis of a composite score combining the variance median square of the standard deviation of the international normalized ratio inr value using a blinded control sample analyzed monthly by a reference laboratory death major complications or discontinuation from the study time within therapeutic inr target range using the standard inr values from the coagulometer and laboratory measurement time within therapeutic inr target range￨selfmanagement was significantly better 016 vs 024 p0003 with regard to the variance in a perprotocol analysis￨sig increase￨low￨low￨low
109￨patients with atrial fibrillation patients with atrial fibrillation making decisions two research clinics deriving participants from general practices in northeast england 109 patients with atrial fibrillation aged over 60￨warfarin or aspirin therapy￨decision conflict scale decision conflict anxiety knowledge decisionmaking preference treatment decision use of primary and secondary care services and health outcomes￨decision conflict was lower immediately following the use of a computerised decision aid in a shared decisionmaking consultation than immediately following direct doctorled advice based on paper guidelines￨sig increase￨low￨low￨low
341￨2 dutch anticoagulation clinics 341 patients aged between 18 and 75 years and receiving longterm oat patient selfmanagement and management by specialized anticoagulation clinics in the netherlands￨oat existing routine care group of patients untrained in selfmanagement a routine care group of trained patients a group managed weekly at an anticoagulation clinic where international normalized ratios were measured by trained patients and weekly patient selfmanagement oat with longacting phenprocoumon acenocoumarol oral anticoagulant therapy distribute patients without informing them to the existing care group or to receive training in selfmanagement oral anticoagulant therapy oat￨quality of oat oat quality￨weekly management with phenprocoumon led to a 65 improvement 95 ci 00131 in time in the international normalized ratio target range when patients were managed at an anticoagulation clinic and to an 87 improvement 95 ci 16159 when patients were selfmanaged￨sig increase￨highunclear￨highunclear￨highunclear
434￨patients with nonvalvular atrial fibrillation patients with nonvalvular atrial fibrillation nvaf 434 nvaf patients from 102 communitybased primary care practices patients with nvaf american college of chest physicians accp recommendations￨patient decision aid on care usual care selfadministered booklet and audiotape decision aid tailored to their personal stroke risk profile￨number of patients receiving therapy appropriate to their stroke risk number of patients receiving appropriate care median duration of nvaf change in antithrombotic therapy￨the beneficial effect of the decision aid did not persist p  044 for differences between study arms after 12 months￨no diff￨highunclear￨highunclear￨highunclear
325￨older patients university hospital in cleveland ohio 325 patients 65 years of age or older who started warfarin therapy during hospitalization patients were stratified according to baseline risk for major bleeding older patients receiving￨warfarin management multicomponent intervention usual care warfarin warfarin patient education about warfarin training to increase patient participation selfmonitoring of prothrombin time and guidelinebased management of warfarin dosing warfarin therapy￨major bleeding frequency of major bleeding proportion of total treatment time major bleeding death recurrent venous thromboembolism and therapeutic control of anticoagulant therapy death and recurrent venous thromboembolism major bleeding complications￨throughout 6 months the proportion of total treatment time during which the international normalized ratio was within the therapeutic range was higher in the intervention group than in the usual care group 56 vs 32 p  0001￨sig decrease￨low￨low￨low
not found￨lifestyle factors after 5 years of intervention 19982003 subjects from the intervention area n2356 and the control area n758 were compared for men and women and for those with a low less than intermediate secondary education and a moderate intermediate vocational or higher secondary education or high higher vocational education or university educational level￨cardiovascular diseaseprevention program hartslag limburg￨time spent bicycling energy intake fat consumption walking and bicycling energy intake total leisuretime physical activity mean change in lifestyle factors lifestyle factors energy intake fat intake time spent on leisuretime physical activity walking bicycling and sports and smoking behavior￨the community intervention hartslag limburg succeeded in preventing age and timerelated unfavorable changes in energy intake fat consumption walking and bicycling particularly among women and those with low ses￨sig increase￨highunclear￨highunclear￨highunclear
not found￨poor communities in pakistan￨￨blood pressure and active and passive smoking on health knowledge levels￨significant positive changes were observed in knowledge levels at a community level in the district of intervention compared with baseline knowledge levels particularly in relation to a heart healthy diet beneficial level of physical activity the causes of high blood pressure and heart attack and the effects of high blood pressure and active and passive smoking on health￨sig increase￨highunclear￨highunclear￨highunclear
not found￨nonoverweight adolescents adolescents by increasing physical activity subjectsnine hundred and fifty four 12yearold sixgraders 2002 in eight middle schools of eastern france overweight in adolescents￨multilevel program￨fat mass index highdensity cholesterol concentrations excessive weight gain supervised physical activity body mass index bmi body composition physical activity by questionnaire plasma lipids and glucose insulin resistance bmi tvvideo viewing￨intervention students had a lower increase in bmi p001 and age and genderadjusted bmi p002 over time than controls￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨￨intervention targeted sedentary 50 to 65yearold residents of wheeling west virginia mediabased community intervention￨￨the intervention consisting of paid advertisements public relations and community participatory planning attained high levels of awareness and effected significant sustained populationwide changes among the most sedentary in wheeling￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨￨physical activity systolic blood pressure diastolic blood pressure￨the female cohort in båtsfjord had a more favourable development when compared with changes in the control communities regarding the 112 increase in use of lowfat milk p  0046 the increase in systolic blood pressure by 21 mmhg p  0024 and the reduction in diastolic blood pressure by 21 mmhg p  0001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨adults aged 1865 years living in deprived neighbourhoods in eindhoven the netherlands￨community intervention dutch community intervention￨vegetable consumption physical activity smoking and alcohol consumption fruit consumption vegetable consumption physical activity smoking alcohol consumption and intermediate outcomes of behaviour ie attitudes selfefficacy awareness knowledge and stages of change healthrelated behaviour￨the intervention demonstrated no evidence for an impact on vegetable consumption physical activity smoking and alcohol consumption and weak evidence for a small impact on intermediate outcomes of fruit consumption￨no diff￨highunclear￨highunclear￨highunclear
not found￨control district with similar socioeconomic status in oslo norway using a baseline investigation of 2950 30 to 67yearold participants and a followup investigation of 1776 67 of those eligible 56 women 18 nonwestern immigrants participants type 2 diabetes and cardiovascular disease lowincome multiethnic district￨￨nonfasting serum levels of lipids and glucose physical activity levels reduced weight gain systolic blood pressure glucose levels triglyceride levels quitting smoking cholesteroltohdl cholesterol ratio body mass beneficial effects physical activity￨the proportion who increased their body mass was 142 lower in the intervention district p  0001 implying a 50 relative reduction compared with the control district and was lower across subgroups￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨7529 residents of pawtucket ri and 7732 residents of the comparison city￨communitybased physical activity program communitybased intervention￨physical activity exercise or prevalence of physical inactivity￨there were no differences in selfreported knowledge of the benefits of physical activity attempts to increase exercise or prevalence of physical inactivity between pawtucket and the comparison community￨no diff￨highunclear￨highunclear￨highunclear
158000￨a rural population of 158000 located in new york state comprised the intervention population￨￨body mass index systolic blood pressure smoking prevalence highdensity lipoprotein cholesterol and triglycerides diastolic blood pressure cvd morbidity and mortality selfreported and objective risk factor measurements￨smoking prevalence declined from 279 to 176 in the intervention population￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨mhhp￨risk factor levels and mortality rates￨early results show comparability of education and comparison communities for most variables￨no diff￨highunclear￨highunclear￨highunclear
not found￨1989 in a rural danish municipality slangerup with about 8000 inhabitants a danish municipality￨communitybased cardiovascular disease prevention project￨smoking eating and exercise behaviours￨more respondents in the intervention 82 than control 67 area were aware of local health projects￨sig increase￨highunclear￨highunclear￨highunclear
872￨ci 432 to 162 660 intervention subjects and 634 comparison subjects completed the followup measurements in 2006 872 randomly selected subjects aged 25 to 75 from the intervention community ghent and 810 from a comparison community participated in the baseline measurements￨￨international physical activity questionnaire ipaq data average daily steps comparison community￨average daily steps increased by 896 95 ci5991192 in the intervention community but there was no increase in the comparison community mean change 135￨sig increase￨highunclear￨highunclear￨highunclear
1056￨residents aged 1874 years who lived in four central california cities baseline n  1056 men and 1183 women subjects who completed all four examinations constituted the cohort sample n  408 men and 499 women￨community health education communitywide health education￨physical activity knowledge attitudes or selfefficacy physical activity knowledge attitudes and behavior physical activity knowledge attitudes selfefficacy and behavior vigorous activities￨results indicated little consistent evidence of a treatment effect on physical activity knowledge attitudes or selfefficacy in either men or women￨no diff￨highunclear￨highunclear￨highunclear
not found￨two iranian communities findings from the isfahan healthy heart program in the islamic republic of iran￨comprehensive integrated communitybased lifestyle intervention communitybased lifestyle intervention programmes￨food consumption physical exercise and smoking behaviours energy expenditure for total daily physical activities daily smoking leisure time devoted to physical activities mean dietary score￨daily smoking had decreased by 09 in the intervention areas and by 26 in the control area at the end of the third year but the difference was not significant￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨six rural intervention communities in the missouri bootheel region and in six comparison communities in arkansas and tennessee rural areas the communities ranged in population from 2399 to 17642 interventions focused on adults aged 18 years￨community input and included individually tailored newsletters interpersonal activities that stressed social support and communitywide events such as walkathons￨physical activity since rate of walkingtrail use walking behavior rates of walkingtrail use total number of minutes walked in the past week and total minutes walked for exercise￨although there was an increase in the rate of walkingtrail use a communitywide change in walking rates in rural communities was not documented￨sig increase￨highunclear￨highunclear￨highunclear
not found￨rural communities six rural intervention communities in missouri and six comparison communities in arkansas and tennessee in 20032004 rural residents￨community input and included individually tailored newsletters interpersonal activities that stressed social support and health provider counseling and communitywide events such as fun walks￨moderate physical activity rates of walking and moderate physical activity in the past week￨among the dependent variables walking showed some evidence of a positive linear trend across dose categories p  0090￨no diff￨highunclear￨highunclear￨highunclear
not found￨adults aged 18 to 65 years living in sthenri a lowincome innercity neighborhood in montreal quebec￨communitybased heart disease prevention program communitybased cardiovascular disease prevention program￨physical inactivity￨there were no statistically significant program effects detected in the independent sample surveys although physical inactivity increased more in the comparison community than in sthenri￨sig increase￨highunclear￨highunclear￨highunclear
not found￨florence south carolina population 56240 forty key persons 31000 participants were involved in 585 activities 1642 persons in florence and 1551 in the comparison who responded to a risk factor questionnaire and underwent a physical assessment 707 of baseline subjects participated in the postintervention￨￨cholesterol and smoking hypertension obesity high cholesterol smoking and exercise physical assessments determined lipid lipoprotein apolipoprotein and blood pressure levels￨the project had a slightly favorable intervention effect on cholesterol and smoking but failed to have an effect on other risk factors for cardiovascular disease￨no diff￨highunclear￨highunclear￨highunclear
46551￨participants with at least one of the six tests that were positive were invited for a diagnostic examination that included colonoscopy from 1976 through 1977 a total of 46551 study subjects aged 5080 years colorectal cancer mortality￨biennial screening￨mortality reduction mortality reductions colorectal cancer mortality rate cumulative 18year colorectal cancer mortality incidence of dukes stage d cancers colorectal cancer mortality numbers of deaths￨the biennial group had a 21 lower colorectal cancer mortality rate than the control group rate ratio 079 95 ci  062097￨sig decrease￨highunclear￨low￨low
not found￨129 subjects with adenomas  or  10 cm 68308 subjects all 68308 inhabitants of göteborg born between 1918 and 1931￨￨￨cancers detected by screening were at a less advanced stage than in the control group￨sig decrease￨highunclear￨highunclear￨highunclear
46551￨46551 participants 50 to 80 years of age to screening for colorectal cancer once a year to screening every two years or to a control group participants who were screened submitted six guaiacimpregnated paper slides with two smears from each of three consecutive stools participants who tested positive underwent a diagnostic evaluation that included colonoscopy￨￨reduced mortality 13year cumulative mortality survival￨the rate in the annually screened group but not in the biennially screened group was significantly lower than that in the control group￨sig decrease￨highunclear￨highunclear￨highunclear
152850￨mortality from colorectal cancer 152 850 randomised individuals were followed up through local health records and central flagging office for national statistics over a median follow up period of 11 years 152 850 individuals between the ages of 45 and 74 years to receive￨faecal occult blood screening biennial haemoccult fob test kit intervention group or to a control group￨mortality reduction mortality colorectal cancer mortality￨at a median follow up of 11 years there was a 13 reduction in colorectal cancer mortality 95 confidence interval 322 in the intervention group despite an uptake at first invitation of only approximately 50￨sig increase￨highunclear￨highunclear￨highunclear
150251￨150 251 people study group patients returning positive tests were offered colonic investigation 1774 underwent complete investigation of the colon colorectal cancer n 75 253 or not to be contacted n74 998￨faecal occult blood screening colonoscopy or flexible sigmoidoscopy and double contrast barium enema dcbe biennial haemoccult fob tests￨survival colonoscopy related deaths complications of dcbe￨sensitivity for colonoscopy or flexible sigmoidoscopy and double contrast barium enema dcbe was 967￨no diff￨highunclear￨highunclear￨highunclear
30967￨only participants who completed the first screening round were invited for further screening 13 years and seven biennial screening rounds 30 967 subjects aged 4575 years and 30966 controls was performed in 1985 from a population of 137485 of the same age￨￨death from crc mortality from crc risk of death from crc rr mortality rates positivity rates risk mortality cumulative ratio of a positive test￨mortality from crc was significantly less in the screening group relative risk rr 082 069097 and the reduction in mortality was most pronounced above the sigmoid colon￨sig decrease￨highunclear￨highunclear￨highunclear
61933￨61933 individuals aged 4575 years￨biennial screening control group or to receive a biennial hemoccultii test￨survival death rates incidence of crc mortality from crc positivity rates mortality￨death rates from causes other than crc among participants never became higher than among controls￨no diff￨highunclear￨highunclear￨highunclear
15￨newly diagnosed epilepsy 14 patients 15 patients with initial phenytoin pht monotherapy served as reference patients￨oxc and pht oxcarbazepine and phenytoin monotherapy oxcarbazepine oxc monotherapy￨memory attention and simple psychomotor speed￨as far as cognitive side effects are concerned our results revealed no evidence favoring either antiepileptic over the other￨no diff￨highunclear￨highunclear￨highunclear
287￨adults with newly diagnosed epilepsy adults with previously untreated epilepsy 287 adult patients with either ps or gtcs adults with ps and gtcs￨phenytoin pht oxc or pht monotherapy pht oxcarbazepine versus phenytoin oxcarbazepine oxc oxc￨seizurefree tolerability reasons tolerability total number of premature discontinuations number of premature discontinuations￨a total of 56 of the patients in the oxc group discontinued treatment prematurely five because of tolerability reasons compared to 61 in the pht group 16 for tolerability reasons￨no diff￨highunclear￨highunclear￨highunclear
193￨children and adolescents with ps and gtcs children and adolescents with epilepsy 193 patients aged 518 years with either ps or gtcs were enrolled patients with partial seizures with or without secondarily generalized seizures ps and generalized tonicclonic seizures without partial onset gtcs children and adolescents with newly diagnosed epilepsy￨phenytoin phenytoin pht oxc or pht monotherapy pht oxcarbazepine oxc￨number of premature discontinuations due to adverse experiences seizurefree￨the number of premature discontinuations due to adverse experiences was statistically significantly lower in the oxc group than in the pht group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨127 patients 63 received women in labor at term with cephalic singleton fetuses￨epi and cse labor epidural epi or combined spinalepidural cse analgesia epi combined spinalepidural versus traditional epidural analgesia cse￨rate of pd or other adverse outcomes hypotension rate of cesarean delivery or mean epidural duration prolonged deceleration pd of fetal heart rate rate of pd vaps ratings hypotension mode of delivery and efficacy of analgesia by visual analog pain scale vaps adverse effects￨there were no differences in the rate of pd or other adverse outcomes￨no diff￨highunclear￨highunclear￨highunclear
42￨fortytwo women whose labor began spontaneously￨bupivacaine intraduralepidural analgesia continuous epidural analgesia versus intraduralepidural analgesia 25 microgram of intradural fentanyl with 25 mg of isobaric bupivacaine with adrenalin after which analgesia was maintained with epidural administration of one 8 ml bolus of 0125 bupivacaine bupivacaine with adrenalin the epidural perfusion of 0125 bupivacaine and 1 microgramml of fentanyl￨visual analog scale extension of sensory and motor block maternal hemodynamic constants number of boluses of bupivacaine used total doses of bupivacaine and oxytocin instruments needed for childbirth and side effects pruritus nausea and vomiting incidence of pruritus analgesic efficacy efficacy and safety￨analgesic efficacy during the first 30 minutes was greater in the iea group￨sig increase￨highunclear￨highunclear￨highunclear
73￨labour patients requesting analgesia in labour￨epidural injection of 10 ml containing bupivacaine 125 mg and fentanyl 50 microg subarachnoid injection of 15 ml containing bupivacaine 25 mg and fentanyl 25 microg for initiation of analgesia￨motor weakness and proprioceptive deficit mean sd onset times to the first painfree contraction incidence of technique failure and sideeffects￨the incidence of technique failure and sideeffects was similar in the two groups￨no diff￨highunclear￨highunclear￨highunclear
251￨251 healthy laboring parturients￨bupivacaine group dp combined spinalepidural technique with 27gauge whitacre needle dural puncture but without subarachnoid drug administration or group nodp traditional epidural technique bupivacaine and 2 microgml fentanyl dural puncture with a 27gauge whitacre needle￨epidural catheter function epidural labor analgesia quality labor epidural catheter function epidural catheter manipulation and replacement rate sacral sparing unilateral block number of topup doses average hourly epidural drug usage highest sensory blockade level and labor analgesia quality catheter manipulation rate catheter replacement rate cerebral spinal fluid return￨a subgroup of 18 patients without cerebral spinal fluid return during dural puncture had a higher catheter replacement rate than those of groups dp and nodp but it did not reach statistical significance￨sig increase￨low￨low￨low
not found￨80 parturients in active labour with a singleton in vertex presentation and a cervical dilatation of 3 cm or less￨bupivacaine ep obstetric analgesia peridural analgesia versus combined spinal and peridural analgesia epidural analgesia ep and combined spinalepidural analgesia cse cse sufentanil￨onset of analgesia analgesia course of labour obstetrical outcome and neonatal status adverse effects rates of instrumental deliveries and caesarien sections length of the first stage of labour analgesic efficiency side effects and obstetrical repercussions additional analgesia apgar scores durations of second stage and expulsion labour length￨technical incidents were more frequent in the cse group 30 vs 7 p  005￨sig increase￨highunclear￨highunclear￨highunclear
93￨early active labour 93 women in early active labour and requesting￨bupivacaine epidural analgesia to receive either epidural n  48 or combined spinalepidural analgesia fentanyl lightweight patientcontrolled epidural analgesia pcea pump spinal epidural vs epidural regional analgesia cse￨pain or maternal satisfaction scores time to first topup motor blockade￨we assessed analgesia and the degree of motor blockade and found no significant differences in pain or maternal satisfaction scores between the two groups￨no diff￨highunclear￨highunclear￨highunclear
40￨i parturients at 3742 weeks gestation and cervical dilatation 6 cm forty asa￨bupivacaine containing fentanyl epidural analgesia group ea or combined spinalepidural analgesia group csea patientcontrolled epidural analgesia total bupivacaine intrathecal fentanyl epidural or combined spinalepidural analgesia￨time to first analgesic demand rate of cervical dilatation delivery type or duration of delivery csea pain relief incidence of pruritus￨both regional analgesia techniques followed by demandonly pcea provided efficient pain relief for labor without changing the duration of labor or rate of cesarean section￨no diff￨highunclear￨highunclear￨highunclear
77￨seventyseven laboring patients who requested pain relief during labor￨intrauterine pressure catheter combined spinalepidural and traditional epidural analgesia combined spinalepidural n41 or epidural analgesia labor analgesia￨elevation of uterine basal tone and fetal heart rate abnormalities uterine contractions and fhr fhr abnormalities elevation of uterine tone fetal heart rate fhr abnormalities uterine tone pain scores elevation of baseline uterine tone and occurrence of fhr prolonged decelerations or bradycardia after analgesia oxytocin use hypotension and speed of pain relief pain relief uterine basal tone probability of uterine hypertonus and fhr changes uterine hypertonus fhr abnormalities￨the incidence of all outcomes was significantly greater in the combined spinalepidural group compared with epidural uterine hypertonus 17 compared with 6 p018 fhr abnormalities 13 compared with 2 p01 and both events simultaneously 11 compared with 1 p01￨sig increase￨low￨low￨low
1054￨1054 nulliparous women requesting￨lowdose mobile versus traditional epidural techniques lowdose combined spinal epidural and lowdose infusion mobile techniques with traditional epidural technique epidural pain relief to traditional n353 lowdose combined spinal epidural n351 or lowdose infusion epidural￨normal vaginal delivery rate instrumental vaginal delivery highlevel resuscitation overall 5 min apgar scores mode of delivery and secondary outcomes were progress of labour efficacy of procedure and effect on neonates￨the normal vaginal delivery rate was 351 in the traditional epidural group 427 in the lowdose combined spinal group odds ratio 138￨no diff￨low￨low￨low
113￨113 women attending a university hospital obstetric department￨bupivacaine bupivacaine 0125  epinephrine 25 microg ml1  sufentanil perispinal analgesia bupivacaine and sufentanil intrathecal bupivacaine 025 1 ml  sufentanil￨unilateral analgesia onset of analgesia adverse effects incidence of posterior presentation nausea hypotension consumption of bupivacaine pruritus duration of labour quality of analgesia and sideeffects somnolence￨in the combined spinalepidural group the onset of analgesia was faster 5 vs 15 min p  0001 the consumption of bupivacaine was lower 75 vs 113 mg h1 p  0003 and there was less unilateral analgesia 148 vs 407 p  0002 than in the epidural group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨low risk women in early labour early labour￨epidural lidocaine and fentanyl lidocaine intrathecal sufentanil fentanyl elf n  19 to combined spinal epidural sufentanil￨mild motor weakness visual analog scores vas for pain vas for pruritus quality of analgesia incidence and severity of pruritus lower limb motor blockade and the ability to ambulate duration of analgesia vas pain scores￨the vas for pruritus were higher in the cses group p  005 but no patient requested treatment for pruritus￨sig decrease￨low￨low￨low
not found￨labour￨bupivacaine elective caesarean section spinal blockade labour analgesia and compared with spinal anaesthesia bupivacaine and fentanyl￨lower limb motor weakness sensory block motor block or dorsal column function abnormal dorsal column function spinal anaesthesia for caesarean section normal lower limb motor power and dorsal column function￨there were no significant differences between the lowdose groups with respect to sensory block motor block or dorsal column function￨no diff￨highunclear￨highunclear￨highunclear
100￨one hundred healthy nulliparous parturients in spontaneous labor with singleton vertex fullterm fetuses healthy nulliparous parturients nulliparous patients￨analgesia via a standardized combined spinalepidural n  50 or epidural n  50 technique￨overall mean cervical dilation rates rapid cervical dilation rate of cervical dilation cervical dilation pain sensory level and motor blockade rate of mean initial cervical dilation mean initial cervical dilation rates￨071 cmh p  00154 in the combined spinalepidural and epidural groups respectively￨sig increase￨highunclear￨highunclear￨highunclear
26￨33 consecutive patients who received labor analgesia parturients receiving 26 consecutive patients who received the 59 healthy parturients admitted for labor and delivery￨subarachnoid morphine and fentanyl conventional epidural analgesia subarachnoid morphine and fentanyl subarachnoid opioids via the combined spinalepidural cse technique with a group receiving epidural analgesia alone cse technique initially receiving subarachnoid morphine sulfate 025 mg and fentanyl 25 micrograms for labor analgesia subarachnoid morphine￨peripartum nausea and vomiting nv pruritus postdural puncture headache and respiratory depression respiratory depression nausea and vomiting and pruritus postdural puncture headache pruritus analgesic efficacy additional analgesia efficacy and adverse effects￨furthermore group 1 reported having more pruritus 50 versus 3 p  01 and required more treatment for pruritus 35 versus 3 p  01 than group 2￨sig increase￨highunclear￨highunclear￨highunclear
63￨thirteen patients delivered without requesting a second injection 63 parturients presenting for vaginal delivery received either￨bupivacaine bupivacaine plus 10 micrograms sufentanil and 125 micrograms epinephrine or cse analgesia bupivacaine sufentanil and epinephrine bupivacaine plus 5 micrograms sufentanil and 25 micrograms epinephrine combined spinalepidural cse injection of a bupivacainesufentanilepinephrine mixture epidural analgesia only epidural analgesia subarachnoid mixture cse sufentanil￨uneventful moderate headache compatible with postdural puncture headache painfree time required to obtain satisfactory analgesia visual analog score pruritus and headache motor impairment hypotension or nausea or vomiting pruritus duration of analgesia￨118 minutes p  05 with more patients being painfree for longer than 150 minutes 40 vs 8 p  05￨sig increase￨highunclear￨highunclear￨highunclear
40￨forty pregnant women in labor with cervical dilation between 4 and 5 cm￨bupivacaine combined anesthesia continuous epidural anesthesia labor analgesia combined spinalepidural anesthesia versus continuous epidural anesthesia￨duration of the expulsive phase incidence of cesarean section related to the analgesia maternal hemodynamic parameters and vitality of the newborn anthropometric measurements gestational age cervical dilation length of time between the blockade and absence of pain according to the visual analogic scale ability to walk length of time between analgesia and complete cervical dilation duration of the expulsive phase maternal hemodynamic parameters and vitality of the newborn pain relief length of time between the beginning of analgesia and complete cervical dilation respiratory depression maternal hypotension pruritus nausea and vomiting￨there were no statistically significant differences between both groups regarding the length of time between the beginning of analgesia and complete cervical dilation as well as regarding the duration of the expulsive phase incidence of cesarean section related to the analgesia maternal hemodynamic parameters and vitality of the newborn￨no diff￨highunclear￨highunclear￨highunclear
50￨50 healthy term parturients in the labour floor of a university hospital at an academic medical centre￨cse analgesia or lumbar epidural analgesia bupivacaine combined spinalepidural and low dose epidural intrathecal 25 microg fentanyl bupivacaine 00625fentanyl 00002 with 005 ml in 10 ml local anesthetic sodium bicarbonate 84 and epinephrine 1200000 combined spinalepidural cse technique cse￨cse technique visual analogue pain score vaps￨there were no differences p005 in time to perform either technique motor blockade or parturient satisfaction or in the number of times that the anesthesiologist was called to perform any intervention￨no diff￨highunclear￨highunclear￨highunclear
62￨62 women in labor were studied parturients￨combination of both using a combined spinalepidural cse technique intrathecal morphine epidural bupivacaine bupivacaine intrathecal it morphine with 0125 epidural bupivacaine morphine it morphine￨nausea vomiting and pruritus analgesia duration of the first stage of labor and the total duration of labor serious respiratory depression efficacy and side effects adequate pain relief urinary retention￨according to a visual analogue scale for assessing analgesia neither it 02 mg morphine nor 10 ml 0125 epidural bupivacaine was effective in producing adequate pain relief in labor whereas the combination produced excellent analgesia￨no diff￨highunclear￨highunclear￨highunclear
not found￨fifty parturients in active labor labor￨bupivacaine combined spinalepidural analgesia and epidural analgesia subarachnoid fentanyl 25 mcg as part of a combined spinal epidural analgesia cse or bupivacaine intrathecal fentanyl with conventional epidural bupivacaine cse intrathecal fentanyl vs epidural bupivacaine￨mean sd onset time to the first pain free contraction side effects pruritus verbal numeric pain scores vnps onset time to pain relief times of additional analgesia and other side effects motor blockage at time of delivery or mode of delivery￨intrathecalfentanyl as part of cse did not produce statistically a significant faster onset compared to epidural bupivacaine bolus￨no diff￨highunclear￨highunclear￨highunclear
70￨early labor analgesia seventy asa physical status i or ii parturients in early labor  or  4 cm cervical dilation analgesia during labor￨lidocaine with epinephrine and sufentanil intrathecal sufentanil with epidural sufentanil lidocaine sufentanil 10 microg with a combined spinalepidural technique cse or epidural sufentanil sufentanil epidural sufentanil epinephrine test dose with intrathecal it sufentanil epidural sufentanil lidocaine with epinephrine intrathecal sufentanil￨time from analgesic to delivery incidence of operative or assisted delivery or cervical dilation analgesia analgesia pain scores and side effects itching motor block mean duration of analgesia pain scores pain relief side effects￨pain relief was rapid for all patients pain scores were significantly lower at 5 and 10 min in the it￨sig decrease￨highunclear￨highunclear￨highunclear
100￨parous patients i or ii parous women at term in early labor 5 cm cervical dilation requesting analgesia onehundred asa physical status parous women￨epid group epidural bupivacaine 25 mgml 3 ml followed by bupivacaine 125 mgml 10 ml with fentanyl 50 microg or the cse group intrathecal bupivacaine breakthrough pain during combined spinalepidural versus epidural labor analgesia bupivacaine 0625 mgml with fentanyl epidural analgesia cse epid cse￨number of topup doses requested to treat breakthrough pain visual analog scale scores￨visual analog scale scores were lower in the cse group compared to the epid group at 10 min after initiation of analgesia median 0 cm 0 0 vs 4 cm 1 6 respectively p  0001 and at 30 min 0 cm 0 0 vs 0 cm 0 1 respectively p  003￨sig decrease￨low￨low￨low
not found￨110 parturients￨bupivacaine epidural and combined spinal epidural analgesia cse analgesia epinephrine combined spinal epidural cse and epidural epi analgesia epi cse sufentanil￨analgesic efficacy and incidence of maternal fetal and neonatal sideeffects pain relief relief of labor pain excellent analgesia incidence of maternal or neonatal side effects patient satisfaction￨79 sec p  005 excellent analgesia using less bupivacaine 235￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨women scheduled for surgical termination of a nonviable fetus before 12 weeks of gestation from october 2008 to june 2009 cervical ripening before surgical termination of pregnancy in the first trimester￨placebo 20 mg vaginally of imn isosorbide mononitrate imn isosorbide mononitrate imn￨mean cervical dilation cervical dilation adverse effects termination complications and patient satisfaction efficacy and patient satisfaction mean operative time visual analogue scale￨imn was comparable to placebo in terms of efficacy and patient satisfaction for cervical priming prior to firsttrimester termination of pregnancy￨no diff￨low￨low￨low
120￨outpatient cervical ripening before firsttrimester surgical abortion one hundred and twenty nulliparous women scheduled for suction termination of pregnancy in the first trimester 60 women￨isosorbide prostaglandin analogues misoprostol isosorbide mononitrate or 200 microg of misoprostol isosorbide mononitrate and nitroglycerin misoprostol isosorbide mononitrate and the prostaglandin analogue misoprostol misoprostol and isosorbide mononitrate￨vaginal bleeding cervical ripening frequency and intensity of side effects abdominal pain headache nausea cervical ripening cervical resistance high frequency of side effects￨misoprostol induced a more pronounced cervical ripening than isosorbide mononitrate but both regimens were associated with a high frequency of side effects￨sig increase￨highunclear￨highunclear￨highunclear
126￨one hundred twentysix healthy women requesting termination of pregnancy between 9 and 12 weeks gestation were recruited￨placebo moistened intravaginal study drugs placebo 40 mg of isosorbide mononitrate or 400 microg of misoprostol intravaginal isosorbide mononitrate misoprostol nitric oxide donor isosorbide mononitrate isosorbide mononitrate and misoprostol cervical ripening before suction evacuation control isosorbide mononitrate and misoprostol prostaglandin e1 analogue misoprostol￨operative blood loss cervical dilatation blood loss baseline cervical dilatation cumulative force and operative blood loss side effects￨there were no differences in the baseline cervical dilatation cumulative force and operative blood loss between the isosorbide mononitrate and placebo groups￨no diff￨low￨low￨low
60￨women with missed abortions tertiary referral maternity teaching hospital cervical ripening women requesting surgical evacuation of the uterus women with missed abortions before surgical evacuation of the uterus population sixty women with missed abortions and no cervical dilation￨nitric oxide no isosorbide dinitrate endocervical 80 mg15 ml isosorbide dinitrate gel solution n 30 or 400 mug15 ml misoprostol gel solution isosorbide dinitrate misoprostol nitric oxide donor isosorbide dinitrate isosorbide dinitrate or misoprostol isosorbide dinitrate and misoprostol￨mainly pelvic pain therapeutic efficacy and safety incidence of nonserious adverse events mean systolic and diastolic blood pressure headache vital signs and symptoms relative risk rr probabilities of induction of cervical ripening systolic and diastolic blood pressures adverse events such as headache abdominal pain pelvic pain backache nausea and vomiting￨intracervical administration of 80 mg isosorbide dinitrate in women with missed abortions appears to be effective for cervical ripening prior to surgical evacuation of the uterus￨no diff￨low￨low￨low
200￨first trimester surgical termination of pregnancy two hundred pregnant patients between 8 to 12 weeks admitted for surgical termination of pregnancy were recruited￨400 microg vaginal misoprostol and intracervical placebo gel or 10 mg intracervical sodium nitroprusside gel and placebo nitric oxide donors sodium nitroprusside sodium nitroprusside gel to misoprostol intracervical sodium nitroprusside vaginal misoprostol￨blood pressure cumulative force to dilate the cervix blood pressure baseline cervical dilatation and cumulative force required to dilate the cervix baseline cervical dilatation duration of operation and operative blood loss￨the cumulative force to dilate the cervix from 4 to 9 mm was significantly higher in the sodium nitroprusside group and the difference remained when a subgroup analysis was performed according to parity￨sig increase￨low￨low￨low
48￨fortyeight primigravid women undergoing surgical termination of pregnancy before 12 weeks of gestation human uterine cervix￨isosorbide nitric oxide donors nitric oxide donors nitric oxide donor isosorbide mononitrate the nitric oxide donor glyceryl trinitrate the prostaglandin analogue gemeprost or no treatment nitric oxide donors isosorbide mononitrate and glyceryl trinitrate glyceryl trinitrate￨cervical diameter cumulative force required to dilate the cervix￨pretreatment with glyceryl trinitrate reduced the cumulative force required to dilate the cervix but had no effect on cervical diameter￨no diff￨highunclear￨highunclear￨highunclear
66￨first trimester preoperative cervical ripening sixtysix primigravid women scheduled for suction termination of pregnancy￨isosorbide mononitrate and misoprostol misoprostol misoprostol 400 microg n  22 or both agents together isosorbide mononitrate 40 mg and misoprostol 400 microg isosorbide mononitrate isosorbide mononitrate or misoprostol isosorbide mononitrate 40 mg isosorbide mononitrate alone isosorbide mononitrate misoprostol and combination therapy￨number of women remaining asymptomatic cervical resistance clinical effectiveness￨the cervical resistance following combination therapy with isosorbide mononitrate and misoprostol was not significantly different than following misoprostol alone 245n vs 185n median difference 95 ci 19n 22 to 49￨no diff￨low￨low￨low
36￨36 primigravid women undergoing pregnancy termination between 9 and 125 weeks were enrolled 18 patients￨placebo nitric oxide no sodium nitroprusside intracervical gel placebo or 2 nitroprusside gel nitroprusside gel sodium nitroprusside placebo or 1 nitroprusside gel nitroprusside￨blood pressure headaches adverse events blood pressure values of cervical resistance￨women treated with both doses of nitroprusside gel showed values of cervical resistance significantly lower than those treated with placebo gel at any tested diameter￨sig decrease￨highunclear￨highunclear￨highunclear
30￨30 stroke subjects into either an upper limb or a mobility group inpatient stroke rehabilitation after stroke￨usual rehabilitation and an additional session of taskrelated practice using a circuit class format upper limb or mobility tasks additional taskrelated practice￨mobility and upper limb function early jebsen taylor hand function test jthft two arm items of the motor assessment scale mas and three mobility measures the timed up and go test tugt step test and six minute walk test 6mwt jthft dexterity scores locomotor ability￨both groups improved significantly between pre and posttests on all of the mobility measures however only the upper limb group made a significant improvement on the jthft and mas upper arm items￨sig increase￨low￨low￨low
not found￨people with moderate walking deficits between may 2000 and february 2003 91 individuals with a residual walking deficit within one year of a first or recurrent stroke consented to participate people with stroke￨taskorientated intervention￨sixminute walk test smwt 5m walk comfortable and maximum pace berg balance scale timed up and go severe walking deficit￨study findings support the efficacy of a taskorientated intervention in enhancing walking distance and speed in the first year post stroke particularly in people with moderate walking deficits￨sig increase￨low￨low￨low
10￨twenty consecutive hemiplegic patients with axial postural disturbance resulting from recent stroke 20 patients had conventional neurorehabilitation for 2 hours daily hemiplegia the 2 groups of 10 patients were similar hemiplegic patients￨device group dg or control group cg saint côme device voluntary trunk control retraining trunk control retraining during exploratory exercises￨spatial cognition deficits gait improved earlier in dg fim scores￨on day 30 postural and neglect tests improved significantly more in dg than in cg￨sig increase￨highunclear￨highunclear￨highunclear
64￨sixtyfour patients with recent stroke admitted for inpatient rehabilitation acute stroke fortyfour patients completed the 9month followup participants stratified by stroke severity￨upperextremity rehabilitation strategies standard care sc functional task practice ft and strength training st 2 upperextremity rehabilitation approaches￨fuglmeyer motor scores functional outcomes isometric torque ftheu and isometric torque isometric muscle torque performance measures of impairment fuglmeyer assessment strength isometric torque and function functional test of the hemiparetic upper extremity fthue￨compared with sc participants those in the ft and st groups had significantly greater increases in fuglmeyer motor scores p04 and isometric torque p02 posttreatment￨sig increase￨highunclear￨highunclear￨highunclear
26￨twentysix people with residual walking difficulties after stroke people affected by stroke￨placebo resourceefficient physiotherapy services homebased program of upperlimb exercises ie sham mobility exercises homebased mobility program control group after discharge from physiotherapy services￨standing standing functional reach walking mas item 5 and quality of life sasip30 mobility and quality of life quality of life￨twentysix people with residual walking difficulties after stroke were randomised into an experimental or control group after discharge from physiotherapy services￨sig increase￨highunclear￨highunclear￨highunclear
not found￨12 chronic stroke subjects chronic stroke￨taskrelated circuit class strengthening the affected lower limb and practicing functional tasks involving the lower limbs while the control group practiced upperlimb tasks taskrelated circuit training 4week training program￨walking speed and endurance peak vertical ground reaction force lowerlimb function number of repetitions of the step test walking speed and endurance force production through the affected leg￨the experimental group demonstrated significant immediate and retained 2month followup improvement p  or  05 compared with the control group in walking speed and endurance force production through the affected leg during sittostand and the number of repetitions of the step test￨sig increase￨highunclear￨highunclear￨highunclear
101￨101 severely disabled patients with a primary middlecerebralartery stroke after primary middlecerebralartery stroke￨intensity of leg and arm training rehabilitation programme with emphasis on arm training a rehabilitation programme with emphasis on leg training or a control programme in which the arm and leg were immobilised with an inflatable pressure splint leg rehabilitation training basic rehabilitation programme leg rehabilitation￨walking ability ability in adl barthel index walking ability functional ambulation categories and dexterity of the paretic arm action research arm test functional recovery of activities of daily living adl walking ability and dexterity￨there were no significant differences in these endpoints at 20 weeks between the armtraining and legtraining groups￨no diff￨low￨low￨low
120￨120 patients admitted to a stroke rehabilitation patients after stroke stroke￨bobath based and movement science bb or msb bobath based bb and movement science based msb physiotherapy interventions￨movement abilities or functional independence area under the curve auc and inserting auc values into mannwhitney u tests rivermead motor assessment and the motor assessment scale functional independence walking speed arm function muscle tone and sensation￨there were no significant differences in movement abilities or functional independence between patients receiving a bb or an msb intervention￨no diff￨low￨low￨low
35￨thirtyfive patients with an acute stroke acute stroke patients acute stroke patients following acute stroke￨lateral weight transference exercises 12 additional therapy sessions over four weeks comprising exercises aimed at improving lateral weight transference in sitting delivered by trained physiotherapy assistants￨lateral weight transference dynamic reaching sitting and standing and static standing balance time to return to their original position during dynamic reaching sway during static standing￨specific measures of weight displacement in standing and reaching and timed standing up and sitting down did not detect any differences over time regardless of group￨no diff￨highunclear￨highunclear￨highunclear
not found￨thirty stroke patients stroke patients stroke subjects￨wmft modified constraintinduced movement therapy modifiedconstraintinduced movement therapy mcimt constraintinduced movement therapy cimt cimt mcimt￨wolf motor function test wmft￨after only 2 weeks of training significant differences p005 in favor of mcimt were found in the following 6 elements of the wmft￨sig increase￨highunclear￨highunclear￨highunclear
61￨stroke rehabilitation stroke patients sixtyone patients patients with acute firstever stroke￨physiotherapy mrp bobath or motor relearning programme￨barthel adl index motor function life quality test nhp use of assistive devices or accommodation after discharge from the hospital length of stay in the hospital use of assistive devices for mobility and the patients accommodation after discharge from the hospital motor assessment scale mas the sødring motor evaluation scale smes the barthel adl index and the nottingham health profile nhp mas and smes￨there were no differences between the groups in the life quality test nhp use of assistive devices or accommodation after discharge from the hospital￨no diff￨highunclear￨highunclear￨highunclear
not found￨people with chronic stroke ninetyone individuals within one year of a first or recurrent stroke consented to participate between may 2000 and february 2003 people with stroke￨taskoriented intervention￨ninehole peg test maximal grip strength the test devaluation des membres supérieurs des personnes agées tempa and the stroke rehabilitation assessment of movement voluntary movement or manual dexterity￨a taskoriented intervention did not improve voluntary movement or manual dexterity of the affected arm in people with chronic stroke￨no diff￨highunclear￨highunclear￨highunclear
20￨nineteen subjects completed the study twenty subjects at least 1 year after stroke￨placebo taskrelated motor training 2week taskrelated training program standardized training program involving practice of reaching beyond arms length taskrelated training sham training involving completion of cognitivemanipulative tasks within arms length￨movement time distance reached vertical ground reaction forces through the feet and muscle activity performance of reaching in sitting walking activation of affected leg muscles reaching or sittostand￨after training experimental subjects were able to reach faster and further increase load through the affected foot and increase activation of affected leg muscles compared with the control group p  01￨sig increase￨highunclear￨highunclear￨highunclear
80￨80 tmd patients patients with temporomandibular disorders 30 tmd patients￨intraoral appliance and biofeedbackstress management alone and in combination biofeedback and stress management bfsm ia and bfsm￨pain temporomandibular disorders tmd intraoral appliances ias and biofeedback bf pain reduction pain and depression￨the results of this study demonstrated that the combined treatment approach was more effective than either of the single treatments alone particularly in pain reduction at the 6month followup￨sig increase￨highunclear￨highunclear￨highunclear
63￨myofascial pain of the jaw muscles 63 subjects were recruited and assigned to 3 groups 1￨oral splints passive control full occlusal splint worn only 30 min at each appointment 2 active control palatal splint worn 24 hday and 3 treatment full occlusal splint worn 24 hday￨quality of life all pain ratings intensity and unpleasantness of myofascial pain￨all pain ratings decreased significantly with time and quality of life improved for all 3 groups￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨twenty patients with mandibular dysfunction all women aged 1741 years mandibular dysfunction￨bite plate with a frontal plateau or a fullcoverage stabilization splint bite plates and stabilization splints￨subjective symptoms emg activity￨use of occlusal appliances at night for 6 weeks did not change the emg activity in the rest position or during maximal biting￨no diff￨highunclear￨highunclear￨highunclear
63￨patients with myofascial face pain 63 women with myofascial face pain myofascial face pain￨active maxillary flatplane hard acrylic splint or a palatal splint that did not interfere with occlusion active splint oral splints￨selfreported pain and functional outcome pain on palpation selfreported pain and functional outcome￨overall the findings showed a modest tendency for subjects receiving the active vs the palatal splint to exhibit improvement on selfreported pain and functional outcome￨sig increase￨highunclear￨highunclear￨highunclear
30￨mandibular dysfunction 30 patients patients were women aged 2040 years without any obvious organic reasons for their symptoms mandibular dysfunction￨electromyographic biofeedback and occlusal splint therapy biofeedback training biofeedback and occlusal splint therapy￨signs and symptoms of mandibular dysfunction￨there were no significant differences between the two groups before the start of treatment in respect of signs and symptoms of mandibular dysfunction￨no diff￨highunclear￨highunclear￨highunclear
not found￨fortyfive individuals with longstanding facial pain or headache of muscular origin facial muscular pain individuals with craniomandibular disorders of muscular origin￨acupuncture acupuncture acupuncture and occlusal splint therapy occlusal splint￨subjective symptoms and clinical signs￨both acupuncture and occlusal splint therapy significantly reduced subjective symptoms and clinical signs from the stomatognathic system￨sig decrease￨highunclear￨highunclear￨highunclear
12￨patients with temporomandibular disorders twelve patients twentyfour patients were selected to participate in this study￨occlusal splint therapy occlusal splint therapy and relaxation procedures simplified relaxation therapy technique￨total mean observable pain scores observable pain scores maximum comfortable interincisal distance and maximum interincisal distances patients pain tenderness or limited opening mean maximum opening mean maximum comfortable opening￨the occlusal splint group showed a significant decrease in total mean observable pain scores decrease score of 105 t  3124 p less than 01￨sig decrease￨highunclear￨highunclear￨highunclear
40￨40 female patients with myofascial pain myofascial pain disorder masticatory myofascial pain disorders mpd￨hypnorelaxation hypnorelaxation occlusal appliance￨￨however only hypnorelaxation but not occlusal appliance was significantly more effective than minimal treatment with regard to the patients subjective report of pain on the visual analog scale￨sig increase￨highunclear￨highunclear￨highunclear
1344￨1344 consecutive patients referred to a tmd clinic twentysix patients fulfilled the strict inclusion criterias of tmd of mainly muscular origin temporomandibular disorders patients with tmd of mainly muscular origin￨therapeutic jaw exercises and interocclusal appliance therapy￨signs and symptoms of tmd￨a further followup by questionnaire one to four years after the final clinical examination showed a lasting treatment result in most patients￨no diff￨highunclear￨highunclear￨highunclear
25￨patients with tmj dysfunction patients with tmj disorders￨acupuncture acupuncture and stomatognathic treatment acupuncture performed by a specialist in physical medicine and rehabilitation and a second similar group received standard stomatognathic treatment￨helkimo dysfunction index mobility painful movement of the mandible except in retrusive movement￨no significant differences could be detected in painful movement of the mandible except in retrusive movement wherein stomatognathic treatment was clearly superior immediately afterward￨no diff￨highunclear￨highunclear￨highunclear
not found￨a live patient￨virtual reality sigmoidoscopy simulator virtual reality flexible sigmoidoscope simulator virtual reality simulator training virtual reality flexible sigmoidoscopy simulator training flexible sigmoidoscopy￨handeye skill measures directional errors shorter mean length of examination percentage of colon visualized examination times and handeye skill measures faster insertion times viewing quality of examination￨there was also significant improvement of handeye skill measures of the experimental group in directional errors 16 versus 86 p  001 percentage of colon visualized 79 versus 45 percent p  002 and viewing quality of examination when compared with the control groups initial performance on live patients￨sig increase￨highunclear￨highunclear￨highunclear
not found￨general surgery and internal medicine residents with limited endoscopic experience general surgery require 50 colonoscopies live patients￨computerbased colonoscopy simulator no additional training colonoscopy simulator prior to their first patientbased colonoscopy virtual reality simulator training￨technical ability global ratings￨residents trained on a colonoscopy simulator prior to their first patientbased colonoscopy performed significantly better in the clinical setting than controls demonstrating skill transfer to live patients￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨computer simulator training cbcs training computerbased colonoscopy simulation cbcs cbcsenhanced training￨￨simulatortrained fellows outperformed traditionally trained fellows during their initial 15 colonoscopies in all performance aspects except insertion time pp  005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨asymptomatic patients referred for colorectal cancer screening internal medicine residents￨virtual reality simulator to bedside teaching virtual reality endoscopy simulator with bedside teaching virtual reality simulator group 1 or via bedside teaching￨average procedure time patient satisfaction and discomfort associated with the procedure splenic flexure retroflexion procedure duration completion ability to perform retroflexion and level of patient comfortdiscomfort difficulty with initial endoscope insertion and negotiation of the rectosigmoid junction￨the splenic flexure was reached independently in 10 of 34 examinations 29  in group 1 compared with 23 of 32 examinations 72  in group 2  p  0001￨sig increase￨highunclear￨highunclear￨highunclear
10￨subjects were 20 hospital medical residents￨esophagogastroduodenoscopy egd training computerbased simulator for basic training computerbased simulator training 5 h of training with the gimentor ii plus bedside training while the nonsimulator group received bedside training computerbased endoscopic simulators computerbased endoscopic simulator￨performance of endoscopy￨the simulator was more effective with regard to the items related to manipulation skills￨sig increase￨highunclear￨highunclear￨highunclear
36￨four academic endoscopy centers in the united kingdom italy and the netherlands 36 novice colonoscopists who were randomized to 16 hours of￨standard patientbased colonoscopy training simulator training subjects or patientbased training controls simulator training simulator versus bedside training￨completion rates superior technical skill reduced simulated pain scores correct use of abdominal pressure and loop management shorter completion times￨subjects had higher completion rates p001 and shorter completion times p  001 and demonstrated superior technical skill reduced simulated pain scores correct use of abdominal pressure and loop management￨sig increase￨highunclear￨highunclear￨low
45￨academic medical centers with accredited gastroenterology training programs fortyfive fellows were randomized from 16 hospitals over 2 years￨virtualreality simulator training unsupervised training on the gi mentor or no simulator experience during the first 8 weeks of fellowship gi mentor training￨median number of cases needed to reach 90 competency objective competency rates objective competence overall￨a mixedeffects model demonstrated a higher objective competence overall in the simulator group p  0001 with the difference between groups being significantly greater during the first 80 cases performed￨sig increase￨highunclear￨highunclear￨highunclear
28￨patients fourteen residents 7 residents in internal medicine without experience of endoscopy from 2003 to 2007 28 residents were enrolled￨simulatortrained 7 not simulatortrained continued endoscopy training simulator training virtual endoscopy simulator training virtual simulator training endoscopic training simulator before conventional training group s or one that received conventional training￨time technique intubation pyloric passage jmaneuver and diagnosis of pathological entities discomfort and pain performance of upper gastrointestinal endoscopy time taken to reach the duodenum technical accuracy diagnostic accuracy discomfort and pain scores discomfort and pain￨after 60 endoscopic examinations investigation time was still shorter in group s technical and diagnostic accuracy improved during onpatient training in both groups here differences between groups were no longer observable￨sig decrease￨highunclear￨highunclear￨highunclear
11￨eleven subjects consisting of six fellows and five residents participated in the study￨simulationtrained group and control group colonoscopy simulator￨￨the results of this study show that the developed colonoscopy simulator is effective in teaching the targeted colonoscopy skills and transferring those skills to actual colonoscopy￨sig increase￨highunclear￨highunclear￨highunclear
not found￨from july 2001june 2002 38 residents received either￨computer simulation training computerbased endoscopy simulator 1 week of patientbased training pbt alone in flexible sigmoidoscopy fs or 3 hours of simulatorbased training sbt cbes training￨residents procedural skill scores median patient discomfort score discomfort scores resident selfevaluation scores discomfort experienced during endoscopy 1 no pain 10 worst pain of life￨no difference was seen in the residents procedural skill scores￨no diff￨highunclear￨highunclear￨highunclear
not found￨12 endoscopy trainees 10 surgeons and two medical gastroenterologists all with experience in gastroscopy but with no specific colonoscopy experience￨virtual reality colonoscopy simulation training group practiced with the accutouch colonoscopy simulator simulator training or to a control group accutouch flexible endoscopy simulator￨shorter procedure time and less patient discomfort￨trainees in the simulatortrained group performed significantly better p00011 and managed to reach the cecum in 52 of their cases vs 19 in the control group and were 453 times more likely to succeed compared with the controls￨sig increase￨highunclear￨highunclear￨highunclear
21￨four novice gi fellows￨computer simulation training pbt simulatoraugmented training sat group in egd prior to beginning 1 month of patientbased egd training￨median patient discomfort ratings median scores￨pbt fellows ratings were also superior in sedation patient discomfort independence and competence during various phases of the evaluation￨sig decrease￨highunclear￨highunclear￨highunclear
420￨twentytwo fellows with no experience in endoscopy￨training with a computerbased simulator computerbased simulator for training preclinical training with a computerbased simulator￨length of procedures complete procedures esophageal intubation procedure duration and completeness and request for assistance￨the computerbased simulator is effective in providing novice trainees with the skills needed for identification of anatomical landmarks and basic endoscopic maneuvers and in reducing the need for assistance by instructors￨sig increase￨highunclear￨highunclear￨highunclear
142￨1994 at bellevue hospital in new york city a total of 142 participants were randomly assigned 78 received￨courtordered treatment which included enhanced services and 64 received the enhancedservice package only￨total number of days hospitalized quality of life and level of coercion rehospitalization arrest quality of life symptomatology treatment noncompliance and perceived level of coercion percentage rehospitalized￨on all major outcome measures no statistically significant differences were found between the two groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨subjects who were hospitalized involuntarily individuals with nonaffective psychotic disorders severely mentally ill individuals individuals with psychotic disorders individuals with severe mental illnesses￨￨total length of courtordered outpatient commitments hospital outcomes hospital readmissions￨outpatient commitment can work to reduce hospital readmissions and total hospital days when court orders are sustained and combined with intensive treatment particularly for individuals with psychotic disorders￨sig decrease￨highunclear￨highunclear￨highunclear
51￨51 volunteers￨naltrexone naltrexone and brief drug counseling or probation plus counseling alone naltrexone and brief drug counseling medication and counseling twice a week controls received counseling at similar intervals naltrexone naltrexone pharmacotherapy￨opioid positive urine tests opioid use￨fiftysix percent of the controls and 26 of the naltrexone group p  05 had their probation status revoked within the 6month study period and returned to prison￨sig increase￨highunclear￨highunclear￨highunclear
56￨opioiddependent patients￨naltrexone plus benzodiazepine ntx alone ntx one 50mg tablet daily plus placebo ntx naltrexone ntx benzodiazepine prazepam ntx one 50mg tablet daily plus prazepam￨relapse rate opioidfree￨at urine tests a significantly higher percent patients of group 4 remained free of delta9tetrahydrocannabinol versus patients of groups 2 and 3￨sig increase￨highunclear￨highunclear￨highunclear
not found￨former opiate dependent patients￨naltrexon naltrexone￨￨naltrexon is an longterm opioid antagonist which can be used in the psychosocial rehabilitation process of former dependents on opiates￨sig increase￨highunclear￨highunclear￨highunclear
31￨31 newly abstinent patients who underwent opioid free detoxification 15 were started on the￨opiate antagonist naltrexone naltrexone placebo naltrexone￨retention rate￨naltrexone did not appear to be superior to the placebo with regards to retention rate￨no diff￨highunclear￨highunclear￨highunclear
50￨50 patients of both sexes aged from 18 to 30 years who fulfilled dsmiiir criteria for opioid dependence were included in the study 50 heroin addicts heroin addicts￨placebo clonidine naltrexone and placebo oral naltrexone naltrexone versus placebo naltrexone￨sociodemographic data and toxicological history degree of treatment acceptance percentage of relapse in heroin consumption presence of side effects and overall retention on naltrexone overall efficacy acceptance of treatment retention rates opioid and other drug consumption drug compliance or side effects￨the efficacy of naltrexone was not superior to that of placebo as there were no significant differences in acceptance of treatment retention rates opioid and other drug consumption drug compliance or side effects￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with residual dependence opiatedependent individuals￨placebo and naltrexone naltrexone￨￨a multiclinic controlled trial of naltrexone in opiatedependent persons led to these conclusions 1 a narcotic antagonist is an acceptable treatment for a small number of patients undergoing treatment for opiate dependence 2 the group most likely to be candidates for such treatment are those who are relatively opiatefree postaddicts and well motivated to seek treatment 3 although differences between patients treated with placebo and naltrexone were slight both retention in treatment and opiatefree urine tests favored the naltrexone group 4 adverse effects of relatively shortterm treatment were slight largely being symptoms and signs of precipitated abstinence in patients with residual dependence￨sig increase￨highunclear￨highunclear￨highunclear
126￨126 detoxified heroindependent patients from an outpatient research clinic and detoxification programme in malaysia patients receiving detoxification and subsequent drug counselling for maintenance of heroin abstinence prevention of relapse and reduction of hiv risk behaviours heroin dependence in malaysia￨buprenorphine and naltrexone placebo buprenorphine buprenorphine naltrexone buprenorphine naltrexone manualguided drug counselling and maintenance with naltrexone￨urine testing three times per week were days to first heroin use days to heroin relapse three consecutive opioidpositive urine tests maximum consecutive days of heroin abstinence and reductions in hiv risk behaviours hiv risk behaviours heroin relapse time to heroin relapse greater time to first heroin￨hiv risk behaviours were significantly reduced from baseline across all three treatments p0003 but the reductions did not differ significantly between the three groups￨sig decrease￨low￨low￨low
not found￨thirtytwo addicts who successfully completed a detoxification program and met research criteria were included in the study￨naltrexone or placebo naltrexone placebo naltrexone￨most psychological parameters compliance or ratio of adverse effects heroinpositive urine tests reabuse of heroin￨throughout the entire study the number of drugfree patients in the naltrexone group was higher than in the placebo group￨sig increase￨highunclear￨highunclear￨highunclear
414￨patients totaling 414 were approached 343 gave informed consent and 280 were randomized mean age 236￨naltrexone with or without fluoxetine placebo fluoxetine fluoxetine placebo naltrexone placebo naltrexone with or without fluoxetine naltrexone￨hiv risk psychiatric symptoms relapse to heroin addiction and for reducing hiv risk psychiatric symptoms and outcome￨hiv risk psychiatric symptoms and overall adjustment were markedly improved among all patients who remained on treatment and did not relapse regardless of group assignment￨no diff￨highunclear￨highunclear￨highunclear
52￨52 consenting patients who completed detoxification in st petersburg to a double blind 6month course of biweekly drug counseling and￨naltrexone or counseling and placebo naltrexone naltrexone naltrexone￨retention and relapse￨significant differences in retention and relapse favoring naltrexone were seen beginning at 1 month and continuing throughout the study￨sig increase￨highunclear￨highunclear￨highunclear
not found￨term pregnant women in labor￨20 cc of 04 chlorhexidine placebo chlorhexidine chlorhexidine vs sterile vaginal￨incidence of neonatal pneumonia culture proven neonatal sepsis and use of the antibiotics in the neonate length of ruptured membranes neonatal infection￨318 min was not significantly different p  085 95 confidence interval 354462￨no diff￨highunclear￨highunclear￨highunclear
1041￨one thousand fortyone women nulliparous women 525 women placebo 516 women nulliparous women at or32 weeks of gestation￨placebo chlorhexidine therapy intrapartum chlorhexidine vaginal irrigations chlorhexidine solution or sterile saline solution placebo chlorhexidine vaginal irrigation chlorhexidine￨clinically diagnosed maternal peripartal infection chorioamnionitis or endometritis adverse reaction rates of peripartal infection major and minor neonatal morbidities￨major and minor neonatal morbidities were similar between the groups￨no diff￨low￨low￨low
1024￨peripartal infection 1024 patients were enrolled 508 in the chlorhexidine group and 516 in the placebo group￨placebo chlorhexidine vaginal irrigation chlorhexidine vaginal irrigation chlorhexidine solution or sterile water placebo chlorhexidine￨rates of nulliparity combined rate of chorioamnionitis and endometritis which were mutually exclusive diagnoses intrauterine pressure catheter usage rates of infection chorioamnionitis  endometritis sepsis rates adverse maternal or neonatal reactions￨rates of infection chorioamnionitis  endometritis did not differ significantly between the groups chlorhexidine 10 versus placebo 13 relative risk 08 95 confidence interval 05 to 11￨no diff￨low￨low￨low
193￨193 patients were randomized and 186 were included in the final analysis patients with leukemia 21 patients went off study due to gvhd 5 in the￨fractionated totalbody irradiation ftbi and etoposide cspmtx 3drug regimen cspmtxpse including 3 doses of mtx ftbi and cyclophosphamide mtx cspmtx bone marrow graft cspmtxpse pse cspmtxpse or cspmtx methotrexate mtx to cyclosporine csp and prednisone pse chemotherapy￨alveolar hemorrhage relapse rate overall survival incidence of chronic gvhd incidence of acute gvhd incidence of acute or chronic gvhd or eventfree or overall survival early posttransplantation complications￨the 2 groups were well balanced with respect to diagnosis disease stage age donorrecipient sex and parity￨no diff￨low￨low￨low
60￨patients with a lymphohematopoietic malignancy considered to be at high risk for posttransplant relapse prophylaxis of graftversushost disease sixty patients￨csp plus mp cyclosporine or cyclosporine plus methylprednisolone cyclosporine csp csp mp methylprednisolone mp and csp for graftversushost disease gvhd prophylaxis￨overall survival incidence of de novo chronic gvhd sustained engraftment probability of chronic gvhd risk of relapse incidence rates of grades iiiv acute gvhd relapsefree survival chronic gvhd risk of infections￨there was a suggestion that the risk of relapse was lower in patients receiving csp plus mp p  10 and although the overall survival in the two groups was not different p  44 there was a slight advantage in favor of csp plus mptreated patients for relapsefree survival p  07￨no diff￨highunclear￨highunclear￨highunclear
53￨108 consecutive patients treated with allogeneic bone marrow transplantation from an hlaidentical sibling donor for malignant blood disease were entered into the study 53 patients bone marrow transplantation from hlaidentical sibling donor￨cyclosporine methotrexate and methylprednisolone prophylactic mp methylprednisolone mp mp cyclosporine a and methotrexate cyclosporine and methotrexate corticosteroids￨relapse rate or survival time spent at hospital total amount of mp incidence of acute gvhd chronic gvhd￨the total amount of mp given was similar in the study groups because of a higher incidence of acute gvhd and its treatment in the group of patients not given prophylactic mp￨no diff￨highunclear￨highunclear￨highunclear
147￨one hundred fortyseven consecutive patients with leukemia myelodysplastic syndrome or aplastic anemia were treated by marrow grafts from genotypically hlaidentical siblings n  122 or hlahaploidentical family members n  25 patients undergoing marrow transplants￨methotrexatecyclosporine prednisone methotrexate methotrexate and cyclosporine￨leukemic relapse transplantrelated mortality acute and also chronic gvhd prevention of acute graftversushost disease gvhd overall diseasefree survival gvhd incidence￨however the resultant increase in transplantrelated mortality in patients administered prednisone was offset by an increase in leukemic relapse in patients not administered prednisone presumably related to the absence of a graftversusleukemia effect￨sig increase￨highunclear￨highunclear￨highunclear
20￨graftversushost disease after hlaidentical sibling marrow transplantation for haematological malignancy patients given hlaidentical sibling bone marrow transplants for haematological malignancy comparing the combination of￨cyclosporin and methotrexate cm cyclosporin and methotrexate versus cyclosporin methotrexate and prednisolone cmp cyclosporin and methotrexate cyclosporin methotrexate and prednisolone cmp prednisolone￨acute gvhd grades iiiv incidence of acute gvhd grades iiv acute gvhd grades iiiv chronic gvhd interstitial pneumonitis relapse survival and diseasefree survival actuarial incidence of acute gvhd grades iiiv leukaemic relapse￨there was no significant differences between the two arms for the incidence of acute gvhd grades iiv acute gvhd grades iiiv chronic gvhd interstitial pneumonitis relapse survival and diseasefree survival￨no diff￨highunclear￨highunclear￨highunclear
156￨156 patients male 98 with opioid dependence icd10 criteria using a subcutaneous implants￨depot opioid antagonists maintenance programme with depot opioid antagonists naltrexone￨retention index￨it is concluded that the programme is safe for the patients and shows a better retention index than programmes using oral antagonists with an improved compliance negative urine analysis compared to the latter￨sig increase￨highunclear￨highunclear￨highunclear
627￨alcoholdependent patients february 2002 and september 2003 at 24 us public hospitals private and veterans administration clinics and tertiary care medical centers alcohol dependence 899 individuals screened 627 who were diagnosed as being actively drinking alcoholdependent adults￨matching volume of placebo n  209 each administered monthly and combined with 12 sessions of lowintensity psychosocial intervention placebo longacting injectable naltrexone naltrexone longacting naltrexone naltrexone intramuscular injection of 380 mg of longacting naltrexone￨overall rate and time to treatment discontinuation efficacy and tolerability heavy drinking discontinuation due to adverse events efficacy and tolerability event rate of heavy drinking days￨longacting naltrexone was well tolerated and resulted in reductions in heavy drinking among treatmentseeking alcoholdependent patients during 6 months of therapy￨sig decrease￨low￨low￨low
not found￨16 alcohol dependent subjects each receiving 300 mg of alcoholics￨naltrexone individual counseling sessions naltrexone depot naltrexone naltrexone depot by intramuscular injection￨number of drinks per day heavy drinking days and proportion of drinking days serious adverse events pharmacokinetics safety and tolerability safety and tolerability of the naltrexone depot formulation blood levels of naltrexone and its main metabolite 6beta naltrexol and selfreported alcohol use￨there were no serious adverse events￨no diff￨highunclear￨highunclear￨highunclear
not found￨10 patients had 21 implants￨naltrexone￨tissue reactions hepatic toxicity patient satisfaction side effects and unwanted medical events abstinence reactions hepatitis c infection transaminases side effects￨side effects were few￨no diff￨highunclear￨highunclear￨highunclear
not found￨one group of subjects n  28 healthy subjects￨oral naltrexone naltrexone oral naltrexone 50 mg followed by a single gluteal intramuscular im injection of longacting naltrexone 190 or 380 mg or placebo oral naltrexone 50 mg daily for 5 days followed by im longacting naltrexone 380 mg or placebo￨naltrexone plasma concentrations￨no serious adverse events occurred￨no diff￨highunclear￨highunclear￨highunclear
13￨13 opioiddependent patients￨naltrexone naltrexone￨duration judged by naltrexone plasma levels plasma levels￨by single implant of 18 g naltrexone the duration judged by naltrexone plasma levels above 1 ngml naltrexone was between 2 and 4 months￨sig increase￨highunclear￨highunclear￨highunclear
not found￨twenty alcoholdependent subjects took fifteen subjects 75 received a￨injectable sustainedrelease preparation srp of naltrexone ntx placebo ntx placebo injection naltrexone single subcutaneous injection of 206 mg of sustainedrelease ntx￨bioavailability tolerability and potential efficacy frequency of heavy drinking days adverse effects ntx plasma concentrations￨compared with placebo the srp of ntx significantly reduced the frequency of heavy drinking days during the injection and followup periods￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨heroin in humans twelve heroindependent individuals participated in an 8week inpatient study￨placebo naltrexone heroin depot naltrexone depot naltrexone naltrexone depotrex naltrexone￨untoward sideeffects plasma levels subjective ratings time course safety and effectiveness subjective performance and physiological effects￨plasma levels of naltrexone remained above 1 ngml for approximately 3 and 4 weeks after administration of 192 mg and 384 mg naltrexone￨no diff￨highunclear￨highunclear￨highunclear
not found￨five heroindependent individuals participated in an 8week inpatient study￨naltrexone heroin depot naltrexone naltrexone depotrex naltrexone￨mean trough pupil diameter subjective ratings of withdrawal time course safety and effectiveness respiratory or cardiovascular function￨there were no clinically significant effects on respiratory or cardiovascular function￨no diff￨highunclear￨highunclear￨highunclear
not found￨participants were stratified by sex and years of heroin use  or  5 vs  5 2 medical centers sixty heroindependent adults opioid dependence￨oral naltrexone naltrexone placebo depot naltrexone￨adverse events percentage of cocainenegative urine samples feasibility efficacy and tolerability safety and efficacy￨retention in treatment was dose related with 39 60 and 68 of patients in the placebo 192 mg of naltrexone and 384 mg of naltrexone groups respectively remaining in treatment at the end of 2 months￨sig increase￨low￨low￨low
13￨subjects with mild childpugh grade a and moderate childpugh grade b hepatic impairment n  6 per group and matched control subjects n  13 were enrolled subjects with mild to moderate hepatic impairment patients with mild or moderate hepatic impairment subjects with hepatic impairment￨longacting naltrexone naltrexone naltrexone￨6betanaltrexol concentrations total exposure auc0infinity￨total exposure auc0infinity of naltrexone and 6betanaltrexol was similar across all groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨two cohorts totalling 101 patients with a note on naltrexone blood levels group 1 were the first 55 consecutive implanted british patients 76 male 51 unemployed 64 in social classes iii  v￨oral opiate antagonist naltrexone ntx diamorphine opiate detoxification ntx naltrexone￨opiate effects typical blood ntx levels troublesome tissue reactions￨ntx implants provide considerable protection against early relapse and may increase the likelihood of therapeutically useful periods of abstinence after opiate withdrawal￨sig increase￨highunclear￨highunclear￨highunclear
not found￨20 persons in the 6 months pretreatment that required emergency department presentation or hospital admission a subgroup of this cohort n146 83 males had previously received treatment with large cohort of heroin dependent persons n361 218 males before and after treatment with a sustained release naltrexone implant regular heroin users patients treated with sustained release naltrexone implants participants were treated under the australian therapeutic goods administrations special access guidelines￨naltrexone oral naltrexone naltrexone￨number of opioid overdoses sedative overdoses opioid overdoses blood naltrexone levels￨for those previously treated with oral naltrexone more opioid overdoses occurred in both the 6months prior to and after oral compared to the 6months postimplant treatment￨sig increase￨highunclear￨highunclear￨highunclear
1001￨patients with advanced hiv disease 1001 patients with symptomatic human immunodeficiency hiv disease and 300 or fewer cd4 cellsmm3 or asymptomatic hiv disease and 200 or fewer cd4 cellsmm3 who had tolerated zidovudine therapy for 6 months or more￨zidovudine zalcitabine zidovudine zalcitabine 225 mgd zalcitabine alone or zalcitabine and zidovudine zidovudine and zalcitabine zalcitabine￨cd4 cell count time to disease progression or death severe toxic effects estimated 12month eventfree rates disease progression progression rates safety and efficacy￨we observed no difference between the zalcitabine and zidovudine groups relative risk 074 ci 040 to 136 p  033￨no diff￨low￨low￨low
2467￨2467 hiv1infected patients 43 percent without prior antiretroviral treatment patients with 200 to 500 cd4 cells per cubic millimeter adults infected with human immunodeficiency virus type 1 hiv1 whose cd4 cell counts were from 200 to 500 per cubic millimeter hivinfected adults with cd4 cell counts from 200 to 500 per cubic millimeter￨nucleoside monotherapy zidovudine plus zalcitabine antiretroviral therapy single nucleoside zidovudine zidovudine plus didanosine zidovudine plus zalcitabine or didanosine zidovudine plus 225 mg of zalcitabine zidovudine plus didanosine zidovudine plus 400 mg of didanosine didanosine￨relative hazard ratios for progression to an aidsdefining event or death progression of hiv disease relative hazard ratios for death survival cd4 cell count development of the acquired immunodeficiency syndrome aids or death￨progression to the primary end point was more frequent with zidovudine alone 32 percent than with zidovudine plus didanosine 18 percent relative hazard ratio 050 p0001 zidovudine plus zalcitabine 20 percent relative hazard ratio 054 p0001 or didanosine alone 22 percent relative hazard ratio 061 p0001￨no diff￨highunclear￨low￨low
1102￨hivinfected patients with the acquired immunodeficiency syndrome or fewer than 200 cd4 cells per cubic millimeter patients with little or no previous zidovudine treatment patients with advanced human immunodeficiency virus hiv infection 1102 patients with the acquired immunodeficiency syndrome or fewer than 200 cd4 cells per cubic millimeter patients with advanced hiv infection combination therapy with￨zidovudine zidovudine plus zalcitabine didanosine or zalcitabine zidovudine zidovudine monotherapy zidovudine plus didanosine zidovudine alone or zidovudine combined with either didanosine or zalcitabine zidovudine alone￨disease progression survival toxic effects and the cd4 cell response relative risk of disease progression or death cd4 cell counts survival disease progression or death gastrointestinal adverse effects￨the mean increases in cd4 cell counts at two months were higher with combination therapy than with zidovudine alone￨sig increase￨highunclear￨highunclear￨highunclear
3207￨hivinfected individuals participants either had symptoms of hiv disease if aids with a cd4 cell count of  50 x 106l or a cd4 count of less than 350 before delta 1 and 1083 3207 participants 699 participants died and 936 of the 2765 without aids at entry developed aids or died￨zidovudine plus didanosine or zalcitabine with zidovudine zidovudine zidovudine with didanosine ddl or zalcitabine ddc zidovudine azt azt plus ddl or ddc azt azt plus ddc￨mortality toxicity survival disease progression￨the overall difference in survival between the treatment groups was significant p  00001 a relative reduction in mortality compared to azt alone of 33 95￨sig increase￨low￨low￨low
not found￨human immunodeficiency virus hiv1infected patients with 300 cd4 cellsmm3 and 4 weeks of prior￨zidovudineresistant virus zidovudine and zalcitabine or zidovudine and didanosine zidovudine plus didanosine combination therapy zidovudine zidovudine and zalcitabine or didanosine zidovudine monotherapy zidovudine zidovudine plus zalcitabine or zidovudine plus didanosine￨cd4 cells virologic and immunologic benefits time to first aidsdefining event or death serum hiv1 rna￨however combination therapy resulted in a significant increase in cd4 cells through 72 weeks compared with zidovudine monotherapy and a greater and more sustained decline in serum hiv1 rna￨sig increase￨highunclear￨highunclear￨highunclear
301￨cervical dysplasia andor cervical cancer cervical intraepithelial neoplasia ii moderate dysplasia 301 women with cin moderate dysplasia 151 women severe dysplasia 150 women evaluated by serial colposcopy papanicolaou cytology and cervical biopsy￨retinoic acid transretinoic acid ra ra placebo￨vaginal and vulvar side effects moderate cervical intraepithelial neoplasia cin ii or severe cin complete histologic regression rate of cin side effects￨patients receiving treatment and those receiving placebo were similar with respect to age ethnicity birthcontrol methods histologic features of the endocervical biopsy specimen and koilocytotic atypia and percentage of involvement of the cervix at study￨no diff￨highunclear￨highunclear￨highunclear
175￨women with cervical intraepithelial neoplasia cin iiiii study participants made up of 175 women with biopsyproven cin iiiii all subjects underwent a repeat colposcopy evaluation and biopsy of the cervix at 12 weeks participants mean ages were 276 years cervical intraepithelial neoplasia ii and iii￨trans retinoic acid cervical cap and sponge trans retinoic acid atra placebo￨systemic adverse events rate of histologic regression mild local selfreported and cliniciandetected toxicities human papillomaviruspositive disease response￨the disease response at 12 weeks to atra or placebo was not significantly different p  049 among the four dose groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨hivpositive women with lowgrade sil human immunodeficiency virusinfected women most subjects 63 of 102 617 used highly active antiretroviral therapy 117 human immunodeficiency virus hivpositive women with lowgrade sil of the cervix received either lowgrade squamous intraepithelial lesions sil of the cervix to highgrade lesions or invasive cervical cancer twentyone of 102 women 206 completing followup experienced progression to highgrade sil 13 in the observation group and eight in the isotretinoin group￨isotretinoin isotretinoin oral isotretinoin at 05 mgkg per day for 6 months or observation￨progression to highgrade sil or cervical cancer invasive cancer baseline cd4 levels￨subjects under age 30 were more likely to progress than those older than 30 p 046￨sig increase￨highunclear￨highunclear￨highunclear
114￨cervical dysplasia patients with histological evidence of cervical intraepithelial neoplasia cin onehundred and fourteen patients with cin 23 were enrolled in the study 112 patients evaluable for￨placebo 9cisretinoic acid aliretinoin aliretinoin highdose aliretinoin 50 mg lowdose of aliretinoin 9cisretinoic acid aliretinoin￨rate of histological regression toxicity headache compliance and side effects￨aliretinoin at these dosages and this schedule does not appear to result in significant regression rates in cin 23 patients when compared with placebo￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with biopsyproven cin23 highgrade squamous intraepithelial lesions hgsils highgrade squamous intraepithelial lesions of the cervix￨placebo placebo or 4hpr n4hydroxyphenylretinamide 4hpr topical transretinoic acid 4hpr 4hydroxyphenylretinamide￨toxicity￨toxicity was not significant in either arm￨no diff￨highunclear￨highunclear￨highunclear
50￨a total of 50 patients were recruited with 27 in group a and 23 in group b women with severe preeclampsia during antepartum and postpartum periods women with preeclampsia during antepartum and postpartum periods women with severe preeclampsia undergoing magnesium sulfate therapy during antepartum and postpartum periods women with severe preeclampsia￨magnesium sulfate mgso4 mgso4 txa2￨maternal age gestational age systolic and diastolic blood pressures txb2 levels prostacyclin and thromboxane levels prostacyclin pgi2 and thromboxane a2 prostacyclin and thromboxane levels enzymelinked immunosorbent assay elisa platelet counts maternal blood pressure pgf1alpha levels plasma levels of 6ketopgf1alpha and txb2 stable metabolites of pgi2 and txa2 maternal blood pressures venous blood￨there were no statistical differences for demographic data between the two groups with regards to maternal age gestational age systolic and diastolic blood pressures at admission 12 hours postpartum and 24 hours postpartum and mode of delivery￨no diff￨highunclear￨highunclear￨highunclear
200￨patients with chronic hypertension and insulinrequiring diabetes between january 2001 and august 2004 200 women were enrolled consenting women with suspected mild preeclampsia women with mild preeclampsia￨mgso4 postpartum therapy abbreviated postpartum magnesium sulfate therapy women receiving 12hour and 24hour postpartum magnesium sulfate mgso4 therapy￨mgso4 treatment blood pressures severe preeclampsia systolic and diastolic pressures insulinrequiring diabetes frequency of progression to severe disease seizures mgso4 toxicity or intolerance￨there were no seizures mgso4 toxicity or intolerance in either group￨no diff￨low￨low￨low
not found￨dhaka medical college and hospital bangladesh between july and november 1999 332 times gestational age 3565 eclampsia eclamptic patients who were eligible for￨mgso4 magnesium sulfate mgso4 therapy magnesium sulfate￨systolic blood pressure fit and delivery interval mean fit and treatment interval rate of recurrent convulsion case fatality rate type of eclampsia number of convulsions diastolic blood pressure proteinuria glasgow coma scale gcs recurrent convulsion rate return of consciousness￨case fatality rate was 445 and 502 in loading and standard regime groups respectively p  005￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients with severe preeclampsia severe preeclampsia￨intravenous and intramuscular magnesium sulphate regimens magnesium sulphate￨magnesium levels average serum magnesium concentrations laboratory parameters and serum magnesium levels￨similar average serum magnesium concentrations were produced by the regimens the only significant difference was that fluctuations in magnesium levels were greater with the im than the iv￨sig decrease￨highunclear￨highunclear￨highunclear
24￨children treated with another 24 children aged 612 years received 400 microg x day1 of each drug or twenty four children aged 612 yrs received 200 microg x day1 of each drug or￨placebo fluticasone propionate budesonide and placebo fluticasone propionate and budesonide budesonide budesonide inhaled corticosteroids fluticasone propionate fluticasone propionate and budesonide budesonide and fluticasone propionate￨growth rate cortisol excretion leg growth rate urine cortisol excretion lower leg length cortisol excretion￨no significant difference p039 in lower leg growth rate was found between treatment with 400 microg x day1 budesonide 030 mm x week1 and 400 microg fluticasone propionate treatment 037 mm x week1￨no diff￨highunclear￨highunclear￨highunclear
25￨25 patients with mild asthma 1934 years forced expiratory volume in one second fev1 75 predicted concentration of histamine provoking a fall in fev1 of 20 or more pc20 4 mgml inhaled asthmatic subjects with patients with asthma￨inhaled glucocorticosteroids placebo fluticasone propionate inhaled steroids￨exhaled no levels pc20 to histamine sputum eosinophil numbers and exhaled no levels airway hyperresponsiveness sputum eosinophils and exhaled nitric oxide levels airway hyperresponsiveness to histamine eosinophil counts in induced sputum and exhaled nitric oxide levels sputum eosinophils sputum eosinophils and exhaled no levels airway hyperresponsiveness induced sputum eosinophils and exhaled nitric oxide no levels pc20 exhaled no levels ppb￨treatment of asthmatic subjects with inhaled steroids for four weeks leads to improvements in airway hyperresponsiveness to histamine eosinophil counts in induced sputum and exhaled nitric oxide levels￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients receiving inhaled corticosteroids patients with asthma receiving an ics￨placebo inhaled corticosteroids icss fluticasone propionate hydrofluoroalkane fluticasone propionate hydrofluoroalkane inhalation aerosol fluticasone propionate hydrofluoroalkane inhalation aerosol fluticasone propionate hydrofluoroalkane fluticasone propionate chlorofluorocarbon￨mean morning predose percent predicted forced expiratory volume 24hour urinary cortisol excretion rates secondary pulmonary function end points and asthma symptoms effective and well tolerated￨mean morning predose percent predicted forced expiratory volume in 1 second increased by 22 32 and 46 in the fluticasone propionate 88 220 and 440microg twicedaily groups respectively compared with an 83 decrease for placebo p  001 vs placebo for all groups￨sig increase￨low￨low￨low
164￨adults with mildtomoderate persistent asthma one hundred sixtyfour patients were randomized and treated 148 patients completed the study adults with mildtomoderate asthma￨fluticasone propionate chlorofluorocarbon propellant ciclesonide hydrofluoroalkane propellant placebo ciclesonide therapy ciclesonide ciclesonide and fluticasone fluticasone propionate sequential low and highdose cosyntropin stimulation￨oral candidiasis rates hypothalamicpituitaryadrenal axis function dynamic cortisol response 24hour urinary free cortisol levels mean low and highdose peak serum cortisol levels serum cortisol levels￨oral candidiasis rates were 25 for 320microgd ciclesonide 24 for 640microgd ciclesonide and 220 for 880microgd fluticasone propionate￨no diff￨highunclear￨highunclear￨highunclear
26￨26 patients with asthma asthmatic patients￨placebo ciclesonide 640 microg od ciclesonide fluticasone propionate ciclesonide inhaled ciclesonide and fluticasone propionate 5monophosphate ciclesonide fluticasone propionate fluticasone propionate pmdi placebo ciclesonide￨cortisol secretion plasma cortisol auc024 24h cortisol secretion cortisol secretion and airway responsiveness 24h urinary cortisol excretion and pc20 for adenosine area under the plasma cortisol concentrationtime curve over 24 h plasma cortisol auc024 relative to placebo￨fluticasone propionate suppressed cortisol secretion as demonstrated by a decrease in plasma cortisol auc024 relative to placebo by 29 95 ci 1541 and 59 95 ci 5166 with 440 and 880 microg bid respectively￨sig increase￨low￨low￨low
not found￨250 microg bid for 6 months at least twentyseven subjects with moderate asthma at the time of diagnosis well controlled under regular￨placebo fluticasone fp fluticasone propionate fp inhaled fluticasone propionate fp￨provocative dose of methacholine daily symptom score and peak expiratory flow symptom recurrence sputum eosinophils clinical and functional data and in sputum eosinophil percentages recurrence of symptoms￨no significant difference in clinical and functional data and in sputum eosinophil percentages was observed between the beginning and the end of the study in both groups 1 and 2￨no diff￨highunclear￨highunclear￨highunclear
31￨mild asthma 31 mild asthmatics under control conditions and during a methacholine challenge before and after 4weeks treatment with￨placebo inhaled fluticasone dipropionate methacholine methacholineinduced bronchoconstriction and gas trapping inhaled steroids fluticasone dipropionate￨inspiratory vital capacity control forced expiratory volume in one second fev1 and maximal flow at 50 of control fvc during forced expiration after a maximal vmax50 and a partial inspiration vp50￨during methacholine challenge fvc decreased less than did fev1 or vmax50 and so did inspiratory vital capacity compared to vp50￨sig increase￨highunclear￨highunclear￨highunclear
353￨mildtomoderate asthma 353 adult and adolescent patients with asthma inadequately controlled with￨theophylline or placebo theophylline placebo inhaled fluticasone propionate fluticasone propionate inhaled betaagonist therapy alone received fluticasone propionate 50 micrograms or fluticasone propionate 100 micrograms by metereddose inhaler theophylline capsules or placebo inhaled corticosteroid fluticasone propionate placebo and fluticasone propionate fluticasone propionate fluticasone propionate 50 micrograms and fluticasone propionate oral bronchodilator theophylline￨incidence of potentially drugrelated adverse events efficacy and safety fev1 and pef￨twice daily treatment with inhaled fluticasone propionate 50 micrograms or 100 micrograms was significantly more effective than theophylline in the treatment of mildtomoderate asthma￨sig increase￨low￨low￨low
258￨asthmatic children 258 children￨placebo fluticasone propionate placebo current therapy fluticasone propionate dry powder formulation inhaled via a diskhaler inhaler or matched placebo￨morning peak expiratory flow rate pefr evening pefr diary card symptom scores beta 2agonist rescue and clinic lung function adverse events and basal plasma cortisol￨fluticasone propionate produced a significantly greater increase in morning peak expiratory flow rate pefr adjusted mean difference over days 128 17 lmin 95 ci 10 24 p  0001 and evening pefr adjusted mean difference over days 128 16 lmin 95 ci 9 23 p  0001￨sig increase￨low￨low￨low
18￨eighteen subjects with mild asthma aged 1865￨corticosteroids fluticasone propionate and budesonide placebo fluticasone budesonide pd20amp fluticasone and budesonide adenosine monophosphate￨nocturnal symptoms progressive increase in pd20amp fev1 and morning peak expiratory flow rate pefr￨fev1 and morning peak expiratory flow rate pefr increased during the first week of both active treatments and were stable thereafter￨sig increase￨highunclear￨highunclear￨highunclear
50￨eighteen patients received steroid naive eosinophilic asthma 50 adults with symptomatic steroid naive asthma and sputum eosinophilia of  or 35￨placebo fluticasone and montelukast fluticasone fluticasone propionate and montelukast inhaled corticosteroids and leukotriene receptor antagonists fluticasone montelukast low dose fluticasone montelukast￨sputum eosinophils geometric mean sd sputum eosinophilia fev1￨montelukast is not as effective as low dose fluticasone in reducing or maintaining an antiinflammatory effect in steroid naive eosinophilic asthma￨no diff￨highunclear￨highunclear￨highunclear
not found￨asthma patients n11 with mild asthma patients with asthma￨placebo fp neurokinin nk methacholine inhaled steroid inhaled glucocorticosteroid fluticasone propionate fp inhaled fluticasone￨mean log2 pc20 for methacholine mean log2 provocative concentration response to nka￨the effects of the inhaled glucocorticosteroid fluticasone propionate fp on the bronchial responsiveness to nka and methacholine were studied￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with persistent asthma treated with or without inhaled corticosteroids 408 patients in the saba study and 401 patients in the ics study patients with asthma previously treated with either patients currently receiving￨inhaled fp placebo fp fluticasone propionate fp fp 250 microg or placebo ics inhaled shortacting betaagonists saba alone or inhaled corticosteroids ics diskus device glaxosmithkline research triangle park nc each morning fluticasone propionate beta2agonists alone or ics fp and placebo￨pulmonary function and asthma symptom control efficacy and safety morning peak expiratory flow rates forced expiratory volume efficacy and safety￨at the study endpoint saba patients treated with fp and placebo had mean increases in forced expiratory volume in 1 second from baseline of 023￨sig increase￨highunclear￨highunclear￨highunclear
23￨patients with asthma 23 patients with asthma using a doubleblind placebocontrolled doubledummy and crossover design adult patients with asthma￨placebo fp budesonide bud and fluticasone propionate fp fluticasone placebo 2 fp 200 micrograms twice a day inhaled from a diskhaler 3 fp fluticasone propionate and budesonide￨area under the curve of serum cortisol versus time auc020 systemic effects￨the fev1 measured the morning after the last inhalation was significantly higher after the active treatments compared with placebo p  002 but did not differ between all active treatments￨sig increase￨low￨low￨low
27￨twenty three patients completed the study 11 on fp and 12 placebo 27 patients with asthma￨placebo fluticasone propionate inhaled fluticasone propionate fp 2 mg daily inhaled corticosteroids inhaled corticosteroids￨numbers of t cells macrophages and eosinophils in the bronchial wall fev1 delta fev1 fef2575 and fev1fvc cd4cd8 ratio and numbers of activated eg2 eosinophils lung function and the immunopathology of asthma over time￨the numbers of t cells macrophages and eosinophils in the bronchial wall were reduced by two weeks of treatment with fp but were unaltered by placebo￨sig decrease￨highunclear￨highunclear￨highunclear
397￨397 patients with moderate to severe asthma previously treated with bronchodilators alone received adolescents and adults with moderate to severe asthma￨fluticasone propionate hfa134a placebo fluticasone propionate￨incidence of adverse events and 24hour urine cortisol excretion rates morning and evening peak expiratory flow pef asthma symptoms and supplemental albuterol use forced expiratory volume￨morning and evening peak expiratory flow pef asthma symptoms and supplemental albuterol use also improved in all fluticasone propionate groups versus placebo￨sig increase￨low￨low￨low
not found￨asthma twenty patients aged 1855 yrs with mild stable asthma￨fluticasone propionate 250 microg bd fp250 or 3 placebo placebo placebo sm50 placebo fp250 inhaled corticosteroids salmeterol fp250 sm50￨mucosal inflammation numbers of cd3 tlymphocytes cd4 thelper cells cd45ro activated thelper cells and eosinophils percentage of symptomfree days and nights and airways hyperresponsiveness numbers of neutrophils in bronchial biopsy samples and the concentrations of myeloperoxidase and soluble eselectin percentage of eosinophils and soluble intercellular adhesion molecule1￨compared with placebo sm50 significantly reduced the numbers of neutrophils in bronchial biopsy samples and the concentrations of myeloperoxidase and soluble eselectin in serum each of which reflect neutrophil involvement￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients aged between 12 and 79 years with a documented clinical history of asthma for  or 6 months who were currently receiving inhaled shortacting beta2adrenoceptor agonists only were enrolled patients with mild asthma not previously receiving maintenance corticosteroids patients with mild persistent asthma adults and adolescents with asthma￨placebo fluticasone propionate fp sfc sfc 50 microg100 microg twicedaily inhaled fp 100 microg ie twice the dose of fp compared with sfc or placebo salmeterolfluticasone propionate via diskus once daily versus fluticasone propionate salmeterolfluticasone propionate combination sfc therapy￨clinic pef exacerbation rates tolerated and the safety profile clinic forced expiratory flow mean morning pef adjusted mean pef asthma exacerbation rates mean morning peak expiratory flow pef as recorded by patients prior to the use of bronchodilator or study medication and the rate of investigatorrecorded asthma exacerbations efficacy and safety￨oncedaily sfc significantly improved clinic forced expiratory flow between 25 and 75 of forced vital capacity difference in means 0129 ls p  0001 and clinic pef difference in means 108 lmin p  0001 compared with twicedaily fp￨sig increase￨low￨low￨low
10￨ten mild asthmatic patients￨regular fluticasone placebo fluticasone inhaled steroid inhaled glucocorticoid￨early asthmatic response airway responsiveness eosinophil count sputum cell counts and measures of eosinophil activation at 7 h and 24 h and methacholine airway responsiveness airway responsiveness or the sputum eosinophilia late asthmatic response airway responsiveness or sputum eosinophilia sputum eosinophilia prechallenge sem maximum percentage fall in fev1 eosinophilia p0005 and activated eosinophils allergeninduced airway responses and sputum inflammatory markers￨two weeks of regular inhaled fluticasone discontinued 24 h before allergen challenge does not offer any additional protection against the early or late asthmatic responses increased airway responsiveness or sputum eosinophilia compared with a single dose of 250 microg immediately before allergen challenge despite increasing baseline pc20 and decreasing sputum eosinophilia prechallenge￨no diff￨highunclear￨highunclear￨highunclear
160￨160 patients with asthma who had minimal previous exposure to corticosteroids was conducted from july 1994 through june 1997 patients with asthma￨fluticasone propionate fluticasone propionate vs placebo placebo fluticasone￨bone mineral density cortisol production bone hypothalamicpituitaryadrenal hpa axis function hpa axis function and ophthalmic evaluations lumbar spine hpa axis function bmd bone mineral density bmd￨at all time points hpa axis function was similar in the 88microg fluticasone group compared with the placebo group￨no diff￨low￨low￨low
37￨thirtyseven children with asthma aged 6 to 14 years children receiving children with asthma￨placebo fluticasone propionate fp standardized dry air treadmill exercise testing eib pd20 methacholine inhaled steroids methacholineinduced bronchoconstriction fluticasone propionate￨severity of eib eib forced expired volume in 1 sec fev1 geometric mean  fall in fev1￨methacholine improved significantly during the first 6 weeks as compared to placebo p  004 and steadily increased with time in both treatment limbs p  004 the difference in improvement between doses 100 microg fp bid 16 dose steps 250 microg fp bid 33 dose steps approaching significance after 24 weeks p  006￨sig increase￨highunclear￨highunclear￨highunclear
291￨24 outpatient centers 291 male and female patients at least 12 years of age with asthma fev1 between 50 and 80 of predicted value who had previously received maintenance therapy with patients with persistent asthma￨placebo fluticasone triamcinolone fluticasone propionate powder triamcinolone and placebo fluticasone propionate powder fluticasone propionate powder administered through diskhaler versus triamcinolone acetonide aerosol beclomethasone dipropionate or triamcinolone acetonide fluticasone vs placebo triamcinolone acetonide aerosol￨incidence of adverse events and low morning plasma cortisol concentrations supplemental rescue albuterol use morning peak expiratory flow mean increase in fev1￨fluticasone propionate powder twice daily 500 microgday was superior in efficacy to triamcinolone acetonide aerosol four times daily 800 microgday in patients with persistent asthma￨sig increase￨low￨low￨low
not found￨patients n  253 age  or  12 years with a mean fev1 of 67 predicted normal were stratified according to baseline therapy of maintenance inhaled corticosteroids vs beta2agonists alone patients with moderate asthma￨placebo fluticasone propionate fluticasone propionate powder fluticasone propionate powder placebo fluticasone propionate fluticasone propionate￨evening peak expiratory flow systemic effects fev1 albuterol use and withdrawal due to lack of efficacy efficacy parameters fev1 withdrawal due to lack of efficacy nighttime awakenings asthma symptom scores lung function efficacy and safety￨compared to placebo fluticasone propionate administered qd or bid significantly improved fev1 p  0001 morning p  0001 and evening peak expiratory flow pef p  0001 asthma symptom scores p  or  0001 and albuterol use p  0001 and decreased nighttime awakenings￨sig increase￨low￨low￨low
64￨adults with mild asthma 64 adults with mild persistent asthma￨placebo fluticasone propionate powder fluticasone propionate powder 500 microgram or placebo fluticasone propionate therapy inhaled corticosteroids fluticasone propionate￨8hour plasma cortisol area under the curve values markers of bone formation serum osteocalcin and resorption urinary ntelopeptide lumbar spine l1 to l4  bone density morning plasma cortisol concentrations skeletal system efficacious and well tolerated ophthalmic parameters glaucoma and posterior subcapsular cataracts hypothalamicpituitaryadrenal axis and bone mineral density poststimulation mean peak plasma cortisol concentrations hypothalamicpituitaryadrenal axis hypothalamicpituitaryadrenal axis bone density or ophthalmic parameters pulmonary function￨mean change from baseline in lumbar spine l1 to l4  bone density at week 104 was not significantly different between fluticasone propionate 0006  0008 gcm2 and placebo 0007￨no diff￨low￨low￨low
26￨patients with mild asthma twenty six asthmatic patients aged 2159 years patients with mild persistent asthma mild asthma bronchial hyperresponsiveness bhr￨placebo fp inhaled fluticasone propionate ics inhaled fluticasone propionate fp 250 micro g inhaled fp mdi histamine￨increase in pd15fev1 bronchial hyperresponsiveness forced expiratory volume bhr to histamine bhr￨the increase in pd15fev1 from baseline was greater in the fp group than in the placebo group the difference achieved significance within 72 hours and remained significant until the end of treatment￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with mildtomoderate asthma patients with asthma receiving repeated inhaled doses of￨placebo fp fp 500 microg was administered via the diskus or diskhaler for 12 weeks inhaled fluticasone propionate fp diskus or diskhaler dry powder inhalers dpis fluticasone propionate inhaled via the diskhaler and diskus powder devices￨plasma fp concentrations steadystate kinetics area under the plasma fp concentrationtime curve maximum plasma fp concentration cmax diskus to diskhaler ratio for cmax cortisol suppression steadystate plasma fp concentrations plasma cortisol levels ratios of cmax and auclast￨after 4 weeks the maximum plasma fp concentration cmax in this subgroup was 0096 microgl 95 confidence interval ci 00660141 and the area under the plasma fp concentrationtime curve up to the last quantifiable concentration auclast was 0491 microgl x h 95 ci 02560940￨no diff￨low￨low￨low
338￨338 persistent asthma patients 12 years of age or older using shortacting b2agonists alone patients who are symptomatic with the use of shortacting b2agonists alone controlling persistent asthma￨placebo inhaled fluticasone propionate fluticasone propionate zafirlukast zafirlukast a leukotriene modifier oral zafirlukast fluticasone propionate inhaled fluticasone propionate￨asthma exacerbations adverse events and clinically significant laboratory test results clinical parameters symptom scores percentages of symptomfree and albuterolfree days albuterol use and nighttime awakenings exacerbation requiring oral corticosteroids quality of life pulmonary function changes in pulmonary function asthma symptoms rescue albuterol use nighttime awakenings due to asthma and quality of life efficacy and safety￨treatment with fluticasone propionate resulted in significantly greater improvements in pulmonary function compared with zafirlukast p 05 or placebo p 05￨sig increase￨low￨low￨low
356￨asthma 356 patients aged 12 years or older with asthma many patients with persistent asthma need both longacting bronchodilators and inhaled corticosteroids for optimal asthma control￨placebo placebo and salmeterol fluticasone salmeterol 50 microg combined with fluticasone 100 microg combination product salmeterol 50 microg fluticasone 100 microg or placebo placebo fluticasone or salmeterol alone salmeterol and fluticasone propionate placebo salmeterol and fluticasone salmeterol 50 microg and fluticasone salmeterol￨symptom scores mean change in fev1 tolerated percentage of nights with no awakenings efficacy and safety worsening asthma￨the combination product significantly increased p  or 013 area under the curve compared with placebo and fluticasone on day 1 and compared with placebo salmeterol and fluticasone at week 1 and week 12￨sig increase￨low￨low￨low
not found￨patients whose mild to moderate asthma was inadequately controlled by asneeded use of an inhaled betaagonist patients with mild to moderate asthma￨placebo fluticasone propionate aerosol fluticasone propionate aerosol fluticasone propionate fluticasone propionate￨night awakenings and less use of rescue albuterol adverse events morning peak expiratory flow rates pefr pulmonary function maximal improvement in fev1 efficacy and tolerability pulmonary function indexed by forced expiratory volume￨values for patientmeasured morning peak expiratory flow rates pefr were significantly p05 higher and the use of rescue albuterol was significantly p05 lower beginning 3 to 5 days after initiation of therapy in the groups treated with fluticasone propionate compared with the placebo group￨sig increase￨low￨low￨highunclear
26￨26 asthmatic subjects 18 years old not using￨placebo fluticasone fluticasone twice daily or placebo budesonide and fluticasone budesonide inhaled steroid therapy inhaled steroids￨bronchoconstriction and airway inflammation early responses airway eosinophilia and allergeninduced airway hyperresponsiveness partial protection lateresponse allergeninduced sputum eosinophilia￨partial protection was demonstrated against the lateresponse allergeninduced sputum eosinophilia with both treatments  p  001￨sig decrease￨highunclear￨highunclear￨highunclear
33￨nonsmoking atopic asthmatics 33 atopic asthmatics￨placebo fluticasone methacholine fluticasone propionate methacholine￨mdr curves maximal airway narrowing response mdr curve forced expiratory volume in one second pc20  sensitivity slope reactivity and maximal response plateau baseline fev1 stabilization bhr and the different indices of the methacholine doseresponse mdr curve plateau value fall in forced expiratory volume￨in the fluticasone group significant changes occurred after 6 weeks with respect to means of pc20 an increase of 34 doubling doses plateau value fall in forced expiratory volume in one second fev1 from 58 at randomization to 41 at 6 weeks and baseline fev1 from 346 to 375 l in contrast to the placebo group￨sig increase￨highunclear￨highunclear￨highunclear
360￨patients n360 with persistent asthma previously treated with beta2agonists short or longacting or patients with mildtomoderate persistent asthma￨fluticasone propionate fp inhaled corticosteroids ics fluticasone propionatesalmeterol hfa 134a mdi hydrofluoroalkane hfa 134a metered dose inhaler mdi fsc with that of placebo hfa 134a pla fluticasone propionate 44 microg chlorofluorocarbon cfc alone and salmeterol 21 microg cfc alone s fsc￨efficacy and safety safety profile of fsc asthma inflammation and smooth muscle dysfunction eg bronchoconstriction mean fev1 aucbl morning and evening peak expiratory flow need for rescue albuterol and asthma symptom scores efficacy and safety￨finally treatment with fsc resulted in significantly p  or  0007 greater improvements in morning and evening peak expiratory flow need for rescue albuterol and asthma symptom scores compared with fp s and pla￨sig increase￨highunclear￨highunclear￨highunclear
570￨bd patients patients with asthma treated with or without inhaled corticosteroids patients who were currently being treated with bronchodilators only bd patients and in patients who required inhaled corticosteroids for maintenance treatment of asthma ics patients five hundred seventy patients￨placebo ics fp100bid fp200qd and placebo fluticasone propionate powder fp100bid and fp200qd fluticasone propionate 100 microg twice daily fp100bid or 200 microg once daily fp200qd or placebo fluticasone propionate diskus device glaxo wellcome research triangle park nc￨pulmonary function and asthma stability morning peak expiratory flow fev1￨the efficacies of fp100bid and fp200qd were comparable with regard to improvement in pulmonary function and asthma stability in bd patients￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with severe chronic asthma patients with chronic severe asthma patients with severe asthma patients with severe chronic asthma previously treated with dependent 5 to 40 mgday adolescents and adults with asthma n  111 mean fev1  61 of predicted value￨placebo oral prednisone placebo or twice daily fluticasone propionate 500 or 1000 microg administered by means of a multidose powder inhaler fluticasone propionate powder inhaled fluticasone propionate powder oral prednisone fluticasone propionate powder oral corticosteroidsparing controlled prednisone fluticasone propionate￨lung function adrenal function and asthmaspecific quality of life hypothalamicpituitaryadrenal axis suppression adverse events patient quality of life assessed by means of the asthma quality of life questionnaire pulmonary function lung function and quality of life fev1 morning and evening peak expiratory flow asthma symptoms albuterol use and nighttime awakenings￨patient quality of life assessed by means of the asthma quality of life questionnaire was clinically and significantly improved after fluticasone propionate treatment p 003￨sig increase￨low￨low￨low
48￨subjects with early signs of asthma or chronic obstructive pulmonary disease copd fortyeight adult subjects with early signs of copd slightly increased forced expiratory volume in 1 sec fev1 decline of 004lyear and 29 adult subjects with early signs of asthma signs of bronchial hyperresponsiveness or reversibility subjects with early signs of asthma and chronic obstructive pulmonary disease copd without an established diagnosis subjects were selected from a large screening program on early stages of asthma and copd detection intervention and monitoring program of copd and asthma dimca program in the general practice￨placebo fluticasone propionate fp by dry powder inhalation rotadisk fp flixotide 500 microg daily versus placebo inhaled corticosteroids fluticasone propionate￨perceived effectiveness compliance rates compliance side effects mean overall individual compliance rates￨the willingness of patients to use the trial drug in daily practice if efficacy would be proved was statistically significantly related to compliance during the trial p  0017￨sig increase￨highunclear￨highunclear￨highunclear
not found￨128 patients to evaluate adrenal response to 6hour cosyntropin infusion a clinically relevant method for evaluating adrenal function after 28 days of treatment with￨placebo fluticasone triamcinolone fluticasone propionate aerosol 88 microg or 220 microg twice daily triamcinolone acetonide aerosol 200 microg 4 times daily or 400 microg twice daily prednisone 10 mg once daily and placebo fluticasone triamcinolone prednisone fluticasone propionate aerosol triamcinolone acetonide aerosol prednisone and placebo fluticasone propionate triamcinolone acetonide prednisone and placebo fluticasone propionate￨cortisol response adrenal responses mean plasma cortisol response to cosyntropin hypothalamicpituitaryadrenal axis mean 8hour area under the plasma cortisol concentrationtime curves and peak plasma cortisol concentrations plasma cortisol concentration time curves and peak cortisol concentrations￨mean reductions from baseline in area under the plasma cortisol concentration time curves and peak cortisol concentrations were significantly p 05 greater with triamcinolone 400 microg twice daily compared with placebo￨sig decrease￨highunclear￨highunclear￨highunclear
330￨330 patients  or  12 years old previously receiving inhaled corticosteroids or beta2agonists alone patients with moderate asthma patients with moderate asthma fev1 45 to 75 predicted￨inhaled fluticasone propionate fluticasone propionate fluticasone propionate vs placebo fluticasone propionate at 100 200 or 500 microg once daily or matching placebo￨morning plasma cortisol concentrations efficacy variables such as fev1 morning and evening peak expiratory flow pef asthma symptom scores nighttime awakenings albuterol use and duration of study participation clinical efficacy and safety lung function and asthma control￨no doseresponse effect or clinically relevant differences were observed in morning plasma cortisol concentrations or after cosyntropin stimulation￨no diff￨low￨low￨low
not found￨mean age 3841 years white race 7888 and pulmonary function mean percent predicted fev1 6869 mean asthma symptom score 16 scale 05 and mean daily albuterol use 31 puffs adolescent and adult patients with persistent asthma thirtytwo adolescent and 333 adult patients participants had to be  or 12 years of age and have a diagnosis of asthma requiring pharmacotherapy for at least 6 months before the study￨fluticasone propionate fp and salmeterol sal placebo fluticasone propionatesalmeterol inhaled corticosteroids icss hydrofluoroalkane hfa 134a metereddose inhaler mdi with those of its 2 components alone delivered via a chlorofluorocarbon cfc mdi and placebo pla delivered via hfa mdi hydrofluoroalkane 134a metereddose inhaler fsc fp or sal monotherapy or pla fsc 22042 microg hfa pla hfa￨mean fev1 aucbl forced expiratory volume in 1 second fev1 adverse events headache efficacy and tolerability tolerated mean area under the 12hour serial fev1 curve relative to the prerandomization baseline fev1 demographic characteristics morning and evening peak expiratory flow tolerability assessments included electrocardiograms routine clinical laboratory tests vital signs oropharyngeal examinations and physical examinations asthma symptom scores candidiasis of the mouththroat incidence of possibly drugrelated adverse events unspecified oropharyngeal plaques lung function efficacy and tolerability tolerability of fsc throat irritation￨treatment with fsc resulted in significant improvements in morning and evening peak expiratory flow compared with fp sal and pla both p  0001 need for rescue albuterol compared with fp and pla p  or 0005 and asthma symptom scores compared with pla p  0001￨sig increase￨low￨low￨low
35￨patients with relatively mild but symptomatic asthma patients with relatively mild asthma twenty two normal healthy nonasthmatic subjects acted as controls 35 asthmatic patients￨inhaled fp placebo inhaled corticosteroid ics inhaled steroids fluticasone propionate fp 750 microg bd￨bal inflammatory cells bal fluid eosinophils mast cells and epithelial cells bronchoalveolar lavage bal and airway biopsy studies pd20 rbm thickness spirometric indices airway inflammation airway remodelling and bronchial hyperreactivity bhr forced expiratory volume subepithelial reticular basement membrane rbm thickness￨bal inflammatory cells decreased following 3 months of treatment with no further improvement at 12 months p005 v placebo￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨adult patients with mildtomoderate persistent asthma patients with mildtomoderate persistent asthma adult patients with asthma￨placebo oral prednisone fluticasone propionate triamcinolone acetonide and flunisolide flunisolide 500 microg twice daily and placebo inhaled corticosteroids fluticasone propionate triamcinolone acetonide and flunisolide and oral prednisone triamcinolone acetonide triamcinolone acetonide or flunisolide prednisone inhaled corticosteroids fluticasone propionate￨suppression of hpaaxis function auc mean plasma cortisol responses hypothalamicpituitaryadrenal hpa axis function hypothalamicpituitaryadrenal axis systemic effect plasma concentrationtime curve auc and 8hour peak plasma cortisol concentrations￨prednisone produced significantly greater suppression of hpaaxis function than did any of the inhaled corticosteroids or placebo p0001￨sig increase￨highunclear￨highunclear￨highunclear
342￨342 adolescent and adult patients with moderate asthma forced expiratory volume in 1 second fev1 between 50 and 80 of predicted treated previously by patients with moderate asthma patients with moderate asthma previously treated with an inhaled corticosteroid moderate asthma￨placebo fluticasone propionate fluticasone propionate powder fluticasone propionate powder fluticasone propionate powder 50 micrograms 100 micrograms 250 micrograms or placebo beclomethasone dipropionate or triamcinolone acetonide fluticasone propionate powder versus placebo fluticasone propionate￨fev1 lung function time without developing signs of exacerbating asthma comparative efficacy and safety asthma symptom scores supplemental rescue albuterol use and number of nighttime awakenings due to asthma requiring treatment efficacy and safety￨there were no statistically significant differences at endpoint among the three fluticasone propionate groups￨no diff￨low￨low￨low
136￨136 male and female patients at least 12 years of age with asthma forced expiratory volume in 1 second fev between 50 and 80 of predicted asthma patients with asthma treated with shortacting beta2agonists alone patients with asthma who had not previously been treated with inhaled corticosteroids￨fluticasone propionate salmeterol combined with fluticasone propionate salmeterol and fluticasone propionate inhaled salmeterol and fluticasone monotherapy and combination therapy salmeterol salmeterol 42 microg fluticasone propionate 88 microg fluticasone propionate 220 microg salmeterol 42 microg plus fluticasone propionate 88 microg salmeterol 42 microg plus fluticasone propionate 220 microg or placebo￨fev safety measurement patientrated data peak expiratory flow asthma symptom scores percent of days with no asthma symptoms pulmonary function and symptom control￨patients treated with salmeterol combined with fluticasone propionate had improvements over baseline in fev at endpoint that were at least twice as great 06 to 07 l as improvements in patients treated with salmeterol 03 l or fluticasone propionate alone 03 l p  05￨sig increase￨highunclear￨highunclear￨highunclear
34￨children with moderate asthma 34 children with moderate asthma who did not use inhaled steroids for at least 4 wk prior to the study children with asthma children with moderate stable asthma￨placebo fp fluticasone propionate fp fluticasone propionate inhaled corticosteroids￨fev1 and pc20histamine pefr values nocturnal pefr urinary cortisol symptoms and peak flow recordings pefr serum cortisol reversibility serum and urinary cortisol efficacy and safety￨serum cortisol did not change significantly in either treatment group￨no diff￨highunclear￨highunclear￨highunclear
68￨68 children 510 yrs old children with mild asthma children with mild asthma￨fptreated versus placebo inhaled corticosteroids fp 250 microg or placebo fluticasone propionate fp￨parent global evaluation absolute values of fev1 nor pd20 percentage symptomfree days use of beta2mimetics morning and evening pef fev1  pred and wheezing symptom scores use of rescue medication wheezing parent global evaluation and pulmonary function tests including forced expiratory volume in one second fev1 peak expiratory flow pef and bronchial responsiveness provocation dose of methacholine causing a 20 fall in fev1 pd20￨fptreated versus placebotreated children showed significant changes in percentage symptomfree days use of beta2mimetics morning and evening pef fev1  pred and wheezing￨sig increase￨highunclear￨highunclear￨highunclear
not found￨children age 1 to  4 years with asthma preschoolage children with asthma￨placebo hfa fp fp hfa fluticasone propionate hydrofluoroalkane inhalation aerosol fluticasone propionate fp hydrofluoroalkane hfa placebo hfa￨24hour daily composite of daytime and nighttime asthma symptom scores efficacy and safety fp plasma concentrations nighttime symptom scores 24hour daily asthma symptom scores effective and well tolerated daytime asthma symptom scores and albuterol use baseline median urinary cortisol excretion values efficacy and tolerability￨the fptreated children had significantly greater p  or  05 reductions in 24hour daily asthma symptom scores 539 vs 441 and nighttime symptom scores over the entire treatment period compared with the placebo group￨sig decrease￨low￨low￨low
437￨pediatric patients with persistent asthma children children even as young as 4 and 5 years old regardless of whether they were previously treated with 437 children 4 to 11 years old with persistent asthma for 12 weeks large pediatric population with persistent asthma￨inhaled fluticasone propionate placebo fluticasone propionate fluticasone propionate powder fluticasone propionate powder inhaled corticosteroids or cromolyn or beta2agonists alone fluticasone propionate inhaled corticosteroids￨morning plasma cortisol concentrations effective and safe tolerated and improved lung function fev1 nighttime awakenings 24hour urinary freecortisol excretion peak expiratory flow and asthma symptom scores efficacy parameters clinic morning peak expiratory flow efficacy and safety￨fluticasone propionate did not suppress morning plasma cortisol concentrations and did not affect 24hour urinary freecortisol excretion￨no diff￨low￨low￨low
not found￨subjects with mildtomoderate persistent asthma subjects previously treated with inhaled corticosteroids or beta2agonists alone 213 adolescent and adult asthma subjects subjects with mildtomoderate asthma￨fluticasone propionate administered via the diskus and diskhaler powder delivery devices inhaled corticosteroids or beta2agonists alone placebo fluticasone propionate fluticasone propionate powder fluticasone propionate via two dry powder inhalers fluticasone propionate￨tolerated and effective forced expiratory volume nighttime awakenings incidence and severity of adverse events pulmonary function asthma symptom scores plasma fluticasone propionate and cortisol concentrations morning and evening peak expiratory flow safety and efficacy￨at endpoint fluticasone propionate significantly improved forced expiratory volume in 1 second p  001 morning and evening peak expiratory flow p  001 and asthma symptom scores p  or  016 and significantly reduced nighttime awakenings p  016 diskhaler group only and rescue albuterol use p  001￨sig increase￨low￨low￨low
not found￨adolescents and adults with moderate asthma who were previously taking inhaled corticosteroids patients with moderate asthma patients n  304  or  12 years of age with moderate asthma previously treated with inhaled corticosteroids and betasympathomimetic bronchodilators were enrolled￨fluticasone propionate placebo placebo or fluticasone propionate￨efficacy morning peak expiratory flow rate physician overall assessments and patientrated assessment of symptoms and albuterol use for symptom control mean values of forced expiratory volume adverse events asthma stability pulmonary function tests physician and patient assessments and rescue bronchodilator use efficacy and safety￨between baseline and end point mean values of forced expiratory volume in 1 second decreased 031 l in the placebo group and improved 039 l 030 l and 043 l in patients receiving 100micrograms 250micrograms and 500micrograms fluticasone propionate respectively￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with methacholineinduced bronchial hyperresponsiveness patients with mild to moderate asthma 138 patients  or  12 years of age￨placebo placebo fp 50 microg or fp inhaled fluticasone propionate fp inhaled corticosteroids fluticasone propionate methacholine￨clinical efficacy and safety forced expiratory volume in 1 sec fev1 patientmeasured peak expiratory flow pef total symptom scores and rescue bronchodilator use￨the results of methacholine challenge testing averaged over all visits favored fp 200 microgday over placebo and fp 100 microgday p  005 there were no significant differences between placebo and fp 100 microgday￨no diff￨highunclear￨highunclear￨highunclear
not found￨mild asthma 20 nonsmoking asthmatic patients who required only beta2agonists to control their symptoms￨placebo fp bronchoscopy with bronchoalveolar lavage bal and bronchial biopsy inhaled fluticasone propionate fp fluticasone propionate methacholine￨eosinophil cationic protein ecp level number of eosinophils and mast cells in the lamina propria in bronchial biopsies specimens bronchial responsiveness to methacholine number of cells expressing intracellular adhesion molecule1 icam1 and mac1 tryptase level in bal basementmembrane thickness￨bronchial responsiveness to methacholine decreased significantly only after 6 wk of treatment with fp p  005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨ninetysix patients dependent on patients with severe asthma￨placebo oral prednisone fluticasone propionate fluticasone propionate aerosol fluticasone propionate aerosol placebotreated patients used no prednisone placebo or fluticasone propionate aerosol fluticasone propionate￨asthma control and quality of life pulmonary function and quality of life fev1 and peak expiratory flow rates number of night awakenings and symptomatic albuterol patientrated asthma symptoms￨fluticasone propionate aerosol was welltolerated and it improved some dimensions of healthrelated quality of life measured using a standard patient survey￨sig increase￨highunclear￨highunclear￨highunclear
153￨patients with asthma requiring longterm inhaled corticosteroid therapy enrolled patients were nonsmokers 18 to 50 years of age with persistent mildtomoderate asthma and had not used oral nasal or inhaled corticosteroids for 6 months before study adult asthma patients one hundred fiftythree patients￨fluticasone propionate and flunisolide placebo flunisolide prednisone corticosteroids flunisolide and fluticasone propionate versus placebo and oral prednisone fluticasone flunisolide and fluticasone propionate fluticasone propionate flunisolide￨salivary and urinary cortisol data suppression of hpa axis serumcortisol suppression diurnal pattern of serum cortisol suppression area under serum cortisol concentration curve for 22 hours auc022h 24hour urinary cortisol level and 8 am salivary cortisol level￨both fluticasone propionate and flunisolide caused dosedependent suppression of hpa axis which was statistically greater for fluticasone propionate p  00003￨sig increase￨highunclear￨highunclear￨highunclear
18￨eighteen asthmatic adults 15 hispanic with a percentage predicted forced expiratory volume in 1 second fev1 of 50 to 85 on bronchodilators beta2 only were studied asthmatic patients asthmatic patients and comparison with oral zafirlukast adults with moderate asthma￨placebo placebo eno fluticasone propionate fp exhaled nitric oxide eno inhaled and oral antiinflammatory medications blinded zafirlukast zk 20 mg and matching pb fluticasone propionate￨eno spirometry qol ds and beta2 use peak expiratory flow rate beta2 need ds and qol measurements eno spirometry need for rescue medication quality of life qol and diary scores ds mean eno exhaled nitric oxide￨lowdose inhaled fp resulted in significant improvements in eno spirometry qol ds and beta2 use￨sig increase￨highunclear￨highunclear￨highunclear
349￨asthma three hundred fortynine patients with asthma previously treated with medium doses of￨salmeterol placebo salmeterol 50 microg combined with fluticasone propionate fp 250 microg salmeterol 50 microg fp 250 microg or placebo salmeterol 50 microg and fp combined salmeterol 50 microg and fluticasone propionate placebo salmeterol inhaled corticosteroids￨area under the 12h serial fev1 curve relative mean change in fev1 pulmonary function asthma symptom scores percentage of nights with no awakenings probability of remaining in the study without being withdrawn because of worsening asthma￨the combination product significantly p  0011 reduced asthma symptom scores and supplemental albuterol use and significantly increased the percentage of nights with no awakenings as compared with placebo salmeterol and fp p￨sig decrease￨highunclear￨highunclear￨highunclear
331￨asthma adolescent and adult patients n  331 with mildtomoderate asthma previously treated with beta 2agonist therapy alone￨placebo fp fp powder administered via a breathactivated inhaler diskhaler fluticasone propionate powder inhaled fp powder fluticasone propionate fp￨hypothalamicpituitaryadrenal axis function morning peak flow rate adverse events frequency of inhaled albuterol use lung function and diary card parameters morning predose forced expiratory volume number of nighttime awakenings efficacy and safety￨improvement in morning peak flow rate were also significantly p  0001 greater with fp than with placebo 810 increase vs 2 increase￨sig increase￨low￨low￨low
not found￨2050yrold participants who were recruited from an epidemiological study of the general population had never knowingly received any regular treatment for asthma treatmentnaive individualsa lesser benefit in females￨placebo inhaled fluticasone propionate fluticasone propionate placebo fluticasone propionate fluticasone propionate￨fluticasone propionate effect airway responsiveness￨compared with placebo fluticasone propionate was associated with a highly significant decrease in airway responsiveness 19 doublings of the geometric mean pd20 which was maximal at the end of the 6week treatment period￨sig increase￨highunclear￨highunclear￨highunclear
not found￨adults with mild to moderate asthma mild to moderate asthma￨placebo fluticasone propionate fluticasone propionate aerosol fluticasone propionate aerosol fluticasone propionate fluticasone propionate￨mean forced expiratory volume in 1 second forced vital capacity and forced expiratory flow urinary free cortisol and urinary 17hydroxy steroids nighttime awakenings and albuterol use to treat symptoms incidence and severity of adverse events peak expiratory flow and symptom scores stimulated plasma cortisol concentrations safety and efficacy￨measurements of peak expiratory flow and symptom scores significantly improved and nighttime awakenings and albuterol use to treat symptoms significantly declined in fluticasone propionatetreated groups relative to the placebotreated group￨sig decrease￨low￨low￨low
263￨two hundred twentyone 84 patients were atopic and 167 63 had been asthmatic for 1 to 5 years persistent asthma in children one hundred sixtysix 63 patients were male and 224 85 were white with a mean age of 8 years 263 patients children with persistent asthma￨placebo fluticasone fluticasone propionate 50 micrograms bid placebo fluticasone inhaled fluticasone propionate dry powder50 micrograms fluticasone propionate￨efficacy and safety morning pef baseline mean morning peak expiratory flow￨at the end of the first week of treatment patients in both fluticasone groups had significantly greater improvements in morning pef than did those receiving placebo￨sig increase￨highunclear￨highunclear￨highunclear
325￨325 prepubescent children with persistent asthma and normal growth rates children with persistent asthma asthmatic children treated with￨fluticasone propionate fluticasone propionate placebo placebo or inhaled fluticasone propionate powder 50 microg or 100 microg￨safety variables and pulmonary function mean height mean growth velocity or mean skeletal age￨013 cm in the fluticasone propionate 100 microg group p  0308 overall￨no diff￨highunclear￨highunclear￨highunclear
not found￨10 mild atopic asthmatic subjects 6 males fev1  60 of predicted pc20 histamine  or  8 mgml and on inhaled beta 2agonists only￨fluticasone propionate glucocorticoid fluticasone propionate fp placebo fp￨late response pc20 histamine urinary leukotriene e4 excretion excretion of urinary leukotriene e4￨the 2wk treatment with fp significantly inhibited both early and late responses to allergen the maximum  fall in fev1 during the early 0 to 2 h and late response 2 to 6 h was 326￨sig increase￨highunclear￨highunclear￨highunclear
242￨242 patients received children with persistent asthma￨corticosteroid fluticasone propionate fp placebo fluticasone propionate dry powder fluticasone propionate dry powder fp 200 microg each morning dry powder fp 100 microg bid or placebo dry powder fp￨efficacy and safety mean changes in fev1 and morning pef recorded at clinic visits fev1 evening pef and asthma symptoms tolerated morning pef and nighttime awakenings efficacy and safety￨both dry powder fp regimens significantly improved fev1 evening pef and asthma symptoms at the doubleblind phase endpoint p  or  017 compared with placebo￨sig increase￨low￨low￨low
47￨outpatients fortyseven patients were included in the perprotocol population patients with mild asthma who had not received corticosteroids for 4 weeks prior to the study￨diskhaler hfa134a pmdi or placebo placebo fluticasone propionate methacholine fluticasone propionate fp 100 micro g bid delivered either via the diskhaler glaxosmithkline middlesex uk or a hydrofluoroalkane hfa134a pressurized metereddose inhaler pmdi￨airway responsiveness provocative dose of methacholine causing a 20 fall in fev1 baseline pd20 geometric mean fp formulations lung function serum cortisol levels airway hyperresponsiveness￨both significantly decreased airway responsiveness compared to placebo p  0001 and also significantly increased lung function with no difference between the two active groups￨sig increase￨low￨low￨low
422￨advanced endometrial carcinoma 396 assessable patients 202 were randomly allocated to receive wai and 194 were allocated to receive median patient age was 63 years 50 had endometrioid tumors women with stage iii or iv endometrial carcinoma having a maximum of 2 cm of postoperative residual disease four hundred twentytwo patients were entered onto this trial￨doxorubicin 60 mgm2 and cisplatin chemotherapy with ap wholeabdominal irradiation wai and doxorubicincisplatin ap chemotherapy wholeabdominal irradiation versus doxorubicin and cisplatin chemotherapy cisplatin ap￨toxicity hazard ratio for progression adjusted for stage acute toxicity progressionfree and overall survival stageadjusted death hazard ratio alive and disease free￨the stageadjusted death hazard ratio was 068 95 ci 052 to 089 p  01 favoring ap￨no diff￨highunclear￨highunclear￨highunclear
156￨156 patients with stage iab grade 3 n28 or stage iciiia grade 13 n128 patients with highrisk endometrial cancer surgically staged highrisk endometrial cancer￨adjuvant chemotherapy with cisplatin epirubicin and cyclophosphamide platinumbased chemotherapy combined with standard surgery and radiotherapy radiotherapy adjuvant radiotherapy alone vs sequential chemoradiotherapy radiotherapy combined with three courses of cisplatin epirubicin chemotherapy cyclophosphamide￨overall survival diseasespecific overall fiveyear survival median time to recurrence median diseasefree survival grade 34 nausea acute toxicity overall and diseasefree survival intestinal complications demanding surgery acceptable rate of acute toxicity rate of grade 34 leucopenia risk of bowel complications￨adjuvant chemotherapy with cisplatin epirubicin and cyclophosphamide failed to improve overall survival or lower the recurrence rate in patients operated on and radiated for highrisk endometrial carcinoma￨no diff￨highunclear￨highunclear￨highunclear
385￨patients with intermediate and highrisk endometrial cancer 385 evaluated patients 193 patients received intermediate and highrisk endometrial cancer patients women with endometrioid adenocarcinoma with deeper than 50 myometrial invasion￨cap pelvic radiotherapy versus cisplatinbased combined chemotherapy prt adjuvant chemotherapy doxorubicin adjuvant pelvic radiation therapy prt versus cyclophosphamidedoxorubicincisplatin cap chemotherapy cisplatin cyclophosphamide￨5year os rates progressionfree survival pfs and overall survival os 5year pfs rates pfs rate os rate adverse effects￨no statistically significant differences in progressionfree survival pfs and overall survival os were observed￨no diff￨highunclear￨highunclear￨highunclear
345￨highrisk endometrial carcinoma 345 patients with highrisk endometrial carcinoma to patients with highrisk endometrial carcinoma stage icg3 iig3 with myometrial invasion 50 and iii receive￨cyclophosphamide 600 mg m2 ct adjuvant chemotherapy vs radiotherapy external rt adjuvant ct cisplatin 50 mg m2 doxorubicin radiotherapy rt or chemotherapy ct pelvic rt combined with adjuvant cytotoxic therapy adjuvant therapy￨radiotherapy delayed local relapses and ct delayed metastases survival overall and progressionfree survival tolerated 7year overall survivals 7year progressionfree survivals hazard ratio hr for death￨the 3 5 and 7year overall survivals were 78 69 and 62 in the rt group and 76 66 and 62 in the ct group￨no diff￨low￨low￨low
not found￨highrisk endometrial cancer patients n540 534 evaluable with operated endometrial cancer international federation of obstetrics and gynaecology figo stage iiii with no residual tumour and prognostic factors implying highrisk operated endometrial cancer patients with no residual tumour and a highrisk profile endometrial cancer endometrial cancer patients with high grade tumours deep myometrial invasion or advanced stage disease￨adjuvant chemotherapy to radiation radiotherapy radiotherapy rt chemotherapy ct sequential adjuvant chemotherapy and radiotherapy chemotherapy and radiotherapy adjuvant radiotherapy with or without sequential chemotherapy￨overall survival progressionfree survival cancerspecific survival css overall survival os progressionfree survival pfs risk for relapse or death￨addition of adjuvant chemotherapy to radiation improves progressionfree survival in operated endometrial cancer patients with no residual tumour and a highrisk profile￨sig increase￨highunclear￨highunclear￨highunclear
92￨patients with highrisk endometrial carcinoma stage i and occult stage ii patients clinically stage i or ii occult who after surgicalpathologic evaluation had one or more risk factors for recurrence treatment arm and 89 patients entered the nodox arm between november 1977 and july 1986 92 patients were entered into the￨surgery and radiation therapy adjuvant doxorubicin after surgery and radiation therapy doxorubicin bolus therapy surgical staging and postoperative radiation doxorubicin doxorubicin radiation therapy doxorubicin dox￨pelvic or aortic node metastasis cervical involvement or adnexal metastases grade 3 or 4 cardiac toxicity survival or progressionfree interval small bowel obstruction 5year survival rates risk of bowel complications recurrence pattern￨there was no statistically significant difference in survival or progressionfree interval of the two arms￨no diff￨highunclear￨highunclear￨highunclear
1599￨patients with schizophrenia or schizoaffective disorder in general psychiatric practice 1599 outpatients with schizophrenia or schizoaffective disorder patients with schizophrenia or schizoaffective disorder treated in a general psychiatry outpatient practice setting￨aripiprazole placebo aripiprazole aripiprazole n1295 or another antipsychotic medication safety control sc aripiprazole beta￨clinical global impressionimprovement cgii score mean cgii score response rates and preference of medicine pom ratings incidence and severity of adverse events aes￨aripiprazole was effective for the treatment of schizophrenia and schizoaffective disorder in a general psychiatry outpatient practice setting￨sig increase￨low￨low￨low
169￨169 patients with schizophrenia or schizoaffective disorder who were randomly treated with￨aripiprazole olanzapine aripiprazole or olanzapine￨neurocognitive data cognitive deficits dropout rate general cognitive functioning executive functioning and verbal learning neurocognitive effects￨for verbal learning the aripiprazole group improved significantly from baseline to the 8th and 26th week of assessment and there was a betweengroup effect favoring aripiprazole over olanzapine that was largely attributable to the differences in performance within the 8th week￨sig increase￨highunclear￨highunclear￨highunclear
not found￨twothirds 677 of the patients were male and the patients mean age was 376 years patients with schizophrenia individuals with schizophrenia who were treated with schizophrenia￨olanzapine or aripiprazole aripiprazole olanzapine olanzapine olanzapine and aripiprazole olanzapine vs aripiprazole￨costeffectiveness total treatment costs medication acquisition cost effectiveness and lower total costs positive and negative syndrome scale panss and treatmentemergent adverse events incremental costeffectiveness ratio total utility scores costeffectiveness￨olanzapine treatment was associated with statistically significantly greater total utility scores relative to aripiprazole 078 vs 076 p  0024 and lower total treatment costs 22831 vs 24749 p  0013 although medication acquisition cost was significantly higher for olanzapine than aripiprazole 3524 vs 2637 p  0001￨sig increase￨highunclear￨highunclear￨highunclear
83￨chinese patients with acute schizophrenia or schizoaffective disorder chinese patients with chinese patients with acute schizophrenia 83 patients with a primary dsmiv diagnosis of schizophrenia or schizoaffective disorder 5 medical centers in taiwan between march 2004 and january 2005￨aripiprazole aripiprazole risperidone￨efficacy measures efficacy and favorable safety and tolerability profiles efficacy and safety extrapyramidal symptoms eps weight gain serum prolactin level qtc interval and selfreported adverse events eps liability serum prolactin level elevation overall response positive and negative syndrome scale panss total positive and negative scores and clinical global impressionsseverity of illness cgis and improvement scale scores qtc interval prolongation efficacy safety and tolerability safety and tolerability panss total panss positive panss negative and cgis scores mild weight gain￨aripiprazole showed significantly less eps liability as assessed by the simpsonangus scale p  005 and less serum prolactin level elevation p  001 than risperidone￨sig decrease￨highunclear￨highunclear￨highunclear
404￨404 patients patients with acute exacerbation of schizophrenia or schizoaffective disorder patients with schizophrenia and schizoaffective disorder￨aripiprazole placebo aripiprazole risperidone vs placebo risperidone aripiprazole placebo aripiprazole and risperidone￨positive and negative syndrome scale panss scores and clinical global impression scores extrapyramidal symptom rating scales safety and tolerability evaluations included extrapyramidal symptoms and effects on weight prolactin and corrected qt qtc interval efficacy safety and tolerability clinically significant weight gain mean change in qtc interval mean prolactin levels￨there were no significant differences between aripiprazole and placebo in mean change from baseline in the extrapyramidal symptom rating scales￨no diff￨highunclear￨highunclear￨highunclear
317￨patients with dsmiv schizophrenia who were in acute relapse and required hospitalization patients treated with patients with schizophrenia 317 patients￨olanzapine or aripiprazole aripiprazole olanzapine olanzapine aripiprazole and olanzapine￨efficacy measures weight change cgii scores and responder rates weight gain weight gain mean weight loss body weight body weight positive and negative syndrome scale and clinical global impressionsimprovement scale cgii assessments significant weight gain metabolic and cardiovascular risk patients weight safety and tolerability mean weight change fasting plasma levels of total cholesterol highdensity lipoprotein cholesterol and triglycerides plasma lipid profile￨there was a consistent and sustained improvement in symptoms in patients who remained on therapy with either olanzapine or aripiprazole as assessed by cgii scores and responder rates throughout the study￨sig increase￨highunclear￨highunclear￨highunclear
not found￨acute schizophrenia acutely ill patients with schizophrenia or schizoaffective disorder acutely ill patients with schizophrenia￨ziprasidone and aripiprazole aripiprazole ziprasidone￨clinical global impression of severity scale cgis and brief psychiatric rating scale bprsd total derived from the positive and negative syndrome scale cgis score efficacy and tolerability profiles bprsd total score efficacy and safety￨effect sizes for withingroup improvement however were robust for both ziprasidone and aripiprazole effect size range 1011 for cgis and range 1112 for bprsd total￨no diff￨highunclear￨highunclear￨highunclear
110￨patients with chronic schizophrenia patients with either acute relapsing or chronic stable schizophrenia 736 and in patients with acute relapse aripiprazole 3119 olanzapine 2955 sixtynine percent of patients completed the study acutely psychotic and chronic stable schizophrenia patients patients with acutely relapsing or chronic stable schizophrenia patients who completed the initial treatment or who met the protocol definition of relapse after  or 2 weeks of doubleblind treatment￨placebo olanzapine aripiprazole olanzapine aripiprazole longterm aripiprazole therapy aripiprazole with olanzapine￨weight gain fasting glucose and lipid levels fasting glucose and triglycerides positive and negative syndrome scale panss total scores eps extrapyramidal symptoms epsrelated adverse events efficacy improvements total cholesterol low and highdensity lipoprotein weight gain or increased lipid levels￨olanzapine was associated with significantly greater weight gain than aripiprazole at all time points week 52 locf 254 vs 004 kg p  0001￨sig increase￨highunclear￨highunclear￨highunclear
4685￨4685 patients 1233 in standard management 3452 in the triage system general practitioners and nurses and costs of patient care for nurse telephone triage and standard management of requests for same day appointments in routine primary care all patients requesting same day appointments during study weeks were included in the trial￨nurse telephone triage￨mean general practitioner time mean overall time out of hours and accident and emergency attendance costs type of consultation telephone appointment or visit time taken for consultation presenting complaints use of services nursing time￨compared with standard management the triage system had a relative risk 95 confidence interval of 085 072 to 100 for home visits 241 208 to 280 for telephone care and 379 321 to 448 for nurse care￨no diff￨highunclear￨highunclear￨highunclear
not found￨experience in an innercity general medicine clinic physicians and physician access to computerized medical records on hospitalizations and emergency room er visits in an innercity adult general medicine clinic￨￨hospitalizations or er visits￨there were no significant differences in hospitalizations or er visits among the control and two study groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients seeking sameday appointments in general practice telephone consultations with general practitioners gps numbers seeking sameday appointments￨gp telephone triage￨telephone bill￨telephone consultations with general practitioners gps have not been shown to be an effective way to reduce the demandfor faceto face appointments during the surgery hours￨no diff￨highunclear￨highunclear￨highunclear
388￨all patients n  388 seeking sameday appointments in each surgery in two urban practices total population  10420 over a fourweek period￨telephone consultations￨blood pressure doctor time for the index telephone or facetoface consultation lower pei scores subsequent use of investigations and of services in the twoweek period following consultation frequency of blood pressure measurement and antibiotic prescriptions and number of problems considered at consultation patient enablement instrument pei and reported willingness to use telephone consultations￨telephone consultations took less time 82 minutes versus 67 minutes diff  15 95 confidence interval ci  06 to 24 p  0002￨no diff￨low￨low￨low
561￨patients who were to receive care n  561￨specialized telephone service or a control group ambulatory care telephone service￨number of scheduled and unscheduled visits￨patients who were to receive care n  561 were assigned randomly to a specialized telephone service or a control group￨no diff￨highunclear￨highunclear￨highunclear
2￨handling telephone complaints in a large emergency room￨￨￨the new system advised a higher medical examination rate than the current system in the emergency room probably bacause the current system has deficits with respect to collecting necessary information and making explicit decisions￨sig increase￨highunclear￨highunclear￨highunclear
not found￨mean number of annual contacts per inhabitant from 1988 to 1997 all 630000 inhabitants in the county￨￨total number of contacts contact rates attendance rate mean number of contacts with casualty wards￨the decrease in the total number of contacts with the outofhours primary health care after the reform was not met by a corresponding increase in casualty ward contacts￨sig decrease￨highunclear￨highunclear￨highunclear
97000￨one 55 member general practice cooperative serving 97 000 registered patients in wiltshire 14 492 calls were received during the specified times in the trial year 7308 in the control arm and 7184 in the intervention arm concerning 10 134 patients 104 of the registered population out of hours primary care 156 matched pairs of days and weekends in 26 blocks￨nurse telephone consultation general practitioner on duty for telephone advice an appointment at a primary care centre or a home visit referral to the emergency service or advice to attend accident and emergency￨patient attendance home visits number of adverse events deaths overall workload of general practitioners safety and effectiveness safety and effectiveness￨statistical equivalence was observed in the number of deaths within seven days in the number of emergency hospital admissions and in the number of attendances at accident and emergency departments￨no diff￨highunclear￨highunclear￨highunclear
53￨fiftythree hospitalized cirrhotic patients with spontaneous bacterial peritonitis cirrhotic patients spontaneous bacterial peritonitis cirrhotic patients developing spontaneous bacterial peritonitis￨ciprofloxacin intravenous cefotaxime cefotaxime or ceftriaxone cefotaxime and ceftriaxone oral ciprofloxacin cefotaxime or ceftriaxone ceftriaxone intravenous ceftriaxone cefotaxime￨spontaneous bacterial peritonitis resolution spontaneous bacterial peritonitis incidence of complications and hospital mortality adverse events￨the cost of the treatment was statistically lower in the ciprofloxacin group than in the cefotaxime group and ceftriaxone group p  0001￨sig decrease￨highunclear￨highunclear￨highunclear
123￨36 nonazotemic patients with communityacquired spontaneous bacterial peritonitis spontaneous bacterial peritonitis nonazotemic cirrhotic patients with uncomplicated communityacquired spontaneous bacterial peritonitis and without hepatic encephalopathy 59 patients one hundred twentythree cirrhotics with uncomplicated spontaneous bacterial peritonitis no septic shock grade iiiv hepatic encephalopathy serum creatinine level of  3 mgdl and gastrointestinal hemorrhage or ileus uncomplicated spontaneous bacterial peritonitis￨oral ofloxacin intravenous cefotaxime oral antibiotics oral ofloxacin oral ofloxacin ofloxacin cefotaxime￨peak serum levels and trough serum and ascitic fluid levels of ofloxacin and cefotaxime blood urea nitrogen and hepatic encephalopathy hospital survival rate infection resolution rate￨none of the 36 nonazotemic patients with communityacquired spontaneous bacterial peritonitis and without hepatic encephalopathy developed complications during hospitalization and all were alive at time of discharge￨no diff￨highunclear￨highunclear￨highunclear
80￨cirrhotic patients with uncomplicated spontaneous bacterial peritonitis spontaneous bacterial peritonitis eighty patients all patients with this complication oral ciprofloxacin after a short course of intravenous iv all patients with spontaneous bacterial peritonitis admitted to the hospital were included￨ciprofloxacin ciprofloxacin iv oral quinolones oral ciprofloxacin oral quinolones￨hospital survival infection resolution rate clinical data hepatic and renal function tests and child pugh score￨in the baseline condition no differences were found between the two groups in clinical data hepatic and renal function tests and child pugh score￨no diff￨highunclear￨highunclear￨highunclear
30￨cirrhotic patients￨cefonicid ceftriaxone ceftriaxone￨spontaneous bacterial peritonitis antibiotic concentration in ascitic fluidmic ratio patients death hospitalization mortality colonizations with enterococcus faecalis or candida albicans￨hospitalization mortality was 37 in the cefonicid group and 30 in the ceftriaxone group p was not significant￨no diff￨highunclear￨highunclear￨highunclear
16￨cirrhotic patients developing bacterial infections bacterial infections in cirrhosis 38 patients from the cirrhotic patients ninetysix hospitalized cirrhotic patients with suspicion of bacterial infection￨amoxicillinclavulanic acid first intravenously 1 g02 g intravenous cefotaxime amoxicillinclavulanic acid versus cefotaxime amoxicillinclavulanic acid with cefotaxime amoxicillinclavulanic acid norfloxacin cefotaxime amoxicillinclavulanic acid cefotaxime￨cost of antibiotics prophylactic norfloxacin infection resolution adverse events duration of treatment incidence of complications time of hospitalization and hospital mortality spontaneous bacterial peritonitis resolution 24 ascitic fluid infections infection resolution￨infection resolution 868 vs 88 95 ci 015 to 013 p ns spontaneous bacterial peritonitis resolution 875 vs 833 95 ci 015 to 024 p ns duration of treatment incidence of complications time of hospitalization and hospital mortality were similar in both groups￨no diff￨highunclear￨highunclear￨highunclear
116￨all patients who developed type 1 hepatorenal syndrome patients with cirrhosis 116 cirrhotic patients with spontaneous bacterial peritonitis cirrhotic patients who are not on prophylaxis with quinolones￨ciprofloxacin cephalosporin terlipressin ceftazidime ciprofloxacin switch therapy ciprofloxacin vs intravenous ceftazidime intravenous ceftazidime￨hospital stay hepatorenal syndrome spontaneous bacterial peritonitis resolution of infection￨resolution of infection was achieved in 4655 patients treated with ceftazidime 84 and in 4961 patients treated with ciprofloxacin 80 p  ns￨sig increase￨highunclear￨highunclear￨highunclear
100￨100 patients with neutrocytic ascites and suspected spontaneous bacterial peritonitis spontaneous bacterial peritonitis 90 patients who met strict criteria for spontaneous bacterial peritonitis or culturenegative neutrocytic ascites 43 100 patients￨singleagent cefotaxime￨hospitalization mortality recurrence rates bacteriologic cure cost of antibiotic and antibiotic administration infectionrelated mortality recurrence of ascitic fluid infection￨infectionrelated mortality 0 vs 43 hospitalization mortality 326 vs 425 bacteriologic cure 931 vs 912 and recurrence of ascitic fluid infection 116 vs 128 were not significantly different between the 5 and 10day treatment groups respectively￨no diff￨highunclear￨highunclear￨highunclear
143￨spontaneous bacterial peritonitis sbp in cirrhosis 143 patients with sbp 71 group i spontaneous bacterial peritonitis in cirrhosis￨cefotaxime ctx ctx cefotaxime￨hospital survival therapeutic efficacy rate of infection resolution positive ascitic fluid culture duration of antibiotic therapy peak serum levels infection resolution and patient survival￨the rate of infection resolution was similar for both groups 77 vs 79￨no diff￨highunclear￨highunclear￨highunclear
not found￨cirrhotics with severe infections cirrhotic patients with severe infections 73 cirrhotics who had severe bacterial infection￨ampicillintobramycin and cefotaxime cefotaxime ampicillintobramycin ampicillintobramycin cefotaxime￨nephrotoxicity impairment of renal function spontaneous peritonitis andor bacteremia urinary beta 2microglobulin￨ninetytwo per cent of bacteria isolated in group i and 98 of those isolated in group ii were susceptible in vitro to ampicillintobramycin and to cefotaxime respectively￨no diff￨highunclear￨highunclear￨highunclear
37￨spontaneous bacterial peritonitis sbp thirtyseven cirrhotic patients with spontaneous bacterial peritonitis in cirrhotics￨amikacin amikacin vs cefotaxime amikacin qd cefotaxime amikacin sbp cefotaxime￨infection renal impairment efficacy and safety renal impairment or nephrotoxicity￨infection was cured in 15 of 19 patients 789 treated with cefotaxime and in 11 of 18 611 treated with amikacin￨no diff￨highunclear￨highunclear￨highunclear
226￨226 patients treated with one or two major anticonvulsant drugs phenytoin phenobarbitone primidoneinitially the mean bmc value for all epileptic patients was 87 of normal￨vitamin d placebo￨incidence of hypocalcaemia and raised serum alkaline phosphatase bone mineral content￨the biochemical indices of osteomalacia were related to bmc￨no diff￨highunclear￨highunclear￨highunclear
24￨epilepsy in children 24 epileptic children refractory to antiepileptic drugs aeds with generalized tonicclonic and other types of seizures￨dalphatocopheryl acetate vitamin e placebo vitamin e￨vitamin e levels plasma concentration of concomitant aeds adverse side effects hematologic or biochemical test results￨this was significantly different from controls given placebo 0 of 12 p less than 005￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨man￨folic acid phenytoin placebo medication￨phenytoin hyperplasia gingival hyperplasia￨results indicate that throughout the 180day period of the study the topical folate significantly inhibited gingival hyperplasia to a greater extent than either systemic folate or placebo groups￨sig increase￨highunclear￨highunclear￨highunclear
not found￨8 residents of an institution for the developmentally disabled￨folic acid oral supplementation of 5 mg of folic acid folic acid supplementation￨red blood cell folic acid levels gingival overgrowth recurrence of gingival overgrowth recurrence of phenytoininduced gingival overgrowth gingival index scores red blood cell folic acid levels free phenytoin blood levels photographs and impressions plaque and gingival index scores or free phenytoin blood levels overgrowth￨although the treatment group had significantly less recurrence of gingival overgrowth p less than or equal to 005 the mean differences amounted to only 67 at 3 and 6 months￨sig decrease￨highunclear￨highunclear￨highunclear
23￨twentythree children with dphtreatment for more than 1 yr and eight children with shorttime dphtreatment nine severely mentally retarded dphtreated adults man diphenylhydantoininduced gingival hyperplasia￨supplementation with folic acid folic acid 5 mg folacin folic acid supplementation￨plasma and red cell folate levels seizure control serum dphlevels size of the gingival hyperplasias their plasma and red cell folic acid levels￨there were no significant changes in the size of the gingival hyperplasias after 1 yr of folate supplementation￨no diff￨highunclear￨highunclear￨highunclear
25￨epileptic children 25 epileptic children on longterm treatment with phenytoin and in 22 normal children before and during treatment with￨vitamin d or placebo prophylactic vitamin d placebo vitamin d2￨hypocalcaemia and elevated serum alkaline phosphatase iatrogenic osteomalacia bone mineral content￨in the epileptic children hypocalcaemia and elevated serum alkaline phosphatase was found in 20 and 16 respectively￨sig increase￨highunclear￨highunclear￨highunclear
72￨chronic epileptic patients for more than 4 years seventytwo epileptic patients receiving￨placebo the third placebo and thiamine pht thiamine thiamine thiamine and folate treatment phenytoin pht alone or in combination with phenobarbital placebo tablets per day the second folate￨neuropsychological functions such as visuospatial analysis visuomotor speed and verbal abstracting ability neuropsychological functions subnormal blood thiamine levels￨in particular higher scores were recorded on the block design digit symbol similarities and digit span subtests￨sig increase￨highunclear￨highunclear￨highunclear
not found￨outpatients with epilepsy treated with￨folic acid folic acid against placebo phenytoin￨seizure frequency frequency of epileptic attacks￨while the group receiving folic acid in the treatment period showed a significant improvement in seizure frequency the placebo group also showed some improvement￨sig increase￨highunclear￨highunclear￨highunclear
51￨51 epileptic patients having a serum folate level below 36 ngml folatedeficient patients with epilepsy￨folic acid folic acid placebo￨frequency of seizures behaviour and personality or in a number of cognitive functions￨there were no significant changes in the frequency of seizures behaviour and personality or in a number of cognitive functions￨no diff￨highunclear￨highunclear￨highunclear
20￨twenty severely retarded institutionalized epileptic adults with phenytoininduced gingival hyperplasia institutionalized epileptic adults with phenytoininduced gingival hyperplasia￨folic acid daily 3 mg capsule of either folic acid or lactose placebo￨serum folate and phenytoin levels poststudy serum folate levels phenytoin blood levels￨the poststudy serum folate levels were three times baseline levels for the active drug group p less than 0001 but unchanged in the placebo group￨sig decrease￨highunclear￨highunclear￨highunclear
147￨patients who sustained third or fourthdegree perineal tears after a vaginal delivery were recruited for the study 83 patients received one hundred fortyseven patients were recruited for the study￨placebo cephalosporin cefotetan or cefoxitin or placebo antibiotics prophylactic antibiotics antibiotic prophylaxis￨parity incidence of diabetes operative delivery or thirddegree gross disruption or purulent discharge at site of perineal repair by 2 weeks postpartum rate of perineal wound complications postpartum perineal wound complications perineal wound complication￨there were no differences between groups in parity incidence of diabetes operative delivery or thirddegree compared with fourthdegree lacerations￨no diff￨low￨low￨low
12￨remote rural areas of africa children with falciparum malaria four groups of 12 children with acute plasmodium falciparum malaria receiving 8 mgkg quinine base every 8 h either as￨hydrochloride salt solution hydrochloride salt solution 57 and cinchona alkaloid mixture cinchona alkaloid mixture and english hydrochloride salt hydrochloride salt or cinchona alkaloid mixture by a slow 4h intravenous infusion or intrarectal administration quinine hydrochloride salt and cinchona alkaloid mixture￨blood concentrationtime profiles of quinine body temperature and parasitaemia blood quinine concentrations￨quinine cmax values were higher after intravenous infusion of the hydrochloride salt and cinchona alkaloid mixture 6919 micro gml and 5213 micro gml than after intrarectal administration 3514 micro gml and 3116 micro gml but tmax values were similar 3615 4210 4019 and 4720 h respectively￨sig increase￨highunclear￨highunclear￨highunclear
4￨16 children in coma from 1994 to 1996 two open clinical trials were performed in niger in children 215 years severe malaria in children￨quinine intrarectal quinine qir using quinimax sanofi gentilly france 20 mgkg in solution with 2 ml of water￨temperature clearance lethality of severe malaria blantyre coma score hyperthermia hypoglycemia anemia and seizures mortality residual blood quinine concentrations￨four children in the ir group and 9 children in the infusion group died p  005￨no diff￨highunclear￨highunclear￨highunclear
898￨898 children with moderately severe p falciparum malaria who were unable to take oral treatment children with moderately severe plasmodium falciparum malaria moderately severe malaria in children health centre in burkina faso￨intramuscular quinine rectal quinine 20 mgkg diluted to 30 mgml in water solution or intramuscular quinine￨blood in stools and diarrhoea efficacy outcomes late clinical failure late parasitological failure fever clearance time time to starting oral intake and rate of deterioration to severe malaria presence of blood in stools and secondary safety outcome was diarrhoea diarrhoea local pain negative blood slide results fever recurrence safety and efficacy transient impairment of mobility treatment failure and secondary efficacy outcomes were late clinical and parasitological failures fever clearance time and time to oral intake safety and efficacy￨blood in stools and diarrhoea were more common in children given quinine by the rectal route than by the intramuscular route blood in stools 5 v 1 absolute difference 39 95 confidence interval 18 to 61 diarrhoea 5 v 1 35 13 to 57￨sig increase￨low￨low￨low
64￨64 children ranging in age from 8 months to 15 years malaria treatment for children childhood falciparum malaria in outlying health care units in togo patients presenting severe malaria pending transfer to an hospital or signs of intermediate severity such as hyperpyrexia hyperparasitemia unrepeated seizure or intensive vomiting￨diluted injectable quinine injectable quinimax￨efficacy and tolerance parasitemia ulceration or necrosis of the anorectal mucosa residual pain￨similar effect were also observed on parasitemia which disappeared completely in all patients by the end of the 72hour treatment￨no diff￨highunclear￨highunclear￨highunclear
110￨110 children aged 6 months to 5 years who had cerebral malaria childhood cerebral malaria in kampala uganda￨intrarectal or intravenous quinine rectal versus intravenous quinine intravenous quinine￨parasite clearance time fever clearance time coma recovery time time to sit unsupported time to begin oral intake time until oral quinine was tolerated and death fever clearance time coma recovery time clinical and parasitological outcomes parasite clearance time mortality efficacy and safety￨intrarectal quinine is efficacious and could be used as an alternative in the treatment of childhood cerebral malaria especially in situations in which intravenous therapy is not feasible￨sig increase￨low￨low￨low
60￨60 children with moderate malaria children with moderate plasmodium falciparum malaria￨intrarectal cinchona alkaloid combination containing 961 quinine 25 quinidine 068 cinchonine and 067 cinchonidine quinimax￨blood quinine concentrations￨rectal administration of doses of 16 or 20 mgkg of body weight led to concentrationtime profiles in blood similar to those of parenteral regimens and could be an early treatment of childhood malaria￨sig increase￨highunclear￨highunclear￨highunclear
66￨sixtysix children aged from 2 to 10 years with plasmodium falciparum malaria were included in the study which took place in niamey niger 11 children with malaria children in niger￨￨mean fever clearance times tolerated tmax mean parasite clearance times cmax and the area under the concentrationtime curve parasitaemia￨22 h in the intrarectal and intramuscular groups respectively p  005￨sig increase￨highunclear￨highunclear￨highunclear
7￨children with acute uncomplicated plasmodium falciparum malaria in the field children with plasmodium falciparum malaria seven children aged 214 years with acute uncomplicated plasmodium falciparum malaria received 128 mg￨kg1 quinine gluconate by the intrarectal route new cream formulation or 8 mg kg1 quinimax a cinchona alkaloid alkaloid combination new intrarectal quinine formulation intravenous infusion 38￨cmax efficacy and pharmacokinetics parasitaemia tolerability clinical and parasitological status parasitaemia expressed as a percentage of initial values approximate bioavailability of intrarectal quinine￨the decrease in parasitaemia did not differ between the three groups and the time required for a 50 fall in parasitaemia relative to baseline was 123￨no diff￨highunclear￨highunclear￨highunclear
35￨childhood cerebral malaria in niger￨oral chloroquine intravenous quinimax intrarectal quinimax a cinchona alkaloids association intrarectal versus infused quinimax￨fatal outcome and coma recovery time tolerated and no anal irritation died mean coma recovery times￨the intrarectal route has been shown to be an alternative to parenteral therapy for the treatment of acute uncomplicated malaria￨sig increase￨highunclear￨highunclear￨highunclear
130￨workers n  130 from eligible workplaces in the sherbrooke area n  31 who had been absent from work for more than 4 weeks for back pain￨usual care clinical intervention occupational intervention and full intervention￨functional status and pain pain and disability scales￨the full intervention group returned to regular work 241 times faster than the usual care intervention group 95 confidence interval 119489 p  001￨sig increase￨highunclear￨highunclear￨highunclear
205￨federal workers with workrelated upperextremity disorder workers compensation claims n  205￨usual care or icm intervention icm integrated case management icm approach ergonomic and problemsolving intervention￨symptom severity and functional limitations patient satisfaction male gender lower distress lower levels of reported ergonomic exposure and receipt of icm patient satisfaction￨at 12 months predictors of positive outcomes included male gender lower distress lower levels of reported ergonomic exposure and receipt of icm￨sig increase￨highunclear￨highunclear￨highunclear
not found￨employees with musculoskeletalrelated absenteeism patients with physiciandiagnosed msds￨reference group offered the traditional case management routines early workplace intervention￨direct cost savings odds ratio for returning to work time for doing this total mean number of sick days￨the odds ratio for returning to work in the intervention group was 25 95 confidence interval 1251 as compared with the reference group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨workers with low back pain by occupational physicians patients with low back pain for at least 10 days on sick leave patients with back pain health care and university workers with back pain and on sick leave for less than 1 month were included in the study￨occupational physician n  61 or to a reference group with management by the workers supervisor during the first 3 months of sick leave￨total duration of sick leave time until return to work pain intensity functional disability and general health perception￨no significant differences were found after 3 and 12 months of followup evaluation in terms of time until return to work hazard ratio 13 95 ci 090190 or in terms of other health outcomes￨no diff￨highunclear￨highunclear￨highunclear
not found￨subacute low back pain participants sicklisted 2 to 6 weeks due to nonspecific low back pain lbp participants still sicklisted at 8 weeks were randomized for graded activity n  55 or usual care n  57￨workplace intervention workplace intervention multidisciplinary rehabilitation￨time until return to work for workers with workplace intervention lasting return to work pain intensity and functional status￨time until return to work for workers with workplace intervention was 77 versus 104 days median for workers without this intervention p  002￨no diff￨low￨low￨low
105￨one hundred and five patients with asa score iii scheduled for open intestinal resection in the period april 2005december 2007￨fasttrack group ft and nonfasttrack group nonft￨hospital stay frequency of postoperative complications and reduced hospital stay postoperative pain rehabilitation gastrointestinal functions postoperative complications and postop length of stay postoperative pain and faster restoration of gi functions food tolerance postoperative complications￨hospital stay was shorter in the ft group  median seven days 95 ci 7077 versus ten days 95 ci 95113 in nonft p0001￨sig decrease￨highunclear￨highunclear￨highunclear
39￨thirtynine patients undergoing major elective colonic resection patients undergoing major colonic resection patients undergoing a wide range of colorectal procedures￨multimodal optimization package or conventional perioperative care surgical care conventional perioperative management￨shorter median interquartile range hospital stay morbidity or mortality quicker recovery of gut function duration of catheterization duration of intravenous infusion postoperative stay length of hospital stay physical and mental function and gut function grip strength￨grip strength was maintained in the postoperative period in the optimized group p  0241 but not in the control group p  0049￨no diff￨highunclear￨highunclear￨highunclear
64￨patients younger than 70 years of age sixtyfour patients undergoing laparotomy and intestinal or rectal resection￨laparotomy and major intestinal or rectal resection pathway of controlled rehabilitation with early ambulation and diet or to traditional postoperative care controlled rehabilitation with early ambulation and diet and traditional postoperative care after laparotomy and intestinal resection￨time to discharge from hospital complication and readmission rates pain level quality of life and patient satisfaction scores readmission or complication rates pain score quality of life after surgery or overall satisfaction with the hospital stay patient satisfaction pain scores or complication rates shorter hospital stay total time￨there was no difference between pathway and traditional patients for readmission or complication rates pain score quality of life after surgery or overall satisfaction with the hospital stay￨no diff￨low￨low￨low
not found￨patients undergoing colonic resection the groups were similar in terms of age 64 versus 68 years male  female sex ratio 6  8 versus 5  6 and twentyfive patients requiring elective right or left hemicolectomy￨point optimization programme 14 patients or conventional care multimodal optimization and standard perioperative surgical care￨median length of hospital stay time to achieve a predetermined mobilization target time to resumption of normal diet and length of stay hospital stay and improved physical function pain and fatigue scores tolerated a regular hospital diet patients physical and psychological function physiological and operative severity score for the enumeration of mortality and morbidity possum score hand grip strength lung spirometry and pain and fatigue scores maintained grip strength earlier mobilization￨optimization was associated with maintained grip strength earlier mobilization 46 versus 69 h p  0043 and significantly lower pain and fatigue scores￨sig increase￨highunclear￨highunclear￨highunclear
156￨after open colonic surgery patients undergoing colonic surgery patients in 4 teaching hospitals in switzerland included 156 patients undergoing elective open colonic surgery who were assigned to either a patients after open colonic surgery￨fasttrack program or standard care fasttrack protocol￨perioperative morbidity hospital stay and cost shorter hospital stays nonfunctioning epidural analgesia 30day complication rate severe complications rate of postoperative complications and length of hospital stay number of complications complications and length of hospital stay postoperative morbidity severity of complications hospital stay and compliance with the fasttrack protocol￨the fasttrack protocol significantly decreased the number of complications 16 of 76 in the fasttrack group vs 37 of 75 in the standard care group p  0014 resulting in shorter hospital stays median 5 days range 230 vs 9 days respectively range 630 p  0001￨sig decrease￨low￨low￨low
70￨seventy patients were recruited colorectal cancer surgery patients undergoing elective colorectal resection for cancer￨intravenous fluid restriction unrestricted oral intake with prokinetic agents early ambulation and fixed regimen epidural analgesia tme multimodal package multimodal perioperative management protocol elective resection￨median stay cardiorespiratory and anastomotic complications postoperative complications readmission rates and mortality postoperative stay and achievement of independence milestones morbidity and mortality postoperative stay discharge decision￨the median stay was significantly reduced in the multimodal group 5 vs 7 days p  0001 mannwhitney u test￨sig decrease￨low￨low￨low
not found￨patients with stage iibiva cervical cancer received patients with cervical cancer receiving rct patients receiving radiochemotherapy for advanced cervical cancer patients with cervical cancer frequently suffer from anemia￨epoetin beta radiochemotherapy rct epoetin￨overall survival progressionrelapsefree survival overall survival response to rct hemoglobin hb response and safety adverse events anemia correction and treatment failure no complete response or relapsing median hb progressionrelapsefree survival overall complete response￨there were no significant differences between epoetin and control groups in progressionrelapsefree survival 294 vs 325 patients with events p  096 overall survival 235 vs 125 patients with events p  022 or overall complete response 53 vs 58 p  086￨no diff￨highunclear￨highunclear￨highunclear
400￨patients with smallcell lung cancer sclc adult patients with hemoglobin  or  145 gdl starting chemotherapy received patients with smallcell lung cancer prematurely after 224 of a projected 400 patients were accrued patients n  109 and n  115 respectively had mean baseline hemoglobin of 128 gdl and 130 gdl respectively￨epoetin alfa 150 ukg or placebo epoetin alfa placebo epoetin alfa and placebo￨median overall survival tumor response to chemotherapy or survival hemoglobin transfusion proportion of patients with complete or partial response overall mortality overall tumor response survival￨epoetin alfa and placebo groups had similar median overall survival 105 and 104 months respectively and overall mortality 917 and 878 respectively hazard ratio 1172 95 ci 0887 to 1549 p  264￨no diff￨low￨low￨low
320￨patients with lung cancer receiving chemotherapy 297 patients who completed at least the first 28 days of study were assessed for red blood cell transfusions the primary endpoint 320 anemic patients hemoglobin lung cancer patients receiving chemotherapy patients receiving chemotherapy often develop anemia￨darbepoetin alfa or placebo placebo darbepoetin alfa therapy darbepoetin alfa aranesptm darbepoetin alfa darbepoetin alfa with placebo￨hemoglobin concentration ie hematopoietic response adverse events antibody formation to darbepoetin alfa hospitalizations functional assessment of cancer therapy factfatigue score and disease outcome hematopoietic responses adverse events factfatigue scores transfusions hemoglobin concentration and decreased fatigue kaplanmeier analyses cox proportional hazards analyses and chisquare tests safety and efficacy blood transfusion requirements￨patients receiving darbepoetin alfa required fewer transfusions 27 versus 52 mean difference  25 95 confidence interval ci  14 to 36 p001 required fewer units of blood 067 versus 192 mean difference  125 95 ci  065 to 184 p001 had more hematopoietic responses 66 versus 24 mean difference  42 95 ci  31 to 53 p001 and had better improvement in factfatigue scores 56 versus 44 overall improvement 32 versus 19 with or25 improvement mean difference  13 95 ci  2 to 23 p 019 than patients receiving placebo￨sig decrease￨low￨low￨low
226￨patients with anemia of cancer aoc patients with aoc patients with anemia of cancer eligible patients were anemic hemoglobin or11 gdl due to cancer or18 years old and had not received￨darbepoetin alfa q2w darbepoetin alfa chemotherapy or radiotherapy every2week darbepoetin alfa￨hemoglobin improvements hospitalization rate efficacy and safety transfusion incidence functional assessment of cancer therapyfatigue score hemoglobin levels hospitalization days transfusion requirements hemoglobin levels and fatigue hemoglobin transfusion requirements healthrelated quality of life￨transfusion incidence weeks 512 was significantly lower for darbepoetin alfa patients 8 than for observation patients 22 p  0092￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨severely anemic patients with lowgrade nonhodgkins lymphoma nhl chronic lymphocytic leukemia cll or multiple myeloma mm transfusiondependent patients with nhl n  106 cll n  126 or mm n  117 and a low serum erythropoietin concentration hematologic malignancies￨epoetin beta 150 iukg or placebo placebo recombinant human erythropoietin epoetin beta recombinant human erythropoietin epoetin beta￨response rate transfusionfree and transfusion and severe anemiafree survival hb concentration functional assessment of cancer therapy scale anemia transfusion need and quality of life qol qol transfusionfree p 0012 survival and transfusion and severe anemiafree survival￨transfusionfree p 0012 survival and transfusion and severe anemiafree survival p 0001 were significantly greater in the epoetin beta group versus placebo wald chi2 test giving a relative risk reduction of 43 and 51 respectively￨no diff￨low￨low￨low
249￨patients haemoglobin 110 patients with solid tumours receiving anaemic patients receiving chemotherapy￨chemotherapy placebo q3w placebo openlabel darbepoetin alfa darbepoetin alfa darbepoetin alfa q3w darbepoetin alfa￨haematopoietic response safety haemoglobin endpoints and red blood cell rbc transfusions safety and efficacy neutralising antibodies￨administration of darbepoetin alfa q3w has a tolerable safety profile and effectively ameliorates anaemia due to chemotherapy￨sig increase￨highunclear￨highunclear￨highunclear
not found￨anemic cancer patients receiving cancer patients with hemoglobin less than 12 gdl breast cancer patients breast cancer patients receiving chemotherapy breast cancer patients n  354 receiving￨chemotherapy epoetin alfa 40000 u qw or standard of care soc epoetin alfa v 443 epoetin alfa v 355 epoetin alfa epoetin alfa￨functional assessment of cancer therapyanemia hemoglobin responses qol quality of life hemoglobin levels improves quality of life qol and reduces transfusions hemoglobin responses transfusion requirements and prognostic factors for responses qol maintaining hemoglobin level transfusion requirements percentage transfused￨1114 for soc change scores were significantly higher in the epoetin alfa group p  0001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨231 patients survived with patients with mbc treated with patients with metastatic breast cancer receiving patients hemoglobin patients with metastatic breast cancer mbc￨brave anthracycline andor taxanebased chemotherapy anthracycline epoetin beta 30000 u subcutaneously once weekly or control epoetin beta therapy taxanebased chemotherapy epoetin beta epoetin beta￨overall survival thromboembolic events tees progressionfree survival qol median hb level serious tees progressionfree survival transfusion and severe anemiafree survival hb response safety and quality of life qol transfusion and severe anemiafree survival survival￨no difference was detected in overall survival hazard ratio hr  107 95 ci 087 to 133 p  522 or progressionfree survival hr  107 95 ci 089 to 130 p  448￨no diff￨highunclear￨highunclear￨highunclear
not found￨children with cancer children with cancer receiving myelosuppressive chemotherapy one hundred eleven patients received anemic patients 5 years to 18 years of age receiving myelosuppressive chemotherapy for nonmyeloid malignancies excluding brain tumors￨placebo intravenous epo 600 unitskg to 900 unitskg or placebo epoetin alfa epoetin alfa epo epo￨quality of life hematologic end points and safety mean final values for gs total score pedsqlgcs total score adverse events cs domain scores tolerability and hematologic benefits hrqol healthrelated quality of life hrqol hemoglobin hb transfusions and tolerability hrqol changes pediatric healthrelated qualityoflife generic scales gs and cancerspecific scales cs hb overall￨mean final values for gs total score p  763 among patients￨no diff￨low￨low￨low
344￨anaemic patients with lymphoproliferative malignancies patients with lymphoma or myeloma patients with lymphoproliferative malignancies receiving chemotherapy patients n  344 with lymphoma or myeloma received￨darbepoetin alfa darbepoetin alfa placebo darbepoetin alfa 225 microgkg or placebo sc￨red blood cell transfusions percentage of patients achieving a haemoglobin response efficacy and safety haemoglobin quality of life haemoglobin and reduced red blood cell transfusions efficacy and safety￨darbepoetin alfa also resulted in higher mean changes in haemoglobin than placebo from baseline to the last value during the treatment phase 180 gdl vs 019 gdl and after 12 weeks of treatment 266 gdl vs 069 gdl￨sig increase￨highunclear￨highunclear￨highunclear
375￨cancer patients receiving nonplatinum chemotherapy three hundred seventyfive patients with solid or nonmyeloid hematologic malignancies and hemoglobin levels  or  105 gdl or greater than 105 gdl but  or  120 gdl after a hemoglobin decrease of  or  15 gdl per cycle since starting chemotherapy anemic cancer patients receiving nonplatinum chemotherapy￨epoetin alfa placebo epoetin alfa￨primary cancer and anemiaspecific qol domains including energy level ability to do daily activities and fatigue hemoglobin and survival transfusion requirements hematopoietic parameters quality of life qol and safety adverse events proportion of patients transfused hemoglobin qol overall survival favoring epoetin alfa hematologic parameters and quality of life transfusion requirements hemoglobin and qol￨epoetin alfa compared with placebo significantly decreased transfusion requirements p 0057 and increased hemoglobin p 001￨sig decrease￨low￨low￨low
153￨cancer patients 153 anemic cancer patients receiving patients with advanced cancer who were receiving myelosuppressive chemotherapy excluding cisplatin patients with advanced cancer anemic cancer patients on combination chemotherapy patients with chronic renal failure￨placebo myelosuppressive chemotherapy rhuepo zidovudine azt cyclic combination chemotherapy recombinant human erythropoietin rhuepo recombinant human erythropoietin therapy￨mean units of blood transfused per patient hematocrit level diarrhea hematocrit toxic effects energy level and ability to perform daily activities diaphoresis symptomatic anemia qualityoflife assessment hematocrit level transfusion requirements and quality of life￨the two treatment groups showed no statistically significant differences in toxic effects except for increased incidence of diaphoresis p  05 and diarrhea p  05 in the rhuepotreated group￨no diff￨low￨low￨low
94￨patients with breast cancer treated with women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy￨placebo epoetin alfa 40000 u subcutaneously once weekly or placebo epoetin alfa therapy anthracyclinebased adjuvant or neoadjuvant chemotherapy epoetin alfa epoetin alfa therapy epoetin alfa￨cognitive impairment and fatigue mean change in exit25 score impaired cognition fatigue and diminished quality of life qol tolerated executive interview exit25 and clock drawing tasks mood by profile of mood states anemiarelated symptoms including fatigue by the functional assessment of cancer therapyanemia mean hemoglobin levels fatigue and qol cognitive function mean change in exit25 scores executive function cognitive function efficacy and safety subscale scores factan subscale scores￨there was no difference between groups in mean change in exit25 score from baseline to 6month followup assessment￨no diff￨low￨low￨low
36￨patients receiving intensive chemotherapy for smallcell lung cancer patients who undergo intensive chemotherapy for sclc thirtysix patients with smallcell lung carcinoma sclc untreated cancer patients patients who receive cytotoxic chemotherapy￨recombinant human erythropoietin vincristine ifosfamide carboplatin and etoposide vice recombinant human erythropoietin rhuepo rhuepo￨rbc transfusion requirements bone marrow progenitors hematologic parameters plt transfusions hemoglobin hb levels and rbc and platelet plt transfusions plt counts onset of anemia￨in addition there was a nonsignificant trend toward higher plt counts and fewer plt transfusions in patients who received rhuepo￨no diff￨highunclear￨highunclear￨highunclear
316￨patients with mild anemia during platinumbased chemotherapy patients with solid tumors receiving platinumbased chemotherapy three hundred and sixteen patients with hb121gdl￨epo therapy epoetin alfa platinumbased chemotherapy epoetin alfa epo epo 10000 iu thrice weekly subcutaneously n  211 or best supportive care bsc epo￨proportion of patients transfused while secondary end points were changes in hb and qol 12month survival transfusion requirement hemoglobin level and survival transfusion requirements hemoglobin level hb quality of life qol tolerated qol number of patients with metastatic disease transfusion requirements￨epo therapy significantly decreased transfusion requirements p  0001 and increased hb p  0005￨sig decrease￨highunclear￨highunclear￨highunclear
146￨146 patients who had hemoglobin hb levels  or  11 gdl and who had no need for transfusion at the time of enrollment entered this trial anemia associated with multiple myeloma or nonhodgkins lymphoma patients receiving 5000 or 10000 u patients with multiple myeloma mm and nonhodgkins lymphoma nhl￨rhuepo daily subcutaneously for 8 weeks or to receive no therapy chemotherapy rhuepo recombinant human erythropoietin recombinant human erythropoietin rhuepo￨median average increase in hb levels epo level mean baseline hb level median serum serum epo levels endogenous epo production chronic lymphocytic leukemia￨the median average increase in hb levels per week was 004 gdl in the control group and 004 p  57 022 p  05 043 p  01 and 058 p￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨multiple myeloma and nonhodgkins lymphoma one hundred twentyone anemic transfusiondependent patients with multiple myeloma mm or lowgrade nonhodgkins lymphoma nhl transfusiondependent anemic patients with multiple myeloma and nonhodgkins lymphoma￨rhepo rhepo therapy recombinant human erythropoietin rhepo 10000 u recombinant human erythropoietin erythropoietin epoetin beta￨response rate cumulative response frequency tolerated hemoglobin concentration￨multivariate regression analysis showed that relative erythropoietin concentration was the most important factor and the platelet count had no additional influence on response￨sig increase￨highunclear￨highunclear￨highunclear
122￨patients with ovarian cancer receiving patients with ovarian carcinoma treated with platinumbased chemotherapy 122 ovarian cancer patients receiving platinumbased chemotherapy￨recombinant human erythropoietin rhepo rhepo platinumbased chemotherapy subcutaneous recombinant human erythropoietin carboplatin or cisplatin alone or in combination with other cytotoxic agents￨longer time to first erythrocyte transfusion experience nadir haemoglobin levels anaemia and transfusion dependency￨patients treated with rhepo experienced a significantly longer time to first erythrocyte transfusion than the control group and were less likely to experience nadir haemoglobin levels  10 gdl p  0001 and  005 respectively￨sig decrease￨highunclear￨highunclear￨highunclear
262￨anaemic patients with lymphoid or solid tumour malignancies anaemic patients with solid tumours and lymphoid malignancies 262 anaemic patients haemoglobin patients with malignant disease￨epoetin beta epoetin beta vs standard care epoetin epoetin beta therapy￨qol sf36 pcs factf and vas scores hb level without need of transfusion a visual analogue scale vas quality of life qol factan subscale score quality of life improvement in qol as measured using the shortform36 physical component summary sf36 pcs score and the functional assessment of cancer therapy fatigue and anaemia subscales factf and factan￨baseline to final visit changes in sf36 pcs factf and vas scores were significantly greater with epoetin beta than with standard care p005 changes in factan subscale score tended to be greater with epoetin beta p0076￨sig increase￨highunclear￨highunclear￨highunclear
600￨600 patients patients with chemotherapyinduced anemia previously untreated extensivestage smallcell lung cancer treated with patients with extensivestage smallcell lung cancer receiving first￨darbepoetin alpha placebo line platinumcontaining chemotherapy chemotherapy carboplatin plus etoposide or cisplatin plus etoposide darbepoetin alpha 300 microg or placebo platinum plus etoposide￨overall survival overall survival statistical testing of survival transfusion risk darbepoetin alpha maintained hemoglobin levels hemoglobin levels safety and efficacy thromboembolic events hemoglobin change in hemoglobin concentration survival￨there was no statistically significant difference in overall survival between the treatment groups hazard ratio hr 093 95 ci 078 to 111 p  431￨no diff￨low￨low￨low
not found￨ovarian cancer patients receiving anaemic ovarian cancer patients receiving platinum chemotherapy 182 anaemic hb or  12 g dl1 platinumtreated ovarian cancer patients￨platinum chemotherapy epoetin alfa epoetin alfa epoetin alfa 1000020 000 iu three times weekly plus best standard treatment bst or bst only￨mean hb haematologic and quality of life qol parameters haemoglobin hb level transfusion requirements and qol median clas scores energy level ability to do daily activities overall qol and the median average clas score￨the mean change in hb from baseline was significantly p0001 greater for epoetin alfa than bst patients at all postbaseline evaluations￨sig increase￨highunclear￨highunclear￨highunclear
145￨patients with multiple myeloma anaemia of multiple myeloma 145 patients with multiple myeloma and anaemia hb  11 gdl￨epoetin alfa epoetin alfa placebo 150 iukg epoetin alfa or a matching volume of placebo￨adverse events qol measures transfusions haemoglobin hb and quality of life qol incidence of transfusion performance scores￨univariate analysis showed significant p  005 improvement in more qol measures with epoetin alfa than with placebo multivariate analysis discerned no betweentreatment differences￨sig increase￨highunclear￨highunclear￨highunclear
132￨anemic cancer patients receiving one hundred thirtytwo anemic cancer patients receiving anemic cancer patients receiving myelosuppressive cisplatinbased chemotherapy￨placebo myelosuppressive cisplatinbased chemotherapy recombinant human erythropoietin rhuepo cyclic cisplatincontaining myelosuppressive chemotherapy rhuepo cisplatin chemotherapy recombinant human erythropoietin therapy￨transfusion requirement overall quality of life hematocrit and quality of life quality of life pretreatment serum erythropoietin levels mean total number of units transfused mean hematocrit hemoglobinhematocrit transfusion requirement and quality of life￨there was a significant improvement in overall quality of life between the two treatment arms in favor of the rhuepotreated group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with active cancer not receiving patients with active cancer and anemia not receiving or planning to receive patients with anemia of cancer patients with active cancer and anemia not receiving or planning to receive￨darbepoetin alpha placebo cytotoxic chemotherapy or myelosuppressive radiotherapy chemotherapy or radiotherapy da versus placebo darbepoetin alpha da￨shorter survival incidence of cardiovascular and thromboembolic events and more deaths poorer survival transfusions occurrences of transfusions incidence of adverse events and survival incidence of transfusions￨da was associated with an increased incidence of cardiovascular and thromboembolic events and more deaths during the initial 16week treatment period￨sig decrease￨low￨low￨low
351￨patients with head and neck cancer head and neck cancer patients with anaemia undergoing radiotherapy patients undergoing radiotherapy at 60 gy for completely r0 and histologically incomplete r1 resected disease or 70 gy for macroscopically incompletely resected r2 advanced disease t3 t4 or nodal involvement or for primary definitive treatment patients receiving curative cancer treatment and given 351 patients haemoglobin 120 gl in women or 130 gl in men with carcinoma of the oral cavity oropharynx hypopharynx or larynx￨placebo subcutaneous placebo epoetin curative radiotherapy erythropoietin epoetin beta erythropoietin￨cancer control or survival time to locoregional progression and survival haemoglobin concentrations locoregional progressionfree survival survival￨for locoregional progression the relative risk was 169 116247 p0007 and for survival was 139 105184 p002￨no diff￨low￨low￨low
447￨a total of 447 prospective iud tcu380a users￨prophylactic antibiotics doxycycline placebo￨diagnostic criteria for acute pid overall threemonth retention rate removal rate risk of postinsertion pelvic inflammatory disease pid morbidity associated with iud insertion￨the efficacy of administering an antibiotic prior to iud insertion to reduce the risk of introducing an upper genital tract infection during the procedure has not yet been established￨sig decrease￨low￨low￨low
1485￨1485 women in ibadan nigeria evaluating the effectiveness of 200 mg of iudrelated pelvic infection￨prophylactic doxycycline doxycycline placebo doxycycline versus placebo￨rate of pid infection incidence of pid risk of developing pid rate of unscheduled iudrelated visits￨the rate of unscheduled iudrelated visits to the clinic also was not significantly lower among the doxycyclinetreated group￨no diff￨highunclear￨highunclear￨highunclear
1985￨11 clinic sites in southern california enrolled women who requested iud insertion and were at low risk of sexually transmitted infection according to selfreported medical history 118 women did not have an iud inserted￨prophylactic antibiotics azithromycin placebo azithromycin or placebo￨rate of iud removal￨prophylaxis with azithromycin did not affect the likelihood that a woman would retain her iud at 90 days or the frequency of postinsertion medical attention￨no diff￨low￨low￨low
1813￨1813 women in nairobi kenya￨prophylactic doxycycline intrauterine contraceptive device iucd placebo doxycycline￨rate of an unplanned iucdrelated visit to the clinic morbidity occurrence of pid rate of this infection￨the rate of this infection in the doxycyclinetreated group was 31 lower than that in the placebotreated group 13 and 19 respectively rr 069 95 ci 032 to 15￨sig decrease￨highunclear￨highunclear￨highunclear
300￨150 patients received 300 patients who were admitted to our family planning clinic for iud contraception￨prophylactic doxycycline￨overall infection rates risk of infection pid febrile complications positive culture gonorrhea pid infection and febrile complications pid and febrile complications fever with or without leucocytosis and none required hospitalization￨the overall infection rates for group 1 and 2 were 21 and 29 respectively and this difference was not significant￨no diff￨highunclear￨highunclear￨highunclear
24￨patients with severe asthma who require very high doses of systemic corticosteroids shortterm treatment with patients with severe asthma who require very high doses of systemic corticosteroids severe steroiddependent asthma 24 patients with longstanding asthma￨lowdose methotrexate oral methotrexate weekly or matched placebo placebo methotrexate￨steroid consumption￨however there was no difference in steroid consumption between the two groups at any time￨no diff￨highunclear￨highunclear￨highunclear
10￨subjects with corticosteroidrequiring asthma ten subjects completed the study subjects began with a steroid taper steroiddependent asthma￨placebo prednisone mtx methotrexate placebo and methotrexate mtx placebo therapy mtx a week or identical placebo￨steroid requirements symptom scores peak flow rates spirometry and betaagonist frequency steroid requirement symptom scores and spirometry daily steroid requirement anorexia alopecia and stomatitis￨this was a 30 reduction in daily steroid requirement p less than 001￨sig decrease￨highunclear￨highunclear￨highunclear
12￨patients with severe chronic asthma 12 patients with severe asthma requiring continuous treatment with oral steroids at the outpatient department of helsinki university central hospital￨placebo methotrexate methotrexate mtx mtx oral steroids inhaled steroids budesonide or beclomethasone￨wheezing dyspnoea and coughing serum mtx concentration and clinical improvement peak expiratory flow rate pef 1s forced expiratory volume fev1 values￨the peak expiratory flow rate pef 1s forced expiratory volume fev1 values did not differ between mtx and placebo treatments￨no diff￨highunclear￨highunclear￨highunclear
19￨from february 1988 to march 1990 19 patients with severe steroiddependent asthma were enrolled in the study severe asthma asthmatic patients￨lowdose methotrexate methotrexate and placebo placebo methotrexate and prednisone methotrexate methotrexate or placebo￨steroid dose toxicities pneumocystis carinii pneumonia and died steroid use asthma symptom scores pulmonary function airway reactivity blood cellular components and immunoglobulin e levels pulmonary function airway reactivity and symptom scores￨pulmonary function did not differ significantly between the methotrexate and placebo groups￨no diff￨low￨low￨low
24￨21 subjects who completed the study 13 tolerated lower daily prednisone doses during severe glucocorticosteroiddependent asthma 24 subjects with chronic glucocorticosteroiddependent asthma￨methotrexate and placebo placebo oral pulse methotrexate with placebo methotrexate methotrexate with placebo prednisone glucocorticosteroid therapy￨subjective symptom scores mean serum theophylline levels nausea and headache mean forced expiratory volume adverse effects￨when treated with methotrexate subjects required 142 less prednisone than when treated with placebo p  00447 their subjective symptom scores improved 214 p  005 and mean forced expiratory volume in 1 second values tended to improve￨sig decrease￨highunclear￨highunclear￨highunclear
14￨corticosteroiddependent asthma patients with severe asthma we studied 14 patients with corticosteroiddependent bronchial asthma patients with severe asthma without deterioration of pulmonary function￨prednisone placebo methotrexate methotrexate￨forced vital capacity and forced expiratory volume transient nausea corticosteroid requirements￨measurement of forced vital capacity and forced expiratory volume in one second showed that there was no deterioration in the condition of patients in whom the dosage of prednisone was reduced￨no diff￨highunclear￨highunclear￨highunclear
69￨69 patients with steroiddependent asthma mean daily steroiddependent asthma￨placebo methotrexate prednisolone￨lung function liver function tests￨after 24 weeks of treatment the prednisolone dose had been reduced by a significantly greater proportion in the methotrexate than in the placebo group 50 vs 14 and the reduction was not sustained after the study treatment stopped￨sig increase￨low￨low￨low
not found￨chronic steroiddependent asthma severe steroiddependent asthma twelve patients completed the trial eighteen patients who had required 1050 mg week1￨placebo methotrexate prednisolone methotrexate prednisolone￨daily diary cards of symptoms peak expiratory flow rate and medication requirements maximal midexpiratory flow rate methotrexate severe nausea adverse events adverse events fev1 lung function blood taken for full blood count urea and electrolytes and liver function tests￨lung function improved on methotrexate with a significant rise in maximal midexpiratory flow rate and a trend towards improvement in fev1￨sig increase￨highunclear￨highunclear￨highunclear
11￨eleven subjects with stable steroiddependent asthma steroiddependent asthma￨steroid therapy placebo methotrexate￨pulmonary function and reduction of prednisone requirement￨there was significant improvement of pulmonary function and reduction of prednisone requirement in both placebo and methotrexate treatment periods￨sig decrease￨highunclear￨highunclear￨highunclear
2￨asthmatic patients requiring longterm oral prednisone treatment severe steroid dependent asthma eleven patients with severe steroiddependent asthma were included patients with steroiddependent asthma￨steroidsparing agent methotrexate methotrexate placebo￨symptom scores pulmonary function data and exacerbations mean prednisone requirements￨there were no significant differences in symptom scores pulmonary function data and exacerbations between active and placebo treatments￨no diff￨low￨low￨low
500￨400 patients 500 patients between the ages of 1840 meeting dsmiv criteria for schizophrenia schizoaffective disorder or schizophreniform disorder chronic schizophrenia patients unselected sample of first episode schizophrenia patients with minimal prior exposure to antipsychotics￨haloperidol amisulpride quetiapine olanzapine and ziprasidone￨retention in treatment defined as time to discontinuation of study drug changes in different dimensions of psychopathology side effects compliance social needs quality of life substance abuse and cognitive functions￨secondary measures include changes in different dimensions of psychopathology side effects compliance social needs quality of life substance abuse and cognitive functions￨no diff￨highunclear￨highunclear￨highunclear
361￨patients with acute exacerbation of schizophrenia three hundred sixtyone patients from 26 north american centers controlled trial with acute exacerbation of chronic schizophrenia dsmiiir￨haloperidol placebo haloperidol and placebo atypical antipsychotic seroquel quetiapine quetiapine and haloperidol seroquel quetiapine quetiapine quetiapine￨brief psychiatric rating scale bprs clinical global impression cgi and modified scale for the assessment of negative symptoms sans summary scores negative symptoms bprs total bprs positivesymptom cluster and cgi severity of illness item scores positive symptoms￨quetiapine was no different from placebo across the dose range studied regarding incidence of extrapyramidal symptoms or change in prolactin concentrations￨no diff￨highunclear￨highunclear￨highunclear
58￨subjects were 58 stable outpatients with schizophrenia dsm iiir patients with schizophrenia￨quetiapine and haloperidol haloperidol quetiapine quetiapine 600 or 300 mgday or haloperidol￨executive function verbal fluency test p004 attention stroop color word test p03 and verbal memory paragraph recall test p002 benztropine use medication side effects or changes in symptomatology overall cognitive function executive function memory and attention￨specific differences were found for executive function verbal fluency test p004 attention stroop color word test p03 and verbal memory paragraph recall test p002￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with therapyrefractory schizophrenia people with schizophrenia￨risperidone quetiapine and fluphenazine first and secondgeneration antipsychotics quetiapine risperidone fluphenazine￨eps ratings on the simpson angus scale total bprs score total brief psychiatric rating scale bprs or clinical global impression scores side effect occurrence￨no differences were noted in total brief psychiatric rating scale bprs or clinical global impression scores among the drug groups n  38￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with dsmiv schizophrenia or schizoaffective disorder and established tardive dyskinesia subjects were enrolled in the study between april 2000 and march 2002 patients with established tardive dyskinesia tardive dyskinesia￨quetiapine quetiapine and haloperidol haloperidol quetiapine￨response rate cgi dyskinesia serum prolactin levels weight or glucose metabolism dyskinesia esrs dyskinesia severity of tardive dyskinesia extrapyramidal symptom rating scale esrs dyskinesia subscale scores and the clinical global impression cgi dyskinesia scores eps weight serum prolactin level and glycosylated hemoglobin level￨compared with the haloperidol group the quetiapine group showed significantly greater improvements in esrs dyskinesia 6 and 9 months p or01 and cgi dyskinesia from 6 months onward p 05 and with repeatedmeasures analysis p 002￨sig increase￨highunclear￨highunclear￨highunclear
327￨327 newly admitted patients acute schizophrenia hospitalised patients with schizophrenia schizoaffective disorder or schizophreniform disorder acutely ill patients with schizophrenia schizoaffective disorder or schizophreniform disorder￨haloperidol aripiprazole olanzapine ziprasidone aripiprazole haloperidol olanzapine quetiapine risperidone or ziprasidone aripiprazole quetiapine and ziprasidone haloperidol olanzapine and risperidone secondgeneration antipsychotics and haloperidol quetiapine risperidone￨bprs ratings brief psychiatric rating scale bprs scores￨haloperidol olanzapine and risperidone are superior to aripiprazole quetiapine and ziprasidone for the acute treatment of psychosis in hospitalised patients with schizophrenia schizoaffective disorder or schizophreniform disorder￨sig increase￨highunclear￨highunclear￨highunclear
35￨thirtyfive patients in a drugfree period for at least 2 weeks were included to randomized 35 females diagnosed with schizophrenia according to the diagnostic and statistical manual of mental disorders 4th ed￨quetiapine haloperidol quetiapine￨prolactin secretion galactorrhea prl secretion clinical signs prl levels serum prolactin prl levels brief psychiatric rating scale bprs positive and negative syndrome scale panss and extrapyramidal symptoms rating scale esrs control prolactin prl levels prl level￨both treatment groups exhibited significant improvements in clinical signs as evaluated by bprs and panss￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨hospitalized patients with acute exacerbation of subchronic or chronic schizophrenia or schizophreniform disorder schizophrenia￨quetiapine and chlorpromazine quetiapine quetiapine seroquel quetiapine chlorpromazine￨serum prolactin adverse events￨both treatments were effective in the treatment of positive and negative symptoms with a trend towards superior efficacy for quetiapine￨sig increase￨highunclear￨highunclear￨highunclear
25￨25 patients who met the diagnostic and statistical manual of mental disorders fourth edition dsmiv criteria for schizophrenia were recruited from 3 canadian hospitals 25 patients with schizophrenia patients with schizophrenia after treatment with patients with schizophrenia￨quetiapine haloperidol quetiapine quetiapine or haloperidol￨neuropsychological change psychosis and mood without inducing extrapyramidal symptoms cognitive impairment motor skill attention span verbal reasoning and fluency visuospatial construction and fluency executive skills and visuomotor tracking and immediate recall of verbal and nonverbal materials positive syndrome the negative syndrome depression ratings or cognitive skills general clinical status cognitive skills particularly verbal reasoning and fluency skills and immediate recall executive skills and visuomotor tracking and on the average of the 6 cognitive domains￨quetiapine also had beneficial effects on cognitive skills particularly verbal reasoning and fluency skills and immediate recall with additional improvements on executive skills and visuomotor tracking and on the average of the 6 cognitive domains with sustained treatment￨sig increase￨highunclear￨highunclear￨highunclear
448￨448 hospitalized patients with acute exacerbation of chronic or subchronic schizophrenia dsmiiir schizophrenia￨haloperidol quetiapine and haloperidol quetiapine with haloperidol quetiapine quetiapine clozapine￨elevated serum prolactin concentrations mean serum prolactin concentration severity of illness and global improvement scores simpson scale and abnormal involuntary movement scale scores panss total score positive and negative syndrome scale panss scores and clinical global impression cgi￨both quetiapine and haloperidol produced a clear reduction in the positive and negative syndrome scale panss scores and clinical global impression cgi￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨persons with advanced hiv disease 6280 new york state medicaid enrollees diagnosed with aids in 19871992 and managed by one of 157 surveyed clinics were studied patients with hiv infection￨￨adjusted odds of hospitalization￨the adjusted odds of hospitalization were lower for patients in clinics with extended hours or  077 95 ci  063 093 and for patients in clinics with four or more accessibility features compared with those in clinics with less than two features or  067 95 ci  050 089￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨women with aids persons with hiv 117 new york state clinics medicaid enrollees with advanced hiv who used a particular clinic as their dominant provider up to the year of the patients aids diagnosis low experience  20 patients medium 2099 patients high  or  100 patients 887 new york state medicaidenrolled women diagnosed with aids in 19891992 women with aids whose dominant sources of care were clinics￨￨survival relative hazard of death experience and survival￨experience and survival were not significantly associated in the early study years 19891990￨no diff￨highunclear￨highunclear￨highunclear
890￨critically ill patients with pneumocystis carinii pneumonia fiftysix private public and community hospitals in chicago los angeles and miami were selected for the study and the charts of 890 patients with empirically treated or cytologically confirmed pcp hospitalized during 1987 to 1990 were retrospectively reviewed medicaid patients patients were classified by insurance status selfpay n  56 medicaid n  254 or private insurance including health maintenance organizations and medicare n  580 patients with aidsrelated pneumocystis carinii pneumonia pcp￨diagnostic bronchoscopy￨use and timing of bronchoscopy the type and timing of pcp therapy and inhospital mortality￨medicaid patients were approximately threefourths more likely than privately insured patients relative odds  173 95 ci  101 296 p  004 to die inhospital after adjusting for patient severity of illness and hospital characteristics￨sig increase￨highunclear￨highunclear￨highunclear
15￨hivrelated pneumocystis carinii pneumonia hospitalized patients diagnosed as having pcp cared for at two municipal hospitals from 1988 to 1990 at hospital a charts of all patients diagnosed as having pcp were abstracted n209 at hospital b a random sample of 15 were abstracted 136 patients with hivrelated pneumocystis carinii pneumonia pcp at two geographically diverse hivexperienced public municipal hospitals￨￨definitive diagnosis rates survival rates mortality intensive care timing of starting antipneumocystis medications survival￨the process of care for hospitalized patients with pcp in these two institutions differed considerably but the survival rates were not significantly different even after adjusting for confounding factors￨no diff￨highunclear￨highunclear￨highunclear
not found￨hivinfected patients in clinics with greater accessibility and hiv expertise rely less on the ed for care patients in clinics with more than one feature promoting accessibility or hiv expertise patient clinical and health care data came from 19871992 new york state nys medicaid files and clinic data came from interviews of clinic directors medicaid enrollees newly diagnosed with aids who were contemporaneously followed by the patients clinic 157 clinics following 6820 hivinfected patients and associations with repeated  or 2 ed visits by these patients in the year before their first aids diagnosis￨￨adjusted odds ratio aor of repeated ed visits￨patients in clinics with more than one feature promoting accessibility or hiv expertise had a greater reduction in their aor of repeated ed use￨sig increase￨highunclear￨highunclear￨highunclear
not found￨pregnancy emergency department ed utilization by hivinfected women 1826 women who are infected by hiv and who were delivered from 1993 to 1995 while receiving new york state medicaid women with more timely and adequate prenatal care visits or a usual source of prenatal care fiftythree percent of pregnant women visited the ed pregnant women who are infected by human immunodeficiency virus on emergency department use pregnant women infected with hiv receiving medicaid relied heavily on ed care￨pcap ambulatory carethe prenatal care assistance program pcap enhanced prenatal and hivfocused services enhanced prenatal or human immunodeficiency virus hiv medical services￨prenatal care utilization index apncu￨the association of enhanced prenatal care with greater ed use was curbed for women with more timely and adequate prenatal care visits or a usual source of prenatal care￨sig increase￨highunclear￨highunclear￨highunclear
2648￨292 women treated 2 months 28 were adherent on the basis of the pharmacybased measure 2648 new york state medicaidenrolled hivinfected women who delivered from january 1993 through october 1996 and were followed up through september 1997 postpartum hivinfected women 681 26 study women women treated 2 months adherence defined as  or 80 days covered by prescribed therapy from first to last antiretroviral prescription￨antiretroviral therapy￨adjusted odds ratios aors of treatment aors of adherence￨the aors of adherence were greater for women with hivfocused services 213 95 ci 105 to 430 and for former illicit drug users versus nonusers 240 95 ci 105 to 550￨sig increase￨highunclear￨highunclear￨highunclear
not found￨drug users with acquired immunodeficiency syndrome aids 1369 drug users with aids was conducted using data from new york state medicaid research data files linked to telephone interview data from directors of ambulatory care clinics serving this group￨￨hospitalization￨hospitalization was less likely for patients in clinics with case managers adjusted odds ratio  042 95 confidence interval 025 069 or high directors rating of coordination of care adjusted odds ratio  050 95 confidence interval 029 089￨sig increase￨highunclear￨highunclear￨highunclear
217081￨chronically ill persons 2437 hivinfected adults representing 217 081 patients receiving medical care hivinfected persons patients receiving hiv treatment￨￨unmet need for supportive services medical care utilization ambulatory visits emergency department visits and hospitalizations and use of hiv medication receipt of antiretroviral therapy and prophylaxis against pneumocystis carinii pneumonia and toxoplasmosis home health care utilization of ambulatory care hospitalization emergency department visits health insurance emotional counseling￨contact with case managers was not significantly associated with utilization of ambulatory care or 077 ci 057 to 104 hospitalization or 113 ci 084 to 154 or emergency department visits￨no diff￨highunclear￨highunclear￨highunclear
1205￨1205 consecutively admitted patients in 40 units in 20 hospitals and on 820 of their nurses￨￨patient satisfaction mortality￨homosexuals were more likely to be admitted to dedicated aids units which largely explains the underrepresentation of minorities and women￨sig increase￨highunclear￨highunclear￨highunclear
938￨patients with human immunodeficiency virus infection hivinfected patients patient information collected through june 30 1993 was analyzed from the jersey city medical center eip clinic 938 patients enrolled from october 1989 to december 1991 767 had tcell subsets determined within 3 months of enrollment 641 patients were active and 126 were inactive￨eip comprehensive intervention program early intervention program eip￨survival rates survival probability longer survival median cd4 tcell count survival survival￨active patients also had longer survival than inactive patients when stratified by cd4 tcell levels or by clinical status￨sig increase￨highunclear￨highunclear￨highunclear
not found￨women receiving therapy hivinfected womens antiretroviral therapy regimen five hundred ninetyfive new york state nonpregnant hiv women with full medicaid eligibility and at least 1 month of a prescribed antiretroviral regimen in federal fiscal years ffy 19971998 and intervals in ffy 19971998 who had delivered a liveborn baby within 5 years￨protease inhibitor or nonnucleoside analog highly active antiretroviral therapy haart methadone￨hiv specialty care adjusted odds ratios aors of acceptable antiretroviral therapy￨adjusted odds ratios aors of acceptable antiretroviral therapy were higher p  05 for hiv specialty care aor  171 for one or two visits aor  210 for 3 visits or hiv clinical trials site care aor  143 95 confidence interval ci 101 204￨sig increase￨highunclear￨highunclear￨highunclear
138￨individuals in the cohort who received a high number of ancillary services more than 11 ancillary service visits in the twoyear study period n  138 and those who received few services fewer than six ancillary service visits in the twoyear study period n  132 recipients in need of ancillary services and their receipt of hiv medical care in california￨￨￨we found that for federal health programme clients in need of ancillary services a positive relationship existed between their receipt of ancillary services and their access to primary medical care p  0001￨sig increase￨highunclear￨highunclear￨highunclear
2607￨hivinfected pregnant women 2607 hivinfected women who delivered a living child between january 1993 and september 1996 women who had adequate prenatal visits￨methadone￨￨the adjusted odds of being prescribed antiretroviral therapy increased 21 per month in period 2 and decreased to 3 per month in period 3￨sig decrease￨highunclear￨highunclear￨highunclear
209￨hiv positive patients 209 adults with hiv infection two hospitals in west london and 88 general practitioners in 72 general hospitals patients and general practitioners general practitioners enrolled in the project were faxed structured outpatient clinic summaries general practitioners had access to consultant physicians skilled in hiv medicine through a 24 hour mobile telephone service hiv positive patients involving specialist hospital based teams and primary health care teams￨￨number of visits average length of a hospital inpatient stay￨the average length of a hospital inpatient stay was halved for those patients who had participated in the project for two years and the average number of visits to the outpatient clinic per month fell for patients with aids￨sig decrease￨highunclear￨highunclear￨highunclear
4747￨hivpositive patients managed according to a clinical care path at a staffbased health maintenance organization hmo 4747 hivpositive health plan members who received care at kaiser permanentes 18 other medical centers in northern california 230 hivpositive health plan members who received care at the kaiser permanente santa rosa medical center kpmcsro￨multidisciplinary team￨percentages of acquired immunodeficiency syndrome aids social workers services cd4 tcell counts hospital admissions mean cost of hivrelated drugs length of stay￨hospital admissions were fewer aids patients rr  067 hivpositive patients without aids rr  045 and length of stay was briefer compared with patients at the other kaiser permanente medical centers￨no diff￨highunclear￨highunclear￨highunclear
not found￨human immunodeficiency virusrelated pneumocystis carinii pneumonia pcp persons who were hospitalized with human immunodeficiency virusrelated pcp 627 veterans administration va patients and 1547 nonva patients with empirically treated or cytologically confirmed pcp who were hospitalized from 1987 to 1990 hospitalized patients with pneumocystis carinii pneumonia patients who are hospitalized with pcp￨￨process of care for pcp and shortterm mortality rates health insurance status and hospital characteristics￨among va patients black and hispanic patients were not significantly different from white patients with regard to inhospital mortality rates use and timing of a bronchoscopy or receipt of timely antipcp medications￨no diff￨highunclear￨highunclear￨highunclear
not found￨we collected patient clinical and health care data from medicaid files conducted telephone interviews of directors of 125 clinics serving as the usual source of care for study patients and measured aids experience as the cumulative number of aids patients treated by the study clinics since 1986 medicaid enrollees diagnosed with aids in 19901992 of 1876 hivinfected persons 44 had pcp prophylaxis and 38 had primary pcp￨￨￨persons on prophylaxis had 20 lower adjusted odds of developing pcp 95 confidence interval ci 064 099￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨353 hivinfected drugusing women delivering in 1993 and 1994 while enrolled in new york state medicaid women infected with the human immunodeficiency virus hiv￨￨continuity referral services and behavioral risk reduction counseling low birth weight infants and preterm deliveries￨the prenatal care assistance program appeared to be successful in reducing the incidence of low birth weight and preterm delivery in this highrisk population￨no diff￨highunclear￨highunclear￨highunclear
not found￨577 hivpositive adults in new york city medical care in new york city￨ancillary hiv services￨￨the studys principal finding was that specific ancillary services were significantly associated with an increase in an individuals likelihood of entering medical care and maintaining appropriate medical care services for hiv particularly when the services addressed a corresponding need￨sig increase￨highunclear￨highunclear￨highunclear
214￨university hospital in durham nc gmc patients with average length of stay 78 patients infected with human immunodeficiency virus two hundred fourteen consecutive hivinfected patients presenting for primary care￨appropriate preventive care services gmc general medicine clinic gmc or an infectious disease clinic idc teaching intervention￨utilization of services healthrelated quality of life preventive and screening measures and antiretroviral use baseline cd4 cell counts￨at baseline gmc patients were more likely to be african american 85 vs 71 p 03 and had lower baseline cd4 cell counts than idc patients 262￨sig increase￨highunclear￨highunclear￨highunclear
not found￨all hospitalizations identified for a cohort of aids patients diagnosed during 1987 in 40 massachusetts hospitals were included patients with aids all women and all male intravenous drug users n  151 and a random sample of all male nonintravenous drug users diagnosed with aids during 1987 in massachusetts n  149￨￨inpatient mortality and 2 30day mortality relative risk of mortality length of stay and intensive care unit use 30day mortality length of stay cost and intensive care unit use inpatient mortality￨length of stay and intensive care unit use were also significantly higher at lowexperience hospitals after controlling for severity of illness p  05￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨human immunodeficiency virus hiv infected patients hospitalized for pneumocystis carinii pneumonia pcp￨computersupported versus manuallygenerated nursing care plans￨activated patient problems functional status and patients selfratings of physical condition at hospital discharge￨there were no significant differences in patient outcome as measured by functional status and patients selfratings of physical condition at hospital discharge￨no diff￨highunclear￨highunclear￨highunclear
not found￨four hundred mozambican refugee households were systematically identified and followed over a 4month period one fourth of the households refugee population that had experienced repeated outbreaks of cholera and diarrhoea and where contamination of water in the home￨￨diarrhoeal incidence diarrhoea diarrhoeal disease geometric mean of faecal coliform levels￨analysis of water samples demonstrated that there was a 69 reduction in the geometric mean of faecal coliform levels in household water and 31 less diarrhoeal disease p  006 in children under 5 years of age among the group using the improved bucket￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨young children in the socioeconomic and cultural context of rwanda africa children aged 0 to 5 years￨water supply and sanitation￨severe nutritional deficit diarrheal morbidity￨water in homes was contaminated 434 with more than 1100 total coliforms100 ml due to the use of unclean utensils to transport and store water￨sig increase￨highunclear￨highunclear￨highunclear
not found￨206 maasai children aged 516 years whose drinking water was contaminated with faecal coliform bacteria 108 children maasai children￨solar radiation solar disinfection of drinking water and diarrhoea￨episodes of severe diarrhoea performance of duties occurrence and severity of diarrhoea diarrhoea episodes diarrhoea￨among the 108 children in households allocated solar treatment diarrhoea was reported in 439 of the 2week reporting periods during the 12week trial average 41 sd 12 per child￨sig increase￨highunclear￨highunclear￨highunclear
not found￨rural northeastern brazil people living in houses receiving household water with inexpensive hypochlorite by a community health worker was carried out over 18 weeks among 20 families a rural village￨placebo home water chlorination programme￨feasibility and efficacy mean faecal coliform level feasibility acceptability and effect diarrhoea rates diarrhoea rates￨diarrhoea rates were not significantly different among the participants while exposed to water treated with hypochlorite￨no diff￨highunclear￨highunclear￨highunclear
492￨492 rural guatemalan households to five different water treatment groups diarrhea prevention in rural guatemala￨householdbased flocculantdisinfectant drinking water treatment flocculantdisinfectant flocculantdisinfectant plus a customized vessel bleach bleach plus a vessel and control￨diarrhea incidence of diarrhea￨in unannounced evaluations of home drinking water free chlorine was detected in samples from 27 of flocculantdisinfectant households 35 of flocculantdisinfectant plus vessel households 35 of bleach households and 43 of bleach plus vessel households￨sig increase￨highunclear￨highunclear￨highunclear
not found￨maasai by maasai community elders 349 maasai children younger than 6 years old￨alternate household to drink water either left in plastic bottles exposed to sunlight on the roof of the house or kept indoors control￨diarrhoeal disease risk of severe diarrhoeal disease￨children drinking solar disinfected water had a significantly lower risk of severe diarrhoeal disease over 8705 two weekly follow up visits two week period prevalence was 488 compared with 581 in controls corresponding to an attributable fraction of 160￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨in april 2000 150 households received soap 76 received dilute bleach and a water storage vessel and 76 were enrolled as controls￨homebased interventions￨diarrhea￨both of these homebased interventions were ultimately effective in preventing diarrhea but only households of slightly higher socioeconomic status changed their behavior quickly enough to benefit during the first summer￨no diff￨highunclear￨highunclear￨highunclear
127￨127 households in two periurban communities￨￨campylobacter e coli contamination of stored water and less diarrhoea diarrhoea episodes diarrhoea monthly water quality testing and weekly diarrhoea surveillance￨stored water in intervention households was less contaminated with escherichia coli than stored water in control households p  00001￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨diarrhoea with under 5 years of age in four villages of southern côte divoire children less than five years old in the south of ivory coast￨hygiene measures water sanitation and oral rehydration therapy hygiene and water supply and oral rehydration￨incidence rate of diarrhoea mortality rate to diarrhoea diarrhea￨the results show a 50 reduction of the incidence rate of diarrhoea and a 85 reduction of the proportion of deaths related to diarrhoea in the villages with intervention￨sig decrease￨highunclear￨highunclear￨highunclear
166￨a total of 166 intervention households were randomly selected from one community and 94 control households from another zambia￨￨percentage of intervention households storing water safely compliance diarrheal disease risk￨this intervention is a useful tool for preventing waterborne diseases in families in developing countries who lack access to potable water￨sig increase￨highunclear￨highunclear￨highunclear
514￨514 rural guatemalan households divided into 42 neighbourhood clusters for 13 weeks from 4 november 2002 through 31 january 2003 guatemalan children children 1702 people in households receiving the￨disinfectant flocculantdisinfectant￨prevalence of diarrhoea diarrhoea￨the 1702 people in households receiving the disinfectant had a prevalence of diarrhoea that was 40 lower than that among the 1699 people using standard waterhandling practices 09 versus 15 p  0001￨sig decrease￨highunclear￨highunclear￨highunclear
509￨persons with hiv living in africa and large scale implementation persons infected with human immunodeficiency virus hiv persons with hiv living in rural uganda between april 2001 and november 2002 households of 509 persons with hiv and 1521 hivnegative household members received a persons with human immunodeficiency virus in uganda￨safe water intervention trimethoprim and 800 mg of sulfamethoxazole cotrimoxazole prophylaxis homebased water chlorination and safe storage closedmouth plastic container a dilute chlorine solution and hygiene education safe water system sws or simply hygiene education alone￨incidence and severity of diarrhea diarrhea diarrhea visible blood or mucus in stools diarrhea frequency and severity days of work or school lost due to diarrhea diarrhea episodes￨the sws was equally effective with or without cotrimoxazole prophylaxis p  073 for interaction and together they reduced diarrhea episodes by 67 irr  033 95 ci  024046 p  00001 days with diarrhea by 54 irr  046 95 ci  032066 p  00001 and days of work or school lost due to diarrhea by 47 irr  053 95 ci  034083 p  00056￨no diff￨highunclear￨low￨highunclear
not found￨children under 5 years old was evaluated in a rural area of bangladesh children in rural bangladesh by environmental and behavioural modifications￨water sanitation and hygiene education intervention project￨episodes of diarrhoea diarrhoea including dysentery and persistent diarrhoea diarrhoeal diseases rates of diarrhoea diarrhoeal morbidity￨this impact was evident throughout the year but particularly in the monsoon season and in all age groups except those less than 6 months old￨sig increase￨highunclear￨highunclear￨highunclear
not found￨diarrhea diseases in rural areas of east fujian diarrhea diseases was carried out in the rural areas of east fujian china during 1991 to 1993 focusing on improvement of drinking water health education and supervision and direction to villagers to improve their environmental and family health￨comprehensive control￨ratios of cost to benefit incidence of diarrhea diseases￨an intervention trial with comprehensive prevention and control for diarrhea diseases was carried out in the rural areas of east fujian china during 1991 to 1993 focusing on improvement of drinking water health education and supervision and direction to villagers to improve their environmental and family health￨sig increase￨highunclear￨highunclear￨highunclear
62￨we interviewed residents of 240 households 120 with and 120 without access to municipal piped water all study subjects 1583 individuals residents of 62 households without piped water were trained to chlorinate their drinking water at home in a narrownecked water container with a spout￨￨water pressure diarrheal rates diarrhea risk of diarrhea lowest diarrheal rate diarrheal illness￨the home chlorination intervention group had the lowest diarrheal rate 2881000 subjectsmonth despite lack of access to piped water in their homes￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨314 children from the intervention area and 309 children from the control area was analysed in relation to maternal personal and domestic hygiene controlling for education and occupation of household head and household size children aged 623 months from rural areas around teknaf bangladesh young children in rural bangladesh￨maternal personal and domestic hygiene augmented water supply through handpumps and health education while the control area received no project inputs￨mothers personal and domestic hygiene and diarrhoea incidence annual incidence of diarrhoea yearly diarrhoea incidence incidence of diarrhoea diarrhoea incidence￨annual incidence of diarrhoea in 314 children from the intervention area and 309 children from the control area was analysed in relation to maternal personal and domestic hygiene controlling for education and occupation of household head and household size￨sig decrease￨highunclear￨highunclear￨highunclear
77￨participants n236 from 77 households￨￨incidence rate ratio of disease highly credible gastrointestinal illness hcgi￨there were 103 episodes of hcgi during 10790 persondays at risk in the sham group and 82 episodes during 11380 persondays at risk in the active treatment group￨no diff￨low￨low￨low
not found￨171 families residing in the catchment area of the sabtbany bishr primary health care centre in the rural areas of the asir region southwestern saudi arabia rural areas of saudi arabia￨chlorination of water in domestic storage tanks￨childhood diarrhoea diarrhoea risk of diarrhoea￨children under 5 years of age whose families were not using chlorinated water had twice the risk of diarrhoea compared to children from the participating families odds ratio  198 p  0047￨sig increase￨highunclear￨highunclear￨highunclear
144￨chlorinating the public watersupply system in a village in pakistan a village in pakistan 144 children aged less than five years in the village￨￨water quality and childhood diarrhoea occurrence of diarrhoea risk of diarrhoea incidence of diarrhoea water quality￨in this study area under nonepidemic conditions the reduction of faecal bacteria in the public drinkingwater supply by chlorination does not seem to be a priority intervention to reduce childhood diarrhoea￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨rural bolivia 50 participating households in a rural community in bolivia the remaining households continued to use customary water handling practices and served as controls￨￨diarrheal disease risk diarrhea free of thermotolerant coliforms￨for children less than five years old the reduction in risk was 83 95 ci  5194 p  0001￨no diff￨highunclear￨highunclear￨highunclear
not found￨60 households in the pilot community￨￨baseline diarrhoea prevalence of diarrhoea prevalence of diarrhoea turbidity thereby improving water aesthetics￨water filters eliminated thermotolerant faecal coliforms from almost all intervention households and significantly reduced turbidity thereby improving water aesthetics￨sig decrease￨highunclear￨highunclear￨highunclear
36￨total knee arthroplasty patients thirtysix osteoarthritic patients rehabilitation after total knee arthroplasty certain patients￨local heat or cold therapy total condylar knee prosthesis thermal therapy￨range of motion swelling about the knee and pain passive range of motion after total knee arthroplasty￨the role of local heat or cold therapy used in conjunction with exercise in the rehabilitation of total knee arthroplasty patients was investigated￨sig decrease￨highunclear￨highunclear￨highunclear
100￨osteoarthritis of the knee pain subjects n  100 diagnosed with osteoarthritis oa of the knee were treated with these modalities￨tens electroacupuncture and ice massage transcutaneous nerve stimulation tens electroacupuncture ea and ice massage with placebo placebo￨pain pain at rest stiffness 50 foot walking time quadriceps muscle strength and knee flexion degree￨the results showed a that all three methods could be effective in decreasing not only pain but also the objective parameters in a short period of time and b that the treatment results in tens ea and ice massage were superior to placebo￨no diff￨highunclear￨highunclear￨highunclear
253￨acute painful vasoocclusive crisis characteristic of sickle cell anemia sca 127 patients received 253 patients with acute painful crisis but with no other complications of sca randomized to treatment or control groups￨placebo lowmolecularweight heparin tinzaparin innohep tinzaparin vs placebo morphine analgesia tinzaparin￨number of days with the severest pain score overall duration of painful crisis and duration of hospitalization pain intensity safety and efficacy￨analysis revealed a statistically significant reduction in number of days with the severest pain score overall duration of painful crisis and duration of hospitalization p  005 for each comparison of tinzaparin vs placebo￨sig decrease￨highunclear￨highunclear￨highunclear
549￨fivehundredandfortynine patients￨mlcu mlcu 250 and mlcu￨￨both iuds gave good protection against pregnancy gross rates at 24 months 18 and 21￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨postabortion insertion of the nova t and mlcu250￨effectiveness and complication rates￨at this stage of the trial no significant differences had emerged between the two devices in any of the standard termination categories￨no diff￨highunclear￨highunclear￨highunclear
331￨331 women who had an iud inserted immediately after a firsttrimester legal abortion are presented￨￨pregnancy rate for novat overall performance of the iud equals￨there was no statistically significant difference between the two groups though the pregnancy rate for novat was considerable lower than for coppert 200￨no diff￨highunclear￨highunclear￨highunclear
3000￨305 subjects with mirena and 133 with novat as a segment of a larger study of 3000 women￨levonorgestrel and copperreleasing intrauterine systems mirena and novat intrauterine contraceptive devices￨final gross rate cumulative expulsion gross rate for novat tolerated rate of adverse events expulsion bleeding problems pain pelvic inflammatory disease and other medical reasons￨mirena was more effective and the rate of adverse events was lower than with novat special attention should be paid to the insertion procedure when carried out at the time of abortion￨sig increase￨highunclear￨highunclear￨highunclear
400￨tenyear study in yugoslavia￨￨gross cumulative lifetable accidental pregnancy rates expulsiondisplacement rates removal rates for bleeding andor pain￨differences in removal rates for bleeding andor pain were not significantly different at any of the followup intervals￨no diff￨highunclear￨highunclear￨highunclear
123￨123 patients with atopic eczema patients with atopic eczema￨evening primrose oil evening primrose oil linoleic and gammalinolenic acids￨erythema scale excoriation lichenification or overall severity￨we observed no significant effect on erythema scale excoriation lichenification or overall severity in 123 patients with atopic eczema of average severity while they took oral doses of evening primrose oil 2 or 4 gm in children 6 or 8 gm in adults￨no diff￨highunclear￨highunclear￨highunclear
not found￨consecutive new outpatient department opd patients of a referral hospital in kolkata clinically diagnosed as having ad atopic dermatitis in our patients atopic dermatitis atopic dermatitis ad￨placebo placebo capsules identical in appearance and containing 300 mg of sunflower oil epo evening primrose oil evening primrose oil epo gammalinolenic acid gla￨adverse effect efficacy and safety intensity itching and dryness clinical evaluation￨there was significant difference in outcome of treatment between two groups p000001￨sig increase￨highunclear￨highunclear￨highunclear
24￨atopic dermatitis of children 24 patients 317 years old children with atopic dermatitis￨gammalinolenic acid placebo corn seedoil served as placebo gammalinolenicacidrich borage seed oil capsules gammalinolenicacid￨eczema￨after 10 to 14 weeks of treatment there was no improvement of the eczema in the verum phase compared to placebo￨no diff￨highunclear￨highunclear￨highunclear
not found￨151 patients of whom 11 failed to return for assessment leaving an evaluable population of 140 including 69 children acute district general hospital in nuneaton england atopic dermatitis adults and children with atopic eczema children and adults with atopic eczema￨gamma linolenic acid placebo borage oil twice daily 920 mg gamma linolenic acid borage oil￨mean sassad score fell visual analogue scales topical corticosteroid requirement assessed on a five point scale global assessment of response by participants adverse events and tolerability efficacy and tolerability tolerated atopic dermatitis sassad score efficacy and tolerability total sign score￨the difference between the mean improvements in the two groups was 14 95 confidence interval 22 to 50 points in favour of placebo p  045￨no diff￨low￨low￨low
160￨adults with stable atopic eczema atopic eczema one hundred and sixty patients patients with atopic eczema￨placebo glacontaining borage oil borage oil topical diflucortolone21valerate cream borage oilcontaining capsules or the bland lipid miglyol as a placebo gammalinolenic acid gla￨erythrocyte dihomogammalinolenic acid levels adverse effects gla metabolites￨no substancerelated adverse effects were observed￨no diff￨highunclear￨highunclear￨highunclear
123￨patients with atopic dermatitis 123 subjects recruited 102 completed the treatment period atopic dermatitis patients with atopic dermatitis to essential fatty acid supplements￨essential fatty acid supplementation placebo evening primrose oil evening primrose oil and fish oil or placebo placebo￨topical steroid requirement and symptom scores disease activity￨no improvement with active treatment was demonstrated￨no diff￨low￨low￨low
60￨twenty two of these subjects also had asthma 60 children with atopic dermatitis and the need for regular treatment with topical skin steroids completed a 16 weeks treatment period with either atopic dermatitis and asthma￨epogam evening primrose oil or placebo capsules epogam evening primrose oil treatment placebo￨peak expiratory flow was measured and disease activity plasma concentrations of essential fatty acids eczema symptoms￨the study demonstrated significant improvements of the eczema symptoms but no significant difference was found between the placebo and the epogam groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨atopic eczema patients with atopic eczema￨epo evening primrose oil placebo oral evening primrose oil epo￨overall severity and grade of inflammation plasma levels of txb2 6ketopgf1 alpha and pge1 and the amount of txb2 released into serum during clotting inflammation￨evening primrose oil caused a significant rise in the amount of dihomogammalinolenic acid in the plasma phospholipid fatty acids￨sig decrease￨highunclear￨highunclear￨highunclear
12￨patients with atopic dermatitis￨borage seed oil glandola placebo borage oil glandol rich in highly unsaturated socalled omega fatty acids against palm seed oil as placebo highly unsaturated fatty acids￨skin changes￨the analysis revealed that five out of seven patients treated with borage oil showed a favourable effect with regard to the skin changes assessed by the adasiscore￨sig increase￨highunclear￨highunclear￨highunclear
not found￨infants with atopic dermatitis children with atopic dermatitis￨gammalinolenic acid placebo gammalinolenic acid provided by evening primrose oil epo epogam searle uk gammalinolenic acid administration epo￨red cell membrane microviscosity overall severity of the clinical condition proportion of long chain polyunsaturated fatty acids red cell membrane microviscosity dihomogammalinolenic acid dgla￨a significant improvement in the overall severity of the clinical condition was seen in children treated with gammalinolenic acid independent of whether the children had manifestations of igemediated allergy￨sig increase￨highunclear￨highunclear￨highunclear
not found￨2102 adolescents aged 10 to 17 years at baseline who never smoked was conducted by using masked images of 6 cigarette advertisements and 8 other commercial products with all brand information digitally removed thirteen percent n  277 of students initiated smoking during the observation period￨￨adolescent smoking initiation￨compared with low exposure to cigarette advertisements high exposure remained a significant predictor of adolescent smoking initiation after controlling for baseline covariates adjusted relative risk 146 95 confidence interval 108197 p  05￨sig increase￨highunclear￨highunclear￨highunclear
not found￨adolescents between 2003 and 2008 5 sequential telephone interviews were conducted including the participants report of brand of favorite cigarette advertisement teenagers who reported any favorite cigarette ad at baseline mean age 117 years adolescent girls participants were a national longitudinal cohort of 1036 adolescents baseline age 1013 years enrolled in a parenting study camel no 9 cigarettemarketing campaign targeted young teenage girls￨￨response rate￨for boys the proportion with a favorite ad was stable across all 5 surveys as it was for girls across the first 4 surveys￨sig increase￨highunclear￨highunclear￨highunclear
4384￨youth smoking in germany 4384 adolescents age 1115 years at baseline and resurveyed 1 year later ever smoking prevalence was 38 at time 1 baseline never smokers were analyzed separately from those who had tried smoking ever smokers schoolbased surveys conducted in schleswigholstein germany adolescents adolescent smoking￨entertainment media and tobacco marketing￨levels of time 2 smoking tobacco marketing receptivity lifetime and current smoking￨among time 1 ever smokers both tobacco marketing receptivity and exposure to movie smoking predicted higher levels of time 2 smoking 217 178 263 and 162 118 223 respectively and the two estimates were not significantly different￨sig increase￨highunclear￨highunclear￨highunclear
not found￨girls and young women sample of boys and girls aged 12 and 13 years nine variables expressed by neversmokers at pretest stage boys and girls 1125 boys and 1213 girls in northern england￨teaching about smoking between the pre and posttests￨parental smoking best friends smoking perceived positive values of smoking perceived negative values of smoking correct health knowledge cigarettebrand awareness having a favourite cigarette advertisement uptake of smoking￨the most important predictor of smoking for boys having a best friend who smoked was significant on application of the chi 2 test p 0037 although it was nonsignificant when included singly in a logistic regression model 0094 the discrepancy was probably due to the small number of best friends known to smoke￨sig increase￨highunclear￨highunclear￨highunclear
not found￨young adulthood young adolescents become established smokers in young adulthood 1821 years of age adolescents were aged 12 to 15 years and were not established smokers young adolescents young adolescence predicts young adult smoking 6 years later two longitudinal cohorts of adolescents drawn from the 1993 and 1996 versions of the california tobacco surveys were followed 3 and 6 years later￨tobacco advertising and promotions￨rate of established smoking￨two longitudinal cohorts of adolescents drawn from the 1993 and 1996 versions of the california tobacco surveys were followed 3 and 6 years later￨no diff￨highunclear￨highunclear￨highunclear
3664￨3664 spanish children aged 13 and 14 years filled in selfcompletion questionnaires at baseline and 6 12 and 18 months later cohort study spanish adolescents spanish adolescent smoking behaviour and prior awareness of cigarette advertisements on billboards￨cigarette advertising￨smoking behaviour￨the more advertisements identified at baseline the greater was the risk of being a smoker p00001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨children who were in their seventh year at school￨schoolbased educational programme￨prevalence rate of smoking smoking behaviour uptake of smoking prevalence rates of the uptake of smoking relative prevalence rate￨in girls both the teacherled and peerled programmes maintained their effects over the two years of followup with adjusted differences in prevalence rates of the uptake of smoking relative to the control group of 66 95 cl 173 40 and 81 95 cl 189 27 respectively after two years￨sig increase￨highunclear￨highunclear￨highunclear
not found￨cohort of 11 to 12 year olds related to awareness of advertised cigarette brands named primary middle and secondary schools in the north and south of england self completed questionnaires administered to whole classes of schoolchildren in june 1993 and june 1994 1450 pupils aged 11 and 12 years at the time of the first survey cigarette advertising and onset of smoking in children questionnaire survey￨￨risk of taking up smoking￨cigarette advertising appears to increase childrens awareness of smoking at a generic level and encourages them to take up the behaviour beginning with any cigarettes which are available and affordable￨sig increase￨highunclear￨highunclear￨highunclear
1000￨1000 adolescents￨￨demographic characteristics smoking behavior tobacco advertising receptivity noveltyseeking personality depressive symptoms family and peer smoking alcohol use and marijuana use novelty seeking the odds of being more receptive to tobacco advertising odds of smoking progression smoking progression￨for each 1sd increase in novelty seeking the odds of being more receptive to tobacco advertising increased by 12 ie being in a specific category or higher which in turn resulted in an 11 increase in the odds of smoking progression from 9th grade to 12th grade￨sig increase￨highunclear￨highunclear￨highunclear
not found￨schoolchildren 6000 schoolchildren two cohorts aged between 10 and 12 years in 1979 over 12 months are described those who became smokers adopters￨￨knowledge of smoking hazards knowledge scores initial attitude scores￨the older cohort showed significant differences in knowledge which were dependent upon smoking category with 1980 smokers having lower knowledge scores than nonsmokers and showing an apparent decrement in their previous knowledge￨sig increase￨highunclear￨highunclear￨highunclear
not found￨students 1003 students attending 13 schools who served as control units for a study assessing the effects of a schoolbased addictive substances prevention program participants answered the same questionnaire in 1990 and 1991 schoolchildren in sixth and seventh grades in barcelona 1113 years and identifies smoking risk factors through crosssectional and followup analysis￨￨￨among nonsmokers the strongest predictors to emerge are intention to smoke the belief that smoking is fun peers siblings and mother consumption and being male however girls appear to consolidate the consumption more than boys among the cohort of triers￨no diff￨highunclear￨highunclear￨highunclear
not found￨youth smoking 1069 massachusetts youths ages 1215 years at baseline in 1993 and 627 of these youths who were interviewed after 4 years￨￨levels of brandspecific advertising exposure￨among the cohort baseline brandspecific exposure to cigarette advertising in magazines was highly correlated with brand of initiation among new smokers r  093 p  00001 brand smoked by current smokers r  086 p  00004 and brand whose advertisements attracted attention the most r  087 p  00002￨sig increase￨highunclear￨highunclear￨highunclear
not found￨adolescents who at baseline owned a tobacco promotional item and named a brand whose advertisements attracted their attention were more than twice as likely to become established smokers odds ratio  270 than adolescents who did neither massachusetts adolescents n  529 who at baseline had smoked no more than 1 cigarette were reinterviewed by telephone in 1997￨tobacco marketing and adolescent smoking tobacco marketing￨￨adolescents who at baseline owned a tobacco promotional item and named a brand whose advertisements attracted their attention were more than twice as likely to become established smokers odds ratio  270 than adolescents who did neither￨sig increase￨highunclear￨highunclear￨highunclear
2292￨middleschool students n  2292 adolescents susceptibility to smoking using inschool surveys from a culturally diverse sample adolescent smoking susceptibility￨selfreported exposure to pro and antitobacco media television programs and protobacco advertisements protobacco and antitobacco messages￨smoking susceptibility￨no significant interaction effects between pro and antitobacco media exposure on smoking susceptibility were found￨no diff￨highunclear￨highunclear￨highunclear
700000￨more than half the sample n979 named a favorite cigarette advertisement in 1993 and joe camel advertisements 1752 adolescent never smokers who were not susceptible to smoking when first interviewed in 1993 in a populationbased randomdigit dial telephone survey in california were reinterviewed in 1996 700000 adolescents each year never smokers who would not consider experimenting with smoking never smokers who would consider experimenting experimenters smoked at least once but fewer than 100 cigarettes or established smokers smoked at least 100 cigarettes cigarettes and adolescent smoking￨￨￨less than 5 n92 at baseline possessed a promotional item but a further 10n172 were willing to use an item￨sig increase￨highunclear￨highunclear￨highunclear
659￨triethnic sample of adolescents hispanic adolescents a schoolbased ethnically diverse 42 white 37 african american 20 hispanic sample of adolescents in grades 5 8 and 12 who were followed prospectively for 1 year 509 students who were nonsusceptible never smokers at baseline and b ever smoking among all 659 students who were never smokers at baseline both susceptible and nonsusceptible 659 students was identified who were never smokers at baseline and who completed questionnaires both at baseline and at 1year followup￨￨susceptibility to smoking and ever smoking￨exposure to tobaccorelated advertising was a risk factor for white susceptibility and ever smoking and african american susceptibility only adolescents but not for hispanic adolescents￨sig increase￨highunclear￨highunclear￨highunclear
1681￨1681 adolescents aged 1114 years who had never smoked￨retail cigarette advertising and smoking initiation￨moderate visit frequency￨adjusting for multiple risk factors the odds of initiation remained significantly higher odds ratio 164 95 confidence interval 106255 for adolescents who reported moderate visit frequency 0519 visits per week and the odds of initiation more than doubled for those who visited  or  2 times per week odds ratio 258 95 confidence interval 168397￨sig increase￨highunclear￨highunclear￨highunclear
480￨one hundred eightyfive students 385 had moved to a higher category on the smoking index by survey 3 of whom 30 had become smokers attitudes 0  never smokernot susceptible to smoking 1  never smokersusceptible to smoking 2  puffer 1 cigarette or less in lifetime 3  noncurrent experimenter 299 cigarettes in lifetimenone in past 30 days 4  current experimenter and 5  smoker  or 100 cigarettes in lifetime 480 students were equally distributed across grade at baseline 480 4th to 11thgrade students conducted in three rural vermont k12 schools adolescents￨personal item bearing a cigarette brand logo cigarette promotional item cpi cigarette promotions￨cigarette use receptivity to cigarette promotions and confounding factors including grade parental education peer smoking and family smoking higher smoking uptake smoking status smoking uptake￨this study supports a close linkage between tobacco promotional activities and uptake of smoking among adolescents beyond baseline descriptions of receptivity to cigarette promotions￨sig increase￨highunclear￨highunclear￨highunclear
4524￨4524 northern new england adolescents aged 1014 in 1999 with longitudinal followup of 2603 baseline neversmokers 784 experimenters youth smoking￨entertainment media and tobacco marketing movie smoking and tobacco marketing receptivity￨adolescent smoking onset and progression￨among experimental smokers the majority 64 were receptive to tobacco marketing which had a multivariate association with higher level of lifetime smoking movie smoking did not￨sig increase￨highunclear￨highunclear￨highunclear
118￨patients with alcohol dependence treated with the outpatient treatment of alcohol dependence ninetyone 77 patients completed the study and 92 78 were 80 compliant with the medication regimen 118 patients￨placebo naltrexone naltrexone cognitive behavioral therapy opioid antagonist naltrexone naltrexone daily or placebo in combination with either cognitive behavioral therapy cbt or supportive therapy￨tolerated mean time period alcohol consumption craving carbohydratedeficient transferrin medication compliance by tablet count and adverse clinical events relapses to heavy drinking heavydrinking days levels of liver enzyme activities craving score aspartate aminotransferase alanine aminotransferase and gammaglutamyltransferase￨these results are supported by the lower levels of liver enzyme activities p  0010 for aspartate aminotransferase alanine aminotransferase and gammaglutamyltransferase but not by the carbohydratedeficient transferrin levels in the naltrexone group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨alcohol dependence ninetyseven alcoholdependent patients￨placebo naltrexone naltrexone and coping skills therapy naltrexone and two manual guided psychotherapies naltrexone and coping skills therapy naltrexone or placebo and either coping skillsrelapse prevention therapy or a supportive therapy designed to support the patients own efforts at abstinence without teaching specific coping skills naltrexone￨drinking and alcoholrelated problems including abstention rates number of drinking days relapse and severity of alcoholrelated problems cumulative rate of abstinence￨naltrexone proved superior to placebo in measures of drinking and alcoholrelated problems including abstention rates number of drinking days relapse and severity of alcoholrelated problems￨sig increase￨highunclear￨highunclear￨highunclear
not found￨107 patients mean age 45 years fulfilling diagnostic and statistical manual of mental disorders 4th edition criteria for alcohol dependence hospitalbased drug and alcohol clinics 18 march 1998  22 october 1999 patients with alcohol dependence alcohol dependence￨naltrexone naltrexone placebo￨median time to relapse relapse rates tolerated relapse rate time to first relapse side effects￨on an intentiontotreat basis the kaplanmeier survival curve showed a clear advantage in relapse rates for naltrexone over placebo logrank test chi21￨sig increase￨low￨low￨low
50￨patients with bipolar disorder and substanceuse disorders bipolar disorder patients outpatients with bipolar disorder and alcohol dependence fifty adult outpatients with bipolar i or ii disorders and current alcohol dependence with active alcohol use patients with bipolar disorder patients with comorbid bipolar disorder and alcohol dependence￨naltrexone placebo manualdriven cognitive behavioral therapy naltrexone￨drinking days and heavy drinking days alcohol craving liver enzymes and manic and depressed mood symptoms potential value and acceptable tolerability quality of life mood symptoms drinking days binary outcome alcohol craving and some liver enzyme levels side effects￨naltrexone showed trends p  010 toward a greater decrease in drinking days binary outcome alcohol craving and some liver enzyme levels than placebo￨sig decrease￨highunclear￨highunclear￨highunclear
30￨alcoholdependent patients dsmiv alcoholdependent patients patients with alcohol dependence thirty patients￨injectable naltrexone placebo matching placebo injection longacting injectable naltrexone vivitrex naltrexone naltrexone formulation vivitrex￨drinking activity and trough plasma concentrations of naltrexone and its primary metabolite 6betanaltrexol safe and well tolerated adverse events safety and tolerability adverse events nausea and headache￨the most common adverse events nausea and headache occurred at a similar rate for patients in both treatment groups￨no diff￨highunclear￨highunclear￨highunclear
165￨alcoholics medically eligible alcoholdependent patients were recruited￨placebo cet and cst ntx naltrexone ntx cue exposure combined with urgespecific coping skills training cet and communication skills training cst naltrexone and cue exposure with coping and communication skills training cet combined with cst￨coping skills lower urge and higher selfefficacy urge selfefficacy confidence about staying abstinent in risky situations and selfreported coping skills drinking reductions heavy drinking days drinking outcomes selfefficacy lower weekly urge ratings￨drinking reductions at 3 6 and 12 months correlated with more use of coping skills lower urge and higher selfefficacy￨sig decrease￨highunclear￨highunclear￨highunclear
20￨individuals with high familial loading for developing alcoholism individuals with high familial loading 20 eoa￨ondansetron placebo ondansetron  naltrexone ondansetron ondansetron and naltrexone naltrexone ondansetron plus naltrexone￨drinking outcomes of eoa drinking outcomes abstinence rates betaendorphin levels￨individuals with high familial loading for developing alcoholism have lower levels of betaendorphin and demonstrate a more pronounced increase in betaendorphin levels in response to alcohol administration compared with individuals who do not have alcoholic relatives￨sig increase￨low￨low￨low
64￨patients with comorbid alcohol and cocaine use disorders comorbid alcohol and cocaine use disorders 64 subjects with comorbid alcohol and cocaine use disorders￨naltrexone ntx naltrexone placebo ntx￨medication dosage length of treatment sample size and attrition rate risk of relapse￨although subjects in both groups reduced their consumption of both alcohol and cocaine during the 8week trial there was no consistent advantage to ntx over placebo treatment￨no diff￨highunclear￨highunclear￨highunclear
145￨entire sample of participants was divided into two new groups 1 people who drank during the 2 weeks before the start of medication entry drinkers and 2 people who did not drink during this interval entry abstainers 145 patients who presented for treatment at a rural community substance abuse treatment center 133 participants had at least one followup visit￨opiate antagonist naltrexone placebo plus usual treatment placebo naltrexone naltrexone 50 mg daily plus usual program treatment￨drinkingrelated outcomes changes in serum biological markers alkaline phosphatase alanine transaminase aspartate transaminase and gammaglutamyltransferase craving and psychosocial functioning percent days drinking average drinks per drinking day average drinks per day heavy drinking days and time to first heavy drinking day number of drinking days heavy drinking and time to relapse to alcohol use percent days drinking average drinks per drinking day average drinks per day heavy drinking days four or more for women and six or more for men and time to first heavy drinking day￨participants in any of the randomized groups who were entry abstainers had significantly better improvement on all of the primary outcome measures￨sig increase￨low￨low￨low
not found￨older patients with alcohol dependence older adults fortyfour veterans over 50 years of age subjects who drank￨naltrexone naltrexone placebo￨frequency of any selfreported adverse effects or in liver enzyme values tolerated and efficacious￨there were no differences in the frequency of any selfreported adverse effects or in liver enzyme values between the placebo and naltrexonetreated groups￨no diff￨highunclear￨highunclear￨highunclear
169￨a total of 169 alcohol dependent subjects were given alcohol dependence￨placebo naltrexone acamprosate acamprosate and naltrexone naltrexone￨time to first relapse drinking craving or biochemical markers time to the first drink time to first relapse drinks per drinking day and cumulative abstinence alcohol dependence scale ads and depression anxiety and stress scale dass￨differential treatment effects were identified after stratification according to scores on the alcohol dependence scale ads and depression anxiety and stress scale dass￨sig increase￨low￨low￨low
160￨outpatient alcoholics n  160 less patient contact alcohol dependence￨cbt motivational enhancement therapy naltrexone cbtnaltrexone naltrexone combined with either cognitive behavioral or motivational enhancement therapy placebo and either cbt 12 sessions or motivational enhancement therapy naltrexone with cbt cognitive behavioral therapy cbt naltrexone￨time to first relapse alcohol consumption craving and biologic markers of drinking carbohydratedeficient transferrin and gammaglutamyltransferase high retention and adherence to therapy and medication￨however the cbtnaltrexone group did better than the other groups on a variety of outcome measures￨sig increase￨highunclear￨highunclear￨highunclear
not found￨270 recently abstinent outpatient alcoholdependent individuals￨motivational enhancement therapy with a medication compliance component delivered from trained counselors placebo nalmefene￨insomnia dizziness and confusion adverse events nausea dizziness time to first heavy drinking day heavy drinking days craving gammaglutamyl transferase and carbohydratedeficient transferrin concentrations￨although more subjects in the active medication groups terminated the study early secondary to adverse events the rates did not differ significantly from that of placebo￨no diff￨highunclear￨highunclear￨highunclear
1383￨2004 among 1383 recently alcoholabstinent volunteers median age 44 years from 11 us academic sites with diagnostic and statistical manual of mental disorders fourth edition diagnoses of primary alcohol dependence alcohol dependence january 2001january￨placebo combined pharmacotherapies and behavioral interventions naltrexone cbi naltrexone and cbi plus medical management naltrexone cbi acamprosate cbi plus medical management and placebos naltrexone x behavioral intervention interaction placebo cbi without pills or medical management naltrexone plus medical management naltrexone placebos with or without a combined behavioral intervention cbi acamprosate￨risk of a heavy drinking day￨naltrexone also reduced risk of a heavy drinking day hazard ratio 072 975 ci 053098 p  02 over time most evident in those receiving medical management but not cbi￨sig decrease￨low￨low￨low
254￨dually diagnosed individuals twohundred and fiftyfour patients with an axis i psychiatric disorder and comorbid alcohol dependence were treated for 12 weeks in an outpatient medication study conducted at three veterans administration outpatient clinics patients with alcohol dependence and comorbid psychiatric disorders￨placebo placebo alone 3 openlabel disulfiram and blinded naltrexone or 4 openlabel disulfiram and blinded placebo naltrexone and disulfiram disulfiram and naltrexone disulfiram and naltrexone naltrexone￨medication compliance alcohol consumption consecutive weeks of abstinence and less craving psychiatric symptoms alcohol craving gggt levels and adverse events￨subjects treated with an active medication had significantly more consecutive weeks of abstinence and less craving than those treated with placebo but there were no significant group differences in other measures of alcohol consumption￨sig decrease￨highunclear￨highunclear￨highunclear
31￨alcohol abusing patients with schizophrenia patients with schizophrenia individuals with alcohol dependence and comorbid schizophrenia thirtyone patients with schizophrenia and comorbid alcohol abuse or dependence were treated for 12 weeks in an outpatient study using individuals with comorbid alcohol dependence and schizophrenia alcoholabusing schizophrenic patients￨placebo naltrexone cognitivebehavioral drug relapse prevention strategies combined with skills training naltrexone or placebo naltrexone￨drinking measured by the time line followback method craving using the tiffany craving questionnaire psychotic symptoms using the positive and negative symptoms scale panss side effects and a measures of abnormal involuntary movements treatment exposure or medication compliance craving side effects drinking days heavy drinking days￨naltrexone treated patients had significantly fewer drinking days heavy drinking days 5 drinks and reported less craving compared to the placebo treated patients￨sig increase￨highunclear￨highunclear￨highunclear
11￨convenience sample of eleven patients divided in two groups ambulatory patients with alcohol dependence puerto rican male veterans with alcohol dependence￨placebo and naltrexone naltrexone placebo naltrexone￨somatization craving symptoms zung depression zung anxiety mmse ocd screener craving and somatization￨there were no statistically significant differences between the two groups on any of the outcome variables at baseline or follow up measurements￨no diff￨highunclear￨highunclear￨highunclear
not found￨twenty alcoholdependent subjects took fifteen subjects 75 received a￨injectable sustainedrelease preparation srp of naltrexone ntx placebo ntx placebo injection naltrexone single subcutaneous injection of 206 mg of sustainedrelease ntx￨bioavailability tolerability and potential efficacy frequency of heavy drinking days adverse effects ntx plasma concentrations￨compared with placebo the srp of ntx significantly reduced the frequency of heavy drinking days during the injection and followup periods￨sig decrease￨highunclear￨highunclear￨highunclear
121￨patients with a high familial loading of alcohol problems patients with high levels of alcohol craving at the beginning of treatment patients with high levels of alcohol craving or a strong family history of alcoholism a total of 121 patients￨placebo naltrexone and placebo placebocontrolled naltrexone naltrexone naltrexone￨family loading of alcohol problems￨interactions were observed between medication group assignment and both craving level prior to randomization p  02 and family loading of alcohol problems p  05￨sig increase￨highunclear￨highunclear￨highunclear
105￨105 outpatient volunteers were abstinent for a mean of 2 weeks prior to random assignment to the￨placebo cognitive behavioral therapy oral nalmefene naltrexone placebo or 20 or 80mgd dose nalmefene￨odds ratio of relapsing to heavy drinking subsequent relapses safety and efficacy￨patients treated with nalmefene also had fewer subsequent relapses p03 than patients given placebo￨sig decrease￨low￨low￨highunclear
not found￨twentyone alcoholdependent subjects meeting admission criteria alcoholdependent subjects￨naltrexone nalmefene placebo oral nalmefene hcl￨number of drinksdrinking day alcohol craving and consumption alcohol consumption efficacy and safety rate of relapse￨the 40 mg group had a significantly lower rate of relapse p  or  005 and a greater increase in the number of abstinent daysweek p  or  009 than the other treatment groups￨sig decrease￨highunclear￨highunclear￨highunclear
75￨patients with alcohol dependence seventyfive alcohol dependent subjects were detoxified￨aripiprazole naltrexone naltrexone and 515 mg of aripiprazole aripiprazole￨alcoholdrinking indices craving visual analogue scale obsessive and compulsive drinking scale and withdrawal clinical institute withdrawal assessment rating scales number of subjects relapsed craving and psychiatric symptom improvements survival function craving scores￨the survival function showed that patients treated with aripiprazole remained abstinent from any alcohol amount for a longer time with respect to those treated with naltrexone￨sig decrease￨highunclear￨highunclear￨highunclear
160￨160 patients with alcoholism￨naltrexone and acamprosate placebo naltrexone and acamprosate acamprosate naltrexone acamprosate naltrexone acamprosate naltrexone plus acamprosate or placebo naltrexone￨relapse rates nonrelapse rates time to first drink time to relapse and the cumulative abstinence time outcome regarding time to first drink and time to relapse relapse prevention of alcoholism￨the combined medication was most effective with significantly lower relapse rates than placebo and acamprosate but not naltrexone￨sig decrease￨low￨low￨low
164￨164 patients n  116 men and n  48 women with cooccurring cocaine and alcohol dependence patients with cooccurring cocaine and alcohol dependence￨naltrexone or placebo and to either cognitivebehavioral therapy or a type of medical management naltrexone placebo￨rates of cocaine and alcohol use and drug severity cocaine and alcohol use and drug severity cocaine use and alcohol use￨medication interactions were found for cocaine use via urine drug screens three way with time and selfreports two way for drug severity two way and alcohol use two way￨sig increase￨highunclear￨highunclear￨highunclear
202￨a total of 202 alcoholdependent patients alcoholdependence disorder 192 patients who were considered to be assessable￨placebo naltrexone and placebo naltrexone naltrexone or placebo naltrexone and placebo psychosocial intervention naltrexone￨alcohol consumption craving adverse events and changes in the biochemical markers of heavy drinking and possible toxicity relapse rate abdominal pain headache rate of adverse events efficacy safety and tolerability survival function biochemical markers of heavy drinking or alter liver function markers￨naltrexone seemed to reduce relapse rate to heavy drinking but we found no differences in other alcohol consumption variables between naltrexone and placebotreated groups￨no diff￨low￨low￨low
208￨208 patients treating cooccurring cocaine and alcohol dependence patients with cooccurring cocaine and alcohol dependence￨placebo disulfiram disulfiram and naltrexone disulfiram naltrexone disulfiramnaltrexone naltrexone￨medication adherence￨more patients taking the disulfiramnaltrexone combination achieved 3 consecutive weeks of abstinence in treatment than placebotreated patients￨sig increase￨low￨low￨low
not found￨patients who drank any alcohol while attending outpatient treatment alcohol dependence seventy male alcoholdependent patients participated￨naltrexone naltrexone placebo naltrexone hydrochloride￨pain from arthritis alcohol craving significant side effects nausea￨subjects taking naltrexone reported significantly less alcohol craving and days in which any alcohol was consumed￨sig decrease￨highunclear￨highunclear￨highunclear
97￨ninetyseven alcoholdependent subjects individuals who comply with the treatment protocol and take medication subjects who received psychosocial treatment in a more naturalistic setting with respect to the role of treatment attendance and medication compliance alcoholdependent subjects￨matching placebo placebo individual counseling naltrexone naltrexone￨alcohol drinking￨overall naltrexone showed only modest effects in reducing alcohol drinking for the 12 weeks of treatment￨no diff￨highunclear￨highunclear￨highunclear
6￨alcohol dependence or abuse patients who comply with treatment patients who met criteria for alcohol dependence n  169 or alcohol abuse n  6 fortynine 58 patients randomized to individuals with alcohol dependence participating in outpatient psychosocial programmes￨naltrexone placebo opioid antagonist naltrexone naltrexone￨serum ggt activity compliance alcohol craving ocds total score p  005 obsessive subscale score alcohol craving obsessive and compulsive drinking scale ocds time to first episode of heavy drinking secondary efficacy assessments included time to first drink alcohol consumption craving and changes in the serum biological markers gammaglutamyl transferase ggt and aspartate and alanine aminotransferases efficacy and safety￨the median reduction from baseline of serum ggt p  005 and the reductions in alcohol craving obsessive and compulsive drinking scale ocds were greater in the naltrexone group p  005 from approximately halfway through the study￨sig decrease￨low￨low￨low
87￨87 randomized subjects with both cocaine and alcohol dependence cocainealcohol dependence￨cognitive behavioral therapy cbt without cm naltrexone placebo naltrexone versus placebo￨medication compliance rates cocaine urine screens and alcohol use timeline followback frequency of heavy drinking days￨rates of cocaine use and drinks per day did not differ between treatment groups however naltrexone did reduce frequency of heavy drinking days as did cbt without cm￨no diff￨highunclear￨highunclear￨highunclear
40￨40 alcoholic patients who met diagnostic and statistical manual version iii revised dsmiiir criteria for alcohol dependence taiwanese han males with alcohol dependence alcohol dependence in taiwan￨naltrexone placebo naltrexone hydrochloride￨relapse rates alcohol craving￨the relapse rates between the two groups were not significant p  0671￨no diff￨highunclear￨highunclear￨highunclear
627￨men with chronic severe alcohol dependence alcohol dependence 627 veterans almost all men with chronic severe alcohol dependence to 12 months of￨naltrexone naltrexone placebo￨percentage of days on which drinking occurred and the number of drinks per drinking day number of days to relapse￨our findings do not support the use of naltrexone for the treatment of men with chronic severe alcohol dependence￨no diff￨highunclear￨highunclear￨highunclear
80￨eighty outpatients meeting dsmiv criteria for alcohol and cocaine dependence patients with cocainealcohol dependence patients with a single diagnosis of cocaine dependence￨naltrexone ntx pharmacotherapy ntx placebo or 50 mgd combined with psychotherapy relapse prevention rp or drug counseling dc cocainealcohol dependence with naltrexone and relapse prevention therapy ntx￨medication compliance number of adverse events percentage of cocainepositive urine screens self and objective reports of substance use treatment retention medication compliance and adverse effects￨the active medication group showed better medication compliance while the number of adverse events was low overall and not significantly different by group￨no diff￨highunclear￨highunclear￨highunclear
240￨two hundred and forty alcoholdependent subjects alcohol dependency over 24 weeks of treatment 1￨placebo naltrexone naltrexone or placebo cognitivebehavioral therapy cbt  medication clinic 2 brenda naltrexone￨alcohol use medication adherence and adverse events medication adherence￨intenttotreat analyses suggested that there was no overall efficacy of naltrexone and no medication by psychosocial intervention interaction￨no diff￨highunclear￨highunclear￨highunclear
627￨alcoholdependent patients february 2002 and september 2003 at 24 us public hospitals private and veterans administration clinics and tertiary care medical centers alcohol dependence 899 individuals screened 627 who were diagnosed as being actively drinking alcoholdependent adults￨matching volume of placebo n  209 each administered monthly and combined with 12 sessions of lowintensity psychosocial intervention placebo longacting injectable naltrexone naltrexone longacting naltrexone naltrexone intramuscular injection of 380 mg of longacting naltrexone￨overall rate and time to treatment discontinuation efficacy and tolerability heavy drinking discontinuation due to adverse events efficacy and tolerability event rate of heavy drinking days￨longacting naltrexone was well tolerated and resulted in reductions in heavy drinking among treatmentseeking alcoholdependent patients during 6 months of therapy￨sig decrease￨low￨low￨low
103￨a sample of alcoholdependent women some with comorbid eating pathology alcoholdependent women one hundred three women meeting dsmiv criteria for alcohol dependence 29 with comorbid eating disturbances subjects were enrolled between october 1995 and december 2000 at an outpatient research clinic￨cbcst naltrexone cognitive behavioral coping skills therapy cbcst naltrexone 50 mg or placebo naltrexone and cognitive behavioral coping skills therapy naltrexone￨time to first drinking day time to first day of heavy drinking symptoms of eating pathology alcohol drinking and eating disorder features drinking outcomes safety and efficacy￨among those with eating disturbances symptoms of eating pathology improved during treatment but the effects did not differ according to medication condition￨no diff￨highunclear￨highunclear￨highunclear
121￨patients who are dependent on alcohol with fixed medication and time 12 weeks 121 nonabstinent outpatients with alcohol dependence dsmiv alcohol dependence￨placebo naltrexone sessions of cognitive coping skills n  67 or supportive therapy naltrexone without prior detoxification opioid antagonist naltrexone naltrexone￨dropout rate relapses to heavy drinking￨naltrexone was not better than placebo in the supportive groups but it had a significant effect in the coping groups 27 of the copingnaltrexone patients had no relapses to heavy drinking throughout the 32 weeks compared with only 3 of the copingplacebo patients￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with concurrent mental disorders latelife depression complicated by alcohol dependence 74 subjects age 55 and older who met criteria for a depressive disorder along with alcohol dependence older adults with major depression and alcohol dependence elderly patients mental and physical illness￨sertraline naltrexone 50 mgday or placebo naltrexone naltrexone combined with sertraline￨alcohol consumption and depression alcohol relapse drinking relapses￨the overall results are encouraging 42 of the subjects had a remission of their depression and had no drinking relapses during the trial￨no diff￨highunclear￨highunclear￨highunclear
101￨101 alaskans with alcohol dependence including 68 american indiansalaska natives alaska natives and other alaskans living in rural settings alaska natives and nonnatives residing in rural settings 75 individuals who were homozygous for oprm1 asn40 allele￨placebo placebo placebo naltrexone  placebo sertraline naltrexone  sertraline placebo and 3 naltrexone  sertraline 100 mg plus nine sessions of medical management and supportive advice naltrexone naltrexone monotherapy sertraline naltrexone monotherapy sertraline and naltrexone naltrexone￨total abstinence time to first heavy drinking day and total abstinence￨naltrexone treatment response was significant within the group of 75 individuals who were homozygous for oprm1 asn40 allele￨sig increase￨highunclear￨highunclear￨highunclear
171￨171 detoxified patients 977 met the dsmiiir criteria for alcohol dependence were included eightyfour and 87 patients patients had been abstinent for a mean of 195￨naltrexone placebo￨compliance and adverse clinical eventswith the exception of the gammagt time to first drink amount of alcohol consumption intensity of craving severity of alcoholism problems and liver enzymes time to first heavy drinking as derived from selfreports of drinking timelinefollowback method episode of heavy drinking alcohol relapse￨also there were no significant differences between the study groups concerning secondary effectiveness measures as well as compliance and adverse clinical eventswith the exception of the gammagt which was significantly greater reduced in the naltrexone group throughout the study￨no diff￨highunclear￨highunclear￨highunclear
55￨alcohol dependence in a sample of alcoholdependent men fiftyfive subjects outpatient clinic of a combined war veteran and general teaching hospital in melbourne australia forty subjects did not complete 12 weeks of therapy 17 alcohol dependence male alcoholdependent subjects recruited from the community and from veteran groups￨placebo naltrexone 23 placebo naltrexone naltrexone or placebo naltrexone￨consumption of alcohol maintenance of abstinence and relapse to drinking￨naltrexone was well tolerated and there were few adverse experiences￨no diff￨highunclear￨highunclear￨highunclear
155￨university of são paulo brazil alcohol dependence a total of 155 patients 1860 years of age with an international classification of diseases icd10 diagnosis of alcohol dependence￨topiramate placebo topiramate with naltrexone topiramate induction to 300 mgday naltrexone naltrexone￨cumulative abstinence duration and weeks of heavy drinking time to first relapse alcoholics anonymous attendance cumulative abstinence duration heavy drinking￨there were no significant differences between naltrexone versus placebo or naltrexone versus topiramate groups but naltrexone showed trends toward inferior outcomes when compared to topiramate￨no diff￨highunclear￨highunclear￨highunclear
131￨outpatient alcoholics 131 recently abstinent alcoholdependent outpatients￨placebo naltrexone manualguided cognitive behavioral therapy and either 50 mgday of naltrexone cognitive behavioral therapy and naltrexone placebo n  63 with riboflavin naltrexone naltrexone and cognitive behavioral therapy￨alcohol consumption craving adverse events and urinary riboflavin levels cognitive resistance obsessive compulsive drinking scale relapse into heavy drinking levels of blood markers of alcohol abuse medication compliance rates￨the study completion therapy participation and medication compliance rates in the trial were high with no differences between treatment groups￨no diff￨highunclear￨highunclear￨highunclear
315￨315 subjects alcohol dependence￨placebo depot formulation containing naltrexone placebo formulation naltrexone depot manualguided motivational enhancement therapy naltrexone￨drinking days abstinence rate alcohol use and gammaglutamyl transpeptidase level￨naltrexone depot subjects also had significantly fewer drinking days during treatment and a significantly greater abstinence rate than the placebo group 18 vs 10￨sig decrease￨highunclear￨highunclear￨highunclear
183￨183 alcoholdependent subjects receiving weekly relapse prevention psychotherapy alcohol dependence￨naltrexone vs nefazodone placebo naltrexone nefazodone naltrexone opioid antagonist naltrexone and an inactive placebo￨rate of treatment attrition drinking behavior adverse neuropsychiatric and gastrointestinal effects poorer compliance￨naltrexone treatment was associated with significantly more adverse neuropsychiatric and gastrointestinal effects poorer compliance and a greater rate of treatment attrition￨sig decrease￨highunclear￨highunclear￨highunclear
74￨52 patients randomly allocated to undergo either seventyfour patients with grade iii and iv hemorrhoids￨stapled hemorrhoidectomy hemorrhoidectomy with a circular staple device stapled and open hemorrhoidectomy open hemorrhoidectomy stapled or open hemorrhoidectomy stapled 37 patients or open 37 patients hemorrhoidectomy circular stapling device￨postoperative pain return to painfree defecation and normal activities continence and defecation median range symptom severity score median range vas scores operation time for stapled hemorrhoidectomy resumption of painfree defecation occasional pain episodes of bleeding￨hemorrhoidectomy with a circular staple device is easy to perform and achieves better results than the milliganmorgan technique in terms of postoperative pain and recovery￨sig increase￨highunclear￨highunclear￨highunclear
100￨n  100 between march 1997 and december 1998 two hundred patients age of patients in the stapled and surgical groups was 44132 and 491122 years respectively￨conventional haemorrhoidectomy standardized postoperative analgesic and laxative regimens stapled versus milliganmorgan haemorrhoidectomy stapling technique stapled haemorrhoidectomy circular stapler milliganmorgan haemorrhoidectomy current standard surgery￨late complications and functional outcome operating time frequency of postoperative analgesic intake hospital stay time to return to normal activity and postoperative complications shorter operating time less frequent postoperative analgesia intake shorter hospital stay and earlier return to normal activity￨the stapled group had a shorter operating time less frequent postoperative analgesia intake shorter hospital stay and earlier return to normal activity￨sig decrease￨highunclear￨highunclear￨highunclear
40￨40 patients requiring surgical treatment for prolapsing haemorrhoids grade ii or iii prolapsing haemorrhoids￨stapled haemorrhoidopexy mm or pph stapled haemorrhoidopexy pph and milliganmorgan haemorrhoidectomy mm excision haemorrhoidectomy￨complained of recurrent external swelling andor prolapse persistent or recurrent symptoms postoperative pain endoanal ultrasound postoperative pain wound healing resting and squeeze pressures anal pressures and sphincter anatomy healing time￨postoperative pain at rest and during defecation was less important after pph if no resection of external piles or skin tags was associated p  00001￨no diff￨highunclear￨highunclear￨highunclear
84￨eightyfour patients with grade iii and iv hemorrhoidal disease noncomplicated hemorrhoidal disease eightyfour patients averaging 45￨stapled rectal mucosectomy vs closed hemorrhoidectomy stapled rectal mucosectomy and closed hemorrhoidectomy closed hemorrhoidectomy stapled rectal mucosectomy group n  42 and 2 closed hemorrhoidectomy stapled rectal mucosectomy￨patient satisfaction length of surgery and disability postoperative pain and use of analgesics frequency of late complications bleeding control postoperative pain analgesic use symptoms disability early and late complications and patient satisfaction serious complications￨closed hemorrhoidectomy proved to be superior for bleeding control 951 percent closed hemorrhoidectomy 805 percent stapled rectal mucosectomy p 004￨no diff￨highunclear￨highunclear￨highunclear
55￨fiftyfive patients with symptomatic third and fourthdegree haemorrhoids￨conventional haemorrhoidectomy stapled haemorrhoidopexy commonly called stapled haemorrhoidectomy stapled haemorrhoidopexy conventional diathermy haemorrhoid ectomy conventional diathermy haemorrhoidectomy￨rate of recurrent prolapse mean pain intensity operating time postoperative pain time to return to work postoperative complications and effectiveness of haemorrhoidal symptom control total number of complications the length of absence from work or control of symptoms￨seven patients in the stapled group represented with prolapse compared with none in the conventional haemorrhoidectomy group p  0004￨sig decrease￨highunclear￨highunclear￨highunclear
31￨thirtyone patients with symptomatic prolapsed irreducible piles fourthdegree hemorrhoids patients with symptomatic prolapsed irreducible piles patients with fourthdegree hemorrhoids￨stapled hemorrhoidopexy stapled hemorrhoidopexy diathermy excision stapled hemorrhoidopexy vs diathermy excision conventional diathermy hemorrhoidectomy conventional diathermy excision￨pain relief and disappearance of bleeding control of hemorrhoidal symptoms one year after operation recurrent prolapse starting appearance of a new symptom tenesmus persistence of itching tenesmus￨stapled hemorrhoidopexy was not effective as a definitive cure for the symptoms of prolapse and itching in patients with fourthdegree hemorrhoids￨no diff￨highunclear￨highunclear￨highunclear
40￨a university hospital providing primary secondary and tertiary care forty patients with second and thirddegree hemorrhoid disease￨stapled vs excision hemorrhoidectomy stapled vs excision hemorrhoidectomy stapled hemorrhoidectomy longo technique vs excision hemorrhoidectomy ferguson technique stapled hemorrhoidectomy stapled or excision hemorrhoidectomy stapled hemorrhoidectomy￨length of hospital stay reduced postoperative pain a reduced hospital stay complications hemorrhoidal recurrence operating time recurrence rate postoperative pain scores visual analog score postoperative pain earlier recovery time and return to work and a similar recurrence rate operating time postoperative pain measured by the visual analog scale hospital stay histologic features morbidity defecation habit continence recovery time return to work and hemorrhoid recurrence at 1 year￨stapled hemorrhoidectomy offers several advantages over excision hemorrhoidectomy including reduced postoperative pain a reduced hospital stay and an earlier recovery time￨sig increase￨highunclear￨highunclear￨highunclear
22￨patients with third degree haemorrhoids￨haemorrhoidectomy conventional haemorrhoidectomy conventional haemorrhoidectomy by the diathermy dissection or to stapled haemorrhoidectomy with the use of an intraluminal stapling device stapled haemorrhoidectomy with conventional haemorrhoidectomy stapled haemorrhoidectomy haemorrhoidectomy circumferential mucosectomy stapled haemorrhoidectomy￨normal activities sooner mean inpatient stay prolapse discharge and bleeding pain overall postoperative pain￨stapled haemorrhoidectomy is an effective treatment for third degree haemorrhoids with significant advantages for patients compared with conventional haemorrhoidectomy￨sig increase￨highunclear￨highunclear￨highunclear
50￨50 randomly selected patients and operated on a further 50 using the stapler technique￨milliganmorgan hemorrhoidectomy stapled hemorrhoidectomy hemorrhoidal stapler prolapsectomy vs milliganmorgan hemorrhoidectomy conventional hemorrhoidectomy￨normal activity sooner pain control prolapse discharge and bleeding with no stenosis or significant incontinence immediate postoperative period eg type of anesthesia mean duration of operation mean hospitalization time analgesic administration time before returning to work and over a longterm followup period of 48 months later complications such as prolapse relapse bleeding stenosis incontinence hemorrhoidal prolapse￨the stapled group experienced significantly less pain mean number of analgesic tablets 260 vs 159 and returned to normal activity sooner 804 vs 169 days as reported by other authors￨sig decrease￨highunclear￨highunclear￨highunclear
182￨182 patients with symptomatic haemorrhoids grades ii iii iv￨closed haemorrhoidectomy ch excisional haemorrhoidectomy stapled anopexy sa or ch circular stapled anopexy with closed diathermy haemorrhoidectomy excisional haemorrhoidectomy stapled anopexy sa￨clinical efficacy safety and patient acceptability of sa postoperative pain overall symptom control and safety faecal urgency symptom load symptom severity or the disease severity postoperative pain symptom control complications retreatment rates patient satisfaction and quality of life overall complication rates rate of residual symptoms prolapse control￨at 1 year there were no significant differences in the symptom load symptom severity or the disease severity between the two groups￨no diff￨highunclear￨highunclear￨highunclear
84￨grade iii and grade iv hemorrhoids all patients were operated on under spinal anesthesia mean age of patients was 4602 years sd 1233 in the stapled group and 4864 years 1457 in the open group￨stapled stapled hemorrhoidectomy circular stapler stapled technique with the wellaccepted conventional milligan morgan hemorrhoidectomy stapled versus open hemorrhoidectomy￨operative time pain scores complications day of discharge return to work and level of satisfaction mean operative time grade iii or iv hemorrhoids mean hospital stay blood loss pain scores and requirement of analgesics work or routine activities earlier postoperative pain early discharge less time off work complications￨stapled hemorrhoidectomy is a safe and effective daycare procedure for the treatment of grade iii and grade iv hemorrhoids￨no diff￨highunclear￨highunclear￨highunclear
134￨134 patients were included at 7 hospital centers￨stapled hemorrhoidopexy stapled hemorrhoidopexy versus milliganmorgan hemorrhoidectomy stapled hemorrhoidopexy sh hemorroidopexy stapled hemorrhoidopexy sh group circular stapler with that of the milliganmorgan technique mm group￨hemorrhoidal prolapse recurrences overall incidence of complications hospital stay total analgesic requirement pain during bowel movement external hemorrhoidal thrombosis partial residual prolapse resolution of symptoms continence problems postoperative paindiscomfort postoperative pain impaired sphincter function￨impaired sphincter function was observed at 1 year with no significant difference between the groups for urgency 12 continence problems 10 or tenesmus 3￨no diff￨highunclear￨highunclear￨highunclear
95￨95 patients randomly allocated to undergo either ninetyfive patients with grade iii and iv hemorrhoids￨hemorrhoidectomy with a circular stapler device stapled or open hemorrhoidectomy using ligasure stapled hemorrhoidectomy stapled 50 patients or open using ligasure stapled hemorrhoidectomy vs open with ligasure open hemorrhoidectomy hemorrhoidectomy performed using ligasure circular stapling device stapled hemorrhoidectomy￨operation time return to painfree defecation and normal activities postoperative pain intraoperative bleeding median range of vas score vas score visual analog scale vas￨operation time for open hemorrhoidectomy using ligasure was shorter median 13 range 92161 min vs 15 range 817 minutes p  005￨sig decrease￨highunclear￨highunclear￨highunclear
40￨40 patients admitted for surgical treatment of prolapsing haemorrhoids under general anaesthesia patients underwent￨stapling procedure for haemorrhoids versus milliganmorgan haemorrhoidectomy circular stapled procedure for haemorrhoids with current standard surgery standardised diathermy excision haemorrhoidectomy or had a circumferential doughnut of rectal mucosa and submucosa above the dentate line excised and closed with a standard circular endtoend stapling device surgical haemorrhoidectomy circular transanal stapled technique standardised preoperative and postoperative analgesic and laxative regimens circular stapled procedure milliganmorgan haemorrhoidectomy￨hospital stay and time to first bowel motion shorter anaesthesia time average pain average pain experience late complications patientassessed symptom control and functional outcome average pain relative return to normal activity￨the circular transanal stapled technique for the treatment of haemorrhoids has the potential to offer a less painful rectal procedure in place of ablative perianal surgery￨sig decrease￨low￨low￨low
80￨two homogeneous groups of patients affected by circular fourthdegree hemorrhoids with external mucosal prolapse forty patients group a 18 men 22 women mean age 505 years range 21 to 82 underwent from december 1996 to december 1999 80 consecutive patients with fourthdegree hemorrhoids and external mucosal prolapse and 40 patients group b 15 men 25 women mean age 510 years range 29 to 92 underwent advanced hemorrhoids with external mucosal prolapse before surgery all patients were selected with a standard questionnaire for symptom evaluation full proctological examination flexible rectosigmoidoscopy dynamic defecography and anorectal manometry￨lscm hospital leopold bellan hlb technique paris with longo stapled circumferential mucosectomy lscm circular hemorrhoidectomy stapled circumferential mucosectomy and conventional circular hemorrhoidectomy hlb hemorrhoidectomy￨late complications postoperative pain mean hospital stay recurrence rate mean duration of inability to work mean length length of the operation￨postoperative pain was significantly lower in group b p 0001￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨n  300 and fh n  296 at chang gung memorial hospital at chiayi in taiwan between january 2002 and december 2004 patients with prolapsed hemorrhoids grade iii hemorrhoids in taiwan￨sh ferguson hemorrhoidectomy fh stapled hemorrhoidopexy and ferguson hemorrhoidectomy stapled hemorrhoidopexy sh￨operative time intraoperative blood loss postoperative pain intensity and return to work intrapostoperative conditions hospital stay pain intensity scoring time off work and procedurerelated morbidity and over a followup period of minimum 18 months midterm ie relapse of prolapse andor bleeding anal stricture anal sepsis and the acceptability of the procedures to the patients￨sh was superior to fh in operative time intraoperative blood loss postoperative pain intensity and return to work￨sig decrease￨highunclear￨highunclear￨highunclear
156￨patients with prolapsing hemorrhoids grade iii one hundred seventeen patients procedure for prolapse and hemorrhoids 59 ferguson 58 returned for oneyear followup 156 patients procedure for prolapse and hemorrhoids 77 ferguson 79 completed randomization and the surgical procedure 18 procedure for prolapse and hemorrhoids 12 ferguson 6 had significant protocol violations￨stapled hemorrhoidopexy procedure for prolapse and hemorrhoids or ferguson hemorrhoidectomy by colorectal surgeons who had training in using the stapling technique stapled hemorrhoidopexy and ferguson hemorrhoidectomy￨prolapse and hemorrhoids required additional anorectal procedures hemorrhoid symptoms postoperative pain adverse events acute postoperative pain and hemorrhoid symptom recurrence requiring additional treatment at oneyear followup from surgery prolapse and hemorrhoids demographic parameters hemorrhoid symptoms preoperative pain scores and bowel habits pain at first bowel movement and need for postoperative analgesics￨primary end points were acute postoperative pain and hemorrhoid symptom recurrence requiring additional treatment at oneyear followup from surgery￨no diff￨highunclear￨highunclear￨highunclear
88￨88 patients were recruited grade iii hemorrhoidal disease patients with grade iii hemorrhoids who were employed during the trial period￨stapled hemorrhoidopexy with excisional hemorrhoidectomy stapled hemorrhoidopexy harmonic scalpel harmonic scalpel hemorrhoidectomy harmonic scalpel hemorrhoidectomy and 2 stapled hemorrhoidopexy stapled hemorrhoidopexy vs harmonic scalpel hemorrhoidectomy￨postoperative pain scores and satisfaction scores shorter length of stay smooth muscle incorporation and postoperative continence function reduced pain shorter length of stay and earlier resumption to work operative data and complications operation time blood loss day of first bowel movement after surgery and complication rates satisfaction scores pain score￨no significant difference was identified between the two groups in terms of operation time blood loss day of first bowel movement after surgery and complication rates￨no diff￨highunclear￨highunclear￨highunclear
100￨italy group 1 with one hundred patients with symptomatic third and fourthdegree haemorrhoids were enrolled by five hospitals￨conventional open haemorrhoidectomy stapled with open haemorrhoidectomy stapled haemorrhoidectomy using a 33mm circular stapling device stapled haemorrhoidectomy￨moderate pain postoperative bleeding requiring haemostatic procedures severe pain continence score maintaining normal continence to liquid stools median hospital stay postoperative pain shorter hospital stay￨in the early days after operation patients in group 2 had greater difficulty in maintaining normal continence to liquid stools p  001 but after 30 days the continence score was better in group 2 p  004￨sig decrease￨highunclear￨highunclear￨highunclear
60￨sixty patients with thirddegree hemorrhoids￨conventional hemorrhoidectomy stapled hemorrhoidectomy daycase stapled circular vs diathermy hemorrhoidectomy hemorrhoidectomy diathermy hemorrhoidectomy stapled hemorrhoidectomy￨rectal evacuation operation time surgical and functional outcome average pain postoperative morbidity and time off work hospital stay or symptom control patient satisfaction scores average pain visual analog scale￨stapled hemorrhoidectomy may be associated with less pain and faster recovery than conventional hemorrhoidectomy for prolapsing hemorrhoids￨sig decrease￨low￨low￨low
960￨neckpain patients 960 eligible patients 336 enrolled in the study patients with neck pain￨chiropractic manipulation and mobilization manipulation with or without heat manipulation with or without electrical muscle stimulation mobilization with or without heat and mobilization with or without electrical muscle stimulation cervical spine manipulation and mobilization￨pain and disability￨mean reductions in pain and disability were similar in the manipulation and mobilization groups through 6 months￨no diff￨highunclear￨highunclear￨highunclear
86￨osteoarthritis oa of the knee and cervical spine 86 patients with oa of the knee and 81 patients with oa of the cervical spine in which pain was evaluated using a 10 cm visual analog scale activities of daily living using a series of questions answered by the patient as never sometimes most of the time or always pain on passive motion recorded as none slight moderate or severe and joint tenderness recorded using a modified ritchie scale osteoarthritis of the knee and cervical spine￨pulsed electromagnetic fields pemf placebo pemf pulsed electromagnetic fields￨pain pain on motion and tenderness pain pain on motion and both the patient overall assessment and the physician global assessment knee and cervical spine studies￨the means of the treated patients with oa of the cervical spine showed greater improvement from baseline than the placebo group for most variables at the end of treatment and one month followup observations these differences reached statistical significance at one or more observation points for pain pain on motion and tenderness￨sig increase￨low￨low￨low
34￨cervical osteoarthritis patients with cervical osteoarthritis coa thirtyfour patients with coa￨electromagnetic field therapy pemf placebo pemf pulsed electromagnetic fields￨pain range of motion rom and functional status pain levels active rom paravertebral muscle spasm and neck pain and disability scale npds scores￨the active rom paravertebral muscle spasm and neck pain and disability scale npds scores improved significantly after pemf therapy p0001 but no change was observed in the sham group￨sig increase￨highunclear￨highunclear￨highunclear
218￨chronic neck pain patients patients with chronic neck pain two hundred and eighteen patients with chronic neck pain￨tens acupuncture points plus infrared irradiation tens group 2 exercise training plus infrared irradiation exercise group or 3 infrared irradiation alone control transcutaneous electrical nerve stimulation tens tens and exercise￨northwick park neck pain questionnaire score values of verbal numeric pain scale northwick park neck pain questionnaire and isometric neck muscle strength verbal numerical pain scale disability isometric neck muscle strength and pain neck muscle strength￨significant improvement p   0001 to 003 in neck muscle strength was observed in all three groups however the improvement in the control group was not clinically significant and it could not be maintained at the sixmonth followup￨sig increase￨highunclear￨highunclear￨highunclear
40￨40 patients entering the study received active pemt collars the other half acute whiplash injuries acute whiplash syndrome￨pemt facsimile placebo pulsed electromagnetic therapy pemt low energy high frequency pulsed electromagnetic therapy￨pain visual analogue scale￨at 2 and 4 weeks the actively treated group had significantly improved p less than 005 in terms of pain visual analogue scale￨sig increase￨highunclear￨highunclear￨highunclear
101￨101 volunteers 46 males and 55 females neck and shoulder pain 4 divided groups with pain vs without pain matched with magnetic vs nonmagnetic necklace￨magnetic necklace magnetic necklace￨proximal conduction time of the ulnar nerve excitation threshold of the suprascapular nerve intensity or frequency of pain chronic neck and shoulder pain￨the proximal conduction time of the ulnar nerve was significantly reduced by magnetic treatment in the subjects without pain but was not changed in the subjects with pain￨sig increase￨highunclear￨highunclear￨highunclear
30￨thirty patients with acute cervical pain￨transcutaneous nerve stimulation neck collar transcutaneous nerve stimulation or manual therapy￨cervical mobility quick symptom reduction￨the improvement was rapid in all groups but the restoration of the cervical mobility was significantly more rapid in the transcutaneous nerve stimulation group￨sig increase￨highunclear￨highunclear￨highunclear
40￨myofascial pain syndrome forty subjects with upper trapezius mps myofascial pain syndrome mps￨two different treatments frems and tens frems transcutaneous electrical nerve stimulation tens tens frequency modulated neural stimulation frems￨pain levels using the neck pain and disability visual analogue scale npdvas and algometry evaluation of myofascial trigger point characteristics and measurement of the range of cervical movement range of motion rom algometry and cervical extension npdvas algometry in myofascial trigger point characteristics and in the rom homolateral rotation controlateral rotation bending and extension￨the frems group showed a significant improvement in the npdvas algometry in myofascial trigger point characteristics and in the rom homolateral rotation controlateral rotation bending and extension after the end of treatment and at 1 and 3 months followup evaluation￨sig increase￨highunclear￨highunclear￨highunclear
not found￨myofascial pain syndrome subjects with myofascial trigger points tps at the level of the superior trapezius muscle￨placebo repetitive magnetic stimulation transcutaneous electrical nerve stimulation tensfiftythree peripheral repetitive magnetic stimulation rms tens placebo treatment￨npdvas algometry tp characteristics and cervical contralateral rotation neck pain and disability visual analogue scale npdvas an algometric evaluation of pain an evaluation of the tp characteristics and the range of cervical bending and rotation contralateral to the affected trapezius muscle myofascial pain￨at the end of treatment the rms group showed a significant improvement in the npdvas algometry tp characteristics and cervical contralateral rotation￨sig increase￨highunclear￨highunclear￨highunclear
100￨inclusion criteria were as follows either clinically verified painful lumbar radiculopathy in the segments l5s1 and a laségues sign of 30 degrees or more or typical signs of the whiplash syndrome such as painful restriction of rotation and flexionextension 100 patients with lumbar radiculopathy and 92 with the whiplash syndrome patients with lumbar radiculopathy or the whiplash syndrome patients with either lumbar radiculopathy in the segments l5s1 or the whiplash syndrome￨standard medication consisting of diclofenac and tizanidine electromagnetic fields￨neck pain back pain and the whiplash syndrome pain average time until pain relief and painless walking pain￨pain in the head was on average 46 before and 21 after treatment in those receiving magnetic field treatment and 4235 in controls￨sig decrease￨highunclear￨highunclear￨highunclear
18￨sixty patients 25 males and 35 females who had myofascial trigger points in one side of the upper trapezius muscles were studied￨electrical nerve stimulation and electrical muscle stimulation placebo electrotherapy ens electrical muscle stimulation ems therapy placebo treatment control group group b muscles n  20 were treated with electrical nerve stimulation ens therapy￨rom rom ems subjective pain intensity pi with a visual analog scale pressure pain threshold pt with algometry and range of motion rom with a goniometer of upper trapezius muscle lateral bending of cervical spine to the opposite side pain relief ens myofascial trigger points pi and pt￨ems could significantly p  005 improve rom but not pt better than the placebo groups for either subgroup￨sig increase￨highunclear￨highunclear￨highunclear
119￨one hundred nineteen subjects with palpably active myofascial trigger points mtrps copyright 2002 by the american congress of rehabilitation medicine and the american academy of physical medicine and rehabilitation￨ischemic compression therapy physical therapeutic modalities various physical therapeutic modalities b1 hot pack plus active range of motion rom b2 b1 plus ischemic compression b3 b2 plus transcutaneous electric nerve stimulation tens￨ithc itoc and ivc 2 treatment pressures p1 pain threshold p2 averaged pain threshold and tolerance irc myofascial pain pain threshold ithc pain tolerance itoc visual analog scale ivc and rom irc ithc itoc ivc and irc b4 b1 plus stretch with spray b5 b4 plus tens and b6 b1 plus interferential current and myofascial release cervical myofascial pain and triggerpoint sensitivity￨in stage 1 the ithc itoc ivc and irc were significantly improved in the groups p1t3 p2t2 and p2t3 compared with the p1t1 and p1t2 treatments p05￨no diff￨highunclear￨highunclear￨highunclear
not found￨myofascial pain syndrome eighteen patients who presented with myofascial trigger points tps at the level of the superior trapezius￨peripheral repetitive magnetic stimulation rms placebo placebo treatment that consisted of the application of a nonfunctioning ultrasound therapy device to the tp peripheral repetitive magnetic stimulation￨vas npdvas algometry pain levels vas npdvas and algometry the myofascial tp characteristics and the range of cervical movement rom myofascial pain￨the rms group showed a significant improvement in vas npdvas algometry as well as in the characteristics of the tp after conclusion of treatment￨sig increase￨highunclear￨highunclear￨highunclear
20￨20 patients 20 patients with persistent greater than 8 weeks neck pain persistent neck pain patients with neck pain￨placebo active pemt units facsimile placebo units low energy pulsed electromagnetic therapy pemta treatment pulsed high frequency 27mhz electromagnetic therapy￨pain visual analogue scale pain and range of movement￨after 3 weeks both pain visual analogue scale p less than 023 and range of movement p less than 002 had improved in the group on active treatment compared to the controls￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨oropharyngeal candidiasis in the immunocompromised host immunocompromised patients patients with cancer 10 patients in both groups￨topical therapy fluconazole and ketoconazole fluconazole fluconazole vs ketoconazole fluconazole ketoconazole￨rates of relapse oropharyngeal candidiasis eradication of pathogenic yeasts clinical cure￨clinical cure was observed in 15 of 19 and 14 of 18 patients treated with fluconazole and ketoconazole respectively￨no diff￨highunclear￨highunclear￨highunclear
282￨patients with head and neck cancer cancer patients with opc 2007 american cancer society cancer patients who have opc as an alternative to systemic antifungal agents patients with cancer two hundred eightytwo patients with head and neck cancer oropharyngeal candidiasis patients treated with radiotherapy for head and neck cancer￨miconazole 500mg oral gel mog mbt or mog miconazole miconazole mbt mog miconazole 500mg gel￨success rate of mbt loramyc success rate clinical success at day 7 clinical cure improvement in clinical symptoms mycologic cure recurrence rate and safety efficacy and safety clinical success￨the success rate of mbt loramyc was significantly not inferior to that of mog in the treatment of cancer patients with opc and after adjusting for prognostic variables it was more effective than mog￨no diff￨highunclear￨highunclear￨highunclear
not found￨oropharyngeal candidiasis in cancer patients￨clotrimazole￨nausea and abdominal pain local effectiveness and safety cure rate median duration of oropharyngeal candidiasis clinical cures￨side effects were minimal and only one patient experienced nausea and abdominal pain￨no diff￨highunclear￨highunclear￨highunclear
20￨candidiasis cancer patients with oral candidiasis￨placebo ketoconazole ketoconazole￨eradication of culturable organisms regression of visible lesions resolution of lesions plus eradication of candida albicans￨regression of visible lesions was achieved in 26 72 of 36 ketoconazoletreated and four 20 of 20 untreated patients eradication of culturable organisms occurred in 12 36 of 33 ketoconazoletreated and one 7 of 14 untreated patients and resolution of lesions plus eradication of candida albicans occurred in nine 25 of 36 ketoconazoletreated and one 5 of 20 untreated patients￨no diff￨highunclear￨highunclear￨highunclear
252￨cancer patients with oropharyngeal candidiasis patients with cancer and oropharyngeal candidiasis nonneutropenic cancer patients with oropharyngeal candidiasis cancer patients who receive cytotoxic drugs 279 patients who were randomised between the two treatment groups 252 patients were considered to be eligible 126 in each group￨itraconazole fluconazole fluconazole and itraconazole￨efficacy safety and tolerance mycological cure rate safety and tolerance profile clinical cure rate￨the clinical cure rate was 74 for fluconazole and 62 for itraconazole p004 95 confidence interval ci 05233￨no diff￨highunclear￨highunclear￨highunclear
182￨182 immunocompromised infants and children ages 5 months to 14 years with signs of oral thrush and presence of yeasts on potassium hydroxide or gramstained preparations thirtytwo centers participated including hospitals and ambulatory care clinics immunocompromised children￨fluconazole fluconazole suspension fluconazole suspension versus nystatin fluconazole fluconazole suspension nystatin￨eradication of the organism cultured at entry gastrointestinal conditions efficacy safety and tolerance clinical cure tolerated laboratory abnormalities oropharyngeal candidiasis clinical relapse rates￨clinical relapse rates were similar in both groups at 2 weeks 18 and 24 for fluconazole and nystatin respectively and 1 month 28 and 27 respectively after the completion of study drug￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients undergoing radiotherapy for head and neck tumours 73 patients with oropharyngeal candidosis￨amphotericin fluconazole and amphotericin b radiotherapy fluconazole amphotericin b￨cure rate mycological cure￨for both treatments the cure rate was less in denture wearers than in non denture wearers￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients with neoplastic disease￨clotrimazole placebo amphotericin b therapy clotrimazole￨toxicity resolution of symptoms and signs of oral candidiasis￨no toxicity was observed that could be attributed to clotrimazole￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨topiramate placebo topiramate￨weight loss attention concentration and memory problems fatigue sedation transient paraesthesias nausea and anorexia endpoint ymrs change scores baseline ymrs total scores￨adverse effects of topiramate in bipolar subjects include attention concentration and memory problems fatigue sedation transient paraesthesias nausea and anorexia￨no diff￨highunclear￨highunclear￨highunclear
17￨early parkinsons disease patients with early parkinsons disease pd adult persons with neurologic disorders seventeen patients with early pd hoehn and yahr stages i through iii and gait disturbances￨cgt speeddependent treadmill training stt and ltt structured speeddependent treadmill training stt limited progressive treadmill training ltt conventional gait training cgt and a control intervention training interventions￨double stance duration basic gait parameters overground walking speed and stride length at selfadapted speeds and parameters of gait analysis based on vertical ground reaction forces gait parameters gait in pd namely speed and stride length￨significantly higher gains were observed in all basic gait parameters after stt and ltt when compared with cgt and the control intervention p05￨sig increase￨highunclear￨highunclear￨highunclear
54￨patients with idiopathic parkinsons disease fiftyfour patients with idiopathic parkinsons disease in stage 2 or 3 of the hoehn yahr staging entered and 31 patients 21 training 10 control had outcome data twentyone patients with parkinsons disease participated in an patients with parkinsons disease￨incremental speeddependent treadmill training eightweek exercise programme using incremental speeddependent treadmill training specific exercise programmes using incremental speeddependent treadmill training￨walking distance and speed on treadmill updrs berg balance test dynamic gait index and falls efficacy scale postural instability and fear of falling berg balance test dynamic gait index and falls efficacy scale postural instability and fear of falling in parkinsons disease tolerated maximum speed initial total walking distance postural instability dynamic balance and fear of falling balance gait fear of falling and walking distance and speed on treadmill berg balance test dynamic gait index and falls efficacy scale scores motor component of the unified parkinsons disease rating scale updrs￨berg balance test dynamic gait index and falls efficacy scale scores of the training group were improved significantly after the training programme p  001￨sig increase￨highunclear￨highunclear￨highunclear
18￨parkinsons disease individuals with parkinsons disease pd eighteen men with idiopathic pd in stage 2 or 3 of the hoehn and yahr staging individuals with pd patients with pd￨gait and step perturbation training gait and step perturbation training gait training consisted of walking on a treadmill at a speed greater than over ground walking speed while walking gait and step training￨stride lengths falls and improvements in gait and dynamic balance gait parameters 5step test report of falls gait speed cadence and step length 5step test speed gait speed￨the cadence increased for both groups from 1128 to 1203 stepsmin for the trained group and 1177 to 1243 stepsmin for the control group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨parkinsons disease copyright 2002 by the american congress of rehabilitation medicine and the american academy of physical medicine and rehabilitation twentyfour patients hoehn and yahr stages 25 or 3 who were not demented minimental state examination score 27 patients with parkinsons disease pd inpatient rehabilitation unit for neurologic diseases in japan￨body weightsupported treadmill training bwstt body weightsupported treadmill training conventional physical therapy pt￨ambulation speed unified parkinsons disease rating scale updrs ambulation speed s10 m and number of steps taken for a 10m walk as a parameter for stride length baseline updrs￨the bwstt group had significantly greater improvement than the pt group mannwhitney u test bonferroni adjustment for multiple comparison in ambulation speed at 1 month bwstt85 pt108 p005 and in the number of steps at 1 bwstt200 pt227 p005 2 bwstt195 pt224 p005 3 bwstt201 pt231 p005 and 4 months bwstt210 pt230 p006￨sig increase￨highunclear￨highunclear￨highunclear
not found￨parkinsons disease persons with parkinsons disease ten patients 5 men 5 women with hoehn and yahr stage 25 or 3 parkinsonism mean age 676 years mean duration of parkinsons disease 42 years patients with parkinsons disease￨treadmill training with body weight support body weightsupported treadmill training bwstt conventional physical therapy pt￨unified parkinsons disease rating scale updrs ambulation endurance and speed sec10 m and number of steps for 10meter walk activities of daily living motor performance and ambulation mean total updrs￨in persons with parkinsons disease treadmill training with body weight support produces greater improvement in activities of daily living motor performance and ambulation than does physical therapy￨sig increase￨highunclear￨highunclear￨highunclear
30￨twentyfour patients completed the study patients with parkinson disease pd patients with severe cognitive impairments or severe musculoskeletal cardiopulmonary neurologic or other systemic disorders were excluded pd patients thirty consecutive patients diagnosed with idiopathic pd who were on stable regimens of antiparkinsonian medication able to walk independently and had not participated in a rehabilitation program in the previous 3 months￨gait training with treadmill treadmill training￨functional lowerextremity tests exercise test parameters and patients global assessment lowerextremity tasks timed functional lowerextremity tasks walking at a corridor uturn turning around a chair stairs standing on one foot standing from a chair and secondary outcome measures were exercise test and patients global assessment￨there were significant improvements in functional lowerextremity tests exercise test parameters and patients global assessment in group i whereas no significant improvements were observed in group ii￨sig increase￨highunclear￨highunclear￨highunclear
30￨thirty people with pd within 3 years of diagnosis with hoehn and yahr stage 1 or 2 people with early parkinsons disease people with parkinsons disease pd￨exercise training highintensity exercise using body weightsupported treadmill training lowintensity exercise or a zerointensity education group highintensity exercise￨motor performance and corticomotor excitability total and motor updrs gait speed step and stride length and hip and ankle joint excursion during selfselected and fast gait and improved weight distribution unified parkinsons disease rating scales updrs biomechanic analysis of selfselected and fast walking and sittostand tasks corticomotor excitability functional performance gait and sittostand measures￨highintensity group subjects showed postexercise increases in gait speed step and stride length and hip and ankle joint excursion during selfselected and fast gait and improved weight distribution during sittostand tasks￨sig increase￨highunclear￨highunclear￨highunclear
6￨6 subjects with cystic fibrosis patients with cystic fibrosis￨postural drainage c postural drainage plus mechanical percussion d combined maneuvers postural drainage deep breathing with vibrations and percussion administered by a physiotherapist e directed vigorous cough physiotherapy regimen chest physiotherapy￨physiotherapy maneuvers postural drainage removal of mucus cough postural drainage plus percussion removal of lung radioactivity￨compared with the control day all forms of intervention significantly improved the removal of mucus cough p less than 0005 physiotherapy maneuvers 0005 less than or equal to p less than 001 postural drainage p less than 005 and postural drainage plus percussion p less than 001￨sig increase￨highunclear￨highunclear￨highunclear
16￨patients hospitalized for pulmonary exacerbations of cystic fibrosis sixteen patients with cf 8 males 8 females aged 1527 years mean 203  4 met the inclusion criteria 1 age over 14 years 2 mild or moderate airway obstruction 3 sputum volume  30 mlday 4 being proficient in pd and pep cpt patients with cystic fibrosis cf hospitalized for an acute pulmonary exacerbation￨controltreatment cont chrispinnorman chest radiography score 186 chest physiotherapy cpt regimens pd postural drainage pep positive expiratory pressure physiotherapy hfcc highfrequency chest compression physiotherapy chest physiotherapy regimens￨lung function wet and dry weight of sputum shwachmankulczycki clinical score wet and dry weights of sputum￨no significant differences between the three cpt regimens for both wet and dry weights were found when the number of coughs was taken into accountabstract truncated at 250 words￨no diff￨highunclear￨highunclear￨highunclear
10￨cystic fibrosis patients with cystic fibrosis ten patients with cystic fibrosis￨tbc pd  fet and pep  fet chest physiotherapy regimens fet pep  fet postural drainage and the forced expiration technique pd  fet and 2 positive expiratory pressure pepmask and fet pep  fet postural drainage and positive expiratory pressure physiotherapy￨number of spontaneous coughs radioactivity content whole lung or regional tbc clearance of lung radioactivity whole lung and regional tracheobronchial clearance tbc whole lung tbc￨there was no significant difference in whole lung or regional tbc between the pd  fet and pep  fet treatments￨no diff￨highunclear￨highunclear￨highunclear
8￨patients with cystic fibrosis eight patients with cystic fibrosis￨positive expiratory pressure breathing positive expiratory pressure breathing alone and in combination with coughing￨lung volumes mean sem functional residual capacity functional residual capacity and total lung capacity positive expiratory pressure breathing mucus transport total lung capacity￨lung volumes were higher during breathing with an expiratory pressure of 15 cm h2o than with 5 cm h2o both returned to baseline values immediately after positive expiratory pressure breathing￨sig increase￨highunclear￨highunclear￨highunclear
14￨patients with airway hyperreactivity cystic fibrosis fourteen patients with cystic fibrosis￨selfadministered chest physiotherapy chest physiotherapy pt techniques highpressure pepmask physiotherapy pep and autogenic drainage ad pep ad pep followed by ad pepad ad followed by pep adpep￨lung function pepinduced lung function improvement per milliliter of sputum￨lung function improved significantly after pep ad and pepad but pepinduced changes did not exceed those after ad￨sig increase￨highunclear￨highunclear￨highunclear
203￨72 patients patients with submucous cleft palate two hundred and three patients with submucous cleft palate were studied from 1990 to 1999 submucous cleft palate￨individualized velopharyngeal surgery individualized pharyngeal flap or sphincter pharyngoplasty incision palatopharyngoplasty videonasopharyngoscopy and multiview videofluoroscopy individualized pharyngeal flap or sphincter pharyngoplasty videonasopharyngoscopy and multiview videofluoroscopy minimal incision palatopharyngoplasty￨frequency of residual velopharyngeal insufficiency after palatal closure frequency of residual velopharyngeal insufficiency mean size of the gap at the velopharyngeal sphincter during speech residual size of the gap at the velopharyngeal sphincter velopharyngeal insufficiency￨the mean size of the gap at the velopharyngeal sphincter during speech was not significantly different in both groups of patients before surgery 23 percent versus 22 percent p  05￨no diff￨highunclear￨highunclear￨highunclear
900￨patients with dsmiv bipolar n103 suffering from frequent relapses i disorder patients with bipolar disorder bipolar disorder patients up to 1 year￨cognitive therapy cognitive therapy plus medication group or a control condition of medication only￨bipolar episodes relapse prevention relapse reduction mood ratings social functioning coping with bipolar prodromes and dysfunctional goal attainment cognition time to relapse￨however the results showed that cognitive therapy had no significant effect in relapse reduction over the last 18 months of the study period￨no diff￨highunclear￨highunclear￨highunclear
not found￨partners of bipolarmanic patients 14 bipolarmanic patients attending￨psychoeducation sessions￨knowledge of the disease medication and social strategies￨patient compliance did not change over the next year￨no diff￨highunclear￨highunclear￨highunclear
101￨bipolar patients n  101 were recruited shortly after an illness episode￨psychoeducational program manualbased program of familyfocused psychoeducational treatment fft fft comparison treatment involving two family education sessions and followup crisis management￨depressive relapses and longer delays before relapses relapse status symptom severity and medication compliance￨patients assigned to fft had fewer relapses and longer delays before relapses during the study year than did patients in cm￨sig decrease￨highunclear￨highunclear￨highunclear
76￨department of psychology university of tübingen germany n76 patients with bd bipolar disorder bd bipolar disorders￨adjunctive psychosocial interventions such as cognitive behaviour therapy cbt cbt cognitive behaviour therapy and supportive therapy￨number of prior episodes the number of therapy sessions and the type of bd predicted survival time relapse rates kaplanmeier survival analyses survival time￨cbt showed a nonsignificant trend for preventing any affective specifically depressive episode during the time of therapy￨no diff￨highunclear￨highunclear￨highunclear
not found￨subjects referred by general adult psychiatrists subjects with bipolar disorders bipolar disorders￨ct cognitive therapy cognitive therapy ct immediate ct￨relapse and hospitalization rates beck depression inventory the internal state scale and the global assessment of functioning feasibility and efficacy relapse rates￨at 6month followup subjects allocated to ct showed statistically significantly greater improvements in symptoms and functioning as measured on the beck depression inventory the internal state scale and the global assessment of functioning than those in the waitinglist control group￨sig increase￨highunclear￨highunclear￨highunclear
253￨people with bipolar disorder severe and recurrent bipolar disorders individuals with bipolar disorders￨cognitivebehavioural therapy cognitivebehavioural therapy cbt￨recurrence rates of major mood episodes￨post hoc analysis demonstrated a significant interaction p004 such that adjunctive cbt was significantly more effective than treatment as usual in those with fewer than 12 previous episodes but less effective in those with more episodes￨sig increase￨highunclear￨highunclear￨highunclear
120￨patients with bipolar i and ii disorder bipolar patients whose disease is in remission bipolar patients one hundred twenty bipolar i and ii outpatients in remission young mania rating scale score 6 hamilton depression rating scale17 score 8 for at least 6 months prior to inclusion in the study who were receiving standard pharmacologic treatment were included in a controlled trial pharmacologically treated patients with bipolar i and ii disorder￨￨number of relapsed patients and the number of recurrences time to depressive manic hypomanic and mixed recurrences number and length of hospitalizations per patient number of recurrences￨group psychoeducation significantly reduced the number of relapsed patients and the number of recurrences per patient and increased the time to depressive manic hypomanic and mixed recurrences￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨remitted fully compliant dsmiv bipolar i patients n  25 who were compared with a group with similar characteristics n  25 who did not receive psychoeducation bipolar disorders￨naturalistic pharmacologic treatment naturalistic treatment without psychological intervention￨number of total recurrences and the number of depressive episodes￨the number of total recurrences and the number of depressive episodes were significantly lower in psychoeducated patients￨sig decrease￨highunclear￨highunclear￨highunclear
69￨mental health services in four nhs trusts one teaching three nonteaching teaching patients with bipolar disorder manicdepressive psychosis 69 patients with bipolar disorder who had had a relapse in the previous 12 months￨research psychologist plus routine care or routine care alone￨event curves of time to first manic relapse time to first relapse or number of relapses with depression number of manic relapses time to first manic or depressive relapse number of manic or depressive relapses and social functioning overall social functioning 25th centile time to first manic relapse￨event curves of time to first manic relapse significantly differed between experimental and control groups log rank 704 df1 p0008 with significant reductions in the number of manic relapses over 18 months median difference 30 95 confidence interval 8 to 52 p0013￨sig increase￨low￨low￨low
32￨a total of 32 patients children with newly diagnosed acute lymphoblastic leukemia all children with acute lymphoblastic leukemia￨gcsf gcsf supportive therapy granulocyte colonystimulating factor￨granulocyte counts number of bacterial and fungal infections and the number of days of hospitalization median length of this phase￨the number of days during which patients had granulocyte counts of less than 2 x 109l the number of febrile episodes of unknown origin the number of bacterial and fungal infections and the number of days of hospitalization did not differ in a statistically significant manner between the two groups￨sig decrease￨highunclear￨highunclear￨highunclear
40￨childhood acute lymphoblastic leukemia 40 patients with acute lymphoblastic leukemia all￨placebo rhgmcsf 55 microgramskg sc coadministered with chemotherapy recombinant human granulocytemacrophage colonystimulating factor rhgmcsf placebo coadministered with chemotherapy concurrent rhgmcsf rhgmcsf￨absolute neutrophil counts number of days with neutropenia number of days with fever number of days spent in hospital or number of days on antibiotics number type or severity of infectious episodes neutropenia￨in addition the treated and placebo groups showed no significant difference in absolute neutrophil counts number of days with neutropenia number of days with fever number of days spent in hospital or number of days on antibiotics during the 28day study period￨no diff￨highunclear￨highunclear￨highunclear
17￨acute lymphoblastic leukemia seventeen children with acute lymphoblastic leukemia or tcell nonhodgkin lymphoma and treated on standard protocols children with acute lymphoblastic leukemia all￨gcsf intensification chemotherapy recombinant granulocyte colonystimulating factor gcsf granulocyte colonystimulating factor￨hematological toxicity neutropenia neutrophils  1 x 109l and severe neutropenia neutrophils  05 x 109l days in hospital days of fever and days on antibiotics severe neutropenia duration of neutropenia￨there were significant reductions in the duration of neutropenia 95 confidence interval 388 days p  00001 severe neutropenia 95 confidence interval 1874 days p  0002 and days in hospital 95 confidence interval 0963 days p  001 for children receiving gcsf￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with hr pediatric all children with highrisk acute lymphoblastic leukemia 34 patients pediatric acute lymphoblastic leukemia all after cancer chemotherapy in adults hr pediatric all patients￨chemotherapy granulocyte colonystimulating factor recombinant methionyl human granulocyte colonystimulating factor rmethugcsf chemotherapy according to the german allberlinfrankfurtmünster 90 protocol either alone or followed by rmethugcsf administered prophylactically at a dose of 5 microgkg￨survival efs rates cultureconfirmed infections total duration of intravenous antibiotic use toxicity particularly myelosuppression febrile neutropenia myelosuppression median total duration of febrile neutropenia febrile neutropenia cultureconfirmed infections and duration of intravenous antibiotic administration￨the incidence of febrile neutropenia absolute neutrophil count 05 x 109l and oral temperature  or  385 degrees c was 17 in children receiving rmethugcsf as compared with 40 in the control group p  007￨no diff￨highunclear￨highunclear￨highunclear
67￨sixtyseven children with very highrisk all childhood acute lymphoblastic leukemia all very highrisk childhood acute lymphoblastic leukemia￨gcsf recombinant human granulocyte colonystimulating factor gcsf lenogastrim recombinant human granulocyte colonystimulating factor vincristine prednisone cyclophosphamide doxorubicin and methotrexate copadm cytarabine etoposide and dexamethasone r3￨platelet count number of days with fever and intravenous antibiotics and duration of hospitalization cdi 3year probability of eventfree survival hematologic recovery disease control duration of granulocytopenia number of platelet transfusions thrombocytopenia￨duration of granulocytopenia was reduced in the gcsf group but thrombocytopenia was prolonged and the number of platelet transfusions was increased￨sig increase￨highunclear￨highunclear￨highunclear
164￨148 patients 73 in the gcsf group and 75 in the placebo group children with acute lymphoblastic leukemia 164 patients with acute lymphoblastic leukemia age range 2 months to 17 years to receive￨gcsf placebo induction chemotherapy recombinant human granulocyte colonystimulating factor po1 ca20180ilgrastim gcsf treatment human granulocyte colonystimulating factor after induction chemotherapy placebo or gcsf￨probability of subsequent hospitalization area under the plasma gcsf concentrationtime curve likelihood of eventfree survival median total costs of supportive care febrile neutropenia rate of hospitalization for febrile neutropenia rate of hospitalization for febrile neutropenia prolong survival number of severe infections median hospital stays￨patients treated with gcsf had shorter median hospital stays 6 days vs 10 days p0011 and fewer documented infections 12 vs 27 p0009￨sig decrease￨highunclear￨highunclear￨highunclear
32￨antipsychoticinduced erectile dysfunction thirtytwo subjects and their spouses who agreed to take part in the study thirtytwo married male outpatients with schizophrenia or delusional disorder and antipsychoticinduced erectile dysfunction patients with antipsychoticinduced erectile dysfunction￨placebo sildenafil sildenafil citrate sildenafil sildenafil citrate￨number of adequate erections satisfaction with sexual intercourse and the duration of erections odds ratios for adequate erections tolerated satisfactory sexual intercourse sexual function efficacy and tolerability￨patients reported significant improvement while taking sildenafil in the number of adequate erections satisfaction with sexual intercourse and the duration of erections over 2 weeks￨sig increase￨highunclear￨highunclear￨highunclear
not found￨10 neuroleptictreated male schizophrenic outpatients schizophrenictreated patients and the need for schizophrenic patients maintained on neuroleptics￨placebo selegiline selegiline￨sexual dysfunction prolactin levels￨selegiline was not found to be effective in improving any domain of sexual functioning despite a significant decrease in prolactin levels p  005￨no diff￨highunclear￨highunclear￨highunclear
not found￨clinically stable patients with schizophrenia who had hyperprolactinemia defined as 188 ngml for males and 242 ngml for females patients with schizophrenia who have treatmentemergent hyperprolactinemia n14 were 663387 ngml and were 820376 p32 in those remaining on their prestudy antipsychotic medication n14 patients with schizophrenia switched from conventional antipsychotics or female patients hyperprolactinemic patients with schizophrenia￨olanzapine olanzapine risperidone￨baseline prolactin levels resolution of galactorrhea and gynecomastia and sexual functioning mean serum prolactin levels reproductive morbidities and sexual dysfunction serum prolactin and improvement in sexual and reproductive comorbid symptoms free testosterone levels baseline prolactin levels eosinophil counts total testosterone levels hyperprolactinemia and reproductive comorbidities lowdensity lipoproteins and standing blood pressure menstrual cycling￨olanzapinetreated patients experienced significantly lower eosinophil counts and higher elevations in lowdensity lipoproteins and standing blood pressure than nonswitched patients￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨outpatients with schizophrenia or schizoaffective disorder outpatients with risperidoneassociated sexual dysfunction outpatients n42 ageor18 years with schizophrenia or schizoaffective disorder who experienced risperidoneassociated sexual dysfunction￨quetiapine vs risperidone quetiapine switch quetiapine risperidone quetiapine switch vs risperidone quetiapine switch vs risperidone continuation￨fiveitem arizona sexual experience scale asex assessed sexual functioning adjusted mean asex total scores sexual functioning mean asex total scores asex total scores and asex subitems￨treatment group effects were not significantly different in any of the prospective weeks for asex total scores and asex subitems￨no diff￨highunclear￨highunclear￨highunclear
754￨patients with hiv test positive and percentage of those who received cotrimoxazole and who were referred for hiv care 754 adults 18 years and older newly registered as tb patients in the 20 study clinics tuberculosis patients in south africa twenty mediumsized primary care tb clinics in the nelson mandela metropolitan municipality port elizabeth eastern cape province south africa 754 adults newly registered as tb patients were enrolled tuberculosis tb patients who received hiv counseling and testing￨providerinitiated hiv counseling and testing providerinitiated human immunodeficiency virus hiv counseling providerinitiated hiv counseling cotrimoxazole providerinitiated optout hiv counseling￨￨providerinitiated hiv counseling significantly increased the proportion of adult tb patients who received hiv counseling and testing but the magnitude of the effect was small￨sig increase￨highunclear￨highunclear￨highunclear
not found￨rural nepal younger women who are either childless or just beginning their childbearing and those with husbands who have little or no education￨￨future intentions to use family planning knowledge of family planning fertility reduction family planning knowledge use and intentions to use family size preferences fertility and mortality child and infant￨increases in knowledge between 1975 and 1978 while controlling for social and demographic variables were greater in the vertical than the integrated areas￨sig increase￨highunclear￨highunclear￨highunclear
not found￨14 control clinics in cape town patients with a new episode of sexually transmitted infection as compared to standard voluntary counseling and testing vct at the primary care level in south africa a high prevalence and low resource setting patients with sexually transmitted infection in cape town south africa 2007 on new sti patients who were offered and who accepted hiv testing patients with sexually transmitted infection sti￨vct approach providerinitiated hiv testing and counseling pitc providerinitiated optout hiv testing and counseling￨proportion of new sti patients tested for hiv￨the effectiveness of providerinitiated hiv testing and counseling pitc for patients with sexually transmitted infection sti in resourceconstrained settings are of particular concern for high hiv prevalence countries like south africa￨sig decrease￨highunclear￨highunclear￨highunclear
1330￨1330 women at seven truckstops participated in the evaluation study women at truck stop in tanzania tanzania among those aged between 15 and 45 years￨￨acceptability and feasibility￨these findings confirm the fact that it is feasible to provide std services to women at high risk in hiv high transmission areas￨sig increase￨highunclear￨highunclear￨highunclear
not found￨eastern zimbabwe￨integrated community and clinicbased hiv1 control communitybased peer education free condom distribution incomegenerating projects and clinicbased sti treatment and counselling services￨lower hiv1 incidence intentiontotreat basis cessation of symptoms incidence rate ratio of hiv1 reduced incidence of selfreported sti symptoms or highrisk sexual behaviour￨no evidence was found for reduced incidence of selfreported sti symptoms or highrisk sexual behaviour in the intervention communities￨no diff￨low￨low￨low
251￨hiv concordant and discordant couples already using condoms for hiv prevention voluntary hiv testing and counseling clinic in lusaka zambia 251 couples hivpositive women hivpositive women who initially selected injectable contraception hiv concordant and discordant couples in zambia￨family planning education and referral to an outside clinic for nonbarrier contraceptives intervention 1 couples received education and offer of contraceptives at the research clinic and intervention 2 couples received intervention 1 plus a presentation designed to reduce outside pressures to conceive nonbarrier contraceptives￨incident pregnancy largely due to high levels of contraceptive discontinuation and user failure contraceptive initiation rate pregnancy rates￨hivpositive women who initially selected injectable contraception were less likely to abandon the method and significantly less likely to conceive than other study participants￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨￨unobtrusive referral message that linked family planning and the expanded program of immunizations epi services￨￨these positive results indicate that the use of referral can have a significant and dramatic impact on family planning services in a relatively short time￨sig increase￨highunclear￨highunclear￨highunclear
7￨two groups were defined according to whether they were born in even or uneven years so that 955 were the control group who delivered 590 rhesus d positive infants and 927 were the treated group who delivered 599 rhesus d positive infants rhesusnegative women 1969 non immunized rhesus negative primiparous women were followed up in 23 maternity units in the geographical region of paris￨antid immunoglobulin preventive treatment of rhd immunization￨￨the incidence of immunisation during or immediately after the first pregnancy in women who had no previous story of blood transfusions or of terminations of pregnancy is 111 which is a figure relatively low as compared with studies of series carried out in north america but close to those carried out in other european centres￨sig decrease￨highunclear￨highunclear￨highunclear
595￨rhdnegative primigravidae￨antepartum lowdose antid immunoglobulin￨alloimmunization immune antid￨nine 15 out of 595 control patients had immune antid at followup at 6 months and later 4 078 of 513 treated women were immunized￨no diff￨highunclear￨highunclear￨highunclear
30￨thirty patients with ards patients with ards acute respiratory distress syndrome￨inhaled nitric oxide inhaled nitric oxide inhno usual care or usual care plus inhno￨30d mortality rate lung function morbidity and mortality alive and weaned from mechanical ventilation hypoxia score venous admixture￨during the first 24 h the hypoxia score increased greatly in patients treated with inhno 704 mm hg 59 versus 142 mm hg 93 for the control group p  002 venous admixture decreased from 257 to 152 in the inhno group and from only 194 to 149 in the control group p  005￨sig decrease￨highunclear￨highunclear￨highunclear
40￨patients with severe acute respiratory distress syndrome adult patients with acute respiratory distress syndrome ards 40 ards patients analyzed doseresponse dr characteristics during longterm inhaled no￨inhaled nitric oxide no nitric oxide conventional therapy control or continuous treatment with 10 parts per million ppm inhaled￨dr curves of pao2fio2 peak improvement in pao2fio2 duration of mechanical ventilation or stay systemic oxygenation pao2fio2 dr curve￨inhaled nitric oxide no improves systemic oxygenation pao2fio2 in adult patients with acute respiratory distress syndrome ards￨sig increase￨highunclear￨highunclear￨highunclear
24￨twentyfour patients with acute bilateral lung disease requiring a positiveend expiratory pressure 6 cm h2o and a fraction of inspired oxygen 05 for 12 h twentysixbed pediatric icu in a tertiary childrens hospital twelve patients were treated with 10 ppm inhaled nitric oxide from the onset of randomization and 12 control patients children with acute hypoxemic respiratory failure children with severe lung disease￨inhaled nitric oxide therapy 10 ppm inhaled nitric oxide inhaled nitric oxide inhaled nitric oxide conventional therapy alone￨ratio of pulmonary to systemic vascular resistance and improved oxygenation indexes oxygenation indexes oxygenation indexes acutely oxygenation indexes hemodynamic and blood gas measurements￨however 24 h after randomization the oxygenation indexes of 11 surviving treated patients were not improved in comparison to baseline or the oxygenation indexes of 10 surviving control patients￨no diff￨highunclear￨highunclear￨highunclear
20￨patients with severe ards patients with acute respiratory distress syndrome ards￨inhaled nitric oxide versus conventional therapy ino therapy conventional therapy or conventional therapy plus ino conventional therapy or inhaled nitric oxide ino￨pao2fio2 fio2 equivalent improvement in pao2fio2￨beyond 24 h the two groups had an equivalent improvement in pao2fio2￨no diff￨highunclear￨highunclear￨highunclear
177￨patients with ards as defined by the americaneuropean consensus conference were enrolled into the study if the onset of disease was within 72 hrs of randomization 177 patients were enrolled over a 14month period patients with acute respiratory distress syndrome ards intensive care units of 30 academic teaching and community hospitals in the united states patients with acute respiratory distress syndrome￨placebo inhaled nitric oxide placebo nitrogen gas or inhaled no inhaled nitric oxide inhaled nitric oxide no￨number or type of adverse events mean inspired nitrogen dioxide concentration mean pulmonary arterial pressure intensity of mechanical ventilation and oxygenation index mortality rate the number of days alive and off mechanical ventilation or the number of days alive after meeting oxygenation criteria for extubation mortality the number of days alive and off mechanical ventilation and the number of days alive after meeting oxygenation criteria for extubation oxygenation index acute response percentage of patients alive and off mechanical ventilation￨there were no differences among the pooled inhaled no groups and placebo with respect to mortality rate the number of days alive and off mechanical ventilation or the number of days alive after meeting oxygenation criteria for extubation￨no diff￨low￨low￨low
385￨three hundred and eightyfive previously healthy adults with ards acute respiratory distress syndrome ards in previously healthy adults fortysix us centers acute respiratory distress syndrome￨5 ppm inhaled nitric oxide or placebo gas inhaled nitric oxide inhaled nitric oxide vs placebo inhaled nitric oxide inhaled nitric oxide and placebo￨low quality of life healthcare costs hospital costs length of stay or therapeutic intervention scoring system points￨at 1 year survivors reported low quality of life with no differences by treatment arm quality of wellbeing score range 01 061 vs 064 for inhaled nitric oxide vs placebo p  11 and poor function with no differences by treatment arm 325 returned to 5 points of baseline activities of daily living range 0100 633 returned to 10 points and the remaining 367 suffered a mean decrement of 27 points￨no diff￨low￨low￨low
23￨patients with ards acute respiratory distress syndrome ards 23 patients with ards patients with acute respiratory distress syndrome￨nitric oxide no inhalation therapy no inhalation alone inhaled nitric oxide 5 ppm rm alone￨pao2fio2 oxygenation and hemodynamic parameters￨the hemodynamics of the patients was not significantly altered during the entire study period￨no diff￨highunclear￨highunclear￨highunclear
108￨children with severe ahrf children with acute hypoxemic respiratory failure ahrf 108 pediatric patients with ahrf defined as an oxygenation index of 15 twice within 6 hrs patients with poor lung inflation acute hypoxemic respiratory failure in pediatrics tertiary pediatric intensive care units at seven academic centers￨hfov alone highfrequency oscillatory ventilation and inhaled nitric oxide mode of ventilation hfov or cmv hfov plus ino cmv plus ino cmv alone conventional mechanical ventilation cmv cmv or hfov with or without ino highfrequency oscillatory ventilation hfov and inhaled nitric oxide ino hfov￨pao fio ratio pao2fio2 ratio oxygenation and survival￨after 72 hrs treatment with hfov alone resulted in a greater improvement in pao2fio2 ratio than either cmv alone or cmv plus ino p 03￨sig increase￨highunclear￨highunclear￨highunclear
268￨43 university and regional hospitals in europe two hundred and sixtyeight adult patients with early ali acute lung injury patients developing severe hypoxaemia two hundred and sixtyeight patients were recruited of which 180 were randomised no responders￨nitric oxide ino nitric oxide conventional treatment with or without ino inhaled nitric oxide￨severe respiratory failure frequency of reversal of ali reversal of ali frequency of reversal of ali mortality￨the mortality at 30 days was 44  for ino patients 40  for control patients p  02 vs ino and 45  in nonresponders￨no diff￨highunclear￨highunclear￨highunclear
32￨a university hospitals general intensive care unit patients who responded to test doses of patients receiving patients with acute lung injury thirtytwo patients with acute lung injury￨inhaled nitric oxide nitric oxide ventilator therapy with and without inhaled nitric oxide inhaled nitric oxide￨activity of nitric oxide synthase total nitrite and lipid peroxides in serum total nitrite inhaled concentration of nitric oxide nitric oxide synthase activity nitric oxide synthase activity was measured spectrophotometrically and myeloperoxidase elastase interleukin8 and leukotrienes pao2fio2 ratio lipid peroxide concentrations￨nitric oxide synthase activity decreased p  01 and total nitrite increased p  02 in patients receiving inhaled nitric oxide￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨￨￨breast cancer screening appears not to affect the rate of mortality from causes of death other than breast cancer￨no diff￨highunclear￨highunclear￨highunclear
77080￨for breast cancer and 55985 women aged 4074 15344 aged 6574 women aged 65 years or over breast cancer screening after age 65 women aged 65 or more who are regularly screened can expect a reduced risk of dying from breast cancer 77080 women aged 4074 21925 aged 6574￨mammographic screening unscreened control group regular mammographic screening￨lead time sensitivity and predicted mortality cumulative mortality breast cancer mortality￨in the age group 6574 at randomisation there was a significant reduction in breast cancer mortality in the screened group with a relative mortality of 068 and 95 confidence interval of 051 to 089￨sig decrease￨highunclear￨highunclear￨highunclear
17786￨17786 women born between 1933 and 1945 7984 women under age 50 at entry into mmst who were born between 1927 and 1932 women under age 50 fifty four percent of these women were randomly invited to screening between 1978 and 1990￨￨breast cancer mortality￨half were assigned to a control group and were not invited for examination until four years after the code was broken in the mmst in 1988￨sig increase￨highunclear￨highunclear￨highunclear
40000￨screened population aged 4064 years age group 5059 years but not yet in age groups 4049 and 6064 years 40000 women aged 4064 years and 20000 women served as a welldefined control group￨repeated mammographic screening￨cumulative number of advanced mammary carcinomas total rate of breast cancer￨the cumulative number of advanced mammary carcinomas in the screening and the control populations from the first five years of screening have shown a tendency towards more favourable stages in the screened population aged 4064 years￨sig decrease￨highunclear￨highunclear￨highunclear
39405￨women aged 50 to 59 years women with invasive breast cancer through to 7 years 217 in the mp group and 184 in the po group had no node involvement 66 and 56 had one to three nodes involved 32 and 34 had four or more nodes involved and 55 and 46 had an unknown nodal status women with no history of breast cancer and no mammography in the previous 12 months women aged 50 to 59 on entry fifteen urban centres in canada with expertise in the diagnosis and treatment of breast cancer 39405 women enrolled from january 1980 through march 1985 were followed for a mean of 83 years￨annual mammography and physical examination mp group or annual physical examination only po group￨nodepositive tumours detection rates ratio of the proportions of death from breast cancer survival rates rate of screendetected breast cancer on first examination highest survival rate rate of death breast cancer detection and death rates rates of referral from screening rates of detection of breast cancer from screening and from community care nodal status tumour size and rates of death invasive breast cancer￨the survival rates were similar in the two groups￨no diff￨low￨low￨low
not found￨￨￨￨the document experts found no evidence of a deliberate attempt to conceal the alterations￨no diff￨highunclear￨highunclear￨highunclear
not found￨mammographic parenchymal pattern classified according to wolfe cancer 197637248692 were obtained from 38757 89 of all women who were invited to undergo mammography in a populationbased screening program in kopparberg county sweden starting in october 1977 women aged 4650 years than in any younger or older age group￨￨prevalence of the highrisk patterns p2 and dy odds ratio or of having a highrisk pattern￨the prevalence of the highrisk patterns p2 and dy was significantly higher in women aged 4650 years than in any younger or older age group￨sig increase￨highunclear￨highunclear￨highunclear
53884￨from age 40 on breast cancer mortality conducted in 23 national health service screening centers between 1991 and 2004 from age 40 or 41 to age 48 7893 women 146 of women the intervention arm and 181 of women attending at least one routine screen eightynine percent of women who had a falsepositive recall at their previous screen attended their next invitation to routine screening 53884 women in the intervention arm of the uk age trial￨mammographic screening annual invitation to mammography￨falsepositive rates rates of falsepositive recall rates of falsepositive mammography falsepositive screen falsepositive recall rates cumulative falsepositive rate￨the rates of falsepositive mammography at first and subsequent routine screens were 49 and 32 respectively￨no diff￨highunclear￨highunclear￨highunclear
not found￨early detection of breast cancer 314 nonpalpable breast lesions were examined by open biopsy between 1978 and 1983￨mammographic screening￨satisfactory initial biopsies￨in a randomized controlled trial with mammographic screening for early detection of breast cancer 314 nonpalpable breast lesions were examined by open biopsy between 1978 and 1983￨no diff￨highunclear￨highunclear￨highunclear
1864770￨￨mammography screening￨relative risks rr for breast cancer death and mortality 511 breast cancer deaths total mortality breast cancer mortality￨the benefit in terms of cumulative breast cancer mortality started to emerge at about 4 years after randomisation and continued to increase to about 10 years￨no diff￨highunclear￨highunclear￨highunclear
282777￨women aged 7074 years screening 282777 women followed for 513 years breast cancer screening with mammography￨￨mortality reduction cumulative breast cancer mortality breast cancer mortality￨in this younger age group cumulative breast cancer mortality was similar in the invited and control group during the first 8 years of followup￨sig decrease￨highunclear￨highunclear￨highunclear
17447￨194 women of 17447 invited women aged 5069 12765 73 attended the screening 97 women the remaining 211 women 17 were referred for clinical and cytological examination 405 women 32 who were recalled for complete mammography￨mammography alone breast cancer screening with mammography￨axillary metastases￨on the basis of the screening films malignancy was suspected in 405 women 32 who were recalled for complete mammography￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨breast cancer screening￨cardiovascular disease and lung cancer mortality￨mortality from all causes cardiovascular disease and lung cancer over the first 5 year period of follow up are examined￨sig decrease￨highunclear￨highunclear￨highunclear
410￨patients with alzheimers disease ad alzheimers disease four hundred ten patients with ad aged 50 years or older two hundred sixtyfive patients completed the entire 26week treatment phase￨cycloserine placebo cycloserine or placebo cycloserine￨incidence and severity of adverse events cognitive drug research cdr efficacy assessments one section of an implicit memory test￨cognitive drug research cdr efficacy assessments showed no differences between active treatments and placebo from baseline to study weeks 2 6 14 or 26￨no diff￨highunclear￨highunclear￨highunclear
not found￨alzheimers disease patients alzheimers disease￨dcycloserine 15 mg dcycloserine￨￨dcycloserine is a partial agonist on the glycine site of the nmethyldaspartate glutamate receptor￨sig increase￨highunclear￨highunclear￨highunclear
17￨seventeen patients with alzheimers disease patients with alzheimers disease￨placebo dcycloserine￨cognitive subscale of the alzheimers disease assessment scale￨dcycloserine was associated with significant improvement in scores on the cognitive subscale of the alzheimers disease assessment scale improvement of 30 points when given at a dose of 100 mgday￨sig increase￨highunclear￨highunclear￨highunclear
not found￨surgery 20 postoperative coronary artery bypass patients suffering uniform injury￨hypertonic saline hs isotonic crystalloid therapy hypertonic saline fluid therapy normal saline ns hypertonic saline￨serum sodium and osmolality volume of hs thoracic losses physiologic endpoints heart rate blood pressure and pulmonary capillary wedge pressure chest tube drainage negative fluid balance positive fluid balance systemic and pulmonary hemodynamic measurements oxygen delivery oxygen consumption and shunt fraction￨systemic and pulmonary hemodynamic measurements oxygen delivery oxygen consumption and shunt fraction did not differ between the two groups￨no diff￨highunclear￨highunclear￨highunclear
7￨￨transurethral resection of the prostate turp hypertonic lactated ringers solution hls with sodium hypertonic lactated ringers solution hls regular lactated ringers solution￨serum sodium concentration hyponatremia and hypoosmolarity serum adh level plasma sodium level and plasma osmolarity￨plasma sodium level and plasma osmolarity decreased significantly in the patients with regular lactated ringers solution group￨sig decrease￨highunclear￨highunclear￨highunclear
52￨52 patients undergoing aortic reconstruction patients undergoing aortic reconstruction￨hsl hypertonic saline solution sodium of 250 milliequivalents per liter hypertonic sodium lactate hypertonic crystalloid hsl to ringers lactate rl￨serum sodium values serum potassium level renal free water clearance duration of operation operative blood loss or transfusion requirement￨there were no differences between the groups in any of the preoperative measurements the duration of operation operative blood loss or transfusion requirement￨no diff￨highunclear￨highunclear￨highunclear
not found￨two groups of 14 patients each undergoing repair of abdominal aortic aneurysm patients undergoing surgery of abdominal aortic aneurysm￨sodium chloride and the conventional fluid regimen with salinebased 6 hydroxyethyl starch solution sodium  potassium  magnesium  calcium  chloride  lactate hypertonic saline dextran normal saline hypertonic saline dextran hsd or a conventional fluid regimen with 250 ml of hydroxyethyl starch in normal saline solution hns sodium chloride 6 dextran 70￨concentrations of sodium potassium magnesium calcium chloride lactate albumin and phosphate metabolic acidosis reduction of bicarbonate metabolic acidosis of equal extent ph paco2 and serum serum sodium acidbase balance￨both hsd and hns caused concomitant and equal decreases in the amount of weak plasma acid strong ion difference and ph 728730￨no diff￨highunclear￨highunclear￨highunclear
60￨patients suffering from hypotension during spinal anesthesia patients undergoing spinal anesthesia i patients scheduled for herniorrhapy under spinal anesthesia sixty asa class￨prehydration with 3 hypertonic saline isotonic lactated ringers solution hypertonic saline hypertonic saline￨level of anesthesia or maximal heart rate and electrolyte imbalance organ perfusion and patient survival arterial blood pressure and heart rate systemic hypotension incidence of hypotension serum electrolyte concentrations hemodynamic changes and serum electrolyte concentrations￨there was no significant difference between two groups in relation to the level of anesthesia or maximal heart rate and electrolyte imbalance did not occur in either group￨no diff￨highunclear￨highunclear￨highunclear
40￨surgical procedures for prostatic hypertrophy transurethral resection of the prostate 40 patients undergoing￨elective transurethral resection of the prostate for either infusion of hs 3 nacl at 4mlkg1min1 hs group or lactated ringers solution lr at 8 mlkg1min1 hypertonic saline solution hs hypertonic saline￨osmolar gap exceeded 10mosmkg1 plasma sodium plasma sodium chloride and osmolality systolic blood pressure heart rate central venous pressure or arterial blood oxygenation plasma sodium￨there were no differences in systolic blood pressure heart rate central venous pressure or arterial blood oxygenation between the two groups￨no diff￨highunclear￨highunclear￨highunclear
62￨after elective abdominal hysterectomy humans sixtytwo women scheduled to undergo abdominal hysterectomy￨hypertonic saline hypertonic saline infusion￨phytohemagglutinininduced lymphocyte proliferation plasma elastase and neutrophil chemotaxis postoperative cellular immune function leukocyte and differential counts flow cytometric phenotyping of mononuclear cells and natural killer cell activity against k 562 tumor cells postoperative cellular immune response￨infusion of a clinically relevant dose of hypertonic saline did not seem to modify the postoperative cellular immune response after elective abdominal hysterectomy￨no diff￨highunclear￨highunclear￨highunclear
40￨40 asa physical status iii patients undergoing arthroscopy or other lower limb surgery under spinal anesthesia￨hyperbaric bupivacaine hypertonic saline hs and 09 normal saline ns in doses containing 2 mmolkg of sodium etilefrine hypertonic saline normal saline etilefrine hypertonic saline￨mean arterial pressure systolic and diastolic blood pressure heart rate and cardiac index plasma sodium concentrations time and the volume of the first micturition serum osmolality￨systolic and diastolic blood pressure heart rate and cardiac index did not differ between the groups and the amount of etilefrine administered was similar in the treatment groups￨no diff￨highunclear￨highunclear￨highunclear
50￨fifty adults undergoing scheduled surgery under spinal anaesthesia 218 patients undergoing spinal anaesthesia in niger patients not suffering arterial hypertension or congestive heart failure￨atropine lidocaine hypertonic saline group hsg or a isotonic saline group isg ephedrine andor atropine spinal anesthesia hypertonic saline hypertonic saline hypertonic saline solution ephedrine bupivacaine 05 or a mixture of both supplemented with fentanyl￨hypotension arterial hypotension adverse clinical effects occurrence of hypotension arterial pressure ap and heart rate hr mean infused volumes of ringer lactate solution￨hypotension occurred in two out of 24 patients of the hsg and eight out of 24 of the isg p  005￨no diff￨highunclear￨highunclear￨highunclear
30￨fluid preloading before lumbar extradural anaesthesia 30 asa i patients undergoing minor orthopaedic surgery￨ephedrine equal amount of sodium hypertonic saline lumbar extradural anaesthesia with isotonic saline ns 5 hypertonic saline hs and ringers lactate rl solutions lignocaine isotonic saline and ringers lactate solutions￨number of blocked segments and the total amount of ephedrine volume and duration of fluid preload heart rate￨heart rate increased significantly in all groups immediately after the fluid preload and remained increased until the end of the study 90 min￨sig increase￨highunclear￨highunclear￨highunclear
33￨patients undergoing transurethral resection of the prostate under spinal anaesthesia thirtythree patients undergoing elective transurethral resection of the prostate￨phenylephrine isotonic saline 7 ml kg1 16 patients or 3 hypertonic saline 7 ml kg1 17 patients as a preload before spinal anaesthesia hypertonic saline prehydration hypertonic saline￨systolic arterial pressure maintain arterial pressure￨after spinal anaesthesia the incidence of systolic arterial pressure  75 of control value was greater in the normal saline group than in the hypertonic saline group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨24 asa 1 patients undergoing elective lower abdominal or pelvic surgery lumbar epidural anesthesia￨equal amounts of sodium 22 mmolkg1 and the latter group isotonic saline solutions epidural anesthesia with 72 hypertonic saline hs lactate ringers lr or isotonic saline solutions epidural injection 2mepivacaine 01 mlcmheight1 fluid loading hypertonic saline infusion￨stroke index extracellular volume volume of fluid loading magnitude of hypotension heart rate number of blocked segments￨magnitude of hypotension was no significantly different among the groups 20 minutes after fluid loading but recovered to the control level in group hs￨no diff￨highunclear￨highunclear￨highunclear
72￨university teaching hospital cardiac surgical patients￨hypertonic saline hs and 09 normal saline ns hypertonic saline elective coronary artery bypass graft surgery￨intraoperative fluid retention weight gain until the first postoperative morning body weight perioperative weight gain￨weight gain until the first postoperative morning was significantly greater in the ns group than in the hs group 19 plus minus 14 kg median 21 kg 08 plus minus 15 kg median 08 kg p  0005￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨operations on the abdominal aorta fiftyeight patients who were to undergo aortic reconstruction￨perioperative fluid replacement with isotonic and hypertonic crystalloid solutions hsl hypertonic balanced salt solution hsl 250 meq sodiuml 514 mosml hypertonic sodium lactate versus lactated ringers solution￨cumulative sodium balance pulmonary cardiac and renal functions serum sodium and osmolarity co urine output or creatinine clearance persistent elevation in serum osmolarity blood loss￨serum sodium and osmolarity were significantly greater in the hsl group p less than 0001 reaching a maximum of 151￨sig increase￨highunclear￨highunclear￨highunclear
152￨students enrolled in a human sexuality course n  152￨computerassisted instruction caibased intervention to a more traditional lecturebased intervention computerassisted instruction no intervention group received no intervention cai lecture or no intervention group￨scales measuring physical outcome motivation and social outcome motivation scales measuring autoimmune deficiency syndrome aids knowledge selfevaluative outcome motivation and intention to practice hiv preventive behaviors with current partner￨in addition compared to the no intervention group the cai group scored significantly higher on the scales measuring physical outcome motivation and social outcome motivation￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨￨￨increased communication is expected to reduce the feeling of guilt and lead to either consistent abstention from sex or consistent contraceptive use￨sig increase￨highunclear￨highunclear￨highunclear
400￨sexually transmitted disease std and human immunodeficiency virus infection in a military std clinic 400 men who attended a large military std clinic￨standard clinic care alone versus standard care combined with 1 of 3 experimental interventions healthrisk appraisal interactive video and targeted situational behaviors￨questionnaire data readiness to change risky partnerselection behavior￨findings indicated that the healthrisk appraisal and interactive video increased adherence with clinic recommendations to abstain from sex chi231991967 p001 and increased readiness to change risky partnerselection behavior chi22194642 p04￨sig increase￨highunclear￨highunclear￨highunclear
not found￨health science classes from four secondary schools in three midwestern states participated in the quasiexperimental study￨computerassisted instruction regular classroom instruction and control group 2 n  93 received no intervention simulationbased cai￨decisionmaking knowledge and behavior assertiveness knowledge and behavior and interpersonal communication knowledge attitude and behavior￨results suggest simulationbased cai provides an instructional approach that promotes positive change in some interaction skills related to responsible sexuality without many of the risks inherent in regular classroom instruction involving such sensitive topics￨sig increase￨highunclear￨highunclear￨highunclear
90￨ninety men men who have sex with men msm in rural areas￨intervention or waitlist control internetdelivered hiv prevention targeting rural msm internetdelivered hiv riskreduction intervention￨hivacquired immune deficiency syndrome aids knowledge selfefficacy and outcome expectancies acceptability and efficacy￨the internet may be important for delivering human immunodeficiency virus hiv risk reduction to men who have sex with men msm in rural areas￨sig increase￨highunclear￨highunclear￨highunclear
not found￨204 human immunodeficiency virusseronegative subjects human immunodeficiency virus1307 physically asymptomatic adults 103 human immunodeficiency virusseropositive subjects after human immunodeficiency virus antibody testing￨psychoeducational interventions stress prevention training standard counseling counseling plus a threesession interactive video program or counseling plus six individual sessions of stress prevention training￨mean distress measures emotional distress￨among the 204 human immunodeficiency virusseronegative subjects mean distress measures decreased significantly after all three interventions without differential treatment effects￨sig decrease￨highunclear￨highunclear￨highunclear
205￨young women early adolescent females recruited through the auspices of a large social services agency with multiple sites across new york city a volunteer sample of 205 black white and hispanic young women participated in this research early adolescent females aged 11 through 14 years￨brief computermediated intervention brief computermediated intervention relative to no intervention￨hivaidsrelated knowledge and risk reduction selfefficacy hivaidsrelated knowledge protective attitudes and selfefficacy for hiv risk reduction hiv risk￨before and after intervention participants completed measures of hivaidsrelated knowledge protective attitudes and selfefficacy for hiv risk reduction￨sig increase￨highunclear￨highunclear￨highunclear
157￨157 college students educationally disadvantaged adolescents adolescents￨custom computerized hivaids risk reduction intervention individualized computerdelivered sexual risk reduction intervention￨hiv prevention information motivation behavioral skills and behavior selfreported condom use risk reduction behavior￨delivery of brief individually tailored hivaids risk reduction interventions via computer may be an effective hivaids prevention approach for adolescents￨sig decrease￨highunclear￨highunclear￨highunclear
300￨adolescent females std risk 300 urban adolescent girls a￨interactive video behavioral intervention standalone interactive video intervention￨condom failures knowledge about sexually transmitted diseases stds b selfreported sexual risk behavior and c std acquisition￨selfreports revealed that those assigned to the interactive video were significantly more likely to be abstinent in the first 3 months following initial exposure to the intervention and experienced fewer condom failures in the following 3 months compared to controls￨sig decrease￨highunclear￨highunclear￨highunclear
326￨three hundred and twentysix tenthgrade males and females enrolled in two rural appalachian public high schools completed the survey at both points in time rural adolescents￨￨general knowledge greater condom negotiation selfefficacy situational selfefficacy￨regarding the effects of the intervention results indicate that students in the experimental school were less likely to initiate sexual activity and had greater general knowledge greater condom negotiation selfefficacy more favorable attitudes toward waiting to have sex and greater situational selfefficacy than in the control school￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨one hundred and fifteen patients from 5 general practices￨ltryptophan amitriptyline and a combination of ltryptophan and amitriptyline with placebo placebo ltryptophan amitriptyline ltryptophanamitriptyline combination and placebo amitriptyline￨hamilton depression scale and a global rating of depression plasma amitriptyline and nortriptyline levels mean heart rate standard haematological and biochemical profiles free or total plasma tryptophan concentration￨sideeffects necessitated withdrawal of more patients from the amitriptyline group than from the other active treatment groups but this difference was not significant￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with pc9 patients with progressive pc from gastric n  6 and ovarian cancer n  2 and cancer of unknown primary n  1 received patients with peritoneal carcinomatosis￨trab  autologous pbmc  irradiated autologous tumor cells trab 3 escalating doses of trab after surgery andor ineffective chemotherapy her2neu x cd3￨mean survival tumor reactive cd4cd8 tlymphocytes immunological reactivity￨in 5 of 9 patients tumor reactive cd4cd8 tlymphocytes increased significantly indicating specific antitumor immunity￨sig increase￨highunclear￨highunclear￨highunclear
33￨thirtythree patients were available for ab3 analysis removed for progression of disease 6 withdrawal of consent 2 unrelated adverse event 1 patients with epithelial ovarian fallopian tube or primary peritoneal cancer eligible patients from the three participating institutions were any stage at diagnosis had relapsed and had complete or partial response to additional chemotherapy￨abagovomab antiidiotypic monoclonal antibody abagovomab formerly aca125￨safety and immunogenicity primarily determined by ab3 response safety and immunogenicity selflimited pain at injection site myalgia and fever hematologic or nonhematologic toxicity human antimouse antibody interval physical examinations and laboratory assessments with immune assessment including hla typing human antimouse antibody elisa and enzymelinked immunospot￨ab3 was detectable in all patients median 236794 ngml none of route of administration p06268 dose p04602 or cohort p04944 was statistically significant in terms of effect on maximum postbaseline ab3 titer￨no diff￨highunclear￨highunclear￨highunclear
11￨patients with epithelial ovarian fallopian tube or peritoneal cancer eleven patients were included in the safety analysis 9 of 11 patients remained on study for at least 2 weeks past fourth vaccination and were included in the immunologic analysis two withdrew disease progression patients with epithelial ovarian fallopian tube or peritoneal cancer in second or greater complete clinical remission￨heptavalent vaccine sc heptavalent vaccinekeyhole limpet hemocyanin conjugate plus qs21 containing gm2 heptavalent antigenkeyhole limpet hemocyanin klh plus qs21 vaccine klh conjugate plus qs21 vaccine￨reactivity against mcf7 cells antibody titers selflimited and mild fatigue safety complete blood count comprehensive panel amylase thyroidstimulating hormone and urinalysis and antibody production elisa fluorescenceactivated cell sorting and complementdependent cytotoxicity median igm titers tolerated fever myalgia and localized injection site reactions antibody responses hematologic abnormalities￨fluorescenceactivated cell sorting and complementdependent cytotoxicity analysis showed substantially increased reactivity against mcf7 cells in seven of nine patients with some increase seen in all patients￨sig increase￨highunclear￨highunclear￨highunclear
25￨ovarian cancer patients with a ovarian cancer patients in an adjuvant setting 25 patients were immunized with a￨lewisy pentasaccharide leykeyhole limpet hemocyanin klhconjugate vaccine leyklh synthetic lewisyprotein conjugate vaccine￨antiley antibodies tolerated and no gastrointestinal hematologic renal or hepatic toxicity￨the vaccine was well tolerated and no gastrointestinal hematologic renal or hepatic toxicity related to the vaccine was observed￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨￨cellular immune response￨the t cells primed by mab wj02 or ca125 proliferated in the presence of ca125 or mab wj02 respectively￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with epithelial ovarian cancer in highrisk first remission highrisk hlaa0201positive epithelial ovarian cancer patients highrisk epithelial ovarian cancer patients in first clinical remission received patients with both nyeso1positive and nyeso1negative tumors￨hlaa0201restricted nyeso1b peptide nyeso1b peptide and montanide nyeso1b peptide and montanide isa51 vaccination￨median progressionfree survival complete clinical remission grade 1 fatigue anemia pruritus myalgias and hyperthyroidism and grade 2 hypothyroidism nyeso1 specific humoral immunity elisa tcell immunity tetramer and elispot and delayedtype hypersensitivity toxicity tumor expression grade 3grade 4 adverse events￨there were no grade 3grade 4 adverse events￨no diff￨highunclear￨highunclear￨highunclear
25￨25 patients treated with a poxviral vaccine regimen consisting of the genes for patients with metastatic carcinoma￨cea and muc1 along with a triad of costimulatory molecules tricom composed of b71 intercellular adhesion molecule 1 and lymphocyte functionassociated antigen 3 engineered into vaccinia panvacv as a prime vaccination and into fowlpox panvacf vaccination with recombinant ceamuc1tricom poxviralbased vaccines poxviral vaccines muc1￨vaccine safety with immunologic and clinical responses grade  or 2 toxicity tolerated￨carcinoembryonic antigen cea and muc1 are overexpressed in a substantial proportion of common solid carcinomas￨sig increase￨highunclear￨highunclear￨highunclear
10￨patients with advanced breast and ovarian cancer patients with cancer using dendritic cells dcs patients with breast and ovarian cancer￨￨cea and mage3 peptidespecific tcell responses immunologic responses peptidespecific cytotoxic t lymphocytes ctls￨in 5 of 10 patients peptidespecific cytotoxic t lymphocytes ctls could be detected in the peripheral blood using both intracellular ifngamma staining and 51crrelease assays￨sig increase￨highunclear￨highunclear￨highunclear
26￨patients with evaluable disease eligibility criteria included a residual disease at the end of chemotherapy b relapsed disease and c pathologically confirmed second complete remission following salvage chemotherapy all patients had undergone standard debulking surgery where appropriate and at least one regimen of 26 patients with ovarian cancer ovarian cancer￨idiotypic vaccination using the murine monoclonal antibody hmfg1 antimuc1 hmfg1 idiotypic vaccination with hmfg1 platinumbased chemotherapy￨serious adverse events safety and tolerability￨elisa for antiidiotypic antibodies ab2 showed significant levels in patients who completed the protocol￨sig increase￨highunclear￨highunclear￨highunclear
not found￨18 hladp4 eoc patients with minimal disease burden patients with eoc ovarian cancer￨eso157170 mixed with incomplete freunds adjuvant montanide isa51 cognate helper cd4 t cells vaccineinduced cd8 and cd4 t cell clones￨serious vaccinerelated adverse events longlived and functional vaccineelicited cd8 and cd4 t cells￨vaccineinduced cd8 and cd4 t cell clones were shown to recognize nyeso1expressing tumor targets￨sig increase￨highunclear￨highunclear￨highunclear
not found￨women with recurrent ovarian cancer patients with recurrent ovarian cancer 44 patients who were treated with￨murine monoclonal antibodyb4313 technetium 99mlabeled monoclonal antibodyb4313 a murine monoclonal antibody￨biologic activity survival times median survival time survival rates no serious drugassociated adverse events￨median survival time increased approximately 3fold for human antimurine antibody responders 226 months versus nonresponders 72 months p 0016 logrank test and 2fold for ab2 responders 183 months versus nonresponders 93 months￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with nyeso1expressing epithelial ovarian cancer￨cd4cd25 regulatory t cells vaccination with nyeso1157170 peptide emulsified in ifa￨lowhighavidity cd4 t cells cd4 t cells specific hladp4restricted cd4 t cell responses￨specific hladp4restricted cd4 t cell responses were elicited after vaccination with nyeso1157170 peptide emulsified in ifa in patients with nyeso1expressing epithelial ovarian cancer￨sig increase￨highunclear￨highunclear￨highunclear
36￨36 patients with recurrent oc comparing two subcutaneous sc patients with recurrent ovarian cancer￨vaccination schedules nine group l versus six injections￨immunological response dropout rate due to toxicity safe and well tolerated toxicities ifngammaexpressing ca125specific cd8 tcells ab3induction and cellular cytotoxicity premature termination occurred due to patient withdrawal or disease progression cd4 tcells￨there were no differences between the groups with regard to induction of human antimouse antibody p  01006￨no diff￨highunclear￨highunclear￨highunclear
7￨breast and ovarian cancer patients after highdose chemotherapy stem cell rescue and immunization with theratope stnklh cancer vaccine seven ovarian and 33 breast highrisk stage iiiii and stage iv cancer patients 27 evaluable patients who received at least three immunotherapy treatments￨highdose chemotherapy immunotherapy treatment with theratope stnklh cancer vaccine￨antistn th1 antigenspecific tcell response elevated ca2729 muc1 mucin serum levels lytic activity of peripheral blood lymphocytes pbls ca125 levels igg antistn titers￨eleven of the 26 patients tested had evidence of an antistn th1 antigenspecific tcell response as determined by interferongamma but not interleukin il4 production￨sig increase￨highunclear￨highunclear￨highunclear
119￨119 patients with advanced ovarian carcinoma patients with advanced ovarian carcinoma with the antiidiotype aca125￨antiidiotypic antibody vaccine aca125 vaccine aca125￨specific antiantiidiotypic antibody ab3 response safety and immunogenicity ca125specific antibodies ab1 and antibodydependent cellmediated cytotoxicity of ca125positive tumor cells median survival tolerated longer survival￨ab3positive patients showed a significantly longer survival median 234 months p  00001 as compared with ab3negative patients median 49 months￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients injected with mabb4313evidence for antibodymediated antigenprocessing and presentation of ca125 in vivo￨￨survival induction of humoral and cellular antica125 responses generation of ca125specific b and t cell responses induction of ca125specific b and t cell responses￨the generation of ca125specific b and t cell responses after mabb4313 injection correlated with improved survival￨sig increase￨highunclear￨highunclear￨highunclear
not found￨nine participants with epithelial ovarian fallopian tube or primary peritoneal carcinoma who were human leukocyte antigen hlaa1 hlaa2 or hlaa3 patients with ovarian cancer participants with advanced stage ovarian cancer￨5 class i major histocompatibility complexrestricted synthetic peptides derived from multiple ovarian cancerassociated proteins plus a class ii major histocompatibility complexrestricted synthetic helper peptide derived from tetanus toxoid protein granulocyte macrophagecolony stimulating factor in montanide isa51 adjuvant multipeptide vaccine￨headache safety and immunogenicity toxicities cd8 tcell responses￨cd8 tcell responses were detected in 1 participant ex vivo and in 8 of 9 participants 89 after in vitro stimulation￨sig increase￨highunclear￨highunclear￨highunclear
58￨58 patients with advanced ovarian carcinomas ovarian cancer patients ovarian carcinoma patients with advanced stages of ovarian carcinoma patients with advanced ovarian carcinoma who had received mab against the cancerassociated antigen ca125 for diagnostic purposes￨monoclonal antibodies and idiotypic network activation￨production of antiidiotypic antibodies survival rate and immunological effects￨the network structure of the immune system implicates the possibility of a selective immunization by the activation of idiotypic cascades￨sig increase￨highunclear￨highunclear￨highunclear
10￨human ovarian cancer patients against a common carcinoma thomsenfriedenreich nine of the ten ovarian cancer patients ten ovarian cancer patients with extensive metastatic disease despite chemotherapy￨klh immunodominant disaccharide beta gal13 alpha galnac of the thomsenfriedenreich antigen conjugated to klh tf alphaklh plus detox adjuvant low dose of tf alphaklh single lowdose cyclophosphamide treatment synthetic carbohydrate antigen synthetic tf alpha hapten￨toxicity humoral immune responses moderate to strong dth reactions igm titer above preexisting levels cytotoxic antibodies against tfexpressing tumor cell targets vigorous igg response igm antibodies against the synthetic tf alpha hapten￨all four highdose and four of six lowdose patients developed moderate to strong dth reactions at the vaccination sites￨no diff￨highunclear￨highunclear￨highunclear
not found￨85 metastatic breast ovarian and colorectal cancer patients ovarian cancer patients metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic stn vaccine breast cancer patients colorectal cancer patients breast and colorectal cancer patients who had the highest antiosm antibody titers￨cyclophosphamide lowdose intravenous cyclophosphamide enzymelinked immunosorbent assay￨antiklh antibody titers with survival increased antiosm igg titers longer survival and generated higher antiosm antibody titers antiosm antibody titers antiosm immunoglobulin m igm titer increased preasi ca125 serum levels survival￨the postimmunization increase in antiosm immunoglobulin m igm titer was independently associated with longer survival of the colorectal cancer patients￨sig increase￨highunclear￨highunclear￨highunclear
13￨eligibility criteria included recurrence after one or more platinumbased chemotherapy regimens ca125 35 uml evaluable or measurable disease heavily pretreated patients with recurrent ovarian cancer oc recurrent oc recurrent ovarian cancer thirteen women were administered￨oregovomab ovarex concomitant chemotherapy intravenous oregovomab oregovomab oregovomab murine monoclonal antibody to ca125￨tolerated without serious adverse events stabilization of disease and survival 2 years shrinkage of marker lesions tumor burden ca125 levels immune responses including antibodies and t cells to oregovomab and ca125￨immune responses including antibodies and t cells to oregovomab and ca125 were demonstrated in over half the patients￨sig increase￨highunclear￨highunclear￨highunclear
3￨ovarian cancer patients five ovarian cancer patients￨multiple injections of unconjugated chimeric monoclonal antibody mov18￨increased adcc levels cd4 and cd8 fractions cellular and humoral responses adcc activity of cmov18 il2
                toxicity cd4cd8 ratio and the levels of cd25 peripheral blood mononuclear cells pbmc￨cmov18 did not have a mitogenic effect on patients pbmc and adding il2 did not change the degree of proliferation￨no diff￨highunclear￨highunclear￨highunclear
20￨ovarian cancer patients twenty patients with recurrent elevation of ca125 were included eighteen of whom were immunized 4 times with 10 overlapping p53slp in montanide isa51￨p53 synthetic long peptide vaccine p53 synthetic long peptide p53slp vaccine p53slp vaccine immunotherapy￨p53specific tcell responses toxicity safety tolerability immunogenicity p53specific immune responses p53specific response ifngamma producing p53specific tcell responses ca125 levels and ctscans p53specific tcells overall toxicity￨ifngamma producing p53specific tcell responses were induced in all patients who received all 4 immunizations as measured by ifngamma elispot￨sig increase￨highunclear￨highunclear￨highunclear
145￨patients with stage iiiiv ovarian cancer who had a complete clinical response to primary treatment advanced ovarian cancer one hundred fortyfive patients were treated with patients with advanced ovarian cancer￨oregovomab placebo oregovomab or placebo￨time to relapse ttr adverse events immune responses quality of life ttr overall median ttr￨for the population overall median ttr was not different between treatments at 133 months for oregovomab and 103 months for placebo p 71￨no diff￨low￨low￨low
5￨patients with recurrent gynecologic cancers￨peptide vaccination vaccination with predesignated or evidencebased peptides￨clinical response grade 1 adverse effects grade 3 adverse effect ie rectal bleeding peptidespecific cytotoxic t lymphocytes￨with this regimen grade 1 adverse effects were observed in eight patients a grade 2 adverse effect in one patient and a grade 3 adverse effect ie rectal bleeding in one patient￨no diff￨highunclear￨highunclear￨highunclear
20￨patients with recurrent ovarian cancer patients with advanced recurrent ovarian cancer oregovomabtreated recurrent ovarian cancer patients twenty patients were enrolled median followup was 158 months￨oregovomab and chemotherapy oregovomab combined oregovomab and chemotherapy oregovomab￨median progressionfree interval tcell responses immune responses median survival antibody responses including human antimouse antibody hama antiidiotypic antibody ab2 and antica125 elisa tcell responses to ca125 autologous tumor and oregovomab by interferon ifngamma enzymelinked immunospot elispot robust treatmentemergent humoral responses survival benefit survival tolerated and induced multiple antigenspecific immune responses￨significant increases in tcell responses were measured in 718 39 patients in response to ca125 in 58 63 patients in response to autologous tumor and in 918 50 patients in response to oregovomab￨sig increase￨highunclear￨highunclear￨highunclear
373￨patients with stage iii to iv ovarian cancer with preoperatively elevated ca125 and objectively defined characteristics three hundred seventythree patients were accrued at more than 60 centers 251 patients were assigned to oregovomab and 120 patients advanced ovarian cancer patients with advanced ovarian cancer￨carboplatin and paclitaxel chemotherapy placebo oregovomab or placebo oregovomab maintenance monoimmunotherapy￨grade 3 to 4 toxicity median ttr tolerated￨grade 3 to 4 toxicity was reported in 246 of patients in the placebo group and 201 of patients in the oregovomab group respectively￨no diff￨low￨low￨low
not found￨patients with chronic stable schizophrenia chronic schizophrenia patients with stable chronic schizophrenia over a 1year period inpatients￨placebo ziprasidone ziprasidone￨panss negative symptom subscale positive and negative syndrome scale panss efficacy variables probability of relapse kaplanmeier frequency of relapse weight gain or cardiovascular abnormalities￨ziprasidone treatment was indistinguishable from placebo in assessments of movement disorders and was not associated with weight gain or cardiovascular abnormalities￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨￨￨the data obtained from this study have tended to confirm the impression of previous investigators that penfluridol administered in a dosage of 40 to 80 mg on a onceaweek basis in a single dose compares favorably with the antipsychotic activity of those neuroleptics requiring administration on a daily basis￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with schizophrenia mean age  40 years 55 men 66 white and mean transition baseline panss total score sd placebo 695 1689 paliperidone palmitate 693 1739 adults with schizophrenia eligible patients positive and negative syndrome scale panss total score  120 were transitioned from previous antipsychotics to 312 patients￨paliperidone palmitate placebo paliperidone palmitate maintenance paliperidone palmitate injectable atypical antipsychotic paliperidone palmitate continue paliperidone palmitate￨delayed timetorelapse timetorelapse delaying timetorelapse incidence of glucoserelated adverse events mean weight efficacy and tolerability injection site tolerability hazard ratio placebopaliperidone palmitate￨timetorelapse primary endpoint favored paliperidone palmitate p00001 logrank test at interim and final analysis n408￨sig increase￨low￨low￨low
10￨thirtyfive schizophrenic outpatients over the age of 52 who had been stable on neuroleptic medication 23 patients older outpatient schizophrenics￨haloperidol or placebo neuroleptic medication haloperidol placebo￨￨among the patients who completed the study five of 10 randomized to placebo relapsed compared with only one of eight randomized to haloperidol￨sig increase￨highunclear￨highunclear￨highunclear
327￨patients with clinically stable schizophrenia three hundred twentyseven clinically stable patients with schizophrenia clinically stable patients psychotic relapse in schizophrenia patients who were clinically stable for four months￨openlabel quetiapine xr placebo quetiapine xr quetiapine fumarate quetiapine xr quetiapine xr and placebo quetiapine fumarate quetiapine xr￨risk of relapse at six months estimated risk of relapse incidence of treatmentrelated adverse events aes time to relapse time to first schizophrenia relapse￨time to relapse was significantly longer in quetiapine xrtreated patients versus placebo hazard ratio 016￨sig increase￨low￨low￨low
700￨stable schizophrenia patients dsmivtr criteria may 2005 through june 2008 700 enrolled patients treated with openlabel asenapine 386 entered asenapine n  194 placebo n  192 and 207 completed n  135 n  72 the doubleblind phase￨placebo asenapine or switch to placebo asenapine￨positive and negative syndrome scale and the clinical global impressionsseverity of illness scale and discontinuation for any reason insomnia time to relapseimpending relapse anxiety safe and well tolerated incidence of clinically significant weight gain schizophrenia relapse extrapyramidal symptomrelated aes increased weight times to relapseimpending relapse and discontinuation incidence of relapseimpending relapse relapse of schizophrenia￨longterm treatment with asenapine was more effective than placebo in preventing relapse of schizophrenia and appeared to be safe and well tolerated￨sig increase￨low￨low￨low
178￨early psychosis outpatient clinics in hong kong remitted patients with first episode psychosis who either continued or discontinued antipsychotic drugs after at least one year of maintenance treatment patients with remitted first episode psychosis 178 patients with first episode psychosis who had received at least one year of antipsychotic drug treatment between september 2003 and july 2006 and had no positive symptoms of psychosis 178 patients￨placebo quetiapine and 89 to placebo quetiapine￨rate of discontinuation due to adverse or serious adverse events risk of relapse relapse assessed monthly and defined as reemergence of psychotic symptoms delusions conceptual disorganisation hallucinations suspiciousness and unusual thought content rate of relapse￨although quetiapine was generally well tolerated the rate of discontinuation due to adverse or serious adverse events was greater in the quetiapine group 18 1689 than in the placebo group 8 789 relative risk 229 95 confidence interval 099 to 528 chi2320 df1 p007￨sig increase￨low￨low￨low
not found￨twenty eight chronic schizophrenics schizophrenic patients schizophrenia￨haloperidol placebo penfluridol or placebo penfluridol maintenance therapy￨￨evaluation of the results showed no significant differences between the two groups or between the baseline and the final ratings in each group￨no diff￨highunclear￨highunclear￨highunclear
310￨patients with chronic stable schizophrenia stabilized patients with chronic schizophrenia dec 21 2000 and aug 20 2001 310 patients with dsmiv schizophrenia mean positive and negative syndrome scale panss total score  82 adult chronic schizophrenia patients experiencing ongoing stable symptomatology￨aripiprazole placebo aripiprazole 15 mg or placebo aripiprazole￨hyperprolactinemia or prolonged heart ratecorrected qt interval qtc extrapyramidal symptoms time to relapse panss total panss positive panssderived brief psychiatric rating scale and clinical global impressionsseverity of illness scale cgis scores modest mean weight loss time to relapse following randomization efficacy safety and tolerability mean clinical global impressionsglobal improvement scale scores relative risk of relapse￨aripiprazole was significantly superior to placebo from baseline to endpoint in panss total panss positive panssderived brief psychiatric rating scale and clinical global impressionsseverity of illness scale cgis scores and demonstrated significantly better mean clinical global impressionsglobal improvement scale scores p  or  01 for all comparisons except cgis￨sig increase￨low￨low￨low
253￨253 patients fulfilling criteria for a first episode of schizophrenic illness 120 entered a randomised￨placebo maintenance neuroleptic medication prophylactic neuroleptic treatment￨￨of those on active medication 46 relapsed as did 62 of those on placebo the most important determinant of relapse was duration of illness prior to starting neuroleptic medication￨sig increase￨highunclear￨highunclear￨highunclear
27￨27 chronic schizophrenic patients successfully treated for more than 2 years with chronic schizophrenic patients schizophrenic patients￨fluphenazine placebo fluphenazine decanoate￨relapse rate￨these patients showed a significantly higher relapse rate than the matched control group of 26 patients who continued to receive fluphenazine 56 versus 19 p less than 001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨fiftysix chronic schizophrenic patients￨haloperidol decanoate hd or placebo haloperidol placebo haloperidol decanoate vs placebo￨sedatives extrapyramidal symptoms haloperidol plasma concentration mean steadystate level steady state plasma concentrations of haloperidol mean haloperidol plasma concentration￨in the placebo group a 50 decrease in the mean haloperidol plasma concentration was seen 8 weeks after withdrawal of haloperidol￨sig decrease￨highunclear￨highunclear￨highunclear
36￨thirtysix neuroleptictreated patients underwent a patients with covert dyskinesia￨placebocontrolled acute iv challenge with 2 mg benztropine and a placebo benztropine placebo oral benztropine mesylate benztropine benztropine mesylate intravenous iv and oral￨dyskinesia and dysphoric mood dyskinesia ratings and symptom measures dyskinesia and symptom measures dyskinesia scores and dysphoria￨there was a striking absence of correlation between dyskinesia change measures brought about by benztropine and changes following neuroleptic withdrawal￨no diff￨highunclear￨highunclear￨highunclear
not found￨population of outpatients who had recently recovered from an acute episode of schizophrenia schizophrenia￨placebo maintenance therapy phenothiazines￨￨the drug was shown to be significantly more effective than the placebo in preventing relapse￨sig increase￨highunclear￨highunclear￨highunclear
not found￨female patients whose illness started after the age of 40 1 12 years on 30 schizophrenics who had hitherto continuously received neuroleptics and remained apparently in full remission for at least 35 years￨benzodiazepines and neuroleptics benzodiazepine￨relapse rate￨the benzodiazepinegroup had a significantly higher relapse rate than the neurolepticgroup meaning that we cannot stop neuroleptics for these patients yet￨sig decrease￨highunclear￨highunclear￨highunclear
17￨chronic schizophrenic patients patients by ward nurses 17 chronic schizophrenic inpatients with a control group of 14 patients remaining on active medication￨phenothiazine placebo phenothiazine￨￨of the placebo group 35 relapsed relapse being related to the level of previous active medication￨sig decrease￨highunclear￨highunclear￨highunclear
121￨121 patients with chronic schizophrenia and a history of recurrence in the previous 18 months chronic schizophrenia patients with chronic schizophrenia￨zotepine placebo zotepine and placebo zotepine￨level of eps time to recurrence brief psychiatric rating scale bprs the scale for the assessment of negative symptoms sans the clinical global impression cgi severity and improvement scales and the simpson and angus scale for extrapyramidal symptoms eps recurrence estimated 26week risk of recurrence￨the estimated 26week risk of recurrence was six times lower for zotepine than placebo 87 versus 528 hazard ratio 016 95 ci 0053 0484 p0001￨sig decrease￨low￨low￨low
57￨57 schizophrenic outpatients lasting 6 months 2 a doubleblind placebocontrolled discontinuation study in a subgroup of patients who maintained good remission throughout the entire 6month open trial￨fluphenazine decanoate￨psychotic relapse￨to test the clinical efficacy of low dose fluphenazine decanoate 125 mg to 50 mg biweekly we carried out two separate experiments 1 an open trial in 57 schizophrenic outpatients lasting 6 months 2 a doubleblind placebocontrolled discontinuation study in a subgroup of patients who maintained good remission throughout the entire 6month open trial￨sig increase￨highunclear￨highunclear￨highunclear
not found￨chronic schizophrenics￨neuroleptic treatment neuroleptics neuroleptic￨brief psychiatric rating scale￨for total scores on the tdi we were unable to demonstrate a significant reduction in thought pathology although it was evident that thought disorder as reflected in the conceptual disorganization and unusual thought content subscales of the brief psychiatric rating scale is significantly reduced by neuroleptics￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨placebo￨risk of relapse mean rate of life events leds scale￨a proportional hazards regression model showed that life events made a significant cumulative contribution over time p  005 to the risks of relapse and that ceasing medication made an independent contribution￨sig increase￨highunclear￨highunclear￨highunclear
41￨chronic schizophrenic patients 41 chronic schizophrenic outpatients￨placebo neuroleptics fluphenazine decanoate or flupenthixol decanoate fluphenazine decanoate depot fluphenazine decanoate and depot flupenthixol decanoate flupenthixol decanoate￨weight decrease relapse relapse and readmission to hospital￨drugs were significantly more effective than placebo in preventing relapse and readmission to hospital￨sig increase￨highunclear￨highunclear￨highunclear
583￨participants were stable minimally symptomatic outpatients with schizophrenia or schizoaffective disorder patients with psychotic disorders remitted stabilized patients with schizophrenia or schizoaffective disorder￨placebo olanzapine placebo 4day to 9day screeningevaluation n  583 2 6week conversion to openlabel olanzapine antipsychotic therapy￨6month cumulative estimated relapse rate kaplanmeier psychotic relapse longer time to relapse brief psychiatric rating scale bprs positive item cluster or rehospitalization due to positive symptoms￨the olanzapine group had a significantly longer time to relapse p  00001 than the placebo group￨sig decrease￨low￨low￨low
not found￨55 schizophrenics in remission symptomfree schizophrenics￨imipramine psychotropic drugs haloperidol 3 mg haloperidol placebo chlorpromazine and haloperidol diazepam neuroleptics chlorpromazine placebo diazepam or imipramine placebo diazepam 15 mg imipramine 50 mg chlorpromazine￨remission state number of days of remission￨at the end of the 3year trial both chlorpromazine and haloperidol significantly prolonged the remission state as compared to the other three drugs￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨twentyeight patients who had recently recovered from an acuteonset firstepisode schizophrenic illness patients with remitted acute firstepisode schizophrenia￨fluphenazine vs placebo placebo fluphenazine hydrochloride or decanoate or placebo￨psychotic relapse relapse second psychotic relapse￨eighteen 69 of the 26 patients available for followup mean interval 35 years experienced a second psychotic relapse either during the study or afterward and 50 1428 of the original sample experienced a third episode￨no diff￨highunclear￨highunclear￨highunclear
not found￨chronic schizophrenic outpatients chronic schizophrenic female outpatients￨pimozide placebo thiordazine￨headache and restlessness social adjustment ratings sedation ekg and liver function abnormalities extrapyramidal symptoms and insomnia￨social adjustment ratings on a special scale completed by the patients and families alike were also found to be insensitive to treatment differences￨no diff￨highunclear￨highunclear￨highunclear
not found￨symptomfree schizophrenics remitted schizophrenic outpatients￨propericiazine haloperidol placebo haloperidol and propericiazine haloperidol or propericiazine haloperidol placebo haloperidol neuroleptics propericiazine￨serum prolactin levels relapse rate prolactin levels number of symptomfree days dose￨propericiazine at 10 mg and 30 mg also increased the number of symptomfree days dosedependently but at 60 mg the number decreased￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨12 recent onset clinically stable schizophrenics who had been given￨fluphenazine placebo fluphenazine decanoate￨mean fluphenazine levels notable plasma fluphenazine levels plasma fluphenazine levels￨mean fluphenazine levels between drug continuation and withdrawal conditions showed a progressively larger difference over time although significant differences were not seen until week 8￨sig increase￨highunclear￨highunclear￨highunclear
not found￨remitted firstepisode schizophrenia patients schizophrenia patients remitted outpatients with a schizophrenic disorder stable remitted firstepisode schizophrenia patients￨antipsychotic treatment antipsychotic prophylaxis antipsychotic medication￨relapse risk cumulative relapsefree survival risk of relapse￨the cumulative relapsefree survival was 88 se  012 in the continuation and 18 se  012 in the discontinuation group p  0001 at 9 months followup￨no diff￨highunclear￨highunclear￨highunclear
not found￨chronic schizophrenic patients chronic schizophrenic outpatients chronic schizophrenic patients with longacting￨fluphenazine placebo phenothiazine fluphenazine decanoate￨relapse￨relapse was accompanied by a resurgence of specifically schizophrenic symptoms and by an increase in abnormalities described by the relatives￨sig decrease￨highunclear￨highunclear￨highunclear
49￨49 schizophrenic patients￨maintenance antipsychotic medication￨psychosocial distress schizophrenic symptoms￨a poor outcome at 2 years was associated with male sex poor outcome after the first 5 weeks of the first admission negative schizophrenic symptoms on first admission and a diagnosis of definite or probable schizophrenia using the feighner criteria￨sig increase￨highunclear￨highunclear￨highunclear
51￨fiftyone children 32m 19f age and gender matched 10 to 13 years children with class ii division 1 malocclusions treated with functional appliances if according to the￨fränkel function regulators or one treated with harvold activators￨lateral cephalometric radiographs taken peer assessment rating par index par index par scores￨the par scores decreased by more than 30 in 33 of the fränkel group and by 75 in the harvold group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨children with severe 7 mm overjet class ii malocclusions who initially were developmentally at least a year before their peak pubertal growth favorable growth changes were observed in about 75 of those receiving early treatment with either a headgear or a functional appliance￨comprehensive fixed appliance treatment￨skeletal change alignment and occlusion of the teeth or length and complexity of treatment￨the differences created between the treated children and untreated control group by phase 1 treatment before adolescence disappeared when both groups received comprehensive fixed appliance treatment during adolescence￨sig increase￨highunclear￨highunclear￨highunclear
not found￨children enrolled in a randomized controlled trial of early treatment for class ii malocclusion children aged 96￨headgearbiteplane bionator￨anteroposterior skeletal and dental changes￨our data reveal that both bionator and headgear treatments corrected class ii molar relationships reduced overjets and apical base discrepancies and caused posterior maxillary tooth movement￨sig increase￨highunclear￨highunclear￨highunclear
174￨174 children aged 8 to 10 years old with class ii division 1 malocclusion￨twinblock appliance or to an untreated control group early orthodontic treatment with the twinblock appliance￨overjet and severity of malocclusion reduction of overjet correction of molar relationships and reduction in severity of malocclusion￨this study evaluated the effectiveness of early orthodontic treatment with the twinblock appliance for the developing class ii division 1 malocclusion￨sig increase￨highunclear￨highunclear￨highunclear
47￨twentyseven 14 girls 13 boys￨￨sagittal skeletal relationship dental movement favourable growth responses posterior facial heights￨both anterior and posterior facial heights were increased without changes in the inclinations of the palatal and mandibular planes￨no diff￨highunclear￨highunclear￨highunclear
26￨patients in development period with class ii division 1 malocclusion 26 treated children and 26 untreated children￨bionator headgear combination appliance bionator headgear combination appliances￨horizontal mandibular growth development￨the results showed that anb angle was significantly reduced and horizontal mandibular growth development tended to be normal in the treated group￨sig decrease￨highunclear￨highunclear￨highunclear
215￨215 patients aged 1114 years class ii malocclusion with the herbst or twinblock appliances orthodontic departments in the united kingdom established class ii division i malocclusion￨herbst and twinblock appliances herbst or the twinblock appliance￨lower failuretocomplete rate final occlusal result and skeletal discrepancy skeletal and dental changes￨there were no differences in skeletal and dental changes between the appliances however the final occlusal result and skeletal discrepancy were better for girls than for boys￨no diff￨highunclear￨highunclear￨highunclear
47￨47 adolescent patients￨bass bionator and twin block appliances bionator twin block or bass appliance￨mandibular length inclination of the upper incisors to the maxillary plane least forward movement of point greatest proclination of the lower labial segment￨the bionator and twin block groups showed statistically significant reductions in the inclination of the upper incisors to the maxillary plane p  005￨sig increase￨highunclear￨highunclear￨highunclear
15￨eleven patients completed both study periods one patient who died of a heart attack 2 weeks before the end of the study was also included in the analysis 15 patients with a diagnosis of probable alzhemers disease who were refusing food patients with alzheimers disease￨dronabinol placebo dronabinol￨body weight serious intercurrent infections euphoria somnolence and tiredness adverse reactions anorexia and disturbed behavior severity of disturbed behavior￨dronabinol treatment decreased severity of disturbed behavior and this effect persisted during the placebo period in patients who received dronabinol first￨sig decrease￨highunclear￨highunclear￨highunclear
46￨fortysix patients￨titanium implants into extraction sockets 1 implant at the incisor canine or premolar region of the maxilla or the mandible immediate im versus delayed de placement of titanium dental implants with acidetched surfaces osseotite￨bone healing and crestal bone changes mean reductions in parallel width perpendicular width and depth of the largest defect of each implant survival rates capacity of spontaneous healing bone healing bone healing reduction over time￨for both groups a higher degree of bone healing was achieved in the infrabony defects  60 for depth than in dehiscencetype defects approximately 25￨sig increase￨highunclear￨highunclear￨highunclear
32￨fifty patients 25 females 25 males mean age 397 implants in periapical infected sites 50 patients chronic periapical lesions￨immediate implant placement￨survival rate implant survival mean implant stability quotient isq values gingival aesthetics radiographic bone loss and microbiologic characteristics of periapical lesions mean isq gingival aesthetics and radiographic bone resorption and periapical cultures￨mean isq gingival aesthetics and radiographic bone resorption and periapical cultures were not significantly different with the ip and dp implants￨no diff￨highunclear￨highunclear￨highunclear
not found￨sixteen patients 10 women and 6 men with a mean age of 35 years ranging from 21 to 49 years old were treated from 2004 to 2005 for singletooth replacement in the upper arch￨immediate replacement vs immediate restoration of single tooth implants placed and restored nonocclusal loading￨implant stability implant stability quotient implant stability quotient values￨the implant stability quotient values between the test and control groups were significant p005 at the moment of implant placement but were no more significant at the loading of the definitive restoration p005￨sig increase￨highunclear￨highunclear￨highunclear
62￨sixtytwo consecutively treated patients each received an immediate implant for a single tooth replacement at a maxillary anterior or premolar site￨five augmentation treatments and were submerged with connective tissue grafts group 1 n12expanded polytetrafluoroethylene membrane only group 2 n11resorbable polylactidepolyglycolide copolymer membrane only group 3 n13resorbable membrane and autogenous bone graft group 4 n14autogenous bone graft only and group 5 n12no membrane and no bone graft control membranes and autogenous bone grafts￨vertical defect height vdh horizontal defect depth hdd and horizontal defect width hdw hdw reduction vdh vdh and hdd reduction labial plate resorption hdd vdh hdd and hdw￨over 50 more labial plate resorption occurred in the presence of a dehiscence defect irrespective of the augmentation treatment used￨sig increase￨highunclear￨highunclear￨highunclear
76￨55 patients completed their followup twentyone patients were lost to followup because of implant loss n  5 1 treated out of protocol because of labial bone loss found at the time of tooth removal n  1 geographic relocation n  11 dropped for noncompliance n  3 or medical problems n  1 a total of 76 patients￨immediate socket grafting followed by implant placement and provisionalization 4 months later with a single tooth immediate implant placement and provisionalization immediate and delayed provisional single tooth restorations￨bone level position of the facial gingival margin with a more apical position of the facial gingival margin crestal bone response crestal bone levels facial gingival margin position implant integration or crestal interdental bone movement soft tissue measures compared with method￨the analyses showed no significant differences between groups in implant integration or crestal interdental bone movement on either the implant or the adjacent tooth￨no diff￨highunclear￨highunclear￨highunclear
30￨thirty immediate transmucosal implants in maxillary anterior extraction sites of 30 patients randomly received￨biooss n10 bg biooss and resorbable collagen membrane n10 bgm or no graft n10 control￨horizontal defect depth hdd reductions mucosal recession vertical defect height vdh reductions healing of marginal defects marginal mucosa and bone levels horizontal resorption horizontal resorption of buccal bone bgm￨mucosal recession was significantly associated p0032 with buccally positioned implants hdd 1103 mm when compared with lingually positioned implants hdd 2306 mm￨sig increase￨highunclear￨highunclear￨highunclear
4000￨type iv hyperlipoproteinemia screened 4000 employees 89 participation and identified 150 type iv subjects top 5 percentile triglyceride values 100 initial participation 6 drop out 150 healthy type iv subjects ages 20 to 49￨lipid intervention clinic clinic nutritionist and physician with the national heart and lung institutes type iv diet for 6 weeks then diet plus clofibrate￨maximum cholesterol decrease body weight mean fasting serum triglyceride￨group b triglyceride decreased 42 50 41 p less than 00005 at 6 12 24 weeks￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨overweight individuals with a family history of diabetes overweight individuals with a parental history of diabetes participants n  154 who were 30100 over ideal body weight had one or both parents with diabetes and were currently nondiabetic￨diet decreasing calories and fat intake exercise goal of 1500 kcalweek of moderate activity or the combination of diet plus exercise or to a notreatment control group lifestyle intervention lifestyle intervention￨risk of developing diabetes and weight loss gradual deterioration of behavioral and physiological changes weight loss weight losses behavior weight or physiological parameters modest weight loss risk of type 2 diabetes weight coronary heart disease chd risk factors and incidence of diabetes glucose tolerance measures of eating exercise and fitness weight losses￨at 6 months the groups differed significantly on measures of eating exercise and fitness weight losses in the diet and dietplusexercise groups were significantly greater than in the exercise and control conditions￨sig increase￨highunclear￨highunclear￨highunclear
2638￨of those eligible 67 n  683 entered the trial eighty percent of available staff n  2638 were screened participants with blood cholesterol of 52 mmoll 200 mgdl or above￨worksite cholesterol screening and dietary intervention screening only control group a selfhelp package or a nutrition course￨cholesterol reduction blood cholesterol and dietary changes dietary fat total blood or highdensity lipoprotein cholesterol blood cholesterol and dietary intake￨a reduction in reported dietary fat was found for all groups but there were no significant differences between groups￨no diff￨highunclear￨highunclear￨highunclear
6000￨a work sitelocated clinic screened 6000 employees 91 percent participation and identified 146 hypercholesterolemic subjects 100 percent initial participation 12 percent subsequent dropout rate subjects aged 20 to 50 years healthy young adults￨clofibrate diet treatment from a clinic nutritionist with the cooperation of the subjects private physician group c referral for treatment by a private physician and group d no intervention lipid intervention clinic with diet for 6 weeks then diet plus clofibrate￨cholesterol fasting serum triglycerides serum cholesterol serum cholesterol initial mean cholesterol￨decreases in cholesterol were correlated with weight loss and decrease in fasting serum triglycerides but not with the use of clofibrate￨sig decrease￨highunclear￨highunclear￨highunclear
450￨450 adults in phase 1 190 men and 260 women and 480 adults in phase 2 184 men and 296 women with hypercholesterolemia community office practices african americans physician office practices using the national cholesterol education program adult treatment panel 1 guidelines twentytwo physician practices in phase 1 and 23 in phase 2 were recruited from communities in western pennsylvania and west virginia￨nutrition intervention delivered through physician practices nutrition center cholesterollowering intervention program￨patient satisfaction serum cholesterol levels baseline serum cholesterol levels mean cholesterol response serum cholesterol levels two factorslength of time to followup measurement and change in weight￨serum cholesterol levels declined by 014 mmoll 54 mgdl in the usual care model by 031 mmoll 12 mgdl in the office assisted model and by 054 mmoll 209 mgdl in the nutrition center model￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨obese caucasian female chronic dieters ages 3045 y n78￨healthcentered nondiet wellness program nondiet wellness intervention￨many metabolic fitness psychological and eating behavior variables weight loss weight metabolic fitness psychological wellbeing and eating and activity behaviors anthropometry weight body mass index metabolic fitness blood pressure blood lipids energy expenditure eating behavior restraint eating disorder pathology psychology selfesteem depression body image attrition and attendance and participant evaluations of treatment helpfulness cognitive restraint metabolic fitness psychology and eating behavior￨there was high attrition in the diet group 41 compared to 8 in the nondiet group￨sig increase￨highunclear￨highunclear￨highunclear
59￨fiftynine patients patients with peripheral vascular disease￨dietitian group n  31 or to a diet fact sheet group￨blood cholesterol levels total cholesterol level reduction mean cholesterol level fell￨the mean cholesterol level fell by 85 among the dietitian group but only by 19 among the diet fact sheet group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨primary health care subjects with a total serum cholesterol in the range 7078 mmol l1 and no signs of ischaemic heart disease or diabetes mellitus￨mediumintensity n  41 intervention lipid intervention programmes￨total cholesterol total serum cholesterol and intervention costs￨both intervention strategies resulted in small mean 35 decreases in total cholesterol with no significant difference between the groups￨no diff￨highunclear￨highunclear￨highunclear
227￨201 subjects in three english and two french centers completed 1 years followup study subjects with increased but not diabetic fasting plasma glucose selfreferred subjects n  227 thought to be at risk of developing noninsulindependent diabetes mellitus niddm and with fasting plasma glucose fpg in the range of 55 to 77 mmol￨sulfonylurea reinforced healthyliving advice￨calculated maximal oxygen uptake glycemia fpg glucose tolerance or hemoglobin a1c hba1c and 4 showed a greater tendency to withdraw lipid profiles fpg dietary compliance by body weight and food diaries and fitness compliance by bicycle ergometer assessment and exercise diaries body weight insulin sensitivity body weight and glycemia￨both reinforced and basic advice groups had a significant mean reduction in body weight 15 kg at 3 months although the weight subsequently returned to baseline￨sig decrease￨highunclear￨highunclear￨highunclear
2004￨general practice 2004 subjects aged 3564 years were screened for hypercholesterolaemia 163 men and 146 women with a repeat total cholesterol concentration of 6085 mmoll entered the trial￨lipid lowering dietary advice￨total and low density lipoprotein cholesterol concentration concentrations of total cholesterol and low density and high density lipoprotein cholesterol total carotenoid concentration serum lipids lipoproteins and antioxidants mean total cholesterol concentration fell low density lipoprotein cholesterol mean concentrations of lipids lipoproteins and antioxidants or body mass index￨no significant differences were found at the end of the trial between groups in mean concentrations of lipids lipoproteins and antioxidants or body mass index￨no diff￨highunclear￨highunclear￨highunclear
not found￨family practice clinic in a remote community between september 1 1991 and september 30 1992 135 men and women between 20 and 60 years old with mild to moderate hypercholesterolemia ninetynine subjects completed the 6month regimen mild to moderate hypercholesterolemia￨standard dietetic treatment interventions individual consultations with a family physician in his office phase i group sessions with a physician and a dietician phase ii and individual consultations with a dietician phase ii taught the american heart association low fat diet brief dietary intervention￨mean reduction in serum ldlc serum levels of total cholesterol ldlc hdlc and triglycerides relative to initial level body weight smoking and dietary fat consumption physical activity risk factors smoking weight level of physical activity and patients cholesterolsaturated fat index￨the mean reduction in serum ldlc was 008 mmoll 18 in group i 007 mmoll 16 in group ii and 028 mmoll 63 in group iii p  094￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients with ms patients with multiple sclerosis ms all participants were evaluated with a neuropsychological examination ncpc at baseline and at the end of the study ms patients￨personalized cognitive training computerized cognitive training program no training homebased personalized cognitive training￨naming speed speed of information recall focused attention and visuomotor vigilance memorybased cognitive abilities general memory visual working memory and verbal working memory cognitive skills￨posthoc exploration of data from the ncpc showed that cognitive training was also associated with increased naming speed speed of information recall focused attention and visuomotor vigilance￨sig increase￨highunclear￨highunclear￨highunclear
29￨multiple sclerosis ms participants with learning impairment ms participants with mild learning impairments multiple sclerosis participants were 29 individuals with clinically definite ms with documented learning deficits￨story memory technique smt while the control group participated in eight sessions of memory exercises￨learning abilities memory new learning and memory performance memory performance￨ms participants with moderatesevere impairment in learning showed a significant improvement in learning abilities when compared to controls t19￨sig increase￨highunclear￨highunclear￨highunclear
15￨patients with acquired msassociated behavior disorder cognitivelyimpaired multiple sclerosis patients 15 patients with marked cognitive impairment and behavior disorder￨neuropsychological counseling or standard nonspecific supportive psychotherapy neuropsychological counseling neuropsychological counseling newlydeveloped cognitivebehavioral intervention neuropsychological intervention￨cognitive impairment and personalitybehavior disorder social behavior￨both groups showed evidence of cognitive impairment and personalitybehavior disorder prior to treatment and were well matched on demographic disability and cognitive measures￨no diff￨highunclear￨highunclear￨highunclear
45￨patients with multiple sclerosis ms fortyfive ms outpatients patients with multiple sclerosis  comparison of two different training schedules￨16 training sessions scheduled either as a high intensity training control group without training working memory training computer based working memory training brainstim￨short term memory quality of life or depression levels of difficulty fatigue symptoms as well as working memory  and mental speed performances￨in the outcome measures training for both intervention groups led to significantly improved fatigue symptoms as well as working memory  and mental speed performances￨sig increase￨highunclear￨highunclear￨highunclear
not found￨19 patients ms patients with mild to moderate cognitive impairment patients with multiple sclerosis￨neuropsychological training programme specific neurological training programme cognitive training programme specific training programme￨efficacy clinical and sociodemographic data and baseline intelligence level symptoms of fatigue verbal vlt and nonverbal learning and memory nvlt sustained attention executive functions ckv and spatialconstructional abilities hawier depression values bdi fatigue values mfis￨the results of the cognitive training programme were especially evident in the significant improvements in executive functions ckv and spatialconstructional abilities hawier￨sig increase￨highunclear￨highunclear￨highunclear
240￨people with multiple sclerosis 240 patients with clinically definite laboratory supported or clinically probable multiple sclerosis were recruited from an multiple sclerosis management clinic and assessed on a brief screening battery patients with multiple sclerosis￨cognitive assessment or cognitive intervention cognitive assessment and cognitive intervention￨general health questionnaire ghq28 extended activities of daily living scale sf36 everyday memory questionnaire dysexecutive syndrome questionnaire and memory aids questionnaire mood quality of life subjective cognitive impairment or independence￨overall the results showed no effect of the interventions on mood quality of life subjective cognitive impairment or independence￨no diff￨highunclear￨highunclear￨highunclear
40￨40 patients with mild to moderate cognitive and behavioral impairment associated with ms ms patients with cognitive and behavioral dysfunction patients with multiple sclerosis￨specific cognitive treatment 20 pts by direct training compensatory strategies and neuropsychotherapy or to nonspecific deliberately diffuse mental stimulation neuropsychological treatment￨beck depression inventory bdi cognitive measures depression ratings bdi visuospatial memory depression￨after shortterm treatment effects on cognitive measures were not convincing but on the beck depression inventory bdi the specific cognitive treatment group reported significantly less depression￨no diff￨highunclear￨highunclear￨highunclear
150￨patients with rr ms ambulatory patients were sent by the ms referral center twenty patients who scored below certain cutoff measures in both tests multiple sclerosis 150 patients with rr ms and an expanded disability status scale edss score of  or 4 were examined patients with clinicallystable relapsingremitting rr multiple sclerosis ms and low levels of disability￨intensive cognitive rehabilitation of attention and executive functions control group cg intensive computerassisted cognitive rehabilitation of attention information processing and executive functions for 3 months the cg did not receive any rehabilitation computerbased intensive training program￨depression scores tests of attention information processing and executive functions paced auditory serial addition test pasat and executive functions neuropsychological improvement neuropsychological test and scale scores￨after rehabilitation only the sg significantly improved in tests of attention information processing and executive functions pasat 3 p0023 pasat 2 p0004 wcstte p0037 as well as in depression scores madrs p001￨sig increase￨highunclear￨highunclear￨highunclear
42￨relapsingremitting ms patients 42 patients￨intensive homebased cognitive training program methylprednisolone homebased cognitive training program cognitive training￨quality of life qol depression and fatigue using selfrating scales neurological status and on qol or fatigue cognitive disorders verbal learning longdelay verbal memory performance and working memory performance longdelay verbal memory performance cognitive performance￨training had no effect on the neurological status and on qol or fatigue￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with multiple sclerosis using cognitive remediation strategies patients with advanced ms often require continuous supervision in a longterm skilled nursing facility￨skilled nursing facility to either a control condition or an extended treatment protocol￨beck depression inventory and several measures of cognitive functioning￨the results indicate statistically and clinically significant improvements in the depression of patients in the treatment but not in the control condition￨sig increase￨highunclear￨highunclear￨highunclear
11￨group cig n  11 with those of a multiple sclerosis patients group n  14 and an untreated group n  15￨rehabilitation programme placebo cognitive intervention executive function intervention programme￨verbal learning executive functioning and verbal learning￨baseline brain atrophy quantified by the brain parenchymal fraction was associated with treatment effects for one aspect of executive functioning￨sig increase￨highunclear￨highunclear￨highunclear
98￨ninetyeight incarcerated youths who volunteered to participate delinquent adolescent males￨one exercise program 32 subjects emphasized aerobic exercise aerobic exercise aerobic exercise￨selfconcept depression level and physical fitness of juvenile delinquents psychological status and physical fitness physical fitness selfconcept mood and fitness￨improvement in psychological variables was not dependent on improved physical fitness and was not related to preintervention measures￨no diff￨highunclear￨highunclear￨highunclear
54￨boys with learning disabilities fiftyfour boys￨aerobic exercise program aerobic exercise aerobic exercise￨selfconcept and physical fitness psychological status and physical fitness academic achievement or motor proficiency selfconcept academic achievement motor proficiency and cardiovascular fitness￨no effect on academic achievement or motor proficiency could be attributed to the aerobic exercise program￨no diff￨highunclear￨highunclear￨highunclear
not found￨schoolchildren 154 fourth fifth and sixth graders￨aerobic exercise￨running performance 50m dash performance or perceptual skill￨findings showed that although boys tended to run faster than girls overall and that older children run faster than younger children runningprogram participants performed better on an 800m run had lower pulse rates and performed better on a test of creativity than did regular physical education participants￨sig increase￨highunclear￨highunclear￨highunclear
181￨subjects n  181 were pre early and middleadolescent girls ranging in age from 9 to 16 who were enrolled in an independent school preadolescent and adolescent females￨physical activity intervention package￨selfesteem￨results indicated that low selfesteem individuals benefitted from the intervention￨sig increase￨highunclear￨highunclear￨highunclear
40￨young children preschool teachers from four different day care centers assessed fourand fiveyearold children for deficits in grossmotor skill and selfconcept forty subjects￨specialized intervention with perceptualmotor activities perceptual motor training control group received no specialized intervention other than their regular classroom activities￨￨analysis of the projective test supported the hypothesis that a perceptualmotor program may improve the selfconcept of young children￨sig increase￨highunclear￨highunclear￨highunclear
108￨108 subjects participated in the study with 20 students in health science classes serving as the controls 88 women in university physical education service classes participated 3 hr￨selected physical activities￨five activities aerobic dance jogging for fitness swimming for fitness life saving and weight training￨none of the activity groups differed from the controls regarding selfesteem body cathexis body fat or the step test scores at posttest￨no diff￨highunclear￨highunclear￨highunclear
288￨45 minutes daily by 12 to 14yrold junior high school and 16 to 18yrold senior high school boys and girls 288 subjects were selected using a stratified intact class random technique 96 control subjects were randomly selected from one class of each age bracket￨￨total positive self total positive selfconcept scores and increase in sports skills selfconcept scores￨a positive correlation between gain in sports skill and increase in selfconcept scores was noted for both boys and girls within each age group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨36 boys and 36 girls in 4 fourth grades two class groups which included 9 boys and 9 girls each￨selected movement skills￨￨no differences between changes in selfconcept as estimated by the piersharris scale for treatment and control conditions were significant￨no diff￨highunclear￨highunclear￨highunclear
not found￨24 preschoolers 12 children while the remaining 12 children engaged in freeplay on the school playground preschoolers￨aerobic exercise submaximal exercise test on a pediatric bicycle baseline and three workloads an agility test a health knowledge test a selfesteem scale aerobic exercises￨agility and selfesteem heart rate cardiovascular fitness agility and selfesteem￨despite comparability on pretests significant group x repeated measures effects suggested that the aerobic exercise group showed decreases in heart rate at all three workloads as well as increases in agility and selfesteem following the exercise program￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨aerobic training aerobic exercise program ae￨childrens perceived athletic competence physical appearance social acceptance behavioral conduct and global selfworth increased their figural creativity and improved aerobic power childrens creativity selfperception and aerobic power￨the article examines whether participation in an aerobic exercise program ae as compared with a traditional physical education class pe significantly increased childrens perceived athletic competence physical appearance social acceptance behavioral conduct and global selfworth increased their figural creativity and improved aerobic power as measured by an 800meter run around a track￨sig decrease￨highunclear￨highunclear￨highunclear
12￨posthaemorrhagic hydrocephalus 12 premature babies with posthaemorrhagic hydrocephalus small premature babies posthaemorrhagic hydrocephalus of preterm￨intraventricular streptokinase treatment intraventricular streptokinase intraventricular streptokinase￨shunt surgery rebleeding ventriculitis or meningitis￨there were no rebleeding ventriculitis or meningitis in either groups￨no diff￨highunclear￨highunclear￨highunclear
12￨12 neonates affected by intraventricular haemorrhage and subsequent progressive ventriculomegaly neonatal posthaemorrhagic hydrocephalus babies affected by posthaemorrhagic ventricular dilation￨streptokinase fibrinolytic endoventricular treatment￨endoventricular fibrinolysis￨our results show that the percentage of shunted babies was identical in treated and control patients despite the enhancement of endoventricular fibrinolysis obtained in all treated patients￨sig increase￨highunclear￨highunclear￨highunclear
160￨160 pregnant women with the risk to develop preeclampsia received 7 patients with manifest preeclampsia or pregnancyinduced hypertension the pregnancyinduced hypertension or preeclampsia￨placebo trapidil or placebo trapidil￨hypertension or preeclampsia circulating eicosanoid concentrations 6keto pgf1 alpha concentration reduced risk of preterm deliveries and severe fetal growth retardation￨trapidil was associated with an about twofold increase of 6keto pgf1 alpha concentration in the peripheral venous blood while the concentration of thromboxane a2 revealed no changes￨sig increase￨highunclear￨highunclear￨highunclear
not found￨ace dd nonthrombophilic women with history of preeclampsia thrombophilic women eighty nonthrombophilic ace dd women￨angiotensinconverting enzyme ace insertiondeletion id polymorphism lmwh dalteparin￨diastolic p0002 blood pressures fetal growth restriction relative risk for fetal growth restriction risk of clinical negative outcomes systolic recurrence rate of preeclampsia resistance indexes of both uterine arteries relative risk for preeclampsia maternal blood pressure values recurrence of preeclampsia of negative outcomes and the resistance of uteroplacental flow maternal blood pressure increase￨lmwh reduced the risk of clinical negative outcomes 741 reduction of preeclampsia and 775 reduction of fetal growth restriction and the severity 883 reduction of early onset of preeclampsia and 864 reduction of early onset of fetal growth restriction￨sig decrease￨highunclear￨highunclear￨highunclear
107￨pregnant women and their fetuses 107 women diagnosed with fgr￨standard heparin 02  04 ml low molecular weight heparin heparin 50  75 mg standard heparin added to 500 ml 5 glucose sodium chloride control group 20 ml danshen added to 500 ml heparin￨gestational age fetal growth restriction body weight 1 height of fundus of uterus placenta function 2 biophysical score fetal growth indices biophysical score umbilical blood neonatal outcome biparietal diameter of fetus fetal growth indices biophysical score umbilical artery blood flow count of platelet plt prothrombin time pt activated partial thromboplastin time aptt 1minute apgar score body weight and gestational age of the neonates body weight of the neonates femur length head circumference and abdominal circumference of fetus pulsatile index pi and resistance index ri umbilical blood sd ratio rate of one minute apgar score plt pt and aptt￨pulsatile index pi and resistance index ri were significantly lower also p  0054￨sig decrease￨highunclear￨highunclear￨highunclear
116￨between august 1 2000 and june 20 2007 116 pregnant women with 110 women women without thrombophilia￨dalteparin no dalteparin dalteparin￨composite of one or more of severe preeclampsia newborn weight or 5th percentile or major abruptio placentae bleeding problems or thrombocytopenia recurrence of placentalmediated complications of pregnancy nonsevere preeclampsia newborn weight at the 610th percentile and gestational age at delivery￨in this pilot study dalteparin is effective in decreasing the recurrence of placentalmediated complications in women without thrombophilia￨sig increase￨low￨low￨low
286￨286 evaluable patients patients with locoregionally advanced undifferentiated or poorly differentiated nasopharyngeal carcinoma npc meeting one of the following criteria between september 1989 and august 1993 334 patients were enrolled in the study with equal numbers of patients randomized to the neoadjuvant chemotherapy arm ct arm and the radiotherapy arm rt arm patients with locoregionally advanced nasopharyngeal carcinoma two hundred eightysix eligible patients completed the treatment and were evaluable for treatment response 134 in the ct arm 152 in the rt arm￨radiotherapy radiotherapy alone neoadjuvant chemotherapy epirubicin cisplatinepirubicin neoadjuvant chemotherapy radiotherapy versus radiotherapy alone cisplatin cisplatin and epirubicin neoadjuvant chemotherapy￨overall survival overall incidence of recurrence os relapse free survival rfs or overall survival os 3year os rate rfs￨analysis of the 334 patients based on the intention to treat showed no significant difference in relapse free survival rfs or overall survival os between the 2 treatment arms 3year rfs rate 48 in the ct arm vs 42 in the rt arm p  045 3year os rate 78 vs 71 p  057￨no diff￨highunclear￨highunclear￨highunclear
80￨copyright 2002 american cancer society patients with locoregional carcinoma of the nasopharynx from january 1991 to december 1998 80 patients were enrolled in this study patients with advanced nasopharyngeal carcinoma patients with locally advanced nasopharyngeal carcinoma patients with nasopharyngeal carcinoma￨cddp5fu chemotherapy prior to radiotherapy radiotherapy alone neoadjuvant chemotherapy with radiotherapy alone chemotherapy consisting of cisplatin and 5fluorouracil cddp5fu that were administered before radiation therapy ct arm or radiotherapy alone radiation therapy neoadjuvant chemotherapy￨metastasis free survival locoregional failure free survival 5year overall survival rate locoregional recurrence free survival rate disease free survival or overall survival locoregional recurrences overall survival or disease free survival 5year disease free survival rate￨there were no differences in locoregional failure free survival between the two arms￨no diff￨highunclear￨highunclear￨highunclear
82￨locoregionally advanced nasopharyngeal carcinoma advanced nasopharyngeal carcinoma eightytwo patients with histologically proven nasopharyngeal carcinoma who had either hos n3 staging or any n stage with a nodal diameter of  or  4 cm were entered￨chemoradiotherapy against radiotherapy alone radical radiotherapy chemotherapy adjunctive to definitive radiotherapy adjunctive chemotherapy to radiotherapy cisplatin 100 mgm2 day 15fluorouracil 1000 radiotherapy alone neoadjuvant chemotherapy booster radiotherapy postradiotherapy chemotherapy￨degree of mucositis overall response rate 2year overall survival tumor response and survival toxicities 2year diseasefree survival rates of radiotherapy for boosting parapharyngeal disease or residual lymph nodes locoregional relapse rate distant metastatic rate and median time to relapse myelosuppression nephrotoxicity and nausea and vomiting overall complete response rate￨the rates of radiotherapy for boosting parapharyngeal disease or residual lymph nodes were not significantly different in the two arms￨no diff￨highunclear￨highunclear￨highunclear
157￨patients with advanced npc advanced nasopharyngeal carcinoma patients 157 patients enrolled 154 77 radiotherapy 77 combined therapy between november 1994 and march 1999 157 patients with stage iv m0 uiccajcc 1992 advanced npc disease locally advanced nasopharyngeal carcinoma npc patients￨radiotherapyalone infusional chemotherapy 20 mgm2 cisplatin 2200 mgm2 5fluorouracil and 120 mgm2 leucovorin radiotherapy rt standard radiotherapy adjuvant chemotherapy to rt alone adjuvant chemotherapy￨hazard rates ratio survival and toxicity analysis incidence of leukopenia moderate to severe mucositis systemic relapse rate 5year overall survival and relapsefree survival rates overall survival or relapsefree survival￨we conclude that adjuvant chemotherapy after rt for patients with advanced npc has no benefit for overall survival or relapsefree survival￨no diff￨highunclear￨highunclear￨highunclear
185￨193 patients registered 147 69 radiotherapy and 78 chemoradiotherapy patients with advanced nasopharyngeal cancer patients with nasopharyngeal cancers one hundred eightyfive patients were included in a secondary analysis for survival patients with advanced nasopharyngeal cancers￨chemotherapy with cisplatin chemoradiotherapy versus radiotherapy radiotherapy radiotherapy postradiotherapy chemotherapy with cisplatin 80 mgm2 on day 1 and fluorouracil radiotherapy alone radiotherapy chemoradiotherapy radiation therapy oncology group rtog and eastern cooperative oncology group ecog￨median progressionfree survival pfs time 3year survival rate pfs and overall survival survival and toxicity 3year pfs rate median survival time￨we conclude that chemoradiotherapy is superior to radiotherapy alone for patients with advanced nasopharyngeal cancers with respect to pfs and overall survival￨no diff￨highunclear￨highunclear￨highunclear
350￨locoregionally advanced nasopharyngeal carcinoma nasopharyngeal carcinoma npc patients with hos n2 or n3 stage or n1 stage with nodal size  or  4 cm patients with advanced tumor and node stages three hundred fifty eligible patients were randomized patients with advanced npc in endemic areas patients with locoregionally advanced npc￨cisplatin 40 mgm2 weekly up to 8 weeks concurrently with radical rt crt or rt alone concurrent crt radiotherapy alone concurrent cisplatinrt crt with rt alone concurrent chemotherapyradiotherapy radiotherapy rt and chemotherapy￨2year pfs progressionfree survival pfs toxicities including mucositis myelosuppression and weight loss time to first distant failure￨there were no treatmentrelated deaths in the crt arm and one patient died during treatment in the rtalone arm￨no diff￨low￨low￨low
339￨stage iv or  n2 m0 undifferentiated nasopharyngeal carcinoma from november 1989 to october 1993 339 patients with negative metastases workup stratified by accrual center have been randomized 168 to locoregionally advanced undifferentiated nasopharyngeal carcinoma ucnt patients￨radiotherapy alone and 171 to chemotherapy plus radiotherapy bleomycin epirubicin and cisplatin bec protocol bec type neoadjuvant chemotherapy neoadjuvant chemotherapy cisplatin epirubicin bleomycin plus radiotherapy vs radiotherapy alone￨overall survival progressionfree survival proportion of local andor regional metastases disease free survival￨the proportion of local andor regional metastases was comparable in both arms￨no diff￨highunclear￨highunclear￨highunclear
not found￨nasopharyngeal carcinoma nasopharyngeal carcinoma npc patients with hos stage t3 or n2n3 npc or neck node  or  4 cm were eligible￨concurrent chemoradiotherapy crt and adjuvant chemotherapy ac concurrent and adjuvant chemotherapy radiotherapy rt or crt with uracil and tegafur and to have ac or no ac after rtcrt cisplatin fluorouracil vincristine bleomycin and methotrexate￨dmr locoregional failure rates lrfr os with crt year failurefree survival ffs and overall survival os distant metastases rate dmr dmr and lrfr￨dmr and lrfr were not reduced with ac p 34￨no diff￨highunclear￨highunclear￨highunclear
216￨male alcoholics subtyped by comorbid psychiatric disorders three welldefined subtypes were examined alcoholism only alcoholism  affectiveanxiety disorder and alcoholism  antisocial personality disorder 216 male alcoholic patients subtyped by comorbid psychiatric disorders￨nortriptyline bromocriptine and nortriptyline placebo nortriptyline and bromocriptine￨drinking behavior and psychiatric symptoms￨contrary to our predictions the only significant effects found were with the antisocial personality disorder patients who were receiving nortriptyline￨no diff￨highunclear￨highunclear￨highunclear
not found￨cocaine dependence cocaine dependence 59 cocainedependent males maintained on methadone for the treatment of opiate dependence￨desipramine dmi desipramine placebo￨psychiatric symptoms and personal adjustment problems urine toxicology tests￨at the end of treatment there were no overall differences between the placebo and dmi groups on a range of outcome measures including urine toxicology tests￨no diff￨highunclear￨highunclear￨highunclear
60￨sixty inmates￨phenytoin placebo￨amplitudes of p300 erp waveforms p300 erp waveforms impulsive aggressive acts impulsive and premeditated aggression aggression￨the amplitudes of p300 erp waveforms among impulsive aggressive subjects were increased significantly during the phenytoin condition but not during the placebo condition￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with cluster b personality disorders impulsive aggression efficacy in cluster b personality disorders outpatients with a score of  or 15 on the aggression scale of the overt aggression scalemodified oasm and who fulfilled dsmiv criteria for cluster b personality disorder n96 intermittent explosive disorder n116 or posttraumatic stress disorder n34￨divalproex placebo divalproex sodium or placebo divalproex￨oasm aggression score including verbal assault and assault against objects as well as oasm irritability score and clinical global impression cgiseverity impulsive aggression irritability and global severity overall premature discontinuation rate average oasm aggression scores￨based on average oasm aggression scores over the last 4 weeks of treatment a treatment effect was not observed in the intenttotreat data set combined across the three psychiatric disorders but was observed in both intenttotreat and evaluable data sets for patients with cluster b personality disorders￨no diff￨low￨low￨low
254￨dually diagnosed individuals twohundred and fiftyfour patients with an axis i psychiatric disorder and comorbid alcohol dependence were treated for 12 weeks in an outpatient medication study conducted at three veterans administration outpatient clinics patients with alcohol dependence and comorbid psychiatric disorders￨placebo placebo alone 3 openlabel disulfiram and blinded naltrexone or 4 openlabel disulfiram and blinded placebo naltrexone and disulfiram disulfiram and naltrexone disulfiram and naltrexone naltrexone￨medication compliance alcohol consumption consecutive weeks of abstinence and less craving psychiatric symptoms alcohol craving gggt levels and adverse events￨subjects treated with an active medication had significantly more consecutive weeks of abstinence and less craving than those treated with placebo but there were no significant group differences in other measures of alcohol consumption￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨individuals with impulsive aggression individuals meeting previously established criteria for impulsive aggression individuals who display impulsiveaggressive outbursts￨phenytoin placebo pht and placebo phenytoin pht￨psychophysiological measures evoked potentials p1 amplitude frequency of impulsiveaggressive outbursts overt aggression scale oas and the profile of mood states poms￨analysis of the psychophysiological data showed significantly increased p1 amplitude and significantly longer n1 latency during pht administration￨sig increase￨highunclear￨highunclear￨highunclear
not found￨94 cocaineabusing methadone patients with n  75 and without n  19 antisocial personality disorder asp￨desipramine amantadine placebo placebo￨retention percentage of cocainefree urines urine toxicologies￨placebotreated patients in both groups demonstrated no significant difference in their urine toxicologies comparing the first to the last two weeks of treatment￨no diff￨highunclear￨highunclear￨highunclear
not found￨impulsive aggressive men impulsive aggression￨phenytoin placebo carbamazepine phenytoin and valproate valproate￨average aggression score a global severity index from the overt aggression scale impulsive aggression￨analysis showed a significant reduction in impulsive aggression during all 3 anticonvulsant conditions compared with placebo￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨￨lidocaine placebo oral carbamazepine carbamazepine carbamazepine￨￨carbamazepine had less effect than the placebo￨sig increase￨highunclear￨highunclear￨highunclear
50￨50 patients with tinnitus due to various causes￨flunarizine placebo￨serum levels￨for the group as a whole there was no difference between flunarizine and the placebo with respect to the effect on tinnitus but in the 10 patients with dizziness as well there was a significant difference in favor of the drug￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients were chosen from among volunteers from the tinnitus clinic in the local hospital without reference to underlying pathology￨lidocaine placebo lamotrigine or placebo lamotrigine lamotrigine￨perceived intensity and intrusiveness of tinnitus questionnaires and visual analog scales questionnaires visual analog scales and a battery of audiologic measurements￨of the 31 participants who completed the trial questionnaires indicated that lamotrigine was effective in a very few of these persons￨no diff￨highunclear￨highunclear￨highunclear
not found￨seventysix patients completed the trial of these 52 received the drug inclusion criteria included patients between ages 18 and 70 with a complaint of nonpulsatile subjective tinnitus bilateral or unilateral greater than 3 months in duration academic medical center patients with moderate tinnitus￨gabapentin neurontin gabapentin placebo gabapentin￨tinnitus handicap inventory secondary measures include the profile of mood states poms rating scale subjective tinnitus severity diseasespecific quality of life￨no significant differences were found between the two groups after 5 weeks of treatment with gabapentin￨no diff￨low￨low￨low
135￨idiopathic subjective tinnitus one hundred thirtyfive subjects with severe idiopathic subjective tinnitus of 6 months duration or longer academic otolaryngology clinic in st louis mo￨gabapentin placebo gabapentin neurontin lactose placebo gabapentin￨tinnitus handicap inventory score￨gabapentin is no more effective than placebo for the relief of idiopathic subjective tinnitus￨no diff￨low￨low￨low
30￨30 participants received idiopathic subjective tinnitus in the patients￨gabapentin gabapentin placebo￨sensation of subjective idiopathic tinnitus severe idiopathic subjective tinnitus tinnitus annoyance subjective response tinnitus questionnaire tinnitus severity index and the loudness perception￨there was not a significant subjective improvement in tinnitus annoyance for the patients 37 versus controls 42￨no diff￨highunclear￨highunclear￨highunclear
298￨individuals with a psychotic disorder 298 regular smokers with a psychotic disorder residing in the community and randomly assigned them to a people with a psychotic disorder with routine care alone individuals with psychotic disorders people with a psychotic disorder￨nicotine replacement therapy motivational interviewing and cognitive behavior therapy routine care comparison condition n151 or an eightsession individually administered smoking cessation intervention smoking cessation intervention nicotine replacement therapy intervention nicotine replacement therapy plus motivational interviewingcognitive behavior therapy smoking cessation intervention￨daily cigarette consumption continuous and pointprevalence abstinence rates smoking reduction status and changes in symptoms and functioning abstinence rates continuous abstinence￨while there were no overall differences between the treatment group and comparison group in abstinence rates a significantly higher proportion of smokers who completed all treatment sessions stopped smoking at each of the followup occasions pointprevalence rates 3 months 300 versus 60 6 months 186 versus 40 and 12 months 186 versus 66￨no diff￨highunclear￨highunclear￨highunclear
not found￨chronic hospitalized schizophrenic clients inpatients with chronic schizophrenia hospitalized chronic clients with schizophrenia people with schizophrenia￨behavioral grouporiented smoking reduction interventions fivesession smoking reduction intervention nonmedication smoking reduction program￨number of cigarettes smoked smoking behavior weight gain selfreported smoking behavior clinical status positive and negative syndrome scale hamilton rating scale for depression clinical global impression scale for psychosis subjective quality of life quality of life enjoyment and satisfaction questionnaireabbreviated version and weight￨no clinical worsening or weight gain was observed￨no diff￨highunclear￨highunclear￨highunclear
61￨61 schizophrenic patients 46 m 15 f on stable neuroleptic medication were initially enrolled in a smoking reduction program prospective doubleblind only male subjects with at least one short promoter region allele shortshort and shortlong combined schizophrenia￨bupropion and cognitive behavioral therapy cbt bupropion and the promoter region httlpr serotonin transporter slc6a4 polymorphism placebo placebocontrolled including cognitive behavioral therapy plus placebo or cbt plus bupropion￨smoking behavior cigarette consumption￨while both groups of subjects demonstrated significant reductions in smoking behavior due to cbt subjects receiving bupropion did not show significant differences in smoking behavior when compared to placebo￨no diff￨highunclear￨highunclear￨highunclear
120￨120 clinically stable people with schizophrenia people with schizophrenia￨antipsychotics placebo varenicline varenicline adjunctive varenicline antipsychotic medications￨stroop interference continuous performance test hit reaction time neuropsychological clinical and safety assessments total scores on the positive and negative syndrome scale cognitive impairments digital symbol substitution test￨no significant treatment main effects or interactions were noted for total scores on the positive and negative syndrome scale or the scale for the assessment for negative symptoms￨no diff￨low￨low￨low
50￨fifty smokers with a diagnosis of schizophrenia or schizoaffective disorder and whose symptoms had been stable for at least two months were enrolled in a helping persons with schizophrenia remain tobaccofree persons with schizophrenia participants who quit tobacco use completely during the first three months￨placebo program providing group support and nrt patches in individually adjusted doses set to maintain baseline nicotine intake placebo or active nicotine patches nicotine replacement therapy longterm nicotine replacement therapy nrt nrt￨carbon monoxide levels smoking activity feasibility and efficacy￨a significantly greater proportion of those on placebo 8 of 8 compared with those on active patches 3 of 9 relapsed prior to completion of the 6month period￨sig increase￨highunclear￨highunclear￨highunclear
not found￨adults with any dsmiv diagnosed mental illness smoke persons with serious mental illness n181 persons with schizophrenia or other serious mental illness because national data suggests that 1 they smoke at two to three times the rate of the general population 2 cessation interventions for this population are understudied 3 most cessation studies exclude persons with serious mental illness and 4 cessation results in public health care savings and disposable income savings for clients persons with schizophrenia and other serious mental illnesses￨smoking cessation treatments contingent reinforcement cr cr plus nicotine patch 21 mg crnrt smoking cessation interventions minimal intervention selfquit control group￨quit rates saliva cotinine quit rates quit rates￨cotinine showed lower quit rates and small differences between intervention and control participants at weeks 20 and 36￨no diff￨highunclear￨highunclear￨highunclear
5￨38 schizophrenic daily smokers from a doubleblind clozapine trial patients with schizophrenia￨clozapine￨highest plasma clozapine level plasma cotinine levels￨46 125129 also indicated that there was not a significant effect of clozapine on smoking￨no diff￨highunclear￨highunclear￨highunclear
32￨thirtytwo subjects meeting dsmiv criteria for schizophrenia or schizoaffective disorder and nicotine dependence schizophrenic patients patients with schizophrenic disorders smoking cessation in schizophrenia￨bup placebo bupropion bupropion sr bup 300 mgday or placebo pla sustainedrelease sr bupropion with placebo bupropion￨dry mouth gastrointestinal symptoms headache and insomnia cigarette smoking trial endpoint 7day point prevalence smoking abstinence rates smoking abstinence rates reduced co levels positive schizophrenia symptoms treatment retention smoking abstinence rates expired breath carbon monoxide co levels psychotic symptoms and medication side effects smoking cessation responses￨bupropion significantly increased trial endpoint 7day point prevalence smoking abstinence rates compared with placebo bup 816 500 pla 216 125 chi2  524 df  1 p 05 and reduced co levels during the trial medication x time interaction z  309 p 01￨sig increase￨highunclear￨highunclear￨highunclear
45￨for smokers with schizophrenia n28 that schizophrenic patients smoking cessation in schizophrenia patients with schizophrenia or schizoaffective disorder who were also treated with the fortyfive subjects￨nicotine transdermal patch 21 mgday and 10 weekly group therapy sessions and continued to receive their prestudy atypical n18 or typical n27 antipsychotic medications group therapy program of the american lung association n17 or 2 a specialized group therapy program nicotine transdermal patch and atypical antipsychotic medications nicotine transdermal patch psychotherapy programs risperidone and olanzapine nicotine transdermal patch and with either atypical or typical antipsychotic medications emphasized motivational enhancement relapse prevention social skills training and psychoeducation￨treatment retention rate of smoking abstinence and expiredbreath carbon monoxide level smoking abstinence rates rate of smoking cessation highest quit rates carbon monoxide levels￨however atypical antipsychotic agents in combination with the nicotine transdermal patch significantly enhanced the rate of smoking cessation 556 in the atypical agent group versus 222 in the typical group which was reflected by a significant effect of atypical versus typical agents on carbon monoxide levels￨sig decrease￨highunclear￨highunclear￨highunclear
29￨individuals with schizophrenia smoke at higher rates 5888 than the general population approximately 22 and have difficulty quitting smokers with schizophrenia 58 outpatient smokers with schizophrenia smoking cessation in schizophrenia￨bup placebo sustainedrelease sr bupropion bup with the transdermal nicotine patch tnp plotnp bupropion srtnp versus placebotnp bupropion sr bupropion combined with nicotine patch buptnp placebo plotnp tnp￨7day point prevalence abstinence at 6 months posttarget quit date tqd shortterm smoking abstinence continuous smoking abstinence 7day point prevalence smoking abstinence positive or negative symptoms of schizophrenia￨individuals with schizophrenia smoke at higher rates 5888 than the general population approximately 22 and have difficulty quitting￨sig increase￨low￨low￨low
not found￨heavy smokers with schizophrenia smokers with schizophrenia 10 male veteran smokers with schizophrenia were admitted for two brief inpatient stays to smoke while wearing a￨smoking reduction strategy transdermal nicotine or placebo patch smoking while wearing a transdermal nicotine patch￨nicotine plasma level or co level psychiatric symptoms carbon monoxide and cigarettes tolerated carbon monoxide smoking indices dyskinesias nicotine levels expired carbon monoxide carbon monoxide in expired air selfreported cigarettes per day nicotine plasma levels and psychiatric ratings￨psychiatric symptoms carbon monoxide and cigarettes per day did not change although eight subjects had a decrease in expired carbon monoxide on the active patch￨no diff￨highunclear￨highunclear￨highunclear
not found￨individuals with schizophrenia 57 nontreatmentseeking participants individuals with schizophrenia people with schizophrenia smokers with schizophrenia￨cm intervention placebo bupropion contingency management cm intervention bupropion contingency management and bupropion 300 mgday bupropion or placebo￨cotinine levels carbon monoxide co levels and to report number of cigarettes smoked per day nicotine withdrawal symptoms cigarette craving and psychiatric symptoms cigarette craving and psychiatric symptom levels cigarette smoking cotinine and co levels efficacy of cm￨cotinine and co levels significantly decreased during the study period in participants randomized to the cm condition but not the nr condition￨sig increase￨highunclear￨highunclear￨highunclear
not found￨smoking behavior people from this 12week trial who were smokers 18 people with schizophrenia￨galantamine placebo galantamine galantamine 25 placebo￨expired co measures mean ftnd scores expired co mean taub correlation between expired co level and visit cigarette smoking smoking behavior cognitive functioning￨mean ftnd scores in the galantamine group were 4925 at baseline and 5222 at week 12 compared to 4126 at baseline and 3726 at week 12 in the placebo group mantelhaenszel chi2553 df1 p0019 for an effect size of 04￨sig decrease￨highunclear￨highunclear￨highunclear
19￨eighteen subjects completed the trial patients with schizophrenia smoking cessation in schizophrenia 19 stable outpatients with schizophrenia who wanted to quit smoking￨placebo cbt bupropion sustainedrelease sr bupropion to cognitive behavioral therapy cbt bupropion sr cognitive behavioral therapy bupropion￨sustained tobacco abstinence weight loss reduction in smoking as measured by selfreport verified by expiredair carbon monoxide negative symptoms and greater stability of psychotic and depressive symptoms smoking behavior and stability of psychiatric symptoms￨bupropion treatment was associated with improvement in negative symptoms and greater stability of psychotic and depressive symptoms compared with placebo during the quit attempt￨sig decrease￨highunclear￨highunclear￨highunclear
51￨fiftyone adult smokers with schizophrenia schizophrenia￨placebo bupropion sr added to highdose dual nicotine replacement therapy bupropion sr 300 mgd or placebo added to transdermal nicotine patch nicotine polacrilex gum and cbt bupropion sr to highdose combination nicotine replacement therapy nrt and weekly group cognitive behavioral therapy cbt bupropion  dual nrt bupropion  nrt￨relapse rates 7day pointprevalence of 50 to 100 smoking reduction continuous abstinence rate tobacco abstinence and change from baseline in expired air carbon monoxide co and psychiatric symptoms abstinence rates abstinence rates￨subjects on bupropion  nrt had a greater rate of 50 to 100 smoking reduction at weeks 12 60 vs 31 p  0036 and 24 a lower expired air co in the treatment and followup periods f  138 p  0001 and a greater continuous abstinence rate at week 8 before nrt taper 52 vs 19 p  0014￨sig increase￨low￨low￨low
not found￨adults with schizophrenia who smoked more than 10 cigarettes per day and wished to try to quit smoking were recruited from community mental health centers enrolled in a 12week group fiftythree adults 25 on bupropion and 28 on patients with schizophrenia smoking cessation in schizophrenia￨placebo cognitive behavioral therapy intervention bupropion sustainedrelease 300 mgd or identical placebo bupropion￨7day point prevalence abstinence higher rate of 4week continuous abstinence worsening of clinical symptoms relapse rate longer duration of abstinence depressive and negative symptoms￨we conclude that bupropion does not worsen clinical symptoms of schizophrenia and is modestly effective for smoking cessation in patients with schizophrenia￨no diff￨low￨low￨low
69￨smokers and nonsmokers with schizophrenia or schizoaffective disorder schizophrenic patients with specific biological deficits schizophrenia and schizoaffective disorder 69 smoking and nonsmoking patients 64 patients completed week 2 and 59 patients completed week 8 patients with schizophrenia or schizoaffective disorder￨varenicline tartrate varenicline placebo nicotine￨exacerbation of psychiatric symptoms psychosis depression or suicidality neurobiological and cognitive biomarkers prepulse inhibition sensory gating antisaccade spatial working memory eye tracking processing speed and sustained attention startle reactivity spatial working memory predictive and maintenance pursuit measures processing speed or sustained attention by conners continuous performance test antisaccadic error rate executive function p50 sensory gating deficit￨a moderate dose of varenicline had no significant effect on spatial working memory predictive and maintenance pursuit measures processing speed or sustained attention by conners continuous performance test￨no diff￨highunclear￨highunclear￨highunclear
13￨psychiatric patients 13 psychiatric patients who were not trying to stop smoking￨transdermal nicotine placebo nicotine￨￨the patients smoked significantly fewer cigarettes while receiving nicotine than while receiving placebo￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨mallet finger￨new perforated splint and a traditional splint￨￨the perforated splint gives superior results by virtue of the fact that it does not require to be removed for purposes of hygiene and can thus produce a satisfactory result even in those patients who fail to grasp the technique of removal and replacement of the splint￨no diff￨highunclear￨highunclear￨highunclear
not found￨116 cases of mallet finger￨stack or abouna splint￨￨the two splints were equally effective producing a cure or a significant improvement in approximately 50 of cases￨no diff￨highunclear￨highunclear￨highunclear
60￨sixty patients with mallet finger deformity￨simple splint stack or a custommade padded aluminium alloy malleable finger splint￨skin complications￨both splints were equally effective in correcting the deformity but the aluminium alloy splint was able to be fitted to a wider variety of finger shapes and sizes and caused significantly fewer skin complications￨no diff￨highunclear￨highunclear￨highunclear
153￨older women elderly women volunteer sample of 153 elderly women mean age 785 years￨cranberry juice placebo consume 300 ml per day of a commercially available standard cranberry beverage or a specially prepared synthetic placebo drink cranberry juice beverage cranberry beverage￨bacteriuria and pyuria frequency of bacteriuria with pyuria odds of bacteriuria￨subjects randomized to the cranberry beverage had odds of bacteriuria defined as organisms numbering  or  105ml with pyuria that were only 42 of the odds in the control group p  004￨sig increase￨low￨low￨low
21￨pediatric neuropathic bladder population susceptible pediatric population twenty one patients completed the study12 dropped out for reasons related to the cranberry taste caloric load and cost seven patients dropped out for other reasons parents too busy death no stated reason￨liquid cranberry products cranberry cranberry cocktail clean intermittent catheterization with or without pharmacotherapy￨urinary tract infection￨fewer infections were observed in nine patients taking cranberry juice and in nine patients given water no difference was noted in three￨no diff￨highunclear￨highunclear￨highunclear
21￨individuals with neurogenic bladders secondary to spinal cord injury persons with spinal cord injury sci participants with symptomatic infections individuals with neurogenic bladders due to sci individuals with neurogenic bladders 21 individuals with neurogenic bladders secondary to sci￨appropriate antibiotics standardized 400mg cranberry tablets or placebo placebo cranberry tablet placebo cranberry supplement vs placebo cranberry supplement￨urinary bacterial counts and white blood cell urinary tract infections urinary ph bacterial count wbc count or wbc and bacterial counts bacterial counts urinary wbc counts or utis wbc counts and the combination of bacterial and wbc counts￨cranberry tablets were not found to be effective at changing urinary ph or reducing bacterial counts urinary wbc counts or utis in individuals with neurogenic bladders￨no diff￨highunclear￨highunclear￨highunclear
137￨older women older women with recurrent utis one hundred and thirtyseven women with two or more antibiotictreated utis in the previous 12 months￨cranberry extract or 100 mg of trimethoprim trimethoprim cranberry extract with lowdose trimethoprim trimethoprim cranberry or trimethoprim cranberry extract￨relative risk of withdrawal time to first recurrence of uti median time to recurrence of uti antibiotictreated uti￨trimethoprim had a very limited advantage over cranberry extract in the prevention of recurrent utis in older women and had more adverse effects￨no diff￨low￨low￨low
not found￨2011 patients undergoing radiotherapy for cancer of the bladder or cervix patients undergoing pelvic radiotherapy for cancer of the bladder or cervix￨radical pelvic radiotherapy cranberry juice placebo placebo beverage copyright elsevier ltd pelvic radiotherapy￨urinary symptoms such as urinary frequency and cystitis urinary tract infections urinary symptoms and urinary tract infections urinary tract infections and urinary symptoms urinary symptoms or urinary tract infections￨the therapeutic effects of cranberry juice in the prevention and treatment of urinary tract infections in general are well documented￨sig increase￨low￨low￨low
15￨patients with neurogenic bladder receiving intermittent catheterization is 70 15 children receiving children with neurogenic bladder receiving clean intermittent catheterization children with neurogenic bladder receiving intermittent catheterization￨cranberry juice placebo cranberry prophylaxis cranberry concentrate cranberry concentrate or placebo concentrate￨frequency of bacteriuria acidification of urine bacteriuria rates of bacteriuria and symptomatic urinary tract infection signs and symptoms of urinary tract infection￨cultures of 75 114 of 151 of the 151 samples obtained during consumption of placebo were positive for a pathogen 104 colonyforming unitsml compared with 75 120 of 160 of the 160 samples obtained during consumption of cranberry concentrate￨sig increase￨highunclear￨highunclear￨highunclear
84￨eightyfour girls aged between 3 and 14 years children recurrent urinary tract infections children with recurrent urinary tract infections utis￨daily cranberry juice lactobacillus gg drink cranberry juice g1 cranberry juice cranberry lactobacillus or control￨recurrence of symptomatic utis￨there were 34 episodes of utis in this cohort 527 185 in g1 1126 423 in g2 and 1827 481 in the g3 with at least one episode of infection p005￨no diff￨highunclear￨highunclear￨highunclear
280￨280 postmenopausal women women with recurrent urinarytract infections 280 premenopausal women￨oral lactobacilli twice daily a capsule with  109 colonyforming units of lactobacillus rhamnosus gr1 and lactobacillus reuteri rc14 or standardised antibiotic therapy cranberry capsules twice daily 500 mg or standardised antibiotic therapy antibiotic prophylaxis nonantibiotic versus antibiotic prophylaxis trimethoprimsulfamethoxazole￨rate of recurrence of urinarytract infections and the development of antibiotic resistance recurrent urinarytract infections￨patient enrolment in the nonantibiotic versus antibiotic prophylaxis for recurrent urinarytract infections napruti study was started in september 2005￨no diff￨highunclear￨highunclear￨highunclear
not found￨spinal cord injured sci patients paralyzed veterans of america fortyseven subjects completed the trial spinal cord injured patients with neurogenic bladder subjects with spinal cord injury and documentation of neurogenic bladder sci patients with neurogenic bladder￨cranberry extract tablets cranberry extract tablet or placebo placebo cranberry tablets￨frequency of uti glomerular filtration rate gfr urinary tract infections incidence of uti urinary tract infection uti likelihood of uti and symptoms￨we found a reduction in the likelihood of uti and symptoms for any month while receiving the cranberry tablet p005 for all￨sig decrease￨low￨low￨low
376￨older hospital patients 376 older patients in hospital older people older people in hospital￨daily ingestion of 300 ml of cranberry juice or matching placebo beverage cranberry juice placebo cranberry juice ingestion￨actual infection rate infections with escherichia coli time to onset of first uti relative risk rr 051 adherence to beverage drinking courses of antibiotics prescribed and organisms responsible for utis symptomatic uti￨these betweengroup differences were not significant relative risk rr 051￨no diff￨low￨low￨low
319￨319 college women presenting with an acute uti otherwise healthy college women with an acute uti those drinking 8 oz of 27￨cranberry juice cranberry juice placebo cranberry￨distribution of the recurrences presence of urinary symptoms recurrent urinary tract infection recurrence rate 6month incidence of a second uti￨the presence of urinary symptoms at 3 days 12 weeks and at  1 month was similar between study groups with overall no marked differences￨no diff￨low￨low￨low
150￨women adult women one hundred fifty sexually active women aged 21 through 72 years￨placebo concentrated cranberry tablets versus cranberry juice versus placebo cranberry tablets naturopathic cranberry products cranberry juice and cranberry tablets prophylaxis placebo juice  placebo tablets versus placebo juice  cranberry tablets versus cranberry juice  placebo tablets￨number of patients experiencing at least 1 symptomatic utiyear cost effectiveness annual antibiotic consumption symptomatic utis cost savings total antibiotic consumption mean annual cost of prophylaxis￨cost savings were greatest when patients experienced 2 symptomatic utis per year assuming 3 days antibiotic coverage and had 2 days of missed work or required protective undergarments for urgency incontinence￨sig increase￨highunclear￨highunclear￨highunclear
not found￨persons with spinal cord injury sci participants were people with sci residing in the community who were 1 year or longer postinjury with neurogenic bladder managed by intermittent catheterization or external collection device and a baseline urine culture demonstrating at least 105 colonies per milliliter of bacteria persons with neurogenic bladder secondary to spinal cord injury￨concentrated cranberry juice or placebo cranberry extract cranberry extract placebo￨number of urine specimens with bacterial counts of at least 104 colonies per milliliter types and numbers of different bacterial species numbers of urinary leukocytes urinary ph or episodes of symptomatic urinary tract infection bacteriuria and pyuria￨cranberry extract taken in capsule form did not reduce bacteriuria and pyuria in persons with sci and cannot be recommended as a means to treat these conditions￨sig decrease￨low￨low￨low
150￨women university students and staff of university hospital 150 women with urinary tract infection caused by escherichia coli randomly allocated into three groups￨cranberrylingonberry juice and lactobacillus gg drink cranberrylingonberry juice concentrate cranberrylingonberry juice or with lactobacillus gg drink￨recurrence of urinary tract infection first recurrence of symptomatic urinary tract infection defined as bacterial growth 105 colony forming unitsml in a clean voided midstream urine specimen absolute risk urinary tract infections cumulative rate of first recurrence of urinary tract infection￨the cumulative rate of first recurrence of urinary tract infection during the 12 month follow up differed significantly between the groups p0048￨no diff￨low￨low￨low
543￨people with neuropathic bladder following spinal cord injury sci patients with neuropathic bladder following sci 543 eligible predominantly community dwelling patients were invited to participate in the study of whom 305 56 agreed eligible participants were people with sci with neurogenic bladder and stable bladder management￨methenamine hippurate mh or cranberry tablets placebo￨urinary tract infections uti time to occurrence of a symptomatic uti￨multivariate analysis revealed that patients randomized to mh did not have a significantly longer utifree period compared to placebo hr 096 95 ci 068135 p075￨no diff￨low￨low￨low
27￨pregnant subjects pregnant women 27 pregnant women subjects￨placebo cranberry in the am then placebo cranberry juice cocktail c placebo cranberry juice cocktail or placebo￨interleukin il6 of the urinary cytokines urinary cytokines il6 urinary cytokine excretion￨there was a statistically significant difference in interleukin il6 of the urinary cytokines between the multiple daily cranberry dosing group group a c c median 316 range 001 to 734 and the placebo group group c p p 932 053 to 2961 pgml p  0038 kruskalwallis test￨sig increase￨highunclear￨highunclear￨highunclear
386￨young adults with ischemic cerebrovascular disease 386 patients with a first ischemic stroke 217 were selected 106 triflusal 111 aas that completed the approaches of atheromatous infarct 161 males 722 and 58 female 258 the mean age was 43 years standard deviation sd 64 95 cl 2050￨aas lowdosage acetylsalicylic acid and triflusal aas sedergine￨mean time of follow cerebral infarcts ischemic cardiopathy and vascular death hemorrhagic complications cardiovascular events￨the mean time of followup for the group triflusal was of 483 months 2094 while for the group aas was of 463 months 284￨no diff￨highunclear￨highunclear￨highunclear
2124￨acute myocardial infarction patients were randomized within 24 h of acute myocardial infarction symptom onset to receive￨triflusal and aspirin triflusal 600 mg or aspirin aspirin￨death bleeding episodes death nonfatal myocardial reinfarction or a nonfatal cerebrovascular event fatal cerebrovascular events central nervous system bleeding episodes nonfatal reinfarction efficacy and tolerability incidence of nonfatal cerebrovascular events￨the primary endpoint was death nonfatal myocardial reinfarction or a nonfatal cerebrovascular event￨no diff￨low￨low￨low
not found￨patients with chronic peripheral arteriopathy patients affected by chronic peripheral arteriopathy￨placebo 300 mg triflusal with twicedaily placebo￨total walking distance and in painfree walking distance total walking distance peakflow￨patients treated with triflusal showed a more important increase in total walking distance and in painfree walking distance over the basal values than those treated with placebo together with an improvement of the symptomatology correlated with claudication￨sig increase￨highunclear￨highunclear￨highunclear
281￨281 patients patients with unstable angina￨triflusal against acute myocardial infarction placebo new antiplatelet agent triflusal 2acetoxy4trifluoromethyl benzoic acid triflusal en la￨nonfatal myocardial infarction and cardiac or vascular death principal endpoints need for revascularization myocardial infarction low number of deaths incidence of nonfatal acute myocardial infarction￨the need for revascularization was similar in the two groups 24 patients 168 in the triflusal group and 28 203 in the placebo group p  0449￨no diff￨highunclear￨highunclear￨highunclear
2113￨patients after cerebral infarction of 2113 patients 1058 received triflusal and 1055 patients with stroke or transient ischemic attack triflusal versus aspirin in cerebral infarction prevention￨triflusal and aspirin aspirin triflusal 600 mgd versus aspirin￨vascular events overall incidence of hemorrhage hemorrhagic complications nonfatal ischemic stroke nonfatal acute myocardial infarction or vascular death incidence of nonfatal stroke nonfatal acute myocardial infarction incidence of major hemorrhages vascular death survival analysis￨this study failed to show significantly superior efficacy of triflusal over aspirin in the longterm prevention of vascular events after stroke but triflusal was associated with a significantly lower rate of hemorrhagic complications￨no diff￨low￨low￨low
429￨buenos aires argentina from october 1996 to november 1999 429 patients were analyzed all patients had experienced either an ischemic stroke or tia within 6 months from enrollment 431 patients￨aspirin 325 mg daily or triflusal aspirin triflusal vs aspirin triflusal versus aspirin tapirss￨overall incidence of major and minor hemorrhagic events cerebral infarction incidence of vascular death cerebral ischemic infarction nonfatal myocardial infarction or major hemorrhage￨this pilot trial has not found differences between triflusal and aspirin in the prevention of vascular complications after tia or ischemic stroke although given the wide ci potentially important group differences could not be ruled out￨no diff￨low￨low￨low
not found￨patients with at least moderate lower back pain chronic lower back pain three hundred eighteen patients 161 tramadolapap 157 placebo were included in the intenttotreat population defined as all patients who took 1 dose of study medication and had 1 postrandomization efficacy measurement￨tramadolacetaminophen combination tablets placebo tramadol 375 mgapap tramadol and acetaminophen apap tramadolapap per day or placebo tramadolapap tramadol 375 mgapap 325 mg combination tablets tramadolapap￨roleemotional total score pva score scores on the pain relief rating scale prrs shortform mcgill pain questionnaire sfmpq roland disability questionnaire rdq and 36item shortform health survey sf36 the incidence of discontinuation due to insufficient pain relief kaplanmeier analysis and overall assessments of medication by the patients and investigators rdq scores mental health final prrs scores rolephysical nausea constipation bodily pain cumulative incidence of discontinuation due to insufficient pain relief final pva scores mean baseline pva score somnolence pain visual analog pva score health transition￨tramadolapap significantly improved final pva scores p  0015 and final prrs scores p  0001 compared with placebo￨sig increase￨low￨low￨low
380￨chronic low back pain two hundred fiftyfour patients three hundred eighty outpatients between 21 and 79 years with chronic low back pain with no or a distant history of back surgery enrolled in the open label phase and were treated with￨placebo tramadol tramadol or equivalent amount of placebo tramadol￨time to discontinuation due to inadequate pain relief distribution of time to therapeutic failure mcgill pain questionnaire roland disability questionnaire cumulative discontinuation rate due to therapeutic failure adverse event mean pain visual analog scores nausea dizziness somnolence and headache efficacy and safety￨there were significantly lower p  or  00001 mean pain visual analog scores 10 cm scale among tramadol patients 35 cm compared to placebo patients 51 cm at the final visit of the double blind phase￨sig decrease￨low￨low￨low
338￨338 patients with chronic lbp requiring daily medication for  or  3 months chronic low back pain chronic low back pain lbp patients with at least moderate pain pain visual analog scale vas with scores  or  40100 mm￨tramadol acetaminophen combination tablets ultracet placebo tramadol 375 mgapap 325 mg combination tablets tramadol 375 mgacetaminophen 325 mg tramadolapap combination tablets tramadolapap tramadolapap or placebo￨physical functioning and quality of life and in overall medication assessments efficacy failures mean baseline pain vas score analgesic efficacy and safety mean final pain vas scores adverse events mean final pain relief scores analgesic efficacy and safety nausea constipation roland disability questionnaire scores and physicalrelated subcategories of the mcgill pain questionnaire and the medical outcome study short form36 health survey pain relief quality of life and physical functioning efficacy failure and overall medication assessments final pain vas score dizziness pain reduction￨tramadol 375 mgapap 325 mg combination tablets show efficacy in pain reduction in measures of physical functioning and quality of life and in overall medication assessments with a tolerability profile comparable with other opioids used for the treatment of chronic lbp￨sig increase￨low￨low￨low
36￨patients with back pain 36 patients with back pain chronic noncancer back pain￨opioid therapy naproxen only 2 setdose oxycodone or 3 titrateddose oxycodone and sustainedrelease morphine sulfate opioids chronic opioid therapy antiinflammatory drug and two opioid regimens opioid therapy naproxen￨activity or hours asleep adverse events pain and improved mood emotional distress pain activity and sleep pain activity mood medication hours awake and adverse effects chronic back pain pain and mood signs of abuse behavior￨weekly reports during the experimental phase showed the titrateddose group to have less pain p  0001 and less emotional distress p  0001 than the other two groups￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨kindergartens n79 control children from nonintervention kindergartens n40 were retrieved from medical records at the division of school health preschool children in the hautegaronne department in france preschool children￨￨overweight prevalence gain in bmi zscore prevalence of overweight bmi zscore and change in bmi zscore overweight prevalence and bmi zscores￨after intervention prevalence of overweight bmi zscore and change in bmi zscore were significantly lower in intervention groups compared with controls in underprivileged areas￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨chilean primary school children primary school children￨nutrition education schoolbased obesity prevention 6 months nutrition education and physical activity intervention￨physical fitness parameters bmi z adiposity and physical fitness adiposity indices except tsf adiposity indices bmi bmi zscore triceps skinfold thickness tsf waist circumference and physical fitness 20 m shuttle run test and lower back flexibility physical fitness￨positive effect on adiposity indices except tsf was observed in boys p0001 for bmi z while both physical fitness parameters increased significantly in both boys p0001 for each test and girls p00001 for each test￨sig increase￨highunclear￨highunclear￨highunclear
634￨10 schools participating 634 children 350 boys and 284 girls aged 711 years all 10 schools participated throughout the study 10 primary schools in leeds￨primary school based intervention￨physical activity higher score for knowledge attitudes and self reported behaviour for healthy eating and physical activity response rates to questionnaires teachers evaluation of training and input success of school action plans content of school meals and childrens knowledge of healthy living and self reported behaviour￨intervention children showed a higher score for knowledge attitudes and self reported behaviour for healthy eating and physical activity￨sig increase￨highunclear￨highunclear￨highunclear
8￨elementaryschool children boys and girls n268 age 911 years children 8 elementary schools across 1 school year in british columbia canada beginning in 2003￨schoolbased physical activity intervention￨total cholesterol tc totalhighdensity cholesterol tchdlc lowdensity lipoprotein apolipoprotein b creactive protein and fibrinogen on a subset of volunteers n77 bp change in bmi cardiovascular disease risk factors cardiovascular fitness 20m shuttle run blood pressure bp and body mass index bmi wtht2 elevated risk factor fitness bp or bmi cardiovascular disease cvd risk profile￨int children had a 20 greater increase in fitness and a 57 smaller increase in bp compared with children attending up schools p005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨motherdaughter dyads african american women african american mothers and daughters￨obesity prevention program attention placebo culturally specific obesity prevention program￨dietary intake including daily fat intake daily saturated fat intake percentage of daily calories from fat and daily cholesterol intake daily saturated fat intake and percentage of calories from fat eating behavior cardiovascular disease cvd￨results showed significant differences between the treatment and control mothers for daily saturated fat intake and percentage of calories from fat￨sig decrease￨highunclear￨highunclear￨highunclear
311￨in 2002 311 children 78 response 49 boys average age 10 years 8 months were recruited from three government schools in low socioeconomic areas of melbourne australia 295 children at baseline and 268 at 12month followup children 10yearold children￨behavioural modification fundamental movement skills group fms n74 a combined bmfms￨fundamental movement skills higher levels and greater enjoyment of pa excess weight gain reduce time spent in screen behaviours promote participation in and enjoyment of physical activity pa levels of pa and tv viewing￨children in the bmfms group were less likely than controls to be overweightobese between baseline and post intervention adjusted odds ratio aor036 p005 also maintained at 12month followup aor038 p005￨sig decrease￨highunclear￨highunclear￨highunclear
1044￨9 to 10yearold children 1044 children mean age 94 years sd07 at baseline of the province of cuenca spain primary school children recreational noncompetitive physical activity program conducted after school hours on school premises￨school physical activity program physical activity program￨apo ai levels body mass index bmi triceps skinfold thickness tst and percentage body fat blood lipids and blood pressure tst apolipoprotein apo b levels diastolic blood pressure blood lipid results total cholesterol triglycerides or blood pressure bmi percentage of body fat￨no changes in total cholesterol triglycerides or blood pressure were associated with the intervention in either sex except for an increase in diastolic blood pressure 155 mm hg 95 ci 019291 p003 in the intervention versus control boys￨no diff￨low￨highunclear￨highunclear
not found￨latino children preschool minority children preschool children twelve predominantly latino head start centers participated in a grouprandomized trial conducted between fall 2001 and winter 2003 latino preschool children￨culturally proficient 14week three times weekly dietphysical activity intervention dietphysical activity intervention hiphop to health jr general health intervention that did not address either diet or physical activity￨excessive weight gain bmi dietary intake and physical activity change in bmi￨there were no significant differences between intervention and control schools in either primary or secondary outcomes at postintervention year 1 or year 2 followups￨no diff￨highunclear￨highunclear￨highunclear
not found￨minority children in the preschool years september 1999 and june 2002 in 12 head start preschool programs in chicago illinois preschool children preschool minority children￨culturally proficient dietaryphysical activity intervention￨bmi body mass index bmi kgm 2 food intakephysical activity￨intervention children had significantly smaller increases in bmi compared with control children at 1year followup 006 vs 059 kgm 2  difference 053 kgm 2￨sig decrease￨highunclear￨highunclear￨highunclear
76￨mexicanhispanic children 76 children 69 years old 32 of them increased their physical activity and 30 maintained the same level￨recreational physical activity￨insulin levels insulin homeostatic model assessment homa index glucose hdlc ldlc triglycerides and body mass index recreational physical activity homa index recreational activity increased their median daily steps physical activity diminution of insulin levels insulin levels and insulin resistance￨the diminution of insulin levels was more significant in the overweight group p  0007￨sig decrease￨highunclear￨highunclear￨highunclear
100￨8yearold africanamerican girls healthy children girls health enrichment multisite studies gems thirtyfive girls and their parents or caregivers￨special 4week summer day camp followed by a special 8week home internet intervention fun food and fitness project fffp￨body mass index bmi consumption of fruit 100 fruit juice and vegetables fjv physical activity bmi￨overall results at the end of the 12week program demonstrated substantial although not significant differences between treatment and control groups in the hypothesized directions￨no diff￨highunclear￨highunclear￨highunclear
1349￨participants were 1349 students in grades 4 through 6 from 10 schools in a us city in the midatlantic region with  or  50 of students eligible for free or reducedprice meals overweight 850th to 949th percentile and obesity  950th percentile among children in grades 4 through 6 over a 2year period overweight among children in grades 4 through 6 in urban public schools with a high proportion of children eligible for free and reducedpriced school meals￨multicomponent school nutrition policy initiative multicomponent schoolbased intervention￨prevalence of overweight prevalence and remission of overweight and obesity bmi z score total energy and fat intake fruit and vegetable consumption body dissatisfaction and hours of activity and inactivity incidence of overweight overweight and obesity incidence or prevalence of obesity￨a multicomponent schoolbased intervention can be effective in preventing the development of overweight among children in grades 4 through 6 in urban public schools with a high proportion of children eligible for free and reducedpriced school meals￨sig increase￨highunclear￨highunclear￨highunclear
8￨135 schoolchildren recruited from one private and one public school in florianópolis brazil and allocated to either an intervention group n  55 or a nointervention group n  80 overweightobesity and on foods eaten at primary schools overweightobesity and on the foods eaten by schoolchildren in the 2nd grade of primary education￨nutritional education nutritional education program￨intake of artificial juice intake of prohibited foods such as massproduced snacks percentage of overweightobese schoolchildren￨the intervention group significantly p  0013 reduced its intake of artificial juice which is prohibited by the act￨sig decrease￨highunclear￨highunclear￨highunclear
550￨elementary school students seven schools children 550 children who were measured in the fall and spring of both grades￨usual pe or control trained classroom teachers or pe specialists healthrelated physical education pe program physical education￨triceps and calf skinfolds and body mass index bmi bmis adiposity total skinfold levels of body fat￨after two years there was a trend for the children exposed to the pe intervention to have lower levels of body fat but the differences were not significant￨sig decrease￨highunclear￨highunclear￨highunclear
22￨fortyseven classes in twentytwo schools participants were 1140 912yearold fourth graders 435 in the intervention group and 608 in the control group discouraging students from drinking sodas￨￨daily consumption of carbonated drinks bmi reduction excessive weight gain change in bmi bmi  weight kgheight m2 fruit juice consumption￨a statistically significant decrease in the daily consumption of carbonated drinks in the intervention compared to control mean difference￨sig decrease￨highunclear￨highunclear￨highunclear
1323￨youth obesity prevention participants were 1323 children and their parents from 10 schools in two states multiple ecological level child obesity prevention program￨￨child sex for fruit and vegetable consumption physical activity and weight status family involvement for fruit and vegetable consumption and child body mass index for screen time childrens fruit and vegetable consumption and minimizing screen time parentreported fruit and vegetable consumption while childreported fruit and vegetable consumption parentreported screen time physical activity or body mass index key behaviors and body mass index screen time fruit and vegetable consumption￨the effect sizes of the differences between treatment and control groups ranged between small cohens d  015 for body mass index at 6 months postintervention to large 138 parent report of screen time at 6 months postintervention controlling for baseline levels￨no diff￨highunclear￨highunclear￨highunclear
1013￨1013 students in fourth and fifth grades from 69 classes in four states￨multidisciplinary elementary schoolbased intervention entitled wellness academics  you program materials￨consumption of fruits and vegetables and increased physical activity levels bmi consumption of fruits and vegetables and physical activity bmi spss spss inc chicago il￨analysis of postdata shows significant positive shifts p  001 in bmi in the intervention group compared with the comparison group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨from 1996 to 1999 a representative group of 2440 5 to 7yold children was recruited ie 302 of the total population of 5 to 7yold children examined by the school physicians and a full data set was obtained from 1640 children of the children 340 207 were considered as overweight and obese 1108 children 676 were normal weight and underweight was found in 192 children 117￨kops￨median triceps skinfolds￨interventions aimed to improve healthrelated behaviours had significant effects on the agedependent increases in median triceps skinfolds of the whole group from 109 to 113 mm in intervention schools vs from 107 to 130 mm in control schools p001 as well as in percentage fat mass of overweight children increase by 36 vs 04 per year without and with intervention respectively p005￨sig increase￨highunclear￨highunclear￨highunclear
1013￨freeliving children and parents freeliving noninstitutionalized children and parents parents one thousand thirteen children mean age 77 years and 1013 parents mean age 405 years fiftyfour elementary schools in paris france￨family dietary coaching family dietary coaching group a advised to reduce fat and to increase complex carbohydrate intake group b advised to reduce both fat and sugar and to increase complex carbohydrate intake or a control group given no advice monthly phone counseling and internetbased monitoring for 8 months￨energy intake nutritional intakes and body weight control nutritional intake mean changes in body mass index nutritional intakes and weight control nutritional intake body mass index calculated as weight in kilograms divided by height in meters squared fat mass physical activity blood indicators and quality of life￨compared with controls participants in the intervention groups achieved their nutritional targets for fat intake and to a smaller extent for sugar and complex carbohydrate intake leading to a decrease in energy intake children p  001 parents p  02￨sig increase￨low￨low￨low
1704￨american indian schoolchildren american indian communities elementary schools serving american indian communities 1704 children in 41 schools and was conducted over 3 consecutive years from 3rd to 5th grades in schools serving american indian communities in arizona new mexico and south dakota￨schoolbased multicomponent intervention multicomponent program￨percentage body fat percentage body fat other outcomes included dietary intake physical activity and knowledge attitudes and behaviors fat intake and in food and healthrelated knowledge and behaviors dietary intake 2 increase in physical activity 3 a classroom curriculum focused on healthy eating and lifestyle and 4 a familyinvolvement program activity levels total energy intake percentage of energy from fat￨total energy intake by 24h dietary recall was significantly reduced in the intervention schools but energy intake by direct observation was not￨sig increase￨highunclear￨highunclear￨highunclear
not found￨twentyfour elementary schools elementary school children￨physical activity across the curriculum intervention or served as control￨daily physical activity and academic achievement scores physical activity body mass index body mass index for physical activity overweight and obesity daily physical activity and academic achievement￨schools with  or 75 min of physical activity across the curriculumwk showed significantly less increase in body mass index at 3 years compared to schools that had 75 min of physical activity across the curriculum￨sig decrease￨highunclear￨highunclear￨highunclear
241￨all students 307 in the participating schools were invited to participate 153 children from 8 classrooms 1114 year old caucasian subjects 78 male 75 female three middle schools in naples italy children 241 subjects 88 children from 5 classrooms same age and ethnicity 55 male 33 female￨kalèdo questionnaire and anthropometric measures but they did not receive any play sessions with kalèdo￨nutrition knowledge and dietary behaviour nutrition knowledge￨children playing kalèdo showed a significant increase in nutrition knowledge p005 and in weekly vegetable intake p001 with respect to the control￨sig increase￨highunclear￨highunclear￨highunclear
365￨365 children with impending obesity age 4 to 7 years children with impending obesity 59 children of the intervention group opted for a participation and 49 of them took part to the end of the study children￨ageadapted nutrition and exercise program￨percentage of protein intake energy intake standarddeviationscore of the bmi bmi sds bmi sds￨this study population stabilized their bmi sds p  0025￨sig increase￨highunclear￨highunclear￨highunclear
not found￨families that contain at least one obese parent and a nonobese child families with obese parents and nonobese children obese parents and their children families at risk for childhood obesity￨parentfocused behavioral intervention comprehensive behavioral weightcontrol program and were encouraged to increase fruit and vegetable intake or decrease intake of highfathighsugar foods￨fat and sugar intake percentage of overweight￨parents in the increased fruit and vegetable group showed significantly greater decreases in percentage of overweight than parents in the decreased highfathighsugar group￨sig increase￨highunclear￨highunclear￨highunclear
60￨sixty africanamerican girls aged 8 to 10 years with a body mass index bmi  or  25th percentile of the cdc growth charts along with their parentscaregivers community centers in memphis tennessee preadolescent africanamerican girls and their parentscaregivers preadolescent africanamerican girls￨culturally relevant familybased intervention highly interactive weekly group sessions with either girls childtargeted program or parentscaregivers parenttargeted program culturally relevant obesity prevention interventions￨weight gain body mass index waist circumference and body composition physical activity level of moderatetovigorous activity feasibility perceived acceptability and efficacy consumption of sweetened beverages physical activity accelerometer data and in consumption of sweetened beverages and water￨in addition girls in the active intervention groups reduced their consumption of sweetened beverages by 34 increased their level of moderatetovigorous activity by 12 and increased their serving of water by 15￨sig increase￨highunclear￨highunclear￨highunclear
727￨all children who had at least one measurement of height and weight at any time during the study baseline and years 1 or 2 five hundred fiftyfour of 727 eligible children 76 participated children primary school children children who refused to participate n  14 or had moved from the study area n  159 did not differ from the remaining participants in baseline age sex or bmi￨￨mean bmi z score physical activity and healthy eating bmi adjusted body mass index bmi z score￨in a 2y intervention targeting increased physical activity and healthy eating in primary school children the adjusted body mass index bmi z score was 026 units 95 ci 021 032 lower in intervention than in control children￨sig increase￨highunclear￨highunclear￨highunclear
213￨children aged 57 years n213 were recruited from three primary schools in oxford children aged 57 years children￨nutrition group physical activity group and combined nutrition and physical activity group school and familybased intervention￨childrens growth nutrition knowledge diet and physical activity rates of overweight and obesity fruit consumption nutrition knowledge overall fruit and vegetable intake￨significant improvements in nutrition knowledge were seen in all children p001 between baseline and postintervention and results were highly significant in the nutrition and combined group p0001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨preschool nativeamerican children children 23 males were 22 5 years old with a mean bmi of 299 fortythree motherchild pairs were recruited to participate highrisk nativeamerican children mothers were 265￨opps intervention or ps alone parenting support psonly intervention obesity prevention plus parenting support opps intervention opps￨energy intake mean weightforheight z whz scores obesity prevention restriction subscale of the child feeding questionnaire weight and height whz score and weightforheight percentile for children dietary intake 3day food records physical activity measured by accelerometers parental feeding style child feeding questionnaire and maternal outcome expectations selfefficacy and intention to change diet and exercise behaviors whz scores￨scores on the restriction subscale of the child feeding questionnaire decreased significantly in the opps condition 022 042 vs 008 063 p  005 indicating that mothers in the opps group were engaging in less restrictive child feeding practices over time￨sig decrease￨highunclear￨highunclear￨highunclear
15￨middle school children 15 schools with seventh and eight graders￨personalized computertailored interventions intervention with parental involvement ii intervention alone and iii control group physical activity and healthy eating intervention middle school physical activity and healthy eating intervention￨physical activity fat intake fruit water and soft drink consumption physical activity physical activity and eating behaviours￨parental involvement did not increase intervention effects￨no diff￨highunclear￨highunclear￨highunclear
312￨participants were 312 children aged 10207 years attending nine schools in areas of social disadvantage children with high screen time primary school children children with high and low screen time￨health education interventions health education intervention￨selfefficacy for physical activity physical activity and screen time physical activity selfefficacy for physical activity and aerobic fitness physical activity￨crosssectional comparisons at baseline indicated lower physical activity selfefficacy for physical activity and aerobic fitness and a higher bmi in children with high screen time￨sig increase￨highunclear￨highunclear￨highunclear
not found￨77 racially diverse sedentary girls in grades 6 7 and 8 from two middle schools￨intervention or control condition handout listing the pa recommendations computerized individually tailored feedback messages based on her responses to the questionnaires individual counseling from the schools pediatric nurse practitioner pnp and telephone calls and mailings from a trained research assistant￨social support across time physical activity participation social support￨no differences in selfreported pa emerged between the intervention and control groups at weeks 1 baseline and 12 postintervention￨no diff￨highunclear￨highunclear￨highunclear
6￨six schools 89 girls in the intervention and 112 girls in the control conditions adolescent girls￨innovative schoolbased program schoolbased obesity prevention program￨physical activity eating patterns and selfimage physical activity eating patterns selfperceptions and body mass index bmi behavioral change for physical activity￨however for the majority of outcome variables differences between intervention and control schools at postintervention and followup were not statistically significant￨no diff￨highunclear￨highunclear￨highunclear
606￨students participants included 606 fourthgrade students selected from a stratified sample of 35 schools in arizona and placed into four groups youth play on childrens physical activity￨schoolbased intervention called play promoting lifestyle activity for youth play  pe play only pe￨physical activity level physical activity levels and body mass index bmi bmi￨no significant differences between groups were found for bmi￨no diff￨highunclear￨highunclear￨highunclear
103￨103 adolescents aged 13 to 18 years who regularly consumed ssbs to intervention and control groups adolescents￨sugarsweetened beverages ssbs ssb consumption decreasing sugarsweetened beverage consumption￨weight change and baseline bmi body weight ssb consumption consumption of ssbs body mass index bmi bmi change￨consumption of ssbs decreased by 82 in the intervention group and did not change in the control group￨no diff￨highunclear￨highunclear￨highunclear
not found￨preschoolage children subjects were 292 secondyear elementary school pupils from 2 kindergartens in hat yai municipality songkhla province southern thailand preschool children￨schoolbased aerobic exercise program 296wk schoolbased exercise program schoolbased exercise program￨lower likelihood of having an increasing bmi slope bmi gain weight height and triceps skinfold thickness response of body mass index bmi to exercise￨girls in the exercise group had a lower likelihood of having an increasing bmi slope than the control girls did odds ratio 032 95 ci 018 056￨sig increase￨highunclear￨highunclear￨highunclear
not found￨control school children lowincome elementary schools with primarily hispanic students participants were 896 thirdgrade children 473 control schools 224 girls and 249 boys and 423 catch schools 199 girls and 224 boys 93 were hispanic lowincome hispanic communities lowincome schools with hispanic students child risk of overweight in lowincome schools￨￨percentage of risk of overweight or overweight￨girls in control schools had significant increases in percentage of risk of overweight or overweight from third 26 to fifth 39 grades as did girls in catch schools 3032 however the rate of increase for girls in the catch schools was significantly lower 2 compared with the rate for control girls 13￨sig increase￨highunclear￨highunclear￨highunclear
878￨eight hundred seventyeight adolescent girls and boys aged 11 to 15 years adolescents￨primary care officebased computerassisted diet and pa assessment and stagebased goal setting followed by brief health care provider counseling and 12 months of monthly mail and telephone counseling and 2 a comparison condition addressing sun exposure protection primary care and homebased intervention for physical activity and nutrition behaviors pace￨sedentary behaviors body mass index number of servings of fruits and vegetables body mass index￨percentage of adolescents meeting recommended health guidelines was significantly improved for girls for consumption of saturated fat intervention vs control change 234 to 410 vs 185 to 31 respectively relative risk 133 95 confidence interval 101168 and for boys participation in dwk of pa intervention vs control change 453 to 554 vs 419 to 380 respectively relative risk 147 95 confidence interval 119175￨sig increase￨highunclear￨highunclear￨highunclear
3135￨ten schools were selected in stockholm county area and randomized to intervention n5 and control n5 schools overweight in 6 to 10yearold children 3135 boys and girls in grades 14 were included in the study￨schoolbased intervention programme￨normal weight physical activity pa pa healthy eating habits prevalence of overweight and obesity eating habits eating disorders￨eating habits at home were found to be healthier among families with children in intervention schools at the end of the intervention￨sig increase￨highunclear￨highunclear￨highunclear
1108￨dutch adolescents defined as persons between 12 and 14 years of age 1108 adolescents mean age 127 years teenagers￨intervention schoolbased program multicomponent health promotion intervention dutch obesity intervention￨body composition body composition and behavior body composition and dietary and physical activity behavior consumption of snacks or active commuting to school body height and weight waist circumference 4 skinfold thickness measurements and dietary and physical activity behavior data consumption of sugarcontaining beverages screenviewing behavior￨multilevel analyses showed that the intervention remained effective in preventing unfavorable increases in important measures of body composition after 20month followup in girls biceps skinfold and sum of 4 skinfolds and boys triceps biceps and subscapular skinfolds￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨girls middle school girls with englishspeaking skills 36 schools in six geographically diverse areas of the united states adolescent girls 6th graders in 2003 n1721 and 8th graders in 2005 n3504 and 2006 n3502 middle school girls￨mvpa￨daily metweighted minutes of moderatetovigorous physical activity metweighted mvpa physical activity fitness or percent body fat percent body fat￨following the program championdirected intervention girls in intervention schools were more physically active than girls in control schools mean difference 109 metweighted minutes of mvpa 95 ci052212￨sig increase￨highunclear￨highunclear￨highunclear
206￨18 schools medical college of georgia fitkid project 206 youths who remained in the same schools for the 3year period who were measured at all six time points and for the intervention group who attended at least 40 of the sessions in each of the 3 years healthy growth in youths￨school physical activity intervention school physical activity pa intervention academic enrichment activities during which healthy snacks were provided and 80 min of moderatetovigorous pa mvpa￨heart rate response to a benchstepping taskbf and bone density fitness and body composition fitness and body fat bone density fatfree soft tissue weight body mass index aerobic fitness and percent body fat bf￨the group by time interactions were significant for fitness p  001 and bf p  005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨comparison sample was a stratified random selection of preschools n4 and primary schools n12 from the rest of the barwon south western region of victoria with baseline assessment in 20032004 n1183 response rate 44 and followup in 2006 children through community capacitybuilding colac children in four preschools and six primary schools at baseline 2003 n1001 response rate 58 and followup 2006 children aged 412 years in the australian town of colac children without increasing health inequalities￨baew￨waistheight body weight mean changes in underweight and attempted weight loss unhealthy weight gain body mass index zscore￨building community capacity to promote healthy eating and physical activity appears to be a safe and effective way to reduce unhealthy weight gain in children without increasing health inequalities￨sig increase￨highunclear￨highunclear￨highunclear
not found￨16 preschool andor day care centers in rural upstate new york children aged 26 through 55 years preschool children children attending intervention centers young childrens television viewing￨children attending the control centers received a safety and injury prevention program 7session program designed to reduce television viewing as part of a health promotion curriculum￨televisionvideo viewing percentage of children watching televisionvideos child televisionvideo viewing and measured growth variables￨the percentage of children watching televisionvideos more than 2 hd also decreased significantly from 33 to 18 among the intervention group compared with an increase of 41 to 47 among the control group for a difference of 215 95 confidence interval 425 to 05 p 046￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨nonoverweight adolescents adolescents by increasing physical activity subjectsnine hundred and fifty four 12yearold sixgraders 2002 in eight middle schools of eastern france overweight in adolescents￨multilevel program￨fat mass index highdensity cholesterol concentrations excessive weight gain supervised physical activity body mass index bmi body composition physical activity by questionnaire plasma lipids and glucose insulin resistance bmi tvvideo viewing￨intervention students had a lower increase in bmi p001 and age and genderadjusted bmi p002 over time than controls￨sig decrease￨highunclear￨highunclear￨highunclear
545￨young children thirty six nurseries in glasgow scotland 545 children in their preschool year mean age 42 years sd 02 at baseline￨physical activity intervention physical activity￨motor skills body mass index higher performance in movement skills tests physical activity and sedentary behaviour fundamental movement skills and evaluation of the process physical activity and sedentary behaviour by accelerometry￨group allocation had no significant effect on the primary outcome measure at six and 12 months or on measures of physical activity and sedentary behaviour by accelerometry￨no diff￨low￨low￨low
2744￨girls 24 high schools a schoolbased sample of 2744 girls 487 african american 467 white participated in a measurement protocol when they were in eighth and then ninth grade many adolescent girls highschool girls￨comprehensive schoolbased intervention comprehensive physical activity intervention￨physical activity vigorous physical activity￨at followup 45 of girls in the intervention schools and 36 of girls in the control schools reported vigorous physical activity during an average of 1 or more 30minute time blocks per day over a 3day period￨sig increase￨highunclear￨highunclear￨highunclear
82￨families n  105 with at least one 8 to 12yearold child who was atriskforoverweight or overweight designated as the target child were recruited for the study children and adults eightytwo families￨familybased program aimed at increasing steps and cereal consumption for breakfast and snacks specific increases in daily steps an additional 2000 stepsd and consumption of 2 servingsd of readytoeat cereal￨percentage bmiforage and percentage body fat for target children and weight bmi and percentage body fat for parents excessive weight gain weight gain￨the intervention had positive significant effects on percentage bmiforage and percentage body fat for target children and weight bmi and percentage body fat for parents￨sig increase￨highunclear￨highunclear￨highunclear
not found￨adolescent boys adolescent boys with suboptimal cardiorespiratory fitness thirtythree 7th grade boys mean age12504 years￨multifaceted schoolbased intervention usual physical activity curriculum sessions schoolbased obesity prevention program￨feasibility acceptability and potential efficacy percentage body fat waist circumference total weekday physical activity cardiorespiratory fitness unhealthy weight gain implementation and attendance rates fitness improvement and lifestyle awareness bmi bmi and secondary outcomes included waist circumference percentage body fat cardiorespiratory fitness objectively measured physical activity and small screen recreation time time spent in small screen recreation￨at followup compared with boys in the active comparison group boys in the intervention group displayed a smaller increase in bmi adjust diff02 95 confidence interval ci 078 039 cohens d005 greater reductions in waist circumference 165 cm 467 136 d015 percentage body fat 169 498 160 d022 and time spent in small screen recreation on weekends 113 h 506 280 d019 and a greater increase in cardiorespiratory fitness 213 laps 622 1048 d016 and participation in total weekday physical activity 14074 countsmin 15944 44092 d036￨sig decrease￨low￨low￨low
679￨323 children screen viewing and 472 children body mass index participants included 679 children in year 5 age 910 19 primary schools in south west england 50 schools  approximately 1250 pupils￨￨healthy eating physical activity and reducing tv viewing hours of screen activities body mass index mode of transport to school and teachers views of the intervention screenviewing activities mean body mass index￨children from intervention schools spent less time on screenviewing activities after the intervention but these differences were imprecisely estimated mean difference in minutes spent on screen viewing at the end of the intervention intervention schools minus control schools adjusted for baseline levels and clustering within schools was 116￨sig decrease￨low￨low￨low
not found￨africanamerican girls sixtyone 810yearold africanamerican girls and their parentsguardians￨school dance classes and a familybased intervention to reduce television viewing dance and reducing television viewing disseminating newsletters and delivering health education lectures￨feasibility acceptability and potential efficacy reduced household television viewing weight gain recruitment and retention goals waist circumference dinners eaten while watching tv implementation and process measures body mass index waist circumference physical activity measured by accelerometry selfreported media use and meals eaten with tv school physical activity body mass index reduced television videotape and video game use concern about weight school grades￨the treatment group reported significantly reduced household television viewing d  73 p  007 and fewer dinners eaten while watching tv adjusted difference  160 mealsweek 95 ci 299 21 d  59 p  03￨sig decrease￨highunclear￨highunclear￨highunclear
425￨obese children young children young children aged 610 years 425 children in 14 primary schools 2 weekly pa sessions of 1 h each compared to 5 control schools￨physical activity intervention preventive pa intervention schoolbased pa￨body composition bmi bmi zscore waist circumference sum of skinfolds and fatfree mass bmi zscore anthropometric variables adiposity indices prevalence of obesity and anthropometric characteristics bmi￨in contrast in boys only bmi zscore p  0001 and fatfree mass p  0001 were affected￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨girls health enrichment multisite studies gems￨gems￨￨each field center developed its own interventions and corresponding control and tailored its study to the specific hypothesis being tested￨sig increase￨highunclear￨highunclear￨highunclear
not found￨acute mania￨placebo olanzapine olanzapine 10 mg or placebo olanzapine olanzapine and placebo olanzapine hgeh placebo olanzapine capsule olanzapine￨young mania rating scale total score adverse events total score on the young mania rating scale parkinsonism akathisia and dyskinesias efficacy and safety somnolence dizziness dry mouth and weight gain￨somnolence dizziness dry mouth and weight gain occurred significantly more often with olanzapine￨sig increase￨low￨low￨low
30￨30 patients meeting dsmiv criteria for mania in mania￨lithium olanzapine olanzapine neuroleptics olanzapine or lithium￨brief psychiatric rating scale clinical global impression cgi improvement scale cgiseverity scale mania scale￨there were no significant outcome differences between the two groups on any of the primary outcome measures the brief psychiatric rating scale lithium 282 olanzapine 280 p  044 clinical global impression cgi improvement scale lithium 275 olanzapine 236 p  0163 or the mania scale lithium 132 olanzapine 102 p  0315￨no diff￨low￨low￨low
115￨acute bipolar mania 115 patients with a dsmiv diagnosis of bipolar disorder manic or mixed￨olanzapine vs placebo placebo olanzapine olanzapine￨efficacy epss sd weight gain youngmania rating scale ymrs total score tolerated rate of response treatmentemergent somnolence sd improvement in ymrs total score adverse events extrapyramidal symptom eps rating scales laboratory values electrocardiograms vital signs and weight change efficacy and safety￨safety was assessed using adverse events extrapyramidal symptom eps rating scales laboratory values electrocardiograms vital signs and weight change￨no diff￨low￨low￨low
not found￨acute mania patients hospitalized for acute bipolar manic or mixed episodes￨flexibly dosed olanzapine olanzapine olanzapine divalproex olanzapine and divalproex￨proportion of patients achieving protocoldefined remission response and remission rates remission of mania symptoms completion rates average weight gain hamilton depression scale score nausea dry mouth increased appetite and somnolence mean total score on the young mania rating scale weight gain and cases of dry mouth increased appetite and somnolence safety mean improvement of mania ratings young mania rating scale and the hamilton depression rating scale mean young mania rating scale score young mania rating scale score￨the most common treatmentemergent adverse events incidence 10 occurring more frequently during treatment with olanzapine were dry mouth increased appetite and somnolence￨sig increase￨highunclear￨highunclear￨highunclear
344￨mania in patients partially nonresponsive to valproate or lithium monotherapy patients with bipolar disorder n  344 manic or mixed episode who were inadequately responsive to more than 2 weeks of￨olanzapine cotherapy placebo olanzapine cotherapy olanzapine  moodstabilizer or monotherapy placebo  moodstabilizer valproate or lithium valproate or lithium alone olanzapine cotherapy lithium or valproate therapy￨young mania rating scale ymrs scores 21item hamilton depression rating scale hamd21 total scores clinical response rates patients ymrs total scores extrapyramidal symptoms simpsonangus scale barnes akathisia scale abnormal involuntary movement scale hamd21 scores somnolence dry mouth weight gain increased appetite tremor and slurred speech severe depressive symptoms ymrs￨olanzapine cotherapy improved 21item hamilton depression rating scale hamd21 total scores significantly more than monotherapy 498 vs 089 points p 001￨sig increase￨low￨low￨low
25￨twentyfive patients who had been treated in a behaviorally oriented inpatient alcohol dependence treatment program and who lived with a significant other ie spouse sibling parent participated in the study discharged alcohol patients to a disulfiram antabuse regimen alcoholic veterans￨￨antabuse compliance compliance rates￨furthermore 84 of this s sample were abstinent at the 3month followup according to collateral reports￨no diff￨highunclear￨highunclear￨highunclear
2684￨186 screened positive 154 were eligible and 80 enrolled patients wrote with help from a computer program 2684 patients were approached and 2399 screened with the alcohol use disorders identification test audit with problem drinkers in primary medical care￨computergenerated written behavioral contracts￨audit and addiction severity index alcohol scores￨at 12 months the audit and addiction severity index alcohol scores decreased nonsignificantly more in the intervention group than in the controls￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨￨return rates for reaction readings￨return rates under both commitment conditions significantly increased￨sig increase￨highunclear￨highunclear￨highunclear
not found￨fortytwo 7 through 11yearold children with persistent asthma children with asthma￨￨asthma morbidity and mortality adherence￨at week 5 intervention group adherence median  79 was higher than the usual care group adherence median  64 but the difference was not statistically significant￨sig increase￨highunclear￨highunclear￨highunclear
794￨tuberculosis among adolescents a total of 794 adolescents were recruited into the study for a 79 participation rate adolescents infected adolescents at two health centers serving ethnically diverse populations￨peer counseling and a participantparent contingency contract intervention innovative educational strategies behavioral interventions￨overall rate of treatment completion selfefficacy selfefficacy and mastery￨participants randomized to the peer counseling groups demonstrated significantly greater improvements in selfefficacy and mastery than the usual care control group￨sig increase￨highunclear￨highunclear￨highunclear
80￨eighty experienced contact lens patients￨compliance enhancement strategy renu multipurpose solution and medalist 38 soft contact lenses bausch and lomb rochester new york￨compliance levels compliance levels￨the results indicate that the compliance enhancement strategy had little significant effect on the compliance levels of the patients to who it was applied￨no diff￨highunclear￨highunclear￨highunclear
50￨50 male participants in an inpatient alcohol treatment program￨appointmentkeeping intervention calendar prompt and homebased attendance contract intervention experimental group n  25 or standard aftercare treatment arrangements control￨￨the present study provides an effective technology for increasing aftercare attendance and thus potentially increasing the probability of long term maintenance of alcohol treatment effects￨sig increase￨highunclear￨highunclear￨highunclear
112￨one hundred twelve subjects with documented high blood pressure￨education alone home blood pressure monitoring contracts pill packs or a combination of techniques￨blood pressure systolic and diastolic blood pressure￨there was a statistically significant change in both systolic and diastolic blood pressure for all compliance groups 1710 mm hg￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨￨selfreported adherence￨adherence measured by unannounced pill counts was significantly higher for experimental subjects than for control ss￨sig increase￨highunclear￨highunclear￨highunclear
15￨fifteen overweight girls aged 5 to 11 yr￨weightreduction treatments responsecost plus reinforcement responsecost only or a notreatment control group￨weight slower weight gain￨at the end of the 12week treatment period both experimental groups had lost significantly more weight than the control group￨sig decrease￨highunclear￨highunclear￨highunclear
36￨before participating in a bse training workshop subjects n  36￨coworkerdelivered reminders to perform breast selfexamination bse￨bse frequency bse adherence￨a process evaluation indicated that the control group pairs were similar to the contract group pairs in their prompting behavior￨no diff￨highunclear￨highunclear￨highunclear
not found￨participants n  102 entered 6month￨mtt with contingency contracts using monetary reinforcers and targeting abstinence from illicit drug and alcohol use and 51 entered mtt without contingency contracts targeting abstinence methadone transition treatment mtt￨longer periods of continuous abstinence￨after 4 months of treatment individuals in the contingency condition had longer periods of continuous abstinence p005 and more drugfree tests overall p04￨sig increase￨highunclear￨highunclear￨highunclear
35￨people with rheumatoid arthritis people with rheumatoid arthritis ra￨joint protection jp educationalbehavioural joint protection programme￨pain functional disability grip strength selfefficacy or helplessness adherence with jp use of jp￨no significant changes in measures of pain functional disability grip strength selfefficacy or helplessness occurred posteducation although this may have been due to the small sample size recruited￨no diff￨highunclear￨highunclear￨highunclear
2￨￨traditional treatment program that used contingency contracting and that emphasized the necessity for absolute abstinence aa or to b a relapseprevention rp treatment rp intervention￨1year abstinence rates￨participants in the rp intervention were more likely to lapse sooner after quitting and were more likely to quit again during the 1year maintenance period￨sig decrease￨highunclear￨highunclear￨highunclear
91￨ninetyone hypertensive patients￨￨￨ninetyone hypertensive patients randomly assigned among the three programs rated their care in terms of active patient orientation apo￨sig increase￨highunclear￨highunclear￨highunclear
115￨hypertensives 115 patients￨￨adherence to requests for regular medical care max l diastolic blood pressures lowering blood pressures blood pressure levels adherence and lowering blood pressures￨5132 p less than 0001 adherence to requests for regular medical care max l 2  259 p less than 0001 and decreasing diastolic blood pressures f 249￨sig increase￨highunclear￨highunclear￨highunclear
90￨participants were 40 males in an inpatient substance abuse treatment program at a veterans affairs medical center vamc￨20minute aftercare orientation session brief orientation session￨substance abuse aftercare participation￨participants who received the aftercare orientation were more likely to attend aftercare 70 than those who received the minimal treatment 40￨sig increase￨highunclear￨highunclear￨highunclear
not found￨360 new admissions to methadone maintenance￨counseling 1 medication only 2 standard counseling and 3 enhanced services and one of two contingency contracting conditions 1 no contingencies nc and 2 contingency contracting cc￨opiate positives￨for opiate positives a significant level of counseling by contingency contracting interaction was found with medication onlycc subjects obtaining fewer opiate positives than medication onlync subjects￨sig increase￨highunclear￨highunclear￨highunclear
395￨395 patients with noninsulindependent diabetes who underwent the initial patient assessment 352 completed the study patients with diabetes diabetic patients patients with noninsulindependent diabetes mellitus patients with noninsulindependent diabetes￨footcare education and entered into a behavioral contract for desired selffoot care which was reinforced through telephone and postcard reminders patient health care provider and systems intervention￨reduction of lower extremity clinical abnormalities dermatologic abnormalities serious foot lesions￨an intervention designed to reduce risk factors for lower extremity amputations positively affected patient selffootcare behavior as well as the foot care given by health care providers and reduced the prevalence of lower extremity clinical disease in patients with diabetes￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨preterm infants at risk for chronic lung disease cld preterm infants at risk of chronic lung disease patients gestational age 26109 weeks birth weight 826140 g meansd preterm neonates with rds and a birth weight of less than 1200 g preterm infants￨early systemic dexamethasone therapy dexamethasone systemic dexamethasone inhaled beclomethasone inhaled steroids daily inhaled beclomethasone prophylactic treatment with inhaled beclomethasone beclomethasone surfactant￨concentrations of interleukin8 elastase alpha1 proteinase inhibitor and albumin oxygen requirements lung inflammation lung inflammation and pulmonary microvascular permeability levels of interleukin8 elastase alpha1 proteinase inhibitor free elastase activity and albumin inflammatory mediators albumin and oxygen requirements pulmonary inflammation and lung permeability concentrations of the inflammatory mediators and of albumin￨pulmonary inflammation and lung permeability were assessed by analyzing the levels of interleukin8 elastase alpha1 proteinase inhibitor free elastase activity and albumin in tracheal aspirates on days 10 and 14 of life￨sig decrease￨highunclear￨highunclear￨highunclear
24￨copyright 2002 by the american congress of rehabilitation medicine and the american academy of physical medicine and rehabilitation twentyfour women over the age of 75 years with hip fracture quadriceps muscle after hip fracture￨neuromuscular or placebo placebo neuromuscular stimulation neuromuscular stimulation￨indoor mobility ability recovery of walking speed and ability postural stability lowerlimb muscle power and pain faster recovery of mobility recovery of walking speed￨mean difference13ms 95 confidence interval 23 to 01￨sig decrease￨low￨low￨low
209￨a total of 209 women were recruited with an average age of 810 years sd69 older adults following a hip fracture older women posthip fracture￨exercise plus exercise only plus only ie motivation or routine care exercise plus program￨overall trajectory of time in exercise trajectories of recovery time spent exercising￨a statistically significant difference in the overall trajectory of time in exercise was seen p001 with more time spent exercising in all three treatment groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨nutritionally at risk older adults following lower limb fracture frail undernourished older adults with a fallrelated lower limb fracture experience one hundred nutritionally at risk older adults hospitalized following a fallrelated lower limb fracture￨daily multinutrient energydense oral supplement oral nutrition supplementation and resistance training nutritional supplementation and resistance training triweekly resistance training combined treatment n  24 or attention control plus usual care and general nutrition and exercise advice resistance training without concurrent nutrition support￨weight loss significant weight loss weight risk of weight loss health outcomes weight change quadriceps strength gait speed quality of life and health care utilization￨those receiving resistance training alone lost more weight than those receiving the combined treatment p 0029￨sig decrease￨highunclear￨highunclear￨highunclear
120￨one hundred twenty older people entered the trial 40 per group average age after usual care for hip fracture australian communitydwellers 82 and residents of aged care facilities who had completed usual care after a fallrelated hip fracture older people who have completed usual care after a fallrelated hip fracture older people who have had a hip fracture￨home exercise prescribed by a physical therapist weightbearing versus nonweightbearing exercise weightbearing and nonweightbearing home exercise programs and a control program weightbearing home exercise program￨physical ability measures of balance and functional performance physical ability strength balance gait functional performance strength balance gait and functional performance functional performance￨at the 4month retest there were differences between the groups in the extent of improvement since the initial assessment for balance f10196282 p001 and functional performance f6200357 p001 but not for strength f12190109 p37 or gait f820039 p92￨sig increase￨highunclear￨highunclear￨highunclear
40￨twenty control subjects received 40 elderly women who had fractured the neckoffemur fractured neckoffemur￨treadmill gait retraining treadmill gait retraining program gait retraining conventional gait retraining￨mobility level discharge mobility level muscle strength and range of movement of the lower limb temporaldistance gait parameters and mobility level housebound limited or unlimited￨however a significant increase in withingroup variance from admission to discharge p less than 01 was noted and this led to the analysis of a subgroup containing six pairs of subjects matched for number of predictors of poor outcomeabstract truncated at 250 words￨sig increase￨highunclear￨highunclear￨highunclear
not found￨elderly subjects rehabilitating after fracture elderly patients rehabilitating after surgical fixation of proximal femoral fracture 11 patients quadriceps after proximal femoral fracture elderly postsurgical proximal femoral fracture patients￨supplementary electrical stimulation of the quadriceps 15 patients to usual physiotherapy alone electrical stimulation quadriceps using electrical stimulation es￨leg extensor power and decreases disability sustained palpable or visible contractions with no leg movement fractured leg extensor power change in leg extensor power nottingham power rig tolerated sufficient stimulation intensity to produce repetitive knee extension leg extensor power or reduce disability functional mobility elderly mobility scale disability barthel index and health status nottingham health profile leg extensor power￨there was no significant difference in change in leg extensor power or any other outcome measure in the es group compared to usual care controls￨no diff￨low￨low￨low
not found￨fortytwo people 64 to 94 years of age 35 of whom were living independently in the community and 7 of whom were residing in institutional care after hip fracture subjects were recruited on average 7 months after a fallrelated hip fracture hip fracture￨home exercise program home exercise￨strength and walking velocity strength postural control and mobility strength and mobility subjective falls risk walking velocity quadriceps strength weightbearing ability quadriceps strength postural sway functional reach weightbearing ability walking velocity and selfrated fall risk￨within the intervention group improvements in quadriceps strength were significantly associated with improved performances in the weightbearing test measures and with increased walking velocity￨sig increase￨highunclear￨highunclear￨highunclear
not found￨older inpatients following hip fracture eighty people mean age 81 years sd 8 undergoing inpatient rehabilitation after fallrelated hip fracture inpatients soon after hip fracture inpatients after hip fracture￨weightbearing and nonweightbearing exercise programs weightbearing versus nonweightbearing exercise weightbearing and nonweightbearing exercise weightbearing or nonweightbearing exercise prescribed by a physiotherapist￨physical ability strength balance gait and functional performance￨there were also additional functional benefits for the weightbearing groupimproved ability to complete a lateral stepup on the affected leg with nil or one hand supports or 34 95 ci 11 to 123 and the need for less supportive walking aids p  0045￨sig increase￨highunclear￨highunclear￨highunclear
not found￨sixty patients 41 women and 19 men mean age 794 years admitted between march 2004 through december 2004 to the alfred hospital melbourne for surgical management of a hip fracture were studied￨early ambulation ea￨acute hospital length of stay and destination at discharge postoperative cardiovascular instability discharged directly home from the acute care functional levels need highlevel care￨patients in the ea group were more likely to be discharged directly home from the acute care than those in the da group 263 compared with 24 and less likely to need highlevel care 368 compared with 56￨sig increase￨highunclear￨highunclear￨highunclear
not found￨twentyeight 15 intervention 13 control elderly patients with a history of injurious falls admitted to acute care or inpatient rehabilitation because of acute fallrelated hip fracture or elective hip replacement older people living at home and nursing home residents geriatric patients after severe falls and hip surgery patients after hip surgery and a history of injurious falls elderly patients suffering from the acute sequelae of injurious falls or hip surgery￨placebo intensive exercise training intensive progressive physical training intensive physical exercise intensive physical training physical training 68 weeks after hip surgery progressive resistance training and progressive functional training￨strength and functional performance strength feasibility safety and efficacy adherence strength functional motor performance and balance and reduced fallrelated behavioural and emotional problems strength functional performance and emotional state medical problems￨some improvements in strength persisted during 3months followup while other strength variables and functional performances were lost after cessation of training￨sig increase￨highunclear￨highunclear￨highunclear
87￨thirty nine patients were treated with the thompson endoprosthesis and 48 with internal fixation elderly subjects with femoral neck fractures patients mean age was 73 years and 75 of the patients were women elderly patients with femoral neck fractures 87 patients with femoral neck fractures￨intensive physical therapy routine postoperative physical therapy of the department and the other half intensive physical therapy routine physical therapy intensified physical therapy￨wound infections mortality morbidity and mortality rates￨the clinical results in the cases who had received intensive physical therapy and those given routine physical therapy did not differ during the postoperative followup period of 9 weeks￨sig increase￨highunclear￨highunclear￨highunclear
160￨after hip fracture 160 people with surgical fixation for hip fracture transferred to inpatient rehabilitation 150 participants 94 of those recruited completed the trial￨mobility training exercise programme conducted whilst standing and the control group received a lower dose exercise programme 30 minday primarily conducted whilst seatedsupine￨walking speed knee extensor muscle strength in the fractured leg and walking speed measured at 4 and 16 weeks￨however people with hip fracture and cognitive impairment gained greater benefit from the higher dose programme than from the lower dose programme￨sig increase￨highunclear￨highunclear￨highunclear
25￨twentyfive patients recently discharged from an acute orthopedic department patients with hip fracture after surgery patients with hip fracture￨postoperative homebased physical therapy 3month homebased physical therapy pt program homebased pt practice the exercise program￨hip rom strength walking velocity harris hip score and healthrelated quality of life hrqol muscle strengthening range of motion rom balance and functional training function and quality of life physical domain score psychologic domain of hrqol￨moreover the physical domain score of the homebased pt group was also significantly better p05 at 3 months after discharge￨sig increase￨highunclear￨highunclear￨highunclear
33￨elderly patients who have had a hip fracture perform moderate to highintensity exercise at home people with hip fracture thirtythree elderly people 24 women 9 men mean  786 years of age sd  68 range  6489 who had completed a regimen of physical therapy following hip fracture participated in the study￨home exercise program of moderate or highintensity exercise aerobic training portable progressive resistance exercise machine resistance training group an aerobic training group or a control group highintensity exercise￨isometric lowerextremity force 6minutewalk distance free gait speed mental status and physical function distance walked force produced gait speed and physical function depressive symptoms isometric force 6minutewalk distance and gait speed heart rate￨isometric force improved to a greater extent in the intervention groups than in the control group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨40 patients with 40 patients elderly proximal femoral fracture patients eighty patients rehabilitating after proximal femoral fracture patients rehabilitating after proximal femoral fracture￨progressive highintensity quadriceps training quadriceps training quadriceps training systematic progressive highintensity quadriceps training six weeks quadriceps training standard physiotherapy alone￨barthel score leg extensor power and reduces disability elderly mobility scale score leg extensor power nottingham power rig functional mobility elderly mobility score disability barthel index and quality of life nottingham health profile leg extensor power energy subscore of the nottingham health profile leg extensor power and reduced disability￨quadriceps training resulted in a greater increase in elderly mobility scale score compared with standard rehabilitation betweengroup difference of 25 95 ci 1138 at week 6 and 19 0434 at week 16￨sig increase￨low￨low￨low
60￨60 patients with ao 31a2 fractures of the hip who were randomised after stabilisation of the fracture into two equal groups one of which received patients with a trochanteric fracture of the femur￨postoperative treatment using a noninvasive interactive neurostimulation device and the other with a sham device￨visual analogue scale for pain the brief pain inventory and ketorolac for postoperative control of pain and an overall assessment of outcome by the surgeon￨there were significantly better results for the patients receiving treatment by active electrical stimulation repeated measures analysis of variance p  0001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨after hip fracture communitydwelling frail elderly patients with hip fracture 6 months of extended outpatient rehabilitation august 1998 and may 2003 among 90 communitydwelling women and men aged 65 years or older who had had surgical repair of a proximal femur fracture no more than 16 weeks prior and had completed standard physical therapy physically frail elderly patients with hip fracture￨supervised physical therapy and exercise training n  46 or home exercise control condition n  44 lowintensity home exercise extended outpatient rehabilitation physical therapy progressive resistance training￨total scores on a modified physical performance test ppt the functional status questionnaire physical function subscale fsq and activities of daily living scales physical function and quality of life and reduce disability muscle strength walking speed balance and perceived health but not bone mineral density or fatfree mass standardized measures of skeletal muscle strength gait balance quality of life and body composition mean change sd in ppt score for physical therapy mean change sd in fsq score for physical therapy physical function and reduces disability ppt and fsq scores￨changes over time in the ppt and fsq scores favored the physical therapy group p 003 and p 01 respectively￨sig increase￨low￨low￨low
44￨after hip fracture eightyeight patients transferred for rehabilitation after surgical treatment for hip fracture￨physical therapy intensive physical therapy intensive physical therapy￨duration of physical rehabilitation duration of physical rehabilitation until the patient was able to 1 walk 50 metres in less than 2 minutes 2 manage stair climbing to the first floor 3 manage sittostand transfer 4 move in and out of bed 5 manage bathing dressing and lavatory visits￨no difference between the two groups was demonstrated in the duration of physical rehabilitation by a per protocol analysis of the patients who completed the trial￨no diff￨highunclear￨highunclear￨highunclear
62￨patients with bronchial asthma oesophageal dysfunction on bronchial asthma asthmatic patients sixtytwo patients with both bronchial asthma and oesophageal dysfunction od￨od conservative treatment￨alleviation of their oesophageal and bronchial symptoms signs of od consumption of betaadrenergic stimulating drugs oesophageal symptoms lung function tests￨lung function tests did not differ between the group treated for 2 months and the control group but there was a significant reduction in consumption of betaadrenergic stimulating drugs in the treatment group compared with the control group￨no diff￨highunclear￨highunclear￨highunclear
20￨eighteen patients completed the study twenty patients with bronchial asthma who also had gastrooesophageal reflux were investigated￨cimetidine barium swallow and meal fibreoptic endoscopy and biopsy manometry and ph monitoring of the distal oesophagus and an acid infusion test￨reflux and night time asthmatic symptoms severity of their reflux chest symptoms￨significant improvements were seen in reflux and night time asthmatic symptoms both these indices being measured on a scoring system￨sig increase￨highunclear￨highunclear￨highunclear
not found￨asthmatic patients with esophagitis patients with asthma would improve pulmonary function asthmatics with gastroesophageal reflux patients with asthma￨omeprazole omeprazole prilosec placebo￨pulmonary function fev1 pulmonary function gastroesophageal reflux ger respiratory function￨four of 15 27 asthma patients with ger were shown to have a  or  20 net improvement in pulmonary function fev1 after treatment for six weeks with omeprazole￨sig increase￨highunclear￨highunclear￨highunclear
not found￨twenty patients eight female and 12 male completed the study asthma patients with gor adult patients with both asthma and gor adult asthma and gastrooesophageal reflux￨placebo placebo or omeprazole omeprazole omeprazole therapy placebo and omeprazole omeprazole potent gastric acid inhibitor omeprazole￨day and night heartburn symptoms spirometry and diary cards gastrooesophageal reflux gor day time wheeze cough breathlessness beta 2agonist use or night time wheeze and breathlessness upper gastrointestinal endoscopy 24 hour oesophageal ph measurements spirometry and histamine bronchoprovocation test hit evening pefr fev1 fvc histamine bronchial responsiveness and diurnal variation of pefr peak expiratory flow rate pefr asthma symptoms and histamine bronchial responsiveness asthma symptoms inhaled beta 2agonist use and histamine bronchial responsiveness￨no significant differences were found in fev1 fvc histamine bronchial responsiveness and diurnal variation of pefr between placebo and omeprazole treatments￨no diff￨highunclear￨highunclear￨highunclear
11￨patients with nocturnal asthma and gastrooesophageal reflux eleven adult patients with nocturnal asthma and gastrooesophageal reflux documented by endoscopy or ambulatory oesophageal ph monitoring asthmatics with nocturnal symptoms and gastrooesophageal reflux￨omeprazole placebo omeprazole omeprazole 20 mg daily and placebo￨asthma symptoms or peak expiratory flow rate peak expiratory flow rate readings asthma control assessed by symptoms peak expiratory flow rate and bronchodilator usage asthma symptoms￨omeprazole treatment did not improve asthma symptoms during the day or night or peak expiratory flow rate readings￨no diff￨highunclear￨highunclear￨highunclear
37￨asthmatic children and adolescents with or without pathological gastrooesophageal reflux 37 children and adolescents mean age 14 yrs with bronchial asthma children and adolescents with bronchial asthma and pathological gor￨placebo ranitidine acid reflux gastrooesophageal reflux gor ranitidine￨asthma symptoms and the degree of acid reflux nocturnal asthma symptoms pathological gor￨a modest 30 but statistically significant reduction of nocturnal asthma symptoms was produced by ranitidine in the patients with pathological gor when compared to those with normal gor￨sig decrease￨highunclear￨highunclear￨highunclear
9￨asthmatics with gastroesophageal reflux nine patients with documented asthma and gastroesophageal reflux￨omeprazole placebo omeprazole omeprazole 20 mg daily or placebo￨forced expiratory volume at 1 s fev1 peak expiratory flow rate pefr and responses on the asthma quality of life questionnaire a validated disease specific measure of functional status higher fev1 asthma quality of life questionnaire and on the subdomains of activity limitation symptoms and emotions pulmonary function and quality of life mean morning and evening pefr pefr and quality of life peak expiratory flow rate and quality of life￨after omeprazole treatment compared with placebo patients had higher mean morning and evening pefr mean absolute difference 95 ci morning 378 lmin￨sig increase￨low￨low￨low
90￨patients with nonallergic pulmonary disease patients presenting to a chest clinic because of adultonset wheezing with no history of allergy had a 90 percent prevalence of gastroesophageal reflux even though reflux symptoms were mild or absent nonallergic asthma associated with gastroesophageal reflux ninety patients￨cimetidine or an identical placebo or to undergo antireflux surgery placebo cimetidine￨pulmonary medication intake intake of pulmonary medication￨at longterm followup the surgical group maintained clinical improvement and decreased pulmonary medication intake whereas the placebo group worsened￨sig increase￨highunclear￨highunclear￨highunclear
36￨patients with asthma and chronic obstructive pulmonary disease copd patients with severe airway hyperresponsiveness and asymptomatic gastrooesophageal reflux 36 allergic and nonallergic subjects 17 males and 19 females mean age 52 yrs with airway obstruction and severe airway hyperresponsiveness despite maintenance treatment with an inhaled corticosteroid and with increased acid gastrooesophageal reflux patients with asthma and chronic obstructive pulmonary disease who have severe airway hyperresponsiveness despite maintenance treatment with inhaled corticosteroids￨omeprazole 40 mg bid or placebo placebo intensive antireflux therapy omeprazole omeprazole acid gastrooesophageal reflux￨reflux airway hyperresponsiveness as determined by the provocative concentration of methacholine producing a 20 fall in forced expiratory volume in one second pc20 and airway obstruction acid reflux and improvement of reflux symptoms scores peak expiratory flow variability reversibility to inhaled ipratropium bromide as a parameter of vagal activity asthma symptoms scores and medication used￨for 3 months had no beneficial effect on any of the pulmonary parameters despite its profound effect on acid reflux and improvement of reflux symptoms scores compared to placebo￨no diff￨low￨low￨low
107￨asthmatics patients with ger one hundred seven asthmatic patients patients with asthma patients who were found to have ger in ambulatory esophageal ph monitoring asthma patients who benefit from excessive antireflux therapy asthmatic patients who attended the pulmonary outpatient clinic of turku university central hospital finland￨omeprazole placebo￨nocturnal asthma symptoms decline in corrected fev1 values typical reflux symptoms pathologic ger gastroesophageal reflux ger peak expiratory values use of sympathomimetics and pulmonary and gastric symptoms daytime pulmonary symptoms daytime asthma outcome nighttime asthma symptoms gastroesophageal reflux￨daytime pulmonary symptoms did not improve significantly p  014 but a reduction in nighttime asthma symptoms p  004 was found during omeprazole treatment￨no diff￨highunclear￨highunclear￨highunclear
not found￨adults with cystic fibrosis cystic fibrosis cf adults with the disease￨new behavioral homebased nutrition education program eat well with cf behavioral nutrition intervention eat well with cf￨weight change over 6 and 12 months and changes in cfspecific nutrition knowledge score selfefficacy score reported dietary fat intake and healthrelated qualityoflife score specific cf nutrition knowledge score selfefficacy score and reported fat intake body mass index or healthrelated quality of life over time￨there were substantial improvements in the intervention groups specific cf nutrition knowledge score selfefficacy score and reported fat intake compared to control but no substantial change in body mass index or healthrelated quality of life over time￨sig increase￨highunclear￨highunclear￨highunclear
not found￨young asthmatics children with asthma children child or adolescent with asthma asthmatic children￨swimming training swimming intervention 6 week swimming intervention￨pft pef and severity of asthma pulmonary function tests pft pef and severity of asthma severity of asthma pef￨there was a significant improvement p  001 in pef in the experimental group compared with the control group 330 lmin 95 ci 309351 vs 252 lmin 95 ci 235269 after the swimming intervention￨sig increase￨highunclear￨highunclear￨highunclear
7￨another group of seven asthmatics age  114  15 served as control subjects asthmatic children we have trained seven asthmatics age  114 asthmatic children asthmatic children in an exercise readaptation program￨aerobic training individualized aerobic and high intensity training￨ventilatory threshold vth intensity level cardiopulmonary fitness￨another group of seven asthmatics age  114  15 served as control subjects￨no diff￨highunclear￨highunclear￨highunclear
not found￨children and adolescents with mpaa children and adolescents age 718 years with mpaa was carried out at the hospital de clínicas of universidade estadual de campinas unicamp campinas brazil schoolchildren and adolescents with moderate persistent atopic asthma mpaa 61 patients 34 female children and adolescents with moderate persistent atopic asthma￨swim training program inhaled fluticasone swimming program salbutamol￨elastic recoil of the chest wall pc₂₀ bronchial hyperresponsiveness mip mep spirometric parameters and bronchial hyperresponsiveness pc₂₀ values maximal inspiratory pressure mip and maximal expiratory pressure mep￨children and adolescents with mpaa subjected to a swim training program experienced a significant decrease in bronchial hyperresponsiveness as determined by increased pc₂₀ values when compared with asthmatic controls who did not undergo swim training￨sig increase￨highunclear￨highunclear￨highunclear
8￨five children ages 712 years old with moderate persistent asthma asthma children participating in exercise programs asthmatic children eight children with moderate persistent asthma￨swimming lesson group 5 to 6week session standard swimming lessons￨asthma symptoms or pfts asthma symptoms symptoms and pulmonary function tests pfts cardiorespiratory fitness￨swimming lessons did not produce a significant change in asthma symptoms or pfts￨no diff￨highunclear￨highunclear￨highunclear
8￨children with asthma children with bronchial asthma eight children with mild or moderate asthma participated in￨swimming training￨mean sd aerobic capacity at lt mean sd maximum  fall in forced expiratory volume histamine responsiveness aerobic capacity and the degree of eib aerobic capacity exercise induced bronchoconstriction eib and bronchial responsiveness aerobic capacity and exercise induced bronchoconstriction aerobic capacity￨the mean sd aerobic capacity at lt increased by 026 011 kp after training when assessed with the swimming ergometer and by 106 45 w when assessed with the cycle ergometer and these changes were significantly different from the control group￨sig increase￨highunclear￨highunclear￨highunclear
28￨twentyeight children in the swimming group and 17 in the golf group completed the program children with asthma children with asthma 714 years old residing in milwaukees highest asthma prevalence zip codes innercity children with asthma￨vigorous physical activity swimming and moderateintensity activity golf moderate and vigorous exercise programs￨six symptom exacerbations asthma symptom severity scores childhood asthma symptoms and physician office visits and improved parental qol symptoms and quality of life qol safety parental satisfaction asthma symptoms quality of life and urgent asthma physician visits parental qol urgent physician visits for asthma￨participants and parents reported reduced childhood asthma symptoms and physician office visits and improved parental qol￨sig decrease￨highunclear￨highunclear￨highunclear
62￨cirrhotics with highrisk esophageal varices 62 patients with cirrhosis with highrisk esophageal varices patients with cirrhosis with highrisk esophageal varices￨banding and propranolol propranolol titrated to reducing resting pulse by  or 25 or banding performed monthly until varices were eradicated propranolol￨failure rates of failure first esophageal varix hemorrhage and cumulative mortality initial variceal hemorrhage esophageal variceal hemorrhage direct costs of care variceal hemorrhage or a severe medical complication requiring discontinuation of therapy failure rate of propranolol direct costs cumulative mortality rate direct costs of medical care￨significantly more propranolol than banding patients had esophageal variceal hemorrhage 431 vs 031 difference 129 p  0443￨sig decrease￨highunclear￨highunclear￨highunclear
75￨cirrhotic patients with high risk esophageal varices 75 patients with cirrhosis and highrisk esophageal varices hrev￨ppl evl propranolol ppl endoscopic band ligation versus propranolol endoscopic variceal ligation evl￨survival source of bleeding and serious adverse events overall mortality rate of subcardial variceal bleeding rate of esophageal variceal bleeding gastroesophageal variceal bleeding variceal bleeding variceal bleeding actuarial risks of bleeding￨overall mortality was 51 in evl and 33 in ppl group p017￨no diff￨low￨low￨low
100￨100 cirrhotic patients with no history of previous upper gastrointestinal bleeding and with esophageal varices endoscopically judged to be at high risk of hemorrhage patients with cirrhosis cirrhotic patients with highrisk esophageal varices￨endoscopic variceal ligation versus propranolol prophylaxis evl propranolol endoscopic variceal ligation evl￨2year cumulative bleeding rate 2year cumulative mortality rate bleeding and death adverse events mean daily dosage overall mortality variceal bleeding pulse rate rate of first esophageal variceal bleeding hepatic failure mortality efficacy and safety￨lifetable curves showed that prophylactic evl and propranolol were similarly effective for primary prophylaxis of variceal bleeding 1150￨no diff￨highunclear￨highunclear￨highunclear
62￨candidates for liver transplantation lt 62 patients with childturcottepugh bc cirrhosis and high risk varices received transplant candidates who can be treated with bb 31 or variceal banding 31 primary prophylaxis of variceal bleeding in candidates for liver transplantation￨ligation with propranolol propranolol betablockers bb￨mean costs adverse events deaths and bleeding related deaths variceal hemorrhages postbanding ulcers variceal bleeding￨deaths and bleeding related deaths were 3 and 1 for banding and 3 and 2 for bb respectively p  ns￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with large varices f2 f3 and elevated hepatic venous wedge pressure gradient hvwpg  or  12 mm hg highrisk subjects 31 patients child a 11 b 14 c 6 with a mean hvwpg of 19  91 mm hg￨endoscopic band ligation band ligation nonselective betablockers with band ligation nonselective betablockers betablockers liver transplantation￨bleeding bleeding rate variceal bleeding mortality bleeding rates￨treatmentrelated complication were minimal in both groups￨no diff￨highunclear￨highunclear￨highunclear
152￨patients who are not candidates for longterm ppl treatment 10 years alcoholic etiology 51 child one hundred fiftytwo cirrhotic patients with 2 or more esophageal varices diameter 5 mm without prior bleeding primary prophylaxis of variceal bleeding variceal bleeding in cirrhosis￨ppl ligation versus propranolol endoscopic variceal banding ligation vbl with propranolol ppl vbl vbl and ppl￨overall mortality bleeding incidence nor mortality fatal bleeding 2year actuarial risks variceal bleeding variceal bleeding actuarial risks of bleeding￨the actuarial risks of bleeding after 2 years were 20 vbl and 18 ppl￨no diff￨highunclear￨highunclear￨highunclear
30￨patients with cirrhotic pht patients with portal hypertension pht included symptomatic bradycardia requiring reduction of dose in one of 15 patients thirty cirrhotic patients with pht grade iii to iv oesophageal varices hepatic venous pressure gradient  or  12 mmhg and no prior history of upper gastrointestinal bleeding primary prophylaxis of oesophageal variceal bleed￨endoscopic variceal ligation evl endoscopic variceal ligation evl propranolol￨major complication or interval bleeding variceal bleeding varices variceal eradication￨there was no major complication or interval bleeding￨no diff￨highunclear￨highunclear￨highunclear
172￨11 years child 172 patients with cirrhosis grade ii or iii esophageal varices that had never bled were recruited 44 into vbl 66 into ppl and 62 into ismn baseline patient characteristics age 55￨vbl ismn variceal band ligation vbl propranolol ppl and isosorbide5mononitrate ismn propranolol and isosorbide mononitrate￨variceal hemorrhage 2year actuarial risks for first variceal bleed actuarial risk for bleeding side effects variceal bleeding mortality rates￨there were no statistically significant differences in mortality rates in the 3 groups￨no diff￨low￨low￨low
73￨patients with cirrhosis and large esophageal varices forty patients underwent patients with large esophageal varices 73 consecutive patients with liver cirrhosis and large esophageal varices without a history of gastrointestinal bleeding￨evbl or propranolol endoscopic variceal band ligation evbl propranolol evbl nonselective betablockers endoscopic variceal band ligation￨variceal bleeding actuarial probability of death actuarial risk for first variceal bleed￨a total of 73 consecutive patients with liver cirrhosis and large esophageal varices without a history of gastrointestinal bleeding were randomized to receive either evbl or propranolol and were followed for up to 18 months￨no diff￨highunclear￨highunclear￨highunclear
89￨bleeding from esophageal varices patients with highrisk esophageal varices 89 patients 82 of whom had cirrhosis of the liver 44 received consecutive eligible patients who had large varices 5 mm in diameter that were at high risk for bleeding￨endoscopic ligation and propranolol variceal ligation propranolol propranolol therapy propranolol therapy and endoscopic ligation￨recurrent varices mean number of sessions needed to complete variceal ligation variceal bleeding bleeding bleeding before their varices actuarial probability of bleeding mean sd duration heart rate serious complications of variceal ligation￨there were no serious complications of variceal ligation in the propranolol group treatment was stopped in two patients because of side effects￨no diff￨highunclear￨highunclear￨highunclear
100￨100 patients with cirrhosis and endoscopically determined highrisk esophageal varices but no history of bleeding patients with cirrhosis and highrisk esophageal varices patients with cirrhosis￨nadolol endoscopic ligation vs nadolol betablocker￨minor complications uncontrollable variceal hemorrhage variceal obliteration uppergi bleeding pulse rate esophageal variceal bleeding efficacy and safety serious complication￨in the ligation group variceal obliteration was achieved in 41 patients 82 at a mean of 27 11 ligation sessions￨sig increase￨highunclear￨highunclear￨highunclear
60￨cirrhotic patients with highrisk varices cirrhotic patients sixty patients with cirrhosis and oesophageal varices with no history but at high risk of bleeding￨propranolol endoscopic variceal ligation endoscopic variceal ligation vs propranolol propranolol￨actuarial risks of variceal bleeding variceal bleeding prevention of first variceal bleeding variceal obliteration mortality￨variceal ligation is a safe and more effective method than propranolol treatment for the prevention of first variceal bleeding in cirrhotic patients with highrisk varices￨sig increase￨highunclear￨highunclear￨highunclear
152￨seventyseven patients patients with highrisk esophageal varices one hundred fiftytwo cirrhotic patients from five different centers with grade ii or larger esophageal varices￨carvedilol and vbl carvedilol carvedilol 125 mg once daily or vbl propranolol carvedilol vbl￨bleedingrelated mortality overall mortality bleeding rates rates of the first variceal bleed￨carvedilol a noncardioselective vasodilating betablocker is more effective in reducing portal pressure than propranolol however there have been no clinical studies assessing the efficacy of carvedilol in primary prophylaxis￨sig increase￨low￨low￨low
33￨33 patients with a solid renal mass of 7 cm or less 11 patients underwent each type of procedure￨transperitoneal procedure with morcellation and a retroperitoneal procedure with intact specimen extraction laparoscopic radical nephrectomy namely transperitoneal retroperitoneal and hand assisted laparoscopic radical nephrectomy￨operative time blood loss hernia formation incision size hospital stay and time to normal daily activity age american society of anesthesiologists class body mass index or tumor size shorter hospital stay narcotic use mean operative time greatest risk of hernia formation￨in our series the hand assisted approach had significantly shorter operative time than the transperitoneal or retroperitoneal approach but it had the greatest risk of hernia formation￨sig decrease￨highunclear￨highunclear￨highunclear
40￨40 patients with stage ct1t2￨transperitoneal laparoscopic versus retroperitoneoscopic radical nephrectomy robotic assistance system aesop lrn and rrn endoscopic radical nephrectomy transperitoneal and retroperitoneal approaches laparoscopic radical nephrectomy lrn and retroperitoneoscopic radical nephrectomy rrn lrn￨number and size of the trocars used length of incision specimen weight pathologic stage operative time need for additional procedures such as adrenalectomy andor lymph node sampling estimated blood loss need for blood transfusions analgesic requirement length of hospital stay or the incidence of minor or major complications￨no statistically significant differences were found between the two approaches in terms of the number and size of the trocars used length of incision specimen weight pathologic stage operative time need for additional procedures such as adrenalectomy andor lymph node sampling estimated blood loss need for blood transfusions analgesic requirement length of hospital stay or the incidence of minor or major complications￨no diff￨highunclear￨highunclear￨highunclear
not found￨premature neonates born  35 weeks 35 neonates premature neonates  35 weeks premature neonates infants weighing  1500 g with￨dcc delayed cord clamping dcc immediate cord clamping icc immediate versus delayed umbilical cord clamping delayed versus immediate cord clamping￨polycythemia initial diastolic bp and higher hct mean bp bilirubin levels higher blood pressure bp and hematocrit hct￨infants weighing  1500 g with dcc tended to have higher mean bp and needed less mechanical ventilation and surfactant compared with icc neonates￨sig increase￨highunclear￨highunclear￨highunclear
38￨38 women with preterm labour￨umbilical cord clamping￨ultrasonographic evidence of periventricularintraventricular haemorrhage pvhivh periventricularintraventricular haemorrhage and umbilical cord clamping￨ultrasonographic evidence of periventricularintraventricular haemorrhage pvhivh assessed blindly was found in 77 of the group clamped early compared with 35 of those in whom clamping of the cord was delayed for 1 minute￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨preterm infants￨immediate versus delayed clamping delayed versus immediate cord clamping￨apgar scores after birth and daily snap scores rbc volumemass and hct clinical benefits adverse effects higher hct values circulating rbc volumemass multiple clinical and laboratory comparisons over the first 28 days including score for neonatal acute physiology snap rbc volumemass per biotin labeling after delayed clamping initial bilirubin levels red blood cell rbc transfusions weekly hematocrit hct values rbc transfusions￨circulating rbc volumemass increased p  004 and weekly hematocrit hct values were higher p  0005 after delayed clamping￨sig increase￨highunclear￨highunclear￨highunclear
not found￨fourtysix infants born at 2633 weeks gestation preterm infants￨delaying cord clamping delayed umbilical cord clamping delayed cord clamping placental transfusion following a 30 s delay in cord clamping following vaginal and caesarean births￨mean haematocrits venous haematocrit￨the trends were more marked in the infants born by caesarean section and in those born at 2629 weeks gestation￨sig decrease￨highunclear￨highunclear￨highunclear
40￨infants born at less than 29 weeks gestation 40 singleton infants born between 24 and 28 weeks gestation very preterm infants￨umbilical cord milking umbilical cord clamped either immediately control group n  20 or after umbilical cord milking umbilical cord milking￨shorter duration of ventilation or supplemental oxygen initial mean sd haemoglobin value probability of not needing transfusion determined by kaplanmeier analysis and the total number of rbc transfusions gestational age and birth weight haemoglobin value and blood pressure at admission mean sd blood pressure at admission number mean sd of rbc transfusions neonatal adaptation red blood cell rbc transfusion and morbidity mortality needed red cell transfusion￨the initial mean sd haemoglobin value was higher in the milked group 165 14 gl than in the controls 141 16 gl p001￨sig increase￨low￨low￨low
36￨and preterm infants 36 vaginally delivered infants over 27 and under 33 weeks gestation preterm infants￨mechanical ventilation umbilical cord clamping umbilical cord clamping￨arterialalveolar oxygen tension ratio and also packed cell volume initial packed cell volume peak serum bilirubin concentrations red cell transfusion requirements and respiratory impairment assessed by ventilatory requirements arterialalveolar oxygen tension ratio over the first day in ventilated infants and duration of dependence on supplemental oxygen mean minimum arterialalveolar oxygen tension ratio median red cell transfusion requirements median duration of dependence on supplemental oxygen mean initial packed cell volume duration of supplemental oxygen dependence and red cell transfusion requirements￨there were statistically significant differences between the two groups in mean initial packed cell volume regulated group 0564 random group 0509 and median red cell transfusion requirements regulated group zero random group 23 mlkg￨no diff￨highunclear￨highunclear￨highunclear
37￨37 premature infants gestational age 34 weeks 0 days36 weeks 6 days preterm infants delivered at 34 36 weeks gestation￨delayed cord clamping￨neonatal period blood glucose and haemoglobin levels umbilical cord delayed clamping of the umbilical cord and pathological jaundice or polycythaemia haematocrit levels haemoglobin and ferritin levels haemoglobin levels￨the late cordclamped group showed consistently higher haemoglobin levels than the early cordclamped group both at the age of 1 hour mean sd 134 19 mmol￨sig increase￨highunclear￨highunclear￨highunclear
32￨32 infants between 24 and 32 weeks infants born between 24 and 32 weeks￨icc immediate and delayed cord clamping dcc delayed cord clamping dcc versus immediate cord clamping icc￨blood pressure initial glucose levels initial mean blood pressures￨dcc group infants had higher initial glucose levels icc36 mgdl dcc731 mgdl p002￨sig increase￨highunclear￨highunclear￨highunclear
23￨women were excluded for the following reasons their obstetrician refused to participate major congenital anomalies multiple gestations intent to withhold care severe maternal illnesses placenta abruption or previa or rapid delivery after admission male infants 23 male infants in the dcc group had ivh versus 8 of the 19 in the icc group seventytwo motherinfant pairs very low birth weight vlbw infants on 2 primary variables bronchopulmonary dysplasia bpd and suspected necrotizing enterocolitis snec women in labor with singleton fetuses 32 weeks gestation￨icc immediate icc and delayed dcc cord clamping delayed cord clamping dcc￨rates of ivh and los initial hematocrit lateonset sepsis los and intraventricular hemorrhage ivh sepsis maternal and infant demographic clinical and safety variables incidence of our primary outcomes bpd and suspected nec intraventricular hemorrhage and lateonset sepsis￨two of the 23 male infants in the dcc group had ivh versus 8 of the 19 in the icc group￨sig increase￨low￨low￨low
10￨40 infants of  33 gestational weeks preterm infants delivered mainly by 20 infants in group 1 20 s had a mean birth weight of 1070 g and a mean gestational age of 29  47 weeks versus 1190 very low birth weight preterm infants preterm infants below 33 weeks of gestation￨delayed cord clamping caesarean section oxytocin￨apgar scores temperature on admission heart rate blood pressure and requirements for artificial ventilation postpartal adaptation and anaemia of prematurity￨there were no significant differences in apgar scores temperature on admission heart rate blood pressure and requirements for artificial ventilation￨no diff￨highunclear￨highunclear￨highunclear
256￨massachusetts medical society hemodynamically stable patients with acute submassive pulmonary embolism patients with acute pulmonary embolism and pulmonary hypertension or right ventricular dysfunction but without arterial hypotension or shock 256 patients enrolled 118 patients with submassive pulmonary embolism stable patients who have acute submassive pulmonary embolism￨heparinplusalteplase thrombolytic agents heparin plus alteplase heparinplusplacebo heparin plus alteplase heparin heparin alteplase heparin plus placebo heparin plus 100 mg of alteplase or heparin plus placebo heparin alone￨since mortality risk of death or treatment escalation fatal bleeding or cerebral bleeding probability of 30day eventfree survival hospital death or clinical deterioration requiring an escalation of treatment which was defined as catecholamine infusion secondary thrombolysis endotracheal intubation cardiopulmonary resuscitation or emergency surgical embolectomy or thrombus fragmentation by catheter￨the incidence of the primary end point was significantly higher in the heparinplusplacebo group than in the heparinplusalteplase group p0006 and the probability of 30day eventfree survival according to kaplanmeier analysis was higher in the heparinplusalteplase group p0005￨sig decrease￨low￨low￨low
not found￨patients with acute pulmonary embolism patients with objectively established acute symptomatic pulmonary embolism who were receiving patients with pulmonary embolism patients with thrombotic disease rtpa￨rtpa placebo heparin recombinant tissue plasminogen activator rtpa saline placebo recombinant tissue plasminogen activator￨minor bleeding mean relative improvement in the perfusion defect perfusion defect lung scan resolution transfusion requirements major bleeds￨minor bleeding occurred in 15 of the rtpa patients mainly at angiogramcatheter insertion and venipuncture sites￨no diff￨low￨low￨low
20￨patients with lifethreatening pulmonary embolism major pulmonary embolism 20 patients with major pulmonary embolism verified by angiography￨streptokinase of heparin streptokinase and heparin heparin streptokinase or heparin streptokinase￨bleeding angiographic evidence of thrombolysis￨the angiographic evidence of thrombolysis was significantly greater p less than 001 in the 14 patients treated with streptokinase than in the 11 treated with heparin￨sig increase￨highunclear￨highunclear￨highunclear
not found￨thirteen patients with acute pulmonary embolism acute pulmonary embolism￨recombinant tissue plasminogen activator rtpa 40 to 80 mg usually in combination with heparin or with placebo plus heparin placebo tissue plasminogen activator￨total pulmonary resistance massive bleeding￨among the patients who received rtpa there was a modest improvement of the total pulmonary resistance 15 hours after the start of therapy but the angiograms showed no significant changes in two hours￨sig increase￨highunclear￨highunclear￨highunclear
30￨lifethreatening pulmonay embolism 30 patients with lifethreatening pulmonary embolism verified by angiography￨streptokinase and heparin heparin heparin or streptokinase streptokinase￨reduction of systolic and mean pulmonary arterial pressures initial pulmonary angiographic scores systemic systolic blood pressure recordings￨there was significantly greater p  0001 evidence of thrombolysis in those patients treated with streptokinase compared with those treated with heparin￨sig increase￨highunclear￨highunclear￨highunclear
36￨twenty patients 36 patients with angiographically documented pulmonary embolism acute pulmonary embolism￨alteplase alteplase alteplase versus heparin heparin intravenous heparin heparin versus heparin heparin alone￨mean pulmonary artery pressure bleeding episodes vascular obstruction bleeding angiographic and hemodynamic variables miller index at pulmonary angiography recurrent pulmonary embolism efficacy and safety￨the vascular obstruction assessed by the miller index at pulmonary angiography decreased significantly in alteplasetreated patients p less than 001 from a baseline of 283￨sig decrease￨highunclear￨highunclear￨highunclear
24￨twentyfour older adults with persistent psychophysiological insomnia latelife insomnia￨cognitivebehavior therapy immediate or a delayed cognitivebehavioral intervention in a waitinglist control group design￨sleep latency wake after sleep onset and early morning awakening polysomnographic measures sleep efficiency therapeutic gains sleep improvements￨treatment was effective in reducing sleep latency wake after sleep onset and early morning awakening and in increasing sleep efficiency￨sig increase￨highunclear￨highunclear￨highunclear
not found￨older adults with insomnia latelife insomnia￨relaxation and sleep compression placebo relaxation sleep compression and placebo desensitization￨selfreported sleep but objective sleep￨results partially supported the conclusion that individuals with high daytime impairment ie fatigue respond best to treatments that extend sleep as in relaxation and individuals with low daytime impairment respond best to treatments that consolidate sleep as in sleep compression￨sig increase￨highunclear￨highunclear￨highunclear
78￨older adults latelife insomnia seventyeight adults 50 women 28 men mean age 65 years with chronic and primary insomnia￨placebo behavior therapy pharmacotherapy temazepam behavioral and pharmacological therapies cognitivebehavior therapy stimulus control sleep restriction sleep hygiene and cognitive therapy￨time awake after sleep onset and sleep efficiency￨behavioral and pharmacological approaches are effective for the shortterm management of insomnia in late life sleep improvements are better sustained over time with behavioral treatment￨sig increase￨highunclear￨highunclear￨highunclear
not found￨sleepmaintenance insomnia to 34 insomniacsranging in age from 35 to 78 yearsin small groups￨countercontrol behavioral therapy countercontrol therapy countercontrol treatment￨sleep complaint sleep disruption￨countercontrol therapy reduced the sleep complaint for the total group by about 30 at the end of treatment with gradual improvement continuing through a 4week followup￨sig decrease￨highunclear￨highunclear￨highunclear
45￨patients with moderate to severe paraquat poisoning 45 patients with paraquat poisoning were admitted to sina hospital hamadan iran of whom 20 had moderate to severe intoxication in group 1 three patients were females and eight patients were males oral paraquat poisoning patients with paraquat poisoning￨methylprednisolone cyclophosphamide and methylprednisolone conventional treatment plus intravenous infusions of cyclophosphamide conventional treatment methylprednisolone and cyclophosphamide cyclophosphamide cyclophosphamide and glucocorticoids￨mortality rate mean agesd respiratory failure and reducing mortality￨there were no differences between the groups in the time elapsed from ingestion to presentation at hospital or in the beginning of hemodialysis￨no diff￨highunclear￨highunclear￨highunclear
not found￨twentythree paraquatpoisoned patients with 50 and 90 predictive mortality assessed by plasma paraquat levels patients with severe paraquat poisoning academic medical center in taiwan￨methylprednisolone and cyclophosphamide with continuous dexamethasone therapy methylprednisolone novel repeated pulse treatment with longterm steroid therapy novel antiinflammatory therapy conventional therapy dexamethasone 20 mgday until pao2 was 115 kpa 80 mm hg and repeated pulse therapy with methylprednisolone cyclophosphamide￨mortality rate patient mortality￨the mortality rate 857 six of seven of the control group was higher than that of the study group 313 five of 16 p  0272￨sig decrease￨highunclear￨highunclear￨highunclear
19￨19 patients with resistant pruritus￨5hydroxytryptamine receptors ondansetron placebo ondansetron 8 mg or placebo ondansetron￨mean pruritus score using visual analogue scale and scratching activity visual analogue scale and scratching activity mean pruritus perception or scratching activity pruritus of cholestasis￨mean pruritus score using visual analogue scale and scratching activity were reduced on the first treatment day compared with baseline in both the ondansetron and placebo groups p  005 but there were no significant differences in mean pruritus perception or scratching activity between the two groups￨sig decrease￨low￨low￨low
6￨six patients with a prior poor or no response to primary biliary cirrhosis patients with chronic cholestasis pruritus of primary biliary cirrhosis with rifampin fourteen patients￨placebo rifampin cholestyramine rifampin or placebo rifampin￨pruritus relief of pruritus partial response biochemical tests or side effects￨no changes in biochemical tests or side effects were observed during this period￨no diff￨highunclear￨highunclear￨highunclear
26￨severe nondermatological pruritus twentysix patients were included in the study 17 of them had solid tumors 4 had hematological malignancies and 5 had various nonmalignant or idiopathic conditions severe pruritus of nondermatological origin￨placebo paroxetine paroxetine or placebo paroxetine paroxetine and placebo￨mean pruritus score onset of antipruritic action intensity of pruritus pruritus intensity scores adverse effects and patient satisfaction and preferences individual global response cholestatic pruritus paraneoplastic pruritus￨mean difference between placebo and paroxetine was 078￨no diff￨low￨low￨low
16￨sixteen patients with pruritus of chronic cholestasis patients with cholestatic liver disease and itching refractory to regular antipruritic therapy oral cholestatic pruritus￨placebo naltrexone daily or placebo naltrexone oral naltrexone naltrexone￨nighttime itching side effects serum naltrexone and 6 betanaltrexol concentrations daytime itching 6 betanaltrexol levels pruritus quality of sleep fatigue using visual analogue scales side effects and liver function￨naltrexone and 6 betanaltrexol levels did not differ between patients and controls and there was no significant association with treatment response￨no diff￨highunclear￨highunclear￨highunclear
34￨patients on hemodialysis hd uremic pruritus 34 adult patients on maintenance hd were enrolled￨gabapentin gabapentin placebo￨pruritus score pruritus scores￨after four weeks of treatment the mean decrease in pruritus score in gabapentin and placebo groups was 67￨sig decrease￨low￨low￨low
19￨nineteen hemodialysis patients with idiopathic moderate n  5 to severe n  14 pruritus patients receiving hemodialysis hemodialysisrelated pruritus￨placebo capsaicin topical capsaicin capsaicin 0025 cream capsaicin or placebo￨serious side effects prolonged antipruritic effect severity of pruritus and treatmentrelated side effects cutaneous burningstinging sensations dryness or erythema complete remission of pruritus marked relief serum concentrations of albumin calcium phosphorus alkaline phosphatase or intact parathyroid hormone efficacy and safety￨local application of capsaicin depletes the peripheral neurons of substance p and may block the conduction of pain or pruritus￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients undergoing longterm hemodialysis hemodialysisrelated pruritus￨capsaicin 0025 cream topical capsaicin￨adverse reactions efficacy and safety marked relief or complete resolution of itching complete resolution of itching￨no serious treatmentrelated adverse reactions occurred￨no diff￨highunclear￨highunclear￨highunclear
38￨17 took colesevelam 18 took the placebo 22 were female 8 were treatmentnaive 14 had primary biliary cirrhosis and 14 had primary sclerosing cholangitis patients with cholestatic pruritus both treatmentnaive and previously treated received 1875 mg of patients with cholestatic pruritus thirtyeight patients were included and 35 were evaluable cholestatic pruritus￨placebo colesevelam or an identical placebo cholestyramine￨pruritus scores qualityoflife scores and severity of cutaneous scratch lesions proportion of patients with at least a 40 reduction in pruritus visual analogue scale scores mild side effects mean serum bile acid levels daily visual analogue scales qualityoflife scores and evaluations of cutaneous scratch lesions serum bile acid levels severity of pruritus of cholestasis￨there were no significant differences between the groups with respect to pruritus scores qualityoflife scores and severity of cutaneous scratch lesions￨no diff￨low￨low￨low
not found￨50 patients 46 with primary biliary cirrhosis pbc took 19 patients all pbc pruritus associated with primary biliary cirrhosis￨placebo oral flumecinol 600 mg or identical placebo flumecinol flumecinol 3trifluoromethylalphaethylbenzhydrol zixoryn flumecinol 300 mg or placebo￨vas quality of life quality of life quality of life liver function tests antipyrine clearance or serum total bile acids vas pruritus score subjectively pruritus pruritus by scoring a daily 100 mm visual analogue scale vas 0  no itch 100  severe continuous day and night intolerable itch￨flumecinol did not significantly affect liver function tests antipyrine clearance or serum total bile acids and was not associated with any significant sideeffects￨no diff￨low￨low￨low
not found￨422 patients screened between december 1997 and june 1998 93 suffered from pruritus and 23 were eligible for the study sixteen of 23 patients completed the study uremic patients with persistent treatmentresistant pruritus patients on hemodialysis and peritoneal dialysis￨placebo naltrexone naltrexone sequence naloxone oral mureceptor antagonist naltrexone naltrexone￨uremic pruritus visual analogue scale vas and weekly by a detailed score assessing scratching activity distribution of pruritus and frequency of pruritusrelated sleep disturbance adverse effects pruritus intensity pruritus gastrointestinal disturbances efficacy and safety￨during the naltrexone period pruritus decreased by 292 95 confidence interval ci 187 to 396 on the vas and by 176 95 ci 42 to 311 on the detailed score￨sig decrease￨low￨low￨low
52￨296 hemodialyzed patients 65 suffered from uremic pruritus uremic pruritus fiftytwo patients participated in the study￨naltrexone and loratadine naltrexone loratadine naltrexone￨efficacy and tolerance uremic pruritus adverse events visual analogue scale vas pruritus intensity adverse events mainly nausea and sleep disturbances vas scores mean vas scores￨there was no significant difference in the mean vas scores after treatment but naltrexone allowed a dramatic decrease in vas scores delta 310 in 7 patients￨no diff￨highunclear￨highunclear￨highunclear
16￨16 women with chronic liver disease and chronic pruritus patients with the pruritus of cholestasis￨gabapentin gabapentin placebo drug gabapentin or placebo￨perception of pruritus mean hsa hourly scratching activity hsa perception of pruritus and its behavioral manifestation scratching in cholestasis mean vas perception of pruritus and in hsa visual analog score vas of pruritus￨gabapentin was associated with an increase in mean hsa in contrast to the placebo which was associated with a decrease￨sig increase￨low￨low￨low
20￨patients receiving hemodialysis who had severe pruritus twenty patients with uremia of whom 10 had severe pruritus and 10 did not received patients with uremia patients with chronic renal insufficiency￨recombinant human erythropoietin placebo erythropoietin therapy erythropoietin erythropoietin therapy￨mean  se pruritus score plasma histamine concentrations pruritus and plasma histamine levels pruritus scores elevated plasma histamine concentrations hemoglobin level severity of pruritus plasma histamine levels￨therapy with erythropoietin induced a decrease in plasma histamine concentrations in both groups of patients with uremia and recurrences of pruritus after the discontinuation of erythropoietin were accompanied by increases in plasma histamine concentrations￨sig increase￨highunclear￨highunclear￨highunclear
not found￨sixtytwo haemodialysis hd patients with pruritus 21 patients in the cs group and 19 patients in the￨placebo cs or placebo oral cromolyn sodium cs cromolyn sodium cs￨serum tryptase levels level of pruritus visual analogue scale vas renal itch serum tryptase level geometric mean of tryptase ckdassociated pruritus and serum tryptase level geometric mean of serum tryptase severity of pruritus￨although the geometric mean of tryptase had decreased in the cs group this decrease was not statistically significant p  0214￨no diff￨low￨low￨low
50￨fifty patients asa physical status 13 with spinal morphineinduced pruritus￨placebo subhypnotic naloxone 1 ml propofol 10 mg or 1 ml placebo intralipid intravenously after gynecologic orthopedic thoracic or gastrointestinal surgery morphine propofol￨sedation success rate￨the success rate was significantly greater in the propofol group 84 than in the placebo 16 group p less than 005￨sig increase￨highunclear￨highunclear￨highunclear
210￨eighteen patients finished the study uremic pruritus 210 hemodialysis patients 29 cases of refractory uremic pruritus￨thalidomide or placebo thalidomide thalidomide placebo￨￨in conclusion thalidomide can be a precious tool in the handling of uremic pruritus unresponsive to available therapy￨sig increase￨highunclear￨highunclear￨highunclear
9￨primary biliary cirrhosis primary biliary cirrhosis with rifampin nine patients with primary biliary cirrhosis￨placebo cholestyramine rifampin rifampin and placebo rifampin￨antipyrine plasma halflife patient preference changes in a daily visual analogue scale pruritus score and amount of cholestyramine ingested visual analogue scale pruritus scores adverse reactions fasting total serum bile acids pruritus in response to rifampin antipyrine elimination rates and serum bile acids￨rifampin produced a 33 reduction in antipyrine plasma halflife but no change in fasting total serum bile acids￨sig decrease￨highunclear￨low￨highunclear
11￨11 stable patients undergoing maintenance hemodialysis dialysis patients treated with￨placebo oral charcoal placebo dextrose placebo charcoal activated oral charcoal￨adverse effects idiopathic generalized pruritus active scratchinduced skin lesions serum concentrations of standard laboratory variables including lipids alkaline phosphatase phosphorus or calcium relief of idiopathic generalized pruritus relieved pruritus subjectively￨no significant alterations were noted in the serum concentrations of standard laboratory variables including lipids alkaline phosphatase phosphorus or calcium during treatment with either charcoal or placebo￨no diff￨highunclear￨highunclear￨highunclear
not found￨uremic pruritus patients with moderate to severe pruritus￨placebo parathyroid hormone pth capsaicin parathyroid hormone and substance p capsaicin 0025 cream capsaicin or placebo￨serious side effects intensity of itching and serum levels of intact pth alleviating uremic pruritus uremic pruritus serum levels of intact pth￨serum levels of intact pth did not correlate with the intensity of pruritus and did not significantly change during treatment with capsaicin or placebo￨no diff￨highunclear￨highunclear￨highunclear
10￨uraemic pruritus patient with longstanding severe uraemic pruritus who was undergoing chronic haemodialysis 10 other patients with uraemic pruritus who were on chronic haemodialysis￨cholestyramine placebo cholestyramine￨suffered nausea mild and easily reversible constipation pruritus￨the pruritus improved considerably in four of the five treated patients whereas only one of those treated with placebo experienced relief￨sig increase￨highunclear￨highunclear￨highunclear
21￨twenty one subjects with chronic pruritus due to liver disease including primary biliary cirrhosis primary sclerosing cholangitis chronic hepatitis c and postnecrotic cirrhosis cholestatic pruritus￨sertraline placebo sertraline serotonin reuptake inhibitors￨changes in itch distribution duration direction and physical evidence efficacy and tolerability visual analog pruritus score tolerated￨sertraline seems to be an effective welltolerated treatment for pruritus due to chronic liver disease￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨prostaglandin inhibitors hydroxyzine with or without doxepin at night pentoxifylline indomethacin and topical moisturization with mediumstrength topical steroids doxepin indomethacin pentoxifylline￨side effects pruritus degree of relief￨patients on antihistamines with or without doxepin had the highest incidence of side effects although more of these patients reported a greater degree of relief than patients on pentoxifylline￨sig increase￨highunclear￨highunclear￨highunclear
24￨endstage renal disease patients who undergo hemodialysis 24 patients in whom other etiologic factors of pruritus had been ruled out patients with endstage renal disease patients on hemodialysis patients with pruritus resistant to conventional treatment￨placebo doxepin placebo or oral doxepin￨subjective outcome complete resolution of pruritus complained of drowsiness pruritus￨twelve patients 500 complained of drowsiness that alleviated in all cases after 2 days in average￨no diff￨highunclear￨highunclear￨highunclear
not found￨15 haemodialysis patients with severe resistant pruritus uraemic pruritus haemodialysis patients￨placebo naltrexone naltrexoneplacebo naltrexone or placebo naloxone opioid antagonist naltrexone naltrexone￨median pruritus scores basophil histaminerelease plasma histamine and betaendorphin levels plasma histamine levels mean daily scores pruritus plasma betaendorphin levels￨plasma histamine levels were high mean 232￨no diff￨highunclear￨low￨low
34￨34 patients on hemodialysis with uremic pruritus patients on hemodialysis uremic pruritus in patients on hemodialysis patients with endstage renal disease thirtyfour patients on longterm hemodialysis 14 men and 20 women with a mean age of 570￨placebo capsaicin topical capsaicin therapy capsaicin capsaicin 003 and the other placebo￨pruritus score pruritus severity pruritus scores pruritus scores mean of pruritus score￨there was no significant difference in pruritus scores before the treatment between the two groups but after each week the difference was significant p  001￨no diff￨highunclear￨highunclear￨highunclear
144￨for 2 to 4 wk uremic pruritus 144 patients with uremic pruritus to postdialysis intravenous treatment with either severely ill patient population patients who were undergoing routine hemodialysis￨placebo kappaopioid system nalfurafine nalfurafine nalfurafine or placebo￨itching intensity sleep disturbances excoriations￨improvements in itching p  00025 and excoriations p  00060 were noted for the nalfurafinetreated patients￨sig increase￨low￨low￨highunclear
16￨sixteen patients with refractory pruritus 5 hemodialysis centers period diagnosed as myelodysplastic syndrome uremic patients 16 patients whom were included in the study 1 died during the placebo period of myocardial infarction and another patient who received patients with endstage renal disease esrd patients on hemodialysis￨placebo montelukast tablets montelukast montelukast firstly montelukast and then placebo or vice versa montelukast sodium a leukotriene receptor antagonist￨pruritus￨montelukast is more effective than placebo in the treatment of uremic pruritus not responding to the currently available antipruritus drugs and it can be considered as a new and rather safe and effective treatment option in uremic patients￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients undergoing hemodialysis patients with uremia hemodialysisrelated pruritus￨tacrolimus tacrolimus ointment￨antipruritic effect￨the results of this study do not demonstrate that tacrolimus ointment 01 is more effective than vehicle in relieving uremic pruritus￨no diff￨highunclear￨highunclear￨highunclear
25￨patients on haemodialysis for chronic renal failure 25 adult patients on haemodialysis who were asked to daily record the severity of their pruritus on a visual analogue scale haemodialysis patients￨gabapentin therapy gabapentin placebo gabapentin or placebo gabapentin￨effectiveness against renal itch neuropathic pain mean pruritus score mean score￨uraemic pruritus is a common and distressing symptom in patients on haemodialysis for chronic renal failure￨sig decrease￨low￨low￨low
16￨uremic pruritus in hemodialysis patients hemodialysis patients 16 hemodialysis patients with persistent pruritus to treatment with the￨ondansetron and placebo ondansetron therapy ondansetron placebo antihistamines 5ht3receptor antagonist ondansetron ondansetron serotonin 5hydroxytryptamine type 3 5ht3￨median daily pruritus score predialysis biochemistry test results or dialysis efficacy pruritus median daily percentage of escape medication use intensity of pruritus daily on a 0to10 visual analogue scale￨the median daily pruritus score did not change significantly during active or placebo treatment preondansetron 5 3 interquartile range iqr 34 to 63 during ondansetron 39 iqr 27 to 50 p  not significant preplacebo 37 iqr 30 to 4 6 during placebo 36 iqr 24 to 48 p  not significant￨no diff￨highunclear￨highunclear￨highunclear
20￨twenty patients with pruritus and cholestasis were included pruritus of cholestasis￨placebo naltrexone naltrexone or placebo oral naltrexone naltrexone￨mean basal vas baseline pruritus score efficacy and safety visual analogue scale vas serum biochemistry pruritus efficacy and safety￨vas showed greater and more significant changes with naltrexone than with placebo p00003￨sig increase￨highunclear￨highunclear￨highunclear
not found￨24 patients on haemodialysis were enrolled in the trial seventeen patients completed the trial eleven patients expressed a preference seven for renal itch patients with chronic renal failure￨ondansetron placebo ondansetron placeboondansetron sequence ondansetronplacebo sequence￨nausea vas scores pruritus visual analogue scale vas￨pruritus decreased by 16 95 ci 0532 during active treatment and by 25 95 ci 941 during treatment with placebo￨sig decrease￨low￨low￨low
not found￨adult hemodialysis patients all participants were recruited from one community hemodialysis center 28 individuals mean age 535 with moderate to severe uremic pruritus who had been receiving hemodialysis for at least 3 months community hemodialysis center￨pramoxine 1 lotion control lotion pramoxinebased antiitch lotion commercially available antiitch lotion containing 1 pramoxine hydrochloride versus control lotion topical antiitch lotion containing 1 pramoxine￨uremic pruritus rate of decline in itching reduction in itch intensity investigators global assessment and improvement in skin hydration itch intensity￨this safe convenient and effective topical lotion may potentially benefit the large number of patients affected by pruritus associated with endstage renal disease￨no diff￨low￨low￨low
337￨337 haemodialysis patients haemodialysis patients january 2009 by the ministry of health labour and welfare of japan 337 haemodialysis patients with itch that was resistant to currently available treatments such as antihistamines maintenance haemodialysis patients￨nalfurafine hydrochloride novel kappareceptor agonist nalfurafine hydrochloride placebo￨visual analogue scale vas incidence of adverse drug reactions adrs insomnia sleep disturbance quality of life vas pruritus moderate to severe adrs efficacy and safety￨the most common adr was insomnia sleep disturbance seen in 24 of the 226 nalfurafine patients￨sig increase￨low￨low￨low
30￨30 assessable patients had received chemotherapy and 10 had received patients with advanced gastric cancer advanced gastric cancer patients with advanced gastric cancer￨methotrexate modified famtx treatment or supportive measures only control group fluorouracil doxorubicin and methotrexate famtx supportive treatment 5fluorouracil doxorubicin and methotrexate￨median overall survival time overall response rate toxic effects median remission duration toxic death complete responses cr￨the median overall survival time of the treated group was 9 months whereas that of the control group was only 3 months p  0001￨no diff￨highunclear￨highunclear￨highunclear
165￨patients were stratified by extent locally advanced vs metastatic evaluability measurable vs nonmeasurable and by history of prior radiotherapy yes vs no 165 patients with advanced gastric cancer 26 patients were enrolled gastric carcinoma advanced gastric carcinoma￨epirubicin e alone 5fu alone epirubicin epirubicin 5fluorouracil vs epirubicin vs 5fluorouracil plus epirubicin 5fluorouracil 5fu alone 5fu￨toxicity time to progression or overall survival objective responses￨there were no significant differences in all eligible patients with respect to time to progression or overall survival in the three treatment arms￨no diff￨highunclear￨highunclear￨highunclear
not found￨advanced or recurrent gastric carcinoma patients with advanced or recurrent gastric carcinoma￨combined chemotherapy methotrexate mtx 5fluorouracil 5fu and pirarubicin thp vs 5fu alone chemotherapy with 5fu alone mtx 5fu and thp￨incidence of toxicities leukopenia in particular exceeding jcog grade 3 median survival time￨the incidence of toxicities leukopenia in particular exceeding jcog grade 3 was significantly higher for group a but no morbidity was observed￨sig increase￨highunclear￨highunclear￨highunclear
122￨a total of 122 patients was included in the study 110 of them were assessable patients with locally advanced or metastatic gastric cancer advanced gastric cancer￨5fluorouracil and epirubicin fe vs the same combination  cisplatin fep 5fluorouracil and epirubicin cytostatics  cisplatin 5fluorouracil and epirubicin with or without cisplatin fep 5fluorouracil cisplatin￨grade 2 and 3 vomiting partial remissions median survival grade 3 and 4 leukopenia febrile neutropenia survival difference stenocardia survival￨grade 3 and 4 leukopenia was observed in 9 of patients in the fe group and in 13 of patients in the fep group with 6 cases of febrile neutropenia fe 4 fep 7￨sig increase￨highunclear￨highunclear￨highunclear
not found￨metastatic gastroesophageal adenocarcinoma with two hundred twenty patients median age 64 years metastatic 94 patients with advanced gastric cancer patients with previously untreated advanced adenocarcinoma of the stomach or esophagogastric junction￨flo fluorouracil leucovorin and oxaliplatin with fluorouracil leucovorin and cisplatin fluorouracil leucovorin plus either oxaliplatin or cisplatin flp fluorouracil 2600 mgm2 via 24hour infusion leucovorin 200 mgm2 and oxaliplatin 85 mgm2 flo every 2 weeks or fluorouracil 2000 mgm2 via 24hour infusion leucovorin 200 mgm2 weekly and cisplatin 50 mgm2 every 2 weeks flp￨fatigue superior response rates efficacy flo median overall survival time to treatment failure alopecia flo reduced toxicity renal toxicity grade anemia vomiting nausea thromboembolic events serious adverse events median pfs with flo versus flp improved os progressionfree survival pfs peripheral neuropathy pfs￨however in patients older than 65 years n  94 treatment with flo resulted in significantly superior response rates 413 v 167 p  012 time to treatment failure 54 v 23 months p  001 and pfs 60 v 31 month p  029 and an improved os 139 v 72 months as compared with flp respectively￨sig increase￨highunclear￨highunclear￨highunclear
not found￨seventyone patients have been treated in cancer institute tehran iran with upper gastrointestinal carcinoma patients with advanced gastric cancer patients with advanced gastric cancer gc receiving either a standard or an experimental treatment￨tcf docetaxel based treatment tcf docetaxel cisplatin 5fu tcf with epirubicin cisplatin 5fu ecf epirubicin based treatment ecf docetaxel cisplatin 5 fu tcf or epirubicin cisplatin 5fu ecf￨health related quality of life hrqol eorct qlqc30 surgical and pathologic response hrqol response rate hrqol and survival baseline hrqol scores number of items and domains except for cognitive functioning and diarrhoea global qol quality of life survival rate pain decreased and physical functioning￨docetaxel based treatment tcf showed better palliation and improvement of global qol as compared with epirubicin based treatment ecf￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with previously untreated metastatic gastric cancer one hundred thirtysix patients two were ineligible patients with previously untreated metastatic gastric adenocarcinoma and to select the best arm for a phase iii study￨fluorouracil and leucovorin lv5fu2 lv5fu2 plus cisplatin or lv5fu2 plus irinotecan lv5fu2irinotecan leucovorin lv plus fluorouracil fu alone or in combination with cisplatin or irinotecan lv5fu2 plus cisplatin lv5fu2 plus irinotecan lv 200 mgm2 2hour infusion followed by fu 400 mgm2 bolus and fu￨overall response rates efficacy and safety median progressionfree survival and overall survival times￨median progressionfree survival and overall survival times were 32 months 95 ci 18 to 46 months and 68 months 95 ci 26 to 111 months with lv5fu2 respectively 49 months 95 ci 35 to 63 months and 95 months 95 ci 69 to 122 months with lv5fu2cisplatin respectively and 69 months 95 ci 55 to 83 months and 113 months 95 ci 93 to 133 months with lv5fu2irinotecan respectively￨no diff￨highunclear￨highunclear￨highunclear
200￨advanced gastric carcinoma two hundred patients with untreated advanced gastric carcinoma￨pelf pelf or famtx cisplatin epirubicin leucovorin and 5fluorouracil pelf 5fu doxorubicin and mitomycin c fam 5fluorouracil doxorubicin and methotrexate famtx famtx 5fluorouracil 5fu doxorubicin and methotrexate famtx and cisplatin epirubicin leucovorin and 5fu pelf￨toxicities complete response cr rates to pelf and famtx survival rates objective response rates cr plus partial response pr rates￨the survival rates after 12 months 308 versus 224 and 24 months 157 versus 95 were also higher among patients receiving pelf but these differences were not statistically significant￨no diff￨highunclear￨highunclear￨highunclear
not found￨naïve patients with measurable unresectable andor metastatic gastric carcinoma a performance status advanced gastric carcinoma￨tcf epirubicincisplatinfluorouracil ecf ecf epirubicin docetaxel cisplatin 60 mgm2 on day 1 and fluorouracil fu tc docetaxel cisplatin 75 mgm2 on day 1 or tcf tc plus fu chemotherapy docetaxel cisplatin and fluorouracil docetaxel and cisplatin and epirubicin cisplatin and fluorouracil￨myelosuppression and infectious complications orr toxicity grade 3 or 4 neutropenia overall response rate orr global health statusqol median overall survival times response primary survival toxicity and quality of life qol￨orr was 250 95 ci 13 to 41 for ecf 185 95 ci 9 to 34 for tc and 366 95 ci 23 to 53 for tcf n  119￨no diff￨highunclear￨highunclear￨highunclear
305￨advanced pancreatic and gastric carcinoma advanced pancreatic or gastric cancer three hundred five patients with advanced pancreatic and gastric carcinoma￨fluorouracil fluorouracil plus doxorubicin fluorouracil vs fluorouracil and doxorubicin vs fluorouracil doxorubicin and mitomycin adriamycin fa or fluorouracil plus doxorubicin plus mitomycin mitomycin c fam fluorouracil￨survival or palliation unrewarded toxicity and excessive cost meaningful survival advantage interval to disease progression objective response rates and palliative effects improved performance body weight or symptoms stomatitis and diarrhea anorexia nausea vomiting leukopenia thrombocytopenia and cumulative bone marrow suppression￨with regard to toxicity the fam regimen produced more anorexia nausea vomiting leukopenia thrombocytopenia and cumulative bone marrow suppression￨sig increase￨highunclear￨highunclear￨highunclear
50￨patients with advanced gastric carcinoma advanced gastric carcinoma fifty eligible patients￨5fluorouracil doxorubicin and mitomycin c fam combination mitomycin c doxorubicin 30 mgm2 iv fam 5fluorouracil doxorubicin fam cisplatin doxorubicin and mitomycin pam pam combination cisplatin 60 mgm2 iv 5fluorouracil new cisplatin doxorubicin and mitomycin c pam combination that includes cisplatin p instead of 5fluorouracil fam regimen￨response toxicity and survival median time to progression duration of response and duration of survival cr plus pr rate activity and toxicity pam combination complete response cr rate hematologic and nonhematologic toxicity fam combination cr rate cr plus partial response pr rate￨hematologic and nonhematologic toxicity were mild with both regimens￨no diff￨highunclear￨highunclear￨highunclear
not found￨untreated advanced gastric cancer patients patients with untreated advanced gastric cancer advanced gastric cancer gastric cancer patients advanced gastric cancer patients￨cisplatin and fluorouracil dcf docetaxel 75 mgm2 and cisplatin docetaxel and cisplatin plus fluorouracil docetaxel cisplatin fluorouracil docetaxel cisplatin and fluorouracil dcf over docetaxel and cisplatin for comparison against cisplatin and fluorouracil cf reference regimen￨complicated neutropenia toxicity adverse events diarrhea overall response rate stomatitis neutropenia overall survival survival rate ttp survival and response rate lethargy timetoprogression ttp￨overall survival was longer with dcf versus cf 23 risk reduction logrank p  02￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with intermediate tumor bulk 187 evaluable patients were initially stratified according to the presence of measurable or evaluable disease and performance status advanced gastric cancer patients with locally advanced recurrent or metastatic gastric adenocarcinoma who had not previously received￨chemotherapy doxorubicin or the threedrug combination 5fluorouracil 5fu doxorubicin doxorubicin doxorubicin versus 5fluorouracil doxorubicin and bcnu 5fu￨response rate weight loss median survival duration of response and survival toxicity thrombocytopenia￨duration of response and survival were significantly longer for fab in the measurabledisease group but for the total patient population an early advantage for fab in time to disease progression and survival was lost with continued followup￨sig increase￨highunclear￨highunclear￨highunclear
280￨patients with unresectable advanced gastric cancer advanced gastric cancer patients with advanced gastric cancer 280 patients with advanced gastric cancer￨fu fluorouracil fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin fluorouracil fu alone with fu plus cisplatin fp and with uracil and tegafur plus mitomycin uftm￨survival response and toxicity median progressionfree survival response rate overall survival overall response rates longer progressionfree survival hematologic toxic effects survival curves inferior survival median survival times and 1year survival rates survival advantage￨although fp demonstrated a higher response rate p 001 and longer progressionfree survival than did fu alone p 001 no differences in overall survival were observed between the arms￨sig increase￨highunclear￨highunclear￨highunclear
not found￨metastatic gastric cancer untreated metastatic gastric cancer patients with untreated metastatic or locally advanced gastric cancer￨irinotecan plus highdose 5fluorouracil and leucovorin ilf vs 5fluorouracil leucovorin and etoposide elf irinotecan plus highdose 5fluorouracil 5fu and leucovorin lv ilf with etoposide plus 5fulv elf irinotecan etoposide 120 mg m2 lv 300 mg m2 5fu ilf and 58 elf 24h 5fu 2000 mg m2 and elf ilf￨overall response rates median progressionfree survival overall survival tolerated the main grade 34 toxicities being diarrhoea time to treatment failure objective clinical response rates neutropenia efficacy and tolerability￨for ilf and elf respectively median progressionfree survival was 45 vs 23 months time to treatment failure was 36 vs 22 months p  04542 and overall survival was 108 vs 83 months p  02818￨no diff￨highunclear￨highunclear￨highunclear
145￨patients with gastric cancer 145 patients with advanced gastric cancer advanced gastric cancer￨weekly infusional highdose fluorouracil hdfu hdfu plus folinic acid hdfufa or hdfufa plus biweekly cisplatin fu 3000 mgm224 hours hdfu fu 2600 mgm224 hours plus dlfa 500 mgm2 or lfa 250 mgm2 fluorouracil fu or fu plus folinic acid fa and cisplatin cis￨median progressionfree survival response rate median overall survival diarrhea grade 4 toxicities neutropenia survival rate￨the median progressionfree survival of all patients in the hdfu hdfufa and hdfufacis arm was 19 40 and 61 months respectively￨no diff￨highunclear￨highunclear￨highunclear
77￨advanced gastric carcinoma seventyseven patients from 18 major hospitals advanced carcinoma of the stomach￨combination chemotherapy with 5fu adm plus cddp protocol ii 5fu adm plus cddp chemotherapy with 5fd adm plus cddp protocol i￨response rate gastrointestinal disturbances survival time leukopenia plus thrombocytopenia frequency and grade of the side effects￨frequency and grade of the side effects were not significantly different between a and b group￨no diff￨highunclear￨highunclear￨highunclear
72￨patients with advanced gastric cancer a total of 72 patients were enrolled into this study 36 vs 36￨oxaliplatin biweekly oxaliplatin fluorouracil and leucovorin versus cisplatin fluorouracil and leucovorin oxaliplatinfluoropyrimidine containing chemotherapy lv5fu2oxaliplatin lv5fu2 oxaliplatin oxaliplatin 85 mgm2 day 1 folinic acid leucovorin lv 5fluorouracil lv5 fu2cddp lv5 fu2cddp cddp 50 mgm2 day 1 plus lv5fu2 oxaliplatin lv5 fu2oxaliplatin and lv5fu2cisplatin cddp 5fu￨neutropenia 549 thrombocytopenia 26 anemia 616 nauseavomiting median ttp response rate of lv5fu2oxaliplatin grades 34 toxicity toxicity objective response rates time to progression ttp and overall survival os median survival time lv5fu2cddp￨response rate of lv5fu2oxaliplatin was 41 partial responsepr 41 stable diseasesd 31 progressive diseasepd 28 95 confidence internal95 ci 2758 and of lv5fu2cddp was 25 pr 25 sd 36 pd 39 95 ci 1441 p 0013￨no diff￨highunclear￨highunclear￨highunclear
316￨advanced gastric cancer agc patients with advanced gastric cancer 316 patients￨oral capecitabine xp fp capecitabinecisplatin with 5fluorouracilcisplatin capecitabinecisplatin versus 5fluorouracilcisplatin cisplatin 5fu￨median pfs for xp median overall survival neutropenia vomiting unadjusted hazard ratio hr noninferiority of xp versus fp for progressionfree survival pfs￨median overall survival was 105 versus 93 months for xp versus fp unadjusted hr  085 95 ci 064113 p  0008 versus noninferiority margin of 125￨no diff￨low￨low￨low
41￨patients with unresectable or metastatic gastric cancer during the period from july 1986 to june 1992 41 patients patients with advanced gastric cancer patients with nonresectable gastric cancer￨5fu 1500 mg m2 iv fluorouracil epidoxorubicin and methotrexate femtx femtx femtx or best supportive care femtx combined with vitamin a and e leucovorin fluorouracil epidoxorubicin and methotrexate femtx plus supportive care with supportive care alone mtx epidoxorubicin￨prolonged survival who grade iiiiv toxicity partial response pr response rates median survival median time to progression progressive disease pd nauseavomiting 40 diarrhoea increased pain￨similarly the femtx group displayed significantly p  00006 prolonged survival compared with the control group ie median survival 123 months 95 ci 71156 months vs 31 months 95 ci 1646 months￨sig increase￨highunclear￨highunclear￨highunclear
130￨one hundred thirty assessable patients were entered onto the trial 52 received previously untreated patients advanced gastric cancer gastric carcinoma advanced gastric carcinoma￨pelf fluorouracil doxorubicin and mitomycin fam fam and 85 pelf fluorouracil doxorubicin and mitomycin combination versus pelf chemotherapy cisplatin epirubicin and leucovorin preceding fluorouracil pelf￨duration of response survival durations overall response rates complete responses crs and partial responses prs time to progression￨the overall response rates complete responses crs and partial responses prs were 15 and 43 for the fam and the pelf regimens respectively with a statistically significant advantage for the experimental treatment p  001￨no diff￨highunclear￨highunclear￨highunclear
72￨patients with advanced gastric carcinoma with a patients with advanced gastric carcinoma patients with advanced gastric carcinoma similar to cisplatincontaining regimens 72 patients with advanced gastric carcinoma￨bolus 6slv 5fu modulated by 6sleucovorin 6slv and a cisplatincontaining regimen which was comprised of epirubicin etoposide and cisplatin with the addition of the reversal agent lonidamine eepl lonidamine cisplatin epirubicin 30 mgm2 on days 1 and 5 etoposide 5fluorouracil 5fluorouracilbased or a cisplatinbased regimen 5fu modulated with 6slv 5fu￨longest survival patients survival median survival median duration of response￨the most frequent world health organization grade 34 toxic effects were gastrointestinal in study a and hematologic in study b no treatmentrelated death was observed￨sig increase￨highunclear￨highunclear￨highunclear
90￨fortythree of 45 patients in each arm were assessable advanced gastric adenocarcinoma patients with metastatic or locally advanced gastric adenocarcinoma without prior chemotherapy ninety patients￨docetaxel and continuousinfusion fluorouracil versus epirubicin cisplatin and fluorouracil docetaxel and fluorouracil df ecf ecf epirubicin 50 mgm2 day 1 cisplatin 60 mgm2 day 1 and fluorouracil 200 mgm2 days 1 through 21 every 3 weeks or df docetaxel 75 mgm2 day 1 and fluorouracil epirubicin cisplatin and fluorouracil ecf￨median time to tumor progression complete remission median survival partial remission toxicity partial remission overall response rate orr diarrhea stomatitis and leukopenia in the df arm and nausea vomiting and leukopenia complete tumor remission￨toxicity was rarely severe￨no diff￨highunclear￨highunclear￨highunclear
71￨71 patients with advanced gastric carcinoma advanced gastric carcinoma￨folinic acid and 5fluorouracil alone versus folinic acid and 5fluorouracil plus 4epidoxorubicin folinic acid  fluorouracil arm a or the same combination with the addition of 4epidoxorubicin￨hematological toxicity median duration of response overall response rate toxicity median survival duration￨responder patients showed a significantly better median survival duration than nonresponders p  01 in arm b the median survival duration was 16 months for responder patients in contrast to 7 months for nonresponders p  004￨sig increase￨highunclear￨highunclear￨highunclear
305￨patients with advanced gastric cancer 106 patients assigned s1 alone who had target tumours one patient had a complete response and 32 had partial responses ie a total of 31 2341 305 patients were enrolled seven patients were ineligible or withdrew consent therefore 148 patients were assigned to patients with advanced gastric cancer treated with advanced gastric cancer spirits trial 87 patients assigned naive patients with advanced gastric cancer were enrolled between march 26 2002 and nov 30 2004 at 38 centres in japan advanced gastric cancer￨chemotherapy s1 plus cisplatin versus s1 s1 plus cisplatin or s1 alone s1 plus cisplatin versus s1 alone rct s1 plus cisplatin s1 s1 plus cisplatin cisplatin￨overall survival median overall survival progressionfree survival tolerated progressionfree survival proportions of responders and safety leucopenia neutropenia anaemia nausea and anorexia￨median overall survival was significantly longer in patients assigned to s1 plus cisplatin 130 months iqr 76219 than in those assigned to s1 alone 110 months 56198 hazard ratio for death 077 95 ci 061098 p004￨sig increase￨low￨low￨low
333￨chemonaive patients with adenocarcinoma of the stomachesophagogastric junction 333 patients were randomized and treated chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction￨ttp irinotecan5fluorouracil if over cisplatin5fluorouracil cf irinotecan combined with 5fluorouracil and folinic acid to cisplatin combined with 5fluorouracil irinotecan 80 mgm2 cf cisplatin 100 mgm2 13 h with 5fu 1000 mgm2day 24 h 5fluorouracil 5fu folinic acid if iv￨response rate toxic deaths discontinuation for toxicity ttp or os superiority overall survival os severe neutropenia thrombocytopenia and stomatitis ttf￨ttp for if was 50 months 95 confidence interval ci 3858 and 42 months 95 ci 3755 for cf p  0088￨no diff￨highunclear￨highunclear￨highunclear
not found￨metastatic gastric cancer patients with advanced gastric cancer advanced gastric cancer￨mitomycin semustine me triazinate t or cisplatin p 5fluorouracil and doxorubicin fa 5fluorouracil and doxorubicin fat cisplatin￨overall survival improved survival mild neurotoxicity median survival times hematologic toxicity survival rate severe toxicity rates survival advantage￨the improved survival was observed despite decreased 5fluorouracil and doxorubicin dosages for patients on the fat and fap arms￨sig increase￨highunclear￨highunclear￨highunclear
85￨advanced gastric cancer eightytwo evaluable patients with advanced gastric carcinoma￨5fu alone or combined with carmustine doxorubicin and mitomycin bafmi 5fu alone or the combination of carmustine doxorubicin 5fu and mitomycin bafmi 5fu￨median duration of survival objective remissions median duration of objective remission￨the median duration of objective remission 31 vs 40 weeks was longer using bafmi combination and the median duration of survival calculated in the 85 randomized patients was slightly longer using 5fu 28 vs 24 weeks￨sig increase￨highunclear￨highunclear￨highunclear
580￨advanced esophagogastric cancer previously untreated patients with advanced esophagogastric cancer five hundred eighty patients with adenocarcinoma squamous carcinoma or undifferentiated carcinoma￨mitomycin cisplatin and pvi 5fu mcf ecf epirubicin 50 mgm2 every 3 weeks cisplatin 60 mgm2 epirubicin cisplatin and protracted venousinfusion fluorouracil pvi 5fu ecf epirubicin cisplatin and pvi 5fu pvi 5fu 200 mgm2d or mcf mitomycin 7 mgm2 every 6 weeks cisplatin 60 mgm2 every 3 weeks and pvi 5fu ecf mcf mitomycin cisplatin and protracted venousinfusion fluorouracil pvi 5fu￨survival response toxicity and quality of life qol overall response rate median failurefree survival response survival and qol benefits of ecf median survival grade 34 neutropenia and grade 2 alopecia toxicity thrombocytopenia and plantarpalmar erythema global qol scores￨median survival was 94 months with ecf and 87 months with mcf p 315 at 1 year 402 95 ci 34 to 46 of ecf and 327 95 ci 27 to 38 of mcf patients were alive￨no diff￨highunclear￨highunclear￨highunclear
252￨advanced gastric carcinoma patients with advanced gastric cancer advanced gastric cancer two hundred fiftytwo eligible patients selected for study had proven locally unresectable andor metastatic gastric adenocarcinoma￨fluorouracil alone 5fu alone administered by rapid injection fluorouracil 5fu doxorubicin and methyl lomustine ccnu fame 5fu doxorubicin and cisplatin fap and fame alternating with triazinate tzt 5fu alone 5fu￨survival performance score weight gain or patient survival￨none of the three drug combinations showed a significant advantage over 5fu alone in improved performance score weight gain or patient survival￨no diff￨highunclear￨highunclear￨highunclear
274￨two hundred seventyfour patients with adenocarcinoma or undifferentiated carcinoma advanced esophagogastric cancer previously untreated patients with advanced esophagogastric cancer￨5fu doxorubicin and methotrexate famtx epirubicin cisplatin and protracted venous infusion fluorouracil 5fu ecf regimen epirubicin cisplatin and fluorouracil versus fluorouracil doxorubicin and methotrexate ecf famtx￨toxic deaths overall response rate survival and response advantage tolerable toxicity better ql and costeffectiveness hematologic toxicity and serious infections emesis and alopecia toxicity median failurefree survival duration survival tumor response toxicity and quality of life ql median survival duration global ql scores￨the global ql scores were better for ecf at 24 weeks but the remaining ql data showed no differences between either arm of the study￨no diff￨highunclear￨highunclear￨highunclear
not found￨fortyeight patients with unresectable gastric cancer patients with advanced gastric cancer￨fp versus fep gastric cancer chemotherapy fp fp and fep combination chemotherapy 400 mgm2 uft po daily 50 mgm2 etoposide iv and 50 mgm2 cddp iv fep￨leukopenia overall response rate survival time vomiting anorexia toxicities￨fortyeight patients with unresectable gastric cancer were enrolled for a randomized trial of fp n  24 vs fep n  24 combination chemotherapy with respect to their effects on survival period￨no diff￨highunclear￨highunclear￨highunclear
43￨sixty patients with inoperable or recurrent gastric cancers 43 patients fp 21 fpepir 22 advanced gastric cancer￨5fluorouracil and cisplatin fp versus 5fluorouracil cisplatin and 4epirubicin fpepir fp regimen consisting of cisplatin cddp 50 mgbody d1  5fluorouracil 5fu 250 mgbody d2d5 or the fpepir regimen cddp5fu fp  4epirubicin epir combination chemotherapies fpepir￨year survival rates survival rates tolerated neutropenia response rates drug toxicities complete alopecia￨significantly higher survival rates were demonstrated in those patients with recurrent cancers p  001 and those who responded to the fpepir regimen p  005￨sig increase￨highunclear￨highunclear￨highunclear
49￨a total of 49 patients were enrolled in the study 20 patients with stage iiii colon cancer colon cancer eligible patients with colon cancer who were scheduled for an elective colon resection from january 1995 to february 2001￨laparoscopicassisted vs open colectomy lac lac vs open colectomy oc laparoscopicassisted colectomy lac￨anastomotic type perioperative complication recurrence and survival rates wound recurrence converted to oc coc conversion of lac operative time blood loss complications pathologic findings and lymph node yield length of postoperative hospital stay gastrointestinal function use of analgesic drugs recurrence and survival rates incidence of portsite recurrence hospital stay faster recovery of gastrointestinal function and less use of intravenous analgesia￨no incidence of portsite recurrence in the lac group or wound recurrence in the oc and coc groups was found￨no diff￨highunclear￨highunclear￨highunclear
403￨rectosigmoid carcinoma 403 patients with rectosigmoid carcinoma￨laparoscopic resection of rectosigmoid carcinoma laparoscopic resection laparoscopic assisted n203 or conventional open n200 resection of the tumour￨postoperative recovery operative time survival and diseasefree interval overall morbidity and operative mortality probabilities of being disease free probabilities of survival survival￨the distal margin the number of lymph nodes found in the resected specimen overall morbidity and operative mortality did not differ between groups￨no diff￨highunclear￨highunclear￨highunclear
28￨rectal cancer treatment after neoadjuvant chemoradiation patients with distal rectal cancer presenting with incomplete response after chemoradiation patients undergoing laparoscopic abdominoperineal resection after chemoradiation for radical treatment of distal rectal cancer twenty eight patients with distal rectal adenocarcinoma￨conventional abdominoperineal resection surgical treatment by laparoscopic abdominoperineal resection or conventional approach laparoscopic abdominoperineal resection conventional approach x laparoscopic abdominoperineal resection conventional approach laparoscopic abdominoperineal resection and 15 conventional approach￨mean anesthesia duration local recurrence blood transfusion hospital stay after surgery length of resected segment and pathological staging mean operation time safety and efficacy￨mean operation time was 228 minutes for the laparoscopic abdominoperineal resection versus 284 minutes for the conventional approach p004￨no diff￨highunclear￨highunclear￨highunclear
286￨286 eligible patients with curable leftsided colon cancer tumornodemetastasis stage ii and stage iii disease requiring the takedown of colonic splenic flexure to facilitate a curative left hemicolectomy stage ii or iii leftsided colon cancers 135 and 134 patients actually comprised the laparoscopic and open group respectively curative resection of stage ii or iii leftsided colon cancers￨laparoscopic versus conventional open surgery￨cumulative recurrence rate recurrence patterns timetorecurrence of tumor number of dissected lymph node￨the oncologic results were similar p  0362 onesided logrank test in laparoscopic and open group of patients with the estimated cumulative recurrence rate of 132 968 versus 172 1164 in stage ii disease and 209 1467 versus 257 1870 in stage iii disease respectively￨no diff￨highunclear￨highunclear￨highunclear
171￨from june 2001 to september 2002 171 patients with low rectal cancer underwent tme with asp 82 by the laparoscopic procedure and 89 by the open technique patients with low rectal cancer low rectal cancer￨laparoscopic approach of total mesorectal excision tme with anal sphincter preservation asp laparoscopic low and ultralow anterior resections laparoscopic versus open total mesorectal excision with anal sphincter preservation￨anastomotic height hospitalization time blood loss operation time administration of parenteral analgesics start of food intake and mortality rate￨there was no statistical difference in operation time administration of parenteral analgesics start of food intake and mortality rate between the two groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨colon carcinoma january 1993 to november 1995￨laparoscopic colon resection laparoscopically assisted colon resection open o or laparoscopically assisted la colon resection la colon resection laparoscopically assisted colon resection la surgery￨preoperative workup intraoperative results complications length of stay pathologic findings and longterm outcomes no portsite or abdominal wall recurrences￨no portsite or abdominal wall recurrences were noted in any patients￨no diff￨highunclear￨highunclear￨highunclear
391￨391 patients with colorectal cancer cancer patients n  190 or open n  201 resection colorectal cancer patients￨laparoscopic laparoscopic colorectal resection laparoscopic or open surgery laparoscopic vs open colectomy￨social functioning overall and diseasefree survival rates quality of life and survival overall quality of life quality of life quality of life overall longterm morbidity rate longterm complications quality of life and survival rate￨laparoscopic colorectal resection was associated with a lower incidence of longterm complications and a better quality of life in the first 12 months after surgery compared with open surgery￨sig increase￨highunclear￨highunclear￨highunclear
109￨selected patients undergoing large bowel resection for cancer or polyps colorectal cancer surgery 109 patients undergoing bowel resection for colorectal cancers or polyps￨con laparoscopic techniques laparoscopic versus conventional techniques laparoscopic lap and conventional con techniques conventional surgery lap morphine￨flatus overall recovery forced expiratory volume in 1 second and forced vital capacity port site recurrences￨within this prospective randomized trial laparoscopic techniques were as safe as conventional surgical techniques and offered a faster recovery of pulmonary and gastrointestinal function compared with conventional surgery for selected patients undergoing large bowel resection for cancer or polyps￨sig increase￨highunclear￨highunclear￨highunclear
83￨thirtyseven patients eightythree patients￨ocr laparoscopic lcr or open colon resection ocr laparoscopic colon surgery lcr laparoscopic vs open colectomy￨wound infections ocr incisional hernias incision length wound complications lcr extraction site￨incision length was significantly greater p 0001 in the ocr group 194￨sig increase￨highunclear￨highunclear￨highunclear
794￨patients with cancer of the colon and rectum colorectal carcinoma seven hundred ninetyfour patients were recruited 526 laparoscopic and 268 open patients with rectal cancer￨laparoscopic anterior resection ar laparoscopicassisted surgery laparoscopic surgery conventional versus laparoscopicassisted surgery laparoscopicassisted surgery conventional open surgery successful laparoscopicassisted surgery laparoscopicassisted resection￨qol local recurrence survival rates longterm outcomes 3year overall survival os diseasefree survival dfs local recurrence and quality of life qol dfs￨successful laparoscopicassisted surgery for colon cancer is as effective as open surgery in terms of oncological outcomes and preservation of qol longterm outcomes for patients with rectal cancer were similar in those undergoing abdominoperineal resection and ar and support the continued use of laparoscopic surgery in these patients￨sig increase￨highunclear￨highunclear￨highunclear
not found￨219 patients took part in the study 111 lac group 108 oc group from november 1993 to july 1998 all patients with adenocarcinoma of the colon patients with colon cancer nonmetastatic colon cancer￨lac laparoscopyassisted colectomy lac lac and open colectomy oc laparoscopyassisted colectomy versus open colectomy￨death perioperative mortality shorter hospital stays morbidity hospital stay tumour recurrence and cancerrelated survival reduced risk of tumour relapse morbidity cancerrelated survival perioperative morbidity oralintake times probability of cancerrelated survival￨morbidity was lower in the lac group p0001 although lac did not influence perioperative mortality￨no diff￨highunclear￨highunclear￨highunclear
20￨20 anesthetized patients with aneurysmal subarachnoid hemorrhage delayed ischemic dysfunction after aneurysmal subarachnoid hemorrhage and early operation patients with an impaired cbf co2 response￨calcium channel blocker nimodipine nimodipine specific antiischemic treatment￨impaired co2 response cerebral vascular reactivity mean hemispheric cerebral blood flow cbf delayed ischemic deterioration￨one nimodipinetreated patient with a preserved co2 response in whom operation was complicated developed did￨sig increase￨highunclear￨highunclear￨highunclear
40￨forty patients were enrolled in the study 20 15 female and five male patients received treatment and 20 11 female and nine male patients 40 patients who were enrolled within 72 hours following sah and given obstetrical patients with eclampsia aneurysmal subarachnoid hemorrhage sah after aneurysmal subarachnoid hemorrhage￨placebo mgso4 magnesium sulfate therapy intravenous mgso4 or control solution mgso4 therapy control group￨symptomatic vasospasm glasgow outcome scale gos mean middle cerebral artery velocities serum mg levels daily transcranial doppler tcd ultrasonographic recordings neurological complications mean gos scores gos scores￨symptomatic vasospasm confirmed by angiography occurred in six of 20 patients receiving mgso4 and in five of 16 patients receiving placebo￨sig increase￨highunclear￨highunclear￨highunclear
9￨nine patients were excluded because of protocol violation 60 neurosurgical centers in japan 276 patients who underwent surgery within 3 days after subarachnoid hemorrhage sah of hunt and hess grades after aneurysmal subarachnoid hemorrhage patients with a ruptured cerebral aneurysm￨placebo saline at877 new calcium antagonist at877 hexahydro15isoquinolinesulfonyl1h14diazepine hydrochloride or fasudil hydrochloride placebo￨lowdensity regions on computerized tomography associated with vasospasm angiographically demonstrable vasospasm cerebral vasospasm symptomatic vasospasm delayed cerebral vasospasm vasospasm moderate disability or worse on the glasgow outcome scale serious adverse events￨there were no serious adverse events reported in the at877 group￨no diff￨low￨low￨low
41￨41 patients with subarachnoid hemorrhage patients with subarachnoid hemorrhage￨nimodipine placebo nimodipine nimodipine or placebo￨platelet aggregability platelet count adenosine diphosphateinduced platelet thromboxane b2 release inhibitory effect platelet function thromboxane release￨for the first 15 days after the subarachnoid hemorrhage nimodipine treatment did not have any notable effect on adenosine diphosphateinduced platelet thromboxane b2 release but a significant p less than 005 inhibitory effect was observed thereafter￨no diff￨highunclear￨highunclear￨highunclear
75￨aneurysm patients treated early after subarachnoid hemorrhage 75 consecutive patients admitted with subarachnoid hemorrhages 50 eligible patients who had a proven cerebral aneurysm 1 patient 4 on￨placebo nimodipine￨cerebral blood flow mean cerebral blood flow electrocardiographic changes￨analysis of the continuous electrocardiographic traces showed no difference between the nimodipine and placebo groups in the frequency or type of abnormality detected￨no diff￨low￨low￨low
283￨experimental subarachnoid hemorrhage sah in rats aneurysmal subarachnoid hemorrhage 283 patients were randomized patients with aneurysmal sah￨placebo magnesium magnesium sulfate therapy magnesium sulfate magnesium￨occurrence of a new hypodense lesion on computed tomography compatible with clinical features of dci frequency of delayed cerebral ischemia dci risk of dci poor outcome rankin 3 and excellent outcome rankin 0 we used the intentiontotreat principle￨magnesium treatment reduced the risk of dci by 34 hazard ratio 066 95 ci 038 to 114￨no diff￨low￨low￨low
70￨subarachnoid haemorrhage 70 patients suffering from subarachnoid haemorrhage due to aneurysm rupture￨nimodipine placebo nimodipine￨angiographic vasospasm extensive and diffuse vasospasm severe deficit or died severity of ischaemic deficits secondary to vasospasm￨angiographic vasospasm was not significantly different in its frequency or its severity between the two groups￨no diff￨highunclear￨highunclear￨highunclear
125￨125 neurologically normal patients with intracranial aneurysms in a multiinstitution patients with subarachnoid hemorrhage￨placebo nimodipine calcium blocker nimodipine￨cerebral arterial spasm severe or caused death cerebral arterial spasm neurologic outcome subarachnoid blood severity of ischemic neurologic deficits￨there were no side effects from nimodipine￨no diff￨low￨low￨low
1115￨subarachnoid haemorrhage all patients were followed up for three months and were included in the analysis except the patient who had been withdrawn four regional neurosurgical units in the united kingdom 554 patients were recruited between june 1985 and september 1987 out of a population of 1115 patients admitted with subarachnoid haemorrhage proved by the results of lumbar puncture or computed tomography or both￨placebo placebo or nimodipine oral nimodipine oral nimodipine nimodipine￨glasgow coma scale tolerated and reduces cerebral infarction incidence of cerebral infarction and ischaemic neurological deficits cerebral infarction and poor outcomes death and severe disability cerebral infarction￨poor outcomes were also significantly reduced by 40 95 confidence interval 20 to 55 with nimodipine 20 55278 in patients given nimodipine v 33 91278 in those given placebo￨sig decrease￨low￨low￨low
71￨patients treated with myopia control in schoolaged children 71 schoolaged children with myopia who fulfilled the eligibility criteria were recruited￨atropine 025ae atropine and stimulation of the auricular acupoints atropine eyedrops stimulating auricular acupoints enhances lowerlevel atropine eyedrops atropine together with stimulation of the auricular acupoints 025ae￨mean myopia progression axial length elongation ale of eye myopia progression￨furthermore there was no statistical difference among these three groups in axial length elongation ale of eye during this stage of the investigation￨no diff￨highunclear￨highunclear￨highunclear
70￨schoolchildren taiwanese schoolchildren 70 children with visual impairment were recruited from 1 elementary school in taipei taiwan￨acupressure and interactive multimedia 15week visual health intervention￨demographic factors visual health knowledge visual acuity and refractive error visual health knowledge visual acuity and refractive error visual health￨after the intervention the experimental group demonstrated improvements in visual health knowledge visual acuity and refractive error￨sig increase￨highunclear￨highunclear￨highunclear
2￨two psychiatric services in inner london 156 inpatients about to be discharged from compulsory treatment under the mental health act were recruited patients compulsorily admitted to hospital with serious mental illness patients with mental illness leads to lower rates of compulsory readmission to hospital￨usual psychiatric care with usual care plus the completion of an advance directive advance directives￨numbers of compulsory readmissions numbers of patients readmitted voluntarily days spent in hospital or satisfaction with psychiatric services rate of compulsory readmission readmitted compulsorily within 1 year of discharge￨there was no difference in the numbers of compulsory readmissions numbers of patients readmitted voluntarily days spent in hospital or satisfaction with psychiatric services￨no diff￨low￨highunclear￨low
160￨psychiatry patients with severe mental illness 160 people with an operational diagnosis of psychotic illness or nonpsychotic bipolar disorder who had experienced a hospital admission within the previous two years eight community mental health teams in southern england people with severe mental illness￨joint crisis plans￨mean number of days of detention days spent admission to hospital bed days and use of the mental health act mental health act overall admission bed days total number of days spent as an inpatient￨use of the mental health act was significantly reduced for the intervention group 13 1080 of whom experienced compulsory admission or treatment compared with 27 2180 of the control group risk ratio 048 95 confidence interval 024 to 095 p  0028￨sig increase￨low￨low￨low
665￨following elective hip arthroplasty 665 patients who received postoperative orthopedic patients￨unfractionated or lowmolecularweight heparin￨risk of thrombosis frequency of thrombosis sensitivity frequency of hit deep vein thrombosis￨the improved definition showed an even greater absolute difference in frequency of hit between unfractionated and lowmolecularweight heparin 48 vs 06 p001 compared with the standard definition 27 vs 0 p 002￨sig increase￨highunclear￨highunclear￨highunclear
not found￨trauma patients receiving lowmolecularweight lmwh or￨unfractionated heparin ufh heparin heparin￨risk for seroconversion pf4heparin seroconversion￨the risk for seroconversion was higher than major versus minor surgery odds ratio 798 95 confidence interval 2063100 p  003 controlled for potential confounders as was the risk for hit 22 95 confidence interval 0341 vs 00 p  010￨sig increase￨low￨low￨low
400￨patients with proximal deepvein thrombosis four hundred patients with proximal deepvein thrombosis with or without pulmonary embolism￨permanent vena cava filters￨survival risk of pulmonary embolism postthrombotic syndrome vital status venous thromboembolism and postthrombotic syndrome pulmonary embolism deepvein thrombosis symptomatic pulmonary embolism￨at 8 years vena cava filters reduced the risk of pulmonary embolism but increased that of deepvein thrombosis and had no effect on survival￨sig decrease￨highunclear￨highunclear￨highunclear
175￨children 6 months through 5 years of age with a uri of less than 7 days duration preschool children￨antihistaminedecongestant combination adc placebo adc brompheniramine maleatephenylpropanolamine hydrochloride or placebo antihistamine￨sedative effects childs runny nose nasal congestion cough and sleep status symptom improvement uri symptoms￨there were no statistically significant differences in symptom improvement between the adc and the placebo group runny nose p  048 nasal congestion p  094 cough p  066￨no diff￨low￨low￨low
96￨young children with the common cold young children by randomly assigning 96 children￨antihistaminedecongestant combination antihistaminedecongestant placebo placebo antihistaminedecongestant combinations￨symptoms of upper respiratory tract infection proportion of children considered better overall￨there were no differences among the three study groups in the proportion of children considered better overall by the parent 48 hours after the initial assessment drug 67 placebo 71 no treatment 57 p  053￨no diff￨highunclear￨highunclear￨highunclear
466￨199 subjects reported a total of 243 colds 466 healthy adults from four different regions of england￨pseudoephedrine placebo pseudoephedrine and triprolidine antihistamine triprolidine and a decongestant pseudoephedrine alone or in combination￨sneezing nasal obstruction and overall response to treatment￨sneezing nasal obstruction and overall response to treatment were significantly improved p 001 with psuedoephedrine or pseudoephedrine and triprolidine compared with placebo￨sig increase￨highunclear￨highunclear￨highunclear
58￨patients with natural colds experimental rhinovirus colds 58 subjects experimental rhinovirus colds￨pseudoephedrine plus ibuprofen placebo alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent oral alpha agonist alone and in combination with a nonsteroidal antiinflammatory drug pseudoephedrine pseudoephedrine 60 mg alone pseudoephedrine 60 mg plus ibuprofen 200 mg or placebo￨total symptom scores rhinorrhea tolerated nasal secretion weights nasal patency measurements nasal symptom scores frequencies of infection colds occurrence and viral shedding￨total symptom scores were reduced by 59 by pseudoephedrine plus ibuprofen p less than 005 and 48 by pseudoephedrine alone compared with placebo￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨volunteers with uncomplicated common colds￨standardized questionnaire and undergoing a physical examination throatculturing and pulmonary function testing subjects took the active drug or identicalappearing placebo antihistaminedecongestant therapy antihistaminedecongestant therapy placebo￨cough severity severity of cough nasal obstruction nasal discharge and throatclearing cough￨antihistaminedecongestant therapy reduced postnasal drip and significantly decreased the severity of cough nasal obstruction nasal discharge and throatclearing during the first few days of the common cold￨sig decrease￨highunclear￨highunclear￨highunclear
1167￨1167 patients with common cold treated with one of the following medications grippostadc a combination of symptoms of common cold￨grippostadc acetaminophen caffeine and ascorbic acid combined formulation grippostadc chlorpheniramine and ascorbic acid acetaminophen caffeine chlorpheniramine and ascorbic acid verum ascorbic acid control chlorpheniramine and ascorbic acid reference 1 as well as acetaminophen caffeine and ascorbic acid reference 2￨a score of common cold symptoms headache throat pain extremities and joint pain cough blocked nose and disturbances of sleep quality￨grippostadc was significantly superior to all other treatment groups the combination of acetaminophen caffeine and ascorbic acid was significantly superior to the control and the combination of chlorpheniramine and ascorbic acid was not statistically different from the control￨sig increase￨highunclear￨highunclear￨highunclear
142￨one hundred fortytwo 142 subjects were treated with the￨antihistaminedecongestant combination placebo nonsedating antihistamine loratadine 5 mg plus pseudoephedrine nonsedating antihistamine loratadine plus pseudoephedrine loratadinepseudoephedrine￨insomnia frequency of drowsiness nasal congestion sneezing postnasal drainage and nasal discharge nervousness￨differences between groups for the following side effects were found dry mouth 9 for the combination vs 2 for placebo insomnia 6 vs 3 and nervousness 4 vs 2￨sig increase￨highunclear￨highunclear￨highunclear
not found￨four hundred thirty subjects 216 pseudoephedrine and acetaminophen recipients 214 placebo recipients with cold symptoms of 48 hours or less who reported overall sinus symptoms of at least moderate severity￨placebo acetaminophen pseudoephedrine pseudoephedrine plus acetaminophen pseudoephedrine hydrochloride with acetaminophen￨sem weighted average of sinus symptoms headache and rhinorrhea nervousness sem overall sinus symptom assessment score overall sinus symptom assessment and a weighted composite assessment of sinus pressure pain and congestion sinus symptoms￨nervousness occurred in 4 of the pseudoephedrine and acetaminophen recipients compared with 0 of placebo recipients p 007￨sig increase￨low￨low￨low
not found￨eligible subjects had to have at least moderate nasal congestion and a runny nose at least mild cough and at least mild pain with one or more of the following sore throat sore chest headache or body painaches 485 subjects who took the study product 432 224 in group t 208 in group p were evaluable for analysis subjects with multiple cold symptoms subjects with multiple common cold symptoms￨dextromethorphan hydrobromide 75 mg doxylamine succinate 600 mg paracetamol and 8 mg ephedrine sulfate placebo placebo placebo syrup paracetamol dextromethorphan hydrobromide doxylamine succinate and ephedrine sulfate syrup containing paracetamol dextromethorphan hydrobromide doxylamine succinate and ephedrine sulfate group t test syrup or group p placebo syrup￨nighttime symptom relief and sleep satisfaction assessments individual symptoms nasal congestionrunny nosecoughpain relief scores satisfaction on sleep overall nighttime relief￨improvement in individual symptoms after 3 hours was obtained in 1642 more subjects in group t than in group p whereas the percentage of subjects in group t having good or very good relief the morning after dosing increased by 2568 compared to subjects in group p 14 subjects 5 in group t 9 in group p reported aes but none of these occurred with an incidence greater than 1￨sig increase￨low￨low￨low
60￨children 60 children with symptoms of the common cold and associated cough￨sch antihistamine diphenhydramine hydrochloride azatadine maleate pseudoephedrine sulfate and dextromethorphan hydrobromide sch 399 syrup￨overall therapeutic response excellent therapeutic response severity of signs and symptoms degree of relief efficacy and safety￨at days 3 and 5 patients treated with sch 399 experienced a significantly greater degree of relief p less than 0001 than did patients treated with the expectorant product￨sig increase￨highunclear￨highunclear￨highunclear
305￨305 patients with urti nasal airflow resistance nar of  025 pa cm3 s and a global pain score of at least moderate intensity nasal congestion and painrelated symptoms in upper respiratory tract infection￨pseudoephedrine and placebo paracetamol or pseudoephedrine alone and placebo pseudoephedrine or placebo paracetamol and placebo paracetamol combined with 60 mg of pseudoephedrine paracetamol or placebo paracetamolpseudoephedrine combination￨5point verbal rating scale vrs and pain intensity and nasal congestion on a 4point vrs nar and pain reliefintensity scores pain relief tolerated pain relief safety nasal airflow conductance nac and pain relief nasal congestion and pain intensity scores pain reduction￨a single dose of the combination was superior to paracetamol and placebo for nac p  00001 and was superior to pseudoephedrine and placebo for pain relief p  or  0048￨sig increase￨highunclear￨highunclear￨highunclear
not found￨nasal congestion associated with common cold 643 patients who had a history and diagnosis of acute upper respiratory tract infection urti were included they showed symptoms such as nasal congestion scratchysore throat headache generalized muscle ache earache runny nose fever sneezing etc otherwise healthy volunteers were to present with nasal stuffiness of recent onset that reached a score of at least 6 on the 11point scale for nasal congestion 0  not stuffy 10  very stuffy￨pseudoephedrine pse cas placebo acetylsalicylic acid asa cas asa  30 mg pse paracetamol cas 103902  60 mg pse active control acetylsalicylic acid and pseudoephedrine paracetamol  pse￨safe and well tolerated relief of nasal congestion severity moderatesevere and center as main strata nasal congestion scale severe nasal congestion score moderate nasal congestion score ncs￨the lower dose did not reveal significant different results compared with placebo for relief of nasal congestion in patients with a severe nasal congestion score at baseline￨no diff￨low￨low￨low
148￨148 patients with acute nasopharyngitis between ages 2 and 12 years symptomatic treatment of acute nasopharyngitis in children￨acetaminophen acetaminophen combination antihistaminicdecongestantacetaminophen agents otc drugs acetaminophendiphenhydraminepseudoephedrin￨complication rate clinic scores virus isolation rate￨the virus isolation rate in group1 was 279 and in group2 was 226￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with a common cold￨pseudoephedrine placebo ebastine plus pseudoephedrine ebastine 10 mg plus pseudoephedrine￨efficacy and tolerability percentage of subjects showing a good or excellent treatment efficacy tolerability sum of scores for nasal and ocular symptoms p0006 or total symptoms patient evolution of symptoms disposition of the patient to take the medication again and variation in nasal peak flow efficacy and tolerability￨the percentage of subjects showing a good or excellent treatment efficacy was significantly higher in the group treated with ebastine plus pseudoephedrine 758 than in the group treated with placebo 576 p0001￨sig increase￨highunclear￨highunclear￨highunclear
150￨150 healthy men and women aged 1851 years n30 subjects n61 subjects or experimental rhinovirus colds￨intranasal interferon ifnalpha2b 6 x 106 u every 12 h x 3 plus oral chlorpheniramine placebo intranasal and oral placebos chlorpheniramine and ibuprofen combination antiviralantimediator treatment ibuprofen ifnalpha2b chlorpheniramine and ibuprofen placebo plus oral chlorpheniramine and ibuprofen￨daily mean total symptom score severity of rhinorrhea sneezing nasal obstruction sore throat cough and headache and reduced nasal mucus production nasal tissue use and virus concentrations in nasal secretions tolerated￨treatment reduced the severity of rhinorrhea sneezing nasal obstruction sore throat cough and headache and reduced nasal mucus production nasal tissue use and virus concentrations in nasal secretions￨sig decrease￨highunclear￨highunclear￨highunclear
18￨adults and in children with acute rhinitis adults and children with acute congestive rhinitis 18 adults and 18 children with acute rhinitis by comparison to a matching placebo syrup and to a commercial standard decongestant triaminic tablets or drops￨rhinopront syrup placebo￨nasal congestion score nasal resistance global clinical efficacy￨the decongestive effect of rhinopront syrup was assessed in 18 adults and 18 children with acute rhinitis by comparison to a matching placebo syrup and to a commercial standard decongestant triaminic tablets or drops￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨local anaesthetic techniques￨colles fracture￨the results of the reduction were also significantly better using the biers block as judged by the measurement of the residual displacement on the xray￨sig increase￨highunclear￨highunclear￨highunclear
45￨45 patients who had their colles fractures reduced under intravenous regional anaesthesia and compared both to a control group group 1 and to a group who received a￨prilocaine tenoxicam standard biers block combined with the same dose of tenoxicam given intravenously into the contralateral arm￨longer time before first additional analgesia lower pain scores analgesia analgesic effects total analgesic consumption￨patients in group 2 obtained significantly better analgesia than group 1 as judged by a longer time before first additional analgesia was required p  005 less total analgesic consumption p  001 and lower pain scores p  001￨sig increase￨highunclear￨highunclear￨highunclear
100￨one hundred patients￨￨swelling or pain￨in addition there were fewer technical problems associated with venous access and subsequent plaster application in the antecubital fossa group￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with colles fractures￨￨￨in a controlled trial the technique produced anaesthesia more quickly than the other method￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨35 16  19 patients by using blocks of the radial ulnar and median nerves in the elbow region group 1 or the haematoma block method group 2 for the manipulation of colles fracture colles fracture￨cubital nerve block vs haematoma block prilocaine 15 ml of 10 mgml prilocaine￨moderate pain severe pain blocking efficacy and acute toxicity highest individual prilocaine plasma concentration systemic toxicity￨at 15 minutes there was a higher degree of block on average at the median and ulnar nerve innervation areas in group 1￨sig increase￨highunclear￨highunclear￨highunclear
58￨fiftyeight adult patients with closed displaced distal radius fractures adult patients￨haematoma blocks alone and haematoma blocks with sedation with general anaesthesia￨visual analogue scale radiological position waiting time procedure time and cost pain distal radius fractures waiting and manipulation times and resource costs￨there were no complications related to any of these anaesthetic methods￨no diff￨highunclear￨highunclear￨highunclear
200￨200 patients￨bupivacaine bupivacaine and prilocaine prilocaine￨cuff discomfort successful fracture reductions overall success rate for analgesia￨there was little difference in the time from injection to analgesia in the two groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨82 36 bc 972 47 mc 468 52 rc 712 one hundred and twenty traumapatients￨bupivacaine ropivacaine clonidine clonidine mepivacaine ropivacaine and bupivacaine mepivacaine￨duration of motor blockade onsettime and the duration of the sensory block￨duration of motor blockade was prolonged by clonidine only in the mepivacaine and bupivacaine groups in minutes mo 212￨sig increase￨highunclear￨highunclear￨highunclear
36￨36 patients with wrist fractures selected patients with a wrist fracture￨atracurium muscle relaxant￨quality of analgesia￨the addition of 2 mg of atracurium to the biers block improved the ease of reduction p less than 0025 and the quality of analgesia p less than 005 mannwhitney u test￨sig increase￨highunclear￨highunclear￨highunclear
72￨72 patients were recruited into the biers block group and 70 into the haematoma block group adult patients with colles fractures requiring manipulation to receive either biers block or haematoma block￨haematoma block or biers block￨pain score on fracture manipulation overall ae transit time dorsal angulation initial radiological outcome pain fracture manipulation￨there was a trend towards decreased pain on administration of the alkalinised haematoma block when compared with nonalkalinised haematoma block but this did not reach significance￨sig decrease￨highunclear￨highunclear￨highunclear
99￨99 displaced colles fractures colles fracture￨regional intravenous block local anesthesia￨pain grip strength￨patients treated with regional intravenous block had less pain during the manipulation of the fracture and better grip strength at the 6month followup￨sig decrease￨highunclear￨highunclear￨highunclear
33￨33 consecutive patients attending the accident and emergency department for manipulation of distal radius fracture under haematoma block 16 patients received hyaluronidase 17 received￨hyaluronidase hyalase lignocaine plus 1500 iu hyaluronidase lignocaine￨pain assessment cost of adding and risk of allergy￨there was no significant difference between the two groups for any of three methods of pain assessment p  005 mann whitney￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨brachial plexus block using a new subclavian perivascular technique￨￨we describe the proximal cranial needle approach for brachial plexus blockade clear surface markings and cranial direction of the needle lead to satisfactory results with a low incidence of complications￨sig increase￨highunclear￨highunclear￨highunclear
364￨patients with moderatetosevere active ulcerative colitis treated with ulcerative colitis 364 patients with moderatetosevere active ulcerative colitis adults with ulcerative colitis￨infliximab placebo placebo or infliximab infliximab￨clinical response subscore for rectal bleeding mayo score￨infliximab a chimeric monoclonal antibody directed against tumor necrosis factor alpha is an established treatment for crohns disease but not ulcerative colitis￨sig increase￨low￨low￨low
10￨ulcerative colitis twenty patients patients with moderate to severe steroiddependent ulcerative colitis steroiddependent ulcerative colitis￨infliximab antitnf alpha therapy methylprednisolone infliximab￨remission clinical remission clinical remission￨ten patients in group b dai 8714 reached clinical remission at one week dai 1903 p  0005￨no diff￨highunclear￨highunclear￨highunclear
20￨twenty eligible patients glucocorticoid resistant ulcerative colitis moderately severe glucocorticoid resistant ulcerative colitis patients with active ulcerative colitis￨infliximab placebo infliximab￨tumour necrosis factor production remission ucss  or 2 rates median improvement in ucss disease activity and quality of life ibdq and euroqol ulcerative colitis symptom score ucss remission￨improvement in the ibdq and euroqol was not significantly different between the groups p022 and 03 respectively mannwhitney u test￨no diff￨low￨low￨low
45￨fortyfive patients were included 24 patients experiencing an acute severe or moderately severe attack of ulcerative colitis severe to moderately severe ulcerative colitis not responding to conventional treatment severe to moderately severe ulcerative colitis￨infliximab infliximab or placebo placebo infliximab and 21 placebo infliximab cyclosporin infliximabplacebo￨colectomy or death operation for septic complications clinical and endoscopic remission colectomy￨seven patients in the infliximab group and 14 in the placebo group had a colectomy p  017 odds ratio 49 95 confidence interval 1417 within 3 months after randomization￨no diff￨low￨low￨low
not found￨11 patients of 60 planned patients patients having active disease for at least 2 weeks and receiving at least 5 days of intravenous corticosteroids patients with severe active steroidrefractory ulcerative colitis patients with steroidrefractory ulcerative colitis severe steroidrefractory ulcerative colitis￨infliximab placebo infliximab￨erythrocyte sedimentation rates and serum concentrations of creactive protein and interleukin6 modified truelove and witts severity score 2 increase in corticosteroid dosage 3 addition of immunosuppressants 4 colectomy or 5 death physical examination clinical chemistry and hematology laboratory tests and occurrence of adverse experiences￨improvement in erythrocyte sedimentation rates and serum concentrations of creactive protein and interleukin6 correlated with the clinical response observed in patients receiving infliximab￨sig increase￨low￨low￨low
not found￨acute not steroidrefractory ulcerative colitis thirteen patients seven women six men patients were eligible if they had acute disease with a modified truelove and witts activity score of more than 10 for at least 2 weeks and if they were currently not receiving immunomodulators or more than 10 mgday patients with acute ulcerative colitis patients with acute ulcerative pancolitis who were not steroidrefractory￨infliximab infliximab at 5 mgkg group a or highdose prednisolone prednisolone infliximab￨therapy success therapy success median baseline activity scores acute moderate or severe ulcerative colitis￨the antibody to tumor necrosis factor alpha infliximab has shown to be effective in the treatment of steroidrefractory ulcerative colitis in pilot studies￨sig increase￨highunclear￨highunclear￨highunclear
207￨two hundred and seven patients were randomized to be treated with one of the three operations and ninetyone healthy older patients healthy older patients with a displaced intracapsular fracture of the hip￨total hip replacement reduction and fixation bipolar hemiarthroplasty and total hip arthroplasty bipolar hemiarthroplasty with cement and total hip replacement with cement displaced intracapsular hip fractures fixation or bipolar hemiarthroplasty bipolar hemiarthroplasty￨hiprating questionnaire and the euroqol health status measure functional outcome scores mortality and complications rate of secondary surgery direct health service costs mortality rates worst hipratingquestionnaire and euroqol scores￨arthroplasty is more clinically effective and costeffective than reduction and fixation in healthy older patients with a displaced intracapsular fracture of the hip￨sig increase￨highunclear￨highunclear￨highunclear
280￨patients aged 65 to 79 years displaced intracapsular fracture of the proximal femur displaced intracapsular fractures of the hip in 280 patients aged 65 to 79 years displaced intracapsular fracture in a mobile and mentally competent patient under the age of 80 years￨cemented thompson hemiarthroplasty or a cemented monk bipolar hemiarthroplasty internal fixation or cemented hemiarthroplasty￨mean survival time local complications mean patient survival￨the mean patient survival was significantly higher in the group undergoing reduction and internal fixation 79 months compared with that with a cemented thompson hemiarthroplasty or a cemented monk bipolar hemiarthroplasty 61 months and 68 months respectively￨sig increase￨highunclear￨highunclear￨highunclear
115￨elderly patients elderly patients  or  65 years with displaced femoral neck fractures one hundred fifteen patients with a mean age of 821 years￨bipolar endoprosthesis unipolar or bipolar hemiarthroplasty unipolar versus bipolar hemiarthroplasty unipolar or bipolar hemiarthroplasty￨estimated blood loss length of hospital stay mortality rate number of dislocations postoperative complications or ambulatory status postoperative short form36 or musculoskeletal functional assessment instrument scores quality of life and functional outcomes musculoskeletal functional assessment instrument and short form36 health survey quality of life and functional outcomes￨there also were no significant differences between the two groups at either point in postoperative short form36 or musculoskeletal functional assessment instrument scores￨no diff￨highunclear￨highunclear￨highunclear
27￨subcapital fracture of the femoral neck 27 cemented and 26 uncemented bipolar hemiarthroplasties in active patients with displaced subcapital fractures of the femoral neck￨cemented thompson and uncemented moore stems bipolar hemiarthroplasty￨experiencing pain incidence of postoperative complications the early mortality rate and the operating time and blood loss￨using otherwise identical prostheses the early results were much better with a cemented thompson stem than with an uncemented austin moore stem￨sig increase￨highunclear￨highunclear￨highunclear
82￨subcapital fractures of the femur displaced subcapital fractures of the femur 82 patients suffering displaced subcapital fractures of the femur were included￨hydoxyapatitecoated bipolar hemiarthroplasty and an uncemented bipolar prosthesis hydroxyapatitecoated hemiarthroplasty￨￨the functional result was significantly superior in the hydroxyapatitecoated group￨sig increase￨highunclear￨highunclear￨highunclear
112￨75 patients attended the followup study femoral neck fractures 112 patients with fresh femoral neck fractures￨moore hemiarthroplasty cemented with methyl methacrylate and 57 patients a noncemented prosthesis moore hemiarthroplasty with and without bone cement￨pain relief and gait function￨at 6 weeks 3 months and 6 months after the operation the clinical results were significantly better among patients with cemented prosthesis especially in relation to pain relief and gait function￨sig increase￨highunclear￨highunclear￨highunclear
81￨eightyone patients who had been mobile and lived independently before they had sustained a displaced fracture of the femoral neck total hip arthroplasty and hemiarthroplasty in mobile independent patients with a displaced intracapsular fracture of the femoral neck patients who had sustained a displaced fracture of the femoral neck￨total hip arthroplasty or a hemiarthroplasty hemiarthroplasty and total hip arthroplasty hemiarthroplasty￨lower better oxford hip score mean walking distance mean oxford hip score acetabular erosion severe enough to indicate revision radiographic evidence of acetabular erosion oxford hip score and final radiographs￨total hip arthroplasty conferred superior shortterm clinical results and fewer complications when compared with hemiarthroplasty in this prospectively randomized study of mobile independent patients who had sustained a displaced fracture of the femoral neck￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients 70 years and older comparing a cemented implant 112 hips with an uncemented hydroxyapatitecoated implant 108 hips both with a bipolar head displaced femoral neck fractures in the elderly displaced femoral neck fractures￨cemented versus uncemented hemiarthroplasty hemiarthroplasty￨mean duration of surgery mean intraoperative blood loss barthel index and eq5d scores rates of complications and mortality mean harris hip score￨the barthel index and eq5d scores did not show any differences between the groups￨no diff￨highunclear￨highunclear￨highunclear
120￨120 patients with a mean age of 81 years 70 to 90 with an acute displaced intracapsular fracture of the femoral neck displaced intracapsular fractures of the femoral neck in elderly patients￨bipolar hemiarthroplasty with total hip replacement bipolar hemiarthroplasty or total hip replacement￨complications or mortality harris hip score healthrelated quality of life measure perioperative data general and hipspecific complications hip function and healthrelated quality of life complication rate hip function duration of surgery intraoperative blood loss￨the healthrelated quality of life measure was in favour of the total hip replacement group but did not reach statistical significance p0818 at four months and p0636 at 12 months￨no diff￨highunclear￨highunclear￨highunclear
40￨displaced femoral neck fractures in previously independent patients active elderly hip fracture population displaced femoral neck fractures total hip arthroplasty patients forty subjects were enrolled￨hemiarthroplasty to total hip arthroplasty hemiarthroplasty to total hip arthroplasty tha￨displaced femoral neck fracture short form36 sf36 western ontario and mcmaster osteoarthritis index womac and the harris hip score and the timed up  go test superior womac function scores pain sf36 mental health subscale sf36 subscale￨at 24 months tha patients had significantly less pain on the sf36 subscale than hemiarthroplasty patients 548￨sig decrease￨highunclear￨highunclear￨highunclear
129￨one hundred and twentynine participants displaced subcapital hip fractures in patients over 70 years old inclusion criteria were displaced hip fracture and age over 70 years￨surgical operation they underwent hemiarthroplasty total hip arthroplasty￨barthel index and harris hip score barthel index scores harris hip scores range of passive hip motion merete berlin germany total arthroplasty￨the range of passive hip motion in the three groups of patients did not differ significantly p005￨no diff￨highunclear￨highunclear￨highunclear
89￨patients younger than 70 years of age eightynine patients were treated for displaced garden type 3 or 4 fracture with a prosthesis 39 patients had thr 37 had uhrc and 13 had uhrnc femoral neck fractures displaced femoral neck fractures￨uhrc total hip replacement versus cemented and noncemented hemiarthroplasty uhrnc cemented total hip replacement thr cemented hemiarthroplasty uhrc and noncemented hemiarthroplasty uhrnc￨level of pain ambulation or aids required mortality rate endurance capability cardiac or pulmonary disease cancer alcoholism or psychosis pain and decreased ambulation and required assistive devices￨no difference was found in the level of pain ambulation or aids required between the thr group and the uhrc group except for active community ambulators who demonstrated decreased endurance capability when treated with uhrc￨no diff￨highunclear￨highunclear￨highunclear
278￨displaced subcapital fractures of the femur 278 patients aged over 65 years treatment of displaced subcapital fractures elderly patient with a displaced subcapital fracture￨internal fixation hemiarthroplasty and total hip replacement internal fixation and particularly primary total hip replacement closed reduction and internal fixation with a sliding compression screwplate moore hemiarthroplasty or total hip treatment with a howse semicaptive prosthesis￨least pain and most mobility mortality revision rate general complications￨the revision rate within the first year was highest for internal fixation 25 per cent but many of the replacements also required a further anaesthetic for reduction of a dislocation moore 11 per cent howse 125 per cent￨sig increase￨highunclear￨highunclear￨highunclear
not found￨displaced intracapsular hip fracture in octogenarians patients over 80 years of age displaced intracapsular fractures of the hip in patients over 80 years of age￨unipolar or bipolar prosthesis cemented unipolar prosthesis thompson with a cemented bipolar prosthesis monk￨rate of complications degree of return to the preinjury state mortality￨two years after operation there was no statistical difference between the rate of complications in the two groups￨no diff￨highunclear￨highunclear￨highunclear
60￨percutaneous anaesthesia in children 60 children aged 315 yr￨tetracaine tetracaine gel tetracaine gel vs emla cream emla cream emla￨pain adverse effects pain scores￨significantly lower pain scores were recorded by the children treated with tetracaine gel compared with emla cream p  002￨sig increase￨highunclear￨highunclear￨highunclear
120￨120 children￨emla cream and ametop gel￨pain scores adequate analgesia￨however ametop gel was more effective with a statistically significant difference in the pain scores of the two groups p  005￨sig increase￨highunclear￨highunclear￨highunclear
34￨34 children aged children￨lignocaineprilocaine cream and amethocaine gel lignocaineprilocaine cream emla and amethocaine gel ametop￨analgesic effect anticipatory anxiety 100point visual analogue scale vas pain pain and distress of venepuncture￨the efficacy of lignocaineprilocaine cream emla and amethocaine gel ametop in reducing the pain and distress of venepuncture was compared in a singleblind randomized study of 34 children aged￨no diff￨highunclear￨highunclear￨highunclear
not found￨hospital inpatients 115 years of age children children undergoing venipuncture was studied￨lidocaineprilocaine tetracaine lidocaineprilocaine cream tetracaine 4 cream tetracaine lidocaineprilocaine cream tetracaine cream lidocaineprilocaine cream emla astra before undergoing scheduled venipuncture￨venipunctureinduced pain pain mild local erythema adequate pain relief local skin blanching shorter application time vasodilation and lower cost￨lidocaineprilocaine cream was significantly more efficacious in preventing pain than tetracaine 4 cream 97 of the former group n  32 had adequate pain relief compared with 76 of the latter n  34￨sig increase￨highunclear￨highunclear￨highunclear
148￨94 patients using an application time of 40 min 148 children children￨amethocaine gel emla emla cream amethocaine gel preparation￨adverse effects pain of venous cannulation localized erythema clinically acceptable anaesthesia￨there were no significant adverse effects noted in each group although 37 of those children treated with amethocaine gel showed localized erythema at the application site￨no diff￨highunclear￨highunclear￨highunclear
300￨300 patients american society of anesthesiologists asa children venopunctureinduced pain in children￨amli 25 amethocaine and 25 lidocaine amethocainelidocaine cream emla eutectic 25 lidocaine and 25 prilocaine mixture group ii received 4 amethocaine 4 amet anesthetic creams emla￨pain movement and verbalization to puncture pain movement and verbalization frequency of untoward effects adverse effects relieving venous puncture pain untoward effects and amli￨group i emla subgroup a  or  30 minutes experienced significantly more pain movement and verbalization than groups ii and iii￨sig decrease￨highunclear￨highunclear￨highunclear
540￨postnatal mothers in poor communities mothers on infant care and postnatal family planning practices in nepal main maternity hospital in kathmandu nepal 540 mothers mothers on infant care and family planning practices in nepal follow up in urban kathmandu and a periurban area southwest of the city pregnant women to facilitate follow up￨postnatal health education￨infant feeding infant care or immunisation￨there were no other significant differences between groups with regards to infant feeding infant care or immunisation￨no diff￨highunclear￨highunclear￨highunclear
not found￨postponing subsequent pregnancy among teen mothers older teens primiparous pregnant teens ages 1519 were recruited in washington dc adolescent mothers of 849 teens screened 293 n  249 met inclusion criteria consented to participate and completed baseline measures￨counseling intervention delivered by cell phone randomized cell phonebased counseling intervention cell phones￨subsequent pregnancy subsequent pregnancy with increased levels of intervention exposure￨participants who were aged 1517 years at delivery showed a significant reduction in subsequent pregnancy with increased levels of intervention exposure p  001 but not those  18 years￨sig decrease￨highunclear￨highunclear￨highunclear
600￨contraceptive practices of couples 170 women 569 had started using contraceptives whereas 129 431 had decided to start contraceptive use in the next 6 months 600 women was done in two groups matched for age parity and socioeconomic status at the department of obstetrics and gynaecology shifa foundation community health centre shifa international hospital islamabad pakistan￨contraceptive counseling and educational leaflets counseling and educational leaflets nonintervention group was not given any formal contraceptive advice￨contraceptive uptake started contraceptive use￨there is a definite increase in contraceptive uptake in women provided with educational leaflets and counseling session with a shift toward use of more reliable contraceptive methods￨sig increase￨highunclear￨highunclear￨highunclear
not found￨adolescent mothers black adolescent mothers participants were recruited from urban hospitals at delivery and were 181 first time black adolescent mothers  18 years of age 82 149 of 181 completed the 24month evaluation￨usual care mentoring program homebased mentoring program homebased mentoring intervention￨risk practices or contraceptive use risk behavior or contraceptive use baseline contraceptive use or other measures of risk or family formation high selfesteem positive life events and romantic involvement and residence with the first infants father marital rates￨at 24 months there were no differences in marital rates 2 risk practices or contraceptive use between mothers who did and did not have a second infant￨no diff￨highunclear￨highunclear￨highunclear
not found￨urban medical center￨contraceptive counseling physicianpatient counseling written literature or an educational video postpartum contraceptive counseling￨patient satisfaction patient satisfaction with the contraceptive teaching method satisfaction rate￨patients receiving physicianpatient counseling expressed a 99 satisfaction rate p  0044￨sig increase￨highunclear￨highunclear￨highunclear
235￨adolescent mothers pregnant teenagers n  235 aged 18 years and older who were at more than 24 weeks gestation were recruited from urban prenatal clinics serving lowincome predominantly african american communities￨cami computerassisted motivational intervention cami motivational intervention cami plus enhanced home visit n  80 received a multicomponent homebased intervention cami 2 those in camionly n  87 received a single component homebased intervention 3 and those in usualcare control standard usual care cami sessions￨sexual relationships and contraceptionuse intentions and behaviors and readiness to engage in pregnancy prevention hazard ratio hr for repeat birth birth rates risk of repeat birth￨completing 2 or more cami sessions significantly reduced the risk of repeat birth in both groups cami hr  040 95 ci 016098 and camionly hr  019 95 ci 005069￨sig decrease￨highunclear￨highunclear￨highunclear
139￨139 adolescents attending a teenage pregnancy clinic teenage mothers younger than age 18 years 124 teenagers postnatal home visits in teenage mothers￨￨knowledge between groups and incidence of predefined adverse neonatal outcomes knowledge with respect to breastfeeding or infant vaccination schedules adverse neonatal outcomes breastfeeding or infant vaccination knowledge or compliance contraception knowledge￨postnatal home visits were associated with a reduction in adverse neonatal outcomes intervention 2 control 9 relative risk 024 95 ci 005108 and a significant increase in contraception knowledge mean difference 092 95 ci 032152￨sig increase￨low￨low￨low
876￨three groups of new mothers a total of 876 women were allocated and followed up syria￨postnatal home visits 4 postnatal home visits a one visit b or no visit c￨￨a significantly higher proportion of mothers in groups a and b reported exclusively breastfeeding their infants 285 and 30 respectively as compared with group c 20 who received no visits￨sig increase￨highunclear￨highunclear￨highunclear
243￨adolescent mothers and their infants firsttime adolescent mothers and their infants adolescent mothers 17 years old or younger and their infants 243 motherinfant pairs mothers in the special care program who continued to attend clinic used the emergency room less than the mothers who continued to attend in the control group￨routine care and services that included rigorous followup discussions with the mother about her plans for return to school and use of family planning methods and extra health teaching routine wellbaby care special health care program health care program￨dropout rate percentage returning to school repeat pregnancy rate￨mothers in the special care program who continued to attend clinic used the emergency room less than the mothers who continued to attend in the control group￨sig increase￨highunclear￨highunclear￨highunclear
43￨young african american women in the year following an unplanned pregnancy 43 young pregnant women attending prentice ambulatory care northwestern hospital were enrolled and 33￨antepartum multicomponent intervention consisting of counseling a videotape about ocs and written material or residentphysician counseling usual care postpartum educational intervention oral contraceptives oral contraception ocs￨questionnaire data repeat pregnancy knowledge of ocs￨more women in the intervention group were not pregnant and still using contraception and were able to successfully switch contraceptive methods compared to women in the control group￨sig increase￨highunclear￨highunclear￨highunclear
30￨30 patients with myotonic disorders￨mxt and tcd antiarrhythmic drugs mexiletine mxt and tocainide tcd disopyramide phenytoin mexiletine and tocainide￨severity of myotonia￨the severity of myotonia was assessed by clinical and electromyographic criteria at the end of each treatment phase lasting four weeks￨no diff￨highunclear￨highunclear￨highunclear
10￨myotonia in myotonic dystrophy ten patients with myotonic dystrophy￨disopyramide disopyramide and procainamide procainamide￨￨disopyramide was found to be at least as effective as procainamide in the relief of myotonia and two patients who could not tolerate procainamide both tolerated disopyramide￨sig increase￨highunclear￨highunclear￨highunclear
10￨10 patients with myotonic dystrophy myotonia in myotonic dystrophy￨placebo nifedipine nifedipine￨subjective improvement initial grip strength and muscle fatiguability measured by grip strength ergometry severity of myotonia￨a significant improvement in myotonia after nifedipine was recorded by this technique and supported by a subjective improvement in 50 of patients and clinical improvement of greater than 20 in five patients￨sig increase￨highunclear￨highunclear￨highunclear
9￨nine patients with dystrophia myotonica￨potassium chloride placebo chronic oral taurine therapy chronic oral taurine￨side effects severity of myotonia￨no significant side effects were noted￨no diff￨highunclear￨highunclear￨highunclear
12￨12 adult patients with myotonic dystrophy age range 1855 yr￨imipramine imipramine and placebo￨grip and percussion myotonia depressive symptomatology￨both grip and percussion myotonia were significantly improved by imipramine treatment independent of change in depressive symptomatology￨sig increase￨highunclear￨highunclear￨highunclear
4075￨between december 1997 and october 2000 4075 women who attended planned parenthood clinics in washington state were screened women who were positive for highrisk hpv types or had pap results of ascus or higher were considered to have positive screening test results and were referred for colposcopy and biopsy older  or  30 years vs younger women women with negative screening test results was referred for colposcopy women having papanicolaou pap smears showing atypical squamous cells of undetermined significance ascus primary screening for cervical abnormalities cervical intraepithelial neoplasia cin grade 3 or cancer the criterion standard￨simultaneously using thinlayer pap and hpv dna testing by a polymerase chain reaction pcrbased method and by a liquidbased rnadna hybridization capture with signal amplification assay signal amplification hpv dna testing￨sensitivity and specificity sensitivity￨differences in specificities were also observed 824 818831 for thinlayer pap with a result of  or  ascus 788 779797 for pcr and 726 694750 for signal amplification￨no diff￨highunclear￨highunclear￨highunclear
11085￨hpvpositive women with negative or borderline cytology women positive for hpv at baseline who had surveillance 73 45 of 164 women with negative cytology and eight 35 of 23 women with borderline cytology women who test positive for highrisk types of human papillomavirus 11085 women aged 3060 years hpvpositive women hpvpositive women with normal or borderline cytology about 6 of screened women women with borderline cytology and women positive for highrisk hpv with negative cytology women older than 30 years with cytology used to triage hpvpositive women women with an initial negative hpv test with borderline n211 or mild 32 cytology￨immediate colposcopy or to surveillance by repeat hpv testing cytology and colposcopy at 12 months￨￨hpv testing of cervical smears is more sensitive but less specific than cytology for detecting highgrade cervical intraepithelial neoplasia cin2￨no diff￨highunclear￨highunclear￨highunclear
46009￨identifying women with cervical neoplasia women with ascus pap smear results all of whom had liquidbased cytology hpv testing and subsequent repeat pap tests and colposcopy with histologic evaluation conducted at 12 gynecology clinics in a large managed care organization between october 1995 and june 1996 46009 women who had routine cervical examinations 995 women with pap test results of ascus who consented to participate were identified 995 participants with ascus pap test results 973 had both a definitive histologic diagnosis and hpv result￨￨cervical histology hpv test results and repeat pap smear results and sensitivity of hpv testing repeat pap smear result histologic hsil or cancer￨for women with histologic hsil the hpv test was positive in 892 95 confidence interval ci 784952 and the specificity was 641  95 ci 609672￨no diff￨highunclear￨highunclear￨highunclear
197￨women with ascus 197 consecutive women mean age 39 years range 2160 with a diagnosis of ascus from the primary screening were selected for triage￨cytology  hpv   group b cytologyhpv   group c cytology  hpv and group d cytology hpv￨prevalence of a highrisk hpv infection￨adding a highrisk hpv test in secondary screening increased the identification of women with cin23 lesions by 33 in comparison with repeat cytology p001￨sig increase￨highunclear￨highunclear￨highunclear
360￨women with concomitant cervical intraepithelial neoplasia 2 and 3 cin 23 in women with atypical squamous cells of undetermined significance ascus in their pap smears 360 women cytologically diagnosed with ascus￨generation hybrid capture test hc1 digene diagnostics gaithersburg maryland 2 secondgeneration hybrid capture test hc2 and 3 polymerase chain reaction pcr conventional pap smear and human papillomavirus hpv dna testing alone or in combination￨proportion of women referred for colposcopy rate of referral for colposcopy referral rate of women for colposcopy sensitivity and specificity￨the sensitivity and specificity of the repeat pap smear alone for the detection of cin 23 were 737 and 629 respectively when referring all women with a repeat pap smear using an ascuspositive threshold￨no diff￨highunclear￨highunclear￨highunclear
195￨women with atypia on papanicolaou smears women with atypia on papanicolaou smears one hundred ninetyfive consenting women were referred for colposcopy because of atypia on papanicolaou smears between september 1997 and april 1999￨human papillomavirus hpv dna testing and risk assessment routine colposcopy versus reflex hpv testing by either conventional or liquidbased papanicolaou smear media risk assessment and human papillomavirus testing￨costeffectiveness cervical intraepithelial neoplasia highrisk hpv types sensitivity of highrisk hpv cost of reflex hpv testing￨highrisk hpv types were detected in 313 of all subjects 364 of those with cin 1 and 933 of those with cin 23￨sig increase￨highunclear￨highunclear￨highunclear
not found￨women with atypical squamous cells of undetermined significance all new cases with cytologic smears showing ascus that presented in king chulalongkorn memorial hospital from january 2003 to november 2003 excluding known cases of hsils and pregnancies were enrolled women with a cytologic smear showing atypical squamous cells of undetermined significance ascus￨highrisk group human papillomavirus hpv dna testing￨microinvasive cervical carcinoma squamous metaplasia prevalence of hsils and the prevalence of highrisk hpv detection sensitivity specificity and positive and negative predictive values￨highrisk group hpv detection can be used as an additional triage test to detect hsils in women having ascus with high sensitivity and negative predictive value￨no diff￨highunclear￨highunclear￨highunclear
not found￨seven hundred fortynine women 2564 years old median age 42 years women with atypical squamous cells of undetermined significance ascus histologyconfirmed cervical intraepithelial neoplasia grade 2 or worse cin2 were calculated among all women and by age under and above 35 years women diagnosed as having atypical squamous cells of undetermined significance ascus while attending organised screening for cervical carcinoma in five centres of the veneto region women consecutively diagnosed as having ascus￨immediate colposcopy repeat pap test and hpv test colposcopy and collection of cervicovaginal cells for conventional pap test and hpv test hybrid capture 2 highrisk probe set digene￨sensitivity specificity and positive predictive value ppv specificity highest sensitivity highgrade cervical lesions pap smears￨hpv test showed the best performance overall it had the highest sensitivity 923 specificity 786 and ppv 149￨sig increase￨highunclear￨highunclear￨highunclear
1000000￨women with hpvpositive atypical squamous cells of undetermined significance and other abnormal cervical cytology older women but not for asch cytology at any age human papillomavirusnegative women with asch cytology women with hsil and atypical glandular cells cytology human papillomavirusnegative women with lsil women aged 30 and older who were members in kaiser permanente northern california a large health maintenance organization that introduced cotesting in 2003￨￨cervical cancer cervical intraepithelial neoplasia grade 2 cin2 highgrade squamous intraepithelial lesions hsil atypical squamous cells￨human papillomavirusnegative women with asch cytology were at a reduced but significant risk of cin2 or more severe cin2 106 compared with hpvpositive women with asch cytology￨sig decrease￨highunclear￨highunclear￨highunclear
322￨322 cervical cytology specimens with lowgrade abnormalities￨￨￨age did not appear to be a factor in determining which cases went on to manifest highgrade disease within 3 years of a lowgrade result p0678￨no diff￨highunclear￨highunclear￨highunclear
not found￨women with borderline and mild dyskaryosis women with smears read as bmd n278 were referred to the gynaecologist for colposcopy n172 and group b women with two sequential smears n106 read as bmd before referral women at risk of highgrade cin with virtually no risk for missing cin 23 women with bmd women with two serial cervical smears with borderline or mild dyskaryosis bmd within 6 months are referred for colposcopydirected biopsies after exclusion of women who were treated for prevalent highgrade cin the median followup times were 13 years range 0043 years and 16 years range 0045 years for women with hpvnegative and hpvpositive baseline smears respectively￨single smear hybrid capture ii hc ii human papillomavirus hpv￨viral clearance highgrade cervical intraepithelial neoplasia cin highrisk hpv dna sensitivity of a positive highrisk hpv test￨the sensitivity of a positive highrisk hpv test for cin 23 at the first visit was 963 the specificity 602 the positive predictive value 206 and the negative predictive value 993￨no diff￨highunclear￨highunclear￨highunclear
8170￨8170 women with papanicolaou smears of whom 278 34 returned ascus women referred with atypical squamous cells of undetermined significance ascus sixtynine of 178 388 patients with no evidence of cin tested positive for hybrid capture ii￨human papillomavirus deoxyribonucleic acid dna hybrid capture ii polymerase chain reaction pcr￨hybrid capture ii positive rates cin biopsy results￨hybrid capture ii positive rates were 933 for cases with cin iii 722 for cin ii and 510 for cin i p 001￨no diff￨highunclear￨highunclear￨highunclear
not found￨757 or lsil lowgrade squamous intraepithelial lesions 485 and a valid hpv test who received colposcopy women aged over 35 years than those younger￨ascus liquidbased cytology and human papillomavirus hpv dna￨area under the receiver operating characteristic roc curve￨the area under the receiver operating characteristic roc curve was significantly less among women aged 2534 years than in those older both considering ascusagus atypical glandular cells of undetermined significance p00355 and lsil p00009￨sig increase￨highunclear￨highunclear￨highunclear
575￨women with abnormal pap smear human papillomavirus genotypes among highrisk women 575 women referred for colposcopy due to an abnormal pap smear￨hybrid capture ii hcii assay￨hcii and linear array la performance of hcii and la histologic outcomes of cervical intraepithelial neoplasia grade 2 cin2 or worse cin2 and cin3￨in detecting cin2 and cin3 la is 5 and 6 more sensitive but 95 and 87 less specific than hcii area under roc curve p  0317 and p  0875 respectively￨no diff￨highunclear￨highunclear￨highunclear
953￨women with abnormal smears women had highgrade disease cin2 on worst histology with 193 202 having cin3 953 women participated in the study￨liquid preservcyt sample hybrid capture ii digene amplicor roche pretect hpvproofer norchip aptima hpv assay￨sensitivity specificity and positive predictive value ppv￨cintec p16ink4a cytology had a sensitivity of 830 specificity of 687 and ppv of 523￨no diff￨highunclear￨highunclear￨highunclear
317￨women who have atypical squamous cells of undetermined significance ascus or lowgrade squamous intraepithelial lesion lsil cytology undergo unnecessary colposcopy cervical highgrade squamous intraepithelial lesion hsil￨novel immunocytochemical assay proex c routine liquidbased cytology lbc￨sensitivity specificity ppv and negative predictive value npv ppv relative to ascus cytology proex c sensitivity￨the proex c immunocytochemical assay can be integrated into a clinical cytology laboratory and may increase the ppv of lbc for biopsyproven hsil￨sig increase￨highunclear￨highunclear￨highunclear
389￨389 women referred for colposcopy due to an abnormal pap smear had cervical swabs analyzed for oncogenic highrisk hr cervical intraepithelial neoplasia women with ascus or lsil smears￨hybrid capture ii hc2 assay loop electrical excision procedure cone biopsy 88 or colposcopic biopsy human papillomavirus testing hpv dna testing human papillomavirus hpv testing and colposcopy￨high viral load hr hpv sensitivity of the pap smear￨hpv dna testing improves the accuracy of colposcopy in the detection of highgrade cin in women with ascus or lsil smears￨sig increase￨highunclear￨highunclear￨highunclear
148￨women with a histological  cervical intraepithelial neoplasia ii had a higher prevalence of patients with cervical smears diagnosed as atypical squamous or glandular cells of undetermined significance two abnormal quadrants 90 vs 38 cervical intraepithelial neoplasia women with atypical squamous or glandular cells of undetermined significance cytology 148 women with atypical squamous or glandular cells of undetermined significance were evaluated by colposcopy histological sampling and human papillomavirus deoxyribonucleic acid testing￨deoxyribonucleic acid testing colposcopy and human papillomavirus￨highintermediaterisk human papillomavirus histological diagnosis of  cervical intraepithelial neoplasia cervical intraepithelial neoplasia￨two abnormal quadrants 90 vs 38 cervical intraepithelial neoplasia￨no diff￨highunclear￨highunclear￨highunclear
213￨abnormal pap smears women with abnormal pap smear 213 women all referred to colposcopy and histologic diagnosis following an abnormal pap test moderate cervical intraepithelial neoplasia cin2 and highgrade cervical intraepithelial neoplasia cin3cancer￨hybrid capture 2 hc2 human papillomavirus hpv￨￨genotyping of discordant results showed a prevalence of lrhpv types in hc2 positiveamplicor negative samples and a similar prevalence of hr and lrhpv types in amplicor positivehc2 negative samples￨sig increase￨highunclear￨highunclear￨highunclear
180￨highgrade lesions of the cervix 180 women underwent colposcopy cytology and biopsy of suspected lesions 143 cases thirtyseven patients with normal colposcopy findings did not undergo biopsy￨￨rates of detection of hpv dna and of e6 and e7 transcripts hr hpv hpv dna and mrna transcripts￨the rates of detection of hpv dna and of e6 and e7 transcripts were 333 and 25 respectively for specimens with normal findings 514 and 319 respectively for specimens with cervical intraepithelial neoplasia grade 1 cin1 and 611 and 442 for specimens with cin2 respectively￨no diff￨highunclear￨highunclear￨highunclear
378￨women with mild cytologic atypia 378 women with atypical squamous cells of undetermined significance ascus n  111 or lowgrade squamous intraepithelial lesions sils n  267 demonstrated by referral cytology women with mild atypia￨human papillomavirus hpv testing by hybrid capture ii digene diagnostics inc silver spring md￨pcr sensitivity sensitivities of hybrid capture ii for detecting cin and highgrade cin sensitivities of combined triage and cytology for detecting cin sensitivity for detecting cin specificity of combined triage￨sensitivities of hybrid capture ii for detecting cin and highgrade cin 081 and 086 respectively were similar to those of cytology 083 and 082 respectively and pcr 077 and 095 respectively and higher than those of southern blot hybridization 048 and 045 respectively￨no diff￨highunclear￨highunclear￨highunclear
not found￨810 retrospectively collected atypical squamous cells of undetermined significance ascus and lowgrade squamous intraepithelial lesion lsil cases with available biopsy followup data including 94 cases of cervical intraepithelial neoplasia cin 2 and 128 cases of cin 3￨p16ink4a cytology vs hpv testing￨sensitivity rates specificity of p16 cytology for hgcin detection sensitivity values￨the specificity of p16 cytology for hgcin detection was significantly higher than for hpv testing for cytotechnologists and pathologists 632 to 711 p16 cytology vs 378 for hpv in ascus p  001 and 373 to 533 p16 cytology vs 185 for hpv in lsil p  001￨sig increase￨highunclear￨highunclear￨highunclear
3047￨women diagnosed with atypical squamous cells of undetermined significance according to the age 3047 patients women with atypical squamous cells of undetermined significance patients needing a colposcopy￨human papillomavirus testing human papillomavirus testing on liquidbased cytoscreen system hybrid capture ii on liquidbased cytoscreen system￨specificity sensitivity for diagnosing cervical intraepithelial neoplasia￨specificity was 449 in women less than 30 of age and 644 in women more than 30 of age￨no diff￨highunclear￨highunclear￨highunclear
909￨909 women with asc women with atypical squamous cells of undetermined significance smears with atypical squamous cell asc￨hybrid capture ii assay hcii on liquid based cytology lcb￨￨the hpv dna triage showed a good accuracy specificity over 94 sensitivity of 37 and ppv for cin2 lesions around 30￨sig increase￨highunclear￨highunclear￨highunclear
702￨highgrade cervical intraepithelial neoplasia in women with abnormal cytology 702 patients with abnormal cytology who were referred for colposcopy and were tested with liquid based cytology lbc abbott realtime hr hpv and hc2￨abbott realtime high risk hr hpv abbott realtime high risk hpv test￨relative accuracy for detection of highrisk hpv accuracy for detection of highrisk hpv￨the abbott realtime hr hpv showed similar clinical performance for detection of cin2 when compared with hc2 for both the overall population and those with a cytological grade of atypical squamous cells of undetermined significance ascus￨sig increase￨highunclear￨highunclear￨highunclear
1005￨1005 women mean age sd 384 123 range 1683 were referred for a cytology of atypical cells of unknown origin ascus squamous intraepithelial lesion sil or carcinoma in the six months previous to the admission premalignant and malignant lesions of the uterine cervix￨high risk human papillomavirus testing￨hrhpv negative predictive value￨the sensitivity of this test for high gradesil or higher was 902 and the negative predictive value was 965 odds ratio189 95 confidence interval 109331￨sig increase￨highunclear￨highunclear￨highunclear
66￨66 ascuscategorized pap smears with subsequent followup biopsies￨￨sensitivity specificity and positive predictive value cervical intraepithelial neoplasia including lsil negative predictive value hrhpv viral load￨they showed significant differences p  0001 between negative p16 expressions of pap smears with the presence of reactive lesions in followup biopsies and hrhpv viral load￨sig increase￨highunclear￨highunclear￨highunclear
2198￨women aged 29 years or older with ascus referral for repeat cytopathology of ascus 2198 women with ascus and in 848 women with lsil enrolled in alts from november 1996 through december 1998 women with lsil￨lsil￨overall sensitivity of hpv testing sensitivity￨for women with ascus hpv testing was highly sensitive for detecting cin3 and cancer with dramatically fewer referrals of older women￨sig increase￨highunclear￨highunclear￨highunclear
2152￨women with abnormal cervical cytology 2152 women with abnormal cervical cytology￨highrisk human papillomavirus hpv dna testing￨detection rate of grade 23 cervical intraepithelial neoplasia cin 23 or cervical cancer detection of cin 23 and cervical cancer￨in each group the detection rate of grade 23 cervical intraepithelial neoplasia cin 23 or cervical cancer in patients with positive hpv dna was significantly higher than that with negative hpv dna p005￨no diff￨highunclear￨highunclear￨highunclear
3488￨women with ascus minority of women who have clinically significant disease while avoiding excessive followup evaluation for others patients with atypical squamous cells of undetermined significance 3488 women with a referral diagnosis of ascus￨￨equivocal cervical cytologic diagnosis sensitivity to detect cin3 or above by testing for cancerassociated hpv dna￨sensitivity to detect cin3 or above by testing for cancerassociated hpv dna was 963 95 confidence interval ci  916 to 988 with 561 of women referred to colposcopy￨no diff￨highunclear￨highunclear￨highunclear
not found￨cervical cytology specimens diagnosed as low grade squamous intraepithelial lesion for the detection of high grade cervical intraepithelial neoplasia patients with a cytologic diagnosis of low grade squamous intraepithelial lesion lsil 115 lsildiagnosed cervical cytology specimens were evaluated by highrisk human papillomavirus hrhpv￨fish hybrid capture 2 hc2 and fluorescence in situ hybridization fish￨sensitivities of hc2 and fish for cin 2 specificity of hc2￨the sensitivities of hc2 and fish for cin 2 were not significantly different 100 vs 90 p  025 while the specificity of hc2 was significantly lower than that of fish 28 vs 48 p0003￨no diff￨highunclear￨highunclear￨highunclear
not found￨cervical dysplasianeoplasia four hundred thinprep specimens 100 each in 4 categories 100 specimens that were negative for intraepithelial lesions 100 specimens of atypical squamous cells of undetermined significance ascus 100 specimens of lowgrade squamous intraepithelial lesions lsils and 100 specimens of hsils were analyzed￨p16ink4a immunolocalization p16ink4a￨overall specificity ability of p16ink4a and hr hpv detection hc2 cervical intraepithelial neoplasia sensitivity for hsil specificity for hc2￨for lsil the sensitivity was 75 3 of 4 specimens for p16ink4a and 100 4 of 4 specimens for hc2￨no diff￨highunclear￨highunclear￨highunclear
94￨457 patients patients diagnosed with atypical squamous cells of undetermined significance ascuslowgrade squamous intraepithelial lesion lsil sixty 638 of 94 women with lsil and 31 263 of 118 women with ascus tested positive for highrisk hpv patients with diagnoses of atypical squamous cells of undetermined significancelowgrade squamous intraepithelial lesions￨papanicolaou pap tests and subsequent hybrid capture tube hct human papillomavirus hpv testing￨sensitivity values for pap tests sensitivity and specificity of the pap test hpv test sensitivity values of hct ii tests￨testing for highrisk hpv with the hct ii test is useful in the detection of cin 23 in lsil groups and in the selection of patients for colposcopy in ascus groups but it is not suitable for cervical cancer screening tests￨no diff￨highunclear￨highunclear￨highunclear
102￨102 women aged 18 to 60 years who underwent a surepath pap test immediately before colposcopy and cervical biopsy￨￨atypical glandular andor squamous cells￨the surepath inform hpv and hc2 correctly identified highgrade squamous intraepithelial lesions hsils in 15 94 of 16 6 38 of 16 and 14 93 of 15 cases respectively￨no diff￨highunclear￨highunclear￨highunclear
1309￨1309 women for evaluation of abnormal pap smears￨hybrid capture tube hct and the secondgeneration hybrid capture ii hc ii test hct￨cervical intraepithelial neoplasia specificity of hc ii in detection of  or  cin 2￨hc ii was also more often positive in women with negative colposcopic evaluations 29 257324 vs 20 176235 p  005￨sig increase￨highunclear￨highunclear￨highunclear
100￨one hundred women with afr and 100 with ascus were consecutively included in the study￨￨hpv infection lsil￨hpv infection was diagnosed in 112 of afr and 380 of ascus p000003 highrisk hpv types namely hpv16 18 31 66 67 and 70 were found in 67 of afr and 228 of ascus p000239￨no diff￨highunclear￨highunclear￨highunclear
1￨women with minor cytological abnormalities women with lowgrade atypia in the stockholm area detected at a populationbased cytology screening were enrolled 177 participating women cervical intraepithelial neoplasia cin 23 with that of a second pap smear in women who had lowgrade atypia in their first pap smear￨human papillomavirus test and papanicolaou smear human papilloma virus hpvdna testing￨sensitivity of the second pap smear and hpvdna test￨the sensitivity of the second pap smear and hpvdna test to detect cin 23 was 61 95 ci  4574 and 82 95 ci  6791 respectively￨no diff￨highunclear￨highunclear￨highunclear
200￨two hundred patients with ascus diagnoses papanicolaou tests with atypical squamous cell￨proex c immunocytochemistry and highrisk human papillomavirus dna testing proex c￨sensitivities of proex c and hrhpv testing in detecting highgrade cervical intraepithelial neoplasia 2 disease nuclear staining of cytologically atypical squamous cells￨proex c staining is a more sensitive and specific biomarker for detecting cervical disease than adjunct testing for hrhpv status in papanicolaou tests with ascus￨sig increase￨highunclear￨highunclear￨highunclear
76￨seventysix women who were referred to the colposcopy clinic for abnormal cytology were enrolled￨hybrid capture ii hc ii assay￨dna chip and la tests hpvpositive rates cervical intraepithelial neoplasia ii and more severe lesions performance of 4 hpv dna tests namely hc ii linear array la dna chip and cycle sequencing￨the la test has higher hpvpositive rates than hc ii for cervical intraepithelial neoplasia i 833 vs 611 p  001 and for cervical intraepithelial neoplasia ii and more severe lesions 1000 vs 800 p  001￨sig increase￨highunclear￨highunclear￨highunclear
212￨all women were referred for colposcopy by their family physicians 159 women completed the study women with lowgrade cervical cytologic abnormalities 212 women aged 1650 years with ascus or lsil on cervical cytology screening to undergo either immediate hpv dna testing or a repeat pap test in 6 months women who completed the trial using cin 2 or 3 as the reference standard￨lowgrade paps help human papillomavirus dna testing and repeat papanicolaou test￨repeat pap smear showing ascus lsil or hsil hpv effectiveness repeat pap smear showing highgrade intraepithelial neoplasia hsil incremental cost of hpv testing￨compared with hpv dna testing which detected 875 78 of the cases of cin 2 or 3 repeat pap smear showing highgrade intraepithelial neoplasia hsil detected 111 19 of cases p  0004 and repeat pap smear showing ascus lsil or hsil detected 556 59 p  016￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients aged  or 16 years with megaloblastic anemia due to cobalamin deficiency patients with megaloblastic anemia due to cobalamin deficiency megaloblastic anemia sixty patients completed the study 26 in the po patients with megaloblastic anemia due to cobalamin deficiency po group 17 men 17 women mean sd age 64 10 years group 16 men 10 women mean sd age￨1000microg cobalamin po cobalamin treatment oral versus intramuscular cobalamin treatment￨reticulocytosis presence of reticulocytosis therapeutic effectiveness mean serum vitamin b12 concentration hemoglobin levels tolerated alteration of cognitive function loss of memory impaired concentration loss of sense of vibration sensitive peripheral neuropathy mean platelet count neurologic improvement mean white blood cell count neurologic sensory assessment including softtouch and pinprick examinations tolerability￨the mean serum vitamin b12 concentration increased significantly from day 0 to 90 p0001￨sig increase￨highunclear￨highunclear￨highunclear
38￨38 newly diagnosed cobalamin deficient patients to receive five patients were subsequently found to have folate deficiency which left 18 evaluable patients in the oral group and 15 in the parenteral group￨cyanocobalamin cobalamin deficiency with oral cobalamin￨higher serum cobalamin and lower serum methylmalonic acid levels correction of hematologic and neurologic abnormalities therapeutic effectiveness mean pretreatment values for serum cobalamin methylmalonic acid and homocysteine hematologic and neurologic improvement and changes in serum levels of cobalamin￨the higher serum cobalamin and lower serum methylmalonic acid levels at 4 months posttreatment in the oral group versus the parenteral group were significant with p  0005 and p  05 respectively￨sig increase￨highunclear￨highunclear￨highunclear
79￨2011 society of hospital medicine causes habituated drinkers to experience symptoms of alcohol withdrawal syndrome aws 44 subjects who developed symptoms of aws thirtyone subjects 18 baclofen 13 placebo completed 72 hours of assessments either entirely as inpatients or with outpatient followup two tertiarycare hospitals in duluth minnesota inpatients who developed symptoms of aws received symptomtriggered benzodiazepine treatment using inpatient adults admitted for any reason including aws judged to be at high risk for aws seventynine subjects were enrolled￨alcohol withdrawal with oral baclofen placebo benzodiazepine lorazepam benzodiazepines baclofen 10 mg or placebo baclofen or placebo copyright alcohol intake gammaaminobutyric acid gabab agonist baclofen lorazepam￨clinical institute withdrawal assessment of alcohol scale revised ciwaar lorazepam￨we found that the use of baclofen was associated with a significant reduction in the use of high doses of benzodiazepine lorazepam in the management of symptomatic aws￨sig decrease￨low￨low￨low
84￨patients with schizophrenia or schizoaffective disorder with established td eightyfour subjects were randomized of whom 77 were included in the analysis patients with more recent onset of td tardive dyskinesia￨eicosapentaenoic acid placebo ethylepa epa versus placebo￨symptoms of td extrapyramidal symptom rating scale dyskinesia scores response rates dyskinesia scores￨both the epa and placebo groups displayed significant baseline to endpoint improvements in extrapyramidal symptom rating scale dyskinesia scores but there were no significant betweengroup differences p04￨sig increase￨low￨low￨low
69￨firstepisode psychosis firstepisode psychosis fep the first participant was included in november 2000 and the last participant completed the trial in august 2003 sixtynine patients were eligible for analysis a post hoc analysis was computed for a subgroup of nonaffective fep patients n  53 80 fep patients￨ethyleicosapentaenoic acid eepa augmentation placebo ethyleicosapentaenoic acid 2g eepa augmentation￨response rate symptomatic remission extrapyramidal side effects antipsychotic efficacy and tolerability sexual side effects tolerability of antipsychotic medications constipation eepaaugmented participants needed 20 less antipsychotic medication symptom change scores and time to first response while tolerability measures and cumulative antipsychotic dose￨analysis of covariance controlling for baseline symptoms found no significant mean difference between eepa and placebo at week 12 for symptom change scores￨no diff￨low￨low￨low
40￨forty patients with persistent symptoms after at least 6 months of stable antipsychotic treatment received chronic severe schizophrenia schizophrenia￨ethyleicosapentaenoic acid placebo epa eepa or placebo ethyleicosapentaenoic acid eepa￨reduction of positive and negative syndrome scale total scores and of dyskinesia scores efficacy and tolerability￨at 12 weeks the eepa group had significantly greater reduction of positive and negative syndrome scale total scores and of dyskinesia scores than the placebo group￨sig increase￨highunclear￨highunclear￨highunclear
16￨16 patients with tardive dyskinesia tardive dyskinesia￨prostaglandin precursor essential fatty acids essential fatty acid supplementation￨￨no beneficial effects were seen￨no diff￨highunclear￨highunclear￨highunclear
87￨eightyseven patients meeting criteria for schizophrenia or schizoaffective disorder who had residual symptoms despite neuroleptic treatment patients with schizophrenia or schizoaffective disorder residual symptoms and cognitive impairment in schizophrenia￨neuroleptics with 3 gday of ethyl eicosapentaenoic acid epa ethyl epa placebo omega3 fatty acid ethyl eicosapentaenoic acid supplementation￨positive or negative symptoms mood cognition or global impression ratings residual symptoms and cognitive impairment￨results were similar for the intentiontotreat n87 and completer n75 groups￨no diff￨low￨low￨low
45￨fortyfive schizophrenic patients on stable antipsychotic medication who were still symptomatic were treated with either 14 patients on epa were taking antipsychotic drugs 12 patients on schizophrenia￨epa dha or placebo placebo phospholipids and polyunsaturated fatty acids pufa epa n3 pufa eicosapentaenoic acid epa and docohexaenoic acid dha n3 pufa eicosapentaenoic acid￨panss rating scale positive and negative syndrome scale panss epa￨improvement on epa measured by the positive and negative syndrome scale panss was statistically superior to both dha and placebo using changes in percentage scores on the total panss￨sig increase￨highunclear￨highunclear￨highunclear
115￨115 patients with dsmivdefined schizophrenia were studied 31 on clozapine 48 on new atypical drugs and 36 on typical antipsychotics patients receiving different types of antischizophrenic drugs typical antipsychotics new atypical antipsychotics and patients with persistent schizophrenic symptoms￨placebo ethyl eicosapentaenoate ee placebo ethyleicosapentaenoate clozapine￨triglyceride levels side effects or adverse biochemical or haematological effects rating scales and rise in red blood cell arachidonic acid concentration panss and its subscales￨in patients given 2 gday ee there were improvements on the panss and its subscales but there was also a large placebo effect in patients on typical and new atypical antipsychotics and no difference between active treatment and placebo￨sig increase￨highunclear￨highunclear￨highunclear
96￨children and adolescents patients aged 12 years and younger n  48 and those aged 13 years and older n  48 major depressive disorder in child and adolescent outpatients with severe persistent depression ninetysix child and adolescent outpatients aged 717 years with nonpsychotic major depressive disorder children and adolescents with depression 96 patients 48 were randomized to￨placebo fluoxetine antidepressants largely tricyclic agents fluoxetine or placebo fluoxetine￨complete remission of symptoms global improvement of the clinical global impressions scale and the childrens depression rating scalerevised a measure of the severity depressive symptoms clinical global impressions scale equivalent response rates complete symptom remission childrens depression rating scale weekly ratings of the childrens depression rating scalerevised￨significant differences were also noted in weekly ratings of the childrens depression rating scalerevised after 5 weeks of treatment using last observation carried forward￨sig decrease￨low￨low￨low
83￨depressed adolescents adolescent depression adolescent patients with major depressive disorder male and female adolescents aged 1217 years with dsmivdefined major depressive disorder￨escitalopram placebo escitalopram￨discontinuation rates incidence of suicidality mean cdrsr score headache menstrual cramps insomnia and nausea only influenzalike symptoms adverse events effective and well tolerated cdrsr score serious adverse events childrens depression rating scalerevised cdrsr score￨significant improvement was seen in the escitalopram group relative to the placebo group at endpoint in cdrsr score 221 versus 188 p 022 last observation carried forward￨sig increase￨low￨low￨low
122￨122 children and 97 adolescents with mdd children and adolescents child and adolescent outpatients children and adolescents with major depressive disorder mdd￨placebo or fluoxetine placebo fluoxetine fluoxetine￨cdrsr score tolerated and effective childrens depression rating scalerevised cdrsr score￨fluoxetine was associated with greater mean improvement in childrens depression rating scalerevised cdrsr score than placebo after 1 week  05 and throughout the study period￨sig increase￨highunclear￨highunclear￨highunclear
275￨adolescent depression adolescent major depression major depression in adolescents 275 adolescents with major depression began 8 weeks of￨imipramine placebo paroxetine imipramine gradual upward titration to 200300 mg or placebo paroxetine doubleblind paroxetine paroxetine with placebo and imipramine with placebo￨efficacy parent or selfrating measures adverse effects withdrawal rates for adverse effects endpoint response hamilton rating scale for depression hamd total score  or  8 hamd depressed mood item ksadsl depressed mood item and cgi score hamd depressed mood item 2 depression item of the schedule for affective disorders and schizophrenia for adolescentslifetime version ksadsl 3 clinical global impression cgi improvement scores of 1 or 2 4 nineitem depression subscale of ksadsl and 5 mean cgi improvement scores￨paroxetine demonstrated significantly greater improvement compared with placebo in hamd total score  or  8 hamd depressed mood item ksadsl depressed mood item and cgi score of 1 or 2￨sig increase￨low￨low￨low
133￨adolescent patients patients 617 years old with major depressive disorder pediatric depression adults￨escitalopram placebo￨discontinuation rates adverse events childrens depression rating scalerevised cdrsr scores tolerated cdrsr scores headache and abdominal pain￨escitalopram did not significantly improve cdrsr scores compared to placebo at endpoint least squares mean difference  17 p  31 last observation carried forward￨no diff￨low￨low￨low
174￨children and adolescents patients n174 were treated initially with major depression in children and adolescents children ages 711 and adolescents ages 1217 with major depressive disorder pediatric patients with major depression￨citalopram placebo citalopram with placebo citalopram￨score on the childrens depression rating scalerevised the response criterion response rate mean childrens depression rating scalerevised scores tolerated depressive symptoms rhinitis nausea and abdominal pain rates of discontinuation due to adverse events efficacy and safety safety and efficacy￨mean childrens depression rating scalerevised scores decreased significantly more from baseline in the citalopram treatment group than in the placebo treatment group beginning at week 1 and continuing at every observation point to the end of the study effect size29￨sig increase￨low￨low￨low
19￨forty patients aged 13 to 18 years participated in a fifteen subjects in each group completed the eight week study adolescent depression mean age at followup was 18 years range 1522 years￨placebo placebocontrolled fluoxetine fluoxetine fluoxetine￨moderate clinical global improvement￨fluoxetine was superior to placebo on all clinical measures except for sleep disorder but the differences were not statistically significant￨no diff￨highunclear￨highunclear￨highunclear
244￨adolescents with major depressive disorder 244 adolescents 13 to 18 years old with major depression￨citalopram psychotherapy placebo￨response rate remission madrs score suicidal thoughts and tendencies duration of treatment time of onset or dosage headache nausea and insomnia suicidal ideation kiddiesads montgomery asberg depression rating scale madrs serious adverse events￨mild to moderate treatmentemergent adverse events were reported in 75 citalopram and 71 of placebo patients most commonly headache nausea and insomnia￨sig increase￨highunclear￨highunclear￨highunclear
439￨adolescents with 13 us academic and community clinics between spring 2000 and summer 2003 volunteer sample of 439 patients between the ages of 12 to 17 years with a primary diagnostic and statistical manual of mental disorders fourth edition diagnosis of major depressive disorder adolescents with major depressive disorder adolescents with depression￨placebo cbt fluoxetine with cbt fluoxetine fluoxetine cognitivebehavioral therapy and their combination fluoxetine with cbt cognitivebehavioral therapy cbt or a selective serotonin reuptake inhibitor ssri placebo and fluoxetine fluoxetine￨suicidal thinking childrens depression rating scalerevised childrens depression rating scalerevised total score￨on the clinical global impressions improvement responder analysis the 2 fluoxetinecontaining conditions were statistically superior to cbt and to placebo￨no diff￨low￨low￨low
286￨adolescents with unipolar major depression two hundred eightysix 286 adolescents with unipolar major depression adolescents with major depressive disorder￨paroxetine or placebo placebo paroxetine paroxetine￨clinical global impressionimprovement cgii response rate efficacy safety and tolerability proportion of montgomeryasberg depression rating scale madrs responders tolerated￨a post hoc analysis of aes related to suicidal behavior suggested a greater incidence of these events for paroxetine than for placebo 44 versus 21 however this difference was not statistically significant odds ratio 215 95 confidence interval 045 1033 p  0502￨sig increase￨low￨low￨low
109￨patients with cervical dystonia type aresponsive cervical dystonia patients with cd a total of 109 patients patients with cd who continue to respond to botulinum toxin type a placebo or 5000 u or 10000 u of bontb was administered in two to four muscles involved clinically in cd patients with cervical dystonia cd￨botulinum toxin type b bontb neurobloc botulinum toxin type b placebo botulinum toxin type b neurobloc￨toronto western spasmodic torticollis rating scale twstrstotal score twstrstotal scores clinical assessments and adverse events pain disability and severity of cd safety and efficacy￨improvement in pain disability and severity of cd occurred for patients who were treated with bontb when compared with placebotreated patients￨sig increase￨low￨low￨low
not found￨cervical dystonia 122 patients with idiopathic cervical dystonia in a doubleblind￨botulinum toxin type b botb placebo intramuscular injections of either botb botulinum toxin type b￨efficacy was the toronto western spasmodic torticollis rating scale twstrstotal score clinical parameters laboratory tests and adverse events efficacy were twstrsseverity disability and pain subscale scores and analog pain assessment investigator global assessment patient global assessment and sickness impact profile scores￨the primary outcome measure of efficacy was the toronto western spasmodic torticollis rating scale twstrstotal score at 4 weeks following study drug administration￨no diff￨low￨low￨low
77￨type aresistant patients with cd 77 patients participated 38 placebo 39 active type aresistant cervical dystonia patients with type aresistant cervical dystonia patients with type aresistant cervical dystonia cd￨botulinum toxin type b bontb neurobloc botulinum toxin type b placebo botulinum toxin type b bontb neurobloc￨twstrstotal three visual analog scales patient global assessment of change principal investigator global assessment of change patient analog pain assessment and adverse events twstrstotal scores toronto western spasmodic torticollis rating scale twstrs severity disability and pain safety and efficacy￨all three visual analog scales demonstrated improvements at week 4 p  00001 00001 and 0001￨sig increase￨low￨low￨low
42￨fortytwo women who responded poorly to previous conventional controlled ovarian hyperstimulation were included in the study￨recombinant folliclestimulating hormone recfsh recfsh gonadotropinreleasing hormone gnrh agonist regimen recombinant fsh￨higher pregnancy rates number of metaphase m ii oocytes the number of embryos transferred and the pregnancy rate number of mii oocytes￨patients in the study group had a higher number of mii oocytes compared with the control group 68 vs 32 respectively p  0005 received a higher number of embryos 27 vs 12 respectively p  005 and had higher pregnancy rates 38 vs 15 respectively p  0005￨sig increase￨highunclear￨highunclear￨highunclear
60￨poorresponder patients ivf poorresponder patients sixty patients with poor ovarian response in previous treatment cycles￨gnrh antagonist chorionic gonadotrophin gonadotrophinreleasing hormone antagonist gnrh￨duration of ovarian stimulation number of oocytes retrieved number of follicles￨five pregnancies 17 for embryo transfer were obtained with gnrh antagonist protocol and two 7 for embryo transfer with gnrh agonist protocol￨no diff￨highunclear￨highunclear￨highunclear
54￨women with repeated unsuccessful in vitro fertilization ivf cycles due to inadequate ovarian response fifty four women with repeated unsuccessful in vitro fertilization ivf cycles due to inadequate ovarian response to stimulation with human menopausal gonadotropins hmg participated in this study patients with repetitive unsuccessful ivf cycles￨short and long buserelin gonadotropin releasing hormone agonist gnrha buserelin prior to and during induction of ovulation by hmg￨cancellation rate mean follicular phase serum luteinizing hormone lh and progesterone p levels cancellation rates more oocytes per pickup opu more embryos transferred per patient and a higher pregnancy rate￨mean follicular phase serum luteinizing hormone lh and progesterone p levels were significantly lower in group i than in group ii p less than 001￨sig increase￨highunclear￨highunclear￨highunclear
129￨poor responders undergoing in vitro fertilization one hundred twentynine women who were poor responders in a previous ivf cycle three groups according to age or35 years or3639 years or40 years younger patients had a better pr than the other two groups fiftynine women underwent 114 attempts of naturalcycle ivf and 70 women underwent 101 attempts of ivf with controlled ovarian hyperstimulation with microdose gnrh analog flare￨naturalcycle ivf microdose gonadotropinreleasing hormone analog flare cycles￨number of oocytes retrieved pregnancy rate pr per cycle pr per transfer and implantation rate prs per cycle and per transfer implantation rate￨in poor responders naturalcycle ivf is at least as effective as controlled ovarian hyperstimulation especially in younger patients with a better implantation rate￨sig increase￨highunclear￨highunclear￨highunclear
70￨low responder patients undergoing ivf low responder ivf patients seventy low responder patients less than three mature follicles in a previous cycle with normal basal follicle stimulating hormone concentrations and a previous cancelled ivf cycle￨gonadotrophins combined with stop versus nonstop protocol of gnrh analogue administration gonadotrophin releasing hormone analogue gnrha nonstop protocol long gnrha suppression with high doses of gonadotrophins and ii stop protocol in which gnrha administration￨ovulation pregnancy rate number of oocytes number of ampoules of gonadotrophins required implantation rate cancellation rate number of mature oocytes￨a significantly higher number of mature oocytes were obtained in the study group stop protocol compared to the control group nonstop protocol 87  09 versus 62￨sig increase￨highunclear￨highunclear￨highunclear
30￨low responders undergoing in vitro fertilization thirty patients who were known low responders women treated with￨human chorionic gonadotropin hcg gonadotropinreleasing hormone gnrh antagonist exogenous lh human menopausal gonadotropin gnrh agonist flareup protocol and group 2 used antagonist protocol gonadotropinreleasing hormone agonist and antagonist￨serum luteinizing hormone lh levels lower estradiol e2 rate of decline in e2 lh serum e2 levels rate of folliculogenesis higher e2 level￨despite this higher lh serum e2 levels were significantly higher in the agonist group on cycle day 2 only not on day 5 or day 9￨sig increase￨highunclear￨highunclear￨highunclear
not found￨poorresponder patients poor responders undergoing ovarian stimulation thirty patients received￨intracytoplasmic sperm injection icsi fsh gonadotropinreleasing hormone gnrh antagonist and gnrh agonist flareup regimen gnrh agonist exogenous gonadotropins starting￨numbers of mature oocytes retrieved and of topquality embryos transferred fertilization rate number of mature oocytes retrieved embryo quality fertilization implantation and pregnancy rates implantation and pregnancy rate number of ampules and units of fsh￨the numbers of mature oocytes retrieved and of topquality embryos transferred were significantly greater in the flareup than in the gnrhantagonist group￨sig increase￨highunclear￨highunclear￨highunclear
96￨ninetysix patients with poor ovarian response in previous treatment cycles poor responders undergoing in vitro fertilization￨gnrh antagonist and minidose long agonist protocols standard long agonist protocol gonadotropin releasing hormone antagonist gnrh gnrh antagonist multidose protocol￨ovarian response clinical pregnancies duration of stimulation and consumption of gonadotrophins￨there was significantly reduced duration of stimulation and consumption of gonadotrophins in the antagonist group when compared to the agonist group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨premenopausal women with uterine leiomyomas premenopausal women ninety healthy premenopausal women affected by asymptomatic uterine leiomyomas￨raloxifene placebo raloxifene￨uterine and leiomyoma sizes uterine and leiomyoma volumes delta size uterine and leiomyoma size or in delta size severity of the uterine bleedings length and severity of uterine bleedings uterine and leiomyoma size￨throughout the study no significant changes were observed in uterine and leiomyoma size or in delta size among the three groups and within each group of treatment￨no diff￨highunclear￨highunclear￨highunclear
not found￨uterine leiomyomas 100 premenopausal women with symptomatic uterine leiomyomas￨raloxifene hydrochloride placebo leuprolide plus placebo tablet combined gnrh analogue plus raloxifene leuprolide acetate depot plus raloxifene raloxifene￨uterine leiomyoma and nonleiomyoma sizes leiomyoma sizes leiomyomarelated symptoms uterine leiomyoma and nonleiomyoma sizes and leiomyomarelated symptoms uterine and nonleiomyoma sizes leiomyoma sizes￨leiomyoma sizes were significantly p  005 lower in group a than in group b no difference was observed in leiomyomarelated symptoms between groups throughout the study period￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨tertiary care unit university of vienna austria premenopausal women twentyfive premenopausal women with uterine leiomyomas￨raloxifene raloxifene￨leiomyoma volume myoma volume progression of uterine leiomyomas tolerated uterine leiomyoma size growth of uterine leiomyomas￨no significant differences were detected in symptoms related to leiomyomas and hormonal status￨no diff￨highunclear￨highunclear￨highunclear
60￨sixty consecutive patients requiring a catheter for capd￨singlecuff and doublecuff straight tenckhoff catheters straight deep singlecuff tenckhoff catheter or a doublecuff tenckhoff catheter tenckhoff catheters with single or double dacron cuffs￨transfer to haemodialysis overall probability of catheter survival catheter survival episodes of peritonitis and exitsite infections probability of developing first episode of peritonitis or exit site infection￨there was no significant difference between catheters with single or double cuffs with respect to catheter survival episodes of peritonitis and exitsite infections￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨curled tenckhoff catheter continuous ambulatory peritoneal dialysis capd￨￨in the setting of a prospective randomised doubleblind comparison we were unable to demonstrate any advantage of the curled tenckhoff catheter over the conventional straight type￨no diff￨highunclear￨highunclear￨highunclear
40￨forty consecutive patients requiring their first dialysis catheter for future capd capd unit in one university hospital serving a population of 12 million￨continuous ambulatory peritoneal dialysis capd swan neck and tenckhoff catheters twocuff permanently bent swan neck catheter or a twocuff straight tenckhoff catheter peritoneal catheter configuration￨probability of episodes of peritonitis or probability of exitsite infections catheterrelated mechanical or infectious complications dialysate leak catheter migration or tunnel infection catheter survival skin exit mechanical complications catheter survival probability of episodes of peritonitis and probability of exitsite infections￨catheter configuration did not influence the catheterrelated mechanical or infectious complications and equally good results were obtained with both catheter types studied￨no diff￨highunclear￨highunclear￨highunclear
not found￨sixtysix patients having a tenckhoff catheter placement capd patients￨immobilizer tape and nonimmobilized group immobilization device￨infection rates esi rate￨the results show no significant difference in infection rates between the three groups nor do the factors mentioned have any bearing on esi rate￨no diff￨highunclear￨highunclear￨highunclear
37￨permanent peritoneal dialysis catheters 37 patients requiring a dialysis catheter for future capd thirteen catheters 6 midline 7 lateral failed for mechanical reasonsmainly irreversible tip migration￨catheter insertion peritoneal dialysis catheters midline prior standard approach or a lateral incision new approach paramedian versus midline incision￨catheter survival without mechanical failure￨the one year estimated catheter survival without mechanical failure was found to be similar in the two groups midline 59 and lateral 51 04 less than p less than 05￨no diff￨highunclear￨highunclear￨highunclear
40￨patients on capd forty consecutive patients who were commencing capd￨doublecuff swan neck coiled catheter or a doublecuff straight tenckhoff catheter implanted by surgical technique peritoneal catheter configuration swan neck coiled and straight tenckhoff catheters straight catheters straight catheter￨peritonitis rate number of capd patient dropouts number of technique failures cathetertip migration rate of exitsite infection rate of exitsite infections￨there was a lower rate of exitsite infection in the swan neck group compared to the straight catheter group 029 vs 060 episodespatientyear p  005￨sig decrease￨highunclear￨highunclear￨highunclear
50￨fifty patients commencing peritoneal dialysis tertiary referral renal unit￨laparoscopic and open peritoneal dialysis catheter insertion laparoscopic and conventional peritoneal dialysis catheter insertion￨operative discomfort complication rates and catheter survival duration of surgery hospital stay pain scores and analgesic requirements complications earlylate and catheter survival early complication rates￨the conventional procedure was faster than the laparoscopic 143 vs 219 minutes p  00001￨sig decrease￨highunclear￨highunclear￨highunclear
60￨30 patients had catheters left implanted subcutaneously for 6 weeks i and the other 30 patients had mean age was 477 years range 1671 610 were male and 441 diabetics 60 patients patients with catheters placed by conventional access technique subgroups of 15 patients each with new and conventional techniques used yconnector iy cy and remaining patients used standard spikes is cs￨peritoneal catheter prolonged subcutaneous implantation capd catheters inserted by conventional technique￨peritonitis rate peritonitis exit site infection simultaneous peritonitis and exit site infection and complication related to staphylococcus or pseudomonas infections exit site infection simultaneous peritonitis and exit site infection total peritonitisfree period rates of complications related to staphylococcus aureus and pseudomonas infections technique survival lowest incidence of peritonitis total duration of observation peritonitis rate￨the rates of complications related to staphylococcus aureus and pseudomonas infections were also significantly lower in iy than in cy is or cs￨sig decrease￨highunclear￨highunclear￨highunclear
60￨sixty patients￨peritoneal dialysis pd catheters subcutaneously buried peritoneal dialysis catheter technique versus standard technique￨cumulative probability of not developing peritonitis incidence of peritonitis and exitsite infections esi risk of contracting peritonitis or exitsite infection episodes of esi cumulative probability of not developing esi incidence of esi number of esi incidence of the first episode of peritonitis incidence of peritonitis and exitsite infection￨the incidence of esi was 1103 and 195 treatmentmonths in the b and ns groups respectively￨no diff￨highunclear￨highunclear￨highunclear
50￨fifty patients continuous ambulatory peritoneal dialysis catheters peritoneal dialysis￨laparoscopic placement of a tenckhoff catheter simultaneous cholecystectomy incisional hernia repair continuous ambulatory peritoneal dialysis catheter placement via the open laparotomy technique laparoscopic placement of the tenckhoff catheter laparoscopic placement of the catheter with fixation into the pelvis and suture closure of the port wounds laparoscopic versus open laparotomy technique￨peritonitis tip migration mean operative time fluid leakage￨laparoscopic placement of a tenckhoff catheter leads to better function than does the open procedure￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨peritoneal dialysis pd catheters pd catheter placement by either the surgical or the peritoneoscopic technique peritoneoscopically placed pd catheters percutaneous implantation via the peritoneoscopic technique peritoneoscopic versus surgical placement of peritoneal dialysis catheters￨rate of exit site leak and early infection better survival survival rate exit site leak early peritonitis episodes rate of infection￨moreover peritoneoscopically placed catheters were found to have better survival 775 at 12 months 63 at 24 months and 513 at 36 months than those placed surgically 625 at 12 months 415 at 24 months and 36 at 36 months with p  002 001 and 004 respectively￨sig increase￨highunclear￨highunclear￨highunclear
40￨capd unit in one university hospital forty consecutive patients requiring a dialysis catheter for future capd￨continuous ambulatory peritoneal dialysis capd peritoneal catheter configuration singlecuff straight tenckhoff catheter or a permanently bent singlecuff swan neck catheter continuous ambulatory peritoneal dialysis￨probability of episodes of peritonitis or probability of exitsite infections catheter survival dialysate leak skin exit mechanical complications catheter survival probability of episodes of peritonitis and probability of exitsite infections￨no significant differences in catheter survival at 2 years probability of episodes of peritonitis or probability of exitsite infections could be demonstrated￨no diff￨highunclear￨highunclear￨highunclear
72￨seventytwo consecutive patients initiating peritoneal dialysis department of nephrology of a single university hospital￨straight and curled tenckhoff peritoneal dialysis catheters implanted by percutaneous technique peritoneal dialysis catheter configuration curled or straight catheter single cuff straight catheter or a single cuff curled catheter implanted by percutaneous technique￨catheter survival survival rate catheter survival infectious complication￨significantly higher p  001 survival rate of the curled as compared to the straight catheter￨sig increase￨highunclear￨highunclear￨highunclear
not found￨twentytwo subjects who had at least one episode of raynauds phenomenon per day entered the study raynauds phenomenon￨dazoxiben 320 placebo dazoxiben calcium channel blocker nifedipine nifedipine 247 dazoxiben and nifedipine￨side effects mean twoweek episode rate￨similarly there was no difference in the mean twoweek episode rate among the three treatments placebo 304￨no diff￨highunclear￨highunclear￨highunclear
21￨21 patients with primary raynauds phenomenon primary raynauds phenomenon￨enalapril placebo enalapril￨skin temperature visual analogue scales 5 point rating scales and skin temperature response efficacy and acceptability number and severity of raynauds attacks￨following enalapril there were no significant changes in the number and severity of raynauds attacks and no subjective benefit from treatment as measured by visual analogue scales 5 point rating scales and skin temperature response to cold challenge when compared with placebo￨no diff￨highunclear￨highunclear￨highunclear
31￨raynauds phenomenon 31 patients 16 in the buflomedil group 15 in the placebo group suffering from idiopathic raynauds phenomenon and followed up for six months￨placebo buflomedil￨mean daily frequency and severity of winter ischemic attacks￨the efficacy was confirmed by nail fold capillaroscopy which showed a significant alleviation of hemodymanic disturbances and background pallor in comparison with the placebo￨sig decrease￨low￨low￨low
not found￨fifteen patients with primary raynauds phenomenon received patients with primary raynauds phenomenon￨captopril placebo captopril captopril 25 mg or placebo￨cutaneous blood flow frequency or severity of attacks of raynauds phenomenon￨compared with placebo captopril produced a significant improvement in cutaneous blood flow but did not alter the frequency or severity of attacks of raynauds phenomenon￨no diff￨highunclear￨highunclear￨highunclear
41￨41 patients with primary raynauds phenomenon prp patients with primary raynauds phenomenon patients with prp￨ketanserin placebo ketanserin serotonin receptor blocker ketanserin￨blood chemistry nor systemic blood pressure digital skin temperature dst digital systolic blood pressure dbp and doppler spectral analysis dosa of the radial and ulnar arteries diastolic blood flow velocity of dosa severity score the occurrence of numbness and paresthesia and cold weather provocation frequency and duration of the attacks both per se and combined to a severity score cold sensation numbness paresthesia pain cold water and cold weather provocation and the appearance of spontaneous attacks hypertension both systolic and diastolic blood pressure normalized￨the severity score the occurrence of numbness and paresthesia and cold weather provocation improved significantly on ketanserin treatment￨sig increase￨highunclear￨highunclear￨highunclear
62￨62 patients with the common cold by a doubleblind randomized patients with the common cold￨steam inhalation placebo￨subjective response nasal patency nasal patency and on nasal symptoms nasal patency alleviation of cold symptoms nasal patency and nasal symptoms peak nasal expiratory and inspiratory air flow￨steam inhalation resulted in alleviation of cold symptoms and increased nasal patency in a significantly higher percentage of patients in the actively treated group than in the placebotreated group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨sixtyeight cleveland clinic employee volunteers with symptoms of the common cold at the time of enrollment￨placebo inhaling heated vapor steam inhalation 2 lmin of ambient air 40 lmin of heated saturated air that raised the intranasal temperature to 43 degrees c￨nasal resistance nasal resistances subjective symptom scores for nasal congestion nasal drainage and sneezing and objective measures of nasal resistance daily symptom scores￨the only statistically significant differences between the groups were lower nasal resistances at baseline in the steam group p  04 and percent improvement in nasal resistance favoring the placebo group on day 7 p  01￨sig decrease￨highunclear￨highunclear￨highunclear
87￨87 unselected patients with typical acute nasal and upper respiratory symptoms general practice study and 84 volunteers aged 1850 without a history of chronic or allergic diseases￨￨severity of disease symptoms general practice study and observers recorded symptoms and signs weight of nasal secretions isolation of virus and antibody responses￨patients treated for 20 minutes at 43 degrees c had in the succeeding days roughly half the score for symptoms of those treated at 30 degrees c volunteers treated for 30 minutes on three occasions when they were starting a cold showed an 18 corrected reduction in symptoms￨sig increase￨highunclear￨highunclear￨highunclear
20￨by infected volunteers volunteers with experimental rv colds twenty volunteers from the university community who were susceptible to the challenge virus volunteers experimentally infected with rv￨steam inhalation hot humidified air placebo machinegenerated humidified air which was either hot active or at room temperature placebo￨mean titers temperature of active vapor rv shedding mean viral titers viral shedding viral titers viral shedding￨mean viral titers prior to the first treatment were 1017 tissue culture infectious doses per milliliter in the active group and 1015 in the placebo group￨no diff￨highunclear￨highunclear￨highunclear
not found￨common cold symptoms 34 patients in the placebo group and 32 in the active group￨steam inhalation placebo inhaling heated vapor steam technically heated humidified air inhalation￨nasal resistance subjective symptom scores for nasal congestion nasal drainage and sneezing on isolated days￨significant improvements in the placebotreated group were obtained on subjective symptom scores for nasal congestion nasal drainage and sneezing on isolated days during the treatment period 40 vs 25 on day 3 71 vs 60 on day 6 and 100 vs 67 on day 7￨sig increase￨highunclear￨highunclear￨highunclear
130￨premature infants preterm infants receiving lactasetreated feeds 130 infants 2634 weeks postconceptual age￨lactasetreated preterm feeds￨gains in length and head circumference biochemical indexes of nutritional status feeding intolerance and incidence of necrotizing enterocolitis enhanced weight gain weight gain weight gain weight gain and feeding tolerance caloric intakes length gain head circumference gain feeding intolerance and incidence of necrotizing enterocolitis serum albumin level￨sem of the treatment group was significantly greater p 05 than that of the control group 204￨sig increase￨low￨low￨low
75￨patients undergoing hepatectomy seventyfive patients underwent hepatic surgery mostly owing to metastasis patients who underwent partial liver resection university hospital munich germany￨hepatic ischemic preconditioning temporary vascular clampage pringle maneuver during liver surgery ischemic preconditioning group 1 without pringle maneuver group 2 with pringle maneuver and group 3 with ischemic preconditioning using 10 minutes of ischemia and 10 minutes of reperfusion prior to pringle maneuver for resection￨degree of their postischemic activation and the postoperative rise in liver enzyme serum levels sd time serum alanine aminotransferase levels number of circulating pmnls 2 their intrahepatic sequestration 3 their systemic activation attenuation of superoxide anion production beta2integrin upregulation and interleukin 8 serum concentrations pringle maneuver activation of pmnls and cytokine plasma levels￨when ischemic preconditioning preceded the pringle maneuver activation of pmnls and cytokine plasma levels was reduced as evidenced by the attenuation of superoxide anion production beta2integrin upregulation and interleukin 8 serum concentrations followed by a significant reduction in serum alanine aminotransferase levels on the first and second postoperative days￨sig decrease￨highunclear￨highunclear￨highunclear
61￨61 patients undergoing hepatic resection under inflow occlusion after liver resections￨ischemic preconditioning ip ischemic preconditioning clamping of the portal triad pringle maneuver￨postoperative outcome resected liver tissue mean blood loss complications including death severe liver dysfunction and biliary leakage intraoperative blood loss￨ip protects against reperfusion injury reduces the incidence of complications after hepatic resection under inflow occlusion and is simple to use in clinical practice￨sig decrease￨highunclear￨highunclear￨highunclear
60￨major liver resection under vascular exclusion of the liver preserving the caval flow sixty patients￨preconditioning group and without n30 control group ip 10 minutes of portal triad clamping and 10 minutes of reperfusion before major hepatectomy under vascular exclusion of the liver preserving the caval flow ischemic preconditioning ip ischemic preconditioning￨peak concentration of alanine transferase and glutathionestransferase peak postoperative concentrations of aspartate transferase liver tolerance to ischemiareperfusion morbidity and mortality rates and lengths of icu and hospitalization stays morbidity or mortality rates morbidity and mortality serum concentrations of aspartate transferase alanine transferase glutathionestransferase and bilirubin and prothrombin time postoperative liver function￨morbidity and mortality rates and lengths of icu and hospitalization stays were similar in both groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨tobago men with high prostate cancer risk men with elevated prostate cancer risk afrocaribbean men n81 with highgrade prostatic intraepithelial neoplasia atypical foci or repeated noncancerous biopsies ascertained in a populationbased screening program men awaiting prostatectomy￨lycopene supplementation lycopene lycomato plus a multivitamin or to multivitamin only￨serum lycopene levels serum psa and lycopene psa response serum psa serum prostate specific antigen psa￨the psa response was nearly identical in both treatment groups￨no diff￨highunclear￨highunclear￨highunclear
40￨patients diagnosed with benign prostate hyperplasia bph patients with benign prostate hyperplasia elderly men diagnosed with bph 40 patients with histologically proven bph free of pca￨lycopene supplementation placebo lycopene lycopene￨digital rectal examination progression of prostate enlargement psa levels international prostate symptom score questionnaire plasma lycopene concentration inhibition or reduction of increased serum prostatespecific antigen psa levels carotenoid status clinical diagnostic markers of prostate proliferation and symptoms of the disease￨whereas progression of prostate enlargement occurred in the placebo group as assessed by transrectal ultrasonography p  005 and digital rectal examination p  001 the prostate did not enlarge in the lycopene group￨sig increase￨highunclear￨highunclear￨highunclear
40￨highgrade prostate intraepithelial neoplasia highgrade prostate intraepithelial neoplasia hgpin 40 patients with hgpin￨vegetable carotenoid lycopene lycopene lycopene￨￨lycopene is an effective chemopreventive agent in the treatment of hgpin with no toxicity and good patient tolerance￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with severe head injury patients with a motor score of 45 41 patients in the control group 36 in the hv group and 36 in the hv  tham group￨prolonged hyperventilation tromethamine tham normal ventilation paco2 35 prophylactic hyperventilation hyperventilation paco2 25 hyperventilation plus tham paco2 25 hv  tham￨occurrence of cerebral ischemia mean glasgow coma scale score intracranial pressure icp control and reversal of brain and cerebrospinal fluid csf acidosis cerebral blood flow cbf￨accordingly cerebral blood flow cbf was lower in the hv  tham group than in the control and hv groups but neither cbf nor arteriovenous difference of oxygen data indicated the occurrence of cerebral ischemia in any of the three groups￨sig increase￨highunclear￨highunclear￨highunclear
30￨patients with pmd 30 patients with pmd psychotic depression males and females￨mifepristone or placebo placebo mifepristone￨elevated cortisol and acth levels cortisol and acth psychotic major depression pmd bprs positive symptom subscale an index of psychotic symptoms hamilton depression rating scale hdrs and the brief psychiatric rating scale bprs cortisol and acth lower hdrs and bprs scores normal afternoon cortisol release￨patients who received mifepristone had lower hdrs and bprs scores at study completion compared to those who received placebo but these differences were not statistically significant￨sig decrease￨highunclear￨highunclear￨highunclear
16￨patients with treatmentrefractory major depression 16 adults with treatmentrefractory major depressive disorder￨placebo ketoconazole￨hamilton rating scale for depression hamd the beck depression inventory bdi and the clinical global impression scale cgi hamd bdi or cgi scores￨as a group patients assigned to receive ketoconazole showed no significant reductions in hamd bdi or cgi scores during the 6week trial compared with those receiving placebo￨no diff￨highunclear￨highunclear￨highunclear
not found￨hypercortisolemic depressed patients twenty medicationfree depressed patients eight of whom were hypercortisolemic and twelve of whom were not received either the￨placebo ketoconazole cortisol biosynthesis inhibitor ketoconazole ketoconazole￨dehydroepiandrosterone and testosterone levels and increased pregnenolone and pregnenolonesulfate levels depression ratings￨ketoconazole compared to placebo was associated with improvements in depression ratings in the hypercortisolemic but not in the nonhypercortisolemic patients￨sig increase￨highunclear￨highunclear￨highunclear
5￨five patients with psychotic major depression￨placebo mifepristone￨brief psychiatric rating scale scores adverse effects hamilton rating scale for depression scores￨all of the five patients showed substantial improvements in their hamilton rating scale for depression scores while they were receiving mifepristone and four of the five patients showed substantial improvement in their brief psychiatric rating scale scores￨sig increase￨highunclear￨highunclear￨highunclear
not found￨20 bipolar patients bipolar disorder￨mifepristone ru486 placebo corticosteroid receptor antagonist mifepristone ru486 or placebo mifepristone￨hamilton depression rating scale scores mood symptoms neurocognitive and neuroendocrine function adverse events neurocognitive functioning spatial working memory performance montgomeryasberg depression rating scale scores verbal fluency and spatial recognition memory neurocognitive function and mood￨beneficial effects on mood were found hamilton depression rating scale scores were significantly reduced compared to baseline mean reduction of 51 points as were montgomeryasberg depression rating scale scores mean reduction of 605 points￨sig increase￨highunclear￨highunclear￨highunclear
22￨twentytwo patients with major depression either medicationfree or on stabilized antidepressant regimens received either humans patients with major depression￨placebo dehydroepiandrosterone dhea dhea dehydroepiandrosterone dhea or placebo dhea maximum dose  90 mgday or placebo￨hamilton depression scale ratings depressive symptoms hamilton depression rating scale￨dhea was associated with a significantly greater decrease in hamilton depression scale ratings than was placebo￨sig decrease￨highunclear￨highunclear￨highunclear
63￨sixtythree inpatients with a dsmiv diagnosis of major depression and a baseline score 18 points or higher on the major depression patients with major depression￨placebo metyrapone placebo or metyrapone standard serotonergic antidepressants nefazodone or fluvoxamine metyrapone￨responder rates hamilton rating scale for depression tolerated without serious adverse effects baseline hamilton rating scale for depression scores plasma concentrations of corticotropin and deoxycortisol number of responders and the time to onset of action￨the plasma concentrations of corticotropin and deoxycortisol were significantly higher during metyrapone treatment multivariate analysis of covariance p05 whereas cortisol remained largely unchanged￨sig increase￨low￨low￨low
221￨221 patients aged 19 to 75 years who met dsmiv and scid criteria for pmd and were not receiving antidepressants or patients with psychotic major depression￨antipsychotics placebo mifepristone mifepristone antiglucocorticoid mifepristone￨effective and well tolerated measures of depression bprs positive symptom scale pss brief psychiatric rating scale bprs￨no significant differences were observed on measures of depression￨no diff￨highunclear￨highunclear￨highunclear
not found￨eight inpatients with major depression￨hydrocortisone metyrapone and hydrocortisone placebo￨depressive symptoms￨the treatment resulted in a significant reduction in depressive symptoms￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨chronic placental insufficiency 31 patients during late pregnancy with chronic placental insufficiency￨proteinfree calfbloodextract solcoseryl￨urinary estrogen excretion￨under treatment with solcoseryl a significant increase in urinary estrogen excretion occurred in relation to the placebogroup￨sig increase￨highunclear￨highunclear￨highunclear
15￨placental insufficiencyinitial experiences 15 pregnant women￨carnitine carnitine carnitine 3hydroxy and 4trimethylaminobutyrate carnitine substitution￨carnitine spontaneous improvement of fetal growth￨in the control group 8 out of 15 patients showed a spontaneous improvement of fetal growth 2 women did not have a change in their retardation and 5 patients had to be hospitalized because of increasing placental insufficiency￨no diff￨highunclear￨highunclear￨highunclear
45￨suspected intrauterine fetal retardation 45 pregnancies with clinical and sonographic suspicion for intrauterine fetal growth retardation examinations￨glucose infusions or oral galactose applications￨therapeutic effectivity￨there is no positive therapeutic effect either on the impaired endocrine partial function nor on the reduced respiratory function of the fetoplacental unit￨no diff￨highunclear￨highunclear￨highunclear
44￨44 gravidas with fgr 44 pregnant women with fgr and 36 normal gravidas pregnant women with fgr￨amino acid amniotic cavity formula and control group with intravenous infusion of compound amino acid pediatric amino acid￨maternal blood igfi and amniotic fluid igfi and igfii levels better therapeutic effects birth weights igfi and igfii levels levels of igfi and igfii insulinlike growth factors igfs and fetal growth restriction fgr igfi levels in maternal blood￨better therapeutic effects were achieved in the treatment group than in the control group p001 and the birth weights of the neonates in the treatment group were basically normal￨sig increase￨highunclear￨highunclear￨highunclear
not found￨district general maternity unit in italy childbirth two hundred and fiftyone women randomised to aromatherapy and 262 controls￨rct using aromatherapy selected essential oils during labour by midwives specifically trained in their use and modes of application rct comparing aromatherapy aromatherapy aromatherapy￨spontaneous vaginal delivery pain perception operative delivery spontaneous delivery first and secondstage augmentation pharmacological pain relief artificial rupture of membranes vaginal examinations episiotomy labour length neonatal wellbeing apgar scores and transfer to neonatal intensive care unit nicu kristeller manoeuvre outcomes caesarean section￨there were no significant differences for the following outcomes caesarean section relative risk rr 099 95 ci 070141 ventouse rr 15 95 ci 031762 kristeller manoeuvre￨no diff￨low￨low￨low
not found￨one hundred unpremedicated daycare patients￨oral ranitidine 150 mg or placebo with bromosulphthalein bsp placebo preoperative oral fluid and ranitidine ranitidine￨gastric emptying gastric fluid volume and ph residual gastric volume rgv mean ph values￨in patients who ingested 150 ml water there was no correlation between the premedication interval and either rgv or ph values￨no diff￨highunclear￨highunclear￨highunclear
100￨100 elective surgical patients￨￨mean sd residual gastric volume￨problems with aspiration or regurgitation were not encountered￨no diff￨highunclear￨highunclear￨highunclear
23￨￨light standard breakfast￨volume of gastric contents aspirated the median ph of the gastric contents volume and median ph of gastric contents gastric contents￨there were no significant differences between the groups in respect of the volume of gastric contents aspirated the median ph of the gastric contents or the number of patients with a ph of less than 30 unit￨no diff￨highunclear￨highunclear￨highunclear
300￨elective inpatients 300 elective surgical inpatients asa physical status￨150 ml coffee placebo belladonna premedication coffee or orange juice versus overnight fast preoperative oral fluids with and without ranitidine ranitidine￨residual gastric fluid volumes gastric fluid volume and ph￨residual gastric fluid volumes showed no statistically significant differences among the groups group 1 245￨no diff￨highunclear￨highunclear￨highunclear
300￨elective inpatients gastric fluid volume and ph 300 elective surgical inpatients asa physical status i and ii￨150 ml orange juice with oral ranitidine belladonna premedication oral ranitidine alone 150 ml coffee with oral ranitidine coffee or orange juice with ranitidine preoperative oral fluids with and without ranitidine ranitidine￨mean ph gastric fluid volume and ph￨there were no statistically significant differences between groups with respect to volume group 4 143￨no diff￨highunclear￨highunclear￨highunclear
not found￨twohundredfiftytwo elective abdominal surgery patients asa physical status iii elective surgery patients￨cho and placebo placebo placebo cho carbohydrate drink cho placebo flavored water or overnight fasting carbohydraterich drink￨visual analog scales preoperative discomfort residual gastric fluid volumes and gastric acidity nausea tiredness and inability to concentrate gastric fluid volumes or affect acidity visual analog scale scores hungry and less anxious preoperative discomfort discomfort unfitness and malaise thirst hunger anxiety malaise and unfitness hunger thirst tiredness weakness and inability to concentrate￨cho reduced thirst as effectively as placebo p  00001 versus fasted￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨￨￨gastric volume or ph or on plasma osmolality anxiety￨no effect was seen on gastric volume or ph or on plasma osmolality and allowing water preoperatively was associated with a reduction in anxiety in the anaesthetic room￨no diff￨highunclear￨highunclear￨highunclear
40￨40 elective surgical patients ranging in age from 18 to 70 years elective surgical patientsa comparison of tea with apple juice￨isoflurane anesthesia or modified neuroleptic anesthesia thiopental and vecuronium diazepam preoperative oral fluid intake roxatidine tea or apple juice￨volume and ph of gastric contents gastric volume gastric ph￨there was a significant difference in the gastric volume between the two groups p  005 while no significant difference in gastric ph was observed￨no diff￨highunclear￨highunclear￨highunclear
40￨forty elective surgical patients ranging in ages from 20 to 60 years twenty patients who were given either elective surgical patients￨isotonic beverage 250 ml or apple juice 250 ml preanesthetic meals breakfast group took two slices of bread with the above drink￨mean values of gastric volume volume and ph of gastric contents gastric volume and ph mean values of gastric ph￨there were no significant differences in the gastric volume and ph between the two groups￨no diff￨highunclear￨highunclear￨highunclear
50￨women undergoing sterilization between one and five days postpartum fifty postpartum patients received 150 ml water approximately two to three hours before surgery while 50 postpartum and 50 nonpregnant women were fasted from midnight￨￨intragastric volume and acidity gastric ph and volume intragastric ph and volume median range￨there were no differences in intragastric ph and volume median range among the postpartum fasted group 119 074457 22 178 ml postpartum water group 118 07064 255 366 ml and the nonpregnant group 127 051663 25 369 ml￨no diff￨highunclear￨highunclear￨highunclear
83￨eightythree adult inpatients scheduled to receive patients given acid aspiration prophylaxis thirtyfour patients group 2 fasted before surgery but received￨ranitidine and metoclopramide no oral fluids or acid aspiration prophylaxis before surgery general anesthesia for elective surgery oral ranitidine oral clear liquids metoclopramide acid aspiration prophylaxis￨gastric volume and acidity residual gastric volume rgv gastric ph rgv measurements￨gastric ph was significantly higher p less than 0001 in group 1 516  069 and group 2 578  043 than in group 3 197  027￨sig increase￨highunclear￨highunclear￨highunclear
150￨150 elective surgical patients asa physical status 1 and 2 elective surgical patients￨intramuscular morphine 015 mgkg and promethazine morphine morphine￨residual gastric volume￨statistically significant p less than 005 decrease in residual gastric volume was observed in groups 2 and 3 as compared to group 1￨sig decrease￨highunclear￨highunclear￨highunclear
20￨twenty postpartum patients pregnant patients undergoing sterilisation forty consecutive postpartum patients and twenty nonpregnant patients scheduled for sterilisation procedure were selected for the study postpartum patients￨150 ml of plain water two and half hours before surgery preoperative oral fluids￨risk of aspiration syndrome volume and ph mean ph gastric volume and ph mean gastric volume￨the difference in the volume and ph in all the three groups was statistically insignificant￨no diff￨highunclear￨highunclear￨highunclear
not found￨elective inpatients one hundred and twenty healthy elective surgical inpatients healthy patients￨placebo tablet with 150 ml oral fluid group 3 or oral ranitidine 150 mg with oral fluid 150 ml narcoticatropine premedication oral fluid and ranitidine oral diazepam or no premedication placebo tablet alone im narcotic and atropine￨gastric emptying mean ph values mean volumes gastric fluid volume ph and emptying￨mean volumes were group 1 24 ml group 2 13 ml group 3 17 ml group 4 14 ml￨no diff￨highunclear￨highunclear￨highunclear
46￨46 patients who were encouraged to drink water until 3 h preoperatively and 49 receiving the normal fasting regimen prior to minor surgery anaesthesia for minor surgery￨￨postoperative recovery morbidity postoperative morbidity and serum osmolality￨there was significantly less thirst in the postoperative period in those patients allowed to drink and subjectively better recovery than after previous anaesthesia￨sig decrease￨highunclear￨highunclear￨highunclear
152￨152 adolescents ages 1319 yr undergoing elective surgery healthy adolescents￨￨gastric fluid volume gv gv gph and subject hunger￨gv gph and subject hunger were unaffected by ingestion of clear fluids￨no diff￨highunclear￨highunclear￨highunclear
not found￨45 elective surgical patients ranged in ages from 18 to 70 years elective surgical patients after preoperative oral fluid intake￨roxatidine oral roxatidine preoperative oral fluid intake￨vas of hungry and thirsty feeling risk of aspiration gastric ph values volume and ph of gastric fluid taken volume and ph of gastric fluid￨no significant difference in vas of hungry and thirsty feeling was found among the three groups￨no diff￨highunclear￨highunclear￨highunclear
50￨￨￨volume and ph of gastric contents gastric ph mean gastric residue￨although the mean gastric residue was less in those patients who were given water the differences were not statistically significant￨no diff￨highunclear￨highunclear￨highunclear
not found￨one hundred day surgical patients undergoing first trimester termination of pregnancy￨propofol and alfentanil 150 ml of clear fluid 152 hours before anaesthesia or to remain fasted from midnight the night before￨adverse intraoperative events questionnaires about pain nausea and headache scores pain pain nausea and headache scores immediate recovery time or pain nausea and headache scores postoperative morbidity mean pain scores￨there were no significant differences in immediate recovery time or pain nausea and headache scores at 30 or 120 minutes following recovery￨no diff￨highunclear￨highunclear￨highunclear
358￨locally advanced pelvic tumours 358 patients were enrolled from 1990 to 1996 in cancer centres in the netherlands who had bladder cancer stages t2 t3 or t4 no mo cervical cancer stages iib iiib or iv or rectal cancer stage m01 were assessed locally advanced cervical tumours￨radiotherapy standard radiotherapy radiotherapy median total dose 65 gy alone radiotherapy plus hyperthermia hyperthermia to standard radiotherapy￨completeresponse rate with radiotherapy plus hyperthermia completeresponse rates complete response and duration of local control 3year overall survival duration of local control￨the duration of local control was significantly longer with radiotherapy plus hyperthermia than with radiotherapy alone p004￨sig increase￨highunclear￨highunclear￨highunclear
56￨56 patients with locally advanced carcinoma of the rectum t4n0m0 patients with locally advanced carcinoma of the rectum 59 patients with the same stage of disease as those who were only irradiated￨local hyperthermia thermoradiotherapy combined heat and radiation therapy thermoradiotherapy￨5year survival rate￨it was found that thermoradiotherapy allowed the 5year survival rate of patients to increase up to 356 n  12 compared with 66 n  7 in the control group p less than 005￨sig increase￨highunclear￨highunclear￨highunclear
14￨a total of 177 cases examined from january 1985 to december 1988 included 96 cases 54 treated with radiotherapy plus hyperthermia among which 14 cases were preoperative advanced cancer of deepseated organs￨mhz radiofrequency capacitive heating devices thermotron rf8 hyperthermia combined with radiotherapy or chemotherapy chemotherapy plus hyperthermia￨maximum tumour temperature intratumour temperatures complete response cr and partial response pr sideeffects quality of life intracavitary temperatures￨intracavitary temperatures were measured in 133 99 of the 134 tumours of stomach pancreas urinary bladder and rectum￨no diff￨highunclear￨highunclear￨highunclear
37￨75 patients randomized 73 were eligible for inclusion in the study thirtyseven patients locally recurrent and primary unresectable rectal cancer locally recurrent rectal carcinoma￨standard external beam radiotherapy rt radiotherapy adjuvant vhf therapy vhf  rt 434 mhz microwave therapy combined with external beam radiotherapy vhf  rt￨quality of life scores performance status toxicities local response to treatment and systemic disease progression survival and cumulative incidence of pelvic site of first progression extent and duration of local control measures of toxicity or quality of life scores local pelvic tumour recurrence￨no significant difference between the two groups was observed in extent and duration of local control measures of toxicity or quality of life scores￨no diff￨highunclear￨highunclear￨highunclear
122￨44 patients 122 patients with advanced rectal cancer who were randomly treated with three different methods from july 1984 to july 1986 rectal cancer 122 patients 44 were treated with patients treated with preoperative radiation combined with endocavitary hyperthermia￨combination preoperative radiation and endocavitary hyperthermia endocavitary 915 mhz microwave applicators combined with 10 mev xray or 60co followed by surgery￨fiveyear survival rate survival survival advantage￨fiveyear survival rate was 667 2436 in group a 50 1428 in group b and 405 1537 in group c percentage of survival at 5 years was 737 1419 for 40 gy plus heat 571 814 for 40 gy alone 588 1017 for 30 gy plus heat and 429 614 for 30 gy alone￨no diff￨highunclear￨highunclear￨highunclear
50￨fifty newborn infants with nonsyndromic complete unilateral cleft lip and palate or a cleft of the soft and at least two thirds of the hard palate who were referred to the north thames regional cleft centre participated infants with nonsyndromic complete unilateral cleft lip and palate or a cleft of the soft and at least two thirds of the hard palate differ from those of their noncleft peers noncleft cohort was recruited from west middlesex university hospital a general hospital with similar demographics infants with nonsyndromic complete unilateral cleft lip and palate or a cleft of the soft and at least two thirds of the hard palate infants with unrepaired cleft lip andor palate compared with healthy noncleft infants infants with cleft lip and or palate parents of 20 randomly selected noncleft infants agreed to participate infants with unrepaired cleft lip and palate with healthy noncleft infants of a similar age￨￨faster rate of sucking higher suckswallow ratios neonatal oral motor assessment scale proportion of intraoral positive pressure generation￨they used shorter sucks mean difference 030 second p  0005 a faster rate of sucking mean difference 3420 suckssecond p  0005 higher suckswallow ratios mean difference 187 sucksswallow p  0005 and a greater proportion of intraoral positive pressure generation mean difference 4597 positive pressure p  0005￨sig decrease￨highunclear￨highunclear￨highunclear
101￨patients were 101 consecutively born children with cleft lip andor palate who were otherwise healthy children with clefts within the national health service in the north of england infants with clefts￨squeezable and rigid feeding bottles squeezable bottle assisted feeding or to feeding with a rigid bottle￨chl weight head circumference and weight head circumference anthropometric measuresnude weight crownheel length chl and occipitofrontal circumference￨there were statistically significant differences between the two groups in weight at 12 months p  038 with an adjusted mean difference of 043 kg and in head circumference p  004 with an adjusted mean difference of 077 cm indicating increased growth in the squeezable bottle group￨no diff￨highunclear￨highunclear￨highunclear
31￨infants with cleft palate 18 infants squeezable cleft lippalate nurser 13 infants crosscut nipple within sex 21 boys 10 girls and palatal defect 22 cleft lip and palate 9 isolated cleft palate categories thirtyone infants median age  15 days￨squeezable plastic container with a narrow long crosscut nipple squeezable cleft palate nurser and b a standard nipple with a crosscut crosscut nipple nutrition intervention protocol￨mean energy and protein intakes mean energy intake￨p values weight gain grams per day 73 weight 21 length 07 head circumference 18 triceps and subscapular skinfolds and midarm circumference 47 48 and 69 respectively were not significantly different￨no diff￨highunclear￨highunclear￨highunclear
not found￨three academic cleft palate centers infants with unilateral cleft lip and palate cleft palate centers of amsterdam nijmegen and rotterdam the netherlands infants with complete unilateral cleft lip and palate uclp no other malformations￨infant orthopedics io uclp￨weightforage lengthforage and weightforlength z scores feeding weight and length feeding velocity￨feeding velocity increased with time from 29 to 132 mlmin in the io group and from 26 to 138 mlmin in the io group no significant differences were found between groups￨sig increase￨highunclear￨highunclear￨highunclear
40￨40 infants after cleft lip repair￨breast feeding or spoon feeding￨weight gain￨it has been a tradition for plastic surgeons to withhold breast feeding from babies after cleft lip repair to prevent wound disruption￨no diff￨highunclear￨highunclear￨highunclear
61￨fortyfive eyes 50 received artisan lens and 45 eyes 50 received ninety eyes of 61 consecutive patients were enrolled in the study correcting myopia between 900 and 1950 diopters￨irisfixed artisan lens implantation with excimer laser artisan lens artisan lens implantation with laser in situ keratomileusis lasik lasik￨better uncorrected and spectaclecorrected visual acuity and contrast sensitivity contrast sensitivity curve slitlamp microscopy manifest refraction uncorrected and spectaclecorrected visual acuity contrast sensitivity and specular microscopy uncorrected visual acuity mean endothelial cell loss mean spherical equivalent refraction quality of vision severe night glare￨contrast sensitivity curve decreased by 2 or more lines in two artisan 47 and six lasik eyes 146￨no diff￨highunclear￨highunclear￨highunclear
not found￨43 eyes implanted with the ticl 20 bilateral cases and 45 eyes receiving moderate to high myopic astigmatism￨visian toric implantable collamer lens ticl a toric phakic intraocular lens iol and photorefractive keratectomy prk visian toric implantable collamer lens and conventional photorefractive keratectomy ticl prk with mitomycin c￨mean astigmatism correction mean best spectaclecorrected visual acuity bscva change in bscva proportion of cases with improvement of 1 or more lines of bscva proportion of cases with bscva and uncorrected visual acuity ucva safety bscva efficacy ucva predictability and stability mean spherical equivalent refraction predictability 050 d and stability of manifest refraction￨the ticl performed better than prk in all measures of safety bscva efficacy ucva predictability and stability in this comparison supporting the ticl as a viable alternative to existing refractive surgical treatments￨no diff￨highunclear￨highunclear￨highunclear
25￨twentyfive patients with myopia ranging from 800 to 1200 diopters d￨laser in situ keratomileusis lasik and artisan phakic intraocular lens piol￨safety index bestcorrected visual acuity and subjective evaluation of quality of vision spherical equivalent refraction mean spherical equivalent refraction change of two or more lines and safety index ratio postoperative to preoperative bestcorrected visual acuity￨the safety index was significantly better for artisan 112  021 than for lasik 099￨sig increase￨highunclear￨highunclear￨highunclear
169￨patients with moderatetosevere crohns disease active crohns disease one hundred sixtynine patients with moderatetosevere crohns disease￨cdp571 placebo cdp571 or placebo tnf cdp571￨clinical response crohns disease activity index score frequency of severe or serious adverse events￨the frequency of severe or serious adverse events was similar among all groups￨no diff￨low￨low￨low
not found￨crohns disease patients taking and those not taking glucocorticoids or immunosuppressants and in patients who had and those who had not previously taken infliximab patients with a clinical response defined as reduction of at least 100 from the baseline score on the crohns disease activity index cdai at week 6 were stratified according to their baseline creactive protein level patients with moderatetosevere crohns disease who had a response to induction therapy with 400 mg of certolizumab pegol adults with moderatetosevere crohns disease￨certolizumab pegol placebo certolizumab pegol maintenance therapy certolizumab pegol or placebo￨antinuclear antibodies￨antinuclear antibodies developed in 8 of the patients in the certolizumab group antibodies against certolizumab pegol developed in 9 of all patients who entered the induction phase￨sig increase￨low￨low￨low
299￨crohns disease patients with active crohns disease in the classic i trial patients with moderate to severe crohns disease naive to antitnf treatment 299 patients with moderate to severe crohns disease naive to tumour necrosis factor antagonists received 204 patients entered the openlabel arm 276 patients from classic i enrolled in classic ii and received patients not in remission at both weeks 0 and 4 were enrolled in an openlabel arm and received￨induction therapy with adalimumab placebo adalimumab adalimumab maintenance therapy adalimumab openlabel adalimumab￨maintenance of remission clinical remission tolerated￨adalimumab induced and maintained clinical remission for up to 56 weeks in patients with moderate to severe crohns disease naive to antitnf treatment￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with moderate to severe crohns disease cd patients with crohns disease￨placebo adalimumab openlabel induction therapy with adalimumab adalimumab placebo adalimumab 40 mg every other week eow or adalimumab￨efficacy clinical remission crohns disease activity index score adverse event remission efficacy and safety￨among patients who responded to adalimumab both adalimumab eow and weekly were significantly more effective than placebo in maintaining remission in moderate to severe cd through 56 weeks￨sig increase￨highunclear￨highunclear￨highunclear
73￨crohns disease patients with active crohns disease not responding to conventional treatments seventythree patients with active crohns disease who had not adequately responded to conventional therapies and then had demonstrated a clinical response 70point decrease in the crohns disease activity index to an initial infusion of￨infliximab antitumor necrosis factor antibody infliximab placebo infliximab or placebo infliximab￨efficacy and tolerability median values for crohns disease activity index inflammatory bowel disease questionnaire a quality of life measurement and serum creactive protein concentration efficacy safety pharmacokinetics and immunogenicity efficacy and safety￨retreatment with infliximab every 8 weeks maintained serum infliximab concentration and was well tolerated with a low incidence of immunogenicity￨no diff￨low￨low￨low
271￨patients with steroiddependent crohns disease patients with steroiddependent crohns disease n  271￨intravenous cdp571 10 mgkg or placebo placebo cdp571 budesonide prednisolone or prednisone￨adverse events percentage of patients with steroid sparing defined as discontinuation of steroid therapy without a disease flare crohns disease activity index score steroid sparing tolerated￨to evaluate cdp571 a humanized antibody to tumour necrosis factoralpha for the treatment of steroiddependent crohns disease￨sig increase￨low￨low￨low
396￨moderate to severe crohns disease 396 patients with moderate to severe crohns disease 159 patients with baseline c reactive protein crp  or 10 mgl unselected patients with moderate to severe crohns disease￨cdp571 placebo intravenous cdp571￨clinical response clinical response rates clinical response adverse events clinical response a decrease in the crohns disease activity index cdai to  or 100 points or remission cdai score￨to evaluate cdp571 a humanised antibody to tnfalpha for treating active crohns disease￨sig increase￨low￨low￨low
306￨patients with crohns disease without fistulas massachusetts medical society patients with fistulizing crohns disease who have a response to induction therapy with fistulizing crohns disease 195 patients who had a response at weeks 10 and 14 and 87 patients who had no response 306 adult patients with crohns disease and one or more draining abdominal or perianal fistulas of at least three months duration patients with fistulas￨infliximab placebo infliximab maintenance therapy infliximab placebo or 5 mg of infliximab infliximab maintenance therapy placebo maintenance￨complete absence of draining fistulas time to the loss of response time to loss of response￨the time to loss of response was significantly longer for patients who received infliximab maintenance therapy than for those who received placebo maintenance more than 40 weeks vs 14 weeks p0001￨sig decrease￨low￨low￨low
573￨crohns disease patients with crohns disease who respond to an initial dose of patients with active crohns disease who respond to a single infusion of infliximab 573 patients with a score of at least 220 on the crohns disease activity index cdai￨maintenance infliximab maintenance infliximab therapy placebo infliximab￨incidence of serious infections median time to loss of response intention to treat sustain clinical remission infliximab safety￨at week 30 23 of 110 21 group i patients were in remission compared with 44 of 113 39 group ii p0003 and 50 of 112 45 group iii p00002 patients￨sig increase￨low￨low￨low
not found￨hivpositive women in malawi women who were hivpositive and not pregnant were enrolled and followed for 1 year while receiving hiv care and access to family planning fp services malawian women￨hiv voluntary counseling and testing vct￨pregnancy intentions contraceptive use and pregnancy incidence contraceptive use pregnancy incidence￨contraceptive use increased from 38 before hiv testing to 52 1 week later p  00001 and then decreased to 46 by 12 months￨sig increase￨highunclear￨highunclear￨highunclear
164￨hivinfected women attending antenatal care from june 2004 to july 2005 at coronation women and children hospital south africa women with a high mtct risk antenatal care in gauteng province south africa 164 pregnant women initiated arv treatment and 863 received sdnvp￨nevirapine￨cd4 cell count testing risk of mtct timetotreatment initiation hiv infection￨after changes to service delivery timetotreatment initiation was reduced from a median of 56 days to 37 days p  0041￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨primiparous women mothertochild hiv transmission programme in côte divoire five urban health facilities before 20022003 and after 2005 the implementation of a pmtct programme through review of facility data observation of antenatal consultations n  606 before n  591 after and deliveries n  229 before n  231 after and exit interviews of women and interviews of health facility staff￨nevirapine mothertochild hiv transmission pmtct programme￨episiotomy rates overall testing rate quality of antenatal and delivery care quality of antenatal and delivery care services global scores for quality of antenatal and delivery care quality of antenatal and delivery care￨in the maternity ward quality of obstetrical care at admission delivery and postpartum care globally improved in all facilities after the implementation of the programme although some indicators remained poor such as filling in the partograph directly during labour￨sig increase￨highunclear￨highunclear￨highunclear
546￨women after hiv testing in abidjan ivory coast hivpositive and hivnegative women who were offered hiv counselling and testing during a program of prevention of mothertochild hiv transmission￨family planning counselling and free contraceptives￨pregnancy incidence unwanted pregnancy incidence death of the index child and the end of breastfeeding pregnancy incidence￨between 6 and 24 months postpartum proportions of women using modern contraception varied from 52 to 65 among hivpositive women and from 65 to 75 among hivnegative women￨no diff￨highunclear￨highunclear￨highunclear
not found￨71 health facilities in nigeria that analyzes the preintegration and postintegration periods between march 2007 and january 2009 nigeria nigerian public health facilities￨hiv counselling and testing hct antiretroviral therapy art and prevention of mothertochild transmission pmtct mean attendance at family planning clinics and coupleyears of protection cyp￨mean attendance at family planning clinics mean cyp service ratios￨family planninghiv integration using the referral model improved family planning service utilization by clients accessing hiv services but further improvement is possible￨sig increase￨highunclear￨highunclear￨highunclear
706￨706 women were provided with women who had an unsafe abortion single women aged 2024 years and 25 among single women aged 2545 years women who accepted hiv testing with women who did not￨postabortion contraceptive service and offered vct voluntary hiv counselling and testing vct￨hiv prevalence rate￨the hiv prevalence rate was 19 among single women aged 2024 years and 25 among single women aged 2545 years￨no diff￨highunclear￨highunclear￨highunclear
not found￨twentythree publicsector hospitals health centres and dispensaries in two districts of central province kenya health facilities were purposively selected and family planning consultations randomly selected family planning clients through providerinitiated testing and counselling for hiv kenya￨integrated family planninghiv counselling intervention and in providing hiv testing and counselling to family planning clients requesting a test during the consultation and another group of 47 family planning providers were trained in the intervention and in referring clients interested in an hiv test algorithm that integrates hivsexually transmitted infection prevention counselling including offering hiv testing and counselling with family planning counselling integrating providerinitiated testing and counselling within family planning services￨proportion of clients requesting an hiv test￨providerinitiated testing and counselling is feasible and acceptable in family planning services does not adversely affect the quality of the family planning consultation and increases access to and use of hiv testing in a population who would benefit from knowing their status￨no diff￨highunclear￨highunclear￨highunclear
not found￨pregnant women 5801 first visits to 22 antenatal clinics from 1997 to 2004 in lusaka zambia and examined documented syphilis rapid plasma reagin rpr screening and syphilis treatment before and after implementation of research andor service programs in prevention of mothertochild pmtct hiv transmission zambia before and after implementation of prevention of mothertochild hiv transmission programs￨￨rpr screening prevalence odds ratios pors and 95 confidence intervals cis for documented rpr screening￨documented rpr screening was improved after implementation of pmtct research and service were operating simultaneously and not with research or service alone￨sig increase￨highunclear￨highunclear￨highunclear
not found￨male and female clients men attending facilities with higher client loads 4019 vct clients attending eight ethiopian public sector facilities and 4027 additional clients 18 months after introducing family planning services in the same facilities￨contraceptive counseling vct counselors￨vct￨men attending facilities with higher client loads were 88 less likely to receive family planning information and 93 less likely to receive contraceptives than those attending facilities with lower client loads￨no diff￨highunclear￨highunclear￨highunclear
735￨this communitybased cohort study was conducted in dowa district central malawi a rural area 50 km from the capital lilongwe severe acute malnutrition in malawi severely malnourished children children with sam hiv infected children with sam hivinfected children with severe acute malnutrition sam 1273 and 735 children were enrolled in the rc and pc caregivers and children admitted in the dowa ctc programme were prospectively prospective cohort  pc and retrospectively retrospective cohort  rc admitted into the study and offered hiv testing and counseling￨ctc communitybased therapeutic care ctc programme￨uptake of hiv testing and recovery relapse and growth rates of hivpositive hiv prevalence discharge weightforheight wfh overall uptake of hiv testing￨overall uptake of hiv testing was 607 for parents and 94 for children￨no diff￨highunclear￨highunclear￨highunclear
143￨hivinfected women a maternalchild program was started at an hiv outpatient clinic in new orleans 143 women and 557 men serving as controls women with hiv infection￨￨attendance rates high attendance rates￨women were as likely as men to achieve high attendance rates before the interventions but more likely to do so at both 6 months and 1 year postintervention after adjustment for the other variables￨sig increase￨highunclear￨highunclear￨highunclear
not found￨antenatal care clinics mothertochild hiv transmission services in ukraine￨strengthening voluntary counseling and testing for hiv forging partnerships with local organizations and undoing hivrelated stigma training providers to improve skills in communication and referral to communitybased support￨quality of pmtct services￨observational data demonstrated that providers who participated in the training intervention delivered pmtct counseling of a consistently higher quality than did providers who did not undergo training￨sig increase￨highunclear￨highunclear￨highunclear
not found￨rch clinics 60 health facilities identified from five regions that had participated in the pilot phase of pmtct implementation in the mainland tanzania￨scalingup prevention of mothertochild transmission pmtct￨average staff workload￨the average staff workload was found to be 505 8147 for facilities providing pmtct of hiv infection and 378 1182 for facilities without pmtct services￨no diff￨highunclear￨highunclear￨highunclear
not found￨4019 vct clients before the addition of family planning services and 4027 different clients after family planning services clients attended eight public vct facilities in the oromia region ethiopia of those clients who were sexually active 70 were using contraceptives￨voluntary hiv counselling and testing integrated with contraceptive services family planning counselling vct clients vct provider training contraceptive supply provision and monitoring￨number of vct facilities contraceptive prevalence adult hiv prevalence rate￨clients interviewed after the introduction of family planning services received significantly more family planning counselling and accepted significantly more contraceptives than those clients served before the intervention￨sig increase￨highunclear￨highunclear￨highunclear
502￨330 hivpositive and 172 hivnegative women who underwent the intervention 120 either became new hormonal method users n  40 502 women who were not pregnant or infertile and who had been previously hiv tested and counseled viewed an informational video about hormonal contraception followed by a facilitated discussion￨oral or injectable hormonal contraception￨annualized attrition rate incident pregnancy rates of oral and injectable contraceptive use￨access to and information about hormonal contraceptives resulted in increased use and reduced attrition among both hivpositive and hivnegative women in this study￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨communitybased reproductive health agents cbrhas￨￨communitybased reproductive health agents cbrhas can increase community knowledge of and offer immediate access to reproductive health services including hivaids￨sig increase￨highunclear￨highunclear￨highunclear
13917￨hivinfected pregnant women 1566 patients found eligible for art eligible pregnant women in eight public sector clinics in lusaka district zambia between 16 july 2007 and 31 july 2008 13917 women started antenatal care more than 60 days before the intervention rollout and constituted the control cohort 17 619 started antenatal care after art integrated into anc and constituted the intervention cohort￨antiretroviral therapy art antiretroviral therapy￨adjusted odds ratios aors and confidence intervals cis for enrollment and initiation proportions proportion of treatmenteligible pregnant women enrolling into hiv care within 60 days of hiv diagnosis￨main outcome indicators were the proportion of treatmenteligible pregnant women enrolling into hiv care within 60 days of hiv diagnosis and of these the proportion initiating art during pregnancy￨no diff￨highunclear￨highunclear￨highunclear
not found￨hivpositive women offering sexually transmitted infection screening cervical cytology and family planning hivpositive women￨￨sexual and reproductive health￨we completed an audit cycle and showed that all aspects of our care had improved since the introduction of this integrated service￨sig increase￨highunclear￨highunclear￨highunclear
not found￨213 hiv1serodiscordant couples in thika kenya participating in an hiv1 prevention clinical trial contraceptive promotion was initiated through a women within heterosexual hiv1serodiscordant partnerships kenyan hiv1serodiscordant couples enrolled in an hiv1 prevention trial women in hiv1serodiscordant partnerships￨multipronged intervention that included staff training couples family planning sessions and free provision of hormonal contraception onsite￨contraceptive use and pregnancy incidence pregnancy incidence contraceptive uptake￨a multipronged family planning intervention can lead to high nonbarrier contraceptive uptake and reduced pregnancy incidence among women in hiv1serodiscordant partnerships￨sig increase￨highunclear￨highunclear￨highunclear
not found￨15year experience in haiti 19852000 between 1985 and 1999 services for hiv care tuberculosis care treatment of sexually transmitted diseases and reproductive health￨hiv voluntary counseling and testing vct vct￨hiv transmission￨hiv transmission between discordant couples was 0 infections100 followup years 95 ci 032 vertical transmission from mother to child was 11 infections100 live births 95 ci 46219 these rates are significantly lower than expected rates of transmission in haiti￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨￨￨the data obtained from this study have tended to confirm the impression of previous investigators that penfluridol administered in a dosage of 40 to 80 mg on a onceaweek basis in a single dose compares favorably with the antipsychotic activity of those neuroleptics requiring administration on a daily basis￨no diff￨highunclear￨highunclear￨highunclear
25￨chronic schizophrenic patients 25 chronic schizophrenic outpatients chronic schizophrenic outpatients￨penfluridol and trifluoperazine￨low autonomic liability efficacy and safety tolerated akathisia￨other side effects were similar in severity and occurrence between studydrug groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients of chronic schizophrenia chronic schizophrenia￨penfluridol and trifluoperazine trifluoperazine￨efficacy and safety￨a double blind comparative study was conducted to evaluate the efficacy and safety of penfluridol and trifluoperazine in patients of chronic schizophrenia￨no diff￨highunclear￨highunclear￨highunclear
60￨fiftysix out of 60 schizophrenic patients schizophrenia￨flupenthixol decanoate peroral and parenteral administration of longacting neuroleptics neuroleptics penfluridol peroral and flupenthixol decanoate parenteral￨intensity of the symptoms total brief psychiatric rating scale bprs score akathisia parkinsonism and autonomic side effects￨it was found possible to make a sudden switch from penfluridol to flupenthixol decanoate and vice versa without any significant change in the condition of the patient￨no diff￨highunclear￨highunclear￨highunclear
not found￨twenty eight chronic schizophrenics schizophrenic patients schizophrenia￨haloperidol placebo penfluridol or placebo penfluridol maintenance therapy￨￨evaluation of the results showed no significant differences between the two groups or between the baseline and the final ratings in each group￨no diff￨highunclear￨highunclear￨highunclear
not found￨schizophrenic outpatients chronic schizophrenic patients severely ill chronic schizophrenic patients￨penfluridol and fluphenazine decanoate￨￨it is marketed in several european countries and has been used successfully in the treatment of various acute psychoses for severely ill chronic schizophrenic patients and as maintenance therapy for chronic schizophrenic patients￨sig increase￨highunclear￨highunclear￨highunclear
56￨56 schizophrenic patients receiving maintenance treatment on an outpatient basis￨chlorpromazine￨￨both drugs were similar in their clinical effectiveness no major side effects occurred with either drug￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with chronic schizophrenic syndromes chronic schizophrenic syndromes￨penfluridol and thiothixene￨social activities￨this improvement was mainly evident in variables concerned with participation in social activities as assessed with the sscale and by ward behaviour￨sig increase￨highunclear￨highunclear￨highunclear
28￨28 schizophrenic inpatients treated with schizophrenic patients treated with￨penfluridol or thiothixene￨mia leftright and wpv leftright￨wpv leftright before treatment was correlated to changes in factor 4 of the sscale during the trial￨sig increase￨highunclear￨highunclear￨highunclear
59￨chronic schizophrenic patients chronic schizophrenia￨penfluridol and chlorpromazine chlorpromazine￨￨penfluridol administered orally once a week appeared to be well tolerated it was comparable to daily chlorpromazine in treating and maintaining schizophrenic patients￨sig increase￨highunclear￨highunclear￨highunclear
not found￨twenty patients were treated with penfluridol and 21 with chronic schizophrenia￨fluphenazine penfluridol￨￨penfluridol an oral neuroleptic administered weekly was as efficacious as fluphenazine administered twice daily and appeared to be superior to fluphenazine in improving emotional withdrawal and anergia￨sig increase￨highunclear￨highunclear￨highunclear
30￨acute psychosis 30 patients with acute psychoses of varying type and origin￨penfluridol￨￨no significant side effects occurred￨no diff￨highunclear￨highunclear￨highunclear
180￨northeast thailand a total of 180 adult thai patients￨threedrug regimen tmpsmx and doxycycline trimethoprimsulfamethoxazole and doxycycline tmpsmx and doxycycline trimethoprim tmp sulfamethoxazole smx doxycycline and chloramphenicol trimethoprimsulfamethoxazole doxycycline and chloramphenicol￨efficacy and tolerance relapse rates relapse or death tolerated duration of oral therapy￨the cultureconfirmed relapse rates at 1 year were 66 and 56 for the four and threedrug regimens respectively p  079￨no diff￨highunclear￨highunclear￨highunclear
296￨adult thai patients with suspected acute severe melioidosis severe melioidosis acute severe melioidosis 296 patients enrolled 214 had cultureconfirmed melioidosis and 132 617 of them had positive blood cultures￨imipenem imipenem and ceftazidime ceftazidime imipenem￨treatment failure survival overall therapeutic efficacy tolerated mortality death or treatment failure￨there were no differences in survival overall p  96 or after 48 hours p  3￨no diff￨highunclear￨highunclear￨highunclear
84￨severe melioidosis forty of them 48 had cultureproven melioidosis 84 patients were enrolled in the study￨ceftazidime cefoperazonesulbactam cefoperazone 25 mgkgday cotrimoxazole trimethoprim 8 mgkgday vs ceftazidime cotrimoxazole trimethoprim cefoperazonesulbactam cefoperazonesulbactam  cotrimoxazole vs ceftazidime  cotrimoxazole cefoperazonesulbactam  cotrimoxazole￨mortality rate bacteriological responses tolerated￨there was no significant difference in the mortality rate between the two groups16 per cent 319 in the cefoperazonesulbactam group vs 21 per cent 419 in the ceftazidime group p  005￨no diff￨highunclear￨highunclear￨highunclear
241￨severe melioidosis 241 patients with cultureconfirmed melioidosis 51 212 died patients presenting with acute severe melioidosis were started independently at tertiary care hospitals in ubon ratchathani and khon kaen in northeastern thailand and the results were analyzed together as a prospective individualpatient data metaanalysis￨tmpsmx trimethoprimsulfamethoxazole tmpsmx ceftazidime ceftazidime with tmpsmx trimethoprimsulfamethoxazole ceftazidime monotherapy￨hospital mortality rate death rate acute mortality rate death or treatment failure bacteremia respiratory failure and renal failure￨among patients with melioidosis there was no difference in death rate between the 2 treatment groups for either all deaths or 088 95 ci 04816 stratified p70 or for deaths that occurred  or 48 h after hospital admission or 088 95 ci 04119 stratified p73￨no diff￨low￨low￨low
116￨oral maintenance treatment of melioidosis one hundred sixteen patients were enrolled 109 had cultureconfirmed melioidosis and 87 were considered evaluable 43 had received adult thai patients with cultureconfirmed melioidosis￨doxycycline conventional fourdrug combination chloramphenicol trimethoprimsulfamethoxazole and doxycycline chloramphenicol trimethoprimsulfamethoxazole and doxycycline with doxycycline alone doxycycline￨cultureconfirmed relapse therapeutic efficacy cultureconfirmed relapse adverse effects￨cultureconfirmed relapse occurred in one patient randomized to the conventional regimen and in 11 256 randomized to the doxycycline regimen p  009 and treatment failed for 8 182 versus 20 465 respectively p  009￨no diff￨highunclear￨highunclear￨highunclear
379￨severe melioidosis severe melioidosis was conducted in ubon ratchatani in northeastern thailand 379 patients enrolled in the study 212 56 had cultureproven melioidosis 106 patients were in each treatment group￨amoxicillinclavulanate ceftazidime vs amoxicillinclavulanate ceftazidime parenteral ceftazidime parenteral amoxicillinclavulanate amoxicillin amoxicillinclavulanate 160 mgkgd￨overall mortality rate clinical and bacteriologic responses unsatisfactory clinical response tolerated overall therapeutic failure rate￨the overall therapeutic failure rate ie treatment failure or death due to uncontrolled melioidosis was significantly higher for the amoxicillinclavulanate group than for the ceftazidime group p  02￨no diff￨highunclear￨highunclear￨highunclear
60￨severe sepsis due to melioidosis in thailand 60 patients were enrolled to receive either treated patients with severe sepsis caused by suspected melioidosis in thailand 30 patients 23 of whom had cultureconfirmed melioidosis severely septic patients patients with severe sepsis who are suspected of having melioidosis in thailand￨gcsf placebo ceftazidime lenograstim granulocyte colonystimulating factor gcsf granulocyte colonystimulating factor￨duration of survival mortality rates￨receipt of gcsf is associated with a longer duration of survival but is not associated with a mortality benefit in patients with severe sepsis who are suspected of having melioidosis in thailand￨sig decrease￨low￨low￨low
64￨srinagarind and khon kaen hospitals 61 evaluable patients 3 were excluded because of severe drug allergies 42 were septicemic and 31 of these patients had the most severe form disseminated septicemic melioidosis 64 patients with bacteriologically confirmed cases of severe melioidosis who were admitted during september 1986 to january 1989 patients with disseminated septicemia severe melioidosis￨sulfamethoxazole ceftazidime and cotrimoxazole ceftazidime plus cotrimoxazole with chloramphenicol plus doxycycline and cotrimoxazole ceftazidime trimethoprim conventional therapy chloramphenicol 100 mgkgday doxycycline cotrimoxazole trimethoprim 8 mgkgday sulfamethoxazole￨mortality overall mortalities from melioidosis septicemic melioidosis and disseminated septicemic melioidosis cumulative mortalities￨among patients with disseminated septicemia and initial shock there was no significant difference in mortality between the regimens￨no diff￨highunclear￨highunclear￨highunclear
not found￨melioidosis melioidosis was conducted in ubon ratchatani northeastern thailand between 1989 and 1992￨oral conventional regimen combination of chloramphenicol cotrimoxazole and doxycycline and coamoxiclav chloramphenicol doxycycline and cotrimoxazole￨total antibiotic treatment duration relapse rate￨only 50 of patients complied with the 20 weeks treatment regimen and poor compliance proved the most significant risk factor for subsequent relapse relative risk rr 49 95 ci 12203￨no diff￨highunclear￨highunclear￨highunclear
65￨a total 65 patients were enrolled 36 and 29 respectively between august 1997 and july 1998 two tertiarycare hospitals in northeast thailand￨cotrimoxazole and doxycycline ciprofloxacin and azithromycin ciprofloxacin plus azithromycin cotrimoxazole plus doxycycline￨cultureproven relapse in melioidosis￨there were more relapses under regimen a at 22 7 of 32 than in regimen b 3 1 of 33￨sig increase￨highunclear￨highunclear￨highunclear
219￨severe melioidosis 219 patients enrolled in the study 102 47 had cultureproven melioidosis 50 patients 2 patients were excluded￨cefoperazonesulbactam plus cotrimoxazole cefoperazonesulbactam ratio 11 cefoperazone 25 mgkgday plus cotrimoxazole trimethoprimsulfamethoxazole tmpsmz cotrimoxazole tmp ceftazidime cefoperazonesulbactam plus cotrimoxazole ceftazidime plus cotrimoxazole cefoperazonesulbactam￨tolerated mortality rate duration of defervescence and the bacteriological response mortality rates￨mortality rates were not significantly different between the 2 groups 18 in the cefoperazonesulbactam group versus 14 in the ceftazidime group￨no diff￨low￨low￨low
240￨240 adults aged  or 16 years with acute nonrecurrent sinusitis had  or 2 diagnostic criteria purulent rhinorrhea with unilateral predominance local pain with unilateral predominance purulent rhinorrhea bilateral presence of pus in the nasal cavity at 58 family practices 74 family physicians between november 2001 and november 2005 acute maxillary sinusitis￨antibiotics and topical nasal steroid placebo antibiotic and nasal steroid placebo antibiotic and nasal steroid antibiotic and placebo nasal steroid placebo antibiotic and placebo nasal steroid amoxicillin amoxicillin and topical budesonide budesonide topical budesonide￨duration and severity of symptoms severe symptoms￨neither an antibiotic nor a topical steroid alone or in combination was effective as a treatment for acute sinusitis in the primary care setting￨no diff￨low￨low￨low
166￨adults with clinically diagnosed acute rhinosinusitis acute rhinosinusitis patients with acute rhinosinusitis adults with uncomplicated acute rhinosinusitis were recruited from 10 community practices in missouri between november 1 2006 and may 1 2009 166 adults 36 male 78 with white race￨amoxicillin placebo amoxicillin￨mean change in sinonasal outcome test16 scores patients retrospective assessment of change in sinus symptoms and functional status recurrence or relapse and satisfaction with and adverse effects of treatment symptom improvement diseasespecific quality of life pain fever cough and nasal congestion to use as needed￨there was no statistically significant difference in reported symptom improvement at day 3 37 for amoxicillin group vs 34 for control group p  67 or at day 10 78 vs 80 respectively p  71 whereas at day 7 more participants treated with amoxicillin reported symptom improvement 74 vs 56 respectively p  02￨no diff￨low￨low￨low
416￨patients with purulent rhinorrhea 416 patients included from 69 family practices were 12 years or older presenting with acute upper respiratory complaints and having a history of purulent rhinorrhea and no signs of complications of sinusitis all 8 patients recovered with antibiotic therapy patients with an acute upper respiratory tract infection and purulent rhinorrhea￨amoxicillin placebo amoxicillin vs placebo amoxicillin￨duration of general illness or pain diarrhea duration of purulent rhinorrhea exacerbation of symptoms general illness pain and purulent rhinorrhea￨amoxicillin has a beneficial effect on purulent rhinorrhea caused by an acute infection of the nose or sinuses but not on general recovery￨sig increase￨low￨low￨low
265￨patients with acute sinusitis adults with a clinical diagnosis of acute sinusitis or common cold were enrolled 265 patients enrolled 132 received patients with common cold or acute sinusitis￨azithromycin azithromycin 500 mg daily or placebo placebo antibiotic treatment￨median time before resolution of symptoms respiratory complications requiring antibiotic treatment￨respiratory complications requiring antibiotic treatment occurred in 19 of patients in the placebo group and in 3 of the azithromycin group p0025￨sig decrease￨low￨low￨low
981￨patients with acute uncomplicated rhinosinusitis treating acute rhinosinusitis subjects  or 12 years n  981￨placebo mometasone furoate nasal spray intranasal corticosteroid monotherapy mometasone furoate nasal spray mfns mfns amoxicillin mometasone furoate nasal spray amoxicillin and placebo intranasal corticosteroids placebo mfns amoxicillin 500 mg 3 times daily for 10 days or respective placebo amoxicillin and placebo￨rhinosinusitis symptoms pm major symptom score total symptom score adverse events disease recurrence or bacterial infection global response major symptom score disease recurrence￨mometasone furoate nasal spray 200 microg twice daily was significantly superior to placebo p  001 and amoxicillin p  002 at improving major symptom score￨sig increase￨low￨low￨low
135￨all participants were 18 years or older presenting to a family practice clinic with a complaint of sinusitis and with pus in the nasal cavity facial pressure or nasal discharge lasting longer than 7 days patients with sinusitis complaints patients with purulent rhinitis sinusitistype symptoms improved with antibiotics 135 patients￨amoxicillin placebo￨resolution of symptoms within a 14day followup period and the time to improvement days￨although the rates of improvement were not statistically significantly different at the end of 2 weeks the amoxicillin group improved significantly earlier in the course of treatment a median of 8 vs 12 days than did the placebo group p039￨no diff￨low￨low￨low
252￨adults with acute rhinosinusitis that was clinically diagnosed in a general practice setting clinically diagnosed acute rhinosinusitis patients with clinically diagnosed acute rhinosinusitis 252 adults recruited at 24 general practices and 2 outpatient clinics adult patients in general practice with clinically diagnosed acute rhinosinusitis experience no advantage with antibiotic treatment with￨placebo amoxicillin 875 mg and clavulanic acid 125 mg or placebo antibiotics amoxicillin amoxicillinpotassium clavulanate amoxicillinclavulanate￨history of purulent nasal discharge and maxillary or frontal pain diarrhea time to cure primary outcome number of days during which rhinosinusitis restricted activities at home or work and frequency of adverse effects secondary outcomes time to cure￨at 7 days the mean difference between amoxicillinclavulanate and placebo was 029 95 ci 093 to 034 in the number of days with restrictions due to rhinosinusitis and 060 95 ci 141 to 021 in patients with a positive rhinoscopy result￨no diff￨low￨low￨low
150￨acute rhinosinusitis diagnosed by clinical criteria or ultrasound in primary care patients who benefit from antibiotic therapy 146 patients completed the 2week followup 150 adult patients mean age 397 years with a clinical diagnosis of sinusitis patients with clinically diagnosed acute maxillary sinusitis ams￨antibiotics amoxicillin 750 mg x 2 doxycycline 100 mg x 2 or penicillin v 1500 placebo antibiotics and placebo sinus ultrasound examination￨rate of clinical success￨patients receiving antibiotics achieved a slightly higher rate of clinical success than patients receiving placebo 80 vs 66 p  0068￨sig increase￨low￨low￨low
not found￨adults consulting their general practitioner gp with complaints after a common cold or influenza pain in the head when bending forward purulent nasal discharge predominantly unilateral maxillary pain toothache or pain when chewing adults with acute sinusitislike complaints in general practice￨doxycycline placebo￨time to recover resolution of pain resolution of facial pain and the resumption of daily activities kaplanmeier curves and hazard ratios adjusted hazard ratio side effects￨no significant difference was found in time to recover between the doxycyclinetreated group and the placebotreated group￨no diff￨low￨low￨low
65￨patients with chronic idiopathic constipation chronic idiopathic constipation sixtyfive patients with chronic idiopathic constipation￨lactulose and polyethylene glycol4000 lactulose duphalac or polyethylene glycol4000 forlax lactulose and polyethylene glycol polyethylene glycol￨efficacious and well tolerated total shortchain fatty acids betagalactosidase activity faecal bifidobacteria counts clinical efficacy and tolerance lactobacillus clostridial spores bacteroides and enterobacteria ph biliary acids and neutral sterol concentrations faecal bacterial mass￨in the lactulose group an increase in faecal bifidobacteria counts p  004 and betagalactosidase activity p  0001 was observed from day 1 to day 28 whereas in the polyethylene glycol group there was a decrease in total shortchain fatty acids p  002 butyrate p  004 acetate p  002 and faecal bacterial mass p  0001￨sig increase￨highunclear￨highunclear￨highunclear
57￨57 patients who are affected by opiateinduced constipation￨polyethylene glycolelectrolyte solution polyethylene glycolelectrolyte solution placebo methadone maintenance program polyethylene glycol 3350electrolyte solution polyethylene glycol 3350electrolyte solution lactulose polyethylene glycol 3350electrolyte solution and lactulose polyethylene glycol 3350electrolyte solution versus lactulose￨nonhard stools reducing hard stool formation opiate induced constipation loosest diarrheal stool selfreported frequencies consistency and ease of defecation loosest stool￨polyethylene glycol 3350electrolyte solution produced the loosest stool p  00001 compared with the control whereas lactulose had the most adverse effects￨sig increase￨highunclear￨highunclear￨highunclear
216￨216 patients constipation in children over 8 years old childhood constipation children over 8 years old 216 children with constipation from 818 years old from 7 hospitals across china who were matched with a uniform entry criteria were enrolled in this study￨oral forlax forlax lactulose polyethylene glycol 4000 forlax￨laboratory tests and physical examinations median weekly frequency of bowel movement bristol score of stool consistency abdominal pain clinical complete remission rate of constipation bowel movement frequency stool consistency clinical complete remission rate of constipation and abdominal symptoms and the safety of forlax and lactulose stool consistency￨abdominal pain disappeared in 75 of patients in the forlax group but in only 57 in the lactulose group by week 2 of treatment p  005￨sig increase￨highunclear￨highunclear￨highunclear
115￨ninety nine patients completed the trial 115 patients with chronic constipation￨peg and lactulose peg polyethylene glycol peg lactulose polyethylene glycol electrolyte solution with lactulose￨laboratory tests mean number of liquid stools loss of efficacy and no serious toxicity tolerated chronic constipation serious adverse events overall improvement number of stools and a lower median daily score clinical tolerance￨the mean number of liquid stools was higher in the peg group but the difference was significant only for the first two weeks￨sig decrease￨highunclear￨highunclear￨highunclear
7￨children aged 2 to 11 years with a clinical diagnosis of faecal impaction faecal impaction in children￨polyethelene glycol plus electrolytes pge  e peg  e versus lactulose peg  e lactulose peg  e and lactulose polyethylene glycol 3350 plus electrolytes peg  e movicol￨peg  e taking peg  e total incidence rate of adverse events seen￨the total incidence rate of adverse events seen was higher in the lactulose group 83 than in the peg  e group 64￨sig increase￨highunclear￨highunclear￨highunclear
37￨37 children aged 2 to 16 years chronic constipation in children￨polyethylene glycol 3350 and lactulose polyethylene glycol peg 3350 and lactulose lactulose polyethylene glycol￨total colonic transit time￨peg 3350 significantly decreased the total colonic transit time compared to lactulose 47627 vs 55324 hours mean￨sig decrease￨highunclear￨highunclear￨highunclear
91￨one hundred patients aged 6 months15 years with paediatric constipation 91 patients 49 male completed the study childhood functional constipation￨lactulose peg 3350 transipeg versus lactulose polyethylene glycol peg 3350 peg 3350 transipeg polyethylene glycol with electrolytes with lactulose￨side effects paediatric constipation and evaluate clinical efficacyside effects defecation and encopresis frequencyweek and successful treatment encopresis frequency abdominal pain straining and pain at defecation defecation frequency￨however success was significantly higher in the peg group 56 compared with the lactulose group 29￨sig increase￨low￨low￨low
not found￨only patients with primary nocturnal enuresis refractory to the maximal dosage of desmopressin were enrolled monosymptomatic primary nocturnal enuresis children with lower urinary tract symptoms or bowel dysfunction primary nocturnal enuresis in desmopressinnonresponders fortyone desmopressinnonresponders were enrolled and 7 patients were excluded because of noncompliance monosymptomatic nocturnal enuresis￨desmopressin anticholinergic medication placebo desmopressin combination therapy anticholinergic bladderrelaxing therapy combination therapy desmopressin anticholinergic medication or placebo￨mean number of wet nights risk of a wet episode￨after 1 month of treatment there was a significant reduction in the mean number of wet nights in the combination therapy group compared with the placebo group￨sig decrease￨low￨low￨low
40￨forty patients suffering from nocturnal enuresis￨oral hctz placebo hctz diuretic hydrochlorothiazide hctz hydrochlorothiazide hctz and placebo￨average percentage of wet nights tolerated nocturnal enuresis efficacy tolerability and side effects tolerability and side effects monosymptomatic nocturnal enuresis￨hctz resulted in a significantly better reduction than placebo 411 vs 325 p or 0023￨sig decrease￨highunclear￨highunclear￨highunclear
78￨primary nocturnal enuresis 78 patients￨diclofenac sodium prostaglandin synthesis inhibitor diclofenac sodium vasopressin imipramine￨prostaglandins increase detrusor pressure decrease urethral pressure and lead to sodium excretion￨we conclude that diclofenac sodium an inhibitor of prostaglandin synthesis is a good alternative agent for nocturnal enuresis particularly as a supplementary treatment combined to imipramine with 60 complete response and 133 recurrence rate￨sig increase￨highunclear￨highunclear￨highunclear
not found￨nocturnal enuresis 14 enuretic schoolchildren with a competitive alphaadrenoceptor blocking substance indoramin￨imipramine alphaadrenolytic drug indoramin￨nightwetting frequency￨treatment in the doses used had no significant effect on nightwetting frequency￨no diff￨highunclear￨highunclear￨highunclear
30￨30 boys six to ten years of age with primary nocturnal enuresis twenty boys were treated with primary nocturnal enuresis by oral androgen mesterolone￨mesterolone mesterolone placebo￨side effects cystometric bladder capacity and disappearance of uninhibited detrusor contractions￨increased cystometric bladder capacity and disappearance of uninhibited detrusor contractions were noticed in a significant number of cases after treatment￨sig increase￨highunclear￨highunclear￨highunclear
318￨primary nocturnal enuresis pne in children aged 6 to 11 years three hundred eighteen children with pne were enrolled primary nocturnal enuresis in children eligible children had or 8 wet nights during a 14day baseline children aged 6 through 11 years 22 primary care practices in the united states￨ibuprofen and pseudoephedrine administered alone or in combination to placebo placebo ibuprofen ibu and pseudoephedrine pse ibu 125 mgkg and pse hcl ibuprofen and pseudoephedrine pse hcl￨efficacy of ibu mean bladder capacities adverse events tolerated mean number of wet nights bladder capacities number of wet nights￨children responding to treatment had larger mean bladder capacities and larger mean percentage of predicted bladder capacities than children who did not respond in each treatment group￨sig increase￨low￨low￨low
85￨eightyfive children with primary nocturnal enuresis patient and control groups primary nocturnal enuresis￨desmopressin placebo desmopressin and indomethacin desmopressin desmopressin indomethacin or placebo indomethacin desmopressin and indomethacin￨serum and urine pge2 concentrations dry nights prostaglandin e2 pge2 concentrations mean serum and urine pge2 concentrations number of dry nights serum pge2 and urine pge2 concentrations￨there was a significant decrease in the serum and urine pge2 concentrations in group a and group b after the treatment period p 001￨sig decrease￨highunclear￨highunclear￨highunclear
12￨12 girls and 7 boys between 6 and 15 years old primary nocturnal enuresis￨indomethacin placebo prostaglandin synthesis inhibitor indomethacin indomethacin suppository￨￨was significantly more effective than placebo in the treatment of primary enuresis￨sig increase￨highunclear￨highunclear￨highunclear
100￨nocturnal enuresis 100 children with nocturnal enuresis ne aged between six and 14 years who had been randomly selected amongst the enuretic outpatients at the ankara ssk childrens hospital ne children￨placebo piracetam diphenylhydantoin and psychotherapy piracetam￨therapeutic effects￨the study population consisted of 100 children with nocturnal enuresis ne aged between six and 14 years who had been randomly selected amongst the enuretic outpatients at the ankara ssk childrens hospital￨no diff￨highunclear￨highunclear￨highunclear
not found￨12 patients by their parents who had been taught the technique￨acupressure versus oxybutinin acupressure acupressure￨complete and partial responses￨complete and partial responses after 6 months of treatment were seen in 833 and 167 respectively of patients treated with acupressure and in 583 and 333 respectively of children who received oxybutinin￨no diff￨highunclear￨highunclear￨highunclear
not found￨primary enuresis 58 patients 2 groups of enuretic children￨anticholinergic drugs dicyclomine and oxybutynin chloride oxybutynin chloride￨￨2 groups of enuretic children were respectively treated with anticholinergic drugs dicyclomine and oxybutynin chloride￨sig decrease￨highunclear￨highunclear￨highunclear
158￨children had monosymptomatic or polysymptomatic enuresis we enrolled 158 patients from 2003 to 2004 primary nocturnal enuresis with 145 children followed 48 received combination therapy 49 received 68 patients 47 had monosymptomatic enuresis and 77 53 had polysymptomatic enuresis patients 145 100 boys and 45 girls mean age 78 pediatric nocturnal enuresis children with nocturnal enuresis￨desmopressin imipramine desmopressin imipramine or a combination of desmopressin plus oxybutynin imipramine and desmopressin desmopressin and oxybutynin oxybutynin plus desmopressin desmopressin alone or imipramine alone desmopressin plus oxybutynin￨efficacy nocturnal enuretic frequency￨combination therapy produced the best and most rapid results regardless of whether the children had monosymptomatic or polysymptomatic enuresis￨no diff￨highunclear￨highunclear￨highunclear
29￨primary nocturnal enuresis 29 patients with primary nocturnal enuresis￨pseudoephedrine oxybutynin pseudoephedrine and indomethacin oxybutynin indomethacin￨side effects number of dry nights￨oxybutynin and indomethacin did not cause a statistically significant difference in the number of dry nights p  005 but patients treated with pseudoephedrine had a significant increase in the number of dry nights p  005￨no diff￨highunclear￨highunclear￨highunclear
62￨children with nocturnal enuresis nocturnal enuresis sixtytwo children with nocturnal enuresis 43 boys 19 girls aged 615 years children with primary nocturnal enuresis￨desmopressin diclofenac desmopressin adiuretinsd sodium diclofenac desmopressin desmopressin and diclofenac￨nightly excretion of sodium glomerular filtration rate diuresis and solute excretion free water reabsorption and solute clearance prostaglandin production￨a high correlation was found between the free water reabsorption and solute clearance p  0001 in children with nocturnal enuresis￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with enuresis nocturna 77 monosymptomatic nocturnal enuretics between july 1996 and december 1998 children with enuresis nocturna￨combination therapy imipramine combination therapy imipramine and oxybutynin imipramine with oxybutynin￨￨even though there is no statistically significant difference between combination therapy imipramine plus oxybutynin and monotherapy clinical data showed that combination therapy is more effective￨no diff￨highunclear￨highunclear￨highunclear
27￨twentyseven children with enuresis resistant to the alarm and to unselected enuretic patients children with therapyresistant enuresis refractory enuresis￨desmopressin imipramine placebo placebo tolterodine and imipramine imipramine anticholinergics or imipramine placebo tolterodine 12 mg and imipramine tolterodine tolterodine and imipramine￨number of wet nights side effects￨imipramine was significantly better than both placebo p  0001 and tolterodine p  0006￨sig increase￨highunclear￨highunclear￨highunclear
87￨patients with the diagnosis of nocturnal enuresis children with nocturnal enuresis 87 pediatric subjects￨placebo atomoxetine placebo atomoxetine placebo atomoxetine￨efficacy dry nights adverse events nocturnal enuresis average number of dry nights dry night logparent report dnlpr a daily parent diary nocturnal enuresis￨compared with placebo atomoxetine treatment was associated with a significant increase in dry nights in children with nocturnal enuresis￨sig increase￨low￨low￨low
18￨19 patients with chronic angleclosure glaucoma patients with subacute or chronic angleclosure glaucoma patients with subacute or chronic angleclosure glaucoma than trabeculectomy followed by an optional cataract procedure patients with angleclosure glaucoma department of ophthalmology university of amsterdam the netherlands 18 patients with chronic or subacute angleclosure glaucoma group 1￨drainage surgery incipient cataracts or clear lenses lens extraction 22 extracapsular lens extractions with implantation of a posterior chamber intraocular lens￨subsequent cataract surgery mean preoperative iop visual field examination diurnal intraocular pressure iop curves gonioscopic appearance and number of antiglaucoma medications glaucoma control final visual acuity mean postoperative iop mean number of ocular hypotensive medications￨in group 2 the final visual acuity was unchanged or better in 13 eyes 52 and worse in 12 eyes 48 subsequent cataract surgery was performed in 9 75 of these 12 eyes￨no diff￨highunclear￨highunclear￨highunclear
not found￨517 to 1960 eyes with angle closure glaucoma eighteen eyes from 15 patients after laser iridotomy 17 eyes or peripheral iridectomy 1 eye had undergone surgery and were studied￨phacoemulsification and intraocular lens iol implantation for cataract andor uncontrolled intraocular pressure iop phacoemulsification and iol implantation phacoemulsification and intraocular lens implantation￨iop corneal endothelial cell count visual acuity mean iop￨the visual acuity was not worsened in any eyes and became better than 2 snellen lines in 14 eyes￨no diff￨highunclear￨highunclear￨highunclear
262￨262 patients aged 20 to 70 years who had persistent back pain to receive chronic low back pain n  94 therapeutic massage n  78 or selfcare educational materials n  90￨traditional chinese medical acupuncture acupuncture traditional chinese medical acupuncture therapeutic massage and selfcare education massage therapeutic massage￨adverse effects disability scale￨massage was also superior to acupuncture on the disability scale 589 vs 825 respectively p 01￨sig increase￨highunclear￨highunclear￨highunclear
243￨n243 patients chronic low back pain chronic low back pain clbp￨reflexology relaxation or nonintervention usual care complementary and alternative medicine cam reflexology￨general health status pain functioning coping strategies and mood pain reduction pain and functioning￨after adjusting for pretreatment scores repeated measures ancova found no significant differences between the groups pre and post treatment on the primary outcome measures of pain and functioning￨no diff￨highunclear￨highunclear￨highunclear
24￨twentyfour adults 12 women with lower back pain adults m age396 years with low back pain with a duration of at least 6 months received two twentyfour adults m age396 years with low back pain of nociceptive origin with a duration of at least 6 months participated in the study￨massage therapy massage therapy or a progressive muscle relaxation group massage therapy versus relaxation 30min massage or relaxation therapy sessions massage therapy￨trunk and pain flexion performance and their serotonin and dopamine levels pain depression anxiety and stress hormones and sleeplessness and for improving trunk range of motion associated with chronic low back pain pain depression anxiety and their sleep lower back pain pain depression anxiety and improved sleep￨by the end of the study the massage therapy group as compared to the relaxation group reported experiencing less pain depression anxiety and improved sleep￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨adults with subacute or chronic nonspecific low back pain nonspecific low back pain in hong kong￨usual care only acupressure with aromatic lavender oil relaxation acupoint stimulation and acupressure with aromatic lavender essential oil acupoint stimulation with electrodes combined with acupressure using an aromatic essential oil lavender intervention 8session relaxation acupoint stimulation followed by acupressure with lavender oil￨lateral spine flexion range walking time pain intensity by visual analogue scale and duration lateral fingertiptoground distance in centimetres walking time and interference on daily activities adverse effects vas pain intensity baseline vas scores pain relief and enhancing the physical functional activities￨one week after the end of treatment the intervention group had 39 greater reduction in vas pain intensity than the control group  p00001  improved walking time  p005  and greater lateral spine flexion range  p001￨sig decrease￨highunclear￨highunclear￨highunclear
109￨109 patients participating in a complex inpatient rehabilitation program low back pain sufferers low back pain lbp lbp sufferers￨sm acupuncture massage vs swedish massage and individual exercise vs group exercise penzel versus swedish massage sm and individual medical exercises ie versus group exercises ge therapeutic acupuncture massage apm rehabilitation programs apm￨disability and pain mean pain intensity on vas lumbar motility baseline mean ffbh score functional abilitydisability functional questionnaire hanover ffbh and pain intensity 10 cm visual analogue scale vas￨apm showed beneficial effects for both disability and pain compared with sm group differences delta ffbh 70 95 confidence interval ci 25116 p  0003 delta vas 08 cm 95 ci 215 p  0024￨sig increase￨low￨low￨low
100￨chronic low back pain seventytwo out of 100 patients completed the study￨exercise program twice daily exercise program that was tailored to treat their musculoskeletal dysfunctions or given a nonspecific program of general stretching and aerobic conditioning manual therapy with specific adjuvant exercise manual therapy with specific adjuvant exercise manual therapy and specific adjuvant exercise manual therapy or sham manual therapy￨pain disability pain and disability perceived disability￨multivariate tests conducted for measures of pain and disability revealed a significant group by time interaction p  004 and p  005 respectively indicating differential change in these measures pretreatment to posttreatment as a function of the treatment received￨sig increase￨highunclear￨highunclear￨highunclear
146￨146 participants with chronic low back pain orthopedic referral hospital in taiwan was conducted between december 20 2000 and march 2 2001￨physical therapy acupressure acupressure and physical therapy￨low back pain mean of pain score mean of posttreatment pain score selfappraised pain scores￨the mean of posttreatment pain score after a 4week treatment 228 sd  262 in the acupressure group was significantly lower than that in the physical therapy group 505 sd  511 p  00002￨sig decrease￨highunclear￨highunclear￨highunclear
107￨107 subjects who passed screening 98 92 completed posttreatment tests and 91 85 completed followup tests patients with subacute lowback pain subacute lowback pain subjects with subacute lowback pain￨comprehensive massage therapy comprehensive massage therapy softtissue manipulation remedial exercise and posture education 2 components of massage therapy and placebo softtissue manipulation only n  25 remedial exercise with posture education only n  22 or a placebo of sham laser therapy remedial exercise massage therapy￨pain roland disability questionnaire rdq the mcgill pain questionnaire ppi and pri the state anxiety index and the modified schober test lumbar range of motion intense pain quality of pain￨clinical significance was evident for the comprehensive massage therapy group and the softtissue manipulation group on the measure of function￨sig increase￨highunclear￨highunclear￨highunclear
321￨321 patients 274 new cases 47 relapsing cases gambian trypanosomiasis latestage trypanosoma brucei gambiense trypanosomiasis relapsing cases of gambian trypanosomiasis￨intravenous eflornithine eflornithine￨2year probability of cure￨being stuporous on admission was associated with a lower risk of treatment failure hr 018 95 ci 00214 as was increasing age hr 0977 95 ci 09510 for each additional year of age￨sig decrease￨highunclear￨highunclear￨highunclear
767￨sleeping sickness caused by trypanosoma brucei gambiense 767 patients with secondstage disease 500 were enrolled 250 40 patients on the standard schedule and 47 on the new schedule had 50 patients on the standard regimen deviated or withdrew from treatment compared with two on the new regimen patients presenting to a hospital in kwanza norte angola with sleeping sickness￨melarsoprol￨skin reactions adverse events number of patients with encephalopathic syndromes elimination of parasites deaths attributed to treatment and rate of encephalopathy safety and efficacy parasitological cure￨parasitological cure 24 h after treatment was 100 in both groups there were six deaths all due to encephalopathy 30 days after treatment in each group￨no diff￨highunclear￨highunclear￨highunclear
620￨gambiense sleeping sickness 598 patients were evaluable 620 patients who had trypanosoma brucei gambiense trypanosomiasis with central nervous system involvement were treated either with￨prednisolone plus melarsoprol or with melarsoprol only prednisolone￨morbidity and death associated with melarsoprolinduced encephalopathy complications of melarsoprol therapy or in relapse rate￨the two groups did not differ either in the incidence of other complications of melarsoprol therapy or in relapse rate after melarsoprol therapy￨no diff￨highunclear￨highunclear￨highunclear
not found￨n12 and 125 mgkg group ii n13 patients with latestage tb gambiense sleeping sickness patients with latestage tb￨oral dfmo oral dfmo eflornithine alphadifluoromethylornithine￨csf concentrations plasma and csf dfmo concentrations good initial response but relapse average trough cssmin and average cssave plasma dfmo concentrations therapeutic plasma and csf levels concentrationtime profiles of dfmo cmax tmax and auc0 infinity  values gambiense sleeping sickness plasma dfmo concentrations vzf clf and t12z values plasma cerebrospinal fluid csf levels and pharmacokinetics of eflornithine dfmo plasma and csf concentrations of dfmo￨plasma dfmo concentrations did not increase proportionally to doses when the dose increased from 100 mgkg to 125 mgkg body weight given every 6 h 6070 of the expected increase￨no diff￨highunclear￨highunclear￨highunclear
278￨secondstage trypanosoma brucei gambiense sleeping sickness 278 patients were randomized￨melarsoprol melarsoprol combined with oral 75 mgkg nifurtimox standard melarsoprol nifurtimox monotherapy melarsoprolnifurtimox combination melarsoprolnifurtimox combination therapy 06 mgkg iv melarsoprol melarsoprol and nifurtimox monotherapy and combination therapy melarsoprol therapy￨frequency of adverse events encephalopathic syndromes relapse severe adverse events and death attributed to treatment￨nifurtimox has been successfully used to cure melarsoprolrefractory sleeping sickness caused by trypanosoma brucei gambiense infection￨sig decrease￨highunclear￨highunclear￨highunclear
389￨389 patients with latestage trypanosoma brucei gambiense trypanosomiasis trypanosoma brucei gambiense trypanosomiasis￨melarsoprol￨2year probability of relapse convulsions efficacy and toxicity￨the new regimen of 10 daily injections of melarsoprol was as effective and had the same toxicity as the traditional regimen of three series of three injections at the full dose￨sig decrease￨highunclear￨highunclear￨highunclear
54￨latestage human african trypanosomiasis caused by trypanosoma brucei gambiense four patients died who were taking melarsoprolnifurtimox and one who was taking melarsoproleflornithine sleeping sickness treatment center run by médecins sans frontières at omugo arua district uganda
                stage 2 patients diagnosed in northern uganda were screened for inclusion and a total of 54 selected latestage trypanosoma brucei gambiense sleeping sickness￨melarsoprolnifurtimox mn melarsoproleflornithine me and nifurtimoxeflornithine ne eflornithine intravenous iv melarsoprol￨cure rates and adverse events unacceptable toxicity me cure rates efficacy and safety￨larger studies are needed to continue the evaluation of this drug combination in the treatment of t b gambiense sleeping sickness￨sig increase￨highunclear￨highunclear￨highunclear
not found￨four hat treatment centres in the republic of the congo and the democratic republic of the congo patients with secondstage disease secondstage african trypanosoma brucei gambiense trypanosomiasis patients aged 15 years or older with confirmed secondstage t b gambiense infection human african trypanosomiasis hat sleeping sickness￨intravenous eflornithine nect eflornithine nifurtimoxeflornithine combination therapy nect nifurtimoxeflornithine combination therapy￨cure rates cure defined as absence of trypanosomes in body fluids and a leucocyte count adverse events efficacy and safety￨in the pp population 122 917 of 133 patients in the eflornithine group and 129 977 of 132 in the nect group were cured at 18 months difference 60 onesided 95 ci 15 p00001￨no diff￨low￨low￨low
170￨premature infants 170 premature infants with birth weights between 751 and 2000 g in a randomized sequential trial comparing symptomatic patent ductus arteriosus and congestive heart failure in premature infants thirtyfive of 85 infants in the highvolume group acquired murmurs consistent with patent ductus arteriosus and 11 of these 35 had congestive heart failure￨fluid administration high and low volumes of fluid intake￨murmurs consistent with patent ductus arteriosus risk of patent ductus arteriosus with congestive heart failure necrotizing enterocolitis congestive heart failure￨thirtyfive of 85 infants in the highvolume group acquired murmurs consistent with patent ductus arteriosus and 11 of these 35 had congestive heart failure￨sig increase￨highunclear￨highunclear￨highunclear
2￨ventilated vlbw infants onehundredandsixtyeight ventilated infants median gestational age 27 wk range 2333 and birthweight 953 g range 4861500￨￨occurrence of episodes of jaundice hypotension hypoglycaemia hypernatraemia or hyponatraemia serum electrolytes bilirubin creatinine and urine osmolalities episodes of jaundice hypoglycaemia and hypotension requiring treatment arginine vasopressin levels urine osmolalities and lower urine output acute adverse effects fluid balance electrolyte and metabolic disturbances median creatinine and arginine vasopressin levels￨there were no statistically significant differences in the occurrence of episodes of jaundice hypotension hypoglycaemia hypernatraemia or hyponatraemia between infants on the two regimes￨no diff￨highunclear￨highunclear￨highunclear
not found￨one hundred consecutive lowbirthweight infants less than 1751 g￨fluid restriction dry and control groups￨mean weight loss fluid intake alive and had no signs of bronchopulmonary dysplasia weight mortality and morbidity￨twentyseven subjects in the dry group and 15 in the control group were alive and had no signs of bronchopulmonary dysplasia at age 28 days p less than 005 the numbers at term being 28 and 14 respectively p less than 001￨no diff￨highunclear￨highunclear￨highunclear
88￨very lowbirthweight infants 88 very lowbirthweight infants infants with birth weights of 750 to 1500 gm were matched for birth weight in 250 gm increments￨￨incidence of clinically significant patent ductus arteriosus intracranial hemorrhage bronchopulmonary dysplasia necrotizing enterocolitis dehydration acute renal failure or metabolic disturbances duration of respiratory support required in time to regain bw or in time to discharge mean fiveday cumulative fluid input neonatal mortality rate￨there was no difference in duration of respiratory support required in time to regain bw or in time to discharge￨no diff￨highunclear￨highunclear￨highunclear
not found￨28 premature and newborn infants each mostly suffering from a respiratory distress syndrome premature and newborn infants during the first three days of life authors transl￨￨endogenous creatinine clearance excretion of all other electrolytes acids and nitrogenous metabolites osmolal clearance infusion quantity￨on each of the three days an increase of the infusion quantity resulted in a 23 times larger urine flow the osmolal clearance increasing significantly at the same time￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨twenty als patients with sialorrhea refractory to medical therapy als patients￨botulinum toxin type b for sialorrhea placebo botulinum toxin type b btxb or placebo￨global impression of improvement adverse events including dysphagia rate of decline of vital capacity￨there were no significant adverse events including dysphagia in the btxb group and there was no significant increase in the rate of decline of vital capacity￨no diff￨highunclear￨highunclear￨highunclear
not found￨women with hiv women living with hiv infection￨lactobacillus acidophilus clotrimazole tablets placebo clotrimazole￨estimated median time to first episode vc relative risk of experiencing an episode of vc vaginal candidiasis vc vaginal candidiasis lactobacillus acidophilus￨the estimated median time to first episode vc was longer for clotrimazole p  03 log rank test and lactobacillus acidophilus p  09 log rank test compared with placebo￨sig increase￨low￨low￨low
323￨323 women with hiv infection and cd4 cell counts of 300 cellsmm3 or less women who had a history of mucosal candidiasis rr 05 mucosal candidiasis in women women with hiv infection hivinfected women who are at risk for recurrent mucosal candidiasis 14 sites participating in the community programs for clinical research on aids cpcra women infected with hiv￨openlabel fluconazole placebo fluconazole prophylaxis fluconazole￨resistance safety and effectiveness absolute risk reduction oropharyngeal candidiasis vaginal candidiasis episode of candidiasis safe and effective in preventing oropharyngeal and vaginal candidiasis esophageal candidiasis￨weekly fluconazole was effective in preventing oropharyngeal candidiasis rr 050 cl 033 to 074 p  0001 and vaginal candidiasis rr 064￨no diff￨low￨low￨low
44￨discogenic pain due to single level degenerative disc disease ddd 10 men and 13 women with an average age of 41 and an average body mass index of 28 67 patients from 2 study sites involved in the multicenter discogenic pain 23 men and 21 women with an average age of 36 and an average body mass index of 28￨artificial disc replacement flexicore flexicore disc replacement versus standard circumferential fusion metalonmetal artificial lumbar disc replacement flexicore artificial disc replacement versus fusion with a 2year followup￨average hospital stay average operative time skin to skin mean oswestry disability index scores disability and pain mean visual analog scale scores average estimated blood loss oswestry disability index and the visual analog scale￨the mean oswestry disability index scores were 62 flexicore and 58 control before surgery 36 flexicore and 50 control at 6 weeks and 6 flexicore and 12 control at 2 years￨no diff￨highunclear￨highunclear￨highunclear
577￨patients with singlelevel degenerative disc disease patients with degenerative disc disease unresponsive to conservative measures lumbar disc arthroplasty 577 patients were treated in either the investigational group 405 receiving￨lumbar disc arthroplasty or the control group 172 receiving anterior lumbar interbody fusion metalonmetal lumbar disc prosthesis lumbar disc arthroplasty with maverick disc versus standalone interbody fusion￨implant or implantsurgical procedurerelated adverse events hospitalization stays blood loss physical function reduced pain and earlier return to work longer surgical times safety and effectiveness overall success a composite measure of safety and effectiveness as recommended by the food and drug administration and defined in the protocol disc height and segmental angular motion overall success superiority oswestry disability index back pain and short form36 physical component summary scores￨the investigational group had statistically superior outcomes p  005 at all postoperative evaluations in oswestry disability index back pain and short form36 physical component summary scores as well as patient satisfaction￨sig increase￨highunclear￨highunclear￨highunclear
152￨patients had not responded to a conservative treatment programme and suffered from predominantly lbp with varying degrees of leg pain patients referred to a spine clinic for surgical evaluation one hundred and fiftytwo patients with a mean age of 40 years 2155 were included 90 were women and 80 underwent tdr￨total disc replacement tdr with posterior fusion total disc replacement￨complications and reoperations ga pedicle screw removal global assessment ga vas for back and leg pain oswestry disability index sf36 and eq5d at 1 and 2 years maximum recovery totally painfree￨the fusion patients continued to improve and at 2 years had results similar to tdr patients apart from numbers of painfree￨sig increase￨highunclear￨highunclear￨highunclear
304￨three hundred four 304 patients were enrolled in the study at 14 centers across the united states and randomized in a 21 ratio to treatment with the singlelevel degenerative disc disease from l4s1 unresponsive to nonoperative treatment￨lumbar total disc replacement with the charite artificial disc versus lumbar fusion charite artificial disc or the control group instrumented anterior lumbar interbody fusion lumbar total disc replacement using the charite artificial disc depuy spine raynham ma lumbar total disc replacement with the charite artificial disc￨hospital stay levels of disability visual analog scale assessing back pain the oswestry disability index questionnaire and the sf36 health survey rate of satisfaction complication rate rate of reoperations pain and disability scores￨patients in the charite artificial disc group had lower levels of disability at every time interval from 6 weeks to 24 months compared with the control group with statistically lower pain and disability scores at all but the 24 month followup p  005￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨32 patients who underwent surgery between 2002 and 2005 performed by the same surgeon all patients presented primary or postdiscectomy discopathy modic 1 or 2 on mri and one level l4l5 or l5s1 positive on discography chronic lowback pain resulting from disc degeneration￨total artificial disc prosthesis and anterior lumbar interbody fusion lumbar disc prosthesis charité depuy disc prosthesis was implanted in group 1 an intersomatic kla cage scientx￨vas rate of excellent outcome a visual analog scale vas gain in function patient satisfaction￨the lumbar disc prosthesis offers a possible alternative to lumbar arthrodesis for the treatment of severe disc degeneration at one level in the young subject￨sig increase￨highunclear￨highunclear￨highunclear
286￨two hundred eightysix 286 patients were treated on protocol 1level degenerative disc disease discogenic pain at 1 vertebral level between l3 and s1￨prodiscl total disc replacement versus circumferential fusion circumferential spinal fusion prodiscl synthes spine west chester pa lumbar total disc replacement prodiscl implantation￨visual analog scale patient satisfaction visual analog scale pain assessment radiographic range of motion overall neurologic success safety and effectiveness patient selfassessments physical and neurologic examinations and radiographic evaluation oswestry low back pain disability questionnaire oswestry disability index odi sf36 health survey scores￨the visual analog scale pain assessment showed statistically significant improvement from preoperative levels regardless of treatment p  00001￨sig increase￨highunclear￨highunclear￨highunclear
173￨patients with low back pain and degenerative disc five university hospitals in norway patients were treated from april 2004 to september 2007 173 patients with a history of low back pain for at least one year oswestry disability index of at least 30 points and degenerative changes in one or two lower lumbar spine levels 86 patients randomised to surgery patients with chronic low back pain￨surgery with disc prosthesis versus nonsurgical treatment surgery with disc prosthesis versus rehabilitation surgery with disc prosthesis or outpatient multidisciplinary rehabilitation￨oswestry disability index return to work sf36 mental component score eq5d fear avoidance beliefs hopkins symptom check list drug use and the back performance scale oswestry score leg amputation self efficacy for pain score on the oswestry disability index patients satisfaction back performance scale and prolo scale sf36 physical component score prolo scale low back pain satisfaction with life sf36 and euroqol eq5d hopkins symptom check list hscl25 fear avoidance beliefs fabq self efficacy beliefs for pain work status and patients satisfaction and drug use favour of surgery for low back pain￨there were no significant differences in return to work sf36 mental component score eq5d fear avoidance beliefs hopkins symptom check list drug use and the back performance scale￨no diff￨low￨low￨low
80￨unresectable stage iii nonsmall cell lung cancer most unresectable stage iiiaiiib nsclc patients eighty unresectable stage iiiaiiib nsclc patients pathologically nonsmall cell lung cancer nsclc￨cisplatin 40mgm² on days 1 8 29 36 np regimen plus conventional radiotherapy np nvb 25mgm² vinorelbine concurrent chemoradiotherapy concurrent lowdose chemotherapy plus radiation vs sequential chemoradiotherapy sequential chemoradiotherapy concurrent chemotherapy plus radiotherapy concurrent chemotherapy of vinorelbine￨acute radiation pneumonitis rate overall response rate incidences of grade iiiiv acute radiation esophagitis and leukopenia￨the acute radiation pneumonitis rate was 325 in group a and 200 in group b p  01￨no diff￨highunclear￨highunclear￨highunclear
205￨patients with locally advanced nsclc locally advanced nonsmallcell lung cancer two hundred five patients were randomly assigned unresectable stage iii nonsmallcell lung cancer nsclc￨concurrent chemoradiotherapy cisplatin 20 mgm2d and etoposide vinorelbine doncologie thoraciquegroupe français de pneumocancérologie npc consolidation therapy with cisplatin 80 mgm2 on days 78 and 106 and vinorelbine sequential chemoradiotherapy radiotherapy rt and chemotherapy ct induction ct with cisplatin￨esophageal toxicity 4year survival rates median survival survival impact six toxic deaths￨although not statistically significant clinically important differences in the median 2 3 and 4year survival rates were observed with a trend in favor of concurrent chemoradiation therapy suggesting that is the optimal strategy for patients with locally advanced nsclc￨no diff￨highunclear￨highunclear￨highunclear
102￨one hundred and two previously untreated patients aged 4275 years with locally advanced stage iiia n  15 or stage iiib n  87 patients with locally advanced nsclc locally advanced nonsmall cell lung cancer ninetyeight patients were evaluable for response and 101 for toxicity locally advanced nonsmall cell lung cancer nsclc￨concurrent and sequential crt with chemotherapy ct vinorelbine sequential chemoradiotherapy with cisplatin and vinorelbine radiotherapy rt chemoradiotherapy crt over radiation alone cisplatin cisplatin and vinorelbine￨response rate overall survival overall response rate higher toxicity deaths overall survival who grade 3 or 4 toxicity nauseavomiting time to progression ttp leucopenia safety and efficacy￨overall survival was significantly longer in arm a median survival 166 months versus arm b median survival 129 months￨sig increase￨highunclear￨highunclear￨highunclear
240￨two hundred forty patients with biopsyproven unresectable nsclc without distant metastases or lowerstage medically inoperable patients two hundred fifteen patients were eligible and assessable locally advanced unresectable nonsmallcell lung cancer patients with locally advanced unresectable nonsmallcell lung cancer nsclc￨cisplatin thoracic irradiation with or without cisplatin cisplatin to radiation therapy xrt thoracic xrt cisplatin￨overall response rate 5year survival rates response rate progressionfree survival or overall survival progressionfree survival or overall survival median progressionfree survival time median survival time￨cisplatin administered every 3 weeks does not significantly improve response rate progressionfree survival or overall survival when added to thoracic xrt for locally advanced unresectable nsclc￨no diff￨highunclear￨highunclear￨highunclear
46￨elderly patients with unresectable stage iii nonsmall cell lung cancer nsclc elderly patients with locally advanced nonsmall cell lung cancer 46 patients enrolled eligible patients were 71 years of age or older with unresectable stage iii nsclc 46 patients were registered from november 1999 to february 2001￨radiotherapy alone rt arm irradiation with 60 gy or the chemoradiotherapy crt arm the same radiotherapy and additional concurrent use of carboplatin 30 mgm2 per fraction up to the first 20 fractions carboplatin radiotherapy with carboplatin radiotherapy alone standard thoracic radiotherapy with or without concurrent daily lowdose carboplatin￨longer survival median survival time￨as to the effectiveness for the 46 patients enrolled the median survival time was 428 days 95 confidence interval ci  212680 days in the rt arm versus 554 days 95 ci  331 to not estimable in the crt arm￨no diff￨highunclear￨highunclear￨highunclear
214￨inoperable stage iiia or iiib nonsmallcell lung cancer three hundred three patients entered the study and 276 completed induction chemotherapy two hundred fourteen patients were patients with nonsmallcell lung cancer in inoperable stage iiia or iiib received patients without progression at restaging after induction chemotherapy￨induction chemotherapy followed by chemoradiotherapy with weekly paclitaxel simultaneous chemoradiotherapy induction chemotherapy radiotherapy alone after induction chemotherapy radiotherapy paclitaxel 200 mgm2 and carboplatin randomly assigned radiotherapy alone n  113 simultaneous chemoradiotherapy simultaneous chemoradiotherapy induction chemotherapy simultaneous chemoradiotherapy chemoradiotherapy radiotherapy 60 gy or chemoradiotherapy paclitaxel￨overall survival median survival times response time to progression and survival toxicities median followup time median time to progression time to progression response and toxicity overall toxicity rates￨median time to progression significantly favored simultaneous chemoradiotherapy 115 months 95 ci 83 to 147 months versus radiotherapy alone 63 months 95 ci 50 to 76 months p  001 logrank test￨sig increase￨low￨low￨low
283￨patients with inoperable stage iii nonsmallcell lung cancer patients with unresectable stage iii nonsmallcell lung cancer two hundred eightythree patients with inoperable stage iii nonsmallcell lung cancer one hundred thirtyseven patients were randomized to this therapy regimen alone 146 patients￨carboplatin radiation treatment carboplatin at 100 mgm2wk concurrent with the radiation therapy radiotherapy radiosensitization with carboplatin concurrent carboplatin carboplatin induction chemotherapy program with vinblastine and cisplatin￨overall survival disease control or survival relapse rate poorer survival complete response failurefree survival survival￨there was no difference with respect to failurefree survival 10 with carboplatin and 9 with radiotherapy alone or overall survival 13 with carboplatin and 10 with radiotherapy alone at 4 years￨no diff￨highunclear￨highunclear￨highunclear
131￨stage iii nonsmallcell lung cancer between january 1990 and december 1991 131 patients with histologically or cytologically confirmed stage iii nsclc karnofsky performance status kps  or  50 and no previous therapy were randomly treated as follows group stage iii nonsmallcell lung cancer nsclc￨hfx rt and lowdose daily cbdca plus vp16 concurrent hyperfractionated radiation therapy hfx rt and lowdose daily chemotherapy cht hfx rt with cht consisting of 50 mg of carboplatin cbdca and 50 mg of etoposide vp16 hyperfractionated radiation therapy with or without concurrent lowdose daily carboplatinetoposide￨longer survival time toxicity median time to local recurrence and 4year local recurrencefree survival rate median survival 4year survival rates incidence of acute and late highgrade toxicity distant metastasisfree survival rate￨the median time to local recurrence and 4year local recurrencefree survival rate were also significantly higher in group ii than in group￨sig increase￨highunclear￨highunclear￨highunclear
169￨stage iii nonsmallcell lung cancer stage iiia or iiib nonsmallcell lung cancer nsclc between january 1988 and december 1989 169 patients￨hyperfractionated radiation therapy with or without concurrent chemotherapy combined hyperfractionated radiation therapy hfx rt and concurrent chemotherapy cht hfx rt with cht consisting of 200 mg of cbdca on days 1 and 2 and 100 mg of vp16 hfx rt alone hfx rt and continuous cbdcavp16 cht hfx rt with cht consisting of 100 mg of carboplatin cbdca on days 1 and 2 and 100 mg of etoposide vp16 hfx rt￨median survival time mst 3year survival rates relapsefree survival rate survival rate incidence of acute andor late highgrade toxicity￨there was a significant difference in the survival rate between groups i and ii p  0027 logrank test but not between groups i and iii p  17 or between groups ii and iii p  14￨sig increase￨highunclear￨highunclear￨highunclear
331￨inoperable nonsmallcell lung cancer patients with nonmetastatic but inoperable nonsmallcell lung cancer 331 patients with nonmetastatic inoperable nonsmallcell lung cancer to one of three treatments￨cisplatin radiotherapydailycisplatin radiotherapy concomitant cisplatin and radiotherapy cisplatin per square meter given daily before radiotherapy radiotherapyweeklycisplatin cisplatin cisplatin cisdiamminedichloroplatinum￨survival without local recurrence control of local disease survival rates of survival and control of local disease nausea and vomiting survival benefit survival￨the survival benefit of daily combined treatment was due to improved control of local disease p  0003￨sig increase￨highunclear￨highunclear￨highunclear
160￨locally unresectable nonsmallcell lung cancer patients with histologically proven nsclc performance score 2 weight loss 10 and normal organ functions onehundred and sixty patients were included patients with locally unresectable nonsmallcell lung cancer nsclc￨carboplatin radiotherapy or thoracic radiotherapy alone￨progressionfree survival median survival cough and dyspnea improved pain became less and slight paresthesia acute toxicity quality of life toxicity local tumor control or overall survival￨pathologically confirmed persistent tumor was present in 53 of patients in the combination arm versus 58 in the radiotherapy alone arm p05￨sig increase￨highunclear￨highunclear￨highunclear
108￨patients without disease progression on day 43 108 patients who received induction chemotherapy 104 were evaluable for response nonsmallcell lung cancer patients with stage iiiaiiib locally advanced nonsmallcell lung cancer nsclc￨radiotherapy concurrent chemoradiotherapy or radiotherapy alone after docetaxelbased induction chemotherapy docetaxelcisplatin induction therapy docetaxelbased induction therapy prior to radiotherapy with or without docetaxel docetaxel induction chemotherapy with docetaxel cisplatin docetaxel and thoracic radiotherapy￨overall response rate orr orr median survival and time to progression￨the most common toxicities during induction chemotherapy and randomised therapy were grades 34 neutropenia and grade 3 lymphocytopenia respectively￨no diff￨highunclear￨highunclear￨highunclear
204￨204 patients with medically inoperable or technically unresectable nsclc localised to the primary site and regional lymph nodes inoperable nonsmall cell lung cancer patients having radical radiotherapy for inoperable nonsmallcell lung cancer nsclc￨carboplatin concurrent carboplatin standard radiotherapy 60 gy in 30 fractions in 6 weeks r6 accelerated radiotherapy 60 gy in 30 fractions in 3 weeks r3 standard radiotherapy as in r6 with carboplatin 70 mgm2day for 5 days during weeks 1 and 5 of radiotherapy r6c accelerated radiotherapy as in r3 with carboplatin 70 mgm2day for 5 days during week 1 of radiotherapy r3c carboplatin versus no carboplatin accelerated versus conventional radiotherapy accelerated or standard fraction radiotherapy with or without concurrent carboplatin￨median survival oesophageal toxicity haematological toxicity longest survival 2year survival survival advantage￨haematological toxicity was significantly greater in patients treated with carboplatin and oesophageal toxicity was significantly greater and more protracted in patients treated with accelerated radiotherapy￨sig increase￨highunclear￨highunclear￨highunclear
95￨from january 1986 to june 1987 95 patients with unresectable locally advanced nonsmall cell carcinoma of the lung stage iiia b locally advanced nonsmall cell lung cancer￨rt  cisddp radiation therapy v radiation therapy plus cisdichlorodiammine platinum ii rt alone cisdichlorodiammine platinum ii cisddp radiation therapy rt cisddp same rt plus cisddp￨overall response rate intrathoracic relapses toxicity progressionfree interval median survival time￨no statistically significant differences were detected with regard to median survival time 11 months for rt v 16 months for rt  cisddp and progressionfree interval 7 months in the rt arm v 9 months in the rt  cisddp arm but the patterns of the first failure appeared to be affected by treatment￨no diff￨highunclear￨highunclear￨highunclear
60￨60 patients with locally advanced inoperable non small cell lung cancer good performance status and minimal weight loss locally advanced inoperable nonsmall cell lung cancer 60 patients were enrolled in this study between 1998 and 2000 locally advanced nonsmall cell lung cancer outpatients with encouraging results patients with locally advanced nonsmall cell lung cancer￨radiation with concomitant chemotherapy radiotherapy weekly paclitaxel and carboplatin plus radiotherapy radiotherapy with no prior induction chemotherapy carboplatin auc 2 weekly with radiotherapy carboplatin auc 6 on day 1 and 28th followed by concomitant paclitaxel concomitant carboplatin paclitaxel paclitaxel and carboplatin concomitantly with radiotherapy conventional radiotherapy combined modality therapy induction 2 cycles paclitaxel combined chemoradiotherapy concurrent carboplatin paclitaxel and radiotherapy with or without prior induction chemotherapy concomitant chemo induction chemotherapy concomitant chemoradiotherapy and radiation only￨response rate hematological toxicities response or survival response and survival time to infield progression incidence of oesophagitis median 2 year survival prolonged time to infield progression￨hematological toxicities was also significantly higher in group a  b than in group c p0003￨sig increase￨highunclear￨highunclear￨highunclear
92￨ninetytwo patients with stage iii nsclc patients with stage iii nsclc after 2 cycles of induction chemotherapy with cisplatinbased regimens patients with stage iii nonsmall cell lung cancer￨concurrent chemoradiotherapy induction chemotherapy radiotherapy concurrent chemotherapy navelbine concurrent chemoradiotherapy chemoradiotherapy concurrent chemoradiotherapy radiotherapy radiotherapy chemoradiotherapy cisplatin￨response rate acute toxic effect incidences of grade iiiiv radiation esophagitis and leukopenia 1 and 2year survival rates complete response rate 1 and 2year local control rates survival rate￨the 1 and 2year survival rates in the chemoradiotherapy group were similar to those in the radiotherapy group 659 and 425 vs 533 and 333 p  005￨no diff￨highunclear￨highunclear￨highunclear
173￨stage iii nonsmall cell lung cancer between january 1987 and june 1991 173 patients with inoperable nonsmall cell lung cancer stage iii￨rt and a daily low dose of cddp radiotherapy versus radiotherapy radiotherapy cisplatin￨death overall response rate median survivals pattern of relapse toxicity median time to progression￨median time to progression was 106 months for arm a and 142 months for arm b median survivals were 103 months and 997 months respectively￨no diff￨highunclear￨highunclear￨highunclear
176￨stage iii nonsmall cell lung cancer stage iii nonsmall cell lung cancer nsclc 176 patients with stage iii nonsmall cell lung cancer to one of two treatments￨fractionated radiotherapy alone radiotherapy radiotherapy alone fractionated radiotherapy radiotherapy plus cisplatin radiotherapy in the same schedule combined with 20mgm2 cisplatin 1 h before radiotherapy cisplatin to fractionated radiotherapy￨overall survival frequency of locoregional progression locoregional progressionfree survival and overall survival probability of survival free of disease locoregional progressionfree interval and survival￨overall survival at 3 years was 10 among those given radiotherapy plus cisplatin and 2 among those who received radiotherapy alone p  000001￨no diff￨highunclear￨highunclear￨highunclear
not found￨program participants from the counties in which the domiciliary care program was initiated were matched with persons residing in similar counties without the program who were comparable on a large array of characteristics prior to program initiation￨￨quality of life￨this paper reports findings concerning the impact on quality of life of a case management focused program of small board and care facilities serving aging mental health and mental retardation adult target populationsthe pennsylvania domiciliary care program￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨eligible medicaid beneficiaries in arkansas florida and new jersey volunteered to participate in the demonstration elderly and nonelderly adults in all three states and children in florida￨cash and counseling allowance and direct their own medicaid supportive services as cash and counseling consumers the treatment group or to rely on medicaid services￨￨within each state and age group consumers were not more susceptible to adverse health outcomes or injuries under cash and counseling￨no diff￨highunclear￨highunclear￨highunclear
26￨four thousand two hundred twentyseven year 9 ages 1314 pupils in 26 schools british adolescents￨ttm intervention ttm control pupils received no special intervention￨positive change in stage and smoking status￨subgroup analysis by initial smoking status revealed no benefit for prevention or cessation￨no diff￨highunclear￨highunclear￨highunclear
not found￨consecutive sample n  191 of 1317 year olds admitted for psychiatric hospitalisation who smoked at least one cigarette per week for the past four weeks had access to a telephone and did not meet dsmiv criteria for current psychotic disorder adolescent smokers hospitalised for psychiatric and substance use disorders motivational interviewing mi adolescent smokers with psychiatric comorbidity adolescents with comorbid substance adolescents with psychiatric disorders a private university affiliated psychiatric hospital in providence rhode island usa￨mi versus brief advice ba transdermal nicotine patch motivational interviewing￨point prevalence abstinence quit attempts changes in smoking rate and longest quit attempt smoking cessation change smoking behaviour upon hospital discharge and self efficacy for smoking cessation￨mi was more effective than ba for adolescents with little or no intention to change their smoking but was actually less effective for adolescents with preexisting intention to cut down or quit smoking￨no diff￨highunclear￨highunclear￨highunclear
350￨college students three hundred fifty entering freshmen entering freshmen at an urban state university￨hra with feedback hra without feedback initial control and final control￨health risk appraisal hra quit smoking habit of cigarette smoking cigarette consumption￨health risk appraisal when accompanied by feedback counseling was an effective health promotion tool to help prevent nonsmokers from acquiring the habit and to modify cigarette smoking behavior among college freshmen￨sig increase￨highunclear￨highunclear￨highunclear
312￨adolescents n  312 recruited through media and various community venues from march 1 1999 through december 31 2002 who were aged 14 to 17 years smoked 6 or more cigarettes per day had an exhaled carbon monoxide level of 10 ppm or greater had at least 2 previous quit attempts and had no other current major psychiatric diagnosis metropolitan areas of tucson and phoenix arizona adolescent smoking cessation￨sustainedrelease bupropion hydrochloride sustainedrelease bupropion placebo sustainedrelease bupropion hydrochloride￨cotinineconfirmed 7day point prevalence abstinence rates point prevalence rates prevalence abstinence rates 30day prolonged abstinence carbon monoxide level abstinence rates safety and efficacy￨during treatment confirmed point prevalence rates were significantly higher for 300 mg than placebo at every week except week 4￨sig increase￨low￨low￨low
335￨335 smokers participated in the study making this the largest controlled teen smoking cessation field trial conducted to date eighteen schools a teen smoking cessation program￨clinic plus a schoolascommunity sac component and standard care control￨having quit smoking￨seventeen percent of the smokers enrolled in the clinics had reports of having quit smoking for at least the last 30 days at 3month followup 5 months after the program quit day compared to only 8 of the control condition smokers over than same time period￨no diff￨highunclear￨highunclear￨highunclear
75￨participants were smokers aged 14 to 19 years n  75 who presented for treatment in a universityaffiliated hospital emergency department ed teenagers who received the mti with those who received brief advice or care as usual￨motivational interviewing techniques emergency departmentbased motivational teenage smoking intervention theorybased motivational tobacco intervention mti￨￨among teenagers who were available at followup a medium effect size cohens h  38 was found for reduction and a large effect size cohens h  69 was found for percentage reduction although these results also were not statistically significant￨sig increase￨highunclear￨highunclear￨highunclear
not found￨adolescents in substance abuse treatment 54 adolescents in treatment for substance abuse ages 1318 22 female￨copyright 2005 apa cigarette smoking cessation intervention smoking cessation intervention cigarette smoking intervention￨cessation attempts and point abstinence￨a greater proportion of participants in the treatment condition n  26 reported cessation attempts and point abstinence than did control participants n  28 at all time points￨sig increase￨highunclear￨highunclear￨highunclear
3747￨of 3747 teens invited at  or 1 visits 2526 67 consented both smoking and nonsmoking teens 14 to 17 years of age who were being seen for routine visits teens being seen for routine medical care staff members approached teens in waiting rooms of 7 large pediatric and family practice departments within a grouppractice health maintenance organization teens seen in primary medical care￨tobacco reduction program brief counseling plus a computerbased tobacco intervention tobacco intervention or brief dietary advice 5minute motivational intervention to promote increased consumption of fruits and vegetables computerassisted tobacco intervention￨abstinence rates smoking cessation rate￨abstinence rates after 2 years were significantly higher for the tobacco intervention arm relative to the control group in the combined sample of baseline smokers and nonsmokers odds ratio￨sig increase￨low￨low￨low
120￨a total of 120 participants were randomized 72 white 70 female age 152 133 years smoking 188  856 cpd fagerstrom test of nicotine dependence score 704 adolescent smokers adolescent tobacco addiction participants started smoking at 112 thirteen to 17yearold adolescents who smoked  or 10 cigarettes per day cpd scored  or 5 on the fagerstrom test of nicotine dependence and were motivated to quit smoking innercity outpatient clinic on the east coast adolescents who want to quit smoking 198 years of age and had been smoking daily for 266￨placebo nicotine gum cognitivebehavioral group therapy nicotine patch therapy combined with cognitivebehavioral intervention placebo patch and gum nicotine patch or gum therapy with cognitivebehavioral therapy nicotine patch and gum nicotine patch￨co or thiocyanate concentrations numbers of cigarettes smoked mean saliva cotinine concentrations smoking reduction cpd and thiocyanate concentrations mean smoking rates mean compliance safety and efficacy prolonged abstinence assessed through selfreport and verified with exhaled carbon monoxide co levels coconfirmed prolonged abstinence rates abstinence rates tolerated and adverse events safety and efficacy￨mean compliance across groups was higher for the patch mean 784828 than for the gum mean 385507￨sig increase￨low￨low￨low
not found￨56 adolescents 66 male mean age 15 years was recruited through referrals from three state high schools high school students referred by school administrators because of tobacco use￨hyp programtargeted motivational interviewing shortterm tobaccofocused intervention onehour motivational interview mi session or to standard care adviceeducation mi intervention￨quantity and frequency of smoking relative to standard care refusal selfefficacy￨the mi intervention resulted in significant shortterm reductions in quantity and frequency of smoking relative to standard care however effects were not maintained at 3 and 6month followup￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨￨selfhelp intervention and an intensive multisession schoolbased cessation curriculum called not on tobacco not￨smoking cessation outcomes duration of smoking and number of cigarettes smoked daily p05￨further nicotine dependence was positively correlated with duration of smoking and number of cigarettes smoked daily p05￨sig decrease￨highunclear￨highunclear￨highunclear
402￨teen smokers copyright 2004 american psychological association teen smokers n  402 recruited from 11 shopping malls and 1 amusement park in the southeastern united states￨written selfhelp material plus video or written selfhelp material video and telephone counseling selfhelp materials and proactive telephone counseling selfhelp materials with or without proactive telephone counseling￨sustained abstinence reflecting 7day abstinence cessation rates￨sustained abstinence reflecting 7day abstinence at both time points in the selfhelp and counseling arms was 7 and 9 p  59￨no diff￨highunclear￨highunclear￨highunclear
136￨academic and school partners participants were 136 adolescent smokers recruited from high schools randomized to the adolescent smokers adolescent smoking cessation￨intervention or a measurementonly control condition internetbased virtual reality world combined with motivational interviewing conducted in realtime by a smoking cessation counselor￨number of times quit￨those who participated in the program were significantly more likely than controls to report at the immediate postintervention assessment that they had abstained from smoking during the past week por01 smoked fewer days in the past week por001 smoked fewer cigarettes in the past week por01 and considered themselves a former smoke por05￨sig increase￨highunclear￨highunclear￨highunclear
50￨adolescents via public high schools fifty randomly selected washington state high schools adolescent smoking cessation high school junior smokers￨motivational interviewing plus cognitive behavioral skills training telephone intervention proactive personalized telephone counseling intervention personalized telephone counseling intervention telephonebased smoking cessation intervention￨7day abstinence and duration since last cigarette 6months prolonged abstinence from smoking percentage who achieved 6month prolonged smoking abstinence￨there was also generally strong evidence of intervention impact for 3month 1month and 7day abstinence and duration since last cigarette p  09 015 01 and 03 respectively￨no diff￨highunclear￨highunclear￨highunclear
not found￨adolescent smokers ages 1118 years adolescent smoking cessation￨internetbased versus brief office intervention clinicbased brief office intervention boi n69 consisting of four individual counseling sessions or to stomp out smokes sos an internet homebased intervention￨30day pointprevalence smoking abstinence rates for boi and sos￨among participants who continued to smoke sos was associated with a significantly greater reduction in average number of days smoked than boi p0006￨sig increase￨highunclear￨highunclear￨highunclear
not found￨2year demonstration study 19992000 of the american lung associations teen smoking cessation program the not on tobacco not program 20 not and 20 bi florida high schools encompassing 627 students￨not￨not smoking cessation and reduction outcomes successful quit attempts carbon monoxidevalidated quit and reduction rates for not and bi schools￨not smoking cessation and reduction outcomes were significantly better than those of the brief intervention￨no diff￨highunclear￨highunclear￨highunclear
211￨adolescent smokers n  211 adolescent smokers￨nicotine patch plus placebo placebo bupropion combined with nicotine patch nicotine patch plus bupropion sr￨abstinence rates survival curves￨despite the lack of a treatment effect a large majority of adolescents in both treatment groups reduced their consumption to a few cigarettes per day or less and maintained this reduction over time￨no diff￨highunclear￨highunclear￨highunclear
85￨patients were proactively screened and recruited and were not seeking treatment for smoking patients aged 1419 years n85 adolescent patients treated in a hospital outpatient clinic or emergency department adolescent smokers in medical settings￨motivational interviewing mi or standardized brief advice ba to quit smoking brief motivational intervention motivational intervention￨selfreported smoking rate cotinine levels 7day abstinence rates￨at 3month followup only those in mi showed cotinine levels that were significantly reduced compared to baseline￨sig decrease￨highunclear￨highunclear￨highunclear
261￨teens two hundred and sixty one adolescent cigarette smokers 166 male 95 female averaging 158 years of age recruiting students who were caught smoking at school proved to be highly successful students in a behavioural cessation programme and those receiving self help materials only students caught smoking at school eighteen schools in the memphis tennessee area￨smoking cessation programme school based smoking cessation programme session behavioural treatment programme administered individually by a health educator￨attitudes toward smoking retention rates feasibility acceptability and effectiveness smoking rates cessation rates￨although treated participants improved more in tobacco related knowledge relative to controls p  0002 there were no group differences in changes in attitudes toward smoking￨sig increase￨highunclear￨highunclear￨highunclear
45￨total hip replacement 45 patients undergoing total hip arthroplasty￨intra and postoperative autotransfusion of blood salvaged with cellsaver technique group ii or predonated autologous erythrocyte concentrates together with salvaged blood heterologous erythrocyte concentrate perioperative autotransfusion and functional coagulation analysis￨platelet function and fibrin deposition blood losses￨sonoclot coagulation analyses better correlated to both blood loss and dextran dosage than aptt and platelet count in the routine coagulation analyses￨no diff￨highunclear￨highunclear￨highunclear
not found￨1063 vs 279 thirty patients undergoing elective primary isolated coronary bypass grafting￨autotransfusion management keywords cardiopulmonary bypass cardiotomy suction coronary surgery autotransfusion fibrin degradation cardiopulmonary bypass cpb￨postoperative chest tube drainage highest postoperative ddimer levels coagulationfibrinolytic profile ddimer levels ddimer generation intravascular fibrin degradation intravascular fibrin degradation￨postoperative chest tube drainage was higher in the patients from group a which also had the highest postoperative ddimer levels￨sig decrease￨highunclear￨highunclear￨highunclear
21￨21 otherwise healthy patients undergoing cardiac surgery￨coronary artery bypass grafting cabg autotransfusion without aspirin aspirin postoperative autotransfusion either alone or in conjunction with preoperative aspirin aspirin preoperatively or not￨need for donor blood transfusion￨it was also shown that autotransfusion without aspirin does reduce the need for donor blood transfusion without any increase in postoperative bleeding￨no diff￨highunclear￨highunclear￨highunclear
75￨after coronary artery bypass surgery patients undergoing coronary artery bypass grafting cabg 75 consecutive patients into two groups￨standard chest drainage autotransfusion homologous blood transfusion autotransfusion after the completion of the coronary artery bypass grafting cabg￨fibrin degradation products packed red cells prothrombin time￨the fibrin degradation products were elevated only in the serum of the autotransfusion patients p  0002￨sig increase￨highunclear￨highunclear￨highunclear
64￨500 02000 sixtyfour patients scheduled for total hip arthroplasty hip surgery￨autotransfusion with a cell separator autologous transfusion procedures preoperative autologous deposit group iipreoperative hemodilution group iiiintra and postoperative autotransfusion group ivcontrol￨global coagulation tests antithrombin iii and total serum protein postoperative autotransfusion of drainage blood blood loss and hb concentration homologous transfusion requirements predonation hemoglobin hb concentration homologous transfusion requirements￨global coagulation tests antithrombin iii and total serum protein were comparable in the four groups￨no diff￨highunclear￨highunclear￨highunclear
105￨one hundred five patients￨heparinbonded circuit autotransfusion with the circuit of group 3 coated with heparin autotransfusion autotransfusion postoperative autotransfusion with and without a heparinbonded circuit￨platelet aggregation von willebrand factor vwf multimetric analysis or clotting profiles median interquartile range blood loss transfused and circulating blood median transfusion requirements￨whilst autotransfusion does not appear to compromise haemostasis it does not reduce the requirement for homologous blood and heparinbonding of the circuit has no impact￨no diff￨highunclear￨highunclear￨highunclear
150￨new delhi tertiary care hospital and the patients were referred from the northern states of india one hundred fifty consecutive patients undergoing elective valve surgery using cardiopulmonary bypass were included the mean age was 277 years and mean weight was 452 kg patients suffering from rheumatic heart disease in india are usually small and also anemic small adults undergoing valve surgery cardiac valve surgery in this subset of patients patients undergoing coronary artery bypass grafting￨autologous fresh blood donated before bypass and both a cell saver and membrane oxygenator￨chest tube drainage blood conservation mean preoperative hematocrit mean body weight￨group 1 required 15 units of bank blood group 2 90 units p  0001 and group 3 102 units p  0001￨sig decrease￨highunclear￨highunclear￨highunclear
120￨120 patients having elective uncomplicated cabg was performed patients undergoing cabg￨autotransfusion of shed mediastinal blood autotransfusion of shed mediastinal blood after coronary artery bypass grafting cabg autotransfusion autotransfusion after coronary artery bypass grafting￨hemoglobin concentration oxygen transport capacity hemodynamic parameters oxygen delivery or oxygen extraction blood gas and hemoglobin measurements 23dpg levels allogeneic blood￨in the control group 23dpg levels decreased from 43 to 39 mumolml erythrocyte during the same period￨sig increase￨highunclear￨highunclear￨highunclear
not found￨twentyfive patients having aortic surgery had blood scavenged using the sorenson receptal device group a and were compared with twentyfive patients having homologous blood transfusion group h￨autologous blood transfusion￨mean haemoglobin concentration mean homologous blood replacement total intrahospital homologous blood replacement plasmafree haemoglobin and bacterial contamination mean intraoperative blood loss postoperative renal dysfunction coagulopathy or mortality￨total intrahospital homologous blood replacement was not significantly different￨no diff￨highunclear￨highunclear￨highunclear
42￨total endoprosthesis fortytwo patients undergoing total hip surgery and preoperative donor plasmapheresis￨intra and postoperative autologous fresh frozen plasma ffp autologous transfusion preoperative donor plasmapheresis abbott autotrans and postoperative autotransfusion intraoperative blood salvage dideco autotrans￨total amount of infusion intraoperative blood loss autologous transfusion and blood parameters blood coagulation tat and fpa levels blood parameters hemoglobin hematocrit thrombocytes clotting status prothrombin time plasma thromboplastin time thrombin time fibrinogen plasminogen and antithrombin iii and immunological methods such as fibrinopeptide a fpa thrombinantithrombin iii tat and protein c excellent quality of the autologous ffp use of homologous blood￨their administration caused a significant increase in tat and fpa levels in groups 2 and 3 compared to group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨transfusions autotransfusion with cell saver for offpump coronary artery bypass surgery￨complications leading to transfusion hemoglobin levels and costs blood loss hemoglobin levels complications and costs intraoperative net blood loss proportion of patients receiving allogeneic blood and average number of units per patient￨use of cell saver reduced intraoperative net blood loss and seemed to reduce transfusions by 1 unit per patient however this was probably attributable to more complications leading to transfusion in the control group￨sig decrease￨highunclear￨highunclear￨highunclear
40￨patients receiving aprotinin 2 million kiu ima patients treated with twenty patients group 1 received 40 matched patients undergoing internal mammary artery bypass ima surgery and treatment with lowdose aprotinin 2 million kiu￨autotransfusion at aprotinin at with a hard shell cardiotomy reservoir twenty patients group 2 control did not receive at aprotinin￨reduction and avoidance of donor blood requirements blood hemoglobin and total protein content￨the use of any blood product was avoided in 95 and 80 of the patients respectively not significant￨no diff￨highunclear￨highunclear￨highunclear
49￨fortynine consecutive patients received either the after primary unilateral total knee replacement surgery patients undergoing primary unilateral total knee arthroplasty primary unilateral knee arthroplasty￨allogeneic blood transfusion redivac high vacuum drainage system autologous blood transfusion autologous blood transfusion device celltrans blood salvage device￨allogeneic blood requirements total cost per patient preoperative and postoperative haemoglobin levels efficacy and financial cost￨there was an average saving of 11 unit of allogeneic blood per patient in group a p0001￨sig decrease￨highunclear￨highunclear￨highunclear
2￨patients who have a primary total hip arthroplasty without cement and who have donated 2 units of blood before operation primary total hip arthroplasty patients who had donated autologous blood before surgery one hundred fiftythree patients able to donate at least 2 units of autologous blood primary total hip arthroplasty￨blood salvage techniques￨hemoglobin and hematocrit changes intraoperative and postoperative cellsaver haemonetics braintree ma transfusion requirements or wound complications￨there was no statistically significant difference in transfusion requirements or wound complications among the four groups￨no diff￨highunclear￨highunclear￨highunclear
35￨routine cardiac surgical patient 35 consecutive patients into two groups￨autotransfusion of shed mediastinal blood homologous blood transfusion autotransfusion postoperative colloid fluid replacement excluding autotransfusion fluid standard chest drainage and fluid replacement￨total homologous blood product exposure fibrin split products transfusionrelated complications packed red blood cells￨fibrin split products were elevated only in the serum of the autotransfusion patients p  0002￨sig increase￨highunclear￨highunclear￨highunclear
not found￨total knee replacement surgery￨total knee replacement surgery tkr autologous blood transfusion their postoperative wound drainage as an autotransfusion n115 after processing or to have this wound drainage discarded￨incidence of infection requiring intervention allogeneic transfusion allogeneic blood hospital mortality total patient costs￨only 7 of patients in the autotransfusion group required an allogeneic transfusion compared with 28 in the control group p0001￨sig decrease￨highunclear￨highunclear￨highunclear
100￨patients undergoing a total knee replacement tkr one hundred consecutive tkr patients total knee replacement surgery￨cell salvage auto transfusion cell salvage auto transfusion allogeneic blood required transfusion autologous blood using cell salvage or an allogeneic blood transfusion￨autologous blood transfusion no supplementary blood transfusion￨there were no detrimental effects of autologous blood transfusion￨no diff￨highunclear￨highunclear￨highunclear
160￨primary total hip and knee arthroplasty patients with a preoperative hemoglobin hb level of between 130 and 146 g per dl were included 160 patients undergoing primary total hip or knee replacement total hip and knee arthroplasty￨retransfusion system bellovac astratech ab or a regular drain abdovac astratech ab allogeneic blood transfusions postoperative retransfusion of filtered shed blood retransfusion of filtered shed blood￨febrile reactions retransfusions and postoperative febrile reactions allogeneic blood transfusions total knee and total hip arthroplasty allogeneic blood transfusions total volume of blood collected in the bag used for retransfusion perioperative hb levels febrile reaction and other complications￨there was no relationship between retransfusions and postoperative febrile reactions￨no diff￨highunclear￨highunclear￨highunclear
21￨four groups of patients were prospectively studied as follows abdominal aortic aneurysm patients undergoing every patient undergoing routine aortofemoral bypass for occlusive disease￨aaa repair with tube graft n  21 aaa repair with bifemoral or biiliac bypass infrarenal aortic bypass rapid autotransfusion devices aortobifemoral bypass afb or biiliac bypass for occlusive disease either with cell saver autotransfusion device￨preoperative hemoglobin values estimated blood loss cell saver return volumes intraoperative and postoperative homologous blood transfused postoperative hemoglobin values on the day of surgery and on postoperative days 1 and 4 complications and length of hospital stay hemoglobin level blood loss and cell saver return volumes￨the estimated blood loss and cell saver return volumes were less for those patients undergoing afb for occlusive disease compared with those undergoing afb for aneurysmal disease￨sig decrease￨highunclear￨highunclear￨highunclear
40￨40 patients undergoing primary unilateral total knee arthroplasty total knee arthroplasty￨postoperative collection and reinfusion of autologous blood postoperative autologous blood salvage and reinfusion￨mean volume of homologous blood transfused mean volume of autologous blood reinfused safety and efficacy homologous blood transfusion￨homologous blood transfusion was required in only 35 of patients in the study group compared with 95 of patients in the control group p less than 0001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients undergoing elective knee arthroplasty adult patients undergoing unilateral elective arthroplastic knee surgery￨suction drainage attached to an autologous blood drainage and transfusion device or standard suction drainage postoperative autologous blood drainage and transfusion device autologous blood drainage and transfusion device standard suction drainage￨blood loss and postoperative hemoglobin values mean number of allogeneic red cell concentrates required and the number of patients in each group who required no transfusion mean allogeneic red cell utilization percentage of patients not requiring allogeneic red cells￨the postoperative drainage and transfusion device was efficacious in reducing the amount of allogeneic red cells required by patients undergoing knee arthroplasty and its use resulted in a 42 percent reduction in the number of patients requiring allogeneic transfusion￨no diff￨highunclear￨highunclear￨highunclear
not found￨total knee replacement unilateral total knee replacement 86 patients in the control group receiving standard care with a vacuum drain and 92 who received an￨autologous retransfusion autologous drain autologous drains autologous retransfusion drains￨adverse reactions incidence of postoperative complications such as wound infection deepvein thrombosis and chest infection allogenic blood requirement need for allogenic blood￨the incidence of postoperative complications such as wound infection deepvein thrombosis and chest infection was also comparable between the groups￨no diff￨highunclear￨highunclear￨highunclear
213￨routine cardiac surgery andor cardiac valve surgery patients undergoing routine firsttime cardiac surgery in an institution with a rigorous blood conservation program twohundredthirteen patients presenting for firsttime coronary artery bypass grafting￨cell salvage tranexamic acid routine cell salvage￨excessive bleeding units of allogeneic red blood cells mediastinal reexploration for bleeding allogeneic blood blood aspirate￨there was no difference between the two groups in the proportion of patients exposed to allogeneic blood 32 in both groups relative risk 10 p  089￨no diff￨highunclear￨highunclear￨highunclear
24￨24 patients using the solcotrans orthopaedic drainage reinfusion system smith  nephew richards inc memphis tenn for postoperative blood salvage in total joint arthroplasty elective total joint arthroplasty￨postoperative wound drainage reinfusion￨postoperative autologous blood salvage postoperative transfusions transfusion reactions infectious complications or coagulopathies blood transfusions￨the amount of postoperative autologous blood salvage averaged 946 ml only 25 of the study group required postoperative transfusions compared to 83 of the control group p  016￨no diff￨highunclear￨highunclear￨highunclear
50￨opcab surgery 196 vs 316 patients undergoing offpump coronary artery bypass grafting opcab fifty patients enrolled in the study and 49 fulfilled the study criteria￨conventional coronary artery bypass grafting cell saver￨homologous blood transfusions number of patients requiring any blood transfusion mean mediastinal drainage number of hbts adverse effects of blood transfusion homologous blood incidence of reexploration safety and efficacy blood transfusions￨the incidence of reexploration was zero in both the groups￨no diff￨highunclear￨highunclear￨highunclear
155￨155 patients undergoing total knee arthroplasty for primary knee osteoarthritis patients undergoing total knee arthroplasty￨standard vacuum drains methylprednisolone methylprednisolone￨allogeneic blood transfusion levels of haemoglobin postoperative febrile reaction￨patients who received autologous blood had higher levels of haemoglobin at 8 hours p  005 and 24 hours postoperatively p  001 and needed less allogeneic blood transfusion p  001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨total knee arthroplasty 60 patients having unilateral total knee replacements￨autologous blood reinfusion system standard suction drains postoperative autologous blood reinfusion system￨postoperative haematocrit and haemoglobin values postoperative blood requirements total homologous blood requirements values of haemoglobin haematocrit and platelets cost of the blood management￨there was no significant difference in the postoperative haematocrit and haemoglobin values between the two groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨90 primary total knee joint arthroplasties 90 patients￨no drain b an autotransfusion system c a standard disposable closed suction drainage system postoperative drainage after total knee replacement tkr￨hemoglobin and hematocrit values drainage volume and transfusions homologous and autologous range of knee motion knee swelling and hospital stay￨no significant differences were seen between the groups in any of the parameters measured￨no diff￨highunclear￨highunclear￨highunclear
70￨70 patients having unilateral total knee replacement in which transfusion was either with homologous bank blood or by reinfusion of unwashed blood salvaged after operation￨autologous transfusion￨need for bank blood mean length of stay in hospital number of infective episodes complications or adverse effects￨no complications or adverse effects were observed from reinfusion￨no diff￨highunclear￨highunclear￨highunclear
60￨after total knee arthroplasty between june 2002 and may 2004 60 patients undergoing total knee arthroplasty￨blood salvage and reinfusion system with standard allogeneic blood transfusion allogeneic blood transfusions reinfusion group drained blood reinfusion￨allogeneic blood haemoglobin levels and drain output postoperative haemoglobin level demographic data drain output total blood loss and mean postoperative haemoglobin levels￨significantly more allogeneic blood was required by the control group than by the reinfusion group p  0022￨sig decrease￨highunclear￨highunclear￨highunclear
263￨cardiac surgery elective coronary artery bypass grafting 263 adults aged 1880 years undergoing elective coronary artery bypass surgery entered the study of whom 252 completed the trial regional cardiac centre in a teaching hospital in southampton patients undergoing cardiac surgery 84 patients in each group￨intraoperative cell salvage routine perioperative care intraoperative cell salvage intraoperative cell salvage with acute perioperative normovolaemic haemodilution or no mechanical blood conservation￨mean number of units of allogeneic blood transfused blood transfusion￨32 of the patients in the intraoperative cell salvage group were given any blood product compared with 47 in the control group odds ratio 047 025 to 089 p0019￨sig decrease￨highunclear￨highunclear￨highunclear
100￨one hundred consecutive patients who had elective coronary artery or valvular operations were studied 522 and 822￨conventional mediastinal drainage group 1 or reinfusion of shed mediastinal blood group 2 using hardshell cardiotomy reservoir￨blood losses homologous blood consumption homologous blood requirements average mediastinal blood losses￨the two groups were comparable with regard to age sex weight preoperative and postoperative hemoglobin levels and surgical procedure￨no diff￨highunclear￨highunclear￨highunclear
135￨135 adults undergoing cardiac surgery cardiac surgery￨autotransfusion group￨average volume of autotransfusion blood clinical infections hematologic renal or hepatic parameters neurologic function or use of antibiotics postoperative blood average requirement of bank blood￨no clinically significant intergroup differences were found in hematologic renal or hepatic parameters neurologic function or use of antibiotics￨no diff￨highunclear￨highunclear￨highunclear
128￨one hundred twentyeight patients were studied after hip replacement knee replacement or spine fusion autotransfusion after orthopaedic surgery￨autologous shed blood for autotransfusion autologous shed blood￨homologous transfusion red blood cells￨evaluation of clotting studies showed no significant differences between patients who received shed blood and patients who received liquidpreserved red blood cells￨no diff￨highunclear￨highunclear￨highunclear
15￨pulmonary perfusion after total knee arthroplasty fifteen unilateral and one bilateral tkas were performed with￨blood retransfusion autotransfusion postoperative shed blood retransfusion autotransfusion￨postoperative segmental perfusion defect lung perfusion scintigraphy chest xrays abg and ddimer values lung xrays arterial blood gases abg ddimer values and lung perfusion scintigraphies lung perfusion postoperatively￨although both groups had a decrease in lung perfusion postoperatively there were no significant differences among the groups regarding the lung perfusion scintigraphy chest xrays abg and ddimer values￨no diff￨highunclear￨highunclear￨highunclear
66￨sixtysix patients undergoing aortocoronary bypass surgery cardiac surgery￨intraoperative blood recovery system ibrs and a mediastinal drainage blood recovery system mbrs only homologous blood hb￨blood salvage hemoglobin level no infection renal dysfunction or coagulation disorders body surface preoperative and postoperative hematocrits number of grafts bypass duration and postoperative mediastinal blood loss￨the amount of hb that was transfused during the operation was significantly lower in groups ii and iii than in group i p less than 00001￨sig decrease￨highunclear￨highunclear￨highunclear
112￨one hundred and twelve patients undergoing cabg valve or cabg  valve procedures cardiac surgery￨autotransfusion of washed shed mediastinal fluid autotransfusion autotransfusion washed postoperative drainage fluid￨preoperative and operative variables morbidity autologous blood transfusion mean hb concentration homologous transfusion total blood￨the mean hb concentration was significantly higher in group a on day 1￨sig decrease￨highunclear￨highunclear￨highunclear
50￨16 patients in the control group patients undergoing spinal surgery fifty patients were studied and were randomly allocated to control n  25 and solcotrans n  25 groups spinal surgery￨postoperative autotransfusion solcotrans orthopedic plus system postoperative autotransfusion￨fibrinogen concentrations circulating ddimers haematological effects plasma free haemoglobin concentrations prothrombin time pt and activated partial thromboplastin time aptt platelet count volume of blood collected potassium concentrations fibrinogen level￨prothrombin time pt and activated partial thromboplastin time aptt did not increase and potassium concentrations were not significantly affectedabstract truncated at 250 words￨no diff￨highunclear￨highunclear￨highunclear
38￨nineteen patients had the collected rbcs washed and autotransfused autotransfusion group while the remaining patients had their washed cells discarded control group 38 patients￨coronary artery bypass grafting intraoperative autotransfusion￨postoperative hemoglobin and hematocrit values cryoprecipitate and fresh frozen plasma utilization mean volume of banked packed rbcs transfused per patient exposure to banked blood platelet utilization￨cryoprecipitate and fresh frozen plasma utilization also was less in the autotransfusion group than in the control group but this did not reach statistical significance￨sig decrease￨highunclear￨highunclear￨highunclear
82￨82 patients undergoing myocardial revascularization during 1994 at cardiovascular surgery center of parma randomized to receive ats or not noats the system￨ats￨mean 24hours postoperative blood loss mean volume autotransfused bleeding mean immediate and 24hour postoperative hemoglobin values postoperative homologous transfusions￨no differences were noted between two groups in terms of clinical parameters likewise the operative characteristics were similar for the two groups￨no diff￨highunclear￨highunclear￨highunclear
20￨two matched groups of twenty patients undergoing elective coronary artery bypass surgery cardiac surgery￨postoperative autologous blood transfusion at postoperative autologous transfusion calcium 2385￨clinical outcome overall blood loss use of platelets fresh frozen plasma and colloids haematological indices renal and hepatic functions or clotting mechanism haemoglobin safety and efficacy fibrinogen level mean volume of shed mediastinal blood reinfused￨8744 ml in the at patients a reduction of 387 p less than 005￨sig decrease￨highunclear￨highunclear￨highunclear
30￨blood drained after total knee joint arthroplasty 30 patients scheduled for total knee replacement surgery free from tumoral or coagulation disease and allocated randomly in three groups of 10 each the￨orthevac group ogr the solcotrans plus group sgr and the control group cgr orthevac and solcotrans plus orthevac and solcotrans plus devices￨transfusion of homologous blood hematocrit volume of collected blood salvaged blood volume of salvaged and autotransfused blood￨at d  1 the hematocrit was comparable in all groups ogr  28 sgr  282 and cgr  285abstract truncated at 250 words￨no diff￨highunclear￨highunclear￨highunclear
32￨thirtytwo patients undergoing cardiopulmonary bypass for open heart operations￨transfusion therapy nonwashed shed mediastinal blood group 1 n  16 or liquid preserved packed red blood cells￨protein c level patient bleeding times patient blood samples and bleeding times safety and therapeutic effectiveness homologous transfusion total postoperative blood loss￨patient bleeding times were not significantly different between the groups at any of the time points and the total postoperative blood loss was not different between the groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨elective orthopaedic surgery patients eligible consecutive primary and revision total hip and knee replacement patients sixtynine of 70 randomized patients were evaluated￨postoperative autologous shed red blood cell reinfusion￨febrile transfusion reaction safety efficacy and userfriendliness allogeneic blood use efficacy safety and userfriendliness adverse reactions efficacy and safety￨eligible consecutive primary and revision total hip and knee replacement patients were randomized for one of the two systems or for a control group in which shed blood was not reinfused￨no diff￨highunclear￨highunclear￨highunclear
198￨patients undergoing heart operations patients undergoing various cardiac operations reinfusion of mediastinal blood after heart surgery patients undergoing 198 patients who underwent￨coronary artery bypass grafting or a valvular operation autotransfusion of shed mediastinal blood after an operation and a control group autotransfusion￨coagulation parameters analyzed and complication rates number of patients requiring homologous blood transfusion number of reexplorations for excessive bleeding￨the number of patients requiring homologous blood transfusion was significantly different between the 2 groups 5498 55 in autotransfused patients vs 73100 73 in the control group p 01￨no diff￨highunclear￨highunclear￨highunclear
100￨100 patients undergoing myocardial revascularization male patients without impairment of left ventricular function for the study patients with internal mammary artery grafts and a duration of extracorporeal circulation less than 45 minutes or more than 90 minutes were excluded￨retransfusion of oxygenator blood after termination of extracorporeal circulation processing of oxygenator content by means of a cell separator group iii predonation of autologous blood and isovolumetric substitution of hydroxyethyl starch cell separator plus postoperative retransfusion of shed mediastinal blood￨homologous blood requirements autologous blood transfusion blood utilization￨the use of blood conservation techniques resulted in reductions of homologous blood requirements of 34 60 and 80 respectively in groups ii to iv as compared with the requirement in group i￨sig decrease￨highunclear￨highunclear￨highunclear
50￨patients undergoing elective infrarenal abdominal aortic surgery fifty patients undergoing aaa surgery during abdominal aortic aneurysm surgery￨allogeneic versus autologous blood autologous and homologous blood transfusions cell salvage autotransfusion device autologous blood transfusion homologous blood￨perioperative mortality length of stay haemoglobin at the time of hospital discharge risk of infection￨the length of stay was reduced in those patients who received autologous blood 9 days vs 12 days p  005 mannwhitney u test￨sig decrease￨highunclear￨highunclear￨highunclear
50￨coronary surgery fifty patients￨coronary artery bypass grafting cabg autotransfusion of mediastinal shed blood autotransfusion autotransfusion postoperative autotransfusion of mediastinal shed blood or no autotransfusion￨serum level of ckmb levels of the biochemical markers of myocardial injury serum levels of ckmb cardiac troponin t ctnt and hfabp serum levels of ctnt or hfabp higher level of ctnt￨during the first 24 h after surgery the autotransfusion group had a significantly higher serum level of ckmb￨sig decrease￨highunclear￨highunclear￨highunclear
90￨ninety patients who underwent heart surgery with cardiopulmonary bypass cpb cardiac surgery￨centrifuged autologous shed mediastinal blood collected from the cardiotomy reservoir autologous shed mediastinal blood￨allogeneic blood transfusion drained blood loss length of postoperative inhospital stay leucocyte count hb hct values creactive protein and procalcitonin concentration serum procalcitonin pct concentration infective complications postoperative blood loss allogeneic blood transfusion requirements hb hct level and leucocyte count bleeding tendency and systemic inflammatory response creactive protein concentration haemoglobin hb haematocrit hct creactive protein values and leucocyte count serum pct concentration￨at 20 hours after surgery an increase of serum pct concentration 052 ngml was more frequent in group 2 583 vs 333 p  003￨sig increase￨highunclear￨highunclear￨highunclear
104￨total knee replacement 104 consecutive patients undergoing primary cemented total knee arthroplasty into two groups of 52 patients each with one group to receive a￨autotransfusion drains autologous transfusion system bellovac standard suction drain redivac and the other an autologous transfusion drain bellovac￨no sepsis transfusion reactions or coagulopathies autologous blood transfused units of homologous blood transfused￨the use of the autologous transfusion system bellovac proved to be safe but failed to reduce the need for postoperative homologous blood transfusion following uncomplicated total knee arthroplasty￨no diff￨highunclear￨highunclear￨highunclear
60￨sixty adult patients undergoing elective valve surgery patients undergoing cardiac valve surgery patients undergoing valve surgery￨cell saver and lowdose aprotinin control group and underwent routine management which included collection of autologous blood during the precardiopulmonary bypass period aprotinin aprotinin￨hemoglobin concentration blood loss and homologous blood usage chest tube drainage average preoperative hemoglobin concentration bank blood￨the chest tube drainage was significantly less in group 1 compared with groups 2 and 3 with total drainage median interquartile range amounting to 250 ml￨sig decrease￨highunclear￨highunclear￨highunclear
60￨autotransfusion of shed mediastinal blood after open heart surgery sixty patients undergoing coronary artery bypass grafting cabg￨nonwashed shed mediastinal blood autotransfusion banked blood￨drainage and transfusion volume banked blood requirement hb hct plt or length of cardiopulmonary bypass cpb hb rbc hct and plt mean blood loss￨in the two groups no significant difference in the mean blood loss was observed during 24 hours after the operation 660￨no diff￨highunclear￨highunclear￨highunclear
29￨twentynine patients patients undergoing coronary surgery with or without retransfusion of cardiotomy suction blood and mediastinal shed blood￨coronary surgery without cardiotomy suction and autotransfusion cardiotomy suction and autotransfusion of mediastinal shed blood coronary surgery without retransfusion of cardiotomy suction blood and mediastinal shed blood￨creactive protein erythrocyte sedimentation rate troponint and hemoglobin levels postoperative bleeding and hemoglobin levels creactive protein erythrocyte sedimentation rate and troponint postoperative bleeding inflammatory activation myocardial injury bleeding and hemoglobin levels peak delta values plasma concentrations of tumor necrosis factoralpha interleukin6 and c3a postoperative systemic inflammatory response plasma concentrations of the cytokines tumor necrosis factoralpha and interleukin6 and complement factor c3a￨creactive protein erythrocyte sedimentation rate and troponint increased after surgery in both groups without intergroup differences￨no diff￨highunclear￨highunclear￨highunclear
40￨total hip arthroplasty 40 patients primary hip arthroplasty￨homologous blood intraoperative autotransfusion autologous blood using the cell saver whereas the second group served as a control and received homologous bank blood￨intravascular hemolysis operative and postoperative blood losseshence the total blood loss hematologic and coagulation parameters high hemoglobin white blood cell and plasma hemoglobin content and mcv￨postoperatively in both groups at iii plasminogen and protein c decreased￨no diff￨highunclear￨highunclear￨highunclear
109￨patients undergoing total hip or knee arthroplasty decreased the need for transfusion with banked blood 109 patients patients undergoing bilateral total knee arthroplasty total hip and knee arthroplasty￨postoperative blood salvage￨postoperative blood salvage banked blood utilisation adverse effects￨in patients undergoing bilateral total knee arthroplasty there was a 54 reduction in banked blood utilisation￨sig decrease￨highunclear￨highunclear￨highunclear
100￨one hundred patients undergoing abdominal aortic aneurysm aaa repair n  50 or aortofemoral bypass afb for occlusive disease n  50 patients undergoing aortic surgery during the 16month study period patients undergoing elective infrarenal aortic surgery was studied patients undergoing elective infrarenal aortic surgery￨iat routine intraoperative autotransfusion iat intraoperative autotransfusion￨allogeneic blood transfusion postoperative hemoglobinhematocrit levels and complications estimated blood loss ebl allogeneic blood transfusion units administered intraoperatively postoperatively and total proportion of patients not receiving allogeneic blood￨there were no significant differences between patients randomized to iat and control patients in estimated blood loss ebl allogeneic blood transfusion units administered intraoperatively postoperatively and total proportion of patients not receiving allogeneic blood 34 of patients randomized to iat and 28 of control patients postoperative hemoglobinhematocrit levels and complications￨no diff￨highunclear￨highunclear￨highunclear
not found￨primary total hip or knee replacement surgery patients undergoing primary joint replacement surgery joint replacement surgery￨autologous blood transfusion predeposited autologous blood transfusion pabt with and without intrapostoperative blood salvage to reduce or eliminate the need for homologous blood transfusion hbt￨￨a cost comparison analysis showed that blood salvage was more expensive than pabt and therefore it should be limited to patients who had predeposited fewer than three units of autologous blood￨sig increase￨highunclear￨highunclear￨highunclear
40￨2004 british journal of surgery society ltd surgery for abdominal aortic aneurysm forty patients were randomized to iat and 41 underwent surgery with hbt only￨intraoperative autotransfusion copyright c perioperative homologous blood transfusion hbt hbt intraoperative autotransfusion iat iat￨median blood requirement postoperative sirs and infective complications transfusion requirements and incidence of systemic inflammatory response syndrome sirs and infection hbt sirs risk of sirs chest infection haemoglobin levels￨use of autotransfusion effectively reduced the need for hbt and was associated with a reduced incidence of postoperative sirs and infective complications￨sig decrease￨highunclear￨highunclear￨highunclear
415￨patients who had a total knee replacement 200 total joint replacements of which 138 were total knee replacements and sixtytwo total hip replacements 215 total joint replacements of which 137 were total knee replacements and seventyeight total hip replacements total hip or total knee replacement￨closed wound drainage closed wounddrainage system or no postoperative drainage￨total knee replacement mean amount of blood transfused transfused blood and the preoperative and postoperative hemoglobin levels￨no statistical difference was found in the number of patients who had excessive postoperative drainage from a drained or nondrained wound￨no diff￨highunclear￨highunclear￨highunclear
143￨patients with ihd for operations of coronary bypass under conditions of ec 143 patients coronary shunting for ihd under conditions of extracorporeal circulationec ischemic heart disease￨autoblood￨￨the preoperative reservation of autoblood in patients with ihd for operations of coronary bypass under conditions of ec and using the cell saver gives higher values of hemoglobin and erythrocytes by the moment of discharge of the patients from the hospital but non the less does not reduce the frequency of using homologous blood￨sig decrease￨highunclear￨highunclear￨highunclear
113￨group 54 patients or a control group 59 patients cardiac operations 113 patients￨autotransfusion autotransfusion￨safety and effectiveness intraoperative and postoperative hemodilution lack of septic hematological pulmonary renal or hepatic complications￨the clinical safety of this technique was confirmed by the lack of septic hematological pulmonary renal or hepatic complications￨no diff￨highunclear￨highunclear￨highunclear
61￨sixtyone patients undergoing offpump coronary artery bypass grafting surgery￨intraoperative cell salvage and autotransfusion of washed salvaged red blood cells pump coronary artery bypass grafting surgery autotransfused washed blood from intraoperative cell salvage or control n  31 receiving homologous blood only as bloodreplacement therapy autotransfusion intraoperative cell salvage and autotransfusion after offpump coronary artery bypass surgery￨clotting pathway function prothrombin time activated partial thromboplastin time and fibrinogen levels increased postoperative bleeding fluid requirements or adverse clinical events 24hour postoperative hemoglobin concentration transfusion requirements no adverse clinical or coagulopathic effects total operation hospitalization and management costs safety efficacy and cost postoperative hemoglobin concentrations cost frequency of homologous blood product use￨conclusions intraoperative cell salvage and autotransfusion was associated with higher postoperative hemoglobin concentrations a modest reduction in transfusion requirements no adverse clinical or coagulopathic effects and no significant increase in cost compared with controls￨sig increase￨highunclear￨highunclear￨highunclear
113￨￨autotransfusion autotransfused washed blood from intraoperative cell salvage and postoperative mediastinal fluid cell salvage after coronary artery bypass surgery or control n  102 receiving stored homologous blood only after coronary artery bypass surgery autotransfusion perioperative cell salvage and autotransfusion after coronary artery bypass grafting￨mean volume of blood autotransfused homologous blood transfusion demographics comorbidity risk stratification or operative details thromboelastograph values or laboratory measures of clotting pathway function prothrombin time activated partial thromboplastin time fibrinogen and fibrinogen ddimer levels safety and efficacy postoperative blood loss fluid requirements blood product requirements or in the incidence of adverse clinical events￨autotransfusion did not produce any significant derangement of thromboelastograph values or laboratory measures of clotting pathway function prothrombin time activated partial thromboplastin time fibrinogen and fibrinogen ddimer levels when compared with the effect of homologous blood transfusion p  ns repeated measures analysis of variance manova￨no diff￨highunclear￨highunclear￨highunclear
158￨58 patients 76 in the retransfusion group received two groups of patients undergoing primary total hip replacement primary total hip replacement 158 patients was studied￨autologous retransfusion autologous blood autologous blood retransfusion￨postoperative haemoglobin levels and homologous blood requirements mean postoperative haemoglobin levels small overall cost saving￨there was no significant difference in the mean postoperative haemoglobin levels in the two groups￨no diff￨highunclear￨highunclear￨highunclear
80￨eighty patients patients undergoing cabg on patients undergoing cardiac surgery￨cpb with cell saver blood transfusion csbt b oncpb without csbt c offpump with csbt and d offpump without csbt on autologous cell saver blood transfusion cardiopulmonary bypass cell saver autologous blood transfusion autologous blood transfusion in both on and offpump cabg surgery￨coagulation parameters pre and postoperatively prothrombin time and partial thromboplastin time volume of intraoperative autologous blood transfusion postoperative mediastinal blood loss and homologous blood transfusion requirements volume of homologous blood transfusion postoperative blood loss haemoglobin concentration intraoperative blood loss and homologous blood transfusion homologous blood intraoperative mediastinal blood loss homologous transfusion salvaged mediastinal blood available for autologous transfusion postoperative morbidity and blood loss postoperative morbidity blood loss and homologous blood transfusion requirements￨offpump cabg is potentially associated with reduced intraoperative blood loss and homologous blood transfusion in comparison to onpump cabg￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨after total hip arthroplasty patients who were scheduled to have a primary or revision procedure 232 patients managed with a total hip replacement￨postoperative collection and reinfusion of unwashed filtered salvaged blood postoperative blood salvage with use of the autovac postoperative orthopaedic autotransfusion canister and the second with closed suction drainage with use of the hemovac system￨blood salvage intraoperative blood salvage complications or episodes of hypotension confusion cardiac or pulmonary compromise febrile reaction or coagulopathy￨no complications or episodes of hypotension confusion cardiac or pulmonary compromise febrile reaction or coagulopathy were observed during or after the reinfusion of the unwashed filtered salvaged blood￨no diff￨highunclear￨highunclear￨highunclear
111￨primary total hip and total knee arthroplasties patients undergoing elective primary total hip arthroplasty tha and total knee arthroplasty tka 57 patients 35 tkas and 22 thas who received a one hundred eleven patients were enrolled between december 1990 and august 1991￨reinfusion of postoperative shed blood drainage constavac collection unit cbc constavac stryker surgical kalamazoo mi reinfusion system postoperative reinfusion systems￨volume of reinfused blood hemoglobin levels and drainage volumes discharge hemoglobin level hemoglobin levels postoperative hemoglobin levels postoperative hemoglobins postoperative drainage volumes￨additionally there was no statistically significant difference between hemoglobin levels and drainage volumes in both the tha and tka study groups compared to their respective control groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨surgical drainage after total hip arthroplasty patients undergoing total hip replacement patients underwent total hip replacement total hip replacement￨total hip replacement without blood salvage system postoperative autotransfusion￨postoperatively blood salvage values of red blood cells number of red cells hemoglobin hematocrit platelets white blood cells values of potassium sodium free hemoglobin and acid base status￨these values in preoperatively collected autologous blood and allogeneic blood were out of normal range p0001￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨autotransfusion of shed mediastinal blood after cardiac surgery patients having cardiac surgery autologous blood collected from mediastinal tubes was autotransfused preferentially in 63 patients ats whereas 51 patients received￨bank blood for transfusion control￨total postoperative bleeding requirements for transfusion of stored bank blood mean postoperative blood replacement substantial financial savings bank blood requirements￨comparison of the two groups showed no significant difference in regard to age sex operations performed or total postoperative bleeding ats 813￨no diff￨highunclear￨highunclear￨highunclear
239￨after total joint arthroplasty 239 consecutive patients undergoing total knee or total hip arthroplasty￨control group using a standard drainage system or to the study group using the solcotrans blood salvage canister postoperative blood salvage postoperative blood salvage system￨hemoglobin levels median amount of homologous blood postoperative homologous blood transfusions￨the median amount of homologous blood required after operation by the study group was reduced by 74 from the amount required by the control group mean 67 ml vs 256 ml respectively p less than 0001￨sig decrease￨highunclear￨highunclear￨highunclear
4934￨southern nepal 413 communities in sarlahi nepal 4934 infants￨umbilical cord cleansing with antiseptics chlorhexidine￨signs of infection pus redness or swelling neonatal mortality severe omphalitis in chlorhexidine clusters infection or mortality risk frequency of omphalitis infant vital status incidence of neonatal omphalitis and neonatal mortality mortality incidence of omphalitis￨neonatal mortality was 24 lower in the chlorhexidine group relative risk 076￨sig decrease￨low￨low￨low
337￨669 neonates were enrolled in the trial neonates with dry umbilical cord care all neonates of two neonatal care units were invited to take part in the study umbilical cord care of the newborn￨cx powder cx treatment cx dc or uc with cx powder cx chlorhexidine powder versus dry care dc chlorhexidine powder chlorhexidine cx powder versus dry cord care dc￨occurrence of umbilical granuloma cord separation time cord separation time adverse event higher rate of cordrelated adverse events parents treatment satisfaction efficacy and safety omphalitis granuloma of the umbilical ground adverse events and parents treatment satisfaction￨neonates randomized to cx were less likely to have an adverse event 140 in 109 subjects vs 205 in 149 subjects in the dc neonates p  0001￨no diff￨highunclear￨highunclear￨low
311￨normal newborns 311 normal newborn infants￨70 alcohol a mercurochrome m a solution of alcohol and mercurochrome am and 1 chlorhexidine c chlorhexidine￨umbilical colonization￨the use of chlorhexidine resulted in a marked increase in pure cultures positive for gram negative bacteria proteus spp￨sig increase￨highunclear￨highunclear￨highunclear
150￨one hundred and fifty neonates￨umbilical cleansing with 95 alcohol cleaning with 95 alcohol and natural drying alcoholcleansing￨omphalitis or skin infection cord separation time separation time umbilical cord separation time gender gestational age birthweight or length gravidity meconium staining maternal age or presence of discharge separation time￨cord separation time was significantly reduced for the naturaldrying group compared with the alcoholcleansing group p0014￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨newborn infants were tested nursery￨skin and umbilical disinfection daily whole body soap wash control group daily whole body soap wash and umbilical cleansing with i benzine solution or ii 005 chlorhexidine and daily whole body wash and umbilical cleansing with a 4 chlorhexidine detergent solution hibiscrub￨colonization rates bacterial colonization and neonatal infections high colonization rate infections pemphigus paronychia conjunctivitis umbilical infection rate of infections￨in the control group a high colonization rate was found for s aureus 91 e coli 39 and group b streptococci gbs 20￨no diff￨highunclear￨highunclear￨highunclear
100￨fortyeight 100 neonates born at the national tokyo medical centre from march to may 2000 and nursed at a maternity ward were enrolled￨ethanol with or without chlorhexidine 80 ethanol etoh with or without chlorhexidine chd umbilical cord disinfection was performed using 80 etoh containing 05 chd chd group and 52 to disinfection with 80 etoh alone etoh group￨sex gestation period birthweight apgar score or delivery method minimum killing concentration mkc of chd and etoh￨there was no statistically significant difference between the two groups with respect to sex gestation period birthweight apgar score or delivery method￨no diff￨highunclear￨highunclear￨highunclear
9741￨dadu a rural area of sindh province pakistan 9741 newborn babies a rural district of pakistan liveborn infants delivered by participating tbas who received birth kits were eligible for enrolment in the study 187 clusters￨chx chx cleansing birth kits containing 4 chx solution for application to the cord at birth by tbas and once daily by family members for up to 14 days along with soap and educational messages promoting handwashing umbilicalcord cleansing with 4 chlorhexidine chx solution with or without handwashing with antiseptic soap chlorhexidine￨neonatal mortality risk of omphalitis with chx application omphalitis and neonatal mortality risk of omphalitis and neonatal mortality incidence of neonatal omphalitis and neonatal mortality￨application of 4 chx to the umbilical cord was effective in reducing the risk of omphalitis and neonatal mortality in rural pakistan￨sig decrease￨low￨low￨low
180￨180 neonates￨￨umbilical cord separation time umbilical cord separation time ucst complete information infants gender mode of delivery gravidity gestational age birth weight or hospital stay￨the effectiveness of single and multiple applications of triple dye for umbilical cord care in the umbilical cord separation time ucst was evaluated in 180 neonates￨no diff￨highunclear￨highunclear￨highunclear
634￨umbilical cord care 634 infants were enrolled with 599 infants 94 completing the study infants admitted to the wellbaby nursery￨alcohol daily alcohol application alone￨shorter cord separation time infection and monetary savings￨infants in the alcohol alone group had a shorter cord separation time by 3 days 10 versus 13 days p  00001￨sig decrease￨highunclear￨highunclear￨highunclear
427￨newborn infants delivered in the department of obstetrics and gynecology faculty of medicine siriraj hospital newborn infants four hundred and twentyseven infants were enrolled￨￨mean duration for cord detachment relative incidence rate omphalitis￨omphalitis was observed in 9213 42 infants in group a and 23214 107 infants in group b￨no diff￨highunclear￨highunclear￨highunclear
109￨eligible infants 34 weeks gestation admitted to the nicu a total of 109 infants were enrolled 102 completed the study preterm infants￨alcohol versus natural drying umbilical cleansing with 70 isopropyl alcohol at each diaper change or natural drying￨median cord detachment time umbilical stump cultures local umbilical infection￨there were no cases of local umbilical infection in either group￨no diff￨highunclear￨highunclear￨highunclear
3￨newborn infant￨silver sulfadiazine umbilical cord treatment regimens castile soap triple dye and silver sulfadiazine antiseptic cord care￨staphylococcal colonization￨group b streptococcal colonization was inhibited most effectively by silver sulfadiazine while triple dye application to the umbilicus promoted colonization with this microorganism￨sig increase￨highunclear￨highunclear￨highunclear
1876￨newborn cord care tertiarylevel university teaching hospital and level ii community hospital 1876 singleton fullterm newborns enrolled 1811 completed the study￨umbilical cleansing with 70 isopropyl alcohol at each diaper change or b natural drying of the umbilical site without special treatment alcohol versus natural drying￨cord separation time umbilical infection cord separation time maternal comfort and cost costs of alcohol drying similar comfort with cord care and relief with cord separation cord infection￨cord separation time was statistically significantly different alcohol group 98 days natural drying group 816 days t  89 p   001￨no diff￨highunclear￨highunclear￨highunclear
271￨two hundred and seventy one infants￨six umbilical cord care regimens povidoneiodine￨longest attachment time shortest attachment time￨antimicrobial control was equal for all methods￨no diff￨highunclear￨highunclear￨highunclear
1535￨1535 healthy term infants healthy term infants￨salicylic sugar powder eight cordcare regimens 70 alcohol natural drying salicylic sugar powder triple dye micronized green clay powder colloid silverbenzylperoxide powder neomycinbacitracin powder 1 basic fuchsine green clay powder￨sepsis or died cord separation time and other secondary outcomes omphalitis sepsis death cord bleeding compliance satisfaction or dissatisfaction with regard to the type of treatment umbilical cord colonization rate of positive umbilical swabs￨both forms of treatment proved to be more effective p  005 than all the others￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨triple dye plus rubbing alcohol versus triple dye alone triple dye alone brilliant green crystal violet and proflavine hemisulfate versus triple dye plus rubbing alcohol isopropyl alcohol￨time to cord separation cordrelated morbidities or cordrelated urgent care￨for the 90 newborns who completed the study there were no significant differences between treatment groups for time to cord separation cordrelated morbidities or cordrelated urgent care￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨sulphadiazine￨umbilical care and cord separation￨triple dye was associated with a significantly earlier separation of the cord than either 1 neomycin or 1 silver sulphadiazine ointment and it was nearly as effective as bismuth subgallate an astringent powder in causing rapid sloughing￨sig increase￨highunclear￨highunclear￨highunclear
100￨preterm babies preterm babies within the neonatal unit of ninewells hospital dundee￨￨infection rates￨the evidence of the trial suggests that the present method of treating umbilical cords in preterm babies with sterets and sterzac powder is sound￨no diff￨highunclear￨highunclear￨highunclear
410￨536 strains were isolated newborn infants a total of 410 infections were registered in 377 154 of the 2441 infants￨bandage of hydrophobic material sorbact n  1213 and ii daily cleansing with 05 chlorhexidine in 70 ethanol chlorhexidineethanol umbilical disinfection hydrophobic material chlorhexidine￨infection rates separation of the umbilical cord total infection rates rates of different types of infections conjunctivitis pyoderma paronychia omphalitis￨no differences were found between the groups in infection rates in the nursery 89 vs 87 after discharge 74 vs 59 or in rates of different types of infections conjunctivitis pyoderma paronychia omphalitis p greater than 005￨no diff￨highunclear￨highunclear￨highunclear
148￨healthy term neonates healthy newborns of 148 participants 136 92 completed the protocol￨alcohol￨time to cord separation rates of colonization and species of organisms that colonized colonization rates rates of skin colonization￨cords that were cleaned with sterile water separated more quickly than those cleaned with alcohol t  315 p  0002￨sig increase￨highunclear￨highunclear￨highunclear
not found￨373 singleton near to fullterm newborns enrolled in the study 312 completed the study newborn infants primarylevel newborn nursery at a university teaching hospital and a private hospital￨human milk ethyl alcohol 96 and silver sulfadiazine silver sulfadiazine ointment 1 mothers milk group 2 alcohol group 3 silver sulfadiazine group and 4 control no treatment group￨umbilical cord separation time mean cord separation time time to umbilical cord separation and any discomfort such as infection hemorrhage and granuloma formation￨no significant complications were observed in any group￨no diff￨highunclear￨highunclear￨highunclear
29760￨all livebirths were eligible those visited within 7 days by a local female village health worker trained to deliver the cord care intervention were enrolled between june 2007 and september 2009 we enrolled 29 760 newborn babies 10 329 9423 and 10 008 in the multiplecleansing singlecleansing and dry cord care groups respectively 080 133 clusters rural bangladesh￨chlorhexidine cleansing regimens single cleansing as soon as possible after birth daily cleansing for 7 days after birth or promotion of dry cord care cord cleansing with chlorhexidine chlorhexidine cleansing￨occurrence of severe cord infection redness with pus neonatal mortality neonatal mortality￨neonatal mortality was lower in the singlecleansing group 225 per 1000 livebirths than it was in the dry cord care group 283 per 1000 livebirths relative risk rr￨sig increase￨low￨low￨low
244￨244 preterm newborns with a gestational age of 34 weeks and a birth weight of 2500 g all preterm newborns were enrolled regardless of their health condition premature infants newborns who had their programmed cordcare regimen changed because of the presence or the suspicion of omphalitis preterm infants￨cordcare regimens salicylic sugar powder vs chlorhexidine salicylic sugar 2 cordcare regimens salicylic sugar powder vs chlorhexidine salicylic sugar powder chlorhexidine￨cord separation time changing of the programmed cordcare regimen death omphalitis sepsis cord bleeding nurses opinion on treatments efficacy and uc colonization rate of negative umbilical swabs catheterization of umbilical vessels cord separation time slight cord scar bleeding umbilical cord care￨a significantly higher percentage of nurses were satisfied with the salicylic sugar powder treatment 98 than with the chlorhexidine treatment 67 notwithstanding a more frequent occurrence of slight cord scar bleeding in the salicylic sugar group 78 than in the chlorhexidine group 4￨sig increase￨highunclear￨highunclear￨highunclear
63￨sixtythree older individuals aged  or  50 with chronic stroke poststroke duration  or  1 year who were living in the community older adults with chronic stroke older individuals with chronic stroke older adults living with stroke older adults living with chronic conditions￨communitybased group exercise program seated upper extremity program fitness and mobility exercise fame program communitybased fitness and mobility exercise program￨femoral neck bmd of the paretic leg balance activity and participation nonparetic leg muscle strength or nonparetic femoral neck bmd cardiorespiratory fitness mobility leg muscle strength balance and hip bone mineral density bmd gains in cardiorespiratory fitness mobility and paretic leg muscle strength cardiorespiratory fitness maximal oxygen consumption mobility 6minute walk test leg muscle strength isometric knee extension balance berg balance scale activity and participation physical activity scale for individuals with physical disabilities and femoral neck bmd using dualenergy xray absorptiometry￨there was no significant timebygroup interaction for balance activity and participation nonparetic leg muscle strength or nonparetic femoral neck bmd￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients who had reduced mobility due to a stroke more than one year before entry 60 were recruited from a community stroke register and 34 in other ways patients seen more than one year after stroke patients homes in oxfordshire 94 patients entered the trial and 49￨￨mobility including gait speed functional ambulation categories the nottingham extended activities of daily living index and individual items from the barthel activities of daily living index and the frenchay activities index manual dexterity depression and anxiety gait speed time taken to walk 10 m￨a 9 95 confidence interval 0 to 18 decrease in time taken to walk 10 m was associated with treatment and a 12 2 to 19 increase when patients were untreated￨no diff￨highunclear￨highunclear￨highunclear
170￨170 eligible patients assigned treatment or no intervention 359 patients older than 50 years for a singlemasked patients who had mobility problems 1 year after stroke patients with mobility problems patients with mobility problems more than 1 year after stroke stroke patients with longterm mobility problems￨physiotherapy community physiotherapy community physiotherapy community physiotherapy treatment￨mobility measured by the rivermead mobility index patients daily activity social activity anxiety depression and number of falls or on emotional stress of carers gait speed number of falls daily activity barthel index scores social activity frenchay activities index hospital anxiety and depression scale and emotional stress of carers general health questionnaire 28 mobility and gait speed rivermead mobility index gait speed￨gait speed was 26 mmin 030495 higher in the treatment group at 3 months￨sig increase￨low￨low￨low
not found￨12 chronic stroke subjects chronic stroke￨taskrelated circuit class strengthening the affected lower limb and practicing functional tasks involving the lower limbs while the control group practiced upperlimb tasks taskrelated circuit training 4week training program￨walking speed and endurance peak vertical ground reaction force lowerlimb function number of repetitions of the step test walking speed and endurance force production through the affected leg￨the experimental group demonstrated significant immediate and retained 2month followup improvement p  or  05 compared with the control group in walking speed and endurance force production through the affected leg during sittostand and the number of repetitions of the step test￨sig increase￨highunclear￨highunclear￨highunclear
20￨patients more than 1 year after stroke twenty patients were recruited from a community stroke register in nantou county taiwan chronic stroke patients chronic stroke survivors￨lowintensity homebased physical therapy homebased physical therapy￨performance of activities of daily living adl and motor function barthel index bi and stroke rehabilitation assessment of movement stream motor function of upper limbs mobility and adl performance lower limb motor function￨at 22 weeks the motor function of upper limbs mobility and adl performance in group ii had improved slightly more than in group i but the betweengroup differences were not significant￨sig increase￨highunclear￨highunclear￨highunclear
not found￨people with moderate walking deficits between may 2000 and february 2003 91 individuals with a residual walking deficit within one year of a first or recurrent stroke consented to participate people with stroke￨taskorientated intervention￨sixminute walk test smwt 5m walk comfortable and maximum pace berg balance scale timed up and go severe walking deficit￨study findings support the efficacy of a taskorientated intervention in enhancing walking distance and speed in the first year post stroke particularly in people with moderate walking deficits￨sig increase￨low￨low￨low
25￨twentyfive subjects with chronic stroke who were at least limited community ambulatory subjects a minimum gait velocity 58cms subjects with chronic stroke chronic stroke￨4week ball exercise program rehabilitation training dualtaskbased exercise program dualtask exercise￨walking ability walking speed cadence stride time stride length and temporal symmetry index gait performance￨there was a significant difference between groups for all selected gait variables except for temporal symmetry index under both task conditions￨no diff￨highunclear￨highunclear￨highunclear
48￨individuals with stroke individuals with chronic stroke chronic stroke subjects fortyeight subjects at least one year post stroke￨taskoriented progressive resistance strength training progressive resistance strength training rehabilitation training taskoriented progressive resistance strength training￨number of repetitions of the step test lower extremity muscle strength gait velocity cadence stride length sixminute walk test step test and timed up and go test muscle strength changes muscle strength and functional performance muscle strength muscle strength and all functional measures strength gain functional performance extremity muscle strength￨in the control group the number of repetitions of the step test significantly decreased 203 with no change in other functional tests￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients with multivessel coronary artery disease eligible and consenting patients 40 centres in 12 countries throughout europe and canada copyright 1999 harcourt publishers ltd￨coronary artery bypass grafting with percutaneous transluminal coronary angioplasty and primary stent implantation open revascularization by cabg or by ptca with the primary implantation of intracoronary stents stent or surgery trial sos￨￨the stent or surgery trial sos is a randomized controlled trial to compare coronary artery bypass grafting with percutaneous transluminal coronary angioplasty and primary stent implantation in patients with multivessel coronary artery disease￨sig increase￨highunclear￨highunclear￨highunclear
150￨isolated proximal lad lesions 150 patients with an indication for treatment of a lad lesion have been included to compare the midterm outcome after ptca n79 vs midcab n71 618 patients patients with isolated proximal ladlesions isolated proximal high grade lad lesions by minimally invasive coronary artery bypass grafting patients having midcab surgery￨minimally invasive direct coronary artery bypass surgery midcab percutaneous coronary angioplasty ptca and stent implantation ptca midcab￨restenosis and a positive stress test perioperative adverse events learning curve rate of severe stenosis number of perioperative adverse events reintervention 30day mortality conversion rate to sternotomy patency rate perioperative myocardial infarction rate￨when compared to ptca the freedom from angina and the need for additional revascularization procedures after 6 months is statistically better for patients having midcab surgery￨sig decrease￨highunclear￨highunclear￨highunclear
2759￨2759 patients with coronary artery disease were screened at seven clinical sites and 450 patients symptomatic patients with multivessel coronary artery disease both groups had similar clinical demographics unstable angina in 92 38 were older than 65 years and 23 had a history of peripheral vascular disease only patients with multivessel disease and indication for revascularization were enrolled patients with multiplevessel disease eraci ii￨balloon angioplasty versus cabg ptcr conventional coronary artery bypass graft surgery cabg percutaneous transluminal coronary revascularization ptcr employing stent implantation cabg coronary angioplasty with stenting versus coronary bypass surgery￨survival and freedom from mi survival repeat revascularization procedures death lower major adverse events death myocardial infarction repeat revascularization procedures and stroke q myocardial infarction mi￨during the first 30 days ptcr patients had lower major adverse events death myocardial infarction repeat revascularization procedures and stroke compared with cabg patients 36 vs 123 p  0002￨sig decrease￨highunclear￨highunclear￨highunclear
100￨100 patients with canadian cardiovascular society class ii to iv and angiographically confirmed single critical stenosis of the lad type a or b single left anterior descending coronary artery stenosis￨direct primary stenting percutaneous revascularization endoscopic atraumatic coronary artery bypass grafting over direct primary stenting balloon angioplasty primary stenting versus midcab endoscopic atraumatic coronary artery bypass grafting videoassisted left internal thoracic artery lita harvesting and robotic surgery￨acute postoperative complications restenosis of the lad￨no acute postoperative complications were noted at 1 month of followup￨no diff￨highunclear￨highunclear￨highunclear
280￨patients referred for angioplasty n280 patients referred for angioplasty￨stenting n138 or offpump bypass surgery stenting and offpump bypass surgery stenting balloon angioplasty conventional surgery offpump bypass surgery￨overall costs hospital stay survival free from stroke myocardial infarction and repeat revascularization cardiac outcome and quality of life cardiac outcome qualityadjusted lifetime costeffective cardiac outcome quality of life and costeffectiveness morbidity hospital stay and costs￨hospital stay after the initial procedure was 143 and 577 days respectively p001￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients with an isolated highgrade lesion of the proximal lad patients with an isolated highgrade stenosis american college of cardiologyamerican heart association classification type b2c of the proximal lad patients with an isolated highgrade stenosis of the left anterior descending lad coronary artery randomized to￨percutaneous transluminal coronary angioplasty with stenting pci stenting or to offpump coronary artery bypass grafting surgery￨4year clinical outcome freedom from angina pectoris angina pectoris status and need for antianginal medication macces freedom from major adverse cardiac and cerebrovascular events macces including cardiac death myocardial infarction stroke and repeat target vessel revascularization￨need for antianginal medication was significantly lower after surgery compared to stenting p0002￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients with multivessel disease n1205￨pci coronary artery bypass grafting cabg cabg or pci percutaneous coronary intervention with stenting pci coronary stenting versus bypass surgery￨respective repeat revascularization rates maximal pressure for stent deployment incremental cost of surgery survival rates without stroke or myocardial infarction￨survival rates without stroke or myocardial infarction were similar in each group at 1 year and 3 years 905 versus 914 for pci versus cabg at 1 year and 872 versus 884 for pci versus cabg at 3 years￨no diff￨highunclear￨highunclear￨highunclear
2￨patients with isolated proximal left anterior descending coronary artery stenosis patients with proximal isolated de novo left anterior descending coronary artery disease and left ventricular ejection fraction of 45 123 patients who accepted randomization 59 underwent cabg and 62 were treated with￨percutaneous transluminal coronary angioplasty ptca stenting to internal mammary artery grafting coronary artery bypass grafting cabg ptca and stent implantation or to cabg stent implantation and cabg multicenter stenting vs internal mammary artery sima stent implantation stenting vs internal mammary artery￨incidence of death and myocardial infarction death and myocardial infarction eventfree survival including death myocardial infarction and the need for additional revascularization functional class antianginal treatment and quality of life￨the functional class need for antianginal drug and qualityoflife assessment showed no significant differences￨no diff￨low￨low￨low
39￨39 patients with stable or worsening neuropathy and mgus of the igg iga or igm type to receive either￨plasma exchange twice weekly for three weeks or sham plasma exchange￨weakness score neuropathy disability score average neuropathy disability score muscle action potentials of motor nerves muscle action potentials vibratory detection threshold summed motornerve conduction velocity and sensorynerve action potentials plasma exchange￨changes in the vibratory detection threshold summed motornerve conduction velocity and sensorynerve action potentials did not differ significantly between the treatment groups￨no diff￨highunclear￨highunclear￨highunclear
306￨for carcinoma at dukes stage d 306 patients advanced colonic cancer patients with advanced colonic cancer￨allopurinol radical scavengers dimethyl sulphoxide dmso and allopurinol oxygenderived free radicals dmso allopurinol and dmso control group or to electrocoagulation of liver secondaries alone or with allopurinol palliative sigmoid colectomy￨survival advantage￨following palliative sigmoid colectomy for carcinoma at dukes stage d 306 patients were randomized to the control group or to electrocoagulation of liver secondaries alone or with allopurinol 50 mg by mouth 4 times a day or dmso 500 mg by mouth 4 times a day￨sig increase￨highunclear￨highunclear￨highunclear
239￨patients with relapsing multiple sclerosis patients with rrms two hundred thirtynine eligible patients patients with relapsing remitting multiple sclerosis rrms￨placebo 20 mg ga glatiramer acetate ga ga glatiramer acetate magnetic resonance imaging mri glatiramer acetate￨relapse rates disease activity mrimeasured disease activity and burden relapse rate number of new lesions seen on t2weighted images total number of enhancing lesions on t1weighted images proportion of patients with enhancing lesions the number of new enhancing lesions and change in their volume the number of new lesions detected on t2weighted images and change in their volume and the change in volume of hypointense lesions seen on unenhanced t1weighted images total number of enhancing lesions number of new enhancing lesions￨the relapse rate was also significantly reduced by 33 for gatreated patients p  0012￨sig decrease￨low￨low￨low
73￨primary progressive multiple sclerosis seventythree patients were included and three dropped out the study patients with primary progressive multiple sclerosis or transitional forms of multiple sclerosis received patients with primary progressive multiple sclerosis and transitional multiple sclerosis primary progressive and transitional multiple sclerosis￨interferon beta placebo interferon beta1b interferon interferon beta1b at doses of 8 miu or placebo￨multiple sclerosis functional composite score at several timepoints t1 and t2 lesion volume changes safe and well tolerated adverse event time to neurological deterioration expanded disability status scale safety endpoints expanded disability status scale progression safety and tolerability time to neurological deterioration safety and efficacy￨time to neurological deterioration was not different between trial arms logrank test p  03135￨no diff￨low￨low￨low
50￨primary progressive ms patients with primary progressive ms fifty subjects￨im interferon beta1a 30 microg 60 microg or placebo interferon beta1a￨rate of accumulation of t2 lesion load rate of ventricular enlargement timed 10meter walk ninehole peg test and on mri t2 and t1 brain lesion loads and brain and spinal cord atrophy severe flulike reactions and raised liver enzymes time to sustained progression in disability￨subjects on interferon beta1a 30 microg had a lower rate of accumulation of t2 lesion load than controls p  0025 subjects on 60 microg had a greater rate of ventricular enlargement than controls p  0025￨sig increase￨low￨low￨low
318￨secondary progressive multiple sclerosis patients with secondary progressive multiple sclerosis 19 patients in the ivig group and 39 in the 318 patients with clinically definite secondary progressive multiple sclerosis mean age 44 years sd 7￨placebo intravenous immunoglobulin intravenous immunoglobulin intravenous immunoglobulin ivig￨relapse rate and disability change of t2lesion load over time time to confirmed edss progression deep venous thrombosis pulmonary embolism annual relapse rate worsening of disability as defined by the time to first confirmed progression on the expanded disability status scale edss￨no significant differences between the treatment groups were found in any of the other clinical outcome measures or in the change of t2lesion load over time￨no diff￨low￨low￨low
42￨patients with multiple sclerosis with very active disease forty two patients with confirmed multiple sclerosis selected as having a very active disease on clinical and mri criteria multiple sclerosis￨mitoxantrone methylprednisolone mitoxantrone combined with methylprednisolone￨clinical and mri indices of disease activity number of relapses change in edss severe exacerbation number of patients free of exacerbation total number of enhancing lesions number of new enhancing lesions￨there was a significant reduction in the number of relapses 7 v 31 p  001 and an increase in the number of patients free of exacerbation 14 v 7 p  005￨sig decrease￨highunclear￨highunclear￨highunclear
194￨194 patients with worsening relapsingremitting or secondary progressive multiple sclerosis 194 patients enrolled 188 were able to be assessed at 24 months progressive multiple sclerosis patients with secondary progressive multiple sclerosis￨mitoxantrone placebo mitoxantrone placebo or mitoxantrone￨change in ambulation index tolerated and reduced progression of disability and clinical exacerbations adjusted total number of treated relapses expanded disability status scale time to first treated relapse standardised neurological status￨mitoxantrone 12 mgm2 was generally well tolerated and reduced progression of disability and clinical exacerbations￨sig decrease￨low￨low￨low
560￨relapsingremitting multiple sclerosis multiple sclerosis ms 533 95 patients were available at 2 years 560 patients with kurtzke expanded disability status scale edss scores of 050 from 22 centres in nine countries￨interferon beta placebo subcutaneous interferon beta1a subcutaneous recombinant interferon interferon beta1a￨accumulation of burden of disease and number of active lesions on mri relapse rate neurological examinations proportion of relapsefree patients time to first relapse￨the relapse rate was significantly lower at 1 and 2 years with both doses of interferon beta1a than with placebo mean number per patient 182 for 22 microg group 173 for 44 microg group vs 256 for placebo group risk reductions 27 95 ci 1439 and 33 2144￨sig decrease￨low￨low￨low
60￨patients with chronic progressive ms study patients were 21 to 60 years old with a disease duration of longer than 1 year chronic progressive multiple sclerosis 60 patients with clinically definite chronic progressive multiple sclerosis ms attending a referralbased outpatient ms clinic￨placebo methotrexate methotrexate or placebo methotrexate or identical placebo oral methotrexate￨disability status scale scores disability status scale 2 ambulation index 3 box and block test and 4 9hole upperextremity function rate of progression￨significantly less progression of impairment as measured by validated tests of upperextremity function was observed in the methotrexate treatment group in the absence of clinically significant toxicity￨sig increase￨low￨low￨low
not found￨patients with relapsingremitting multiple sclerosis rrms relapsingremitting multiple sclerosis￨recombinant human interferonbeta 1b betaseron berlex laboratories richmond ca betaseron or placebo systemic recombinant human interferonbeta treatment￨side effects exacerbation frequency and sideeffect profile neutralizing antibody neopterin levels￨although some side effects were noted in all groups a doserelated trend in reduction of exacerbation frequency and sideeffect profile was noted￨no diff￨highunclear￨highunclear￨highunclear
371￨patients with secondary progressive ms secondary progressive multiple sclerosis 371 patients with clinically definite spms￨interferon ifn beta placebo placebo or subcutaneous ifn beta1a￨regional functional status scale time to sustained disability expanded disability status scale edss sensitive disability measure and relapse rate edss hazard ratio hr disability measures annual relapse rate￨annual relapse rate was 027 with placebo and 025 with ifn rate ratio  090 95 ci 064 to 127 p  055￨no diff￨low￨low￨low
188￨188 patients with relapsingremitting ms￨interferon beta1b n96 or interferon beta1a interferon beta preparations￨proportion of patients free from relapses and that of patients free from new proton densityt2 lesions at mri assessment delay of confirmed disease progression relapsefree￨there were also significant differences in favour of interferon beta1b in most of the secondary outcome measures including delay of confirmed disease progression￨no diff￨low￨low￨low
943￨primary progressive multiple sclerosis male patients 943 patients with primary progressive multiple sclerosis￨placebo glatiramer acetate ga ga ga or placebo pbo glatiramer acetate￨t2 lesion volumes intentiontotreat analysis of time to 1 disability status scale change entry expanded disability status scale enhancing lesions survival curves￨post hoc analysis showed that survival curves for gatreated male patients diverged early from pbotreated male subjects hazard ratio 071 95 confidence interval 053095￨sig increase￨low￨low￨low
436￨436 subjects with spms and expanded disability status scale edss score 35 to 65￨interferon beta1a ifnbeta1a 60 micro g or placebo interferon beta1a ifnbeta1a avonex￨msfc progression relapses quality of life and mri activity first time in a largescale ms trial median msfc zscore change new or enlarging t2hyperintense brain mri lesions and gadoliniumenhancing lesions ms functional composite msfc comprising quantitative tests of ambulation timed 25foot walk arm function ninehole peg test 9hpt and cognition paced auditory serial addition test pasat 11 ms quality of life inventory subscales neutralizing antibodies￨new or enlarging t2hyperintense brain mri lesions and gadoliniumenhancing lesions were reduced at months 12 and 24 both p  0001￨sig increase￨low￨low￨low
939￨secondary progressive ms subjects with secondary progressive multiple sclerosis spms 939 subjects from the united states and canada with spms and expanded disability status scale edss scores ranging from 30 to 65￨placebo or ifnbeta1b placebo interferon interferon beta1b ifnbeta1b￨clinical relapses newly active mri lesions and accumulated burden of disease on t2weighted mri neutralizing antibodies to ifnbeta1b time to progression by  or 10 edss point 05 point if edss score tolerated edss scores mean change in edss score from baseline relapserelated measures mri activity and a standardized neuropsychological function test efficacy and safety￨there was no significant difference in time to confirmed progression of edss scores between placebotreated patients and either of the ifnbeta1b treatment groups￨no diff￨low￨low￨low
251￨two hundred fiftyone patients patients with relapsingremitting multiple sclerosis ms relapsingremitting multiple sclerosis patients receiving copolymer 1 and 168￨placebo copolymer 1 copolymer 1 copaxone￨disability relapse rate and improves disability tolerated ms relapse rate final 2year relapse rate expanded disability status scale edss￨013 for those receiving placebo a 29 reduction in favor of copolymer 1 p  0007 annualized rates  059 for copolymer 1 and 084 for placebo￨sig decrease￨low￨low￨low
106￨106 chronicprogressive patients chronic progressive multiple sclerosis￨placebo￨overall survival curves progression rates kurtzke expanded disability status scale unconfirmed progression and progression of 05 edss units￨progression rates at 12 and 24 months were higher for the placebo group p  0088 with 2year probabilities of progressing of 204 for cop 1 and 295 for placebo￨sig increase￨low￨low￨low
not found￨ninetyeight patients with multiple sclerosis ms in the chronic progression phase entered a 3year clinical trial to determine if multiple sclerosis patients with chronic progressive ms￨placebo az with or without steroids azathioprine az alone or with adrenal cortical steroids methylprednisolone mp mp azathioprine with and without methylprednisolone az and placebo￨rates of progression standard neurological examination scores relapse rate hematologic and hepatic abnormalities adverse effects adverse reactions mickeys illness severity scores or kurtzkes disability status scale￨the intenttotreat groups had no statistically significant differences in the rates of progression among the 3 treatments￨no diff￨low￨low￨low
2447￨2447 patients with relapsingremitting multiple sclerosis were screened and 2244 patients relapsingremitting multiple sclerosis￨glatiramer acetate interferon beta1b versus 20 mg glatiramer acetate interferon beta1b with glatiramer acetate interferon beta1b 250 microg or 500 microg subcutaneously every other day or 20 mg glatiramer acetate subcutaneously every day￨injectionsite reactions flulike symptoms relapse risk edss progression t1hypointense lesion volume or normalised brain volume overall tolerability progression on the expanded disability status scale edss and change in t1hypointense lesion volume efficacy safety and tolerability relapse risk defined as new or recurrent neurological symptoms patient attrition rates￨flulike symptoms were more common in patients treated with interferon beta1b p00001 whereas injectionsite reactions were more common in patients treated with glatiramer acetate p00005￨sig decrease￨low￨low￨low
42￨forty two patients from the kaiser permanente medical care program northern california were studied chronic progressive multiple sclerosis stabilising chronic progressive multiple sclerosis ms￨placebo intensive immunosuppression with cyclophosphamide folic acid immunosuppression therapy cyclophosphamide and folic acid cyclophosphamide￨disability status scale level of disability impairment of functional systems and performance of social roles mean level of disability￨although immunosuppression therapy can be safely administered to ms patients in an outpatient clinic evidence of substantial benefits was not found￨no diff￨highunclear￨highunclear￨highunclear
677￨patients with relapsing ms a total of 677 patients were enrolled in the study and evenly randomized to treatment 605 patients completed the comparative phase and 439 completed the crossover phase￨interferon ifnbeta therapy sc ifnbeta1a 44 lag tiw rebif serono inc geneva switzerland or im ifnbetala 30 mug qw avonex biogen idec cambridge massachusetts￨prolonged time to first relapse mean relapse rates annualized relapse rate and time to first relapse re spectively adverse events mri measures of disease activity injectionsite reactions annualized relapse rate neutralizing antibody formation adverse events mri activity￨injectionsite reactions were significantly more common with highdose tiw treatment than with lowdose qw treatment 85 vs 33 p  0001￨sig increase￨highunclear￨low￨low
18￨twohundred and thirtyone patients stratified for ppms n34 and spms n197 patients with chronic progressive ms primary and secondary chronic progressive multiple sclerosis eighteen patients with ppms and 102 patients with spms withdrew from the study for various reasons primary ppms and secondary spms chronic progressive ms patients with spms patients with relapsingremitting multiple sclerosis ms￨placebo intravenous immunoglobulin ivig infusion￨relapse rate and progression of disability time to sustained progression sustained progression delay progression of disease tolerated proportion of patients with sustained progression the relapse rate the assessment of fine motor skills visual evoked potentials contrast sensitivity depression and quality of life mean time to sustained progression ppms neurological functions time to sustained progression of disease identified as worsening of the expanded disability status scale edss sustained for 3 months and 2 the improvement of neurological functions￨when ppms and spms patients were analysed separately the time to sustained progression was also longer in the ivig group but the difference was not significant￨sig increase￨low￨low￨low
764￨between february and december 2004 764 patients were randomly assigned 386 to patients with rrms 460 patients 230 from each group also had serial mri scans to assess t2weighted and gadoliniumenhancing lesion number and volume patients with relapsing multiple sclerosis relapsingremitting multiple sclerosis rrms patients with rrms diagnosed with the mcdonald criteria who had had at least one relapse within the previous 12 months￨regard rebif vs glatiramer acetate interferon beta1a and glatiramer acetate 44 mug subcutaneous interferon beta1a three times per week or 20 mg subcutaneous glatiramer acetate interferon beta1a and 378 to glatiramer acetate glatiramer acetate subcutaneous interferon beta1a with glatiramer acetate￨time to first relapse volume of gadoliniumenhancing lesions number and change in volume of t2 active lesions gadoliniumenhancing lesions overall number and severity of adverse events safety and tolerability profiles relapse rates interferon beta1a and glatiramer acetate￨the overall number and severity of adverse events were similar between the treatments and were not an important cause for discontinuation of the trial during the 96 weeks￨no diff￨low￨low￨low
51￨51 relapsingremitting multiple sclerosis patients relapsingremitting multiple sclerosis￨mitoxantrone placebo mitoxantrone 19 placebo￨mean number of exacerbations mean edss progression disease activity edss scale kurtzke expanded disability scale edss￨a statistically significant difference in the mean number of exacerbations was observed between the mitoxantrone group and placebo group both during the 1st and the 2nd year￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients with relapsingremitting multiple sclerosis 243 patients screened 150 met our eligibility criteria patients with relapsingremitting multiple sclerosis relapsingremitting multiple sclerosis￨intravenous immunoglobulin ivig placebo immunoglobulin therapy￨edss score sideeffects clinical disabilitymeasured by the absolute change in kurtzkes expanded disability status scale edss score and the proportion of patients with improved stable or worse clinical disability numbers of patients with improved stable or worse clinical disability￨the edss score decreased in the ivigtreated patients and increased in the placebo group 023￨sig decrease￨low￨low￨low
143￨from june 1996 through october 1997 the authors offered participation to all danish rrms patients who met the following criteria definite ms at least two relapses within 2 years age 18 to 55 and an expanded disability status scale edss score of  or  55 relapsingremitting multiple sclerosis￨interferonbeta ifnbeta ifnbeta1b interferonbeta treatments￨time to sustained progression annual relapse rates relapsingremitting ms rrms annual relapse rate annualized relapse rate the time to first relapse and neutralizing antibody formation￨in the nonrandomized patients ifnbeta1b the annual relapse rate was not significantly different but the time to progression was shorter￨no diff￨highunclear￨highunclear￨highunclear
1171￨patients with relapsing multiple sclerosis 1171 patients who despite interferon beta1a therapy had had at least one relapse during the 12month period before randomization to receive￨placebo continued interferon beta1a in combination with 300 mg of natalizumab natalizumab natalizumab plus interferon interferon beta￨annualized rate of relapse anxiety pharyngitis sinus congestion and peripheral edema relative risk of sustained disability progression rate of clinical relapse at 1 year and the cumulative probability of disability progression sustained for 12 weeks as measured by the expanded disability status scale￨combination therapy resulted in a 24 percent reduction in the relative risk of sustained disability progression hazard ratio 076 95 percent confidence interval 061 to 096 p002￨sig decrease￨low￨low￨low
127￨one hundred twentyseven patients with rrms relapsingremitting multiple sclerosis￨iv immunoglobulin ivig placebo intravenous immunoglobulin equal volume of placebo￨rates of adverse events proportion of relapse proportion of relapsefree patients cumulative number of unique newly active mri lesions lesion activity assessed by 6weekly mri￨after 1 year the proportion of relapsefree patients did not differ statistically according to treatment ivig 02 gkg 57 ivig 04￨no diff￨low￨low￨low
49￨relapsingremitting rr multiple sclerosis ms patients n  49 with clinical definite rr ms￨ivig and placebo intravenous immunoglobulins placebo intravenous immunoglobulins ivig￨efficacy neurologic impairment total lesion volume on t2wi arr cumulative numbers of gdenhancing lesions and new t2wi lesions neurological disability measured with edss annual relapse rate arr and change of the mean expanded disability status scale edss and neurological rating scale score nrss ms activity for mri activity total lesion volume on t2weighted image t2wi new lesions and gadolinium gdenhanced lesions￨the cumulative numbers of gdenhancing lesions and new t2wi lesions in the ivig groups were reduced in comparison with the placebo group￨sig increase￨low￨low￨low
90￨relapsingremitting multiple sclerosis rrms patients with rrms relapsingremitting multiple sclerosis ninety patients with rrms￨betaferon the second group received avonex betaferon avonex and rebif betaferon avenox and rebif￨relapse rate relapse rate and edss score expanded disability status scale edss relapsefree mean sd of relapse rate￨expanded disability status scale edss decreased by 07 u in betaferontreated patients p  0001 03 u in rebiftreated patients p  005 and remained stable in avonex patients￨sig increase￨highunclear￨highunclear￨highunclear
301￨relapsing multiple sclerosis patients three hundred one patients with relapsing multiple sclerosis￨placebo intramuscular interferon￨number and volume of gadoliniumenhanced brain lesions on magnetic resonance images time to sustained disability progression exacerbations time to sustained edss progression kurtzke expanded disability status scale edss annual exacerbation rate accumulation of permanent physical disability exacerbation frequency and disease activity￨interferon beta1a treatment produced a significant delay in time to sustained edss progression p  002￨sig decrease￨low￨low￨low
not found￨forty patients affected by multiple sclerosis with remittingrelapsing or progressive course multiple sclerosis￨azathioprine￨expanded disability status scale relapse frequency￨the mean changes on the expanded disability status scale and in the survival analysis show a trend in favour of azathioprine both in slowing disease progression and reducing relapse frequency￨sig increase￨highunclear￨highunclear￨highunclear
942￨patients with relapsing multiple sclerosis relapsing multiple sclerosis 25 patients receiving of a total of 942 patients￨natalizumab natalizumab placebo￨risk of sustained progression of disability fatigue accumulation of new or enlarging hyperintense lesions rate of clinical relapse serious hypersensitivity reactions gadoliniumenhanced mri adverse events rate of clinical relapse at one year and the rate of sustained progression of disability as measured by the expanded disability status scale hypersensitivity reactions allergic reaction cumulative probability of progression￨natalizumab reduced the rate of clinical relapse at one year by 68 percent p0001 and led to an 83 percent reduction in the accumulation of new or enlarging hyperintense lesions as detected by t2weighted magnetic resonance imaging mri over two years mean numbers of lesions 19 with natalizumab and 110 with placebo p0001￨sig decrease￨low￨low￨low
50￨50 patients with the exacerbatingremitting form of multiple sclerosis who selfinjected either 20 mg of alone daily for two years￨placebo cop 1 dissolved in 1 ml of saline or saline￨disabled on entry kurtzke disability score￨more disabled patients worsened by 03 cop 1 group and 04 placebo group unit￨sig decrease￨low￨low￨highunclear
not found￨forty otherwise healthy patients over 50 years of age with early severe painful herpes zoster￨carbamazepine corticosteroids prednisolone￨incidence and duration of postherpetic neuralgia postherpetic neuralgia lasting￨forty otherwise healthy patients over 50 years of age with early severe painful herpes zoster were randomly allocated to two groups for treatment￨no diff￨highunclear￨highunclear￨highunclear
6￨trigeminal neuralgia six patients￨tizanidine carbamazepine tizanidine￨efficacy and tolerability visual analog scale vas and the overall efficacy tolerated￨the results indicate that tizanidine was well tolerated but the effects if any were inferior to those of carbamazepine￨no diff￨highunclear￨highunclear￨highunclear
16￨diabetic neuropathy sixteen patients with severe dpn participated in the study patients with severe distal symmetrical predominantly sensitive diabetic polyneuropathy dpn￨placebo nortriptylinefluphenazine nf vs carbamazepine cmz nortriptylinefluphenazine vs carbamazepine cmz nf￨efficacy and tolerance pain or paresthesia pain and paresthesia hba1 fasting serum glucose and safety tests side effects￨no statistically significant differences were observed between both therapies for either pain or paresthesia￨no diff￨highunclear￨highunclear￨highunclear
15￨15 patients with central poststroke pain cpsp but without signs of depression￨placebo carbamazepine carbamazepine amitriptyline and carbamazepine amitriptyline amitriptyline￨pain pain relief median total ami and nortriptyline concentrations effect and plasma concentration side effects global rating of the analgesic effect on a 5step verbal scale comprehensive psychopathological rating scale cprs daily ratings of pain intensity on a 10step verbal scale￨five of the 14 patients treated with carbamazepine reported some pain relief but the effect did not reach statistical significance when compared to placebo￨no diff￨highunclear￨highunclear￨highunclear
12￨trigeminal neuralgia 12 patients with trigeminal neuralgia in a doubleblind crossover study for 2 weeks￨carbamazepine lidocaine tocainide tocainide￨analgesic effect￨the similarity in analgesic effect of the two drugs was striking￨no diff￨highunclear￨highunclear￨highunclear
48￨trigeminal neuralgia 48 patients with trigeminal neuralgia who were refractory to medical therapy￨carbamazepine pimozide pimozide therapy pimozide￨trigeminal neuralgia symptoms adverse effects relieved of their pain￨pimozide was compared with carbamazepine in a doubleblind crossover trial in 48 patients with trigeminal neuralgia who were refractory to medical therapy￨sig increase￨highunclear￨highunclear￨highunclear
not found￨eighteen chronic schizophrenic patients who had shown improvement from increased maintenance dosages of chronic schizophrenic patients maintained on a high dose regime￨ciszflupenthixol decanoate￨tardive dyskinesia prolactin levels morbidity greatest deterioration schizophrenic relapse deterioration of schizophrenic and depressive features and ciszflupenthixol plasma levels￨sideeffects were few and there was no emergence of tardive dyskinesia￨no diff￨highunclear￨highunclear￨highunclear
126￨outpatient schizophrenics￨fluphenazine decanoate￨severity of relapse and total cumulative dosage relapse rates cumulative relapse rates￨for the first 126 patients studied cumulative relapse rates at one year for the low dose were 56 and for the standard dose 7 a significant difference￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with dsmiv schizophrenia or schizoaffective disorder and established tardive dyskinesia subjects were enrolled in the study between april 2000 and march 2002 patients with established tardive dyskinesia tardive dyskinesia￨quetiapine quetiapine and haloperidol haloperidol quetiapine￨response rate cgi dyskinesia serum prolactin levels weight or glucose metabolism dyskinesia esrs dyskinesia severity of tardive dyskinesia extrapyramidal symptom rating scale esrs dyskinesia subscale scores and the clinical global impression cgi dyskinesia scores eps weight serum prolactin level and glycosylated hemoglobin level￨compared with the haloperidol group the quetiapine group showed significantly greater improvements in esrs dyskinesia 6 and 9 months p or01 and cgi dyskinesia from 6 months onward p 05 and with repeatedmeasures analysis p 002￨sig increase￨highunclear￨highunclear￨highunclear
not found￨18 neuroleptictreated schizophrenic patients exhibiting operationally defined withdrawalexacerbated tardive dyskinesia tardive dyskinesia￨haloperidol haloperidol versus molindone neuroleptic agentsmolindone and haloperidol￨total aims score￨an experimental method was utilized to compare the masking effects of two neuroleptic agentsmolindone and haloperidolon 18 neuroleptictreated schizophrenic patients exhibiting operationally defined withdrawalexacerbated tardive dyskinesia￨sig decrease￨highunclear￨highunclear￨highunclear
19￨patients were all the women admitted to the labor and delivery ward with diagnosis of severe preeclampsia and viable conceptus cases of severe preeclampsia severe preeclampsia￨diazepam magnesium sulfate diazepam and magnesium sulfate diazepam and magnesium sulfate￨hiporreflexia flaccidity or neonatal respiratory distress maternofetal effects￨none of the newborns showed hiporreflexia flaccidity or neonatal respiratory distress that could be implicated to the anticonvulsivant therapy￨no diff￨highunclear￨highunclear￨highunclear
1089￨hypertensive women during labor women with hypertension who were admitted for delivery to receive either ten of 1089 women randomly assigned to the pregnant women with hypertension women with severe preeclampsia hypertensive pregnant women￨phenytoin magnesium sulfate with phenytoin magnesium sulfate anticonvulsant therapy magnesium sulfate or phenytoin magnesium sulfate￨eclamptic seizures risk factors for eclampsia eclamptic convulsions￨maternal and infant outcomes were also similar in the two study groups￨no diff￨highunclear￨highunclear￨highunclear
33￨33 patients with pregnancyinduced hypertension pregnancies complicated with hypertension￨48hour magnesium infusion followed by oral magnesium tablets methyldopa magnesium and methyldopa magnesium and 17 methyldopa magnesium magnesium or methyldopa treatment￨diastolic systolic blood pressure gestational age at delivery birth weight apgar scores and ph in umbilical cord blood blood pressure measurements blood pressure diastolic blood pressure systolic and diastolic blood pressure￨from the 5th day of inclusion and until delivery both systolic and diastolic blood pressure were significantly lower in the magnesium group p  005￨sig increase￨highunclear￨highunclear￨highunclear
not found￨women with mild preeclampsia at term women with a diagnosis of mild preeclampsia at term women with mild preeclampsia￨placebo magnesium sulfate matching placebo solution standard therapy oxytocin magnesium sulfate and placebo magnesium sulfate therapy￨length of the active phase of labor total length of labor side effects associated with magnesium sulfate therapy hours and maximum dose of oxytocin incidence of progression to severe preeclampsia incidence of cesarean delivery change in maternal hematocrit incidence of postpartum hemorrhage incidence of maternal infection and apgar scores duration of labor oxytocin use change in hematocrit frequency of maternal infection progression to severe preeclampsia incidence of cesarean delivery and apgar scores incidence of postpartum hemorrhage￨there was no difference between magnesium sulfate and placebo with respect to the primary outcome variables total length of labor median 178 hours vs 165 hours p  07 and length of the active phase of labor median 54 hours vs 60 hours p  05￨no diff￨low￨low￨low
not found￨1201 of 4999 24 women given eligible women n10141 had not given birth or were 24 h or less postpartum blood pressure of 14090 mm hg or more and proteinuria of 1 30 mgdl or more and there was clinical uncertainty about magnesium sulphate￨magnesium sulphate n5071 or placebo placebo magnesium sulphate magnesium sulphate￨sideeffects risk of eclampsia maternal or neonatal morbidity risk of maternal death risk of the baby dying eclampsia and for women randomised before delivery death of the baby maternal mortality￨maternal mortality was also lower among women allocated magnesium sulphate relative risk 055 026114￨sig decrease￨low￨low￨low
54￨fiftyfour women women with rupture of the membranes spontaneous contractions resulting in cervical change or an initial cervical examination showing  2 cm dilatation and 50 effacement were excluded women with a singleton pregnancy in vertex presentation between 32 and 42 weeks gestation who required induction of labor for either preeclampsia preeclampsia superimposed on chronic hypertension or transient hypertension women with pregnancyassociated hypertension￨phenytoin magnesium sulfate or phenytoin dilantin magnesium sulfate phenytoin magnesium sulfate seizure prophylaxis￨prolongation or failure of labor induction length of labor induction cesarean deliveries￨compared with phenytoin magnesium sulfate seizure prophylaxis in women with pregnancyassociated hypertension does not prolong the induction of labor nor does it result in an increase in cesarean deliveries￨sig increase￨highunclear￨highunclear￨highunclear
222￨patients with chronic hypertension or severe preeclampsia 222 women with mild preeclampsia neonates born to women assigned women with mild preeclampsia￨placebo magnesium sulfate magnesium magnesium sulfate intravenous magnesium sulfate magnesium￨rates of cesarean delivery infectious morbidity obstetric hemorrhage or neonatal depression postpartum hemorrhage signs or symptoms of severe preeclampsia eclampsia or laboratory abnormalities of full or partial hellp hemolysis elevated liver enzymes low platelets syndrome mild preeclampsia severe preeclampsia blood pressure rates of cesarean delivery chorioamnionitis disease progression endometritis mean apgar scores eclampsia or thrombocytopenia￨neonates born to women assigned magnesium had similar mean apgar scores at 1 and 5 minutes as those born to women assigned placebo 77￨no diff￨low￨low￨low
822￨women with severe preeclampsia 699 women were evaluated eight hundred and twentytwo women with severe preeclampsia requiring termination of pregnancy by induction of labour or caesarean section 345 women who received￨placebo saline or magnesium sulphate intravenously placebo magnesium sulphate versus placebo magnesium sulphate prophylactic intravenous magnesium sulphate￨occurrence of eclampsia eclampsia overall incidence of eclampsia￨of 345 women who received magnesium sulphate one developed eclampsia 03 in the placebo group 11340 women 32 developed eclampsia relative risk 009 95 confidence interval 001069 p  0003￨sig decrease￨low￨low￨low
not found￨preeclamptic patients preeclampsia￨phenytoin phenytoin or magnesium sulfate magnesium sulfate phenytoin￨hot flushes rapid cervical dilation rate of cervical dilation acceptable serum phenytoin levels dyspnea and weakness￨a significantly lower incidence of hot flushes 15 versus 46 p  0005 and a trend toward less dyspnea and weakness were reported by phenytointreated patients￨sig decrease￨highunclear￨highunclear￨highunclear
64￨64 patients diagnosed with severe preeclampsia severe preeclampsia￨magnesium sulfate mgso4 and group ii 30 patients managed without mgso4￨babies with poor apgar score eclampsia rate in cesarean section fetal distress￨furthermore group i had significantly more babies with poor apgar score than group ii p  0019￨sig decrease￨highunclear￨highunclear￨highunclear
1650￨1650 women with severe preeclampsia women with severe preeclampsia massachusetts medical society￨magnesium sulfate magnesium sulfate and nimodipine magnesium sulfate nimodipine intravenous magnesium sulfate hydralazine nimodipine￨antepartum seizure rates cerebral vasoconstriction and ischemia development of eclampsia as defined by a witnessed tonicclonic seizure adjusted risk ratio for eclampsia control blood pressure rate of postpartum seizures high blood pressure neonatal outcome￨more women in the magnesium sulfate group than in the nimodipine group needed hydralazine to control blood pressure 543 percent vs 457 percent p0001￨sig decrease￨low￨low￨low
not found￨very preterm infants utilizing a very preterm children very preterm children and caregiver mental health at twoyears corrected age infants born at 30 weeks gestation infants born very preterm 30 weeks of gestational age and their families compared with standard medical followup￨preventative care program￨caregiverchild interaction measured using an observational task and infant behavior parenting caregiver mental health and social support measured via standardized parental questionnaires infant development cognitive motor and language behavioral regulation caregiverchild interactions and caregiver mental health cognitive motor and behavioral outcomes motor development assessed using the alberta infant motor scale and the neurological sensory motor developmental assessment corrected age and include cognitive motor and language development assessed with the bayley scales of infant and toddler development bayleyiii￨the infants will be stratified by severity of brain white matter injury assessed by magnetic resonance imaging at term equivalent age and then randomized￨no diff￨low￨low￨low
not found￨neonates weighing less than 2200 grams and under 37 weeks gestational age￨early intervention program￨selfconfidence and satisfaction cognitive scores favorable perception of infant temperament￨a progressive divergence between the lbw experimental and lbw control children on cognitive scores culminated in significant group differences on the mccarthy gci at ages 36 and 48 months when the lbw experimental group caught up to the nbw group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨families with very preterm children very preterm children children with birthweights  1250 g 53 gq points 02 to 104 and in those with an abnormal neonatal cerebral ultrasound scan 73 gq points 16 to 130 309 consecutive survivors of 32 weeks gestation or less born to mothers resident in greater bristol between december 1990 and july 1993￨home based developmental education programme research nurses trained in either portage a developmental education programme or in nondirectional counselling parent adviser scheme developmental or social support intervention￨mean sem griffiths quotients gq developmental benefit from long term family support after preterm birth￨using linear regression analysis intervention was associated with improved scores portage 43 gq points 95 ci 16 to 70 parent adviser 34 gq points 14 to 61￨sig increase￨low￨low￨low
not found￨preterm infants of adult mothers preterm infants born to lowerclass black teenage mothers￨￨realistic developmental milestones and childrearing attitudes optimal growth denver scores and facetoface interactions￨their mothers rated their infants temperaments more optimally expressed more realistic developmental milestones and childrearing attitudes and received higher ratings on facetoface interactions￨sig increase￨highunclear￨highunclear￨highunclear
156￨up to march 1996 156 cases were over the age 152 years corrected age 52 in the intervention group 51 in the conventional care group and 53 in the normal control group premature infants premature infants at gestational age of 28369 weeks normal newborn infants during the same period were included in the control group routine care￨infant development tests of child development center of china cdcc scale intervention and conventional care groups￨mental development index mdi height weight and head circumference mdi and pdi intelligence tests average mental development index mdi psychomotor development index pdi biological factors￨there was no significant difference in biological factors among the two premature groups and in cultural and social factors among the three groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨premature infants with low less than 1500 g and higher 15002000 g birth weights infants from each weight condition￨￨bayley mental and motor scores bayley mental scores and the home observation for measurement of the environment home inventory￨the low birth weight infants obtained significantly lower bayley mental and motor scores and were more passive and less intense than the higher birth weight infants￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨229 infants initially included 39 17 were dropped from the study within the first 12 months assessment due to lack of participation from the families two hundred and twentynine infants born at less than 34 weeks gestation with birth weight  or  2000 g cared for in the neonatal intensive care unit of hacettepe university hospital between january 1997june 1999 were included in this study premature infants eleven of the 30 infants at risk 2 of the 80 infants from the intervention group and 4 of the 80 from the control group were diagnosed as having cp within the first six months of life thirty of the remaining 190 infants 160 infants not considered at risk preterm infants premature babies without risk of cp other than prematurity￨early physiotherapy intervention control group that received no program￨perinatal hypoxia or abnormal neurosonography age of loss or acquisition of reflexes and general abilities prevalence of cp disabling cerebral palsy cp￨there was no difference in the age of loss or acquisition of reflexes and general abilities between the intervention and control groups￨no diff￨highunclear￨highunclear￨highunclear
84￨thai infants born preterm infants born preterm 27 lowrisk preterm infants eightyfour preterm born infants preterm born infants￨motor developmental program control or intervention group developmental program￨motor performance motor performance￨the intervention group showed the greatest improvement￨sig increase￨highunclear￨highunclear￨highunclear
80￨80 low birthweight infants normal and atrisk survivors of neonatal intensive care￨early neurodevelopmental therapy monthly hospitalbased neurodevelopmental therapy in addition to a home exercise programme￨mean birthweight and gestational age mean neurodevelopmental scores￨atrisk infants had higher mean neurodevelopmental scores throughout the study period and lower 1year development quotients dq than normals￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨very preterm infants 6 neonatal centers two hundred thirtythree babies 32 weeks gestation were recruited intervention  112 control  121 all 195 infants remaining in the study at 24 months corrected age were assessed by psychologists blinded to group allocation preterm infants with high biological and social risk￨standard care weekly parent baby interaction programme pbip sessions parenting intervention pbip neonatal parenting intervention￨mental development index or psychomotor development index scores mental development index psychomotor development index￨there was no significant difference in mental development index 09 points 95 ci 50 32 or psychomotor development index 25 33 84 scores between the intervention and control groups and no significant effect of intervention on mental development index or psychomotor development index scores for subgroups dichotomized by gestational age 28 weeks or 28 weeks parity 1stother child or mothers cohabiting status supportedunsupported￨no diff￨low￨low￨low
36￨vlbw children vlbw infants very low birth weight infants children born very low birth weight vlbw 36 vlbw infants mean sd￨early postdischarge developmental motherchild intervention program preventive early intervention programs early developmental motherchild intervention program￨personalsocial subscales eyehand coordination practical reasoning development scale￨at 36 months of chronological age as compared to controls children in intervention group exhibited higher scores in personalsocial subscales mean sd1014 93 vs 929 121 p002 eyehand coordination 927 45 vs 871 99 p0041 practical reasoning 986 82 vs 894 101 p001￨sig increase￨highunclear￨highunclear￨highunclear
37￨severe prematurity and central nervous system injury neonatal intensive care unit thirtyseven infants with severe central nervous system injury or extreme prematurity￨multisensory auditorytactilevisualvestibular intervention or control group auditorytactilevisualvestibular intervention￨periventricular leukomalacia cerebral palsy diagnoses motor and mental performance￨experimental infants tended to exhibit better motor and mental performance and had 23 fewer cerebral palsy diagnoses at 1 year but these trends were not statistically significant￨sig increase￨highunclear￨highunclear￨highunclear
not found￨42 mothers of lowbirthweight lbw premature infants hospitalized in a neonatal intensive care unit nicu with followup at 3 months and 6 months corrected ages mothers lowbirthweight premature infants with the cope program￨parentfocused intervention program cope early nicu intervention￨mental development scores infant cognitive development and maternal coping￨cope mothers were significantly less stressed by the nicu sights and sounds and had significantly stronger beliefs about what behaviors and characteristics to expect from their premature infants￨sig increase￨highunclear￨highunclear￨highunclear
72￨infants born very preterm with vlbw infants born very preterm with very low birth weight vlbw seventytwo infants born very preterm with vlbw very preterm very low birth weight infants￨physical therapy pt intervention pt intervention early physical therapy intervention nontreatment nt￨parental compliance t groups motor performance abnormal motor development motor performance￨the t group subjects with high levels of parental compliance had better scores on the aims than those with lower parental compliance p  005￨sig increase￨highunclear￨highunclear￨highunclear
69￨low birth weight children at 2 years corrected age low birth weight children sixtynine children in the intervention group and 67 in the control group were assessed at 2 years infants with a birth weight 2000￨early intervention program￨bayley scales of infant development and the child behavior checklist23 cbcl and the parenting stress index cognitive motor and behavioral outcomes and parenting stress cbcl syndrome scales risk of cognitive motor and behavioral problems cognitive or motor outcomes cognitive motor and behavioral problems and parenting stress parenting stress parental stress cognitive motor or behavioral outcomes￨there were no differences between the groups in cognitive or motor outcomes￨no diff￨highunclear￨highunclear￨highunclear
86￨very low birth weight infants at 6 months corrected age 86 infants to 1 intervention before discharge and to 6 to 8 home interventions until 6 months corrected age and 90 control infants received very low birth weight vlbw infants￨infant behavioral assessment and intervention program ibaip standard care￨mental developmental index developmental and behavioral outcomes infant behavioral assessment iba psychomotor developmental index behavioral rating scale of the bsidii neurobehavioral functioning ibaip improved the mental motor and behavioral outcomes iba￨the behavioral rating scale of the bsidii p  000 and the iba more approach p  003 and less stress p  001 over time also favored the intervention infants￨sig increase￨highunclear￨highunclear￨highunclear
not found￨lowbirthweight premature infants￨ihdp intervention￨￨the data we present reveal the considerable effectiveness of the ihdp intervention in enhancing several aspects of early and later child and family development￨sig increase￨highunclear￨highunclear￨highunclear
15￨premature infants 15 premature infants highrisk infants￨rice infant sensorimotor stimulation treatment￨mental development weight gain neurological development￨the results indicated the experimental infants made significant gains in neurological development p less than 001 weight gain p less than 04 and mental development p less than 05￨sig increase￨highunclear￨highunclear￨highunclear
104￨104 infants with birth weights of less than 1000 grams￨occupational therapy based on sensory integration si and neurodevelopmental therapy ndt occupational therapy￨social development￨it is concluded that this amount of occupational therapy in atrisk children does not have a relevant effect on neurological development￨no diff￨highunclear￨highunclear￨highunclear
41￨41 premature infants weighing less than 1800 infants and their caregivers highrisk premature infants￨developmental intervention program traditional remedially oriented care￨mental development and on the quality of caregiverinfant interactions￨changes in mental development were not independent of changes in the glos￨no diff￨highunclear￨highunclear￨highunclear
23￨low birthweight infants with cerebral injuries subjects were 23 highrisk low birthweight infants periventricular leukomalacia 15 intraventricular haemorrhage 5 both 3 receiving care in the neonatal intensive care unit nicu at nagasaki university hospital￨eip early intervention programme routine medical nursing care without the eip early intervention programme eip neonatal behavioral assessment scale nbasbased intervention combined with developmental support￨bayley mental developmental index mdi score maternal anxiety status stai and maternal feelings of confidence in dealing with her baby lcc orientation and state regulation of infant behavioural profiles the stai and lcc scores neonatal neurobehavioural development and maternal mental health￨orientation and state regulation of infant behavioural profiles the stai and lcc scores significantly improved in the eip group mean difference 95 ci￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨￨￨comparison of the recidivism rates of offenders subject to this policy with offenders in similar nearby courts not using interlocks indicated that the policy was producing substantial reductions in dui recidivism￨no diff￨highunclear￨highunclear￨highunclear
not found￨dui offenders participating in interlock programs for 6 months for first offenders and 2 years for second offenders were compared with similar offenders who chose not to participate a provincewide program in alberta canada 35132 drivers convicted of dui between 1 july 1998 and 30 september 1996 were analyzed
                repeat dui offenses during and after the interlock period￨￨overall effectiveness dui rate￨interlocks are associated with a major reduction in dui recidivism while on the vehicle of the offender￨sig decrease￨highunclear￨highunclear￨highunclear
1387￨1387 multiple offenders eligible for license reinstatement drivers with multiple alcohol offenses drivers with multiple alcoholrelated traffic offenses￨ignition interlock program experimental group or in the conventional postlicensing treatment program control group statewide ignition interlock license restriction program ignition interlock license restrictions￨alcohol traffic violation rate￨the alcohol traffic violation rate during the first year was significantly less for participants in the interlock program 24 than for those in the control group 67￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients with postoperative pain after third molar surgery over a 6 h investigation period postoperative pain after third molar surgery￨placebo ketoprofen ketoprofen and paracetamol acetaminophen paracetamol racemic ketoprofen￨later time to taking escape analgesics pain scores pain relief overall pain scores overall pain scores auc0360 min maximum pain relief pain relief at 1 h after dosage and the number of patients taking escape analgesics￨at 1 h after dosage pain scores were significantly less p  001 after both doses of ketoprofen when compared with placebo￨sig decrease￨highunclear￨highunclear￨highunclear
120￨120 patients suffering from pain as a result of oral surgery rated their pain intensity and pain relief for up to 5 hours after a single dose of one of 1000 mg￨acetaminophen placebo codeine codeine 1000 mg acetaminophen plus 60 mg codeine or placebo￨adverse effects additive analgesic efficacy efficacy sum of pain intensity differences largest pain intensity difference total pain relief largest pain relief and time to remedication analgesic effectiveness￨the factorial analysis showed that both 1000 mg acetaminophen and 60 mg codeine made a statistically significant p less than 005 contribution to the analgesic effectiveness of the combination on all measures of efficacy sum of pain intensity differences largest pain intensity difference total pain relief largest pain relief and time to remedication￨sig increase￨highunclear￨highunclear￨highunclear
146￨146 patients were evaluated￨combination suprofen 100 mg  apap suprofen 400 mg and apap suprofen alphamethyl42thienylcarbonylbenzene acetic acid suprol 200 mg suprofen 400 mg paracetamol apap acetaminophen 650 mg and combination suprofen 100 mg  apap 650 mg versus placebo suprofen suprofen 100 mg  apap￨analgesic effects side effects￨statistical significance was only seen for the parameter pain intensity spid on comparison of suprofen 100 mg  apap 650 mg versus suprofen 200 mg￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with acute pain acute pain 184 patients who had undergone dental impaction surgery rated￨ibuprofen 400 mg and acetaminophen placebo acetaminophen ibuprofen and acetaminophen ibuprofen ibuprofen￨total pain relief totpar pain intensity and relief on categorical scales and pain halfgone on a dichotomous nominal scale a categorical overall evaluation relative analgesic efficacy sum pain halfgone and overall evaluation sum pain intensity difference spid side effects￨ibuprofen 400 mg was more effective than acetaminophen 1000 mg for sum pain intensity difference spid￨sig increase￨highunclear￨highunclear￨highunclear
210￨oral surgery pain 210 patients experiencing moderate or severe postoperative pain patients experiencing moderate or severe pain after surgical removal of impacted third molars￨placebo ibuprofen liquigel 200 mg ibuprofen liquigel 400 mg acetaminophen caplets 1000 mg and placebo ibuprofen liquigel acetaminophen ibuprofen￨peak and overall analgesic effects ratings of pain intensity and pain relief pain relief pain intensity difference total pain relief totpar and summed pain intensity difference spid rapid onset to meaningful relief analgesic efficacy and tolerability meaningful relief onsets of first perceptible relief and meaningful relief drug tolerability￨ibuprofen liquigel 200 and 400 mg were also significantly more efficacious than acetaminophen 1000 mg on the summary measures totpar 6 and spid 6 p  001 and p  0001 respectively￨sig increase￨low￨highunclear￨low
706￨postoperative dental pain 706 patients who were experiencing moderate to severe pain￨ibuprofen acetaminophen or placebo ibuprofen ibuprofen and acetaminophen￨degree of pain relief and tolerance￨oral surgery pain is a reliable model to reference the effectiveness of commonly used analgesics such as ibuprofen and acetaminophen￨sig increase￨highunclear￨highunclear￨highunclear
not found￨subjects were healthy postpartum women on the obstetric service of goa medical college each of whom received only one experimental medication postepisiotomy pain￨analgesics namely ibuprofen analgin paracetamol and aspirin placebo ibuprofen aspirin￨analgesic efficacy pain intensity or relief￨ibuprofen was found to be the most effective analgesic in postepisiotomy pain followed by analgin and paracetamol in that order￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨acetaminophen acetaminophen analgesia oral acetaminophen 1 g n50 or placebo placebo￨adverse events parameters pain relief pain intensity patients global evaluation duration of analgesia local adverse events analgesic efficacy efficacy and safety￨propacetamol bolus resulted in a much higher incidence of local adverse events than the infusion propacetamol bolus 90 vs propacetamol infusion 52 with no clinically significant benefits in terms of analgesic efficacy￨sig increase￨highunclear￨highunclear￨highunclear
not found￨postsurgical dental outpatients as subjects￨acetaminophen acetaminophen 650 of acetaminophen with 60 mg of codeine 650 mg of acetaminophen with 100 mg of dpropoxyphene n and a placebo placebo indoprofen￨small additive effects sum pain intensity difference total relief of pain and overall evaluation parameters intensity of pain relief of pain and side effects￨all four active treatments were statistically superior to placebo for sum pain intensity difference total relief of pain and overall evaluation parameters￨sig increase￨highunclear￨highunclear￨highunclear
not found￨oral surgery pain subjects were dental outpatients undergoing oral surgery involving bone removal￨codeine and caffeine placebo acetaminophen acetaminophencodeinecaffeine combination acetaminophen 1000 mg acetaminophen 1000 mg  codeine 16 mg  caffeine 30 mg and placebo￨￨overall the combination was slightly better than acetaminophen alone￨sig increase￨highunclear￨highunclear￨highunclear
240￨patients with postoperative dental pain 240 patients with moderatetosevere postoperative dental pain￨placebo ibuprofen lysine 400 mg and acetaminophen ibuprofen lysine acetaminophen ibuprofen lysine and acetaminophen ibuprofen lysine 400 mg with acetaminophen 1000 mg and placebo￨patient selfrating of pain intensity pain relief time to meaningful pain relief need for additional analgesic medication and patient global evaluation overall analgesic effect tolerated analgesic efficacy relative onset of analgesic response overall analgesic efficacy duration of effect and safety￨ibuprofen lysine had a significantly p  or  005 faster onset of action with greater peak and overall analgesic effect than did effect than did acetaminophen￨sig increase￨highunclear￨highunclear￨highunclear
242￨postoperative dental pain 242 patients with moderate or severe pain following dental surgery￨acetaminophen effervescent acetaminophen tablet acetaminophen placebo￨analgesia pain intensity and pain relief and summary measures pain relief median time to onset of analgesia median time to meaningful pain relief analgesic efficacy￨at 4 hours after administration the pain relief was significantly better with tablet acetaminophen than with effervescent acetaminophen￨sig increase￨highunclear￨highunclear￨highunclear
not found￨n  38 in postpartum patients who had moderate to severe pain after episiotomy￨placebo acetaminophen ibuprofen and acetaminophen ibuprofen ibuprofen￨relative analgesic efficacy adverse effects pain intensity difference total pain relief and reduction of pain relief of postpartum episiotomy pain pain severity and relief on categorical scales￨ibuprofen 400 mg was more effective than acetaminophen 1000 mg for the sum of pain intensity difference total pain relief and reduction of pain by more than 50 p less than 05 suggesting a more rapid onset of action and a more prolonged effect by ibuprofen 400 mg￨sig increase￨highunclear￨highunclear￨highunclear
206￨twohundred six outpatients with postoperative pain after the surgical removal of impacted third molars postoperative oral surgery pain￨ketorolac tromethamine 10 and 20 mg ibuprofen 400 mg acetaminophen 600 mg a combination of acetaminophen 600 mg plus codeine 60 mg or placebo placebo acetaminophen acetaminophencodeine ketorolac ketorolac ibuprofen acetaminophen and an acetaminophencodeine combination ibuprofen￨frequency of adverse effects analgesia￨analgesia was similar for ketorolac 10 and 20 mg and ibuprofen 400 mg however these treatments were superior to acetaminophen alone and the acetaminophencodeine combination￨no diff￨highunclear￨highunclear￨highunclear
120￨acute pain relief after third molar surgery 120 patients with moderate to severe pain after third molar surgery￨rofecoxib placebo paracetamol and rofecoxib paracetamol paracetamol with a selective cyclooxygenase2 inhibitor rofecoxib rofecoxib  paracetamol rofecoxib alone paracetamol alone or placebo paracetamol and rofecoxib paracetamol￨analgesic effect level of pain and pain relief severe pain pain relief analgesic effects￨paracetamol and rofecoxib combined improved the analgesic effect compared with rofecoxib alone for the first 15 h rofecoxib alone and the combination of paracetamol and rofecoxib had a significantly better analgesic effect than paracetamol alone from 3 h onwards￨sig increase￨low￨low￨low
not found￨orthopedic postoperative pain￨prostaglandin synthetase inhibitor bromfenac were compared with acetaminophen acetaminophen acetaminophen and placebo placebo￨standard verbal rating and visual analog scales pain intensity and pain relief measurements pain intensity and pain relief remedication time￨for most pain intensity and pain relief measurements 1000 mg acetaminophen was statistically superior to placebo demonstrating assay sensitivity and 10 and 25 mg doses of bromfenac were statistically better than both placebo and 5 mg bromfenac for ordinal and analog ratings of pain intensity and pain relief 25 mg bromfenac produced significantly longer time to remedication than acetaminophen￨sig increase￨highunclear￨highunclear￨highunclear
148￨patients with headache and musculoskeletal pain 148 outpatients with pain after oral surgery postoperative oral surgery pain￨acetaminophen acetaminophen phenyltoloxamine acetaminophenphenyltoloxamine acetaminophen 650 mg phenyltoloxamine 60 mg a combination of acetaminophen 650 mg with phenyltoloxamine 60 mg or placebo￨analgesic effect total and peak analgesia analgesia￨although efficacy was lower for the acetaminophenphenyltoloxamine combination than for acetaminophen alone for every variable the contrast for interaction was not statistically significant￨sig increase￨highunclear￨highunclear￨highunclear
not found￨129 inpatients after surgery￨placebo codeine nalbuphine acetaminophen acetaminophen acetaminophen or placebo nalbuphine nalbuphine and acetaminophen nalbuphine hydrochloride aspirin or acetaminophen nalbuphine 30 mg and acetaminophen￨analgesic effect total and peak analgesia￨there were few adverse effects other than sedation which occurred twice as frequently in patients treated with nalbuphine as in those receiving acetaminophen or placebo￨no diff￨highunclear￨highunclear￨highunclear
239￨239 patients with moderate or severe pain following third molar extractions￨liquigel ibuprofen placebo placebo ketoprofen ibuprofen acetaminophen ibuprofen ketoprofen ibuprofen and ketoprofen ibuprofen liquigel ibuprofen 400 mg ketoprofen acetaminophen and ketoprofen￨faster relief and superior overall efficacy time to onset of relief and overall analgesic efficacy pain relief and pain intensity difference postoperative dental pain serious adverse effects onset of meaningful relief pain intensity and relief and stopwatch onset of meaningful relief median times to onset of relief meaningful relief￨in addition both ibuprofen and ketoprofen showed statistical superiority over acetaminophen at earlier time points on the timeeffect curves for pain relief and pain intensity difference￨no diff￨highunclear￨highunclear￨highunclear
not found￨two hundred ninetyeight patients with postoperative pain after the surgical removal of an impacted third molar postoperative oral surgery pain￨placebo piroxicambetacyclodextrin and paracetamol piroxicam piroxicam 20 mg or piroxicambetacyclodextrin equivalent to 20 mg piroxicam or paracetamol 500 mg or placebo piroxicambetacyclodextrin piroxicam paracetamol and placebo paracetamol￨tolerability￨piroxicambetacyclodextrin and paracetamol were more rapid than piroxicam in inducing analgesia￨sig increase￨highunclear￨highunclear￨highunclear
not found￨outpatients who experienced moderate to severe pain after surgical removal of inpacted third molars￨oxycodone and acetaminophen oxycodone placebo acetaminophen acetaminophen and oxycodone oxycodone￨postoperative dental pain￨a positive doseeffect relationship was evident for both acetaminophen 500 mg￨sig increase￨highunclear￨highunclear￨highunclear
not found￨eighty patients took part pain relief after orthopedic surgery￨paracetamol tiaramide and placebo tiaramide hydrochloride 100 mg and 200 mg paracetamol 1000 mg and placebo placebo paracetamol￨pain relief pain intensity differences pain relief visual analogue pain scale and a pain score adverse reactions analgesic efficacy￨statistically significant pain relief mean pain intensity differences and sum of pain intensity differences was seen in the group receiving paracetamol compared to those receiving placebo or tiaramide from 1 h to 6 h after drug ingestion￨sig increase￨highunclear￨highunclear￨highunclear
17￨moderate and strong postoperative pain after abdominal surgery 17 patients were excluded from the analysis of effects 108 patients included in the analysis of analgesic effect 49 patients had moderate baseline pain vas between 40 and 60 mm on a 100 mm scale and 59 patients had strong baseline pain vas more than 60 mm after caesarean section in 125 patients pain after surgery￨placebo paracetamol codeine codeine and paracetamol paracetamol 800 mg plus codeine 60 mg paralgin forte and placebo￨assaysensitivity and test power time to rescue analgesic efficacy variables visual analogue pain intensity score vas 0100 mm and categorical pain relief score total pain relief during the first 3 and 6 h global evaluation score pain relief pain intensity difference and summed pain intensity differences￨however in patients with moderate baseline pain no differences were found between the study drugs in any of the analgesic efficacy variables￨no diff￨low￨low￨low
not found￨subjects undergoing the surgical removal of impacted third molars ambulatory patients￨placebo acetaminophen 650 mg plus codeine acetaminophen acetaminophen plus codeine and placebo acetaminophen placebo acetaminophen and acetaminophen plus codeine acetaminophen plus codeine acetaminophen and codeine flurbiprofen￨side effects analgesic efficacy pain intensity pain relief and side effects pain intensity difference pain relief and global evaluation analgesic efficacy severe postoperative pain￨both doses of flurbiprofen resulted in significant analgesia in comparison with placebo acetaminophen and acetaminophen plus codeine as measured by pain intensity difference pain relief and global evaluation￨sig increase￨highunclear￨highunclear￨highunclear
162￨162 outpatients who had experienced moderate or severe pain as a result of dental surgery involving bone removal patients with severe initial pain￨placebo acetaminophen acetaminophen and aspirin acetaminophen aspirin￨maximum pain relief intensity of their pain intensity of pain postoperative pain analgesic effects￨acetaminophen was significantly better than aspirin with respect to the maximum difference in the intensity of pain p less than 005 and the maximum pain relief achieved p less than 003 and according to the global evaluation p less than 002￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨postoperative dental pain 177 patients experiencing moderate to severe pain after surgical removal of their impacted third molars￨placebo acetaminophen 1000 mg and placebo r ketoprofen acetaminophen ketoprofen both r ketoprofen acetaminophen 1000 mg r ketoprofen r ketoprofen￨side effects serious adverse events analgesic efficacy and safety analgesic efficacy and safety￨r ketoprofen possesses analgesic activity and an acceptable sideeffect profile in the oral surgery pain model￨sig increase￨highunclear￨highunclear￨highunclear
not found￨two hundred male and female patients underwent a oral postsurgical pain￨placebo drug alone or placebo acetaminophen variety of oral surgical procedures analgesic codeineasa orphenadrine orphenadrineacetaminophen￨moderately severe baseline pain intensity posttreatment pain relief pain intensity difference pid and sums of pain intensity difference spid pain relief pid and spid scores analgesic efficacy additional pain relief￨statistical analyses indicated better analgesic efficacy in both pid and spid scores for the orphenadrineacetaminophen combination over the three other treatments￨sig increase￨highunclear￨highunclear￨highunclear
45￨postoperative dental pain￨placebo acetaminophen naproxen sodium naproxen sodium naproxen sodium acetaminophen and placebo￨analgesic efficacy peak pain intensity difference visual analog scale summed pain intensity differences total pain relief peak pain relief time to reduction of pain duration of analgesic effect￨time to remedication a measure of duration of analgesic effect was significantly longer p  0001 with naproxen sodium median 99 hours than with either acetaminophen median 31 hours or placebo median 20 hours￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨a total of 226 postsurgical dental patients 146 females and 80 males participated in the study￨acetaminophencodeine flurbiprofen flurbiprofen acetaminophen 650 mg with codeine 60 mg zomepirac sodium 100 mg and placebo acetaminophen with codeine￨analgesic efficacy effective analgesic activity￨flurbiprofen in 50 mg and 100 mg dosages demonstrated effective analgesic activity with the 100 mg dosage being at least as effective as the acetaminophencodeine combination￨sig increase￨highunclear￨highunclear￨highunclear
1345￨1345 patients 173 patients￨acetaminophen and 65 mg caffeine acetaminophen placebo caffeine￨analgesic efficacy acetaminophen analgesia pain intensity differences￨the mean scores for the summary variable percent sum of the pain intensity differences  spid were higher in all for the combination than for acetaminophen alone and in two studies the null hypothesis of no differences was rejected￨sig increase￨highunclear￨highunclear￨highunclear
not found￨128 hospitalized patients with postoperative pain postoperative pain￨placebo oral nalbuphine acetaminophen nalbuphine acetaminophen and placebo acetaminophen nalbuphine nalbuphine and acetaminophen￨analgesic response analgesic effects total and peak analgesia frequency or intensity of side effects￨both nalbuphine and acetaminophen were significantly superior to placebo for most measures of total and peak analgesia￨sig increase￨highunclear￨highunclear￨highunclear
240￨severe postoperative pain 240 patients with severe postoperative pain after cesarean section￨ketoprofen acetaminophen or placebo ketoprofen orudis ketoprofen acetaminophen plus 5 mg oxycodone ketoprofen acetaminophen plus oxycodone and acetaminophen acetaminophen plus 10 mg oxycodone hydrochloride acetaminophen and placebo￨analgesia analgesia adverse effects relief of postoperative pain remedication time efficacy and safety￨the 100 and 50 mg doses of ketoprofen and the combination were statistically superior to acetaminophen and placebo for many analgesic measures￨sig increase￨highunclear￨highunclear￨highunclear
not found￨patients with moderate to severe postoperative pain following the surgical removal of a wisdom tooth￨paracetamol tylenol and acetyl salicylic acid aspirin placebo paracetamol acetyl salicylic acid￨￨the most important finding was the statistically significantly shorter period until the onset of the action of paracetamol as against acetyl salicylic acid￨no diff￨highunclear￨highunclear￨highunclear
not found￨116 patients￨placebo codeine codeine codeine and acetaminophen codeine 60 mg acetaminophen￨pain relief￨codeine 60 mg was not consistently superior to placebo in this postoperative single dose analysis￨no diff￨highunclear￨highunclear￨highunclear
60￨120 postoperative patients employing a doubleblind experimental design postoperative pain￨combination product butorphanol 2 mgacetaminophen placebo butorphanolacetaminophen acetaminophen butorphanolacetaminophen butorphanol￨pain relief analgesic activity￨the combination product was significantly p less than 005 superior to either butorphanol 4 mg or acetaminophen 650 mg as well as placebo￨sig increase￨highunclear￨highunclear￨highunclear
not found￨two hundred female inpatients who had severe pain associated with a recent episiotomy procedure￨acetaminophen analgesia acetaminophen plus 60 mg phenyltoloxamine citrate placebo antihistamine phenyltoloxamine acetaminophen alone acetaminophen phenyltoloxamine￨analgesic activity analgesia spid total and global ratings￨the combination was significantly superior to acetaminophen alone for all analgesic measures including spid total and global ratings￨sig increase￨highunclear￨highunclear￨highunclear
167￨postoperative pain after third molar surgery patients with postoperative pain after third molar surgery 3470 one hundred and sixtyseven patients consented to take part in the study but only 153 were medicated one hundred and sixtyseven 104 female patients who required the removal of their impacted third molars under general anaesthesia￨placebo soluble aspirin and solid paracetamol soluble aspirin 900 mg and paracetamol soluble aspirin 900 mg solid paracetamol 1000 mg or placebo soluble aspirin paracetamol￨number of patients requiring rescue medication rapid analgesia pain intensity pain pain intensity adverse reaction￨there were no significant differences between treatment groups with respect to the number of patients requiring rescue medication however the time to dosing was significantly longer for those taking soluble aspirin when compared with placebo hazard ratio 234 95 ci 141 to 388 p0001￨no diff￨low￨low￨low
not found￨postoperative dental pain patients with moderate or severe pain within 8 hours of extraction of impacted third molars pain resulting from extraction of impacted third molar teeth￨placebo diclofenack 125 mg tablets vs paracetamol 500 mg tablets and placebo paracetamol and placebo lowdose diclofenac diclofenack paracetamol￨incidence of adverse events pain relief overall pain relief analgesic efficacy efficacy and safety￨pain relief after the initial dose of diclofenack 2 x 125 mg was superior to placebo p  01 for all efficacy outcomes and comparable to paracetamol 2 x 500 mg￨sig increase￨highunclear￨highunclear￨highunclear
500￨patients with moderate to severe postpartum pain 500 postpartum patients experiencing moderate to severe pain a single oral dose of an￨aspirincaffeine combination 800 mg aspirin 65 mg caffeine placebo acetaminophen acetaminophen alone 1000 mg acetaminophen acetaminophenaspirin combination aspirincaffeine acetaminophen 648 mg aspirin acetaminophenaspirin aspirincaffeine combination versus acetaminophenaspirin combination versus acetaminophen versus placebo caffeine￨pain relief adverse reactions￨at 3 and 4 hours the acetaminophenaspirin combination as well as the aspirincaffeine combination were significantly superior to acetaminophen alone￨sig increase￨highunclear￨highunclear￨highunclear
88￨eightyeight outpatients with postoperative pain after the surgical removal of impacted third molars postoperative oral surgery pain￨placebo acetaminophen codeine acetaminophen flurbiprofen flurbiprofen 100 mg acetaminophen 600 mg a combination of acetaminophen 600 mg with codeine 60 mg or placebo acetaminophencodeine combination and placebo acetaminophencodeine flurbiprofen acetaminophen flurbiprofen￨frequency of adverse effects number of hours until remedication total and peak analgesia pain intensity differences peak pain intensity differences total relief peak relief and hours of 50 relief￨flurbiprofen was significantly superior to the acetaminophen codeine combination with respect to the number of hours until remedication￨sig increase￨highunclear￨highunclear￨highunclear
182￨182 patients entered the study with moderate pain from a third molar extraction and were evaluated for six hours￨placebo codeine acetaminophen alone and placebo acetaminophen flurbiprofen ansaid upjohn flurbiprofen zomepirac sodium acetaminophen plus codeine and acetaminophen acetaminophen plus codeine acetaminophen acetaminophen plus codeine or placebo zomepirac sodium 650 mg of acetaminophen plus 60 mg of codeine flurbiprofen￨relative analgesic efficacy and safety adverse reactions pain relief mean scores mean response with zomepirac postsurgical dental pain analgesic effects￨for many efficacy variables all active treatments were significantly p less than or equal to 005 more effective than placebo￨sig increase￨highunclear￨highunclear￨highunclear
132￨postoperative pain 132 inpatients with postoperative pain￨placebo acetaminophen 600 mg with codeine 60 mg and placebo acetaminophen diflunisal diflunisal acetaminophencodeine acetaminophen diflunisal acetaminophen and acetaminophencodeine combination and placebo￨analgesic effect analgesic efficacy total or peak analgesia total and peak analgesia￨acetaminophen alone and the acetaminophencodeine combination were significantly superior to placebo for most measures of analgesia and their effects were significant for 4 and 5 hours respectively￨sig increase￨highunclear￨highunclear￨highunclear
not found￨159 oral surgery outpatients￨placebo diflunisal dolobid acetaminophen diflunisal diflunisal acetaminophencodeine acetaminophen codeine phosphate 60 mg and placebo￨analgesic efficacy side effects peak analgesia￨both doses of diflunisal were significantly more effective than acetaminophen alone and produced peak analgesia comparable to that of the acetaminophencodeine combination￨sig increase￨highunclear￨highunclear￨highunclear
359￨359 patients were randomised eligible patients requiring patients with an increase in forced expiratory volume in 1s fev1 of 7 or 015 l persistent asthma￨ciclesonide and budesonide ciclesonide 320 microg exactuator equivalent to 400 microg exvalve via a hydrofluoroalkanemetered dose inhaler hfamdi without a spacer or budesonide budesonide or equivalent 320640 microg exmouthpiece equivalent to 400800 microg turbohalertrade mark daily entered a 2week baseline and then a 2 to 4week pretreatment period budesonide 1280 microgday exmouthpiece ciclesonide budesonide ciclesonide fev1 ciclesonide￨rescue medication use asthma symptom scores frequency of adverse events fev1 and forced vital capacity fvc efficacy and safety￨for fvc ciclesonide was statistically superior to budesonide p0010￨sig increase￨highunclear￨highunclear￨highunclear
554￨five hundred fiftyfour patients were randomized 301 men 253 women mean age 413 years male and female patients aged 12 to 75 years with primarily mild to moderate asthma were enrolled 62 study sites across europe patients with persistent asthma patients with asthma 182 patients patients with primarily mild to moderate asthma￨inhaled ciclesonide 80 or 320 microg qd morning or budesonide ciclesonide and budesonide corticosteroid ics ciclesonide budesonide budesonide ciclesonide ciclesonide ciclesonide 80 microg qd ciclesonide qd with budesonide bid placebofor budesonide￨forced expiratory volume in 1 second fev1 efficacy and tolerability assessments urinary cortisol suppression pulmonary function controlling asthma symptoms standard laboratory variables hematology and biochemistry physical examination including vital signs reporting of adverse events aes and 24hour urinary cortisol as a measure of hypothalamicpituitaryadrenalaxis function morning peak expiratory flow pef asthma symptom scores and rescue medication use week12 daily daytime and nighttime asthma symptom scores and rescue medication use prevalences of aes efficacy and tolerability tolerability week12 mean urinary cortisol excretion￨week12 daily daytime and nighttime asthma symptom scores and rescue medication use were significantly decreased from baseline in all 3 treatment groups all p0001￨sig decrease￨low￨low￨low
556￨children with asthma 556 children ages 615 years with asthma children and adolescents with persistent asthma￨fp cic with fluticasone propionate fp cic inhaled ciclesonide cic 80 microg exactuator equivalent to 100 microg exvalve or fp 88 microg exactuator equivalent to 100 microg exvalve administered via a hydrofluoroalkanepropelled metereddose inhaler ciclesonide cic fluticasone propionate￨creatinineadjusted 24hr urine cortisol levels asthma symptoms use of rescue medication and asthma symptomfree days fev1 voice alteration morning and evening peak expiratory flow oral candidiasis efficacy and safety￨significant improvements were seen in asthma symptoms use of rescue medication and asthma symptomfree days in both treatment groups without any differences between the treatment groups in changes from baseline￨sig increase￨highunclear￨highunclear￨highunclear
528￨528 patients were patients with moderate or severe persistent asthma enrolled patients aged 1275 years with a 6month history of bronchial asthma patients with moderatetosevere persistent asthma six patients receiving￨ciclesonide 320 microg exactuator or twicedaily fp randomized ciclesonide ciclesonide 11 ml fp 24 ml ciclesonide 320 microg and fp ciclesonide ciclesonide and seven receiving fp itt analysis oral corticosteroids ciclesonide and fluticasone propionate ciclesonide and fluticasone propionate fp ciclesonide salbutamol￨efficacy reversibility of delta fev candidiasis and dysphonia with fp asthma symptom score standardized version of the asthma quality of life questionnaire aqlqs overall aqlqs score lung function asthma exacerbations asthma symptoms and rescue medication use adverse events aes including local oropharyngeal aes￨both treatments significantly decreased asthma symptom score sum itt and pp analyses p00001 and rescue medication use itt and pp analyses p005 with no significant difference between treatments￨sig decrease￨low￨low￨low
not found￨patients with persistent asthma patients aged 1275 years with persistent asthma￨ciclesonide and twice daily fluticasone propionate fluticasone ciclesonide fluticasone propionate ciclesonide 80 micro g or 160 micro￨efficacy and tolerability efficacy and safety forced expiratory volume in 1 second asthma symptom scores and rescue medication use asthma exacerbation rates￨significant improvements from baseline were seen in all three treatment groups for forced expiratory volume in 1 second asthma symptom scores and rescue medication use all p  00001￨sig increase￨highunclear￨highunclear￨highunclear
164￨adults with mildtomoderate persistent asthma one hundred sixtyfour patients were randomized and treated 148 patients completed the study adults with mildtomoderate asthma￨fluticasone propionate chlorofluorocarbon propellant ciclesonide hydrofluoroalkane propellant placebo ciclesonide therapy ciclesonide ciclesonide and fluticasone fluticasone propionate sequential low and highdose cosyntropin stimulation￨oral candidiasis rates hypothalamicpituitaryadrenal axis function dynamic cortisol response 24hour urinary free cortisol levels mean low and highdose peak serum cortisol levels serum cortisol levels￨oral candidiasis rates were 25 for 320microgd ciclesonide 24 for 640microgd ciclesonide and 220 for 880microgd fluticasone propionate￨no diff￨highunclear￨highunclear￨highunclear
311￨adults with mild to moderate asthma adult patients with mild to moderate asthma￨placebo ciclesonide beclomethasone dipropionate ciclesonide or placebo ciclesonide inhaled corticosteroids￨safety and tolerability profile efficacy and safety morning pef efficacy and safety￨oncedaily administration of ciclesonide at doses of 100 200 or 400 microg was shown to be effective in adult patients with mild to moderate asthma￨sig increase￨low￨low￨low
not found￨patients with mild allergic asthma￨fluticasone ciclesonide ciclesonide and fluticasone ciclesonide and fluticasone propionate ciclesonide￨clinical improvement asthmatic symptoms and consumption of rescue medication feno levels exhaled nitric oxide feno pulmonary function spirometric indices exhaled nitric oxide￨statistical differences between the groups were not found however there was a trend toward higher increase in the group receiving 160 microg of ciclesonide￨no diff￨highunclear￨highunclear￨highunclear
529￨asthma 529 patients patients with asthma￨ciclesonide ciclesonide 160 microg once daily or fluticasone propionate ciclesonide and fluticasone propionate ciclesonide fluticasone propionate inhaled corticosteroids￨forced expiratory volume in 1s forced vital capacity and morning peak expiratory flow asthma symptoms and rescue medication use change in lung function equally safe and well tolerated lung function and asthma symptoms efficacy and safety￨both ciclesonide and fluticasone propionate significantly improved forced expiratory volume in 1s forced vital capacity and morning peak expiratory flow compared with baseline￨sig increase￨low￨low￨low
405￨adults with persistent asthma adults with stable asthma that was pretreated with inhaled corticosteroids patients n  405￨openlabel budesonide ciclesonide 160 mug qd ciclesonide ciclesonide 160 microg qd am budesonide ciclesonide 160 microg qd and budesonide 200 microg bid ciclesonide and budesonide maintained fev1 ciclesonide budesonide 200 microg bid ciclesonide 160 microg qdwas medication or placebo￨spirometric forced expiratory volume in 1 second fev1 in liters incidence of adverse events adverse events tolerated pulmonary function asthma symptom scores and rescue medication use forced vital capacity peak expiratory flow by spirometry and diary assessments of peak expiratory flow asthma symptoms and rescue medication use￨the incidence of adverse events was not significantly different among the treatment groups and most adverse events were not related to study medication￨no diff￨low￨low￨low
621￨six hundred and twentyone children aged 611 yr with asthma children with asthma￨ciclesonide vs budesonide ciclesonide and budesonide corticosteroid ics ciclesonide ciclesonide 160 microg exactuator once daily via hydrofluoroalkane metereddose inhaler and aerochamber plus spacer or budesonide 400 microg once daily via turbohaler both given in the evening for 12 wk budesonide ciclesonide￨body height and suppression of 24h urinary cortisol excretion quality of life qol asthma symptoms morning pef use of rescue medication and qol daily peak expiratory flow pef change in asthma symptom score sum change in use of rescue medication paediatric and caregiver asthma qol questionnaire paqlqs and pacqlq respectively scores change in body height assessed by stadiometry change in 24h urinary cortisol adjusted for creatinine and adverse events fev1 tolerated body height hypothalamicpituitaryadrenal axis forced expiratory volume in 1 s fev1 efficacy and safety fev1 morning pef and paqlqs and pacqlq scores and improved asthma symptom score sums and the need for rescue medication￨both ciclesonide and budesonide increased fev1 morning pef and paqlqs and pacqlq scores and improved asthma symptom score sums and the need for rescue medication after 12 wk vs baseline￨sig increase￨low￨low￨low
403￨adolescents with severe asthma patients aged 1217 years with severe asthma four hundred and three patients were randomized￨ciclesonide and budesonide ciclesonide 320 microg qd and budesonide ciclesonide ciclesonide 320 microg qd exactuator or budesonide 800 microg qd budesonide eudract ciclesonide budesonide 400 microg once daily qd￨urine cortisol levels median percentage of days without asthma symptoms median creatinineadjusted urine cortisol fev1 asthma symptom score and rescue medication use in diaries adverse events aes and 24h urine cortisol forced expiratory volume in 1s fev1 efficacy and safety￨ciclesonide 320 microg qd showed similar efficacy to budesonide 800 microg qd in adolescents with severe asthma￨no diff￨low￨low￨low
14￨patients with moderate persistent asthma fourteen patients with moderate persistent asthma mean fev1 67 predicted prior to each randomized treatment moderate persistent asthma￨cic 200 microg exvalve salmeterol and montelukast fpplacebo cicplacebo montelukast ciclesonide and fluticasone salmeterol usual inhaled corticosteroids ciclesonide cic and fluticasone propionate fp￨exhaled nitric oxide levels hypothalamicpituitaryadrenal axis outcomes with ouc levels plasma cortisol response overnight 10h urinary cortisol ouc levels exhaled nitric oxide levels lung function symptoms and quality of life plasma cortisol levels airway outcomes ouc levels￨both drugs significantly improved airway outcomes in terms of methacholine bronchial hyperresponsiveness and exhaled nitric oxide levels￨sig increase￨low￨low￨low
not found￨patients were required to stop their usual inhaled corticosteroid therapy for the duration of the study mildtomoderate persistent asthma nineteen mildtomoderate asthmatic patients￨salmeterol sm 50 microg one puff twice daily  montelukast ml hfa fluticasone cic 200 microg two puffs once daily 0800 h  cicplacebo ciclesonide hydrofluoroalkane hfa formulations of ciclesonide cic and fluticasone propionate fp cic sm  ml hydrofluoroalkane￨methacholine hyperresponsiveness exhaled nitric oxide lung function diary cards and quality of life￨there were no differences between 4 weeks of cic 400 microg once daily and fp 250 microg twice daily on methacholine hyperresponsiveness in mildtomoderate persistent asthma￨no diff￨low￨low￨low
399￨patients with persistent asthma 399 patients with asthma patients with asthma￨ciclesonide 320 microg exactuator equivalent to 400 microg exvalve or oncedaily budesonide ciclesonide and budesonide ciclesonide budesonide ciclesonide￨adverse events forced vital capacity fvc peak expiratory flow pef asthma symptoms use of rescue medication and time to onset of effect fev1 good safety and tolerability profiles forced expiratory volume in 1s fev1 fvc and pef urinary cortisol levels efficacy and safety fev1 fvc and pef￨the increase in fev1 was significantly greater in ciclesonidetreated patients 95 confidence interval 00160174 p0019 versus budesonide￨sig increase￨highunclear￨highunclear￨highunclear
not found￨91 patients in primary care who had major depression major depression in primary care patients were satisfied with problem solving treatment all patients who completed treatment 2830 rated the treatment as helpful or very helpful￨amitriptyline and placebo placebo amitriptyline plus standard clinical management and drug placebo plus standard clinical management amitriptyline￨hamilton rating scale for depression severity of depression self reported measure of social outcome and observer measure of psychological symptoms hamilton scale patient satisfaction￨at six and 12 weeks the difference in score on the hamilton rating scale for depression between problem solving and placebo treatments was significant 53 95 confidence interval 16 to 90 and 47 04 to 90 respectively but the difference between problem solving and amitriptyline was not significant 18 18 to 55 and 09 33 to 52 respectively￨no diff￨low￨low￨low
229￨depressive illness in general practice 229 patients with a research diagnostic criteria diagnosis of major minor or intermittent depression￨imipramine placebo imipramine and placebo venlafaxine venlafaxine and imipramine venlafaxine￨symptoms of depression and anxiety sars total score and the items socialleisure and extended family total madrs and percentage of responders the cgi improvement the cgi severity of illness the bsa psychic anxiety item and the hscl￨venlafaxine produced a significant improvement compared to placebo in symptoms of depression and anxiety as rated by the total madrs and percentage of responders the cgi improvement the cgi severity of illness the bsa psychic anxiety item and the hscl￨sig increase￨highunclear￨highunclear￨highunclear
not found￨primary care patients with major depressive disorder￨placebo escitalopram escitalopram and citalopram flexible doses of 1020 mgday escitalopram n155 2040 mgday citalopram citalopram￨placebolevel adverse event withdrawal rates montgomeryasberg depression rating scale total score antidepressant efficacy and excellent tolerability effective and well tolerated￨escitalopram produced a statistically significant therapeutic difference of 29 points p0002 compared to placebo and escitalopram was consistently and statistically significantly more efficacious than placebo from week 1 onwards￨sig increase￨highunclear￨highunclear￨highunclear
not found￨women attending their general practitioners and suffering from a depressive illness￨amylobarbitone amitriptyline￨troublesome side effects relieving depression and anxiety several measures of depression and anxiety￨improvement at 7 and 28 days was noted on several measures of depression and anxiety in all treatment groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨primary care patients with a dsmiiirdsmiv diagnosis of major depressive disorder￨imipramine antidepressant treatment placebo esm￨quality of life frequency and severity of physical complaints quality of daily life mean mqol ratings￨at 18 weeks remitted patients still showed deficits on esm daily life measures relative to healthy controls even though qol had returned to normal on retrospective measures￨sig increase￨highunclear￨highunclear￨highunclear
not found￨general practice patients with dsmiiir major depressive disorder sertraline 50 or 100 mgday major depression in general practice￨placebo 150 mg dothiepin sertraline and dothiepin sertraline dothiepin￨madrs and cgi tolerated madrs cgi and leeds selfrating scales somnolence and headache nausea dizziness and headache￨statistically significant differences p  005 between sertraline and placebo were found on madrs and cgi but not the leeds scales￨sig increase￨highunclear￨highunclear￨highunclear
not found￨depressed patients in general practice depressed patients in general practice mildly ill patients patients were relatively mildly ill and satisfied diagnostic criteria for depression and treatment with antidepressants in routine practice￨placebo amitriptyline amitriptyline￨￨amitriptyline was found to be considerably superior to placebo after six weeks and significantly so as early as two weeks after the start of treatment￨sig increase￨highunclear￨highunclear￨highunclear
not found￨263 patients 66 men 197 women with moderate depression according to icd10 international classification of diseases 10th revision codes f32 18 general practitioners from four german states bavaria berlin rhineland palatinate and saxony patients with moderate depression patients in primary care with a current episode of moderate depression￨hypericum extract versus imipramine or placebo imipramine placebo hypericum extract hypericum extract imipramine and placebo hypericum extract stei 300 steiner arzneimittel berlin￨hamilton depression scores hamilton anxiety and clinical global impressions scales hamilton depression scale the hamilton anxiety scale the clinical global impressions scale zungs self rating depression scale and sf36 and adverse events profile standardised mental component scale rate of adverse events quality of life quality of life zung self rating depression scale physical component scale efficacy and safety￨comparable results were found for hamilton anxiety and clinical global impressions scales and were most pronounced for the zung self rating depression scale￨no diff￨low￨low￨low
279￨all patients had a diagnosis of primary depression 279 patients depressive illness￨placebo chlordiazepoxide amitriptyline and chlordiazepoxide limbitrol versus its components amitriptyline and chlordiazepoxide amitriptyline￨hamilton depression scale the beck depression inventory and physician and patient global change measures overall incidence of side effects limbitrol￨statistically significant differences favoring limbitrol occurred after 1 week of treatment and a trend in favor of limbitrol continued throughout the remaining 3 weeks￨sig increase￨highunclear￨highunclear￨highunclear
372￨372 patients with depression￨sertraline placebo mianserin emotional support and counselling combined with placebo or antidepressants with single or dual mechanism of action￨patient montgomery asberg depression rating scale and the physician clinical global improvement and impression scales recurrent depression￨intention to treat analyses showed 47 remission in patients randomised to placebo compared with 61 remission in patients randomised to sertraline odds ratio 056 95 confidence interval 033 to 096 and 54 in patients randomised to mianserin 075 044 to 127￨sig increase￨low￨low￨low
not found￨patients with major depressive disorder dsmiv who had baseline montgomeryasberg depression rating scale madrs total scores or22 and or40￨escitalopram a selective serotonin reuptake inhibitor ssri placebo escitalopram 10 mgday n191 or placebo￨nausea effective and well tolerated safe and very well tolerated madrs total score antidepressant effect￨nausea was the only adverse event reported significantly more in escitalopramtreated patients than in placebotreated patients although it was infrequent and transient￨sig increase￨highunclear￨highunclear￨highunclear
not found￨residents large private chain of uk care homes during the winters of 20034 and 20045 nursing home staff n1703 and residents n2604 in 44 care homes 22 intervention homes and 22 matched control homes￨influenza vaccine programme￨influenzalike illness and health service use in residents influenzalike illness cause mortality of residents death morbidity and health service mortality national influenza rates￨in the 20034 period of influenza activity significant decreases were found in mortality of residents in intervention homes compared with control homes rate difference 50 per 100 residents 95 confidence interval 70 to 20 and in influenzalike illness p0004 consultations with general practitioners for influenzalike illness p0008 and admissions to hospital with influenzalike illness p0009￨sig decrease￨low￨low￨low
not found￨nursing home residents forty nursing homes matched for size staff vaccination coverage during the previous season and resident disability index institutionalized elderly people nursing home staff on mortality of residents all persons aged 60 and older residing in the nursing homes￨influenza vaccine influenza vaccination staff influenza vaccination￨rates of hospitalization and influenzalike illness ili in residents and sick leave from work in staff resident hospitalization rates total mortality rate staff vaccination coverage and allcause mortality staff influenza vaccination rates mortality sick leave from work in staff￨primary unadjusted analysis did not show significantly lower mortality in residents in the vaccination arm odds ratio086 p08 although multivariateadjusted analysis showed 20 lower mortality p02 and a strong correlation was observed between staff vaccination coverage and allcause mortality in residents correlation coefficient042 p007￨no diff￨highunclear￨highunclear￨highunclear
not found￨elderly patients elderly patients in longterm care during the winter of 19941995 1059 patients in 12 geriatric medical longtermcare sites randomized for vaccination of hcws were studied frail elderly longtermcare patients￨influenza vaccination health care workers hcws￨total patient mortality mortality influenzalike illness￨vaccination of patients was not associated with significant effects on mortality or 115 95 ci 081164￨no diff￨highunclear￨highunclear￨highunclear
not found￨elderly patients in longterm care random sample of 50 of patients for virological surveillance for influenza with combined nasal and throat swabs taken every 2 weeks during the epidemic period 20 longterm elderlycare hospitals range 44105 patients elderly people in longterm care￨influenza vaccine cluster randomisation stratified for policy for vaccination of patients and hospital size influenza vaccination of healthcare workers￨influenza infection mortality nonfatal influenza infection uncorrected rate of mortality￨vaccination of healthcare workers has been claimed to prevent nosocomial influenza infection of elderly patients in longterm care￨sig increase￨highunclear￨highunclear￨highunclear
not found￨elderly people in niigata japan during an influenza a h3n2 epidemic institutionalized elderly people￨￨influenza vaccination levels and influenzalike illness￨outbreaks and number of cases were significantly reduced by vaccination which should be strongly recommended for institutionalized elderly people￨sig decrease￨highunclear￨highunclear￨highunclear
45￨volunteers ranged in age from 2049 mean age  303 yr and were entered into the study between april 1990 and january 1991 twentyfour fortyfive women with a history of primary dysmenorrhea were recruited from the local community women with primary dysmenorrhea all subjects were treated at the national college chiropractic clinic a private chiropractic clinic in the suburban chicago area￨spinal manipulation spinal manipulation vs sham manipulation spinal manipulation treatment smt or a sham manipulation spinal manipulation were placed in a sidelying position with the bottom leg straight and the top leg flexed at the knee and hip smt￨menstrual distress questionnaire pain and prostaglandin levels perceived abdominal and back pain plasma kdpgf2a prostaglandin f2a metabolite 15keto1314dihydroprostaglandin kdpgf2a b perceived abdominal and back pain and c perceived menstrual distress perception of pain and the level of menstrual distress plasma levels of kdgpf2a pain and distress of primary dysmenorrhea visual analog scale and menstrual distress￨immediately after treatment the perception of pain and the level of menstrual distress were significantly reduced by smt￨sig decrease￨highunclear￨highunclear￨highunclear
1999￨women were recruited from the chicago metropolitan area and evaluated for inclusion through four screening levels one hundred thirty eight women ages 1845 with primary dysmenorrhea diagnosed by participating gynecologists women with primary dysmenorrhea￨smt or a lowforce mimic lfm maneuver spinal manipulative therapy smt spinal manipulative therapy versus a low force mimic maneuver￨mdq visual analog scale vas and plasma concentration of the prostaglandin f2alpha metabolite 15keto1314dihydroprostaglandin f2alpha kdpgf2alpha pre to posttreatment kdpgf2alpha levels vas scores pre to posttreatment scores vas kdpgf2alpha or mdq moos menstrual distress questionnaire mdq￨the changes in pre to posttreatment kdpgf2alpha levels were not statistically different between the smt and lfm groups p  015￨no diff￨highunclear￨highunclear￨highunclear
60￨60 patients with stage pt1bnomo carcinoma of the uterine cervix treated by ib carcinoma of the cervix uteri￨combined surgery and radiotherapy postoperative radiotherapy radical surgery only wertheimmeigs radical surgery followed by a postoperative external radiotherapy radical pelvic surgery versus radical surgery plus radiotherapy radical hysterectomy with pelvic lymphonodectomy￨tumor size survival probability therapy morbidity median duration￨comparing the survival probability analyzed by lifetablemethod up to 18 months there was a significant better result for patients treated with surgery only￨sig increase￨highunclear￨highunclear￨highunclear
277￨eligible patients had stage ib cervical cancer with negative lymph nodes but with 2 or more of the following features more than one third deep stromal invasion capillary lymphatic space involvement and tumor diameter of 4 cm or more 277 patients 137 randomized to stage ib cervical carcinoma with poor prognostic features patients with adenocarcinoma or adenosquamous histologies women with stage ib cervical cancer women with stage ib cervical cancers with negative lymph nodes and certain poor prognostic features treated by￨radical hysterectomy and pelvic lymphadenectomy pelvic irradiation rt and 140 randomized to observation obs pelvic radiotherapy rt postoperative externalbeam irradiation postoperative pelvic irradiation￨risk of recurrence overall survival recurrencefree interval and overall survival os overall survival differences risk of recurrence and prolongs progressionfree survival risk of progression or death￨pelvic radiotherapy after radical surgery significantly reduces the risk of recurrence and prolongs progressionfree survival in women with stage ib cervical cancer￨sig increase￨highunclear￨highunclear￨highunclear
110￨patients with stage iii or iv endometriosis who were undergoing iui or ivficsi patients with severe endometriosis patients with endometriosis one hundred ten patients with stage ii to iv endometriosis according to asrm criteria￨gonadotropinreleasing hormone analogs gnrh ultralong gnrha therapy art alone immediately after surgery ultralong gnrh analog gnrha therapy￨pregnancy rate per patient clinical pregnancy rates pregnancy rate of art pregnancy rates￨the same results were found in patients with stage iii or iv endometriosis who were undergoing iui or ivficsi￨no diff￨highunclear￨highunclear￨highunclear
not found￨patients with endometriosis infertile patients with endometriosis￨longacting gnrh agonist prolonged gonadotropinreleasing hormone agonist therapy standard controlled ovarian hyperstimulation with midluteal phase gnrh agonist downregulation or microdose flare regimens gnrh agonist administered immediately before ivfet gnrh agonist before ivfet￨vitro fertilizationembryo transfer ovarian response dose or duration of gonadotropin stimulation number of oocytes retrieved fertilization rate or number of embryos transferred implantation rates pregnancy rates ongoing pregnancy rates pregnancy rates per cycle group implantation rates and implantation rate per embryo transfer procedure￨the groups did not differ significantly in terms of dose or duration of gonadotropin stimulation number of oocytes retrieved fertilization rate or number of embryos transferred￨no diff￨highunclear￨highunclear￨highunclear
67￨patients with severe endometriosis undergoing in vitro fertilizationembryo transfer 67 women with severe endometriosis referred to us for in vitro fertilizationembryo transfer ivfet 32 underwent ovarian stimulation for oocyte retrieval with menotropins protocol a whereas the other 35 were admitted for the procedure after a 6month period of hormonal suppression with a gnrh agonist protocol b￨gonadotropinreleasing hormone analogue treatment gonadotropinreleasing hormone analogue gnrha therapy￨oocyte classification and embryo quality score preclinical pregnancy rate mean embryo quality score clinical pregnancy rate per cycle and per transfer number of preclinical pregnancies￨a significantly higher number of preclinical pregnancies p less than 00001 occurred in patients treated by protocol a￨sig increase￨highunclear￨highunclear￨highunclear
107￨urinary incontinence following bladder neck bn sparing rrp 152 patients with localized prostate cancer underwent rrp with bn preservation incontinent patients with 24 hr pad test 2 g the t group received after bladder necksparing radical prostatectomy 107 incontinent patients into 2 groups￨early intensive prolonged pelvic floor exercises pfe instructions regarding an intensive program of pfe early intensive prolonged pelvic floor exercises￨overall spontaneous continence rate proportion of men still incontinent vas and the response to the qol question 24 hr pad test a visual analogue scale vas and a single question of qol results urinary continence recovery￨the proportion of men still incontinent was significantly higher in the c group than treatment t group at 1 975 vs 833 p  004 3 775 vs 537 p  003 6 60 vs 333 p  001 and 12 months 525 vs 166 p  001￨sig increase￨highunclear￨highunclear￨highunclear
36￨urinary incontinence after radical prostatectomy urinary incontinence after retropubic radical prostatectomy thirtysix patients with urinary incontinence after radical prostatectomy￨extracorporeal magnetic innervation exmi and functional electrical stimulation fes extracorporeal magnetic innervation versus electrical stimulation exmi and fes therapies￨average 24hour leakage weight bladder diaries 24hour pad weight testing and a qualityoflife survey leakage weight qualityoflife measures￨at 1 month it was 72 83 and 175 g fes versus control p 005 and at 2 months was 54 18 and 92 g exmi versus control p 005 in the fes exmi and control groups respectively￨sig increase￨highunclear￨highunclear￨highunclear
38￨38 patients were divided into groups of 19 before￨radical prostatectomy with previous kinesic perineal physiotherapy preoperative perineal kinetic physiotherapy preoperative kinetic physiotherapy radical prostatectomy rp radical prostatectomy kinesic perineal exercises before radical prostatectomy preoperative kinesic treatment￨times of urinary continence recovery urinary continence urinary continence￨kinesic perineal exercises before radical prostatectomy did not diminish the times of urinary continence recovery or its appearance￨no diff￨highunclear￨highunclear￨highunclear
82￨96 men 34 and 36 men 82 randomized patients 70 completed the study￨physiotherapistguided pelvic floor muscle exercises verbal instruction and an information folder on pfme radical retropubic prostatectomy fpfme retropubic radical prostatectomy rrp of intensive physiotherapistguided pelvic floor muscle exercises pgpfme￨urinary continence urine loss￨pgpfme seems to have no beneficial effect on the recovery of continence within the first 6 months after rrp over an instruction folderguided approach￨no diff￨highunclear￨highunclear￨highunclear
60￨60 consecutive patients who underwent urinary continence after radical prostatectomy￨radical prostatectomy using early pelvic floor electrical stimulation and biofeedback associated treatment pelvic floor electrical stimulation plus biofeedback noninvasive physical treatment with biofeedback and pelvic floor electrical stimulation radical prostatectomy functional pelvic floor electrical stimulation and biofeedback biofeedback 15 minutes followed by pelvic floor electrical stimulation￨urinary continence mean leakage weight￨a significant difference p 005 between groups 1 and 2 in terms of percentage of continent patients was achieved from 4 weeks 633 group 1 and 300 group 2 to 6 months 967 group 1 and 667 group 2￨sig increase￨highunclear￨highunclear￨highunclear
100￨one hundred men scheduled to undergo radical prostatectomy men undergoing radical prostatectomy￨preoperative biofeedback training graded pelvic muscle exercise training with biofeedback 2 to 4 weeks before surgery or to a control group performing pelvic muscle exercises without biofeedback written and brief verbal instructions in pelvic muscle exercises before surgery and again after catheter removal preoperative biofeedback training preoperative biofeedbackpelvic floor training￨urinary continence rate of return continence rates overall continence or the rate of return of urinary control urinary continence overall or the rate of return of continence￨preoperative biofeedback training did not improve the outcome of pelvic muscle exercises on overall continence or the rate of return of urinary control in men undergoing radical prostatectomy￨no diff￨highunclear￨highunclear￨highunclear
not found￨twentynine incontinent prostate cancer patients learned￨pelvic floor muscle exercises through biofeedback control group or a support group entailing six meetings over 3 months￨continence and quality of life obtained consent rate￨twentynine incontinent prostate cancer patients learned pelvic floor muscle exercises through biofeedback and were randomly assigned to a control group or a support group entailing six meetings over 3 months￨no diff￨highunclear￨highunclear￨highunclear
216￨a total of 216 men were enrolled 11 were dry or withdrew at 4 weeks three canadian centers men at 4 weeks after radical prostatectomy ninetynine￨postoperative pelvic floor muscle training pfmt radical retropubic prostatectomy verbal and written instructions versus therapistdirected pelvic floor muscle therapy supportive telephone contact￨gleason score prostatespecific antigen level ipss iiq7 score pad test or voiding diary grams of urine loss on pad test secondary outcomes were international prostate symptom score ipss incontinence impact questionnaire iiq7 score cost and perception of urine loss as a problem￨at 8 weeks 23 of the control group and 20 of the treatment group were continent at 12 weeks 28 and 32 16 weeks 40 and 44 28 weeks 50 and 47 and at 52 weeks 64 and 60 respectively￨no diff￨low￨low￨low
not found￨men in the uk who were incontinent 6 weeks after men who are incontinent after prostate surgery men after formal onetoone￨pelvicfloor muscle training following radical prostatectomy or transurethral resection of the prostate maps radical prostatectomy trial 1 or transurethral resection of the prostate turp trial 2 to compare four sessions with a therapist over 3 months with standard care and lifestyle advice only￨rate of urinary incontinence urinary incontinence adverse effects absolute risk difference rd urinary incontinence and incremental cost per qualityadjusted life year qaly￨we undertook two randomised trials in men in the uk who were incontinent 6 weeks after radical prostatectomy trial 1 or transurethral resection of the prostate turp trial 2 to compare four sessions with a therapist over 3 months with standard care and lifestyle advice only￨no diff￨low￨low￨low
102￨102 consecutive incontinent patients who had had for clinically localised prostate cancer and who could comply with the ambulatory treatment schedule in our hospital patients with urinary incontinence incontinence after radical prostatectomy￨placebo therapy radical prostatectomy pelvicfloor reeducation radical retropubic prostatectomy￨spontaneous recovery of normal urinary control urinary incontinence incontinence visual analogue scale degree of incontinence continence rate￨in the treatment group improvement in both duration logrank test p00001 and degree of incontinence wald test p00010 was significantly better than in the control group￨sig increase￨low￨low￨low
not found￨urinary incontinence following prostate surgery￨behavior therapy methods￨number of pathologic prostates￨having objective measures that are costeffective and accessible can assist with equaling subjective and objective assessments of continence as well as determining successful outcomes and the need for more complex behavioral treatments￨sig increase￨highunclear￨highunclear￨highunclear
125￨125 men 53 to 68 years old who elected radical prostatectomy for prostate cancer decrease postprostatectomy incontinence￨biofeedback assisted behavioral training plus daily home exercise or a usual care control condition consisting of simple postoperative instructions to interrupt the urinary stream preoperative behavioral training to usual care preoperative biofeedback assisted behavioral training preoperative behavioral training radical prostatectomy preoperative biofeedback assisted behavioral training￨duration of incontinence time to continence as derived from bladder diaries incontinence severity the proportion with severecontinual leakage pad use incontinence impact questionnaire psychological distress hopkins symptom checklist and health related quality of life medical outcomes study short form health survey return to work and usual activities or quality of life measures time to continence severity of incontinence urine loss with coughing proportion of patients with severecontinual leakage duration and severity of incontinence and improving quality of life sneezing￨preoperative behavioral training significantly decreased time to continence p  003 and the proportion of patients with severecontinual leakage at the 6month end point 59 vs 196 p  004￨sig decrease￨highunclear￨highunclear￨highunclear
58￨fiftyeight men with benign prostatic obstruction were included and 49 completed the study training group n26 control group n23 men scheduled for transurethral resection of the prostate turp￨verbal instructions regarding pfmt pelvic floor muscle training before transurethral resection of the prostate home training programme preoperative pelvic floor muscle training pfmt￨total score on the danish prostatic symptom score questionnaire pelvic floor muscle function relevant storage or voiding improvements static endurance subjective and objective voiding and incontinence parameters and four tests of the pelvic floor muscle function strength static endurance and dynamic endurance pelvic floor muscle endurance￨at followup at 2 and 4 weeks and 3 months there were no differences between the groups in any of the lower urinary tract parameters￨no diff￨low￨low￨low
38￨patients with severe urinary incontinence 16 weeks after surgery 19 men underwent 19 patients was referred to physical therapy and underwent pfe sessions before and after surgery 38 consecutive patients undergoing radical prostatectomy from november 1998 to june 1999￨pelvic floor exercise pfe pelvic floor exercises preoperative and early postoperative biofeedback enhanced pfe with a dedicated physical therapist pfe therapy instituted prior to radical prostatectomy aids pfe surgery without formal pfe instructions￨postoperative urinary incontinence questionnaires severe incontinence incontinence urinary continence earlier￨there is a minimal longterm benefit of pfe training since continence rates at 1 year were similar in the 2 groups￨no diff￨highunclear￨highunclear￨highunclear
53￨fiftythree men urinary incontinence after prostatectomy￨education intervention group or a control group pme bladder diaries and behavioral management techniques pme control group did not receive instruction in pme technique pelvic muscle exercisebiofeedback pelvic muscle exercise pme with biofeedback radical prostatectomy instruction in pmebiofeedback￨1 length of time urine loss was experienced 2 episodes and frequency of urine loss and 3 ounces of urine lost and number of pads used length of time urinary incontinence ui urine losses episodes frequency ounces of urine lost by ui and pad usage￨although the pme group demonstrated reductions in episodes frequency ounces of urine lost by ui and pad usage they were not statistically significant￨sig decrease￨highunclear￨highunclear￨highunclear
139￨urinary incontinence after radical retropubic prostatectomy 139 patients who underwent￨pelvic floor exercises electrical stimulation and biofeedback after radical prostatectomy instructions about postoperative pmes bfb pelvic muscle exercises pmes electrical stimulation es and biofeedback bfb radical retropubic prostatectomy￨overall subjective spontaneous continence rate questionnaire overall objective spontaneous continence rate 20minute pad test and a urine symptom inventory continence rate￨a treatment program of es and bfb enhanced pmes did not affect continence after radical prostatectomy after 3 or 12 months￨no diff￨highunclear￨highunclear￨highunclear
30￨30 patients who underwent￨radical retropubic prostatectomy biofeedback enhanced pelvic floor exercises radical retropubic prostatectomy into a group that received 5 biofeedback sessions and a control group￨pad test results or voiding diary￨overall 87 of patients were padfree at 6 months with similar results in the treatment and control groups 86 versus 88￨no diff￨highunclear￨highunclear￨highunclear
300￨300 consecutive patients who had undergone rrp for clinically confined prostate cancer a large population that had undergone radical retropubic prostatectomy rrp at our department postprostatectomy incontinence 150 patients took part in a structured pfmt program￨radical prostatectomy early pelvic floor rehabilitation treatment early pelvic floor muscle training pfmt￨urinary incontinence continence recovery time incontinence￨patient age did not correlate with continence in the control group p005 although a significant correlation was revealed within the treated group p001￨no diff￨highunclear￨highunclear￨highunclear
58￨patients after turp early pelvic floor rehabilitation after transurethral resection of the prostate fiftyeight consecutive patients who were selected to undergo turp for benign prostatic hyperplasia bph were admitted into the study 28 patients after transurethral prostatectomy turp￨teaching pelvic floor muscle exercises pme￨micturition parameters urinary incontinence postmicturition dribbling and quality of life urinary symptoms and of quality of life grade of muscle contraction strength american urological association symptom score average quality of life score number of patients with incontinence episodes and postmicturition dribbling￨our results show that pelvic floor muscle reeducation produces a quicker improvement of urinary symptoms and of quality of life in patients after turp￨sig increase￨highunclear￨highunclear￨highunclear
143￨143 patients with severe blunt trauma enrolled hemodynamically unstable polytrauma patients with traumatic brain injury trauma patients patients with tbi and severe blunt polytrauma thirty polytrauma patients placebo n  13 rfviia n  17￨recombinant activated factor viia placebo rfviia intravenous rfviia￨rates of mortality risk of mortality or with thromboembolic or adverse events serious adverse events incidences of ventilatorfree days intensive care unitfree days and thromboembolic serious and adverse events rates of thromboembolic adverse events￨no significant differences in rates of mortality placebo n  6 46 90 confidence interval ci 22 to 71 rfviia n  5 29 90 ci 12 to 56 p  019 in median numbers of intensive care unitfree days placebo  0 rfviia  3 p  026 or ventilatorfree days placebo  0 rfviia  10 p  019 or in rates of thromboembolic adverse events placebo 15 90 ci 3 to 51 rfviia 0 90 ci 0 to 53 p  018 or serious adverse events placebo 92 90 ci 68 to 98 rfviia 82 90 ci 60 to 92 p  061 were observed between treatment groups￨no diff￨low￨low￨low
not found￨traumatic intracerebral hemorrhage subjects were enrolled if they had tich lesions of at least 2 ml on a baseline ct scan obtained within 6 h of a head injury￨serial computed tomography ct scanning￨24h ct scans baseline adverse event ae profile thromboembolic complications ct scans tich volume￨the earlier after injury that the initial ct scan is obtained the greater is the likelihood that the hematoma will expand on subsequent scans￨sig increase￨highunclear￨highunclear￨highunclear
60￨patients with advanced cancer and decreased weight and appetite patients with advanced cancer and anorexiacachexia patients with advanced cancer sixty patients￨placebo fish oil fish oil eicosapentaenoic acid and 12 g of docosahexaenoic acid fish oil capsules or placebo￨baseline appetite baseline weight loss appetite tiredness nausea wellbeing caloric intake nutritional status or function appetite tiredness nausea wellbeing caloric intake nutritional status and function symptomatic or nutritional parameters￨fish oil did not significantly influence appetite tiredness nausea wellbeing caloric intake nutritional status or function after 2 weeks compared with placebo in patients with advanced cancer and loss of both weight and appetite￨no diff￨low￨low￨low
200￨cachectic patients with advanced pancreatic cancer cancer cachexia 200 patients 95 e 105 c￨protein and energy dense n3 fatty acid enriched oral supplement n3 fatty acids n3 fatty acids especially eicosapentaenoic acid epa n3 fatty acids and antioxidants experimental e with an isocaloric isonitrogenous control supplement c n3 enriched supplements￨weight lean body mass lbm dietary intake and quality of life weight gain weight gain weight loss loss of weight and lean tissue lbm quality of life weight and lbm gain net gain of weight lean tissue and improved quality of life plasma epa levels￨weight gain was associated with improved quality of life p001 only in the e group￨sig increase￨highunclear￨highunclear￨highunclear
421￨patients with cancerassociated wasting four hundred twentyone assessable patients with cancerassociated wasting eligible patients reported a 5lb 2month weight loss andor intake of less than 20 calorieskgd￨epa supplementadministered alone or with megestrol acetate mawas eicosapentaenoic acid epa eicosapentaenoic acid supplement versus megestrol acetate epa supplement 109 g administered bid plus placebo ma liquid suspension 600 mgd plus an isocaloric isonitrogenous supplement￨superior appetite stimulation toxicity weight gain global quality of life weight or appetite better survival percentage of patients with appetite improvement￨combination therapy resulted in weight gain of or 10 in 11 of patients p 17 across all arms￨no diff￨highunclear￨highunclear￨highunclear
not found￨cachectic cancer patients cachectic cancer patients and healthy subjects weightlosing cancer patients and in healthy subjects seventeen weightlosing cancer patients of different tumor types and 16 healthy subjects healthy subjects￨n3 fatty acid eicosapentaenoic acid 205n3 epa placebo oleic acid oaee epaee shortterm oral epa ethyl ester ee supplementation epaee supplementation eicosapentaenoic acid ethyl ester supplementation￨plasmafree fatty acid and triacylglycerol concentrations palmitate oxidation wholebody lipolysis palmitic acid release or palmitate oxidation lipolysis or lipid oxidation￨epaee supplementation reduced plasmafree fatty acid and triacylglycerol concentrations significantly in healthy subjects but not in cancer patients￨sig decrease￨highunclear￨highunclear￨highunclear
60￨sixty patients with generalized solid tumors malnourished cancer patients patients with end stage malignant disease severely ill patients with generalized malignancy 15 malnourished patients malnourished patients with generalized malignancy￨omega3 polyunsaturated fatty acids dietary omega3 polyunsaturated fatty acids plus vitamin e restore immunodeficiency dietary supplementation with either fish oil 18 g of omega3 polyunsaturated fatty acids pufa or placebo omega3 pufa dietary omega3 polyunsaturated fatty acids plus vitamin e￨mean survival ratio of thelper cells to tsuppressor cells total t cells thelper cells tsuppressor cells natural killer cells and the synthesis of interleukin1 interleukin6 and tumor necrosis factor by peripheral blood mononuclear cells tumor necrosis factor production cytokine production karnofsky performance status nutritional state and survival￨there were no significant differences in cytokine production among the various groups except for a decrease in tumor necrosis factor production in malnourished cancer patients which was restored by omega3 fatty acids￨no diff￨highunclear￨highunclear￨highunclear
100￨chronic trophic ulcers in leprosy 100 patients with 110 trophic leprosy ulcers of varying chronicity fifty patients￨phenytoin topical phenytoin powder saline therapy topical phenytoin saline phenytoin topical phenytoin with normal saline￨wound healing effects ulcer volume reduction￨over the 4week treatment period healthy granulation tissue appeared earlier and mean percentage of ulcer volume reduction was greater in the phenytoin group 721￨sig increase￨highunclear￨highunclear￨highunclear
45￨leprosy patients leprosy trophic ulcers 45 leprosy inpatients with acute trophic ulcers￨phenytoin normal saline dressing topical phenytoin topical phenytoin suspension and normal saline normal saline topical phenytoin sodium suspension￨appearance of healthy granulation tissue and cessation of ulcer discharge acute trophic ulcers ulcer area reduction side effects surface area of the ulcer bacterial culture of the ulcer swab appearance of healthy granulation tissue cessation of ulcer discharge and overall gradation of clinical healing and safety￨the ulcer area reduction was greater in the 2 and 4 phenytoin groups compared with the normal saline group p0001￨sig decrease￨highunclear￨highunclear￨highunclear
66￨66 leprosy patients with ulcers ulcers in leprosy patients￨ketanserin gel topical ketanserin clioquinol cream￨ulcer sizes healing ulcers￨a comparative study was carried out in which 66 leprosy patients with ulcers were randomly divided in two groups of 33 patients each group a experimental group was treated with ketanserin gel 2 and group b with clioquinol cream￨sig increase￨highunclear￨highunclear￨highunclear
not found￨leprosy patients with plantar ulcers in sulawesi tengah indonesia leprosy patients in indonesia 38 leprosy patients with simple ulcers￨povidone iodine adhesive zinc oxide tape zinc oxide tape￨plantar ulcers effectiveness degree of wound healing wound healing average wound healing￨using the ttest there was no statistically significant difference in wound healing between the two therapies p  17￨no diff￨highunclear￨highunclear￨highunclear
50￨pain associated with laser vaporization of the cervix fifty women undergoing laser vaporization of the cervix for cervical intraepithelial neoplasia￨octapressin prilocaine citanest with octapressin felypressin￨verbal rating scale visual analogue and verbal rating scales pain troublesome bleeding bleeding visual analogue scale￨the pain experienced by those women receiving local anaesthesia was significantly reduced as assessed by the visual analogue scale p  0011 and this reduction was not quite significant by the verbal rating scale p  006￨sig decrease￨highunclear￨highunclear￨highunclear
51￨51 women pain associated with local anaesthetic injection prior to biopsy or loop diathermy to the cervix in the outpatient colposcopy clinic￨local anaesthetic spray placebo￨pain or discomfort pain or discomfort￨our results show that the use of local anaesthetic spray has no effect on the pain or discomfort experienced by patients having local anaesthetic injections to the cervix and cannot be recommended￨no diff￨highunclear￨highunclear￨highunclear
45￨fortyfive patients￨lidocaine epinephrine submucosal cervical injection of 1 lidocaine naproxen sodium or ketoprofen local anesthesia￨pain mean vas score pain experienced with a visual analog scale vas￨these findings indicate that a submucosal local injection of lidocaine with epinephrine is effective in reducing pain during cervical cryosurgery￨no diff￨highunclear￨highunclear￨highunclear
100￨100 women with cin and no previous experience of cervical surgery￨lignocaine tens ii local anaesthetic and iii tens plus local anaesthetic direct infiltration of 2 lignocaine and 003 iuml octopressin tens transcutaneous electrical nerve stimulation tens￨visual linear analogue pain scores median pain score pain scores￨although there was considerable consumer satisfaction with tens it provided no additional pain relieving effect in addition to direct infiltration of lignocaine￨no diff￨highunclear￨highunclear￨highunclear
60￨60 women undergoing￨local anaesthetic injection techniques prior to lletz lletz local anaesthesia local anaesthetic￨pain pain￨women in the study arm experienced less pain than controls during injection of local anaesthetic￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨patients experience considerable pain during coldcoagulation treatment of the cervix￨intracervical lignocaine placebo lignocaine analgesia￨￨we found that intracervical lignocaine leads to a significant p  001 reduction in this pain￨sig decrease￨highunclear￨highunclear￨highunclear
50￨fifty consecutive women scheduled for loop electrosurgical excision pain during loop electrosurgical excision of the cervix￨benzocaine gel benzocaine topical 20 benzocaine computergenerated numbers to receive cervical application of either 20 benzocaine or placebo gel local anesthetic and tissue excision￨pain mean pain scores￨preoperative cervical application of 20 benzocaine does not appear to reduce the pain associated with either subsequent local anesthetic injection or tissue excision during the loop electrosurgical excision procedure of the cervix￨no diff￨highunclear￨highunclear￨highunclear
396￨one hundred and ninetyeight women womens experience of outpatient treatment at colposcopy three hundred and ninetysix women scheduled for treatment of cervical intraepithelial neoplasia cin by large loop excision of the transformation zone lletz￨isoflurane and desflurane placebo selfadministered analgesia￨anxiety levels satisfaction pain total helpfulness total treatment acceptability helpfulness of the gas and willingness to undergo a similar procedure patient satisfaction pain and anxiety anxious by hospital anxiety and depression scale hads score mean pain score for cervical surgery￨the mean pain score for cervical surgery was significantly lower for women using isoflurane and desflurane 224 than the placebo arm 296 p 0003￨sig decrease￨low￨low￨low
100￨one hundred consecutive women referred with abnormal cervical smears for colposcopic assessment and considered suitable for treatment with the semm coagulator controlled trial conducted in a colposcopy clinic in a university teaching hospital women undergoing cervical biopsy and treatment with the semm coagulator pain associated with cervical biopsy and treatment with the semm coagulator￨placebo prilocaine with felypressin prilocaine and felypressin citanest and octapressin prilocaine and felypressin prilocaine and felypressin citanest and octapressin or placebo￨moderate pain severe pain intensity of the pain experienced pain intensity of pain mild pain pain scores anticipated pain￨women receiving the local anesthesia experienced a significantly greater reduction in pain p  05 with only 43 and 67 experiencing moderate pain during biopsy and treatment respectively￨sig decrease￨low￨low￨low
200￨two hundred consecutive women undergoing large loop excision of the transformation zone of the cervix women undergoing large loop excision of the transformation zone colposcopy clinic in a large district general hospital large loop excision of the transformation zone of the cervix￨felypressin prilocaine with felypressin and lignocaine with adrenaline lignocaine with adrenaline adrenaline prilocaine prilocaine lignocaine￨side effects perioperative blood loss and any side effects blood loss￨lignocaine with adrenaline resulted in less blood loss p  0006 but was more likely to cause side effects such as feeling faint p  0017 and shaking p  0001￨sig increase￨highunclear￨highunclear￨highunclear
50￨50 patients undergoing laser vaporization of the cervix for cervical intraepithelial neoplasia￨placebo solution cocaine cocaine spray￨blood loss verbal rating scale pain relief pain visual analogue scale￨women in the cocaine group had significantly less pain as assessed by a visual analogue scale p less than 0001 and by a verbal rating scale p  0002￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨63 pts affected by cin of various degrees cervical intraepithelial neoplasia all pts were premenopausal and ages ranged between 19 and 39 years￨placebo laser vaporization laser vaporization of the lesion analgesia or anaesthesia before laser surgery for cin carbon dioxide laser vaporization naproxene sodium￨mean vas value pain evaluation severity of pain￨analysis of data from the 3 groups showed no statistically significant difference￨no diff￨highunclear￨highunclear￨highunclear
not found￨￨￨healing rate healing frequencies￨at the 12month recall a statistically significant p  005 higher healing rate was observed for cases surgically retreated￨sig increase￨highunclear￨highunclear￨highunclear
92￨ninetytwo patients with 95 rootfilled incisors and canine teeth exhibiting apical periodontitis￨￨pain and swelling vas values postoperative discomfort postoperative symptoms analgesics discomfort high pain scores swelling and discoloration of the skin degree of swelling and pain on horizontal 100mm visual analog scales vas indirect costs￨conclusively surgical retreatment resulted in more discomfort and tended to bring about greater indirect costs than nonsurgical retreatment￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨root canal treated teeth with nonhealing periradicular pathosis 38 patients￨rootend resection and rootend filling surgical intervention￨success rate for surgery￨the success rate for surgery was higher than for conventional retreatment but the difference was not statistically significant￨no diff￨highunclear￨highunclear￨highunclear
6￨six patients with cleft palate who were similar in age velopharyngeal function and type of misarticulation were selected for this study patients with cleft palate patients with cleft palate who exhibited abnormal posterior tongue posturing during the production of dental or alveolar sounds￨visual feedback treatment visual feedback or no visual feedback￨visual feedback visual feedback￨the results indicated that visual feedback for tongue placement and frication was especially useful in the treatment of defective s sounds in patients with cleft palate who exhibited abnormal posterior tongue posturing during the production of dental or alveolar sounds￨sig increase￨highunclear￨highunclear￨highunclear
341￨three hundred fortyone students completed the 26item pretest and posttest questionnaires n  166 for the intervention group n  175 for the control group child abuse prevention curriculum for thirdgrade students￨child abuse prevention program￨child abuse knowledge efficacy expectations￨however no significant increases occurred in efficacy expectations regarding abusive situations from pretest to posttest for either the intervention or control groups￨no diff￨highunclear￨highunclear￨highunclear
231￨231 children elementary schoolaged children child sexual abuse prevention programs￨sexual abuse prevention program￨33item childrens knowledge of abuse questionnairerevised ckaqr knowledge levels of both inappropriate touch knowledge and skills￨age also significantly differentiated the knowledge levels regarding inappropriate touch with younger children knowing fewer concepts both at pretest and posttest p  000￨sig increase￨highunclear￨highunclear￨highunclear
133￨elementary school children 133 children 64 firstgraders and 69 thirdgraders participated in the study￨espace cap program child sexual abuse prevention program￨preventive knowledge and skills relative preventive skills global skill scores￨the findings suggest that the quebec adaptation of the cap program was effective in training children in abuse prevention concepts and skills￨sig increase￨highunclear￨highunclear￨highunclear
458￨458 high school students teenagers on sexual coercion student health education classes￨￨sexual attitude scales initial coercive attitude scores￨students examined individual and social attitudes underlying coercive sexual behavior and learned communication skills aimed at preventing or dealing with unwanted sexual advances￨no diff￨highunclear￨highunclear￨highunclear
not found￨educating school children in awareness of physical and sexual abuse￨￨knowledge of correct actions￨relative to controls children who received the program showed an overall increase in knowledge of correct actions to take in the event of potential or actual abuse￨sig increase￨highunclear￨highunclear￨highunclear
not found￨subjects were kindergarten and firstgrade students￨videotape program with behavior rehearsal videotape with behavior rehearsal videotape only a standard safety program and no training videotape program videotape training program￨acquisition of selfprotective behaviors￨results revealed that the videotape program with behavior rehearsal was highly effective in teaching children safe responses to potential abductors￨sig increase￨highunclear￨highunclear￨highunclear
not found￨chinese adolescents with mental retardation 72 female chinese adolescents with mild mental retardation female chinese adolescents with mild mental retardation￨sexual abuse prevention program behavioral skills training behavioral skills training program modified behavior skill training program behavior skills training program or an attention control program￨knowledge regarding sexual abuse and selfprotection skills￨the behavioral skills training group demonstrated greater knowledge regarding sexual abuse and selfprotection skills at posttest which was maintained at 2month followup though the scores on the recognition of appropriatetouch requests showed a decreasing trend￨sig increase￨highunclear￨highunclear￨highunclear
not found￨elementary school students￨victimization prevention program project trust project trust￨anxiety scores knowledge of maltreatment prevention information￨firsttime student abuse disclosures were greater in the experimental than in the control group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨￨￨childrens safety discrimination skills knowledge scale the statetrait anxiety inventory for children a videotape vignettes measure a parent questionnaire and disclosure data ongoing or past sexual abuse￨treatment children exhibited significantly greater knowledge and better ability to discriminate safe from unsafe situations on the video measure than control children at posttesting￨sig increase￨highunclear￨highunclear￨highunclear
not found￨155 patients received eligible patients were those who presented to the clinics with acute uncomplicated plasmodium falciparum malaria or mixed infection who were older than 6 months and who weighed more than 5 kg clinics in rakhine state kachin state and shan state in myanmar burma between dec 30 2008 and march 20 2009 burmese adults and children uncomplicated falciparum malaria￨artesunateamodiaquine artesunateamodiaquine 162 artemetherlumefantrine 169 artesunatemefloquine 161 loose artesunatemefloquine and 161 dihydroartemisininpiperaquine mefloquine artemetherlumefantrine dihydroartemisininpiperaquine artesunateamodiaquine primaquine loose artesunatemefloquine whorecommended fixeddose acts artesunatemefloquine artesunateamodiaquine dihydroartemisininpiperaquine artemetherlumefantrine and loose artesunatemefloquine artesunatemefloquine artesunatemefloquine artemisinincombination therapy act primaquine 075 mg basekg or not artesunate and mefloquine five artemisinin combination regimens with or without primaquine￨recrudescent p falciparum infections vomiting and dizziness adverse events hazard ratios for reinfection tolerated plasmodium vivax infection 63 day recrudescence rate mixed falciparum and vivax infections￨the addition of a single dose of primaquine 075 mgkg reduced p falciparum gametocyte carriage substantially rate ratio 119 95 ci 74205￨sig increase￨low￨low￨low
not found￨patients with plasmodium falciparum malaria in mumbai india adults with uncomplicated or severe plasmodium falciparum malaria￨primaquine 45 mg primaquine￨gametocytaemia and gametocyte viability￨among those with uncomplicated malaria six 273 of the 22 who did not receive primaquine but only one 42 of the 24 who did receive the drug on day 4 remained gametocytaemic on day 29 p  005￨no diff￨highunclear￨highunclear￨highunclear
not found￨a total of 308 87 patients completed the trial south west asia￨cq cqsingledosepq cq3 das pq gametocytocidal primaquine pq artesunate as or primaquine primaquine combined with chloroquine or sp chloroquine cq sulfadoxinepyrimethamine cq￨failure rates failure rates gametocyte carriage of cq or sp monotherapy against the respective combinations pq or as trophozoite and gametocyte clearance read by light microscopy and clinical and parasitological failure￨pq was more effective at clearing older gametocyte infections whereas as was more effective at preventing emergence of mature gametocytes except in cases that recrudesced￨no diff￨highunclear￨highunclear￨highunclear
50￨between april 2007 and february 2008 50 patients were recruited for the trial in turbo antioquia patients with uncomplicated p falciparum malaria￨artesunate asmefloquine mq treatment program primaquine pq asmq with or without pq artesunatemefloquineprimaquine￨efficacy and gametocytocidal activity clinical response and parasite elimination efficacy gametocyte elimination parasitemia and fever￨gametocyte elimination was superior when pq was used92 95 ci 7499 of patients who received pq had no gametocytes on day 3 compared to 783 95 ci 5993 of patients who only received asmq￨no diff￨highunclear￨highunclear￨highunclear
9￨twentyseven patients with gametocytes of plasmodium falciparum pf patients treated with artemisinin￨mefloquine combined with 45 mg primaquine to group mefloquine￨gametocyte count density of gametocyte and infectivity￨in group c gametocytes disappeared in 5 out of 9 patients with failure of infecting mosquitoes in all 9 patients on day 4 after treatment￨no diff￨highunclear￨highunclear￨highunclear
104￨104 individuals who had low density parasitaemia at screening dry season in an area of distinct seasonal malaria in two villages in gedarif state in eastern sudan participants were asymptomatic adults and children aged over 6 months with lowdensity p falciparum infection detected by pcr eastern sudan carriers with lowdensity parasitaemia in the dry season￨artesunatesulfadoxinepyrimethamine assp combination assppq primaquine pq artesunate sulfadoxinepyrimethamine with or without primaquine assp primaquine￨elimination of parasitaemia and prevention of gametocyte carriage parasitaemia￨addition of primaquine to artemisinin combination treatment did not improve elimination of parasitaemia and prevention of gametocyte carriage in carriers with lowdensity parasitaemia in the dry season￨no diff￨highunclear￨highunclear￨highunclear
23￨23 children hospitalized in the hospital for tropical diseases faculty of tropical medicine bangkok thailand falciparum malaria in thailand thai children aged 512 years suffering from uncomplicated falciparum malaria treated with￨mefloquine msp equivalent to 20 mg base of mefloquinekg body weight and group ii received msp plus primaquine msp and primaquine msp or msp plus primaquine msp plus primaquine primaquine primaquine mefloquine sulfadoxine and pyrimethamine msp msp￨serious side effects mean t12 clf and vd gametocyte clearance time mean cmax￨no statistical difference was noted for clinical response except the gametocyte clearance time was shorter in children given msp plus primaquine 7￨no diff￨highunclear￨highunclear￨highunclear
not found￨n  29 subjects versus n  88 for clinical and parasitological cure of uncomplicated falciparum malaria in the menoreh hills region of southern central java indonesia￨cq combined with sp cq  sp with or without primaquine primaquine pq chloroquine sulfadoxinepyrimethamine and primaquine primaquine cq chloroquine cq or sulfadoxinepyrimethamine sp monotherapy￨reinfectionadjusted cure rates gametocyte clearance rates cleared parasitaemia and remained aparasitaemic cure of asexual stage parasitaemia￨cq combined with sp was safe and welltolerated with superior efficacy over cq for p falciparum parasitaemia in this study￨sig increase￨highunclear￨highunclear￨highunclear
176￨falciparum malaria 176 adult thai patients with uncomplicated plasmodium falciparum malaria￨quinine or artesunate artesunate alone or vi artesunate with primaquine primaquine artesunate alone or in combination with primaquine quinine alone ii quinine with tetracycline iii quinine with primaquine at 15 mgday iv quinine with primaquine primaquine artesunate and primaquine￨shorter gametocyte clearance times gametocyte clearance fever clearance times rates of p falciparum reappearance or recurrent vivax malaria therapeutic response clinical recovery gametocyte carriage rates appearance of gametocytemia parasite clearance times gametocytemia￨artesunate reduced the appearance of gametocytemia relative risk 95 confidence interval  034 017 to 070 whereas combinations containing primaquine resulted in shorter gametocyte clearance times medians of 66 versus 271 h for quinine groups and 73 versus 137 h for artesunate groups p  or  0038￨sig decrease￨highunclear￨highunclear￨highunclear
108￨108 individuals were randomized mnyuzi an area of hyperendemic malaria in northeastern tanzania children aged 315 years with uncomplicated p falciparum malaria with an asexual parasite density between 500100000 parasitesmicrol￨spas primaquine pq spaspq primaquine spas or spaspq sulphadoxinepyrimethamine and artesunate sulphadoxinepyrimethamine sp plus artesunate as￨clearing gametocytaemia children harboured gametocytes haemoglobin levels hb hb levels pfs25 qtnasba gametocyte prevalence gametocyte prevalence and density￨pfs25 qtnasba gametocyte prevalence was 8891 at enrolment and decreased afterwards for both treatment arms￨no diff￨highunclear￨highunclear￨highunclear
393￨393 patients studied 192 received 2 gm of￨prophylactic antibiotics no antibiotics intravenous cefotetan￨￨there were seven cases of endomyometritis in the group given no antibiotic and none in the cefotetan group a statistically significant difference p less than 01￨sig decrease￨highunclear￨highunclear￨highunclear
89￨communityresiding persons with neurogenic bladder who used indwelling catheters persons with neurogenic bladder eightynine persons with bacteriuria￨bladder irrigation twice daily bladder irrigation irrigate their bladders twice daily for 8 weeks with 30 ml of a sterile saline b acetic acid or c neomycinpolymyxin solution bladder irrigation￨numbers and types of bacteria urinary ph urinary leukocytes and generation of antimicrobialresistant organisms degree of bacteriuria or pyuria urinalysis cultures and antimicrobial susceptibility tests urinary bacterial load and inflammation urinary ph resistance to oral antimicrobials￨no advantages were detected for neomycinpolymyxin or acetic acid over saline in terms of reducing the urinary bacterial load and inflammation￨no diff￨highunclear￨highunclear￨highunclear
73￨one hundred twelve potential participants were screened 73 were enrolled randomized and included in the final analysis adults with longterm indwelling catheters that required changing every 3 weeks or less living in the community and requiring supportive or continuing care were recruited￨saline or commercial solution acidic washout solution normal saline washout or standard care control usual care no washout saline washout or commercially available acidic washout solution contisol maelor pharmaceuticals ltd wrexham uk￨risk of uti patency time catheter changes or selfreported uti symptomatic urinary tract infection uti requiring antibiotics catheter life￨participants were randomly assigned to 1 of 3 groups control usual care no washout saline washout or commercially available acidic washout solution contisol maelor pharmaceuticals ltd wrexham uk￨no diff￨low￨low￨low
32￨32 longterm catheterized women￨normal saline of longterm urethral catheters normal saline irrigation periodic catheter irrigation oncedaily irrigation of longterm urethral catheters with normal saline￨urinary incontinence polymicrobial bacteriuria catheter obstruction fever bacteremia urinary tract stones and death incidence of catheter obstructions and febrile episodes and the prevalence and species of bacteriuria￨the incidence of catheter obstructions and febrile episodes and the prevalence and species of bacteriuria were similar whether examined as completed crossover patients n  23 or as partially completed trials n  9￨no diff￨highunclear￨highunclear￨highunclear
25￨patients with longterm indwelling catheters 25 elderly females with longterm catheters in order to examine crystal formation and catheter encrustation￨bladder washoutsinstillations 3 bladder washout treatmentssaline suby g and solution r￨catheter encrustation uric acid crystals struvite crystals￨there was no significant difference in catheter encrustation between the various washouts￨no diff￨highunclear￨highunclear￨highunclear
123￨group 1 included cryoextirpation 29 patients 46 cryoresection 20 patients 32 and cryodestruction 14 patients 22 solely one hundred twentythree patients with lm 87 males and 36 females a ratio 2410 age 413￨cryogenic and conventional surgery conventional surgical techniques cryogenic surgery￨curative effects intraoperative tumor reduction colorectal cancers 3year survival rate diseasefree survival 5year survival rate 5year and 10year survival rate hepatic cryosurgical procedures survival￨during a followup period recurrence in the liver was observed in 54 patients 85 in group 1 and in 57 patients 95 in control subjects￨no diff￨highunclear￨highunclear￨highunclear
2382￨nine academic medical centers recruited 2382 men and women age range 3054 years not taking antihypertensive drugs with a diastolic bp of 83 to 89 mm hg a systolic bp lower than 140 mm hg and a body mass index the weight in kilograms divided by the square of the height in meters representing 110 to 165 of desirable body weight overweight people with highnormal blood pressure￨weight loss and sodium reduction intervention￨lowering systolic and diastolic bp hypertension incidence bp decreases weight loss bp levels lowering diastolic bp systolic bp and the incidence of hypertension bp systolic and diastolic bp systolic bp weight weight changes high blood pressure bp average bp incidence of hypertension blood pressure and hypertension incidence sodium excretion￨differences were statistically significant for systolic and diastolic bp in the weight loss group and for systolic bp in the sodium reduction group￨sig increase￨highunclear￨highunclear￨highunclear
not found￨five kitchens of a veteran retirement home elderly veterans 1981 veterans 768 in the experimental x sd age 748 71 y and 1213 in the control age 749 elderly men￨potassiumenriched salt experimental group or regular salt control group for approximately 31 mo potassiumenriched salt￨incidence of cvdrelated deaths cardiovascular disease cvd mortality and medical expenditures cvd mortality cvd mortality and medical expenditure cardiovascular mortality and medical expenses blood pressure death health insurance claims cardiovascular mortality cvd survivorship￨a significant reduction in cvd mortality ageadjusted hazard ratio 059 95 ci 037 095 was observed in the experimental group￨sig decrease￨highunclear￨highunclear￨highunclear
975￨older persons with hypertension four academic health centers older persons a total of 975 corrected men and women aged 60 to 80 years with systolic blood pressure lower than 145 mm hg and diastolic blood pressure lower than 85 mm hg while receiving treatment with a single antihypertensive medication 390 nonobese participants hypertension in older persons 585 obese participants￨nonpharmacologic interventions reduced sodium intake or usual care nonpharmacologic interventions weight loss or reduced sodium intake sodium￨weight loss frequency of cardiovascular events reduced sodium intake￨relative to usual care hazard ratios among the obese participants were 060 95 ci 045080 p001 for reduced sodium intake alone 064 95 ci 049085 p002 for weight loss alone and 047 95 ci 035064 p001 for reduced sodium intake and weight loss combined￨no diff￨low￨low￨low
841￨841 healthy men and women aged 25 to 49 years with diastolic blood pressures of 78 to 89 mm hg￨control treatment group no dietary counseling or to one of four dietary counseling treatment groups reduced calories reduced sodium reduced sodium and calories or reduced sodium and increased potassium￨hypertensive events sodium and weight reductions potassium change blood pressure mean blood pressures mean body weight diastolic pressure￨all four dietary counseling treatment groups had lower mean blood pressures than the control group￨sig decrease￨highunclear￨highunclear￨highunclear
4￨persons with high normal diastolic blood pressure normotensive persons persons with high normal levels of 16821 screenees 2182 men and women aged 30 through 54 years with diastolic blood pressure from 80 through 89 mm hg were selected volunteers recruited from the community treated and followed up at special clinics￨nonpharmacologic interventions four nutritional supplement groups calcium magnesium potassium and fish oil seven nonpharmacologic interventions placebo￨systolic blood pressure systolic blood pressure and intervention compliance measures diastolic blood pressure or systolic blood pressure weight loss diastolic blood pressure change blood pressure diastolic blood pressure lifestyle change groups weight reduction sodium reduction and stress management systolic blood pressure change urinary sodium excretion￨sodium reduction interventions lowered urinary sodium excretion by 44 mmol24 h p less than 01 diastolic blood pressure by 09 mm hg p less than 05 and systolic blood pressure by 17 mm hg p less than 01￨sig decrease￨highunclear￨highunclear￨highunclear
41￨41 women having gynaecological surgery in which the team of surgeons and nurses wore or did not wear masks￨￨number of streptococci wound infections￨after major abdominal surgery 3 of 5 patients in the unmasked group developed wound infections whereas no infection was observed in the 4 patients of the masked group￨no diff￨highunclear￨highunclear￨highunclear
827￨eight hundred twentyseven participants undergoing elective or emergency obstetric gynecological general orthopaedic breast or urological surgery in an australian tertiary hospital were enrolled￨mask group all nonscrubbed staff wore a mask or no mask group none of the nonscrubbed staff wore masks￨preoperative stay surgical site infection rates surgical site infections￨overall 83 102 surgical site infections were recorded 46401 115 in the masked group and 37410 90 in the no mask group odds ratio or 077￨no diff￨low￨low￨low
3088￨3088 patients were included in the study￨￨wound infections general surgery wound infection rates postoperative wound infections and surgical face masks￨this difference was not statistically significant p greater than 005 and the bacterial species cultured from the wound infections did not differ in any way which would have supported the fact￨no diff￨highunclear￨highunclear￨highunclear
1027￨1413 adult smokers who volunteered for the study 1027 were enrolled 65 of randomized participants completed the study smoking cessation june 2003 and march 2005 at 14 research centers with a 12week treatment period and followup of smoking status to week 52￨placebo varenicline varenicline placebo or sustainedrelease bupropion bupropion sr bupropion sr￨nausea adverse events efficacy and safety￨the most common adverse event with varenicline was nausea which occurred in 101 participants 294￨no diff￨low￨low￨low
1202￨smokers using varenicline 2010 american journal of preventive medicine smoking cessation eligible participants current treatmentseeking smokers n1202 were recruited from a large healthcare organization between october 2006 and october 2007￨behavioral smokingcessation program varenicline smokingcessation interventions webbased counseling n401 proactive telephonebased counseling ptc n402 or combined ptc and web counseling behavioral counseling and varenicline phone counseling￨percentage of abstinence abstinence outcomes medication adherence￨the ptc group had a significantly higher percentage of abstinence than the web group at 3 months or148 95 ci112 196 but no betweengroup differences in abstinence outcomes were seen at 6 months￨sig increase￨highunclear￨highunclear￨highunclear
130￨healthy smokers aged 1865 years￨varenicline tartrate placebo varenicline varenicline varenicline tartrate 05 mg twice daily nontitrated varenicline tartrate novel selective nicotinic acetylcholine receptor partial agonist varenicline￨efficacy and safety tolerated with nausea nausea efficacy safety and tolerability carbon monoxideconfirmed 4week continuous quit rates continuous abstinence rates￨weeks 9 through 12 continuous quit rates were greater in the 10mg group 494 and the 05mg group 440 vs placebo 116￨sig increase￨highunclear￨highunclear￨highunclear
602￨602 generally healthy cigarette smokers￨varenicline dianicline dianicline placebo￨cigarette smoking abstinence rates craving and nicotine withdrawal symptoms craving hughes and hatsukami minnesota withdrawal scale exhaled carbon monoxide and cotinineconfirmed continuous abstinence rates nicotine withdrawal symptoms abstinence rates￨craving for a cigarettes was reduced by dianicline compared with placebo after 7 weeks p  0175￨sig decrease￨low￨low￨low
1542￨1542 adult smokers screened 740 were enrolled and 370 were randomly assigned to each study group￨cytisine placebo cytisine or matching placebo placebo￨rate of sustained 12month abstinence smoking abstinence gastrointestinal adverse events 7day point prevalence for abstinence efficacy and safety￨the rate of sustained 12month abstinence was 84 31 participants in the cytisine group as compared with 24 9 participants in the placebo group difference 60 percentage points 95 confidence interval ci 27 to 92 p0001￨no diff￨low￨low￨low
198￨588 subjects varenicline 390 placebo 198 groups were 431 108 and 439 108 years respectively 577 and 657 were male and the mean sd weights were 750 160 and 767 163 kg participants of caucasian origin adult smokers 42 centers in 11 countries latin america brazil colombia costa rica mexico and venezuela africa egypt and south africa middle east jordan lebanon saudi arabia and the united arab emirates participants were male and female smokers aged 18 to 75 years who were motivated to stop smoking smoked 10 cigarettesd with no cumulative period of abstinence 3 months in the previous year and who had no serious or unstable disease within the previous 6 months￨placebo varenicline smokingcessation medication varenicline brief smokingcessation counseling varenicline 1 mg or placebo copyright￨adverse events aes car carbon monoxideconfirmed continuous abstinence rate car psychiatric saes nausea headache and insomnia efficacy and tolerability tolerability assessment￨car at weeks 9 to 12 was significantly higher with varenicline than with placebo 5359 vs 1869 odds ratio or￨sig increase￨low￨low￨low
128￨healthy smokers 1865 years old￨varenicline tartrate placebo bupropion hydrochloride varenicline varenicline varenicline tartrate placebo for 1 week to 150mg sustainedrelease bupropion hydrochloride￨continuous quit rates adverse events efficacy tolerability and safety bupropion rate carbon monoxideconfirmed continuous quit rates￨discontinuation owing to treatmentemergent adverse events was 159 for bupropion 112 to 143 for varenicline and 98 for placebo￨no diff￨low￨low￨low
618￨japanese smokers 385 748 subjects were male and the mean age was within the range of 390 to 402 years 618 subjects who received treatment 515 833 were classified as nicotine dependent scoring or5 on the tobacco dependence screener and constituted the primary analysis group￨varenicline varenicline placebo￨cars nausea minnesota nicotine withdrawal scale the brief questionnaire on smoking urges and the modified cigarette evaluation questionnaire efficacy and tolerability headache nausea smoking abstinence rates nasopharyngitis continuous abstinence rate car defined as no reported smoking not even a puff or other nicotine use and confirmed by endexpiratory carbon monoxide level craving withdrawal and smoking satisfaction￨nausea was the only ae that appeared dose related 72 11153 at 025 mg bid 97 15155 at 05 mg bid and 244 38156 at 1 mg bid versus placebo 78 12154￨no diff￨low￨low￨low
32￨adult smokers 32 adult smokers￨varenicline vs nicotine patch varenicline nicotine patch￨gastrointestinal disorder efficacy safety and withdrawal symptoms skin allergy 12 and 24week smokingabstinence rates safety and withdrawal symptoms including stress abstinence rates￨adverse sideeffects associated with a gastrointestinal disorder occurred in 14 cases and 1 case in the vg and ng respectively and skin allergy was seen in 0 and 9 cases respectively￨no diff￨highunclear￨highunclear￨highunclear
714￨healthy smokers 714 smokers with stable cardiovascular disease patients with cardiovascular disease smokers with cardiovascular disease￨varenicline and placebo placebo varenicline varenicline with placebo varenicline information url￨cardiovascular events or mortality continuous abstinence rate efficacy and safety carbon monoxideconfirmed continuous abstinence rate cardiovascular events serious adverse events cardiovascular mortality cause mortality efficacy and safety￨the varenicline and placebo groups did not differ significantly in cardiovascular mortality 03 versus 06 difference 03 95 ci 13 to 07 allcause mortality 06 versus 14 difference 08 95 ci 23 to 06 cardiovascular events 71 versus 57 difference 14 95 ci 23 to 50 or serious adverse events 65 and 60 difference 05 95 ci 31 to 41￨no diff￨low￨low￨low
not found￨adult smokers 320 healthy motivatedtoquit smokers  or 10 cigarettesday aged 1865 years participants were primarily healthy caucasians￨varenicline tartrate varenicline placebo varenicline or placebo￨car from weeks 9 through 24 7day point prevalence of abstinence safety assessments and measures of craving withdrawal and smoking reward carbon monoxideconfirmed continuous abstinence rate car superior cars overall medication compliance efficacy and safety￨superior cars were observed in vareniclinetreated n  157 versus placebo participants n155 for weeks 4 through 7 382 vs 116 9 through 12 401 vs 116 9 through 24 280 vs 90 and 9 through 52 223 vs 77 all p0001￨sig increase￨low￨low￨low
1210￨smokers who quit after 12 weeks of treatment with 1927 cigarette smokers recruited between april 2003 and february 2004 and treated for 12 weeks with multiple medical clinics in 7 countries with followup to 52 weeks after study baseline￨carbon monoxide placebo varenicline a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline varenicline openlabel varenicline nicotine replacement therapy doubleblind varenicline￨adverse events adverse events smoking cessation carbon monoxideconfirmed continuous abstinence rate continuous abstinence abstinence relapse￨the carbon monoxideconfirmed continuous abstinence rate was significantly higher for the varenicline group than for the placebo group for weeks 13 to 24 705 vs 496 odds ratio or 248 95 confidence interval ci 195316 p001 as well as for weeks 13 to 52 436 vs 369 or 134 95 ci 106169 p  02￨sig increase￨low￨low￨low
504￨504 patients with mild to moderate copd postbronchodilator fev1fvc 70 fev1 percent predicted normal value 50 and without known psychiatric disturbances smokers with mild to moderate copd patients with mild to moderate copd￨varenicline varenicline varenicline tartrate vs placebo placebo￨car nausea abnormal dreams upperrespiratory tract infection and insomnia smoking cessation carbon monoxideconfirmed continuous abstinence rate car efficacy and safety￨varenicline was more efficacious than placebo for smoking cessation in patients with mild to moderate copd and demonstrated a safety profile consistent with that observed in previous trials￨sig increase￨low￨low￨low
251￨251 subjects eligible adult smokers 1875 years who smoked an average of  or 10 cigarettesday￨placebo varenicline varenicline 468 placebo varenicline varenicline 1 mg twice daily bid or placebo￨vital signs adverse events aes and smoking status abnormal dreams insomnia prevalence abstinence rates nausea effective smoking cessation￨treatmentemergent aes were observed in 964 of varenicline and 825 of placebotreated subjects during the study￨no diff￨low￨low￨low
1025￨smoking cessation participants were 1025 generally healthy smokers  or 10 cigarettesd with fewer than 3 months of smoking abstinence in the past year 18 to 75 years old recruited via advertising 19 us centers from june 19 2003 to april 22 2005￨placebo bupropion and placebo bupropion bupropion sr bupropion sr varenicline varenicline brief counseling and varenicline bupropion sr￨continuous abstinence rate insomnia nausea exhaled carbon monoxideconfirmed 4week rate of continuous abstinence from smoking efficacy and safety continuous abstinence rates￨varenicline was significantly more efficacious than placebo for smoking cessation at all time points and significantly more efficacious than bupropion sr at the end of 12 weeks of drug treatment and at 24 weeks￨sig increase￨low￨low￨low
493￨subjects using a flexible quit date paradigm after starting medication 493 subjects smokers of 10 cigarettesday aged 1875 years and who were motivated to quit￨varenicline 1 mg bid varenicline placebo varenicline￨carbon monoxideconfirmed continuous abstinence depressionrelated adverse events serious adverse events efficacy and safety continuous abstinence￨continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment weeks 912 531 vs 193 odds ratio or 59 95 ci 3794 p  0001 and through 24 weeks followup weeks 924 347 vs 127 or 44 95 ci 2675 p  0001￨sig increase￨low￨low￨low
79￨hospitalized smokers seventynine smokers admitted to a universitybased hospital with various diagnoses were enrolled from 2007 to 2009￨placebo varenicline varenicline and postdischarge inperson behavioral treatment tobacco dependence treatment varenicline vs 10 placebo￨withdrawal symptoms motivation utilization of treatment and medical events overall adverse events overall abstinence nausea motivation to stop smoking or withdrawal symptoms abstinence rates￨overall adverse events were similar in both treatment groups with the only significant difference being more nausea in the varenicline group 25 vs 5 p001￨no diff￨low￨low￨low
24￨asian smokers groups respectively and the mean range body weights were 690 4481100 kg and 714 4551020 kg respectively eligible subjects smoking or10 cigarettesd received brief smokingcessation counseling 126 subjects 849 male received subjects had smoked a mean of 23 cigarettes 5 sites each in korea and taiwan subjects were aged 21 to 73 years mean age 397 and 409 years for smokers in taiwan and korea subjects had smoked for 3 to 52 years mean 202 and 221 years in the varenicline and placebo groups respectively￨varenicline and placebo placebo varenicline varenicline bid varenicline￨rates of smoking abnormal dreams 7day pp smokingcessation rates insomnia increased appetite anxiety adverse events car from weeks 9 to 24 and 7day point prevalence pp of abstinence minnesota nicotine withdrawal scale the brief questionnaire of smoking urges and the modified cigarette evaluation questionnaire nausea constipation continuous abstinence rate car efficacy and tolerability craving withdrawal and smoking satisfaction￨smokingcessation rates at the end of treatment were 595 with varenicline versus 323 with placebo p  0001￨sig increase￨low￨low￨low
22071￨22071 us male physicians￨placebo aspirin and beta carotene aspirin and placebo regular aspirin aspirin and placebo lowdose aspirin aspirin￨stage or prevalence of rectal bleeding colorectal cancer incidence or mortality decreasing rr rectal bleeding and early stage at diagnosis rr of developing colorectal cancer￨the rr of developing colorectal cancer for aspirin compared with placebo was 115 95 ci  080165￨no diff￨low￨low￨low
77￨patients with familial adenomatous polyposis patients with familial adenomatous polyposis familial adenomatous polyposis 77 patients to treatment with￨placebo celecoxib￨mean number of colorectal polyps number of colorectal polyps extent of colorectal polyposis adverse events polyp burden￨the reductions in the group receiving 100 mg of celecoxib twice a day were 119 percent p033 for the comparison with placebo and 146 percent p009 respectively￨sig decrease￨low￨highunclear￨low
635￨517 randomized patients had at least one colonoscopic examination a median of 128 months after randomization patients with previous colorectal cancer 635 patients with previous colorectal cancer massachusetts medical society￨placebo aspirin per day or placebo aspirin￨time to the detection of a first adenoma risk of colorectal adenomas incidence of colorectal adenomas colorectal adenomas mean sd number of adenomas adjusted relative risk of any recurrent adenoma￨one or more adenomas were found in 17 percent of patients in the aspirin group and 27 percent of patients in the placebo group p0004￨sig increase￨low￨low￨low
1121￨massachusetts medical society 1121 patients with a recent history of histologically documented adenomas to receive colorectal adenomas￨placebo aspirin￨severe dysplasia or invasive cancer unadjusted relative risks of any adenoma incidence of one or more adenomas￨unadjusted relative risks of any adenoma as compared with the placebo group were 081 in the 81mg group 95 percent confidence interval 069 to 096 and 096 in the 325mg group 95 percent confidence interval 081 to 113￨sig increase￨low￨low￨low
22￨four patients were dropped from the study sulindac group due to urosepsis 1 patient heartburn 2 patients and anemia 1 patient sporadic colonic polyps asymptomatic patients undergoing routine screening flexible sigmoidoscopy were enrolled if they had polyps of  or  1 cm in size 162 patients screened 22 patients￨sulindac placebo sulindac vs placebo￨polyp regression or size compliance￨four months of treatment with sulindac does not result in a clinically significant regression of sporadic colonic polyps although a small effect may not have been detected by the size of our study￨no diff￨highunclear￨highunclear￨highunclear
41￨41 young subjects age range 8 to 25 years who were genotypically affected with familial adenomatous polyposis but phenotypically unaffected subjects with familial adenomatous polyposis￨sulindac placebo sulindac orally twice a day or identicalappearing placebo tablets sulindac￨number and size of new adenomas and side effects of therapy average rate of compliance mean number levels of five major prostaglandins mucosal prostaglandin levels￨there were no significant differences in the mean number p069 or size p017 of polyps between the groups￨no diff￨low￨low￨low
10￨familial adenomatous polyposis 10 patients with rectal polyps that had been previously treated by colectomy and ileorectal anastomosis￨sulindac and placebo placebo sulindac 300 mgday or placebo sulindac sulindac￨￨the difference between sulindac and placebo was statistically significant p less than 001￨sig decrease￨highunclear￨highunclear￨highunclear
272￨272 patients with a history of colorectal adenomas at least one more than 5 mm in diameter or more than 3 to￨daily lysine acetylsalicylate placebo daily soluble aspirin aspirin￨absence of personal history of adenoma colorectal adenoma recurrence adenoma recurrence￨at least one adenoma of more than 5 mm diameter was observed in 13 patients 10 in the aspirin group and 26 23 in the placebo group p  001￨no diff￨low￨low￨low
6￨537 patients received either patients undergoing transrectal prostatic biopsy two hundred twentyseven 84 of 269 ciprofloxacin patients and 230 86 of 268 placebo patients￨ciprofloxacin placebo ciprofloxacin oral ciprofloxacin 500 mg or placebo six ciprofloxacin antimicrobial prophylaxis￨bacteriologic response bacteriuria more than 104 colonyforming units cfuml versus no bacteriuria clinical signs and symptoms of a urinary tract infection uti hospitalization rate net costs of treating infectious complications bacteriuria actual rate of bacteriuria￨singledose oral ciprofloxacin reduced bacteriuria after biopsy compared with placebo in patients undergoing transrectal prostatic biopsy and provided an economic advantage￨sig increase￨low￨low￨low
83￨patients with symptomatic urinary tract infections utis prostatitis indwelling catheters diabetes and those receiving steroid therapy were excluded for 24 h
                eightythree patients undergoing prostatic biopsy transrectal prostatic biopsies￨oral coamoxiclav oral coamoxiclav group 1 or no further antibiotics intravenous coamoxiclav coamoxiclav given alone before transrectal prostatic biopsy￨rate of positive msus positive msus incidence of infections￨there was no statistically significant difference in the rate of positive msus between the groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨between february 2006 and december 2007 322 men who underwent prostate biopsy￨antibiotic prophylaxis by ciprofloxacin transrectal ultrasoundguided prostate biopsy antibiotic prophylaxis￨urinary tract infection asymptomatic bacteriuria￨there was no significant difference between the two antibiotic prophylaxis regimen one single dose or three days for patients undergoing trus guided biopsies￨no diff￨highunclear￨highunclear￨highunclear
40￨40 patients undergoing transrectal needle prostatic biopsy bacteremia and bacteriuria after transrectal prostatic biopsy￨parenteral gentamicin versus povidoneiodine enema pie gentamicin￨postbiopsy bacteriuria bacteriuria￨in 69 per cent of patients not receiving pie bacteremia developed and 32 per cent acquired bacteriuria whereas only 19 per cent of patients given pie alone or in combination with gentamicin because bacteremic and 95 per cent had postbiopsy bacteriuria￨sig increase￨highunclear￨highunclear￨highunclear
497￨497 patients enrolled 247 were randomized to men undergoing transrectal needle biopsy of the prostate trnbp patients who required trnbp patients undergoing transrectal needle biopsy of the prostate patients with diabetes mellitus and patients with a history of prostatitis￨ciprofloxacin placebo ciprofloxacin ciprofloxacin xr ciprofloxacin xr oral ciprofloxacin xr 1day ciprofloxacin xr￨clinical success rate bacteriological and clinical success rates￨in a multivariate analysis patients with diabetes mellitus and patients with a history of prostatitis had higher microbiological and clinical failure rates respectively than those without such conditions￨sig increase￨low￨low￨low
63￨48 patients was considered evaluable 63 patients￨placebo carbenicillin transrectal prostatic biopsy transrectal biopsy carbenicillin indanyl sodium￨complications of fever and urinary tract infections positive urine cultures blood cultures incidence of fever and urinary tract infections fever￨of 23 patients who received the study drug 2 86 per cent had positive urine cultures at 48 hours compared to 9 of 25 36 per cent from the placebo group￨no diff￨highunclear￨highunclear￨highunclear
192￨transrectal prostate biopsy september 1998 and march 2001 a total of 192 patients who had an abnormal digital rectal examination andor prostate specific antigen 4 ngml or greater underwent patients undergoing transrectal prostate biopsy￨ciprofloxacin singledose oral antibiotic prophylaxis transrectal ultrasound guided systematic 13 cores prostate biopsy placebo vit c tablet antibiotic prophylaxis metronidazole￨infective complications urinary tract infection and fever noninfective complications rectal bleeding haematuria and pain urine cultures efficacy and safety￨there was no significant difference among the three groups in noninfective complications but the incidence of infective complications in group a was significantly higher than in groups b and c p  001￨no diff￨highunclear￨highunclear￨highunclear
400￨400 patients who underwent prostate biopsy with trus guidance were included all patients had urine cultures prior to biopsy and on the second day after biopsy 12core transrectal prostate biopsy￨ciprofloxacin single gram of intramuscular ceftriaxone antibiotic prophylaxis antimicrobial prophylaxis traditional 3day antimicrobial prophylaxis￨major complications requiring hospitalization positive urine cultures morbidity rates rate of infectious complications￨overall only seven patients 18 of the cases had positive urine cultures with no difference between these three groups￨no diff￨highunclear￨highunclear￨highunclear
117￨patients undergoing transrectal prostatic biopsy transrectal prostatic biopsy 117 patients enrolled in the study 101 were evaluated and of these patients 47 received postoperative infections associated with transrectal prostatic biopsy￨trimethoprimsulfamethoxazole netilmycinmetronidazole trimethoprimsulfamethoxazole versus netilmycinmetronidazole trimethoprimsulfamethoxazole cotrimoxazole￨bacteremia rate urinary tract infection rates￨urinary tract infection rates were greater in the netilmycinmetronidazole group 17 8 of 47 patients versus 2 1 of 54 in the trimethoprimsulfamethoxazole group p  001￨sig increase￨highunclear￨highunclear￨highunclear
111￨transrectal prostatic biopsy 111 eligible men consecutively undergoing￨transrectal prostatic corebiopsy tpb cefuroxime piperacillintazobactam cefuroxime or combined piperacillintazobactam pt ultrasonographically guided tpb antimicrobial prophylaxis￨bacteriuria microbiological success no bacteriuria  105 organismsml or bacteraemia after tpb urine and blood cultures￨microbiological success no bacteriuria  105 organismsml or bacteraemia after tpb was observed in 98 of 103 men 95 of whom 48 received pt and 50 cefuroxime￨no diff￨highunclear￨highunclear￨highunclear
110￨transrectal prostate biopsy in 110 men transrectal biopsy of the prostate￨ofloxacin trimethoprimsulfamethoxazole fluoroquinolone versus trimethoprimsulfamethoxazole fluoroquinolone or trimethoprimsulfamethoxazole prophylaxis ofloxacin and trimethoprimsulfamethoxazole regimens antibiotic prophylaxis￨urinary infection￨both of these antibiotic regimens produced a statistically significant reduction in urinary infection p002 p005￨sig decrease￨highunclear￨highunclear￨highunclear
231￨transrectal needle biopsy of the prostate between june 1996 and september 1998 231 patients who satisfied the inclusion and exclusion criteria entered the study the patients￨ciprofloxacin tinidazole ciprofloxacintinidazole placebo tablet antibiotic prophylaxis transrectal needle biopsy antibiotic prophylaxis￨urinary infection rate infective complications urinary tract symptoms rectal bleeding haematuria and perineal pain urinary tract infection urinary tract infection and fever incidence of infective complications noninfective complications urine cultures fever￨there was no significant difference among the three groups in noninfective complications 27 29 and 31 in groups 13 respectively but the incidence of infective complications 19 six and eight respectively was significantly higher in group 1 p  0003￨no diff￨highunclear￨highunclear￨highunclear
81￨81 patients undergoing after transrectal biopsy of the prostate￨povidoneiodine enema parenteral piperacillin piperacillin in combination with povidoneiodine enema povidoneiodine transrectal needle biopsy prophylactic antimicrobial regimens￨postbiopsy infectious complications incidence of infectious complications infectious complications￨when parenteral piperacillin alone in group b n  22 was administered the rates of the same complications were 9 and 14 respectively while both rates were as low as 4 in group c n  25 when piperacillin in combination with povidoneiodine enema was given￨no diff￨highunclear￨highunclear￨highunclear
89￨89 men undergoing transrectal prostatic biopsies patients having transrectal needle biopsy of the prostate￨trimethoprimsulfamethoxazole trimethoprimsulfamethoxazole prophylaxis trimethoprimsulfamethoxazole￨frequency of fever or bacteremia postoperative fever bacteremia and bacteriuria bacteremia bacteriuria￨trimethoprimsulfamethoxazole did not reduce the frequency of fever or bacteremia but did produce a significant reduction in bacteriuria 0 versus 21 p equals 0008￨no diff￨highunclear￨highunclear￨highunclear
5￨patients with indwelling urethral catheters or taking antibiotics or immunosuppressive drugs were excluded as were patients with positive msu cultures before tpb transrectal prostatic biopsy after transrectal prostatic biopsy tpb 138 evaluable patients 72 received parenteral pt and 66 oral patients scheduled for tpb￨piperacillintazobactam pt ciprofloxacin 100ml phosphate enema 3 h before tpb ciprofloxacin vs piperacillintazobactam antimicrobial prophylaxis￨infective complications pyrexia selfrecording of body temperature bacteriuria tpb￨this prospective study showed that shortterm prophylaxis with pt was associated with a low rate of asymptomatic bacteriuria requiring no further treatment whereas although the rate was similar on longterm prophylaxis with ciprofloxacin patients required further treatment with one needing hospitalization￨sig decrease￨highunclear￨highunclear￨highunclear
115￨115 patients were available for final analysis patients undergoing transrectal ultrasoundguided biopsies of the prostate patients undergoing transrectal biopsies of the prostate gland 19951997 all the patients undergoing transrectal ultrasoundguided biopsy of the prostate bacteriuria following the transrectal biopsy of the prostate￨trimethoprim with gentamicin trimethoprim and gentamicin trimethoprim gentamicin and 62 trimethoprim gentamicin trimethoprim or gentamicin prophylaxis trimethoprim versus gentamicin￨bacteriuria preexisting bacteriuria midstream urine msu samples rates of bacteriuria￨though there was no statistical significant difference in the rates of bacteriuria following administration of trimethoprim and gentamicin data appear to favour trimethoprim prophylaxis￨no diff￨highunclear￨highunclear￨highunclear
140￨transrectal ultrasoundguided prostate biopsies 140 patients submitted to prostate biopsy with transrectal ultrasonographic control urologic patients￨transrectal ultrasoundguided prostate biopsies norfloxacin 400mg single dose before the procedure and group 2 receiving norfloxacin short and long term antimicrobial therapy￨incidence of urinary tract infection uti and complications incidence of minor complications￨efficiency control was determined by the incidence of urinary tract infection uti and complications in both groups after statistical analysis￨no diff￨highunclear￨highunclear￨highunclear
20￨lower limb complex regional pain syndrome type 1￨radiofrequency lumbar sympathectomy percutaneous radiofrequency lumbar sympathectomy or lumbar sympathetic neurolysis with phenol percutaneous radiofrequency thermal lumbar sympathectomy therapeutic options percutaneous radiofrequency thermal lumbar sympathectomy￨pain relief and side effects various pain scores mean pain scores safety and efficacy￨however there was no statistically significant difference in mean pain scores between the groups￨no diff￨highunclear￨highunclear￨highunclear
39￨primary sclerosing cholangitis 39 patients received￨placebo penicillamine￨overall survival progressive symptoms deterioration in serial hepatic laboratory values or histologic progression on sequential liver biopsy specimens levels of hepatic copper disease progression￨progressive symptoms deterioration in serial hepatic laboratory values or histologic progression on sequential liver biopsy specimens were similar in both groups occurring in greater than 80 of the entire study population￨no diff￨highunclear￨highunclear￨highunclear
not found￨obese pregnant women with gestational diabetes obese gestationally diabetic women￨1200kcal diet calorie restriction￨mean glucose levels urine ketones metabolic effects fasting plasma glucose and glucose tolerance fasting levels of betahydroxybutyrate fasting plasma insulin￨finally urine ketones increased significantly p less than 002 in the calorierestricted group whereas they remained absent in the control groupabstract truncated at 250 words￨sig decrease￨highunclear￨highunclear￨highunclear
5￨70 women who met the inclusion criteria 62 completed the study 32 in the lgi and 30 in the hgi groups healthy women￨lowglycemicindex diet dietary counseling that encouraged either lowgi lgi carbohydrate foods or highfiber moderatetohigh gi hgi foods lgi lowgi and conventional dietary strategies￨higher ponderal index pregnancy outcomes obstetric outcomes mean diet gi fell higher birth centile fetal size compliance and acceptability￨the mean diet gi fell significantly in the lgi group but not in the hgi group￨sig decrease￨highunclear￨highunclear￨highunclear
80000￨both pregnant and nonpregnant women￨carbohydrate eaten high v lowglycaemic sources￨substrate utilization glucose oxidation v lipid oxidation and insulin resistance and sensitivity substrate level or flow alter fetoplacental growth rate postprandial glucose and insulin responses maternal carbohydrate intake and pregnancy outcome￨thus altering the source of maternal dietary carbohydrate may prove to be a valuable tool in the management of pregnancies at risk for anomalous fetoplacental growth and for the prevention andor treatment of obesity and insulin resistance in the nonpregnant state￨sig increase￨highunclear￨highunclear￨highunclear
189￨a 3900bed medical centre in northern taiwan with around 3000 births annually taiwanese childbearing women 189 women who had regular checkups during pregnancy and gave birth at the medical centre taiwanese women￨diet and physical activity intervention ep group attended regularly scheduled clinic visits with individualised dietary and physical activity education plans individual counselling epp routine outpatient department obstetric educational programme￨average gestational weight gain average weight retention body weight body mass index healthpromoting behaviour and psychosocial variables selfefficacy body image depression and social support weight retention￨average gestational weight gain was 1402 1527 and 1622 kg in the three ep epp and comparison groups respectively and average weight retention at six months post partum was 234 406 and 508 kg in the three groups respectively￨no diff￨highunclear￨highunclear￨highunclear
not found￨overweight and obese women pregnant women were approached at their first antenatal visit and body mass index bmi was calculated to determine whether they were overweight or obese bmi  25 australian and new zealand journal of obstetrics and gynaecology eligible women obese pregnant women 2011￨standard obstetric antenatal care or fourstep multidisciplinary antenatal care clinic protocol included i continuity of obstetric provider ii weighing on arrival at each visit iii a five brief minute intervention by a food technologist who asked about the womens eating habits of the previous day provided information on reading food labels shopping lists of affordable foods available from local shops and recipes for a healthy pregnancy diet and iv clinical psychology management￨incidence of gestational diabetes gestational diabetes and weight gain weight gain in pregnancy birthweight of newborns￨the intervention was associated with a significant reduction in the incidence of gestational diabetes 6 versus 29 or 017 95 ci 003095 p  004￨no diff￨highunclear￨highunclear￨low
80￨eighty sedentary women healthy women during their entire pregnancy on their perception of health status￨exercise copyright exercise group￨maternal perception of health status and several pregnancy outcomes maternal health perception maternal perception of health status￨significant differences p  03 were found between study groups in the percentage of women who perceived their health status as very good the values that corresponded to the exercise group n  18 545 were better than those of the control group n  9 273￨sig increase￨highunclear￨highunclear￨highunclear
100￨nulliparous women 100 women were randomized to the study lifestyle counseling 57 routine prenatal care 43￨organized consistent program of intensive dietary and lifestyle counseling or routine prenatal care dietary and lifestyle counseling￨weight gain iom adherence excessive weight gain proportion of patients whose gestational weight gain weight mode of delivery rate of operative vaginal delivery neonatal weight and the incidence of preeclampsia gestational diabetes mellitus gdm vaginalperineal lacerations and shoulder dystocia adherence to iom guidelines rate of cesarean delivery preeclampsia gdm operative vaginal delivery or vaginal lacerations cesarean deliveries￨no statistically significant differences were noted between the groups in adherence to iom guidelines rate of cesarean delivery preeclampsia gdm operative vaginal delivery or vaginal lacerations￨no diff￨low￨low￨low
not found￨normalweight women bmi body mass index of 198260 gain 2535 lb 114159 kg during pregnancy and that overweight women bmi of 261290 gain 1525 lbs 68114 kg normal weight women women n120 who had a bmi198 age18 and 20 weeks gestation were recruited from a hospitalbased clinic serving lowincome women and randomized by race and bmi category to the intervention or control group women who gain more than the iom recommendation pregnant women￨education about weight gain healthy eating and exercise and individual graphs of their weight gain stepped care behavioral intervention steppedcare behavioral intervention with usual care￨postpartum weight retention weight gain excessive weight gain postpartum weight retention percentage of normalweight weight gain during pregnancy categorized as above the iom recommendations￨the intervention significantly decreased the percentage of normalweight women who exceeded the iom recommendations 33 vs 58 p005￨sig decrease￨highunclear￨highunclear￨highunclear
75￨seventyfive women who exercised regularly were evaluated before pregnancy￨￨fetoplacental growth fat mass maternal weight gain fresh placental volumes and histomorphometric indices of placental function placental growth rate birth weight and placental volume at term￨the offspring of the women who were randomly assigned to a high volume of exercise in mid and late pregnancy were significantly lighter 339 kg vs 381 kg and thinner 83 fat vs 121 fat than those offspring born of women who were randomly assigned to reduce their exercise volume after the 20th week￨sig increase￨highunclear￨highunclear￨highunclear
200￨nw women and prevented postpartum weight retention in nw and owob women women who exceeded the 1990 institute of medicine iom recommendations for gestational weight gains and increase the proportion of women who returned to pregravid weights by 6 mo postpartum participants were pregnant 135 wk gestation normalweight nw n  201 and overweight or obese owob n  200 women whose average age was 288 y participants￨lowintensity behavioral intervention facetoface visit weekly mailed materials that promoted an appropriate weight gain healthy eating and exercise individual graphs of weight gain and telephonebased feedback 1990 iom weight category nw compared with owob to standard care n  200 or to a behavioral intervention to prevent excessive gestational weight gain behavioral intervention￨percentage of nw women who exceeded iom recommendations excessive weight gain excessive gestational weight gain excessive gestational weight gains percentages of nw and owob￨a lowintensity behavioral intervention during pregnancy reduced excessive gestational weight gains in nw women and prevented postpartum weight retention in nw and owob women￨sig decrease￨highunclear￨highunclear￨low
315￨three hundred and fifteen pregnant women between the 10th and 29th week of gestation 185 to 249 kgm² overweight 250 to 299 kgm² and obesity 30 kgm² known health unit located in the metropolitan region of the city of porto alegre in rio grande pregnant women attended in a primary care service pregnant women who were served in a public health service facility pregnant women who were overweight￨dietary counseling according to nutritional status eutrophy dietary counseling program dietary counseling￨weight gain prevalence of clinical complications weight and height controlling weight gain gain weight speed pregestational nutritional status rate of weekly weight gain rates of prevalence of excessive weight body mass index bmi￨dietary counseling was effective in decreasing the weight gain of pregnant women who were overweight and reducing clinical complications such as gestational diabetes preeclampsia infant low weight and prematurity in the intervention group￨sig decrease￨highunclear￨highunclear￨highunclear
not found￨obese pregnant women obese pregnant women intervention group gestational diabetes￨exercise intervention individualized exercise program individualized exercise program n  25 control group usual care￨fasting glucose and insulin and homeostasis model assessment of insulin resistance homair insulin resistance homair exercisebased activity gestational diabetes mellitus gdm physical activity￨however insulin resistance homair did not differ between the groups￨no diff￨highunclear￨highunclear￨highunclear
not found￨pregnant women ethnically diverse lowincome englishspeaking pregnant women pregnancy with video doctor counseling￨video doctor intervention￨nutrition knowledge exercise and dietary behaviors baseline in exercise 28 min intake of fruits and vegetables whole grains fish avocado and nuts and significant decreases in intake of sugary foods refined grains high fat meats fried foods solid fats and fast food weight gain￨nutrition knowledge improved significantly over time in both groups but more so in the video doctor group￨sig increase￨highunclear￨highunclear￨highunclear
46￨overweight and obese pregnant women 46 overweight or obese pregnant women to￨receive a lowgl or a lowfat diet carbohydraterich foods fats and snack foods through home delivery or study visits lowglycemic load lowgl diet lowglycemic load diet￨triglycerides creactive protein adjusted head circumference longer pregnancy duration greater infant head circumference and improved maternal cardiovascular risk factors total cholesterol deliveries birth weight z score gestational duration infant anthropometric measurements gestational duration maternal weight gain and maternal metabolic parameters￨there were no significant differences in birth weight z score or other measures of infant adiposity between groups￨no diff￨low￨low￨low
195￨obese pregnant women obese women during pregnancy 195 white obese pregnant women age 29  or  4 y body mass index in kgm2 336  or  42￨lifestyle intervention based on a brochure or on active education lifestyle intervention nutritional advice from a brochure a group that received the brochure and lifestyle education by a nutritionist and a control group lifestyle interventions￨dietary habits increase physical activity pa and reduce gwg dietary habits physical activity and gestational weight gain nutritional habits pa maternal obesity and excessive gestational weight gain gwg fat intake nutritional habits gwg and obstetrical or neonatal outcome energy intake protein intake calcium intake and vegetable consumption￨fat intake specifically saturated fat intake decreased and protein intake increased from the first to the third trimester in the passive and active groups compared with an opposite change in the control group￨sig decrease￨highunclear￨highunclear￨highunclear
24￨a pregnant adolescent african american population pregnant teens￨nutrition education intervention computerassisted selfinterview and nutrition education computerassisted selfinterview casi nutrition assessment￨gestational weight gain gestational weight gain patterns and postpartum weight retention fat content and daily caloric content postpartum weight retention gestational weight gainpostpartum weight retention patterns￨fat content and daily caloric content of participants in the control group were significantly higher than the experimental group￨sig increase￨highunclear￨highunclear￨highunclear
54￨pregnant women gestational diabetes gdm women at high risk for gdm n  54 early pregnancy n  102 women at a highrisk for gdm in finland￨75g oral glucose tolerance test ogtt lifestyle intervention insulin therapy intensive lifestyle intervention￨deterioration of glucose tolerance weight gain gdm￨the values of the ogtt during the second trimester did not differ between the lifestyle intervention and close followup groups￨no diff￨highunclear￨highunclear￨highunclear
63￨individuals with diabetes gestational diabetes mellitus women with gdm women with gestational diabetes mellitus gdm women n  63￨lowglycemic index diet lowglycemic index diet or a conventional highfiber and higher glycemic index diet￨key obstetric and fetal outcomes￨a lowglycemic index diet is effective as a treatment for individuals with diabetes and has been shown to improve pregnancy outcomes when used from the first trimester￨sig increase￨highunclear￨highunclear￨highunclear
257￨a total of 257 patients nutritionally monitored obese pregnant women women were eligible for the study if they were pregnant with a single fetus between 12 and 28 weeks of gestation and had a prepregnancy body mass index of more than 30 kgm2 obese pregnant women￨conventional prenatal dietary management￨perinatal outcomes￨omnibus manova showed statistically significant differences between the study and control groups regarding 3 variables 1 gestational hypertension p  46 2 mothers last weight before delivery p  001 and 3 mothers 6week postpartum weight p  001￨sig increase￨highunclear￨highunclear￨highunclear
not found￨obese women with gestational diabetes gestational diabetes￨dietary energy restriction moderate 30 maternal dietary energy restriction￨energy restriction mean birthweight ketonemia frequency of insulin therapy￨energy restriction did not alter the frequency of insulin therapy 175 in the intervention group and 169 in the control group￨no diff￨highunclear￨highunclear￨highunclear
256￨at the first trimester of pregnancy 256 women normoglycaemic pregnant women￨placebo placebo and controlplacebo probiotics with dietary counselling placebo controlplacebo probiotics lactobacillus rhamnosus gg and bifidobacterium lactis bb12 dietprobiotics or placebo dietplacebo probiotics and dietary counselling nutrition counselling to modify dietary intake according to current recommendations or as controls the dietary intervention￨reduced risk of elevated glucose concentration homeostasis model assessment blood glucose concentrations better glucose tolerance highest quantitative insulin sensitivity check index lowest insulin concentration￨better glucose tolerance in the dietprobiotics group was confirmed by a reduced risk of elevated glucose concentration compared with the controlplacebo group or 031 95  ci 012 078 p  0013 as well as by the lowest insulin concentration adjusted means 755 932 and 927 mul p  0032 and homeostasis model assessment adjusted means 149 190 and 188 p  0028 and the highest quantitative insulin sensitivity check index adjusted means 037 035 and 035 p  0028 during the last trimester of pregnancy￨sig increase￨low￨low￨low
236￨236 pregnant women recruited at  or  14 weeks gestation pregnancy a tertiary obstetric hospital in melbourne between july 2007 and may 2008 women who were overweight but not obese before pregnancy￨personalised weight measurement card advised of their optimal gestational weight gain￨gestational weight gain weight gain mean sd perweek weight gain weight gain excessive weight gain excessive gestational weight gain￨regular weight measurement in pregnancy was not found to be effective in reducing weight gain except among women who were overweight but not obese before pregnancy￨no diff￨low￨low￨low
399￨euglycemic n  399 women with at least one gdm risk factor body mass index bmi  25 kgm2 glucose intolerance or newborns macrosomia  4500 g in any earlier pregnancy family history of diabetes 14 municipalities in finland where 2271 women were screened by oral glucose tolerance test ogtt at 812 wk gestation gestational diabetes mellitus and largeforgestationalage newborns by lifestyle counseling age  40 y were included pregnant women at high risk of gdm￨individual intensified counseling on physical activity and diet and weight gain at five antenatal visits￨risk of gdm physical activity weekly metabolic equivalent task met minutes and diet intake of total fat saturated and polyunsaturated fatty acids saccharose and fiber incidence of gdm as assessed by ogtt maternal outcome and newborns birthweight adjusted for gestational age neonatal outcome maternal weight gain and the need for insulin treatment during pregnancy intake of saturated fatty acids intake of dietary fiber neonatal birthweight lga newborns intensity activity polyunsaturated fatty acids intake of saccharose adjusted coefficient gdm￨neonatal birthweight was lower in the intervention than in the usual care group absolute effect size 133 g 95 ci 231 to 35 p  0008 as was proportion of largeforgestationalage lga newborns 26216 121 versus 34179 197 p  0042￨sig increase￨low￨low￨low
not found￨referral center prenatal clinic during the period 20002002 overweight pregnant women 132 overweight body mass index 2631 kgm2 but otherwise healthy volunteers at 20 years of age or older with gestational age of 20 weeks or less and without diabetes or hypertension 92 consented to participate and were randomized￨aerobic training 3 onehour aerobic exercise sessions per week the control group received weekly relaxation and focus group discussions aerobic training aerobic exercise￨submaximal cardiorespiratory capacity oxygen uptake oxygen consumption kg1 regular or good cardiorespiratory capacity submaximal exercise capacity evaluated by oxygen uptake at the anaerobic first ventilatory submaximal exercise capacity￨women in the exercise group were approximately 5 times more likely than those in the control group to have regular or good cardiorespiratory capacity 1238 versus 238 relative risk 52 95 confidence interval 12 to 220 number needed to treat 5￨sig increase￨low￨low￨low
not found￨obese pregnant women fifty nondiabetic nonsmoking caucasian obese pregnant women obese women￨dietary counseling￨gestational weight gain energy intake gestational weight gain and glucose metabolism both sinsulin and sleptin weight development fasting bglucose￨both sinsulin and sleptin were reduced by 20 in the intervention group compared to the control group at week 27 mean difference 16 pmol l1￨sig decrease￨low￨low￨low